-DOCSTART- -X- -X- O
   
Selegiline NN NN O
- NN NN O
induced NN NN O
postural NN NN B-Disease
hypotension NN NN I-Disease
in NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
: NN NN O
a NN NN O
longitudinal NN NN O
study NN NN O
on NN NN O
the NN NN O
effects NN NN O
of NN NN O
drug NN NN O
withdrawal NN NN O
. NN NN O
   
OBJECTIVES NN NN O
: NN NN O
The NN NN O
United NN NN O
Kingdom NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
Disease NN NN I-Disease
Research NN NN O
Group NN NN O
( NN NN O
UKPDRG NN NN O
) NN NN O
trial NN NN O
found NN NN O
an NN NN O
increased NN NN O
mortality NN NN O
in NN NN O
patients NN NN O
with NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
( NN NN O
PD NN NN B-Disease
) NN NN O
randomized NN NN O
to NN NN O
receive NN NN O
10 NN NN O
mg NN NN O
selegiline NN NN O
per NN NN O
day NN NN O
and NN NN O
L NN NN O
- NN NN O
dopa NN NN O
compared NN NN O
with NN NN O
those NN NN O
taking NN NN O
L NN NN O
- NN NN O
dopa NN NN O
alone NN NN O
. NN NN O
   
Recently NN NN O
, NN NN O
we NN NN O
found NN NN O
that NN NN O
therapy NN NN O
with NN NN O
selegiline NN NN O
and NN NN O
L NN NN O
- NN NN O
dopa NN NN O
was NN NN O
associated NN NN O
with NN NN O
selective NN NN O
systolic NN NN B-Disease
orthostatic NN NN I-Disease
hypotension NN NN I-Disease
which NN NN O
was NN NN O
abolished NN NN O
by NN NN O
withdrawal NN NN O
of NN NN O
selegiline NN NN O
. NN NN O
   
This NN NN O
unwanted NN NN O
effect NN NN O
on NN NN O
postural NN NN O
blood NN NN O
pressure NN NN O
was NN NN O
not NN NN O
the NN NN O
result NN NN O
of NN NN O
underlying NN NN O
autonomic NN NN O
failure NN NN O
. NN NN O
   
The NN NN O
aims NN NN O
of NN NN O
this NN NN O
study NN NN O
were NN NN O
to NN NN O
confirm NN NN O
our NN NN O
previous NN NN O
findings NN NN O
in NN NN O
a NN NN O
separate NN NN O
cohort NN NN O
of NN NN O
patients NN NN O
and NN NN O
to NN NN O
determine NN NN O
the NN NN O
time NN NN O
course NN NN O
of NN NN O
the NN NN O
cardiovascular NN NN O
consequences NN NN O
of NN NN O
stopping NN NN O
selegiline NN NN O
in NN NN O
the NN NN O
expectation NN NN O
that NN NN O
this NN NN O
might NN NN O
shed NN NN O
light NN NN O
on NN NN O
the NN NN O
mechanisms NN NN O
by NN NN O
which NN NN O
the NN NN O
drug NN NN O
causes NN NN O
orthostatic NN NN B-Disease
hypotension NN NN I-Disease
. NN NN O
   
METHODS NN NN O
: NN NN O
The NN NN O
cardiovascular NN NN O
responses NN NN O
to NN NN O
standing NN NN O
and NN NN O
head NN NN O
- NN NN O
up NN NN O
tilt NN NN O
were NN NN O
studied NN NN O
repeatedly NN NN O
in NN NN O
PD NN NN B-Disease
patients NN NN O
receiving NN NN O
selegiline NN NN O
and NN NN O
as NN NN O
the NN NN O
drug NN NN O
was NN NN O
withdrawn NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Head NN NN O
- NN NN O
up NN NN O
tilt NN NN O
caused NN NN O
systolic NN NN B-Disease
orthostatic NN NN I-Disease
hypotension NN NN I-Disease
which NN NN O
was NN NN O
marked NN NN O
in NN NN O
six NN NN O
of NN NN O
20 NN NN O
PD NN NN B-Disease
patients NN NN O
on NN NN O
selegiline NN NN O
, NN NN O
one NN NN O
of NN NN O
whom NN NN O
lost NN NN O
consciousness NN NN O
with NN NN O
unrecordable NN NN O
blood NN NN O
pressures NN NN O
. NN NN O
   
A NN NN O
lesser NN NN O
degree NN NN O
of NN NN O
orthostatic NN NN B-Disease
hypotension NN NN I-Disease
occurred NN NN O
with NN NN O
standing NN NN O
. NN NN O
   
Orthostatic NN NN B-Disease
hypotension NN NN I-Disease
was NN NN O
ameliorated NN NN O
4 NN NN O
days NN NN O
after NN NN O
withdrawal NN NN O
of NN NN O
selegiline NN NN O
and NN NN O
totally NN NN O
abolished NN NN O
7 NN NN O
days NN NN O
after NN NN O
discontinuation NN NN O
of NN NN O
the NN NN O
drug NN NN O
. NN NN O
   
Stopping NN NN O
selegiline NN NN O
also NN NN O
significantly NN NN O
reduced NN NN B-Disease
the NN NN I-Disease
supine NN NN I-Disease
systolic NN NN I-Disease
and NN NN I-Disease
diastolic NN NN I-Disease
blood NN NN I-Disease
pressures NN NN I-Disease
consistent NN NN O
with NN NN O
a NN NN O
previously NN NN O
undescribed NN NN O
supine NN NN O
pressor NN NN O
action NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
This NN NN O
study NN NN O
confirms NN NN O
our NN NN O
previous NN NN O
finding NN NN O
that NN NN O
selegiline NN NN O
in NN NN O
combination NN NN O
with NN NN O
L NN NN O
- NN NN O
dopa NN NN O
is NN NN O
associated NN NN O
with NN NN O
selective NN NN O
orthostatic NN NN B-Disease
hypotension NN NN I-Disease
. NN NN O
   
The NN NN O
possibilities NN NN O
that NN NN O
these NN NN O
cardiovascular NN NN O
findings NN NN O
might NN NN O
be NN NN O
the NN NN O
result NN NN O
of NN NN O
non NN NN O
- NN NN O
selective NN NN O
inhibition NN NN O
of NN NN O
monoamine NN NN O
oxidase NN NN O
or NN NN O
of NN NN O
amphetamine NN NN O
and NN NN O
metamphetamine NN NN O
are NN NN O
discussed NN NN O
. NN NN O
   
Further NN NN O
studies NN NN O
on NN NN O
effects NN NN O
of NN NN O
irrigation NN NN O
solutions NN NN O
on NN NN O
rat NN NN O
bladders NN NN O
. NN NN O
   
Further NN NN O
studies NN NN O
on NN NN O
the NN NN O
effects NN NN O
of NN NN O
certain NN NN O
irrigating NN NN O
fluids NN NN O
on NN NN O
the NN NN O
rat NN NN O
bladder NN NN O
for NN NN O
18 NN NN O
hours NN NN O
are NN NN O
reported NN NN O
. NN NN O
   
The NN NN O
results NN NN O
have NN NN O
shown NN NN O
that NN NN O
the NN NN O
degradation NN NN O
product NN NN O
p NN NN O
- NN NN O
choloroaniline NN NN O
is NN NN O
not NN NN O
a NN NN O
significant NN NN O
factor NN NN O
in NN NN O
chlorhexidine NN NN O
- NN NN O
digluconate NN NN O
associated NN NN O
erosive NN NN O
cystitis NN NN B-Disease
. NN NN O
   
A NN NN O
high NN NN O
percentage NN NN O
of NN NN O
kanamycin NN NN O
- NN NN O
colistin NN NN O
and NN NN O
povidone NN NN O
- NN NN O
iodine NN NN O
irrigations NN NN O
were NN NN O
associated NN NN O
with NN NN O
erosive NN NN O
cystitis NN NN B-Disease
and NN NN O
suggested NN NN O
a NN NN O
possible NN NN O
complication NN NN O
with NN NN O
human NN NN O
usage NN NN O
. NN NN O
   
Picloxydine NN NN O
irrigations NN NN O
appeared NN NN O
to NN NN O
have NN NN O
a NN NN O
lower NN NN O
incidence NN NN O
of NN NN O
erosive NN NN O
cystitis NN NN B-Disease
but NN NN O
further NN NN O
studies NN NN O
would NN NN O
have NN NN O
to NN NN O
be NN NN O
performed NN NN O
before NN NN O
it NN NN O
could NN NN O
be NN NN O
recommended NN NN O
for NN NN O
use NN NN O
in NN NN O
urological NN NN O
procedures NN NN O
. NN NN O
   
Effects NN NN O
of NN NN O
tetrandrine NN NN O
and NN NN O
fangchinoline NN NN O
on NN NN O
experimental NN NN O
thrombosis NN NN B-Disease
in NN NN O
mice NN NN O
and NN NN O
human NN NN O
platelet NN NN B-Disease
aggregation NN NN I-Disease
. NN NN O
   
Tetrandrine NN NN O
( NN NN O
TET NN NN O
) NN NN O
and NN NN O
fangchinoline NN NN O
( NN NN O
FAN NN NN O
) NN NN O
are NN NN O
two NN NN O
naturally NN NN O
occurring NN NN O
analogues NN NN O
with NN NN O
a NN NN O
bisbenzylisoquinoline NN NN O
structure NN NN O
. NN NN O
   
The NN NN O
present NN NN O
study NN NN O
was NN NN O
undertaken NN NN O
to NN NN O
investigate NN NN O
the NN NN O
effects NN NN O
of NN NN O
TET NN NN O
and NN NN O
FAN NN NN O
on NN NN O
the NN NN O
experimental NN NN O
thrombosis NN NN B-Disease
induced NN NN O
by NN NN O
collagen NN NN O
plus NN NN O
epinephrine NN NN O
( NN NN O
EP NN NN O
) NN NN O
in NN NN O
mice NN NN O
, NN NN O
and NN NN O
platelet NN NN B-Disease
aggregation NN NN I-Disease
and NN NN O
blood NN NN B-Disease
coagulation NN NN I-Disease
in NN NN O
vitro NN NN O
. NN NN O
   
In NN NN O
the NN NN O
in NN NN O
vivo NN NN O
study NN NN O
, NN NN O
the NN NN O
administration NN NN O
( NN NN O
50 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
of NN NN O
TET NN NN O
and NN NN O
FAN NN NN O
in NN NN O
mice NN NN O
showed NN NN O
the NN NN O
inhibition NN NN O
of NN NN O
thrombosis NN NN B-Disease
by NN NN O
55 NN NN O
% NN NN O
and NN NN O
35 NN NN O
% NN NN O
, NN NN O
respectively NN NN O
, NN NN O
while NN NN O
acetylsalicylic NN NN O
acid NN NN O
( NN NN O
ASA NN NN O
, NN NN O
50 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
, NN NN O
a NN NN O
positive NN NN O
control NN NN O
, NN NN O
showed NN NN O
only NN NN O
30 NN NN O
% NN NN O
inhibition NN NN O
. NN NN O
   
In NN NN O
the NN NN O
vitro NN NN O
human NN NN O
platelet NN NN B-Disease
aggregations NN NN I-Disease
induced NN NN O
by NN NN O
the NN NN O
agonists NN NN O
used NN NN O
in NN NN O
tests NN NN O
, NN NN O
TET NN NN O
and NN NN O
FAN NN NN O
showed NN NN O
the NN NN O
inhibitions NN NN O
dose NN NN O
dependently NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
neither NN NN O
TET NN NN O
nor NN NN O
FAN NN NN O
showed NN NN O
any NN NN O
anticoagulation NN NN O
activities NN NN O
in NN NN O
the NN NN O
measurement NN NN O
of NN NN O
the NN NN O
activated NN NN O
partial NN NN O
thromboplastin NN NN O
time NN NN O
( NN NN O
APTT NN NN O
) NN NN O
, NN NN O
prothrombin NN NN O
time NN NN O
( NN NN O
PT NN NN O
) NN NN O
and NN NN O
thrombin NN NN O
time NN NN O
( NN NN O
TT NN NN O
) NN NN O
using NN NN O
human NN NN O
- NN NN O
citrated NN NN O
plasma NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
antithrombosis NN NN O
of NN NN O
TET NN NN O
and NN NN O
FAN NN NN O
in NN NN O
mice NN NN O
may NN NN O
be NN NN O
mainly NN NN O
related NN NN O
to NN NN O
the NN NN O
antiplatelet NN NN O
aggregation NN NN O
activities NN NN O
. NN NN O
   
Angioedema NN NN B-Disease
due NN NN O
to NN NN O
ACE NN NN O
inhibitors NN NN O
: NN NN O
common NN NN O
and NN NN O
inadequately NN NN O
diagnosed NN NN O
. NN NN O
   
The NN NN O
estimated NN NN O
incidence NN NN O
of NN NN O
angioedema NN NN B-Disease
during NN NN O
angiotensin NN NN O
- NN NN O
converting NN NN O
enzyme NN NN O
( NN NN O
ACE NN NN O
) NN NN O
inhibitor NN NN O
treatment NN NN O
is NN NN O
between NN NN O
1 NN NN O
and NN NN O
7 NN NN O
per NN NN O
thousand NN NN O
patients NN NN O
. NN NN O
   
This NN NN O
potentially NN NN O
serious NN NN O
adverse NN NN O
effect NN NN O
is NN NN O
often NN NN O
preceded NN NN O
by NN NN O
minor NN NN O
manifestations NN NN O
that NN NN O
may NN NN O
serve NN NN O
as NN NN O
a NN NN O
warning NN NN O
. NN NN O
   
Cocaine NN NN O
- NN NN O
induced NN NN O
mood NN NN B-Disease
disorder NN NN I-Disease
: NN NN O
prevalence NN NN O
rates NN NN O
and NN NN O
psychiatric NN NN B-Disease
symptoms NN NN O
in NN NN O
an NN NN O
outpatient NN NN O
cocaine NN NN O
- NN NN O
dependent NN NN O
sample NN NN O
. NN NN O
   
This NN NN O
paper NN NN O
attempts NN NN O
to NN NN O
examine NN NN O
and NN NN O
compare NN NN O
prevalence NN NN O
rates NN NN O
and NN NN O
symptom NN NN O
patterns NN NN O
of NN NN O
DSM NN NN O
substance NN NN O
- NN NN O
induced NN NN O
and NN NN O
other NN NN O
mood NN NN B-Disease
disorders NN NN I-Disease
. NN NN O
   
243 NN NN O
cocaine NN NN O
- NN NN O
dependent NN NN O
outpatients NN NN O
with NN NN O
cocaine NN NN O
- NN NN O
induced NN NN O
mood NN NN B-Disease
disorder NN NN I-Disease
( NN NN O
CIMD NN NN B-Disease
) NN NN O
, NN NN O
other NN NN O
mood NN NN B-Disease
disorders NN NN I-Disease
, NN NN O
or NN NN O
no NN NN O
mood NN NN B-Disease
disorder NN NN I-Disease
were NN NN O
compared NN NN O
on NN NN O
measures NN NN O
of NN NN O
psychiatric NN NN B-Disease
symptoms NN NN O
. NN NN O
   
The NN NN O
prevalence NN NN O
rate NN NN O
for NN NN O
CIMD NN NN B-Disease
was NN NN O
12 NN NN O
% NN NN O
at NN NN O
baseline NN NN O
. NN NN O
   
Introduction NN NN O
of NN NN O
the NN NN O
DSM NN NN O
- NN NN O
IV NN NN O
diagnosis NN NN O
of NN NN O
CIMD NN NN B-Disease
did NN NN O
not NN NN O
substantially NN NN O
affect NN NN O
rates NN NN O
of NN NN O
the NN NN O
other NN NN O
depressive NN NN B-Disease
disorders NN NN I-Disease
. NN NN O
   
Patients NN NN O
with NN NN O
CIMD NN NN B-Disease
had NN NN O
symptom NN NN O
severity NN NN O
levels NN NN O
between NN NN O
those NN NN O
of NN NN O
patients NN NN O
with NN NN O
and NN NN O
without NN NN O
a NN NN O
mood NN NN B-Disease
disorder NN NN I-Disease
. NN NN O
   
These NN NN O
findings NN NN O
suggest NN NN O
some NN NN O
validity NN NN O
for NN NN O
the NN NN O
new NN NN O
DSM NN NN O
- NN NN O
IV NN NN O
diagnosis NN NN O
of NN NN O
CIMD NN NN B-Disease
, NN NN O
but NN NN O
also NN NN O
suggest NN NN O
that NN NN O
it NN NN O
requires NN NN O
further NN NN O
specification NN NN O
and NN NN O
replication NN NN O
. NN NN O
   
Effect NN NN O
of NN NN O
fucoidan NN NN O
treatment NN NN O
on NN NN O
collagenase NN NN O
- NN NN O
induced NN NN O
intracerebral NN NN B-Disease
hemorrhage NN NN I-Disease
in NN NN O
rats NN NN O
. NN NN O
   
Inflammatory NN NN O
cells NN NN O
are NN NN O
postulated NN NN O
to NN NN O
mediate NN NN O
some NN NN O
of NN NN O
the NN NN O
brain NN NN B-Disease
damage NN NN I-Disease
following NN NN O
ischemic NN NN B-Disease
stroke NN NN I-Disease
. NN NN O
   
Intracerebral NN NN B-Disease
hemorrhage NN NN I-Disease
is NN NN O
associated NN NN O
with NN NN O
more NN NN O
inflammation NN NN B-Disease
than NN NN O
ischemic NN NN B-Disease
stroke NN NN I-Disease
. NN NN O
   
We NN NN O
tested NN NN O
the NN NN O
sulfated NN NN O
polysaccharide NN NN O
fucoidan NN NN O
, NN NN O
which NN NN O
has NN NN O
been NN NN O
reported NN NN O
to NN NN O
reduce NN NN O
inflammatory NN NN O
brain NN NN B-Disease
damage NN NN I-Disease
, NN NN O
in NN NN O
a NN NN O
rat NN NN O
model NN NN O
of NN NN O
intracerebral NN NN B-Disease
hemorrhage NN NN I-Disease
induced NN NN O
by NN NN O
injection NN NN O
of NN NN O
bacterial NN NN O
collagenase NN NN O
into NN NN O
the NN NN O
caudate NN NN O
nucleus NN NN O
. NN NN O
   
Rats NN NN O
were NN NN O
treated NN NN O
with NN NN O
seven NN NN O
day NN NN O
intravenous NN NN O
infusion NN NN O
of NN NN O
fucoidan NN NN O
( NN NN O
30 NN NN O
micrograms NN NN O
h NN NN O
- NN NN O
1 NN NN O
) NN NN O
or NN NN O
vehicle NN NN O
. NN NN O
   
The NN NN O
hematoma NN NN B-Disease
was NN NN O
assessed NN NN O
in NN NN O
vivo NN NN O
by NN NN O
magnetic NN NN O
resonance NN NN O
imaging NN NN O
. NN NN O
   
Motor NN NN O
behavior NN NN O
, NN NN O
passive NN NN O
avoidance NN NN O
, NN NN O
and NN NN O
skilled NN NN O
forelimb NN NN O
function NN NN O
were NN NN O
tested NN NN O
repeatedly NN NN O
for NN NN O
six NN NN O
weeks NN NN O
. NN NN O
   
Fucoidan NN NN O
- NN NN O
treated NN NN O
rats NN NN O
exhibited NN NN O
evidence NN NN O
of NN NN O
impaired NN NN B-Disease
blood NN NN I-Disease
clotting NN NN I-Disease
and NN NN O
hemodilution NN NN B-Disease
, NN NN O
had NN NN O
larger NN NN O
hematomas NN NN B-Disease
, NN NN O
and NN NN O
tended NN NN O
to NN NN O
have NN NN O
less NN NN O
inflammation NN NN B-Disease
in NN NN O
the NN NN O
vicinity NN NN O
of NN NN O
the NN NN O
hematoma NN NN B-Disease
after NN NN O
three NN NN O
days NN NN O
. NN NN O
   
They NN NN O
showed NN NN O
significantly NN NN O
more NN NN O
rapid NN NN O
improvement NN NN O
of NN NN O
motor NN NN O
function NN NN O
in NN NN O
the NN NN O
first NN NN O
week NN NN O
following NN NN O
hemorrhage NN NN B-Disease
and NN NN O
better NN NN O
memory NN NN O
retention NN NN O
in NN NN O
the NN NN O
passive NN NN O
avoidance NN NN O
test NN NN O
. NN NN O
   
Acute NN NN O
white NN NN B-Disease
matter NN NN I-Disease
edema NN NN I-Disease
and NN NN O
eventual NN NN O
neuronal NN NN B-Disease
loss NN NN I-Disease
in NN NN O
the NN NN O
striatum NN NN O
adjacent NN NN O
to NN NN O
the NN NN O
hematoma NN NN B-Disease
did NN NN O
not NN NN O
differ NN NN O
between NN NN O
the NN NN O
two NN NN O
groups NN NN O
. NN NN O
   
Investigation NN NN O
of NN NN O
more NN NN O
specific NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
agents NN NN O
and NN NN O
hemodiluting NN NN O
agents NN NN O
are NN NN O
warranted NN NN O
in NN NN O
intracerebral NN NN B-Disease
hemorrhage NN NN I-Disease
. NN NN O
   
Recurarization NN NN O
in NN NN O
the NN NN O
recovery NN NN O
room NN NN O
. NN NN O
   
A NN NN O
case NN NN O
of NN NN O
recurarization NN NN O
in NN NN O
the NN NN O
recovery NN NN O
room NN NN O
is NN NN O
reported NN NN O
. NN NN O
   
Accumulation NN NN O
of NN NN O
atracurium NN NN O
in NN NN O
the NN NN O
intravenous NN NN O
line NN NN O
led NN NN O
to NN NN O
recurarization NN NN O
after NN NN O
flushing NN NN O
the NN NN O
line NN NN O
in NN NN O
the NN NN O
recovery NN NN O
room NN NN O
. NN NN O
   
A NN NN O
respiratory NN NN B-Disease
arrest NN NN I-Disease
with NN NN O
severe NN NN O
desaturation NN NN B-Disease
and NN NN O
bradycardia NN NN B-Disease
occurred NN NN O
. NN NN O
   
Circumstances NN NN O
leading NN NN O
to NN NN O
this NN NN O
event NN NN O
and NN NN O
the NN NN O
mechanisms NN NN O
enabling NN NN O
a NN NN O
neuromuscular NN NN B-Disease
blockade NN NN I-Disease
to NN NN O
occur NN NN O
, NN NN O
following NN NN O
the NN NN O
administration NN NN O
of NN NN O
a NN NN O
small NN NN O
dose NN NN O
of NN NN O
relaxant NN NN O
, NN NN O
are NN NN O
discussed NN NN O
. NN NN O
   
The NN NN O
haemodynamic NN NN O
effects NN NN O
of NN NN O
propofol NN NN O
in NN NN O
combination NN NN O
with NN NN O
ephedrine NN NN O
in NN NN O
elderly NN NN O
patients NN NN O
( NN NN O
ASA NN NN O
groups NN NN O
3 NN NN O
and NN NN O
4 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
marked NN NN O
vasodilator NN NN O
and NN NN O
negative NN NN O
inotropic NN NN O
effects NN NN O
of NN NN O
propofol NN NN O
are NN NN O
disadvantages NN NN O
in NN NN O
frail NN NN O
elderly NN NN O
patients NN NN O
. NN NN O
   
We NN NN O
investigated NN NN O
the NN NN O
safety NN NN O
and NN NN O
efficacy NN NN O
of NN NN O
adding NN NN O
different NN NN O
doses NN NN O
of NN NN O
ephedrine NN NN O
to NN NN O
propofol NN NN O
in NN NN O
order NN NN O
to NN NN O
obtund NN NN O
the NN NN O
hypotensive NN NN B-Disease
response NN NN O
. NN NN O
   
The NN NN O
haemodynamic NN NN O
effects NN NN O
of NN NN O
adding NN NN O
15 NN NN O
, NN NN O
20 NN NN O
or NN NN O
25 NN NN O
mg NN NN O
of NN NN O
ephedrine NN NN O
to NN NN O
200 NN NN O
mg NN NN O
of NN NN O
propofol NN NN O
were NN NN O
compared NN NN O
to NN NN O
control NN NN O
in NN NN O
40 NN NN O
ASA NN NN O
3 NN NN O
/ NN NN O
4 NN NN O
patients NN NN O
over NN NN O
60 NN NN O
years NN NN O
presenting NN NN O
for NN NN O
genito NN NN O
- NN NN O
urinary NN NN O
surgery NN NN O
. NN NN O
   
The NN NN O
addition NN NN O
of NN NN O
ephedrine NN NN O
to NN NN O
propofol NN NN O
appears NN NN O
to NN NN O
be NN NN O
an NN NN O
effective NN NN O
method NN NN O
of NN NN O
obtunding NN NN O
the NN NN O
hypotensive NN NN B-Disease
response NN NN O
to NN NN O
propofol NN NN O
at NN NN O
all NN NN O
doses NN NN O
used NN NN O
in NN NN O
this NN NN O
study NN NN O
. NN NN O
   
However NN NN O
, NN NN O
marked NN NN O
tachycardia NN NN B-Disease
associated NN NN O
with NN NN O
the NN NN O
use NN NN O
of NN NN O
ephedrine NN NN O
in NN NN O
combination NN NN O
with NN NN O
propofol NN NN O
occurred NN NN O
in NN NN O
the NN NN O
majority NN NN O
of NN NN O
patients NN NN O
, NN NN O
occasionally NN NN O
reaching NN NN O
high NN NN O
levels NN NN O
in NN NN O
individual NN NN O
patients NN NN O
. NN NN O
   
Due NN NN O
to NN NN O
the NN NN O
risk NN NN O
of NN NN O
this NN NN O
tachycardia NN NN B-Disease
inducing NN NN O
myocardial NN NN B-Disease
ischemia NN NN I-Disease
, NN NN O
we NN NN O
would NN NN O
not NN NN O
recommend NN NN O
the NN NN O
use NN NN O
in NN NN O
elderly NN NN O
patients NN NN O
of NN NN O
any NN NN O
of NN NN O
the NN NN O
ephedrine NN NN O
/ NN NN O
propofol NN NN O
/ NN NN O
mixtures NN NN O
studied NN NN O
. NN NN O
   
Gemcitabine NN NN O
plus NN NN O
vinorelbine NN NN O
in NN NN O
nonsmall NN NN B-Disease
cell NN NN I-Disease
lung NN NN I-Disease
carcinoma NN NN I-Disease
patients NN NN O
age NN NN O
70 NN NN O
years NN NN O
or NN NN O
older NN NN O
or NN NN O
patients NN NN O
who NN NN O
cannot NN NN O
receive NN NN O
cisplatin NN NN O
. NN NN O
   
Oncopaz NN NN O
Cooperative NN NN O
Group NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Although NN NN O
the NN NN O
prevalence NN NN O
of NN NN O
nonsmall NN NN B-Disease
cell NN NN I-Disease
lung NN NN I-Disease
carcinoma NN NN I-Disease
( NN NN O
NSCLC NN NN B-Disease
) NN NN O
is NN NN O
high NN NN O
among NN NN O
elderly NN NN O
patients NN NN O
, NN NN O
few NN NN O
data NN NN O
are NN NN O
available NN NN O
regarding NN NN O
the NN NN O
efficacy NN NN O
and NN NN O
toxicity NN NN B-Disease
of NN NN O
chemotherapy NN NN O
in NN NN O
this NN NN O
group NN NN O
of NN NN O
patients NN NN O
. NN NN O
   
Recent NN NN O
reports NN NN O
indicate NN NN O
that NN NN O
single NN NN O
agent NN NN O
therapy NN NN O
with NN NN O
vinorelbine NN NN O
( NN NN O
VNB NN NN O
) NN NN O
or NN NN O
gemcitabine NN NN O
( NN NN O
GEM NN NN O
) NN NN O
may NN NN O
obtain NN NN O
a NN NN O
response NN NN O
rate NN NN O
of NN NN O
20 NN NN O
- NN NN O
30 NN NN O
% NN NN O
in NN NN O
elderly NN NN O
patients NN NN O
, NN NN O
with NN NN O
acceptable NN NN O
toxicity NN NN B-Disease
and NN NN O
improvement NN NN O
in NN NN O
symptoms NN NN O
and NN NN O
quality NN NN O
of NN NN O
life NN NN O
. NN NN O
   
In NN NN O
the NN NN O
current NN NN O
study NN NN O
the NN NN O
efficacy NN NN O
and NN NN O
toxicity NN NN B-Disease
of NN NN O
the NN NN O
combination NN NN O
of NN NN O
GEM NN NN O
and NN NN O
VNB NN NN O
in NN NN O
elderly NN NN O
patients NN NN O
with NN NN O
advanced NN NN O
NSCLC NN NN B-Disease
or NN NN O
those NN NN O
with NN NN O
some NN NN O
contraindication NN NN O
to NN NN O
receiving NN NN O
cisplatin NN NN O
were NN NN O
assessed NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Forty NN NN O
- NN NN O
nine NN NN O
patients NN NN O
with NN NN O
advanced NN NN O
NSCLC NN NN B-Disease
were NN NN O
included NN NN O
, NN NN O
38 NN NN O
of NN NN O
whom NN NN O
were NN NN O
age NN NN O
> NN NN O
/ NN NN O
= NN NN O
70 NN NN O
years NN NN O
and NN NN O
11 NN NN O
were NN NN O
age NN NN O
< NN NN O
70 NN NN O
years NN NN O
but NN NN O
who NN NN O
had NN NN O
some NN NN O
contraindication NN NN O
to NN NN O
receiving NN NN O
cisplatin NN NN O
. NN NN O
   
All NN NN O
patients NN NN O
were NN NN O
evaluable NN NN O
for NN NN O
response NN NN O
and NN NN O
toxicity NN NN B-Disease
. NN NN O
   
Treatment NN NN O
was NN NN O
comprised NN NN O
of NN NN O
VNB NN NN O
, NN NN O
25 NN NN O
mg NN NN O
/ NN NN O
m NN NN O
( NN NN O
2 NN NN O
) NN NN O
, NN NN O
plus NN NN O
GEM NN NN O
, NN NN O
1000 NN NN O
mg NN NN O
/ NN NN O
m NN NN O
( NN NN O
2 NN NN O
) NN NN O
, NN NN O
both NN NN O
on NN NN O
Days NN NN O
1 NN NN O
, NN NN O
8 NN NN O
, NN NN O
and NN NN O
15 NN NN O
every NN NN O
28 NN NN O
days NN NN O
. NN NN O
   
Patients NN NN O
received NN NN O
a NN NN O
minimum NN NN O
of NN NN O
three NN NN O
courses NN NN O
unless NN NN O
progressive NN NN O
disease NN NN O
was NN NN O
detected NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
One NN NN O
hundred NN NN O
sixty NN NN O
- NN NN O
five NN NN O
courses NN NN O
were NN NN O
administered NN NN O
, NN NN O
with NN NN O
a NN NN O
median NN NN O
of NN NN O
3 NN NN O
. NN NN O
   
6 NN NN O
courses NN NN O
per NN NN O
patient NN NN O
. NN NN O
   
The NN NN O
overall NN NN O
response NN NN O
rate NN NN O
was NN NN O
26 NN NN O
% NN NN O
( NN NN O
95 NN NN O
% NN NN O
confidence NN NN O
interval NN NN O
, NN NN O
15 NN NN O
- NN NN O
41 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
Two NN NN O
patients NN NN O
attained NN NN O
a NN NN O
complete NN NN O
response NN NN O
( NN NN O
4 NN NN O
% NN NN O
) NN NN O
and NN NN O
11 NN NN O
patients NN NN O
( NN NN O
22 NN NN O
% NN NN O
) NN NN O
achieved NN NN O
a NN NN O
partial NN NN O
response NN NN O
. NN NN O
   
Eastern NN NN O
Cooperative NN NN O
Oncology NN NN O
Group NN NN O
performance NN NN O
status NN NN O
improved NN NN O
in NN NN O
35 NN NN O
% NN NN O
of NN NN O
those NN NN O
patients NN NN O
with NN NN O
an NN NN O
initial NN NN O
value NN NN O
> NN NN O
0 NN NN O
, NN NN O
whereas NN NN O
relief NN NN O
of NN NN O
at NN NN O
least NN NN O
1 NN NN O
symptom NN NN O
without NN NN O
worsening NN NN O
of NN NN O
other NN NN O
symptoms NN NN O
was NN NN O
noted NN NN O
in NN NN O
27 NN NN O
patients NN NN O
( NN NN O
55 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
The NN NN O
median NN NN O
time NN NN O
to NN NN O
progression NN NN O
was NN NN O
16 NN NN O
weeks NN NN O
and NN NN O
the NN NN O
1 NN NN O
- NN NN O
year NN NN O
survival NN NN O
rate NN NN O
was NN NN O
33 NN NN O
% NN NN O
. NN NN O
   
Toxicity NN NN B-Disease
was NN NN O
mild NN NN O
. NN NN O
   
Six NN NN O
patients NN NN O
( NN NN O
12 NN NN O
% NN NN O
) NN NN O
had NN NN O
World NN NN O
Health NN NN O
Organization NN NN O
Grade NN NN O
3 NN NN O
- NN NN O
4 NN NN O
neutropenia NN NN B-Disease
, NN NN O
2 NN NN O
patients NN NN O
( NN NN O
4 NN NN O
% NN NN O
) NN NN O
had NN NN O
Grade NN NN O
3 NN NN O
- NN NN O
4 NN NN O
thrombocytopenia NN NN B-Disease
, NN NN O
and NN NN O
2 NN NN O
patients NN NN O
( NN NN O
4 NN NN O
% NN NN O
) NN NN O
had NN NN O
Grade NN NN O
3 NN NN O
neurotoxicity NN NN B-Disease
. NN NN O
   
Three NN NN O
patients NN NN O
with NN NN O
severe NN NN O
neutropenia NN NN B-Disease
( NN NN O
6 NN NN O
% NN NN O
) NN NN O
died NN NN O
of NN NN O
sepsis NN NN B-Disease
. NN NN O
   
The NN NN O
median NN NN O
age NN NN O
of NN NN O
those NN NN O
patients NN NN O
developing NN NN O
Grade NN NN O
3 NN NN O
- NN NN O
4 NN NN O
neutropenia NN NN B-Disease
was NN NN O
significantly NN NN O
higher NN NN O
than NN NN O
that NN NN O
of NN NN O
the NN NN O
remaining NN NN O
patients NN NN O
( NN NN O
75 NN NN O
years NN NN O
vs NN NN O
. NN NN O
72 NN NN O
years NN NN O
; NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
047 NN NN O
) NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
The NN NN O
combination NN NN O
of NN NN O
GEM NN NN O
and NN NN O
VNB NN NN O
is NN NN O
moderately NN NN O
active NN NN O
and NN NN O
well NN NN O
tolerated NN NN O
except NN NN O
in NN NN O
patients NN NN O
age NN NN O
> NN NN O
/ NN NN O
= NN NN O
75 NN NN O
years NN NN O
. NN NN O
   
This NN NN O
age NN NN O
group NN NN O
had NN NN O
an NN NN O
increased NN NN O
risk NN NN O
of NN NN O
myelosuppression NN NN B-Disease
. NN NN O
   
Therefore NN NN O
the NN NN O
prophylactic NN NN O
use NN NN O
of NN NN O
granulocyte NN NN O
- NN NN O
colony NN NN O
stimulating NN NN O
factor NN NN O
should NN NN O
be NN NN O
considered NN NN O
with NN NN O
this NN NN O
treatment NN NN O
. NN NN O
   
New NN NN O
chemotherapy NN NN O
combinations NN NN O
with NN NN O
higher NN NN O
activity NN NN O
and NN NN O
lower NN NN O
toxicity NN NN B-Disease
are NN NN O
needed NN NN O
for NN NN O
elderly NN NN O
patients NN NN O
with NN NN O
advanced NN NN O
NSCLC NN NN B-Disease
. NN NN O
   
A NN NN O
selective NN NN O
dopamine NN NN O
D4 NN NN O
receptor NN NN O
antagonist NN NN O
, NN NN O
NRA0160 NN NN O
: NN NN O
a NN NN O
preclinical NN NN O
neuropharmacological NN NN O
profile NN NN O
. NN NN O
   
NRA0160 NN NN O
, NN NN O
5 NN NN O
- NN NN O
[ NN NN O
2 NN NN O
- NN NN O
( NN NN O
4 NN NN O
- NN NN O
( NN NN O
3 NN NN O
- NN NN O
fluorobenzylidene NN NN O
) NN NN O
piperidin NN NN O
- NN NN O
1 NN NN O
- NN NN O
yl NN NN O
) NN NN O
ethyl NN NN O
] NN NN O
- NN NN O
4 NN NN O
- NN NN O
( NN NN O
4 NN NN O
- NN NN O
fluorophenyl NN NN O
) NN NN O
thiazole NN NN O
- NN NN O
2 NN NN O
- NN NN O
carboxamide NN NN O
, NN NN O
has NN NN O
a NN NN O
high NN NN O
affinity NN NN O
for NN NN O
human NN NN O
cloned NN NN O
dopamine NN NN O
D4 NN NN O
. NN NN O
2 NN NN O
, NN NN O
D4 NN NN O
. NN NN O
4 NN NN O
and NN NN O
D4 NN NN O
. NN NN O
7 NN NN O
receptors NN NN O
, NN NN O
with NN NN O
Ki NN NN O
values NN NN O
of NN NN O
0 NN NN O
. NN NN O
5 NN NN O
, NN NN O
0 NN NN O
. NN NN O
9 NN NN O
and NN NN O
2 NN NN O
. NN NN O
7 NN NN O
nM NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
NRA0160 NN NN O
is NN NN O
over NN NN O
20 NN NN O
, NN NN O
000fold NN NN O
more NN NN O
potent NN NN O
at NN NN O
the NN NN O
dopamine NN NN O
D4 NN NN O
. NN NN O
2 NN NN O
receptor NN NN O
compared NN NN O
with NN NN O
the NN NN O
human NN NN O
cloned NN NN O
dopamine NN NN O
D2L NN NN O
receptor NN NN O
. NN NN O
   
NRA0160 NN NN O
has NN NN O
negligible NN NN O
affinity NN NN O
for NN NN O
the NN NN O
human NN NN O
cloned NN NN O
dopamine NN NN O
D3 NN NN O
receptor NN NN O
( NN NN O
Ki NN NN O
= NN NN O
39 NN NN O
nM NN NN O
) NN NN O
, NN NN O
rat NN NN O
serotonin NN NN O
( NN NN O
5 NN NN O
- NN NN O
HT NN NN O
) NN NN O
2A NN NN O
receptors NN NN O
( NN NN O
Ki NN NN O
= NN NN O
180 NN NN O
nM NN NN O
) NN NN O
and NN NN O
rat NN NN O
alpha1 NN NN O
adrenoceptor NN NN O
( NN NN O
Ki NN NN O
= NN NN O
237 NN NN O
nM NN NN O
) NN NN O
. NN NN O
   
NRA0160 NN NN O
and NN NN O
clozapine NN NN O
antagonized NN NN O
locomotor NN NN O
hyperactivity NN NN B-Disease
induced NN NN O
by NN NN O
methamphetamine NN NN O
( NN NN O
MAP NN NN O
) NN NN O
in NN NN O
mice NN NN O
. NN NN O
   
NRA0160 NN NN O
and NN NN O
clozapine NN NN O
antagonized NN NN O
MAP NN NN O
- NN NN O
induced NN NN O
stereotyped NN NN O
behavior NN NN O
in NN NN O
mice NN NN O
, NN NN O
although NN NN O
their NN NN O
effects NN NN O
did NN NN O
not NN NN O
exceed NN NN O
50 NN NN O
% NN NN O
inhibition NN NN O
, NN NN O
even NN NN O
at NN NN O
the NN NN O
highest NN NN O
dose NN NN O
given NN NN O
. NN NN O
   
NRA0160 NN NN O
and NN NN O
clozapine NN NN O
significantly NN NN O
induced NN NN O
catalepsy NN NN B-Disease
in NN NN O
rats NN NN O
, NN NN O
although NN NN O
their NN NN O
effects NN NN O
did NN NN O
not NN NN O
exceed NN NN O
50 NN NN O
% NN NN O
induction NN NN O
even NN NN O
at NN NN O
the NN NN O
highest NN NN O
dose NN NN O
given NN NN O
. NN NN O
   
NRA0160 NN NN O
and NN NN O
clozapine NN NN O
significantly NN NN O
reversed NN NN O
the NN NN O
disruption NN NN O
of NN NN O
prepulse NN NN O
inhibition NN NN O
( NN NN O
PPI NN NN O
) NN NN O
in NN NN O
rats NN NN O
produced NN NN O
by NN NN O
apomorphine NN NN O
. NN NN O
   
NRA0160 NN NN O
and NN NN O
clozapine NN NN O
significantly NN NN O
shortened NN NN O
the NN NN O
phencyclidine NN NN O
( NN NN O
PCP NN NN O
) NN NN O
- NN NN O
induced NN NN O
prolonged NN NN O
swimming NN NN O
latency NN NN O
in NN NN O
rats NN NN O
in NN NN O
a NN NN O
water NN NN O
maze NN NN O
task NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
NRA0160 NN NN O
may NN NN O
have NN NN O
unique NN NN O
antipsychotic NN NN O
activities NN NN O
without NN NN O
the NN NN O
liability NN NN O
of NN NN O
motor NN NN O
side NN NN O
effects NN NN O
typical NN NN O
of NN NN O
classical NN NN O
antipsychotics NN NN O
. NN NN O
   
Warfarin NN NN O
- NN NN O
induced NN NN O
artery NN NN B-Disease
calcification NN NN I-Disease
is NN NN O
accelerated NN NN O
by NN NN O
growth NN NN O
and NN NN O
vitamin NN NN O
D NN NN O
. NN NN O
   
The NN NN O
present NN NN O
studies NN NN O
demonstrate NN NN O
that NN NN O
growth NN NN O
and NN NN O
vitamin NN NN O
D NN NN O
treatment NN NN O
enhance NN NN O
the NN NN O
extent NN NN O
of NN NN O
artery NN NN B-Disease
calcification NN NN I-Disease
in NN NN O
rats NN NN O
given NN NN O
sufficient NN NN O
doses NN NN O
of NN NN O
Warfarin NN NN O
to NN NN O
inhibit NN NN O
gamma NN NN O
- NN NN O
carboxylation NN NN O
of NN NN O
matrix NN NN O
Gla NN NN O
protein NN NN O
, NN NN O
a NN NN O
calcification NN NN B-Disease
inhibitor NN NN O
known NN NN O
to NN NN O
be NN NN O
expressed NN NN O
by NN NN O
smooth NN NN O
muscle NN NN O
cells NN NN O
and NN NN O
macrophages NN NN O
in NN NN O
the NN NN O
artery NN NN O
wall NN NN O
. NN NN O
   
The NN NN O
first NN NN O
series NN NN O
of NN NN O
experiments NN NN O
examined NN NN O
the NN NN O
influence NN NN O
of NN NN O
age NN NN O
and NN NN O
growth NN NN O
status NN NN O
on NN NN O
artery NN NN B-Disease
calcification NN NN I-Disease
in NN NN O
Warfarin NN NN O
- NN NN O
treated NN NN O
rats NN NN O
. NN NN O
   
Treatment NN NN O
for NN NN O
2 NN NN O
weeks NN NN O
with NN NN O
Warfarin NN NN O
caused NN NN O
massive NN NN O
focal NN NN O
calcification NN NN B-Disease
of NN NN I-Disease
the NN NN I-Disease
artery NN NN I-Disease
media NN NN O
in NN NN O
20 NN NN O
- NN NN O
day NN NN O
- NN NN O
old NN NN O
rats NN NN O
and NN NN O
less NN NN O
extensive NN NN O
focal NN NN O
calcification NN NN B-Disease
in NN NN O
42 NN NN O
- NN NN O
day NN NN O
- NN NN O
old NN NN O
rats NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
no NN NN O
artery NN NN B-Disease
calcification NN NN I-Disease
could NN NN O
be NN NN O
detected NN NN O
in NN NN O
10 NN NN O
- NN NN O
month NN NN O
- NN NN O
old NN NN O
adult NN NN O
rats NN NN O
even NN NN O
after NN NN O
4 NN NN O
weeks NN NN O
of NN NN O
Warfarin NN NN O
treatment NN NN O
. NN NN O
   
To NN NN O
directly NN NN O
examine NN NN O
the NN NN O
importance NN NN O
of NN NN O
growth NN NN O
to NN NN O
Warfarin NN NN O
- NN NN O
induced NN NN O
artery NN NN B-Disease
calcification NN NN I-Disease
in NN NN O
animals NN NN O
of NN NN O
the NN NN O
same NN NN O
age NN NN O
, NN NN O
20 NN NN O
- NN NN O
day NN NN O
- NN NN O
old NN NN O
rats NN NN O
were NN NN O
fed NN NN O
for NN NN O
2 NN NN O
weeks NN NN O
either NN NN O
an NN NN O
ad NN NN O
libitum NN NN O
diet NN NN O
or NN NN O
a NN NN O
6 NN NN O
- NN NN O
g NN NN O
/ NN NN O
d NN NN O
restricted NN NN O
diet NN NN O
that NN NN O
maintains NN NN O
weight NN NN O
but NN NN O
prevents NN NN O
growth NN NN O
. NN NN O
   
Concurrent NN NN O
treatment NN NN O
of NN NN O
both NN NN O
dietary NN NN O
groups NN NN O
with NN NN O
Warfarin NN NN O
produced NN NN O
massive NN NN O
focal NN NN O
calcification NN NN B-Disease
of NN NN I-Disease
the NN NN I-Disease
artery NN NN I-Disease
media NN NN O
in NN NN O
the NN NN O
ad NN NN O
libitum NN NN O
- NN NN O
fed NN NN O
rats NN NN O
but NN NN O
no NN NN O
detectable NN NN O
artery NN NN B-Disease
calcification NN NN I-Disease
in NN NN O
the NN NN O
restricted NN NN O
- NN NN O
diet NN NN O
, NN NN O
growth NN NN O
- NN NN O
inhibited NN NN O
group NN NN O
. NN NN O
   
Although NN NN O
the NN NN O
explanation NN NN O
for NN NN O
the NN NN O
association NN NN O
between NN NN O
artery NN NN B-Disease
calcification NN NN I-Disease
and NN NN O
growth NN NN O
status NN NN O
cannot NN NN O
be NN NN O
determined NN NN O
from NN NN O
the NN NN O
present NN NN O
study NN NN O
, NN NN O
there NN NN O
was NN NN O
a NN NN O
relationship NN NN O
between NN NN O
higher NN NN O
serum NN NN O
phosphate NN NN O
and NN NN O
susceptibility NN NN O
to NN NN O
artery NN NN B-Disease
calcification NN NN I-Disease
, NN NN O
with NN NN O
30 NN NN O
% NN NN O
higher NN NN O
levels NN NN O
of NN NN O
serum NN NN O
phosphate NN NN O
in NN NN O
young NN NN O
, NN NN O
ad NN NN O
libitum NN NN O
- NN NN O
fed NN NN O
rats NN NN O
compared NN NN O
with NN NN O
either NN NN O
of NN NN O
the NN NN O
groups NN NN O
that NN NN O
was NN NN O
resistant NN NN O
to NN NN O
Warfarin NN NN O
- NN NN O
induced NN NN O
artery NN NN B-Disease
calcification NN NN I-Disease
, NN NN O
ie NN NN O
, NN NN O
the NN NN O
10 NN NN O
- NN NN O
month NN NN O
- NN NN O
old NN NN O
rats NN NN O
and NN NN O
the NN NN O
restricted NN NN O
- NN NN O
diet NN NN O
, NN NN O
growth NN NN O
- NN NN O
inhibited NN NN O
young NN NN O
rats NN NN O
. NN NN O
   
This NN NN O
observation NN NN O
suggests NN NN O
that NN NN O
increased NN NN O
susceptibility NN NN O
to NN NN O
Warfarin NN NN O
- NN NN O
induced NN NN O
artery NN NN B-Disease
calcification NN NN I-Disease
could NN NN O
be NN NN O
related NN NN O
to NN NN O
higher NN NN O
serum NN NN O
phosphate NN NN O
levels NN NN O
. NN NN O
   
The NN NN O
second NN NN O
set NN NN O
of NN NN O
experiments NN NN O
examined NN NN O
the NN NN O
possible NN NN O
synergy NN NN O
between NN NN O
vitamin NN NN O
D NN NN O
and NN NN O
Warfarin NN NN O
in NN NN O
artery NN NN B-Disease
calcification NN NN I-Disease
. NN NN O
   
High NN NN O
doses NN NN O
of NN NN O
vitamin NN NN O
D NN NN O
are NN NN O
known NN NN O
to NN NN O
cause NN NN O
calcification NN NN B-Disease
of NN NN I-Disease
the NN NN I-Disease
artery NN NN I-Disease
media NN NN O
in NN NN O
as NN NN O
little NN NN O
as NN NN O
3 NN NN O
to NN NN O
4 NN NN O
days NN NN O
. NN NN O
   
High NN NN O
doses NN NN O
of NN NN O
the NN NN O
vitamin NN NN O
K NN NN O
antagonist NN NN O
Warfarin NN NN O
are NN NN O
also NN NN O
known NN NN O
to NN NN O
cause NN NN O
calcification NN NN B-Disease
of NN NN I-Disease
the NN NN I-Disease
artery NN NN I-Disease
media NN NN O
, NN NN O
but NN NN O
at NN NN O
treatment NN NN O
times NN NN O
of NN NN O
2 NN NN O
weeks NN NN O
or NN NN O
longer NN NN O
yet NN NN O
not NN NN O
at NN NN O
1 NN NN O
week NN NN O
. NN NN O
   
In NN NN O
the NN NN O
current NN NN O
study NN NN O
, NN NN O
we NN NN O
investigated NN NN O
the NN NN O
synergy NN NN O
between NN NN O
these NN NN O
2 NN NN O
treatments NN NN O
and NN NN O
found NN NN O
that NN NN O
concurrent NN NN O
Warfarin NN NN O
administration NN NN O
dramatically NN NN O
increased NN NN O
the NN NN O
extent NN NN O
of NN NN O
calcification NN NN B-Disease
in NN NN O
the NN NN O
media NN NN O
of NN NN O
vitamin NN NN O
D NN NN O
- NN NN O
treated NN NN O
rats NN NN O
at NN NN O
3 NN NN O
and NN NN O
4 NN NN O
days NN NN O
. NN NN O
   
There NN NN O
was NN NN O
a NN NN O
close NN NN O
parallel NN NN O
between NN NN O
the NN NN O
effect NN NN O
of NN NN O
vitamin NN NN O
D NN NN O
dose NN NN O
on NN NN O
artery NN NN B-Disease
calcification NN NN I-Disease
and NN NN O
the NN NN O
effect NN NN O
of NN NN O
vitamin NN NN O
D NN NN O
dose NN NN O
on NN NN O
the NN NN O
elevation NN NN O
of NN NN O
serum NN NN O
calcium NN NN O
, NN NN O
which NN NN O
suggests NN NN O
that NN NN O
vitamin NN NN O
D NN NN O
may NN NN O
induce NN NN O
artery NN NN B-Disease
calcification NN NN I-Disease
through NN NN O
its NN NN O
effect NN NN O
on NN NN O
serum NN NN O
calcium NN NN O
. NN NN O
   
Because NN NN O
Warfarin NN NN O
treatment NN NN O
had NN NN O
no NN NN O
effect NN NN O
on NN NN O
the NN NN O
elevation NN NN O
in NN NN O
serum NN NN O
calcium NN NN O
produced NN NN O
by NN NN O
vitamin NN NN O
D NN NN O
, NN NN O
the NN NN O
synergy NN NN O
between NN NN O
Warfarin NN NN O
and NN NN O
vitamin NN NN O
D NN NN O
is NN NN O
probably NN NN O
best NN NN O
explained NN NN O
by NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
Warfarin NN NN O
inhibits NN NN O
the NN NN O
activity NN NN O
of NN NN O
matrix NN NN O
Gla NN NN O
protein NN NN O
as NN NN O
a NN NN O
calcification NN NN B-Disease
inhibitor NN NN O
. NN NN O
   
High NN NN O
levels NN NN O
of NN NN O
matrix NN NN O
Gla NN NN O
protein NN NN O
are NN NN O
found NN NN O
at NN NN O
sites NN NN O
of NN NN O
artery NN NN B-Disease
calcification NN NN I-Disease
in NN NN O
rats NN NN O
treated NN NN O
with NN NN O
vitamin NN NN O
D NN NN O
plus NN NN O
Warfarin NN NN O
, NN NN O
and NN NN O
chemical NN NN O
analysis NN NN O
showed NN NN O
that NN NN O
the NN NN O
protein NN NN O
that NN NN O
accumulated NN NN O
was NN NN O
indeed NN NN O
not NN NN O
gamma NN NN O
- NN NN O
carboxylated NN NN O
. NN NN O
   
These NN NN O
observations NN NN O
indicate NN NN O
that NN NN O
although NN NN O
the NN NN O
gamma NN NN O
- NN NN O
carboxyglutamate NN NN O
residues NN NN O
of NN NN O
matrix NN NN O
Gla NN NN O
protein NN NN O
are NN NN O
apparently NN NN O
required NN NN O
for NN NN O
its NN NN O
function NN NN O
as NN NN O
a NN NN O
calcification NN NN B-Disease
inhibitor NN NN O
, NN NN O
they NN NN O
are NN NN O
not NN NN O
required NN NN O
for NN NN O
its NN NN O
accumulation NN NN O
at NN NN O
calcification NN NN B-Disease
sites NN NN O
. NN NN O
   
Test NN NN O
conditions NN NN O
influence NN NN O
the NN NN O
response NN NN O
to NN NN O
a NN NN O
drug NN NN O
challenge NN NN O
in NN NN O
rodents NN NN O
. NN NN O
   
These NN NN O
studies NN NN O
were NN NN O
conducted NN NN O
to NN NN O
examine NN NN O
the NN NN O
differential NN NN O
response NN NN O
to NN NN O
a NN NN O
drug NN NN O
challenge NN NN O
under NN NN O
varied NN NN O
experimental NN NN O
test NN NN O
conditions NN NN O
routinely NN NN O
employed NN NN O
to NN NN O
study NN NN O
drug NN NN O
- NN NN O
induced NN NN O
behavioral NN NN O
and NN NN O
neurophysiological NN NN O
responses NN NN O
in NN NN O
rodents NN NN O
. NN NN O
   
Apomorphine NN NN O
, NN NN O
a NN NN O
nonselective NN NN O
dopamine NN NN O
agonist NN NN O
, NN NN O
was NN NN O
selected NN NN O
due NN NN O
to NN NN O
its NN NN O
biphasic NN NN O
behavioral NN NN O
effects NN NN O
, NN NN O
its NN NN O
ability NN NN O
to NN NN O
induce NN NN O
hypothermia NN NN B-Disease
, NN NN O
and NN NN O
to NN NN O
produce NN NN O
distinct NN NN O
changes NN NN O
to NN NN O
dopamine NN NN O
turnover NN NN O
in NN NN O
the NN NN O
rodent NN NN O
brain NN NN O
. NN NN O
   
From NN NN O
such NN NN O
experiments NN NN O
there NN NN O
is NN NN O
evidence NN NN O
that NN NN O
characterization NN NN O
and NN NN O
detection NN NN O
of NN NN O
apomorphine NN NN O
- NN NN O
induced NN NN O
activity NN NN O
in NN NN O
rodents NN NN O
critically NN NN O
depends NN NN O
upon NN NN O
the NN NN O
test NN NN O
conditions NN NN O
employed NN NN O
. NN NN O
   
In NN NN O
rats NN NN O
, NN NN O
detection NN NN O
of NN NN O
apomorphine NN NN O
- NN NN O
induced NN NN O
hyperactivity NN NN B-Disease
was NN NN O
facilitated NN NN O
by NN NN O
a NN NN O
period NN NN O
of NN NN O
acclimatization NN NN O
to NN NN O
the NN NN O
test NN NN O
conditions NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
test NN NN O
conditions NN NN O
can NN NN O
impact NN NN O
upon NN NN O
other NN NN O
physiological NN NN O
responses NN NN O
to NN NN O
apomorphine NN NN O
such NN NN O
as NN NN O
drug NN NN O
- NN NN O
induced NN NN O
hypothermia NN NN B-Disease
. NN NN O
   
In NN NN O
mice NN NN O
, NN NN O
apomorphine NN NN O
produced NN NN O
qualitatively NN NN O
different NN NN O
responses NN NN O
under NN NN O
novel NN NN O
conditions NN NN O
when NN NN O
compared NN NN O
to NN NN O
those NN NN O
behaviors NN NN O
elicited NN NN O
in NN NN O
the NN NN O
home NN NN O
test NN NN O
cage NN NN O
. NN NN O
   
Drug NN NN O
- NN NN O
induced NN NN O
gross NN NN O
activity NN NN O
counts NN NN O
were NN NN O
increased NN NN O
in NN NN O
the NN NN O
novel NN NN O
exploratory NN NN O
box NN NN O
only NN NN O
, NN NN O
while NN NN O
measures NN NN O
of NN NN O
stereotypic NN NN O
behavior NN NN O
were NN NN O
similar NN NN O
in NN NN O
both NN NN O
. NN NN O
   
By NN NN O
contrast NN NN O
, NN NN O
apomorphine NN NN O
- NN NN O
induced NN NN O
locomotion NN NN O
was NN NN O
more NN NN O
prominent NN NN O
in NN NN O
the NN NN O
novel NN NN O
exploratory NN NN O
box NN NN O
. NN NN O
   
Dopamine NN NN O
turnover NN NN O
ratios NN NN O
( NN NN O
DOPAC NN NN O
: NN NN O
DA NN NN O
and NN NN O
HVA NN NN O
: NN NN O
DA NN NN O
) NN NN O
were NN NN O
found NN NN O
to NN NN O
be NN NN O
lower NN NN O
in NN NN O
those NN NN O
animals NN NN O
exposed NN NN O
to NN NN O
the NN NN O
exploratory NN NN O
box NN NN O
when NN NN O
compared NN NN O
to NN NN O
their NN NN O
home NN NN O
cage NN NN O
counterparts NN NN O
. NN NN O
   
However NN NN O
, NN NN O
apomorphine NN NN O
- NN NN O
induced NN NN O
reductions NN NN O
in NN NN O
striatal NN NN O
dopamine NN NN O
turnover NN NN O
were NN NN O
detected NN NN O
in NN NN O
both NN NN O
novel NN NN O
and NN NN O
home NN NN O
cage NN NN O
environments NN NN O
. NN NN O
   
The NN NN O
implications NN NN O
of NN NN O
these NN NN O
findings NN NN O
are NN NN O
discussed NN NN O
with NN NN O
particular NN NN O
emphasis NN NN O
upon NN NN O
conducting NN NN O
psychopharmacological NN NN O
challenge NN NN O
tests NN NN O
in NN NN O
rodents NN NN O
. NN NN O
   
Hemolysis NN NN B-Disease
of NN NN O
human NN NN O
erythrocytes NN NN O
induced NN NN O
by NN NN O
tamoxifen NN NN O
is NN NN O
related NN NN O
to NN NN O
disruption NN NN O
of NN NN O
membrane NN NN O
structure NN NN O
. NN NN O
   
Tamoxifen NN NN O
( NN NN O
TAM NN NN O
) NN NN O
, NN NN O
the NN NN O
antiestrogenic NN NN O
drug NN NN O
most NN NN O
widely NN NN O
prescribed NN NN O
in NN NN O
the NN NN O
chemotherapy NN NN O
of NN NN O
breast NN NN B-Disease
cancer NN NN I-Disease
, NN NN O
induces NN NN O
changes NN NN O
in NN NN O
normal NN NN O
discoid NN NN O
shape NN NN O
of NN NN O
erythrocytes NN NN O
and NN NN O
hemolytic NN NN B-Disease
anemia NN NN I-Disease
. NN NN O
   
This NN NN O
work NN NN O
evaluates NN NN O
the NN NN O
effects NN NN O
of NN NN O
TAM NN NN O
on NN NN O
isolated NN NN O
human NN NN O
erythrocytes NN NN O
, NN NN O
attempting NN NN O
to NN NN O
identify NN NN O
the NN NN O
underlying NN NN O
mechanisms NN NN O
on NN NN O
TAM NN NN O
- NN NN O
induced NN NN O
hemolytic NN NN B-Disease
anemia NN NN I-Disease
and NN NN O
the NN NN O
involvement NN NN O
of NN NN O
biomembranes NN NN O
in NN NN O
its NN NN O
cytostatic NN NN O
action NN NN O
mechanisms NN NN O
. NN NN O
   
TAM NN NN O
induces NN NN O
hemolysis NN NN B-Disease
of NN NN O
erythrocytes NN NN O
as NN NN O
a NN NN O
function NN NN O
of NN NN O
concentration NN NN O
. NN NN O
   
The NN NN O
extension NN NN O
of NN NN O
hemolysis NN NN B-Disease
is NN NN O
variable NN NN O
with NN NN O
erythrocyte NN NN O
samples NN NN O
, NN NN O
but NN NN O
12 NN NN O
. NN NN O
5 NN NN O
microM NN NN O
TAM NN NN O
induces NN NN O
total NN NN O
hemolysis NN NN B-Disease
of NN NN O
all NN NN O
tested NN NN O
suspensions NN NN O
. NN NN O
   
Despite NN NN O
inducing NN NN O
extensive NN NN O
erythrocyte NN NN O
lysis NN NN O
, NN NN O
TAM NN NN O
does NN NN O
not NN NN O
shift NN NN O
the NN NN O
osmotic NN NN O
fragility NN NN O
curves NN NN O
of NN NN O
erythrocytes NN NN O
. NN NN O
   
The NN NN O
hemolytic NN NN B-Disease
effect NN NN O
of NN NN O
TAM NN NN O
is NN NN O
prevented NN NN O
by NN NN O
low NN NN O
concentrations NN NN O
of NN NN O
alpha NN NN O
- NN NN O
tocopherol NN NN O
( NN NN O
alpha NN NN O
- NN NN O
T NN NN O
) NN NN O
and NN NN O
alpha NN NN O
- NN NN O
tocopherol NN NN O
acetate NN NN O
( NN NN O
alpha NN NN O
- NN NN O
TAc NN NN O
) NN NN O
( NN NN O
inactivated NN NN O
functional NN NN O
hydroxyl NN NN O
) NN NN O
indicating NN NN O
that NN NN O
TAM NN NN O
- NN NN O
induced NN NN O
hemolysis NN NN B-Disease
is NN NN O
not NN NN O
related NN NN O
to NN NN O
oxidative NN NN O
membrane NN NN O
damage NN NN O
. NN NN O
   
This NN NN O
was NN NN O
further NN NN O
evidenced NN NN O
by NN NN O
absence NN NN O
of NN NN O
oxygen NN NN O
consumption NN NN O
and NN NN O
hemoglobin NN NN O
oxidation NN NN O
both NN NN O
determined NN NN O
in NN NN O
parallel NN NN O
with NN NN O
TAM NN NN O
- NN NN O
induced NN NN O
hemolysis NN NN B-Disease
. NN NN O
   
Furthermore NN NN O
, NN NN O
it NN NN O
was NN NN O
observed NN NN O
that NN NN O
TAM NN NN O
inhibits NN NN O
the NN NN O
peroxidation NN NN O
of NN NN O
human NN NN O
erythrocytes NN NN O
induced NN NN O
by NN NN O
AAPH NN NN O
, NN NN O
thus NN NN O
ruling NN NN O
out NN NN O
TAM NN NN O
- NN NN O
induced NN NN O
cell NN NN O
oxidative NN NN O
stress NN NN O
. NN NN O
   
Hemolysis NN NN B-Disease
caused NN NN O
by NN NN O
TAM NN NN O
was NN NN O
not NN NN O
preceded NN NN O
by NN NN O
the NN NN O
leakage NN NN O
of NN NN O
K NN NN O
( NN NN O
+ NN NN O
) NN NN O
from NN NN O
the NN NN O
cells NN NN O
, NN NN O
also NN NN O
excluding NN NN O
a NN NN O
colloid NN NN O
- NN NN O
osmotic NN NN O
type NN NN O
mechanism NN NN O
of NN NN O
hemolysis NN NN B-Disease
, NN NN O
according NN NN O
to NN NN O
the NN NN O
effects NN NN O
on NN NN O
osmotic NN NN O
fragility NN NN O
curves NN NN O
. NN NN O
   
However NN NN O
, NN NN O
TAM NN NN O
induces NN NN O
release NN NN O
of NN NN O
peripheral NN NN O
proteins NN NN O
of NN NN O
membrane NN NN O
- NN NN O
cytoskeleton NN NN O
and NN NN O
cytosol NN NN O
proteins NN NN O
essentially NN NN O
bound NN NN O
to NN NN O
band NN NN O
3 NN NN O
. NN NN O
   
Either NN NN O
alpha NN NN O
- NN NN O
T NN NN O
or NN NN O
alpha NN NN O
- NN NN O
TAc NN NN O
increases NN NN O
membrane NN NN O
packing NN NN O
and NN NN O
prevents NN NN O
TAM NN NN O
partition NN NN O
into NN NN O
model NN NN O
membranes NN NN O
. NN NN O
   
These NN NN O
effects NN NN O
suggest NN NN O
that NN NN O
the NN NN O
protection NN NN O
from NN NN O
hemolysis NN NN B-Disease
by NN NN O
tocopherols NN NN O
is NN NN O
related NN NN O
to NN NN O
a NN NN O
decreased NN NN O
TAM NN NN O
incorporation NN NN O
in NN NN O
condensed NN NN O
membranes NN NN O
and NN NN O
the NN NN O
structural NN NN O
damage NN NN O
of NN NN O
the NN NN O
erythrocyte NN NN O
membrane NN NN O
is NN NN O
consequently NN NN O
avoided NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
TAM NN NN O
- NN NN O
induced NN NN O
hemolysis NN NN B-Disease
results NN NN O
from NN NN O
a NN NN O
structural NN NN O
perturbation NN NN O
of NN NN O
red NN NN O
cell NN NN O
membrane NN NN O
, NN NN O
leading NN NN O
to NN NN O
changes NN NN O
in NN NN O
the NN NN O
framework NN NN O
of NN NN O
the NN NN O
erythrocyte NN NN O
membrane NN NN O
and NN NN O
its NN NN O
cytoskeleton NN NN O
caused NN NN O
by NN NN O
its NN NN O
high NN NN O
partition NN NN O
in NN NN O
the NN NN O
membrane NN NN O
. NN NN O
   
These NN NN O
defects NN NN O
explain NN NN O
the NN NN O
abnormal NN NN O
erythrocyte NN NN O
shape NN NN O
and NN NN O
decreased NN NN O
mechanical NN NN O
stability NN NN O
promoted NN NN O
by NN NN O
TAM NN NN O
, NN NN O
resulting NN NN O
in NN NN O
hemolytic NN NN B-Disease
anemia NN NN I-Disease
. NN NN O
   
Additionally NN NN O
, NN NN O
since NN NN O
membrane NN NN O
leakage NN NN O
is NN NN O
a NN NN O
final NN NN O
stage NN NN O
of NN NN O
cytotoxicity NN NN O
, NN NN O
the NN NN O
disruption NN NN O
of NN NN O
the NN NN O
structural NN NN O
characteristics NN NN O
of NN NN O
biomembranes NN NN O
by NN NN O
TAM NN NN O
may NN NN O
contribute NN NN O
to NN NN O
the NN NN O
multiple NN NN O
mechanisms NN NN O
of NN NN O
its NN NN O
anticancer NN NN O
action NN NN O
. NN NN O
   
Changes NN NN O
of NN NN O
sodium NN NN O
and NN NN O
ATP NN NN O
affinities NN NN O
of NN NN O
the NN NN O
cardiac NN NN O
( NN NN O
Na NN NN O
, NN NN O
K NN NN O
) NN NN O
- NN NN O
ATPase NN NN O
during NN NN O
and NN NN O
after NN NN O
nitric NN NN O
oxide NN NN O
deficient NN NN O
hypertension NN NN B-Disease
. NN NN O
   
In NN NN O
the NN NN O
cardiovascular NN NN O
system NN NN O
, NN NN O
NO NN NN O
is NN NN O
involved NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
a NN NN O
variety NN NN O
of NN NN O
functions NN NN O
. NN NN O
   
Inhibition NN NN O
of NN NN O
NO NN NN O
synthesis NN NN O
induces NN NN O
sustained NN NN O
hypertension NN NN B-Disease
. NN NN O
   
In NN NN O
several NN NN O
models NN NN O
of NN NN O
hypertension NN NN B-Disease
, NN NN O
elevation NN NN O
of NN NN O
intracellular NN NN O
sodium NN NN O
level NN NN O
was NN NN O
documented NN NN O
in NN NN O
cardiac NN NN O
tissue NN NN O
. NN NN O
   
To NN NN O
assess NN NN O
the NN NN O
molecular NN NN O
basis NN NN O
of NN NN O
disturbances NN NN O
in NN NN O
transmembraneous NN NN O
transport NN NN O
of NN NN O
Na NN NN O
+ NN NN O
, NN NN O
we NN NN O
studied NN NN O
the NN NN O
response NN NN O
of NN NN O
cardiac NN NN O
( NN NN O
Na NN NN O
, NN NN O
K NN NN O
) NN NN O
- NN NN O
ATPase NN NN O
to NN NN O
NO NN NN O
- NN NN O
deficient NN NN O
hypertension NN NN B-Disease
induced NN NN O
in NN NN O
rats NN NN O
by NN NN O
NO NN NN O
- NN NN O
synthase NN NN O
inhibition NN NN O
with NN NN O
40 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
N NN NN O
( NN NN O
G NN NN O
) NN NN O
- NN NN O
nitro NN NN O
- NN NN O
L NN NN O
- NN NN O
arginine NN NN O
methyl NN NN O
ester NN NN O
( NN NN O
L NN NN O
- NN NN O
NAME NN NN O
) NN NN O
for NN NN O
4 NN NN O
four NN NN O
weeks NN NN O
. NN NN O
   
After NN NN O
4 NN NN O
- NN NN O
week NN NN O
administration NN NN O
of NN NN O
L NN NN O
- NN NN O
NAME NN NN O
, NN NN O
the NN NN O
systolic NN NN O
blood NN NN O
pressure NN NN O
( NN NN O
SBP NN NN O
) NN NN O
increased NN NN O
by NN NN O
36 NN NN O
% NN NN O
. NN NN O
   
Two NN NN O
weeks NN NN O
after NN NN O
terminating NN NN O
the NN NN O
treatment NN NN O
, NN NN O
the NN NN O
SBP NN NN O
recovered NN NN O
to NN NN O
control NN NN O
value NN NN O
. NN NN O
   
When NN NN O
activating NN NN O
the NN NN O
( NN NN O
Na NN NN O
, NN NN O
K NN NN O
) NN NN O
- NN NN O
ATPase NN NN O
with NN NN O
its NN NN O
substrate NN NN O
ATP NN NN O
, NN NN O
no NN NN O
changes NN NN O
in NN NN O
Km NN NN O
and NN NN O
Vmax NN NN O
values NN NN O
were NN NN O
observed NN NN O
in NN NN O
NO NN NN O
- NN NN O
deficient NN NN O
rats NN NN O
. NN NN O
   
During NN NN O
activation NN NN O
with NN NN O
Na NN NN O
+ NN NN O
, NN NN O
the NN NN O
Vmax NN NN O
remained NN NN O
unchanged NN NN O
, NN NN O
however NN NN O
the NN NN O
K NN NN O
( NN NN O
Na NN NN O
) NN NN O
increased NN NN O
by NN NN O
50 NN NN O
% NN NN O
, NN NN O
indicating NN NN O
a NN NN O
profound NN NN O
decrease NN NN O
in NN NN O
the NN NN O
affinity NN NN O
of NN NN O
the NN NN O
Na NN NN O
+ NN NN O
- NN NN O
binding NN NN O
site NN NN O
in NN NN O
NO NN NN O
- NN NN O
deficient NN NN O
rats NN NN O
. NN NN O
   
After NN NN O
recovery NN NN O
from NN NN O
hypertension NN NN B-Disease
, NN NN O
the NN NN O
activity NN NN O
of NN NN O
( NN NN O
Na NN NN O
, NN NN O
K NN NN O
) NN NN O
- NN NN O
ATPase NN NN O
increased NN NN O
, NN NN O
due NN NN O
to NN NN O
higher NN NN O
affinity NN NN O
of NN NN O
the NN NN O
ATP NN NN O
- NN NN O
binding NN NN O
site NN NN O
, NN NN O
as NN NN O
revealed NN NN O
from NN NN O
the NN NN O
lowered NN NN O
Km NN NN O
value NN NN O
for NN NN O
ATP NN NN O
. NN NN O
   
The NN NN O
K NN NN O
( NN NN O
Na NN NN O
) NN NN O
value NN NN O
for NN NN O
Na NN NN O
+ NN NN O
returned NN NN O
to NN NN O
control NN NN O
value NN NN O
. NN NN O
   
Inhibition NN NN O
of NN NN O
NO NN NN O
- NN NN O
synthase NN NN O
induced NN NN O
a NN NN O
reversible NN NN O
hypertension NN NN B-Disease
accompanied NN NN O
by NN NN O
depressed NN NN B-Disease
Na NN NN O
+ NN NN O
- NN NN O
extrusion NN NN O
from NN NN O
cardiac NN NN O
cells NN NN O
as NN NN O
a NN NN O
consequence NN NN O
of NN NN O
deteriorated NN NN O
Na NN NN O
+ NN NN O
- NN NN O
binding NN NN O
properties NN NN O
of NN NN O
the NN NN O
( NN NN O
Na NN NN O
, NN NN O
K NN NN O
) NN NN O
- NN NN O
ATPase NN NN O
. NN NN O
   
After NN NN O
recovery NN NN O
of NN NN O
blood NN NN O
pressure NN NN O
to NN NN O
control NN NN O
values NN NN O
, NN NN O
the NN NN O
extrusion NN NN O
of NN NN O
Na NN NN O
+ NN NN O
from NN NN O
cardiac NN NN O
cells NN NN O
was NN NN O
normalized NN NN O
, NN NN O
as NN NN O
revealed NN NN O
by NN NN O
restoration NN NN O
of NN NN O
the NN NN O
( NN NN O
Na NN NN O
, NN NN O
K NN NN O
) NN NN O
- NN NN O
ATPase NN NN O
activity NN NN O
. NN NN O
   
Effects NN NN O
of NN NN O
long NN NN O
- NN NN O
term NN NN O
pretreatment NN NN O
with NN NN O
isoproterenol NN NN O
on NN NN O
bromocriptine NN NN O
- NN NN O
induced NN NN O
tachycardia NN NN B-Disease
in NN NN O
conscious NN NN O
rats NN NN O
. NN NN O
   
It NN NN O
has NN NN O
been NN NN O
shown NN NN O
that NN NN O
bromocriptine NN NN O
- NN NN O
induced NN NN O
tachycardia NN NN B-Disease
, NN NN O
which NN NN O
persisted NN NN O
after NN NN O
adrenalectomy NN NN O
, NN NN O
is NN NN O
( NN NN O
i NN NN O
) NN NN O
mediated NN NN O
by NN NN O
central NN NN O
dopamine NN NN O
D2 NN NN O
receptor NN NN O
activation NN NN O
and NN NN O
( NN NN O
ii NN NN O
) NN NN O
reduced NN NN O
by NN NN O
5 NN NN O
- NN NN O
day NN NN O
isoproterenol NN NN O
pretreatment NN NN O
, NN NN O
supporting NN NN O
therefore NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
this NN NN O
effect NN NN O
is NN NN O
dependent NN NN O
on NN NN O
sympathetic NN NN O
outflow NN NN O
to NN NN O
the NN NN O
heart NN NN O
. NN NN O
   
This NN NN O
study NN NN O
was NN NN O
conducted NN NN O
to NN NN O
examine NN NN O
whether NN NN O
prolonged NN NN O
pretreatment NN NN O
with NN NN O
isoproterenol NN NN O
could NN NN O
abolish NN NN O
bromocriptine NN NN O
- NN NN O
induced NN NN O
tachycardia NN NN B-Disease
in NN NN O
conscious NN NN O
rats NN NN O
. NN NN O
   
Isoproterenol NN NN O
pretreatment NN NN O
for NN NN O
15 NN NN O
days NN NN O
caused NN NN O
cardiac NN NN B-Disease
hypertrophy NN NN I-Disease
without NN NN O
affecting NN NN O
baseline NN NN O
blood NN NN O
pressure NN NN O
and NN NN O
heart NN NN O
rate NN NN O
. NN NN O
   
In NN NN O
control NN NN O
rats NN NN O
, NN NN O
intravenous NN NN O
bromocriptine NN NN O
( NN NN O
150 NN NN O
microg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
induced NN NN O
significant NN NN O
hypotension NN NN B-Disease
and NN NN O
tachycardia NN NN B-Disease
. NN NN O
   
Bromocriptine NN NN O
- NN NN O
induced NN NN O
hypotension NN NN B-Disease
was NN NN O
unaffected NN NN O
by NN NN O
isoproterenol NN NN O
pretreatment NN NN O
, NN NN O
while NN NN O
tachycardia NN NN B-Disease
was NN NN O
reversed NN NN O
to NN NN O
significant NN NN O
bradycardia NN NN B-Disease
, NN NN O
an NN NN O
effect NN NN O
that NN NN O
was NN NN O
partly NN NN O
reduced NN NN O
by NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
domperidone NN NN O
( NN NN O
0 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
. NN NN O
   
Neither NN NN O
cardiac NN NN O
vagal NN NN O
nor NN NN O
sympathetic NN NN O
tone NN NN O
was NN NN O
altered NN NN O
by NN NN O
isoproterenol NN NN O
pretreatment NN NN O
. NN NN O
   
In NN NN O
isolated NN NN O
perfused NN NN O
heart NN NN O
preparations NN NN O
from NN NN O
isoproterenol NN NN O
- NN NN O
pretreated NN NN O
rats NN NN O
, NN NN O
the NN NN O
isoproterenol NN NN O
- NN NN O
induced NN NN O
maximal NN NN O
increase NN NN O
in NN NN O
left NN NN O
ventricular NN NN O
systolic NN NN O
pressure NN NN O
was NN NN O
significantly NN NN O
reduced NN NN O
, NN NN O
compared NN NN O
with NN NN O
saline NN NN O
- NN NN O
pretreated NN NN O
rats NN NN O
( NN NN O
the NN NN O
EC50 NN NN O
of NN NN O
the NN NN O
isoproterenol NN NN O
- NN NN O
induced NN NN O
increase NN NN O
in NN NN O
left NN NN O
ventricular NN NN O
systolic NN NN O
pressure NN NN O
was NN NN O
enhanced NN NN O
approximately NN NN O
22 NN NN O
- NN NN O
fold NN NN O
) NN NN O
. NN NN O
   
These NN NN O
results NN NN O
show NN NN O
that NN NN O
15 NN NN O
- NN NN O
day NN NN O
isoproterenol NN NN O
pretreatment NN NN O
not NN NN O
only NN NN O
abolished NN NN O
but NN NN O
reversed NN NN O
bromocriptine NN NN O
- NN NN O
induced NN NN O
tachycardia NN NN B-Disease
to NN NN O
bradycardia NN NN B-Disease
, NN NN O
an NN NN O
effect NN NN O
that NN NN O
is NN NN O
mainly NN NN O
related NN NN O
to NN NN O
further NN NN O
cardiac NN NN O
beta NN NN O
- NN NN O
adrenoceptor NN NN O
desensitization NN NN O
rather NN NN O
than NN NN O
to NN NN O
impairment NN NN O
of NN NN O
autonomic NN NN O
regulation NN NN O
of NN NN O
the NN NN O
heart NN NN O
. NN NN O
   
They NN NN O
suggest NN NN O
that NN NN O
, NN NN O
in NN NN O
normal NN NN O
conscious NN NN O
rats NN NN O
, NN NN O
the NN NN O
central NN NN O
tachycardia NN NN B-Disease
of NN NN O
bromocriptine NN NN O
appears NN NN O
to NN NN O
predominate NN NN O
and NN NN O
to NN NN O
mask NN NN O
the NN NN O
bradycardia NN NN B-Disease
of NN NN O
this NN NN O
agonist NN NN O
at NN NN O
peripheral NN NN O
dopamine NN NN O
D2 NN NN O
receptors NN NN O
. NN NN O
   
A NN NN O
developmental NN NN O
analysis NN NN O
of NN NN O
clonidine NN NN O
' NN NN O
s NN NN O
effects NN NN O
on NN NN O
cardiac NN NN O
rate NN NN O
and NN NN O
ultrasound NN NN O
production NN NN O
in NN NN O
infant NN NN O
rats NN NN O
. NN NN O
   
Under NN NN O
controlled NN NN O
conditions NN NN O
, NN NN O
infant NN NN O
rats NN NN O
emit NN NN O
ultrasonic NN NN O
vocalizations NN NN O
during NN NN O
extreme NN NN O
cold NN NN O
exposure NN NN O
and NN NN O
after NN NN O
administration NN NN O
of NN NN O
the NN NN O
alpha NN NN O
( NN NN O
2 NN NN O
) NN NN O
adrenoceptor NN NN O
agonist NN NN O
, NN NN O
clonidine NN NN O
. NN NN O
   
Previous NN NN O
investigations NN NN O
have NN NN O
determined NN NN O
that NN NN O
, NN NN O
in NN NN O
response NN NN O
to NN NN O
clonidine NN NN O
, NN NN O
ultrasound NN NN O
production NN NN O
increases NN NN O
through NN NN O
the NN NN O
2nd NN NN O
- NN NN O
week NN NN O
postpartum NN NN O
and NN NN O
decreases NN NN O
thereafter NN NN O
. NN NN O
   
Given NN NN O
that NN NN O
sympathetic NN NN O
neural NN NN O
dominance NN NN O
exhibits NN NN O
a NN NN O
similar NN NN O
developmental NN NN O
pattern NN NN O
, NN NN O
and NN NN O
given NN NN O
that NN NN O
clonidine NN NN O
induces NN NN O
sympathetic NN NN O
withdrawal NN NN O
and NN NN O
bradycardia NN NN B-Disease
, NN NN O
we NN NN O
hypothesized NN NN O
that NN NN O
clonidine NN NN O
' NN NN O
s NN NN O
developmental NN NN O
effects NN NN O
on NN NN O
cardiac NN NN O
rate NN NN O
and NN NN O
ultrasound NN NN O
production NN NN O
would NN NN O
mirror NN NN O
each NN NN O
other NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
in NN NN O
the NN NN O
present NN NN O
experiment NN NN O
, NN NN O
the NN NN O
effects NN NN O
of NN NN O
clonidine NN NN O
administration NN NN O
( NN NN O
0 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
on NN NN O
cardiac NN NN O
rate NN NN O
and NN NN O
ultrasound NN NN O
production NN NN O
were NN NN O
examined NN NN O
in NN NN O
2 NN NN O
- NN NN O
, NN NN O
8 NN NN O
- NN NN O
, NN NN O
15 NN NN O
- NN NN O
, NN NN O
and NN NN O
20 NN NN O
- NN NN O
day NN NN O
- NN NN O
old NN NN O
rats NN NN O
. NN NN O
   
Age NN NN O
- NN NN O
related NN NN O
changes NN NN O
in NN NN O
ultrasound NN NN O
production NN NN O
corresponded NN NN O
with NN NN O
changes NN NN O
in NN NN O
cardiovascular NN NN O
variables NN NN O
, NN NN O
including NN NN O
baseline NN NN O
cardiac NN NN O
rate NN NN O
and NN NN O
clonidine NN NN O
- NN NN O
induced NN NN O
bradycardia NN NN B-Disease
. NN NN O
   
This NN NN O
experiment NN NN O
is NN NN O
discussed NN NN O
with NN NN O
regard NN NN O
to NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
ultrasound NN NN O
production NN NN O
is NN NN O
the NN NN O
acoustic NN NN O
by NN NN O
- NN NN O
product NN NN O
of NN NN O
a NN NN O
physiological NN NN O
maneuver NN NN O
that NN NN O
compensates NN NN O
for NN NN O
clonidine NN NN O
' NN NN O
s NN NN O
detrimental NN NN O
effects NN NN O
on NN NN O
cardiovascular NN NN O
function NN NN O
. NN NN O
   
Recurrent NN NN O
use NN NN O
of NN NN O
newer NN NN O
oral NN NN O
contraceptives NN NN O
and NN NN O
the NN NN O
risk NN NN O
of NN NN O
venous NN NN B-Disease
thromboembolism NN NN I-Disease
. NN NN O
   
The NN NN O
epidemiological NN NN O
studies NN NN O
that NN NN O
assessed NN NN O
the NN NN O
risk NN NN O
of NN NN O
venous NN NN B-Disease
thromboembolism NN NN I-Disease
( NN NN O
VTE NN NN B-Disease
) NN NN O
associated NN NN O
with NN NN O
newer NN NN O
oral NN NN O
contraceptives NN NN O
( NN NN O
OC NN NN O
) NN NN O
did NN NN O
not NN NN O
distinguish NN NN O
between NN NN O
patterns NN NN O
of NN NN O
OC NN NN O
use NN NN O
, NN NN O
namely NN NN O
first NN NN O
- NN NN O
time NN NN O
users NN NN O
, NN NN O
repeaters NN NN O
and NN NN O
switchers NN NN O
. NN NN O
   
Data NN NN O
from NN NN O
a NN NN O
Transnational NN NN O
case NN NN O
- NN NN O
control NN NN O
study NN NN O
were NN NN O
used NN NN O
to NN NN O
assess NN NN O
the NN NN O
risk NN NN O
of NN NN O
VTE NN NN B-Disease
for NN NN O
the NN NN O
latter NN NN O
patterns NN NN O
of NN NN O
use NN NN O
, NN NN O
while NN NN O
accounting NN NN O
for NN NN O
duration NN NN O
of NN NN O
use NN NN O
. NN NN O
   
Over NN NN O
the NN NN O
period NN NN O
1993 NN NN O
- NN NN O
1996 NN NN O
, NN NN O
551 NN NN O
cases NN NN O
of NN NN O
VTE NN NN B-Disease
were NN NN O
identified NN NN O
in NN NN O
Germany NN NN O
and NN NN O
the NN NN O
UK NN NN O
along NN NN O
with NN NN O
2066 NN NN O
controls NN NN O
. NN NN O
   
Totals NN NN O
of NN NN O
128 NN NN O
cases NN NN O
and NN NN O
650 NN NN O
controls NN NN O
were NN NN O
analysed NN NN O
for NN NN O
repeat NN NN O
use NN NN O
and NN NN O
135 NN NN O
cases NN NN O
and NN NN O
622 NN NN O
controls NN NN O
for NN NN O
switching NN NN O
patterns NN NN O
. NN NN O
   
The NN NN O
adjusted NN NN O
rate NN NN O
ratio NN NN O
of NN NN O
VTE NN NN B-Disease
for NN NN O
repeat NN NN O
users NN NN O
of NN NN O
third NN NN O
generation NN NN O
OC NN NN O
was NN NN O
0 NN NN O
. NN NN O
6 NN NN O
( NN NN O
95 NN NN O
% NN NN O
CI NN NN O
: NN NN O
0 NN NN O
. NN NN O
3 NN NN O
- NN NN O
1 NN NN O
. NN NN O
2 NN NN O
) NN NN O
relative NN NN O
to NN NN O
repeat NN NN O
users NN NN O
of NN NN O
second NN NN O
generation NN NN O
pills NN NN O
, NN NN O
whereas NN NN O
it NN NN O
was NN NN O
1 NN NN O
. NN NN O
3 NN NN O
( NN NN O
95 NN NN O
% NN NN O
CI NN NN O
: NN NN O
0 NN NN O
. NN NN O
7 NN NN O
- NN NN O
2 NN NN O
. NN NN O
4 NN NN O
) NN NN O
for NN NN O
switchers NN NN O
from NN NN O
second NN NN O
to NN NN O
third NN NN O
generation NN NN O
pills NN NN O
relative NN NN O
to NN NN O
switchers NN NN O
from NN NN O
third NN NN O
to NN NN O
second NN NN O
generation NN NN O
pills NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
second NN NN O
and NN NN O
third NN NN O
generation NN NN O
agents NN NN O
are NN NN O
associated NN NN O
with NN NN O
equivalent NN NN O
risks NN NN O
of NN NN O
VTE NN NN B-Disease
when NN NN O
the NN NN O
same NN NN O
agent NN NN O
is NN NN O
used NN NN O
repeatedly NN NN O
after NN NN O
interruption NN NN O
periods NN NN O
or NN NN O
when NN NN O
users NN NN O
are NN NN O
switched NN NN O
between NN NN O
the NN NN O
two NN NN O
generations NN NN O
of NN NN O
pills NN NN O
. NN NN O
   
These NN NN O
analyses NN NN O
suggest NN NN O
that NN NN O
the NN NN O
higher NN NN O
risk NN NN O
observed NN NN O
for NN NN O
the NN NN O
newer NN NN O
OC NN NN O
in NN NN O
other NN NN O
studies NN NN O
may NN NN O
be NN NN O
the NN NN O
result NN NN O
of NN NN O
inadequate NN NN O
comparisons NN NN O
of NN NN O
pill NN NN O
users NN NN O
with NN NN O
different NN NN O
patterns NN NN O
of NN NN O
pill NN NN O
use NN NN O
. NN NN O
   
Differential NN NN O
effects NN NN O
of NN NN O
systemically NN NN O
administered NN NN O
ketamine NN NN O
and NN NN O
lidocaine NN NN O
on NN NN O
dynamic NN NN O
and NN NN O
static NN NN O
hyperalgesia NN NN B-Disease
induced NN NN O
by NN NN O
intradermal NN NN O
capsaicin NN NN O
in NN NN O
humans NN NN O
. NN NN O
   
We NN NN O
have NN NN O
examined NN NN O
the NN NN O
effect NN NN O
of NN NN O
systemic NN NN O
administration NN NN O
of NN NN O
ketamine NN NN O
and NN NN O
lidocaine NN NN O
on NN NN O
brush NN NN O
- NN NN O
evoked NN NN O
( NN NN O
dynamic NN NN O
) NN NN O
pain NN NN B-Disease
and NN NN O
punctate NN NN O
- NN NN O
evoked NN NN O
( NN NN O
static NN NN O
) NN NN O
hyperalgesia NN NN B-Disease
induced NN NN O
by NN NN O
capsaicin NN NN O
. NN NN O
   
In NN NN O
a NN NN O
randomized NN NN O
, NN NN O
double NN NN O
- NN NN O
blind NN NN O
, NN NN O
placebo NN NN O
- NN NN O
controlled NN NN O
, NN NN O
crossover NN NN O
study NN NN O
, NN NN O
we NN NN O
studied NN NN O
12 NN NN O
volunteers NN NN O
in NN NN O
three NN NN O
experiments NN NN O
. NN NN O
   
Capsaicin NN NN O
100 NN NN O
micrograms NN NN O
was NN NN O
injected NN NN O
intradermally NN NN O
on NN NN O
the NN NN O
volar NN NN O
forearm NN NN O
followed NN NN O
by NN NN O
an NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
infusion NN NN O
of NN NN O
ketamine NN NN O
( NN NN O
bolus NN NN O
0 NN NN O
. NN NN O
1 NN NN O
mg NN NN O
kg NN NN O
- NN NN O
1 NN NN O
over NN NN O
10 NN NN O
min NN NN O
followed NN NN O
by NN NN O
infusion NN NN O
of NN NN O
7 NN NN O
micrograms NN NN O
kg NN NN O
- NN NN O
1 NN NN O
min NN NN O
- NN NN O
1 NN NN O
) NN NN O
, NN NN O
lidocaine NN NN O
5 NN NN O
mg NN NN O
kg NN NN O
- NN NN O
1 NN NN O
or NN NN O
saline NN NN O
for NN NN O
50 NN NN O
min NN NN O
. NN NN O
   
Infusion NN NN O
started NN NN O
15 NN NN O
min NN NN O
after NN NN O
injection NN NN O
of NN NN O
capsaicin NN NN O
. NN NN O
   
The NN NN O
following NN NN O
were NN NN O
measured NN NN O
: NN NN O
spontaneous NN NN O
pain NN NN B-Disease
, NN NN O
pain NN NN B-Disease
evoked NN NN O
by NN NN O
punctate NN NN O
and NN NN O
brush NN NN O
stimuli NN NN O
( NN NN O
VAS NN NN O
) NN NN O
, NN NN O
and NN NN O
areas NN NN O
of NN NN O
brush NN NN O
- NN NN O
evoked NN NN O
and NN NN O
punctate NN NN O
- NN NN O
evoked NN NN O
hyperalgesia NN NN B-Disease
. NN NN O
   
Ketamine NN NN O
reduced NN NN O
both NN NN O
the NN NN O
area NN NN O
of NN NN O
brush NN NN O
- NN NN O
evoked NN NN O
and NN NN O
punctate NN NN O
- NN NN O
evoked NN NN O
hyperalgesia NN NN B-Disease
significantly NN NN O
and NN NN O
it NN NN O
tended NN NN O
to NN NN O
reduce NN NN O
brush NN NN O
- NN NN O
evoked NN NN O
pain NN NN B-Disease
. NN NN O
   
Lidocaine NN NN O
reduced NN NN O
the NN NN O
area NN NN O
of NN NN O
punctate NN NN O
- NN NN O
evoked NN NN O
hyperalgesia NN NN B-Disease
significantly NN NN O
. NN NN O
   
It NN NN O
tended NN NN O
to NN NN O
reduce NN NN O
VAS NN NN O
scores NN NN O
of NN NN O
spontaneous NN NN O
pain NN NN B-Disease
but NN NN O
had NN NN O
no NN NN O
effect NN NN O
on NN NN O
evoked NN NN O
pain NN NN B-Disease
. NN NN O
   
The NN NN O
differential NN NN O
effects NN NN O
of NN NN O
ketamine NN NN O
and NN NN O
lidocaine NN NN O
on NN NN O
static NN NN O
and NN NN O
dynamic NN NN O
hyperalgesia NN NN B-Disease
suggest NN NN O
that NN NN O
the NN NN O
two NN NN O
types NN NN O
of NN NN O
hyperalgesia NN NN B-Disease
are NN NN O
mediated NN NN O
by NN NN O
separate NN NN O
mechanisms NN NN O
and NN NN O
have NN NN O
a NN NN O
distinct NN NN O
pharmacology NN NN O
. NN NN O
   
Development NN NN O
of NN NN O
apomorphine NN NN O
- NN NN O
induced NN NN O
aggressive NN NN B-Disease
behavior NN NN I-Disease
: NN NN O
comparison NN NN O
of NN NN O
adult NN NN O
male NN NN O
and NN NN O
female NN NN O
Wistar NN NN O
rats NN NN O
. NN NN O
   
The NN NN O
development NN NN O
of NN NN O
apomorphine NN NN O
- NN NN O
induced NN NN O
( NN NN O
1 NN NN O
. NN NN O
0 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
s NN NN O
. NN NN O
c NN NN O
. NN NN O
once NN NN O
daily NN NN O
) NN NN O
aggressive NN NN B-Disease
behavior NN NN I-Disease
of NN NN O
adult NN NN O
male NN NN O
and NN NN O
female NN NN O
Wistar NN NN O
rats NN NN O
obtained NN NN O
from NN NN O
the NN NN O
same NN NN O
breeder NN NN O
was NN NN O
studied NN NN O
in NN NN O
two NN NN O
consecutive NN NN O
sets NN NN O
. NN NN O
   
In NN NN O
male NN NN O
animals NN NN O
, NN NN O
repeated NN NN O
apomorphine NN NN O
treatment NN NN O
induced NN NN O
a NN NN O
gradual NN NN O
development NN NN O
of NN NN O
aggressive NN NN B-Disease
behavior NN NN I-Disease
as NN NN O
evidenced NN NN O
by NN NN O
the NN NN O
increased NN NN O
intensity NN NN O
of NN NN O
aggressiveness NN NN B-Disease
and NN NN O
shortened NN NN O
latency NN NN O
before NN NN O
the NN NN O
first NN NN O
attack NN NN O
toward NN NN O
the NN NN O
opponent NN NN O
. NN NN O
   
In NN NN O
female NN NN O
rats NN NN O
, NN NN O
only NN NN O
a NN NN O
weak NN NN O
tendency NN NN O
toward NN NN O
aggressiveness NN NN B-Disease
was NN NN O
found NN NN O
. NN NN O
   
In NN NN O
conclusion NN NN O
, NN NN O
the NN NN O
present NN NN O
study NN NN O
demonstrates NN NN O
gender NN NN O
differences NN NN O
in NN NN O
the NN NN O
development NN NN O
of NN NN O
the NN NN O
apomorphine NN NN O
- NN NN O
induced NN NN O
aggressive NN NN B-Disease
behavior NN NN I-Disease
and NN NN O
indicates NN NN O
that NN NN O
the NN NN O
female NN NN O
rats NN NN O
do NN NN O
not NN NN O
fill NN NN O
the NN NN O
validation NN NN O
criteria NN NN O
for NN NN O
use NN NN O
in NN NN O
this NN NN O
method NN NN O
. NN NN O
   
Intracranial NN NN B-Disease
aneurysms NN NN I-Disease
and NN NN O
cocaine NN NN B-Disease
abuse NN NN I-Disease
: NN NN O
analysis NN NN O
of NN NN O
prognostic NN NN O
indicators NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
The NN NN O
outcome NN NN O
of NN NN O
subarachnoid NN NN B-Disease
hemorrhage NN NN I-Disease
associated NN NN O
with NN NN O
cocaine NN NN B-Disease
abuse NN NN I-Disease
is NN NN O
reportedly NN NN O
poor NN NN O
. NN NN O
   
However NN NN O
, NN NN O
no NN NN O
study NN NN O
in NN NN O
the NN NN O
literature NN NN O
has NN NN O
reported NN NN O
the NN NN O
use NN NN O
of NN NN O
a NN NN O
statistical NN NN O
model NN NN O
to NN NN O
analyze NN NN O
the NN NN O
variables NN NN O
that NN NN O
influence NN NN O
outcome NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
A NN NN O
review NN NN O
of NN NN O
admissions NN NN O
during NN NN O
a NN NN O
6 NN NN O
- NN NN O
year NN NN O
period NN NN O
revealed NN NN O
14 NN NN O
patients NN NN O
with NN NN O
cocaine NN NN O
- NN NN O
related NN NN O
aneurysms NN NN B-Disease
. NN NN O
   
This NN NN O
group NN NN O
was NN NN O
compared NN NN O
with NN NN O
a NN NN O
control NN NN O
group NN NN O
of NN NN O
135 NN NN O
patients NN NN O
with NN NN O
ruptured NN NN B-Disease
aneurysms NN NN I-Disease
and NN NN O
no NN NN O
history NN NN O
of NN NN O
cocaine NN NN B-Disease
abuse NN NN I-Disease
. NN NN O
   
Age NN NN O
at NN NN O
presentation NN NN O
, NN NN O
time NN NN O
of NN NN O
ictus NN NN O
after NN NN O
intoxication NN NN O
, NN NN O
Hunt NN NN O
and NN NN O
Hess NN NN O
grade NN NN O
of NN NN O
subarachnoid NN NN B-Disease
hemorrhage NN NN I-Disease
, NN NN O
size NN NN O
of NN NN O
the NN NN O
aneurysm NN NN B-Disease
, NN NN O
location NN NN O
of NN NN O
the NN NN O
aneurysm NN NN B-Disease
, NN NN O
and NN NN O
the NN NN O
Glasgow NN NN O
Outcome NN NN O
Scale NN NN O
score NN NN O
were NN NN O
assessed NN NN O
and NN NN O
compared NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
The NN NN O
patients NN NN O
in NN NN O
the NN NN O
study NN NN O
group NN NN O
were NN NN O
significantly NN NN O
younger NN NN O
than NN NN O
the NN NN O
patients NN NN O
in NN NN O
the NN NN O
control NN NN O
group NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
002 NN NN O
) NN NN O
. NN NN O
   
In NN NN O
patients NN NN O
in NN NN O
the NN NN O
study NN NN O
group NN NN O
, NN NN O
all NN NN O
aneurysms NN NN B-Disease
were NN NN O
located NN NN O
in NN NN O
the NN NN O
anterior NN NN O
circulation NN NN O
. NN NN O
   
The NN NN O
majority NN NN O
of NN NN O
these NN NN O
aneurysms NN NN B-Disease
were NN NN O
smaller NN NN O
than NN NN O
those NN NN O
of NN NN O
the NN NN O
control NN NN O
group NN NN O
( NN NN O
8 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
6 NN NN O
. NN NN O
08 NN NN O
mm NN NN O
versus NN NN O
11 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
5 NN NN O
. NN NN O
4 NN NN O
mm NN NN O
; NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
differences NN NN O
in NN NN O
mortality NN NN O
and NN NN O
morbidity NN NN O
between NN NN O
the NN NN O
two NN NN O
groups NN NN O
were NN NN O
not NN NN O
significant NN NN O
. NN NN O
   
Hunt NN NN O
and NN NN O
Hess NN NN O
grade NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
005 NN NN O
) NN NN O
and NN NN O
age NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
007 NN NN O
) NN NN O
were NN NN O
significant NN NN O
predictors NN NN O
of NN NN O
outcome NN NN O
for NN NN O
the NN NN O
patients NN NN O
with NN NN O
cocaine NN NN O
- NN NN O
related NN NN O
aneurysms NN NN B-Disease
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Cocaine NN NN O
use NN NN O
predisposed NN NN O
aneurysmal NN NN B-Disease
rupture NN NN I-Disease
at NN NN O
a NN NN O
significantly NN NN O
earlier NN NN O
age NN NN O
and NN NN O
in NN NN O
much NN NN O
smaller NN NN O
aneurysms NN NN B-Disease
. NN NN O
   
Contrary NN NN O
to NN NN O
the NN NN O
published NN NN O
literature NN NN O
, NN NN O
this NN NN O
group NN NN O
did NN NN O
reasonably NN NN O
well NN NN O
with NN NN O
aggressive NN NN O
management NN NN O
. NN NN O
   
Effect NN NN O
of NN NN O
intravenous NN NN O
nimodipine NN NN O
on NN NN O
blood NN NN O
pressure NN NN O
and NN NN O
outcome NN NN O
after NN NN O
acute NN NN B-Disease
stroke NN NN I-Disease
. NN NN O
   
BACKGROUND NN NN O
AND NN NN O
PURPOSE NN NN O
: NN NN O
The NN NN O
Intravenous NN NN O
Nimodipine NN NN O
West NN NN O
European NN NN O
Stroke NN NN B-Disease
Trial NN NN O
( NN NN O
INWEST NN NN O
) NN NN O
found NN NN O
a NN NN O
correlation NN NN O
between NN NN O
nimodipine NN NN O
- NN NN O
induced NN NN O
reduction NN NN B-Disease
in NN NN I-Disease
blood NN NN I-Disease
pressure NN NN I-Disease
( NN NN O
BP NN NN O
) NN NN O
and NN NN O
an NN NN O
unfavorable NN NN O
outcome NN NN O
in NN NN O
acute NN NN B-Disease
stroke NN NN I-Disease
. NN NN O
   
We NN NN O
sought NN NN O
to NN NN O
confirm NN NN O
this NN NN O
correlation NN NN O
with NN NN O
and NN NN O
without NN NN O
adjustment NN NN O
for NN NN O
prognostic NN NN O
variables NN NN O
and NN NN O
to NN NN O
investigate NN NN O
outcome NN NN O
in NN NN O
subgroups NN NN O
with NN NN O
increasing NN NN O
levels NN NN O
of NN NN O
BP NN NN B-Disease
reduction NN NN I-Disease
. NN NN O
   
METHODS NN NN O
: NN NN O
Patients NN NN O
with NN NN O
a NN NN O
clinical NN NN O
diagnosis NN NN O
of NN NN O
ischemic NN NN B-Disease
stroke NN NN I-Disease
( NN NN O
within NN NN O
24 NN NN O
hours NN NN O
) NN NN O
were NN NN O
consecutively NN NN O
allocated NN NN O
to NN NN O
receive NN NN O
placebo NN NN O
( NN NN O
n NN NN O
= NN NN O
100 NN NN O
) NN NN O
, NN NN O
1 NN NN O
mg NN NN O
/ NN NN O
h NN NN O
( NN NN O
low NN NN O
- NN NN O
dose NN NN O
) NN NN O
nimodipine NN NN O
( NN NN O
n NN NN O
= NN NN O
101 NN NN O
) NN NN O
, NN NN O
or NN NN O
2 NN NN O
mg NN NN O
/ NN NN O
h NN NN O
( NN NN O
high NN NN O
- NN NN O
dose NN NN O
) NN NN O
nimodipine NN NN O
( NN NN O
n NN NN O
= NN NN O
94 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
correlation NN NN O
between NN NN O
average NN NN O
BP NN NN O
change NN NN O
during NN NN O
the NN NN O
first NN NN O
2 NN NN O
days NN NN O
and NN NN O
the NN NN O
outcome NN NN O
at NN NN O
day NN NN O
21 NN NN O
was NN NN O
analyzed NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Two NN NN O
hundred NN NN O
sixty NN NN O
- NN NN O
five NN NN O
patients NN NN O
were NN NN O
included NN NN O
in NN NN O
this NN NN O
analysis NN NN O
( NN NN O
n NN NN O
= NN NN O
92 NN NN O
, NN NN O
93 NN NN O
, NN NN O
and NN NN O
80 NN NN O
for NN NN O
placebo NN NN O
, NN NN O
low NN NN O
dose NN NN O
, NN NN O
and NN NN O
high NN NN O
dose NN NN O
, NN NN O
respectively NN NN O
) NN NN O
. NN NN O
   
Nimodipine NN NN O
treatment NN NN O
resulted NN NN O
in NN NN O
a NN NN O
statistically NN NN O
significant NN NN O
reduction NN NN B-Disease
in NN NN I-Disease
systolic NN NN I-Disease
BP NN NN I-Disease
( NN NN O
SBP NN NN O
) NN NN O
and NN NN O
diastolic NN NN O
BP NN NN O
( NN NN O
DBP NN NN O
) NN NN O
from NN NN O
baseline NN NN O
compared NN NN O
with NN NN O
placebo NN NN O
during NN NN O
the NN NN O
first NN NN O
few NN NN O
days NN NN O
. NN NN O
   
In NN NN O
multivariate NN NN O
analysis NN NN O
, NN NN O
a NN NN O
significant NN NN O
correlation NN NN O
between NN NN O
DBP NN NN B-Disease
reduction NN NN I-Disease
and NN NN O
worsening NN NN O
of NN NN O
the NN NN O
neurological NN NN O
score NN NN O
was NN NN O
found NN NN O
for NN NN O
the NN NN O
high NN NN O
- NN NN O
dose NN NN O
group NN NN O
( NN NN O
beta NN NN O
= NN NN O
0 NN NN O
. NN NN O
49 NN NN O
, NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
048 NN NN O
) NN NN O
. NN NN O
   
Patients NN NN O
with NN NN O
a NN NN O
DBP NN NN B-Disease
reduction NN NN I-Disease
of NN NN O
> NN NN O
or NN NN O
= NN NN O
20 NN NN O
% NN NN O
in NN NN O
the NN NN O
high NN NN O
- NN NN O
dose NN NN O
group NN NN O
had NN NN O
a NN NN O
significantly NN NN O
increased NN NN O
adjusted NN NN O
OR NN NN O
for NN NN O
the NN NN O
compound NN NN O
outcome NN NN O
variable NN NN O
death NN NN B-Disease
or NN NN O
dependency NN NN O
( NN NN O
Barthel NN NN O
Index NN NN O
< NN NN O
60 NN NN O
) NN NN O
( NN NN O
n NN NN O
/ NN NN O
N NN NN O
= NN NN O
25 NN NN O
/ NN NN O
26 NN NN O
, NN NN O
OR NN NN O
10 NN NN O
. NN NN O
16 NN NN O
, NN NN O
95 NN NN O
% NN NN O
CI NN NN O
1 NN NN O
. NN NN O
02 NN NN O
to NN NN O
101 NN NN O
. NN NN O
74 NN NN O
) NN NN O
and NN NN O
death NN NN B-Disease
alone NN NN O
( NN NN O
n NN NN O
/ NN NN O
N NN NN O
= NN NN O
9 NN NN O
/ NN NN O
26 NN NN O
, NN NN O
OR NN NN O
4 NN NN O
. NN NN O
336 NN NN O
, NN NN O
95 NN NN O
% NN NN O
CI NN NN O
1 NN NN O
. NN NN O
131 NN NN O
16 NN NN O
. NN NN O
619 NN NN O
) NN NN O
compared NN NN O
with NN NN O
all NN NN O
placebo NN NN O
patients NN NN O
( NN NN O
n NN NN O
/ NN NN O
N NN NN O
= NN NN O
62 NN NN O
/ NN NN O
92 NN NN O
and NN NN O
14 NN NN O
/ NN NN O
92 NN NN O
, NN NN O
respectively NN NN O
) NN NN O
. NN NN O
   
There NN NN O
was NN NN O
no NN NN O
correlation NN NN O
between NN NN O
SBP NN NN O
change NN NN O
and NN NN O
outcome NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
DBP NN NN O
, NN NN O
but NN NN O
not NN NN O
SBP NN NN O
, NN NN O
reduction NN NN O
was NN NN O
associated NN NN O
with NN NN O
neurological NN NN O
worsening NN NN O
after NN NN O
the NN NN O
intravenous NN NN O
administration NN NN O
of NN NN O
high NN NN O
- NN NN O
dose NN NN O
nimodipine NN NN O
after NN NN O
acute NN NN B-Disease
stroke NN NN I-Disease
. NN NN O
   
For NN NN O
low NN NN O
- NN NN O
dose NN NN O
nimodipine NN NN O
, NN NN O
the NN NN O
results NN NN O
were NN NN O
not NN NN O
conclusive NN NN O
. NN NN O
   
These NN NN O
results NN NN O
do NN NN O
not NN NN O
confirm NN NN O
or NN NN O
exclude NN NN O
a NN NN O
neuroprotective NN NN O
property NN NN O
of NN NN O
nimodipine NN NN O
. NN NN O
   
Neonatal NN NN O
pyridoxine NN NN O
responsive NN NN O
convulsions NN NN B-Disease
due NN NN O
to NN NN O
isoniazid NN NN O
therapy NN NN O
. NN NN O
   
A NN NN O
17 NN NN O
- NN NN O
day NN NN O
- NN NN O
old NN NN O
infant NN NN O
on NN NN O
isoniazid NN NN O
therapy NN NN O
13 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
daily NN NN O
from NN NN O
birth NN NN O
because NN NN O
of NN NN O
maternal NN NN O
tuberculosis NN NN B-Disease
was NN NN O
admitted NN NN O
after NN NN O
4 NN NN O
days NN NN O
of NN NN O
clonic NN NN B-Disease
fits NN NN I-Disease
. NN NN O
   
No NN NN O
underlying NN NN O
infective NN NN O
or NN NN O
biochemical NN NN O
cause NN NN O
could NN NN O
be NN NN O
found NN NN O
. NN NN O
   
The NN NN O
fits NN NN B-Disease
ceased NN NN O
within NN NN O
4 NN NN O
hours NN NN O
of NN NN O
administering NN NN O
intramuscular NN NN O
pyridoxine NN NN O
, NN NN O
suggesting NN NN O
an NN NN O
aetiology NN NN O
of NN NN O
pyridoxine NN NN O
deficiency NN NN O
secondary NN NN O
to NN NN O
isoniazid NN NN O
medication NN NN O
. NN NN O
   
Ketamine NN NN O
sedation NN NN O
for NN NN O
the NN NN O
reduction NN NN O
of NN NN O
children NN NN O
' NN NN O
s NN NN O
fractures NN NN B-Disease
in NN NN O
the NN NN O
emergency NN NN O
department NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
There NN NN O
recently NN NN O
has NN NN O
been NN NN O
a NN NN O
resurgence NN NN O
in NN NN O
the NN NN O
utilization NN NN O
of NN NN O
ketamine NN NN O
, NN NN O
a NN NN O
unique NN NN O
anesthetic NN NN O
, NN NN O
for NN NN O
emergency NN NN O
- NN NN O
department NN NN O
procedures NN NN O
requiring NN NN O
sedation NN NN O
. NN NN O
   
The NN NN O
purpose NN NN O
of NN NN O
the NN NN O
present NN NN O
study NN NN O
was NN NN O
to NN NN O
examine NN NN O
the NN NN O
safety NN NN O
and NN NN O
efficacy NN NN O
of NN NN O
ketamine NN NN O
for NN NN O
sedation NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
children NN NN O
' NN NN O
s NN NN O
fractures NN NN B-Disease
in NN NN O
the NN NN O
emergency NN NN O
department NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
One NN NN O
hundred NN NN O
and NN NN O
fourteen NN NN O
children NN NN O
( NN NN O
average NN NN O
age NN NN O
, NN NN O
5 NN NN O
. NN NN O
3 NN NN O
years NN NN O
; NN NN O
range NN NN O
, NN NN O
twelve NN NN O
months NN NN O
to NN NN O
ten NN NN O
years NN NN O
and NN NN O
ten NN NN O
months NN NN O
) NN NN O
who NN NN O
underwent NN NN O
closed NN NN O
reduction NN NN O
of NN NN O
an NN NN O
isolated NN NN O
fracture NN NN B-Disease
or NN NN O
dislocation NN NN B-Disease
in NN NN O
the NN NN O
emergency NN NN O
department NN NN O
at NN NN O
a NN NN O
level NN NN O
- NN NN O
I NN NN O
trauma NN NN B-Disease
center NN NN O
were NN NN O
prospectively NN NN O
evaluated NN NN O
. NN NN O
   
Ketamine NN NN O
hydrochloride NN NN O
was NN NN O
administered NN NN O
intravenously NN NN O
( NN NN O
at NN NN O
a NN NN O
dose NN NN O
of NN NN O
two NN NN O
milligrams NN NN O
per NN NN O
kilogram NN NN O
of NN NN O
body NN NN O
weight NN NN O
) NN NN O
in NN NN O
ninety NN NN O
- NN NN O
nine NN NN O
of NN NN O
the NN NN O
patients NN NN O
and NN NN O
intramuscularly NN NN O
( NN NN O
at NN NN O
a NN NN O
dose NN NN O
of NN NN O
four NN NN O
milligrams NN NN O
per NN NN O
kilogram NN NN O
of NN NN O
body NN NN O
weight NN NN O
) NN NN O
in NN NN O
the NN NN O
other NN NN O
fifteen NN NN O
. NN NN O
   
A NN NN O
board NN NN O
- NN NN O
certified NN NN O
emergency NN NN O
physician NN NN O
skilled NN NN O
in NN NN O
airway NN NN O
management NN NN O
supervised NN NN O
administration NN NN O
of NN NN O
the NN NN O
anesthetic NN NN O
, NN NN O
and NN NN O
the NN NN O
patients NN NN O
were NN NN O
monitored NN NN O
by NN NN O
a NN NN O
registered NN NN O
nurse NN NN O
. NN NN O
   
Any NN NN O
pain NN NN B-Disease
during NN NN O
the NN NN O
reduction NN NN O
was NN NN O
rated NN NN O
by NN NN O
the NN NN O
orthopaedic NN NN O
surgeon NN NN O
treating NN NN O
the NN NN O
patient NN NN O
according NN NN O
to NN NN O
the NN NN O
Children NN NN O
' NN NN O
s NN NN O
Hospital NN NN O
of NN NN O
Eastern NN NN O
Ontario NN NN O
Pain NN NN B-Disease
Scale NN NN O
( NN NN O
CHEOPS NN NN O
) NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
The NN NN O
average NN NN O
time NN NN O
from NN NN O
intravenous NN NN O
administration NN NN O
of NN NN O
ketamine NN NN O
to NN NN O
manipulation NN NN O
of NN NN O
the NN NN O
fracture NN NN B-Disease
or NN NN O
dislocation NN NN B-Disease
was NN NN O
one NN NN O
minute NN NN O
and NN NN O
thirty NN NN O
- NN NN O
six NN NN O
seconds NN NN O
( NN NN O
range NN NN O
, NN NN O
twenty NN NN O
seconds NN NN O
to NN NN O
five NN NN O
minutes NN NN O
) NN NN O
, NN NN O
and NN NN O
the NN NN O
average NN NN O
time NN NN O
from NN NN O
intramuscular NN NN O
administration NN NN O
to NN NN O
manipulation NN NN O
was NN NN O
four NN NN O
minutes NN NN O
and NN NN O
forty NN NN O
- NN NN O
two NN NN O
seconds NN NN O
( NN NN O
range NN NN O
, NN NN O
sixty NN NN O
seconds NN NN O
to NN NN O
fifteen NN NN O
minutes NN NN O
) NN NN O
. NN NN O
   
The NN NN O
average NN NN O
score NN NN O
according NN NN O
to NN NN O
the NN NN O
Children NN NN O
' NN NN O
s NN NN O
Hospital NN NN O
of NN NN O
Eastern NN NN O
Ontario NN NN O
Pain NN NN B-Disease
Scale NN NN O
was NN NN O
6 NN NN O
. NN NN O
4 NN NN O
points NN NN O
( NN NN O
range NN NN O
, NN NN O
5 NN NN O
to NN NN O
10 NN NN O
points NN NN O
) NN NN O
, NN NN O
reflecting NN NN O
minimal NN NN O
or NN NN O
no NN NN O
pain NN NN B-Disease
during NN NN O
fracture NN NN B-Disease
reduction NN NN O
. NN NN O
   
Adequate NN NN O
fracture NN NN B-Disease
reduction NN NN O
was NN NN O
obtained NN NN O
in NN NN O
111 NN NN O
of NN NN O
the NN NN O
children NN NN O
. NN NN O
   
Ninety NN NN O
- NN NN O
nine NN NN O
percent NN NN O
( NN NN O
sixty NN NN O
- NN NN O
eight NN NN O
) NN NN O
of NN NN O
the NN NN O
sixty NN NN O
- NN NN O
nine NN NN O
parents NN NN O
present NN NN O
during NN NN O
the NN NN O
reduction NN NN O
were NN NN O
pleased NN NN O
with NN NN O
the NN NN O
sedation NN NN O
and NN NN O
would NN NN O
allow NN NN O
it NN NN O
to NN NN O
be NN NN O
used NN NN O
again NN NN O
in NN NN O
a NN NN O
similar NN NN O
situation NN NN O
. NN NN O
   
Patency NN NN O
of NN NN O
the NN NN O
airway NN NN O
and NN NN O
independent NN NN O
respiration NN NN O
were NN NN O
maintained NN NN O
in NN NN O
all NN NN O
of NN NN O
the NN NN O
patients NN NN O
. NN NN O
   
Blood NN NN O
pressure NN NN O
and NN NN O
heart NN NN O
rate NN NN O
remained NN NN O
stable NN NN O
. NN NN O
   
Minor NN NN O
side NN NN O
effects NN NN O
included NN NN O
nausea NN NN B-Disease
( NN NN O
thirteen NN NN O
patients NN NN O
) NN NN O
, NN NN O
emesis NN NN B-Disease
( NN NN O
eight NN NN O
of NN NN O
the NN NN O
thirteen NN NN O
patients NN NN O
with NN NN O
nausea NN NN B-Disease
) NN NN O
, NN NN O
clumsiness NN NN B-Disease
( NN NN O
evident NN NN O
as NN NN O
ataxic NN NN B-Disease
movements NN NN I-Disease
in NN NN O
ten NN NN O
patients NN NN O
) NN NN O
, NN NN O
and NN NN O
dysphoric NN NN B-Disease
reaction NN NN I-Disease
( NN NN O
one NN NN O
patient NN NN O
) NN NN O
. NN NN O
   
No NN NN O
long NN NN O
- NN NN O
term NN NN O
sequelae NN NN O
were NN NN O
noted NN NN O
, NN NN O
and NN NN O
no NN NN O
patients NN NN O
had NN NN O
hallucinations NN NN B-Disease
or NN NN O
nightmares NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Ketamine NN NN O
reliably NN NN O
, NN NN O
safely NN NN O
, NN NN O
and NN NN O
quickly NN NN O
provided NN NN O
adequate NN NN O
sedation NN NN O
to NN NN O
effectively NN NN O
facilitate NN NN O
the NN NN O
reduction NN NN O
of NN NN O
children NN NN O
' NN NN O
s NN NN O
fractures NN NN B-Disease
in NN NN O
the NN NN O
emergency NN NN O
department NN NN O
at NN NN O
our NN NN O
institution NN NN O
. NN NN O
   
Ketamine NN NN O
should NN NN O
only NN NN O
be NN NN O
used NN NN O
in NN NN O
an NN NN O
environment NN NN O
such NN NN O
as NN NN O
the NN NN O
emergency NN NN O
department NN NN O
, NN NN O
where NN NN O
proper NN NN O
one NN NN O
- NN NN O
on NN NN O
- NN NN O
one NN NN O
monitoring NN NN O
is NN NN O
used NN NN O
and NN NN O
board NN NN O
- NN NN O
certified NN NN O
physicians NN NN O
skilled NN NN O
in NN NN O
airway NN NN O
management NN NN O
are NN NN O
directly NN NN O
involved NN NN O
in NN NN O
the NN NN O
care NN NN O
of NN NN O
the NN NN O
patient NN NN O
. NN NN O
   
Cyclosporine NN NN O
and NN NN O
tacrolimus NN NN O
- NN NN O
associated NN NN O
thrombotic NN NN B-Disease
microangiopathy NN NN I-Disease
. NN NN O
   
The NN NN O
development NN NN O
of NN NN O
thrombotic NN NN B-Disease
microangiopathy NN NN I-Disease
( NN NN O
TMA NN NN B-Disease
) NN NN O
associated NN NN O
with NN NN O
the NN NN O
use NN NN O
of NN NN O
cyclosporine NN NN O
has NN NN O
been NN NN O
well NN NN O
documented NN NN O
. NN NN O
   
Treatments NN NN O
have NN NN O
included NN NN O
discontinuation NN NN O
or NN NN O
reduction NN NN O
of NN NN O
cyclosporine NN NN O
dose NN NN O
with NN NN O
or NN NN O
without NN NN O
concurrent NN NN O
plasma NN NN O
exchange NN NN O
, NN NN O
plasma NN NN O
infusion NN NN O
, NN NN O
anticoagulation NN NN O
, NN NN O
and NN NN O
intravenous NN NN O
immunoglobulin NN NN O
G NN NN O
infusion NN NN O
. NN NN O
   
However NN NN O
, NN NN O
for NN NN O
recipients NN NN O
of NN NN O
organ NN NN O
transplantation NN NN O
, NN NN O
removing NN NN O
the NN NN O
inciting NN NN O
agent NN NN O
is NN NN O
not NN NN O
without NN NN O
the NN NN O
attendant NN NN O
risk NN NN O
of NN NN O
precipitating NN NN O
acute NN NN O
rejection NN NN O
and NN NN O
graft NN NN O
loss NN NN O
. NN NN O
   
The NN NN O
last NN NN O
decade NN NN O
has NN NN O
seen NN NN O
the NN NN O
emergence NN NN O
of NN NN O
tacrolimus NN NN O
as NN NN O
a NN NN O
potent NN NN O
immunosuppressive NN NN O
agent NN NN O
with NN NN O
mechanisms NN NN O
of NN NN O
action NN NN O
virtually NN NN O
identical NN NN O
to NN NN O
those NN NN O
of NN NN O
cyclosporine NN NN O
. NN NN O
   
As NN NN O
a NN NN O
result NN NN O
, NN NN O
switching NN NN O
to NN NN O
tacrolimus NN NN O
has NN NN O
been NN NN O
reported NN NN O
to NN NN O
be NN NN O
a NN NN O
viable NN NN O
therapeutic NN NN O
option NN NN O
in NN NN O
the NN NN O
setting NN NN O
of NN NN O
cyclosporine NN NN O
- NN NN O
induced NN NN O
TMA NN NN B-Disease
. NN NN O
   
With NN NN O
the NN NN O
more NN NN O
widespread NN NN O
application NN NN O
of NN NN O
tacrolimus NN NN O
in NN NN O
organ NN NN O
transplantation NN NN O
, NN NN O
tacrolimus NN NN O
- NN NN O
associated NN NN O
TMA NN NN B-Disease
has NN NN O
also NN NN O
been NN NN O
recognized NN NN O
. NN NN O
   
However NN NN O
, NN NN O
literature NN NN O
regarding NN NN O
the NN NN O
incidence NN NN O
of NN NN O
the NN NN O
recurrence NN NN O
of NN NN O
TMA NN NN B-Disease
in NN NN O
patients NN NN O
exposed NN NN O
sequentially NN NN O
to NN NN O
cyclosporine NN NN O
and NN NN O
tacrolimus NN NN O
is NN NN O
limited NN NN O
. NN NN O
   
We NN NN O
report NN NN O
a NN NN O
case NN NN O
of NN NN O
a NN NN O
living NN NN O
donor NN NN O
renal NN NN O
transplant NN NN O
recipient NN NN O
who NN NN O
developed NN NN O
cyclosporine NN NN O
- NN NN O
induced NN NN O
TMA NN NN B-Disease
that NN NN O
responded NN NN O
to NN NN O
the NN NN O
withdrawal NN NN O
of NN NN O
cyclosporine NN NN O
in NN NN O
conjunction NN NN O
with NN NN O
plasmapheresis NN NN O
and NN NN O
fresh NN NN O
frozen NN NN O
plasma NN NN O
replacement NN NN O
therapy NN NN O
. NN NN O
   
Introduction NN NN O
of NN NN O
tacrolimus NN NN O
as NN NN O
an NN NN O
alternative NN NN O
immunosuppressive NN NN O
agent NN NN O
resulted NN NN O
in NN NN O
the NN NN O
recurrence NN NN O
of NN NN O
TMA NN NN B-Disease
and NN NN O
the NN NN O
subsequent NN NN O
loss NN NN O
of NN NN O
the NN NN O
renal NN NN O
allograft NN NN O
. NN NN O
   
Patients NN NN O
who NN NN O
are NN NN O
switched NN NN O
from NN NN O
cyclosporine NN NN O
to NN NN O
tacrolimus NN NN O
or NN NN O
vice NN NN O
versa NN NN O
should NN NN O
be NN NN O
closely NN NN O
monitored NN NN O
for NN NN O
the NN NN O
signs NN NN O
and NN NN O
symptoms NN NN O
of NN NN O
recurrent NN NN O
TMA NN NN B-Disease
. NN NN O
   
Analgesic NN NN O
effect NN NN O
of NN NN O
intravenous NN NN O
ketamine NN NN O
in NN NN O
cancer NN NN B-Disease
patients NN NN O
on NN NN O
morphine NN NN O
therapy NN NN O
: NN NN O
a NN NN O
randomized NN NN O
, NN NN O
controlled NN NN O
, NN NN O
double NN NN O
- NN NN O
blind NN NN O
, NN NN O
crossover NN NN O
, NN NN O
double NN NN O
- NN NN O
dose NN NN O
study NN NN O
. NN NN O
   
Pain NN NN B-Disease
not NN NN O
responsive NN NN O
to NN NN O
morphine NN NN O
is NN NN O
often NN NN O
problematic NN NN O
. NN NN O
   
Animal NN NN O
and NN NN O
clinical NN NN O
studies NN NN O
have NN NN O
suggested NN NN O
that NN NN O
N NN NN O
- NN NN O
methyl NN NN O
- NN NN O
D NN NN O
- NN NN O
aspartate NN NN O
( NN NN O
NMDA NN NN O
) NN NN O
antagonists NN NN O
, NN NN O
such NN NN O
as NN NN O
ketamine NN NN O
, NN NN O
may NN NN O
be NN NN O
effective NN NN O
in NN NN O
improving NN NN O
opioid NN NN O
analgesia NN NN O
in NN NN O
difficult NN NN O
pain NN NN B-Disease
syndromes NN NN O
, NN NN O
such NN NN O
as NN NN O
neuropathic NN NN B-Disease
pain NN NN I-Disease
. NN NN O
   
A NN NN O
slow NN NN O
bolus NN NN O
of NN NN O
subhypnotic NN NN O
doses NN NN O
of NN NN O
ketamine NN NN O
( NN NN O
0 NN NN O
. NN NN O
25 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
or NN NN O
0 NN NN O
. NN NN O
50 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
was NN NN O
given NN NN O
to NN NN O
10 NN NN O
cancer NN NN B-Disease
patients NN NN O
whose NN NN O
pain NN NN B-Disease
was NN NN O
unrelieved NN NN O
by NN NN O
morphine NN NN O
in NN NN O
a NN NN O
randomized NN NN O
, NN NN O
double NN NN O
- NN NN O
blind NN NN O
, NN NN O
crossover NN NN O
, NN NN O
double NN NN O
- NN NN O
dose NN NN O
study NN NN O
. NN NN O
   
Pain NN NN B-Disease
intensity NN NN O
on NN NN O
a NN NN O
0 NN NN O
to NN NN O
10 NN NN O
numerical NN NN O
scale NN NN O
; NN NN O
nausea NN NN B-Disease
and NN NN O
vomiting NN NN B-Disease
, NN NN O
drowsiness NN NN O
, NN NN O
confusion NN NN B-Disease
, NN NN O
and NN NN O
dry NN NN B-Disease
mouth NN NN I-Disease
, NN NN O
using NN NN O
a NN NN O
scale NN NN O
from NN NN O
0 NN NN O
to NN NN O
3 NN NN O
( NN NN O
not NN NN O
at NN NN O
all NN NN O
, NN NN O
slight NN NN O
, NN NN O
a NN NN O
lot NN NN O
, NN NN O
awful NN NN O
) NN NN O
; NN NN O
Mini NN NN O
- NN NN O
Mental NN NN O
State NN NN O
Examination NN NN O
( NN NN O
MMSE NN NN O
) NN NN O
( NN NN O
0 NN NN O
- NN NN O
30 NN NN O
) NN NN O
; NN NN O
and NN NN O
arterial NN NN O
pressure NN NN O
were NN NN O
recorded NN NN O
before NN NN O
administration NN NN O
of NN NN O
drugs NN NN O
( NN NN O
T0 NN NN O
) NN NN O
and NN NN O
after NN NN O
30 NN NN O
minutes NN NN O
( NN NN O
T30 NN NN O
) NN NN O
, NN NN O
60 NN NN O
minutes NN NN O
( NN NN O
T60 NN NN O
) NN NN O
, NN NN O
120 NN NN O
minutes NN NN O
( NN NN O
T120 NN NN O
) NN NN O
, NN NN O
and NN NN O
180 NN NN O
minutes NN NN O
( NN NN O
T180 NN NN O
) NN NN O
. NN NN O
   
Ketamine NN NN O
, NN NN O
but NN NN O
not NN NN O
saline NN NN O
solution NN NN O
, NN NN O
significantly NN NN O
reduced NN NN O
the NN NN O
pain NN NN B-Disease
intensity NN NN O
in NN NN O
almost NN NN O
all NN NN O
the NN NN O
patients NN NN O
at NN NN O
both NN NN O
doses NN NN O
. NN NN O
   
This NN NN O
effect NN NN O
was NN NN O
more NN NN O
relevant NN NN O
in NN NN O
patients NN NN O
treated NN NN O
with NN NN O
higher NN NN O
doses NN NN O
. NN NN O
   
Hallucinations NN NN B-Disease
occurred NN NN O
in NN NN O
4 NN NN O
patients NN NN O
, NN NN O
and NN NN O
an NN NN O
unpleasant NN NN O
sensation NN NN O
( NN NN O
"""""""" NN NN O
empty NN NN O
head NN NN O
"""""""" NN NN O
) NN NN O
was NN NN O
also NN NN O
reported NN NN O
by NN NN O
2 NN NN O
patients NN NN O
. NN NN O
   
These NN NN O
episodes NN NN O
reversed NN NN O
after NN NN O
the NN NN O
administration NN NN O
of NN NN O
diazepam NN NN O
1 NN NN O
mg NN NN O
intravenously NN NN O
. NN NN O
   
Significant NN NN O
increases NN NN O
in NN NN O
drowsiness NN NN O
were NN NN O
reported NN NN O
in NN NN O
patients NN NN O
treated NN NN O
with NN NN O
ketamine NN NN O
in NN NN O
both NN NN O
groups NN NN O
and NN NN O
were NN NN O
more NN NN O
marked NN NN O
with NN NN O
ketamine NN NN O
0 NN NN O
. NN NN O
50 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
. NN NN O
   
A NN NN O
significant NN NN O
difference NN NN O
in NN NN O
MMSE NN NN O
was NN NN O
observed NN NN O
at NN NN O
T30 NN NN O
in NN NN O
patients NN NN O
who NN NN O
received NN NN O
0 NN NN O
. NN NN O
50 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
of NN NN O
ketamine NN NN O
. NN NN O
   
Ketamine NN NN O
can NN NN O
improve NN NN O
morphine NN NN O
analgesia NN NN O
in NN NN O
difficult NN NN O
pain NN NN B-Disease
syndromes NN NN O
, NN NN O
such NN NN O
as NN NN O
neuropathic NN NN B-Disease
pain NN NN I-Disease
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
central NN NN O
adverse NN NN O
effects NN NN O
should NN NN O
be NN NN O
taken NN NN O
into NN NN O
account NN NN O
, NN NN O
especially NN NN O
when NN NN O
using NN NN O
higher NN NN O
doses NN NN O
. NN NN O
   
This NN NN O
observation NN NN O
should NN NN O
be NN NN O
tested NN NN O
in NN NN O
studies NN NN O
of NN NN O
prolonged NN NN O
ketamine NN NN O
administration NN NN O
. NN NN O
   
Paclitaxel NN NN O
, NN NN O
cisplatin NN NN O
, NN NN O
and NN NN O
gemcitabine NN NN O
combination NN NN O
chemotherapy NN NN O
within NN NN O
a NN NN O
multidisciplinary NN NN O
therapeutic NN NN O
approach NN NN O
in NN NN O
metastatic NN NN O
nonsmall NN NN B-Disease
cell NN NN I-Disease
lung NN NN I-Disease
carcinoma NN NN I-Disease
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Cisplatin NN NN O
- NN NN O
based NN NN O
chemotherapy NN NN O
combinations NN NN O
improve NN NN O
quality NN NN O
of NN NN O
life NN NN O
and NN NN O
survival NN NN O
in NN NN O
advanced NN NN O
nonsmall NN NN B-Disease
cell NN NN I-Disease
lung NN NN I-Disease
carcinoma NN NN I-Disease
( NN NN O
NSCLC NN NN B-Disease
) NN NN O
. NN NN O
   
The NN NN O
emergence NN NN O
of NN NN O
new NN NN O
active NN NN O
drugs NN NN O
might NN NN O
translate NN NN O
into NN NN O
more NN NN O
effective NN NN O
regimens NN NN O
for NN NN O
the NN NN O
treatment NN NN O
of NN NN O
this NN NN O
disease NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
The NN NN O
objective NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
determine NN NN O
the NN NN O
feasibility NN NN O
, NN NN O
response NN NN O
rate NN NN O
, NN NN O
and NN NN O
toxicity NN NN B-Disease
of NN NN O
a NN NN O
paclitaxel NN NN O
, NN NN O
cisplatin NN NN O
, NN NN O
and NN NN O
gemcitabine NN NN O
combination NN NN O
to NN NN O
treat NN NN O
metastatic NN NN O
NSCLC NN NN B-Disease
. NN NN O
   
Thirty NN NN O
- NN NN O
five NN NN O
consecutive NN NN O
chemotherapy NN NN O
- NN NN O
naive NN NN O
patients NN NN O
with NN NN O
Stage NN NN O
IV NN NN O
NSCLC NN NN B-Disease
and NN NN O
an NN NN O
Eastern NN NN O
Cooperative NN NN O
Oncology NN NN O
Group NN NN O
performance NN NN O
status NN NN O
of NN NN O
0 NN NN O
- NN NN O
2 NN NN O
were NN NN O
treated NN NN O
with NN NN O
a NN NN O
combination NN NN O
of NN NN O
paclitaxel NN NN O
( NN NN O
135 NN NN O
mg NN NN O
/ NN NN O
m NN NN O
( NN NN O
2 NN NN O
) NN NN O
given NN NN O
intravenously NN NN O
in NN NN O
3 NN NN O
hours NN NN O
) NN NN O
on NN NN O
Day NN NN O
1 NN NN O
, NN NN O
cisplatin NN NN O
( NN NN O
120 NN NN O
mg NN NN O
/ NN NN O
m NN NN O
( NN NN O
2 NN NN O
) NN NN O
given NN NN O
intravenously NN NN O
in NN NN O
6 NN NN O
hours NN NN O
) NN NN O
on NN NN O
Day NN NN O
1 NN NN O
, NN NN O
and NN NN O
gemcitabine NN NN O
( NN NN O
800 NN NN O
mg NN NN O
/ NN NN O
m NN NN O
( NN NN O
2 NN NN O
) NN NN O
given NN NN O
intravenously NN NN O
in NN NN O
30 NN NN O
minutes NN NN O
) NN NN O
on NN NN O
Days NN NN O
1 NN NN O
and NN NN O
8 NN NN O
, NN NN O
every NN NN O
4 NN NN O
weeks NN NN O
. NN NN O
   
Although NN NN O
responding NN NN O
patients NN NN O
were NN NN O
scheduled NN NN O
to NN NN O
receive NN NN O
consolidation NN NN O
radiotherapy NN NN O
and NN NN O
24 NN NN O
patients NN NN O
received NN NN O
preplanned NN NN O
second NN NN O
- NN NN O
line NN NN O
chemotherapy NN NN O
after NN NN O
disease NN NN O
progression NN NN O
, NN NN O
the NN NN O
response NN NN O
and NN NN O
toxicity NN NN B-Disease
rates NN NN O
reported NN NN O
refer NN NN O
only NN NN O
to NN NN O
the NN NN O
chemotherapy NN NN O
regimen NN NN O
given NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
All NN NN O
the NN NN O
patients NN NN O
were NN NN O
examined NN NN O
for NN NN O
toxicity NN NN B-Disease
; NN NN O
34 NN NN O
were NN NN O
examinable NN NN O
for NN NN O
response NN NN O
. NN NN O
   
An NN NN O
objective NN NN O
response NN NN O
was NN NN O
observed NN NN O
in NN NN O
73 NN NN O
. NN NN O
5 NN NN O
% NN NN O
of NN NN O
the NN NN O
patients NN NN O
( NN NN O
95 NN NN O
% NN NN O
confidence NN NN O
interval NN NN O
[ NN NN O
CI NN NN O
] NN NN O
, NN NN O
55 NN NN O
. NN NN O
6 NN NN O
- NN NN O
87 NN NN O
. NN NN O
1 NN NN O
% NN NN O
) NN NN O
, NN NN O
including NN NN O
4 NN NN O
complete NN NN O
responses NN NN O
( NN NN O
11 NN NN O
. NN NN O
7 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
According NN NN O
to NN NN O
intention NN NN O
- NN NN O
to NN NN O
- NN NN O
treat NN NN O
, NN NN O
the NN NN O
overall NN NN O
response NN NN O
rate NN NN O
was NN NN O
71 NN NN O
. NN NN O
4 NN NN O
% NN NN O
( NN NN O
95 NN NN O
% NN NN O
CI NN NN O
, NN NN O
53 NN NN O
. NN NN O
7 NN NN O
- NN NN O
85 NN NN O
. NN NN O
4 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
After NN NN O
154 NN NN O
courses NN NN O
of NN NN O
therapy NN NN O
, NN NN O
the NN NN O
median NN NN O
dose NN NN O
intensity NN NN O
was NN NN O
131 NN NN O
mg NN NN O
/ NN NN O
m NN NN O
( NN NN O
2 NN NN O
) NN NN O
for NN NN O
paclitaxel NN NN O
( NN NN O
97 NN NN O
. NN NN O
3 NN NN O
% NN NN O
) NN NN O
, NN NN O
117 NN NN O
mg NN NN O
/ NN NN O
m NN NN O
( NN NN O
2 NN NN O
) NN NN O
for NN NN O
cisplatin NN NN O
( NN NN O
97 NN NN O
. NN NN O
3 NN NN O
% NN NN O
) NN NN O
, NN NN O
and NN NN O
1378 NN NN O
mg NN NN O
/ NN NN O
m NN NN O
( NN NN O
2 NN NN O
) NN NN O
for NN NN O
gemcitabine NN NN O
( NN NN O
86 NN NN O
. NN NN O
2 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
World NN NN O
Health NN NN O
Organization NN NN O
Grade NN NN O
3 NN NN O
- NN NN O
4 NN NN O
neutropenia NN NN B-Disease
and NN NN O
thrombocytopenia NN NN B-Disease
occurred NN NN O
in NN NN O
39 NN NN O
. NN NN O
9 NN NN O
% NN NN O
and NN NN O
11 NN NN O
. NN NN O
4 NN NN O
% NN NN O
of NN NN O
patients NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
There NN NN O
was NN NN O
one NN NN O
treatment NN NN O
- NN NN O
related NN NN O
death NN NN B-Disease
. NN NN O
   
Nonhematologic NN NN O
toxicities NN NN B-Disease
were NN NN O
mild NN NN O
. NN NN O
   
After NN NN O
a NN NN O
median NN NN O
follow NN NN O
- NN NN O
up NN NN O
of NN NN O
22 NN NN O
months NN NN O
, NN NN O
the NN NN O
median NN NN O
progression NN NN O
free NN NN O
survival NN NN O
rate NN NN O
was NN NN O
7 NN NN O
months NN NN O
, NN NN O
and NN NN O
the NN NN O
median NN NN O
survival NN NN O
time NN NN O
was NN NN O
16 NN NN O
months NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
The NN NN O
combination NN NN O
of NN NN O
paclitaxel NN NN O
, NN NN O
cisplatin NN NN O
, NN NN O
and NN NN O
gemcitabine NN NN O
is NN NN O
well NN NN O
tolerated NN NN O
and NN NN O
shows NN NN O
high NN NN O
activity NN NN O
in NN NN O
metastatic NN NN O
NSCLC NN NN B-Disease
. NN NN O
   
This NN NN O
treatment NN NN O
merits NN NN O
further NN NN O
comparison NN NN O
with NN NN O
other NN NN O
cisplatin NN NN O
- NN NN O
based NN NN O
regimens NN NN O
. NN NN O
   
Serotonergic NN NN O
antidepressants NN NN O
and NN NN O
urinary NN NN B-Disease
incontinence NN NN I-Disease
. NN NN O
   
Many NN NN O
new NN NN O
serotonergic NN NN O
antidepressants NN NN O
have NN NN O
been NN NN O
introduced NN NN O
over NN NN O
the NN NN O
past NN NN O
decade NN NN O
. NN NN O
   
Although NN NN O
urinary NN NN B-Disease
incontinence NN NN I-Disease
is NN NN O
listed NN NN O
as NN NN O
one NN NN O
side NN NN O
effect NN NN O
of NN NN O
these NN NN O
drugs NN NN O
in NN NN O
their NN NN O
package NN NN O
inserts NN NN O
there NN NN O
is NN NN O
only NN NN O
one NN NN O
report NN NN O
in NN NN O
the NN NN O
literature NN NN O
. NN NN O
   
This NN NN O
concerns NN NN O
2 NN NN O
male NN NN O
patients NN NN O
who NN NN O
experienced NN NN O
incontinence NN NN B-Disease
while NN NN O
taking NN NN O
venlafaxine NN NN O
. NN NN O
   
In NN NN O
the NN NN O
present NN NN O
paper NN NN O
the NN NN O
authors NN NN O
describe NN NN O
2 NN NN O
female NN NN O
patients NN NN O
who NN NN O
developed NN NN O
incontinence NN NN B-Disease
secondary NN NN O
to NN NN O
the NN NN O
selective NN NN O
serotonin NN NN O
reuptake NN NN O
inhibitors NN NN O
paroxetine NN NN O
and NN NN O
sertraline NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
a NN NN O
third NN NN O
who NN NN O
developed NN NN O
this NN NN O
side NN NN O
effect NN NN O
on NN NN O
venlafaxine NN NN O
. NN NN O
   
In NN NN O
2 NN NN O
of NN NN O
the NN NN O
3 NN NN O
cases NN NN O
the NN NN O
patients NN NN O
were NN NN O
also NN NN O
taking NN NN O
lithium NN NN O
carbonate NN NN O
and NN NN O
beta NN NN O
- NN NN O
blockers NN NN O
, NN NN O
both NN NN O
of NN NN O
which NN NN O
could NN NN O
have NN NN O
contributed NN NN O
to NN NN O
the NN NN O
incontinence NN NN B-Disease
. NN NN O
   
Animal NN NN O
studies NN NN O
suggest NN NN O
that NN NN O
incontinence NN NN B-Disease
secondary NN NN O
to NN NN O
serotonergic NN NN O
antidepressants NN NN O
could NN NN O
be NN NN O
mediated NN NN O
by NN NN O
the NN NN O
5HT4 NN NN O
receptors NN NN O
found NN NN O
on NN NN O
the NN NN O
bladder NN NN O
. NN NN O
   
Further NN NN O
research NN NN O
is NN NN O
needed NN NN O
to NN NN O
delineate NN NN O
the NN NN O
frequency NN NN O
of NN NN O
this NN NN O
troubling NN NN O
side NN NN O
effect NN NN O
and NN NN O
how NN NN O
best NN NN O
to NN NN O
treat NN NN O
it NN NN O
. NN NN O
   
Acute NN NN O
cocaine NN NN O
- NN NN O
induced NN NN O
seizures NN NN B-Disease
: NN NN O
differential NN NN O
sensitivity NN NN O
of NN NN O
six NN NN O
inbred NN NN O
mouse NN NN O
strains NN NN O
. NN NN O
   
Mature NN NN O
male NN NN O
and NN NN O
female NN NN O
mice NN NN O
from NN NN O
six NN NN O
inbred NN NN O
stains NN NN O
were NN NN O
tested NN NN O
for NN NN O
susceptibility NN NN O
to NN NN O
behavioral NN NN O
seizures NN NN B-Disease
induced NN NN O
by NN NN O
a NN NN O
single NN NN O
injection NN NN O
of NN NN O
cocaine NN NN O
. NN NN O
   
Cocaine NN NN O
was NN NN O
injected NN NN O
ip NN NN O
over NN NN O
a NN NN O
range NN NN O
of NN NN O
doses NN NN O
( NN NN O
50 NN NN O
- NN NN O
100 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
and NN NN O
behavior NN NN O
was NN NN O
monitored NN NN O
for NN NN O
20 NN NN O
minutes NN NN O
. NN NN O
   
Seizure NN NN B-Disease
end NN NN O
points NN NN O
included NN NN O
latency NN NN O
to NN NN O
forelimb NN NN O
or NN NN O
hindlimb NN NN O
clonus NN NN O
, NN NN O
latency NN NN O
to NN NN O
clonic NN NN O
running NN NN O
seizure NN NN B-Disease
and NN NN O
latency NN NN O
to NN NN O
jumping NN NN O
bouncing NN NN O
seizure NN NN B-Disease
. NN NN O
   
A NN NN O
range NN NN O
of NN NN O
strain NN NN O
specific NN NN O
sensitivities NN NN O
was NN NN O
documented NN NN O
with NN NN O
A NN NN O
/ NN NN O
J NN NN O
and NN NN O
SJL NN NN O
mice NN NN O
being NN NN O
most NN NN O
sensitive NN NN O
and NN NN O
C57BL NN NN O
/ NN NN O
6J NN NN O
most NN NN O
resistant NN NN O
. NN NN O
   
DBA NN NN O
/ NN NN O
2J NN NN O
, NN NN O
BALB NN NN O
/ NN NN O
cByJ NN NN O
and NN NN O
NZW NN NN O
/ NN NN O
LacJ NN NN O
strains NN NN O
exhibited NN NN O
intermediate NN NN O
sensitivity NN NN O
. NN NN O
   
EEG NN NN O
recordings NN NN O
were NN NN O
made NN NN O
in NN NN O
SJL NN NN O
, NN NN O
A NN NN O
/ NN NN O
J NN NN O
and NN NN O
C57BL NN NN O
/ NN NN O
6J NN NN O
mice NN NN O
revealing NN NN O
a NN NN O
close NN NN O
correspondence NN NN O
between NN NN O
electrical NN NN O
activity NN NN O
and NN NN O
behavior NN NN O
. NN NN O
   
Additionally NN NN O
, NN NN O
levels NN NN O
of NN NN O
cocaine NN NN O
determined NN NN O
in NN NN O
hippocampus NN NN O
and NN NN O
cortex NN NN O
were NN NN O
not NN NN O
different NN NN O
between NN NN O
sensitive NN NN O
and NN NN O
resistant NN NN O
strains NN NN O
. NN NN O
   
Additional NN NN O
studies NN NN O
of NN NN O
these NN NN O
murine NN NN O
strains NN NN O
may NN NN O
be NN NN O
useful NN NN O
for NN NN O
investigating NN NN O
genetic NN NN O
influences NN NN O
on NN NN O
cocaine NN NN O
- NN NN O
induced NN NN O
seizures NN NN B-Disease
. NN NN O
   
Hypotension NN NN B-Disease
following NN NN O
the NN NN O
initiation NN NN O
of NN NN O
tizanidine NN NN O
in NN NN O
a NN NN O
patient NN NN O
treated NN NN O
with NN NN O
an NN NN O
angiotensin NN NN O
converting NN NN O
enzyme NN NN O
inhibitor NN NN O
for NN NN O
chronic NN NN O
hypertension NN NN B-Disease
. NN NN O
   
Centrally NN NN O
acting NN NN O
alpha NN NN O
- NN NN O
2 NN NN O
adrenergic NN NN O
agonists NN NN O
are NN NN O
one NN NN O
of NN NN O
several NN NN O
pharmacologic NN NN O
agents NN NN O
used NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
spasticity NN NN B-Disease
related NN NN O
to NN NN O
disorders NN NN B-Disease
of NN NN I-Disease
the NN NN I-Disease
central NN NN I-Disease
nervous NN NN I-Disease
system NN NN I-Disease
. NN NN O
   
In NN NN O
addition NN NN O
to NN NN O
their NN NN O
effects NN NN O
on NN NN O
spasticity NN NN B-Disease
, NN NN O
certain NN NN O
adverse NN NN O
cardiorespiratory NN NN O
effects NN NN O
have NN NN O
been NN NN O
reported NN NN O
. NN NN O
   
Adults NN NN O
chronically NN NN O
treated NN NN O
with NN NN O
angiotensin NN NN O
converting NN NN O
enzyme NN NN O
inhibitors NN NN O
may NN NN O
have NN NN O
a NN NN O
limited NN NN O
ability NN NN O
to NN NN O
respond NN NN O
to NN NN O
hypotension NN NN B-Disease
when NN NN O
the NN NN O
sympathetic NN NN O
response NN NN O
is NN NN O
simultaneously NN NN O
blocked NN NN O
. NN NN O
   
The NN NN O
authors NN NN O
present NN NN O
a NN NN O
10 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
boy NN NN O
chronically NN NN O
treated NN NN O
with NN NN O
lisinopril NN NN O
, NN NN O
an NN NN O
angiotensin NN NN O
converting NN NN O
enzyme NN NN O
inhibitor NN NN O
, NN NN O
to NN NN O
control NN NN O
hypertension NN NN B-Disease
who NN NN O
developed NN NN O
hypotension NN NN B-Disease
following NN NN O
the NN NN O
addition NN NN O
of NN NN O
tizanidine NN NN O
, NN NN O
an NN NN O
alpha NN NN O
- NN NN O
2 NN NN O
agonist NN NN O
, NN NN O
for NN NN O
the NN NN O
treatment NN NN O
of NN NN O
spasticity NN NN B-Disease
. NN NN O
   
The NN NN O
possible NN NN O
interaction NN NN O
of NN NN O
tizanidine NN NN O
and NN NN O
other NN NN O
antihypertensive NN NN O
agents NN NN O
should NN NN O
be NN NN O
kept NN NN O
in NN NN O
mind NN NN O
when NN NN O
prescribing NN NN O
therapy NN NN O
to NN NN O
treat NN NN O
either NN NN O
hypertension NN NN B-Disease
or NN NN O
spasticity NN NN B-Disease
in NN NN O
such NN NN O
patients NN NN O
. NN NN O
   
Two NN NN O
mouse NN NN O
lines NN NN O
selected NN NN O
for NN NN O
differential NN NN O
sensitivities NN NN O
to NN NN O
beta NN NN O
- NN NN O
carboline NN NN O
- NN NN O
induced NN NN O
seizures NN NN B-Disease
are NN NN O
also NN NN O
differentially NN NN O
sensitive NN NN O
to NN NN O
various NN NN O
pharmacological NN NN O
effects NN NN O
of NN NN O
other NN NN O
GABA NN NN O
( NN NN O
A NN NN O
) NN NN O
receptor NN NN O
ligands NN NN O
. NN NN O
   
Two NN NN O
mouse NN NN O
lines NN NN O
were NN NN O
selectively NN NN O
bred NN NN O
according NN NN O
to NN NN O
their NN NN O
sensitivity NN NN O
( NN NN O
BS NN NN O
line NN NN O
) NN NN O
or NN NN O
resistance NN NN O
( NN NN O
BR NN NN O
line NN NN O
) NN NN O
to NN NN O
seizures NN NN B-Disease
induced NN NN O
by NN NN O
a NN NN O
single NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
injection NN NN O
of NN NN O
methyl NN NN O
beta NN NN O
- NN NN O
carboline NN NN O
- NN NN O
3 NN NN O
- NN NN O
carboxylate NN NN O
( NN NN O
beta NN NN O
- NN NN O
CCM NN NN O
) NN NN O
, NN NN O
an NN NN O
inverse NN NN O
agonist NN NN O
of NN NN O
the NN NN O
GABA NN NN O
( NN NN O
A NN NN O
) NN NN O
receptor NN NN O
benzodiazepine NN NN O
site NN NN O
. NN NN O
   
Our NN NN O
aim NN NN O
was NN NN O
to NN NN O
characterize NN NN O
both NN NN O
lines NN NN O
' NN NN O
sensitivities NN NN O
to NN NN O
various NN NN O
physiological NN NN O
effects NN NN O
of NN NN O
other NN NN O
ligands NN NN O
of NN NN O
the NN NN O
GABA NN NN O
( NN NN O
A NN NN O
) NN NN O
receptor NN NN O
. NN NN O
   
We NN NN O
measured NN NN O
diazepam NN NN O
- NN NN O
induced NN NN O
anxiolysis NN NN O
with NN NN O
the NN NN O
elevated NN NN O
plus NN NN O
- NN NN O
maze NN NN O
test NN NN O
, NN NN O
diazepam NN NN O
- NN NN O
induced NN NN O
sedation NN NN O
by NN NN O
recording NN NN O
the NN NN O
vigilance NN NN O
states NN NN O
, NN NN O
and NN NN O
picrotoxin NN NN O
- NN NN O
and NN NN O
pentylenetetrazol NN NN O
- NN NN O
induced NN NN O
seizures NN NN B-Disease
after NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
injections NN NN O
. NN NN O
   
Results NN NN O
presented NN NN O
here NN NN O
show NN NN O
that NN NN O
the NN NN O
differential NN NN O
sensitivities NN NN O
of NN NN O
BS NN NN O
and NN NN O
BR NN NN O
lines NN NN O
to NN NN O
beta NN NN O
- NN NN O
CCM NN NN O
can NN NN O
be NN NN O
extended NN NN O
to NN NN O
diazepam NN NN O
, NN NN O
picrotoxin NN NN O
, NN NN O
and NN NN O
pentylenetetrazol NN NN O
, NN NN O
suggesting NN NN O
a NN NN O
genetic NN NN O
selection NN NN O
of NN NN O
a NN NN O
general NN NN O
sensitivity NN NN O
and NN NN O
resistance NN NN O
to NN NN O
several NN NN O
ligands NN NN O
of NN NN O
the NN NN O
GABA NN NN O
( NN NN O
A NN NN O
) NN NN O
receptor NN NN O
. NN NN O
   
Propylthiouracil NN NN O
- NN NN O
induced NN NN O
perinuclear NN NN O
- NN NN O
staining NN NN O
antineutrophil NN NN O
cytoplasmic NN NN O
autoantibody NN NN O
- NN NN O
positive NN NN O
vasculitis NN NN B-Disease
in NN NN O
conjunction NN NN O
with NN NN O
pericarditis NN NN B-Disease
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
To NN NN O
describe NN NN O
a NN NN O
case NN NN O
of NN NN O
propylthiouracil NN NN O
- NN NN O
induced NN NN O
vasculitis NN NN B-Disease
manifesting NN NN O
with NN NN O
pericarditis NN NN B-Disease
. NN NN O
   
METHODS NN NN O
: NN NN O
We NN NN O
present NN NN O
the NN NN O
first NN NN O
case NN NN O
report NN NN O
of NN NN O
a NN NN O
woman NN NN O
with NN NN O
hyperthyroidism NN NN B-Disease
treated NN NN O
with NN NN O
propylthiouracil NN NN O
in NN NN O
whom NN NN O
a NN NN O
syndrome NN NN O
of NN NN O
pericarditis NN NN B-Disease
, NN NN O
fever NN NN B-Disease
, NN NN O
and NN NN O
glomerulonephritis NN NN B-Disease
developed NN NN O
. NN NN O
   
Serologic NN NN O
testing NN NN O
and NN NN O
immunologic NN NN O
studies NN NN O
were NN NN O
done NN NN O
, NN NN O
and NN NN O
a NN NN O
pericardial NN NN O
biopsy NN NN O
was NN NN O
performed NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
A NN NN O
25 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
woman NN NN O
with NN NN O
Graves NN NN B-Disease
' NN NN I-Disease
disease NN NN I-Disease
had NN NN O
a NN NN O
febrile NN NN B-Disease
illness NN NN I-Disease
and NN NN O
evidence NN NN O
of NN NN O
pericarditis NN NN B-Disease
, NN NN O
which NN NN O
was NN NN O
confirmed NN NN O
by NN NN O
biopsy NN NN O
. NN NN O
   
Serologic NN NN O
evaluation NN NN O
revealed NN NN O
the NN NN O
presence NN NN O
of NN NN O
perinuclear NN NN O
- NN NN O
staining NN NN O
antineutrophil NN NN O
cytoplasmic NN NN O
autoantibodies NN NN O
( NN NN O
pANCA NN NN O
) NN NN O
against NN NN O
myeloperoxidase NN NN O
( NN NN O
MPO NN NN O
) NN NN O
. NN NN O
   
Propylthiouracil NN NN O
therapy NN NN O
was NN NN O
withdrawn NN NN O
, NN NN O
and NN NN O
she NN NN O
was NN NN O
treated NN NN O
with NN NN O
a NN NN O
1 NN NN O
- NN NN O
month NN NN O
course NN NN O
of NN NN O
prednisone NN NN O
, NN NN O
which NN NN O
alleviated NN NN O
her NN NN O
symptoms NN NN O
. NN NN O
   
A NN NN O
literature NN NN O
review NN NN O
revealed NN NN O
no NN NN O
prior NN NN O
reports NN NN O
of NN NN O
pericarditis NN NN B-Disease
in NN NN O
anti NN NN O
- NN NN O
MPO NN NN O
pANCA NN NN O
- NN NN O
positive NN NN O
vasculitis NN NN B-Disease
associated NN NN O
with NN NN O
propylthio NN NN O
- NN NN O
uracil NN NN O
therapy NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Pericarditis NN NN B-Disease
may NN NN O
be NN NN O
the NN NN O
initial NN NN O
manifestation NN NN O
of NN NN O
drug NN NN O
- NN NN O
induced NN NN O
vasculitis NN NN B-Disease
attributable NN NN O
to NN NN O
propylthio NN NN O
- NN NN O
uracil NN NN O
therapy NN NN O
. NN NN O
   
Repeated NN NN O
transient NN NN O
anuria NN NN B-Disease
following NN NN O
losartan NN NN O
administration NN NN O
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
a NN NN O
solitary NN NN O
kidney NN NN O
. NN NN O
   
We NN NN O
report NN NN O
the NN NN O
case NN NN O
of NN NN O
a NN NN O
70 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
hypertensive NN NN B-Disease
man NN NN O
with NN NN O
a NN NN O
solitary NN NN O
kidney NN NN O
and NN NN O
chronic NN NN B-Disease
renal NN NN I-Disease
insufficiency NN NN I-Disease
who NN NN O
developed NN NN O
two NN NN O
episodes NN NN O
of NN NN O
transient NN NN O
anuria NN NN B-Disease
after NN NN O
losartan NN NN O
administration NN NN O
. NN NN O
   
He NN NN O
was NN NN O
hospitalized NN NN O
for NN NN O
a NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
with NN NN O
pulmonary NN NN B-Disease
edema NN NN I-Disease
, NN NN O
treated NN NN O
with NN NN O
high NN NN O
- NN NN O
dose NN NN O
diuretics NN NN O
. NN NN O
   
Due NN NN O
to NN NN O
severe NN NN O
systolic NN NN B-Disease
dysfunction NN NN I-Disease
losartan NN NN O
was NN NN O
prescribed NN NN O
. NN NN O
   
Surprisingly NN NN O
, NN NN O
the NN NN O
first NN NN O
dose NN NN O
of NN NN O
50 NN NN O
mg NN NN O
of NN NN O
losartan NN NN O
resulted NN NN O
in NN NN O
a NN NN O
sudden NN NN O
anuria NN NN B-Disease
, NN NN O
which NN NN O
lasted NN NN O
eight NN NN O
hours NN NN O
despite NN NN O
high NN NN O
- NN NN O
dose NN NN O
furosemide NN NN O
and NN NN O
amine NN NN O
infusion NN NN O
. NN NN O
   
One NN NN O
week NN NN O
later NN NN O
, NN NN O
by NN NN O
mistake NN NN O
, NN NN O
losartan NN NN O
was NN NN O
prescribed NN NN O
again NN NN O
and NN NN O
after NN NN O
the NN NN O
second NN NN O
dose NN NN O
of NN NN O
50 NN NN O
mg NN NN O
, NN NN O
the NN NN O
patient NN NN O
developed NN NN O
a NN NN O
second NN NN O
episode NN NN O
of NN NN O
transient NN NN O
anuria NN NN B-Disease
lasting NN NN O
10 NN NN O
hours NN NN O
. NN NN O
   
During NN NN O
these NN NN O
two NN NN O
episodes NN NN O
, NN NN O
his NN NN O
blood NN NN O
pressure NN NN O
diminished NN NN O
but NN NN O
no NN NN O
severe NN NN O
hypotension NN NN B-Disease
was NN NN O
noted NN NN O
. NN NN O
   
Ultimately NN NN O
, NN NN O
an NN NN O
arteriography NN NN O
showed NN NN O
a NN NN O
70 NN NN O
- NN NN O
80 NN NN O
% NN NN O
renal NN NN B-Disease
artery NN NN I-Disease
stenosis NN NN I-Disease
. NN NN O
   
In NN NN O
this NN NN O
patient NN NN O
, NN NN O
renal NN NN B-Disease
artery NN NN I-Disease
stenosis NN NN I-Disease
combined NN NN O
with NN NN O
heart NN NN B-Disease
failure NN NN I-Disease
and NN NN O
diuretic NN NN O
therapy NN NN O
certainly NN NN O
resulted NN NN O
in NN NN O
a NN NN O
strong NN NN O
activation NN NN O
of NN NN O
the NN NN O
renin NN NN O
- NN NN O
angiotensin NN NN O
system NN NN O
( NN NN O
RAS NN NN O
) NN NN O
. NN NN O
   
Under NN NN O
such NN NN O
conditions NN NN O
, NN NN O
angiotensin NN NN O
II NN NN O
receptor NN NN O
blockade NN NN O
by NN NN O
losartan NN NN O
probably NN NN O
induced NN NN O
a NN NN O
critical NN NN O
fall NN NN O
in NN NN O
glomerular NN NN O
filtration NN NN O
pressure NN NN O
. NN NN O
   
This NN NN O
case NN NN O
report NN NN O
highlights NN NN O
the NN NN O
fact NN NN O
that NN NN O
the NN NN O
angiotensin NN NN O
II NN NN O
receptor NN NN O
antagonist NN NN O
losartan NN NN O
can NN NN O
cause NN NN O
serious NN NN O
unexpected NN NN O
complications NN NN O
in NN NN O
patients NN NN O
with NN NN O
renovascular NN NN B-Disease
disease NN NN I-Disease
and NN NN O
should NN NN O
be NN NN O
used NN NN O
with NN NN O
extreme NN NN O
caution NN NN O
in NN NN O
this NN NN O
setting NN NN O
. NN NN O
   
Calcineurin NN NN O
- NN NN O
inhibitor NN NN O
induced NN NN O
pain NN NN B-Disease
syndrome NN NN O
( NN NN O
CIPS NN NN B-Disease
) NN NN O
: NN NN O
a NN NN O
severe NN NN O
disabling NN NN O
complication NN NN O
after NN NN O
organ NN NN O
transplantation NN NN O
. NN NN O
   
Bone NN NN O
pain NN NN B-Disease
after NN NN O
transplantation NN NN O
is NN NN O
a NN NN O
frequent NN NN O
complication NN NN O
that NN NN O
can NN NN O
be NN NN O
caused NN NN O
by NN NN O
several NN NN O
diseases NN NN O
. NN NN O
   
Treatment NN NN O
strategies NN NN O
depend NN NN O
on NN NN O
the NN NN O
correct NN NN O
diagnosis NN NN O
of NN NN O
the NN NN O
pain NN NN B-Disease
. NN NN O
   
Nine NN NN O
patients NN NN O
with NN NN O
severe NN NN O
pain NN NN B-Disease
in NN NN O
their NN NN O
feet NN NN O
, NN NN O
which NN NN O
was NN NN O
registered NN NN O
after NN NN O
transplantation NN NN O
, NN NN O
were NN NN O
investigated NN NN O
. NN NN O
   
Bone NN NN O
scans NN NN O
showed NN NN O
an NN NN O
increased NN NN O
tracer NN NN O
uptake NN NN O
of NN NN O
the NN NN O
foot NN NN O
bones NN NN O
. NN NN O
   
Magnetic NN NN O
resonance NN NN O
imaging NN NN O
demonstrated NN NN O
bone NN NN B-Disease
marrow NN NN I-Disease
oedema NN NN I-Disease
in NN NN O
the NN NN O
painful NN NN O
bones NN NN O
. NN NN O
   
Pain NN NN B-Disease
was NN NN O
not NN NN O
explained NN NN O
by NN NN O
other NN NN O
diseases NN NN O
causing NN NN O
foot NN NN O
pain NN NN B-Disease
, NN NN O
like NN NN O
reflex NN NN B-Disease
sympathetic NN NN I-Disease
dystrophy NN NN I-Disease
, NN NN O
polyneuropathy NN NN B-Disease
, NN NN O
Morton NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
neuralgia NN NN I-Disease
, NN NN O
gout NN NN B-Disease
, NN NN O
osteoporosis NN NN B-Disease
, NN NN O
avascular NN NN B-Disease
necrosis NN NN I-Disease
, NN NN O
intermittent NN NN B-Disease
claudication NN NN I-Disease
, NN NN O
orthopaedic NN NN O
foot NN NN B-Disease
deformities NN NN I-Disease
, NN NN O
stress NN NN B-Disease
fractures NN NN I-Disease
, NN NN O
and NN NN O
hyperparathyroidism NN NN B-Disease
. NN NN O
   
The NN NN O
reduction NN NN O
of NN NN O
cyclosporine NN NN O
- NN NN O
or NN NN O
tacrolimus NN NN O
trough NN NN O
levels NN NN O
and NN NN O
the NN NN O
administration NN NN O
of NN NN O
calcium NN NN O
channel NN NN O
blockers NN NN O
led NN NN O
to NN NN O
relief NN NN O
of NN NN O
pain NN NN B-Disease
. NN NN O
   
The NN NN O
Calcineurin NN NN O
- NN NN O
inhibitor NN NN O
Induced NN NN O
Pain NN NN B-Disease
Syndrome NN NN O
( NN NN O
CIPS NN NN B-Disease
) NN NN O
is NN NN O
a NN NN O
rare NN NN O
but NN NN O
severe NN NN O
side NN NN O
effect NN NN O
of NN NN O
cyclosporine NN NN O
or NN NN O
tacrolimus NN NN O
and NN NN O
is NN NN O
accurately NN NN O
diagnosed NN NN O
by NN NN O
its NN NN O
typical NN NN O
presentation NN NN O
, NN NN O
magnetic NN NN O
resonance NN NN O
imaging NN NN O
and NN NN O
bone NN NN O
scans NN NN O
. NN NN O
   
Incorrect NN NN O
diagnosis NN NN O
of NN NN O
the NN NN O
syndrome NN NN O
will NN NN O
lead NN NN O
to NN NN O
a NN NN O
significant NN NN O
reduction NN NN O
of NN NN O
life NN NN O
quality NN NN O
in NN NN O
patients NN NN O
suffering NN NN O
from NN NN O
CIPS NN NN B-Disease
. NN NN O
   
Brain NN NN O
natriuretic NN NN O
peptide NN NN O
is NN NN O
a NN NN O
predictor NN NN O
of NN NN O
anthracycline NN NN O
- NN NN O
induced NN NN O
cardiotoxicity NN NN B-Disease
. NN NN O
   
Anthracyclines NN NN O
are NN NN O
effective NN NN O
antineoplastic NN NN O
drugs NN NN O
, NN NN O
but NN NN O
they NN NN O
frequently NN NN O
cause NN NN O
dose NN NN O
- NN NN O
related NN NN O
cardiotoxicity NN NN B-Disease
. NN NN O
   
The NN NN O
cardiotoxicity NN NN B-Disease
of NN NN O
conventional NN NN O
anthracycline NN NN O
therapy NN NN O
highlights NN NN O
a NN NN O
need NN NN O
to NN NN O
search NN NN O
for NN NN O
methods NN NN O
that NN NN O
are NN NN O
highly NN NN O
sensitive NN NN O
and NN NN O
capable NN NN O
of NN NN O
predicting NN NN O
cardiac NN NN B-Disease
dysfunction NN NN I-Disease
. NN NN O
   
We NN NN O
measured NN NN O
the NN NN O
plasma NN NN O
level NN NN O
of NN NN O
brain NN NN O
natriuretic NN NN O
peptide NN NN O
( NN NN O
BNP NN NN O
) NN NN O
to NN NN O
determine NN NN O
whether NN NN O
BNP NN NN O
might NN NN O
serve NN NN O
as NN NN O
a NN NN O
simple NN NN O
diagnostic NN NN O
indicator NN NN O
of NN NN O
anthracycline NN NN O
- NN NN O
induced NN NN O
cardiotoxicity NN NN B-Disease
in NN NN O
patients NN NN O
with NN NN O
acute NN NN B-Disease
leukemia NN NN I-Disease
treated NN NN O
with NN NN O
a NN NN O
daunorubicin NN NN O
( NN NN O
DNR NN NN O
) NN NN O
- NN NN O
containing NN NN O
regimen NN NN O
. NN NN O
   
Thirteen NN NN O
patients NN NN O
with NN NN O
acute NN NN B-Disease
leukemia NN NN I-Disease
were NN NN O
treated NN NN O
with NN NN O
a NN NN O
DNR NN NN O
- NN NN O
containing NN NN O
regimen NN NN O
. NN NN O
   
Cardiac NN NN O
functions NN NN O
were NN NN O
evaluated NN NN O
with NN NN O
radionuclide NN NN O
angiography NN NN O
before NN NN O
chemotherapies NN NN O
. NN NN O
   
The NN NN O
plasma NN NN O
levels NN NN O
of NN NN O
atrial NN NN O
natriuretic NN NN O
peptide NN NN O
( NN NN O
ANP NN NN O
) NN NN O
and NN NN O
BNP NN NN O
were NN NN O
measured NN NN O
at NN NN O
the NN NN O
time NN NN O
of NN NN O
radionuclide NN NN O
angiography NN NN O
. NN NN O
   
Three NN NN O
patients NN NN O
developed NN NN O
congestive NN NN B-Disease
heart NN NN I-Disease
failure NN NN I-Disease
after NN NN O
the NN NN O
completion NN NN O
of NN NN O
chemotherapy NN NN O
. NN NN O
   
Five NN NN O
patients NN NN O
were NN NN O
diagnosed NN NN O
as NN NN O
having NN NN O
subclinical NN NN O
heart NN NN B-Disease
failure NN NN I-Disease
after NN NN O
the NN NN O
completion NN NN O
of NN NN O
chemotherapy NN NN O
. NN NN O
   
The NN NN O
plasma NN NN O
levels NN NN O
of NN NN O
BNP NN NN O
in NN NN O
all NN NN O
the NN NN O
patients NN NN O
with NN NN O
clinical NN NN O
and NN NN O
subclinical NN NN O
heart NN NN B-Disease
failure NN NN I-Disease
increased NN NN O
above NN NN O
the NN NN O
normal NN NN O
limit NN NN O
( NN NN O
40 NN NN O
pg NN NN O
/ NN NN O
ml NN NN O
) NN NN O
before NN NN O
the NN NN O
detection NN NN O
of NN NN O
clinical NN NN O
or NN NN O
subclinical NN NN O
heart NN NN B-Disease
failure NN NN I-Disease
by NN NN O
radionuclide NN NN O
angiography NN NN O
. NN NN O
   
On NN NN O
the NN NN O
other NN NN O
hand NN NN O
, NN NN O
BNP NN NN O
did NN NN O
not NN NN O
increase NN NN O
in NN NN O
the NN NN O
patients NN NN O
without NN NN O
heart NN NN B-Disease
failure NN NN I-Disease
given NN NN O
DNR NN NN O
, NN NN O
even NN NN O
at NN NN O
more NN NN O
than NN NN O
700 NN NN O
mg NN NN O
/ NN NN O
m NN NN O
( NN NN O
2 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
plasma NN NN O
level NN NN O
of NN NN O
ANP NN NN O
did NN NN O
not NN NN O
always NN NN O
increase NN NN O
in NN NN O
all NN NN O
the NN NN O
patients NN NN O
with NN NN O
clinical NN NN O
and NN NN O
subclinical NN NN O
heart NN NN B-Disease
failure NN NN I-Disease
. NN NN O
   
These NN NN O
preliminary NN NN O
results NN NN O
suggest NN NN O
that NN NN O
BNP NN NN O
may NN NN O
be NN NN O
useful NN NN O
as NN NN O
an NN NN O
early NN NN O
and NN NN O
sensitive NN NN O
indicator NN NN O
of NN NN O
anthracycline NN NN O
- NN NN O
induced NN NN O
cardiotoxicity NN NN B-Disease
. NN NN O
   
Nephrotoxicity NN NN B-Disease
of NN NN O
combined NN NN O
cephalothin NN NN O
- NN NN O
gentamicin NN NN O
regimen NN NN O
. NN NN O
   
Two NN NN O
patients NN NN O
developed NN NN O
acute NN NN B-Disease
tubular NN NN I-Disease
necrosis NN NN I-Disease
, NN NN O
characterized NN NN O
clinically NN NN O
by NN NN O
acute NN NN O
oliguric NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
, NN NN O
while NN NN O
they NN NN O
were NN NN O
receiving NN NN O
a NN NN O
combination NN NN O
of NN NN O
cephalothin NN NN O
sodium NN NN O
and NN NN O
gentamicin NN NN O
sulfate NN NN O
therapy NN NN O
. NN NN O
   
Patients NN NN O
who NN NN O
are NN NN O
given NN NN O
this NN NN O
drug NN NN O
regimen NN NN O
should NN NN O
be NN NN O
observed NN NN O
very NN NN O
carefully NN NN O
for NN NN O
early NN NN O
signs NN NN O
of NN NN O
nephrotoxicity NN NN B-Disease
. NN NN O
   
High NN NN O
doses NN NN O
of NN NN O
this NN NN O
antibiotic NN NN O
combination NN NN O
should NN NN O
be NN NN O
avoided NN NN O
especially NN NN O
in NN NN O
elderly NN NN O
patients NN NN O
. NN NN O
   
Patients NN NN O
with NN NN O
renal NN NN B-Disease
insufficiency NN NN I-Disease
should NN NN O
not NN NN O
be NN NN O
given NN NN O
this NN NN O
regimen NN NN O
. NN NN O
   
In NN NN O
vivo NN NN O
protection NN NN O
of NN NN O
dna NN NN O
damage NN NN O
associated NN NN O
apoptotic NN NN O
and NN NN O
necrotic NN NN B-Disease
cell NN NN O
deaths NN NN O
during NN NN O
acetaminophen NN NN O
- NN NN O
induced NN NN O
nephrotoxicity NN NN B-Disease
, NN NN O
amiodarone NN NN O
- NN NN O
induced NN NN O
lung NN NN B-Disease
toxicity NN NN I-Disease
and NN NN O
doxorubicin NN NN O
- NN NN O
induced NN NN O
cardiotoxicity NN NN B-Disease
by NN NN O
a NN NN O
novel NN NN O
IH636 NN NN O
grape NN NN O
seed NN NN O
proanthocyanidin NN NN O
extract NN NN O
. NN NN O
   
Grape NN NN O
seed NN NN O
extract NN NN O
, NN NN O
primarily NN NN O
a NN NN O
mixture NN NN O
of NN NN O
proanthocyanidins NN NN O
, NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
modulate NN NN O
a NN NN O
wide NN NN O
- NN NN O
range NN NN O
of NN NN O
biological NN NN O
, NN NN O
pharmacological NN NN O
and NN NN O
toxicological NN NN O
effects NN NN O
which NN NN O
are NN NN O
mainly NN NN O
cytoprotective NN NN O
. NN NN O
   
This NN NN O
study NN NN O
assessed NN NN O
the NN NN O
ability NN NN O
of NN NN O
IH636 NN NN O
grape NN NN O
seed NN NN O
proanthocyanidin NN NN O
extract NN NN O
( NN NN O
GSPE NN NN O
) NN NN O
to NN NN O
prevent NN NN O
acetaminophen NN NN O
( NN NN O
AAP NN NN O
) NN NN O
- NN NN O
induced NN NN O
nephrotoxicity NN NN B-Disease
, NN NN O
amiodarone NN NN O
( NN NN O
AMI NN NN O
) NN NN O
- NN NN O
induced NN NN O
lung NN NN B-Disease
toxicity NN NN I-Disease
, NN NN O
and NN NN O
doxorubicin NN NN O
( NN NN O
DOX NN NN O
) NN NN O
- NN NN O
induced NN NN O
cardiotoxicity NN NN B-Disease
in NN NN O
mice NN NN O
. NN NN O
   
Experimental NN NN O
design NN NN O
consisted NN NN O
of NN NN O
four NN NN O
groups NN NN O
: NN NN O
control NN NN O
( NN NN O
vehicle NN NN O
alone NN NN O
) NN NN O
, NN NN O
GSPE NN NN O
alone NN NN O
, NN NN O
drug NN NN O
alone NN NN O
and NN NN O
GSPE NN NN O
+ NN NN O
drug NN NN O
. NN NN O
   
For NN NN O
the NN NN O
cytoprotection NN NN O
study NN NN O
, NN NN O
animals NN NN O
were NN NN O
orally NN NN O
gavaged NN NN O
100 NN NN O
mg NN NN O
/ NN NN O
Kg NN NN O
GSPE NN NN O
for NN NN O
7 NN NN O
- NN NN O
10 NN NN O
days NN NN O
followed NN NN O
by NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
injections NN NN O
of NN NN O
organ NN NN O
specific NN NN O
three NN NN O
drugs NN NN O
( NN NN O
AAP NN NN O
: NN NN O
500 NN NN O
mg NN NN O
/ NN NN O
Kg NN NN O
for NN NN O
24 NN NN O
h NN NN O
; NN NN O
AMI NN NN O
: NN NN O
50 NN NN O
mg NN NN O
/ NN NN O
Kg NN NN O
/ NN NN O
day NN NN O
for NN NN O
four NN NN O
days NN NN O
; NN NN O
DOX NN NN O
: NN NN O
20 NN NN O
mg NN NN O
/ NN NN O
Kg NN NN O
for NN NN O
48 NN NN O
h NN NN O
) NN NN O
. NN NN O
   
Parameters NN NN O
of NN NN O
study NN NN O
included NN NN O
analysis NN NN O
of NN NN O
serum NN NN O
chemistry NN NN O
( NN NN O
ALT NN NN O
, NN NN O
BUN NN NN O
and NN NN O
CPK NN NN O
) NN NN O
, NN NN O
and NN NN O
orderly NN NN O
fragmentation NN NN O
of NN NN O
genomic NN NN O
DNA NN NN O
( NN NN O
both NN NN O
endonuclease NN NN O
- NN NN O
dependent NN NN O
and NN NN O
independent NN NN O
) NN NN O
in NN NN O
addition NN NN O
to NN NN O
microscopic NN NN O
evaluation NN NN O
of NN NN O
damage NN NN O
and NN NN O
/ NN NN O
or NN NN O
protection NN NN O
in NN NN O
corresponding NN NN O
PAS NN NN O
stained NN NN O
tissues NN NN O
. NN NN O
   
Results NN NN O
indicate NN NN O
that NN NN O
GSPE NN NN O
preexposure NN NN O
prior NN NN O
to NN NN O
AAP NN NN O
, NN NN O
AMI NN NN O
and NN NN O
DOX NN NN O
, NN NN O
provided NN NN O
near NN NN O
complete NN NN O
protection NN NN O
in NN NN O
terms NN NN O
of NN NN O
serum NN NN O
chemistry NN NN O
changes NN NN O
( NN NN O
ALT NN NN O
, NN NN O
BUN NN NN O
and NN NN O
CPK NN NN O
) NN NN O
, NN NN O
and NN NN O
significantly NN NN O
reduced NN NN O
DNA NN NN O
fragmentation NN NN O
. NN NN O
   
Histopathological NN NN O
examination NN NN O
of NN NN O
kidney NN NN O
, NN NN O
heart NN NN O
and NN NN O
lung NN NN O
sections NN NN O
revealed NN NN O
moderate NN NN O
to NN NN O
massive NN NN O
tissue NN NN B-Disease
damage NN NN I-Disease
with NN NN O
a NN NN O
variety NN NN O
of NN NN O
morphological NN NN O
aberrations NN NN O
by NN NN O
all NN NN O
the NN NN O
three NN NN O
drugs NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
GSPE NN NN O
preexposure NN NN O
than NN NN O
in NN NN O
its NN NN O
presence NN NN O
. NN NN O
   
GSPE NN NN O
+ NN NN O
drug NN NN O
exposed NN NN O
tissues NN NN O
exhibited NN NN O
minor NN NN O
residual NN NN O
damage NN NN O
or NN NN O
near NN NN O
total NN NN O
recovery NN NN O
. NN NN O
   
Additionally NN NN O
, NN NN O
histopathological NN NN O
alterations NN NN O
mirrored NN NN O
both NN NN O
serum NN NN O
chemistry NN NN O
changes NN NN O
and NN NN O
the NN NN O
pattern NN NN O
of NN NN O
DNA NN NN O
fragmentation NN NN O
. NN NN O
   
Interestingly NN NN O
, NN NN O
all NN NN O
the NN NN O
drugs NN NN O
, NN NN O
such NN NN O
as NN NN O
, NN NN O
AAP NN NN O
, NN NN O
AMI NN NN O
and NN NN O
DOX NN NN O
induced NN NN O
apoptotic NN NN O
death NN NN O
in NN NN O
addition NN NN O
to NN NN O
necrosis NN NN B-Disease
in NN NN O
the NN NN O
respective NN NN O
organs NN NN O
which NN NN O
was NN NN O
very NN NN O
effectively NN NN O
blocked NN NN O
by NN NN O
GSPE NN NN O
. NN NN O
   
Since NN NN O
AAP NN NN O
, NN NN O
AMI NN NN O
and NN NN O
DOX NN NN O
undergo NN NN O
biotransformation NN NN O
and NN NN O
are NN NN O
known NN NN O
to NN NN O
produce NN NN O
damaging NN NN O
radicals NN NN O
in NN NN O
vivo NN NN O
, NN NN O
the NN NN O
protection NN NN O
by NN NN O
GSPE NN NN O
may NN NN O
be NN NN O
linked NN NN O
to NN NN O
both NN NN O
inhibition NN NN O
of NN NN O
metabolism NN NN O
and NN NN O
/ NN NN O
or NN NN O
detoxification NN NN O
of NN NN O
cytotoxic NN NN O
radicals NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
its NN NN O
' NN NN O
presumed NN NN O
contribution NN NN O
to NN NN O
DNA NN NN O
repair NN NN O
may NN NN O
be NN NN O
another NN NN O
important NN NN O
attribute NN NN O
, NN NN O
which NN NN O
played NN NN O
a NN NN O
role NN NN O
in NN NN O
the NN NN O
chemoprevention NN NN O
process NN NN O
. NN NN O
   
Additionally NN NN O
, NN NN O
this NN NN O
may NN NN O
have NN NN O
been NN NN O
the NN NN O
first NN NN O
report NN NN O
on NN NN O
AMI NN NN O
- NN NN O
induced NN NN O
apoptotic NN NN O
death NN NN O
in NN NN O
the NN NN O
lung NN NN O
tissue NN NN O
. NN NN O
   
Taken NN NN O
together NN NN O
, NN NN O
these NN NN O
events NN NN O
undoubtedly NN NN O
establish NN NN O
GSPE NN NN O
' NN NN O
s NN NN O
abundant NN NN O
bioavailability NN NN O
, NN NN O
and NN NN O
the NN NN O
power NN NN O
to NN NN O
defend NN NN O
multiple NN NN O
target NN NN O
organs NN NN O
from NN NN O
toxic NN NN O
assaults NN NN O
induced NN NN O
by NN NN O
structurally NN NN O
diverse NN NN O
and NN NN O
functionally NN NN O
different NN NN O
entities NN NN O
in NN NN O
vivo NN NN O
. NN NN O
   
Antidepressant NN NN O
- NN NN O
induced NN NN O
mania NN NN B-Disease
in NN NN O
bipolar NN NN B-Disease
patients NN NN O
: NN NN O
identification NN NN O
of NN NN O
risk NN NN O
factors NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Concerns NN NN O
about NN NN O
possible NN NN O
risks NN NN O
of NN NN O
switching NN NN O
to NN NN O
mania NN NN B-Disease
associated NN NN O
with NN NN O
antidepressants NN NN O
continue NN NN O
to NN NN O
interfere NN NN O
with NN NN O
the NN NN O
establishment NN NN O
of NN NN O
an NN NN O
optimal NN NN O
treatment NN NN O
paradigm NN NN O
for NN NN O
bipolar NN NN B-Disease
depression NN NN I-Disease
. NN NN O
   
METHOD NN NN O
: NN NN O
The NN NN O
response NN NN O
of NN NN O
44 NN NN O
patients NN NN O
meeting NN NN O
DSM NN NN O
- NN NN O
IV NN NN O
criteria NN NN O
for NN NN O
bipolar NN NN B-Disease
disorder NN NN I-Disease
to NN NN O
naturalistic NN NN O
treatment NN NN O
was NN NN O
assessed NN NN O
for NN NN O
at NN NN O
least NN NN O
6 NN NN O
weeks NN NN O
using NN NN O
the NN NN O
Montgomery NN NN O
- NN NN O
Asberg NN NN O
Depression NN NN O
Rating NN NN O
Scale NN NN O
and NN NN O
the NN NN O
Bech NN NN O
- NN NN O
Rafaelson NN NN O
Mania NN NN O
Rating NN NN O
Scale NN NN O
. NN NN O
   
Patients NN NN O
who NN NN O
experienced NN NN O
a NN NN O
manic NN NN B-Disease
or NN NN O
hypomanic NN NN B-Disease
switch NN NN O
were NN NN O
compared NN NN O
with NN NN O
those NN NN O
who NN NN O
did NN NN O
not NN NN O
on NN NN O
several NN NN O
variables NN NN O
including NN NN O
age NN NN O
, NN NN O
sex NN NN O
, NN NN O
diagnosis NN NN O
( NN NN O
DSM NN NN B-Disease
- NN NN I-Disease
IV NN NN I-Disease
bipolar NN NN I-Disease
I NN NN I-Disease
vs NN NN O
. NN NN O
bipolar NN NN B-Disease
II NN NN I-Disease
) NN NN O
, NN NN O
number NN NN O
of NN NN O
previous NN NN O
manic NN NN B-Disease
episodes NN NN O
, NN NN O
type NN NN O
of NN NN O
antidepressant NN NN O
therapy NN NN O
used NN NN O
( NN NN O
electroconvulsive NN NN O
therapy NN NN O
vs NN NN O
. NN NN O
antidepressant NN NN O
drugs NN NN O
and NN NN O
, NN NN O
more NN NN O
particularly NN NN O
, NN NN O
selective NN NN O
serotonin NN NN O
reuptake NN NN O
inhibitors NN NN O
[ NN NN O
SSRIs NN NN O
] NN NN O
) NN NN O
, NN NN O
use NN NN O
and NN NN O
type NN NN O
of NN NN O
mood NN NN O
stabilizers NN NN O
( NN NN O
lithium NN NN O
vs NN NN O
. NN NN O
anticonvulsants NN NN O
) NN NN O
, NN NN O
and NN NN O
temperament NN NN O
of NN NN O
the NN NN O
patient NN NN O
, NN NN O
assessed NN NN O
during NN NN O
a NN NN O
normothymic NN NN O
period NN NN O
using NN NN O
the NN NN O
hyperthymia NN NN O
component NN NN O
of NN NN O
the NN NN O
Semi NN NN O
- NN NN O
structured NN NN O
Affective NN NN O
Temperament NN NN O
Interview NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Switches NN NN O
to NN NN O
hypomania NN NN B-Disease
or NN NN O
mania NN NN B-Disease
occurred NN NN O
in NN NN O
27 NN NN O
% NN NN O
of NN NN O
all NN NN O
patients NN NN O
( NN NN O
N NN NN O
= NN NN O
12 NN NN O
) NN NN O
( NN NN O
and NN NN O
in NN NN O
24 NN NN O
% NN NN O
of NN NN O
the NN NN O
subgroup NN NN O
of NN NN O
patients NN NN O
treated NN NN O
with NN NN O
SSRIs NN NN O
[ NN NN O
8 NN NN O
/ NN NN O
33 NN NN O
] NN NN O
) NN NN O
; NN NN O
16 NN NN O
% NN NN O
( NN NN O
N NN NN O
= NN NN O
7 NN NN O
) NN NN O
experienced NN NN O
manic NN NN B-Disease
episodes NN NN O
, NN NN O
and NN NN O
11 NN NN O
% NN NN O
( NN NN O
N NN NN O
= NN NN O
5 NN NN O
) NN NN O
experienced NN NN O
hypomanic NN NN B-Disease
episodes NN NN O
. NN NN O
   
Sex NN NN O
, NN NN O
age NN NN O
, NN NN O
diagnosis NN NN O
( NN NN O
bipolar NN NN B-Disease
I NN NN I-Disease
vs NN NN O
. NN NN O
bipolar NN NN B-Disease
II NN NN I-Disease
) NN NN O
, NN NN O
and NN NN O
additional NN NN O
treatment NN NN O
did NN NN O
not NN NN O
affect NN NN O
the NN NN O
risk NN NN O
of NN NN O
switching NN NN O
. NN NN O
   
The NN NN O
incidence NN NN O
of NN NN O
mood NN NN O
switches NN NN O
seemed NN NN O
not NN NN O
to NN NN O
differ NN NN O
between NN NN O
patients NN NN O
receiving NN NN O
an NN NN O
anticonvulsant NN NN O
and NN NN O
those NN NN O
receiving NN NN O
no NN NN O
mood NN NN O
stabilizer NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
mood NN NN O
switches NN NN O
were NN NN O
less NN NN O
frequent NN NN O
in NN NN O
patients NN NN O
receiving NN NN O
lithium NN NN O
( NN NN O
15 NN NN O
% NN NN O
, NN NN O
4 NN NN O
/ NN NN O
26 NN NN O
) NN NN O
than NN NN O
in NN NN O
patients NN NN O
not NN NN O
treated NN NN O
with NN NN O
lithium NN NN O
( NN NN O
44 NN NN O
% NN NN O
, NN NN O
8 NN NN O
/ NN NN O
18 NN NN O
; NN NN O
p NN NN O
= NN NN O
. NN NN O
04 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
number NN NN O
of NN NN O
previous NN NN O
manic NN NN B-Disease
episodes NN NN O
did NN NN O
not NN NN O
affect NN NN O
the NN NN O
probability NN NN O
of NN NN O
switching NN NN O
, NN NN O
whereas NN NN O
a NN NN O
high NN NN O
score NN NN O
on NN NN O
the NN NN O
hyperthymia NN NN O
component NN NN O
of NN NN O
the NN NN O
Semistructured NN NN O
Affective NN NN O
Temperament NN NN O
Interview NN NN O
was NN NN O
associated NN NN O
with NN NN O
a NN NN O
greater NN NN O
risk NN NN O
of NN NN O
switching NN NN O
( NN NN O
p NN NN O
= NN NN O
. NN NN O
008 NN NN O
) NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
The NN NN O
frequency NN NN O
of NN NN O
mood NN NN O
switching NN NN O
associated NN NN O
with NN NN O
acute NN NN O
antidepressant NN NN O
therapy NN NN O
may NN NN O
be NN NN O
reduced NN NN O
by NN NN O
lithium NN NN O
treatment NN NN O
. NN NN O
   
Particular NN NN O
attention NN NN O
should NN NN O
be NN NN O
paid NN NN O
to NN NN O
patients NN NN O
with NN NN O
a NN NN O
hyperthymic NN NN O
temperament NN NN O
, NN NN O
who NN NN O
have NN NN O
a NN NN O
greater NN NN O
risk NN NN O
of NN NN O
mood NN NN O
switches NN NN O
. NN NN O
   
Peritubular NN NN O
capillary NN NN O
basement NN NN O
membrane NN NN O
reduplication NN NN O
in NN NN O
allografts NN NN O
and NN NN O
native NN NN O
kidney NN NN B-Disease
disease NN NN I-Disease
: NN NN O
a NN NN O
clinicopathologic NN NN O
study NN NN O
of NN NN O
278 NN NN O
consecutive NN NN O
renal NN NN O
specimens NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
An NN NN O
association NN NN O
has NN NN O
been NN NN O
found NN NN O
between NN NN O
transplant NN NN B-Disease
glomerulopathy NN NN I-Disease
( NN NN O
TG NN NN B-Disease
) NN NN O
and NN NN O
reduplication NN NN O
of NN NN O
peritubular NN NN O
capillary NN NN O
basement NN NN O
membranes NN NN O
( NN NN O
PTCR NN NN O
) NN NN O
. NN NN O
   
Although NN NN O
such NN NN O
an NN NN O
association NN NN O
is NN NN O
of NN NN O
practical NN NN O
and NN NN O
theoretical NN NN O
importance NN NN O
, NN NN O
only NN NN O
one NN NN O
prospective NN NN O
study NN NN O
has NN NN O
tried NN NN O
to NN NN O
confirm NN NN O
it NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
We NN NN O
examined NN NN O
278 NN NN O
consecutive NN NN O
renal NN NN O
specimens NN NN O
( NN NN O
from NN NN O
135 NN NN O
transplants NN NN O
and NN NN O
143 NN NN O
native NN NN O
kidneys NN NN O
) NN NN O
for NN NN O
ultrastructural NN NN O
evidence NN NN O
of NN NN O
PTCR NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
to NN NN O
renal NN NN O
allografts NN NN O
with NN NN O
TG NN NN B-Disease
, NN NN O
we NN NN O
also NN NN O
examined NN NN O
grafts NN NN O
with NN NN O
acute NN NN O
rejection NN NN O
, NN NN O
recurrent NN NN O
glomerulonephritis NN NN B-Disease
, NN NN O
chronic NN NN B-Disease
allograft NN NN I-Disease
nephropathy NN NN I-Disease
and NN NN O
stable NN NN O
grafts NN NN O
( NN NN O
"""""""" NN NN O
protocol NN NN O
biopsies NN NN O
"""""""" NN NN O
) NN NN O
. NN NN O
   
Native NN NN O
kidney NN NN O
specimens NN NN O
included NN NN O
a NN NN O
wide NN NN O
range NN NN O
of NN NN O
glomerulopathies NN NN B-Disease
as NN NN O
well NN NN O
as NN NN O
cases NN NN O
of NN NN O
thrombotic NN NN B-Disease
microangiopathy NN NN I-Disease
, NN NN O
malignant NN NN B-Disease
hypertension NN NN I-Disease
, NN NN O
acute NN NN O
interstitial NN NN B-Disease
nephritis NN NN I-Disease
, NN NN O
and NN NN O
acute NN NN B-Disease
tubular NN NN I-Disease
necrosis NN NN I-Disease
. NN NN O
   
RESULTS NN NN O
: NN NN O
We NN NN O
found NN NN O
PTCR NN NN O
in NN NN O
14 NN NN O
of NN NN O
15 NN NN O
cases NN NN O
of NN NN O
TG NN NN B-Disease
, NN NN O
in NN NN O
7 NN NN O
transplant NN NN O
biopsy NN NN O
specimens NN NN O
without NN NN O
TG NN NN B-Disease
, NN NN O
and NN NN O
in NN NN O
13 NN NN O
of NN NN O
143 NN NN O
native NN NN O
kidney NN NN O
biopsy NN NN O
specimens NN NN O
. NN NN O
   
These NN NN O
13 NN NN O
included NN NN O
cases NN NN O
of NN NN O
malignant NN NN B-Disease
hypertension NN NN I-Disease
, NN NN O
thrombotic NN NN B-Disease
microangiopathy NN NN I-Disease
, NN NN O
lupus NN NN B-Disease
nephritis NN NN I-Disease
, NN NN O
Henoch NN NN B-Disease
- NN NN I-Disease
Schonlein NN NN I-Disease
nephritis NN NN I-Disease
, NN NN O
crescentic NN NN O
glomerulonephritis NN NN B-Disease
, NN NN O
and NN NN O
cocaine NN NN O
- NN NN O
related NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
. NN NN O
   
Mild NN NN O
PTCR NN NN O
in NN NN O
allografts NN NN O
without NN NN O
TG NN NN B-Disease
did NN NN O
not NN NN O
predict NN NN O
renal NN NN B-Disease
failure NN NN I-Disease
or NN NN O
significant NN NN O
proteinuria NN NN B-Disease
after NN NN O
follow NN NN O
- NN NN O
up NN NN O
periods NN NN O
of NN NN O
between NN NN O
3 NN NN O
months NN NN O
and NN NN O
1 NN NN O
year NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
We NN NN O
conclude NN NN O
that NN NN O
in NN NN O
transplants NN NN O
, NN NN O
there NN NN O
is NN NN O
a NN NN O
strong NN NN O
association NN NN O
between NN NN O
well NN NN O
- NN NN O
developed NN NN O
PTCR NN NN O
and NN NN O
TG NN NN B-Disease
, NN NN O
while NN NN O
the NN NN O
significance NN NN O
of NN NN O
mild NN NN O
PTCR NN NN O
and NN NN O
its NN NN O
predictive NN NN O
value NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
TG NN NN B-Disease
is NN NN O
unclear NN NN O
. NN NN O
   
PTCR NN NN O
also NN NN O
occurs NN NN O
in NN NN O
certain NN NN O
native NN NN O
kidney NN NN B-Disease
diseases NN NN I-Disease
, NN NN O
though NN NN O
the NN NN O
association NN NN O
is NN NN O
not NN NN O
as NN NN O
strong NN NN O
as NN NN O
that NN NN O
for NN NN O
TG NN NN B-Disease
. NN NN O
   
We NN NN O
suggest NN NN O
that NN NN O
repeated NN NN O
endothelial NN NN B-Disease
injury NN NN I-Disease
, NN NN O
including NN NN O
immunologic NN NN B-Disease
injury NN NN I-Disease
, NN NN O
may NN NN O
be NN NN O
the NN NN O
cause NN NN O
of NN NN O
this NN NN O
lesion NN NN O
both NN NN O
in NN NN O
allografts NN NN O
and NN NN O
native NN NN O
kidneys NN NN O
. NN NN O
   
Caffeine NN NN O
- NN NN O
induced NN NN O
cardiac NN NN B-Disease
arrhythmia NN NN I-Disease
: NN NN O
an NN NN O
unrecognised NN NN O
danger NN NN O
of NN NN O
healthfood NN NN O
products NN NN O
. NN NN O
   
We NN NN O
describe NN NN O
a NN NN O
25 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
woman NN NN O
with NN NN O
pre NN NN O
- NN NN O
existing NN NN O
mitral NN NN B-Disease
valve NN NN I-Disease
prolapse NN NN I-Disease
who NN NN O
developed NN NN O
intractable NN NN O
ventricular NN NN B-Disease
fibrillation NN NN I-Disease
after NN NN O
consuming NN NN O
a NN NN O
"""""""" NN NN O
natural NN NN O
energy NN NN O
"""""""" NN NN O
guarana NN NN O
health NN NN O
drink NN NN O
containing NN NN O
a NN NN O
high NN NN O
concentration NN NN O
of NN NN O
caffeine NN NN O
. NN NN O
   
This NN NN O
case NN NN O
highlights NN NN O
the NN NN O
need NN NN O
for NN NN O
adequate NN NN O
labelling NN NN O
and NN NN O
regulation NN NN O
of NN NN O
such NN NN O
products NN NN O
. NN NN O
   
Conformationally NN NN O
restricted NN NN O
analogs NN NN O
of NN NN O
BD1008 NN NN O
and NN NN O
an NN NN O
antisense NN NN O
oligodeoxynucleotide NN NN O
targeting NN NN O
sigma1 NN NN O
receptors NN NN O
produce NN NN O
anti NN NN O
- NN NN O
cocaine NN NN O
effects NN NN O
in NN NN O
mice NN NN O
. NN NN O
   
Cocaine NN NN O
' NN NN O
s NN NN O
ability NN NN O
to NN NN O
interact NN NN O
with NN NN O
sigma NN NN O
receptors NN NN O
suggests NN NN O
that NN NN O
these NN NN O
proteins NN NN O
mediate NN NN O
some NN NN O
of NN NN O
its NN NN O
behavioral NN NN O
effects NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
three NN NN O
novel NN NN O
sigma NN NN O
receptor NN NN O
ligands NN NN O
with NN NN O
antagonist NN NN O
activity NN NN O
were NN NN O
evaluated NN NN O
in NN NN O
Swiss NN NN O
Webster NN NN O
mice NN NN O
: NN NN O
BD1018 NN NN O
( NN NN O
3S NN NN O
- NN NN O
1 NN NN O
- NN NN O
[ NN NN O
2 NN NN O
- NN NN O
( NN NN O
3 NN NN O
, NN NN O
4 NN NN O
- NN NN O
dichlorophenyl NN NN O
) NN NN O
ethyl NN NN O
] NN NN O
- NN NN O
1 NN NN O
, NN NN O
4 NN NN O
- NN NN O
diazabicyclo NN NN O
[ NN NN O
4 NN NN O
. NN NN O
3 NN NN O
. NN NN O
0 NN NN O
] NN NN O
nonane NN NN O
) NN NN O
, NN NN O
BD1063 NN NN O
( NN NN O
1 NN NN O
- NN NN O
[ NN NN O
2 NN NN O
- NN NN O
( NN NN O
3 NN NN O
, NN NN O
4 NN NN O
- NN NN O
dichlorophenyl NN NN O
) NN NN O
ethyl NN NN O
] NN NN O
- NN NN O
4 NN NN O
- NN NN O
methylpiperazine NN NN O
) NN NN O
, NN NN O
and NN NN O
LR132 NN NN O
( NN NN O
1R NN NN O
, NN NN O
2S NN NN O
- NN NN O
( NN NN O
+ NN NN O
) NN NN O
- NN NN O
cis NN NN O
- NN NN O
N NN NN O
- NN NN O
[ NN NN O
2 NN NN O
- NN NN O
( NN NN O
3 NN NN O
, NN NN O
4 NN NN O
- NN NN O
dichlorophenyl NN NN O
) NN NN O
ethyl NN NN O
] NN NN O
- NN NN O
2 NN NN O
- NN NN O
( NN NN O
1 NN NN O
- NN NN O
pyrrolidinyl NN NN O
) NN NN O
cyclohexylamine NN NN O
) NN NN O
. NN NN O
   
Competition NN NN O
binding NN NN O
assays NN NN O
demonstrated NN NN O
that NN NN O
all NN NN O
three NN NN O
compounds NN NN O
have NN NN O
high NN NN O
affinities NN NN O
for NN NN O
sigma1 NN NN O
receptors NN NN O
. NN NN O
   
The NN NN O
three NN NN O
compounds NN NN O
vary NN NN O
in NN NN O
their NN NN O
affinities NN NN O
for NN NN O
sigma2 NN NN O
receptors NN NN O
and NN NN O
exhibit NN NN O
negligible NN NN O
affinities NN NN O
for NN NN O
dopamine NN NN O
, NN NN O
opioid NN NN O
, NN NN O
GABA NN NN O
( NN NN O
A NN NN O
) NN NN O
and NN NN O
NMDA NN NN O
receptors NN NN O
. NN NN O
   
In NN NN O
behavioral NN NN O
studies NN NN O
, NN NN O
pre NN NN O
- NN NN O
treatment NN NN O
of NN NN O
mice NN NN O
with NN NN O
BD1018 NN NN O
, NN NN O
BD1063 NN NN O
, NN NN O
or NN NN O
LR132 NN NN O
significantly NN NN O
attenuated NN NN O
cocaine NN NN O
- NN NN O
induced NN NN O
convulsions NN NN B-Disease
and NN NN O
lethality NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
post NN NN O
- NN NN O
treatment NN NN O
with NN NN O
LR132 NN NN O
prevented NN NN O
cocaine NN NN O
- NN NN O
induced NN NN O
lethality NN NN O
in NN NN O
a NN NN O
significant NN NN O
proportion NN NN O
of NN NN O
animals NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
to NN NN O
the NN NN O
protection NN NN O
provided NN NN O
by NN NN O
the NN NN O
putative NN NN O
antagonists NN NN O
, NN NN O
the NN NN O
well NN NN O
- NN NN O
characterized NN NN O
sigma NN NN O
receptor NN NN O
agonist NN NN O
di NN NN O
- NN NN O
o NN NN O
- NN NN O
tolylguanidine NN NN O
( NN NN O
DTG NN NN O
) NN NN O
and NN NN O
the NN NN O
novel NN NN O
sigma NN NN O
receptor NN NN O
agonist NN NN O
BD1031 NN NN O
( NN NN O
3R NN NN O
- NN NN O
1 NN NN O
- NN NN O
[ NN NN O
2 NN NN O
- NN NN O
( NN NN O
3 NN NN O
, NN NN O
4 NN NN O
- NN NN O
dichlorophenyl NN NN O
) NN NN O
ethyl NN NN O
] NN NN O
- NN NN O
1 NN NN O
, NN NN O
4 NN NN O
- NN NN O
diazabicyclo NN NN O
[ NN NN O
4 NN NN O
. NN NN O
3 NN NN O
. NN NN O
0 NN NN O
] NN NN O
nonane NN NN O
) NN NN O
each NN NN O
worsened NN NN O
the NN NN O
behavioral NN NN O
toxicity NN NN B-Disease
of NN NN O
cocaine NN NN O
. NN NN O
   
At NN NN O
doses NN NN O
where NN NN O
alone NN NN O
, NN NN O
they NN NN O
produced NN NN O
no NN NN O
significant NN NN O
effects NN NN O
on NN NN O
locomotion NN NN O
, NN NN O
BD1018 NN NN O
, NN NN O
BD1063 NN NN O
and NN NN O
LR132 NN NN O
significantly NN NN O
attenuated NN NN O
the NN NN O
locomotor NN NN O
stimulatory NN NN O
effects NN NN O
of NN NN O
cocaine NN NN O
. NN NN O
   
To NN NN O
further NN NN O
validate NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
the NN NN O
anti NN NN O
- NN NN O
cocaine NN NN O
effects NN NN O
of NN NN O
the NN NN O
novel NN NN O
ligands NN NN O
involved NN NN O
antagonism NN NN O
of NN NN O
sigma NN NN O
receptors NN NN O
, NN NN O
an NN NN O
antisense NN NN O
oligodeoxynucleotide NN NN O
against NN NN O
sigma1 NN NN O
receptors NN NN O
was NN NN O
also NN NN O
shown NN NN O
to NN NN O
significantly NN NN O
attenuate NN NN O
the NN NN O
convulsive NN NN B-Disease
and NN NN O
locomotor NN NN O
stimulatory NN NN O
effects NN NN O
of NN NN O
cocaine NN NN O
. NN NN O
   
Together NN NN O
, NN NN O
the NN NN O
data NN NN O
suggests NN NN O
that NN NN O
functional NN NN O
antagonism NN NN O
of NN NN O
sigma NN NN O
receptors NN NN O
is NN NN O
capable NN NN O
of NN NN O
attenuating NN NN O
a NN NN O
number NN NN O
of NN NN O
cocaine NN NN O
- NN NN O
induced NN NN O
behaviors NN NN O
. NN NN O
   
Ranitidine NN NN O
- NN NN O
induced NN NN O
acute NN NN O
interstitial NN NN B-Disease
nephritis NN NN I-Disease
in NN NN O
a NN NN O
cadaveric NN NN O
renal NN NN O
allograft NN NN O
. NN NN O
   
Ranitidine NN NN O
frequently NN NN O
is NN NN O
used NN NN O
for NN NN O
preventing NN NN O
peptic NN NN O
ulceration NN NN O
after NN NN O
renal NN NN O
transplantation NN NN O
. NN NN O
   
This NN NN O
drug NN NN O
occasionally NN NN O
has NN NN O
been NN NN O
associated NN NN O
with NN NN O
acute NN NN O
interstitial NN NN B-Disease
nephritis NN NN I-Disease
in NN NN O
native NN NN O
kidneys NN NN O
. NN NN O
   
There NN NN O
are NN NN O
no NN NN O
similar NN NN O
reports NN NN O
with NN NN O
renal NN NN O
transplantation NN NN O
. NN NN O
   
We NN NN O
report NN NN O
a NN NN O
case NN NN O
of NN NN O
ranitidine NN NN O
- NN NN O
induced NN NN O
acute NN NN O
interstitial NN NN B-Disease
nephritis NN NN I-Disease
in NN NN O
a NN NN O
recipient NN NN O
of NN NN O
a NN NN O
cadaveric NN NN O
renal NN NN O
allograft NN NN O
presenting NN NN O
with NN NN O
acute NN NN O
allograft NN NN O
dysfunction NN NN O
within NN NN O
48 NN NN O
hours NN NN O
of NN NN O
exposure NN NN O
to NN NN O
the NN NN O
drug NN NN O
. NN NN O
   
The NN NN O
biopsy NN NN O
specimen NN NN O
showed NN NN O
pathognomonic NN NN O
features NN NN O
, NN NN O
including NN NN O
eosinophilic NN NN O
infiltration NN NN O
of NN NN O
the NN NN O
interstitial NN NN O
compartment NN NN O
. NN NN O
   
Allograft NN NN O
function NN NN O
improved NN NN O
rapidly NN NN O
and NN NN O
returned NN NN O
to NN NN O
baseline NN NN O
after NN NN O
stopping NN NN O
the NN NN O
drug NN NN O
. NN NN O
   
Liver NN NN B-Disease
disease NN NN I-Disease
caused NN NN O
by NN NN O
propylthiouracil NN NN O
. NN NN O
   
This NN NN O
report NN NN O
presents NN NN O
the NN NN O
clinical NN NN O
, NN NN O
laboratory NN NN O
, NN NN O
and NN NN O
light NN NN O
and NN NN O
electron NN NN O
microscopic NN NN O
observations NN NN O
on NN NN O
a NN NN O
patient NN NN O
with NN NN O
chronic NN NN B-Disease
active NN NN I-Disease
( NN NN I-Disease
aggressive NN NN I-Disease
) NN NN I-Disease
hepatitis NN NN I-Disease
caused NN NN O
by NN NN O
the NN NN O
administration NN NN O
of NN NN O
propylthiouracil NN NN O
. NN NN O
   
This NN NN O
is NN NN O
an NN NN O
addition NN NN O
to NN NN O
the NN NN O
list NN NN O
of NN NN O
drugs NN NN O
that NN NN O
must NN NN O
be NN NN O
considered NN NN O
in NN NN O
the NN NN O
evaluation NN NN O
of NN NN O
chronic NN NN O
liver NN NN B-Disease
disease NN NN I-Disease
. NN NN O
   
Withdrawal NN NN B-Disease
- NN NN I-Disease
emergent NN NN I-Disease
rabbit NN NN I-Disease
syndrome NN NN I-Disease
during NN NN O
dose NN NN O
reduction NN NN O
of NN NN O
risperidone NN NN O
. NN NN O
   
Rabbit NN NN B-Disease
syndrome NN NN I-Disease
( NN NN O
RS NN NN B-Disease
) NN NN O
is NN NN O
a NN NN O
rare NN NN O
extrapyramidal NN NN O
side NN NN O
effect NN NN O
caused NN NN O
by NN NN O
prolonged NN NN O
neuroleptic NN NN O
medication NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
present NN NN O
a NN NN O
case NN NN O
of NN NN O
withdrawal NN NN B-Disease
- NN NN I-Disease
emergent NN NN I-Disease
RS NN NN I-Disease
, NN NN O
which NN NN O
is NN NN O
the NN NN O
first NN NN O
of NN NN O
its NN NN O
kind NN NN O
to NN NN O
be NN NN O
reported NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
developed NN NN O
RS NN NN B-Disease
during NN NN O
dose NN NN O
reduction NN NN O
of NN NN O
risperidone NN NN O
. NN NN O
   
The NN NN O
symptom NN NN O
was NN NN O
treated NN NN O
successfully NN NN O
with NN NN O
trihexyphenidyl NN NN O
anticholinergic NN NN O
therapy NN NN O
. NN NN O
   
The NN NN O
underlying NN NN O
mechanism NN NN O
of NN NN O
withdrawal NN NN B-Disease
- NN NN I-Disease
emergent NN NN I-Disease
RS NN NN I-Disease
in NN NN O
the NN NN O
present NN NN O
case NN NN O
may NN NN O
have NN NN O
been NN NN O
related NN NN O
to NN NN O
the NN NN O
pharmacological NN NN O
profile NN NN O
of NN NN O
risperidone NN NN O
, NN NN O
a NN NN O
serotonin NN NN O
- NN NN O
dopamine NN NN O
antagonist NN NN O
, NN NN O
suggesting NN NN O
the NN NN O
pathophysiologic NN NN O
influence NN NN O
of NN NN O
the NN NN O
serotonin NN NN O
system NN NN O
in NN NN O
the NN NN O
development NN NN O
of NN NN O
RS NN NN B-Disease
. NN NN O
   
Pharmacokinetic NN NN O
/ NN NN O
pharmacodynamic NN NN O
assessment NN NN O
of NN NN O
the NN NN O
effects NN NN O
of NN NN O
E4031 NN NN O
, NN NN O
cisapride NN NN O
, NN NN O
terfenadine NN NN O
and NN NN O
terodiline NN NN O
on NN NN O
monophasic NN NN O
action NN NN O
potential NN NN O
duration NN NN O
in NN NN O
dog NN NN O
. NN NN O
   
1 NN NN O
. NN NN O
   
Torsades NN NN B-Disease
de NN NN I-Disease
pointes NN NN I-Disease
( NN NN O
TDP NN NN B-Disease
) NN NN O
is NN NN O
a NN NN O
potentially NN NN O
fatal NN NN O
ventricular NN NN B-Disease
tachycardia NN NN I-Disease
associated NN NN O
with NN NN O
increases NN NN O
in NN NN O
QT NN NN O
interval NN NN O
and NN NN O
monophasic NN NN O
action NN NN O
potential NN NN O
duration NN NN O
( NN NN O
MAPD NN NN O
) NN NN O
. NN NN O
   
TDP NN NN B-Disease
is NN NN O
a NN NN O
side NN NN O
- NN NN O
effect NN NN O
that NN NN O
has NN NN O
led NN NN O
to NN NN O
withdrawal NN NN O
of NN NN O
several NN NN O
drugs NN NN O
from NN NN O
the NN NN O
market NN NN O
( NN NN O
e NN NN O
. NN NN O
g NN NN O
. NN NN O
terfenadine NN NN O
and NN NN O
terodiline NN NN O
) NN NN O
. NN NN O
   
2 NN NN O
. NN NN O
   
The NN NN O
potential NN NN O
of NN NN O
compounds NN NN O
to NN NN O
cause NN NN O
TDP NN NN B-Disease
was NN NN O
evaluated NN NN O
by NN NN O
monitoring NN NN O
their NN NN O
effects NN NN O
on NN NN O
MAPD NN NN O
in NN NN O
dog NN NN O
. NN NN O
   
Four NN NN O
compounds NN NN O
known NN NN O
to NN NN O
increase NN NN O
QT NN NN O
interval NN NN O
and NN NN O
cause NN NN O
TDP NN NN B-Disease
were NN NN O
investigated NN NN O
: NN NN O
terfenadine NN NN O
, NN NN O
terodiline NN NN O
, NN NN O
cisapride NN NN O
and NN NN O
E4031 NN NN O
. NN NN O
   
On NN NN O
the NN NN O
basis NN NN O
that NN NN O
only NN NN O
free NN NN O
drug NN NN O
in NN NN O
the NN NN O
systemic NN NN O
circulation NN NN O
will NN NN O
elicit NN NN O
a NN NN O
pharmacological NN NN O
response NN NN O
target NN NN O
, NN NN O
free NN NN O
concentrations NN NN O
in NN NN O
plasma NN NN O
were NN NN O
selected NN NN O
to NN NN O
mimic NN NN O
the NN NN O
free NN NN O
drug NN NN O
exposures NN NN O
in NN NN O
man NN NN O
. NN NN O
   
Infusion NN NN O
regimens NN NN O
were NN NN O
designed NN NN O
that NN NN O
rapidly NN NN O
achieved NN NN O
and NN NN O
maintained NN NN O
target NN NN O
- NN NN O
free NN NN O
concentrations NN NN O
of NN NN O
these NN NN O
drugs NN NN O
in NN NN O
plasma NN NN O
and NN NN O
data NN NN O
on NN NN O
the NN NN O
relationship NN NN O
between NN NN O
free NN NN O
concentration NN NN O
and NN NN O
changes NN NN O
in NN NN O
MAPD NN NN O
were NN NN O
obtained NN NN O
for NN NN O
these NN NN O
compounds NN NN O
. NN NN O
   
3 NN NN O
. NN NN O
   
These NN NN O
data NN NN O
indicate NN NN O
that NN NN O
the NN NN O
free NN NN O
ED50 NN NN O
in NN NN O
plasma NN NN O
for NN NN O
terfenadine NN NN O
( NN NN O
1 NN NN O
. NN NN O
9 NN NN O
nM NN NN O
) NN NN O
, NN NN O
terodiline NN NN O
( NN NN O
76 NN NN O
nM NN NN O
) NN NN O
, NN NN O
cisapride NN NN O
( NN NN O
11 NN NN O
nM NN NN O
) NN NN O
and NN NN O
E4031 NN NN O
( NN NN O
1 NN NN O
. NN NN O
9 NN NN O
nM NN NN O
) NN NN O
closely NN NN O
correlate NN NN O
with NN NN O
the NN NN O
free NN NN O
concentration NN NN O
in NN NN O
man NN NN O
causing NN NN O
QT NN NN O
effects NN NN O
. NN NN O
   
For NN NN O
compounds NN NN O
that NN NN O
have NN NN O
shown NN NN O
TDP NN NN B-Disease
in NN NN O
the NN NN O
clinic NN NN O
( NN NN O
terfenadine NN NN O
, NN NN O
terodiline NN NN O
, NN NN O
cisapride NN NN O
) NN NN O
there NN NN O
is NN NN O
little NN NN O
differentiation NN NN O
between NN NN O
the NN NN O
dog NN NN O
ED50 NN NN O
and NN NN O
the NN NN O
efficacious NN NN O
free NN NN O
plasma NN NN O
concentrations NN NN O
in NN NN O
man NN NN O
( NN NN O
< NN NN O
10 NN NN O
- NN NN O
fold NN NN O
) NN NN O
reflecting NN NN O
their NN NN O
limited NN NN O
safety NN NN O
margins NN NN O
. NN NN O
   
These NN NN O
data NN NN O
underline NN NN O
the NN NN O
need NN NN O
to NN NN O
maximize NN NN O
the NN NN O
therapeutic NN NN O
ratio NN NN O
with NN NN O
respect NN NN O
to NN NN O
TDP NN NN B-Disease
in NN NN O
potential NN NN O
development NN NN O
candidates NN NN O
and NN NN O
the NN NN O
importance NN NN O
of NN NN O
using NN NN O
free NN NN O
drug NN NN O
concentrations NN NN O
in NN NN O
pharmacokinetic NN NN O
/ NN NN O
pharmacodynamic NN NN O
studies NN NN O
. NN NN O
   
Bladder NN NN O
retention NN NN B-Disease
of NN NN I-Disease
urine NN NN I-Disease
as NN NN O
a NN NN O
result NN NN O
of NN NN O
continuous NN NN O
intravenous NN NN O
infusion NN NN O
of NN NN O
fentanyl NN NN O
: NN NN O
2 NN NN O
case NN NN O
reports NN NN O
. NN NN O
   
Sedation NN NN O
has NN NN O
been NN NN O
commonly NN NN O
used NN NN O
in NN NN O
the NN NN O
neonate NN NN O
to NN NN O
decrease NN NN O
the NN NN O
stress NN NN O
and NN NN O
pain NN NN B-Disease
from NN NN O
the NN NN O
noxious NN NN O
stimuli NN NN O
and NN NN O
invasive NN NN O
procedures NN NN O
in NN NN O
the NN NN O
neonatal NN NN O
intensive NN NN O
care NN NN O
unit NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
to NN NN O
facilitate NN NN O
synchrony NN NN O
between NN NN O
ventilator NN NN O
and NN NN O
spontaneous NN NN O
breaths NN NN O
. NN NN O
   
Fentanyl NN NN O
, NN NN O
an NN NN O
opioid NN NN O
analgesic NN NN O
, NN NN O
is NN NN O
frequently NN NN O
used NN NN O
in NN NN O
the NN NN O
neonatal NN NN O
intensive NN NN O
care NN NN O
unit NN NN O
setting NN NN O
for NN NN O
these NN NN O
very NN NN O
purposes NN NN O
. NN NN O
   
Various NN NN O
reported NN NN O
side NN NN O
effects NN NN O
of NN NN O
fentanyl NN NN O
administration NN NN O
include NN NN O
chest NN NN B-Disease
wall NN NN I-Disease
rigidity NN NN I-Disease
, NN NN O
hypotension NN NN B-Disease
, NN NN O
respiratory NN NN B-Disease
depression NN NN I-Disease
, NN NN O
and NN NN O
bradycardia NN NN B-Disease
. NN NN O
   
Here NN NN O
, NN NN O
2 NN NN O
cases NN NN O
of NN NN O
urinary NN NN B-Disease
bladder NN NN I-Disease
retention NN NN I-Disease
leading NN NN O
to NN NN O
renal NN NN O
pelvocalyceal NN NN O
dilatation NN NN O
mimicking NN NN O
hydronephrosis NN NN B-Disease
as NN NN O
a NN NN O
result NN NN O
of NN NN O
continuous NN NN O
infusion NN NN O
of NN NN O
fentanyl NN NN O
are NN NN O
reported NN NN O
. NN NN O
   
Fatal NN NN O
myeloencephalopathy NN NN B-Disease
due NN NN O
to NN NN O
accidental NN NN O
intrathecal NN NN O
vincristin NN NN O
administration NN NN O
: NN NN O
a NN NN O
report NN NN O
of NN NN O
two NN NN O
cases NN NN O
. NN NN O
   
We NN NN O
report NN NN O
on NN NN O
two NN NN O
fatal NN NN O
cases NN NN O
of NN NN O
accidental NN NN O
intrathecal NN NN O
vincristine NN NN O
instillation NN NN O
in NN NN O
a NN NN O
5 NN NN O
- NN NN O
year NN NN O
old NN NN O
girl NN NN O
with NN NN O
recurrent NN NN O
acute NN NN B-Disease
lymphoblastic NN NN I-Disease
leucemia NN NN I-Disease
and NN NN O
a NN NN O
57 NN NN O
- NN NN O
year NN NN O
old NN NN O
man NN NN O
with NN NN O
lymphoblastic NN NN B-Disease
lymphoma NN NN I-Disease
. NN NN O
   
The NN NN O
girl NN NN O
died NN NN O
seven NN NN O
days NN NN O
, NN NN O
the NN NN O
man NN NN O
four NN NN O
weeks NN NN O
after NN NN O
intrathecal NN NN O
injection NN NN O
of NN NN O
vincristine NN NN O
. NN NN O
   
Clinically NN NN O
, NN NN O
the NN NN O
onset NN NN O
was NN NN O
characterized NN NN O
by NN NN O
the NN NN O
signs NN NN O
of NN NN O
opistothonus NN NN B-Disease
, NN NN I-Disease
sensory NN NN I-Disease
and NN NN I-Disease
motor NN NN I-Disease
dysfunction NN NN I-Disease
and NN NN O
ascending NN NN O
paralysis NN NN B-Disease
. NN NN O
   
Histological NN NN O
and NN NN O
immunohistochemical NN NN O
investigations NN NN O
( NN NN O
HE NN NN O
- NN NN O
LFB NN NN O
, NN NN O
CD NN NN O
- NN NN O
68 NN NN O
, NN NN O
Neurofilament NN NN O
) NN NN O
revealed NN NN O
degeneration NN NN B-Disease
of NN NN I-Disease
myelin NN NN I-Disease
and NN NN I-Disease
axons NN NN I-Disease
as NN NN O
well NN NN O
as NN NN O
pseudocystic NN NN B-Disease
transformation NN NN I-Disease
in NN NN O
areas NN NN O
exposed NN NN O
to NN NN O
vincristine NN NN O
, NN NN O
accompanied NN NN O
by NN NN O
secondary NN NN O
changes NN NN O
with NN NN O
numerous NN NN O
prominent NN NN O
macrophages NN NN O
. NN NN O
   
The NN NN O
clinical NN NN O
course NN NN O
and NN NN O
histopathological NN NN O
results NN NN O
of NN NN O
the NN NN O
two NN NN O
cases NN NN O
are NN NN O
presented NN NN O
. NN NN O
   
A NN NN O
review NN NN O
of NN NN O
all NN NN O
reported NN NN O
cases NN NN O
in NN NN O
the NN NN O
literature NN NN O
is NN NN O
given NN NN O
. NN NN O
   
A NN NN O
better NN NN O
controlled NN NN O
regimen NN NN O
for NN NN O
administering NN NN O
vincristine NN NN O
and NN NN O
intrathecal NN NN O
chemotherapy NN NN O
is NN NN O
recommended NN NN O
. NN NN O
   
Palpebral NN NN B-Disease
twitching NN NN I-Disease
in NN NN O
a NN NN O
depressed NN NN B-Disease
adolescent NN NN O
on NN NN O
citalopram NN NN O
. NN NN O
   
Current NN NN O
estimates NN NN O
suggest NN NN O
that NN NN O
between NN NN O
0 NN NN O
. NN NN O
4 NN NN O
% NN NN O
and NN NN O
8 NN NN O
. NN NN O
3 NN NN O
% NN NN O
of NN NN O
children NN NN O
and NN NN O
adolescents NN NN O
are NN NN O
affected NN NN O
by NN NN O
major NN NN B-Disease
depression NN NN I-Disease
. NN NN O
   
We NN NN O
report NN NN O
a NN NN O
favorable NN NN O
response NN NN O
to NN NN O
treatment NN NN O
with NN NN O
citalopram NN NN O
by NN NN O
a NN NN O
15 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
boy NN NN O
with NN NN O
major NN NN B-Disease
depression NN NN I-Disease
who NN NN O
exhibited NN NN O
palpebral NN NN B-Disease
twitching NN NN I-Disease
during NN NN O
his NN NN O
first NN NN O
2 NN NN O
weeks NN NN O
of NN NN O
treatment NN NN O
. NN NN O
   
This NN NN O
may NN NN O
have NN NN O
been NN NN O
a NN NN O
side NN NN O
effect NN NN O
of NN NN O
citalopram NN NN O
as NN NN O
it NN NN O
remitted NN NN O
with NN NN O
redistribution NN NN O
of NN NN O
doses NN NN O
. NN NN O
   
The NN NN O
3 NN NN O
- NN NN O
week NN NN O
sulphasalazine NN NN O
syndrome NN NN O
strikes NN NN O
again NN NN O
. NN NN O
   
A NN NN O
34 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
lady NN NN O
developed NN NN O
a NN NN O
constellation NN NN O
of NN NN O
dermatitis NN NN B-Disease
, NN NN O
fever NN NN B-Disease
, NN NN O
lymphadenopathy NN NN B-Disease
and NN NN O
hepatitis NN NN B-Disease
, NN NN O
beginning NN NN O
on NN NN O
the NN NN O
17th NN NN O
day NN NN O
of NN NN O
a NN NN O
course NN NN O
of NN NN O
oral NN NN O
sulphasalazine NN NN O
for NN NN O
sero NN NN O
- NN NN O
negative NN NN O
rheumatoid NN NN B-Disease
arthritis NN NN I-Disease
. NN NN O
   
Cervical NN NN O
and NN NN O
inguinal NN NN O
lymph NN NN O
node NN NN O
biopsies NN NN O
showed NN NN O
the NN NN O
features NN NN O
of NN NN O
severe NN NN O
necrotising NN NN O
lymphadenitis NN NN B-Disease
, NN NN O
associated NN NN O
with NN NN O
erythrophagocytosis NN NN O
and NN NN O
prominent NN NN O
eosinophilic NN NN O
infiltrates NN NN O
, NN NN O
without NN NN O
viral NN NN O
inclusion NN NN O
bodies NN NN O
, NN NN O
suggestive NN NN O
of NN NN O
an NN NN O
adverse NN NN B-Disease
drug NN NN I-Disease
reaction NN NN I-Disease
. NN NN O
A NN NN O
week NN NN O
later NN NN O
, NN NN O
fulminant NN NN O
drug NN NN B-Disease
- NN NN I-Disease
induced NN NN I-Disease
hepatitis NN NN I-Disease
, NN NN O
associated NN NN O
with NN NN O
the NN NN O
presence NN NN O
of NN NN O
anti NN NN O
- NN NN O
nuclear NN NN O
autoantibodies NN NN O
( NN NN O
but NN NN O
not NN NN O
with NN NN O
other NN NN O
markers NN NN O
of NN NN O
autoimmunity NN NN B-Disease
) NN NN O
, NN NN O
and NN NN O
accompanied NN NN O
by NN NN O
multi NN NN B-Disease
- NN NN I-Disease
organ NN NN I-Disease
failure NN NN I-Disease
and NN NN O
sepsis NN NN B-Disease
, NN NN O
supervened NN NN O
. NN NN O
   
She NN NN O
subsequently NN NN O
died NN NN O
some NN NN O
5 NN NN O
weeks NN NN O
after NN NN O
the NN NN O
commencement NN NN O
of NN NN O
her NN NN O
drug NN NN O
therapy NN NN O
. NN NN O
Post NN NN O
- NN NN O
mortem NN NN O
examination NN NN O
showed NN NN O
evidence NN NN O
of NN NN O
massive NN NN B-Disease
hepatocellular NN NN I-Disease
necrosis NN NN I-Disease
, NN NN O
acute NN NN O
hypersensitivity NN NN O
myocarditis NN NN B-Disease
, NN NN O
focal NN NN O
acute NN NN O
tubulo NN NN O
- NN NN O
interstitial NN NN O
nephritis NN NN B-Disease
and NN NN O
extensive NN NN O
bone NN NN B-Disease
marrow NN NN I-Disease
necrosis NN NN I-Disease
, NN NN O
with NN NN O
no NN NN O
evidence NN NN O
of NN NN O
malignancy NN NN B-Disease
. NN NN O
   
It NN NN O
is NN NN O
thought NN NN O
that NN NN O
the NN NN O
clinico NN NN O
- NN NN O
pathological NN NN O
features NN NN O
and NN NN O
chronology NN NN O
of NN NN O
this NN NN O
case NN NN O
bore NN NN O
the NN NN O
hallmarks NN NN O
of NN NN O
the NN NN O
so NN NN O
- NN NN O
called NN NN O
"""""""" NN NN O
3 NN NN O
- NN NN O
week NN NN O
sulphasalazine NN NN O
syndrome NN NN O
"""""""" NN NN O
, NN NN O
a NN NN O
rare NN NN O
, NN NN O
but NN NN O
often NN NN O
fatal NN NN O
, NN NN O
immunoallergic NN NN O
reaction NN NN O
to NN NN O
sulphasalazine NN NN O
. NN NN O
   
Intravenous NN NN O
administration NN NN O
of NN NN O
prochlorperazine NN NN O
by NN NN O
15 NN NN O
- NN NN O
minute NN NN O
infusion NN NN O
versus NN NN O
2 NN NN O
- NN NN O
minute NN NN O
bolus NN NN O
does NN NN O
not NN NN O
affect NN NN O
the NN NN O
incidence NN NN O
of NN NN O
akathisia NN NN B-Disease
: NN NN O
a NN NN O
prospective NN NN O
, NN NN O
randomized NN NN O
, NN NN O
controlled NN NN O
trial NN NN O
. NN NN O
   
STUDY NN NN O
OBJECTIVE NN NN O
: NN NN O
We NN NN O
sought NN NN O
to NN NN O
compare NN NN O
the NN NN O
rate NN NN O
of NN NN O
akathisia NN NN B-Disease
after NN NN O
administration NN NN O
of NN NN O
intravenous NN NN O
prochlorperazine NN NN O
as NN NN O
a NN NN O
2 NN NN O
- NN NN O
minute NN NN O
bolus NN NN O
or NN NN O
15 NN NN O
- NN NN O
minute NN NN O
infusion NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
We NN NN O
conducted NN NN O
a NN NN O
prospective NN NN O
, NN NN O
randomized NN NN O
, NN NN O
double NN NN O
- NN NN O
blind NN NN O
study NN NN O
in NN NN O
the NN NN O
emergency NN NN O
department NN NN O
of NN NN O
a NN NN O
central NN NN O
- NN NN O
city NN NN O
teaching NN NN O
hospital NN NN O
. NN NN O
   
Patients NN NN O
aged NN NN O
18 NN NN O
years NN NN O
or NN NN O
older NN NN O
treated NN NN O
with NN NN O
prochlorperazine NN NN O
for NN NN O
headache NN NN B-Disease
, NN NN O
nausea NN NN B-Disease
, NN NN O
or NN NN O
vomiting NN NN B-Disease
were NN NN O
eligible NN NN O
for NN NN O
inclusion NN NN O
. NN NN O
   
Study NN NN O
participants NN NN O
were NN NN O
randomized NN NN O
to NN NN O
receive NN NN O
10 NN NN O
mg NN NN O
of NN NN O
prochlorperazine NN NN O
administered NN NN O
intravenously NN NN O
by NN NN O
means NN NN O
of NN NN O
2 NN NN O
- NN NN O
minute NN NN O
push NN NN O
( NN NN O
bolus NN NN O
group NN NN O
) NN NN O
or NN NN O
10 NN NN O
mg NN NN O
diluted NN NN O
in NN NN O
50 NN NN O
mL NN NN O
of NN NN O
normal NN NN O
saline NN NN O
solution NN NN O
administered NN NN O
by NN NN O
means NN NN O
of NN NN O
intravenous NN NN O
infusion NN NN O
during NN NN O
a NN NN O
15 NN NN O
- NN NN O
minute NN NN O
period NN NN O
( NN NN O
infusion NN NN O
group NN NN O
) NN NN O
. NN NN O
   
The NN NN O
main NN NN O
outcome NN NN O
was NN NN O
the NN NN O
number NN NN O
of NN NN O
study NN NN O
participants NN NN O
experiencing NN NN O
akathisia NN NN B-Disease
within NN NN O
60 NN NN O
minutes NN NN O
of NN NN O
administration NN NN O
. NN NN O
   
Akathisia NN NN O
was NN NN O
defined NN NN O
as NN NN O
either NN NN O
a NN NN O
spontaneous NN NN O
report NN NN O
of NN NN O
restlessness NN NN O
or NN NN O
agitation NN NN B-Disease
or NN NN O
a NN NN O
change NN NN O
of NN NN O
2 NN NN O
or NN NN O
more NN NN O
in NN NN O
the NN NN O
patient NN NN O
- NN NN O
reported NN NN O
akathisia NN NN B-Disease
rating NN NN O
scale NN NN O
and NN NN O
a NN NN O
change NN NN O
of NN NN O
at NN NN O
least NN NN O
1 NN NN O
in NN NN O
the NN NN O
investigator NN NN O
- NN NN O
observed NN NN O
akathisia NN NN B-Disease
rating NN NN O
scale NN NN O
. NN NN O
   
The NN NN O
intensity NN NN O
of NN NN O
headache NN NN B-Disease
and NN NN O
nausea NN NN B-Disease
was NN NN O
measured NN NN O
with NN NN O
a NN NN O
100 NN NN O
- NN NN O
mm NN NN O
visual NN NN O
analog NN NN O
scale NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
One NN NN O
hundred NN NN O
patients NN NN O
were NN NN O
enrolled NN NN O
. NN NN O
   
One NN NN O
study NN NN O
participant NN NN O
was NN NN O
excluded NN NN O
after NN NN O
protocol NN NN O
violation NN NN O
. NN NN O
   
Seventy NN NN O
- NN NN O
three NN NN O
percent NN NN O
( NN NN O
73 NN NN O
/ NN NN O
99 NN NN O
) NN NN O
of NN NN O
the NN NN O
study NN NN O
participants NN NN O
were NN NN O
treated NN NN O
for NN NN O
headache NN NN B-Disease
and NN NN O
70 NN NN O
% NN NN O
( NN NN O
70 NN NN O
/ NN NN O
99 NN NN O
) NN NN O
for NN NN O
nausea NN NN B-Disease
. NN NN O
   
In NN NN O
the NN NN O
bolus NN NN O
group NN NN O
, NN NN O
26 NN NN O
. NN NN O
0 NN NN O
% NN NN O
( NN NN O
13 NN NN O
/ NN NN O
50 NN NN O
) NN NN O
had NN NN O
akathisia NN NN B-Disease
compared NN NN O
with NN NN O
32 NN NN O
. NN NN O
7 NN NN O
% NN NN O
( NN NN O
16 NN NN O
/ NN NN O
49 NN NN O
) NN NN O
in NN NN O
the NN NN O
infusion NN NN O
group NN NN O
( NN NN O
Delta NN NN O
= NN NN O
- NN NN O
6 NN NN O
. NN NN O
7 NN NN O
% NN NN O
; NN NN O
95 NN NN O
% NN NN O
confidence NN NN O
interval NN NN O
[ NN NN O
CI NN NN O
] NN NN O
- NN NN O
24 NN NN O
. NN NN O
6 NN NN O
% NN NN O
to NN NN O
11 NN NN O
. NN NN O
2 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
The NN NN O
difference NN NN O
between NN NN O
the NN NN O
bolus NN NN O
and NN NN O
infusion NN NN O
groups NN NN O
in NN NN O
the NN NN O
percentage NN NN O
of NN NN O
participants NN NN O
who NN NN O
saw NN NN O
a NN NN O
50 NN NN O
% NN NN O
reduction NN NN O
in NN NN O
their NN NN O
headache NN NN B-Disease
intensity NN NN O
within NN NN O
30 NN NN O
minutes NN NN O
was NN NN O
11 NN NN O
. NN NN O
8 NN NN O
% NN NN O
( NN NN O
95 NN NN O
% NN NN O
CI NN NN O
- NN NN O
9 NN NN O
. NN NN O
6 NN NN O
% NN NN O
to NN NN O
33 NN NN O
. NN NN O
3 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
The NN NN O
difference NN NN O
in NN NN O
the NN NN O
percentage NN NN O
of NN NN O
patients NN NN O
with NN NN O
a NN NN O
50 NN NN O
% NN NN O
reduction NN NN O
in NN NN O
their NN NN O
nausea NN NN B-Disease
was NN NN O
12 NN NN O
. NN NN O
6 NN NN O
% NN NN O
( NN NN O
95 NN NN O
% NN NN O
CI NN NN O
- NN NN O
4 NN NN O
. NN NN O
6 NN NN O
% NN NN O
to NN NN O
29 NN NN O
. NN NN O
8 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
A NN NN O
50 NN NN O
% NN NN O
reduction NN NN O
in NN NN O
the NN NN O
incidence NN NN O
of NN NN O
akathisia NN NN B-Disease
when NN NN O
prochlorperazine NN NN O
was NN NN O
administered NN NN O
by NN NN O
means NN NN O
of NN NN O
15 NN NN O
- NN NN O
minute NN NN O
intravenous NN NN O
infusion NN NN O
versus NN NN O
a NN NN O
2 NN NN O
- NN NN O
minute NN NN O
intravenous NN NN O
push NN NN O
was NN NN O
not NN NN O
detected NN NN O
. NN NN O
   
The NN NN O
efficacy NN NN O
of NN NN O
prochlorperazine NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
headache NN NN B-Disease
and NN NN O
nausea NN NN B-Disease
likewise NN NN O
did NN NN O
not NN NN O
appear NN NN O
to NN NN O
be NN NN O
affected NN NN O
by NN NN O
the NN NN O
rate NN NN O
of NN NN O
administration NN NN O
, NN NN O
although NN NN O
no NN NN O
formal NN NN O
statistical NN NN O
comparisons NN NN O
were NN NN O
made NN NN O
. NN NN O
   
Combined NN NN O
antiretroviral NN NN O
therapy NN NN O
causes NN NN O
cardiomyopathy NN NN B-Disease
and NN NN O
elevates NN NN O
plasma NN NN O
lactate NN NN O
in NN NN O
transgenic NN NN O
AIDS NN NN B-Disease
mice NN NN O
. NN NN O
   
Highly NN NN O
active NN NN O
antiretroviral NN NN O
therapy NN NN O
( NN NN O
HAART NN NN O
) NN NN O
is NN NN O
implicated NN NN O
in NN NN O
cardiomyopathy NN NN B-Disease
( NN NN O
CM NN NN B-Disease
) NN NN O
and NN NN O
in NN NN O
elevated NN NN O
plasma NN NN O
lactate NN NN O
( NN NN O
LA NN NN O
) NN NN O
in NN NN O
AIDS NN NN B-Disease
through NN NN O
mechanisms NN NN O
of NN NN O
mitochondrial NN NN B-Disease
dysfunction NN NN I-Disease
. NN NN O
   
To NN NN O
determine NN NN O
mitochondrial NN NN O
events NN NN O
from NN NN O
HAART NN NN O
in NN NN O
vivo NN NN O
, NN NN O
8 NN NN O
- NN NN O
week NN NN O
- NN NN O
old NN NN O
hemizygous NN NN O
transgenic NN NN O
AIDS NN NN B-Disease
mice NN NN O
( NN NN O
NL4 NN NN O
- NN NN O
3Delta NN NN O
gag NN NN O
/ NN NN O
pol NN NN O
; NN NN O
TG NN NN O
) NN NN O
and NN NN O
wild NN NN O
- NN NN O
type NN NN O
FVB NN NN O
/ NN NN O
n NN NN O
littermates NN NN O
were NN NN O
treated NN NN O
with NN NN O
the NN NN O
HAART NN NN O
combination NN NN O
of NN NN O
zidovudine NN NN O
, NN NN O
lamivudine NN NN O
, NN NN O
and NN NN O
indinavir NN NN O
or NN NN O
vehicle NN NN O
control NN NN O
for NN NN O
10 NN NN O
days NN NN O
or NN NN O
35 NN NN O
days NN NN O
. NN NN O
   
At NN NN O
termination NN NN O
of NN NN O
the NN NN O
experiments NN NN O
, NN NN O
mice NN NN O
underwent NN NN O
echocardiography NN NN O
, NN NN O
quantitation NN NN O
of NN NN O
abundance NN NN O
of NN NN O
molecular NN NN O
markers NN NN O
of NN NN O
CM NN NN B-Disease
( NN NN O
ventricular NN NN O
mRNA NN NN O
encoding NN NN O
atrial NN NN O
natriuretic NN NN O
factor NN NN O
[ NN NN O
ANF NN NN O
] NN NN O
and NN NN O
sarcoplasmic NN NN O
calcium NN NN O
ATPase NN NN O
[ NN NN O
SERCA2 NN NN O
] NN NN O
) NN NN O
, NN NN O
and NN NN O
determination NN NN O
of NN NN O
plasma NN NN O
LA NN NN O
. NN NN O
   
Myocardial NN NN O
histologic NN NN O
features NN NN O
were NN NN O
analyzed NN NN O
semiquantitatively NN NN O
and NN NN O
results NN NN O
were NN NN O
confirmed NN NN O
by NN NN O
transmission NN NN O
electron NN NN O
microscopy NN NN O
. NN NN O
   
After NN NN O
35 NN NN O
days NN NN O
in NN NN O
the NN NN O
TG NN NN O
+ NN NN O
HAART NN NN O
cohort NN NN O
, NN NN O
left NN NN O
ventricular NN NN O
mass NN NN O
increased NN NN O
160 NN NN O
% NN NN O
by NN NN O
echocardiography NN NN O
. NN NN O
   
Molecularly NN NN O
, NN NN O
ANF NN NN O
mRNA NN NN O
increased NN NN O
250 NN NN O
% NN NN O
and NN NN O
SERCA2 NN NN O
mRNA NN NN O
decreased NN NN O
57 NN NN O
% NN NN O
. NN NN O
   
Biochemically NN NN O
, NN NN O
LA NN NN O
was NN NN O
elevated NN NN O
( NN NN O
8 NN NN O
. NN NN O
5 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
. NN NN O
0 NN NN O
mM NN NN O
) NN NN O
. NN NN O
   
Pathologically NN NN O
, NN NN O
granular NN NN O
cytoplasmic NN NN O
changes NN NN O
were NN NN O
found NN NN O
in NN NN O
cardiac NN NN O
myocytes NN NN O
, NN NN O
indicating NN NN O
enlarged NN NN O
, NN NN O
damaged NN NN O
mitochondria NN NN O
. NN NN O
   
Findings NN NN O
were NN NN O
confirmed NN NN O
ultrastructurally NN NN O
. NN NN O
   
No NN NN O
changes NN NN O
were NN NN O
found NN NN O
in NN NN O
other NN NN O
cohorts NN NN O
. NN NN O
   
After NN NN O
10 NN NN O
days NN NN O
, NN NN O
only NN NN O
ANF NN NN O
was NN NN O
elevated NN NN O
, NN NN O
and NN NN O
only NN NN O
in NN NN O
the NN NN O
TG NN NN O
+ NN NN O
HAART NN NN O
cohort NN NN O
. NN NN O
   
Results NN NN O
show NN NN O
that NN NN O
cumulative NN NN O
HAART NN NN O
caused NN NN O
mitochondrial NN NN O
CM NN NN B-Disease
with NN NN O
elevated NN NN O
LA NN NN O
in NN NN O
AIDS NN NN B-Disease
transgenic NN NN O
mice NN NN O
. NN NN O
   
A NN NN O
Phase NN NN O
II NN NN O
trial NN NN O
of NN NN O
cisplatin NN NN O
plus NN NN O
WR NN NN O
- NN NN O
2721 NN NN O
( NN NN O
amifostine NN NN O
) NN NN O
for NN NN O
metastatic NN NN O
breast NN NN B-Disease
carcinoma NN NN I-Disease
: NN NN O
an NN NN O
Eastern NN NN O
Cooperative NN NN O
Oncology NN NN O
Group NN NN O
Study NN NN O
( NN NN O
E8188 NN NN O
) NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Cisplatin NN NN O
has NN NN O
minimal NN NN O
antitumor NN NN O
activity NN NN O
when NN NN O
used NN NN O
as NN NN O
second NN NN O
- NN NN O
or NN NN O
third NN NN O
- NN NN O
line NN NN O
treatment NN NN O
of NN NN O
metastatic NN NN O
breast NN NN B-Disease
carcinoma NN NN I-Disease
. NN NN O
   
Older NN NN O
reports NN NN O
suggest NN NN O
an NN NN O
objective NN NN O
response NN NN O
rate NN NN O
of NN NN O
8 NN NN O
% NN NN O
when NN NN O
60 NN NN O
- NN NN O
120 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
of NN NN O
cisplatin NN NN O
is NN NN O
administered NN NN O
every NN NN O
3 NN NN O
- NN NN O
4 NN NN O
weeks NN NN O
. NN NN O
   
Although NN NN O
a NN NN O
dose NN NN O
- NN NN O
response NN NN O
effect NN NN O
has NN NN O
been NN NN O
observed NN NN O
with NN NN O
cisplatin NN NN O
, NN NN O
the NN NN O
dose NN NN O
- NN NN O
limiting NN NN O
toxicities NN NN B-Disease
associated NN NN O
with NN NN O
cisplatin NN NN O
( NN NN O
e NN NN O
. NN NN O
g NN NN O
. NN NN O
, NN NN O
nephrotoxicity NN NN B-Disease
, NN NN O
ototoxicity NN NN B-Disease
, NN NN O
and NN NN O
neurotoxicity NN NN B-Disease
) NN NN O
have NN NN O
limited NN NN O
its NN NN O
use NN NN O
as NN NN O
a NN NN O
treatment NN NN O
for NN NN O
breast NN NN B-Disease
carcinoma NN NN I-Disease
. NN NN O
   
WR NN NN O
- NN NN O
2721 NN NN O
or NN NN O
amifostine NN NN O
initially NN NN O
was NN NN O
developed NN NN O
to NN NN O
protect NN NN O
military NN NN O
personnel NN NN O
in NN NN O
the NN NN O
event NN NN O
of NN NN O
nuclear NN NN O
war NN NN O
. NN NN O
   
Amifostine NN NN O
subsequently NN NN O
was NN NN O
shown NN NN O
to NN NN O
protect NN NN O
normal NN NN O
tissues NN NN O
from NN NN O
the NN NN O
toxic NN NN O
effects NN NN O
of NN NN O
alkylating NN NN O
agents NN NN O
and NN NN O
cisplatin NN NN O
without NN NN O
decreasing NN NN O
the NN NN O
antitumor NN NN O
effect NN NN O
of NN NN O
the NN NN O
chemotherapy NN NN O
. NN NN O
   
Early NN NN O
trials NN NN O
of NN NN O
cisplatin NN NN O
and NN NN O
amifostine NN NN O
also NN NN O
suggested NN NN O
that NN NN O
the NN NN O
incidence NN NN O
and NN NN O
severity NN NN O
of NN NN O
cisplatin NN NN O
- NN NN O
induced NN NN O
nephrotoxicity NN NN B-Disease
, NN NN O
ototoxicity NN NN B-Disease
, NN NN O
and NN NN O
neuropathy NN NN B-Disease
were NN NN O
reduced NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
A NN NN O
Phase NN NN O
II NN NN O
study NN NN O
of NN NN O
the NN NN O
combination NN NN O
of NN NN O
cisplatin NN NN O
plus NN NN O
amifostine NN NN O
was NN NN O
conducted NN NN O
in NN NN O
patients NN NN O
with NN NN O
progressive NN NN O
metastatic NN NN O
breast NN NN B-Disease
carcinoma NN NN I-Disease
who NN NN O
had NN NN O
received NN NN O
one NN NN O
, NN NN O
but NN NN O
not NN NN O
more NN NN O
than NN NN O
one NN NN O
, NN NN O
chemotherapy NN NN O
regimen NN NN O
for NN NN O
metastatic NN NN O
disease NN NN O
. NN NN O
   
Patients NN NN O
received NN NN O
amifostine NN NN O
, NN NN O
910 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
intravenously NN NN O
over NN NN O
15 NN NN O
minutes NN NN O
. NN NN O
   
After NN NN O
completion NN NN O
of NN NN O
the NN NN O
amifostine NN NN O
infusion NN NN O
, NN NN O
cisplatin NN NN O
120 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
was NN NN O
administered NN NN O
over NN NN O
30 NN NN O
minutes NN NN O
. NN NN O
   
Intravenous NN NN O
hydration NN NN O
and NN NN O
mannitol NN NN O
was NN NN O
administered NN NN O
before NN NN O
and NN NN O
after NN NN O
cisplatin NN NN O
. NN NN O
   
Treatment NN NN O
was NN NN O
administered NN NN O
every NN NN O
3 NN NN O
weeks NN NN O
until NN NN O
disease NN NN O
progression NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Forty NN NN O
- NN NN O
four NN NN O
patients NN NN O
were NN NN O
enrolled NN NN O
in NN NN O
the NN NN O
study NN NN O
of NN NN O
which NN NN O
7 NN NN O
( NN NN O
16 NN NN O
% NN NN O
) NN NN O
were NN NN O
ineligible NN NN O
. NN NN O
   
A NN NN O
median NN NN O
of NN NN O
2 NN NN O
cycles NN NN O
of NN NN O
therapy NN NN O
was NN NN O
administered NN NN O
to NN NN O
the NN NN O
37 NN NN O
eligible NN NN O
patients NN NN O
. NN NN O
   
Six NN NN O
partial NN NN O
responses NN NN O
were NN NN O
observed NN NN O
for NN NN O
an NN NN O
overall NN NN O
response NN NN O
rate NN NN O
of NN NN O
16 NN NN O
% NN NN O
. NN NN O
   
Most NN NN O
patients NN NN O
( NN NN O
57 NN NN O
% NN NN O
) NN NN O
stopped NN NN O
treatment NN NN O
because NN NN O
of NN NN O
disease NN NN O
progression NN NN O
. NN NN O
   
Neurologic NN NN B-Disease
toxicity NN NN I-Disease
was NN NN O
reported NN NN O
in NN NN O
52 NN NN O
% NN NN O
of NN NN O
patients NN NN O
. NN NN O
   
Seven NN NN O
different NN NN O
life NN NN O
- NN NN O
threatening NN NN O
toxicities NN NN B-Disease
were NN NN O
observed NN NN O
in NN NN O
patients NN NN O
while NN NN O
receiving NN NN O
treatment NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
The NN NN O
combination NN NN O
of NN NN O
cisplatin NN NN O
and NN NN O
amifostine NN NN O
in NN NN O
this NN NN O
study NN NN O
resulted NN NN O
in NN NN O
an NN NN O
overall NN NN O
response NN NN O
rate NN NN O
of NN NN O
16 NN NN O
% NN NN O
. NN NN O
   
Neither NN NN O
a NN NN O
tumor NN NN B-Disease
- NN NN O
protective NN NN O
effect NN NN O
nor NN NN O
reduced NN NN O
toxicity NN NN B-Disease
to NN NN O
normal NN NN O
tissues NN NN O
was NN NN O
observed NN NN O
with NN NN O
the NN NN O
addition NN NN O
of NN NN O
amifostine NN NN O
to NN NN O
cisplatin NN NN O
in NN NN O
this NN NN O
trial NN NN O
. NN NN O
   
Oral NN NN O
contraceptives NN NN O
and NN NN O
the NN NN O
risk NN NN O
of NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
An NN NN O
association NN NN O
between NN NN O
the NN NN O
use NN NN O
of NN NN O
oral NN NN O
contraceptives NN NN O
and NN NN O
the NN NN O
risk NN NN O
of NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
has NN NN O
been NN NN O
found NN NN O
in NN NN O
some NN NN O
, NN NN O
but NN NN O
not NN NN O
all NN NN O
, NN NN O
studies NN NN O
. NN NN O
   
We NN NN O
investigated NN NN O
this NN NN O
association NN NN O
, NN NN O
according NN NN O
to NN NN O
the NN NN O
type NN NN O
of NN NN O
progestagen NN NN O
included NN NN O
in NN NN O
third NN NN O
- NN NN O
generation NN NN O
( NN NN O
i NN NN O
. NN NN O
e NN NN O
. NN NN O
, NN NN O
desogestrel NN NN O
or NN NN O
gestodene NN NN O
) NN NN O
and NN NN O
second NN NN O
- NN NN O
generation NN NN O
( NN NN O
i NN NN O
. NN NN O
e NN NN O
. NN NN O
, NN NN O
levonorgestrel NN NN O
) NN NN O
oral NN NN O
contraceptives NN NN O
, NN NN O
the NN NN O
dose NN NN O
of NN NN O
estrogen NN NN O
, NN NN O
and NN NN O
the NN NN O
presence NN NN O
or NN NN O
absence NN NN O
of NN NN O
prothrombotic NN NN O
mutations NN NN O
METHODS NN NN O
: NN NN O
In NN NN O
a NN NN O
nationwide NN NN O
, NN NN O
population NN NN O
- NN NN O
based NN NN O
, NN NN O
case NN NN O
- NN NN O
control NN NN O
study NN NN O
, NN NN O
we NN NN O
identified NN NN O
and NN NN O
enrolled NN NN O
248 NN NN O
women NN NN O
18 NN NN O
through NN NN O
49 NN NN O
years NN NN O
of NN NN O
age NN NN O
who NN NN O
had NN NN O
had NN NN O
a NN NN O
first NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
between NN NN O
1990 NN NN O
and NN NN O
1995 NN NN O
and NN NN O
925 NN NN O
control NN NN O
women NN NN O
who NN NN O
had NN NN O
not NN NN O
had NN NN O
a NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
and NN NN O
who NN NN O
were NN NN O
matched NN NN O
for NN NN O
age NN NN O
, NN NN O
calendar NN NN O
year NN NN O
of NN NN O
the NN NN O
index NN NN O
event NN NN O
, NN NN O
and NN NN O
area NN NN O
of NN NN O
residence NN NN O
. NN NN O
   
Subjects NN NN O
supplied NN NN O
information NN NN O
on NN NN O
oral NN NN O
- NN NN O
contraceptive NN NN O
use NN NN O
and NN NN O
major NN NN O
cardiovascular NN NN O
risk NN NN O
factors NN NN O
. NN NN O
   
An NN NN O
analysis NN NN O
for NN NN O
factor NN NN O
V NN NN O
Leiden NN NN O
and NN NN O
the NN NN O
G20210A NN NN O
mutation NN NN O
in NN NN O
the NN NN O
prothrombin NN NN O
gene NN NN O
was NN NN O
conducted NN NN O
in NN NN O
217 NN NN O
patients NN NN O
and NN NN O
763 NN NN O
controls NN NN O
RESULTS NN NN O
: NN NN O
The NN NN O
odds NN NN O
ratio NN NN O
for NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
among NN NN O
women NN NN O
who NN NN O
used NN NN O
any NN NN O
type NN NN O
of NN NN O
combined NN NN O
oral NN NN O
contraceptive NN NN O
, NN NN O
as NN NN O
compared NN NN O
with NN NN O
nonusers NN NN O
, NN NN O
was NN NN O
2 NN NN O
. NN NN O
0 NN NN O
( NN NN O
95 NN NN O
percent NN NN O
confidence NN NN O
interval NN NN O
, NN NN O
1 NN NN O
. NN NN O
5 NN NN O
to NN NN O
2 NN NN O
. NN NN O
8 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
adjusted NN NN O
odds NN NN O
ratio NN NN O
was NN NN O
2 NN NN O
. NN NN O
5 NN NN O
( NN NN O
95 NN NN O
percent NN NN O
confidence NN NN O
interval NN NN O
, NN NN O
1 NN NN O
. NN NN O
5 NN NN O
to NN NN O
4 NN NN O
. NN NN O
1 NN NN O
) NN NN O
among NN NN O
women NN NN O
who NN NN O
used NN NN O
second NN NN O
- NN NN O
generation NN NN O
oral NN NN O
contraceptives NN NN O
and NN NN O
1 NN NN O
. NN NN O
3 NN NN O
( NN NN O
95 NN NN O
percent NN NN O
confidence NN NN O
interval NN NN O
, NN NN O
0 NN NN O
. NN NN O
7 NN NN O
to NN NN O
2 NN NN O
. NN NN O
5 NN NN O
) NN NN O
among NN NN O
those NN NN O
who NN NN O
used NN NN O
third NN NN O
- NN NN O
generation NN NN O
oral NN NN O
contraceptives NN NN O
. NN NN O
   
Among NN NN O
women NN NN O
who NN NN O
used NN NN O
oral NN NN O
contraceptives NN NN O
, NN NN O
the NN NN O
odds NN NN O
ratio NN NN O
was NN NN O
2 NN NN O
. NN NN O
1 NN NN O
( NN NN O
95 NN NN O
percent NN NN O
confidence NN NN O
interval NN NN O
, NN NN O
1 NN NN O
. NN NN O
5 NN NN O
to NN NN O
3 NN NN O
. NN NN O
0 NN NN O
) NN NN O
for NN NN O
those NN NN O
without NN NN O
a NN NN O
prothrombotic NN NN O
mutation NN NN O
and NN NN O
1 NN NN O
. NN NN O
9 NN NN O
( NN NN O
95 NN NN O
percent NN NN O
confidence NN NN O
interval NN NN O
, NN NN O
0 NN NN O
. NN NN O
6 NN NN O
to NN NN O
5 NN NN O
. NN NN O
5 NN NN O
) NN NN O
for NN NN O
those NN NN O
with NN NN O
a NN NN O
mutation NN NN O
CONCLUSIONS NN NN O
: NN NN O
The NN NN O
risk NN NN O
of NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
was NN NN O
increased NN NN O
among NN NN O
women NN NN O
who NN NN O
used NN NN O
second NN NN O
- NN NN O
generation NN NN O
oral NN NN O
contraceptives NN NN O
. NN NN O
   
The NN NN O
results NN NN O
with NN NN O
respect NN NN O
to NN NN O
the NN NN O
use NN NN O
of NN NN O
third NN NN O
- NN NN O
generation NN NN O
oral NN NN O
contraceptives NN NN O
were NN NN O
inconclusive NN NN O
but NN NN O
suggested NN NN O
that NN NN O
the NN NN O
risk NN NN O
was NN NN O
lower NN NN O
than NN NN O
the NN NN O
risk NN NN O
associated NN NN O
with NN NN O
second NN NN O
- NN NN O
generation NN NN O
oral NN NN O
contraceptives NN NN O
. NN NN O
   
The NN NN O
risk NN NN O
of NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
was NN NN O
similar NN NN O
among NN NN O
women NN NN O
who NN NN O
used NN NN O
oral NN NN O
contraceptives NN NN O
whether NN NN O
or NN NN O
not NN NN O
they NN NN O
had NN NN O
a NN NN O
prothrombotic NN NN O
mutation NN NN O
. NN NN O
   
End NN NN B-Disease
- NN NN I-Disease
stage NN NN I-Disease
renal NN NN I-Disease
disease NN NN I-Disease
( NN NN O
ESRD NN NN B-Disease
) NN NN O
after NN NN O
orthotopic NN NN O
liver NN NN O
transplantation NN NN O
( NN NN O
OLTX NN NN O
) NN NN O
using NN NN O
calcineurin NN NN O
- NN NN O
based NN NN O
immunotherapy NN NN O
: NN NN O
risk NN NN O
of NN NN O
development NN NN O
and NN NN O
treatment NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
The NN NN O
calcineurin NN NN O
inhibitors NN NN O
cyclosporine NN NN O
and NN NN O
tacrolimus NN NN O
are NN NN O
both NN NN O
known NN NN O
to NN NN O
be NN NN O
nephrotoxic NN NN B-Disease
. NN NN O
   
Their NN NN O
use NN NN O
in NN NN O
orthotopic NN NN O
liver NN NN O
transplantation NN NN O
( NN NN O
OLTX NN NN O
) NN NN O
has NN NN O
dramatically NN NN O
improved NN NN O
success NN NN O
rates NN NN O
. NN NN O
   
Recently NN NN O
, NN NN O
however NN NN O
, NN NN O
we NN NN O
have NN NN O
had NN NN O
an NN NN O
increase NN NN O
of NN NN O
patients NN NN O
who NN NN O
are NN NN O
presenting NN NN O
after NN NN O
OLTX NN NN O
with NN NN O
end NN NN B-Disease
- NN NN I-Disease
stage NN NN I-Disease
renal NN NN I-Disease
disease NN NN I-Disease
( NN NN O
ESRD NN NN B-Disease
) NN NN O
. NN NN O
   
This NN NN O
retrospective NN NN O
study NN NN O
examines NN NN O
the NN NN O
incidence NN NN O
and NN NN O
treatment NN NN O
of NN NN O
ESRD NN NN B-Disease
and NN NN O
chronic NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
( NN NN O
CRF NN NN B-Disease
) NN NN O
in NN NN O
OLTX NN NN O
patients NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Patients NN NN O
receiving NN NN O
an NN NN O
OLTX NN NN O
only NN NN O
from NN NN O
June NN NN O
1985 NN NN O
through NN NN O
December NN NN O
of NN NN O
1994 NN NN O
who NN NN O
survived NN NN O
6 NN NN O
months NN NN O
postoperatively NN NN O
were NN NN O
studied NN NN O
( NN NN O
n NN NN O
= NN NN O
834 NN NN O
) NN NN O
. NN NN O
   
Our NN NN O
prospectively NN NN O
collected NN NN O
database NN NN O
was NN NN O
the NN NN O
source NN NN O
of NN NN O
information NN NN O
. NN NN O
   
Patients NN NN O
were NN NN O
divided NN NN O
into NN NN O
three NN NN O
groups NN NN O
: NN NN O
Controls NN NN O
, NN NN O
no NN NN O
CRF NN NN B-Disease
or NN NN O
ESRD NN NN B-Disease
, NN NN O
n NN NN O
= NN NN O
748 NN NN O
; NN NN O
CRF NN NN B-Disease
, NN NN O
sustained NN NN O
serum NN NN O
creatinine NN NN O
> NN NN O
2 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
dl NN NN O
, NN NN O
n NN NN O
= NN NN O
41 NN NN O
; NN NN O
and NN NN O
ESRD NN NN B-Disease
, NN NN O
n NN NN O
= NN NN O
45 NN NN O
. NN NN O
   
Groups NN NN O
were NN NN O
compared NN NN O
for NN NN O
preoperative NN NN O
laboratory NN NN O
variables NN NN O
, NN NN O
diagnosis NN NN O
, NN NN O
postoperative NN NN O
variables NN NN O
, NN NN O
survival NN NN O
, NN NN O
type NN NN O
of NN NN O
ESRD NN NN B-Disease
therapy NN NN O
, NN NN O
and NN NN O
survival NN NN O
from NN NN O
onset NN NN O
of NN NN O
ESRD NN NN B-Disease
. NN NN O
   
RESULTS NN NN O
: NN NN O
At NN NN O
13 NN NN O
years NN NN O
after NN NN O
OLTX NN NN O
, NN NN O
the NN NN O
incidence NN NN O
of NN NN O
severe NN NN O
renal NN NN B-Disease
dysfunction NN NN I-Disease
was NN NN O
18 NN NN O
. NN NN O
1 NN NN O
% NN NN O
( NN NN O
CRF NN NN B-Disease
8 NN NN O
. NN NN O
6 NN NN O
% NN NN O
and NN NN O
ESRD NN NN B-Disease
9 NN NN O
. NN NN O
5 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
Compared NN NN O
with NN NN O
control NN NN O
patients NN NN O
, NN NN O
CRF NN NN B-Disease
and NN NN O
ESRD NN NN B-Disease
patients NN NN O
had NN NN O
higher NN NN O
preoperative NN NN O
serum NN NN O
creatinine NN NN O
levels NN NN O
, NN NN O
a NN NN O
greater NN NN O
percentage NN NN O
of NN NN O
patients NN NN O
with NN NN O
hepatorenal NN NN B-Disease
syndrome NN NN I-Disease
, NN NN O
higher NN NN O
percentage NN NN O
requirement NN NN O
for NN NN O
dialysis NN NN O
in NN NN O
the NN NN O
first NN NN O
3 NN NN O
months NN NN O
postoperatively NN NN O
, NN NN O
and NN NN O
a NN NN O
higher NN NN O
1 NN NN O
- NN NN O
year NN NN O
serum NN NN O
creatinine NN NN O
. NN NN O
   
Multivariate NN NN O
stepwise NN NN O
logistic NN NN O
regression NN NN O
analysis NN NN O
using NN NN O
preoperative NN NN O
and NN NN O
postoperative NN NN O
variables NN NN O
identified NN NN O
that NN NN O
an NN NN O
increase NN NN O
of NN NN O
serum NN NN O
creatinine NN NN O
compared NN NN O
with NN NN O
average NN NN O
at NN NN O
1 NN NN O
year NN NN O
, NN NN O
3 NN NN O
months NN NN O
, NN NN O
and NN NN O
4 NN NN O
weeks NN NN O
postoperatively NN NN O
were NN NN O
independent NN NN O
risk NN NN O
factors NN NN O
for NN NN O
the NN NN O
development NN NN O
of NN NN O
CRF NN NN B-Disease
or NN NN O
ESRD NN NN B-Disease
with NN NN O
odds NN NN O
ratios NN NN O
of NN NN O
2 NN NN O
. NN NN O
6 NN NN O
, NN NN O
2 NN NN O
. NN NN O
2 NN NN O
, NN NN O
and NN NN O
1 NN NN O
. NN NN O
6 NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
Overall NN NN O
survival NN NN O
from NN NN O
the NN NN O
time NN NN O
of NN NN O
OLTX NN NN O
was NN NN O
not NN NN O
significantly NN NN O
different NN NN O
among NN NN O
groups NN NN O
, NN NN O
but NN NN O
by NN NN O
year NN NN O
13 NN NN O
, NN NN O
the NN NN O
survival NN NN O
of NN NN O
the NN NN O
patients NN NN O
who NN NN O
had NN NN O
ESRD NN NN B-Disease
was NN NN O
only NN NN O
28 NN NN O
. NN NN O
2 NN NN O
% NN NN O
compared NN NN O
with NN NN O
54 NN NN O
. NN NN O
6 NN NN O
% NN NN O
in NN NN O
the NN NN O
control NN NN O
group NN NN O
. NN NN O
   
Patients NN NN O
developing NN NN O
ESRD NN NN B-Disease
had NN NN O
a NN NN O
6 NN NN O
- NN NN O
year NN NN O
survival NN NN O
after NN NN O
onset NN NN O
of NN NN O
ESRD NN NN B-Disease
of NN NN O
27 NN NN O
% NN NN O
for NN NN O
the NN NN O
patients NN NN O
receiving NN NN O
hemodialysis NN NN O
versus NN NN O
71 NN NN O
. NN NN O
4 NN NN O
% NN NN O
for NN NN O
the NN NN O
patients NN NN O
developing NN NN O
ESRD NN NN B-Disease
who NN NN O
subsequently NN NN O
received NN NN O
kidney NN NN O
transplants NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Patients NN NN O
who NN NN O
are NN NN O
more NN NN O
than NN NN O
10 NN NN O
years NN NN O
post NN NN O
- NN NN O
OLTX NN NN O
have NN NN O
CRF NN NN B-Disease
and NN NN O
ESRD NN NN B-Disease
at NN NN O
a NN NN O
high NN NN O
rate NN NN O
. NN NN O
   
The NN NN O
development NN NN O
of NN NN O
ESRD NN NN B-Disease
decreases NN NN O
survival NN NN O
, NN NN O
particularly NN NN O
in NN NN O
those NN NN O
patients NN NN O
treated NN NN O
with NN NN O
dialysis NN NN O
only NN NN O
. NN NN O
   
Patients NN NN O
who NN NN O
develop NN NN O
ESRD NN NN B-Disease
have NN NN O
a NN NN O
higher NN NN O
preoperative NN NN O
and NN NN O
1 NN NN O
- NN NN O
year NN NN O
serum NN NN O
creatinine NN NN O
and NN NN O
are NN NN O
more NN NN O
likely NN NN O
to NN NN O
have NN NN O
hepatorenal NN NN B-Disease
syndrome NN NN I-Disease
. NN NN O
   
However NN NN O
, NN NN O
an NN NN O
increase NN NN O
of NN NN O
serum NN NN O
creatinine NN NN O
at NN NN O
various NN NN O
times NN NN O
postoperatively NN NN O
is NN NN O
more NN NN O
predictive NN NN O
of NN NN O
the NN NN O
development NN NN O
of NN NN O
CRF NN NN B-Disease
or NN NN O
ESRD NN NN B-Disease
. NN NN O
   
New NN NN O
strategies NN NN O
for NN NN O
long NN NN O
- NN NN O
term NN NN O
immunosuppression NN NN O
may NN NN O
be NN NN O
needed NN NN O
to NN NN O
decrease NN NN O
this NN NN O
complication NN NN O
. NN NN O
   
Epileptic NN NN B-Disease
seizures NN NN I-Disease
following NN NN O
cortical NN NN O
application NN NN O
of NN NN O
fibrin NN NN O
sealants NN NN O
containing NN NN O
tranexamic NN NN O
acid NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Fibrin NN NN O
sealants NN NN O
( NN NN O
FS NN NN O
) NN NN O
derived NN NN O
from NN NN O
human NN NN O
plasma NN NN O
are NN NN O
frequently NN NN O
used NN NN O
in NN NN O
neurosurgery NN NN O
. NN NN O
   
In NN NN O
order NN NN O
to NN NN O
increase NN NN O
clot NN NN O
stability NN NN O
, NN NN O
FS NN NN O
typically NN NN O
contain NN NN O
aprotinin NN NN O
, NN NN O
a NN NN O
natural NN NN O
fibrinolysis NN NN O
inhibitor NN NN O
. NN NN O
   
Recently NN NN O
, NN NN O
synthetic NN NN O
fibrinolysis NN NN O
inhibitors NN NN O
such NN NN O
as NN NN O
tranexamic NN NN O
acid NN NN O
( NN NN O
tAMCA NN NN O
) NN NN O
have NN NN O
been NN NN O
considered NN NN O
as NN NN O
substitutes NN NN O
for NN NN O
aprotinin NN NN O
. NN NN O
   
However NN NN O
, NN NN O
tAMCA NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
cause NN NN O
epileptic NN NN B-Disease
seizures NN NN I-Disease
. NN NN O
   
We NN NN O
wanted NN NN O
to NN NN O
study NN NN O
whether NN NN O
tAMCA NN NN O
retains NN NN O
its NN NN O
convulsive NN NN B-Disease
action NN NN O
if NN NN O
incorporated NN NN O
into NN NN O
a NN NN O
FS NN NN O
. NN NN O
   
METHOD NN NN O
: NN NN O
FS NN NN O
containing NN NN O
aprotinin NN NN O
or NN NN O
different NN NN O
concentrations NN NN O
of NN NN O
tAMCA NN NN O
( NN NN O
0 NN NN O
. NN NN O
5 NN NN O
- NN NN O
47 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
ml NN NN O
) NN NN O
were NN NN O
applied NN NN O
to NN NN O
the NN NN O
pial NN NN O
surface NN NN O
of NN NN O
the NN NN O
cortex NN NN O
of NN NN O
anaesthetized NN NN O
rats NN NN O
. NN NN O
   
The NN NN O
response NN NN O
of NN NN O
the NN NN O
animals NN NN O
was NN NN O
evaluated NN NN O
using NN NN O
electroencephalography NN NN O
and NN NN O
by NN NN O
monitoring NN NN O
the NN NN O
clinical NN NN O
behaviour NN NN O
during NN NN O
and NN NN O
after NN NN O
recovery NN NN O
from NN NN O
anaesthesia NN NN O
. NN NN O
   
FINDINGS NN NN O
: NN NN O
FS NN NN O
containing NN NN O
tAMCA NN NN O
caused NN NN O
paroxysmal NN NN O
brain NN NN O
activity NN NN O
which NN NN O
was NN NN O
associated NN NN O
with NN NN O
distinct NN NN O
convulsive NN NN B-Disease
behaviours NN NN O
. NN NN O
   
The NN NN O
degree NN NN O
of NN NN O
these NN NN O
seizures NN NN B-Disease
increased NN NN O
with NN NN O
increasing NN NN O
concentration NN NN O
of NN NN O
tAMCA NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
FS NN NN O
containing NN NN O
47 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
ml NN NN O
tAMCA NN NN O
evoked NN NN O
generalized NN NN B-Disease
seizures NN NN I-Disease
in NN NN O
all NN NN O
tested NN NN O
rats NN NN O
( NN NN O
n NN NN O
= NN NN O
6 NN NN O
) NN NN O
while NN NN O
the NN NN O
lowest NN NN O
concentration NN NN O
of NN NN O
tAMCA NN NN O
( NN NN O
0 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
ml NN NN O
) NN NN O
only NN NN O
evoked NN NN O
brief NN NN O
episodes NN NN O
of NN NN O
jerk NN NN O
- NN NN O
correlated NN NN O
convulsive NN NN B-Disease
potentials NN NN O
in NN NN O
1 NN NN O
of NN NN O
6 NN NN O
rats NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
FS NN NN O
containing NN NN O
aprotinin NN NN O
did NN NN O
not NN NN O
evoke NN NN O
any NN NN O
paroxysmal NN NN O
activity NN NN O
. NN NN O
   
INTERPRETATION NN NN O
: NN NN O
Tranexamic NN NN O
acid NN NN O
retains NN NN O
its NN NN O
convulsive NN NN B-Disease
action NN NN O
within NN NN O
FS NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
use NN NN O
of NN NN O
FS NN NN O
containing NN NN O
tAMCA NN NN O
for NN NN O
surgery NN NN O
within NN NN O
or NN NN O
close NN NN O
to NN NN O
the NN NN O
CNS NN NN O
may NN NN O
pose NN NN O
a NN NN O
substantial NN NN O
risk NN NN O
to NN NN O
the NN NN O
patient NN NN O
. NN NN O
   
Sequential NN NN O
observations NN NN O
of NN NN O
exencephaly NN NN B-Disease
and NN NN O
subsequent NN NN O
morphological NN NN O
changes NN NN O
by NN NN O
mouse NN NN O
exo NN NN O
utero NN NN O
development NN NN O
system NN NN O
: NN NN O
analysis NN NN O
of NN NN O
the NN NN O
mechanism NN NN O
of NN NN O
transformation NN NN O
from NN NN O
exencephaly NN NN B-Disease
to NN NN O
anencephaly NN NN B-Disease
. NN NN O
   
Anencephaly NN NN B-Disease
has NN NN O
been NN NN O
suggested NN NN O
to NN NN O
develop NN NN O
from NN NN O
exencephaly NN NN B-Disease
; NN NN O
however NN NN O
, NN NN O
there NN NN O
is NN NN O
little NN NN O
direct NN NN O
experimental NN NN O
evidence NN NN O
to NN NN O
support NN NN O
this NN NN O
, NN NN O
and NN NN O
the NN NN O
mechanism NN NN O
of NN NN O
transformation NN NN O
remains NN NN O
unclear NN NN O
. NN NN O
   
We NN NN O
examined NN NN O
this NN NN O
theory NN NN O
using NN NN O
the NN NN O
exo NN NN O
utero NN NN O
development NN NN O
system NN NN O
that NN NN O
allows NN NN O
direct NN NN O
and NN NN O
sequential NN NN O
observations NN NN O
of NN NN O
mid NN NN O
- NN NN O
to NN NN O
late NN NN O
- NN NN O
gestation NN NN O
mouse NN NN O
embryos NN NN O
. NN NN O
   
We NN NN O
observed NN NN O
the NN NN O
exencephaly NN NN B-Disease
induced NN NN O
by NN NN O
5 NN NN O
- NN NN O
azacytidine NN NN O
at NN NN O
embryonic NN NN O
day NN NN O
13 NN NN O
. NN NN O
5 NN NN O
( NN NN O
E13 NN NN O
. NN NN O
5 NN NN O
) NN NN O
, NN NN O
let NN NN O
the NN NN O
embryos NN NN O
develop NN NN O
exo NN NN O
utero NN NN O
until NN NN O
E18 NN NN O
. NN NN O
5 NN NN O
, NN NN O
and NN NN O
re NN NN O
- NN NN O
observed NN NN O
the NN NN O
same NN NN O
embryos NN NN O
at NN NN O
E18 NN NN O
. NN NN O
5 NN NN O
. NN NN O
   
We NN NN O
confirmed NN NN O
several NN NN O
cases NN NN O
of NN NN O
transformation NN NN O
from NN NN O
exencephaly NN NN B-Disease
to NN NN O
anencephaly NN NN B-Disease
. NN NN O
   
However NN NN O
, NN NN O
in NN NN O
many NN NN O
cases NN NN O
, NN NN O
the NN NN O
exencephalic NN NN B-Disease
brain NN NN O
tissue NN NN O
was NN NN O
preserved NN NN O
with NN NN O
more NN NN O
or NN NN O
less NN NN O
reduction NN NN O
during NN NN O
this NN NN O
period NN NN O
. NN NN O
   
To NN NN O
analyze NN NN O
the NN NN O
transformation NN NN O
patterns NN NN O
, NN NN O
we NN NN O
classified NN NN O
the NN NN O
exencephaly NN NN B-Disease
by NN NN O
size NN NN O
and NN NN O
shape NN NN O
of NN NN O
the NN NN O
exencephalic NN NN B-Disease
tissue NN NN O
into NN NN O
several NN NN O
types NN NN O
at NN NN O
E13 NN NN O
. NN NN O
5 NN NN O
and NN NN O
E18 NN NN O
. NN NN O
5 NN NN O
. NN NN O
   
It NN NN O
was NN NN O
found NN NN O
that NN NN O
the NN NN O
transformation NN NN O
of NN NN O
exencephalic NN NN B-Disease
tissue NN NN O
was NN NN O
not NN NN O
simply NN NN O
size NN NN O
- NN NN O
dependent NN NN O
, NN NN O
and NN NN O
all NN NN O
cases NN NN O
of NN NN O
anencephaly NN NN B-Disease
at NN NN O
E18 NN NN O
. NN NN O
5 NN NN O
resulted NN NN O
from NN NN O
embryos NN NN O
with NN NN O
a NN NN O
large NN NN O
amount NN NN O
of NN NN O
exencephalic NN NN B-Disease
tissue NN NN O
at NN NN O
E13 NN NN O
. NN NN O
5 NN NN O
. NN NN O
   
Microscopic NN NN O
observation NN NN O
showed NN NN O
the NN NN O
configuration NN NN O
of NN NN O
exencephaly NN NN B-Disease
at NN NN O
E13 NN NN O
. NN NN O
5 NN NN O
, NN NN O
frequent NN NN O
hemorrhaging NN NN B-Disease
and NN NN O
detachment NN NN O
of NN NN O
the NN NN O
neural NN NN O
plate NN NN O
from NN NN O
surface NN NN O
ectoderm NN NN O
in NN NN O
the NN NN O
exencephalic NN NN B-Disease
head NN NN O
at NN NN O
E15 NN NN O
. NN NN O
5 NN NN O
, NN NN O
and NN NN O
multiple NN NN O
modes NN NN O
of NN NN O
reduction NN NN O
in NN NN O
the NN NN O
exencephalic NN NN B-Disease
tissue NN NN O
at NN NN O
E18 NN NN O
. NN NN O
5 NN NN O
. NN NN O
   
From NN NN O
observations NN NN O
of NN NN O
the NN NN O
vasculature NN NN O
, NN NN O
altered NN NN O
distribution NN NN O
patterns NN NN O
of NN NN O
vessels NN NN O
were NN NN O
identified NN NN O
in NN NN O
the NN NN O
exencephalic NN NN B-Disease
head NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
overgrowth NN NN O
of NN NN O
the NN NN O
exencephalic NN NN B-Disease
neural NN NN O
tissue NN NN O
causes NN NN O
the NN NN O
altered NN NN O
distribution NN NN O
patterns NN NN O
of NN NN O
vessels NN NN O
, NN NN O
subsequent NN NN O
peripheral NN NN O
circulatory NN NN B-Disease
failure NN NN I-Disease
and NN NN O
/ NN NN O
or NN NN O
hemorrhaging NN NN B-Disease
in NN NN O
various NN NN O
parts NN NN O
of NN NN O
the NN NN O
exencephalic NN NN B-Disease
head NN NN O
, NN NN O
leading NN NN O
to NN NN O
the NN NN O
multiple NN NN O
modes NN NN O
of NN NN O
tissue NN NN O
reduction NN NN O
during NN NN O
transformation NN NN O
from NN NN O
exencephaly NN NN B-Disease
to NN NN O
anencephaly NN NN B-Disease
. NN NN O
   
99mTc NN NN O
- NN NN O
glucarate NN NN O
for NN NN O
detection NN NN O
of NN NN O
isoproterenol NN NN O
- NN NN O
induced NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
in NN NN O
rats NN NN O
. NN NN O
   
Infarct NN NN B-Disease
- NN NN O
avid NN NN O
radiopharmaceuticals NN NN O
are NN NN O
necessary NN NN O
for NN NN O
rapid NN NN O
and NN NN O
timely NN NN O
diagnosis NN NN O
of NN NN O
acute NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
. NN NN O
   
The NN NN O
animal NN NN O
model NN NN O
used NN NN O
to NN NN O
produce NN NN O
infarction NN NN B-Disease
implies NN NN O
artery NN NN O
ligation NN NN O
but NN NN O
chemical NN NN O
induction NN NN O
can NN NN O
be NN NN O
easily NN NN O
obtained NN NN O
with NN NN O
isoproterenol NN NN O
. NN NN O
   
A NN NN O
new NN NN O
infarct NN NN B-Disease
- NN NN O
avid NN NN O
radiopharmaceutical NN NN O
based NN NN O
on NN NN O
glucaric NN NN O
acid NN NN O
was NN NN O
prepared NN NN O
in NN NN O
the NN NN O
hospital NN NN O
radiopharmacy NN NN O
of NN NN O
the NN NN O
INCMNSZ NN NN O
. NN NN O
   
99mTc NN NN O
- NN NN O
glucarate NN NN O
was NN NN O
easy NN NN O
to NN NN O
prepare NN NN O
, NN NN O
stable NN NN O
for NN NN O
96 NN NN O
h NN NN O
and NN NN O
was NN NN O
used NN NN O
to NN NN O
study NN NN O
its NN NN O
biodistribution NN NN O
in NN NN O
rats NN NN O
with NN NN O
isoproterenol NN NN O
- NN NN O
induced NN NN O
acute NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
. NN NN O
   
Histological NN NN O
studies NN NN O
demonstrated NN NN O
that NN NN O
the NN NN O
rats NN NN O
developed NN NN O
an NN NN O
infarct NN NN B-Disease
18 NN NN O
h NN NN O
after NN NN O
isoproterenol NN NN O
administration NN NN O
. NN NN O
   
The NN NN O
rat NN NN O
biodistribution NN NN O
studies NN NN O
showed NN NN O
a NN NN O
rapid NN NN O
blood NN NN O
clearance NN NN O
via NN NN O
the NN NN O
kidneys NN NN O
. NN NN O
   
Thirty NN NN O
minutes NN NN O
after NN NN O
99mTc NN NN O
- NN NN O
glucarate NN NN O
administration NN NN O
the NN NN O
standardised NN NN O
heart NN NN O
uptake NN NN O
value NN NN O
S NN NN O
( NN NN O
h NN NN O
) NN NN O
UV NN NN O
was NN NN O
4 NN NN O
. NN NN O
7 NN NN O
in NN NN O
infarcted NN NN O
rat NN NN O
heart NN NN O
which NN NN O
is NN NN O
six NN NN O
times NN NN O
more NN NN O
than NN NN O
in NN NN O
normal NN NN O
rats NN NN O
. NN NN O
   
ROIs NN NN O
drawn NN NN O
over NN NN O
the NN NN O
gamma NN NN O
camera NN NN O
images NN NN O
showed NN NN O
a NN NN O
ratio NN NN O
of NN NN O
4 NN NN O
. NN NN O
4 NN NN O
. NN NN O
   
The NN NN O
high NN NN O
image NN NN O
quality NN NN O
suggests NN NN O
that NN NN O
high NN NN O
contrast NN NN O
images NN NN O
can NN NN O
be NN NN O
obtained NN NN O
in NN NN O
humans NN NN O
and NN NN O
the NN NN O
96 NN NN O
h NN NN O
stability NN NN O
makes NN NN O
it NN NN O
an NN NN O
ideal NN NN O
agent NN NN O
to NN NN O
detect NN NN O
, NN NN O
in NN NN O
patients NN NN O
, NN NN O
early NN NN O
cardiac NN NN B-Disease
infarction NN NN I-Disease
. NN NN O
   
Bupropion NN NN O
( NN NN O
Zyban NN NN O
) NN NN O
toxicity NN NN B-Disease
. NN NN O
   
Bupropion NN NN O
is NN NN O
a NN NN O
monocyclic NN NN O
antidepressant NN NN O
structurally NN NN O
related NN NN O
to NN NN O
amphetamine NN NN O
. NN NN O
   
Zyban NN NN O
, NN NN O
a NN NN O
sustained NN NN O
- NN NN O
release NN NN O
formulation NN NN O
of NN NN O
bupropion NN NN O
hydrochloride NN NN O
, NN NN O
was NN NN O
recently NN NN O
released NN NN O
in NN NN O
Ireland NN NN O
, NN NN O
as NN NN O
a NN NN O
smoking NN NN O
cessation NN NN O
aid NN NN O
. NN NN O
   
In NN NN O
the NN NN O
initial NN NN O
6 NN NN O
months NN NN O
since NN NN O
it NN NN O
' NN NN O
s NN NN O
introduction NN NN O
, NN NN O
12 NN NN O
overdose NN NN B-Disease
cases NN NN O
have NN NN O
been NN NN O
reported NN NN O
to NN NN O
The NN NN O
National NN NN O
Poisons NN NN O
Information NN NN O
Centre NN NN O
. NN NN O
   
8 NN NN O
patients NN NN O
developed NN NN O
symptoms NN NN O
of NN NN O
toxicity NN NN B-Disease
. NN NN O
   
Common NN NN O
features NN NN O
included NN NN O
tachycardia NN NN B-Disease
, NN NN O
drowsiness NN NN O
, NN NN O
hallucinations NN NN B-Disease
and NN NN O
convulsions NN NN B-Disease
. NN NN O
   
Two NN NN O
patients NN NN O
developed NN NN O
severe NN NN O
cardiac NN NN B-Disease
arrhythmias NN NN I-Disease
, NN NN O
including NN NN O
one NN NN O
patient NN NN O
who NN NN O
was NN NN O
resuscitated NN NN O
following NN NN O
a NN NN O
cardiac NN NN B-Disease
arrest NN NN I-Disease
. NN NN O
   
All NN NN O
patients NN NN O
recovered NN NN O
without NN NN O
sequelae NN NN O
. NN NN O
   
We NN NN O
report NN NN O
a NN NN O
case NN NN O
of NN NN O
a NN NN O
31 NN NN O
year NN NN O
old NN NN O
female NN NN O
who NN NN O
required NN NN O
admission NN NN O
to NN NN O
the NN NN O
Intensive NN NN O
Care NN NN O
Unit NN NN O
for NN NN O
ventilation NN NN O
and NN NN O
full NN NN O
supportive NN NN O
therapy NN NN O
, NN NN O
following NN NN O
ingestion NN NN O
of NN NN O
13 NN NN O
. NN NN O
5g NN NN O
bupropion NN NN O
. NN NN O
   
Recurrent NN NN O
seizures NN NN B-Disease
were NN NN O
treated NN NN O
with NN NN O
diazepam NN NN O
and NN NN O
broad NN NN O
complex NN NN O
tachycardia NN NN B-Disease
was NN NN O
successfully NN NN O
treated NN NN O
with NN NN O
adenosine NN NN O
. NN NN O
   
Zyban NN NN O
caused NN NN O
significant NN NN O
neurological NN NN B-Disease
and NN NN I-Disease
cardiovascular NN NN I-Disease
toxicity NN NN I-Disease
in NN NN O
overdose NN NN B-Disease
. NN NN O
   
The NN NN O
potential NN NN O
toxic NN NN O
effects NN NN O
should NN NN O
be NN NN O
considered NN NN O
when NN NN O
prescribing NN NN O
it NN NN O
as NN NN O
a NN NN O
smoking NN NN O
cessation NN NN O
aid NN NN O
. NN NN O
   
GLEPP1 NN NN O
receptor NN NN O
tyrosine NN NN O
phosphatase NN NN O
( NN NN O
Ptpro NN NN O
) NN NN O
in NN NN O
rat NN NN O
PAN NN NN O
nephrosis NN NN B-Disease
. NN NN O
   
A NN NN O
marker NN NN O
of NN NN O
acute NN NN O
podocyte NN NN O
injury NN NN O
. NN NN O
   
Glomerular NN NN O
epithelial NN NN O
protein NN NN O
1 NN NN O
( NN NN O
GLEPP1 NN NN O
) NN NN O
is NN NN O
a NN NN O
podocyte NN NN O
receptor NN NN O
membrane NN NN O
protein NN NN O
tyrosine NN NN O
phosphatase NN NN O
located NN NN O
on NN NN O
the NN NN O
apical NN NN O
cell NN NN O
membrane NN NN O
of NN NN O
visceral NN NN O
glomerular NN NN O
epithelial NN NN O
cell NN NN O
and NN NN O
foot NN NN O
processes NN NN O
. NN NN O
   
This NN NN O
receptor NN NN O
plays NN NN O
a NN NN O
role NN NN O
in NN NN O
regulating NN NN O
the NN NN O
structure NN NN O
and NN NN O
function NN NN O
of NN NN O
podocyte NN NN O
foot NN NN O
process NN NN O
. NN NN O
   
To NN NN O
better NN NN O
understand NN NN O
the NN NN O
utility NN NN O
of NN NN O
GLEPP1 NN NN O
as NN NN O
a NN NN O
marker NN NN O
of NN NN O
glomerular NN NN B-Disease
injury NN NN I-Disease
, NN NN O
the NN NN O
amount NN NN O
and NN NN O
distribution NN NN O
of NN NN O
GLEPP1 NN NN O
protein NN NN O
and NN NN O
mRNA NN NN O
were NN NN O
examined NN NN O
by NN NN O
immunohistochemistry NN NN O
, NN NN O
Western NN NN O
blot NN NN O
and NN NN O
RNase NN NN O
protection NN NN O
assay NN NN O
in NN NN O
a NN NN O
model NN NN O
of NN NN O
podocyte NN NN O
injury NN NN O
in NN NN O
the NN NN O
rat NN NN O
. NN NN O
   
Puromycin NN NN O
aminonucleoside NN NN O
nephrosis NN NN B-Disease
was NN NN O
induced NN NN O
by NN NN O
single NN NN O
intraperitoneal NN NN O
injection NN NN O
of NN NN O
puromycin NN NN O
aminonucleoside NN NN O
( NN NN O
PAN NN NN O
, NN NN O
20 NN NN O
mg NN NN O
/ NN NN O
100g NN NN O
BW NN NN O
) NN NN O
. NN NN O
   
Tissues NN NN O
were NN NN O
analyzed NN NN O
at NN NN O
0 NN NN O
, NN NN O
5 NN NN O
, NN NN O
7 NN NN O
, NN NN O
11 NN NN O
, NN NN O
21 NN NN O
, NN NN O
45 NN NN O
, NN NN O
80 NN NN O
and NN NN O
126 NN NN O
days NN NN O
after NN NN O
PAN NN NN O
injection NN NN O
so NN NN O
as NN NN O
to NN NN O
include NN NN O
both NN NN O
the NN NN O
acute NN NN O
phase NN NN O
of NN NN O
proteinuria NN NN B-Disease
associated NN NN O
with NN NN O
foot NN NN O
process NN NN O
effacement NN NN O
( NN NN O
days NN NN O
5 NN NN O
- NN NN O
11 NN NN O
) NN NN O
and NN NN O
the NN NN O
chronic NN NN O
phase NN NN O
of NN NN O
proteinuria NN NN B-Disease
associated NN NN O
with NN NN O
glomerulosclerosis NN NN B-Disease
( NN NN O
days NN NN O
45 NN NN O
- NN NN O
126 NN NN O
) NN NN O
. NN NN O
   
At NN NN O
day NN NN O
5 NN NN O
, NN NN O
GLEPP1 NN NN O
protein NN NN O
and NN NN O
mRNA NN NN O
were NN NN O
reduced NN NN O
from NN NN O
the NN NN O
normal NN NN O
range NN NN O
( NN NN O
265 NN NN O
. NN NN O
2 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
79 NN NN O
. NN NN O
6 NN NN O
x NN NN O
10 NN NN O
( NN NN O
6 NN NN O
) NN NN O
moles NN NN O
/ NN NN O
glomerulus NN NN O
and NN NN O
100 NN NN O
% NN NN O
) NN NN O
to NN NN O
15 NN NN O
% NN NN O
of NN NN O
normal NN NN O
( NN NN O
41 NN NN O
. NN NN O
8 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
4 NN NN O
. NN NN O
8 NN NN O
x NN NN O
10 NN NN O
( NN NN O
6 NN NN O
) NN NN O
moles NN NN O
/ NN NN O
glomerulus NN NN O
, NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
005 NN NN O
) NN NN O
. NN NN O
   
This NN NN O
occurred NN NN O
in NN NN O
association NN NN O
with NN NN O
an NN NN O
increase NN NN O
in NN NN O
urinary NN NN O
protein NN NN O
content NN NN O
from NN NN O
1 NN NN O
. NN NN O
8 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
to NN NN O
99 NN NN O
. NN NN O
0 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
61 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
podocalyxin NN NN O
did NN NN O
not NN NN O
change NN NN O
significantly NN NN O
at NN NN O
this NN NN O
time NN NN O
. NN NN O
   
By NN NN O
day NN NN O
11 NN NN O
, NN NN O
GLEPP1 NN NN O
protein NN NN O
and NN NN O
mRNA NN NN O
had NN NN O
begun NN NN O
to NN NN O
return NN NN O
towards NN NN O
baseline NN NN O
. NN NN O
   
By NN NN O
day NN NN O
45 NN NN O
- NN NN O
126 NN NN O
, NN NN O
at NN NN O
a NN NN O
time NN NN O
when NN NN O
glomerular NN NN O
scarring NN NN O
was NN NN O
present NN NN O
, NN NN O
GLEPP1 NN NN O
was NN NN O
absent NN NN O
from NN NN O
glomerulosclerotic NN NN O
areas NN NN O
although NN NN O
the NN NN O
total NN NN O
glomerular NN NN O
content NN NN O
of NN NN O
GLEPP1 NN NN O
was NN NN O
not NN NN O
different NN NN O
from NN NN O
normal NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
GLEPP1 NN NN O
expression NN NN O
, NN NN O
unlike NN NN O
podocalyxin NN NN O
, NN NN O
reflects NN NN O
podocyte NN NN O
injury NN NN O
induced NN NN O
by NN NN O
PAN NN NN O
. NN NN O
   
GLEPP1 NN NN O
expression NN NN O
may NN NN O
be NN NN O
a NN NN O
useful NN NN O
marker NN NN O
of NN NN O
podocyte NN NN O
injury NN NN O
. NN NN O
   
Antithymocyte NN NN O
globulin NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
D NN NN O
- NN NN O
penicillamine NN NN O
- NN NN O
induced NN NN O
aplastic NN NN B-Disease
anemia NN NN I-Disease
. NN NN O
   
A NN NN O
patient NN NN O
who NN NN O
received NN NN O
antithymocyte NN NN O
globulin NN NN O
therapy NN NN O
for NN NN O
aplastic NN NN B-Disease
anemia NN NN I-Disease
due NN NN O
to NN NN O
D NN NN O
- NN NN O
penicillamine NN NN O
therapy NN NN O
is NN NN O
described NN NN O
. NN NN O
   
Bone NN NN O
marrow NN NN O
recovery NN NN O
and NN NN O
peripheral NN NN O
blood NN NN O
recovery NN NN O
were NN NN O
complete NN NN O
1 NN NN O
month NN NN O
and NN NN O
3 NN NN O
months NN NN O
, NN NN O
respectively NN NN O
, NN NN O
after NN NN O
treatment NN NN O
, NN NN O
and NN NN O
blood NN NN O
transfusion NN NN O
or NN NN O
other NN NN O
therapies NN NN O
were NN NN O
not NN NN O
necessary NN NN O
in NN NN O
a NN NN O
follow NN NN O
- NN NN O
up NN NN O
period NN NN O
of NN NN O
more NN NN O
than NN NN O
2 NN NN O
years NN NN O
. NN NN O
   
Use NN NN O
of NN NN O
antithymocyte NN NN O
globulin NN NN O
may NN NN O
be NN NN O
the NN NN O
optimal NN NN O
treatment NN NN O
of NN NN O
D NN NN O
- NN NN O
penicillamine NN NN O
- NN NN O
induced NN NN O
aplastic NN NN B-Disease
anemia NN NN I-Disease
. NN NN O
   
Metamizol NN NN O
potentiates NN NN O
morphine NN NN O
antinociception NN NN O
but NN NN O
not NN NN O
constipation NN NN B-Disease
after NN NN O
chronic NN NN O
treatment NN NN O
. NN NN O
   
This NN NN O
work NN NN O
evaluates NN NN O
the NN NN O
antinociceptive NN NN O
and NN NN O
constipating NN NN B-Disease
effects NN NN O
of NN NN O
the NN NN O
combination NN NN O
of NN NN O
3 NN NN O
. NN NN O
2 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
s NN NN O
. NN NN O
c NN NN O
. NN NN O
morphine NN NN O
with NN NN O
177 NN NN O
. NN NN O
8 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
s NN NN O
. NN NN O
c NN NN O
. NN NN O
metamizol NN NN O
in NN NN O
acutely NN NN O
and NN NN O
chronically NN NN O
treated NN NN O
( NN NN O
once NN NN O
a NN NN O
day NN NN O
for NN NN O
12 NN NN O
days NN NN O
) NN NN O
rats NN NN O
. NN NN O
   
On NN NN O
the NN NN O
13th NN NN O
day NN NN O
, NN NN O
antinociceptive NN NN O
effects NN NN O
were NN NN O
assessed NN NN O
using NN NN O
a NN NN O
model NN NN O
of NN NN O
inflammatory NN NN O
nociception NN NN O
, NN NN O
pain NN NN B-Disease
- NN NN O
induced NN NN O
functional NN NN O
impairment NN NN O
model NN NN O
, NN NN O
and NN NN O
the NN NN O
charcoal NN NN O
meal NN NN O
test NN NN O
was NN NN O
used NN NN O
to NN NN O
evaluate NN NN O
the NN NN O
intestinal NN NN O
transit NN NN O
. NN NN O
   
Simultaneous NN NN O
administration NN NN O
of NN NN O
morphine NN NN O
with NN NN O
metamizol NN NN O
resulted NN NN O
in NN NN O
a NN NN O
markedly NN NN O
antinociceptive NN NN O
potentiation NN NN O
and NN NN O
an NN NN O
increasing NN NN O
of NN NN O
the NN NN O
duration NN NN O
of NN NN O
action NN NN O
after NN NN O
a NN NN O
single NN NN O
( NN NN O
298 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
7 NN NN O
vs NN NN O
. NN NN O
139 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
36 NN NN O
units NN NN O
area NN NN O
( NN NN O
ua NN NN O
) NN NN O
; NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
and NN NN O
repeated NN NN O
administration NN NN O
( NN NN O
280 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
17 NN NN O
vs NN NN O
. NN NN O
131 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
22 NN NN O
ua NN NN O
; NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
. NN NN O
   
Antinociceptive NN NN O
effect NN NN O
of NN NN O
morphine NN NN O
was NN NN O
reduced NN NN O
in NN NN O
chronically NN NN O
treated NN NN O
rats NN NN O
( NN NN O
39 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
10 NN NN O
vs NN NN O
. NN NN O
18 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
5 NN NN O
au NN NN O
) NN NN O
while NN NN O
the NN NN O
combination NN NN O
- NN NN O
induced NN NN O
antinociception NN NN O
was NN NN O
remained NN NN O
similar NN NN O
as NN NN O
an NN NN O
acute NN NN O
treatment NN NN O
( NN NN O
298 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
7 NN NN O
vs NN NN O
. NN NN O
280 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
17 NN NN O
au NN NN O
) NN NN O
. NN NN O
   
Acute NN NN O
antinociceptive NN NN O
effects NN NN O
of NN NN O
the NN NN O
combination NN NN O
were NN NN O
partially NN NN O
prevented NN NN O
by NN NN O
3 NN NN O
. NN NN O
2 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
naloxone NN NN O
s NN NN O
. NN NN O
c NN NN O
. NN NN O
   
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
, NN NN O
suggesting NN NN O
the NN NN O
partial NN NN O
involvement NN NN O
of NN NN O
the NN NN O
opioidergic NN NN O
system NN NN O
in NN NN O
the NN NN O
synergism NN NN O
observed NN NN O
. NN NN O
   
In NN NN O
independent NN NN O
groups NN NN O
, NN NN O
morphine NN NN O
inhibited NN NN O
the NN NN O
intestinal NN NN O
transit NN NN O
in NN NN O
48 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
4 NN NN O
% NN NN O
and NN NN O
38 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
4 NN NN O
% NN NN O
after NN NN O
acute NN NN O
and NN NN O
chronic NN NN O
treatment NN NN O
, NN NN O
respectively NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
tolerance NN NN O
did NN NN O
not NN NN O
develop NN NN O
to NN NN O
the NN NN O
constipating NN NN B-Disease
effects NN NN O
. NN NN O
   
The NN NN O
combination NN NN O
inhibited NN NN O
intestinal NN NN O
transit NN NN O
similar NN NN O
to NN NN O
that NN NN O
produced NN NN O
by NN NN O
morphine NN NN O
regardless NN NN O
of NN NN O
the NN NN O
time NN NN O
of NN NN O
treatment NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
metamizol NN NN O
did NN NN O
not NN NN O
potentiate NN NN O
morphine NN NN O
- NN NN O
induced NN NN O
constipation NN NN B-Disease
. NN NN O
   
These NN NN O
findings NN NN O
show NN NN O
a NN NN O
significant NN NN O
interaction NN NN O
between NN NN O
morphine NN NN O
and NN NN O
metamizol NN NN O
in NN NN O
chronically NN NN O
treated NN NN O
rats NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
this NN NN O
combination NN NN O
could NN NN O
be NN NN O
useful NN NN O
for NN NN O
the NN NN O
treatment NN NN O
of NN NN O
chronic NN NN B-Disease
pain NN NN I-Disease
. NN NN O
   
Ifosfamide NN NN O
encephalopathy NN NN B-Disease
presenting NN NN O
with NN NN O
asterixis NN NN B-Disease
. NN NN O
   
CNS NN NN O
toxic NN NN O
effects NN NN O
of NN NN O
the NN NN O
antineoplastic NN NN O
agent NN NN O
ifosfamide NN NN O
( NN NN O
IFX NN NN O
) NN NN O
are NN NN O
frequent NN NN O
and NN NN O
include NN NN O
a NN NN O
variety NN NN O
of NN NN O
neurological NN NN O
symptoms NN NN O
that NN NN O
can NN NN O
limit NN NN O
drug NN NN O
use NN NN O
. NN NN O
   
We NN NN O
report NN NN O
a NN NN O
case NN NN O
of NN NN O
a NN NN O
51 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
man NN NN O
who NN NN O
developed NN NN O
severe NN NN O
, NN NN O
disabling NN NN O
negative NN NN O
myoclonus NN NN B-Disease
of NN NN O
the NN NN O
upper NN NN O
and NN NN O
lower NN NN O
extremities NN NN O
after NN NN O
the NN NN O
infusion NN NN O
of NN NN O
ifosfamide NN NN O
for NN NN O
plasmacytoma NN NN B-Disease
. NN NN O
   
He NN NN O
was NN NN O
awake NN NN O
, NN NN O
revealed NN NN O
no NN NN O
changes NN NN O
of NN NN O
mental NN NN O
status NN NN O
and NN NN O
at NN NN O
rest NN NN O
there NN NN O
were NN NN O
no NN NN O
further NN NN O
motor NN NN O
symptoms NN NN O
. NN NN O
   
Cranial NN NN O
magnetic NN NN O
resonance NN NN O
imaging NN NN O
and NN NN O
extensive NN NN O
laboratory NN NN O
studies NN NN O
failed NN NN O
to NN NN O
reveal NN NN O
structural NN NN B-Disease
lesions NN NN I-Disease
of NN NN I-Disease
the NN NN I-Disease
brain NN NN I-Disease
and NN NN O
metabolic NN NN B-Disease
abnormalities NN NN I-Disease
. NN NN O
   
An NN NN O
electroencephalogram NN NN O
showed NN NN O
continuous NN NN O
, NN NN O
generalized NN NN O
irregular NN NN O
slowing NN NN O
with NN NN O
admixed NN NN O
periodic NN NN O
triphasic NN NN O
waves NN NN O
indicating NN NN O
symptomatic NN NN O
encephalopathy NN NN B-Disease
. NN NN O
   
The NN NN O
administration NN NN O
of NN NN O
ifosfamide NN NN O
was NN NN O
discontinued NN NN O
and NN NN O
within NN NN O
12 NN NN O
h NN NN O
the NN NN O
asterixis NN NN B-Disease
resolved NN NN O
completely NN NN O
. NN NN O
   
In NN NN O
the NN NN O
patient NN NN O
described NN NN O
, NN NN O
the NN NN O
presence NN NN O
of NN NN O
asterixis NN NN B-Disease
during NN NN O
infusion NN NN O
of NN NN O
ifosfamide NN NN O
, NN NN O
normal NN NN O
laboratory NN NN O
findings NN NN O
and NN NN O
imaging NN NN O
studies NN NN O
and NN NN O
the NN NN O
resolution NN NN O
of NN NN O
symptoms NN NN O
following NN NN O
the NN NN O
discontinuation NN NN O
of NN NN O
the NN NN O
drug NN NN O
suggest NN NN O
that NN NN O
negative NN NN O
myoclonus NN NN B-Disease
is NN NN O
associated NN NN O
with NN NN O
the NN NN O
use NN NN O
of NN NN O
IFX NN NN O
. NN NN O
   
Antagonism NN NN O
between NN NN O
interleukin NN NN O
3 NN NN O
and NN NN O
erythropoietin NN NN O
in NN NN O
mice NN NN O
with NN NN O
azidothymidine NN NN O
- NN NN O
induced NN NN O
anemia NN NN B-Disease
and NN NN O
in NN NN O
bone NN NN O
marrow NN NN O
endothelial NN NN O
cells NN NN O
. NN NN O
   
Azidothymidine NN NN O
( NN NN O
AZT NN NN O
) NN NN O
- NN NN O
induced NN NN O
anemia NN NN B-Disease
in NN NN O
mice NN NN O
can NN NN O
be NN NN O
reversed NN NN O
by NN NN O
the NN NN O
administration NN NN O
of NN NN O
IGF NN NN O
- NN NN O
IL NN NN O
- NN NN O
3 NN NN O
( NN NN O
fusion NN NN O
protein NN NN O
of NN NN O
insulin NN NN O
- NN NN O
like NN NN O
growth NN NN O
factor NN NN O
II NN NN O
( NN NN O
IGF NN NN O
II NN NN O
) NN NN O
and NN NN O
interleukin NN NN O
3 NN NN O
) NN NN O
. NN NN O
   
Although NN NN O
interleukin NN NN O
3 NN NN O
( NN NN O
IL NN NN O
- NN NN O
3 NN NN O
) NN NN O
and NN NN O
erythropoietin NN NN O
( NN NN O
EPO NN NN O
) NN NN O
are NN NN O
known NN NN O
to NN NN O
act NN NN O
synergistically NN NN O
on NN NN O
hematopoietic NN NN O
cell NN NN O
proliferation NN NN O
in NN NN O
vitro NN NN O
, NN NN O
injection NN NN O
of NN NN O
IGF NN NN O
- NN NN O
IL NN NN O
- NN NN O
3 NN NN O
and NN NN O
EPO NN NN O
in NN NN O
AZT NN NN O
- NN NN O
treated NN NN O
mice NN NN O
resulted NN NN O
in NN NN O
a NN NN O
reduction NN NN O
of NN NN O
red NN NN O
cells NN NN O
and NN NN O
an NN NN O
increase NN NN O
of NN NN O
plasma NN NN O
EPO NN NN O
levels NN NN O
as NN NN O
compared NN NN O
to NN NN O
animals NN NN O
treated NN NN O
with NN NN O
IGF NN NN O
- NN NN O
IL NN NN O
- NN NN O
3 NN NN O
or NN NN O
EPO NN NN O
alone NN NN O
. NN NN O
   
We NN NN O
tested NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
the NN NN O
antagonistic NN NN O
effect NN NN O
of NN NN O
IL NN NN O
- NN NN O
3 NN NN O
and NN NN O
EPO NN NN O
on NN NN O
erythroid NN NN O
cells NN NN O
may NN NN O
be NN NN O
mediated NN NN O
by NN NN O
endothelial NN NN O
cells NN NN O
. NN NN O
   
Bovine NN NN O
liver NN NN O
erythroid NN NN O
cells NN NN O
were NN NN O
cultured NN NN O
on NN NN O
monolayers NN NN O
of NN NN O
human NN NN O
bone NN NN O
marrow NN NN O
endothelial NN NN O
cells NN NN O
previously NN NN O
treated NN NN O
with NN NN O
EPO NN NN O
and NN NN O
IGF NN NN O
- NN NN O
IL NN NN O
- NN NN O
3 NN NN O
. NN NN O
   
There NN NN O
was NN NN O
a NN NN O
significant NN NN O
reduction NN NN O
of NN NN O
thymidine NN NN O
incorporation NN NN O
into NN NN O
both NN NN O
erythroid NN NN O
and NN NN O
endothelial NN NN O
cells NN NN O
in NN NN O
cultures NN NN O
pre NN NN O
- NN NN O
treated NN NN O
with NN NN O
IGF NN NN O
- NN NN O
IL NN NN O
- NN NN O
3 NN NN O
and NN NN O
EPO NN NN O
. NN NN O
   
Endothelial NN NN O
cell NN NN O
culture NN NN O
supernatants NN NN O
separated NN NN O
by NN NN O
ultrafiltration NN NN O
and NN NN O
ultracentrifugation NN NN O
from NN NN O
cells NN NN O
treated NN NN O
with NN NN O
EPO NN NN O
and NN NN O
IL NN NN O
- NN NN O
3 NN NN O
significantly NN NN O
reduced NN NN O
thymidine NN NN O
incorporation NN NN O
into NN NN O
erythroid NN NN O
cells NN NN O
as NN NN O
compared NN NN O
to NN NN O
identical NN NN O
fractions NN NN O
obtained NN NN O
from NN NN O
the NN NN O
media NN NN O
of NN NN O
cells NN NN O
cultured NN NN O
with NN NN O
EPO NN NN O
alone NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
endothelial NN NN O
cells NN NN O
treated NN NN O
simultaneously NN NN O
with NN NN O
EPO NN NN O
and NN NN O
IL NN NN O
- NN NN O
3 NN NN O
have NN NN O
a NN NN O
negative NN NN O
effect NN NN O
on NN NN O
erythroid NN NN O
cell NN NN O
production NN NN O
. NN NN O
   
The NN NN O
relationship NN NN O
between NN NN O
hippocampal NN NN O
acetylcholine NN NN O
release NN NN O
and NN NN O
cholinergic NN NN O
convulsant NN NN O
sensitivity NN NN O
in NN NN O
withdrawal NN NN O
seizure NN NN B-Disease
- NN NN O
prone NN NN O
and NN NN O
withdrawal NN NN O
seizure NN NN B-Disease
- NN NN O
resistant NN NN O
selected NN NN O
mouse NN NN O
lines NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
The NN NN O
septo NN NN O
- NN NN O
hippocampal NN NN O
cholinergic NN NN O
pathway NN NN O
has NN NN O
been NN NN O
implicated NN NN O
in NN NN O
epileptogenesis NN NN O
, NN NN O
and NN NN O
genetic NN NN O
factors NN NN O
influence NN NN O
the NN NN O
response NN NN O
to NN NN O
cholinergic NN NN O
agents NN NN O
, NN NN O
but NN NN O
limited NN NN O
data NN NN O
are NN NN O
available NN NN O
on NN NN O
cholinergic NN NN O
involvement NN NN O
in NN NN O
alcohol NN NN O
withdrawal NN NN O
severity NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
the NN NN O
relationship NN NN O
between NN NN O
cholinergic NN NN O
activity NN NN O
and NN NN O
responsiveness NN NN O
and NN NN O
alcohol NN NN O
withdrawal NN NN O
was NN NN O
investigated NN NN O
in NN NN O
a NN NN O
genetic NN NN O
animal NN NN O
model NN NN O
of NN NN O
ethanol NN NN O
withdrawal NN NN O
severity NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Cholinergic NN NN O
convulsant NN NN O
sensitivity NN NN O
was NN NN O
examined NN NN O
in NN NN O
alcohol NN NN O
- NN NN O
na NN NN O
ve NN NN O
Withdrawal NN NN O
Seizure NN NN B-Disease
- NN NN O
Prone NN NN O
( NN NN O
WSP NN NN O
) NN NN O
and NN NN O
- NN NN O
Resistant NN NN O
( NN NN O
WSR NN NN O
) NN NN O
mice NN NN O
. NN NN O
   
Animals NN NN O
were NN NN O
administered NN NN O
nicotine NN NN O
, NN NN O
carbachol NN NN O
, NN NN O
or NN NN O
neostigmine NN NN O
via NN NN O
timed NN NN O
tail NN NN O
vein NN NN O
infusion NN NN O
, NN NN O
and NN NN O
the NN NN O
latencies NN NN O
to NN NN O
onset NN NN O
of NN NN O
tremor NN NN B-Disease
and NN NN O
clonus NN NN O
were NN NN O
recorded NN NN O
and NN NN O
converted NN NN O
to NN NN O
threshold NN NN O
dose NN NN O
. NN NN O
   
We NN NN O
also NN NN O
used NN NN O
microdialysis NN NN O
to NN NN O
measure NN NN O
basal NN NN O
and NN NN O
potassium NN NN O
- NN NN O
stimulated NN NN O
acetylcholine NN NN O
( NN NN O
ACh NN NN O
) NN NN O
release NN NN O
in NN NN O
the NN NN O
CA1 NN NN O
region NN NN O
of NN NN O
the NN NN O
hippocampus NN NN O
. NN NN O
   
Potassium NN NN O
was NN NN O
applied NN NN O
by NN NN O
reverse NN NN O
dialysis NN NN O
twice NN NN O
, NN NN O
separated NN NN O
by NN NN O
75 NN NN O
min NN NN O
. NN NN O
   
Hippocampal NN NN O
ACh NN NN O
also NN NN O
was NN NN O
measured NN NN O
during NN NN O
testing NN NN O
for NN NN O
handling NN NN O
- NN NN O
induced NN NN O
convulsions NN NN B-Disease
. NN NN O
   
RESULTS NN NN O
: NN NN O
Sensitivity NN NN O
to NN NN O
several NN NN O
convulsion NN NN B-Disease
endpoints NN NN O
induced NN NN O
by NN NN O
nicotine NN NN O
, NN NN O
carbachol NN NN O
, NN NN O
and NN NN O
neostigmine NN NN O
were NN NN O
significantly NN NN O
greater NN NN O
in NN NN O
WSR NN NN O
versus NN NN O
WSP NN NN O
mice NN NN O
. NN NN O
   
In NN NN O
microdialysis NN NN O
experiments NN NN O
, NN NN O
the NN NN O
lines NN NN O
did NN NN O
not NN NN O
differ NN NN O
in NN NN O
basal NN NN O
release NN NN O
of NN NN O
ACh NN NN O
, NN NN O
and NN NN O
50 NN NN O
mM NN NN O
KCl NN NN O
increased NN NN O
ACh NN NN O
output NN NN O
in NN NN O
both NN NN O
lines NN NN O
of NN NN O
mice NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
increase NN NN O
in NN NN O
release NN NN O
of NN NN O
ACh NN NN O
produced NN NN O
by NN NN O
the NN NN O
first NN NN O
application NN NN O
of NN NN O
KCl NN NN O
was NN NN O
2 NN NN O
- NN NN O
fold NN NN O
higher NN NN O
in NN NN O
WSP NN NN O
versus NN NN O
WSR NN NN O
mice NN NN O
. NN NN O
   
When NN NN O
hippocampal NN NN O
ACh NN NN O
was NN NN O
measured NN NN O
during NN NN O
testing NN NN O
for NN NN O
handling NN NN O
- NN NN O
induced NN NN O
convulsions NN NN B-Disease
, NN NN O
extracellular NN NN O
ACh NN NN O
was NN NN O
significantly NN NN O
elevated NN NN O
( NN NN O
192 NN NN O
% NN NN O
) NN NN O
in NN NN O
WSP NN NN O
mice NN NN O
, NN NN O
but NN NN O
was NN NN O
nonsignificantly NN NN O
elevated NN NN O
( NN NN O
59 NN NN O
% NN NN O
) NN NN O
in NN NN O
WSR NN NN O
mice NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
differences NN NN O
in NN NN O
cholinergic NN NN O
activity NN NN O
and NN NN O
postsynaptic NN NN O
sensitivity NN NN O
to NN NN O
cholinergic NN NN O
convulsants NN NN B-Disease
may NN NN O
be NN NN O
associated NN NN O
with NN NN O
ethanol NN NN O
withdrawal NN NN O
severity NN NN O
and NN NN O
implicate NN NN O
cholinergic NN NN O
mechanisms NN NN O
in NN NN O
alcohol NN NN O
withdrawal NN NN O
. NN NN O
   
Specifically NN NN O
, NN NN O
WSP NN NN O
mice NN NN O
may NN NN O
have NN NN O
lower NN NN O
sensitivity NN NN O
to NN NN O
cholinergic NN NN O
convulsants NN NN B-Disease
compared NN NN O
with NN NN O
WSR NN NN O
because NN NN O
of NN NN O
postsynaptic NN NN O
receptor NN NN O
desensitization NN NN O
brought NN NN O
on NN NN O
by NN NN O
higher NN NN O
activity NN NN O
of NN NN O
cholinergic NN NN O
neurons NN NN O
. NN NN O
   
Capsaicin NN NN O
- NN NN O
induced NN NN O
muscle NN NN B-Disease
pain NN NN I-Disease
alters NN NN O
the NN NN O
excitability NN NN O
of NN NN O
the NN NN O
human NN NN O
jaw NN NN O
- NN NN O
stretch NN NN O
reflex NN NN O
. NN NN O
   
The NN NN O
pathophysiology NN NN O
of NN NN O
painful NN NN O
temporomandibular NN NN B-Disease
disorders NN NN I-Disease
is NN NN O
not NN NN O
fully NN NN O
understood NN NN O
, NN NN O
but NN NN O
evidence NN NN O
suggests NN NN O
that NN NN O
muscle NN NN B-Disease
pain NN NN I-Disease
modulates NN NN O
motor NN NN O
function NN NN O
in NN NN O
characteristic NN NN O
ways NN NN O
. NN NN O
   
This NN NN O
study NN NN O
tested NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
activation NN NN O
of NN NN O
nociceptive NN NN B-Disease
muscle NN NN I-Disease
afferent NN NN O
fibers NN NN O
would NN NN O
be NN NN O
linked NN NN O
to NN NN O
an NN NN O
increased NN NN O
excitability NN NN O
of NN NN O
the NN NN O
human NN NN O
jaw NN NN O
- NN NN O
stretch NN NN O
reflex NN NN O
and NN NN O
whether NN NN O
this NN NN O
process NN NN O
would NN NN O
be NN NN O
sensitive NN NN O
to NN NN O
length NN NN O
and NN NN O
velocity NN NN O
of NN NN O
the NN NN O
stretch NN NN O
. NN NN O
   
Capsaicin NN NN O
( NN NN O
10 NN NN O
micro NN NN O
g NN NN O
) NN NN O
was NN NN O
injected NN NN O
into NN NN O
the NN NN O
masseter NN NN O
muscle NN NN O
to NN NN O
induce NN NN O
pain NN NN B-Disease
in NN NN O
11 NN NN O
healthy NN NN O
volunteers NN NN O
. NN NN O
   
Short NN NN O
- NN NN O
latency NN NN O
reflex NN NN O
responses NN NN O
were NN NN O
evoked NN NN O
in NN NN O
the NN NN O
masseter NN NN O
and NN NN O
temporalis NN NN O
muscles NN NN O
by NN NN O
a NN NN O
stretch NN NN O
device NN NN O
with NN NN O
different NN NN O
velocities NN NN O
and NN NN O
displacements NN NN O
before NN NN O
, NN NN O
during NN NN O
, NN NN O
and NN NN O
after NN NN O
the NN NN O
pain NN NN B-Disease
. NN NN O
   
The NN NN O
normalized NN NN O
reflex NN NN O
amplitude NN NN O
increased NN NN O
with NN NN O
an NN NN O
increase NN NN O
in NN NN O
velocity NN NN O
at NN NN O
a NN NN O
given NN NN O
displacement NN NN O
, NN NN O
but NN NN O
remained NN NN O
constant NN NN O
with NN NN O
different NN NN O
displacements NN NN O
at NN NN O
a NN NN O
given NN NN O
velocity NN NN O
. NN NN O
   
The NN NN O
normalized NN NN O
reflex NN NN O
amplitude NN NN O
was NN NN O
significantly NN NN O
higher NN NN O
during NN NN O
pain NN NN B-Disease
, NN NN O
but NN NN O
only NN NN O
at NN NN O
faster NN NN O
stretches NN NN O
in NN NN O
the NN NN O
painful NN NN B-Disease
muscle NN NN I-Disease
. NN NN O
   
Increased NN NN O
sensitivity NN NN O
of NN NN O
the NN NN O
fusimotor NN NN O
system NN NN O
during NN NN O
acute NN NN O
muscle NN NN B-Disease
pain NN NN I-Disease
could NN NN O
be NN NN O
one NN NN O
likely NN NN O
mechanism NN NN O
to NN NN O
explain NN NN O
the NN NN O
findings NN NN O
. NN NN O
   
Effects NN NN O
of NN NN O
5 NN NN O
- NN NN O
HT1B NN NN O
receptor NN NN O
ligands NN NN O
microinjected NN NN O
into NN NN O
the NN NN O
accumbal NN NN O
shell NN NN O
or NN NN O
core NN NN O
on NN NN O
the NN NN O
cocaine NN NN O
- NN NN O
induced NN NN O
locomotor NN NN B-Disease
hyperactivity NN NN I-Disease
in NN NN O
rats NN NN O
. NN NN O
   
The NN NN O
present NN NN O
study NN NN O
was NN NN O
designed NN NN O
to NN NN O
examine NN NN O
the NN NN O
effect NN NN O
of NN NN O
5 NN NN O
- NN NN O
HT1B NN NN O
receptor NN NN O
ligands NN NN O
microinjected NN NN O
into NN NN O
the NN NN O
subregions NN NN O
of NN NN O
the NN NN O
nucleus NN NN O
accumbens NN NN O
( NN NN O
the NN NN O
shell NN NN O
and NN NN O
the NN NN O
core NN NN O
) NN NN O
on NN NN O
the NN NN O
locomotor NN NN B-Disease
hyperactivity NN NN I-Disease
induced NN NN O
by NN NN O
cocaine NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
Male NN NN O
Wistar NN NN O
rats NN NN O
were NN NN O
implanted NN NN O
bilaterally NN NN O
with NN NN O
cannulae NN NN O
into NN NN O
the NN NN O
accumbens NN NN O
shell NN NN O
or NN NN O
core NN NN O
, NN NN O
and NN NN O
then NN NN O
were NN NN O
locally NN NN O
injected NN NN O
with NN NN O
GR NN NN O
55562 NN NN O
( NN NN O
an NN NN O
antagonist NN NN O
of NN NN O
5 NN NN O
- NN NN O
HT1B NN NN O
receptors NN NN O
) NN NN O
or NN NN O
CP NN NN O
93129 NN NN O
( NN NN O
an NN NN O
agonist NN NN O
of NN NN O
5 NN NN O
- NN NN O
HT1B NN NN O
receptors NN NN O
) NN NN O
. NN NN O
   
Given NN NN O
alone NN NN O
to NN NN O
any NN NN O
accumbal NN NN O
subregion NN NN O
, NN NN O
GR NN NN O
55562 NN NN O
( NN NN O
0 NN NN O
. NN NN O
1 NN NN O
- NN NN O
10 NN NN O
microg NN NN O
/ NN NN O
side NN NN O
) NN NN O
or NN NN O
CP NN NN O
93129 NN NN O
( NN NN O
0 NN NN O
. NN NN O
1 NN NN O
- NN NN O
10 NN NN O
microg NN NN O
/ NN NN O
side NN NN O
) NN NN O
did NN NN O
not NN NN O
change NN NN O
basal NN NN O
locomotor NN NN O
activity NN NN O
. NN NN O
   
Systemic NN NN O
cocaine NN NN O
( NN NN O
10 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
significantly NN NN O
increased NN NN O
the NN NN O
locomotor NN NN O
activity NN NN O
of NN NN O
rats NN NN O
. NN NN O
   
GR NN NN O
55562 NN NN O
( NN NN O
0 NN NN O
. NN NN O
1 NN NN O
- NN NN O
10 NN NN O
microg NN NN O
/ NN NN O
side NN NN O
) NN NN O
, NN NN O
administered NN NN O
intra NN NN O
- NN NN O
accumbens NN NN O
shell NN NN O
prior NN NN O
to NN NN O
cocaine NN NN O
, NN NN O
dose NN NN O
- NN NN O
dependently NN NN O
attenuated NN NN O
the NN NN O
psychostimulant NN NN O
- NN NN O
induced NN NN O
locomotor NN NN B-Disease
hyperactivity NN NN I-Disease
. NN NN O
   
Such NN NN O
attenuation NN NN O
was NN NN O
not NN NN O
found NN NN O
in NN NN O
animals NN NN O
which NN NN O
had NN NN O
been NN NN O
injected NN NN O
with NN NN O
GR NN NN O
55562 NN NN O
into NN NN O
the NN NN O
accumbens NN NN O
core NN NN O
. NN NN O
   
When NN NN O
injected NN NN O
into NN NN O
the NN NN O
accumbens NN NN O
shell NN NN O
( NN NN O
but NN NN O
not NN NN O
the NN NN O
core NN NN O
) NN NN O
before NN NN O
cocaine NN NN O
, NN NN O
CP NN NN O
93129 NN NN O
( NN NN O
0 NN NN O
. NN NN O
1 NN NN O
- NN NN O
10 NN NN O
microg NN NN O
/ NN NN O
side NN NN O
) NN NN O
enhanced NN NN O
the NN NN O
locomotor NN NN O
response NN NN O
to NN NN O
cocaine NN NN O
; NN NN O
the NN NN O
maximum NN NN O
effect NN NN O
being NN NN O
observed NN NN O
after NN NN O
10 NN NN O
microg NN NN O
/ NN NN O
side NN NN O
of NN NN O
the NN NN O
agonist NN NN O
. NN NN O
   
The NN NN O
later NN NN O
enhancement NN NN O
was NN NN O
attenuated NN NN O
after NN NN O
intra NN NN O
- NN NN O
accumbens NN NN O
shell NN NN O
treatment NN NN O
with NN NN O
GR NN NN O
55562 NN NN O
( NN NN O
1 NN NN O
microg NN NN O
/ NN NN O
side NN NN O
) NN NN O
. NN NN O
   
Our NN NN O
findings NN NN O
indicate NN NN O
that NN NN O
cocaine NN NN O
induced NN NN O
hyperlocomotion NN NN B-Disease
is NN NN O
modified NN NN O
by NN NN O
5 NN NN O
- NN NN O
HT1B NN NN O
receptor NN NN O
ligands NN NN O
microinjected NN NN O
into NN NN O
the NN NN O
accumbens NN NN O
shell NN NN O
, NN NN O
but NN NN O
not NN NN O
core NN NN O
, NN NN O
this NN NN O
modification NN NN O
consisting NN NN O
in NN NN O
inhibitory NN NN O
and NN NN O
facilitatory NN NN O
effects NN NN O
of NN NN O
the NN NN O
5 NN NN O
- NN NN O
HT1B NN NN O
receptor NN NN O
antagonist NN NN O
( NN NN O
GR NN NN O
55562 NN NN O
) NN NN O
and NN NN O
agonist NN NN O
( NN NN O
CP NN NN O
93129 NN NN O
) NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
In NN NN O
other NN NN O
words NN NN O
, NN NN O
the NN NN O
present NN NN O
results NN NN O
suggest NN NN O
that NN NN O
the NN NN O
accumbal NN NN O
shell NN NN O
5 NN NN O
- NN NN O
HT1B NN NN O
receptors NN NN O
play NN NN O
a NN NN O
permissive NN NN O
role NN NN O
in NN NN O
the NN NN O
behavioural NN NN O
response NN NN O
to NN NN O
the NN NN O
psychostimulant NN NN O
. NN NN O
   
Cocaine NN NN O
related NN NN O
chest NN NN B-Disease
pain NN NN I-Disease
: NN NN O
are NN NN O
we NN NN O
seeing NN NN O
the NN NN O
tip NN NN O
of NN NN O
an NN NN O
iceberg NN NN O
? NN NN O
   
The NN NN O
recreational NN NN O
use NN NN O
of NN NN O
cocaine NN NN O
is NN NN O
on NN NN O
the NN NN O
increase NN NN O
. NN NN O
   
The NN NN O
emergency NN NN O
nurse NN NN O
ought NN NN O
to NN NN O
be NN NN O
familiar NN NN O
with NN NN O
some NN NN O
of NN NN O
the NN NN O
cardiovascular NN NN O
consequences NN NN O
of NN NN O
cocaine NN NN O
use NN NN O
. NN NN O
   
In NN NN O
particular NN NN O
, NN NN O
the NN NN O
tendency NN NN O
of NN NN O
cocaine NN NN O
to NN NN O
produce NN NN O
chest NN NN B-Disease
pain NN NN I-Disease
ought NN NN O
to NN NN O
be NN NN O
in NN NN O
the NN NN O
mind NN NN O
of NN NN O
the NN NN O
emergency NN NN O
nurse NN NN O
when NN NN O
faced NN NN O
with NN NN O
a NN NN O
young NN NN O
victim NN NN O
of NN NN O
chest NN NN B-Disease
pain NN NN I-Disease
who NN NN O
is NN NN O
otherwise NN NN O
at NN NN O
low NN NN O
risk NN NN O
. NN NN O
   
The NN NN O
mechanism NN NN O
of NN NN O
chest NN NN B-Disease
pain NN NN I-Disease
related NN NN O
to NN NN O
cocaine NN NN O
use NN NN O
is NN NN O
discussed NN NN O
and NN NN O
treatment NN NN O
dilemmas NN NN O
are NN NN O
discussed NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
moral NN NN O
issues NN NN O
relating NN NN O
to NN NN O
the NN NN O
testing NN NN O
of NN NN O
potential NN NN O
cocaine NN NN O
users NN NN O
will NN NN O
be NN NN O
addressed NN NN O
. NN NN O
   
Crossover NN NN O
comparison NN NN O
of NN NN O
efficacy NN NN O
and NN NN O
preference NN NN O
for NN NN O
rizatriptan NN NN O
10 NN NN O
mg NN NN O
versus NN NN O
ergotamine NN NN O
/ NN NN O
caffeine NN NN O
in NN NN O
migraine NN NN B-Disease
. NN NN O
   
Rizatriptan NN NN O
is NN NN O
a NN NN O
selective NN NN O
5 NN NN O
- NN NN O
HT NN NN O
( NN NN O
1B NN NN O
/ NN NN O
1D NN NN O
) NN NN O
receptor NN NN O
agonist NN NN O
with NN NN O
rapid NN NN O
oral NN NN O
absorption NN NN O
and NN NN O
early NN NN O
onset NN NN O
of NN NN O
action NN NN O
in NN NN O
the NN NN O
acute NN NN O
treatment NN NN O
of NN NN O
migraine NN NN B-Disease
. NN NN O
   
This NN NN O
randomized NN NN O
double NN NN O
- NN NN O
blind NN NN O
crossover NN NN O
outpatient NN NN O
study NN NN O
assessed NN NN O
the NN NN O
preference NN NN O
for NN NN O
1 NN NN O
rizatriptan NN NN O
10 NN NN O
mg NN NN O
tablet NN NN O
to NN NN O
2 NN NN O
ergotamine NN NN O
1 NN NN O
mg NN NN O
/ NN NN O
caffeine NN NN O
100 NN NN O
mg NN NN O
tablets NN NN O
in NN NN O
439 NN NN O
patients NN NN O
treating NN NN O
a NN NN O
single NN NN O
migraine NN NN B-Disease
attack NN NN O
with NN NN O
each NN NN O
therapy NN NN O
. NN NN O
   
Of NN NN O
patients NN NN O
expressing NN NN O
a NN NN O
preference NN NN O
( NN NN O
89 NN NN O
. NN NN O
1 NN NN O
% NN NN O
) NN NN O
, NN NN O
more NN NN O
than NN NN O
twice NN NN O
as NN NN O
many NN NN O
preferred NN NN O
rizatriptan NN NN O
to NN NN O
ergotamine NN NN O
/ NN NN O
caffeine NN NN O
( NN NN O
69 NN NN O
. NN NN O
9 NN NN O
vs NN NN O
. NN NN O
30 NN NN O
. NN NN O
1 NN NN O
% NN NN O
, NN NN O
p NN NN O
< NN NN O
or NN NN O
= NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
. NN NN O
   
Faster NN NN O
relief NN NN O
of NN NN O
headache NN NN B-Disease
was NN NN O
the NN NN O
most NN NN O
important NN NN O
reason NN NN O
for NN NN O
preference NN NN O
, NN NN O
cited NN NN O
by NN NN O
67 NN NN O
. NN NN O
3 NN NN O
% NN NN O
of NN NN O
patients NN NN O
preferring NN NN O
rizatriptan NN NN O
and NN NN O
54 NN NN O
. NN NN O
2 NN NN O
% NN NN O
of NN NN O
patients NN NN O
who NN NN O
preferred NN NN O
ergotamine NN NN O
/ NN NN O
caffeine NN NN O
. NN NN O
   
The NN NN O
co NN NN O
- NN NN O
primary NN NN O
endpoint NN NN O
of NN NN O
being NN NN O
pain NN NN B-Disease
free NN NN O
at NN NN O
2 NN NN O
h NN NN O
was NN NN O
also NN NN O
in NN NN O
favor NN NN O
of NN NN O
rizatriptan NN NN O
. NN NN O
   
Forty NN NN O
- NN NN O
nine NN NN O
percent NN NN O
of NN NN O
patients NN NN O
were NN NN O
pain NN NN B-Disease
free NN NN O
2 NN NN O
h NN NN O
after NN NN O
rizatriptan NN NN O
, NN NN O
compared NN NN O
with NN NN O
24 NN NN O
. NN NN O
3 NN NN O
% NN NN O
treated NN NN O
with NN NN O
ergotamine NN NN O
/ NN NN O
caffeine NN NN O
( NN NN O
p NN NN O
< NN NN O
or NN NN O
= NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
, NN NN O
rizatriptan NN NN O
being NN NN O
superior NN NN O
within NN NN O
1 NN NN O
h NN NN O
of NN NN O
treatment NN NN O
. NN NN O
   
Headache NN NN B-Disease
relief NN NN O
at NN NN O
2 NN NN O
h NN NN O
was NN NN O
75 NN NN O
. NN NN O
9 NN NN O
% NN NN O
for NN NN O
rizatriptan NN NN O
and NN NN O
47 NN NN O
. NN NN O
3 NN NN O
% NN NN O
for NN NN O
ergotamine NN NN O
/ NN NN O
caffeine NN NN O
( NN NN O
p NN NN O
< NN NN O
or NN NN O
= NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
, NN NN O
with NN NN O
rizatriptan NN NN O
being NN NN O
superior NN NN O
to NN NN O
ergotamine NN NN O
/ NN NN O
caffeine NN NN O
within NN NN O
30 NN NN O
min NN NN O
of NN NN O
dosing NN NN O
. NN NN O
   
Almost NN NN O
36 NN NN O
% NN NN O
of NN NN O
patients NN NN O
taking NN NN O
rizatriptan NN NN O
were NN NN O
pain NN NN B-Disease
free NN NN O
at NN NN O
2 NN NN O
h NN NN O
and NN NN O
had NN NN O
no NN NN O
recurrence NN NN O
or NN NN O
need NN NN O
for NN NN O
additional NN NN O
medication NN NN O
within NN NN O
24 NN NN O
h NN NN O
, NN NN O
compared NN NN O
to NN NN O
20 NN NN O
% NN NN O
of NN NN O
patients NN NN O
on NN NN O
ergotamine NN NN O
/ NN NN O
caffeine NN NN O
( NN NN O
p NN NN O
< NN NN O
or NN NN O
= NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
. NN NN O
   
Rizatriptan NN NN O
was NN NN O
also NN NN O
superior NN NN O
to NN NN O
ergotamine NN NN O
/ NN NN O
caffeine NN NN O
in NN NN O
the NN NN O
proportions NN NN O
of NN NN O
patients NN NN O
with NN NN O
no NN NN O
nausea NN NN B-Disease
, NN NN O
vomiting NN NN B-Disease
, NN NN O
phonophobia NN NN B-Disease
or NN NN O
photophobia NN NN B-Disease
and NN NN O
for NN NN O
patients NN NN O
with NN NN O
normal NN NN O
function NN NN O
2 NN NN O
h NN NN O
after NN NN O
drug NN NN O
intake NN NN O
( NN NN O
p NN NN O
< NN NN O
or NN NN O
= NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
. NN NN O
   
More NN NN O
patients NN NN O
were NN NN O
( NN NN O
completely NN NN O
, NN NN O
very NN NN O
or NN NN O
somewhat NN NN O
) NN NN O
satisfied NN NN O
2 NN NN O
h NN NN O
after NN NN O
treatment NN NN O
with NN NN O
rizatriptan NN NN O
( NN NN O
69 NN NN O
. NN NN O
8 NN NN O
% NN NN O
) NN NN O
than NN NN O
at NN NN O
2 NN NN O
h NN NN O
after NN NN O
treatment NN NN O
with NN NN O
ergotamine NN NN O
/ NN NN O
caffeine NN NN O
( NN NN O
38 NN NN O
. NN NN O
6 NN NN O
% NN NN O
, NN NN O
p NN NN O
< NN NN O
or NN NN O
= NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
. NN NN O
   
Recurrence NN NN O
rates NN NN O
were NN NN O
31 NN NN O
. NN NN O
4 NN NN O
% NN NN O
with NN NN O
rizatriptan NN NN O
and NN NN O
15 NN NN O
. NN NN O
3 NN NN O
% NN NN O
with NN NN O
ergotamine NN NN O
/ NN NN O
caffeine NN NN O
. NN NN O
   
Both NN NN O
active NN NN O
treatments NN NN O
were NN NN O
well NN NN O
tolerated NN NN O
. NN NN O
   
The NN NN O
most NN NN O
common NN NN O
adverse NN NN O
events NN NN O
( NN NN O
incidence NN NN O
> NN NN O
or NN NN O
= NN NN O
5 NN NN O
% NN NN O
in NN NN O
one NN NN O
group NN NN O
) NN NN O
after NN NN O
rizatriptan NN NN O
and NN NN O
ergotamine NN NN O
/ NN NN O
caffeine NN NN O
, NN NN O
respectively NN NN O
, NN NN O
were NN NN O
dizziness NN NN B-Disease
( NN NN O
6 NN NN O
. NN NN O
7 NN NN O
and NN NN O
5 NN NN O
. NN NN O
3 NN NN O
% NN NN O
) NN NN O
, NN NN O
nausea NN NN B-Disease
( NN NN O
4 NN NN O
. NN NN O
2 NN NN O
and NN NN O
8 NN NN O
. NN NN O
5 NN NN O
% NN NN O
) NN NN O
and NN NN O
somnolence NN NN B-Disease
( NN NN O
5 NN NN O
. NN NN O
5 NN NN O
and NN NN O
2 NN NN O
. NN NN O
3 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
Severe NN NN O
ocular NN NN B-Disease
and NN NN I-Disease
orbital NN NN I-Disease
toxicity NN NN I-Disease
after NN NN O
intracarotid NN NN O
injection NN NN O
of NN NN O
carboplatin NN NN O
for NN NN O
recurrent NN NN O
glioblastomas NN NN B-Disease
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Glioblastoma NN NN B-Disease
is NN NN O
a NN NN O
malignant NN NN B-Disease
tumor NN NN I-Disease
that NN NN O
occurs NN NN O
in NN NN O
the NN NN O
cerebrum NN NN O
during NN NN O
adulthood NN NN O
. NN NN O
   
With NN NN O
current NN NN O
treatment NN NN O
regimens NN NN O
including NN NN O
combined NN NN O
surgery NN NN O
, NN NN O
radiation NN NN O
and NN NN O
chemotherapy NN NN O
, NN NN O
the NN NN O
average NN NN O
life NN NN O
expectancy NN NN O
of NN NN O
the NN NN O
patients NN NN O
is NN NN O
limited NN NN O
to NN NN O
approximately NN NN O
1 NN NN O
year NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
patients NN NN O
with NN NN O
glioblastoma NN NN B-Disease
sometimes NN NN O
have NN NN O
intracarotid NN NN O
injection NN NN O
of NN NN O
carcinostatics NN NN O
added NN NN O
to NN NN O
the NN NN O
treatment NN NN O
regimen NN NN O
. NN NN O
   
Generally NN NN O
, NN NN O
carboplatin NN NN O
is NN NN O
said NN NN O
to NN NN O
have NN NN O
milder NN NN O
side NN NN O
effects NN NN O
than NN NN O
cisplatin NN NN O
, NN NN O
whose NN NN O
ocular NN NN B-Disease
and NN NN I-Disease
orbital NN NN I-Disease
toxicity NN NN I-Disease
are NN NN O
well NN NN O
known NN NN O
. NN NN O
   
However NN NN O
, NN NN O
we NN NN O
experienced NN NN O
a NN NN O
case NN NN O
of NN NN O
severe NN NN O
ocular NN NN B-Disease
and NN NN I-Disease
orbital NN NN I-Disease
toxicity NN NN I-Disease
after NN NN O
intracarotid NN NN O
injection NN NN O
of NN NN O
carboplatin NN NN O
, NN NN O
which NN NN O
is NN NN O
infrequently NN NN O
reported NN NN O
. NN NN O
   
CASE NN NN O
: NN NN O
A NN NN O
58 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
man NN NN O
received NN NN O
an NN NN O
intracarotid NN NN O
injection NN NN O
of NN NN O
carboplatin NN NN O
for NN NN O
recurrent NN NN O
glioblastomas NN NN B-Disease
in NN NN O
his NN NN O
left NN NN O
temporal NN NN O
lobe NN NN O
. NN NN O
   
He NN NN O
complained NN NN O
of NN NN O
pain NN NN B-Disease
and NN NN I-Disease
visual NN NN I-Disease
disturbance NN NN I-Disease
in NN NN I-Disease
the NN NN I-Disease
ipsilateral NN NN I-Disease
eye NN NN I-Disease
30 NN NN O
h NN NN O
after NN NN O
the NN NN O
injection NN NN O
. NN NN O
   
Various NN NN O
ocular NN NN O
symptoms NN NN O
and NN NN O
findings NN NN O
caused NN NN O
by NN NN O
carboplatin NN NN O
toxicity NN NN B-Disease
were NN NN O
seen NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
He NN NN O
was NN NN O
treated NN NN O
with NN NN O
intravenous NN NN O
administration NN NN O
of NN NN O
corticosteroids NN NN O
and NN NN O
glycerin NN NN O
for NN NN O
6 NN NN O
days NN NN O
after NN NN O
the NN NN O
injection NN NN O
. NN NN O
   
Although NN NN O
the NN NN O
intraocular NN NN O
pressure NN NN O
elevation NN NN O
caused NN NN O
by NN NN O
secondary NN NN O
acute NN NN O
angle NN NN O
- NN NN O
closure NN NN O
glaucoma NN NN B-Disease
decreased NN NN O
and NN NN O
ocular NN NN B-Disease
pain NN NN I-Disease
diminished NN NN O
, NN NN O
inexorable NN NN O
papilledema NN NN B-Disease
and NN NN O
exudative NN NN O
retinal NN NN B-Disease
detachment NN NN I-Disease
continued NN NN O
for NN NN O
3 NN NN O
weeks NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
6 NN NN O
weeks NN NN O
later NN NN O
, NN NN O
diffuse NN NN O
chorioretinal NN NN B-Disease
atrophy NN NN I-Disease
with NN NN O
optic NN NN B-Disease
atrophy NN NN I-Disease
occurred NN NN O
and NN NN O
the NN NN O
vision NN NN O
in NN NN O
his NN NN O
left NN NN O
eye NN NN O
was NN NN O
lost NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
When NN NN O
performing NN NN O
intracarotid NN NN O
injection NN NN O
of NN NN O
carboplatin NN NN O
, NN NN O
we NN NN O
must NN NN O
be NN NN O
aware NN NN O
of NN NN O
its NN NN O
potentially NN NN O
blinding NN NN O
ocular NN NN B-Disease
toxicity NN NN I-Disease
. NN NN O
   
It NN NN O
is NN NN O
recommended NN NN O
that NN NN O
further NN NN O
studies NN NN O
and NN NN O
investigations NN NN O
are NN NN O
undertaken NN NN O
in NN NN O
the NN NN O
effort NN NN O
to NN NN O
minimize NN NN O
such NN NN O
severe NN NN O
side NN NN O
effects NN NN O
. NN NN O
   
Visual NN NN B-Disease
hallucinations NN NN I-Disease
associated NN NN O
with NN NN O
zonisamide NN NN O
. NN NN O
   
Zonisamide NN NN O
is NN NN O
a NN NN O
broad NN NN O
- NN NN O
spectrum NN NN O
antiepileptic NN NN O
drug NN NN O
used NN NN O
to NN NN O
treat NN NN O
various NN NN O
types NN NN O
of NN NN O
seizures NN NN B-Disease
. NN NN O
   
Although NN NN O
visual NN NN B-Disease
hallucinations NN NN I-Disease
have NN NN O
not NN NN O
been NN NN O
reported NN NN O
as NN NN O
an NN NN O
adverse NN NN O
effect NN NN O
of NN NN O
this NN NN O
agent NN NN O
, NN NN O
we NN NN O
describe NN NN O
three NN NN O
patients NN NN O
who NN NN O
experienced NN NN O
complex NN NN O
visual NN NN B-Disease
hallucinations NN NN I-Disease
and NN NN O
altered NN NN O
mental NN NN O
status NN NN O
after NN NN O
zonisamide NN NN O
treatment NN NN O
was NN NN O
begun NN NN O
or NN NN O
its NN NN O
dosage NN NN O
increased NN NN O
. NN NN O
   
All NN NN O
three NN NN O
had NN NN O
been NN NN O
diagnosed NN NN O
earlier NN NN O
with NN NN O
epilepsy NN NN B-Disease
, NN NN O
and NN NN O
their NN NN O
electroencephalogram NN NN O
( NN NN O
EEG NN NN O
) NN NN O
findings NN NN O
were NN NN O
abnormal NN NN O
. NN NN O
   
During NN NN O
monitoring NN NN O
, NN NN O
visual NN NN B-Disease
hallucinations NN NN I-Disease
did NN NN O
not NN NN O
correlate NN NN O
with NN NN O
EEG NN NN O
readings NN NN O
, NN NN O
nor NN NN O
did NN NN O
video NN NN O
recording NN NN O
capture NN NN O
any NN NN O
of NN NN O
the NN NN O
described NN NN O
events NN NN O
. NN NN O
   
   O
of NN NN O
the NN NN O
patients NN NN O
had NN NN O
experienced NN NN O
visual NN NN B-Disease
hallucinations NN NN I-Disease
before NN NN O
this NN NN O
event NN NN O
. NN NN O
   
The NN NN O
only NN NN O
recent NN NN O
change NN NN O
in NN NN O
their NN NN O
treatment NN NN O
was NN NN O
the NN NN O
introduction NN NN O
or NN NN O
increased NN NN O
dosage NN NN O
of NN NN O
zonisamide NN NN O
. NN NN O
   
With NN NN O
either NN NN O
discontinuation NN NN O
or NN NN O
decreased NN NN O
dosage NN NN O
of NN NN O
the NN NN O
drug NN NN O
the NN NN O
symptoms NN NN O
disappeared NN NN O
and NN NN O
did NN NN O
not NN NN O
recur NN NN O
. NN NN O
   
Further NN NN O
observations NN NN O
and NN NN O
reports NN NN O
will NN NN O
help NN NN O
clarify NN NN O
this NN NN O
adverse NN NN O
effect NN NN O
. NN NN O
   
Until NN NN O
then NN NN O
, NN NN O
clinicians NN NN O
need NN NN O
to NN NN O
be NN NN O
aware NN NN O
of NN NN O
this NN NN O
possible NN NN O
complication NN NN O
associated NN NN O
with NN NN O
zonisamide NN NN O
. NN NN O
   
Anti NN NN O
- NN NN O
epileptic NN NN B-Disease
drugs NN NN O
- NN NN O
induced NN NN O
de NN NN O
novo NN NN O
absence NN NN B-Disease
seizures NN NN I-Disease
. NN NN O
   
The NN NN O
authors NN NN O
present NN NN O
three NN NN O
patients NN NN O
with NN NN O
de NN NN O
novo NN NN O
absence NN NN B-Disease
epilepsy NN NN I-Disease
after NN NN O
administration NN NN O
of NN NN O
carbamazepine NN NN O
and NN NN O
vigabatrin NN NN O
. NN NN O
   
Despite NN NN O
the NN NN O
underlying NN NN O
diseases NN NN O
, NN NN O
the NN NN O
prognosis NN NN O
for NN NN O
drug NN NN O
- NN NN O
induced NN NN O
de NN NN O
novo NN NN O
absence NN NN B-Disease
seizure NN NN I-Disease
is NN NN O
good NN NN O
because NN NN O
it NN NN O
subsides NN NN O
rapidly NN NN O
after NN NN O
discontinuing NN NN O
the NN NN O
use NN NN O
of NN NN O
the NN NN O
offending NN NN O
drugs NN NN O
. NN NN O
   
The NN NN O
gamma NN NN O
- NN NN O
aminobutyric NN NN O
acid NN NN O
- NN NN O
transmitted NN NN O
thalamocortical NN NN O
circuitry NN NN O
accounts NN NN O
for NN NN O
a NN NN O
major NN NN O
part NN NN O
of NN NN O
the NN NN O
underlying NN NN O
neurophysiology NN NN O
of NN NN O
the NN NN O
absence NN NN B-Disease
epilepsy NN NN I-Disease
. NN NN O
   
Because NN NN O
drug NN NN O
- NN NN O
induced NN NN O
de NN NN O
novo NN NN O
absence NN NN B-Disease
seizure NN NN I-Disease
is NN NN O
rare NN NN O
, NN NN O
pro NN NN O
- NN NN O
absence NN NN O
drugs NN NN O
can NN NN O
only NN NN O
be NN NN O
considered NN NN O
a NN NN O
promoting NN NN O
factor NN NN O
. NN NN O
   
The NN NN O
underlying NN NN O
epileptogenecity NN NN O
of NN NN O
the NN NN O
patients NN NN O
or NN NN O
the NN NN O
synergistic NN NN O
effects NN NN O
of NN NN O
the NN NN O
accompanying NN NN O
drugs NN NN O
is NN NN O
required NN NN O
to NN NN O
trigger NN NN O
the NN NN O
de NN NN O
novo NN NN O
absence NN NN B-Disease
seizure NN NN I-Disease
. NN NN O
   
The NN NN O
possibility NN NN O
of NN NN O
drug NN NN O
- NN NN O
induced NN NN O
aggravation NN NN O
should NN NN O
be NN NN O
considered NN NN O
whenever NN NN O
an NN NN O
unexpected NN NN O
increase NN NN O
in NN NN O
seizure NN NN B-Disease
frequency NN NN O
and NN NN O
/ NN NN O
or NN NN O
new NN NN O
seizure NN NN B-Disease
types NN NN O
appear NN NN O
following NN NN O
a NN NN O
change NN NN O
in NN NN O
drug NN NN O
treatment NN NN O
. NN NN O
   
By NN NN O
understanding NN NN O
the NN NN O
underlying NN NN O
mechanism NN NN O
of NN NN O
absence NN NN B-Disease
epilepsy NN NN I-Disease
, NN NN O
we NN NN O
can NN NN O
avoid NN NN O
the NN NN O
inappropriate NN NN O
use NN NN O
of NN NN O
anticonvulsants NN NN O
in NN NN O
children NN NN O
with NN NN O
epilepsy NN NN B-Disease
and NN NN O
prevent NN NN O
drug NN NN O
- NN NN O
induced NN NN O
absence NN NN B-Disease
seizures NN NN I-Disease
. NN NN O
   
Prenatal NN NN O
dexamethasone NN NN O
programs NN NN O
hypertension NN NN B-Disease
and NN NN O
renal NN NN B-Disease
injury NN NN I-Disease
in NN NN O
the NN NN O
rat NN NN O
. NN NN O
   
Dexamethasone NN NN O
is NN NN O
frequently NN NN O
administered NN NN O
to NN NN O
the NN NN O
developing NN NN O
fetus NN NN O
to NN NN O
accelerate NN NN O
pulmonary NN NN O
development NN NN O
. NN NN O
   
The NN NN O
purpose NN NN O
of NN NN O
the NN NN O
present NN NN O
study NN NN O
was NN NN O
to NN NN O
determine NN NN O
if NN NN O
prenatal NN NN O
dexamethasone NN NN O
programmed NN NN O
a NN NN O
progressive NN NN O
increase NN NN B-Disease
in NN NN I-Disease
blood NN NN I-Disease
pressure NN NN I-Disease
and NN NN O
renal NN NN B-Disease
injury NN NN I-Disease
in NN NN O
rats NN NN O
. NN NN O
   
Pregnant NN NN O
rats NN NN O
were NN NN O
given NN NN O
either NN NN O
vehicle NN NN O
or NN NN O
2 NN NN O
daily NN NN O
intraperitoneal NN NN O
injections NN NN O
of NN NN O
dexamethasone NN NN O
( NN NN O
0 NN NN O
. NN NN O
2 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
body NN NN O
weight NN NN O
) NN NN O
on NN NN O
gestational NN NN O
days NN NN O
11 NN NN O
and NN NN O
12 NN NN O
, NN NN O
13 NN NN O
and NN NN O
14 NN NN O
, NN NN O
15 NN NN O
and NN NN O
16 NN NN O
, NN NN O
17 NN NN O
and NN NN O
18 NN NN O
, NN NN O
or NN NN O
19 NN NN O
and NN NN O
20 NN NN O
. NN NN O
   
Offspring NN NN O
of NN NN O
rats NN NN O
administered NN NN O
dexamethasone NN NN O
on NN NN O
days NN NN O
15 NN NN O
and NN NN O
16 NN NN O
gestation NN NN O
had NN NN O
a NN NN O
20 NN NN O
% NN NN O
reduction NN NN B-Disease
in NN NN I-Disease
glomerular NN NN I-Disease
number NN NN I-Disease
compared NN NN O
with NN NN O
control NN NN O
at NN NN O
6 NN NN O
to NN NN O
9 NN NN O
months NN NN O
of NN NN O
age NN NN O
( NN NN O
22 NN NN O
527 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
509 NN NN O
versus NN NN O
28 NN NN O
050 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
561 NN NN O
, NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
, NN NN O
which NN NN O
was NN NN O
comparable NN NN O
to NN NN O
the NN NN O
percent NN NN O
reduction NN NN O
in NN NN O
glomeruli NN NN O
measured NN NN O
at NN NN O
3 NN NN O
weeks NN NN O
of NN NN O
age NN NN O
. NN NN O
   
Six NN NN O
- NN NN O
to NN NN O
9 NN NN O
- NN NN O
month NN NN O
old NN NN O
rats NN NN O
receiving NN NN O
prenatal NN NN O
dexamethasone NN NN O
on NN NN O
days NN NN O
17 NN NN O
and NN NN O
18 NN NN O
of NN NN O
gestation NN NN O
had NN NN O
a NN NN O
17 NN NN O
% NN NN O
reduction NN NN O
in NN NN O
glomeruli NN NN O
( NN NN O
23 NN NN O
380 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
587 NN NN O
) NN NN O
compared NN NN O
with NN NN O
control NN NN O
rats NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
Male NN NN O
rats NN NN O
that NN NN O
received NN NN O
prenatal NN NN O
dexamethasone NN NN O
on NN NN O
days NN NN O
15 NN NN O
and NN NN O
16 NN NN O
, NN NN O
17 NN NN O
and NN NN O
18 NN NN O
, NN NN O
and NN NN O
13 NN NN O
and NN NN O
14 NN NN O
of NN NN O
gestation NN NN O
had NN NN O
elevated NN NN B-Disease
blood NN NN I-Disease
pressures NN NN I-Disease
at NN NN O
6 NN NN O
months NN NN O
of NN NN O
age NN NN O
; NN NN O
the NN NN O
latter NN NN O
group NN NN O
did NN NN O
not NN NN O
have NN NN O
a NN NN O
reduction NN NN B-Disease
in NN NN I-Disease
glomerular NN NN I-Disease
number NN NN I-Disease
. NN NN O
   
Adult NN NN O
rats NN NN O
given NN NN O
dexamethasone NN NN O
on NN NN O
days NN NN O
15 NN NN O
and NN NN O
16 NN NN O
of NN NN O
gestation NN NN O
had NN NN O
more NN NN O
glomeruli NN NN O
with NN NN O
glomerulosclerosis NN NN B-Disease
than NN NN O
control NN NN O
rats NN NN O
. NN NN O
   
This NN NN O
study NN NN O
shows NN NN O
that NN NN O
prenatal NN NN O
dexamethasone NN NN O
in NN NN O
rats NN NN O
results NN NN O
in NN NN O
a NN NN O
reduction NN NN B-Disease
in NN NN I-Disease
glomerular NN NN I-Disease
number NN NN I-Disease
, NN NN O
glomerulosclerosis NN NN B-Disease
, NN NN O
and NN NN O
hypertension NN NN B-Disease
when NN NN O
administered NN NN O
at NN NN O
specific NN NN O
points NN NN O
during NN NN O
gestation NN NN O
. NN NN O
   
Hypertension NN NN B-Disease
was NN NN O
observed NN NN O
in NN NN O
animals NN NN O
that NN NN O
had NN NN O
a NN NN O
reduction NN NN O
in NN NN O
glomeruli NN NN O
as NN NN O
well NN NN O
as NN NN O
in NN NN O
a NN NN O
group NN NN O
that NN NN O
did NN NN O
not NN NN O
have NN NN O
a NN NN O
reduction NN NN B-Disease
in NN NN I-Disease
glomerular NN NN I-Disease
number NN NN I-Disease
, NN NN O
suggesting NN NN O
that NN NN O
a NN NN O
reduction NN NN B-Disease
in NN NN I-Disease
glomerular NN NN I-Disease
number NN NN I-Disease
is NN NN O
not NN NN O
the NN NN O
sole NN NN O
cause NN NN O
for NN NN O
the NN NN O
development NN NN O
of NN NN O
hypertension NN NN B-Disease
. NN NN O
   
Kidney NN NN O
function NN NN O
and NN NN O
morphology NN NN O
after NN NN O
short NN NN O
- NN NN O
term NN NN O
combination NN NN O
therapy NN NN O
with NN NN O
cyclosporine NN NN O
A NN NN O
, NN NN O
tacrolimus NN NN O
and NN NN O
sirolimus NN NN O
in NN NN O
the NN NN O
rat NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Sirolimus NN NN O
( NN NN O
SRL NN NN O
) NN NN O
may NN NN O
supplement NN NN O
calcineurin NN NN O
inhibitors NN NN O
in NN NN O
clinical NN NN O
organ NN NN O
transplantation NN NN O
. NN NN O
   
These NN NN O
are NN NN O
nephrotoxic NN NN B-Disease
, NN NN O
but NN NN O
SRL NN NN O
seems NN NN O
to NN NN O
act NN NN O
differently NN NN O
displaying NN NN O
only NN NN O
minor NN NN O
nephrotoxic NN NN B-Disease
effects NN NN O
, NN NN O
although NN NN O
this NN NN O
question NN NN O
is NN NN O
still NN NN O
open NN NN O
. NN NN O
   
In NN NN O
a NN NN O
number NN NN O
of NN NN O
treatment NN NN O
protocols NN NN O
where NN NN O
SRL NN NN O
was NN NN O
combined NN NN O
with NN NN O
a NN NN O
calcineurin NN NN O
inhibitor NN NN O
indications NN NN O
of NN NN O
a NN NN O
synergistic NN NN O
nephrotoxic NN NN B-Disease
effect NN NN O
were NN NN O
described NN NN O
. NN NN O
   
The NN NN O
aim NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
examine NN NN O
further NN NN O
the NN NN O
renal NN NN O
function NN NN O
, NN NN O
including NN NN O
morphological NN NN O
analysis NN NN O
of NN NN O
the NN NN O
kidneys NN NN O
of NN NN O
male NN NN O
Sprague NN NN O
- NN NN O
Dawley NN NN O
rats NN NN O
treated NN NN O
with NN NN O
either NN NN O
cyclosporine NN NN O
A NN NN O
( NN NN O
CsA NN NN O
) NN NN O
, NN NN O
tacrolimus NN NN O
( NN NN O
FK506 NN NN O
) NN NN O
or NN NN O
SRL NN NN O
as NN NN O
monotherapies NN NN O
or NN NN O
in NN NN O
different NN NN O
combinations NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
For NN NN O
a NN NN O
period NN NN O
of NN NN O
2 NN NN O
weeks NN NN O
, NN NN O
CsA NN NN O
15 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
( NN NN O
given NN NN O
orally NN NN O
) NN NN O
, NN NN O
FK506 NN NN O
3 NN NN O
. NN NN O
0 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
( NN NN O
given NN NN O
orally NN NN O
) NN NN O
or NN NN O
SRL NN NN O
0 NN NN O
. NN NN O
4 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
( NN NN O
given NN NN O
intraperitoneally NN NN O
) NN NN O
was NN NN O
administered NN NN O
once NN NN O
a NN NN O
day NN NN O
as NN NN O
these NN NN O
doses NN NN O
have NN NN O
earlier NN NN O
been NN NN O
found NN NN O
to NN NN O
achieve NN NN O
a NN NN O
significant NN NN O
immunosuppressive NN NN O
effect NN NN O
in NN NN O
Sprague NN NN O
- NN NN O
Dawley NN NN O
rats NN NN O
. NN NN O
   
In NN NN O
the NN NN O
' NN NN O
conscious NN NN O
catheterized NN NN O
rat NN NN O
' NN NN O
model NN NN O
, NN NN O
the NN NN O
glomerular NN NN O
filtration NN NN O
rate NN NN O
( NN NN O
GFR NN NN O
) NN NN O
was NN NN O
measured NN NN O
as NN NN O
the NN NN O
clearance NN NN O
of NN NN O
Cr NN NN O
( NN NN O
EDTA NN NN O
) NN NN O
. NN NN O
   
The NN NN O
morphological NN NN O
analysis NN NN O
of NN NN O
the NN NN O
kidneys NN NN O
included NN NN O
a NN NN O
semi NN NN O
- NN NN O
quantitative NN NN O
scoring NN NN O
system NN NN O
analysing NN NN O
the NN NN O
degree NN NN O
of NN NN O
striped NN NN O
fibrosis NN NN B-Disease
, NN NN O
subcapsular NN NN O
fibrosis NN NN B-Disease
and NN NN O
the NN NN O
number NN NN O
of NN NN O
basophilic NN NN O
tubules NN NN O
, NN NN O
plus NN NN O
an NN NN O
additional NN NN O
stereological NN NN O
analysis NN NN O
of NN NN O
the NN NN O
total NN NN O
grade NN NN O
of NN NN O
fibrosis NN NN B-Disease
in NN NN O
the NN NN O
cortex NN NN O
stained NN NN O
with NN NN O
Sirius NN NN O
Red NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
CsA NN NN O
, NN NN O
FK506 NN NN O
and NN NN O
SRL NN NN O
all NN NN O
significantly NN NN O
decreased NN NN O
the NN NN O
GFR NN NN O
. NN NN O
   
A NN NN O
further NN NN O
deterioration NN NN O
was NN NN O
seen NN NN O
when NN NN O
CsA NN NN O
was NN NN O
combined NN NN O
with NN NN O
either NN NN O
FK506 NN NN O
or NN NN O
SRL NN NN O
, NN NN O
whereas NN NN O
the NN NN O
GFR NN NN O
remained NN NN O
unchanged NN NN O
in NN NN O
the NN NN O
group NN NN O
treated NN NN O
with NN NN O
FK506 NN NN O
plus NN NN O
SRL NN NN O
when NN NN O
compared NN NN O
with NN NN O
treatment NN NN O
with NN NN O
any NN NN O
of NN NN O
the NN NN O
single NN NN O
substances NN NN O
. NN NN O
   
The NN NN O
morphological NN NN O
changes NN NN O
presented NN NN O
a NN NN O
similar NN NN O
pattern NN NN O
. NN NN O
   
The NN NN O
semi NN NN O
- NN NN O
quantitative NN NN O
scoring NN NN O
was NN NN O
significantly NN NN O
worst NN NN O
in NN NN O
the NN NN O
group NN NN O
treated NN NN O
with NN NN O
CsA NN NN O
plus NN NN O
SRL NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
compared NN NN O
with NN NN O
controls NN NN O
) NN NN O
and NN NN O
the NN NN O
analysis NN NN O
of NN NN O
the NN NN O
total NN NN O
grade NN NN O
of NN NN O
fibrosis NN NN B-Disease
also NN NN O
showed NN NN O
the NN NN O
highest NN NN O
proportion NN NN O
in NN NN O
the NN NN O
same NN NN O
group NN NN O
and NN NN O
was NN NN O
significantly NN NN O
different NN NN O
from NN NN O
controls NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
02 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
FK506 NN NN O
plus NN NN O
SRL NN NN O
combination NN NN O
showed NN NN O
only NN NN O
a NN NN O
marginally NN NN O
higher NN NN O
degree NN NN O
of NN NN O
fibrosis NN NN B-Disease
as NN NN O
compared NN NN O
with NN NN O
controls NN NN O
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
This NN NN O
rat NN NN O
study NN NN O
demonstrated NN NN O
a NN NN O
synergistic NN NN O
nephrotoxic NN NN B-Disease
effect NN NN O
of NN NN O
CsA NN NN O
plus NN NN O
SRL NN NN O
, NN NN O
whereas NN NN O
FK506 NN NN O
plus NN NN O
SRL NN NN O
was NN NN O
better NN NN O
tolerated NN NN O
. NN NN O
   
Evaluation NN NN O
of NN NN O
cardiac NN NN O
troponin NN NN O
I NN NN O
and NN NN O
T NN NN O
levels NN NN O
as NN NN O
markers NN NN O
of NN NN O
myocardial NN NN B-Disease
damage NN NN I-Disease
in NN NN O
doxorubicin NN NN O
- NN NN O
induced NN NN O
cardiomyopathy NN NN B-Disease
rats NN NN O
, NN NN O
and NN NN O
their NN NN O
relationship NN NN O
with NN NN O
echocardiographic NN NN O
and NN NN O
histological NN NN O
findings NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Cardiac NN NN O
troponins NN NN O
I NN NN O
( NN NN O
cTnI NN NN O
) NN NN O
and NN NN O
T NN NN O
( NN NN O
cTnT NN NN O
) NN NN O
have NN NN O
been NN NN O
shown NN NN O
to NN NN O
be NN NN O
highly NN NN O
sensitive NN NN O
and NN NN O
specific NN NN O
markers NN NN O
of NN NN O
myocardial NN NN B-Disease
cell NN NN I-Disease
injury NN NN I-Disease
. NN NN O
   
We NN NN O
investigated NN NN O
the NN NN O
diagnostic NN NN O
value NN NN O
of NN NN O
cTnI NN NN O
and NN NN O
cTnT NN NN O
for NN NN O
the NN NN O
diagnosis NN NN O
of NN NN O
myocardial NN NN B-Disease
damage NN NN I-Disease
in NN NN O
a NN NN O
rat NN NN O
model NN NN O
of NN NN O
doxorubicin NN NN O
( NN NN O
DOX NN NN O
) NN NN O
- NN NN O
induced NN NN O
cardiomyopathy NN NN B-Disease
, NN NN O
and NN NN O
we NN NN O
examined NN NN O
the NN NN O
relationship NN NN O
between NN NN O
serial NN NN O
cTnI NN NN O
and NN NN O
cTnT NN NN O
with NN NN O
the NN NN O
development NN NN O
of NN NN O
cardiac NN NN B-Disease
disorders NN NN I-Disease
monitored NN NN O
by NN NN O
echocardiography NN NN O
and NN NN O
histological NN NN O
examinations NN NN O
in NN NN O
this NN NN O
model NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Thirty NN NN O
- NN NN O
five NN NN O
Wistar NN NN O
rats NN NN O
were NN NN O
given NN NN O
1 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
DOX NN NN O
, NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
, NN NN O
weekly NN NN O
for NN NN O
up NN NN O
to NN NN O
8 NN NN O
weeks NN NN O
for NN NN O
a NN NN O
total NN NN O
cumulative NN NN O
dose NN NN O
of NN NN O
12 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
BW NN NN O
. NN NN O
   
Ten NN NN O
rats NN NN O
received NN NN O
saline NN NN O
as NN NN O
a NN NN O
control NN NN O
group NN NN O
. NN NN O
   
cTnI NN NN O
was NN NN O
measured NN NN O
with NN NN O
Access NN NN O
( NN NN O
R NN NN O
) NN NN O
( NN NN O
ng NN NN O
/ NN NN O
ml NN NN O
) NN NN O
and NN NN O
a NN NN O
research NN NN O
immunoassay NN NN O
( NN NN O
pg NN NN O
/ NN NN O
ml NN NN O
) NN NN O
, NN NN O
and NN NN O
compared NN NN O
with NN NN O
cTnT NN NN O
, NN NN O
CK NN NN O
- NN NN O
MB NN NN O
mass NN NN O
and NN NN O
CK NN NN O
. NN NN O
   
By NN NN O
using NN NN O
transthoracic NN NN O
echocardiography NN NN O
, NN NN O
anterior NN NN O
and NN NN O
posterior NN NN O
wall NN NN O
thickness NN NN O
, NN NN O
LV NN NN O
diameters NN NN O
and NN NN O
LV NN NN O
fractional NN NN O
shortening NN NN O
( NN NN O
FS NN NN O
) NN NN O
were NN NN O
measured NN NN O
in NN NN O
all NN NN O
rats NN NN O
before NN NN O
DOX NN NN O
or NN NN O
saline NN NN O
, NN NN O
and NN NN O
at NN NN O
weeks NN NN O
6 NN NN O
and NN NN O
9 NN NN O
after NN NN O
treatment NN NN O
in NN NN O
all NN NN O
surviving NN NN O
rats NN NN O
. NN NN O
   
Histology NN NN O
was NN NN O
performed NN NN O
in NN NN O
DOX NN NN O
- NN NN O
rats NN NN O
at NN NN O
6 NN NN O
and NN NN O
9 NN NN O
weeks NN NN O
after NN NN O
the NN NN O
last NN NN O
DOX NN NN O
dose NN NN O
and NN NN O
in NN NN O
all NN NN O
controls NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Eighteen NN NN O
of NN NN O
the NN NN O
DOX NN NN O
rats NN NN O
died NN NN O
prematurely NN NN O
of NN NN O
general NN NN O
toxicity NN NN B-Disease
during NN NN O
the NN NN O
9 NN NN O
- NN NN O
week NN NN O
period NN NN O
. NN NN O
   
End NN NN O
- NN NN O
diastolic NN NN O
( NN NN O
ED NN NN O
) NN NN O
and NN NN O
end NN NN O
- NN NN O
systolic NN NN O
( NN NN O
ES NN NN O
) NN NN O
LV NN NN O
diameters NN NN O
/ NN NN O
BW NN NN O
significantly NN NN O
increased NN NN O
, NN NN O
whereas NN NN O
LV NN NN O
FS NN NN O
was NN NN O
decreased NN NN O
after NN NN O
9 NN NN O
weeks NN NN O
in NN NN O
the NN NN O
DOX NN NN O
group NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
. NN NN O
   
These NN NN O
parameters NN NN O
remained NN NN O
unchanged NN NN O
in NN NN O
controls NN NN O
. NN NN O
   
Histological NN NN O
evaluation NN NN O
of NN NN O
hearts NN NN O
from NN NN O
all NN NN O
rats NN NN O
given NN NN O
DOX NN NN O
revealed NN NN O
significant NN NN O
slight NN NN O
degrees NN NN O
of NN NN O
perivascular NN NN O
and NN NN O
interstitial NN NN O
fibrosis NN NN B-Disease
. NN NN O
   
In NN NN O
7 NN NN O
of NN NN O
the NN NN O
18 NN NN O
rats NN NN O
, NN NN O
degeneration NN NN O
and NN NN O
myocyte NN NN O
vacuolisation NN NN O
were NN NN O
found NN NN O
. NN NN O
   
Only NN NN O
five NN NN O
of NN NN O
the NN NN O
controls NN NN O
exhibited NN NN O
evidence NN NN O
of NN NN O
very NN NN O
slight NN NN O
perivascular NN NN O
fibrosis NN NN B-Disease
. NN NN O
   
A NN NN O
significant NN NN O
rise NN NN O
in NN NN O
cTnT NN NN O
was NN NN O
found NN NN O
in NN NN O
DOX NN NN O
rats NN NN O
after NN NN O
cumulative NN NN O
doses NN NN O
of NN NN O
7 NN NN O
. NN NN O
5 NN NN O
and NN NN O
12 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
in NN NN O
comparison NN NN O
with NN NN O
baseline NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
cTnT NN NN O
found NN NN O
in NN NN O
rats NN NN O
after NN NN O
12 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
were NN NN O
significantly NN NN O
greater NN NN O
than NN NN O
that NN NN O
found NN NN O
after NN NN O
7 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
DOX NN NN O
. NN NN O
   
Maximal NN NN O
cTnI NN NN O
( NN NN O
pg NN NN O
/ NN NN O
ml NN NN O
) NN NN O
and NN NN O
cTnT NN NN O
levels NN NN O
were NN NN O
significantly NN NN O
increased NN NN O
in NN NN O
DOX NN NN O
rats NN NN O
compared NN NN O
with NN NN O
controls NN NN O
( NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
006 NN NN O
, NN NN O
0 NN NN O
. NN NN O
007 NN NN O
) NN NN O
. NN NN O
   
cTnI NN NN O
( NN NN O
ng NN NN O
/ NN NN O
ml NN NN O
) NN NN O
, NN NN O
CK NN NN O
- NN NN O
MB NN NN O
mass NN NN O
and NN NN O
CK NN NN O
remained NN NN O
unchanged NN NN O
in NN NN O
DOX NN NN O
rats NN NN O
compared NN NN O
with NN NN O
controls NN NN O
. NN NN O
   
All NN NN O
markers NN NN O
remained NN NN O
stable NN NN O
in NN NN O
controls NN NN O
. NN NN O
   
Analysis NN NN O
of NN NN O
data NN NN O
revealed NN NN O
a NN NN O
significant NN NN O
correlation NN NN O
between NN NN O
maximal NN NN O
cTnT NN NN O
and NN NN O
ED NN NN O
and NN NN O
ES NN NN O
LV NN NN O
diameters NN NN O
/ NN NN O
BW NN NN O
( NN NN O
r NN NN O
= NN NN O
0 NN NN O
. NN NN O
81 NN NN O
and NN NN O
0 NN NN O
. NN NN O
65 NN NN O
; NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
0001 NN NN O
) NN NN O
. NN NN O
   
A NN NN O
significant NN NN O
relationship NN NN O
was NN NN O
observed NN NN O
between NN NN O
maximal NN NN O
cTnT NN NN O
and NN NN O
the NN NN O
extent NN NN O
of NN NN O
myocardial NN NN O
morphological NN NN O
changes NN NN O
, NN NN O
and NN NN O
between NN NN O
LV NN NN O
diameters NN NN O
/ NN NN O
BW NN NN O
and NN NN O
histological NN NN O
findings NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Among NN NN O
markers NN NN O
of NN NN O
ischemic NN NN B-Disease
injury NN NN I-Disease
after NN NN O
DOX NN NN O
in NN NN O
rats NN NN O
, NN NN O
cTnT NN NN O
showed NN NN O
the NN NN O
greatest NN NN O
ability NN NN O
to NN NN O
detect NN NN O
myocardial NN NN B-Disease
damage NN NN I-Disease
assessed NN NN O
by NN NN O
echocardiographic NN NN O
detection NN NN O
and NN NN O
histological NN NN O
changes NN NN O
. NN NN O
   
Although NN NN O
there NN NN O
was NN NN O
a NN NN O
discrepancy NN NN O
between NN NN O
the NN NN O
amount NN NN O
of NN NN O
cTnI NN NN O
and NN NN O
cTnT NN NN O
after NN NN O
DOX NN NN O
, NN NN O
probably NN NN O
due NN NN O
to NN NN O
heterogeneity NN NN O
in NN NN O
cross NN NN O
- NN NN O
reactivities NN NN O
of NN NN O
mAbs NN NN O
to NN NN O
various NN NN O
cTnI NN NN O
and NN NN O
cTnT NN NN O
forms NN NN O
, NN NN O
it NN NN O
is NN NN O
likely NN NN O
that NN NN O
cTnT NN NN O
in NN NN O
rats NN NN O
after NN NN O
DOX NN NN O
indicates NN NN O
cell NN NN O
damage NN NN O
determined NN NN O
by NN NN O
the NN NN O
magnitude NN NN O
of NN NN O
injury NN NN O
induced NN NN O
and NN NN O
that NN NN O
cTnT NN NN O
should NN NN O
be NN NN O
a NN NN O
useful NN NN O
marker NN NN O
for NN NN O
the NN NN O
prediction NN NN O
of NN NN O
experimentally NN NN O
induced NN NN O
cardiotoxicity NN NN B-Disease
and NN NN O
possibly NN NN O
for NN NN O
cardioprotective NN NN O
experiments NN NN O
. NN NN O
   
Octreotide NN NN O
- NN NN O
induced NN NN O
hypoxemia NN NN B-Disease
and NN NN O
pulmonary NN NN B-Disease
hypertension NN NN I-Disease
in NN NN O
premature NN NN O
neonates NN NN O
. NN NN O
   
The NN NN O
authors NN NN O
report NN NN O
2 NN NN O
cases NN NN O
of NN NN O
premature NN NN O
neonates NN NN O
who NN NN O
had NN NN O
enterocutaneous NN NN O
fistula NN NN B-Disease
complicating NN NN O
necrotizing NN NN B-Disease
enterocolitis NN NN I-Disease
. NN NN O
   
Pulmonary NN NN B-Disease
hypertension NN NN I-Disease
developed NN NN O
after NN NN O
administration NN NN O
of NN NN O
a NN NN O
somatostatin NN NN O
analogue NN NN O
, NN NN O
octreotide NN NN O
, NN NN O
to NN NN O
enhance NN NN O
resolution NN NN O
of NN NN O
the NN NN O
fistula NN NN B-Disease
. NN NN O
   
The NN NN O
authors NN NN O
discuss NN NN O
the NN NN O
mechanism NN NN O
of NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
this NN NN O
complication NN NN O
and NN NN O
recommend NN NN O
caution NN NN O
of NN NN O
its NN NN O
use NN NN O
in NN NN O
high NN NN O
- NN NN O
risk NN NN O
premature NN NN O
neonates NN NN O
. NN NN O
   
The NN NN O
risk NN NN O
of NN NN O
venous NN NN B-Disease
thromboembolism NN NN I-Disease
in NN NN O
women NN NN O
prescribed NN NN O
cyproterone NN NN O
acetate NN NN O
in NN NN O
combination NN NN O
with NN NN O
ethinyl NN NN O
estradiol NN NN O
: NN NN O
a NN NN O
nested NN NN O
cohort NN NN O
analysis NN NN O
and NN NN O
case NN NN O
- NN NN O
control NN NN O
study NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Cyproterone NN NN O
acetate NN NN O
combined NN NN O
with NN NN O
ethinyl NN NN O
estradiol NN NN O
( NN NN O
CPA NN NN O
/ NN NN O
EE NN NN O
) NN NN O
is NN NN O
licensed NN NN O
in NN NN O
the NN NN O
UK NN NN O
for NN NN O
the NN NN O
treatment NN NN O
of NN NN O
women NN NN O
with NN NN O
acne NN NN B-Disease
and NN NN O
hirsutism NN NN B-Disease
and NN NN O
is NN NN O
also NN NN O
a NN NN O
treatment NN NN O
option NN NN O
for NN NN O
polycystic NN NN B-Disease
ovary NN NN I-Disease
syndrome NN NN I-Disease
( NN NN O
PCOS NN NN B-Disease
) NN NN O
. NN NN O
   
Previous NN NN O
studies NN NN O
have NN NN O
demonstrated NN NN O
an NN NN O
increased NN NN O
risk NN NN O
of NN NN O
venous NN NN B-Disease
thromboembolism NN NN I-Disease
( NN NN O
VTE NN NN B-Disease
) NN NN O
associated NN NN O
with NN NN O
CPA NN NN O
/ NN NN O
EE NN NN O
compared NN NN O
with NN NN O
conventional NN NN O
combined NN NN O
oral NN NN O
contraceptives NN NN O
( NN NN O
COCs NN NN O
) NN NN O
. NN NN O
   
We NN NN O
believe NN NN O
the NN NN O
results NN NN O
of NN NN O
those NN NN O
studies NN NN O
may NN NN O
have NN NN O
been NN NN O
affected NN NN O
by NN NN O
residual NN NN O
confounding NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Using NN NN O
the NN NN O
General NN NN O
Practice NN NN O
Research NN NN O
Database NN NN O
we NN NN O
conducted NN NN O
a NN NN O
cohort NN NN O
analysis NN NN O
and NN NN O
case NN NN O
- NN NN O
control NN NN O
study NN NN O
nested NN NN O
within NN NN O
a NN NN O
population NN NN O
of NN NN O
women NN NN O
aged NN NN O
between NN NN O
15 NN NN O
and NN NN O
39 NN NN O
years NN NN O
with NN NN O
acne NN NN B-Disease
, NN NN O
hirsutism NN NN B-Disease
or NN NN O
PCOS NN NN B-Disease
to NN NN O
estimate NN NN O
the NN NN O
risk NN NN O
of NN NN O
VTE NN NN B-Disease
associated NN NN O
with NN NN O
CPA NN NN O
/ NN NN O
EE NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
The NN NN O
age NN NN O
- NN NN O
adjusted NN NN O
incidence NN NN O
rate NN NN O
ratio NN NN O
for NN NN O
CPA NN NN O
/ NN NN O
EE NN NN O
versus NN NN O
conventional NN NN O
COCs NN NN O
was NN NN O
2 NN NN O
. NN NN O
20 NN NN O
[ NN NN O
95 NN NN O
% NN NN O
confidence NN NN O
interval NN NN O
( NN NN O
CI NN NN O
) NN NN O
1 NN NN O
. NN NN O
35 NN NN O
- NN NN O
3 NN NN O
. NN NN O
58 NN NN O
] NN NN O
. NN NN O
   
Using NN NN O
as NN NN O
the NN NN O
reference NN NN O
group NN NN O
women NN NN O
who NN NN O
were NN NN O
not NN NN O
using NN NN O
oral NN NN O
contraception NN NN O
, NN NN O
had NN NN O
no NN NN O
recent NN NN O
pregnancy NN NN O
or NN NN O
menopausal NN NN O
symptoms NN NN O
, NN NN O
the NN NN O
case NN NN O
- NN NN O
control NN NN O
analysis NN NN O
gave NN NN O
an NN NN O
adjusted NN NN O
odds NN NN O
ratio NN NN O
( NN NN O
OR NN NN O
( NN NN O
adj NN NN O
) NN NN O
) NN NN O
of NN NN O
7 NN NN O
. NN NN O
44 NN NN O
( NN NN O
95 NN NN O
% NN NN O
CI NN NN O
3 NN NN O
. NN NN O
67 NN NN O
- NN NN O
15 NN NN O
. NN NN O
08 NN NN O
) NN NN O
for NN NN O
CPA NN NN O
/ NN NN O
EE NN NN O
use NN NN O
compared NN NN O
with NN NN O
an NN NN O
OR NN NN O
( NN NN O
adj NN NN O
) NN NN O
of NN NN O
2 NN NN O
. NN NN O
58 NN NN O
( NN NN O
95 NN NN O
% NN NN O
CI NN NN O
1 NN NN O
. NN NN O
60 NN NN O
- NN NN O
4 NN NN O
. NN NN O
18 NN NN O
) NN NN O
for NN NN O
use NN NN O
of NN NN O
conventional NN NN O
COCs NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
We NN NN O
have NN NN O
demonstrated NN NN O
an NN NN O
increased NN NN O
risk NN NN O
of NN NN O
VTE NN NN B-Disease
associated NN NN O
with NN NN O
the NN NN O
use NN NN O
of NN NN O
CPA NN NN O
/ NN NN O
EE NN NN O
in NN NN O
women NN NN O
with NN NN O
acne NN NN B-Disease
, NN NN O
hirsutism NN NN B-Disease
or NN NN O
PCOS NN NN B-Disease
although NN NN O
residual NN NN O
confounding NN NN O
by NN NN O
indication NN NN O
cannot NN NN O
be NN NN O
excluded NN NN O
. NN NN O
   
The NN NN O
effect NN NN O
of NN NN O
treatment NN NN O
with NN NN O
gum NN NN O
Arabic NN NN O
on NN NN O
gentamicin NN NN O
nephrotoxicity NN NN B-Disease
in NN NN O
rats NN NN O
: NN NN O
a NN NN O
preliminary NN NN O
study NN NN O
. NN NN O
   
In NN NN O
the NN NN O
present NN NN O
work NN NN O
we NN NN O
assessed NN NN O
the NN NN O
effect NN NN O
of NN NN O
treatment NN NN O
of NN NN O
rats NN NN O
with NN NN O
gum NN NN O
Arabic NN NN O
on NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
induced NN NN O
by NN NN O
gentamicin NN NN O
( NN NN O
GM NN NN O
) NN NN O
nephrotoxicity NN NN B-Disease
. NN NN O
   
Rats NN NN O
were NN NN O
treated NN NN O
with NN NN O
the NN NN O
vehicle NN NN O
( NN NN O
2 NN NN O
mL NN NN O
/ NN NN O
kg NN NN O
of NN NN O
distilled NN NN O
water NN NN O
and NN NN O
5 NN NN O
% NN NN O
w NN NN O
/ NN NN O
v NN NN O
cellulose NN NN O
, NN NN O
10 NN NN O
days NN NN O
) NN NN O
, NN NN O
gum NN NN O
Arabic NN NN O
( NN NN O
2 NN NN O
mL NN NN O
/ NN NN O
kg NN NN O
of NN NN O
a NN NN O
10 NN NN O
% NN NN O
w NN NN O
/ NN NN O
v NN NN O
aqueous NN NN O
suspension NN NN O
of NN NN O
gum NN NN O
Arabic NN NN O
powder NN NN O
, NN NN O
orally NN NN O
for NN NN O
10 NN NN O
days NN NN O
) NN NN O
, NN NN O
or NN NN O
gum NN NN O
Arabic NN NN O
concomitantly NN NN O
with NN NN O
GM NN NN O
( NN NN O
80mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
intramuscularly NN NN O
, NN NN O
during NN NN O
the NN NN O
last NN NN O
six NN NN O
days NN NN O
of NN NN O
the NN NN O
treatment NN NN O
period NN NN O
) NN NN O
. NN NN O
   
Nephrotoxicity NN NN B-Disease
was NN NN O
assessed NN NN O
by NN NN O
measuring NN NN O
the NN NN O
concentrations NN NN O
of NN NN O
creatinine NN NN O
and NN NN O
urea NN NN O
in NN NN O
the NN NN O
plasma NN NN O
and NN NN O
reduced NN NN O
glutathione NN NN O
( NN NN O
GSH NN NN O
) NN NN O
in NN NN O
the NN NN O
kidney NN NN O
cortex NN NN O
, NN NN O
and NN NN O
by NN NN O
light NN NN O
microscopic NN NN O
examination NN NN O
of NN NN O
kidney NN NN O
sections NN NN O
. NN NN O
   
The NN NN O
results NN NN O
indicated NN NN O
that NN NN O
concomitant NN NN O
treatment NN NN O
with NN NN O
gum NN NN O
Arabic NN NN O
and NN NN O
GM NN NN O
significantly NN NN O
increased NN NN O
creatinine NN NN O
and NN NN O
urea NN NN O
by NN NN O
about NN NN O
183 NN NN O
and NN NN O
239 NN NN O
% NN NN O
, NN NN O
respectively NN NN O
( NN NN O
compared NN NN O
to NN NN O
432 NN NN O
and NN NN O
346 NN NN O
% NN NN O
, NN NN O
respectively NN NN O
, NN NN O
in NN NN O
rats NN NN O
treated NN NN O
with NN NN O
cellulose NN NN O
and NN NN O
GM NN NN O
) NN NN O
, NN NN O
and NN NN O
decreased NN NN O
that NN NN O
of NN NN O
cortical NN NN O
GSH NN NN O
by NN NN O
21 NN NN O
% NN NN O
( NN NN O
compared NN NN O
to NN NN O
27 NN NN O
% NN NN O
in NN NN O
the NN NN O
cellulose NN NN O
plus NN NN O
GM NN NN O
group NN NN O
) NN NN O
The NN NN O
GM NN NN O
- NN NN O
induced NN NN O
proximal NN NN O
tubular NN NN B-Disease
necrosis NN NN I-Disease
appeared NN NN O
to NN NN O
be NN NN O
slightly NN NN O
less NN NN O
severe NN NN O
in NN NN O
rats NN NN O
given NN NN O
GM NN NN O
together NN NN O
with NN NN O
gum NN NN O
Arabic NN NN O
than NN NN O
in NN NN O
those NN NN O
given NN NN O
GM NN NN O
and NN NN O
cellulose NN NN O
. NN NN O
   
It NN NN O
could NN NN O
be NN NN O
inferred NN NN O
that NN NN O
gum NN NN O
Arabic NN NN O
treatment NN NN O
has NN NN O
induced NN NN O
a NN NN O
modest NN NN O
amelioration NN NN O
of NN NN O
some NN NN O
of NN NN O
the NN NN O
histological NN NN O
and NN NN O
biochemical NN NN O
indices NN NN O
of NN NN O
GM NN NN O
nephrotoxicity NN NN B-Disease
. NN NN O
   
Further NN NN O
work NN NN O
is NN NN O
warranted NN NN O
on NN NN O
the NN NN O
effect NN NN O
of NN NN O
the NN NN O
treatments NN NN O
on NN NN O
renal NN NN O
functional NN NN O
aspects NN NN O
in NN NN O
models NN NN O
of NN NN O
chronic NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
, NN NN O
and NN NN O
on NN NN O
the NN NN O
mechanism NN NN O
( NN NN O
s NN NN O
) NN NN O
involved NN NN O
. NN NN O
   
Increased NN NN O
frequency NN NN O
of NN NN O
venous NN NN B-Disease
thromboembolism NN NN I-Disease
with NN NN O
the NN NN O
combination NN NN O
of NN NN O
docetaxel NN NN O
and NN NN O
thalidomide NN NN O
in NN NN O
patients NN NN O
with NN NN O
metastatic NN NN O
androgen NN NN O
- NN NN O
independent NN NN O
prostate NN NN B-Disease
cancer NN NN I-Disease
. NN NN O
   
STUDY NN NN O
OBJECTIVE NN NN O
: NN NN O
To NN NN O
evaluate NN NN O
the NN NN O
frequency NN NN O
of NN NN O
venous NN NN B-Disease
thromboembolism NN NN I-Disease
( NN NN O
VTE NN NN B-Disease
) NN NN O
in NN NN O
patients NN NN O
with NN NN O
advanced NN NN O
androgen NN NN O
- NN NN O
independent NN NN O
prostate NN NN B-Disease
cancer NN NN I-Disease
who NN NN O
were NN NN O
treated NN NN O
with NN NN O
docetaxel NN NN O
alone NN NN O
or NN NN O
in NN NN O
combination NN NN O
with NN NN O
thalidomide NN NN O
. NN NN O
   
DESIGN NN NN O
: NN NN O
Retrospective NN NN O
analysis NN NN O
of NN NN O
a NN NN O
randomized NN NN O
phase NN NN O
II NN NN O
trial NN NN O
. NN NN O
   
SETTING NN NN O
: NN NN O
National NN NN O
Institutes NN NN O
of NN NN O
Health NN NN O
clinical NN NN O
research NN NN O
center NN NN O
. NN NN O
   
PATIENTS NN NN O
: NN NN O
Seventy NN NN O
men NN NN O
, NN NN O
aged NN NN O
50 NN NN O
- NN NN O
80 NN NN O
years NN NN O
, NN NN O
with NN NN O
advanced NN NN O
androgen NN NN O
- NN NN O
independent NN NN O
prostate NN NN B-Disease
cancer NN NN I-Disease
. NN NN O
   
INTERVENTION NN NN O
: NN NN O
Each NN NN O
patient NN NN O
received NN NN O
either NN NN O
intravenous NN NN O
docetaxel NN NN O
30 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
/ NN NN O
week NN NN O
for NN NN O
3 NN NN O
consecutive NN NN O
weeks NN NN O
, NN NN O
followed NN NN O
by NN NN O
1 NN NN O
week NN NN O
off NN NN O
, NN NN O
or NN NN O
the NN NN O
combination NN NN O
of NN NN O
continuous NN NN O
oral NN NN O
thalidomide NN NN O
200 NN NN O
mg NN NN O
every NN NN O
evening NN NN O
plus NN NN O
the NN NN O
same NN NN O
docetaxel NN NN O
regimen NN NN O
. NN NN O
   
This NN NN O
4 NN NN O
- NN NN O
week NN NN O
cycle NN NN O
was NN NN O
repeated NN NN O
until NN NN O
there NN NN O
was NN NN O
evidence NN NN O
of NN NN O
excessive NN NN O
toxicity NN NN B-Disease
or NN NN O
disease NN NN O
progression NN NN O
. NN NN O
   
MEASUREMENTS NN NN O
AND NN NN O
MAIN NN NN O
RESULTS NN NN O
: NN NN O
   O
of NN NN O
23 NN NN O
patients NN NN O
who NN NN O
received NN NN O
docetaxel NN NN O
alone NN NN O
developed NN NN O
VTE NN NN B-Disease
, NN NN O
whereas NN NN O
9 NN NN O
of NN NN O
47 NN NN O
patients NN NN O
( NN NN O
19 NN NN O
% NN NN O
) NN NN O
who NN NN O
received NN NN O
docetaxel NN NN O
plus NN NN O
thalidomide NN NN O
developed NN NN O
VTE NN NN B-Disease
( NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
025 NN NN O
) NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
The NN NN O
addition NN NN O
of NN NN O
thalidomide NN NN O
to NN NN O
docetaxel NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
prostate NN NN B-Disease
cancer NN NN I-Disease
significantly NN NN O
increases NN NN O
the NN NN O
frequency NN NN O
of NN NN O
VTE NN NN B-Disease
. NN NN O
   
Clinicians NN NN O
should NN NN O
be NN NN O
aware NN NN O
of NN NN O
this NN NN O
potential NN NN O
complication NN NN O
when NN NN O
adding NN NN O
thalidomide NN NN O
to NN NN O
chemotherapeutic NN NN O
regimens NN NN O
. NN NN O
   
Ticlopidine NN NN O
- NN NN O
induced NN NN O
cholestatic NN NN B-Disease
hepatitis NN NN I-Disease
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
To NN NN O
report NN NN O
2 NN NN O
cases NN NN O
of NN NN O
ticlopidine NN NN O
- NN NN O
induced NN NN O
cholestatic NN NN B-Disease
hepatitis NN NN I-Disease
, NN NN O
investigate NN NN O
its NN NN O
mechanism NN NN O
, NN NN O
and NN NN O
compare NN NN O
the NN NN O
observed NN NN O
main NN NN O
characteristics NN NN O
with NN NN O
those NN NN O
of NN NN O
the NN NN O
published NN NN O
cases NN NN O
. NN NN O
   
CASE NN NN O
SUMMARIES NN NN O
: NN NN O
Two NN NN O
patients NN NN O
developed NN NN O
prolonged NN NN O
cholestatic NN NN B-Disease
hepatitis NN NN I-Disease
after NN NN O
receiving NN NN O
ticlopidine NN NN O
following NN NN O
percutaneous NN NN O
coronary NN NN O
angioplasty NN NN O
, NN NN O
with NN NN O
complete NN NN O
remission NN NN O
during NN NN O
the NN NN O
follow NN NN O
- NN NN O
up NN NN O
period NN NN O
. NN NN O
   
T NN NN O
- NN NN O
cell NN NN O
stimulation NN NN O
by NN NN O
therapeutic NN NN O
concentration NN NN O
of NN NN O
ticlopidine NN NN O
was NN NN O
demonstrated NN NN O
in NN NN O
vitro NN NN O
in NN NN O
the NN NN O
patients NN NN O
, NN NN O
but NN NN O
not NN NN O
in NN NN O
healthy NN NN O
controls NN NN O
. NN NN O
   
DISCUSSION NN NN O
: NN NN O
Cholestatic NN NN B-Disease
hepatitis NN NN I-Disease
is NN NN O
a NN NN O
rare NN NN O
complication NN NN O
of NN NN O
the NN NN O
antiplatelet NN NN O
agent NN NN O
ticlopidine NN NN O
; NN NN O
several NN NN O
cases NN NN O
have NN NN O
been NN NN O
reported NN NN O
but NN NN O
few NN NN O
in NN NN O
the NN NN O
English NN NN O
literature NN NN O
. NN NN O
   
Our NN NN O
patients NN NN O
developed NN NN O
jaundice NN NN B-Disease
following NN NN O
treatment NN NN O
with NN NN O
ticlopidine NN NN O
and NN NN O
showed NN NN O
the NN NN O
clinical NN NN O
and NN NN O
laboratory NN NN O
characteristics NN NN O
of NN NN O
cholestatic NN NN B-Disease
hepatitis NN NN I-Disease
, NN NN O
which NN NN O
resolved NN NN O
after NN NN O
discontinuation NN NN O
of NN NN O
the NN NN O
drug NN NN O
. NN NN O
   
Hepatitis NN NN B-Disease
may NN NN O
develop NN NN O
weeks NN NN O
after NN NN O
discontinuation NN NN O
of NN NN O
the NN NN O
drug NN NN O
and NN NN O
may NN NN O
run NN NN O
a NN NN O
prolonged NN NN O
course NN NN O
, NN NN O
but NN NN O
complete NN NN O
remission NN NN O
was NN NN O
observed NN NN O
in NN NN O
all NN NN O
reported NN NN O
cases NN NN O
. NN NN O
   
An NN NN O
objective NN NN O
causality NN NN O
assessment NN NN O
revealed NN NN O
that NN NN O
the NN NN O
adverse NN NN O
drug NN NN O
event NN NN O
was NN NN O
probably NN NN O
related NN NN O
to NN NN O
the NN NN O
use NN NN O
of NN NN O
ticlopidine NN NN O
. NN NN O
   
The NN NN O
mechanisms NN NN O
of NN NN O
this NN NN O
ticlopidine NN NN O
- NN NN O
induced NN NN O
cholestasis NN NN B-Disease
are NN NN O
unclear NN NN O
. NN NN O
   
Immune NN NN O
mechanisms NN NN O
may NN NN O
be NN NN O
involved NN NN O
in NN NN O
the NN NN O
drug NN NN O
' NN NN O
s NN NN O
hepatotoxicity NN NN B-Disease
, NN NN O
as NN NN O
suggested NN NN O
by NN NN O
the NN NN O
T NN NN O
- NN NN O
cell NN NN O
stimulation NN NN O
study NN NN O
reported NN NN O
here NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Cholestatic NN NN B-Disease
hepatitis NN NN I-Disease
is NN NN O
a NN NN O
rare NN NN O
adverse NN NN O
effect NN NN O
of NN NN O
ticlopidine NN NN O
that NN NN O
may NN NN O
be NN NN O
immune NN NN O
mediated NN NN O
. NN NN O
   
Patients NN NN O
receiving NN NN O
the NN NN O
drug NN NN O
should NN NN O
be NN NN O
monitored NN NN O
with NN NN O
liver NN NN O
function NN NN O
tests NN NN O
along NN NN O
with NN NN O
complete NN NN O
blood NN NN O
cell NN NN O
counts NN NN O
. NN NN O
   
This NN NN O
complication NN NN O
will NN NN O
be NN NN O
observed NN NN O
even NN NN O
less NN NN O
often NN NN O
in NN NN O
the NN NN O
future NN NN O
as NN NN O
ticlopidine NN NN O
is NN NN O
being NN NN O
replaced NN NN O
by NN NN O
the NN NN O
newer NN NN O
antiplatelet NN NN O
agent NN NN O
clopidogrel NN NN O
. NN NN O
   
Epithelial NN NN O
sodium NN NN O
channel NN NN O
( NN NN O
ENaC NN NN O
) NN NN O
subunit NN NN O
mRNA NN NN O
and NN NN O
protein NN NN O
expression NN NN O
in NN NN O
rats NN NN O
with NN NN O
puromycin NN NN O
aminonucleoside NN NN O
- NN NN O
induced NN NN O
nephrotic NN NN B-Disease
syndrome NN NN I-Disease
. NN NN O
   
In NN NN O
experimental NN NN O
nephrotic NN NN B-Disease
syndrome NN NN I-Disease
, NN NN O
urinary NN NN O
sodium NN NN O
excretion NN NN O
is NN NN O
decreased NN NN O
during NN NN O
the NN NN O
early NN NN O
phase NN NN O
of NN NN O
the NN NN O
disease NN NN O
. NN NN O
   
The NN NN O
molecular NN NN O
mechanism NN NN O
( NN NN O
s NN NN O
) NN NN O
leading NN NN O
to NN NN O
salt NN NN O
retention NN NN O
has NN NN O
not NN NN O
been NN NN O
completely NN NN O
elucidated NN NN O
. NN NN O
   
The NN NN O
rate NN NN O
- NN NN O
limiting NN NN O
constituent NN NN O
of NN NN O
collecting NN NN O
duct NN NN O
sodium NN NN O
transport NN NN O
is NN NN O
the NN NN O
epithelial NN NN O
sodium NN NN O
channel NN NN O
( NN NN O
ENaC NN NN O
) NN NN O
. NN NN O
   
We NN NN O
examined NN NN O
the NN NN O
abundance NN NN O
of NN NN O
ENaC NN NN O
subunit NN NN O
mRNAs NN NN O
and NN NN O
proteins NN NN O
in NN NN O
puromycin NN NN O
aminonucleoside NN NN O
( NN NN O
PAN NN NN O
) NN NN O
- NN NN O
induced NN NN O
nephrotic NN NN B-Disease
syndrome NN NN I-Disease
. NN NN O
   
The NN NN O
time NN NN O
courses NN NN O
of NN NN O
urinary NN NN O
sodium NN NN O
excretion NN NN O
, NN NN O
plasma NN NN O
aldosterone NN NN O
concentration NN NN O
and NN NN O
proteinuria NN NN B-Disease
were NN NN O
studied NN NN O
in NN NN O
male NN NN O
Sprague NN NN O
- NN NN O
Dawley NN NN O
rats NN NN O
treated NN NN O
with NN NN O
a NN NN O
single NN NN O
dose NN NN O
of NN NN O
either NN NN O
PAN NN NN O
or NN NN O
vehicle NN NN O
. NN NN O
   
The NN NN O
relative NN NN O
amounts NN NN O
of NN NN O
alphaENaC NN NN O
, NN NN O
betaENaC NN NN O
and NN NN O
gammaENaC NN NN O
mRNAs NN NN O
were NN NN O
determined NN NN O
in NN NN O
kidneys NN NN O
from NN NN O
these NN NN O
rats NN NN O
by NN NN O
real NN NN O
- NN NN O
time NN NN O
quantitative NN NN O
TaqMan NN NN O
PCR NN NN O
, NN NN O
and NN NN O
the NN NN O
amounts NN NN O
of NN NN O
proteins NN NN O
by NN NN O
Western NN NN O
blot NN NN O
. NN NN O
   
The NN NN O
kinetics NN NN O
of NN NN O
urinary NN NN O
sodium NN NN O
excretion NN NN O
and NN NN O
the NN NN O
appearance NN NN O
of NN NN O
proteinuria NN NN B-Disease
were NN NN O
comparable NN NN O
with NN NN O
those NN NN O
reported NN NN O
previously NN NN O
. NN NN O
   
Sodium NN NN O
retention NN NN O
occurred NN NN O
on NN NN O
days NN NN O
2 NN NN O
, NN NN O
3 NN NN O
and NN NN O
6 NN NN O
after NN NN O
PAN NN NN O
injection NN NN O
. NN NN O
   
A NN NN O
significant NN NN O
up NN NN O
- NN NN O
regulation NN NN O
of NN NN O
alphaENaC NN NN O
and NN NN O
betaENaC NN NN O
mRNA NN NN O
abundance NN NN O
on NN NN O
days NN NN O
1 NN NN O
and NN NN O
2 NN NN O
preceded NN NN O
sodium NN NN O
retention NN NN O
on NN NN O
days NN NN O
2 NN NN O
and NN NN O
3 NN NN O
. NN NN O
   
Conversely NN NN O
, NN NN O
down NN NN O
- NN NN O
regulation NN NN O
of NN NN O
alphaENaC NN NN O
, NN NN O
betaENaC NN NN O
and NN NN O
gammaENaC NN NN O
mRNA NN NN O
expression NN NN O
on NN NN O
day NN NN O
3 NN NN O
occurred NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
high NN NN O
aldosterone NN NN O
concentrations NN NN O
, NN NN O
and NN NN O
was NN NN O
followed NN NN O
by NN NN O
a NN NN O
return NN NN O
of NN NN O
sodium NN NN O
excretion NN NN O
to NN NN O
control NN NN O
values NN NN O
. NN NN O
   
The NN NN O
amounts NN NN O
of NN NN O
alphaENaC NN NN O
, NN NN O
betaENaC NN NN O
and NN NN O
gammaENaC NN NN O
proteins NN NN O
were NN NN O
not NN NN O
increased NN NN O
during NN NN O
PAN NN NN O
- NN NN O
induced NN NN O
sodium NN NN O
retention NN NN O
. NN NN O
   
In NN NN O
conclusion NN NN O
, NN NN O
ENaC NN NN O
mRNA NN NN O
expression NN NN O
, NN NN O
especially NN NN O
alphaENaC NN NN O
, NN NN O
is NN NN O
increased NN NN O
in NN NN O
the NN NN O
very NN NN O
early NN NN O
phase NN NN O
of NN NN O
the NN NN O
experimental NN NN O
model NN NN O
of NN NN O
PAN NN NN O
- NN NN O
induced NN NN O
nephrotic NN NN B-Disease
syndrome NN NN I-Disease
in NN NN O
rats NN NN O
, NN NN O
but NN NN O
appears NN NN O
to NN NN O
escape NN NN O
from NN NN O
the NN NN O
regulation NN NN O
by NN NN O
aldosterone NN NN O
after NN NN O
day NN NN O
3 NN NN O
. NN NN O
   
Sub NN NN O
- NN NN O
chronic NN NN O
low NN NN O
dose NN NN O
gamma NN NN O
- NN NN O
vinyl NN NN O
GABA NN NN O
( NN NN O
vigabatrin NN NN O
) NN NN O
inhibits NN NN O
cocaine NN NN O
- NN NN O
induced NN NN O
increases NN NN O
in NN NN O
nucleus NN NN O
accumbens NN NN O
dopamine NN NN O
. NN NN O
   
RATIONALE NN NN O
: NN NN O
gamma NN NN O
- NN NN O
Vinyl NN NN O
GABA NN NN O
( NN NN O
GVG NN NN O
) NN NN O
irreversibly NN NN O
inhibits NN NN O
GABA NN NN O
- NN NN O
transaminase NN NN O
. NN NN O
   
This NN NN O
non NN NN O
- NN NN O
receptor NN NN O
mediated NN NN O
inhibition NN NN O
requires NN NN O
de NN NN O
novo NN NN O
synthesis NN NN O
for NN NN O
restoration NN NN O
of NN NN O
functional NN NN O
GABA NN NN O
catabolism NN NN O
. NN NN O
   
OBJECTIVES NN NN O
: NN NN O
Given NN NN O
its NN NN O
preclinical NN NN O
success NN NN O
for NN NN O
treating NN NN O
substance NN NN B-Disease
abuse NN NN I-Disease
and NN NN O
the NN NN O
increased NN NN O
risk NN NN O
of NN NN O
visual NN NN B-Disease
field NN NN I-Disease
defects NN NN I-Disease
( NN NN O
VFD NN NN B-Disease
) NN NN O
associated NN NN O
with NN NN O
cumulative NN NN O
lifetime NN NN O
exposure NN NN O
, NN NN O
we NN NN O
explored NN NN O
the NN NN O
effects NN NN O
of NN NN O
sub NN NN O
- NN NN O
chronic NN NN O
low NN NN O
dose NN NN O
GVG NN NN O
on NN NN O
cocaine NN NN O
- NN NN O
induced NN NN O
increases NN NN O
in NN NN O
nucleus NN NN O
accumbens NN NN O
( NN NN O
NAcc NN NN O
) NN NN O
dopamine NN NN O
( NN NN O
DA NN NN O
) NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Using NN NN O
in NN NN O
vivo NN NN O
microdialysis NN NN O
, NN NN O
we NN NN O
compared NN NN O
acute NN NN O
exposure NN NN O
( NN NN O
450 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
to NN NN O
an NN NN O
identical NN NN O
sub NN NN O
- NN NN O
chronic NN NN O
exposure NN NN O
( NN NN O
150 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
per NN NN O
day NN NN O
for NN NN O
3 NN NN O
days NN NN O
) NN NN O
, NN NN O
followed NN NN O
by NN NN O
1 NN NN O
- NN NN O
or NN NN O
3 NN NN O
- NN NN O
day NN NN O
washout NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
we NN NN O
examined NN NN O
the NN NN O
low NN NN O
dose NN NN O
of NN NN O
150 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
( NN NN O
50 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
per NN NN O
day NN NN O
) NN NN O
using NN NN O
a NN NN O
similar NN NN O
washout NN NN O
period NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Sub NN NN O
- NN NN O
chronic NN NN O
GVG NN NN O
exposure NN NN O
inhibited NN NN O
the NN NN O
effect NN NN O
of NN NN O
cocaine NN NN O
for NN NN O
3 NN NN O
days NN NN O
, NN NN O
which NN NN O
exceeded NN NN O
in NN NN O
magnitude NN NN O
and NN NN O
duration NN NN O
the NN NN O
identical NN NN O
acute NN NN O
dose NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Sub NN NN O
- NN NN O
chronic NN NN O
low NN NN O
dose NN NN O
GVG NN NN O
potentiates NN NN O
and NN NN O
extends NN NN O
the NN NN O
inhibition NN NN O
of NN NN O
cocaine NN NN O
- NN NN O
induced NN NN O
increases NN NN O
in NN NN O
dopamine NN NN O
, NN NN O
effectively NN NN O
reducing NN NN O
cumulative NN NN O
exposures NN NN O
and NN NN O
the NN NN O
risk NN NN O
for NN NN O
VFDS NN NN O
. NN NN O
   
MR NN NN O
imaging NN NN O
with NN NN O
quantitative NN NN O
diffusion NN NN O
mapping NN NN O
of NN NN O
tacrolimus NN NN O
- NN NN O
induced NN NN O
neurotoxicity NN NN B-Disease
in NN NN O
organ NN NN O
transplant NN NN O
patients NN NN O
. NN NN O
   
Our NN NN O
objective NN NN O
was NN NN O
to NN NN O
investigate NN NN O
brain NN NN O
MR NN NN O
imaging NN NN O
findings NN NN O
and NN NN O
the NN NN O
utility NN NN O
of NN NN O
diffusion NN NN O
- NN NN O
weighted NN NN O
( NN NN O
DW NN NN O
) NN NN O
imaging NN NN O
in NN NN O
organ NN NN O
transplant NN NN O
patients NN NN O
who NN NN O
developed NN NN O
neurologic NN NN O
symptoms NN NN O
during NN NN O
tacrolimus NN NN O
therapy NN NN O
. NN NN O
   
Brain NN NN O
MR NN NN O
studies NN NN O
, NN NN O
including NN NN O
DW NN NN O
imaging NN NN O
, NN NN O
were NN NN O
prospectively NN NN O
performed NN NN O
in NN NN O
14 NN NN O
organ NN NN O
transplant NN NN O
patients NN NN O
receiving NN NN O
tacrolimus NN NN O
who NN NN O
developed NN NN O
neurologic NN NN B-Disease
complications NN NN I-Disease
. NN NN O
   
In NN NN O
each NN NN O
patient NN NN O
who NN NN O
had NN NN O
abnormalities NN NN O
on NN NN O
the NN NN O
initial NN NN O
MR NN NN O
study NN NN O
, NN NN O
a NN NN O
follow NN NN O
- NN NN O
up NN NN O
MR NN NN O
study NN NN O
was NN NN O
performed NN NN O
1 NN NN O
month NN NN O
later NN NN O
. NN NN O
   
Apparent NN NN O
diffusion NN NN O
coefficient NN NN O
( NN NN O
ADC NN NN O
) NN NN O
values NN NN O
on NN NN O
the NN NN O
initial NN NN O
MR NN NN O
study NN NN O
were NN NN O
correlated NN NN O
with NN NN O
reversibility NN NN O
of NN NN O
the NN NN O
lesions NN NN O
. NN NN O
   
Of NN NN O
the NN NN O
14 NN NN O
patients NN NN O
, NN NN O
5 NN NN O
( NN NN O
35 NN NN O
. NN NN O
7 NN NN O
% NN NN O
) NN NN O
had NN NN O
white NN NN B-Disease
matter NN NN I-Disease
abnormalities NN NN I-Disease
, NN NN O
1 NN NN O
( NN NN O
7 NN NN O
. NN NN O
1 NN NN O
% NN NN O
) NN NN O
had NN NN O
putaminal NN NN B-Disease
hemorrhage NN NN I-Disease
, NN NN O
and NN NN O
8 NN NN O
( NN NN O
57 NN NN O
. NN NN O
1 NN NN O
% NN NN O
) NN NN O
had NN NN O
normal NN NN O
findings NN NN O
on NN NN O
initial NN NN O
MR NN NN O
images NN NN O
. NN NN O
   
Among NN NN O
the NN NN O
5 NN NN O
patients NN NN O
with NN NN O
white NN NN B-Disease
matter NN NN I-Disease
abnormalities NN NN I-Disease
, NN NN O
4 NN NN O
patients NN NN O
( NN NN O
80 NN NN O
. NN NN O
0 NN NN O
% NN NN O
) NN NN O
showed NN NN O
higher NN NN O
than NN NN O
normal NN NN O
ADC NN NN O
values NN NN O
on NN NN O
initial NN NN O
MR NN NN O
images NN NN O
, NN NN O
and NN NN O
all NN NN O
showed NN NN O
complete NN NN O
resolution NN NN O
on NN NN O
follow NN NN O
- NN NN O
up NN NN O
images NN NN O
. NN NN O
   
The NN NN O
remaining NN NN O
1 NN NN O
patient NN NN O
( NN NN O
20 NN NN O
. NN NN O
0 NN NN O
% NN NN O
) NN NN O
showed NN NN O
lower NN NN O
than NN NN O
normal NN NN O
ADC NN NN O
value NN NN O
and NN NN O
showed NN NN O
incomplete NN NN O
resolution NN NN O
with NN NN O
cortical NN NN B-Disease
laminar NN NN I-Disease
necrosis NN NN I-Disease
. NN NN O
   
Diffusion NN NN O
- NN NN O
weighted NN NN O
imaging NN NN O
may NN NN O
be NN NN O
useful NN NN O
in NN NN O
predicting NN NN O
the NN NN O
outcomes NN NN O
of NN NN O
the NN NN O
lesions NN NN O
of NN NN O
tacrolimus NN NN O
- NN NN O
induced NN NN O
neurotoxicity NN NN B-Disease
. NN NN O
   
L NN NN O
- NN NN O
arginine NN NN O
transport NN NN O
in NN NN O
humans NN NN O
with NN NN O
cortisol NN NN O
- NN NN O
induced NN NN O
hypertension NN NN B-Disease
. NN NN O
   
A NN NN O
deficient NN NN O
L NN NN O
- NN NN O
arginine NN NN O
- NN NN O
nitric NN NN O
oxide NN NN O
system NN NN O
is NN NN O
implicated NN NN O
in NN NN O
cortisol NN NN O
- NN NN O
induced NN NN O
hypertension NN NN B-Disease
. NN NN O
   
We NN NN O
investigate NN NN O
whether NN NN O
abnormalities NN NN O
in NN NN O
L NN NN O
- NN NN O
arginine NN NN O
uptake NN NN O
contribute NN NN O
to NN NN O
this NN NN O
deficiency NN NN O
. NN NN O
   
Eight NN NN O
healthy NN NN O
men NN NN O
were NN NN O
recruited NN NN O
. NN NN O
   
Hydrocortisone NN NN O
acetate NN NN O
( NN NN O
50 NN NN O
mg NN NN O
) NN NN O
was NN NN O
given NN NN O
orally NN NN O
every NN NN O
6 NN NN O
hours NN NN O
for NN NN O
24 NN NN O
hours NN NN O
after NN NN O
a NN NN O
5 NN NN O
- NN NN O
day NN NN O
fixed NN NN O
- NN NN O
salt NN NN O
diet NN NN O
( NN NN O
150 NN NN O
mmol NN NN O
/ NN NN O
d NN NN O
) NN NN O
. NN NN O
   
Crossover NN NN O
studies NN NN O
were NN NN O
performed NN NN O
2 NN NN O
weeks NN NN O
apart NN NN O
. NN NN O
   
Thirty NN NN O
milliliters NN NN O
of NN NN O
blood NN NN O
was NN NN O
obtained NN NN O
for NN NN O
isolation NN NN O
of NN NN O
peripheral NN NN O
blood NN NN O
mononuclear NN NN O
cells NN NN O
after NN NN O
each NN NN O
treatment NN NN O
period NN NN O
. NN NN O
   
L NN NN O
- NN NN O
arginine NN NN O
uptake NN NN O
was NN NN O
assessed NN NN O
in NN NN O
mononuclear NN NN O
cells NN NN O
incubated NN NN O
with NN NN O
L NN NN O
- NN NN O
arginine NN NN O
( NN NN O
1 NN NN O
to NN NN O
300 NN NN O
micromol NN NN O
/ NN NN O
L NN NN O
) NN NN O
, NN NN O
incorporating NN NN O
100 NN NN O
nmol NN NN O
/ NN NN O
L NN NN O
[ NN NN O
3H NN NN O
] NN NN O
- NN NN O
l NN NN O
- NN NN O
arginine NN NN O
for NN NN O
a NN NN O
period NN NN O
of NN NN O
5 NN NN O
minutes NN NN O
at NN NN O
37 NN NN O
degrees NN NN O
C NN NN O
. NN NN O
   
Forearm NN NN O
[ NN NN O
3H NN NN O
] NN NN O
- NN NN O
L NN NN O
- NN NN O
arginine NN NN O
extraction NN NN O
was NN NN O
calculated NN NN O
after NN NN O
infusion NN NN O
of NN NN O
[ NN NN O
3H NN NN O
] NN NN O
- NN NN O
L NN NN O
- NN NN O
arginine NN NN O
into NN NN O
the NN NN O
brachial NN NN O
artery NN NN O
at NN NN O
a NN NN O
rate NN NN O
of NN NN O
100 NN NN O
nCi NN NN O
/ NN NN O
min NN NN O
for NN NN O
80 NN NN O
minutes NN NN O
. NN NN O
   
Deep NN NN O
forearm NN NN O
venous NN NN O
samples NN NN O
were NN NN O
collected NN NN O
for NN NN O
determination NN NN O
of NN NN O
L NN NN O
- NN NN O
arginine NN NN O
extraction NN NN O
. NN NN O
   
Plasma NN NN O
cortisol NN NN O
concentrations NN NN O
were NN NN O
significantly NN NN O
raised NN NN O
during NN NN O
the NN NN O
active NN NN O
phase NN NN O
( NN NN O
323 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
43 NN NN O
to NN NN O
1082 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
245 NN NN O
mmol NN NN O
/ NN NN O
L NN NN O
, NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
Systolic NN NN O
blood NN NN O
pressure NN NN O
was NN NN O
elevated NN NN O
by NN NN O
an NN NN O
average NN NN O
of NN NN O
7 NN NN O
mm NN NN O
Hg NN NN O
. NN NN O
   
Neither NN NN O
L NN NN O
- NN NN O
arginine NN NN O
transport NN NN O
into NN NN O
mononuclear NN NN O
cells NN NN O
( NN NN O
placebo NN NN O
vs NN NN O
active NN NN O
, NN NN O
26 NN NN O
. NN NN O
3 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
3 NN NN O
. NN NN O
6 NN NN O
vs NN NN O
29 NN NN O
. NN NN O
0 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
. NN NN O
1 NN NN O
pmol NN NN O
/ NN NN O
10 NN NN O
000 NN NN O
cells NN NN O
per NN NN O
5 NN NN O
minutes NN NN O
, NN NN O
respectively NN NN O
, NN NN O
at NN NN O
an NN NN O
l NN NN O
- NN NN O
arginine NN NN O
concentration NN NN O
of NN NN O
300 NN NN O
micromol NN NN O
/ NN NN O
L NN NN O
) NN NN O
nor NN NN O
L NN NN O
- NN NN O
arginine NN NN O
extraction NN NN O
in NN NN O
the NN NN O
forearm NN NN O
( NN NN O
at NN NN O
80 NN NN O
minutes NN NN O
, NN NN O
placebo NN NN O
vs NN NN O
active NN NN O
, NN NN O
1 NN NN O
868 NN NN O
904 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
434 NN NN O
962 NN NN O
vs NN NN O
2 NN NN O
013 NN NN O
910 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
770 NN NN O
619 NN NN O
disintegrations NN NN O
per NN NN O
minute NN NN O
) NN NN O
was NN NN O
affected NN NN O
by NN NN O
cortisol NN NN O
treatment NN NN O
; NN NN O
ie NN NN O
, NN NN O
that NN NN O
L NN NN O
- NN NN O
arginine NN NN O
uptake NN NN O
is NN NN O
not NN NN O
affected NN NN O
by NN NN O
short NN NN O
- NN NN O
term NN NN O
cortisol NN NN O
treatment NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
cortisol NN NN O
- NN NN O
induced NN NN O
increases NN NN B-Disease
in NN NN I-Disease
blood NN NN I-Disease
pressure NN NN I-Disease
are NN NN O
not NN NN O
associated NN NN O
with NN NN O
abnormalities NN NN O
in NN NN O
the NN NN O
l NN NN O
- NN NN O
arginine NN NN O
transport NN NN O
system NN NN O
. NN NN O
   
Amount NN NN O
of NN NN O
bleeding NN NN B-Disease
and NN NN O
hematoma NN NN B-Disease
size NN NN O
in NN NN O
the NN NN O
collagenase NN NN O
- NN NN O
induced NN NN O
intracerebral NN NN B-Disease
hemorrhage NN NN I-Disease
rat NN NN O
model NN NN O
. NN NN O
   
The NN NN O
aggravated NN NN O
risk NN NN O
on NN NN O
intracerebral NN NN B-Disease
hemorrhage NN NN I-Disease
( NN NN O
ICH NN NN B-Disease
) NN NN O
with NN NN O
drugs NN NN O
used NN NN O
for NN NN O
stroke NN NN B-Disease
patients NN NN O
should NN NN O
be NN NN O
estimated NN NN O
carefully NN NN O
. NN NN O
   
We NN NN O
therefore NN NN O
established NN NN O
sensitive NN NN O
quantification NN NN O
methods NN NN O
and NN NN O
provided NN NN O
a NN NN O
rat NN NN O
ICH NN NN B-Disease
model NN NN O
for NN NN O
detection NN NN O
of NN NN O
ICH NN NN B-Disease
deterioration NN NN O
. NN NN O
   
In NN NN O
ICH NN NN B-Disease
intrastriatally NN NN O
induced NN NN O
by NN NN O
0 NN NN O
. NN NN O
014 NN NN O
- NN NN O
unit NN NN O
, NN NN O
0 NN NN O
. NN NN O
070 NN NN O
- NN NN O
unit NN NN O
, NN NN O
and NN NN O
0 NN NN O
. NN NN O
350 NN NN O
- NN NN O
unit NN NN O
collagenase NN NN O
, NN NN O
the NN NN O
amount NN NN O
of NN NN O
bleeding NN NN B-Disease
was NN NN O
measured NN NN O
using NN NN O
a NN NN O
hemoglobin NN NN O
assay NN NN O
developed NN NN O
in NN NN O
the NN NN O
present NN NN O
study NN NN O
and NN NN O
was NN NN O
compared NN NN O
with NN NN O
the NN NN O
morphologically NN NN O
determined NN NN O
hematoma NN NN B-Disease
volume NN NN O
. NN NN O
   
The NN NN O
blood NN NN O
amounts NN NN O
and NN NN O
hematoma NN NN B-Disease
volumes NN NN O
were NN NN O
significantly NN NN O
correlated NN NN O
, NN NN O
and NN NN O
the NN NN O
hematoma NN NN B-Disease
induced NN NN O
by NN NN O
0 NN NN O
. NN NN O
014 NN NN O
- NN NN O
unit NN NN O
collagenase NN NN O
was NN NN O
adequate NN NN O
to NN NN O
detect NN NN O
ICH NN NN B-Disease
deterioration NN NN O
. NN NN O
   
In NN NN O
ICH NN NN B-Disease
induction NN NN O
using NN NN O
0 NN NN O
. NN NN O
014 NN NN O
- NN NN O
unit NN NN O
collagenase NN NN O
, NN NN O
heparin NN NN O
enhanced NN NN O
the NN NN O
hematoma NN NN B-Disease
volume NN NN O
3 NN NN O
. NN NN O
4 NN NN O
- NN NN O
fold NN NN O
over NN NN O
that NN NN O
seen NN NN O
in NN NN O
control NN NN O
ICH NN NN B-Disease
animals NN NN O
and NN NN O
the NN NN O
bleeding NN NN B-Disease
7 NN NN O
. NN NN O
6 NN NN O
- NN NN O
fold NN NN O
. NN NN O
   
Data NN NN O
suggest NN NN O
that NN NN O
this NN NN O
sensitive NN NN O
hemoglobin NN NN O
assay NN NN O
is NN NN O
useful NN NN O
for NN NN O
ICH NN NN B-Disease
detection NN NN O
, NN NN O
and NN NN O
that NN NN O
a NN NN O
model NN NN O
with NN NN O
a NN NN O
small NN NN O
ICH NN NN B-Disease
induced NN NN O
with NN NN O
a NN NN O
low NN NN O
- NN NN O
dose NN NN O
collagenase NN NN O
should NN NN O
be NN NN O
used NN NN O
for NN NN O
evaluation NN NN O
of NN NN O
drugs NN NN O
that NN NN O
may NN NN O
affect NN NN O
ICH NN NN B-Disease
. NN NN O
   
Estradiol NN NN O
reduces NN NN O
seizure NN NN B-Disease
- NN NN O
induced NN NN O
hippocampal NN NN B-Disease
injury NN NN I-Disease
in NN NN O
ovariectomized NN NN O
female NN NN O
but NN NN O
not NN NN O
in NN NN O
male NN NN O
rats NN NN O
. NN NN O
   
Estrogens NN NN O
protect NN NN O
ovariectomized NN NN O
rats NN NN O
from NN NN O
hippocampal NN NN B-Disease
injury NN NN I-Disease
induced NN NN O
by NN NN O
kainic NN NN O
acid NN NN O
- NN NN O
induced NN NN O
status NN NN B-Disease
epilepticus NN NN I-Disease
( NN NN O
SE NN NN B-Disease
) NN NN O
. NN NN O
   
We NN NN O
compared NN NN O
the NN NN O
effects NN NN O
of NN NN O
17beta NN NN O
- NN NN O
estradiol NN NN O
in NN NN O
adult NN NN O
male NN NN O
and NN NN O
ovariectomized NN NN O
female NN NN O
rats NN NN O
subjected NN NN O
to NN NN O
lithium NN NN O
- NN NN O
pilocarpine NN NN O
- NN NN O
induced NN NN O
SE NN NN B-Disease
. NN NN O
   
Rats NN NN O
received NN NN O
subcutaneous NN NN O
injections NN NN O
of NN NN O
17beta NN NN O
- NN NN O
estradiol NN NN O
( NN NN O
2 NN NN O
microg NN NN O
/ NN NN O
rat NN NN O
) NN NN O
or NN NN O
oil NN NN O
once NN NN O
daily NN NN O
for NN NN O
four NN NN O
consecutive NN NN O
days NN NN O
. NN NN O
   
SE NN NN B-Disease
was NN NN O
induced NN NN O
20 NN NN O
h NN NN O
following NN NN O
the NN NN O
second NN NN O
injection NN NN O
and NN NN O
terminated NN NN O
3 NN NN O
h NN NN O
later NN NN O
. NN NN O
   
The NN NN O
extent NN NN O
of NN NN O
silver NN NN O
- NN NN O
stained NN NN O
CA3 NN NN O
and NN NN O
CA1 NN NN O
hippocampal NN NN O
neurons NN NN O
was NN NN O
evaluated NN NN O
2 NN NN O
days NN NN O
after NN NN O
SE NN NN B-Disease
. NN NN O
   
17beta NN NN O
- NN NN O
Estradiol NN NN O
did NN NN O
not NN NN O
alter NN NN O
the NN NN O
onset NN NN O
of NN NN O
first NN NN O
clonus NN NN O
in NN NN O
ovariectomized NN NN O
rats NN NN O
but NN NN O
accelerated NN NN O
it NN NN O
in NN NN O
males NN NN O
. NN NN O
   
17beta NN NN O
- NN NN O
Estradiol NN NN O
reduced NN NN O
the NN NN O
argyrophilic NN NN O
neurons NN NN O
in NN NN O
the NN NN O
CA1 NN NN O
and NN NN O
CA3 NN NN O
- NN NN O
C NN NN O
sectors NN NN O
of NN NN O
ovariectomized NN NN O
rats NN NN O
. NN NN O
   
In NN NN O
males NN NN O
, NN NN O
estradiol NN NN O
increased NN NN O
the NN NN O
total NN NN O
damage NN NN O
score NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
the NN NN O
effects NN NN O
of NN NN O
estradiol NN NN O
on NN NN O
seizure NN NN B-Disease
threshold NN NN O
and NN NN O
damage NN NN O
may NN NN O
be NN NN O
altered NN NN O
by NN NN O
sex NN NN O
- NN NN O
related NN NN O
differences NN NN O
in NN NN O
the NN NN O
hormonal NN NN O
environment NN NN O
. NN NN O
   
Pseudoacromegaly NN NN B-Disease
induced NN NN O
by NN NN O
the NN NN O
long NN NN O
- NN NN O
term NN NN O
use NN NN O
of NN NN O
minoxidil NN NN O
. NN NN O
   
Acromegaly NN NN B-Disease
is NN NN O
an NN NN O
endocrine NN NN B-Disease
disorder NN NN I-Disease
caused NN NN O
by NN NN O
chronic NN NN O
excessive NN NN O
growth NN NN O
hormone NN NN O
secretion NN NN O
from NN NN O
the NN NN O
anterior NN NN O
pituitary NN NN O
gland NN NN O
. NN NN O
   
Significant NN NN O
disfiguring NN NN O
changes NN NN O
occur NN NN O
as NN NN O
a NN NN O
result NN NN O
of NN NN O
bone NN NN O
, NN NN O
cartilage NN NN O
, NN NN O
and NN NN O
soft NN NN O
tissue NN NN O
hypertrophy NN NN B-Disease
, NN NN O
including NN NN O
the NN NN O
thickening NN NN O
of NN NN O
the NN NN O
skin NN NN O
, NN NN O
coarsening NN NN O
of NN NN O
facial NN NN O
features NN NN O
, NN NN O
and NN NN O
cutis NN NN B-Disease
verticis NN NN I-Disease
gyrata NN NN I-Disease
. NN NN O
   
Pseudoacromegaly NN NN B-Disease
, NN NN O
on NN NN O
the NN NN O
other NN NN O
hand NN NN O
, NN NN O
is NN NN O
the NN NN O
presence NN NN O
of NN NN O
similar NN NN O
acromegaloid NN NN O
features NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
elevated NN NN O
growth NN NN O
hormone NN NN O
or NN NN O
insulin NN NN O
- NN NN O
like NN NN O
growth NN NN O
factor NN NN O
levels NN NN O
. NN NN O
   
We NN NN O
present NN NN O
a NN NN O
patient NN NN O
with NN NN O
pseudoacromegaly NN NN B-Disease
that NN NN O
resulted NN NN O
from NN NN O
the NN NN O
long NN NN O
- NN NN O
term NN NN O
use NN NN O
of NN NN O
minoxidil NN NN O
at NN NN O
an NN NN O
unusually NN NN O
high NN NN O
dose NN NN O
. NN NN O
   
This NN NN O
is NN NN O
the NN NN O
first NN NN O
case NN NN O
report NN NN O
of NN NN O
pseudoacromegaly NN NN B-Disease
as NN NN O
a NN NN O
side NN NN O
effect NN NN O
of NN NN O
minoxidil NN NN O
use NN NN O
. NN NN O
   
Combined NN NN O
androgen NN NN O
blockade NN NN O
- NN NN O
induced NN NN O
anemia NN NN B-Disease
in NN NN O
prostate NN NN B-Disease
cancer NN NN I-Disease
patients NN NN O
without NN NN O
bone NN NN O
involvement NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
To NN NN O
determine NN NN O
the NN NN O
onset NN NN O
and NN NN O
extent NN NN O
of NN NN O
combined NN NN O
androgen NN NN O
blockade NN NN O
( NN NN O
CAB NN NN O
) NN NN O
- NN NN O
induced NN NN O
anemia NN NN B-Disease
in NN NN O
prostate NN NN B-Disease
cancer NN NN I-Disease
patients NN NN O
without NN NN O
bone NN NN O
involvement NN NN O
. NN NN O
   
PATIENTS NN NN O
AND NN NN O
METHODS NN NN O
: NN NN O
Forty NN NN O
- NN NN O
two NN NN O
patients NN NN O
with NN NN O
biopsy NN NN O
- NN NN O
proven NN NN O
prostatic NN NN B-Disease
adenocarcinoma NN NN I-Disease
[ NN NN O
26 NN NN O
with NN NN O
stage NN NN O
C NN NN O
( NN NN O
T3N0M0 NN NN O
) NN NN O
and NN NN O
16 NN NN O
with NN NN O
stage NN NN O
D1 NN NN O
( NN NN O
T3N1M0 NN NN O
) NN NN O
] NN NN O
were NN NN O
included NN NN O
in NN NN O
this NN NN O
study NN NN O
. NN NN O
   
All NN NN O
patients NN NN O
received NN NN O
CAB NN NN O
[ NN NN O
leuprolide NN NN O
acetate NN NN O
( NN NN O
LHRH NN NN O
- NN NN O
A NN NN O
) NN NN O
3 NN NN O
. NN NN O
75 NN NN O
mg NN NN O
, NN NN O
intramuscularly NN NN O
, NN NN O
every NN NN O
28 NN NN O
days NN NN O
plus NN NN O
250 NN NN O
mg NN NN O
flutamide NN NN O
, NN NN O
tid NN NN O
, NN NN O
per NN NN O
Os NN NN O
] NN NN O
and NN NN O
were NN NN O
evaluated NN NN O
for NN NN O
anemia NN NN B-Disease
by NN NN O
physical NN NN O
examination NN NN O
and NN NN O
laboratory NN NN O
tests NN NN O
at NN NN O
baseline NN NN O
and NN NN O
4 NN NN O
subsequent NN NN O
intervals NN NN O
( NN NN O
1 NN NN O
, NN NN O
2 NN NN O
, NN NN O
3 NN NN O
and NN NN O
6 NN NN O
months NN NN O
post NN NN O
- NN NN O
CAB NN NN O
) NN NN O
. NN NN O
   
Hb NN NN O
, NN NN O
PSA NN NN O
and NN NN O
Testosterone NN NN O
measurements NN NN O
were NN NN O
recorded NN NN O
. NN NN O
   
Patients NN NN O
with NN NN O
stage NN NN O
D2 NN NN O
- NN NN O
3 NN NN O
disease NN NN O
, NN NN O
abnormal NN NN O
hemoglobin NN NN O
level NN NN O
or NN NN O
renal NN NN O
and NN NN O
liver NN NN O
function NN NN O
tests NN NN O
that NN NN O
were NN NN O
higher NN NN O
than NN NN O
the NN NN O
upper NN NN O
limits NN NN O
were NN NN O
excluded NN NN O
from NN NN O
the NN NN O
study NN NN O
. NN NN O
   
The NN NN O
duration NN NN O
of NN NN O
the NN NN O
study NN NN O
was NN NN O
six NN NN O
months NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
The NN NN O
mean NN NN O
hemoglobin NN NN O
( NN NN O
Hb NN NN O
) NN NN O
levels NN NN O
were NN NN O
significantly NN NN O
declined NN NN O
in NN NN O
all NN NN O
patients NN NN O
from NN NN O
baseline NN NN O
of NN NN O
14 NN NN O
. NN NN O
2 NN NN O
g NN NN O
/ NN NN O
dl NN NN O
to NN NN O
14 NN NN O
. NN NN O
0 NN NN O
g NN NN O
/ NN NN O
dl NN NN O
, NN NN O
13 NN NN O
. NN NN O
5 NN NN O
g NN NN O
/ NN NN O
dl NN NN O
, NN NN O
13 NN NN O
. NN NN O
2 NN NN O
g NN NN O
/ NN NN O
dl NN NN O
and NN NN O
12 NN NN O
. NN NN O
7 NN NN O
g NN NN O
/ NN NN O
dl NN NN O
at NN NN O
1 NN NN O
, NN NN O
2 NN NN O
, NN NN O
3 NN NN O
and NN NN O
6 NN NN O
months NN NN O
post NN NN O
- NN NN O
CAB NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
Severe NN NN O
and NN NN O
clinically NN NN O
evident NN NN O
anemia NN NN B-Disease
of NN NN O
Hb NN NN O
< NN NN O
11 NN NN O
g NN NN O
/ NN NN O
dl NN NN O
with NN NN O
clinical NN NN O
symptoms NN NN O
was NN NN O
detected NN NN O
in NN NN O
6 NN NN O
patients NN NN O
( NN NN O
14 NN NN O
. NN NN O
3 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
This NN NN O
CAB NN NN O
- NN NN O
induced NN NN O
anemia NN NN B-Disease
was NN NN O
normochromic NN NN O
and NN NN O
normocytic NN NN O
. NN NN O
   
At NN NN O
six NN NN O
months NN NN O
post NN NN O
- NN NN O
CAB NN NN O
, NN NN O
patients NN NN O
with NN NN O
severe NN NN O
anemia NN NN B-Disease
had NN NN O
a NN NN O
Hb NN NN O
mean NN NN O
value NN NN O
of NN NN O
10 NN NN O
. NN NN O
2 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
1 NN NN O
g NN NN O
/ NN NN O
dl NN NN O
( NN NN O
X NN NN O
+ NN NN O
/ NN NN O
- NN NN O
SE NN NN O
) NN NN O
, NN NN O
whereas NN NN O
the NN NN O
other NN NN O
patients NN NN O
had NN NN O
mild NN NN O
anemia NN NN B-Disease
with NN NN O
Hb NN NN O
mean NN NN O
value NN NN O
of NN NN O
13 NN NN O
. NN NN O
2 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
17 NN NN O
( NN NN O
X NN NN O
+ NN NN O
/ NN NN O
- NN NN O
SE NN NN O
) NN NN O
. NN NN O
   
The NN NN O
development NN NN O
of NN NN O
severe NN NN O
anemia NN NN B-Disease
at NN NN O
6 NN NN O
months NN NN O
post NN NN O
- NN NN O
CAB NN NN O
was NN NN O
predictable NN NN O
by NN NN O
the NN NN O
reduction NN NN O
of NN NN O
Hb NN NN O
baseline NN NN O
value NN NN O
of NN NN O
more NN NN O
than NN NN O
2 NN NN O
. NN NN O
5 NN NN O
g NN NN O
/ NN NN O
dl NN NN O
after NN NN O
3 NN NN O
months NN NN O
of NN NN O
CAB NN NN O
( NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
development NN NN O
of NN NN O
severe NN NN O
CAB NN NN O
- NN NN O
induced NN NN O
anemia NN NN B-Disease
in NN NN O
prostate NN NN B-Disease
cancer NN NN I-Disease
patients NN NN O
did NN NN O
not NN NN O
correlate NN NN O
with NN NN O
T NN NN O
baseline NN NN O
values NN NN O
( NN NN O
T NN NN O
< NN NN O
3 NN NN O
ng NN NN O
/ NN NN O
ml NN NN O
versus NN NN O
T NN NN O
> NN NN O
or NN NN O
= NN NN O
3 NN NN O
ng NN NN O
/ NN NN O
ml NN NN O
) NN NN O
, NN NN O
with NN NN O
age NN NN O
( NN NN O
< NN NN O
76 NN NN O
yrs NN NN O
versus NN NN O
> NN NN O
or NN NN O
= NN NN O
76 NN NN O
yrs NN NN O
) NN NN O
, NN NN O
and NN NN O
clinical NN NN O
stage NN NN O
( NN NN O
stage NN NN O
C NN NN O
versus NN NN O
stage NN NN O
D1 NN NN O
) NN NN O
. NN NN O
   
Severe NN NN O
and NN NN O
clinically NN NN O
evident NN NN O
anemia NN NN B-Disease
was NN NN O
easily NN NN O
corrected NN NN O
by NN NN O
subcutaneous NN NN O
injections NN NN O
( NN NN O
3 NN NN O
times NN NN O
/ NN NN O
week NN NN O
for NN NN O
1 NN NN O
month NN NN O
) NN NN O
of NN NN O
recombinant NN NN O
erythropoietin NN NN O
( NN NN O
rHuEPO NN NN O
- NN NN O
beta NN NN O
) NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Our NN NN O
data NN NN O
suggest NN NN O
that NN NN O
rHuEPO NN NN O
- NN NN O
beta NN NN O
correctable NN NN O
CAB NN NN O
- NN NN O
induced NN NN O
anemia NN NN B-Disease
occurs NN NN O
in NN NN O
14 NN NN O
. NN NN O
3 NN NN O
% NN NN O
of NN NN O
prostate NN NN B-Disease
cancer NN NN I-Disease
patients NN NN O
after NN NN O
6 NN NN O
months NN NN O
of NN NN O
therapy NN NN O
. NN NN O
   
Delirium NN NN B-Disease
during NN NN O
clozapine NN NN O
treatment NN NN O
: NN NN O
incidence NN NN O
and NN NN O
associated NN NN O
risk NN NN O
factors NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Incidence NN NN O
and NN NN O
risk NN NN O
factors NN NN O
for NN NN O
delirium NN NN B-Disease
during NN NN O
clozapine NN NN O
treatment NN NN O
require NN NN O
further NN NN O
clarification NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
We NN NN O
used NN NN O
computerized NN NN O
pharmacy NN NN O
records NN NN O
to NN NN O
identify NN NN O
all NN NN O
adult NN NN O
psychiatric NN NN B-Disease
inpatients NN NN O
treated NN NN O
with NN NN O
clozapine NN NN O
( NN NN O
1995 NN NN O
- NN NN O
96 NN NN O
) NN NN O
, NN NN O
reviewed NN NN O
their NN NN O
medical NN NN O
records NN NN O
to NN NN O
score NN NN O
incidence NN NN O
and NN NN O
severity NN NN O
of NN NN O
delirium NN NN B-Disease
, NN NN O
and NN NN O
tested NN NN O
associations NN NN O
with NN NN O
potential NN NN O
risk NN NN O
factors NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Subjects NN NN O
( NN NN O
n NN NN O
= NN NN O
139 NN NN O
) NN NN O
were NN NN O
72 NN NN O
women NN NN O
and NN NN O
67 NN NN O
men NN NN O
, NN NN O
aged NN NN O
40 NN NN O
. NN NN O
8 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
12 NN NN O
. NN NN O
1 NN NN O
years NN NN O
, NN NN O
hospitalized NN NN O
for NN NN O
24 NN NN O
. NN NN O
9 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
23 NN NN O
. NN NN O
3 NN NN O
days NN NN O
, NN NN O
and NN NN O
given NN NN O
clozapine NN NN O
, NN NN O
gradually NN NN O
increased NN NN O
to NN NN O
an NN NN O
average NN NN O
daily NN NN O
dose NN NN O
of NN NN O
282 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
203 NN NN O
mg NN NN O
( NN NN O
3 NN NN O
. NN NN O
45 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
. NN NN O
45 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
for NN NN O
18 NN NN O
. NN NN O
9 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
16 NN NN O
. NN NN O
4 NN NN O
days NN NN O
. NN NN O
   
Delirium NN NN B-Disease
was NN NN O
diagnosed NN NN O
in NN NN O
14 NN NN O
( NN NN O
10 NN NN O
. NN NN O
1 NN NN O
% NN NN O
incidence NN NN O
, NN NN O
or NN NN O
1 NN NN O
. NN NN O
48 NN NN O
cases NN NN O
/ NN NN O
person NN NN O
- NN NN O
years NN NN O
of NN NN O
exposure NN NN O
) NN NN O
; NN NN O
71 NN NN O
. NN NN O
4 NN NN O
% NN NN O
of NN NN O
cases NN NN O
were NN NN O
moderate NN NN O
or NN NN O
severe NN NN O
. NN NN O
   
Associated NN NN O
factors NN NN O
were NN NN O
co NN NN O
- NN NN O
treatment NN NN O
with NN NN O
other NN NN O
centrally NN NN O
antimuscarinic NN NN O
agents NN NN O
, NN NN O
poor NN NN O
clinical NN NN O
outcome NN NN O
, NN NN O
older NN NN O
age NN NN O
, NN NN O
and NN NN O
longer NN NN O
hospitalization NN NN O
( NN NN O
by NN NN O
17 NN NN O
. NN NN O
5 NN NN O
days NN NN O
, NN NN O
increasing NN NN O
cost NN NN O
) NN NN O
; NN NN O
sex NN NN O
, NN NN O
diagnosis NN NN O
or NN NN O
medical NN NN O
co NN NN O
- NN NN O
morbidity NN NN O
, NN NN O
and NN NN O
daily NN NN O
clozapine NN NN O
dose NN NN O
, NN NN O
which NN NN O
fell NN NN O
with NN NN O
age NN NN O
, NN NN O
were NN NN O
unrelated NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Delirium NN NN B-Disease
was NN NN O
found NN NN O
in NN NN O
10 NN NN O
% NN NN O
of NN NN O
clozapine NN NN O
- NN NN O
treated NN NN O
inpatients NN NN O
, NN NN O
particularly NN NN O
in NN NN O
older NN NN O
patients NN NN O
exposed NN NN O
to NN NN O
other NN NN O
central NN NN O
anticholinergics NN NN O
. NN NN O
   
Delirium NN NN B-Disease
was NN NN O
inconsistently NN NN O
recognized NN NN O
clinically NN NN O
in NN NN O
milder NN NN O
cases NN NN O
and NN NN O
was NN NN O
associated NN NN O
with NN NN O
increased NN NN O
length NN NN O
- NN NN O
of NN NN O
- NN NN O
stay NN NN O
and NN NN O
higher NN NN O
costs NN NN O
, NN NN O
and NN NN O
inferior NN NN O
clinical NN NN O
outcome NN NN O
. NN NN O
   
Neuroprotective NN NN O
action NN NN O
of NN NN O
MPEP NN NN O
, NN NN O
a NN NN O
selective NN NN O
mGluR5 NN NN O
antagonist NN NN O
, NN NN O
in NN NN O
methamphetamine NN NN O
- NN NN O
induced NN NN O
dopaminergic NN NN O
neurotoxicity NN NN B-Disease
is NN NN O
associated NN NN O
with NN NN O
a NN NN O
decrease NN NN O
in NN NN O
dopamine NN NN O
outflow NN NN O
and NN NN O
inhibition NN NN O
of NN NN O
hyperthermia NN NN B-Disease
in NN NN O
rats NN NN O
. NN NN O
   
The NN NN O
aim NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
examine NN NN O
the NN NN O
role NN NN O
of NN NN O
metabotropic NN NN O
glutamate NN NN O
receptor NN NN O
5 NN NN O
( NN NN O
mGluR5 NN NN O
) NN NN O
in NN NN O
the NN NN O
toxic NN NN O
action NN NN O
of NN NN O
methamphetamine NN NN O
on NN NN O
dopaminergic NN NN O
neurones NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
Methamphetamine NN NN O
( NN NN O
10 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
sc NN NN O
) NN NN O
, NN NN O
administered NN NN O
five NN NN O
times NN NN O
, NN NN O
reduced NN NN O
the NN NN O
levels NN NN O
of NN NN O
dopamine NN NN O
and NN NN O
its NN NN O
metabolites NN NN O
in NN NN O
striatal NN NN O
tissue NN NN O
when NN NN O
measured NN NN O
72 NN NN O
h NN NN O
after NN NN O
the NN NN O
last NN NN O
injection NN NN O
. NN NN O
   
A NN NN O
selective NN NN O
antagonist NN NN O
of NN NN O
mGluR5 NN NN O
, NN NN O
2 NN NN O
- NN NN O
methyl NN NN O
- NN NN O
6 NN NN O
- NN NN O
( NN NN O
phenylethynyl NN NN O
) NN NN O
pyridine NN NN O
( NN NN O
MPEP NN NN O
; NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
ip NN NN O
) NN NN O
, NN NN O
when NN NN O
administered NN NN O
five NN NN O
times NN NN O
immediately NN NN O
before NN NN O
each NN NN O
methamphetamine NN NN O
injection NN NN O
reversed NN NN O
the NN NN O
above NN NN O
- NN NN O
mentioned NN NN O
methamphetamine NN NN O
effects NN NN O
. NN NN O
   
A NN NN O
single NN NN O
MPEP NN NN O
( NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
ip NN NN O
) NN NN O
injection NN NN O
reduced NN NN O
the NN NN O
basal NN NN O
extracellular NN NN O
dopamine NN NN O
level NN NN O
in NN NN O
the NN NN O
striatum NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
dopamine NN NN O
release NN NN O
stimulated NN NN O
either NN NN O
by NN NN O
methamphetamine NN NN O
( NN NN O
10 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
sc NN NN O
) NN NN O
or NN NN O
by NN NN O
intrastriatally NN NN O
administered NN NN O
veratridine NN NN O
( NN NN O
100 NN NN O
microM NN NN O
) NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
it NN NN O
transiently NN NN O
diminished NN NN O
the NN NN O
methamphetamine NN NN O
( NN NN O
10 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
sc NN NN O
) NN NN O
- NN NN O
induced NN NN O
hyperthermia NN NN B-Disease
and NN NN O
reduced NN NN O
basal NN NN O
body NN NN O
temperature NN NN O
. NN NN O
   
MPEP NN NN O
administered NN NN O
into NN NN O
the NN NN O
striatum NN NN O
at NN NN O
high NN NN O
concentrations NN NN O
( NN NN O
500 NN NN O
microM NN NN O
) NN NN O
increased NN NN O
extracellular NN NN O
dopamine NN NN O
levels NN NN O
, NN NN O
while NN NN O
lower NN NN O
concentrations NN NN O
( NN NN O
50 NN NN O
- NN NN O
100 NN NN O
microM NN NN O
) NN NN O
were NN NN O
devoid NN NN O
of NN NN O
any NN NN O
effect NN NN O
. NN NN O
   
The NN NN O
results NN NN O
of NN NN O
this NN NN O
study NN NN O
suggest NN NN O
that NN NN O
the NN NN O
blockade NN NN O
of NN NN O
mGluR5 NN NN O
by NN NN O
MPEP NN NN O
may NN NN O
protect NN NN O
dopaminergic NN NN O
neurones NN NN O
against NN NN O
methamphetamine NN NN O
- NN NN O
induced NN NN O
toxicity NN NN B-Disease
. NN NN O
   
Neuroprotection NN NN O
rendered NN NN O
by NN NN O
MPEP NN NN O
may NN NN O
be NN NN O
associated NN NN O
with NN NN O
the NN NN O
reduction NN NN O
of NN NN O
the NN NN O
methamphetamine NN NN O
- NN NN O
induced NN NN O
dopamine NN NN O
efflux NN NN O
in NN NN O
the NN NN O
striatum NN NN O
due NN NN O
to NN NN O
the NN NN O
blockade NN NN O
of NN NN O
extrastriatal NN NN O
mGluR5 NN NN O
, NN NN O
and NN NN O
with NN NN O
a NN NN O
decrease NN NN O
in NN NN O
hyperthermia NN NN B-Disease
. NN NN O
   
Protective NN NN O
efficacy NN NN O
of NN NN O
neuroactive NN NN O
steroids NN NN O
against NN NN O
cocaine NN NN O
kindled NN NN O
- NN NN O
seizures NN NN B-Disease
in NN NN O
mice NN NN O
. NN NN O
   
Neuroactive NN NN O
steroids NN NN O
demonstrate NN NN O
pharmacological NN NN O
actions NN NN O
that NN NN O
have NN NN O
relevance NN NN O
for NN NN O
a NN NN O
host NN NN O
of NN NN O
neurological NN NN B-Disease
and NN NN I-Disease
psychiatric NN NN I-Disease
disorders NN NN I-Disease
. NN NN O
   
They NN NN O
offer NN NN O
protection NN NN O
against NN NN O
seizures NN NN B-Disease
in NN NN O
a NN NN O
range NN NN O
of NN NN O
models NN NN O
and NN NN O
seem NN NN O
to NN NN O
inhibit NN NN O
certain NN NN O
stages NN NN O
of NN NN O
drug NN NN B-Disease
dependence NN NN I-Disease
in NN NN O
preclinical NN NN O
assessments NN NN O
. NN NN O
   
The NN NN O
present NN NN O
study NN NN O
was NN NN O
designed NN NN O
to NN NN O
evaluate NN NN O
two NN NN O
endogenous NN NN O
and NN NN O
one NN NN O
synthetic NN NN O
neuroactive NN NN O
steroid NN NN O
that NN NN O
positively NN NN O
modulate NN NN O
the NN NN O
gamma NN NN O
- NN NN O
aminobutyric NN NN O
acid NN NN O
( NN NN O
GABA NN NN O
( NN NN O
A NN NN O
) NN NN O
) NN NN O
receptor NN NN O
against NN NN O
the NN NN O
increase NN NN O
in NN NN O
sensitivity NN NN O
to NN NN O
the NN NN O
convulsant NN NN O
effects NN NN O
of NN NN O
cocaine NN NN O
engendered NN NN O
by NN NN O
repeated NN NN O
cocaine NN NN O
administration NN NN O
( NN NN O
seizure NN NN B-Disease
kindling NN NN O
) NN NN O
. NN NN O
   
Allopregnanolone NN NN O
( NN NN O
3alpha NN NN O
- NN NN O
hydroxy NN NN O
- NN NN O
5alpha NN NN O
- NN NN O
pregnan NN NN O
- NN NN O
20 NN NN O
- NN NN O
one NN NN O
) NN NN O
, NN NN O
pregnanolone NN NN O
( NN NN O
3alpha NN NN O
- NN NN O
hydroxy NN NN O
- NN NN O
5beta NN NN O
- NN NN O
pregnan NN NN O
- NN NN O
20 NN NN O
- NN NN O
one NN NN O
) NN NN O
and NN NN O
ganaxolone NN NN O
( NN NN O
a NN NN O
synthetic NN NN O
derivative NN NN O
of NN NN O
allopregnanolone NN NN O
3alpha NN NN O
- NN NN O
hydroxy NN NN O
- NN NN O
3beta NN NN O
- NN NN O
methyl NN NN O
- NN NN O
5alpha NN NN O
- NN NN O
pregnan NN NN O
- NN NN O
20 NN NN O
- NN NN O
one NN NN O
) NN NN O
were NN NN O
tested NN NN O
for NN NN O
their NN NN O
ability NN NN O
to NN NN O
suppress NN NN O
the NN NN O
expression NN NN O
( NN NN O
anticonvulsant NN NN O
effect NN NN O
) NN NN O
and NN NN O
development NN NN O
( NN NN O
antiepileptogenic NN NN O
effect NN NN O
) NN NN O
of NN NN O
cocaine NN NN O
- NN NN O
kindled NN NN O
seizures NN NN B-Disease
in NN NN O
male NN NN O
, NN NN O
Swiss NN NN O
- NN NN O
Webster NN NN O
mice NN NN O
. NN NN O
   
Kindled NN NN O
seizures NN NN B-Disease
were NN NN O
induced NN NN O
by NN NN O
daily NN NN O
administration NN NN O
of NN NN O
60 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
cocaine NN NN O
for NN NN O
5 NN NN O
days NN NN O
. NN NN O
   
All NN NN O
of NN NN O
these NN NN O
positive NN NN O
GABA NN NN O
( NN NN O
A NN NN O
) NN NN O
modulators NN NN O
suppressed NN NN O
the NN NN O
expression NN NN O
of NN NN O
kindled NN NN O
seizures NN NN B-Disease
, NN NN O
whereas NN NN O
only NN NN O
allopregnanolone NN NN O
and NN NN O
ganaxolone NN NN O
inhibited NN NN O
the NN NN O
development NN NN O
of NN NN O
kindling NN NN O
. NN NN O
   
Allopregnanolone NN NN O
and NN NN O
pregnanolone NN NN O
, NN NN O
but NN NN O
not NN NN O
ganaxolone NN NN O
, NN NN O
also NN NN O
reduced NN NN O
cumulative NN NN O
lethality NN NN O
associated NN NN O
with NN NN O
kindling NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
demonstrate NN NN O
that NN NN O
some NN NN O
neuroactive NN NN O
steroids NN NN O
attenuate NN NN O
convulsant NN NN O
and NN NN O
sensitizing NN NN O
properties NN NN O
of NN NN O
cocaine NN NN O
and NN NN O
add NN NN O
to NN NN O
a NN NN O
growing NN NN O
literature NN NN O
on NN NN O
their NN NN O
potential NN NN O
use NN NN O
in NN NN O
the NN NN O
modulation NN NN O
of NN NN O
effects NN NN O
of NN NN O
drugs NN NN O
of NN NN O
abuse NN NN O
. NN NN O
   
Effect NN NN O
of NN NN O
humoral NN NN O
modulators NN NN O
of NN NN O
morphine NN NN O
- NN NN O
induced NN NN O
increase NN NN B-Disease
in NN NN I-Disease
locomotor NN NN I-Disease
activity NN NN I-Disease
of NN NN O
mice NN NN O
. NN NN O
   
The NN NN O
effect NN NN O
of NN NN O
humoral NN NN O
modulators NN NN O
on NN NN O
the NN NN O
morphine NN NN O
- NN NN O
induced NN NN O
increase NN NN B-Disease
in NN NN I-Disease
locomotor NN NN I-Disease
activity NN NN I-Disease
of NN NN O
mice NN NN O
was NN NN O
studied NN NN O
. NN NN O
   
The NN NN O
subcutaneous NN NN O
administration NN NN O
of NN NN O
10 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
of NN NN O
morphine NN NN O
- NN NN O
HC1 NN NN O
produced NN NN O
a NN NN O
marked NN NN O
increase NN NN B-Disease
in NN NN I-Disease
locomotor NN NN I-Disease
activity NN NN I-Disease
in NN NN O
mice NN NN O
. NN NN O
   
The NN NN O
morphine NN NN O
- NN NN O
induced NN NN O
hyperactivity NN NN B-Disease
was NN NN O
potentiated NN NN O
by NN NN O
scopolamine NN NN O
and NN NN O
attenuated NN NN O
by NN NN O
physostigmine NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
both NN NN O
methscopolamine NN NN O
and NN NN O
neostigmine NN NN O
, NN NN O
which NN NN O
do NN NN O
not NN NN O
penetrate NN NN O
the NN NN O
blood NN NN O
- NN NN O
brain NN NN O
barrier NN NN O
, NN NN O
had NN NN O
no NN NN O
effect NN NN O
on NN NN O
the NN NN O
hyperactivity NN NN B-Disease
produced NN NN O
by NN NN O
morphine NN NN O
. NN NN O
   
Pretreatment NN NN O
of NN NN O
mice NN NN O
with NN NN O
alpha NN NN O
- NN NN O
methyltyrosine NN NN O
( NN NN O
20 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
, NN NN O
one NN NN O
hour NN NN O
) NN NN O
, NN NN O
an NN NN O
inhibitor NN NN O
of NN NN O
tyrosine NN NN O
hydroxylase NN NN O
, NN NN O
significantly NN NN O
decreased NN NN O
the NN NN O
activity NN NN O
- NN NN O
increasing NN NN O
effects NN NN O
of NN NN O
morphine NN NN O
. NN NN O
   
On NN NN O
the NN NN O
other NN NN O
hand NN NN O
, NN NN O
pretreatment NN NN O
with NN NN O
p NN NN O
- NN NN O
chlorophenylalamine NN NN O
( NN NN O
3 NN NN O
X NN NN O
320 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
, NN NN O
24 NN NN O
hr NN NN O
) NN NN O
, NN NN O
a NN NN O
serotonin NN NN O
depletor NN NN O
, NN NN O
caused NN NN O
no NN NN O
significant NN NN O
change NN NN O
in NN NN O
the NN NN O
hyperactivity NN NN B-Disease
. NN NN O
   
The NN NN O
study NN NN O
suggests NN NN O
that NN NN O
the NN NN O
activity NN NN O
- NN NN O
increasing NN NN O
effects NN NN O
of NN NN O
morphine NN NN O
are NN NN O
mediated NN NN O
by NN NN O
the NN NN O
release NN NN O
of NN NN O
catecholamines NN NN O
from NN NN O
adrenergic NN NN O
neurons NN NN O
in NN NN O
the NN NN O
brain NN NN O
. NN NN O
   
And NN NN O
the NN NN O
results NN NN O
are NN NN O
consistent NN NN O
with NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
morphine NN NN O
acts NN NN O
by NN NN O
retarding NN NN O
the NN NN O
release NN NN O
of NN NN O
acetylcholine NN NN O
at NN NN O
some NN NN O
central NN NN O
cholinergic NN NN O
synapses NN NN O
. NN NN O
   
It NN NN O
is NN NN O
also NN NN O
suggested NN NN O
from NN NN O
collected NN NN O
evidence NN NN O
that NN NN O
the NN NN O
activity NN NN O
- NN NN O
increasing NN NN O
effects NN NN O
of NN NN O
morphine NN NN O
in NN NN O
mice NN NN O
are NN NN O
mediated NN NN O
by NN NN O
mechanisms NN NN O
different NN NN O
from NN NN O
those NN NN O
which NN NN O
mediate NN NN O
the NN NN O
activity NN NN O
- NN NN O
increasing NN NN O
effects NN NN O
of NN NN O
morphine NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
Effects NN NN O
of NN NN O
uninephrectomy NN NN O
and NN NN O
high NN NN O
protein NN NN O
feeding NN NN O
on NN NN O
lithium NN NN O
- NN NN O
induced NN NN O
chronic NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
in NN NN O
rats NN NN O
. NN NN O
   
Rats NN NN O
with NN NN O
lithium NN NN O
- NN NN O
induced NN NN O
nephropathy NN NN B-Disease
were NN NN O
subjected NN NN O
to NN NN O
high NN NN O
protein NN NN O
( NN NN O
HP NN NN O
) NN NN O
feeding NN NN O
, NN NN O
uninephrectomy NN NN O
( NN NN O
NX NN NN O
) NN NN O
or NN NN O
a NN NN O
combination NN NN O
of NN NN O
these NN NN O
, NN NN O
in NN NN O
an NN NN O
attempt NN NN O
to NN NN O
induce NN NN O
glomerular NN NN O
hyperfiltration NN NN O
and NN NN O
further NN NN O
progression NN NN O
of NN NN O
renal NN NN B-Disease
failure NN NN I-Disease
. NN NN O
   
Newborn NN NN O
female NN NN O
Wistar NN NN O
rats NN NN O
were NN NN O
fed NN NN O
a NN NN O
lithium NN NN O
- NN NN O
containing NN NN O
diet NN NN O
( NN NN O
50 NN NN O
mmol NN NN O
/ NN NN O
kg NN NN O
) NN NN O
for NN NN O
8 NN NN O
weeks NN NN O
and NN NN O
then NN NN O
randomized NN NN O
to NN NN O
normal NN NN O
diet NN NN O
, NN NN O
HP NN NN O
diet NN NN O
( NN NN O
40 NN NN O
vs NN NN O
. NN NN O
19 NN NN O
% NN NN O
) NN NN O
, NN NN O
NX NN NN O
or NN NN O
HP NN NN O
+ NN NN O
NX NN NN O
for NN NN O
another NN NN O
8 NN NN O
weeks NN NN O
. NN NN O
   
Corresponding NN NN O
non NN NN O
- NN NN O
lithium NN NN O
pretreated NN NN O
groups NN NN O
were NN NN O
generated NN NN O
. NN NN O
   
When NN NN O
comparing NN NN O
all NN NN O
lithium NN NN O
treated NN NN O
versus NN NN O
non NN NN O
- NN NN O
lithium NN NN O
- NN NN O
treated NN NN O
groups NN NN O
, NN NN O
lithium NN NN O
caused NN NN O
a NN NN O
reduction NN NN O
in NN NN O
glomerular NN NN O
filtration NN NN O
rate NN NN O
( NN NN O
GFR NN NN O
) NN NN O
without NN NN O
significant NN NN O
changes NN NN O
in NN NN O
effective NN NN O
renal NN NN O
plasma NN NN O
flow NN NN O
( NN NN O
as NN NN O
determined NN NN O
by NN NN O
a NN NN O
marker NN NN O
secreted NN NN O
into NN NN O
the NN NN O
proximal NN NN O
tubules NN NN O
) NN NN O
or NN NN O
lithium NN NN O
clearance NN NN O
. NN NN O
   
Consequently NN NN O
, NN NN O
lithium NN NN O
pretreatment NN NN O
caused NN NN O
a NN NN O
fall NN NN O
in NN NN O
filtration NN NN O
fraction NN NN O
and NN NN O
an NN NN O
increase NN NN O
in NN NN O
fractional NN NN O
Li NN NN O
excretion NN NN O
. NN NN O
   
Lithium NN NN O
also NN NN O
caused NN NN O
proteinuria NN NN B-Disease
and NN NN O
systolic NN NN O
hypertension NN NN B-Disease
in NN NN O
absence NN NN O
of NN NN O
glomerulosclerosis NN NN B-Disease
. NN NN O
   
HP NN NN O
failed NN NN O
to NN NN O
accentuante NN NN O
progression NN NN O
of NN NN O
renal NN NN B-Disease
failure NN NN I-Disease
and NN NN O
in NN NN O
fact NN NN O
tended NN NN O
to NN NN O
increase NN NN O
GFR NN NN O
and NN NN O
decrease NN NN O
plasma NN NN O
creatinine NN NN O
levels NN NN O
in NN NN O
lithium NN NN O
pretreated NN NN O
rats NN NN O
. NN NN O
   
NX NN NN O
caused NN NN O
an NN NN O
additive NN NN O
deterioration NN NN O
in NN NN O
GFR NN NN O
which NN NN O
, NN NN O
however NN NN O
, NN NN O
was NN NN O
ameliorated NN NN O
by NN NN O
HP NN NN O
. NN NN O
   
NX NN NN O
+ NN NN O
HP NN NN O
caused NN NN O
a NN NN O
further NN NN O
rise NN NN O
in NN NN O
blood NN NN O
pressure NN NN O
in NN NN O
Li NN NN O
- NN NN O
pretreated NN NN O
rats NN NN O
. NN NN O
   
The NN NN O
results NN NN O
indicate NN NN O
that NN NN O
Li NN NN O
- NN NN O
induced NN NN O
nephropathy NN NN B-Disease
, NN NN O
even NN NN O
when NN NN O
the NN NN O
GFR NN NN O
is NN NN O
only NN NN O
modestly NN NN O
reduced NN NN O
, NN NN O
is NN NN O
associated NN NN O
with NN NN O
proteinuria NN NN B-Disease
and NN NN O
arterial NN NN O
systolic NN NN O
hypertension NN NN B-Disease
. NN NN O
   
In NN NN O
this NN NN O
model NN NN O
of NN NN O
chronic NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
the NN NN O
decline NN NN O
in NN NN O
GFR NN NN O
is NN NN O
not NN NN O
accompanied NN NN O
by NN NN O
a NN NN O
corresponding NN NN O
fall NN NN O
in NN NN O
effective NN NN O
renal NN NN O
plasma NN NN O
flow NN NN O
, NN NN O
which NN NN O
may NN NN O
be NN NN O
the NN NN O
functional NN NN O
expression NN NN O
of NN NN O
the NN NN O
formation NN NN O
of NN NN O
nonfiltrating NN NN O
atubular NN NN O
glomeruli NN NN O
. NN NN O
   
The NN NN O
fractional NN NN O
reabsorption NN NN O
of NN NN O
tubular NN NN O
fluid NN NN O
by NN NN O
the NN NN O
proximal NN NN O
tubules NN NN O
is NN NN O
reduced NN NN O
, NN NN O
leaving NN NN O
the NN NN O
distal NN NN O
delivery NN NN O
unchanged NN NN O
. NN NN O
( NN NN O
ABSTRACT NN NN O
TRUNCATED NN NN O
AT NN NN O
250 NN NN O
WORDS NN NN O
) NN NN O
   
Treatment NN NN O
of NN NN O
Crohn NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
with NN NN O
fusidic NN NN O
acid NN NN O
: NN NN O
an NN NN O
antibiotic NN NN O
with NN NN O
immunosuppressive NN NN O
properties NN NN O
similar NN NN O
to NN NN O
cyclosporin NN NN O
. NN NN O
   
Fusidic NN NN O
acid NN NN O
is NN NN O
an NN NN O
antibiotic NN NN O
with NN NN O
T NN NN O
- NN NN O
cell NN NN O
specific NN NN O
immunosuppressive NN NN O
effects NN NN O
similar NN NN O
to NN NN O
those NN NN O
of NN NN O
cyclosporin NN NN O
. NN NN O
   
Because NN NN O
of NN NN O
the NN NN O
need NN NN O
for NN NN O
the NN NN O
development NN NN O
of NN NN O
new NN NN O
treatments NN NN O
for NN NN O
Crohn NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
, NN NN O
a NN NN O
pilot NN NN O
study NN NN O
was NN NN O
undertaken NN NN O
to NN NN O
estimate NN NN O
the NN NN O
pharmacodynamics NN NN O
and NN NN O
tolerability NN NN O
of NN NN O
fusidic NN NN O
acid NN NN O
treatment NN NN O
in NN NN O
chronic NN NN O
active NN NN O
, NN NN O
therapy NN NN O
- NN NN O
resistant NN NN O
patients NN NN O
. NN NN O
   
Eight NN NN O
Crohn NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
patients NN NN O
were NN NN O
included NN NN O
. NN NN O
   
Fusidic NN NN O
acid NN NN O
was NN NN O
administered NN NN O
orally NN NN O
in NN NN O
a NN NN O
dose NN NN O
of NN NN O
500 NN NN O
mg NN NN O
t NN NN O
. NN NN O
d NN NN O
. NN NN O
s NN NN O
. NN NN O
and NN NN O
the NN NN O
treatment NN NN O
was NN NN O
planned NN NN O
to NN NN O
last NN NN O
8 NN NN O
weeks NN NN O
. NN NN O
   
The NN NN O
disease NN NN O
activity NN NN O
was NN NN O
primarily NN NN O
measured NN NN O
by NN NN O
a NN NN O
modified NN NN O
individual NN NN O
grading NN NN O
score NN NN O
. NN NN O
   
Five NN NN O
of NN NN O
8 NN NN O
patients NN NN O
( NN NN O
63 NN NN O
% NN NN O
) NN NN O
improved NN NN O
during NN NN O
fusidic NN NN O
acid NN NN O
treatment NN NN O
: NN NN O
3 NN NN O
at NN NN O
two NN NN O
weeks NN NN O
and NN NN O
2 NN NN O
after NN NN O
four NN NN O
weeks NN NN O
. NN NN O
   
There NN NN O
were NN NN O
no NN NN O
serious NN NN O
clinical NN NN O
side NN NN O
effects NN NN O
, NN NN O
but NN NN O
dose NN NN O
reduction NN NN O
was NN NN O
required NN NN O
in NN NN O
two NN NN O
patients NN NN O
because NN NN O
of NN NN O
nausea NN NN B-Disease
. NN NN O
   
Biochemically NN NN O
, NN NN O
an NN NN O
increase NN NN O
in NN NN O
alkaline NN NN O
phosphatases NN NN O
was NN NN O
noted NN NN O
in NN NN O
5 NN NN O
of NN NN O
8 NN NN O
cases NN NN O
( NN NN O
63 NN NN O
% NN NN O
) NN NN O
, NN NN O
and NN NN O
the NN NN O
greatest NN NN O
increases NN NN O
were NN NN O
seen NN NN O
in NN NN O
those NN NN O
who NN NN O
had NN NN O
elevated NN NN O
levels NN NN O
prior NN NN O
to NN NN O
treatment NN NN O
. NN NN O
   
All NN NN O
reversed NN NN O
to NN NN O
pre NN NN O
- NN NN O
treatment NN NN O
levels NN NN O
after NN NN O
cessation NN NN O
of NN NN O
treatment NN NN O
. NN NN O
   
The NN NN O
results NN NN O
of NN NN O
this NN NN O
pilot NN NN O
study NN NN O
suggest NN NN O
that NN NN O
fusidic NN NN O
acid NN NN O
may NN NN O
be NN NN O
of NN NN O
benefit NN NN O
in NN NN O
selected NN NN O
chronic NN NN O
active NN NN O
Crohn NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
patients NN NN O
in NN NN O
whom NN NN O
conventional NN NN O
treatment NN NN O
is NN NN O
ineffective NN NN O
. NN NN O
   
Because NN NN O
there NN NN O
seems NN NN O
to NN NN O
exist NN NN O
a NN NN O
scientific NN NN O
rationale NN NN O
for NN NN O
the NN NN O
use NN NN O
of NN NN O
fusidic NN NN O
acid NN NN O
at NN NN O
the NN NN O
cytokine NN NN O
level NN NN O
in NN NN O
inflammatory NN NN B-Disease
bowel NN NN I-Disease
disease NN NN I-Disease
, NN NN O
we NN NN O
suggest NN NN O
that NN NN O
the NN NN O
role NN NN O
of NN NN O
this NN NN O
treatment NN NN O
should NN NN O
be NN NN O
further NN NN O
investigated NN NN O
. NN NN O
   
Changes NN NN O
in NN NN O
depressive NN NN B-Disease
status NN NN O
associated NN NN O
with NN NN O
topical NN NN O
beta NN NN O
- NN NN O
blockers NN NN O
. NN NN O
   
Depression NN NN B-Disease
and NN NN O
sexual NN NN B-Disease
dysfunction NN NN I-Disease
have NN NN O
been NN NN O
related NN NN O
to NN NN O
side NN NN O
effects NN NN O
of NN NN O
topical NN NN O
beta NN NN O
- NN NN O
blockers NN NN O
. NN NN O
   
We NN NN O
performed NN NN O
a NN NN O
preliminary NN NN O
study NN NN O
in NN NN O
order NN NN O
to NN NN O
determine NN NN O
any NN NN O
difference NN NN O
between NN NN O
a NN NN O
non NN NN O
selective NN NN O
beta NN NN O
- NN NN O
blocker NN NN O
( NN NN O
timolol NN NN O
) NN NN O
and NN NN O
a NN NN O
selective NN NN O
beta NN NN O
- NN NN O
blocker NN NN O
( NN NN O
betaxolol NN NN O
) NN NN O
regarding NN NN O
CNS NN NN O
side NN NN O
effects NN NN O
. NN NN O
   
Eight NN NN O
glaucomatous NN NN B-Disease
patients NN NN O
chronically NN NN O
treated NN NN O
with NN NN O
timolol NN NN O
0 NN NN O
. NN NN O
5 NN NN O
% NN NN O
/ NN NN O
12h NN NN O
, NN NN O
suffering NN NN O
from NN NN O
depression NN NN B-Disease
diagnosed NN NN O
through NN NN O
DMS NN NN O
- NN NN O
III NN NN O
- NN NN O
R NN NN O
criteria NN NN O
, NN NN O
were NN NN O
included NN NN O
in NN NN O
the NN NN O
study NN NN O
. NN NN O
   
During NN NN O
the NN NN O
six NN NN O
- NN NN O
month NN NN O
follow NN NN O
up NN NN O
, NN NN O
depression NN NN B-Disease
was NN NN O
quantified NN NN O
through NN NN O
the NN NN O
Beck NN NN O
and NN NN O
Zung NN NN O
- NN NN O
Conde NN NN O
scales NN NN O
every NN NN O
two NN NN O
months NN NN O
. NN NN O
   
In NN NN O
a NN NN O
double NN NN O
blind NN NN O
cross NN NN O
- NN NN O
over NN NN O
study NN NN O
with NN NN O
control NN NN O
group NN NN O
, NN NN O
the NN NN O
patients NN NN O
under NN NN O
timolol NN NN O
treatment NN NN O
presented NN NN O
higher NN NN O
depression NN NN B-Disease
values NN NN O
measured NN NN O
through NN NN O
the NN NN O
Beck NN NN O
and NN NN O
the NN NN O
Zung NN NN O
- NN NN O
Conde NN NN O
scales NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
vs NN NN O
control NN NN O
) NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
betaxolol NN NN O
could NN NN O
be NN NN O
less NN NN O
of NN NN O
a NN NN O
depression NN NN B-Disease
- NN NN O
inducer NN NN O
than NN NN O
timolol NN NN O
in NN NN O
predisposed NN NN O
patients NN NN O
. NN NN O
   
Protection NN NN O
against NN NN O
amphetamine NN NN O
- NN NN O
induced NN NN O
neurotoxicity NN NN B-Disease
toward NN NN O
striatal NN NN O
dopamine NN NN O
neurons NN NN O
in NN NN O
rodents NN NN O
by NN NN O
LY274614 NN NN O
, NN NN O
an NN NN O
excitatory NN NN O
amino NN NN O
acid NN NN O
antagonist NN NN O
. NN NN O
   
LY274614 NN NN O
, NN NN O
3SR NN NN O
, NN NN O
4aRS NN NN O
, NN NN O
6SR NN NN O
, NN NN O
8aRS NN NN O
- NN NN O
6 NN NN O
- NN NN O
[ NN NN O
phosphonomethyl NN NN O
] NN NN O
decahydr NN NN O
oisoquinoline NN NN O
- NN NN O
3 NN NN O
- NN NN O
carboxylic NN NN O
acid NN NN O
, NN NN O
has NN NN O
been NN NN O
described NN NN O
as NN NN O
a NN NN O
potent NN NN O
antagonist NN NN O
of NN NN O
the NN NN O
N NN NN O
- NN NN O
methyl NN NN O
- NN NN O
D NN NN O
- NN NN O
aspartate NN NN O
( NN NN O
NMDA NN NN O
) NN NN O
subtype NN NN O
of NN NN O
glutamate NN NN O
receptor NN NN O
. NN NN O
   
Here NN NN O
its NN NN O
ability NN NN O
to NN NN O
antagonize NN NN O
the NN NN O
prolonged NN NN O
depletion NN NN O
of NN NN O
dopamine NN NN O
in NN NN O
the NN NN O
striatum NN NN O
by NN NN O
amphetamine NN NN O
in NN NN O
iprindole NN NN O
- NN NN O
treated NN NN O
rats NN NN O
is NN NN O
reported NN NN O
. NN NN O
   
A NN NN O
single NN NN O
18 NN NN O
. NN NN O
4 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
( NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
dose NN NN O
of NN NN O
( NN NN O
+ NN NN O
/ NN NN O
- NN NN O
) NN NN O
- NN NN O
amphetamine NN NN O
hemisulfate NN NN O
, NN NN O
given NN NN O
to NN NN O
rats NN NN O
pretreated NN NN O
with NN NN O
iprindole NN NN O
, NN NN O
resulted NN NN O
in NN NN O
persistent NN NN O
depletion NN NN O
of NN NN O
dopamine NN NN O
in NN NN O
the NN NN O
striatum NN NN O
1 NN NN O
week NN NN O
later NN NN O
. NN NN O
   
This NN NN O
prolonged NN NN O
depletion NN NN O
of NN NN O
dopamine NN NN O
in NN NN O
the NN NN O
striatum NN NN O
was NN NN O
antagonized NN NN O
by NN NN O
dizocilpine NN NN O
( NN NN O
MK NN NN O
- NN NN O
801 NN NN O
, NN NN O
a NN NN O
non NN NN O
- NN NN O
competitive NN NN O
antagonist NN NN O
of NN NN O
NMDA NN NN O
receptors NN NN O
) NN NN O
or NN NN O
by NN NN O
LY274614 NN NN O
( NN NN O
a NN NN O
competitive NN NN O
antagonist NN NN O
of NN NN O
NMDA NN NN O
receptors NN NN O
) NN NN O
. NN NN O
   
The NN NN O
protective NN NN O
effect NN NN O
of NN NN O
LY274614 NN NN O
was NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
, NN NN O
being NN NN O
maximum NN NN O
at NN NN O
10 NN NN O
- NN NN O
40 NN NN O
mgkg NN NN O
( NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
. NN NN O
   
A NN NN O
10 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
dose NN NN O
of NN NN O
LY274614 NN NN O
was NN NN O
effective NN NN O
in NN NN O
antagonizing NN NN O
the NN NN O
depletion NN NN O
of NN NN O
dopamine NN NN O
in NN NN O
the NN NN O
striatum NN NN O
, NN NN O
when NN NN O
given NN NN O
as NN NN O
long NN NN O
as NN NN O
8 NN NN O
hr NN NN O
prior NN NN O
to NN NN O
amphetamine NN NN O
but NN NN O
not NN NN O
when NN NN O
given NN NN O
24 NN NN O
hr NN NN O
prior NN NN O
to NN NN O
amphetamine NN NN O
. NN NN O
   
Depletion NN NN O
of NN NN O
dopamine NN NN O
in NN NN O
the NN NN O
striatum NN NN O
was NN NN O
also NN NN O
antagonized NN NN O
when NN NN O
LY274614 NN NN O
was NN NN O
given NN NN O
after NN NN O
the NN NN O
injection NN NN O
of NN NN O
amphetamine NN NN O
; NN NN O
LY274614 NN NN O
protected NN NN O
when NN NN O
given NN NN O
up NN NN O
to NN NN O
4 NN NN O
hr NN NN O
after NN NN O
but NN NN O
not NN NN O
when NN NN O
given NN NN O
8 NN NN O
or NN NN O
24 NN NN O
hr NN NN O
after NN NN O
amphetamine NN NN O
. NN NN O
   
The NN NN O
prolonged NN NN O
depletion NN NN O
of NN NN O
dopamine NN NN O
in NN NN O
the NN NN O
striatum NN NN O
in NN NN O
mice NN NN O
, NN NN O
given NN NN O
multiple NN NN O
injections NN NN O
of NN NN O
methamphetamine NN NN O
, NN NN O
was NN NN O
also NN NN O
antagonized NN NN O
dose NN NN O
- NN NN O
dependently NN NN O
and NN NN O
completely NN NN O
by NN NN O
LY274614 NN NN O
. NN NN O
   
The NN NN O
data NN NN O
strengthen NN NN O
the NN NN O
evidence NN NN O
that NN NN O
the NN NN O
neurotoxic NN NN B-Disease
effect NN NN O
of NN NN O
amphetamine NN NN O
and NN NN O
related NN NN O
compounds NN NN O
toward NN NN O
nigrostriatal NN NN O
dopamine NN NN O
neurons NN NN O
involves NN NN O
NMDA NN NN O
receptors NN NN O
and NN NN O
that NN NN O
LY274614 NN NN O
is NN NN O
an NN NN O
NMDA NN NN O
receptor NN NN O
antagonist NN NN O
with NN NN O
long NN NN O
- NN NN O
lasting NN NN O
in NN NN O
vivo NN NN O
effects NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
Ketoconazole NN NN O
- NN NN O
induced NN NN O
neurologic NN NN B-Disease
sequelae NN NN I-Disease
. NN NN O
   
A NN NN O
77 NN NN O
- NN NN O
y NN NN O
- NN NN O
old NN NN O
patient NN NN O
developed NN NN O
weakness NN NN B-Disease
of NN NN I-Disease
extremities NN NN I-Disease
, NN NN O
legs NN NN B-Disease
paralysis NN NN I-Disease
, NN NN O
dysarthria NN NN B-Disease
and NN NN O
tremor NN NN B-Disease
1 NN NN O
h NN NN O
after NN NN O
ingestion NN NN O
of NN NN O
200 NN NN O
mg NN NN O
ketoconazole NN NN O
for NN NN O
the NN NN O
first NN NN O
time NN NN O
in NN NN O
his NN NN O
life NN NN O
. NN NN O
   
All NN NN O
complaints NN NN O
faded NN NN O
away NN NN O
within NN NN O
24 NN NN O
h NN NN O
. NN NN O
   
Few NN NN O
days NN NN O
later NN NN O
, NN NN O
the NN NN O
patient NN NN O
used NN NN O
another NN NN O
200 NN NN O
mg NN NN O
ketoconazole NN NN O
tablet NN NN O
, NN NN O
and NN NN O
within NN NN O
an NN NN O
hour NN NN O
experienced NN NN O
a NN NN O
similar NN NN O
clinical NN NN O
picture NN NN O
, NN NN O
which NN NN O
resolved NN NN O
again NN NN O
spontaneously NN NN O
within NN NN O
hours NN NN O
. NN NN O
   
Laboratory NN NN O
evaluations NN NN O
, NN NN O
including NN NN O
head NN NN O
CT NN NN O
scan NN NN O
, NN NN O
were NN NN O
normal NN NN O
. NN NN O
   
This NN NN O
case NN NN O
illustrates NN NN O
the NN NN O
need NN NN O
for NN NN O
close NN NN O
vigilance NN NN O
in NN NN O
adverse NN NN B-Disease
drug NN NN I-Disease
reactions NN NN I-Disease
, NN NN O
particularly NN NN O
in NN NN O
the NN NN O
elderly NN NN O
. NN NN O
   
Development NN NN O
of NN NN O
levodopa NN NN O
- NN NN O
induced NN NN O
dyskinesias NN NN B-Disease
in NN NN O
parkinsonian NN NN B-Disease
monkeys NN NN O
may NN NN O
depend NN NN O
upon NN NN O
rate NN NN O
of NN NN O
symptom NN NN O
onset NN NN O
and NN NN O
/ NN NN O
or NN NN O
duration NN NN O
of NN NN O
symptoms NN NN O
. NN NN O
   
Levodopa NN NN O
- NN NN O
induced NN NN O
dyskinesias NN NN B-Disease
( NN NN O
LIDs NN NN B-Disease
) NN NN O
present NN NN O
a NN NN O
major NN NN O
problem NN NN O
for NN NN O
the NN NN O
long NN NN O
- NN NN O
term NN NN O
management NN NN O
of NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
( NN NN O
PD NN NN B-Disease
) NN NN O
patients NN NN O
. NN NN O
   
Due NN NN O
to NN NN O
the NN NN O
interdependence NN NN O
of NN NN O
risk NN NN O
factors NN NN O
in NN NN O
clinical NN NN O
populations NN NN O
, NN NN O
it NN NN O
is NN NN O
difficult NN NN O
to NN NN O
independently NN NN O
examine NN NN O
factors NN NN O
that NN NN O
may NN NN O
influence NN NN O
the NN NN O
development NN NN O
of NN NN O
LIDs NN NN B-Disease
. NN NN O
   
Using NN NN O
macaque NN NN O
monkeys NN NN O
with NN NN O
different NN NN O
types NN NN O
of NN NN O
MPTP NN NN O
- NN NN O
induced NN NN O
parkinsonism NN NN B-Disease
, NN NN O
the NN NN O
current NN NN O
study NN NN O
evaluated NN NN O
the NN NN O
degree NN NN O
to NN NN O
which NN NN O
rate NN NN O
of NN NN O
symptom NN NN O
progression NN NN O
, NN NN O
symptom NN NN O
severity NN NN O
, NN NN O
and NN NN O
response NN NN O
to NN NN O
and NN NN O
duration NN NN O
of NN NN O
levodopa NN NN O
therapy NN NN O
may NN NN O
be NN NN O
involved NN NN O
in NN NN O
the NN NN O
development NN NN O
of NN NN O
LIDs NN NN B-Disease
. NN NN O
   
Monkeys NN NN O
with NN NN O
acute NN NN O
( NN NN O
short NN NN O
- NN NN O
term NN NN O
) NN NN O
MPTP NN NN O
exposure NN NN O
, NN NN O
rapid NN NN O
symptom NN NN O
onset NN NN O
and NN NN O
short NN NN O
symptom NN NN O
duration NN NN O
prior NN NN O
to NN NN O
initiation NN NN O
of NN NN O
levodopa NN NN O
therapy NN NN O
developed NN NN O
dyskinesia NN NN B-Disease
between NN NN O
11 NN NN O
and NN NN O
24 NN NN O
days NN NN O
of NN NN O
daily NN NN O
levodopa NN NN O
administration NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
monkeys NN NN O
with NN NN O
long NN NN O
- NN NN O
term NN NN O
MPTP NN NN O
exposure NN NN O
, NN NN O
slow NN NN O
symptom NN NN O
progression NN NN O
and NN NN O
/ NN NN O
or NN NN O
long NN NN O
symptom NN NN O
duration NN NN O
prior NN NN O
to NN NN O
initiation NN NN O
of NN NN O
levodopa NN NN O
therapy NN NN O
were NN NN O
more NN NN O
resistant NN NN O
to NN NN O
developing NN NN O
LIDs NN NN B-Disease
( NN NN O
e NN NN O
. NN NN O
g NN NN O
. NN NN O
, NN NN O
dyskinesia NN NN B-Disease
developed NN NN O
no NN NN O
sooner NN NN O
than NN NN O
146 NN NN O
days NN NN O
of NN NN O
chronic NN NN O
levodopa NN NN O
administration NN NN O
) NN NN O
. NN NN O
   
All NN NN O
animals NN NN O
were NN NN O
similarly NN NN O
symptomatic NN NN O
at NN NN O
the NN NN O
start NN NN O
of NN NN O
levodopa NN NN O
treatment NN NN O
and NN NN O
had NN NN O
similar NN NN O
therapeutic NN NN O
responses NN NN O
to NN NN O
the NN NN O
drug NN NN O
. NN NN O
   
These NN NN O
data NN NN O
suggest NN NN O
distinct NN NN O
differences NN NN O
in NN NN O
the NN NN O
propensity NN NN O
to NN NN O
develop NN NN O
LIDs NN NN B-Disease
in NN NN O
monkeys NN NN O
with NN NN O
different NN NN O
rates NN NN O
of NN NN O
symptom NN NN O
progression NN NN O
or NN NN O
symptom NN NN O
durations NN NN O
prior NN NN O
to NN NN O
levodopa NN NN O
and NN NN O
demonstrate NN NN O
the NN NN O
value NN NN O
of NN NN O
these NN NN O
models NN NN O
for NN NN O
further NN NN O
studying NN NN O
the NN NN O
pathophysiology NN NN O
of NN NN O
LIDs NN NN B-Disease
. NN NN O
   
A NN NN O
diet NN NN O
promoting NN NN O
sugar NN NN B-Disease
dependency NN NN I-Disease
causes NN NN O
behavioral NN NN B-Disease
cross NN NN I-Disease
- NN NN I-Disease
sensitization NN NN I-Disease
to NN NN O
a NN NN O
low NN NN O
dose NN NN O
of NN NN O
amphetamine NN NN O
. NN NN O
   
Previous NN NN O
research NN NN O
in NN NN O
this NN NN O
laboratory NN NN O
has NN NN O
shown NN NN O
that NN NN O
a NN NN O
diet NN NN O
of NN NN O
intermittent NN NN O
excessive NN NN O
sugar NN NN O
consumption NN NN O
produces NN NN O
a NN NN O
state NN NN O
with NN NN O
neurochemical NN NN O
and NN NN O
behavioral NN NN O
similarities NN NN O
to NN NN O
drug NN NN B-Disease
dependency NN NN I-Disease
. NN NN O
   
The NN NN O
present NN NN O
study NN NN O
examined NN NN O
whether NN NN O
female NN NN O
rats NN NN O
on NN NN O
various NN NN O
regimens NN NN O
of NN NN O
sugar NN NN O
access NN NN O
would NN NN O
show NN NN O
behavioral NN NN B-Disease
cross NN NN I-Disease
- NN NN I-Disease
sensitization NN NN I-Disease
to NN NN O
a NN NN O
low NN NN O
dose NN NN O
of NN NN O
amphetamine NN NN O
. NN NN O
   
After NN NN O
a NN NN O
30 NN NN O
- NN NN O
min NN NN O
baseline NN NN O
measure NN NN O
of NN NN O
locomotor NN NN O
activity NN NN O
( NN NN O
day NN NN O
0 NN NN O
) NN NN O
, NN NN O
animals NN NN O
were NN NN O
maintained NN NN O
on NN NN O
a NN NN O
cyclic NN NN O
diet NN NN O
of NN NN O
12 NN NN O
- NN NN O
h NN NN O
deprivation NN NN O
followed NN NN O
by NN NN O
12 NN NN O
- NN NN O
h NN NN O
access NN NN O
to NN NN O
10 NN NN O
% NN NN O
sucrose NN NN O
solution NN NN O
and NN NN O
chow NN NN O
pellets NN NN O
( NN NN O
12 NN NN O
h NN NN O
access NN NN O
starting NN NN O
4 NN NN O
h NN NN O
after NN NN O
onset NN NN O
of NN NN O
the NN NN O
dark NN NN O
period NN NN O
) NN NN O
for NN NN O
21 NN NN O
days NN NN O
. NN NN O
   
Locomotor NN NN O
activity NN NN O
was NN NN O
measured NN NN O
again NN NN O
for NN NN O
30 NN NN O
min NN NN O
at NN NN O
the NN NN O
beginning NN NN O
of NN NN O
days NN NN O
1 NN NN O
and NN NN O
21 NN NN O
of NN NN O
sugar NN NN O
access NN NN O
. NN NN O
   
Beginning NN NN O
on NN NN O
day NN NN O
22 NN NN O
, NN NN O
all NN NN O
rats NN NN O
were NN NN O
maintained NN NN O
on NN NN O
ad NN NN O
libitum NN NN O
chow NN NN O
. NN NN O
   
Nine NN NN O
days NN NN O
later NN NN O
locomotor NN NN O
activity NN NN O
was NN NN O
measured NN NN O
in NN NN O
response NN NN O
to NN NN O
a NN NN O
single NN NN O
low NN NN O
dose NN NN O
of NN NN O
amphetamine NN NN O
( NN NN O
0 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
. NN NN O
   
The NN NN O
animals NN NN O
that NN NN O
had NN NN O
experienced NN NN O
cyclic NN NN O
sucrose NN NN O
and NN NN O
chow NN NN O
were NN NN O
hyperactive NN NN B-Disease
in NN NN O
response NN NN O
to NN NN O
amphetamine NN NN O
compared NN NN O
with NN NN O
four NN NN O
control NN NN O
groups NN NN O
( NN NN O
ad NN NN O
libitum NN NN O
10 NN NN O
% NN NN O
sucrose NN NN O
and NN NN O
chow NN NN O
followed NN NN O
by NN NN O
amphetamine NN NN O
injection NN NN O
, NN NN O
cyclic NN NN O
chow NN NN O
followed NN NN O
by NN NN O
amphetamine NN NN O
injection NN NN O
, NN NN O
ad NN NN O
libitum NN NN O
chow NN NN O
with NN NN O
amphetamine NN NN O
, NN NN O
or NN NN O
cyclic NN NN O
10 NN NN O
% NN NN O
sucrose NN NN O
and NN NN O
chow NN NN O
with NN NN O
a NN NN O
saline NN NN O
injection NN NN O
) NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
a NN NN O
diet NN NN O
comprised NN NN O
of NN NN O
alternating NN NN O
deprivation NN NN O
and NN NN O
access NN NN O
to NN NN O
a NN NN O
sugar NN NN O
solution NN NN O
and NN NN O
chow NN NN O
produces NN NN O
bingeing NN NN O
on NN NN O
sugar NN NN O
that NN NN O
leads NN NN O
to NN NN O
a NN NN O
long NN NN O
lasting NN NN O
state NN NN O
of NN NN O
increased NN NN O
sensitivity NN NN O
to NN NN O
amphetamine NN NN O
, NN NN O
possibly NN NN O
due NN NN O
to NN NN O
a NN NN O
lasting NN NN O
alteration NN NN O
in NN NN O
the NN NN O
dopamine NN NN O
system NN NN O
. NN NN O
   
Reversible NN NN O
dilated NN NN B-Disease
cardiomyopathy NN NN I-Disease
related NN NN O
to NN NN O
amphotericin NN NN O
B NN NN O
therapy NN NN O
. NN NN O
   
We NN NN O
describe NN NN O
a NN NN O
patient NN NN O
who NN NN O
developed NN NN O
dilated NN NN B-Disease
cardiomyopathy NN NN I-Disease
and NN NN O
clinical NN NN O
congestive NN NN O
heart NN NN B-Disease
failure NN NN I-Disease
after NN NN O
2 NN NN O
months NN NN O
of NN NN O
therapy NN NN O
with NN NN O
amphotericin NN NN O
B NN NN O
( NN NN O
AmB NN NN O
) NN NN O
for NN NN O
disseminated NN NN O
coccidioidomycosis NN NN B-Disease
. NN NN O
   
His NN NN O
echocardiographic NN NN O
abnormalities NN NN O
and NN NN O
heart NN NN B-Disease
failure NN NN I-Disease
resolved NN NN O
after NN NN O
posaconazole NN NN O
was NN NN O
substituted NN NN O
for NN NN O
AmB NN NN O
. NN NN O
   
It NN NN O
is NN NN O
important NN NN O
to NN NN O
recognize NN NN O
the NN NN O
rare NN NN O
and NN NN O
potentially NN NN O
reversible NN NN O
toxicity NN NN B-Disease
of NN NN O
AmB NN NN O
. NN NN O
   
NO NN NN O
- NN NN O
induced NN NN O
migraine NN NN B-Disease
attack NN NN O
: NN NN O
strong NN NN O
increase NN NN O
in NN NN O
plasma NN NN O
calcitonin NN NN O
gene NN NN O
- NN NN O
related NN NN O
peptide NN NN O
( NN NN O
CGRP NN NN O
) NN NN O
concentration NN NN O
and NN NN O
negative NN NN O
correlation NN NN O
with NN NN O
platelet NN NN O
serotonin NN NN O
release NN NN O
. NN NN O
   
The NN NN O
aim NN NN O
of NN NN O
the NN NN O
present NN NN O
study NN NN O
was NN NN O
to NN NN O
investigate NN NN O
changes NN NN O
in NN NN O
the NN NN O
plasma NN NN O
calcitonin NN NN O
gene NN NN O
- NN NN O
related NN NN O
peptide NN NN O
( NN NN O
CGRP NN NN O
) NN NN O
concentration NN NN O
and NN NN O
platelet NN NN O
serotonin NN NN O
( NN NN O
5 NN NN O
- NN NN O
hydroxytriptamine NN NN O
, NN NN O
5 NN NN O
- NN NN O
HT NN NN O
) NN NN O
content NN NN O
during NN NN O
the NN NN O
immediate NN NN O
headache NN NN B-Disease
and NN NN O
the NN NN O
delayed NN NN O
genuine NN NN O
migraine NN NN B-Disease
attack NN NN O
provoked NN NN O
by NN NN O
nitroglycerin NN NN O
. NN NN O
   
Fifteen NN NN O
female NN NN O
migraineurs NN NN B-Disease
( NN NN I-Disease
without NN NN I-Disease
aura NN NN I-Disease
) NN NN I-Disease
and NN NN O
eight NN NN O
controls NN NN O
participated NN NN O
in NN NN O
the NN NN O
study NN NN O
. NN NN O
   
Sublingual NN NN O
nitroglycerin NN NN O
( NN NN O
0 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
) NN NN O
was NN NN O
administered NN NN O
. NN NN O
   
Blood NN NN O
was NN NN O
collected NN NN O
from NN NN O
the NN NN O
antecubital NN NN O
vein NN NN O
four NN NN O
times NN NN O
: NN NN O
60 NN NN O
min NN NN O
before NN NN O
and NN NN O
after NN NN O
the NN NN O
nitroglycerin NN NN O
application NN NN O
, NN NN O
and NN NN O
60 NN NN O
and NN NN O
120 NN NN O
min NN NN O
after NN NN O
the NN NN O
beginning NN NN O
of NN NN O
the NN NN O
migraine NN NN B-Disease
attack NN NN O
( NN NN O
mean NN NN O
344 NN NN O
and NN NN O
404 NN NN O
min NN NN O
; NN NN O
12 NN NN O
subjects NN NN O
) NN NN O
. NN NN O
   
In NN NN O
those NN NN O
subjects NN NN O
who NN NN O
had NN NN O
no NN NN O
migraine NN NN B-Disease
attack NN NN O
( NN NN O
11 NN NN O
subjects NN NN O
) NN NN O
a NN NN O
similar NN NN O
time NN NN O
schedule NN NN O
was NN NN O
used NN NN O
. NN NN O
   
Plasma NN NN O
CGRP NN NN O
concentration NN NN O
increased NN NN O
significantly NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
during NN NN O
the NN NN O
migraine NN NN B-Disease
attack NN NN O
and NN NN O
returned NN NN O
to NN NN O
baseline NN NN O
after NN NN O
the NN NN O
cessation NN NN O
of NN NN O
the NN NN O
migraine NN NN B-Disease
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
both NN NN O
change NN NN O
and NN NN O
peak NN NN O
, NN NN O
showed NN NN O
significant NN NN O
positive NN NN O
correlations NN NN O
with NN NN O
migraine NN NN B-Disease
headache NN NN B-Disease
intensity NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
. NN NN O
   
However NN NN O
, NN NN O
plasma NN NN O
CGRP NN NN O
concentrations NN NN O
failed NN NN O
to NN NN O
change NN NN O
during NN NN O
immediate NN NN O
headache NN NN B-Disease
and NN NN O
in NN NN O
the NN NN O
subjects NN NN O
with NN NN O
no NN NN O
migraine NN NN B-Disease
attack NN NN O
. NN NN O
   
Basal NN NN O
CGRP NN NN O
concentration NN NN O
was NN NN O
significantly NN NN O
higher NN NN O
and NN NN O
platelet NN NN O
5 NN NN O
- NN NN O
HT NN NN O
content NN NN O
tended NN NN O
to NN NN O
be NN NN O
lower NN NN O
in NN NN O
subjects NN NN O
who NN NN O
experienced NN NN O
a NN NN O
migraine NN NN B-Disease
attack NN NN O
. NN NN O
   
Platelet NN NN O
serotonin NN NN O
content NN NN O
decreased NN NN O
significantly NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
after NN NN O
nitroglycerin NN NN O
in NN NN O
subjects NN NN O
with NN NN O
no NN NN O
migraine NN NN B-Disease
attack NN NN O
but NN NN O
no NN NN O
consistent NN NN O
change NN NN O
was NN NN O
observed NN NN O
in NN NN O
patients NN NN O
with NN NN O
migraine NN NN B-Disease
attack NN NN O
. NN NN O
   
In NN NN O
conclusion NN NN O
, NN NN O
the NN NN O
fact NN NN O
that NN NN O
plasma NN NN O
CGRP NN NN O
concentration NN NN O
correlates NN NN O
with NN NN O
the NN NN O
timing NN NN O
and NN NN O
severity NN NN O
of NN NN O
a NN NN O
migraine NN NN B-Disease
headache NN NN B-Disease
suggests NN NN O
a NN NN O
direct NN NN O
relationship NN NN O
between NN NN O
CGRP NN NN O
and NN NN O
migraine NN NN B-Disease
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
serotonin NN NN O
release NN NN O
from NN NN O
platelets NN NN O
does NN NN O
not NN NN O
provoke NN NN O
migraine NN NN B-Disease
, NN NN O
it NN NN O
may NN NN O
even NN NN O
counteract NN NN O
the NN NN O
headache NN NN B-Disease
and NN NN O
the NN NN O
concomitant NN NN O
CGRP NN NN O
release NN NN O
in NN NN O
this NN NN O
model NN NN O
. NN NN O
   
Hyperbaric NN NN O
oxygen NN NN O
therapy NN NN O
for NN NN O
control NN NN O
of NN NN O
intractable NN NN O
cyclophosphamide NN NN O
- NN NN O
induced NN NN O
hemorrhagic NN NN B-Disease
cystitis NN NN I-Disease
. NN NN O
   
We NN NN O
report NN NN O
a NN NN O
case NN NN O
of NN NN O
intractable NN NN O
hemorrhagic NN NN B-Disease
cystitis NN NN I-Disease
due NN NN O
to NN NN O
cyclophosphamide NN NN O
therapy NN NN O
for NN NN O
Wegener NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
granulomatosis NN NN I-Disease
. NN NN O
   
Conservative NN NN O
treatment NN NN O
, NN NN O
including NN NN O
bladder NN NN O
irrigation NN NN O
with NN NN O
physiological NN NN O
saline NN NN O
and NN NN O
instillation NN NN O
of NN NN O
prostaglandin NN NN O
F2 NN NN O
alpha NN NN O
, NN NN O
failed NN NN O
to NN NN O
totally NN NN O
control NN NN O
hemorrhage NN NN B-Disease
. NN NN O
   
We NN NN O
then NN NN O
used NN NN O
hyperbaric NN NN O
oxygen NN NN O
at NN NN O
an NN NN O
absolute NN NN O
pressure NN NN O
of NN NN O
2 NN NN O
atm NN NN O
, NN NN O
5 NN NN O
days NN NN O
a NN NN O
week NN NN O
for NN NN O
8 NN NN O
consecutive NN NN O
weeks NN NN O
. NN NN O
   
The NN NN O
bleeding NN NN B-Disease
ceased NN NN O
completely NN NN O
by NN NN O
the NN NN O
end NN NN O
of NN NN O
treatment NN NN O
and NN NN O
the NN NN O
patient NN NN O
remained NN NN O
free NN NN O
of NN NN O
hematuria NN NN B-Disease
thereafter NN NN O
. NN NN O
   
No NN NN O
side NN NN O
effect NN NN O
was NN NN O
noted NN NN O
during NN NN O
the NN NN O
course NN NN O
of NN NN O
therapy NN NN O
. NN NN O
   
In NN NN O
future NN NN O
, NN NN O
this NN NN O
form NN NN O
of NN NN O
therapy NN NN O
can NN NN O
offer NN NN O
a NN NN O
safe NN NN O
alternative NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
cyclophosphamide NN NN O
- NN NN O
induced NN NN O
hemorrhagic NN NN B-Disease
cystitis NN NN I-Disease
. NN NN O
   
Acute NN NN B-Disease
psychosis NN NN I-Disease
due NN NN O
to NN NN O
treatment NN NN O
with NN NN O
phenytoin NN NN O
in NN NN O
a NN NN O
nonepileptic NN NN O
patient NN NN O
. NN NN O
   
The NN NN O
development NN NN O
of NN NN O
psychosis NN NN B-Disease
related NN NN O
to NN NN O
antiepileptic NN NN O
drug NN NN O
treatment NN NN O
is NN NN O
usually NN NN O
attributed NN NN O
to NN NN O
the NN NN O
interaction NN NN O
between NN NN O
the NN NN O
epileptic NN NN B-Disease
brain NN NN O
substratum NN NN O
and NN NN O
the NN NN O
antiepileptic NN NN O
drugs NN NN O
. NN NN O
   
The NN NN O
case NN NN O
of NN NN O
a NN NN O
nonepileptic NN NN O
patient NN NN O
who NN NN O
developed NN NN O
psychosis NN NN B-Disease
following NN NN O
phenytoin NN NN O
treatment NN NN O
for NN NN O
trigeminal NN NN B-Disease
neuralgia NN NN I-Disease
is NN NN O
described NN NN O
. NN NN O
   
This NN NN O
case NN NN O
suggests NN NN O
that NN NN O
the NN NN O
psychotic NN NN B-Disease
symptoms NN NN I-Disease
that NN NN O
occur NN NN O
following NN NN O
phenytoin NN NN O
treatment NN NN O
in NN NN O
some NN NN O
epileptic NN NN B-Disease
patients NN NN O
may NN NN O
be NN NN O
the NN NN O
direct NN NN O
result NN NN O
of NN NN O
medication NN NN O
, NN NN O
unrelated NN NN O
to NN NN O
seizures NN NN B-Disease
. NN NN O
   
Risks NN NN O
of NN NN O
the NN NN O
consumption NN NN O
of NN NN O
beverages NN NN O
containing NN NN O
quinine NN NN O
. NN NN O
   
Although NN NN O
the NN NN O
United NN NN O
States NN NN O
Food NN NN O
and NN NN O
Drug NN NN O
Administration NN NN O
banned NN NN O
its NN NN O
use NN NN O
for NN NN O
nocturnal NN NN B-Disease
leg NN NN I-Disease
cramps NN NN I-Disease
due NN NN O
to NN NN O
lack NN NN O
of NN NN O
safety NN NN O
and NN NN O
efficacy NN NN O
, NN NN O
quinine NN NN O
is NN NN O
widely NN NN O
available NN NN O
in NN NN O
beverages NN NN O
including NN NN O
tonic NN NN O
water NN NN O
and NN NN O
bitter NN NN O
lemon NN NN O
. NN NN O
   
Numerous NN NN O
anecdotal NN NN O
reports NN NN O
suggest NN NN O
that NN NN O
products NN NN O
containing NN NN O
quinine NN NN O
may NN NN O
produce NN NN O
neurological NN NN B-Disease
complications NN NN I-Disease
, NN NN O
including NN NN O
confusion NN NN B-Disease
, NN NN O
altered NN NN O
mental NN NN O
status NN NN O
, NN NN O
seizures NN NN B-Disease
, NN NN O
and NN NN O
coma NN NN B-Disease
, NN NN O
particularly NN NN O
in NN NN O
older NN NN O
women NN NN O
. NN NN O
   
Psychologists NN NN O
need NN NN O
to NN NN O
inquire NN NN O
about NN NN O
consumption NN NN O
of NN NN O
quinine NN NN O
- NN NN O
containing NN NN O
beverages NN NN O
as NN NN O
part NN NN O
of NN NN O
an NN NN O
evaluation NN NN O
process NN NN O
. NN NN O
   
Transient NN NN O
platypnea NN NN B-Disease
- NN NN I-Disease
orthodeoxia NN NN I-Disease
- NN NN I-Disease
like NN NN I-Disease
syndrome NN NN I-Disease
induced NN NN O
by NN NN O
propafenone NN NN O
overdose NN NN B-Disease
in NN NN O
a NN NN O
young NN NN O
woman NN NN O
with NN NN O
Ebstein NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
anomaly NN NN I-Disease
. NN NN O
   
In NN NN O
this NN NN O
report NN NN O
we NN NN O
describe NN NN O
the NN NN O
case NN NN O
of NN NN O
a NN NN O
37 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
white NN NN O
woman NN NN O
with NN NN O
Ebstein NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
anomaly NN NN I-Disease
, NN NN O
who NN NN O
developed NN NN O
a NN NN O
rare NN NN O
syndrome NN NN O
called NN NN O
platypnea NN NN B-Disease
- NN NN I-Disease
orthodeoxia NN NN I-Disease
, NN NN O
characterized NN NN O
by NN NN O
massive NN NN O
right NN NN O
- NN NN O
to NN NN O
- NN NN O
left NN NN O
interatrial NN NN O
shunting NN NN O
with NN NN O
transient NN NN O
profound NN NN O
hypoxia NN NN B-Disease
and NN NN O
cyanosis NN NN B-Disease
. NN NN O
   
This NN NN O
shunt NN NN O
of NN NN O
blood NN NN O
via NN NN O
a NN NN O
patent NN NN B-Disease
foramen NN NN I-Disease
ovale NN NN I-Disease
occurred NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
a NN NN O
normal NN NN O
pulmonary NN NN O
artery NN NN O
pressure NN NN O
, NN NN O
and NN NN O
was NN NN O
probably NN NN O
precipitated NN NN O
by NN NN O
a NN NN O
propafenone NN NN O
overdose NN NN B-Disease
. NN NN O
   
This NN NN O
drug NN NN O
caused NN NN O
biventricular NN NN B-Disease
dysfunction NN NN I-Disease
, NN NN O
due NN NN O
to NN NN O
its NN NN O
negative NN NN O
inotropic NN NN O
effect NN NN O
, NN NN O
and NN NN O
hypotension NN NN B-Disease
, NN NN O
due NN NN O
to NN NN O
its NN NN O
peripheral NN NN O
vasodilatory NN NN O
effect NN NN O
. NN NN O
   
These NN NN O
effects NN NN O
gave NN NN O
rise NN NN O
to NN NN O
an NN NN O
increase NN NN O
in NN NN O
the NN NN O
right NN NN O
atrial NN NN O
pressure NN NN O
and NN NN O
a NN NN O
decrease NN NN O
in NN NN O
the NN NN O
left NN NN O
one NN NN O
with NN NN O
a NN NN O
consequent NN NN O
stretching NN NN O
of NN NN O
the NN NN O
foramen NN NN O
ovale NN NN O
and NN NN O
the NN NN O
creation NN NN O
of NN NN O
massive NN NN O
right NN NN O
- NN NN O
to NN NN O
- NN NN O
left NN NN O
shunting NN NN O
. NN NN O
   
In NN NN O
our NN NN O
case NN NN O
this NN NN O
interatrial NN NN O
shunt NN NN O
was NN NN O
very NN NN O
accurately NN NN O
detected NN NN O
at NN NN O
bubble NN NN O
contrast NN NN O
echocardiography NN NN O
. NN NN O
   
Noxious NN NN O
chemical NN NN O
stimulation NN NN O
of NN NN O
rat NN NN O
facial NN NN O
mucosa NN NN O
increases NN NN O
intracranial NN NN O
blood NN NN O
flow NN NN O
through NN NN O
a NN NN O
trigemino NN NN O
- NN NN O
parasympathetic NN NN O
reflex NN NN O
- NN NN O
- NN NN O
an NN NN O
experimental NN NN O
model NN NN O
for NN NN O
vascular NN NN B-Disease
dysfunctions NN NN I-Disease
in NN NN O
cluster NN NN B-Disease
headache NN NN I-Disease
. NN NN O
   
Cluster NN NN B-Disease
headache NN NN I-Disease
is NN NN O
characterized NN NN O
by NN NN O
typical NN NN O
autonomic NN NN O
dysfunctions NN NN O
including NN NN O
facial NN NN O
and NN NN O
intracranial NN NN B-Disease
vascular NN NN I-Disease
disturbances NN NN I-Disease
. NN NN O
   
Both NN NN O
the NN NN O
trigeminal NN NN O
and NN NN O
the NN NN O
cranial NN NN O
parasympathetic NN NN O
systems NN NN O
may NN NN O
be NN NN O
involved NN NN O
in NN NN O
mediating NN NN O
these NN NN O
dysfunctions NN NN O
. NN NN O
   
An NN NN O
experimental NN NN O
model NN NN O
was NN NN O
developed NN NN O
in NN NN O
the NN NN O
rat NN NN O
to NN NN O
measure NN NN O
changes NN NN O
in NN NN O
lacrimation NN NN O
and NN NN O
intracranial NN NN O
blood NN NN O
flow NN NN O
following NN NN O
noxious NN NN O
chemical NN NN O
stimulation NN NN O
of NN NN O
facial NN NN O
mucosa NN NN O
. NN NN O
   
Blood NN NN O
flow NN NN O
was NN NN O
monitored NN NN O
in NN NN O
arteries NN NN O
of NN NN O
the NN NN O
exposed NN NN O
cranial NN NN O
dura NN NN O
mater NN NN O
and NN NN O
the NN NN O
parietal NN NN O
cortex NN NN O
using NN NN O
laser NN NN O
Doppler NN NN O
flowmetry NN NN O
. NN NN O
   
Capsaicin NN NN O
( NN NN O
0 NN NN O
. NN NN O
01 NN NN O
- NN NN O
1 NN NN O
mm NN NN O
) NN NN O
applied NN NN O
to NN NN O
oral NN NN O
or NN NN O
nasal NN NN O
mucosa NN NN O
induced NN NN O
increases NN NN B-Disease
in NN NN I-Disease
dural NN NN I-Disease
and NN NN I-Disease
cortical NN NN I-Disease
blood NN NN I-Disease
flow NN NN I-Disease
and NN NN O
provoked NN NN O
lacrimation NN NN O
. NN NN O
   
These NN NN O
responses NN NN O
were NN NN O
blocked NN NN O
by NN NN O
systemic NN NN O
pre NN NN O
- NN NN O
administration NN NN O
of NN NN O
hexamethonium NN NN O
chloride NN NN O
( NN NN O
20 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
. NN NN O
   
The NN NN O
evoked NN NN O
increases NN NN B-Disease
in NN NN I-Disease
dural NN NN I-Disease
blood NN NN I-Disease
flow NN NN I-Disease
were NN NN O
also NN NN O
abolished NN NN O
by NN NN O
topical NN NN O
pre NN NN O
- NN NN O
administration NN NN O
of NN NN O
atropine NN NN O
( NN NN O
1 NN NN O
mm NN NN O
) NN NN O
and NN NN O
[ NN NN O
Lys1 NN NN O
, NN NN O
Pro2 NN NN O
, NN NN O
5 NN NN O
, NN NN O
Arg3 NN NN O
, NN NN O
4 NN NN O
, NN NN O
Tyr6 NN NN O
] NN NN O
- NN NN O
VIP NN NN O
( NN NN O
0 NN NN O
. NN NN O
1 NN NN O
mm NN NN O
) NN NN O
, NN NN O
a NN NN O
vasoactive NN NN O
intestinal NN NN O
polypeptide NN NN O
( NN NN O
VIP NN NN O
) NN NN O
antagonist NN NN O
, NN NN O
onto NN NN O
the NN NN O
exposed NN NN O
dura NN NN O
mater NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
noxious NN NN O
stimulation NN NN O
of NN NN O
facial NN NN O
mucosa NN NN O
increases NN NN O
intracranial NN NN O
blood NN NN O
flow NN NN O
and NN NN O
lacrimation NN NN O
via NN NN O
a NN NN O
trigemino NN NN O
- NN NN O
parasympathetic NN NN O
reflex NN NN O
. NN NN O
   
The NN NN O
blood NN NN O
flow NN NN O
responses NN NN O
seem NN NN O
to NN NN O
be NN NN O
mediated NN NN O
by NN NN O
the NN NN O
release NN NN O
of NN NN O
acetylcholine NN NN O
and NN NN O
VIP NN NN O
within NN NN O
the NN NN O
meninges NN NN O
. NN NN O
   
Similar NN NN O
mechanisms NN NN O
may NN NN O
be NN NN O
involved NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
cluster NN NN B-Disease
headache NN NN I-Disease
. NN NN O
   
Organophosphate NN NN O
- NN NN O
induced NN NN O
convulsions NN NN B-Disease
and NN NN O
prevention NN NN O
of NN NN O
neuropathological NN NN B-Disease
damages NN NN I-Disease
. NN NN O
   
Such NN NN O
organophosphorus NN NN O
( NN NN O
OP NN NN O
) NN NN O
compounds NN NN O
as NN NN O
diisopropylfluorophosphate NN NN O
( NN NN O
DFP NN NN O
) NN NN O
, NN NN O
sarin NN NN O
and NN NN O
soman NN NN O
are NN NN O
potent NN NN O
inhibitors NN NN O
of NN NN O
acetylcholinesterases NN NN O
( NN NN O
AChEs NN NN O
) NN NN O
and NN NN O
butyrylcholinesterases NN NN O
( NN NN O
BChEs NN NN O
) NN NN O
. NN NN O
   
The NN NN O
acute NN NN O
toxicity NN NN B-Disease
of NN NN O
OPs NN NN O
is NN NN O
the NN NN O
result NN NN O
of NN NN O
their NN NN O
irreversible NN NN O
binding NN NN O
with NN NN O
AChEs NN NN O
in NN NN O
the NN NN O
central NN NN O
nervous NN NN O
system NN NN O
( NN NN O
CNS NN NN O
) NN NN O
, NN NN O
which NN NN O
elevates NN NN O
acetylcholine NN NN O
( NN NN O
ACh NN NN O
) NN NN O
levels NN NN O
. NN NN O
   
The NN NN O
protective NN NN O
action NN NN O
of NN NN O
subcutaneously NN NN O
( NN NN O
SC NN NN O
) NN NN O
administered NN NN O
antidotes NN NN O
or NN NN O
their NN NN O
combinations NN NN O
in NN NN O
DFP NN NN O
( NN NN O
2 NN NN O
. NN NN O
0 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
BW NN NN O
) NN NN O
intoxication NN NN O
was NN NN O
studied NN NN O
in NN NN O
9 NN NN O
- NN NN O
10 NN NN O
- NN NN O
weeks NN NN O
- NN NN O
old NN NN O
Han NN NN O
- NN NN O
Wistar NN NN O
male NN NN O
rats NN NN O
. NN NN O
   
The NN NN O
rats NN NN O
received NN NN O
AChE NN NN O
reactivator NN NN O
pralidoxime NN NN O
- NN NN O
2 NN NN O
- NN NN O
chloride NN NN O
( NN NN O
2PAM NN NN O
) NN NN O
( NN NN O
30 NN NN O
. NN NN O
0 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
BW NN NN O
) NN NN O
, NN NN O
anticonvulsant NN NN O
diazepam NN NN O
( NN NN O
2 NN NN O
. NN NN O
0 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
BW NN NN O
) NN NN O
, NN NN O
A NN NN O
( NN NN O
1 NN NN O
) NN NN O
- NN NN O
adenosine NN NN O
receptor NN NN O
agonist NN NN O
N NN NN O
( NN NN O
6 NN NN O
) NN NN O
- NN NN O
cyclopentyl NN NN O
adenosine NN NN O
( NN NN O
CPA NN NN O
) NN NN O
( NN NN O
2 NN NN O
. NN NN O
0 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
BW NN NN O
) NN NN O
, NN NN O
NMDA NN NN O
- NN NN O
receptor NN NN O
antagonist NN NN O
dizocilpine NN NN O
maleate NN NN O
( NN NN O
+ NN NN O
- NN NN O
MK801 NN NN O
hydrogen NN NN O
maleate NN NN O
) NN NN O
( NN NN O
2 NN NN O
. NN NN O
0 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
BW NN NN O
) NN NN O
or NN NN O
their NN NN O
combinations NN NN O
with NN NN O
cholinolytic NN NN O
drug NN NN O
atropine NN NN O
sulfate NN NN O
( NN NN O
50 NN NN O
. NN NN O
0 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
BW NN NN O
) NN NN O
immediately NN NN O
or NN NN O
30 NN NN O
min NN NN O
after NN NN O
the NN NN O
single NN NN O
SC NN NN O
injection NN NN O
of NN NN O
DFP NN NN O
. NN NN O
   
The NN NN O
control NN NN O
rats NN NN O
received NN NN O
atropine NN NN O
sulfate NN NN O
, NN NN O
but NN NN O
also NN NN O
saline NN NN O
and NN NN O
olive NN NN O
oil NN NN O
instead NN NN O
of NN NN O
other NN NN O
antidotes NN NN O
and NN NN O
DFP NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
All NN NN O
rats NN NN O
were NN NN O
terminated NN NN O
either NN NN O
24 NN NN O
h NN NN O
or NN NN O
3 NN NN O
weeks NN NN O
after NN NN O
the NN NN O
DFP NN NN O
injection NN NN O
. NN NN O
   
The NN NN O
rats NN NN O
treated NN NN O
with NN NN O
DFP NN NN O
- NN NN O
atropine NN NN O
showed NN NN O
severe NN NN O
typical NN NN O
OP NN NN O
- NN NN O
induced NN NN O
toxicity NN NN B-Disease
signs NN NN O
. NN NN O
   
When NN NN O
CPA NN NN O
, NN NN O
diazepam NN NN O
or NN NN O
2PAM NN NN O
was NN NN O
given NN NN O
immediately NN NN O
after NN NN O
DFP NN NN O
- NN NN O
atropine NN NN O
, NN NN O
these NN NN O
treatments NN NN O
prevented NN NN O
, NN NN O
delayed NN NN O
or NN NN O
shortened NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
serious NN NN O
signs NN NN O
of NN NN O
poisoning NN NN B-Disease
. NN NN O
   
Atropine NN NN O
- NN NN O
MK801 NN NN O
did NN NN O
not NN NN O
offer NN NN O
any NN NN O
additional NN NN O
protection NN NN O
against NN NN O
DFP NN NN O
toxicity NN NN B-Disease
. NN NN O
   
In NN NN O
conclusion NN NN O
, NN NN O
CPA NN NN O
, NN NN O
diazepam NN NN O
and NN NN O
2PAM NN NN O
in NN NN O
combination NN NN O
with NN NN O
atropine NN NN O
prevented NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
serious NN NN O
signs NN NN O
of NN NN O
poisoning NN NN B-Disease
and NN NN O
thus NN NN O
reduced NN NN O
the NN NN O
toxicity NN NN B-Disease
of NN NN O
DFP NN NN O
in NN NN O
rat NN NN O
. NN NN O
   
A NN NN O
pyridoxine NN NN O
- NN NN O
dependent NN NN O
behavioral NN NN B-Disease
disorder NN NN I-Disease
unmasked NN NN O
by NN NN O
isoniazid NN NN O
. NN NN O
   
A NN NN O
3 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
girl NN NN O
had NN NN O
behavioral NN NN B-Disease
deterioration NN NN I-Disease
, NN NN O
with NN NN O
hyperkinesis NN NN B-Disease
, NN NN O
irritability NN NN B-Disease
, NN NN O
and NN NN O
sleeping NN NN B-Disease
difficulties NN NN I-Disease
after NN NN O
the NN NN O
therapeutic NN NN O
administration NN NN O
of NN NN O
isoniazid NN NN O
. NN NN O
   
The NN NN O
administration NN NN O
of NN NN O
pharmacologic NN NN O
doses NN NN O
of NN NN O
pyridoxine NN NN O
hydrochloride NN NN O
led NN NN O
to NN NN O
a NN NN O
disappearance NN NN O
of NN NN O
symptoms NN NN O
. NN NN O
   
After NN NN O
discontinuing NN NN O
isoniazid NN NN O
therapy NN NN O
a NN NN O
similar NN NN O
pattern NN NN O
of NN NN O
behavior NN NN O
was NN NN O
noted NN NN O
that NN NN O
was NN NN O
controlled NN NN O
by NN NN O
pyridoxine NN NN O
. NN NN O
   
A NN NN O
placebo NN NN O
had NN NN O
no NN NN O
effect NN NN O
, NN NN O
but NN NN O
niacinamide NN NN O
was NN NN O
as NN NN O
effective NN NN O
as NN NN O
pyridoxine NN NN O
. NN NN O
   
Periodic NN NN O
withdrawal NN NN O
of NN NN O
pyridoxine NN NN O
was NN NN O
associated NN NN O
with NN NN O
return NN NN O
of NN NN O
the NN NN O
hyperkinesis NN NN B-Disease
. NN NN O
   
The NN NN O
level NN NN O
of NN NN O
pyridoxal NN NN O
in NN NN O
the NN NN O
blood NN NN O
was NN NN O
normal NN NN O
during NN NN O
the NN NN O
periods NN NN O
of NN NN O
relapse NN NN O
. NN NN O
   
Metabolic NN NN O
studies NN NN O
suggested NN NN O
a NN NN O
block NN NN O
in NN NN O
the NN NN O
kynurenine NN NN O
pathway NN NN O
of NN NN O
tryptophan NN NN O
metabolism NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
has NN NN O
been NN NN O
followed NN NN O
for NN NN O
six NN NN O
years NN NN O
and NN NN O
has NN NN O
required NN NN O
pharmacologic NN NN O
doses NN NN O
of NN NN O
pyridoxine NN NN O
to NN NN O
control NN NN O
her NN NN O
behavior NN NN O
. NN NN O
   
Recurrent NN NN O
excitation NN NN O
in NN NN O
the NN NN O
dentate NN NN O
gyrus NN NN O
of NN NN O
a NN NN O
murine NN NN O
model NN NN O
of NN NN O
temporal NN NN B-Disease
lobe NN NN I-Disease
epilepsy NN NN I-Disease
. NN NN O
   
Similar NN NN O
to NN NN O
rats NN NN O
, NN NN O
systemic NN NN O
pilocarpine NN NN O
injection NN NN O
causes NN NN O
status NN NN B-Disease
epilepticus NN NN I-Disease
( NN NN O
SE NN NN B-Disease
) NN NN O
and NN NN O
the NN NN O
eventual NN NN O
development NN NN O
of NN NN O
spontaneous NN NN O
seizures NN NN B-Disease
and NN NN O
mossy NN NN O
fiber NN NN O
sprouting NN NN O
in NN NN O
C57BL NN NN O
/ NN NN O
6 NN NN O
and NN NN O
CD1 NN NN O
mice NN NN O
, NN NN O
but NN NN O
the NN NN O
physiological NN NN O
correlates NN NN O
of NN NN O
these NN NN O
events NN NN O
have NN NN O
not NN NN O
been NN NN O
identified NN NN O
in NN NN O
mice NN NN O
. NN NN O
   
Population NN NN O
responses NN NN O
in NN NN O
granule NN NN O
cells NN NN O
of NN NN O
the NN NN O
dentate NN NN O
gyrus NN NN O
were NN NN O
examined NN NN O
in NN NN O
transverse NN NN O
slices NN NN O
of NN NN O
the NN NN O
ventral NN NN O
hippocampus NN NN O
from NN NN O
pilocarpine NN NN O
- NN NN O
treated NN NN O
and NN NN O
untreated NN NN O
mice NN NN O
. NN NN O
   
In NN NN O
Mg NN NN O
( NN NN O
2 NN NN O
+ NN NN O
) NN NN O
- NN NN O
free NN NN O
bathing NN NN O
medium NN NN O
containing NN NN O
bicuculline NN NN O
, NN NN O
conditions NN NN O
designed NN NN O
to NN NN O
increase NN NN O
excitability NN NN O
in NN NN O
the NN NN O
slices NN NN O
, NN NN O
electrical NN NN O
stimulation NN NN O
of NN NN O
the NN NN O
hilus NN NN O
resulted NN NN O
in NN NN O
a NN NN O
single NN NN O
population NN NN O
spike NN NN O
in NN NN O
granule NN NN O
cells NN NN O
from NN NN O
control NN NN O
mice NN NN O
and NN NN O
pilocarpine NN NN O
- NN NN O
treated NN NN O
mice NN NN O
that NN NN O
did NN NN O
not NN NN O
experience NN NN O
SE NN NN B-Disease
. NN NN O
   
In NN NN O
SE NN NN B-Disease
survivors NN NN O
, NN NN O
similar NN NN O
stimulation NN NN O
resulted NN NN O
in NN NN O
a NN NN O
population NN NN O
spike NN NN O
followed NN NN O
, NN NN O
at NN NN O
a NN NN O
variable NN NN O
latency NN NN O
, NN NN O
by NN NN O
negative NN NN O
DC NN NN O
shifts NN NN O
and NN NN O
repetitive NN NN O
afterdischarges NN NN O
of NN NN O
3 NN NN O
- NN NN O
60 NN NN O
s NN NN O
duration NN NN O
, NN NN O
which NN NN O
were NN NN O
blocked NN NN O
by NN NN O
ionotropic NN NN O
glutamate NN NN O
receptor NN NN O
antagonists NN NN O
. NN NN O
   
Focal NN NN O
glutamate NN NN O
photostimulation NN NN O
of NN NN O
the NN NN O
granule NN NN O
cell NN NN O
layer NN NN O
at NN NN O
sites NN NN O
distant NN NN O
from NN NN O
the NN NN O
recording NN NN O
pipette NN NN O
resulted NN NN O
in NN NN O
population NN NN O
responses NN NN O
of NN NN O
1 NN NN O
- NN NN O
30 NN NN O
s NN NN O
duration NN NN O
in NN NN O
slices NN NN O
from NN NN O
SE NN NN B-Disease
survivors NN NN O
but NN NN O
not NN NN O
other NN NN O
groups NN NN O
. NN NN O
   
These NN NN O
data NN NN O
support NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
SE NN NN B-Disease
- NN NN O
induced NN NN O
mossy NN NN O
fiber NN NN O
sprouting NN NN O
and NN NN O
synaptic NN NN O
reorganization NN NN O
are NN NN O
relevant NN NN O
characteristics NN NN O
of NN NN O
seizure NN NN B-Disease
development NN NN O
in NN NN O
these NN NN O
murine NN NN O
strains NN NN O
, NN NN O
resembling NN NN O
rat NN NN O
models NN NN O
of NN NN O
human NN NN O
temporal NN NN B-Disease
lobe NN NN I-Disease
epilepsy NN NN I-Disease
. NN NN O
   
Urinary NN NN B-Disease
bladder NN NN I-Disease
cancer NN NN I-Disease
in NN NN O
Wegener NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
granulomatosis NN NN I-Disease
: NN NN O
risks NN NN O
and NN NN O
relation NN NN O
to NN NN O
cyclophosphamide NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
To NN NN O
assess NN NN O
and NN NN O
characterise NN NN O
the NN NN O
risk NN NN O
of NN NN O
bladder NN NN B-Disease
cancer NN NN I-Disease
, NN NN O
and NN NN O
its NN NN O
relation NN NN O
to NN NN O
cyclophosphamide NN NN O
, NN NN O
in NN NN O
patients NN NN O
with NN NN O
Wegener NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
granulomatosis NN NN I-Disease
. NN NN O
   
METHODS NN NN O
: NN NN O
In NN NN O
the NN NN O
population NN NN O
based NN NN O
, NN NN O
nationwide NN NN O
Swedish NN NN O
Inpatient NN NN O
Register NN NN O
a NN NN O
cohort NN NN O
of NN NN O
1065 NN NN O
patients NN NN O
with NN NN O
Wegener NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
granulomatosis NN NN I-Disease
, NN NN O
1969 NN NN O
- NN NN O
95 NN NN O
, NN NN O
was NN NN O
identified NN NN O
. NN NN O
   
Through NN NN O
linkage NN NN O
with NN NN O
the NN NN O
Swedish NN NN O
Cancer NN NN B-Disease
Register NN NN O
, NN NN O
all NN NN O
subjects NN NN O
in NN NN O
this NN NN O
cohort NN NN O
diagnosed NN NN O
with NN NN O
bladder NN NN B-Disease
cancer NN NN I-Disease
were NN NN O
identified NN NN O
. NN NN O
   
Nested NN NN O
within NN NN O
the NN NN O
cohort NN NN O
, NN NN O
a NN NN O
matched NN NN O
case NN NN O
- NN NN O
control NN NN O
study NN NN O
was NN NN O
performed NN NN O
to NN NN O
estimate NN NN O
the NN NN O
association NN NN O
between NN NN O
cyclophosphamide NN NN O
and NN NN O
bladder NN NN B-Disease
cancer NN NN I-Disease
using NN NN O
odds NN NN O
ratios NN NN O
( NN NN O
ORs NN NN O
) NN NN O
as NN NN O
relative NN NN O
risk NN NN O
. NN NN O
   
In NN NN O
the NN NN O
cohort NN NN O
the NN NN O
cumulative NN NN O
risk NN NN O
of NN NN O
bladder NN NN B-Disease
cancer NN NN I-Disease
after NN NN O
Wegener NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
granulomatosis NN NN I-Disease
, NN NN O
and NN NN O
the NN NN O
relative NN NN O
prevalence NN NN O
of NN NN O
a NN NN O
history NN NN O
of NN NN O
bladder NN NN B-Disease
cancer NN NN I-Disease
at NN NN O
the NN NN O
time NN NN O
of NN NN O
diagnosis NN NN O
of NN NN O
Wegener NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
granulomatosis NN NN I-Disease
, NN NN O
were NN NN O
also NN NN O
estimated NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
The NN NN O
median NN NN O
cumulative NN NN O
doses NN NN O
of NN NN O
cyclophosphamide NN NN O
among NN NN O
cases NN NN O
( NN NN O
n NN NN O
= NN NN O
11 NN NN O
) NN NN O
and NN NN O
controls NN NN O
( NN NN O
n NN NN O
= NN NN O
25 NN NN O
) NN NN O
were NN NN O
113 NN NN O
g NN NN O
and NN NN O
25 NN NN O
g NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
The NN NN O
risk NN NN O
of NN NN O
bladder NN NN B-Disease
cancer NN NN I-Disease
doubled NN NN O
for NN NN O
every NN NN O
10 NN NN O
g NN NN O
increment NN NN O
in NN NN O
cyclophosphamide NN NN O
( NN NN O
OR NN NN O
= NN NN O
2 NN NN O
. NN NN O
0 NN NN O
, NN NN O
95 NN NN O
% NN NN O
confidence NN NN O
interval NN NN O
( NN NN O
CI NN NN O
) NN NN O
0 NN NN O
. NN NN O
8 NN NN O
to NN NN O
4 NN NN O
. NN NN O
9 NN NN O
) NN NN O
. NN NN O
   
Treatment NN NN O
duration NN NN O
longer NN NN O
than NN NN O
1 NN NN O
year NN NN O
was NN NN O
associated NN NN O
with NN NN O
an NN NN O
eightfold NN NN O
increased NN NN O
risk NN NN O
( NN NN O
OR NN NN O
= NN NN O
7 NN NN O
. NN NN O
7 NN NN O
, NN NN O
95 NN NN O
% NN NN O
CI NN NN O
0 NN NN O
. NN NN O
9 NN NN O
to NN NN O
69 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
absolute NN NN O
risk NN NN O
for NN NN O
bladder NN NN B-Disease
cancer NN NN I-Disease
in NN NN O
the NN NN O
cohort NN NN O
reached NN NN O
10 NN NN O
% NN NN O
16 NN NN O
years NN NN O
after NN NN O
diagnosis NN NN O
of NN NN O
Wegener NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
granulomatosis NN NN I-Disease
, NN NN O
and NN NN O
a NN NN O
history NN NN O
of NN NN O
bladder NN NN B-Disease
cancer NN NN I-Disease
was NN NN O
( NN NN O
non NN NN O
- NN NN O
significantly NN NN O
) NN NN O
twice NN NN O
as NN NN O
common NN NN O
as NN NN O
expected NN NN O
at NN NN O
the NN NN O
time NN NN O
of NN NN O
diagnosis NN NN O
of NN NN O
Wegener NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
granulomatosis NN NN I-Disease
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
The NN NN O
results NN NN O
indicate NN NN O
a NN NN O
dose NN NN O
- NN NN O
response NN NN O
relationship NN NN O
between NN NN O
cyclophosphamide NN NN O
and NN NN O
the NN NN O
risk NN NN O
of NN NN O
bladder NN NN B-Disease
cancer NN NN I-Disease
, NN NN O
high NN NN O
cumulative NN NN O
risks NN NN O
in NN NN O
the NN NN O
entire NN NN O
cohort NN NN O
, NN NN O
and NN NN O
also NN NN O
the NN NN O
possibility NN NN O
of NN NN O
risk NN NN O
factors NN NN O
operating NN NN O
even NN NN O
before NN NN O
Wegener NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
granulomatosis NN NN I-Disease
. NN NN O
   
Differential NN NN O
modulation NN NN O
by NN NN O
estrogen NN NN O
of NN NN O
alpha2 NN NN O
- NN NN O
adrenergic NN NN O
and NN NN O
I1 NN NN O
- NN NN O
imidazoline NN NN O
receptor NN NN O
- NN NN O
mediated NN NN O
hypotension NN NN B-Disease
in NN NN O
female NN NN O
rats NN NN O
. NN NN O
   
We NN NN O
have NN NN O
recently NN NN O
shown NN NN O
that NN NN O
estrogen NN NN O
negatively NN NN O
modulates NN NN O
the NN NN O
hypotensive NN NN B-Disease
effect NN NN O
of NN NN O
clonidine NN NN O
( NN NN O
mixed NN NN O
alpha2 NN NN O
- NN NN O
/ NN NN O
I1 NN NN O
- NN NN O
receptor NN NN O
agonist NN NN O
) NN NN O
in NN NN O
female NN NN O
rats NN NN O
and NN NN O
implicates NN NN O
the NN NN O
cardiovascular NN NN O
autonomic NN NN O
control NN NN O
in NN NN O
this NN NN O
interaction NN NN O
. NN NN O
   
The NN NN O
present NN NN O
study NN NN O
investigated NN NN O
whether NN NN O
this NN NN O
effect NN NN O
of NN NN O
estrogen NN NN O
involves NN NN O
interaction NN NN O
with NN NN O
alpha2 NN NN O
- NN NN O
and NN NN O
/ NN NN O
or NN NN O
I1 NN NN O
- NN NN O
receptors NN NN O
. NN NN O
   
Changes NN NN O
evoked NN NN O
by NN NN O
a NN NN O
single NN NN O
intraperitoneal NN NN O
injection NN NN O
of NN NN O
rilmenidine NN NN O
( NN NN O
600 NN NN O
microg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
or NN NN O
alpha NN NN O
- NN NN O
methyldopa NN NN O
( NN NN O
100 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
, NN NN O
selective NN NN O
I1 NN NN O
- NN NN O
and NN NN O
alpha2 NN NN O
- NN NN O
receptor NN NN O
agonists NN NN O
, NN NN O
respectively NN NN O
, NN NN O
in NN NN O
blood NN NN O
pressure NN NN O
, NN NN O
hemodynamic NN NN O
variability NN NN O
, NN NN O
and NN NN O
locomotor NN NN O
activity NN NN O
were NN NN O
assessed NN NN O
in NN NN O
radiotelemetered NN NN O
sham NN NN O
- NN NN O
operated NN NN O
and NN NN O
ovariectomized NN NN O
( NN NN O
Ovx NN NN O
) NN NN O
Sprague NN NN O
- NN NN O
Dawley NN NN O
female NN NN O
rats NN NN O
with NN NN O
or NN NN O
without NN NN O
12 NN NN O
- NN NN O
wk NN NN O
estrogen NN NN O
replacement NN NN O
. NN NN O
   
Three NN NN O
time NN NN O
domain NN NN O
indexes NN NN O
of NN NN O
hemodynamic NN NN O
variability NN NN O
were NN NN O
employed NN NN O
: NN NN O
the NN NN O
standard NN NN O
deviation NN NN O
of NN NN O
mean NN NN O
arterial NN NN O
pressure NN NN O
as NN NN O
a NN NN O
measure NN NN O
of NN NN O
blood NN NN O
pressure NN NN O
variability NN NN O
and NN NN O
the NN NN O
standard NN NN O
deviation NN NN O
of NN NN O
beat NN NN O
- NN NN O
to NN NN O
- NN NN O
beat NN NN O
intervals NN NN O
( NN NN O
SDRR NN NN O
) NN NN O
and NN NN O
the NN NN O
root NN NN O
mean NN NN O
square NN NN O
of NN NN O
successive NN NN O
differences NN NN O
in NN NN O
R NN NN O
- NN NN O
wave NN NN O
- NN NN O
to NN NN O
- NN NN O
R NN NN O
- NN NN O
wave NN NN O
intervals NN NN O
as NN NN O
measures NN NN O
of NN NN O
heart NN NN O
rate NN NN O
variability NN NN O
. NN NN O
   
In NN NN O
sham NN NN O
- NN NN O
operated NN NN O
rats NN NN O
, NN NN O
rilmenidine NN NN O
or NN NN O
alpha NN NN O
- NN NN O
methyldopa NN NN O
elicited NN NN O
similar NN NN O
hypotension NN NN B-Disease
that NN NN O
lasted NN NN O
at NN NN O
least NN NN O
5 NN NN O
h NN NN O
and NN NN O
was NN NN O
associated NN NN O
with NN NN O
reductions NN NN O
in NN NN O
standard NN NN O
deviation NN NN O
of NN NN O
mean NN NN O
arterial NN NN O
pressure NN NN O
. NN NN O
   
SDRR NN NN O
was NN NN O
reduced NN NN O
only NN NN O
by NN NN O
alpha NN NN O
- NN NN O
methyldopa NN NN O
. NN NN O
   
Ovx NN NN O
significantly NN NN O
enhanced NN NN O
the NN NN O
hypotensive NN NN B-Disease
response NN NN O
to NN NN O
alpha NN NN O
- NN NN O
methyldopa NN NN O
, NN NN O
in NN NN O
contrast NN NN O
to NN NN O
no NN NN O
effect NN NN O
on NN NN O
rilmenidine NN NN O
hypotension NN NN B-Disease
. NN NN O
   
The NN NN O
enhanced NN NN O
alpha NN NN O
- NN NN O
methyldopa NN NN O
hypotension NN NN B-Disease
in NN NN O
Ovx NN NN O
rats NN NN O
was NN NN O
paralleled NN NN O
with NN NN O
further NN NN O
reduction NN NN O
in NN NN O
SDRR NN NN O
and NN NN O
a NN NN B-Disease
reduced NN NN I-Disease
locomotor NN NN I-Disease
activity NN NN I-Disease
. NN NN O
   
Estrogen NN NN O
replacement NN NN O
( NN NN O
17beta NN NN O
- NN NN O
estradiol NN NN O
subcutaneous NN NN O
pellet NN NN O
, NN NN O
14 NN NN O
. NN NN O
2 NN NN O
microg NN NN O
/ NN NN O
day NN NN O
, NN NN O
12 NN NN O
wk NN NN O
) NN NN O
of NN NN O
Ovx NN NN O
rats NN NN O
restored NN NN O
the NN NN O
hemodynamic NN NN O
and NN NN O
locomotor NN NN O
effects NN NN O
of NN NN O
alpha NN NN O
- NN NN O
methyldopa NN NN O
to NN NN O
sham NN NN O
- NN NN O
operated NN NN O
levels NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
estrogen NN NN O
downregulates NN NN O
alpha2 NN NN O
- NN NN O
but NN NN O
not NN NN O
I1 NN NN O
- NN NN O
receptor NN NN O
- NN NN O
mediated NN NN O
hypotension NN NN B-Disease
and NN NN O
highlight NN NN O
a NN NN O
role NN NN O
for NN NN O
the NN NN O
cardiac NN NN O
autonomic NN NN O
control NN NN O
in NN NN O
alpha NN NN O
- NN NN O
methyldopa NN NN O
- NN NN O
estrogen NN NN O
interaction NN NN O
. NN NN O
   
Severe NN NN O
reversible NN NN O
left NN NN B-Disease
ventricular NN NN I-Disease
systolic NN NN I-Disease
and NN NN I-Disease
diastolic NN NN I-Disease
dysfunction NN NN I-Disease
due NN NN O
to NN NN O
accidental NN NN O
iatrogenic NN NN O
epinephrine NN NN O
overdose NN NN B-Disease
. NN NN O
   
Catecholamine NN NN O
- NN NN O
induced NN NN O
cardiomyopathy NN NN B-Disease
due NN NN O
to NN NN O
chronic NN NN O
excess NN NN O
of NN NN O
endogenous NN NN O
catecholamines NN NN O
has NN NN O
been NN NN O
recognized NN NN O
for NN NN O
decades NN NN O
as NN NN O
a NN NN O
clinical NN NN O
phenomenon NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
reports NN NN O
of NN NN O
myocardial NN NN B-Disease
dysfunction NN NN I-Disease
due NN NN O
to NN NN O
acute NN NN O
iatrogenic NN NN O
overdose NN NN B-Disease
are NN NN O
rare NN NN O
. NN NN O
   
A NN NN O
35 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
woman NN NN O
whose NN NN O
cervix NN NN O
uteri NN NN O
was NN NN O
inadvertently NN NN O
injected NN NN O
with NN NN O
8 NN NN O
mg NN NN O
of NN NN O
epinephrine NN NN O
developed NN NN O
myocardial NN NN B-Disease
stunning NN NN I-Disease
that NN NN O
was NN NN O
characterized NN NN O
by NN NN O
severe NN NN O
hemodynamic NN NN O
compromise NN NN O
, NN NN O
profound NN NN O
, NN NN O
albeit NN NN O
transient NN NN O
, NN NN O
left NN NN B-Disease
ventricular NN NN I-Disease
systolic NN NN I-Disease
and NN NN I-Disease
diastolic NN NN I-Disease
dysfunction NN NN I-Disease
, NN NN O
and NN NN O
only NN NN O
modestly NN NN O
elevated NN NN O
biochemical NN NN O
markers NN NN O
of NN NN O
myocardial NN NN B-Disease
necrosis NN NN I-Disease
. NN NN O
   
Our NN NN O
case NN NN O
illustrates NN NN O
the NN NN O
serious NN NN O
consequences NN NN O
of NN NN O
medical NN NN O
errors NN NN O
that NN NN O
can NN NN O
be NN NN O
avoided NN NN O
through NN NN O
improved NN NN O
medication NN NN O
labeling NN NN O
and NN NN O
staff NN NN O
supervision NN NN O
. NN NN O
   
Cardioprotective NN NN O
effect NN NN O
of NN NN O
tincture NN NN O
of NN NN O
Crataegus NN NN O
on NN NN O
isoproterenol NN NN O
- NN NN O
induced NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
in NN NN O
rats NN NN O
. NN NN O
   
Tincture NN NN O
of NN NN O
Crataegus NN NN O
( NN NN O
TCR NN NN O
) NN NN O
, NN NN O
an NN NN O
alcoholic NN NN O
extract NN NN O
of NN NN O
the NN NN O
berries NN NN O
of NN NN O
hawthorn NN NN O
( NN NN O
Crataegus NN NN O
oxycantha NN NN O
) NN NN O
, NN NN O
is NN NN O
used NN NN O
in NN NN O
herbal NN NN O
and NN NN O
homeopathic NN NN O
medicine NN NN O
. NN NN O
   
The NN NN O
present NN NN O
study NN NN O
was NN NN O
done NN NN O
to NN NN O
investigate NN NN O
the NN NN O
protective NN NN O
effect NN NN O
of NN NN O
TCR NN NN O
on NN NN O
experimentally NN NN O
induced NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
in NN NN O
rats NN NN O
. NN NN O
   
Pretreatment NN NN O
of NN NN O
TCR NN NN O
, NN NN O
at NN NN O
a NN NN O
dose NN NN O
of NN NN O
0 NN NN O
. NN NN O
5 NN NN O
mL NN NN O
/ NN NN O
100 NN NN O
g NN NN O
bodyweight NN NN O
per NN NN O
day NN NN O
, NN NN O
orally NN NN O
for NN NN O
30 NN NN O
days NN NN O
, NN NN O
prevented NN NN O
the NN NN O
increase NN NN O
in NN NN O
lipid NN NN O
peroxidation NN NN O
and NN NN O
activity NN NN O
of NN NN O
marker NN NN O
enzymes NN NN O
observed NN NN O
in NN NN O
isoproterenol NN NN O
- NN NN O
induced NN NN O
rats NN NN O
( NN NN O
85 NN NN O
mg NN NN O
kg NN NN O
( NN NN O
- NN NN O
1 NN NN O
) NN NN O
s NN NN O
. NN NN O
c NN NN O
. NN NN O
for NN NN O
2 NN NN O
days NN NN O
at NN NN O
an NN NN O
interval NN NN O
of NN NN O
24 NN NN O
h NN NN O
) NN NN O
. NN NN O
   
TCR NN NN O
prevented NN NN O
the NN NN O
isoproterenol NN NN O
- NN NN O
induced NN NN O
decrease NN NN O
in NN NN O
antioxidant NN NN O
enzymes NN NN O
in NN NN O
the NN NN O
heart NN NN O
and NN NN O
increased NN NN O
the NN NN O
rate NN NN O
of NN NN O
ADP NN NN O
- NN NN O
stimulated NN NN O
oxygen NN NN O
uptake NN NN O
and NN NN O
respiratory NN NN O
coupling NN NN O
ratio NN NN O
. NN NN O
   
TCR NN NN O
protected NN NN O
against NN NN O
pathological NN NN O
changes NN NN O
induced NN NN O
by NN NN O
isoproterenol NN NN O
in NN NN O
rat NN NN O
heart NN NN O
. NN NN O
   
The NN NN O
results NN NN O
show NN NN O
that NN NN O
pretreatment NN NN O
with NN NN O
TCR NN NN O
may NN NN O
be NN NN O
useful NN NN O
in NN NN O
preventing NN NN O
the NN NN O
damage NN NN O
induced NN NN O
by NN NN O
isoproterenol NN NN O
in NN NN O
rat NN NN O
heart NN NN O
. NN NN O
   
Treatment NN NN O
of NN NN O
tinnitus NN NN B-Disease
by NN NN O
intratympanic NN NN O
instillation NN NN O
of NN NN O
lignocaine NN NN O
( NN NN O
lidocaine NN NN O
) NN NN O
2 NN NN O
per NN NN O
cent NN NN O
through NN NN O
ventilation NN NN O
tubes NN NN O
. NN NN O
   
Idiopathic NN NN B-Disease
subjective NN NN I-Disease
tinnitus NN NN I-Disease
( NN NN O
IST NN NN B-Disease
) NN NN O
is NN NN O
one NN NN O
of NN NN O
the NN NN O
most NN NN O
obscure NN NN O
otological NN NN O
pathologies NN NN O
. NN NN O
   
This NN NN O
paper NN NN O
presents NN NN O
the NN NN O
results NN NN O
of NN NN O
treating NN NN O
IST NN NN B-Disease
by NN NN O
intratympanic NN NN O
instillation NN NN O
of NN NN O
lignocaine NN NN O
( NN NN O
lidocaine NN NN O
) NN NN O
2 NN NN O
per NN NN O
cent NN NN O
through NN NN O
a NN NN O
grommet NN NN O
, NN NN O
for NN NN O
five NN NN O
weekly NN NN O
courses NN NN O
. NN NN O
   
Fifty NN NN O
- NN NN O
two NN NN O
patients NN NN O
suffering NN NN O
from NN NN O
intractable NN NN O
tinnitus NN NN B-Disease
entered NN NN O
this NN NN O
therapeutic NN NN O
trial NN NN O
, NN NN O
but NN NN O
only NN NN O
nine NN NN O
finished NN NN O
all NN NN O
five NN NN O
courses NN NN O
. NN NN O
   
In NN NN O
one NN NN O
patient NN NN O
, NN NN O
the NN NN O
tinnitus NN NN B-Disease
was NN NN O
almost NN NN O
completely NN NN O
abolished NN NN O
, NN NN O
but NN NN O
in NN NN O
all NN NN O
the NN NN O
nine NN NN O
patients NN NN O
the NN NN O
decompensated NN NN O
tinnitus NN NN B-Disease
changed NN NN O
to NN NN O
a NN NN O
compensated NN NN O
one NN NN O
. NN NN O
   
We NN NN O
suggest NN NN O
this NN NN O
mode NN NN O
of NN NN O
treatment NN NN O
for NN NN O
patients NN NN O
that NN NN O
were NN NN O
previously NN NN O
treated NN NN O
by NN NN O
drugs NN NN O
, NN NN O
acupuncture NN NN O
and NN NN O
biofeedback NN NN O
, NN NN O
with NN NN O
disappointing NN NN O
results NN NN O
. NN NN O
   
Patients NN NN O
should NN NN O
be NN NN O
warned NN NN O
about NN NN O
the NN NN O
side NN NN O
effects NN NN O
of NN NN O
vertigo NN NN B-Disease
and NN NN O
vomiting NN NN B-Disease
, NN NN O
which NN NN O
subsides NN NN O
gradually NN NN O
with NN NN O
every NN NN O
new NN NN O
instillation NN NN O
, NN NN O
and NN NN O
that NN NN O
the NN NN O
tinnitus NN NN B-Disease
may NN NN O
not NN NN O
disappear NN NN O
but NN NN O
will NN NN O
be NN NN O
alleviated NN NN O
, NN NN O
enabling NN NN O
them NN NN O
to NN NN O
cope NN NN O
more NN NN O
easily NN NN O
with NN NN O
the NN NN O
disease NN NN O
and NN NN O
lead NN NN O
a NN NN O
more NN NN O
normal NN NN O
life NN NN O
. NN NN O
   
The NN NN O
alpha3 NN NN O
and NN NN O
beta4 NN NN O
nicotinic NN NN O
acetylcholine NN NN O
receptor NN NN O
subunits NN NN O
are NN NN O
necessary NN NN O
for NN NN O
nicotine NN NN O
- NN NN O
induced NN NN O
seizures NN NN B-Disease
and NN NN O
hypolocomotion NN NN B-Disease
in NN NN O
mice NN NN O
. NN NN O
   
Binding NN NN O
of NN NN O
nicotine NN NN O
to NN NN O
nicotinic NN NN O
acetylcholine NN NN O
receptors NN NN O
( NN NN O
nAChRs NN NN O
) NN NN O
elicits NN NN O
a NN NN O
series NN NN O
of NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
behaviors NN NN O
that NN NN O
go NN NN O
from NN NN O
altered NN NN O
exploration NN NN O
, NN NN O
sedation NN NN O
, NN NN O
and NN NN O
tremors NN NN B-Disease
, NN NN O
to NN NN O
seizures NN NN B-Disease
and NN NN O
death NN NN B-Disease
. NN NN O
   
nAChRs NN NN O
are NN NN O
pentameric NN NN O
ion NN NN O
channels NN NN O
usually NN NN O
composed NN NN O
of NN NN O
alpha NN NN O
and NN NN O
beta NN NN O
subunits NN NN O
. NN NN O
   
A NN NN O
gene NN NN O
cluster NN NN O
comprises NN NN O
the NN NN O
alpha3 NN NN O
, NN NN O
alpha5 NN NN O
and NN NN O
beta4 NN NN O
subunits NN NN O
, NN NN O
which NN NN O
coassemble NN NN O
to NN NN O
form NN NN O
functional NN NN O
receptors NN NN O
. NN NN O
   
We NN NN O
examined NN NN O
the NN NN O
role NN NN O
of NN NN O
the NN NN O
beta4 NN NN O
subunits NN NN O
in NN NN O
nicotine NN NN O
- NN NN O
induced NN NN O
seizures NN NN B-Disease
and NN NN O
hypolocomotion NN NN B-Disease
in NN NN O
beta4 NN NN O
homozygous NN NN O
null NN NN O
( NN NN O
beta4 NN NN O
- NN NN O
/ NN NN O
- NN NN O
) NN NN O
and NN NN O
alpha3 NN NN O
heterozygous NN NN O
( NN NN O
+ NN NN O
/ NN NN O
- NN NN O
) NN NN O
mice NN NN O
. NN NN O
   
beta4 NN NN O
- NN NN O
/ NN NN O
- NN NN O
mice NN NN O
were NN NN O
less NN NN O
sensitive NN NN O
to NN NN O
the NN NN O
effects NN NN O
of NN NN O
nicotine NN NN O
both NN NN O
at NN NN O
low NN NN O
doses NN NN O
, NN NN O
measured NN NN O
as NN NN O
decreased NN NN O
exploration NN NN O
in NN NN O
an NN NN O
open NN NN O
field NN NN O
, NN NN O
and NN NN O
at NN NN O
high NN NN O
doses NN NN O
, NN NN O
measured NN NN O
as NN NN O
sensitivity NN NN O
to NN NN O
nicotine NN NN O
- NN NN O
induced NN NN O
seizures NN NN B-Disease
. NN NN O
   
Using NN NN O
in NN NN O
situ NN NN O
hybridization NN NN O
probes NN NN O
for NN NN O
the NN NN O
alpha3 NN NN O
and NN NN O
alpha5 NN NN O
subunits NN NN O
, NN NN O
we NN NN O
showed NN NN O
that NN NN O
alpha5 NN NN O
mRNA NN NN O
levels NN NN O
are NN NN O
unchanged NN NN O
, NN NN O
whereas NN NN O
alpha3 NN NN O
mRNA NN NN O
levels NN NN O
are NN NN O
selectively NN NN O
decreased NN NN O
in NN NN O
the NN NN O
mitral NN NN O
cell NN NN O
layer NN NN O
of NN NN O
the NN NN O
olfactory NN NN O
bulb NN NN O
, NN NN O
and NN NN O
the NN NN O
inferior NN NN O
and NN NN O
the NN NN O
superior NN NN O
colliculus NN NN O
of NN NN O
beta4 NN NN O
- NN NN O
/ NN NN O
- NN NN O
brains NN NN O
. NN NN O
   
alpha3 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
mice NN NN O
were NN NN O
partially NN NN O
resistant NN NN O
to NN NN O
nicotine NN NN O
- NN NN O
induced NN NN O
seizures NN NN B-Disease
when NN NN O
compared NN NN O
to NN NN O
wild NN NN O
- NN NN O
type NN NN O
littermates NN NN O
. NN NN O
   
mRNA NN NN O
levels NN NN O
for NN NN O
the NN NN O
alpha5 NN NN O
and NN NN O
the NN NN O
beta4 NN NN O
subunits NN NN O
were NN NN O
unchanged NN NN O
in NN NN O
alpha3 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
brains NN NN O
. NN NN O
   
Together NN NN O
, NN NN O
these NN NN O
results NN NN O
suggest NN NN O
that NN NN O
the NN NN O
beta4 NN NN O
and NN NN O
the NN NN O
alpha3 NN NN O
subunits NN NN O
are NN NN O
mediators NN NN O
of NN NN O
nicotine NN NN O
- NN NN O
induced NN NN O
seizures NN NN B-Disease
and NN NN O
hypolocomotion NN NN B-Disease
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
sevoflurane NN NN O
on NN NN O
lidocaine NN NN O
- NN NN O
induced NN NN O
convulsions NN NN B-Disease
. NN NN O
   
The NN NN O
influence NN NN O
of NN NN O
sevoflurane NN NN O
on NN NN O
lidocaine NN NN O
- NN NN O
induced NN NN O
convulsions NN NN B-Disease
was NN NN O
studied NN NN O
in NN NN O
cats NN NN O
. NN NN O
   
The NN NN O
convulsive NN NN B-Disease
threshold NN NN O
( NN NN O
mean NN NN O
+ NN NN O
/ NN NN O
- NN NN O
SD NN NN O
) NN NN O
was NN NN O
41 NN NN O
. NN NN O
4 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
6 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
. NN NN O
   
l NN NN O
( NN NN O
- NN NN O
1 NN NN O
) NN NN O
with NN NN O
lidocaine NN NN O
infusion NN NN O
( NN NN O
6 NN NN O
mg NN NN O
. NN NN O
kg NN NN O
( NN NN O
- NN NN O
1 NN NN O
) NN NN O
. NN NN O
min NN NN O
( NN NN O
- NN NN O
1 NN NN O
) NN NN O
) NN NN O
, NN NN O
increasing NN NN O
significantly NN NN O
to NN NN O
66 NN NN O
. NN NN O
6 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
10 NN NN O
. NN NN O
9 NN NN O
mg NN NN O
. NN NN O
   
l NN NN O
( NN NN O
- NN NN O
1 NN NN O
) NN NN O
when NN NN O
the NN NN O
end NN NN O
- NN NN O
tidal NN NN O
concentration NN NN O
of NN NN O
sevoflurane NN NN O
was NN NN O
0 NN NN O
. NN NN O
8 NN NN O
% NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
threshold NN NN O
( NN NN O
61 NN NN O
. NN NN O
6 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
8 NN NN O
. NN NN O
7 NN NN O
mg NN NN O
. NN NN O
l NN NN O
( NN NN O
- NN NN O
1 NN NN O
) NN NN O
) NN NN O
during NN NN O
1 NN NN O
. NN NN O
6 NN NN O
% NN NN O
sevoflurane NN NN O
was NN NN O
not NN NN O
significant NN NN O
from NN NN O
that NN NN O
during NN NN O
0 NN NN O
. NN NN O
8 NN NN O
% NN NN O
sevoflurane NN NN O
, NN NN O
indicating NN NN O
a NN NN O
celling NN NN O
effect NN NN O
. NN NN O
   
There NN NN O
was NN NN O
no NN NN O
significant NN NN O
difference NN NN O
in NN NN O
the NN NN O
convulsive NN NN B-Disease
threshold NN NN O
between NN NN O
sevoflurane NN NN O
and NN NN O
enflurane NN NN O
. NN NN O
   
The NN NN O
rise NN NN O
in NN NN O
blood NN NN O
pressure NN NN O
became NN NN O
less NN NN O
marked NN NN O
when NN NN O
higher NN NN O
concentrations NN NN O
of NN NN O
sevoflurane NN NN O
or NN NN O
enflurane NN NN O
were NN NN O
administered NN NN O
and NN NN O
the NN NN O
blood NN NN O
pressure NN NN O
at NN NN O
convulsions NN NN B-Disease
decreased NN NN O
significantly NN NN O
in NN NN O
1 NN NN O
. NN NN O
6 NN NN O
% NN NN O
sevoflurane NN NN O
, NN NN O
and NN NN O
in NN NN O
0 NN NN O
. NN NN O
8 NN NN O
% NN NN O
and NN NN O
1 NN NN O
. NN NN O
6 NN NN O
% NN NN O
enflurane NN NN O
. NN NN O
   
However NN NN O
, NN NN O
there NN NN O
was NN NN O
no NN NN O
significant NN NN O
difference NN NN O
in NN NN O
the NN NN O
lidocaine NN NN O
concentrations NN NN O
measured NN NN O
when NN NN O
the NN NN O
systolic NN NN O
blood NN NN O
pressure NN NN O
became NN NN O
70 NN NN O
mmHg NN NN O
. NN NN O
   
Apamin NN NN O
, NN NN O
a NN NN O
selective NN NN O
blocker NN NN O
of NN NN O
calcium NN NN O
- NN NN O
dependent NN NN O
potassium NN NN O
channels NN NN O
, NN NN O
was NN NN O
administered NN NN O
intracerebroventricularly NN NN O
in NN NN O
rats NN NN O
anesthetized NN NN O
with NN NN O
0 NN NN O
. NN NN O
8 NN NN O
% NN NN O
sevoflurane NN NN O
to NN NN O
investigate NN NN O
the NN NN O
mechanism NN NN O
of NN NN O
the NN NN O
anticonvulsive NN NN O
effects NN NN O
. NN NN O
   
Apamin NN NN O
( NN NN O
10 NN NN O
ng NN NN O
) NN NN O
had NN NN O
a NN NN O
tendency NN NN O
to NN NN O
decrease NN NN O
the NN NN O
convulsive NN NN B-Disease
threshold NN NN O
( NN NN O
21 NN NN O
. NN NN O
6 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
. NN NN O
2 NN NN O
to NN NN O
19 NN NN O
. NN NN O
9 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
. NN NN O
l NN NN O
( NN NN O
- NN NN O
1 NN NN O
) NN NN O
) NN NN O
but NN NN O
this NN NN O
was NN NN O
not NN NN O
statistically NN NN O
significant NN NN O
. NN NN O
   
It NN NN O
is NN NN O
suggested NN NN O
that NN NN O
sevoflurane NN NN O
reduces NN NN O
the NN NN O
convulsive NN NN B-Disease
effect NN NN O
of NN NN O
lidocaine NN NN O
toxicity NN NN B-Disease
but NN NN O
carries NN NN O
some NN NN O
risk NN NN O
due NN NN O
to NN NN O
circulatory NN NN O
depression NN NN B-Disease
. NN NN O
   
Cardiac NN NN B-Disease
toxicity NN NN I-Disease
observed NN NN O
in NN NN O
association NN NN O
with NN NN O
high NN NN O
- NN NN O
dose NN NN O
cyclophosphamide NN NN O
- NN NN O
based NN NN O
chemotherapy NN NN O
for NN NN O
metastatic NN NN O
breast NN NN B-Disease
cancer NN NN I-Disease
. NN NN O
   
INTRODUCTION NN NN O
: NN NN O
Cyclophosphamide NN NN O
is NN NN O
an NN NN O
alkylating NN NN O
agent NN NN O
given NN NN O
frequently NN NN O
as NN NN O
a NN NN O
component NN NN O
of NN NN O
many NN NN O
conditioning NN NN O
regimens NN NN O
. NN NN O
   
In NN NN O
high NN NN O
doses NN NN O
, NN NN O
its NN NN O
nonhematological NN NN O
dose NN NN O
- NN NN O
limiting NN NN O
toxicity NN NN B-Disease
is NN NN O
cardiomyopathy NN NN B-Disease
. NN NN O
   
STUDY NN NN O
DESIGN NN NN O
: NN NN O
We NN NN O
combined NN NN O
paclitaxel NN NN O
, NN NN O
melphalan NN NN O
and NN NN O
high NN NN O
- NN NN O
dose NN NN O
cyclophosphamide NN NN O
, NN NN O
thiotepa NN NN O
, NN NN O
and NN NN O
carboplatin NN NN O
in NN NN O
a NN NN O
triple NN NN O
sequential NN NN O
high NN NN O
- NN NN O
dose NN NN O
regimen NN NN O
for NN NN O
patients NN NN O
with NN NN O
metastatic NN NN O
breast NN NN B-Disease
cancer NN NN I-Disease
. NN NN O
   
Analysis NN NN O
was NN NN O
performed NN NN O
on NN NN O
61 NN NN O
women NN NN O
with NN NN O
chemotherapy NN NN O
- NN NN O
responsive NN NN O
metastatic NN NN O
breast NN NN B-Disease
cancer NN NN I-Disease
receiving NN NN O
96 NN NN O
- NN NN O
h NN NN O
infusional NN NN O
cyclophosphamide NN NN O
as NN NN O
part NN NN O
of NN NN O
a NN NN O
triple NN NN O
sequential NN NN O
high NN NN O
- NN NN O
dose NN NN O
regimen NN NN O
to NN NN O
assess NN NN O
association NN NN O
between NN NN O
presence NN NN O
of NN NN O
peritransplant NN NN O
congestive NN NN B-Disease
heart NN NN I-Disease
failure NN NN I-Disease
( NN NN O
CHF NN NN B-Disease
) NN NN O
and NN NN O
the NN NN O
following NN NN O
pretreatment NN NN O
characteristics NN NN O
: NN NN O
presence NN NN O
of NN NN O
electrocardiogram NN NN O
( NN NN O
EKG NN NN O
) NN NN O
abnormalities NN NN O
, NN NN O
age NN NN O
, NN NN O
hypertension NN NN B-Disease
, NN NN O
prior NN NN O
cardiac NN NN O
history NN NN O
, NN NN O
smoking NN NN O
, NN NN O
diabetes NN NN B-Disease
mellitus NN NN I-Disease
, NN NN O
prior NN NN O
use NN NN O
of NN NN O
anthracyclines NN NN O
, NN NN O
and NN NN O
left NN NN O
- NN NN O
sided NN NN O
chest NN NN O
irradiation NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Six NN NN O
of NN NN O
61 NN NN O
women NN NN O
( NN NN O
10 NN NN O
% NN NN O
) NN NN O
developed NN NN O
clinically NN NN O
reversible NN NN O
grade NN NN O
3 NN NN O
CHF NN NN B-Disease
following NN NN O
infusional NN NN O
cyclophosphamide NN NN O
with NN NN O
a NN NN O
median NN NN O
percent NN NN O
decline NN NN O
in NN NN O
ejection NN NN O
fraction NN NN O
of NN NN O
31 NN NN O
% NN NN O
. NN NN O
   
Incidence NN NN O
of NN NN O
transient NN NN O
cyclophosphamide NN NN O
- NN NN O
related NN NN O
cardiac NN NN B-Disease
toxicity NN NN I-Disease
( NN NN O
10 NN NN O
% NN NN O
) NN NN O
is NN NN O
comparable NN NN O
to NN NN O
previous NN NN O
recorded NN NN O
literature NN NN O
. NN NN O
   
Older NN NN O
age NN NN O
was NN NN O
significantly NN NN O
correlated NN NN O
with NN NN O
the NN NN O
CHF NN NN B-Disease
development NN NN O
; NN NN O
with NN NN O
median NN NN O
ages NN NN O
for NN NN O
the NN NN O
entire NN NN O
group NN NN O
and NN NN O
for NN NN O
patients NN NN O
developing NN NN O
CHF NN NN B-Disease
of NN NN O
45 NN NN O
and NN NN O
59 NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
No NN NN O
association NN NN O
was NN NN O
found NN NN O
with NN NN O
other NN NN O
pretreatment NN NN O
characteristics NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
As NN NN O
a NN NN O
result NN NN O
of NN NN O
these NN NN O
findings NN NN O
, NN NN O
oncologists NN NN O
should NN NN O
carefully NN NN O
monitor NN NN O
fluid NN NN O
balance NN NN O
in NN NN O
older NN NN O
patients NN NN O
. NN NN O
   
Routine NN NN O
EKG NN NN O
monitoring NN NN O
during NN NN O
infusional NN NN O
cyclophosphamide NN NN O
did NN NN O
not NN NN O
predict NN NN O
CHF NN NN B-Disease
development NN NN O
. NN NN O
   
Tremor NN NN B-Disease
side NN NN O
effects NN NN O
of NN NN O
salbutamol NN NN O
, NN NN O
quantified NN NN O
by NN NN O
a NN NN O
laser NN NN O
pointer NN NN O
technique NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
To NN NN O
study NN NN O
tremor NN NN B-Disease
side NN NN O
effects NN NN O
of NN NN O
salbutamol NN NN O
an NN NN O
easily NN NN O
applicable NN NN O
, NN NN O
quick NN NN O
and NN NN O
low NN NN O
- NN NN O
priced NN NN O
method NN NN O
is NN NN O
needed NN NN O
. NN NN O
   
A NN NN O
new NN NN O
method NN NN O
using NN NN O
a NN NN O
commercially NN NN O
available NN NN O
, NN NN O
pen NN NN O
- NN NN O
shaped NN NN O
laser NN NN O
pointer NN NN O
was NN NN O
developed NN NN O
. NN NN O
   
Aim NN NN O
of NN NN O
the NN NN O
study NN NN O
was NN NN O
to NN NN O
determine NN NN O
sensitivity NN NN O
, NN NN O
reproducibility NN NN O
, NN NN O
reference NN NN O
values NN NN O
and NN NN O
the NN NN O
agreement NN NN O
with NN NN O
a NN NN O
questionnaire NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Tremor NN NN B-Disease
was NN NN O
measured NN NN O
using NN NN O
a NN NN O
laser NN NN O
pointer NN NN O
technique NN NN O
. NN NN O
   
To NN NN O
determine NN NN O
sensitivity NN NN O
we NN NN O
assessed NN NN O
tremor NN NN B-Disease
in NN NN O
44 NN NN O
patients NN NN O
with NN NN O
obstructive NN NN B-Disease
lung NN NN I-Disease
disease NN NN I-Disease
after NN NN O
administration NN NN O
of NN NN O
cumulative NN NN O
doses NN NN O
of NN NN O
salbutamol NN NN O
. NN NN O
   
Subjects NN NN O
were NN NN O
asked NN NN O
to NN NN O
aim NN NN O
at NN NN O
the NN NN O
centre NN NN O
of NN NN O
a NN NN O
target NN NN O
, NN NN O
subdivided NN NN O
in NN NN O
concentric NN NN O
circles NN NN O
, NN NN O
from NN NN O
5 NN NN O
m NN NN O
distance NN NN O
. NN NN O
   
The NN NN O
circle NN NN O
in NN NN O
which NN NN O
the NN NN O
participant NN NN O
succeeded NN NN O
to NN NN O
aim NN NN O
was NN NN O
recorded NN NN O
in NN NN O
millimetres NN NN O
radius NN NN O
. NN NN O
   
In NN NN O
another NN NN O
series NN NN O
of NN NN O
measurements NN NN O
, NN NN O
reproducibility NN NN O
and NN NN O
reference NN NN O
values NN NN O
of NN NN O
the NN NN O
tremor NN NN B-Disease
was NN NN O
assessed NN NN O
in NN NN O
65 NN NN O
healthy NN NN O
subjects NN NN O
in NN NN O
three NN NN O
sessions NN NN O
, NN NN O
at NN NN O
9 NN NN O
a NN NN O
. NN NN O
m NN NN O
. NN NN O
, NN NN O
4 NN NN O
p NN NN O
. NN NN O
m NN NN O
. NN NN O
and NN NN O
9 NN NN O
a NN NN O
. NN NN O
m NN NN O
. NN NN O
, NN NN O
respectively NN NN O
, NN NN O
1 NN NN O
week NN NN O
later NN NN O
. NN NN O
   
Postural NN NN O
tremor NN NN B-Disease
was NN NN O
measured NN NN O
with NN NN O
the NN NN O
arm NN NN O
horizontally NN NN O
outstretched NN NN O
rest NN NN O
tremor NN NN B-Disease
with NN NN O
the NN NN O
arm NN NN O
supported NN NN O
by NN NN O
an NN NN O
armrest NN NN O
and NN NN O
finally NN NN O
tremor NN NN B-Disease
was NN NN O
measured NN NN O
after NN NN O
holding NN NN O
a NN NN O
2 NN NN O
- NN NN O
kg NN NN O
weight NN NN O
until NN NN O
exhaustion NN NN O
. NN NN O
   
Inter NN NN O
- NN NN O
observer NN NN O
variability NN NN O
was NN NN O
measured NN NN O
in NN NN O
a NN NN O
series NN NN O
of NN NN O
10 NN NN O
healthy NN NN O
subjects NN NN O
. NN NN O
   
Tremor NN NN B-Disease
was NN NN O
measured NN NN O
simultaneously NN NN O
by NN NN O
two NN NN O
independent NN NN O
observers NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Salbutamol NN NN O
significantly NN NN O
increased NN NN O
tremor NN NN B-Disease
severity NN NN O
in NN NN O
patients NN NN O
in NN NN O
a NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
way NN NN O
. NN NN O
   
Within NN NN O
healthy NN NN O
adults NN NN O
no NN NN O
age NN NN O
- NN NN O
dependency NN NN O
could NN NN O
be NN NN O
found NN NN O
( NN NN O
b NN NN O
= NN NN O
0 NN NN O
. NN NN O
262 NN NN O
mm NN NN O
/ NN NN O
year NN NN O
; NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
72 NN NN O
) NN NN O
. NN NN O
   
There NN NN O
was NN NN O
no NN NN O
agreement NN NN O
between NN NN O
the NN NN O
questionnaire NN NN O
and NN NN O
tremor NN NN B-Disease
severity NN NN O
( NN NN O
r NN NN O
= NN NN O
0 NN NN O
. NN NN O
093 NN NN O
; NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
53 NN NN O
) NN NN O
. NN NN O
   
Postural NN NN O
tremor NN NN B-Disease
showed NN NN O
no NN NN O
significant NN NN O
difference NN NN O
between NN NN O
the NN NN O
first NN NN O
and NN NN O
third NN NN O
session NN NN O
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
07 NN NN O
) NN NN O
. NN NN O
   
Support NN NN O
of NN NN O
the NN NN O
arm NN NN O
decreased NN NN O
tremor NN NN B-Disease
severity NN NN O
, NN NN O
exhaustion NN NN O
increased NN NN O
tremor NN NN B-Disease
severity NN NN O
significantly NN NN O
. NN NN O
   
A NN NN O
good NN NN O
agreement NN NN O
was NN NN O
found NN NN O
between NN NN O
two NN NN O
independent NN NN O
observers NN NN O
( NN NN O
interclass NN NN O
correlation NN NN O
coefficient NN NN O
0 NN NN O
. NN NN O
72 NN NN O
) NN NN O
. NN NN O
   
DISCUSSION NN NN O
: NN NN O
Quantifying NN NN O
tremor NN NN B-Disease
by NN NN O
using NN NN O
an NN NN O
inexpensive NN NN O
laser NN NN O
pointer NN NN O
is NN NN O
, NN NN O
with NN NN O
the NN NN O
exception NN NN O
of NN NN O
children NN NN O
( NN NN O
< NN NN O
12 NN NN O
years NN NN O
) NN NN O
a NN NN O
sensitive NN NN O
and NN NN O
reproducible NN NN O
method NN NN O
. NN NN O
   
Safety NN NN O
and NN NN O
adverse NN NN O
effects NN NN O
associated NN NN O
with NN NN O
raloxifene NN NN O
: NN NN O
multiple NN NN O
outcomes NN NN O
of NN NN O
raloxifene NN NN O
evaluation NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
To NN NN O
examine NN NN O
the NN NN O
effect NN NN O
of NN NN O
raloxifene NN NN O
on NN NN O
major NN NN O
adverse NN NN O
events NN NN O
that NN NN O
occur NN NN O
with NN NN O
postmenopausal NN NN O
estrogen NN NN O
therapy NN NN O
or NN NN O
tamoxifen NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
The NN NN O
Multiple NN NN O
Outcomes NN NN O
of NN NN O
Raloxifene NN NN O
Evaluation NN NN O
, NN NN O
a NN NN O
multicenter NN NN O
, NN NN O
randomized NN NN O
, NN NN O
double NN NN O
- NN NN O
blind NN NN O
trial NN NN O
, NN NN O
enrolled NN NN O
7 NN NN O
, NN NN O
705 NN NN O
postmenopausal NN NN O
women NN NN O
with NN NN O
osteoporosis NN NN B-Disease
. NN NN O
   
Women NN NN O
were NN NN O
randomly NN NN O
assigned NN NN O
to NN NN O
raloxifene NN NN O
60 NN NN O
mg NN NN O
/ NN NN O
d NN NN O
or NN NN O
120 NN NN O
mg NN NN O
/ NN NN O
d NN NN O
or NN NN O
placebo NN NN O
. NN NN O
   
Outcomes NN NN O
included NN NN O
venous NN NN B-Disease
thromboembolism NN NN I-Disease
, NN NN O
cataracts NN NN B-Disease
, NN NN O
gallbladder NN NN B-Disease
disease NN NN I-Disease
, NN NN O
and NN NN O
endometrial NN NN B-Disease
hyperplasia NN NN I-Disease
or NN NN I-Disease
cancer NN NN I-Disease
. NN NN O
   
RESULTS NN NN O
: NN NN O
During NN NN O
a NN NN O
mean NN NN O
follow NN NN O
- NN NN O
up NN NN O
of NN NN O
3 NN NN O
. NN NN O
3 NN NN O
years NN NN O
, NN NN O
raloxifene NN NN O
was NN NN O
associated NN NN O
with NN NN O
an NN NN O
increased NN NN O
risk NN NN O
for NN NN O
venous NN NN B-Disease
thromboembolism NN NN I-Disease
( NN NN O
relative NN NN O
risk NN NN O
[ NN NN O
RR NN NN O
] NN NN O
2 NN NN O
. NN NN O
1 NN NN O
; NN NN O
95 NN NN O
% NN NN O
confidence NN NN O
interval NN NN O
[ NN NN O
CI NN NN O
] NN NN O
1 NN NN O
. NN NN O
2 NN NN O
- NN NN O
3 NN NN O
. NN NN O
8 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
excess NN NN O
event NN NN O
rate NN NN O
was NN NN O
1 NN NN O
. NN NN O
8 NN NN O
per NN NN O
1 NN NN O
, NN NN O
000 NN NN O
woman NN NN O
- NN NN O
years NN NN O
( NN NN O
95 NN NN O
% NN NN O
CI NN NN O
- NN NN O
0 NN NN O
. NN NN O
5 NN NN O
- NN NN O
4 NN NN O
. NN NN O
1 NN NN O
) NN NN O
, NN NN O
and NN NN O
the NN NN O
number NN NN O
needed NN NN O
to NN NN O
treat NN NN O
to NN NN O
cause NN NN O
1 NN NN O
event NN NN O
was NN NN O
170 NN NN O
( NN NN O
95 NN NN O
% NN NN O
CI NN NN O
100 NN NN O
- NN NN O
582 NN NN O
) NN NN O
over NN NN O
3 NN NN O
. NN NN O
3 NN NN O
years NN NN O
. NN NN O
   
Risk NN NN O
in NN NN O
the NN NN O
raloxifene NN NN O
group NN NN O
was NN NN O
higher NN NN O
than NN NN O
in NN NN O
the NN NN O
placebo NN NN O
group NN NN O
for NN NN O
the NN NN O
first NN NN O
2 NN NN O
years NN NN O
, NN NN O
but NN NN O
decreased NN NN O
to NN NN O
about NN NN O
the NN NN O
same NN NN O
rate NN NN O
as NN NN O
in NN NN O
the NN NN O
placebo NN NN O
group NN NN O
thereafter NN NN O
. NN NN O
   
Raloxifene NN NN O
did NN NN O
not NN NN O
increase NN NN O
risk NN NN O
for NN NN O
cataracts NN NN B-Disease
( NN NN O
RR NN NN O
0 NN NN O
. NN NN O
9 NN NN O
; NN NN O
95 NN NN O
% NN NN O
CI NN NN O
0 NN NN O
. NN NN O
8 NN NN O
- NN NN O
1 NN NN O
. NN NN O
1 NN NN O
) NN NN O
, NN NN O
gallbladder NN NN B-Disease
disease NN NN I-Disease
( NN NN O
RR NN NN O
1 NN NN O
. NN NN O
0 NN NN O
; NN NN O
95 NN NN O
% NN NN O
CI NN NN O
0 NN NN O
. NN NN O
7 NN NN O
- NN NN O
1 NN NN O
. NN NN O
3 NN NN O
) NN NN O
, NN NN O
endometrial NN NN B-Disease
hyperplasia NN NN I-Disease
( NN NN O
RR NN NN O
1 NN NN O
. NN NN O
3 NN NN O
; NN NN O
95 NN NN O
% NN NN O
CI NN NN O
0 NN NN O
. NN NN O
4 NN NN O
- NN NN O
5 NN NN O
. NN NN O
1 NN NN O
) NN NN O
, NN NN O
or NN NN O
endometrial NN NN B-Disease
cancer NN NN I-Disease
( NN NN O
RR NN NN O
0 NN NN O
. NN NN O
9 NN NN O
; NN NN O
95 NN NN O
% NN NN O
CI NN NN O
0 NN NN O
. NN NN O
3 NN NN O
- NN NN O
2 NN NN O
. NN NN O
7 NN NN O
) NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Raloxifene NN NN O
was NN NN O
associated NN NN O
with NN NN O
an NN NN O
increased NN NN O
risk NN NN O
for NN NN O
venous NN NN B-Disease
thromboembolism NN NN I-Disease
, NN NN O
but NN NN O
there NN NN O
was NN NN O
no NN NN O
increased NN NN O
risk NN NN O
for NN NN O
cataracts NN NN B-Disease
, NN NN O
gallbladder NN NN B-Disease
disease NN NN I-Disease
, NN NN O
endometrial NN NN B-Disease
hyperplasia NN NN I-Disease
, NN NN O
or NN NN O
endometrial NN NN B-Disease
cancer NN NN I-Disease
. NN NN O
   
LEVEL NN NN O
OF NN NN O
EVIDENCE NN NN O
: NN NN O
I NN NN O
   
Optimization NN NN O
of NN NN O
levodopa NN NN O
therapy NN NN O
. NN NN O
   
While NN NN O
there NN NN O
is NN NN O
no NN NN O
single NN NN O
correct NN NN O
starting NN NN O
dose NN NN O
for NN NN O
levodopa NN NN O
therapy NN NN O
, NN NN O
many NN NN O
individuals NN NN O
can NN NN O
be NN NN O
started NN NN O
on NN NN O
either NN NN O
the NN NN O
25 NN NN O
/ NN NN O
100 NN NN O
or NN NN O
controlled NN NN O
- NN NN O
release NN NN O
formula NN NN O
, NN NN O
following NN NN O
the NN NN O
general NN NN O
rule NN NN O
not NN NN O
to NN NN O
attempt NN NN O
to NN NN O
titrate NN NN O
carbidopa NN NN O
- NN NN O
levodopa NN NN O
to NN NN O
the NN NN O
point NN NN O
of NN NN O
"""""""" NN NN O
normality NN NN O
, NN NN O
"""""""" NN NN O
which NN NN O
can NN NN O
lead NN NN O
to NN NN O
toxicity NN NN B-Disease
. NN NN O
   
The NN NN O
physician NN NN O
should NN NN O
also NN NN O
determine NN NN O
the NN NN O
proper NN NN O
use NN NN O
of NN NN O
any NN NN O
adjunctive NN NN O
medications NN NN O
; NN NN O
such NN NN O
combined NN NN O
therapy NN NN O
has NN NN O
become NN NN O
the NN NN O
standard NN NN O
approach NN NN O
to NN NN O
treatment NN NN O
. NN NN O
   
Following NN NN O
the NN NN O
initial NN NN O
period NN NN O
of NN NN O
therapy NN NN O
, NN NN O
emerging NN NN O
difficulties NN NN O
require NN NN O
a NN NN O
reassessment NN NN O
of NN NN O
therapeutic NN NN O
approaches NN NN O
, NN NN O
such NN NN O
as NN NN O
dosage NN NN O
adjustment NN NN O
or NN NN O
introduction NN NN O
of NN NN O
a NN NN O
dopamine NN NN O
agonist NN NN O
. NN NN O
   
Other NN NN O
possible NN NN O
adverse NN NN O
effects NN NN O
- NN NN O
- NN NN O
such NN NN O
as NN NN O
gastrointestinal NN NN B-Disease
disorders NN NN I-Disease
, NN NN O
orthostatic NN NN B-Disease
hypotension NN NN I-Disease
, NN NN O
levodopa NN NN O
- NN NN O
induced NN NN O
psychosis NN NN B-Disease
, NN NN O
sleep NN NN B-Disease
disturbances NN NN I-Disease
or NN NN O
parasomnias NN NN B-Disease
, NN NN O
or NN NN O
drug NN NN O
interactions NN NN O
- NN NN O
- NN NN O
also NN NN O
require NN NN O
carefully NN NN O
monitored NN NN O
individual NN NN O
treatment NN NN O
. NN NN O
   
Nonpharmacologic NN NN O
concerns NN NN O
can NN NN O
help NN NN O
the NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
patient NN NN O
achieve NN NN O
and NN NN O
maintain NN NN O
optimal NN NN O
functioning NN NN O
, NN NN O
including NN NN O
daily NN NN O
exercise NN NN O
, NN NN O
physical NN NN O
therapy NN NN O
, NN NN O
and NN NN O
involvement NN NN O
with NN NN O
support NN NN O
groups NN NN O
. NN NN O
   
Long NN NN O
term NN NN O
audiological NN NN O
evaluation NN NN O
of NN NN O
beta NN NN B-Disease
- NN NN I-Disease
thalassemic NN NN I-Disease
patients NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
The NN NN O
objective NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
identify NN NN O
the NN NN O
incidence NN NN O
and NN NN O
to NN NN O
monitor NN NN O
the NN NN O
progression NN NN O
of NN NN O
hearing NN NN B-Disease
loss NN NN I-Disease
in NN NN O
children NN NN O
and NN NN O
young NN NN O
adults NN NN O
with NN NN O
beta NN NN B-Disease
- NN NN I-Disease
thalassemia NN NN I-Disease
major NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
One NN NN O
hundred NN NN O
and NN NN O
four NN NN O
( NN NN O
104 NN NN O
) NN NN O
patients NN NN O
aged NN NN O
6 NN NN O
- NN NN O
35 NN NN O
years NN NN O
( NN NN O
mean NN NN O
17 NN NN O
, NN NN O
2 NN NN O
years NN NN O
) NN NN O
participated NN NN O
in NN NN O
the NN NN O
study NN NN O
. NN NN O
   
All NN NN O
patients NN NN O
were NN NN O
on NN NN O
a NN NN O
regular NN NN O
transfusion NN NN O
- NN NN O
chelation NN NN O
program NN NN O
maintaining NN NN O
a NN NN O
mean NN NN O
hemoglobin NN NN O
level NN NN O
of NN NN O
9 NN NN O
. NN NN O
5 NN NN O
gr NN NN O
/ NN NN O
dl NN NN O
. NN NN O
   
Subjects NN NN O
were NN NN O
receiving NN NN O
desferrioxamine NN NN O
( NN NN O
DFO NN NN O
) NN NN O
chelation NN NN O
treatment NN NN O
with NN NN O
a NN NN O
mean NN NN O
daily NN NN O
dose NN NN O
of NN NN O
50 NN NN O
- NN NN O
60 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
5 NN NN O
- NN NN O
6 NN NN O
days NN NN O
a NN NN O
week NN NN O
during NN NN O
the NN NN O
first NN NN O
six NN NN O
years NN NN O
of NN NN O
the NN NN O
study NN NN O
, NN NN O
which NN NN O
was NN NN O
then NN NN O
reduced NN NN O
to NN NN O
40 NN NN O
- NN NN O
50 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
for NN NN O
the NN NN O
following NN NN O
eight NN NN O
years NN NN O
. NN NN O
   
Patients NN NN O
were NN NN O
followed NN NN O
for NN NN O
8 NN NN O
- NN NN O
14 NN NN O
years NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Overall NN NN O
, NN NN O
21 NN NN O
out NN NN O
of NN NN O
104 NN NN O
patients NN NN O
( NN NN O
20 NN NN O
. NN NN O
2 NN NN O
% NN NN O
) NN NN O
presented NN NN O
with NN NN O
high NN NN O
frequency NN NN O
sensorineural NN NN B-Disease
hearing NN NN I-Disease
loss NN NN I-Disease
( NN NN O
SNHL NN NN B-Disease
) NN NN O
, NN NN O
either NN NN O
unilateral NN NN O
or NN NN O
bilateral NN NN O
. NN NN O
   
No NN NN O
ototoxic NN NN B-Disease
factor NN NN O
, NN NN O
other NN NN O
than NN NN O
DFO NN NN O
, NN NN O
was NN NN O
present NN NN O
in NN NN O
any NN NN O
of NN NN O
the NN NN O
patients NN NN O
. NN NN O
   
Patients NN NN O
with NN NN O
SNHL NN NN B-Disease
presented NN NN O
with NN NN O
relatively NN NN O
lower NN NN O
serum NN NN O
ferritin NN NN O
levels NN NN O
than NN NN O
those NN NN O
with NN NN O
normal NN NN O
hearing NN NN O
, NN NN O
however NN NN O
, NN NN O
no NN NN O
statistically NN NN O
significant NN NN O
difference NN NN O
was NN NN O
observed NN NN O
. NN NN O
   
Subjects NN NN O
with NN NN O
SNHL NN NN B-Disease
were NN NN O
submitted NN NN O
to NN NN O
DFO NN NN O
reduction NN NN O
or NN NN O
temporary NN NN O
withdrawal NN NN O
. NN NN O
   
Following NN NN O
intervention NN NN O
, NN NN O
7 NN NN O
out NN NN O
of NN NN O
21 NN NN O
affected NN NN O
patients NN NN O
recovered NN NN O
, NN NN O
10 NN NN O
remained NN NN O
stable NN NN O
and NN NN O
4 NN NN O
demonstrated NN NN O
aggravation NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
The NN NN O
findings NN NN O
are NN NN O
indicative NN NN O
of NN NN O
DFO NN NN O
' NN NN O
s NN NN O
contributing NN NN O
role NN NN O
in NN NN O
the NN NN O
development NN NN O
of NN NN O
hearing NN NN B-Disease
impairment NN NN I-Disease
. NN NN O
   
Regular NN NN O
audiologic NN NN O
evaluation NN NN O
is NN NN O
imperative NN NN O
in NN NN O
all NN NN O
thalassemic NN NN B-Disease
patients NN NN O
so NN NN O
that NN NN O
early NN NN O
changes NN NN O
may NN NN O
be NN NN O
recognized NN NN O
and NN NN O
treatment NN NN O
may NN NN O
be NN NN O
judiciously NN NN O
adjusted NN NN O
in NN NN O
order NN NN O
to NN NN O
prevent NN NN O
or NN NN O
reverse NN NN O
hearing NN NN B-Disease
impairment NN NN I-Disease
. NN NN O
   
Individual NN NN O
differences NN NN O
in NN NN O
renal NN NN O
ACE NN NN O
activity NN NN O
in NN NN O
healthy NN NN O
rats NN NN O
predict NN NN O
susceptibility NN NN O
to NN NN O
adriamycin NN NN O
- NN NN O
induced NN NN O
renal NN NN B-Disease
damage NN NN I-Disease
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
In NN NN O
man NN NN O
, NN NN O
differences NN NN O
in NN NN O
angiotensin NN NN O
- NN NN O
converting NN NN O
enzyme NN NN O
( NN NN O
ACE NN NN O
) NN NN O
levels NN NN O
, NN NN O
related NN NN O
to NN NN O
ACE NN NN O
( NN NN O
I NN NN O
/ NN NN O
D NN NN O
) NN NN O
genotype NN NN O
, NN NN O
are NN NN O
associated NN NN O
with NN NN O
renal NN NN O
prognosis NN NN O
. NN NN O
   
This NN NN O
raises NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
individual NN NN O
differences NN NN O
in NN NN O
renal NN NN O
ACE NN NN O
activity NN NN O
are NN NN O
involved NN NN O
in NN NN O
renal NN NN O
susceptibility NN NN O
to NN NN O
inflicted NN NN O
damage NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
we NN NN O
studied NN NN O
the NN NN O
predictive NN NN O
effect NN NN O
of NN NN O
renal NN NN O
ACE NN NN O
activity NN NN O
for NN NN O
the NN NN O
severity NN NN O
of NN NN O
renal NN NN B-Disease
damage NN NN I-Disease
induced NN NN O
by NN NN O
a NN NN O
single NN NN O
injection NN NN O
of NN NN O
adriamycin NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Renal NN NN O
ACE NN NN O
activity NN NN O
( NN NN O
Hip NN NN O
- NN NN O
His NN NN O
- NN NN O
Leu NN NN O
cleavage NN NN O
by NN NN O
cortical NN NN O
homogenates NN NN O
) NN NN O
was NN NN O
determined NN NN O
by NN NN O
renal NN NN O
biopsy NN NN O
in NN NN O
27 NN NN O
adult NN NN O
male NN NN O
Wistar NN NN O
rats NN NN O
. NN NN O
   
After NN NN O
1 NN NN O
week NN NN O
of NN NN O
recovery NN NN O
, NN NN O
proteinuria NN NN B-Disease
was NN NN O
induced NN NN O
by NN NN O
adriamycin NN NN O
[ NN NN O
1 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
intravenously NN NN O
( NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
) NN NN O
n NN NN O
= NN NN O
18 NN NN O
; NN NN O
controls NN NN O
, NN NN O
saline NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
n NN NN O
= NN NN O
9 NN NN O
] NN NN O
. NN NN O
   
Proteinuria NN NN B-Disease
was NN NN O
measured NN NN O
every NN NN O
2 NN NN O
weeks NN NN O
. NN NN O
   
After NN NN O
12 NN NN O
weeks NN NN O
, NN NN O
rats NN NN O
were NN NN O
sacrificed NN NN O
and NN NN O
their NN NN O
kidneys NN NN O
harvested NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
As NN NN O
anticipated NN NN O
, NN NN O
adriamycin NN NN O
elicited NN NN O
nephrotic NN NN B-Disease
range NN NN O
proteinuria NN NN B-Disease
, NN NN O
renal NN NN B-Disease
interstitial NN NN I-Disease
damage NN NN I-Disease
and NN NN O
mild NN NN O
focal NN NN B-Disease
glomerulosclerosis NN NN I-Disease
. NN NN O
   
Baseline NN NN O
renal NN NN O
ACE NN NN O
positively NN NN O
correlated NN NN O
with NN NN O
the NN NN O
relative NN NN O
rise NN NN O
in NN NN O
proteinuria NN NN B-Disease
after NN NN O
adriamycin NN NN O
( NN NN O
r NN NN O
= NN NN O
0 NN NN O
. NN NN O
62 NN NN O
, NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
, NN NN O
renal NN NN O
interstitial NN NN O
alpha NN NN O
- NN NN O
smooth NN NN O
muscle NN NN O
actin NN NN O
( NN NN O
r NN NN O
= NN NN O
0 NN NN O
. NN NN O
49 NN NN O
, NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
, NN NN O
interstitial NN NN O
macrophage NN NN O
influx NN NN O
( NN NN O
r NN NN O
= NN NN O
0 NN NN O
. NN NN O
56 NN NN O
, NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
, NN NN O
interstitial NN NN O
collagen NN NN O
III NN NN O
( NN NN O
r NN NN O
= NN NN O
0 NN NN O
. NN NN O
53 NN NN O
, NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
, NN NN O
glomerular NN NN O
alpha NN NN O
- NN NN O
smooth NN NN O
muscle NN NN O
actin NN NN O
( NN NN O
r NN NN O
= NN NN O
0 NN NN O
. NN NN O
74 NN NN O
, NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
and NN NN O
glomerular NN NN O
desmin NN NN O
( NN NN O
r NN NN O
= NN NN O
0 NN NN O
. NN NN O
48 NN NN O
, NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
Baseline NN NN O
renal NN NN O
ACE NN NN O
did NN NN O
not NN NN O
correlate NN NN O
with NN NN O
focal NN NN B-Disease
glomerulosclerosis NN NN I-Disease
( NN NN O
r NN NN O
= NN NN O
0 NN NN O
. NN NN O
22 NN NN O
, NN NN O
NS NN NN O
) NN NN O
. NN NN O
   
In NN NN O
controls NN NN O
, NN NN O
no NN NN O
predictive NN NN O
values NN NN O
for NN NN O
renal NN NN O
parameters NN NN O
were NN NN O
observed NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Individual NN NN O
differences NN NN O
in NN NN O
renal NN NN O
ACE NN NN O
activity NN NN O
predict NN NN O
the NN NN O
severity NN NN O
of NN NN O
adriamycin NN NN O
- NN NN O
induced NN NN O
renal NN NN B-Disease
damage NN NN I-Disease
in NN NN O
this NN NN O
outbred NN NN O
rat NN NN O
strain NN NN O
. NN NN O
   
This NN NN O
supports NN NN O
the NN NN O
assumption NN NN O
that NN NN O
differences NN NN O
in NN NN O
renal NN NN O
ACE NN NN O
activity NN NN O
predispose NN NN O
to NN NN O
a NN NN O
less NN NN O
favourable NN NN O
course NN NN O
of NN NN O
renal NN NN B-Disease
damage NN NN I-Disease
. NN NN O
   
Recurrent NN NN O
acute NN NN O
interstitial NN NN B-Disease
nephritis NN NN I-Disease
induced NN NN O
by NN NN O
azithromycin NN NN O
. NN NN O
   
A NN NN O
14 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
girl NN NN O
is NN NN O
reported NN NN O
with NN NN O
recurrent NN NN O
, NN NN O
azithromycin NN NN O
- NN NN O
induced NN NN O
, NN NN O
acute NN NN O
interstitial NN NN B-Disease
nephritis NN NN I-Disease
. NN NN O
   
The NN NN O
second NN NN O
episode NN NN O
was NN NN O
more NN NN O
severe NN NN O
than NN NN O
the NN NN O
first NN NN O
; NN NN O
and NN NN O
although NN NN O
both NN NN O
were NN NN O
treated NN NN O
with NN NN O
intensive NN NN O
corticosteroid NN NN O
therapy NN NN O
, NN NN O
renal NN NN O
function NN NN O
remained NN NN O
impaired NN NN O
. NN NN O
   
Although NN NN O
most NN NN O
cases NN NN O
of NN NN O
antibiotic NN NN O
induced NN NN O
acute NN NN O
interstitial NN NN B-Disease
nephritis NN NN I-Disease
are NN NN O
benign NN NN O
and NN NN O
self NN NN O
- NN NN O
limited NN NN O
, NN NN O
some NN NN O
patients NN NN O
are NN NN O
at NN NN O
risk NN NN O
for NN NN O
permanent NN NN O
renal NN NN B-Disease
injury NN NN I-Disease
. NN NN O
   
Spironolactone NN NN O
- NN NN O
induced NN NN O
renal NN NN B-Disease
insufficiency NN NN I-Disease
and NN NN O
hyperkalemia NN NN B-Disease
in NN NN O
patients NN NN O
with NN NN O
heart NN NN B-Disease
failure NN NN I-Disease
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
A NN NN O
previous NN NN O
randomized NN NN O
controlled NN NN O
trial NN NN O
evaluating NN NN O
the NN NN O
use NN NN O
of NN NN O
spironolactone NN NN O
in NN NN O
heart NN NN B-Disease
failure NN NN I-Disease
patients NN NN O
reported NN NN O
a NN NN O
low NN NN O
risk NN NN O
of NN NN O
hyperkalemia NN NN B-Disease
( NN NN O
2 NN NN O
% NN NN O
) NN NN O
and NN NN O
renal NN NN B-Disease
insufficiency NN NN I-Disease
( NN NN O
0 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
Because NN NN O
treatments NN NN O
for NN NN O
heart NN NN B-Disease
failure NN NN I-Disease
have NN NN O
changed NN NN O
since NN NN O
the NN NN O
benefits NN NN O
of NN NN O
spironolactone NN NN O
were NN NN O
reported NN NN O
, NN NN O
the NN NN O
prevalence NN NN O
of NN NN O
these NN NN O
complications NN NN O
may NN NN O
differ NN NN O
in NN NN O
current NN NN O
clinical NN NN O
practice NN NN O
. NN NN O
   
We NN NN O
therefore NN NN O
sought NN NN O
to NN NN O
determine NN NN O
the NN NN O
prevalence NN NN O
and NN NN O
clinical NN NN O
associations NN NN O
of NN NN O
hyperkalemia NN NN B-Disease
and NN NN O
renal NN NN B-Disease
insufficiency NN NN I-Disease
in NN NN O
heart NN NN B-Disease
failure NN NN I-Disease
patients NN NN O
treated NN NN O
with NN NN O
spironolactone NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
We NN NN O
performed NN NN O
a NN NN O
case NN NN O
control NN NN O
study NN NN O
of NN NN O
heart NN NN B-Disease
failure NN NN I-Disease
patients NN NN O
treated NN NN O
with NN NN O
spironolactone NN NN O
in NN NN O
our NN NN O
clinical NN NN O
practice NN NN O
. NN NN O
   
Cases NN NN O
were NN NN O
patients NN NN O
who NN NN O
developed NN NN O
hyperkalemia NN NN B-Disease
( NN NN O
K NN NN O
( NN NN O
+ NN NN O
) NN NN O
> NN NN O
5 NN NN O
. NN NN O
0 NN NN O
mEq NN NN O
/ NN NN O
L NN NN O
) NN NN O
or NN NN O
renal NN NN B-Disease
insufficiency NN NN I-Disease
( NN NN O
Cr NN NN O
> NN NN O
or NN NN O
= NN NN O
2 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
dL NN NN O
) NN NN O
, NN NN O
and NN NN O
they NN NN O
were NN NN O
compared NN NN O
to NN NN O
2 NN NN O
randomly NN NN O
selected NN NN O
controls NN NN O
per NN NN O
case NN NN O
. NN NN O
   
Clinical NN NN O
characteristics NN NN O
, NN NN O
medications NN NN O
, NN NN O
and NN NN O
serum NN NN O
chemistries NN NN O
at NN NN O
baseline NN NN O
and NN NN O
follow NN NN O
- NN NN O
up NN NN O
time NN NN O
periods NN NN O
were NN NN O
compared NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Sixty NN NN O
- NN NN O
seven NN NN O
of NN NN O
926 NN NN O
patients NN NN O
( NN NN O
7 NN NN O
. NN NN O
2 NN NN O
% NN NN O
) NN NN O
required NN NN O
discontinuation NN NN O
of NN NN O
spironolactone NN NN O
due NN NN O
to NN NN O
hyperkalemia NN NN B-Disease
( NN NN O
n NN NN O
= NN NN O
33 NN NN O
) NN NN O
or NN NN O
renal NN NN B-Disease
failure NN NN I-Disease
( NN NN O
n NN NN O
= NN NN O
34 NN NN O
) NN NN O
. NN NN O
   
Patients NN NN O
who NN NN O
developed NN NN O
hyperkalemia NN NN B-Disease
were NN NN O
older NN NN O
and NN NN O
more NN NN O
likely NN NN O
to NN NN O
have NN NN O
diabetes NN NN B-Disease
, NN NN O
had NN NN O
higher NN NN O
baseline NN NN O
serum NN NN O
potassium NN NN O
levels NN NN O
and NN NN O
lower NN NN O
baseline NN NN O
potassium NN NN O
supplement NN NN O
doses NN NN O
, NN NN O
and NN NN O
were NN NN O
more NN NN O
likely NN NN O
to NN NN O
be NN NN O
treated NN NN O
with NN NN O
beta NN NN O
- NN NN O
blockers NN NN O
than NN NN O
controls NN NN O
( NN NN O
n NN NN O
= NN NN O
134 NN NN O
) NN NN O
. NN NN O
   
Patients NN NN O
who NN NN O
developed NN NN O
renal NN NN B-Disease
insufficiency NN NN I-Disease
had NN NN O
lower NN NN O
baseline NN NN O
body NN NN O
weight NN NN O
and NN NN O
higher NN NN O
baseline NN NN O
serum NN NN O
creatinine NN NN O
, NN NN O
required NN NN O
higher NN NN O
doses NN NN O
of NN NN O
loop NN NN O
diuretics NN NN O
, NN NN O
and NN NN O
were NN NN O
more NN NN O
likely NN NN O
to NN NN O
be NN NN O
treated NN NN O
with NN NN O
thiazide NN NN O
diuretics NN NN O
than NN NN O
controls NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Spironolactone NN NN O
- NN NN O
induced NN NN O
hyperkalemia NN NN B-Disease
and NN NN O
renal NN NN B-Disease
insufficiency NN NN I-Disease
are NN NN O
more NN NN O
common NN NN O
in NN NN O
our NN NN O
clinical NN NN O
experience NN NN O
than NN NN O
reported NN NN O
previously NN NN O
. NN NN O
   
This NN NN O
difference NN NN O
is NN NN O
explained NN NN O
by NN NN O
patient NN NN O
comorbidities NN NN O
and NN NN O
more NN NN O
frequent NN NN O
use NN NN O
of NN NN O
beta NN NN O
- NN NN O
blockers NN NN O
. NN NN O
   
Acute NN NN O
reserpine NN NN O
and NN NN O
subchronic NN NN O
haloperidol NN NN O
treatments NN NN O
change NN NN O
synaptosomal NN NN O
brain NN NN O
glutamate NN NN O
uptake NN NN O
and NN NN O
elicit NN NN O
orofacial NN NN B-Disease
dyskinesia NN NN I-Disease
in NN NN O
rats NN NN O
. NN NN O
   
Reserpine NN NN O
- NN NN O
and NN NN O
haloperidol NN NN O
- NN NN O
induced NN NN O
orofacial NN NN B-Disease
dyskinesia NN NN I-Disease
are NN NN O
putative NN NN O
animal NN NN O
models NN NN O
of NN NN O
tardive NN NN B-Disease
dyskinesia NN NN I-Disease
( NN NN O
TD NN NN B-Disease
) NN NN O
whose NN NN O
pathophysiology NN NN O
has NN NN O
been NN NN O
related NN NN O
to NN NN O
free NN NN O
radical NN NN O
generation NN NN O
and NN NN O
oxidative NN NN O
stress NN NN O
. NN NN O
   
In NN NN O
the NN NN O
present NN NN O
study NN NN O
, NN NN O
the NN NN O
authors NN NN O
induced NN NN O
orofacial NN NN B-Disease
dyskinesia NN NN I-Disease
by NN NN O
acute NN NN O
reserpine NN NN O
and NN NN O
subchronic NN NN O
haloperidol NN NN O
administration NN NN O
to NN NN O
rats NN NN O
. NN NN O
   
Reserpine NN NN O
injection NN NN O
( NN NN O
one NN NN O
dose NN NN O
of NN NN O
1 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
s NN NN O
. NN NN O
c NN NN O
. NN NN O
) NN NN O
every NN NN O
other NN NN O
day NN NN O
for NN NN O
3 NN NN O
days NN NN O
caused NN NN O
a NN NN O
significant NN NN O
increase NN NN O
in NN NN O
vacuous NN NN O
chewing NN NN O
, NN NN O
tongue NN NN O
protrusion NN NN O
and NN NN O
duration NN NN O
of NN NN O
facial NN NN O
twitching NN NN O
, NN NN O
compared NN NN O
to NN NN O
the NN NN O
control NN NN O
. NN NN O
   
Haloperidol NN NN O
administration NN NN O
( NN NN O
one NN NN O
dose NN NN O
of NN NN O
12 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
once NN NN O
a NN NN O
week NN NN O
s NN NN O
. NN NN O
c NN NN O
. NN NN O
) NN NN O
for NN NN O
4 NN NN O
weeks NN NN O
caused NN NN O
an NN NN O
increase NN NN O
in NN NN O
vacuous NN NN O
chewing NN NN O
, NN NN O
tongue NN NN O
protrusion NN NN O
and NN NN O
duration NN NN O
of NN NN O
facial NN NN O
twitching NN NN O
observed NN NN O
in NN NN O
four NN NN O
weekly NN NN O
evaluations NN NN O
. NN NN O
   
After NN NN O
the NN NN O
treatments NN NN O
and NN NN O
behavioral NN NN O
observation NN NN O
, NN NN O
glutamate NN NN O
uptake NN NN O
by NN NN O
segments NN NN O
of NN NN O
the NN NN O
brain NN NN O
was NN NN O
analyzed NN NN O
. NN NN O
   
A NN NN O
decreased NN NN O
glutamate NN NN O
uptake NN NN O
was NN NN O
observed NN NN O
in NN NN O
the NN NN O
subcortical NN NN O
parts NN NN O
of NN NN O
animals NN NN O
treated NN NN O
with NN NN O
reserpine NN NN O
and NN NN O
haloperidol NN NN O
, NN NN O
compared NN NN O
to NN NN O
the NN NN O
control NN NN O
. NN NN O
   
Importantly NN NN O
, NN NN O
a NN NN O
decrease NN NN O
in NN NN O
glutamate NN NN O
uptake NN NN O
correlates NN NN O
negatively NN NN O
with NN NN O
an NN NN O
increase NN NN O
in NN NN O
the NN NN O
incidence NN NN O
of NN NN O
orofacial NN NN B-Disease
diskinesia NN NN I-Disease
. NN NN O
   
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
early NN NN O
changes NN NN O
in NN NN O
glutamate NN NN O
transport NN NN O
may NN NN O
be NN NN O
related NN NN O
to NN NN O
the NN NN O
development NN NN O
of NN NN O
vacuous NN NN O
chewing NN NN O
movements NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
Ceftriaxone NN NN O
- NN NN O
associated NN NN O
biliary NN NN B-Disease
pseudolithiasis NN NN I-Disease
in NN NN O
paediatric NN NN O
surgical NN NN O
patients NN NN O
. NN NN O
   
It NN NN O
is NN NN O
well NN NN O
known NN NN O
that NN NN O
ceftriaxone NN NN O
leads NN NN O
to NN NN O
pseudolithiasis NN NN B-Disease
in NN NN O
some NN NN O
patients NN NN O
. NN NN O
   
Clinical NN NN O
and NN NN O
experimental NN NN O
studies NN NN O
also NN NN O
suggest NN NN O
that NN NN O
situations NN NN O
causing NN NN O
gallbladder NN NN B-Disease
dysfunction NN NN I-Disease
, NN NN O
such NN NN O
as NN NN O
fasting NN NN O
, NN NN O
may NN NN O
have NN NN O
a NN NN O
role NN NN O
for NN NN O
the NN NN O
development NN NN O
of NN NN O
pseudolithiasis NN NN B-Disease
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
prospectively NN NN O
evaluated NN NN O
the NN NN O
incidence NN NN O
and NN NN O
clinical NN NN O
importance NN NN O
of NN NN O
pseudolithiasis NN NN B-Disease
in NN NN O
paediatric NN NN O
surgical NN NN O
patients NN NN O
receiving NN NN O
ceftriaxone NN NN O
treatment NN NN O
, NN NN O
who NN NN O
often NN NN O
had NN NN O
to NN NN O
fast NN NN O
in NN NN O
the NN NN O
post NN NN O
- NN NN O
operative NN NN O
period NN NN O
. NN NN O
   
Fifty NN NN O
children NN NN O
who NN NN O
were NN NN O
given NN NN O
ceftriaxone NN NN O
were NN NN O
evaluated NN NN O
by NN NN O
serial NN NN O
abdominal NN NN O
sonograms NN NN O
. NN NN O
   
Of NN NN O
those NN NN O
, NN NN O
13 NN NN O
( NN NN O
26 NN NN O
% NN NN O
) NN NN O
developed NN NN O
biliary NN NN O
pathology NN NN O
. NN NN O
   
Comparison NN NN O
of NN NN O
the NN NN O
patients NN NN O
with NN NN O
or NN NN O
without NN NN O
pseudolithiasis NN NN B-Disease
revealed NN NN O
no NN NN O
significant NN NN O
difference NN NN O
with NN NN O
respect NN NN O
to NN NN O
age NN NN O
, NN NN O
sex NN NN O
, NN NN O
duration NN NN O
of NN NN O
the NN NN O
treatment NN NN O
and NN NN O
starvation NN NN O
variables NN NN O
. NN NN O
   
After NN NN O
cessation NN NN O
of NN NN O
the NN NN O
treatment NN NN O
, NN NN O
pseudolithiasis NN NN B-Disease
resolved NN NN O
spontaneously NN NN O
within NN NN O
a NN NN O
short NN NN O
period NN NN O
. NN NN O
   
The NN NN O
incidence NN NN O
of NN NN O
pseudolithiasis NN NN B-Disease
is NN NN O
not NN NN O
affected NN NN O
by NN NN O
fasting NN NN O
. NN NN O
   
Coronary NN NN B-Disease
aneurysm NN NN I-Disease
after NN NN O
implantation NN NN O
of NN NN O
a NN NN O
paclitaxel NN NN O
- NN NN O
eluting NN NN O
stent NN NN O
. NN NN O
   
Formation NN NN O
of NN NN O
coronary NN NN B-Disease
aneurysm NN NN I-Disease
is NN NN O
a NN NN O
rare NN NN O
complication NN NN O
of NN NN O
stenting NN NN O
with NN NN O
bare NN NN O
metal NN NN O
stents NN NN O
, NN NN O
but NN NN O
based NN NN O
on NN NN O
experimental NN NN O
studies NN NN O
drug NN NN O
- NN NN O
eluting NN NN O
stents NN NN O
may NN NN O
induce NN NN O
toxic NN NN O
effects NN NN O
on NN NN O
the NN NN O
vessel NN NN O
wall NN NN O
with NN NN O
incomplete NN NN O
stent NN NN O
apposition NN NN O
, NN NN O
aneurysm NN NN B-Disease
formation NN NN O
and NN NN O
with NN NN O
the NN NN O
potential NN NN O
of NN NN O
stent NN NN O
thrombosis NN NN B-Disease
or NN NN O
vessel NN NN B-Disease
rupture NN NN I-Disease
. NN NN O
   
We NN NN O
present NN NN O
a NN NN O
43 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
man NN NN O
who NN NN O
developed NN NN O
a NN NN O
coronary NN NN B-Disease
aneurysm NN NN I-Disease
in NN NN O
the NN NN O
right NN NN O
coronary NN NN O
artery NN NN O
6 NN NN O
months NN NN O
after NN NN O
receiving NN NN O
a NN NN O
paclitaxel NN NN O
- NN NN O
eluting NN NN O
stent NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
was NN NN O
asymptomatic NN NN O
and NN NN O
the NN NN O
aneurysm NN NN B-Disease
was NN NN O
detected NN NN O
in NN NN O
a NN NN O
routine NN NN O
control NN NN O
. NN NN O
   
Angiography NN NN O
and NN NN O
intracoronary NN NN O
ultrasound NN NN O
demonstrated NN NN O
lack NN NN O
of NN NN O
contact NN NN O
between NN NN O
stent NN NN O
and NN NN O
vessel NN NN O
wall NN NN O
in NN NN O
a NN NN O
15 NN NN O
- NN NN O
mm NN NN O
long NN NN O
segment NN NN O
with NN NN O
maximal NN NN O
aneurysm NN NN B-Disease
diameter NN NN O
of NN NN O
6 NN NN O
. NN NN O
0 NN NN O
mm NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
was NN NN O
successfully NN NN O
treated NN NN O
with NN NN O
a NN NN O
graft NN NN O
stent NN NN O
. NN NN O
   
Causes NN NN O
of NN NN O
acute NN NN O
thrombotic NN NN B-Disease
microangiopathy NN NN I-Disease
in NN NN O
patients NN NN O
receiving NN NN O
kidney NN NN O
transplantation NN NN O
. NN NN O
   
OBJECTIVES NN NN O
: NN NN O
Thrombotic NN NN B-Disease
microangiopathy NN NN I-Disease
is NN NN O
a NN NN O
well NN NN O
- NN NN O
known NN NN O
problem NN NN O
in NN NN O
patients NN NN O
following NN NN O
renal NN NN O
transplantation NN NN O
. NN NN O
   
In NN NN O
postrenal NN NN O
transplantation NN NN O
, NN NN O
thrombotic NN NN B-Disease
microangiopathy NN NN I-Disease
is NN NN O
often NN NN O
a NN NN O
reflection NN NN O
of NN NN O
hemolytic NN NN B-Disease
uremic NN NN I-Disease
syndrome NN NN I-Disease
. NN NN O
   
We NN NN O
aimed NN NN O
to NN NN O
determine NN NN O
the NN NN O
causes NN NN O
of NN NN O
thrombotic NN NN B-Disease
microangiopathy NN NN I-Disease
in NN NN O
a NN NN O
population NN NN O
of NN NN O
renal NN NN O
transplantation NN NN O
recipients NN NN O
and NN NN O
discuss NN NN O
the NN NN O
literature NN NN O
. NN NN O
   
MATERIALS NN NN O
AND NN NN O
METHODS NN NN O
: NN NN O
We NN NN O
investigated NN NN O
the NN NN O
causes NN NN O
of NN NN O
thrombotic NN NN B-Disease
microangiopathy NN NN I-Disease
during NN NN O
a NN NN O
1 NN NN O
- NN NN O
year NN NN O
period NN NN O
, NN NN O
from NN NN O
June NN NN O
2003 NN NN O
to NN NN O
June NN NN O
2004 NN NN O
, NN NN O
at NN NN O
the NN NN O
King NN NN O
Fahad NN NN O
National NN NN O
Guard NN NN O
Hospital NN NN O
in NN NN O
Riyadh NN NN O
, NN NN O
Saudi NN NN O
Arabia NN NN O
, NN NN O
by NN NN O
reviewing NN NN O
the NN NN O
slides NN NN O
of NN NN O
all NN NN O
transplant NN NN O
biopsies NN NN O
( NN NN O
n NN NN O
= NN NN O
25 NN NN O
) NN NN O
performed NN NN O
during NN NN O
this NN NN O
interval NN NN O
. NN NN O
   
Pre NN NN O
- NN NN O
and NN NN O
posttransplant NN NN O
crossmatching NN NN O
was NN NN O
done NN NN O
when NN NN O
possible NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Five NN NN O
cases NN NN O
of NN NN O
thrombotic NN NN B-Disease
microangiopathy NN NN I-Disease
were NN NN O
found NN NN O
. NN NN O
   
Three NN NN O
of NN NN O
these NN NN O
cases NN NN O
were NN NN O
from NN NN O
the NN NN O
25 NN NN O
transplantations NN NN O
performed NN NN O
at NN NN O
King NN NN O
Fahad NN NN O
National NN NN O
Guard NN NN O
Hospital NN NN O
, NN NN O
while NN NN O
the NN NN O
other NN NN O
2 NN NN O
transplantations NN NN O
had NN NN O
been NN NN O
performed NN NN O
abroad NN NN O
and NN NN O
were NN NN O
referred NN NN O
to NN NN O
us NN NN O
for NN NN O
follow NN NN O
- NN NN O
up NN NN O
. NN NN O
   
Three NN NN O
cases NN NN O
were NN NN O
related NN NN O
to NN NN O
cyclosporine NN NN O
, NN NN O
and NN NN O
1 NN NN O
case NN NN O
was NN NN O
secondary NN NN O
to NN NN O
both NN NN O
cyclosporine NN NN O
and NN NN O
tacrolimus NN NN O
. NN NN O
   
The NN NN O
fifth NN NN O
case NN NN O
had NN NN O
features NN NN O
of NN NN O
thrombotic NN NN B-Disease
microangiopathy NN NN I-Disease
related NN NN O
to NN NN O
an NN NN O
antiphospholipid NN NN B-Disease
syndrome NN NN I-Disease
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
systemic NN NN B-Disease
lupus NN NN I-Disease
erythematosus NN NN I-Disease
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
In NN NN O
the NN NN O
literature NN NN O
, NN NN O
the NN NN O
most NN NN O
- NN NN O
frequent NN NN O
cause NN NN O
of NN NN O
hemolytic NN NN B-Disease
uremic NN NN I-Disease
syndrome NN NN I-Disease
in NN NN O
patients NN NN O
following NN NN O
renal NN NN O
transplantation NN NN O
is NN NN O
recurrence NN NN O
of NN NN O
the NN NN O
hemolytic NN NN B-Disease
uremic NN NN I-Disease
syndrome NN NN I-Disease
. NN NN O
   
Other NN NN O
causes NN NN O
include NN NN O
drug NN NN O
- NN NN O
related NN NN O
( NN NN O
cyclosporine NN NN O
, NN NN O
tacrolimus NN NN O
) NN NN O
toxicity NN NN B-Disease
, NN NN O
procoagulant NN NN O
status NN NN O
, NN NN O
and NN NN O
antibody NN NN O
- NN NN O
mediated NN NN O
rejection NN NN O
. NN NN O
   
We NN NN O
found NN NN O
that NN NN O
the NN NN O
most NN NN O
- NN NN O
frequent NN NN O
cause NN NN O
of NN NN O
thrombotic NN NN B-Disease
microangiopathy NN NN I-Disease
was NN NN O
drug NN NN O
related NN NN O
, NN NN O
secondary NN NN O
mainly NN NN O
to NN NN O
cyclosporine NN NN O
. NN NN O
   
In NN NN O
the NN NN O
current NN NN O
study NN NN O
, NN NN O
the NN NN O
frequency NN NN O
of NN NN O
thrombotic NN NN B-Disease
microangiopathy NN NN I-Disease
was NN NN O
similar NN NN O
to NN NN O
the NN NN O
percentage NN NN O
reported NN NN O
in NN NN O
the NN NN O
literature NN NN O
( NN NN O
20 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
Comparison NN NN O
of NN NN O
developmental NN NN O
toxicity NN NN B-Disease
of NN NN O
selective NN NN O
and NN NN O
non NN NN O
- NN NN O
selective NN NN O
cyclooxygenase NN NN O
- NN NN O
2 NN NN O
inhibitors NN NN O
in NN NN O
CRL NN NN O
: NN NN O
( NN NN O
WI NN NN O
) NN NN O
WUBR NN NN O
Wistar NN NN O
rats NN NN O
- NN NN O
- NN NN O
DFU NN NN O
and NN NN O
piroxicam NN NN O
study NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Cyclooxygenase NN NN O
( NN NN O
COX NN NN O
) NN NN O
inhibitors NN NN O
are NN NN O
one NN NN O
of NN NN O
the NN NN O
most NN NN O
often NN NN O
ingested NN NN O
drugs NN NN O
during NN NN O
pregnancy NN NN O
. NN NN O
   
Unlike NN NN O
general NN NN O
toxicity NN NN B-Disease
data NN NN O
, NN NN O
their NN NN O
prenatal NN NN O
toxic NN NN O
effects NN NN O
were NN NN O
not NN NN O
extensively NN NN O
studied NN NN O
before NN NN O
. NN NN O
   
The NN NN O
aim NN NN O
of NN NN O
the NN NN O
experiment NN NN O
was NN NN O
to NN NN O
evaluate NN NN O
the NN NN O
developmental NN NN O
toxicity NN NN B-Disease
of NN NN O
the NN NN O
non NN NN O
- NN NN O
selective NN NN O
( NN NN O
piroxicam NN NN O
) NN NN O
and NN NN O
selective NN NN O
( NN NN O
DFU NN NN O
; NN NN O
5 NN NN O
, NN NN O
5 NN NN O
- NN NN O
dimethyl NN NN O
- NN NN O
3 NN NN O
- NN NN O
( NN NN O
3 NN NN O
- NN NN O
fluorophenyl NN NN O
) NN NN O
- NN NN O
4 NN NN O
- NN NN O
( NN NN O
4 NN NN O
- NN NN O
methylsulphonyl NN NN O
) NN NN O
phenyl NN NN O
- NN NN O
2 NN NN O
( NN NN O
5H NN NN O
) NN NN O
- NN NN O
furanon NN NN O
) NN NN O
COX NN NN O
- NN NN O
2 NN NN O
inhibitors NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Drugs NN NN O
were NN NN O
separately NN NN O
, NN NN O
orally NN NN O
once NN NN O
daily NN NN O
dosed NN NN O
to NN NN O
pregnant NN NN O
rats NN NN O
from NN NN O
day NN NN O
8 NN NN O
to NN NN O
21 NN NN O
( NN NN O
GD1 NN NN O
= NN NN O
plug NN NN O
day NN NN O
) NN NN O
. NN NN O
   
Doses NN NN O
were NN NN O
set NN NN O
at NN NN O
0 NN NN O
. NN NN O
3 NN NN O
, NN NN O
3 NN NN O
. NN NN O
0 NN NN O
and NN NN O
30 NN NN O
. NN NN O
0mg NN NN O
/ NN NN O
kg NN NN O
for NN NN O
piroxicam NN NN O
and NN NN O
0 NN NN O
. NN NN O
2 NN NN O
, NN NN O
2 NN NN O
. NN NN O
0 NN NN O
and NN NN O
20 NN NN O
. NN NN O
0mg NN NN O
/ NN NN O
kg NN NN O
for NN NN O
DFU NN NN O
. NN NN O
   
Fetuses NN NN O
were NN NN O
delivered NN NN O
on NN NN O
GD NN NN O
21 NN NN O
and NN NN O
routinely NN NN O
examined NN NN O
. NN NN O
   
Comprehensive NN NN O
clinical NN NN O
and NN NN O
developmental NN NN O
measurements NN NN O
were NN NN O
done NN NN O
. NN NN O
   
The NN NN O
pooled NN NN O
statistical NN NN O
analysis NN NN O
for NN NN O
ventricular NN NN B-Disease
septal NN NN I-Disease
( NN NN I-Disease
VSD NN NN I-Disease
) NN NN I-Disease
and NN NN I-Disease
midline NN NN I-Disease
( NN NN I-Disease
MD NN NN I-Disease
) NN NN I-Disease
defects NN NN I-Disease
was NN NN O
performed NN NN O
for NN NN O
rat NN NN O
fetuses NN NN O
exposed NN NN O
to NN NN O
piroxicam NN NN O
, NN NN O
selective NN NN O
and NN NN O
non NN NN O
- NN NN O
selective NN NN O
COX NN NN O
- NN NN O
2 NN NN O
inhibitor NN NN O
based NN NN O
on NN NN O
present NN NN O
and NN NN O
historic NN NN O
data NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Maternal NN NN O
toxicity NN NN B-Disease
, NN NN O
intrauterine NN NN B-Disease
growth NN NN I-Disease
retardation NN NN I-Disease
, NN NN O
and NN NN O
increase NN NN B-Disease
of NN NN I-Disease
external NN NN I-Disease
and NN NN I-Disease
skeletal NN NN I-Disease
variations NN NN I-Disease
were NN NN O
found NN NN O
in NN NN O
rats NN NN O
treated NN NN O
with NN NN O
the NN NN O
highest NN NN O
dose NN NN O
of NN NN O
piroxicam NN NN O
. NN NN O
   
Decrease NN NN O
of NN NN O
fetal NN NN O
length NN NN O
was NN NN O
the NN NN O
only NN NN O
signs NN NN O
of NN NN O
the NN NN O
DFU NN NN O
developmental NN NN O
toxicity NN NN B-Disease
observed NN NN O
in NN NN O
pups NN NN O
exposed NN NN O
to NN NN O
the NN NN O
highest NN NN O
compound NN NN O
dose NN NN O
. NN NN O
   
Lack NN NN O
of NN NN O
teratogenicity NN NN O
was NN NN O
found NN NN O
in NN NN O
piroxicam NN NN O
and NN NN O
DFU NN NN O
- NN NN O
exposed NN NN O
groups NN NN O
. NN NN O
   
Prenatal NN NN O
exposure NN NN O
to NN NN O
non NN NN O
- NN NN O
selective NN NN O
COX NN NN O
inhibitors NN NN O
increases NN NN O
the NN NN O
risk NN NN O
of NN NN O
VSD NN NN O
and NN NN O
MD NN NN O
when NN NN O
compared NN NN O
to NN NN O
historic NN NN O
control NN NN O
but NN NN O
not NN NN O
with NN NN O
selective NN NN O
COX NN NN O
- NN NN O
2 NN NN O
inhibitors NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Both NN NN O
selective NN NN O
and NN NN O
non NN NN O
- NN NN O
selective NN NN O
COX NN NN O
- NN NN O
2 NN NN O
inhibitors NN NN O
were NN NN O
toxic NN NN O
for NN NN O
rats NN NN O
fetuses NN NN O
when NN NN O
administered NN NN O
in NN NN O
the NN NN O
highest NN NN O
dose NN NN O
. NN NN O
   
Unlike NN NN O
DFU NN NN O
, NN NN O
piroxicam NN NN O
was NN NN O
also NN NN O
highly NN NN O
toxic NN NN O
to NN NN O
the NN NN O
dams NN NN O
. NN NN O
   
Prenatal NN NN O
exposure NN NN O
to NN NN O
selective NN NN O
COX NN NN O
- NN NN O
2 NN NN O
inhibitors NN NN O
does NN NN O
not NN NN O
increase NN NN O
the NN NN O
risk NN NN O
of NN NN O
ventricular NN NN B-Disease
septal NN NN I-Disease
and NN NN I-Disease
midline NN NN I-Disease
defects NN NN I-Disease
in NN NN O
rat NN NN O
when NN NN O
compared NN NN O
to NN NN O
non NN NN O
- NN NN O
selective NN NN O
drugs NN NN O
and NN NN O
historic NN NN O
control NN NN O
. NN NN O
   
Lone NN NN O
atrial NN NN B-Disease
fibrillation NN NN I-Disease
associated NN NN O
with NN NN O
creatine NN NN O
monohydrate NN NN O
supplementation NN NN O
. NN NN O
   
Atrial NN NN B-Disease
fibrillation NN NN I-Disease
in NN NN O
young NN NN O
patients NN NN O
without NN NN O
structural NN NN O
heart NN NN B-Disease
disease NN NN I-Disease
is NN NN O
rare NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
when NN NN O
the NN NN O
arrhythmia NN NN B-Disease
is NN NN O
present NN NN O
in NN NN O
this NN NN O
population NN NN O
, NN NN O
reversible NN NN O
causes NN NN O
must NN NN O
be NN NN O
identified NN NN O
and NN NN O
resolved NN NN O
. NN NN O
   
Thyroid NN NN B-Disease
disorders NN NN I-Disease
, NN NN O
illicit NN NN O
drug NN NN O
or NN NN O
stimulant NN NN O
use NN NN O
, NN NN O
and NN NN O
acute NN NN B-Disease
alcohol NN NN I-Disease
intoxication NN NN I-Disease
are NN NN O
among NN NN O
these NN NN O
causes NN NN O
. NN NN O
   
We NN NN O
report NN NN O
the NN NN O
case NN NN O
of NN NN O
a NN NN O
30 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
Caucasian NN NN O
man NN NN O
who NN NN O
came NN NN O
to NN NN O
the NN NN O
emergency NN NN O
department NN NN O
in NN NN O
atrial NN NN B-Disease
fibrillation NN NN I-Disease
with NN NN O
rapid NN NN O
ventricular NN NN O
response NN NN O
. NN NN O
   
His NN NN O
medical NN NN O
history NN NN O
was NN NN O
unremarkable NN NN O
, NN NN O
except NN NN O
for NN NN O
minor NN NN O
fractures NN NN B-Disease
of NN NN O
the NN NN O
fingers NN NN O
and NN NN O
foot NN NN O
. NN NN O
   
Thyroid NN NN O
- NN NN O
stimulating NN NN O
hormone NN NN O
, NN NN O
magnesium NN NN O
, NN NN O
and NN NN O
potassium NN NN O
levels NN NN O
were NN NN O
within NN NN O
normal NN NN O
limits NN NN O
, NN NN O
urine NN NN O
drug NN NN O
screen NN NN O
was NN NN O
negative NN NN O
, NN NN O
and NN NN O
alcohol NN NN O
use NN NN O
was NN NN O
denied NN NN O
. NN NN O
   
However NN NN O
, NN NN O
when NN NN O
the NN NN O
patient NN NN O
was NN NN O
questioned NN NN O
about NN NN O
use NN NN O
of NN NN O
herbal NN NN O
products NN NN O
and NN NN O
supplements NN NN O
, NN NN O
the NN NN O
use NN NN O
of NN NN O
creatine NN NN O
monohydrate NN NN O
was NN NN O
revealed NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
was NN NN O
admitted NN NN O
to NN NN O
the NN NN O
hospital NN NN O
, NN NN O
anticoagulated NN NN O
with NN NN O
unfractionated NN NN O
heparin NN NN O
, NN NN O
and NN NN O
given NN NN O
intravenous NN NN O
diltiazem NN NN O
for NN NN O
rate NN NN O
control NN NN O
and NN NN O
intravenous NN NN O
amiodarone NN NN O
for NN NN O
rate NN NN O
and NN NN O
rhythm NN NN O
control NN NN O
. NN NN O
   
When NN NN O
discharged NN NN O
less NN NN O
than NN NN O
24 NN NN O
hours NN NN O
later NN NN O
, NN NN O
he NN NN O
was NN NN O
receiving NN NN O
metoprolol NN NN O
and NN NN O
aspirin NN NN O
, NN NN O
with NN NN O
follow NN NN O
- NN NN O
up NN NN O
plans NN NN O
for NN NN O
echocardiography NN NN O
and NN NN O
nuclear NN NN O
imaging NN NN O
to NN NN O
assess NN NN O
perfusion NN NN O
. NN NN O
   
Exogenous NN NN O
creatine NN NN O
is NN NN O
used NN NN O
by NN NN O
athletes NN NN O
to NN NN O
theoretically NN NN O
improve NN NN O
exercise NN NN O
performance NN NN O
. NN NN O
   
Vegetarians NN NN O
may NN NN O
also NN NN O
take NN NN O
creatine NN NN O
to NN NN O
replace NN NN O
what NN NN O
they NN NN O
are NN NN O
not NN NN O
consuming NN NN O
from NN NN O
meat NN NN O
, NN NN O
fish NN NN O
, NN NN O
and NN NN O
other NN NN O
animal NN NN O
products NN NN O
. NN NN O
   
Previous NN NN O
anecdotal NN NN O
reports NN NN O
have NN NN O
linked NN NN O
creatine NN NN O
to NN NN O
the NN NN O
development NN NN O
of NN NN O
arrhythmia NN NN B-Disease
. NN NN O
   
Clinicians NN NN O
must NN NN O
be NN NN O
diligent NN NN O
when NN NN O
interviewing NN NN O
patients NN NN O
about NN NN O
their NN NN O
drug NN NN O
therapy NN NN O
histories NN NN O
and NN NN O
include NN NN O
questions NN NN O
about NN NN O
their NN NN O
use NN NN O
of NN NN O
herbal NN NN O
products NN NN O
and NN NN O
dietary NN NN O
supplements NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
it NN NN O
is NN NN O
important NN NN O
to NN NN O
report NN NN O
adverse NN NN O
effects NN NN O
associated NN NN O
with NN NN O
frequently NN NN O
consumed NN NN O
supplements NN NN O
and NN NN O
herbal NN NN O
products NN NN O
to NN NN O
the NN NN O
Food NN NN O
and NN NN O
Drug NN NN O
Administration NN NN O
and NN NN O
in NN NN O
the NN NN O
literature NN NN O
. NN NN O
   
Seizures NN NN B-Disease
induced NN NN O
by NN NN O
the NN NN O
cocaine NN NN O
metabolite NN NN O
benzoylecgonine NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
The NN NN O
half NN NN O
- NN NN O
life NN NN O
( NN NN O
t1 NN NN O
/ NN NN O
2 NN NN O
) NN NN O
of NN NN O
cocaine NN NN O
is NN NN O
relatively NN NN O
short NN NN O
, NN NN O
but NN NN O
some NN NN O
of NN NN O
the NN NN O
consequences NN NN O
of NN NN O
its NN NN O
use NN NN O
, NN NN O
such NN NN O
as NN NN O
seizures NN NN B-Disease
and NN NN O
strokes NN NN B-Disease
, NN NN O
can NN NN O
occur NN NN O
hours NN NN O
after NN NN O
exposure NN NN O
. NN NN O
   
This NN NN O
led NN NN O
us NN NN O
to NN NN O
hypothesize NN NN O
that NN NN O
a NN NN O
metabolite NN NN O
of NN NN O
cocaine NN NN O
may NN NN O
be NN NN O
responsible NN NN O
for NN NN O
some NN NN O
of NN NN O
those NN NN O
delayed NN NN O
sequelae NN NN O
. NN NN O
   
We NN NN O
evaluated NN NN O
the NN NN O
potential NN NN O
of NN NN O
the NN NN O
major NN NN O
metabolite NN NN O
of NN NN O
cocaine NN NN O
, NN NN O
benzoylecgonine NN NN O
( NN NN O
BE NN NN O
) NN NN O
, NN NN O
to NN NN O
cause NN NN O
seizures NN NN B-Disease
. NN NN O
   
Two NN NN O
separate NN NN O
equimolar NN NN O
doses NN NN O
( NN NN O
0 NN NN O
. NN NN O
2 NN NN O
and NN NN O
0 NN NN O
. NN NN O
4 NN NN O
mumol NN NN O
) NN NN O
of NN NN O
either NN NN O
cocaine NN NN O
or NN NN O
BE NN NN O
were NN NN O
injected NN NN O
ventricularly NN NN O
in NN NN O
unanesthetized NN NN O
juvenile NN NN O
rats NN NN O
. NN NN O
   
Treated NN NN O
rats NN NN O
were NN NN O
then NN NN O
evaluated NN NN O
for NN NN O
incidence NN NN O
, NN NN O
latency NN NN O
, NN NN O
and NN NN O
seizure NN NN B-Disease
pattern NN NN O
or NN NN O
for NN NN O
locomotor NN NN O
activity NN NN O
in NN NN O
animals NN NN O
without NN NN O
seizures NN NN B-Disease
. NN NN O
   
BE NN NN O
- NN NN O
Induced NN NN O
seizures NN NN B-Disease
occurred NN NN O
more NN NN O
frequently NN NN O
and NN NN O
had NN NN O
significantly NN NN O
longer NN NN O
latencies NN NN O
than NN NN O
those NN NN O
induced NN NN O
by NN NN O
equimolar NN NN O
amounts NN NN O
of NN NN O
cocaine NN NN O
. NN NN O
   
Whereas NN NN O
cocaine NN NN O
- NN NN O
induced NN NN O
seizures NN NN B-Disease
were NN NN O
best NN NN O
characterized NN NN O
as NN NN O
brief NN NN O
, NN NN O
generalized NN NN O
, NN NN O
and NN NN O
tonic NN NN O
and NN NN O
resulted NN NN O
in NN NN O
death NN NN B-Disease
, NN NN O
those NN NN O
induced NN NN O
by NN NN O
BE NN NN O
were NN NN O
prolonged NN NN O
, NN NN O
often NN NN O
multiple NN NN O
and NN NN O
mixed NN NN O
in NN NN O
type NN NN O
, NN NN O
and NN NN O
rarely NN NN O
resulted NN NN O
in NN NN O
death NN NN B-Disease
. NN NN O
   
Electrical NN NN O
recordings NN NN O
from NN NN O
the NN NN O
hippocampus NN NN O
showed NN NN O
a NN NN O
rhythmic NN NN O
progression NN NN O
in NN NN O
EEG NN NN O
frequency NN NN O
and NN NN O
voltage NN NN O
with NN NN O
clinical NN NN O
seizure NN NN B-Disease
expression NN NN O
. NN NN O
   
BE NN NN O
- NN NN O
Injected NN NN O
rats NN NN O
that NN NN O
did NN NN O
not NN NN O
have NN NN O
seizures NN NN B-Disease
had NN NN O
significantly NN NN O
more NN NN O
locomotor NN NN O
activity NN NN O
than NN NN O
cocaine NN NN O
- NN NN O
injected NN NN O
animals NN NN O
without NN NN O
seizures NN NN B-Disease
. NN NN O
   
The NN NN O
finding NN NN O
that NN NN O
cocaine NN NN O
- NN NN O
and NN NN O
BE NN NN O
- NN NN O
induced NN NN O
seizures NN NN B-Disease
differ NN NN O
in NN NN O
several NN NN O
respects NN NN O
suggests NN NN O
more NN NN O
than NN NN O
one NN NN O
mechanism NN NN O
for NN NN O
cocaine NN NN O
- NN NN O
induced NN NN O
seizures NN NN B-Disease
and NN NN O
emphasizes NN NN O
the NN NN O
importance NN NN O
of NN NN O
a NN NN O
cocaine NN NN O
metabolite NN NN O
, NN NN O
BE NN NN O
. NN NN O
   
The NN NN O
selective NN NN O
5 NN NN O
- NN NN O
HT6 NN NN O
receptor NN NN O
antagonist NN NN O
Ro4368554 NN NN O
restores NN NN O
memory NN NN O
performance NN NN O
in NN NN O
cholinergic NN NN O
and NN NN O
serotonergic NN NN O
models NN NN O
of NN NN O
memory NN NN B-Disease
deficiency NN NN I-Disease
in NN NN O
the NN NN O
rat NN NN O
. NN NN O
   
Antagonists NN NN O
at NN NN O
serotonin NN NN O
type NN NN O
6 NN NN O
( NN NN O
5 NN NN O
- NN NN O
HT NN NN O
( NN NN O
6 NN NN O
) NN NN O
) NN NN O
receptors NN NN O
show NN NN O
activity NN NN O
in NN NN O
models NN NN O
of NN NN O
learning NN NN O
and NN NN O
memory NN NN O
. NN NN O
   
Although NN NN O
the NN NN O
underlying NN NN O
mechanism NN NN O
( NN NN O
s NN NN O
) NN NN O
are NN NN O
not NN NN O
well NN NN O
understood NN NN O
, NN NN O
these NN NN O
effects NN NN O
may NN NN O
involve NN NN O
an NN NN O
increase NN NN O
in NN NN O
acetylcholine NN NN O
( NN NN O
ACh NN NN O
) NN NN O
levels NN NN O
. NN NN O
   
The NN NN O
present NN NN O
study NN NN O
sought NN NN O
to NN NN O
characterize NN NN O
the NN NN O
cognitive NN NN O
- NN NN O
enhancing NN NN O
effects NN NN O
of NN NN O
the NN NN O
5 NN NN O
- NN NN O
HT NN NN O
( NN NN O
6 NN NN O
) NN NN O
antagonist NN NN O
Ro4368554 NN NN O
( NN NN O
3 NN NN O
- NN NN O
benzenesulfonyl NN NN O
- NN NN O
7 NN NN O
- NN NN O
( NN NN O
4 NN NN O
- NN NN O
methyl NN NN O
- NN NN O
piperazin NN NN O
- NN NN O
1 NN NN O
- NN NN O
yl NN NN O
) NN NN O
1H NN NN O
- NN NN O
indole NN NN O
) NN NN O
in NN NN O
a NN NN O
rat NN NN O
object NN NN O
recognition NN NN O
task NN NN O
employing NN NN O
a NN NN O
cholinergic NN NN O
( NN NN O
scopolamine NN NN O
pretreatment NN NN O
) NN NN O
and NN NN O
a NN NN O
serotonergic NN NN O
- NN NN O
( NN NN O
tryptophan NN NN O
( NN NN O
TRP NN NN O
) NN NN O
depletion NN NN O
) NN NN O
deficient NN NN O
model NN NN O
, NN NN O
and NN NN O
compared NN NN O
its NN NN O
pattern NN NN O
of NN NN O
action NN NN O
with NN NN O
that NN NN O
of NN NN O
the NN NN O
acetylcholinesterase NN NN O
inhibitor NN NN O
metrifonate NN NN O
. NN NN O
   
Initial NN NN O
testing NN NN O
in NN NN O
a NN NN O
time NN NN O
- NN NN O
dependent NN NN O
forgetting NN NN O
task NN NN O
employing NN NN O
a NN NN O
24 NN NN O
- NN NN O
h NN NN O
delay NN NN O
between NN NN O
training NN NN O
and NN NN O
testing NN NN O
showed NN NN O
that NN NN O
metrifonate NN NN O
improved NN NN O
object NN NN O
recognition NN NN O
( NN NN O
at NN NN O
10 NN NN O
and NN NN O
30 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
p NN NN O
. NN NN O
o NN NN O
. NN NN O
) NN NN O
, NN NN O
whereas NN NN O
Ro4368554 NN NN O
was NN NN O
inactive NN NN O
. NN NN O
   
Both NN NN O
, NN NN O
Ro4368554 NN NN O
( NN NN O
3 NN NN O
and NN NN O
10 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
intraperitoneally NN NN O
( NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
) NN NN O
and NN NN O
metrifonate NN NN O
( NN NN O
10 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
p NN NN O
. NN NN O
o NN NN O
. NN NN O
, NN NN O
respectively NN NN O
) NN NN O
reversed NN NN O
memory NN NN B-Disease
deficits NN NN I-Disease
induced NN NN O
by NN NN O
scopolamine NN NN O
and NN NN O
TRP NN NN O
depletion NN NN O
( NN NN O
10 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
, NN NN O
and NN NN O
3 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
p NN NN O
. NN NN O
o NN NN O
. NN NN O
, NN NN O
respectively NN NN O
) NN NN O
. NN NN O
   
In NN NN O
conclusion NN NN O
, NN NN O
although NN NN O
Ro4368554 NN NN O
did NN NN O
not NN NN O
improve NN NN O
a NN NN O
time NN NN O
- NN NN O
related NN NN O
retention NN NN O
deficit NN NN O
, NN NN O
it NN NN O
reversed NN NN O
a NN NN O
cholinergic NN NN O
and NN NN O
a NN NN O
serotonergic NN NN O
memory NN NN B-Disease
deficit NN NN I-Disease
, NN NN O
suggesting NN NN O
that NN NN O
both NN NN O
mechanisms NN NN O
may NN NN O
be NN NN O
involved NN NN O
in NN NN O
the NN NN O
facilitation NN NN O
of NN NN O
object NN NN O
memory NN NN O
by NN NN O
Ro4368554 NN NN O
and NN NN O
, NN NN O
possibly NN NN O
, NN NN O
other NN NN O
5 NN NN O
- NN NN O
HT NN NN O
( NN NN O
6 NN NN O
) NN NN O
receptor NN NN O
antagonists NN NN O
. NN NN O
   
Evaluation NN NN O
of NN NN O
the NN NN O
anticocaine NN NN O
monoclonal NN NN O
antibody NN NN O
GNC92H2 NN NN O
as NN NN O
an NN NN O
immunotherapy NN NN O
for NN NN O
cocaine NN NN B-Disease
overdose NN NN I-Disease
. NN NN O
   
The NN NN O
illicit NN NN O
use NN NN O
of NN NN O
cocaine NN NN O
continues NN NN O
in NN NN O
epidemic NN NN O
proportions NN NN O
and NN NN O
treatment NN NN O
for NN NN O
cocaine NN NN B-Disease
overdose NN NN I-Disease
remains NN NN O
elusive NN NN O
. NN NN O
   
Current NN NN O
protein NN NN O
- NN NN O
based NN NN O
technology NN NN O
offers NN NN O
a NN NN O
new NN NN O
therapeutic NN NN O
venue NN NN O
by NN NN O
which NN NN O
antibodies NN NN O
bind NN NN O
the NN NN O
drug NN NN O
in NN NN O
the NN NN O
blood NN NN O
stream NN NN O
, NN NN O
inactivating NN NN O
its NN NN O
toxic NN NN O
effects NN NN O
. NN NN O
   
The NN NN O
therapeutic NN NN O
potential NN NN O
of NN NN O
the NN NN O
anticocaine NN NN O
antibody NN NN O
GNC92H2 NN NN O
was NN NN O
examined NN NN O
using NN NN O
a NN NN O
model NN NN O
of NN NN O
cocaine NN NN B-Disease
overdose NN NN I-Disease
. NN NN O
   
Swiss NN NN O
albino NN NN O
mice NN NN O
prepared NN NN O
with NN NN O
intrajugular NN NN O
catheters NN NN O
were NN NN O
tested NN NN O
in NN NN O
photocell NN NN O
cages NN NN O
after NN NN O
administration NN NN O
of NN NN O
93 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
( NN NN O
LD50 NN NN O
) NN NN O
of NN NN O
cocaine NN NN O
and NN NN O
GNC92H2 NN NN O
infusions NN NN O
ranging NN NN O
from NN NN O
30 NN NN O
to NN NN O
190 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
. NN NN O
   
GNC92H2 NN NN O
was NN NN O
delivered NN NN O
30 NN NN O
min NN NN O
before NN NN O
, NN NN O
concomitantly NN NN O
or NN NN O
3 NN NN O
min NN NN O
after NN NN O
cocaine NN NN O
treatment NN NN O
. NN NN O
   
Significant NN NN O
blockade NN NN O
of NN NN O
cocaine NN NN O
toxicity NN NN B-Disease
was NN NN O
observed NN NN O
with NN NN O
the NN NN O
higher NN NN O
dose NN NN O
of NN NN O
GNC92H2 NN NN O
( NN NN O
190 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
, NN NN O
where NN NN O
premorbid NN NN O
behaviors NN NN O
were NN NN O
reduced NN NN O
up NN NN O
to NN NN O
40 NN NN O
% NN NN O
, NN NN O
seizures NN NN B-Disease
up NN NN O
to NN NN O
77 NN NN O
% NN NN O
and NN NN O
death NN NN B-Disease
by NN NN O
72 NN NN O
% NN NN O
. NN NN O
   
Importantly NN NN O
, NN NN O
GNC92H2 NN NN O
prevented NN NN O
death NN NN B-Disease
even NN NN O
post NN NN O
- NN NN O
cocaine NN NN O
injection NN NN O
. NN NN O
   
The NN NN O
results NN NN O
support NN NN O
the NN NN O
important NN NN O
potential NN NN O
of NN NN O
GNC92H2 NN NN O
as NN NN O
a NN NN O
therapeutic NN NN O
tool NN NN O
against NN NN O
cocaine NN NN B-Disease
overdose NN NN I-Disease
. NN NN O
   
Electrocardiographic NN NN O
evidence NN NN O
of NN NN O
myocardial NN NN B-Disease
injury NN NN I-Disease
in NN NN O
psychiatrically NN NN O
hospitalized NN NN O
cocaine NN NN O
abusers NN NN O
. NN NN O
   
The NN NN O
electrocardiograms NN NN O
( NN NN O
ECG NN NN O
) NN NN O
of NN NN O
99 NN NN O
cocaine NN NN O
- NN NN O
abusing NN NN O
patients NN NN O
were NN NN O
compared NN NN O
with NN NN O
the NN NN O
ECGs NN NN O
of NN NN O
50 NN NN O
schizophrenic NN NN B-Disease
controls NN NN O
. NN NN O
   
Eleven NN NN O
of NN NN O
the NN NN O
cocaine NN NN O
abusers NN NN O
and NN NN O
none NN NN O
of NN NN O
the NN NN O
controls NN NN O
had NN NN O
ECG NN NN O
evidence NN NN O
of NN NN O
significant NN NN O
myocardial NN NN B-Disease
injury NN NN I-Disease
defined NN NN O
as NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
, NN NN O
ischemia NN NN B-Disease
, NN NN O
and NN NN O
bundle NN NN B-Disease
branch NN NN I-Disease
block NN NN I-Disease
. NN NN O
   
Behavioral NN NN O
effects NN NN O
of NN NN O
urotensin NN NN O
- NN NN O
II NN NN O
centrally NN NN O
administered NN NN O
in NN NN O
mice NN NN O
. NN NN O
   
Urotensin NN NN O
- NN NN O
II NN NN O
( NN NN O
U NN NN O
- NN NN O
II NN NN O
) NN NN O
receptors NN NN O
are NN NN O
widely NN NN O
distributed NN NN O
in NN NN O
the NN NN O
central NN NN O
nervous NN NN O
system NN NN O
. NN NN O
   
Intracerebroventricular NN NN O
( NN NN O
i NN NN O
. NN NN O
c NN NN O
. NN NN O
v NN NN O
. NN NN O
) NN NN O
injection NN NN O
of NN NN O
U NN NN O
- NN NN O
II NN NN O
causes NN NN O
hypertension NN NN B-Disease
and NN NN O
bradycardia NN NN B-Disease
and NN NN O
stimulates NN NN O
prolactin NN NN O
and NN NN O
thyrotropin NN NN O
secretion NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
behavioral NN NN O
effects NN NN O
of NN NN O
centrally NN NN O
administered NN NN O
U NN NN O
- NN NN O
II NN NN O
have NN NN O
received NN NN O
little NN NN O
attention NN NN O
. NN NN O
   
In NN NN O
the NN NN O
present NN NN O
study NN NN O
, NN NN O
we NN NN O
tested NN NN O
the NN NN O
effects NN NN O
of NN NN O
i NN NN O
. NN NN O
c NN NN O
. NN NN O
v NN NN O
. NN NN O
injections NN NN O
of NN NN O
U NN NN O
- NN NN O
II NN NN O
on NN NN O
behavioral NN NN O
, NN NN O
metabolic NN NN O
, NN NN O
and NN NN O
endocrine NN NN O
responses NN NN O
in NN NN O
mice NN NN O
. NN NN O
   
Administration NN NN O
of NN NN O
graded NN NN O
doses NN NN O
of NN NN O
U NN NN O
- NN NN O
II NN NN O
( NN NN O
1 NN NN O
- NN NN O
10 NN NN O
, NN NN O
000 NN NN O
ng NN NN O
/ NN NN O
mouse NN NN O
) NN NN O
provoked NN NN O
: NN NN O
( NN NN O
1 NN NN O
) NN NN O
a NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
reduction NN NN O
in NN NN O
the NN NN O
number NN NN O
of NN NN O
head NN NN O
dips NN NN O
in NN NN O
the NN NN O
hole NN NN O
- NN NN O
board NN NN O
test NN NN O
; NN NN O
( NN NN O
2 NN NN O
) NN NN O
a NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
reduction NN NN O
in NN NN O
the NN NN O
number NN NN O
of NN NN O
entries NN NN O
in NN NN O
the NN NN O
white NN NN O
chamber NN NN O
in NN NN O
the NN NN O
black NN NN O
- NN NN O
and NN NN O
- NN NN O
white NN NN O
compartment NN NN O
test NN NN O
, NN NN O
and NN NN O
in NN NN O
the NN NN O
number NN NN O
of NN NN O
entries NN NN O
in NN NN O
the NN NN O
central NN NN O
platform NN NN O
and NN NN O
open NN NN O
arms NN NN O
in NN NN O
the NN NN O
plus NN NN O
- NN NN O
maze NN NN O
test NN NN O
; NN NN O
and NN NN O
( NN NN O
3 NN NN O
) NN NN O
a NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
increase NN NN O
in NN NN O
the NN NN O
duration NN NN O
of NN NN O
immobility NN NN O
in NN NN O
the NN NN O
forced NN NN O
- NN NN O
swimming NN NN O
test NN NN O
and NN NN O
tail NN NN O
suspension NN NN O
test NN NN O
. NN NN O
   
Intracerebroventricular NN NN O
injection NN NN O
of NN NN O
U NN NN O
- NN NN O
II NN NN O
also NN NN O
caused NN NN O
an NN NN O
increase NN NN O
in NN NN O
: NN NN O
food NN NN O
intake NN NN O
at NN NN O
doses NN NN O
of NN NN O
100 NN NN O
and NN NN O
1 NN NN O
, NN NN O
000 NN NN O
ng NN NN O
/ NN NN O
mouse NN NN O
, NN NN O
water NN NN O
intake NN NN O
at NN NN O
doses NN NN O
of NN NN O
100 NN NN O
- NN NN O
10 NN NN O
, NN NN O
000 NN NN O
ng NN NN O
/ NN NN O
mouse NN NN O
, NN NN O
and NN NN O
horizontal NN NN O
locomotion NN NN O
activity NN NN O
at NN NN O
a NN NN O
dose NN NN O
of NN NN O
10 NN NN O
, NN NN O
000 NN NN O
ng NN NN O
/ NN NN O
mouse NN NN O
. NN NN O
   
Whatever NN NN O
was NN NN O
the NN NN O
dose NN NN O
, NN NN O
the NN NN O
central NN NN O
administration NN NN O
of NN NN O
U NN NN O
- NN NN O
II NN NN O
had NN NN O
no NN NN O
effect NN NN O
on NN NN O
body NN NN O
temperature NN NN O
, NN NN O
nociception NN NN O
, NN NN O
apomorphine NN NN O
- NN NN O
induced NN NN O
penile NN NN B-Disease
erection NN NN I-Disease
and NN NN O
climbing NN NN O
behavior NN NN O
, NN NN O
and NN NN O
stress NN NN O
- NN NN O
induced NN NN O
plasma NN NN O
corticosterone NN NN O
level NN NN O
. NN NN O
   
Taken NN NN O
together NN NN O
, NN NN O
the NN NN O
present NN NN O
study NN NN O
demonstrates NN NN O
that NN NN O
the NN NN O
central NN NN O
injection NN NN O
of NN NN O
U NN NN O
- NN NN O
II NN NN O
at NN NN O
doses NN NN O
of NN NN O
1 NN NN O
- NN NN O
10 NN NN O
, NN NN O
000 NN NN O
ng NN NN O
/ NN NN O
mouse NN NN O
induces NN NN O
anxiogenic NN NN O
- NN NN O
and NN NN O
depressant NN NN O
- NN NN O
like NN NN O
effects NN NN O
in NN NN O
mouse NN NN O
. NN NN O
   
These NN NN O
data NN NN O
suggest NN NN O
that NN NN O
U NN NN O
- NN NN O
II NN NN O
may NN NN O
be NN NN O
involved NN NN O
in NN NN O
some NN NN O
aspects NN NN O
of NN NN O
psychiatric NN NN B-Disease
disorders NN NN I-Disease
. NN NN O
   
Learning NN NN O
of NN NN O
rats NN NN O
under NN NN O
amnesia NN NN B-Disease
caused NN NN O
by NN NN O
pentobarbital NN NN O
. NN NN O
   
Dissociated NN NN O
learning NN NN O
of NN NN O
rats NN NN O
in NN NN O
the NN NN O
normal NN NN O
state NN NN O
and NN NN O
the NN NN O
state NN NN O
of NN NN O
amnesia NN NN B-Disease
produced NN NN O
by NN NN O
pentobarbital NN NN O
( NN NN O
15 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
ip NN NN O
) NN NN O
was NN NN O
carried NN NN O
out NN NN O
. NN NN O
   
Rats NN NN O
were NN NN O
trained NN NN O
to NN NN O
approach NN NN O
a NN NN O
shelf NN NN O
where NN NN O
they NN NN O
received NN NN O
food NN NN O
reinforcement NN NN O
. NN NN O
   
In NN NN O
Group NN NN O
1 NN NN O
the NN NN O
rats NN NN O
were NN NN O
trained NN NN O
under NN NN O
the NN NN O
influence NN NN O
of NN NN O
pentobarbital NN NN O
to NN NN O
run NN NN O
to NN NN O
the NN NN O
same NN NN O
shelf NN NN O
as NN NN O
in NN NN O
the NN NN O
normal NN NN O
state NN NN O
. NN NN O
   
In NN NN O
Group NN NN O
2 NN NN O
the NN NN O
rats NN NN O
were NN NN O
trained NN NN O
to NN NN O
approach NN NN O
different NN NN O
shelves NN NN O
in NN NN O
different NN NN O
drug NN NN O
states NN NN O
. NN NN O
   
It NN NN O
was NN NN O
shown NN NN O
that NN NN O
memory NN NN B-Disease
dissociation NN NN I-Disease
occurred NN NN O
in NN NN O
both NN NN O
groups NN NN O
. NN NN O
   
Differences NN NN O
in NN NN O
the NN NN O
parameters NN NN O
of NN NN O
training NN NN O
under NN NN O
the NN NN O
influence NN NN O
of NN NN O
pentobarbital NN NN O
between NN NN O
Groups NN NN O
1 NN NN O
and NN NN O
2 NN NN O
were NN NN O
revealed NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
show NN NN O
that NN NN O
the NN NN O
brain NN NN O
- NN NN O
dissociated NN NN O
state NN NN O
induced NN NN O
by NN NN O
pentobarbital NN NN O
is NN NN O
formed NN NN O
with NN NN O
the NN NN O
participation NN NN O
of NN NN O
the NN NN O
mechanisms NN NN O
of NN NN O
information NN NN O
perception NN NN O
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
short NN NN O
- NN NN O
term NN NN O
raloxifene NN NN O
therapy NN NN O
on NN NN O
fibrinolysis NN NN O
markers NN NN O
: NN NN O
TAFI NN NN O
, NN NN O
tPA NN NN O
, NN NN O
and NN NN O
PAI NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Markers NN NN O
of NN NN O
fibrinolysis NN NN O
, NN NN O
thrombin NN NN O
- NN NN O
activatable NN NN O
fibrinolysis NN NN O
inhibitor NN NN O
( NN NN O
TAFI NN NN O
) NN NN O
, NN NN O
tissue NN NN O
- NN NN O
type NN NN O
plasminogen NN NN O
activator NN NN O
( NN NN O
tPA NN NN O
) NN NN O
, NN NN O
and NN NN O
plasminogen NN NN O
activator NN NN O
inhibitor NN NN O
- NN NN O
1 NN NN O
( NN NN O
PAI NN NN O
- NN NN O
1 NN NN O
) NN NN O
levels NN NN O
were NN NN O
studied NN NN O
for NN NN O
the NN NN O
evaluation NN NN O
of NN NN O
short NN NN O
- NN NN O
term NN NN O
effects NN NN O
of NN NN O
raloxifene NN NN O
administration NN NN O
in NN NN O
postmenopausal NN NN O
women NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Thirty NN NN O
- NN NN O
nine NN NN O
postmenopausal NN NN O
women NN NN O
with NN NN O
osteopenia NN NN B-Disease
or NN NN O
osteoporosis NN NN B-Disease
were NN NN O
included NN NN O
in NN NN O
this NN NN O
prospective NN NN O
, NN NN O
controlled NN NN O
clinical NN NN O
study NN NN O
. NN NN O
   
Twenty NN NN O
- NN NN O
five NN NN O
women NN NN O
were NN NN O
given NN NN O
raloxifene NN NN O
hydrochloride NN NN O
( NN NN O
60 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
) NN NN O
plus NN NN O
calcium NN NN O
( NN NN O
500 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
) NN NN O
. NN NN O
   
Age NN NN O
- NN NN O
matched NN NN O
controls NN NN O
( NN NN O
n NN NN O
= NN NN O
14 NN NN O
) NN NN O
were NN NN O
given NN NN O
only NN NN O
calcium NN NN O
. NN NN O
   
Plasma NN NN O
TAFI NN NN O
, NN NN O
tPA NN NN O
, NN NN O
and NN NN O
PAI NN NN O
- NN NN O
1 NN NN O
antigen NN NN O
levels NN NN O
were NN NN O
measured NN NN O
at NN NN O
baseline NN NN O
and NN NN O
after NN NN O
3 NN NN O
months NN NN O
of NN NN O
treatment NN NN O
by NN NN O
commercially NN NN O
available NN NN O
ELISA NN NN O
kits NN NN O
. NN NN O
   
Variations NN NN O
of NN NN O
individuals NN NN O
were NN NN O
assessed NN NN O
by NN NN O
Wilcoxon NN NN O
' NN NN O
s NN NN O
test NN NN O
. NN NN O
   
Relationship NN NN O
between NN NN O
those NN NN O
markers NN NN O
and NN NN O
demographic NN NN O
characteristics NN NN O
were NN NN O
investigated NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Three NN NN O
months NN NN O
of NN NN O
raloxifene NN NN O
treatment NN NN O
was NN NN O
associated NN NN O
with NN NN O
a NN NN O
significant NN NN O
decrease NN NN O
in NN NN O
the NN NN O
plasma NN NN O
TAFI NN NN O
antigen NN NN O
concentrations NN NN O
( NN NN O
16 NN NN O
% NN NN O
change NN NN O
, NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
, NN NN O
and NN NN O
a NN NN O
significant NN NN O
increase NN NN O
in NN NN O
tPA NN NN O
antigen NN NN O
concentrations NN NN O
( NN NN O
25 NN NN O
% NN NN O
change NN NN O
, NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
A NN NN O
significant NN NN O
correlation NN NN O
was NN NN O
found NN NN O
between NN NN O
baseline NN NN O
TAFI NN NN O
antigen NN NN O
concentrations NN NN O
and NN NN O
the NN NN O
duration NN NN O
of NN NN O
amenorrhea NN NN B-Disease
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
; NN NN O
r NN NN O
= NN NN O
0 NN NN O
. NN NN O
33 NN NN O
) NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
We NN NN O
suggest NN NN O
that NN NN O
the NN NN O
increased NN NN O
risk NN NN O
of NN NN O
venous NN NN B-Disease
thromboembolism NN NN I-Disease
due NN NN O
to NN NN O
raloxifene NN NN O
treatment NN NN O
may NN NN O
be NN NN O
related NN NN O
to NN NN O
increased NN NN O
tPA NN NN O
levels NN NN O
, NN NN O
but NN NN O
not NN NN O
TAFI NN NN O
levels NN NN O
. NN NN O
   
Valproate NN NN O
- NN NN O
induced NN NN O
encephalopathy NN NN B-Disease
. NN NN O
   
Valproate NN NN O
- NN NN O
induced NN NN O
encephalopathy NN NN B-Disease
is NN NN O
a NN NN O
rare NN NN O
syndrome NN NN O
that NN NN O
may NN NN O
manifest NN NN O
in NN NN O
otherwise NN NN O
normal NN NN O
epileptic NN NN B-Disease
individuals NN NN O
. NN NN O
   
It NN NN O
may NN NN O
even NN NN O
present NN NN O
in NN NN O
patients NN NN O
who NN NN O
have NN NN O
tolerated NN NN O
this NN NN O
medicine NN NN O
well NN NN O
in NN NN O
the NN NN O
past NN NN O
. NN NN O
   
It NN NN O
is NN NN O
usually NN NN O
but NN NN O
not NN NN O
necessarily NN NN O
associated NN NN O
with NN NN O
hyperammonemia NN NN B-Disease
. NN NN O
   
The NN NN O
EEG NN NN O
shows NN NN O
characteristic NN NN O
triphasic NN NN O
waves NN NN O
in NN NN O
most NN NN O
patients NN NN O
with NN NN O
this NN NN O
complication NN NN O
. NN NN O
   
A NN NN O
case NN NN O
of NN NN O
valproate NN NN O
- NN NN O
induced NN NN O
encephalopathy NN NN B-Disease
is NN NN O
presented NN NN O
. NN NN O
   
The NN NN O
problems NN NN O
in NN NN O
diagnosing NN NN O
this NN NN O
condition NN NN O
are NN NN O
subsequently NN NN O
discussed NN NN O
. NN NN O
   
Recurrent NN NN O
dysphonia NN NN B-Disease
and NN NN O
acitretin NN NN O
. NN NN O
   
We NN NN O
report NN NN O
the NN NN O
case NN NN O
of NN NN O
a NN NN O
woman NN NN O
complaining NN NN O
of NN NN O
dysphonia NN NN B-Disease
while NN NN O
she NN NN O
was NN NN O
treated NN NN O
by NN NN O
acitretin NN NN O
. NN NN O
   
Her NN NN O
symptoms NN NN O
totally NN NN O
regressed NN NN O
after NN NN O
drug NN NN O
withdrawal NN NN O
and NN NN O
reappeared NN NN O
when NN NN O
acitretin NN NN O
was NN NN O
reintroduced NN NN O
. NN NN O
   
To NN NN O
our NN NN O
knowledge NN NN O
, NN NN O
this NN NN O
is NN NN O
the NN NN O
first NN NN O
case NN NN O
of NN NN O
acitretin NN NN O
- NN NN O
induced NN NN O
dysphonia NN NN B-Disease
. NN NN O
   
This NN NN O
effect NN NN O
may NN NN O
be NN NN O
related NN NN O
to NN NN O
the NN NN O
pharmacological NN NN O
effect NN NN O
of NN NN O
this NN NN O
drug NN NN O
on NN NN O
mucous NN NN O
membranes NN NN O
. NN NN O
   
Nitro NN NN O
- NN NN O
L NN NN O
- NN NN O
arginine NN NN O
methyl NN NN O
ester NN NN O
: NN NN O
a NN NN O
potential NN NN O
protector NN NN O
against NN NN O
gentamicin NN NN O
ototoxicity NN NN B-Disease
. NN NN O
   
The NN NN O
nitric NN NN O
oxide NN NN O
( NN NN O
NO NN NN O
) NN NN O
inhibitor NN NN O
nitro NN NN O
- NN NN O
L NN NN O
- NN NN O
arginine NN NN O
methyl NN NN O
ester NN NN O
( NN NN O
L NN NN O
- NN NN O
NAME NN NN O
) NN NN O
may NN NN O
act NN NN O
as NN NN O
an NN NN O
otoprotectant NN NN O
against NN NN O
high NN NN B-Disease
- NN NN I-Disease
frequency NN NN I-Disease
hearing NN NN I-Disease
loss NN NN I-Disease
caused NN NN O
by NN NN O
gentamicin NN NN O
, NN NN O
but NN NN O
further NN NN O
studies NN NN O
are NN NN O
needed NN NN O
to NN NN O
confirm NN NN O
this NN NN O
. NN NN O
Aminoglycoside NN NN O
antibiotics NN NN O
are NN NN O
still NN NN O
widely NN NN O
used NN NN O
by NN NN O
virtue NN NN O
of NN NN O
their NN NN O
efficacy NN NN O
and NN NN O
low NN NN O
cost NN NN O
. NN NN O
   
Their NN NN O
ototoxicity NN NN B-Disease
is NN NN O
a NN NN O
serious NN NN O
health NN NN O
problem NN NN O
and NN NN O
, NN NN O
as NN NN O
their NN NN O
ototoxic NN NN B-Disease
mechanism NN NN O
involves NN NN O
the NN NN O
production NN NN O
of NN NN O
NO NN NN O
, NN NN O
we NN NN O
need NN NN O
to NN NN O
assess NN NN O
the NN NN O
use NN NN O
of NN NN O
NO NN NN O
inhibitors NN NN O
for NN NN O
the NN NN O
prevention NN NN O
of NN NN O
aminoglycoside NN NN O
- NN NN O
induced NN NN O
sensorineural NN NN B-Disease
hearing NN NN I-Disease
loss NN NN I-Disease
. NN NN O
   
In NN NN O
this NN NN O
experimental NN NN O
study NN NN O
we NN NN O
used NN NN O
30 NN NN O
Sprague NN NN O
- NN NN O
Dawley NN NN O
rats NN NN O
, NN NN O
27 NN NN O
of NN NN O
which NN NN O
had NN NN O
gentamicin NN NN O
instilled NN NN O
into NN NN O
the NN NN O
middle NN NN O
ear NN NN O
. NN NN O
   
The NN NN O
otoprotectant NN NN O
L NN NN O
- NN NN O
NAME NN NN O
was NN NN O
administered NN NN O
topically NN NN O
to NN NN O
12 NN NN O
/ NN NN O
27 NN NN O
animals NN NN O
. NN NN O
   
Its NN NN O
effect NN NN O
was NN NN O
determined NN NN O
in NN NN O
terms NN NN O
of NN NN O
attenuation NN NN O
of NN NN O
hearing NN NN B-Disease
loss NN NN I-Disease
, NN NN O
measured NN NN O
by NN NN O
shifts NN NN O
in NN NN O
the NN NN O
auditory NN NN O
brainstem NN NN O
response NN NN O
threshold NN NN O
. NN NN O
   
L NN NN O
- NN NN O
NAME NN NN O
reduced NN NN O
gentamicin NN NN O
- NN NN O
induced NN NN O
hearing NN NN B-Disease
loss NN NN I-Disease
in NN NN O
the NN NN O
high NN NN O
- NN NN O
frequency NN NN O
range NN NN O
, NN NN O
but NN NN O
gave NN NN O
no NN NN O
protection NN NN O
in NN NN O
the NN NN O
middle NN NN O
or NN NN O
low NN NN O
frequencies NN NN O
. NN NN O
   
Safety NN NN O
profile NN NN O
of NN NN O
a NN NN O
nicotine NN NN O
lozenge NN NN O
compared NN NN O
with NN NN O
that NN NN O
of NN NN O
nicotine NN NN O
gum NN NN O
in NN NN O
adult NN NN O
smokers NN NN O
with NN NN O
underlying NN NN O
medical NN NN O
conditions NN NN O
: NN NN O
a NN NN O
12 NN NN O
- NN NN O
week NN NN O
, NN NN O
randomized NN NN O
, NN NN O
open NN NN O
- NN NN O
label NN NN O
study NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Nicotine NN NN O
polacrilex NN NN O
lozenges NN NN O
deliver NN NN O
25 NN NN O
% NN NN O
to NN NN O
27 NN NN O
% NN NN O
more NN NN O
nicotine NN NN O
compared NN NN O
with NN NN O
equivalent NN NN O
doses NN NN O
of NN NN O
nicotine NN NN O
polacrilex NN NN O
gum NN NN O
. NN NN O
   
The NN NN O
increased NN NN O
nicotine NN NN O
exposure NN NN O
from NN NN O
the NN NN O
lozenge NN NN O
has NN NN O
raised NN NN O
questions NN NN O
about NN NN O
the NN NN O
relative NN NN O
safety NN NN O
of NN NN O
the NN NN O
lozenge NN NN O
and NN NN O
gum NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
The NN NN O
objective NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
compare NN NN O
the NN NN O
safety NN NN O
profiles NN NN O
of NN NN O
the NN NN O
4 NN NN O
- NN NN O
mg NN NN O
nicotine NN NN O
lozenge NN NN O
and NN NN O
4 NN NN O
- NN NN O
mg NN NN O
nicotine NN NN O
gum NN NN O
in NN NN O
smokers NN NN O
with NN NN O
selected NN NN O
label NN NN O
- NN NN O
restricted NN NN O
diseases NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
This NN NN O
was NN NN O
a NN NN O
multicenter NN NN O
, NN NN O
randomized NN NN O
, NN NN O
open NN NN O
- NN NN O
label NN NN O
study NN NN O
in NN NN O
adult NN NN O
smokers NN NN O
with NN NN O
heart NN NN B-Disease
disease NN NN I-Disease
, NN NN O
hypertension NN NN B-Disease
not NN NN O
controlled NN NN O
by NN NN O
medication NN NN O
, NN NN O
and NN NN O
/ NN NN O
or NN NN O
diabetes NN NN B-Disease
mellitus NN NN I-Disease
. NN NN O
   
Patients NN NN O
were NN NN O
randomized NN NN O
in NN NN O
a NN NN O
1 NN NN O
: NN NN O
1 NN NN O
ratio NN NN O
to NN NN O
receive NN NN O
the NN NN O
4 NN NN O
- NN NN O
mg NN NN O
nicotine NN NN O
lozenge NN NN O
or NN NN O
4 NN NN O
- NN NN O
mg NN NN O
nicotine NN NN O
gum NN NN O
. NN NN O
   
Safety NN NN O
assessments NN NN O
were NN NN O
made NN NN O
at NN NN O
baseline NN NN O
and NN NN O
at NN NN O
2 NN NN O
, NN NN O
4 NN NN O
, NN NN O
6 NN NN O
, NN NN O
and NN NN O
12 NN NN O
weeks NN NN O
after NN NN O
the NN NN O
start NN NN O
of NN NN O
product NN NN O
use NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Nine NN NN O
hundred NN NN O
one NN NN O
patients NN NN O
were NN NN O
randomized NN NN O
to NN NN O
treatment NN NN O
, NN NN O
447 NN NN O
who NN NN O
received NN NN O
the NN NN O
lozenge NN NN O
and NN NN O
454 NN NN O
who NN NN O
received NN NN O
the NN NN O
gum NN NN O
( NN NN O
safety NN NN O
population NN NN O
) NN NN O
. NN NN O
   
The NN NN O
majority NN NN O
were NN NN O
women NN NN O
( NN NN O
52 NN NN O
. NN NN O
7 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
Patients NN NN O
' NN NN O
mean NN NN O
age NN NN O
was NN NN O
53 NN NN O
. NN NN O
9 NN NN O
years NN NN O
, NN NN O
their NN NN O
mean NN NN O
weight NN NN O
was NN NN O
193 NN NN O
. NN NN O
9 NN NN O
pounds NN NN O
, NN NN O
and NN NN O
they NN NN O
smoked NN NN O
a NN NN O
mean NN NN O
of NN NN O
25 NN NN O
. NN NN O
2 NN NN O
cigarettes NN NN O
per NN NN O
day NN NN O
at NN NN O
baseline NN NN O
. NN NN O
   
Five NN NN O
hundred NN NN O
fifty NN NN O
- NN NN O
three NN NN O
patients NN NN O
, NN NN O
264 NN NN O
taking NN NN O
the NN NN O
lozenge NN NN O
and NN NN O
289 NN NN O
taking NN NN O
the NN NN O
gum NN NN O
, NN NN O
used NN NN O
the NN NN O
study NN NN O
product NN NN O
for NN NN O
> NN NN O
or NN NN O
= NN NN O
4 NN NN O
days NN NN O
per NN NN O
week NN NN O
during NN NN O
the NN NN O
first NN NN O
2 NN NN O
weeks NN NN O
( NN NN O
evaluable NN NN O
population NN NN O
) NN NN O
. NN NN O
   
The NN NN O
nicotine NN NN O
lozenge NN NN O
and NN NN O
nicotine NN NN O
gum NN NN O
were NN NN O
equally NN NN O
well NN NN O
tolerated NN NN O
, NN NN O
despite NN NN O
increased NN NN O
nicotine NN NN O
exposure NN NN O
from NN NN O
the NN NN O
lozenge NN NN O
. NN NN O
   
The NN NN O
incidence NN NN O
of NN NN O
adverse NN NN O
events NN NN O
in NN NN O
the NN NN O
2 NN NN O
groups NN NN O
was NN NN O
similar NN NN O
during NN NN O
the NN NN O
first NN NN O
2 NN NN O
weeks NN NN O
of NN NN O
product NN NN O
use NN NN O
( NN NN O
evaluation NN NN O
population NN NN O
: NN NN O
55 NN NN O
. NN NN O
3 NN NN O
% NN NN O
lozenge NN NN O
, NN NN O
54 NN NN O
. NN NN O
7 NN NN O
% NN NN O
gum NN NN O
) NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
during NN NN O
the NN NN O
entire NN NN O
study NN NN O
( NN NN O
safety NN NN O
population NN NN O
: NN NN O
63 NN NN O
. NN NN O
8 NN NN O
% NN NN O
and NN NN O
58 NN NN O
. NN NN O
6 NN NN O
% NN NN O
, NN NN O
respectively NN NN O
) NN NN O
. NN NN O
   
Stratification NN NN O
of NN NN O
patients NN NN O
by NN NN O
sex NN NN O
, NN NN O
age NN NN O
, NN NN O
extent NN NN O
of NN NN O
concurrent NN NN O
smoking NN NN O
, NN NN O
extent NN NN O
of NN NN O
product NN NN O
use NN NN O
, NN NN O
and NN NN O
severity NN NN O
of NN NN O
adverse NN NN O
events NN NN O
revealed NN NN O
no NN NN O
clinically NN NN O
significant NN NN O
differences NN NN O
between NN NN O
the NN NN O
lozenge NN NN O
and NN NN O
gum NN NN O
. NN NN O
   
The NN NN O
most NN NN O
common NN NN O
adverse NN NN O
events NN NN O
were NN NN O
nausea NN NN B-Disease
( NN NN O
17 NN NN O
. NN NN O
2 NN NN O
% NN NN O
and NN NN O
16 NN NN O
. NN NN O
1 NN NN O
% NN NN O
; NN NN O
95 NN NN O
% NN NN O
CI NN NN O
, NN NN O
- NN NN O
3 NN NN O
. NN NN O
7 NN NN O
to NN NN O
6 NN NN O
. NN NN O
0 NN NN O
) NN NN O
, NN NN O
hiccups NN NN B-Disease
( NN NN O
10 NN NN O
. NN NN O
7 NN NN O
% NN NN O
and NN NN O
6 NN NN O
. NN NN O
6 NN NN O
% NN NN O
; NN NN O
95 NN NN O
% NN NN O
CI NN NN O
, NN NN O
0 NN NN O
. NN NN O
5 NN NN O
to NN NN O
7 NN NN O
. NN NN O
8 NN NN O
) NN NN O
, NN NN O
and NN NN O
headache NN NN B-Disease
( NN NN O
8 NN NN O
. NN NN O
7 NN NN O
% NN NN O
and NN NN O
9 NN NN O
. NN NN O
9 NN NN O
% NN NN O
; NN NN O
95 NN NN O
% NN NN O
Cl NN NN O
, NN NN O
- NN NN O
5 NN NN O
. NN NN O
0 NN NN O
to NN NN O
2 NN NN O
. NN NN O
6 NN NN O
) NN NN O
. NN NN O
   
Serious NN NN O
adverse NN NN O
events NN NN O
were NN NN O
reported NN NN O
in NN NN O
11 NN NN O
and NN NN O
13 NN NN O
patients NN NN O
in NN NN O
the NN NN O
respective NN NN O
groups NN NN O
. NN NN O
   
Fewer NN NN O
than NN NN O
6 NN NN O
% NN NN O
of NN NN O
patients NN NN O
in NN NN O
either NN NN O
group NN NN O
were NN NN O
considered NN NN O
by NN NN O
the NN NN O
investigator NN NN O
to NN NN O
have NN NN O
a NN NN O
worsening NN NN O
of NN NN O
their NN NN O
overall NN NN O
disease NN NN O
condition NN NN O
during NN NN O
the NN NN O
study NN NN O
. NN NN O
   
The NN NN O
majority NN NN O
of NN NN O
patients NN NN O
( NN NN O
> NN NN O
60 NN NN O
% NN NN O
) NN NN O
experienced NN NN O
no NN NN O
change NN NN O
in NN NN O
their NN NN O
disease NN NN O
status NN NN O
from NN NN O
baseline NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
The NN NN O
4 NN NN O
- NN NN O
mg NN NN O
nicotine NN NN O
lozenge NN NN O
and NN NN O
4 NN NN O
- NN NN O
mg NN NN O
nicotine NN NN O
gum NN NN O
had NN NN O
comparable NN NN O
safety NN NN O
profiles NN NN O
in NN NN O
these NN NN O
patients NN NN O
with NN NN O
label NN NN O
- NN NN O
restricted NN NN O
medical NN NN O
conditions NN NN O
. NN NN O
   
Pharmacological NN NN O
modulation NN NN O
of NN NN O
pain NN NN B-Disease
- NN NN O
related NN NN O
brain NN NN O
activity NN NN O
during NN NN O
normal NN NN O
and NN NN O
central NN NN O
sensitization NN NN O
states NN NN O
in NN NN O
humans NN NN O
. NN NN O
   
Abnormal NN NN O
processing NN NN O
of NN NN O
somatosensory NN NN O
inputs NN NN O
in NN NN O
the NN NN O
central NN NN O
nervous NN NN O
system NN NN O
( NN NN O
central NN NN O
sensitization NN NN O
) NN NN O
is NN NN O
the NN NN O
mechanism NN NN O
accounting NN NN O
for NN NN O
the NN NN O
enhanced NN NN O
pain NN NN B-Disease
sensitivity NN NN O
in NN NN O
the NN NN O
skin NN NN O
surrounding NN NN O
tissue NN NN B-Disease
injury NN NN I-Disease
( NN NN O
secondary NN NN B-Disease
hyperalgesia NN NN I-Disease
) NN NN O
. NN NN O
   
Secondary NN NN B-Disease
hyperalgesia NN NN I-Disease
shares NN NN O
clinical NN NN O
characteristics NN NN O
with NN NN O
neurogenic NN NN B-Disease
hyperalgesia NN NN I-Disease
in NN NN O
patients NN NN O
with NN NN O
neuropathic NN NN B-Disease
pain NN NN I-Disease
. NN NN O
   
Abnormal NN NN O
brain NN NN O
responses NN NN O
to NN NN O
somatosensory NN NN O
stimuli NN NN O
have NN NN O
been NN NN O
found NN NN O
in NN NN O
patients NN NN O
with NN NN O
hyperalgesia NN NN B-Disease
as NN NN O
well NN NN O
as NN NN O
in NN NN O
normal NN NN O
subjects NN NN O
during NN NN O
experimental NN NN O
central NN NN O
sensitization NN NN O
. NN NN O
   
The NN NN O
aim NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
assess NN NN O
the NN NN O
effects NN NN O
of NN NN O
gabapentin NN NN O
, NN NN O
a NN NN O
drug NN NN O
effective NN NN O
in NN NN O
neuropathic NN NN B-Disease
pain NN NN I-Disease
patients NN NN O
, NN NN O
on NN NN O
brain NN NN O
processing NN NN O
of NN NN O
nociceptive NN NN O
information NN NN O
in NN NN O
normal NN NN O
and NN NN O
central NN NN O
sensitization NN NN O
states NN NN O
. NN NN O
   
Using NN NN O
functional NN NN O
magnetic NN NN O
resonance NN NN O
imaging NN NN O
( NN NN O
fMRI NN NN O
) NN NN O
in NN NN O
normal NN NN O
volunteers NN NN O
, NN NN O
we NN NN O
studied NN NN O
the NN NN O
gabapentin NN NN O
- NN NN O
induced NN NN O
modulation NN NN O
of NN NN O
brain NN NN O
activity NN NN O
in NN NN O
response NN NN O
to NN NN O
nociceptive NN NN O
mechanical NN NN O
stimulation NN NN O
of NN NN O
normal NN NN O
skin NN NN O
and NN NN O
capsaicin NN NN O
- NN NN O
induced NN NN O
secondary NN NN B-Disease
hyperalgesia NN NN I-Disease
. NN NN O
   
The NN NN O
dose NN NN O
of NN NN O
gabapentin NN NN O
was NN NN O
1 NN NN O
, NN NN O
800 NN NN O
mg NN NN O
per NN NN O
os NN NN O
, NN NN O
in NN NN O
a NN NN O
single NN NN O
administration NN NN O
. NN NN O
   
We NN NN O
found NN NN O
that NN NN O
( NN NN O
i NN NN O
) NN NN O
gabapentin NN NN O
reduced NN NN O
the NN NN O
activations NN NN O
in NN NN O
the NN NN O
bilateral NN NN O
operculoinsular NN NN O
cortex NN NN O
, NN NN O
independently NN NN O
of NN NN O
the NN NN O
presence NN NN O
of NN NN O
central NN NN O
sensitization NN NN O
; NN NN O
( NN NN O
ii NN NN O
) NN NN O
gabapentin NN NN O
reduced NN NN O
the NN NN O
activation NN NN O
in NN NN O
the NN NN O
brainstem NN NN O
, NN NN O
only NN NN O
during NN NN O
central NN NN O
sensitization NN NN O
; NN NN O
( NN NN O
iii NN NN O
) NN NN O
gabapentin NN NN O
suppressed NN NN O
stimulus NN NN O
- NN NN O
induced NN NN O
deactivations NN NN O
, NN NN O
only NN NN O
during NN NN O
central NN NN O
sensitization NN NN O
; NN NN O
this NN NN O
effect NN NN O
was NN NN O
more NN NN O
robust NN NN O
than NN NN O
the NN NN O
effect NN NN O
on NN NN O
brain NN NN O
activation NN NN O
. NN NN O
   
The NN NN O
observed NN NN O
drug NN NN O
- NN NN O
induced NN NN O
effects NN NN O
were NN NN O
not NN NN O
due NN NN O
to NN NN O
changes NN NN O
in NN NN O
the NN NN O
baseline NN NN O
fMRI NN NN O
signal NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
indicate NN NN O
that NN NN O
gabapentin NN NN O
has NN NN O
a NN NN O
measurable NN NN O
antinociceptive NN NN O
effect NN NN O
and NN NN O
a NN NN O
stronger NN NN O
antihyperalgesic NN NN O
effect NN NN O
most NN NN O
evident NN NN O
in NN NN O
the NN NN O
brain NN NN O
areas NN NN O
undergoing NN NN O
deactivation NN NN O
, NN NN O
thus NN NN O
supporting NN NN O
the NN NN O
concept NN NN O
that NN NN O
gabapentin NN NN O
is NN NN O
more NN NN O
effective NN NN O
in NN NN O
modulating NN NN O
nociceptive NN NN O
transmission NN NN O
when NN NN O
central NN NN O
sensitization NN NN O
is NN NN O
present NN NN O
. NN NN O
   
Investigation NN NN O
of NN NN O
mitochondrial NN NN O
involvement NN NN O
in NN NN O
the NN NN O
experimental NN NN O
model NN NN O
of NN NN O
epilepsy NN NN B-Disease
induced NN NN O
by NN NN O
pilocarpine NN NN O
. NN NN O
   
Mitochondrial NN NN B-Disease
abnormalities NN NN I-Disease
have NN NN O
been NN NN O
associated NN NN O
with NN NN O
several NN NN O
aspects NN NN O
of NN NN O
epileptogenesis NN NN O
, NN NN O
such NN NN O
as NN NN O
energy NN NN O
generation NN NN O
, NN NN O
control NN NN O
of NN NN O
cell NN NN O
death NN NN B-Disease
, NN NN O
neurotransmitter NN NN O
synthesis NN NN O
, NN NN O
and NN NN O
free NN NN O
radical NN NN O
( NN NN O
FR NN NN O
) NN NN O
production NN NN O
. NN NN O
   
Increased NN NN O
production NN NN O
of NN NN O
FRs NN NN O
may NN NN O
cause NN NN O
mtDNA NN NN O
damage NN NN O
leading NN NN O
to NN NN O
decreased NN NN O
activities NN NN O
of NN NN O
oxidative NN NN O
phosphorylation NN NN O
complexes NN NN O
containing NN NN O
mtDNA NN NN O
- NN NN O
encoded NN NN O
subunits NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
investigated NN NN O
whether NN NN O
increased NN NN O
generation NN NN O
of NN NN O
FR NN NN O
during NN NN O
status NN NN B-Disease
epilepticus NN NN I-Disease
would NN NN O
be NN NN O
sufficient NN NN O
to NN NN O
provoke NN NN O
abnormalities NN NN O
in NN NN O
mtDNA NN NN O
and NN NN O
in NN NN O
the NN NN O
expression NN NN O
and NN NN O
activity NN NN O
of NN NN O
cytochrome NN NN O
c NN NN O
oxidase NN NN O
( NN NN O
CCO NN NN O
) NN NN O
, NN NN O
complex NN NN O
IV NN NN O
of NN NN O
the NN NN O
respiratory NN NN O
chain NN NN O
, NN NN O
in NN NN O
the NN NN O
chronic NN NN O
phase NN NN O
of NN NN O
the NN NN O
pilocarpine NN NN O
model NN NN O
of NN NN O
temporal NN NN B-Disease
lobe NN NN I-Disease
epilepsy NN NN I-Disease
. NN NN O
   
DNA NN NN O
analysis NN NN O
revealed NN NN O
low NN NN O
amounts NN NN O
of NN NN O
a NN NN O
4 NN NN O
. NN NN O
8 NN NN O
kb NN NN O
mtDNA NN NN O
deletion NN NN O
but NN NN O
with NN NN O
no NN NN O
differences NN NN O
in NN NN O
frequency NN NN O
or NN NN O
quantity NN NN O
in NN NN O
the NN NN O
control NN NN O
and NN NN O
experimental NN NN O
groups NN NN O
. NN NN O
   
We NN NN O
did NN NN O
not NN NN O
find NN NN O
abnormalities NN NN O
in NN NN O
the NN NN O
expression NN NN O
and NN NN O
distribution NN NN O
of NN NN O
an NN NN O
mtDNA NN NN O
- NN NN O
encoded NN NN O
subunit NN NN O
of NN NN O
CCO NN NN O
( NN NN O
CCO NN NN O
- NN NN O
I NN NN O
) NN NN O
or NN NN O
a NN NN O
relative NN NN O
decrease NN NN O
in NN NN O
CCO NN NN O
- NN NN O
I NN NN O
when NN NN O
compared NN NN O
with NN NN O
nuclear NN NN O
- NN NN O
encoded NN NN O
subunits NN NN O
( NN NN O
CCO NN NN O
- NN NN O
IV NN NN O
and NN NN O
SDH NN NN O
- NN NN O
fp NN NN O
) NN NN O
. NN NN O
   
No NN NN O
abnormality NN NN O
in NN NN O
CCO NN NN O
activity NN NN O
was NN NN O
observed NN NN O
through NN NN O
histochemistry NN NN O
. NN NN O
   
Although NN NN O
evidences NN NN O
of NN NN O
mitochondrial NN NN B-Disease
abnormalities NN NN I-Disease
were NN NN O
found NN NN O
in NN NN O
previously NN NN O
published NN NN O
studies NN NN O
, NN NN O
our NN NN O
results NN NN O
do NN NN O
not NN NN O
suggest NN NN O
that NN NN O
the NN NN O
FRs NN NN O
, NN NN O
generated NN NN O
during NN NN O
the NN NN O
acute NN NN O
phase NN NN O
, NN NN O
determined NN NN O
important NN NN O
abnormalities NN NN O
in NN NN O
mtDNA NN NN O
, NN NN O
in NN NN O
expression NN NN O
of NN NN O
CCO NN NN O
- NN NN O
I NN NN O
, NN NN O
and NN NN O
in NN NN O
CCO NN NN O
activity NN NN O
. NN NN O
   
Adverse NN NN O
effect NN NN O
of NN NN O
the NN NN O
calcium NN NN O
channel NN NN O
blocker NN NN O
nitrendipine NN NN O
on NN NN O
nephrosclerosis NN NN B-Disease
in NN NN O
rats NN NN O
with NN NN O
renovascular NN NN B-Disease
hypertension NN NN I-Disease
. NN NN O
   
The NN NN O
effect NN NN O
of NN NN O
a NN NN O
6 NN NN O
- NN NN O
week NN NN O
treatment NN NN O
with NN NN O
the NN NN O
calcium NN NN O
channel NN NN O
blocker NN NN O
nitrendipine NN NN O
or NN NN O
the NN NN O
angiotensin NN NN O
converting NN NN O
enzyme NN NN O
inhibitor NN NN O
enalapril NN NN O
on NN NN O
blood NN NN O
pressure NN NN O
, NN NN O
albuminuria NN NN B-Disease
, NN NN O
renal NN NN O
hemodynamics NN NN O
, NN NN O
and NN NN O
morphology NN NN O
of NN NN O
the NN NN O
nonclipped NN NN O
kidney NN NN O
was NN NN O
studied NN NN O
in NN NN O
rats NN NN O
with NN NN O
two NN NN O
- NN NN O
kidney NN NN O
, NN NN O
one NN NN O
clip NN NN O
renovascular NN NN B-Disease
hypertension NN NN I-Disease
. NN NN O
   
Six NN NN O
weeks NN NN O
after NN NN O
clipping NN NN O
of NN NN O
one NN NN O
renal NN NN O
artery NN NN O
, NN NN O
hypertensive NN NN B-Disease
rats NN NN O
( NN NN O
178 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
4 NN NN O
mm NN NN O
Hg NN NN O
) NN NN O
were NN NN O
randomly NN NN O
assigned NN NN O
to NN NN O
three NN NN O
groups NN NN O
: NN NN O
untreated NN NN O
hypertensive NN NN B-Disease
controls NN NN O
( NN NN O
n NN NN O
= NN NN O
8 NN NN O
) NN NN O
, NN NN O
enalapril NN NN O
- NN NN O
treated NN NN O
( NN NN O
n NN NN O
= NN NN O
8 NN NN O
) NN NN O
, NN NN O
or NN NN O
nitrendipine NN NN O
- NN NN O
treated NN NN O
( NN NN O
n NN NN O
= NN NN O
10 NN NN O
) NN NN O
. NN NN O
   
Sham NN NN O
- NN NN O
operated NN NN O
rats NN NN O
served NN NN O
as NN NN O
normotensive NN NN O
controls NN NN O
( NN NN O
128 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
3 NN NN O
mm NN NN O
Hg NN NN O
, NN NN O
n NN NN O
= NN NN O
8 NN NN O
) NN NN O
. NN NN O
   
After NN NN O
6 NN NN O
weeks NN NN O
of NN NN O
treatment NN NN O
, NN NN O
renal NN NN O
hemodynamics NN NN O
( NN NN O
glomerular NN NN O
filtration NN NN O
rate NN NN O
and NN NN O
renal NN NN O
plasma NN NN O
flow NN NN O
) NN NN O
were NN NN O
measured NN NN O
in NN NN O
the NN NN O
anesthetized NN NN O
rats NN NN O
. NN NN O
   
Renal NN NN O
tissue NN NN O
was NN NN O
obtained NN NN O
for NN NN O
determination NN NN O
of NN NN O
glomerular NN NN O
size NN NN O
and NN NN O
sclerosis NN NN O
. NN NN O
   
Enalapril NN NN O
but NN NN O
not NN NN O
nitrendipine NN NN O
reduced NN NN O
blood NN NN O
pressure NN NN O
significantly NN NN O
. NN NN O
   
After NN NN O
6 NN NN O
weeks NN NN O
of NN NN O
therapy NN NN O
, NN NN O
glomerular NN NN O
filtration NN NN O
rate NN NN O
was NN NN O
not NN NN O
different NN NN O
among NN NN O
the NN NN O
studied NN NN O
groups NN NN O
. NN NN O
   
Renal NN NN O
plasma NN NN O
flow NN NN O
increased NN NN O
, NN NN O
but NN NN O
albumin NN NN O
excretion NN NN O
and NN NN O
glomerulosclerosis NN NN B-Disease
did NN NN O
not NN NN O
change NN NN O
after NN NN O
enalapril NN NN O
treatment NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
in NN NN O
the NN NN O
nitrendipine NN NN O
- NN NN O
treated NN NN O
group NN NN O
albuminuria NN NN B-Disease
increased NN NN O
from NN NN O
12 NN NN O
. NN NN O
8 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
progressively NN NN O
to NN NN O
163 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
55 NN NN O
compared NN NN O
with NN NN O
19 NN NN O
. NN NN O
2 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
9 NN NN O
mg NN NN O
/ NN NN O
24 NN NN O
hr NN NN O
in NN NN O
the NN NN O
hypertensive NN NN B-Disease
controls NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
glomerulosclerosis NN NN B-Disease
index NN NN O
was NN NN O
significantly NN NN O
increased NN NN O
in NN NN O
the NN NN O
nitrendipine NN NN O
- NN NN O
treated NN NN O
group NN NN O
compared NN NN O
with NN NN O
the NN NN O
hypertensive NN NN B-Disease
controls NN NN O
( NN NN O
0 NN NN O
. NN NN O
38 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
1 NN NN O
versus NN NN O
0 NN NN O
. NN NN O
13 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
04 NN NN O
) NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
glomerular NN NN O
size NN NN O
was NN NN O
higher NN NN O
in NN NN O
the NN NN O
nitrendipine NN NN O
- NN NN O
treated NN NN O
group NN NN O
( NN NN O
14 NN NN O
. NN NN O
9 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
17 NN NN O
10 NN NN O
( NN NN O
- NN NN O
3 NN NN O
) NN NN O
mm2 NN NN O
) NN NN O
but NN NN O
lower NN NN O
in NN NN O
the NN NN O
enalapril NN NN O
- NN NN O
treated NN NN O
group NN NN O
( NN NN O
11 NN NN O
. NN NN O
5 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
15 NN NN O
10 NN NN O
( NN NN O
- NN NN O
3 NN NN O
) NN NN O
mm2 NN NN O
) NN NN O
compared NN NN O
with NN NN O
the NN NN O
hypertensive NN NN B-Disease
controls NN NN O
( NN NN O
12 NN NN O
. NN NN O
1 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
17 NN NN O
10 NN NN O
( NN NN O
- NN NN O
3 NN NN O
) NN NN O
mm2 NN NN O
) NN NN O
. NN NN O
( NN NN O
ABSTRACT NN NN O
TRUNCATED NN NN O
AT NN NN O
250 NN NN O
WORDS NN NN O
) NN NN O
   
Ketoconazole NN NN O
induced NN NN O
torsades NN NN B-Disease
de NN NN I-Disease
pointes NN NN I-Disease
without NN NN O
concomitant NN NN O
use NN NN O
of NN NN O
QT NN NN O
interval NN NN O
- NN NN O
prolonging NN NN O
drug NN NN O
. NN NN O
   
Ketoconazole NN NN O
is NN NN O
not NN NN O
known NN NN O
to NN NN O
be NN NN O
proarrhythmic NN NN O
without NN NN O
concomitant NN NN O
use NN NN O
of NN NN O
QT NN NN O
interval NN NN O
- NN NN O
prolonging NN NN O
drugs NN NN O
. NN NN O
   
We NN NN O
report NN NN O
a NN NN O
woman NN NN O
with NN NN O
coronary NN NN B-Disease
artery NN NN I-Disease
disease NN NN I-Disease
who NN NN O
developed NN NN O
a NN NN O
markedly NN NN O
prolonged NN NN B-Disease
QT NN NN I-Disease
interval NN NN I-Disease
and NN NN O
torsades NN NN B-Disease
de NN NN I-Disease
pointes NN NN I-Disease
( NN NN O
TdP NN NN B-Disease
) NN NN O
after NN NN O
taking NN NN O
ketoconazole NN NN O
for NN NN O
treatment NN NN O
of NN NN O
fungal NN NN B-Disease
infection NN NN I-Disease
. NN NN O
   
Her NN NN O
QT NN NN O
interval NN NN O
returned NN NN O
to NN NN O
normal NN NN O
upon NN NN O
withdrawal NN NN O
of NN NN O
ketoconazole NN NN O
. NN NN O
   
Genetic NN NN O
study NN NN O
did NN NN O
not NN NN O
find NN NN O
any NN NN O
mutation NN NN O
in NN NN O
her NN NN O
genes NN NN O
that NN NN O
encode NN NN O
cardiac NN NN O
IKr NN NN O
channel NN NN O
proteins NN NN O
. NN NN O
   
We NN NN O
postulate NN NN O
that NN NN O
by NN NN O
virtue NN NN O
of NN NN O
its NN NN O
direct NN NN O
blocking NN NN O
action NN NN O
on NN NN O
IKr NN NN O
, NN NN O
ketoconazole NN NN O
alone NN NN O
may NN NN O
prolong NN NN O
QT NN NN O
interval NN NN O
and NN NN O
induce NN NN O
TdP NN NN B-Disease
. NN NN O
   
This NN NN O
calls NN NN O
for NN NN O
attention NN NN O
when NN NN O
ketoconazole NN NN O
is NN NN O
administered NN NN O
to NN NN O
patients NN NN O
with NN NN O
risk NN NN O
factors NN NN O
for NN NN O
acquired NN NN O
long NN NN B-Disease
QT NN NN I-Disease
syndrome NN NN I-Disease
. NN NN O
   
Cerebral NN NN B-Disease
vasculitis NN NN I-Disease
following NN NN O
oral NN NN O
methylphenidate NN NN O
intake NN NN O
in NN NN O
an NN NN O
adult NN NN O
: NN NN O
a NN NN O
case NN NN O
report NN NN O
. NN NN O
   
Methylphenidate NN NN O
is NN NN O
structurally NN NN O
and NN NN O
functionally NN NN O
similar NN NN O
to NN NN O
amphetamine NN NN O
. NN NN O
   
Cerebral NN NN B-Disease
vasculitis NN NN I-Disease
associated NN NN O
with NN NN O
amphetamine NN NN B-Disease
abuse NN NN I-Disease
is NN NN O
well NN NN O
documented NN NN O
, NN NN O
and NN NN O
in NN NN O
rare NN NN O
cases NN NN O
ischaemic NN NN B-Disease
stroke NN NN I-Disease
has NN NN O
been NN NN O
reported NN NN O
after NN NN O
methylphenidate NN NN O
intake NN NN O
in NN NN O
children NN NN O
. NN NN O
   
We NN NN O
report NN NN O
the NN NN O
case NN NN O
of NN NN O
a NN NN O
63 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
female NN NN O
who NN NN O
was NN NN O
treated NN NN O
with NN NN O
methylphenidate NN NN O
due NN NN O
to NN NN O
hyperactivity NN NN B-Disease
and NN NN O
suffered NN NN O
from NN NN O
multiple NN NN O
ischaemic NN NN B-Disease
strokes NN NN I-Disease
. NN NN O
   
We NN NN O
consider NN NN O
drug NN NN O
- NN NN O
induced NN NN O
cerebral NN NN B-Disease
vasculitis NN NN I-Disease
as NN NN O
the NN NN O
most NN NN O
likely NN NN O
cause NN NN O
of NN NN O
recurrent NN NN O
ischaemic NN NN B-Disease
strokes NN NN I-Disease
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
any NN NN O
pathological NN NN O
findings NN NN O
during NN NN O
the NN NN O
diagnostic NN NN O
work NN NN O
- NN NN O
up NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
methylphenidate NN NN O
mediated NN NN O
vasculitis NN NN B-Disease
should NN NN O
be NN NN O
considered NN NN O
in NN NN O
patients NN NN O
with NN NN O
neurological NN NN O
symptoms NN NN O
and NN NN O
a NN NN O
history NN NN O
of NN NN O
methylphenidate NN NN O
therapy NN NN O
. NN NN O
   
This NN NN O
potential NN NN O
side NN NN O
- NN NN O
effect NN NN O
, NN NN O
though NN NN O
very NN NN O
rare NN NN O
, NN NN O
represents NN NN O
one NN NN O
more NN NN O
reason NN NN O
to NN NN O
be NN NN O
very NN NN O
restrictive NN NN O
in NN NN O
the NN NN O
use NN NN O
of NN NN O
methylphenidate NN NN O
. NN NN O
   
MDMA NN NN O
polydrug NN NN O
users NN NN O
show NN NN O
process NN NN O
- NN NN O
specific NN NN O
central NN NN O
executive NN NN O
impairments NN NN O
coupled NN NN O
with NN NN O
impaired NN NN B-Disease
social NN NN I-Disease
and NN NN I-Disease
emotional NN NN I-Disease
judgement NN NN I-Disease
processes NN NN I-Disease
. NN NN O
   
In NN NN O
recent NN NN O
years NN NN O
working NN NN O
memory NN NN B-Disease
deficits NN NN I-Disease
have NN NN O
been NN NN O
reported NN NN O
in NN NN O
users NN NN O
of NN NN O
MDMA NN NN O
( NN NN O
3 NN NN O
, NN NN O
4 NN NN O
- NN NN O
methylenedioxymethamphetamine NN NN O
, NN NN O
ecstasy NN NN O
) NN NN O
. NN NN O
   
The NN NN O
current NN NN O
study NN NN O
aimed NN NN O
to NN NN O
assess NN NN O
the NN NN O
impact NN NN O
of NN NN O
MDMA NN NN O
use NN NN O
on NN NN O
three NN NN O
separate NN NN O
central NN NN O
executive NN NN O
processes NN NN O
( NN NN O
set NN NN O
shifting NN NN O
, NN NN O
inhibition NN NN O
and NN NN O
memory NN NN O
updating NN NN O
) NN NN O
and NN NN O
also NN NN O
on NN NN O
"""""""" NN NN O
prefrontal NN NN O
"""""""" NN NN O
mediated NN NN O
social NN NN O
and NN NN O
emotional NN NN O
judgement NN NN O
processes NN NN O
. NN NN O
   
Fifteen NN NN O
polydrug NN NN O
ecstasy NN NN O
users NN NN O
and NN NN O
15 NN NN O
polydrug NN NN O
non NN NN O
- NN NN O
ecstasy NN NN O
user NN NN O
controls NN NN O
completed NN NN O
a NN NN O
general NN NN O
drug NN NN O
use NN NN O
questionnaire NN NN O
, NN NN O
the NN NN O
Brixton NN NN O
Spatial NN NN O
Anticipation NN NN O
task NN NN O
( NN NN O
set NN NN O
shifting NN NN O
) NN NN O
, NN NN O
Backward NN NN O
Digit NN NN O
Span NN NN O
procedure NN NN O
( NN NN O
memory NN NN O
updating NN NN O
) NN NN O
, NN NN O
Inhibition NN NN O
of NN NN O
Return NN NN O
( NN NN O
inhibition NN NN O
) NN NN O
, NN NN O
an NN NN O
emotional NN NN O
intelligence NN NN O
scale NN NN O
, NN NN O
the NN NN O
Tromso NN NN O
Social NN NN O
Intelligence NN NN O
Scale NN NN O
and NN NN O
the NN NN O
Dysexecutive NN NN O
Questionnaire NN NN O
( NN NN O
DEX NN NN O
) NN NN O
. NN NN O
   
Compared NN NN O
with NN NN O
MDMA NN NN O
- NN NN O
free NN NN O
polydrug NN NN O
controls NN NN O
, NN NN O
MDMA NN NN O
polydrug NN NN O
users NN NN O
showed NN NN O
impairments NN NN O
in NN NN O
set NN NN O
shifting NN NN O
and NN NN O
memory NN NN O
updating NN NN O
, NN NN O
and NN NN O
also NN NN O
in NN NN O
social NN NN O
and NN NN O
emotional NN NN O
judgement NN NN O
processes NN NN O
. NN NN O
   
The NN NN O
latter NN NN O
two NN NN O
deficits NN NN O
remained NN NN O
significant NN NN O
after NN NN O
controlling NN NN O
for NN NN O
other NN NN O
drug NN NN O
use NN NN O
. NN NN O
   
These NN NN O
data NN NN O
lend NN NN O
further NN NN O
support NN NN O
to NN NN O
the NN NN O
proposal NN NN O
that NN NN O
cognitive NN NN O
processes NN NN O
mediated NN NN O
by NN NN O
the NN NN O
prefrontal NN NN O
cortex NN NN O
may NN NN O
be NN NN O
impaired NN NN O
by NN NN O
recreational NN NN O
ecstasy NN NN O
use NN NN O
. NN NN O
   
Phase NN NN O
II NN NN O
study NN NN O
of NN NN O
the NN NN O
amsacrine NN NN O
analogue NN NN O
CI NN NN O
- NN NN O
921 NN NN O
( NN NN O
NSC NN NN O
343499 NN NN O
) NN NN O
in NN NN O
non NN NN B-Disease
- NN NN I-Disease
small NN NN I-Disease
cell NN NN I-Disease
lung NN NN I-Disease
cancer NN NN I-Disease
. NN NN O
   
CI NN NN O
- NN NN O
921 NN NN O
( NN NN O
NSC NN NN O
343499 NN NN O
; NN NN O
9 NN NN O
- NN NN O
[ NN NN O
[ NN NN O
2 NN NN O
- NN NN O
methoxy NN NN O
- NN NN O
4 NN NN O
- NN NN O
[ NN NN O
( NN NN O
methylsulphonyl NN NN O
) NN NN O
amino NN NN O
] NN NN O
phenyl NN NN O
] NN NN O
amino NN NN O
] NN NN O
- NN NN O
N NN NN O
, NN NN O
5 NN NN O
- NN NN O
dimethyl NN NN O
- NN NN O
4 NN NN O
- NN NN O
acridinecarboxamide NN NN O
) NN NN O
is NN NN O
a NN NN O
topoisomerase NN NN O
II NN NN O
poison NN NN O
with NN NN O
high NN NN O
experimental NN NN O
antitumour NN NN O
activity NN NN O
. NN NN O
   
It NN NN O
was NN NN O
administered NN NN O
by NN NN O
15 NN NN O
min NN NN O
infusion NN NN O
to NN NN O
16 NN NN O
evaluable NN NN O
patients NN NN O
with NN NN O
non NN NN B-Disease
- NN NN I-Disease
small NN NN I-Disease
cell NN NN I-Disease
lung NN NN I-Disease
cancer NN NN I-Disease
( NN NN O
NSCLC NN NN B-Disease
) NN NN O
( NN NN O
7 NN NN O
with NN NN O
no NN NN O
prior NN NN O
treatment NN NN O
, NN NN O
9 NN NN O
patients NN NN O
in NN NN O
relapse NN NN O
following NN NN O
surgery NN NN O
/ NN NN O
radiotherapy NN NN O
) NN NN O
at NN NN O
a NN NN O
dose NN NN O
( NN NN O
648 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
divided NN NN O
over NN NN O
3 NN NN O
days NN NN O
, NN NN O
repeated NN NN O
every NN NN O
3 NN NN O
weeks NN NN O
) NN NN O
determined NN NN O
by NN NN O
phase NN NN O
I NN NN O
trial NN NN O
. NN NN O
   
Patients NN NN O
had NN NN O
a NN NN O
median NN NN O
performance NN NN O
status NN NN O
of NN NN O
1 NN NN O
( NN NN O
WHO NN NN O
) NN NN O
, NN NN O
and NN NN O
median NN NN O
age NN NN O
of NN NN O
61 NN NN O
years NN NN O
. NN NN O
   
The NN NN O
histology NN NN O
comprised NN NN O
squamous NN NN B-Disease
carcinoma NN NN I-Disease
( NN NN O
11 NN NN O
) NN NN O
, NN NN O
adenocarcinoma NN NN B-Disease
( NN NN O
1 NN NN O
) NN NN O
, NN NN O
mixed NN NN O
histology NN NN O
( NN NN O
2 NN NN O
) NN NN O
, NN NN O
bronchio NN NN B-Disease
- NN NN I-Disease
alveolar NN NN I-Disease
carcinoma NN NN I-Disease
( NN NN O
1 NN NN O
) NN NN O
and NN NN O
large NN NN O
cell NN NN O
undifferentiated NN NN B-Disease
carcinoma NN NN I-Disease
( NN NN O
1 NN NN O
) NN NN O
. NN NN O
   
Neutropenia NN NN B-Disease
grade NN NN O
greater NN NN O
than NN NN O
or NN NN O
equal NN NN O
to NN NN O
3 NN NN O
was NN NN O
seen NN NN O
in NN NN O
15 NN NN O
patients NN NN O
, NN NN O
infections NN NN B-Disease
with NN NN O
recovery NN NN O
in NN NN O
3 NN NN O
, NN NN O
and NN NN O
grand NN NN O
mal NN NN O
seizures NN NN B-Disease
in NN NN O
1 NN NN O
patient NN NN O
. NN NN O
   
Grade NN NN O
less NN NN O
than NN NN O
or NN NN O
equal NN NN O
to NN NN O
2 NN NN O
nausea NN NN B-Disease
and NN NN O
vomiting NN NN B-Disease
occurred NN NN O
in NN NN O
66 NN NN O
% NN NN O
courses NN NN O
and NN NN O
phlebitis NN NN B-Disease
in NN NN O
the NN NN O
infusion NN NN O
arm NN NN O
in NN NN O
37 NN NN O
% NN NN O
. NN NN O
   
1 NN NN O
patient NN NN O
with NN NN O
squamous NN NN B-Disease
cell NN NN I-Disease
carcinoma NN NN I-Disease
achieved NN NN O
a NN NN O
partial NN NN O
response NN NN O
lasting NN NN O
5 NN NN O
months NN NN O
. NN NN O
   
Further NN NN O
testing NN NN O
in NN NN O
this NN NN O
and NN NN O
other NN NN O
tumour NN NN B-Disease
types NN NN O
using NN NN O
multiple NN NN O
daily NN NN O
schedules NN NN O
is NN NN O
warranted NN NN O
. NN NN O
   
Pharmacokinetics NN NN O
of NN NN O
desipramine NN NN O
HCl NN NN O
when NN NN O
administered NN NN O
with NN NN O
cinacalcet NN NN O
HCl NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
In NN NN O
vitro NN NN O
work NN NN O
has NN NN O
demonstrated NN NN O
that NN NN O
cinacalcet NN NN O
is NN NN O
a NN NN O
strong NN NN O
inhibitor NN NN O
of NN NN O
cytochrome NN NN O
P450 NN NN O
isoenzyme NN NN O
( NN NN O
CYP NN NN O
) NN NN O
2D6 NN NN O
. NN NN O
   
The NN NN O
purpose NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
evaluate NN NN O
the NN NN O
effect NN NN O
of NN NN O
cinacalcet NN NN O
on NN NN O
CYP2D6 NN NN O
activity NN NN O
, NN NN O
using NN NN O
desipramine NN NN O
as NN NN O
a NN NN O
probe NN NN O
substrate NN NN O
, NN NN O
in NN NN O
healthy NN NN O
subjects NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Seventeen NN NN O
subjects NN NN O
who NN NN O
were NN NN O
genotyped NN NN O
as NN NN O
CYP2D6 NN NN O
extensive NN NN O
metabolizers NN NN O
were NN NN O
enrolled NN NN O
in NN NN O
this NN NN O
randomized NN NN O
, NN NN O
open NN NN O
- NN NN O
label NN NN O
, NN NN O
crossover NN NN O
study NN NN O
to NN NN O
receive NN NN O
a NN NN O
single NN NN O
oral NN NN O
dose NN NN O
of NN NN O
desipramine NN NN O
( NN NN O
50 NN NN O
mg NN NN O
) NN NN O
on NN NN O
two NN NN O
separate NN NN O
occasions NN NN O
, NN NN O
once NN NN O
alone NN NN O
and NN NN O
once NN NN O
after NN NN O
multiple NN NN O
doses NN NN O
of NN NN O
cinacalcet NN NN O
( NN NN O
90 NN NN O
mg NN NN O
for NN NN O
7 NN NN O
days NN NN O
) NN NN O
. NN NN O
   
Blood NN NN O
samples NN NN O
were NN NN O
obtained NN NN O
predose NN NN O
and NN NN O
up NN NN O
to NN NN O
72 NN NN O
h NN NN O
postdose NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Fourteen NN NN O
subjects NN NN O
completed NN NN O
both NN NN O
treatment NN NN O
arms NN NN O
. NN NN O
   
Relative NN NN O
to NN NN O
desipramine NN NN O
alone NN NN O
, NN NN O
mean NN NN O
AUC NN NN O
and NN NN O
C NN NN O
( NN NN O
max NN NN O
) NN NN O
of NN NN O
desipramine NN NN O
increased NN NN O
3 NN NN O
. NN NN O
6 NN NN O
- NN NN O
and NN NN O
1 NN NN O
. NN NN O
8 NN NN O
- NN NN O
fold NN NN O
when NN NN O
coadministered NN NN O
with NN NN O
cinacalcet NN NN O
. NN NN O
   
The NN NN O
t NN NN O
( NN NN O
1 NN NN O
/ NN NN O
2 NN NN O
, NN NN O
z NN NN O
) NN NN O
of NN NN O
desipramine NN NN O
was NN NN O
longer NN NN O
when NN NN O
desipramine NN NN O
was NN NN O
coadministered NN NN O
with NN NN O
cinacalcet NN NN O
( NN NN O
21 NN NN O
. NN NN O
0 NN NN O
versus NN NN O
43 NN NN O
. NN NN O
3 NN NN O
hs NN NN O
) NN NN O
. NN NN O
   
The NN NN O
t NN NN O
( NN NN O
max NN NN O
) NN NN O
was NN NN O
similar NN NN O
between NN NN O
the NN NN O
regimens NN NN O
. NN NN O
   
Fewer NN NN O
subjects NN NN O
reported NN NN O
adverse NN NN O
events NN NN O
following NN NN O
treatment NN NN O
with NN NN O
desipramine NN NN O
alone NN NN O
than NN NN O
when NN NN O
receiving NN NN O
desipramine NN NN O
with NN NN O
cinacalcet NN NN O
( NN NN O
33 NN NN O
versus NN NN O
86 NN NN O
% NN NN O
) NN NN O
, NN NN O
the NN NN O
most NN NN O
frequent NN NN O
of NN NN O
which NN NN O
( NN NN O
nausea NN NN B-Disease
and NN NN O
headache NN NN B-Disease
) NN NN O
have NN NN O
been NN NN O
reported NN NN O
for NN NN O
patients NN NN O
treated NN NN O
with NN NN O
either NN NN O
desipramine NN NN O
or NN NN O
cinacalcet NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
This NN NN O
study NN NN O
demonstrates NN NN O
that NN NN O
cinacalcet NN NN O
is NN NN O
a NN NN O
strong NN NN O
inhibitor NN NN O
of NN NN O
CYP2D6 NN NN O
. NN NN O
   
These NN NN O
data NN NN O
suggest NN NN O
that NN NN O
during NN NN O
concomitant NN NN O
treatment NN NN O
with NN NN O
cinacalcet NN NN O
, NN NN O
dose NN NN O
adjustment NN NN O
may NN NN O
be NN NN O
necessary NN NN O
for NN NN O
drugs NN NN O
that NN NN O
demonstrate NN NN O
a NN NN O
narrow NN NN O
therapeutic NN NN O
index NN NN O
and NN NN O
are NN NN O
metabolized NN NN O
by NN NN O
CYP2D6 NN NN O
. NN NN O
   
Case NN NN O
report NN NN O
: NN NN O
acute NN NN O
unintentional NN NN O
carbachol NN NN O
intoxication NN NN O
. NN NN O
   
INTRODUCTION NN NN O
: NN NN O
Intoxications NN NN O
with NN NN O
carbachol NN NN O
, NN NN O
a NN NN O
muscarinic NN NN O
cholinergic NN NN O
receptor NN NN O
agonist NN NN O
are NN NN O
rare NN NN O
. NN NN O
   
We NN NN O
report NN NN O
an NN NN O
interesting NN NN O
case NN NN O
investigating NN NN O
a NN NN O
( NN NN O
near NN NN O
) NN NN O
fatal NN NN O
poisoning NN NN B-Disease
. NN NN O
   
METHODS NN NN O
: NN NN O
The NN NN O
son NN NN O
of NN NN O
an NN NN O
84 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
male NN NN O
discovered NN NN O
a NN NN O
newspaper NN NN O
report NN NN O
stating NN NN O
clinical NN NN O
success NN NN O
with NN NN O
plant NN NN O
extracts NN NN O
in NN NN O
Alzheimer NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
The NN NN O
mode NN NN O
of NN NN O
action NN NN O
was NN NN O
said NN NN O
to NN NN O
be NN NN O
comparable NN NN O
to NN NN O
that NN NN O
of NN NN O
the NN NN O
synthetic NN NN O
compound NN NN O
' NN NN O
carbamylcholin NN NN O
' NN NN O
; NN NN O
that NN NN O
is NN NN O
, NN NN O
carbachol NN NN O
. NN NN O
   
He NN NN O
bought NN NN O
25 NN NN O
g NN NN O
of NN NN O
carbachol NN NN O
as NN NN O
pure NN NN O
substance NN NN O
in NN NN O
a NN NN O
pharmacy NN NN O
, NN NN O
and NN NN O
the NN NN O
father NN NN O
was NN NN O
administered NN NN O
400 NN NN O
to NN NN O
500 NN NN O
mg NN NN O
. NN NN O
   
Carbachol NN NN O
concentrations NN NN O
in NN NN O
serum NN NN O
and NN NN O
urine NN NN O
on NN NN O
day NN NN O
1 NN NN O
and NN NN O
2 NN NN O
of NN NN O
hospital NN NN O
admission NN NN O
were NN NN O
analysed NN NN O
by NN NN O
HPLC NN NN O
- NN NN O
mass NN NN O
spectrometry NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Minutes NN NN O
after NN NN O
oral NN NN O
administration NN NN O
, NN NN O
the NN NN O
patient NN NN O
developed NN NN O
nausea NN NN B-Disease
, NN NN O
sweating NN NN O
and NN NN O
hypotension NN NN B-Disease
, NN NN O
and NN NN O
finally NN NN O
collapsed NN NN O
. NN NN O
   
Bradycardia NN NN B-Disease
, NN NN O
cholinergic NN NN O
symptoms NN NN O
and NN NN O
asystole NN NN B-Disease
occurred NN NN O
. NN NN O
   
Initial NN NN O
cardiopulmonary NN NN O
resuscitation NN NN O
and NN NN O
immediate NN NN O
treatment NN NN O
with NN NN O
adrenaline NN NN O
( NN NN O
epinephrine NN NN O
) NN NN O
, NN NN O
atropine NN NN O
and NN NN O
furosemide NN NN O
was NN NN O
successful NN NN O
. NN NN O
   
On NN NN O
hospital NN NN O
admission NN NN O
, NN NN O
blood NN NN O
pressure NN NN O
of NN NN O
the NN NN O
intubated NN NN O
, NN NN O
bradyarrhythmic NN NN O
patient NN NN O
was NN NN O
100 NN NN O
/ NN NN O
65 NN NN O
mmHg NN NN O
. NN NN O
   
Further NN NN O
signs NN NN O
were NN NN O
hyperhidrosis NN NN B-Disease
, NN NN O
hypersalivation NN NN B-Disease
, NN NN O
bronchorrhoea NN NN B-Disease
, NN NN O
and NN NN O
severe NN NN O
miosis NN NN B-Disease
; NN NN O
the NN NN O
electrocardiographic NN NN O
finding NN NN O
was NN NN O
atrio NN NN B-Disease
- NN NN I-Disease
ventricular NN NN I-Disease
dissociation NN NN I-Disease
. NN NN O
   
High NN NN O
doses NN NN O
of NN NN O
atropine NN NN O
( NN NN O
up NN NN O
to NN NN O
50 NN NN O
mg NN NN O
per NN NN O
24 NN NN O
hours NN NN O
) NN NN O
, NN NN O
adrenaline NN NN O
and NN NN O
dopamine NN NN O
were NN NN O
necessary NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
was NN NN O
extubated NN NN O
1 NN NN O
week NN NN O
later NN NN O
. NN NN O
   
However NN NN O
, NN NN O
increased NN NN O
dyspnoea NN NN B-Disease
and NN NN O
bronchospasm NN NN B-Disease
necessitated NN NN O
reintubation NN NN O
. NN NN O
   
Respiratory NN NN B-Disease
insufficiency NN NN I-Disease
was NN NN O
further NN NN O
worsened NN NN O
by NN NN O
Proteus NN NN B-Disease
mirabilis NN NN I-Disease
infection NN NN I-Disease
and NN NN O
severe NN NN O
bronchoconstriction NN NN O
. NN NN O
   
One NN NN O
week NN NN O
later NN NN O
, NN NN O
the NN NN O
patient NN NN O
was NN NN O
again NN NN O
extubated NN NN O
and NN NN O
3 NN NN O
days NN NN O
later NN NN O
was NN NN O
transferred NN NN O
to NN NN O
a NN NN O
peripheral NN NN O
ward NN NN O
. NN NN O
   
On NN NN O
the NN NN O
next NN NN O
day NN NN O
he NN NN O
died NN NN O
, NN NN O
probably NN NN O
as NN NN O
a NN NN O
result NN NN O
of NN NN O
heart NN NN B-Disease
failure NN NN I-Disease
. NN NN O
   
Serum NN NN O
samples NN NN O
from NN NN O
the NN NN O
first NN NN O
and NN NN O
second NN NN O
days NN NN O
contained NN NN O
3 NN NN O
. NN NN O
6 NN NN O
and NN NN O
1 NN NN O
. NN NN O
9 NN NN O
mg NN NN O
/ NN NN O
l NN NN O
carbachol NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
The NN NN O
corresponding NN NN O
urine NN NN O
concentrations NN NN O
amounted NN NN O
to NN NN O
374 NN NN O
and NN NN O
554 NN NN O
mg NN NN O
/ NN NN O
l NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
This NN NN O
case NN NN O
started NN NN O
with NN NN O
a NN NN O
media NN NN O
report NN NN O
in NN NN O
a NN NN O
popular NN NN O
newspaper NN NN O
, NN NN O
initiated NN NN O
by NN NN O
published NN NN O
, NN NN O
peer NN NN O
- NN NN O
reviewed NN NN O
research NN NN O
on NN NN O
herbals NN NN O
, NN NN O
and NN NN O
involved NN NN O
human NN NN O
failure NN NN O
in NN NN O
a NN NN O
case NN NN O
history NN NN O
, NN NN O
medical NN NN O
examination NN NN O
and NN NN O
clinical NN NN O
treatment NN NN O
. NN NN O
   
For NN NN O
the NN NN O
first NN NN O
time NN NN O
, NN NN O
an NN NN O
analytical NN NN O
method NN NN O
for NN NN O
the NN NN O
determination NN NN O
of NN NN O
carbachol NN NN O
in NN NN O
plasma NN NN O
and NN NN O
urine NN NN O
has NN NN O
been NN NN O
developed NN NN O
. NN NN O
   
The NN NN O
analysed NN NN O
carbachol NN NN O
concentration NN NN O
exceeded NN NN O
the NN NN O
supposed NN NN O
serum NN NN O
level NN NN O
resulting NN NN O
from NN NN O
a NN NN O
therapeutic NN NN O
dose NN NN O
by NN NN O
a NN NN O
factor NN NN O
of NN NN O
130 NN NN O
to NN NN O
260 NN NN O
. NN NN O
   
Especially NN NN O
in NN NN O
old NN NN O
patients NN NN O
, NN NN O
intensivists NN NN O
should NN NN O
consider NN NN O
intoxications NN NN O
( NN NN O
with NN NN O
cholinergics NN NN O
) NN NN O
as NN NN O
a NN NN O
cause NN NN O
of NN NN O
acute NN NN B-Disease
cardiovascular NN NN I-Disease
failure NN NN I-Disease
. NN NN O
   
Pharmacological NN NN O
evidence NN NN O
for NN NN O
the NN NN O
potential NN NN O
of NN NN O
Daucus NN NN O
carota NN NN O
in NN NN O
the NN NN O
management NN NN O
of NN NN O
cognitive NN NN B-Disease
dysfunctions NN NN I-Disease
. NN NN O
   
The NN NN O
present NN NN O
study NN NN O
was NN NN O
aimed NN NN O
at NN NN O
investigating NN NN O
the NN NN O
effects NN NN O
of NN NN O
Daucus NN NN O
carota NN NN O
seeds NN NN O
on NN NN O
cognitive NN NN O
functions NN NN O
, NN NN O
total NN NN O
serum NN NN O
cholesterol NN NN O
levels NN NN O
and NN NN O
brain NN NN O
cholinesterase NN NN O
activity NN NN O
in NN NN O
mice NN NN O
. NN NN O
   
The NN NN O
ethanolic NN NN O
extract NN NN O
of NN NN O
Daucus NN NN O
carota NN NN O
seeds NN NN O
( NN NN O
DCE NN NN O
) NN NN O
was NN NN O
administered NN NN O
orally NN NN O
in NN NN O
three NN NN O
doses NN NN O
( NN NN O
100 NN NN O
, NN NN O
200 NN NN O
, NN NN O
400 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
for NN NN O
seven NN NN O
successive NN NN O
days NN NN O
to NN NN O
different NN NN O
groups NN NN O
of NN NN O
young NN NN O
and NN NN O
aged NN NN O
mice NN NN O
. NN NN O
   
Elevated NN NN O
plus NN NN O
maze NN NN O
and NN NN O
passive NN NN O
avoidance NN NN O
apparatus NN NN O
served NN NN O
as NN NN O
the NN NN O
exteroceptive NN NN O
behavioral NN NN O
models NN NN O
for NN NN O
testing NN NN O
memory NN NN O
. NN NN O
   
Diazepam NN NN O
- NN NN O
, NN NN O
scopolamine NN NN O
- NN NN O
and NN NN O
ageing NN NN O
- NN NN O
induced NN NN O
amnesia NN NN B-Disease
served NN NN O
as NN NN O
the NN NN O
interoceptive NN NN O
behavioral NN NN O
models NN NN O
. NN NN O
   
DCE NN NN O
( NN NN O
200 NN NN O
, NN NN O
400 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
p NN NN O
. NN NN O
o NN NN O
. NN NN O
) NN NN O
showed NN NN O
significant NN NN O
improvement NN NN O
in NN NN O
memory NN NN O
scores NN NN O
of NN NN O
young NN NN O
and NN NN O
aged NN NN O
mice NN NN O
. NN NN O
   
The NN NN O
extent NN NN O
of NN NN O
memory NN NN O
improvement NN NN O
evoked NN NN O
by NN NN O
DCE NN NN O
was NN NN O
23 NN NN O
% NN NN O
at NN NN O
the NN NN O
dose NN NN O
of NN NN O
200 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
and NN NN O
35 NN NN O
% NN NN O
at NN NN O
the NN NN O
dose NN NN O
of NN NN O
400 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
in NN NN O
young NN NN O
mice NN NN O
using NN NN O
elevated NN NN O
plus NN NN O
maze NN NN O
. NN NN O
   
Similarly NN NN O
, NN NN O
significant NN NN O
improvements NN NN O
in NN NN O
memory NN NN O
scores NN NN O
were NN NN O
observed NN NN O
using NN NN O
passive NN NN O
avoidance NN NN O
apparatus NN NN O
and NN NN O
aged NN NN O
mice NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
DCE NN NN O
reversed NN NN O
the NN NN O
amnesia NN NN B-Disease
induced NN NN O
by NN NN O
scopolamine NN NN O
( NN NN O
0 NN NN O
. NN NN O
4 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
and NN NN O
diazepam NN NN O
( NN NN O
1 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
. NN NN O
   
Daucus NN NN O
carota NN NN O
extract NN NN O
( NN NN O
200 NN NN O
, NN NN O
400 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
p NN NN O
. NN NN O
o NN NN O
. NN NN O
) NN NN O
reduced NN NN O
significantly NN NN O
the NN NN O
brain NN NN O
acetylcholinesterase NN NN O
activity NN NN O
and NN NN O
cholesterol NN NN O
levels NN NN O
in NN NN O
young NN NN O
and NN NN O
aged NN NN O
mice NN NN O
. NN NN O
   
The NN NN O
extent NN NN O
of NN NN O
inhibition NN NN O
of NN NN O
brain NN NN O
cholinesterase NN NN O
activity NN NN O
evoked NN NN O
by NN NN O
DCE NN NN O
at NN NN O
the NN NN O
dose NN NN O
of NN NN O
400 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
was NN NN O
22 NN NN O
% NN NN O
in NN NN O
young NN NN O
and NN NN O
19 NN NN O
% NN NN O
in NN NN O
aged NN NN O
mice NN NN O
. NN NN O
   
There NN NN O
was NN NN O
a NN NN O
remarkable NN NN O
reduction NN NN O
in NN NN O
total NN NN O
cholesterol NN NN O
level NN NN O
as NN NN O
well NN NN O
, NN NN O
to NN NN O
the NN NN O
extent NN NN O
of NN NN O
23 NN NN O
% NN NN O
in NN NN O
young NN NN O
and NN NN O
21 NN NN O
% NN NN O
in NN NN O
aged NN NN O
animals NN NN O
with NN NN O
this NN NN O
dose NN NN O
of NN NN O
DCE NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
DCE NN NN O
may NN NN O
prove NN NN O
to NN NN O
be NN NN O
a NN NN O
useful NN NN O
remedy NN NN O
for NN NN O
the NN NN O
management NN NN O
of NN NN O
cognitive NN NN B-Disease
dysfunctions NN NN I-Disease
on NN NN O
account NN NN O
of NN NN O
its NN NN O
multifarious NN NN O
beneficial NN NN O
effects NN NN O
such NN NN O
as NN NN O
, NN NN O
memory NN NN O
improving NN NN O
property NN NN O
, NN NN O
cholesterol NN NN O
lowering NN NN O
property NN NN O
and NN NN O
anticholinesterase NN NN O
activity NN NN O
. NN NN O
   
Valproic NN NN O
acid NN NN O
induced NN NN O
encephalopathy NN NN B-Disease
- NN NN O
- NN NN O
19 NN NN O
new NN NN O
cases NN NN O
in NN NN O
Germany NN NN O
from NN NN O
1994 NN NN O
to NN NN O
2003 NN NN O
- NN NN O
- NN NN O
a NN NN O
side NN NN O
effect NN NN O
associated NN NN O
to NN NN O
VPA NN NN O
- NN NN O
therapy NN NN O
not NN NN O
only NN NN O
in NN NN O
young NN NN O
children NN NN O
. NN NN O
   
Valproic NN NN O
acid NN NN O
( NN NN O
VPA NN NN O
) NN NN O
is NN NN O
a NN NN O
broad NN NN O
- NN NN O
spectrum NN NN O
antiepileptic NN NN O
drug NN NN O
and NN NN O
is NN NN O
usually NN NN O
well NN NN O
- NN NN O
tolerated NN NN O
. NN NN O
   
Rare NN NN O
serious NN NN O
complications NN NN O
may NN NN O
occur NN NN O
in NN NN O
some NN NN O
patients NN NN O
, NN NN O
including NN NN O
haemorrhagic NN NN O
pancreatitis NN NN B-Disease
, NN NN O
bone NN NN B-Disease
marrow NN NN I-Disease
suppression NN NN I-Disease
, NN NN O
VPA NN NN O
- NN NN O
induced NN NN O
hepatotoxicity NN NN B-Disease
and NN NN O
VPA NN NN O
- NN NN O
induced NN NN O
encephalopathy NN NN B-Disease
. NN NN O
   
The NN NN O
typical NN NN O
signs NN NN O
of NN NN O
VPA NN NN O
- NN NN O
induced NN NN O
encephalopathy NN NN B-Disease
are NN NN O
impaired NN NN B-Disease
consciousness NN NN I-Disease
, NN NN O
sometimes NN NN O
marked NN NN O
EEG NN NN O
background NN NN O
slowing NN NN O
, NN NN O
increased NN NN O
seizure NN NN B-Disease
frequency NN NN O
, NN NN O
with NN NN O
or NN NN O
without NN NN O
hyperammonemia NN NN B-Disease
. NN NN O
   
There NN NN O
is NN NN O
still NN NN O
no NN NN O
proof NN NN O
of NN NN O
causative NN NN O
effect NN NN O
of NN NN O
VPA NN NN O
in NN NN O
patients NN NN O
with NN NN O
encephalopathy NN NN B-Disease
, NN NN O
but NN NN O
only NN NN O
of NN NN O
an NN NN O
association NN NN O
with NN NN O
an NN NN O
assumed NN NN O
causal NN NN O
relation NN NN O
. NN NN O
   
We NN NN O
report NN NN O
19 NN NN O
patients NN NN O
with NN NN O
VPA NN NN O
- NN NN O
associated NN NN O
encephalopathy NN NN B-Disease
in NN NN O
Germany NN NN O
from NN NN O
the NN NN O
years NN NN O
1994 NN NN O
to NN NN O
2003 NN NN O
, NN NN O
none NN NN O
of NN NN O
whom NN NN O
had NN NN O
been NN NN O
published NN NN O
previously NN NN O
. NN NN O
   
Cerebral NN NN B-Disease
haemorrhage NN NN I-Disease
induced NN NN O
by NN NN O
warfarin NN NN O
- NN NN O
the NN NN O
influence NN NN O
of NN NN O
drug NN NN O
- NN NN O
drug NN NN O
interactions NN NN O
. NN NN O
   
PURPOSE NN NN O
: NN NN O
To NN NN O
evaluate NN NN O
the NN NN O
frequency NN NN O
, NN NN O
severity NN NN O
and NN NN O
preventability NN NN O
of NN NN O
warfarin NN NN O
- NN NN O
induced NN NN O
cerebral NN NN B-Disease
haemorrhages NN NN I-Disease
due NN NN O
to NN NN O
warfarin NN NN O
and NN NN O
warfarin NN NN O
- NN NN O
drug NN NN O
interactions NN NN O
in NN NN O
patients NN NN O
living NN NN O
in NN NN O
the NN NN O
county NN NN O
of NN NN O
Osterg NN NN O
tland NN NN O
, NN NN O
Sweden NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
All NN NN O
patients NN NN O
with NN NN O
a NN NN O
diagnosed NN NN O
cerebral NN NN B-Disease
haemorrhage NN NN I-Disease
at NN NN O
three NN NN O
hospitals NN NN O
during NN NN O
the NN NN O
period NN NN O
2000 NN NN O
- NN NN O
2002 NN NN O
were NN NN O
identified NN NN O
. NN NN O
   
Medical NN NN O
records NN NN O
were NN NN O
studied NN NN O
retrospectively NN NN O
to NN NN O
evaluate NN NN O
whether NN NN O
warfarin NN NN O
and NN NN O
warfarin NN NN O
- NN NN O
drug NN NN O
interactions NN NN O
could NN NN O
have NN NN O
caused NN NN O
the NN NN O
cerebral NN NN B-Disease
haemorrhage NN NN I-Disease
. NN NN O
   
The NN NN O
proportion NN NN O
of NN NN O
possibly NN NN O
avoidable NN NN O
cases NN NN O
due NN NN O
to NN NN O
drug NN NN O
interactions NN NN O
was NN NN O
estimated NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Among NN NN O
593 NN NN O
patients NN NN O
with NN NN O
cerebral NN NN B-Disease
haemorrhage NN NN I-Disease
, NN NN O
59 NN NN O
( NN NN O
10 NN NN O
% NN NN O
) NN NN O
were NN NN O
assessed NN NN O
as NN NN O
related NN NN O
to NN NN O
warfarin NN NN O
treatment NN NN O
. NN NN O
   
This NN NN O
imply NN NN O
an NN NN O
incidence NN NN O
of NN NN O
1 NN NN O
. NN NN O
7 NN NN O
/ NN NN O
100 NN NN O
, NN NN O
000 NN NN O
treatment NN NN O
years NN NN O
. NN NN O
   
Of NN NN O
the NN NN O
59 NN NN O
cases NN NN O
, NN NN O
26 NN NN O
( NN NN O
44 NN NN O
% NN NN O
) NN NN O
had NN NN O
a NN NN O
fatal NN NN O
outcome NN NN O
, NN NN O
compared NN NN O
to NN NN O
136 NN NN O
( NN NN O
25 NN NN O
% NN NN O
) NN NN O
among NN NN O
the NN NN O
non NN NN O
- NN NN O
warfarin NN NN O
patients NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
. NN NN O
   
A NN NN O
warfarin NN NN O
- NN NN O
drug NN NN O
interaction NN NN O
could NN NN O
have NN NN O
contributed NN NN O
to NN NN O
the NN NN O
haemorrhage NN NN B-Disease
in NN NN O
24 NN NN O
( NN NN O
41 NN NN O
% NN NN O
) NN NN O
of NN NN O
the NN NN O
warfarin NN NN O
patients NN NN O
and NN NN O
in NN NN O
7 NN NN O
of NN NN O
these NN NN O
( NN NN O
12 NN NN O
% NN NN O
) NN NN O
the NN NN O
bleeding NN NN B-Disease
complication NN NN O
was NN NN O
considered NN NN O
being NN NN O
possible NN NN O
to NN NN O
avoid NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Warfarin NN NN O
- NN NN O
induced NN NN O
cerebral NN NN B-Disease
haemorrhages NN NN I-Disease
are NN NN O
a NN NN O
major NN NN O
clinical NN NN O
problem NN NN O
with NN NN O
a NN NN O
high NN NN O
fatality NN NN O
rate NN NN O
. NN NN O
   
Almost NN NN O
half NN NN O
of NN NN O
the NN NN O
cases NN NN O
was NN NN O
related NN NN O
to NN NN O
a NN NN O
warfarin NN NN O
- NN NN O
drug NN NN O
interaction NN NN O
. NN NN O
   
A NN NN O
significant NN NN O
proportion NN NN O
of NN NN O
warfarin NN NN O
- NN NN O
related NN NN O
cerebral NN NN B-Disease
haemorrhages NN NN I-Disease
might NN NN O
have NN NN O
been NN NN O
prevented NN NN O
if NN NN O
greater NN NN O
caution NN NN O
had NN NN O
been NN NN O
taken NN NN O
when NN NN O
prescribing NN NN O
drugs NN NN O
known NN NN O
to NN NN O
interact NN NN O
with NN NN O
warfarin NN NN O
. NN NN O
   
Antipsychotic NN NN O
- NN NN O
like NN NN O
profile NN NN O
of NN NN O
thioperamide NN NN O
, NN NN O
a NN NN O
selective NN NN O
H3 NN NN O
- NN NN O
receptor NN NN O
antagonist NN NN O
in NN NN O
mice NN NN O
. NN NN O
   
Experimental NN NN O
and NN NN O
clinical NN NN O
evidence NN NN O
points NN NN O
to NN NN O
a NN NN O
role NN NN O
of NN NN O
central NN NN O
histaminergic NN NN O
system NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
schizophrenia NN NN B-Disease
. NN NN O
   
The NN NN O
present NN NN O
study NN NN O
was NN NN O
designed NN NN O
to NN NN O
study NN NN O
the NN NN O
effect NN NN O
of NN NN O
histamine NN NN O
H NN NN O
( NN NN O
3 NN NN O
) NN NN O
- NN NN O
receptor NN NN O
ligands NN NN O
on NN NN O
neuroleptic NN NN O
- NN NN O
induced NN NN O
catalepsy NN NN B-Disease
, NN NN O
apomorphine NN NN O
- NN NN O
induced NN NN O
climbing NN NN O
behavior NN NN O
and NN NN O
amphetamine NN NN O
- NN NN O
induced NN NN O
locomotor NN NN O
activities NN NN O
in NN NN O
mice NN NN O
. NN NN O
   
Catalepsy NN NN B-Disease
was NN NN O
induced NN NN O
by NN NN O
haloperidol NN NN O
( NN NN O
2 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
p NN NN O
. NN NN O
o NN NN O
. NN NN O
) NN NN O
, NN NN O
while NN NN O
apomorphine NN NN O
( NN NN O
1 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
s NN NN O
. NN NN O
c NN NN O
. NN NN O
) NN NN O
and NN NN O
amphetamine NN NN O
( NN NN O
2 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
s NN NN O
. NN NN O
c NN NN O
. NN NN O
) NN NN O
were NN NN O
used NN NN O
for NN NN O
studying NN NN O
climbing NN NN O
behavior NN NN O
and NN NN O
locomotor NN NN O
activities NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
( NN NN O
R NN NN O
) NN NN O
- NN NN O
alpha NN NN O
- NN NN O
methylhistamine NN NN O
( NN NN O
RAMH NN NN O
) NN NN O
( NN NN O
5 NN NN O
microg NN NN O
i NN NN O
. NN NN O
c NN NN O
. NN NN O
v NN NN O
. NN NN O
) NN NN O
and NN NN O
thioperamide NN NN O
( NN NN O
THP NN NN O
) NN NN O
( NN NN O
15 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
, NN NN O
per NN NN O
se NN NN O
did NN NN O
not NN NN O
cause NN NN O
catalepsy NN NN B-Disease
. NN NN O
   
Administration NN NN O
of NN NN O
THP NN NN O
( NN NN O
3 NN NN O
. NN NN O
75 NN NN O
, NN NN O
7 NN NN O
. NN NN O
5 NN NN O
and NN NN O
15 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
1 NN NN O
h NN NN O
prior NN NN O
to NN NN O
haloperidol NN NN O
resulted NN NN O
in NN NN O
a NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
increase NN NN O
in NN NN O
the NN NN O
catalepsy NN NN B-Disease
times NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
However NN NN O
, NN NN O
pretreatment NN NN O
with NN NN O
RAMH NN NN O
significantly NN NN O
reversed NN NN O
such NN NN O
an NN NN O
effect NN NN O
of NN NN O
THP NN NN O
( NN NN O
15 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
. NN NN O
   
RAMH NN NN O
per NN NN O
se NN NN O
showed NN NN O
significant NN NN O
reduction NN NN O
in NN NN O
locomotor NN NN O
time NN NN O
, NN NN O
distance NN NN O
traveled NN NN O
and NN NN O
average NN NN O
speed NN NN O
but NN NN O
THP NN NN O
( NN NN O
15 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
per NN NN O
se NN NN O
had NN NN O
no NN NN O
effect NN NN O
on NN NN O
these NN NN O
parameters NN NN O
. NN NN O
   
On NN NN O
amphetamine NN NN O
- NN NN O
induced NN NN O
hyperactivity NN NN B-Disease
, NN NN O
THP NN NN O
( NN NN O
3 NN NN O
. NN NN O
75 NN NN O
and NN NN O
7 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
reduced NN NN O
locomotor NN NN O
time NN NN O
, NN NN O
distance NN NN O
traveled NN NN O
and NN NN O
average NN NN O
speed NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
Pretreatment NN NN O
with NN NN O
RAMH NN NN O
( NN NN O
5 NN NN O
microg NN NN O
i NN NN O
. NN NN O
c NN NN O
. NN NN O
v NN NN O
. NN NN O
) NN NN O
could NN NN O
partially NN NN O
reverse NN NN O
such NN NN O
effects NN NN O
of NN NN O
THP NN NN O
( NN NN O
3 NN NN O
. NN NN O
75 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
. NN NN O
   
Climbing NN NN O
behavior NN NN O
induced NN NN O
by NN NN O
apomorphine NN NN O
was NN NN O
reduced NN NN O
in NN NN O
animals NN NN O
treated NN NN O
with NN NN O
THP NN NN O
. NN NN O
   
Such NN NN O
an NN NN O
effect NN NN O
was NN NN O
, NN NN O
however NN NN O
, NN NN O
reversed NN NN O
in NN NN O
presence NN NN O
of NN NN O
RAMH NN NN O
. NN NN O
   
THP NN NN O
exhibited NN NN O
an NN NN O
antipsychotic NN NN O
- NN NN O
like NN NN O
profile NN NN O
by NN NN O
potentiating NN NN O
haloperidol NN NN O
- NN NN O
induced NN NN O
catalepsy NN NN B-Disease
, NN NN O
reducing NN NN O
amphetamine NN NN O
- NN NN O
induced NN NN O
hyperactivity NN NN B-Disease
and NN NN O
reducing NN NN O
apomorphine NN NN O
- NN NN O
induced NN NN O
climbing NN NN O
in NN NN O
mice NN NN O
. NN NN O
   
Such NN NN O
effects NN NN O
of NN NN O
THP NN NN O
were NN NN O
reversed NN NN O
by NN NN O
RAMH NN NN O
indicating NN NN O
the NN NN O
involvement NN NN O
of NN NN O
histamine NN NN O
H NN NN O
( NN NN O
3 NN NN O
) NN NN O
- NN NN O
receptors NN NN O
. NN NN O
   
Findings NN NN O
suggest NN NN O
a NN NN O
potential NN NN O
for NN NN O
H NN NN O
( NN NN O
3 NN NN O
) NN NN O
- NN NN O
receptor NN NN O
antagonists NN NN O
in NN NN O
improving NN NN O
the NN NN O
refractory NN NN O
cases NN NN O
of NN NN O
schizophrenia NN NN B-Disease
. NN NN O
   
Cauda NN NN B-Disease
equina NN NN I-Disease
syndrome NN NN I-Disease
after NN NN O
epidural NN NN O
steroid NN NN O
injection NN NN O
: NN NN O
a NN NN O
case NN NN O
report NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
Conventional NN NN O
treatment NN NN O
methods NN NN O
of NN NN O
lumbusacral NN NN O
radiculopathy NN NN B-Disease
are NN NN O
physical NN NN O
therapy NN NN O
, NN NN O
epidural NN NN O
steroid NN NN O
injections NN NN O
, NN NN O
oral NN NN O
medications NN NN O
, NN NN O
and NN NN O
spinal NN NN O
manipulative NN NN O
therapy NN NN O
. NN NN O
   
Cauda NN NN B-Disease
equina NN NN I-Disease
syndrome NN NN I-Disease
is NN NN O
a NN NN O
rare NN NN O
complication NN NN O
of NN NN O
epidural NN NN O
anesthesia NN NN O
. NN NN O
   
The NN NN O
following NN NN O
case NN NN O
is NN NN O
a NN NN O
report NN NN O
of NN NN O
cauda NN NN B-Disease
equina NN NN I-Disease
syndrome NN NN I-Disease
possibly NN NN O
caused NN NN O
by NN NN O
epidural NN NN O
injection NN NN O
of NN NN O
triamcinolone NN NN O
and NN NN O
bupivacaine NN NN O
. NN NN O
   
CLINICAL NN NN O
FEATURES NN NN O
: NN NN O
A NN NN O
50 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
woman NN NN O
with NN NN O
low NN NN B-Disease
back NN NN I-Disease
and NN NN I-Disease
right NN NN I-Disease
leg NN NN I-Disease
pain NN NN I-Disease
was NN NN O
scheduled NN NN O
for NN NN O
epidural NN NN O
steroid NN NN O
injection NN NN O
. NN NN O
   
INTERVENTION NN NN O
AND NN NN O
OUTCOME NN NN O
: NN NN O
An NN NN O
18 NN NN O
- NN NN O
gauge NN NN O
Touhy NN NN O
needle NN NN O
was NN NN O
inserted NN NN O
until NN NN O
loss NN NN O
of NN NN O
resistance NN NN O
occurred NN NN O
at NN NN O
the NN NN O
L4 NN NN O
- NN NN O
5 NN NN O
level NN NN O
. NN NN O
   
Spread NN NN O
of NN NN O
the NN NN O
contrast NN NN O
medium NN NN O
within NN NN O
the NN NN O
epidural NN NN O
space NN NN O
was NN NN O
determined NN NN O
by NN NN O
radiographic NN NN O
imaging NN NN O
. NN NN O
   
After NN NN O
verifying NN NN O
the NN NN O
epidural NN NN O
space NN NN O
, NN NN O
bupivacaine NN NN O
and NN NN O
triamcinolone NN NN O
diacetate NN NN O
were NN NN O
injected NN NN O
. NN NN O
   
After NN NN O
the NN NN O
injection NN NN O
, NN NN O
there NN NN O
was NN NN O
a NN NN O
reduction NN NN O
in NN NN O
radicular NN NN O
symptoms NN NN O
. NN NN O
   
Three NN NN O
hours NN NN O
later NN NN O
, NN NN O
she NN NN O
complained NN NN O
of NN NN O
perineal NN NN O
numbness NN NN B-Disease
and NN NN O
lower NN NN B-Disease
extremity NN NN I-Disease
weakness NN NN I-Disease
. NN NN O
   
The NN NN O
neurologic NN NN O
evaluation NN NN O
revealed NN NN O
loss NN NN B-Disease
of NN NN I-Disease
sensation NN NN I-Disease
in NN NN O
the NN NN O
saddle NN NN O
area NN NN O
and NN NN O
medial NN NN O
aspect NN NN O
of NN NN O
her NN NN O
right NN NN O
leg NN NN O
. NN NN O
   
There NN NN O
was NN NN O
a NN NN O
decrease NN NN O
in NN NN O
the NN NN O
perception NN NN O
of NN NN O
pinprick NN NN O
test NN NN O
. NN NN O
   
Deep NN NN O
- NN NN O
tendon NN NN O
reflexes NN NN O
were NN NN O
decreased NN NN O
especially NN NN O
in NN NN O
the NN NN O
right NN NN O
leg NN NN O
. NN NN O
   
She NN NN O
was NN NN O
unable NN NN O
to NN NN O
urinate NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
' NN NN O
s NN NN O
symptoms NN NN O
improved NN NN O
slightly NN NN O
over NN NN O
the NN NN O
next NN NN O
few NN NN O
hours NN NN O
. NN NN O
   
She NN NN O
had NN NN O
a NN NN O
gradual NN NN O
return NN NN O
of NN NN O
motor NN NN O
function NN NN O
and NN NN O
ability NN NN O
of NN NN O
feeling NN NN O
Foley NN NN O
catheter NN NN O
. NN NN O
   
All NN NN O
of NN NN O
the NN NN O
symptoms NN NN O
were NN NN O
completely NN NN O
resolved NN NN O
over NN NN O
the NN NN O
next NN NN O
8 NN NN O
hours NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Complications NN NN O
associated NN NN O
with NN NN O
epidural NN NN O
steroid NN NN O
injections NN NN O
are NN NN O
rare NN NN O
. NN NN O
   
Clinical NN NN O
examination NN NN O
and NN NN O
continued NN NN O
vigilance NN NN O
for NN NN O
neurologic NN NN B-Disease
deterioration NN NN I-Disease
after NN NN O
epidural NN NN O
steroid NN NN O
injections NN NN O
is NN NN O
important NN NN O
. NN NN O
   
High NN NN O
- NN NN O
dose NN NN O
testosterone NN NN O
is NN NN O
associated NN NN O
with NN NN O
atherosclerosis NN NN B-Disease
in NN NN O
postmenopausal NN NN O
women NN NN O
. NN NN O
   
OBJECTIVES NN NN O
: NN NN O
To NN NN O
study NN NN O
the NN NN O
long NN NN O
- NN NN O
term NN NN O
effects NN NN O
of NN NN O
androgen NN NN O
treatment NN NN O
on NN NN O
atherosclerosis NN NN B-Disease
in NN NN O
postmenopausal NN NN O
women NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
In NN NN O
a NN NN O
population NN NN O
- NN NN O
based NN NN O
study NN NN O
in NN NN O
513 NN NN O
naturally NN NN O
postmenopausal NN NN O
women NN NN O
aged NN NN O
54 NN NN O
- NN NN O
67 NN NN O
years NN NN O
, NN NN O
we NN NN O
studied NN NN O
the NN NN O
association NN NN O
between NN NN O
self NN NN O
- NN NN O
reported NN NN O
intramuscularly NN NN O
administered NN NN O
high NN NN O
- NN NN O
dose NN NN O
estrogen NN NN O
- NN NN O
testosterone NN NN O
therapy NN NN O
( NN NN O
estradiol NN NN O
- NN NN O
and NN NN O
testosterone NN NN O
esters NN NN O
) NN NN O
and NN NN O
aortic NN NN O
atherosclerosis NN NN B-Disease
. NN NN O
   
Aortic NN NN O
atherosclerosis NN NN B-Disease
was NN NN O
diagnosed NN NN O
by NN NN O
radiographic NN NN O
detection NN NN O
of NN NN O
calcified NN NN O
deposits NN NN O
in NN NN O
the NN NN O
abdominal NN NN O
aorta NN NN O
, NN NN O
which NN NN O
have NN NN O
been NN NN O
shown NN NN O
to NN NN O
reflect NN NN O
intima NN NN O
atherosclerosis NN NN B-Disease
. NN NN O
   
Hormone NN NN O
therapy NN NN O
users NN NN O
were NN NN O
compared NN NN O
with NN NN O
never NN NN O
users NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Intramuscular NN NN O
hormone NN NN O
therapy NN NN O
use NN NN O
for NN NN O
1 NN NN O
year NN NN O
or NN NN O
longer NN NN O
was NN NN O
reported NN NN O
by NN NN O
25 NN NN O
women NN NN O
. NN NN O
   
In NN NN O
almost NN NN O
half NN NN O
of NN NN O
these NN NN O
women NN NN O
severe NN NN O
atherosclerosis NN NN B-Disease
of NN NN O
the NN NN O
aorta NN NN O
was NN NN O
present NN NN O
( NN NN O
n NN NN O
= NN NN O
11 NN NN O
) NN NN O
, NN NN O
while NN NN O
in NN NN O
women NN NN O
without NN NN O
hormone NN NN O
use NN NN O
severe NN NN O
atherosclerosis NN NN B-Disease
of NN NN O
the NN NN O
aorta NN NN O
was NN NN O
present NN NN O
in NN NN O
less NN NN O
than NN NN O
20 NN NN O
% NN NN O
( NN NN O
OR NN NN O
3 NN NN O
. NN NN O
1 NN NN O
; NN NN O
95 NN NN O
% NN NN O
CI NN NN O
, NN NN O
1 NN NN O
. NN NN O
1 NN NN O
- NN NN O
8 NN NN O
. NN NN O
5 NN NN O
, NN NN O
adjusted NN NN O
for NN NN O
age NN NN O
, NN NN O
years NN NN O
since NN NN O
menopause NN NN O
, NN NN O
smoking NN NN O
, NN NN O
and NN NN O
body NN NN O
mass NN NN O
index NN NN O
) NN NN O
. NN NN O
   
The NN NN O
association NN NN O
remained NN NN O
after NN NN O
additional NN NN O
adjustment NN NN O
for NN NN O
diabetes NN NN B-Disease
, NN NN O
cholesterol NN NN O
level NN NN O
, NN NN O
systolic NN NN O
blood NN NN O
pressure NN NN O
, NN NN O
or NN NN O
alcohol NN NN O
use NN NN O
. NN NN O
   
No NN NN O
association NN NN O
was NN NN O
found NN NN O
for NN NN O
hormone NN NN O
use NN NN O
less NN NN O
than NN NN O
1 NN NN O
year NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Our NN NN O
results NN NN O
suggest NN NN O
that NN NN O
high NN NN O
- NN NN O
dose NN NN O
testosterone NN NN O
therapy NN NN O
may NN NN O
adversely NN NN O
affect NN NN O
atherosclerosis NN NN B-Disease
in NN NN O
postmenopausal NN NN O
women NN NN O
and NN NN O
indicate NN NN O
that NN NN O
androgen NN NN O
replacement NN NN O
in NN NN O
these NN NN O
women NN NN O
may NN NN O
not NN NN O
be NN NN O
harmless NN NN O
. NN NN O
   
Optimising NN NN O
stroke NN NN B-Disease
prevention NN NN O
in NN NN O
non NN NN O
- NN NN O
valvular NN NN O
atrial NN NN B-Disease
fibrillation NN NN I-Disease
. NN NN O
   
Atrial NN NN B-Disease
fibrillation NN NN I-Disease
is NN NN O
associated NN NN O
with NN NN O
substantial NN NN O
morbidity NN NN O
and NN NN O
mortality NN NN O
. NN NN O
   
Pooled NN NN O
data NN NN O
from NN NN O
trials NN NN O
comparing NN NN O
antithrombotic NN NN O
treatment NN NN O
with NN NN O
placebo NN NN O
have NN NN O
shown NN NN O
that NN NN O
warfarin NN NN O
reduces NN NN O
the NN NN O
risk NN NN O
of NN NN O
stroke NN NN B-Disease
by NN NN O
62 NN NN O
% NN NN O
, NN NN O
and NN NN O
that NN NN O
aspirin NN NN O
alone NN NN O
reduces NN NN O
the NN NN O
risk NN NN O
by NN NN O
22 NN NN O
% NN NN O
. NN NN O
   
Overall NN NN O
, NN NN O
in NN NN O
high NN NN O
- NN NN O
risk NN NN O
patients NN NN O
, NN NN O
warfarin NN NN O
is NN NN O
superior NN NN O
to NN NN O
aspirin NN NN O
in NN NN O
preventing NN NN O
strokes NN NN B-Disease
, NN NN O
with NN NN O
a NN NN O
relative NN NN O
risk NN NN O
reduction NN NN O
of NN NN O
36 NN NN O
% NN NN O
. NN NN O
   
Ximelagatran NN NN O
, NN NN O
an NN NN O
oral NN NN O
direct NN NN O
thrombin NN NN O
inhibitor NN NN O
, NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
as NN NN O
efficient NN NN O
as NN NN O
vitamin NN NN O
K NN NN O
antagonist NN NN O
drugs NN NN O
in NN NN O
the NN NN O
prevention NN NN O
of NN NN O
embolic NN NN B-Disease
events NN NN I-Disease
, NN NN O
but NN NN O
has NN NN O
been NN NN O
recently NN NN O
withdrawn NN NN O
because NN NN O
of NN NN O
abnormal NN NN B-Disease
liver NN NN I-Disease
function NN NN I-Disease
tests NN NN O
. NN NN O
   
The NN NN O
ACTIVE NN NN O
- NN NN O
W NN NN O
( NN NN O
Atrial NN NN B-Disease
Fibrillation NN NN I-Disease
Clopidogrel NN NN O
Trial NN NN O
with NN NN O
Irbesartan NN NN O
for NN NN O
Prevention NN NN O
of NN NN O
Vascular NN NN O
Events NN NN O
) NN NN O
study NN NN O
has NN NN O
demonstrated NN NN O
that NN NN O
warfarin NN NN O
is NN NN O
superior NN NN O
to NN NN O
platelet NN NN O
therapy NN NN O
( NN NN O
clopidogrel NN NN O
plus NN NN O
aspirin NN NN O
) NN NN O
in NN NN O
the NN NN O
prevention NN NN O
af NN NN O
embolic NN NN B-Disease
events NN NN I-Disease
. NN NN O
   
Idraparinux NN NN O
, NN NN O
a NN NN O
Factor NN NN O
Xa NN NN O
inhibitor NN NN O
, NN NN O
is NN NN O
being NN NN O
evaluated NN NN O
in NN NN O
patients NN NN O
with NN NN O
atrial NN NN B-Disease
fibrillation NN NN I-Disease
. NN NN O
   
Angiotensin NN NN O
- NN NN O
converting NN NN O
enzyme NN NN O
inhibitors NN NN O
and NN NN O
angiotensin NN NN O
II NN NN O
receptor NN NN O
- NN NN O
blocking NN NN O
drugs NN NN O
hold NN NN O
promise NN NN O
in NN NN O
atrial NN NN B-Disease
fibrillation NN NN I-Disease
through NN NN O
cardiac NN NN B-Disease
remodelling NN NN I-Disease
. NN NN O
   
Preliminary NN NN O
studies NN NN O
suggest NN NN O
that NN NN O
statins NN NN O
could NN NN O
interfere NN NN O
with NN NN O
the NN NN O
risk NN NN O
of NN NN O
recurrence NN NN O
after NN NN O
electrical NN NN O
cardioversion NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
percutaneous NN NN O
methods NN NN O
for NN NN O
the NN NN O
exclusion NN NN O
of NN NN O
left NN NN O
atrial NN NN O
appendage NN NN O
are NN NN O
under NN NN O
investigation NN NN O
in NN NN O
high NN NN O
- NN NN O
risk NN NN O
patients NN NN O
. NN NN O
   
Anti NN NN O
- NN NN O
oxidant NN NN O
effects NN NN O
of NN NN O
atorvastatin NN NN O
in NN NN O
dexamethasone NN NN O
- NN NN O
induced NN NN O
hypertension NN NN B-Disease
in NN NN O
the NN NN O
rat NN NN O
. NN NN O
   
1 NN NN O
. NN NN O
   
Dexamethasone NN NN O
( NN NN O
Dex NN NN O
) NN NN O
- NN NN O
induced NN NN O
hypertension NN NN B-Disease
is NN NN O
characterized NN NN O
by NN NN O
endothelial NN NN O
dysfunction NN NN O
associated NN NN O
with NN NN O
nitric NN NN O
oxide NN NN O
( NN NN O
NO NN NN O
) NN NN O
deficiency NN NN O
and NN NN O
increased NN NN O
superoxide NN NN O
( NN NN O
O2 NN NN O
- NN NN O
) NN NN O
production NN NN O
. NN NN O
   
Atorvastatin NN NN O
( NN NN O
Ato NN NN O
) NN NN O
possesses NN NN O
pleiotropic NN NN O
properties NN NN O
that NN NN O
have NN NN O
been NN NN O
reported NN NN O
to NN NN O
improve NN NN O
endothelial NN NN O
function NN NN O
through NN NN O
increased NN NN O
availability NN NN O
of NN NN O
NO NN NN O
and NN NN O
reduced NN NN O
O2 NN NN O
- NN NN O
production NN NN O
in NN NN O
various NN NN O
forms NN NN O
of NN NN O
hypertension NN NN B-Disease
. NN NN O
   
In NN NN O
the NN NN O
present NN NN O
study NN NN O
, NN NN O
we NN NN O
investigated NN NN O
whether NN NN O
50 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
per NN NN O
day NN NN O
, NN NN O
p NN NN O
. NN NN O
o NN NN O
. NN NN O
, NN NN O
Ato NN NN O
could NN NN O
prevent NN NN O
endothelial NN NN O
NO NN NN O
synthase NN NN O
( NN NN O
eNOS NN NN O
) NN NN O
downregulation NN NN O
and NN NN O
the NN NN O
increase NN NN O
in NN NN O
O2 NN NN O
- NN NN O
in NN NN O
Sprague NN NN O
- NN NN O
Dawley NN NN O
( NN NN O
SD NN NN O
) NN NN O
rats NN NN O
, NN NN O
thereby NN NN O
reducing NN NN O
blood NN NN O
pressure NN NN O
. NN NN O
   
2 NN NN O
. NN NN O
   
Male NN NN O
SD NN NN O
rats NN NN O
( NN NN O
n NN NN O
= NN NN O
30 NN NN O
) NN NN O
were NN NN O
treated NN NN O
with NN NN O
Ato NN NN O
( NN NN O
50 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
per NN NN O
day NN NN O
in NN NN O
drinking NN NN O
water NN NN O
) NN NN O
or NN NN O
tap NN NN O
water NN NN O
for NN NN O
15 NN NN O
days NN NN O
. NN NN O
   
Dexamethasone NN NN O
( NN NN O
10 NN NN O
microg NN NN O
/ NN NN O
kg NN NN O
per NN NN O
day NN NN O
, NN NN O
s NN NN O
. NN NN O
c NN NN O
. NN NN O
) NN NN O
or NN NN O
saline NN NN O
was NN NN O
started NN NN O
after NN NN O
4 NN NN O
days NN NN O
in NN NN O
Ato NN NN O
- NN NN O
treated NN NN O
and NN NN O
non NN NN O
- NN NN O
treated NN NN O
rats NN NN O
and NN NN O
continued NN NN O
for NN NN O
11 NN NN O
- NN NN O
13 NN NN O
days NN NN O
. NN NN O
   
Systolic NN NN O
blood NN NN O
pressure NN NN O
( NN NN O
SBP NN NN O
) NN NN O
was NN NN O
measured NN NN O
on NN NN O
alternate NN NN O
days NN NN O
using NN NN O
the NN NN O
tail NN NN O
- NN NN O
cuff NN NN O
method NN NN O
. NN NN O
   
Endothelial NN NN O
function NN NN O
was NN NN O
assessed NN NN O
by NN NN O
acetylcholine NN NN O
- NN NN O
induced NN NN O
vasorelaxation NN NN O
and NN NN O
phenylephrine NN NN O
- NN NN O
induced NN NN O
vasoconstriction NN NN O
in NN NN O
aortic NN NN O
segments NN NN O
. NN NN O
   
Vascular NN NN O
eNOS NN NN O
mRNA NN NN O
was NN NN O
assessed NN NN O
by NN NN O
semi NN NN O
- NN NN O
quantitative NN NN O
reverse NN NN O
transcription NN NN O
- NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
. NN NN O
   
3 NN NN O
. NN NN O
   
In NN NN O
rats NN NN O
treated NN NN O
with NN NN O
Dex NN NN O
alone NN NN O
, NN NN O
SBP NN NN O
was NN NN O
increased NN NN O
from NN NN O
109 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
to NN NN O
133 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
mmHg NN NN O
on NN NN O
Days NN NN O
4 NN NN O
and NN NN O
Day NN NN O
14 NN NN O
, NN NN O
respectively NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
. NN NN O
   
In NN NN O
the NN NN O
Ato NN NN O
+ NN NN O
Dex NN NN O
group NN NN O
, NN NN O
SBP NN NN O
was NN NN O
increased NN NN O
from NN NN O
113 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
to NN NN O
119 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
mmHg NN NN O
on NN NN O
Days NN NN O
4 NN NN O
to NN NN O
14 NN NN O
, NN NN O
respectively NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
, NN NN O
but NN NN O
was NN NN O
significantly NN NN O
lower NN NN O
than NN NN O
SBP NN NN O
in NN NN O
the NN NN O
group NN NN O
treated NN NN O
with NN NN O
Dex NN NN O
alone NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
Endothelial NN NN O
- NN NN O
dependent NN NN O
relaxation NN NN O
and NN NN O
eNOS NN NN O
mRNA NN NN O
expression NN NN O
were NN NN O
greater NN NN O
in NN NN O
the NN NN O
Dex NN NN O
+ NN NN O
Ato NN NN O
group NN NN O
than NN NN O
in NN NN O
the NN NN O
Dex NN NN O
only NN NN O
group NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
and NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
0001 NN NN O
, NN NN O
respectively NN NN O
) NN NN O
. NN NN O
   
Aortic NN NN O
superoxide NN NN O
production NN NN O
was NN NN O
lower NN NN O
in NN NN O
the NN NN O
Dex NN NN O
+ NN NN O
Ato NN NN O
group NN NN O
compared NN NN O
with NN NN O
the NN NN O
group NN NN O
treated NN NN O
with NN NN O
Dex NN NN O
alone NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
0001 NN NN O
) NN NN O
. NN NN O
   
4 NN NN O
. NN NN O
   
Treatment NN NN O
with NN NN O
Ato NN NN O
improved NN NN O
endothelial NN NN O
function NN NN O
, NN NN O
reduced NN NN O
superoxide NN NN O
production NN NN O
and NN NN O
reduced NN NN O
SBP NN NN O
in NN NN O
Dex NN NN O
- NN NN O
treated NN NN O
SD NN NN O
rats NN NN O
. NN NN O
   
Severe NN NN O
citrate NN NN O
toxicity NN NN B-Disease
complicating NN NN O
volunteer NN NN O
apheresis NN NN O
platelet NN NN O
donation NN NN O
. NN NN O
   
We NN NN O
report NN NN O
a NN NN O
case NN NN O
of NN NN O
severe NN NN O
citrate NN NN O
toxicity NN NN B-Disease
during NN NN O
volunteer NN NN O
donor NN NN O
apheresis NN NN O
platelet NN NN O
collection NN NN O
. NN NN O
   
The NN NN O
donor NN NN O
was NN NN O
a NN NN O
40 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
female NN NN O
, NN NN O
first NN NN O
- NN NN O
time NN NN O
apheresis NN NN O
platelet NN NN O
donor NN NN O
. NN NN O
   
Past NN NN O
medical NN NN O
history NN NN O
was NN NN O
remarkable NN NN O
for NN NN O
hypertension NN NN B-Disease
, NN NN O
hyperlipidemia NN NN B-Disease
, NN NN O
and NN NN O
depression NN NN B-Disease
. NN NN O
   
Reported NN NN O
medications NN NN O
included NN NN O
bumetanide NN NN O
, NN NN O
pravastatin NN NN O
, NN NN O
and NN NN O
paroxetine NN NN O
. NN NN O
   
Thirty NN NN O
minutes NN NN O
from NN NN O
the NN NN O
start NN NN O
of NN NN O
the NN NN O
procedure NN NN O
, NN NN O
the NN NN O
donor NN NN O
noted NN NN O
tingling NN NN O
around NN NN O
the NN NN O
mouth NN NN O
, NN NN O
hands NN NN O
, NN NN O
and NN NN O
feet NN NN O
. NN NN O
   
She NN NN O
then NN NN O
very NN NN O
rapidly NN NN O
developed NN NN O
acute NN NN O
onset NN NN O
of NN NN O
severe NN NN O
facial NN NN O
and NN NN O
extremity NN NN O
tetany NN NN B-Disease
. NN NN O
   
Empirical NN NN O
treatment NN NN O
with NN NN O
intravenous NN NN O
calcium NN NN O
gluconate NN NN O
was NN NN O
initiated NN NN O
, NN NN O
and NN NN O
muscle NN NN B-Disease
contractions NN NN I-Disease
slowly NN NN O
subsided NN NN O
over NN NN O
approximately NN NN O
10 NN NN O
to NN NN O
15 NN NN O
minutes NN NN O
. NN NN O
   
The NN NN O
events NN NN O
are NN NN O
consistent NN NN O
with NN NN O
a NN NN O
severe NN NN O
reaction NN NN O
to NN NN O
calcium NN NN O
chelation NN NN O
by NN NN O
sodium NN NN O
citrate NN NN O
anticoagulant NN NN O
resulting NN NN O
in NN NN O
symptomatic NN NN O
systemic NN NN O
hypocalcemia NN NN B-Disease
. NN NN O
   
Upon NN NN O
additional NN NN O
retrospective NN NN O
analysis NN NN O
, NN NN O
it NN NN O
was NN NN O
noted NN NN O
that NN NN O
bumetanide NN NN O
is NN NN O
a NN NN O
loop NN NN O
diuretic NN NN O
that NN NN O
may NN NN O
cause NN NN O
significant NN NN O
hypocalcemia NN NN B-Disease
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
careful NN NN O
screening NN NN O
for NN NN O
medications NN NN O
and NN NN O
underlying NN NN O
conditions NN NN O
predisposing NN NN O
to NN NN O
hypocalcemia NN NN B-Disease
is NN NN O
recommended NN NN O
to NN NN O
help NN NN O
prevent NN NN O
severe NN NN O
reactions NN NN O
due NN NN O
to NN NN O
citrate NN NN O
toxicity NN NN B-Disease
. NN NN O
   
Laboratory NN NN O
measurement NN NN O
of NN NN O
pre NN NN O
- NN NN O
procedure NN NN O
serum NN NN O
calcium NN NN O
levels NN NN O
in NN NN O
selected NN NN O
donors NN NN O
may NN NN O
identify NN NN O
cases NN NN O
requiring NN NN O
heightened NN NN O
vigilance NN NN O
. NN NN O
   
The NN NN O
case NN NN O
also NN NN O
illustrates NN NN O
the NN NN O
importance NN NN O
of NN NN O
maintaining NN NN O
preparedness NN NN O
for NN NN O
managing NN NN O
rare NN NN O
but NN NN O
serious NN NN O
reactions NN NN O
in NN NN O
volunteer NN NN O
apheresis NN NN O
blood NN NN O
donors NN NN O
. NN NN O
   
Sirolimus NN NN O
- NN NN O
associated NN NN O
proteinuria NN NN B-Disease
and NN NN O
renal NN NN B-Disease
dysfunction NN NN I-Disease
. NN NN O
   
Sirolimus NN NN O
is NN NN O
a NN NN O
novel NN NN O
immunosuppressant NN NN O
with NN NN O
potent NN NN O
antiproliferative NN NN O
actions NN NN O
through NN NN O
its NN NN O
ability NN NN O
to NN NN O
inhibit NN NN O
the NN NN O
raptor NN NN O
- NN NN O
containing NN NN O
mammalian NN NN O
target NN NN O
of NN NN O
rapamycin NN NN O
protein NN NN O
kinase NN NN O
. NN NN O
   
Sirolimus NN NN O
represents NN NN O
a NN NN O
major NN NN O
therapeutic NN NN O
advance NN NN O
in NN NN O
the NN NN O
prevention NN NN O
of NN NN O
acute NN NN O
renal NN NN O
allograft NN NN O
rejection NN NN O
and NN NN O
chronic NN NN O
allograft NN NN O
nephropathy NN NN B-Disease
. NN NN O
   
Its NN NN O
role NN NN O
in NN NN O
the NN NN O
therapy NN NN O
of NN NN O
glomerulonephritis NN NN B-Disease
, NN NN O
autoimmunity NN NN B-Disease
, NN NN O
cystic NN NN B-Disease
renal NN NN I-Disease
diseases NN NN I-Disease
and NN NN O
renal NN NN B-Disease
cancer NN NN I-Disease
is NN NN O
under NN NN O
investigation NN NN O
. NN NN O
   
Because NN NN O
sirolimus NN NN O
does NN NN O
not NN NN O
share NN NN O
the NN NN O
vasomotor NN NN O
renal NN NN O
adverse NN NN O
effects NN NN O
exhibited NN NN O
by NN NN O
calcineurin NN NN O
inhibitors NN NN O
, NN NN O
it NN NN O
has NN NN O
been NN NN O
designated NN NN O
a NN NN O
' NN NN O
non NN NN O
- NN NN O
nephrotoxic NN NN B-Disease
drug NN NN O
' NN NN O
. NN NN O
   
However NN NN O
, NN NN O
clinical NN NN O
reports NN NN O
suggest NN NN O
that NN NN O
, NN NN O
under NN NN O
some NN NN O
circumstances NN NN O
, NN NN O
sirolimus NN NN O
is NN NN O
associated NN NN O
with NN NN O
proteinuria NN NN B-Disease
and NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
dysfunction NN NN I-Disease
. NN NN O
   
A NN NN O
common NN NN O
risk NN NN O
factor NN NN O
appears NN NN O
to NN NN O
be NN NN O
presence NN NN O
of NN NN O
pre NN NN O
- NN NN O
existing NN NN O
chronic NN NN B-Disease
renal NN NN I-Disease
damage NN NN I-Disease
. NN NN O
   
The NN NN O
mechanisms NN NN O
of NN NN O
sirolimus NN NN O
- NN NN O
associated NN NN O
proteinuria NN NN B-Disease
are NN NN O
multifactorial NN NN O
and NN NN O
may NN NN O
be NN NN O
due NN NN O
to NN NN O
an NN NN O
increase NN NN O
in NN NN O
glomerular NN NN O
capillary NN NN O
pressure NN NN O
following NN NN O
calcineurin NN NN O
inhibitor NN NN O
withdrawal NN NN O
. NN NN O
   
It NN NN O
has NN NN O
also NN NN O
been NN NN O
suggested NN NN O
that NN NN O
sirolimus NN NN O
directly NN NN O
causes NN NN O
increased NN NN O
glomerular NN NN O
permeability NN NN O
/ NN NN O
injury NN NN O
, NN NN O
but NN NN O
evidence NN NN O
for NN NN O
this NN NN O
mechanism NN NN O
is NN NN O
currently NN NN O
inconclusive NN NN O
. NN NN O
   
The NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
dysfunction NN NN I-Disease
associated NN NN O
with NN NN O
sirolimus NN NN O
( NN NN O
such NN NN O
as NN NN O
in NN NN O
delayed NN NN O
graft NN NN O
function NN NN O
) NN NN O
may NN NN O
be NN NN O
due NN NN O
to NN NN O
suppression NN NN O
of NN NN O
compensatory NN NN O
renal NN NN O
cell NN NN O
proliferation NN NN O
and NN NN O
survival NN NN O
/ NN NN O
repair NN NN O
processes NN NN O
. NN NN O
   
Although NN NN O
these NN NN O
adverse NN NN O
effects NN NN O
occur NN NN O
in NN NN O
some NN NN O
patients NN NN O
, NN NN O
their NN NN O
occurrence NN NN O
could NN NN O
be NN NN O
minimised NN NN O
by NN NN O
knowledge NN NN O
of NN NN O
the NN NN O
molecular NN NN O
effects NN NN O
of NN NN O
sirolimus NN NN O
on NN NN O
the NN NN O
kidney NN NN O
, NN NN O
the NN NN O
use NN NN O
of NN NN O
sirolimus NN NN O
in NN NN O
appropriate NN NN O
patient NN NN O
populations NN NN O
, NN NN O
close NN NN O
monitoring NN NN O
of NN NN O
proteinuria NN NN B-Disease
and NN NN O
renal NN NN O
function NN NN O
, NN NN O
use NN NN O
of NN NN O
angiotensin NN NN O
- NN NN O
converting NN NN O
enzyme NN NN O
inhibitors NN NN O
or NN NN O
angiotensin NN NN O
II NN NN O
receptor NN NN O
blockers NN NN O
if NN NN O
proteinuria NN NN B-Disease
occurs NN NN O
and NN NN O
withdrawal NN NN O
if NN NN O
needed NN NN O
. NN NN O
   
Further NN NN O
long NN NN O
- NN NN O
term NN NN O
analysis NN NN O
of NN NN O
renal NN NN O
allograft NN NN O
studies NN NN O
using NN NN O
sirolimus NN NN O
as NN NN O
de NN NN O
novo NN NN O
immunosuppression NN NN O
along NN NN O
with NN NN O
clinical NN NN O
and NN NN O
laboratory NN NN O
studies NN NN O
will NN NN O
refine NN NN O
these NN NN O
issues NN NN O
in NN NN O
the NN NN O
future NN NN O
. NN NN O
   
Proteinuria NN NN B-Disease
after NN NN O
conversion NN NN O
to NN NN O
sirolimus NN NN O
in NN NN O
renal NN NN O
transplant NN NN O
recipients NN NN O
. NN NN O
   
Sirolimus NN NN O
( NN NN O
SRL NN NN O
) NN NN O
is NN NN O
a NN NN O
new NN NN O
, NN NN O
potent NN NN O
immunosuppressive NN NN O
agent NN NN O
. NN NN O
   
More NN NN O
recently NN NN O
, NN NN O
proteinuria NN NN B-Disease
has NN NN O
been NN NN O
reported NN NN O
as NN NN O
a NN NN O
consequence NN NN O
of NN NN O
sirolimus NN NN O
therapy NN NN O
, NN NN O
although NN NN O
the NN NN O
mechanism NN NN O
has NN NN O
remained NN NN O
unclear NN NN O
. NN NN O
   
We NN NN O
retrospectively NN NN O
examined NN NN O
the NN NN O
records NN NN O
of NN NN O
25 NN NN O
renal NN NN O
transplant NN NN O
patients NN NN O
, NN NN O
who NN NN O
developed NN NN O
or NN NN O
displayed NN NN O
increased NN NN O
proteinuria NN NN B-Disease
after NN NN O
SRL NN NN O
conversion NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
cohort NN NN O
( NN NN O
14 NN NN O
men NN NN O
, NN NN O
11 NN NN O
women NN NN O
) NN NN O
was NN NN O
treated NN NN O
with NN NN O
SRL NN NN O
as NN NN O
conversion NN NN O
therapy NN NN O
, NN NN O
due NN NN O
to NN NN O
chronic NN NN B-Disease
allograft NN NN I-Disease
nephropathy NN NN I-Disease
( NN NN O
CAN NN NN B-Disease
) NN NN O
( NN NN O
n NN NN O
= NN NN O
15 NN NN O
) NN NN O
neoplasia NN NN B-Disease
( NN NN O
n NN NN O
= NN NN O
8 NN NN O
) NN NN O
; NN NN O
Kaposi NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
sarcoma NN NN I-Disease
, NN NN O
Four NN NN O
skin NN NN B-Disease
cancers NN NN I-Disease
, NN NN O
One NN NN O
intestinal NN NN B-Disease
tumors NN NN I-Disease
, NN NN O
One NN NN O
renal NN NN B-Disease
cell NN NN I-Disease
carsinom NN NN I-Disease
) NN NN O
or NN NN O
BK NN NN O
virus NN NN O
nephropathy NN NN B-Disease
( NN NN O
n NN NN O
= NN NN O
2 NN NN O
) NN NN O
. NN NN O
   
SRL NN NN O
was NN NN O
started NN NN O
at NN NN O
a NN NN O
mean NN NN O
of NN NN O
78 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
42 NN NN O
( NN NN O
15 NN NN O
to NN NN O
163 NN NN O
) NN NN O
months NN NN O
after NN NN O
transplantation NN NN O
. NN NN O
   
Mean NN NN O
follow NN NN O
- NN NN O
up NN NN O
on NN NN O
SRL NN NN O
therapy NN NN O
was NN NN O
20 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
12 NN NN O
( NN NN O
6 NN NN O
to NN NN O
43 NN NN O
) NN NN O
months NN NN O
. NN NN O
   
Proteinuria NN NN B-Disease
increased NN NN O
from NN NN O
0 NN NN O
. NN NN O
445 NN NN O
( NN NN O
0 NN NN O
to NN NN O
1 NN NN O
. NN NN O
5 NN NN O
) NN NN O
g NN NN O
/ NN NN O
d NN NN O
before NN NN O
conversion NN NN O
to NN NN O
3 NN NN O
. NN NN O
2 NN NN O
g NN NN O
/ NN NN O
dL NN NN O
( NN NN O
0 NN NN O
. NN NN O
2 NN NN O
to NN NN O
12 NN NN O
) NN NN O
after NN NN O
conversion NN NN O
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
. NN NN O
   
Before NN NN O
conversion NN NN O
8 NN NN O
( NN NN O
32 NN NN O
% NN NN O
) NN NN O
patients NN NN O
had NN NN O
no NN NN O
proteinuria NN NN B-Disease
, NN NN O
whereas NN NN O
afterwards NN NN O
all NN NN O
patients NN NN O
had NN NN O
proteinuria NN NN B-Disease
. NN NN O
   
In NN NN O
28 NN NN O
% NN NN O
of NN NN O
patients NN NN O
proteinuria NN NN B-Disease
remained NN NN O
unchanged NN NN O
, NN NN O
whereas NN NN O
it NN NN O
increased NN NN O
in NN NN O
68 NN NN O
% NN NN O
of NN NN O
patients NN NN O
. NN NN O
   
In NN NN O
40 NN NN O
% NN NN O
it NN NN O
increased NN NN O
by NN NN O
more NN NN O
than NN NN O
100 NN NN O
% NN NN O
. NN NN O
   
Twenty NN NN O
- NN NN O
eight NN NN O
percent NN NN O
of NN NN O
patients NN NN O
showed NN NN O
increased NN NN O
proteinuria NN NN B-Disease
to NN NN O
the NN NN O
nephrotic NN NN B-Disease
range NN NN O
. NN NN O
   
Biopsies NN NN O
performed NN NN O
in NN NN O
five NN NN O
patients NN NN O
revealed NN NN O
new NN NN O
pathological NN NN O
changes NN NN O
: NN NN O
One NN NN O
membranoproliferative NN NN B-Disease
glomerulopathy NN NN I-Disease
and NN NN O
interstitial NN NN B-Disease
nephritis NN NN I-Disease
. NN NN O
   
These NN NN O
patients NN NN O
showed NN NN O
persistently NN NN O
good NN NN O
graft NN NN O
function NN NN O
. NN NN O
   
Serum NN NN O
creatinine NN NN O
values NN NN O
did NN NN O
not NN NN O
change NN NN O
significantly NN NN O
: NN NN O
1 NN NN O
. NN NN O
98 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
8 NN NN O
mg NN NN O
/ NN NN O
dL NN NN O
before NN NN O
SRL NN NN O
therapy NN NN O
and NN NN O
2 NN NN O
. NN NN O
53 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
9 NN NN O
mg NN NN O
/ NN NN O
dL NN NN O
at NN NN O
last NN NN O
follow NN NN O
- NN NN O
up NN NN O
( NN NN O
P NN NN O
= NN NN O
. NN NN O
14 NN NN O
) NN NN O
. NN NN O
   
Five NN NN O
grafts NN NN O
were NN NN O
lost NN NN O
and NN NN O
the NN NN O
patients NN NN O
returned NN NN O
to NN NN O
dialysis NN NN O
. NN NN O
   
Five NN NN O
patients NN NN O
displayed NN NN O
CAN NN NN B-Disease
and NN NN O
Kaposi NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
sarcoma NN NN I-Disease
. NN NN O
   
Mean NN NN O
urinary NN NN O
protein NN NN O
of NN NN O
patients NN NN O
who NN NN O
returned NN NN O
to NN NN O
dialysis NN NN O
was NN NN O
1 NN NN O
. NN NN O
26 NN NN O
( NN NN O
0 NN NN O
. NN NN O
5 NN NN O
to NN NN O
3 NN NN O
. NN NN O
5 NN NN O
) NN NN O
g NN NN O
/ NN NN O
d NN NN O
before NN NN O
and NN NN O
4 NN NN O
. NN NN O
7 NN NN O
( NN NN O
3 NN NN O
to NN NN O
12 NN NN O
) NN NN O
g NN NN O
/ NN NN O
d NN NN O
after NN NN O
conversion NN NN O
( NN NN O
P NN NN O
= NN NN O
. NN NN O
01 NN NN O
) NN NN O
. NN NN O
   
Mean NN NN O
serum NN NN O
creatinine NN NN O
level NN NN O
before NN NN O
conversion NN NN O
was NN NN O
2 NN NN O
. NN NN O
21 NN NN O
mg NN NN O
/ NN NN O
dL NN NN O
and NN NN O
thereafter NN NN O
, NN NN O
4 NN NN O
. NN NN O
93 NN NN O
mg NN NN O
/ NN NN O
dL NN NN O
( NN NN O
P NN NN O
= NN NN O
. NN NN O
02 NN NN O
) NN NN O
. NN NN O
   
Heavy NN NN O
proteinuria NN NN B-Disease
was NN NN O
common NN NN O
after NN NN O
the NN NN O
use NN NN O
of NN NN O
SRL NN NN O
as NN NN O
rescue NN NN O
therapy NN NN O
for NN NN O
renal NN NN O
transplantation NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
conversion NN NN O
should NN NN O
be NN NN O
considered NN NN O
for NN NN O
patients NN NN O
who NN NN O
have NN NN O
not NN NN O
developed NN NN O
advanced NN NN O
CAN NN NN B-Disease
and NN NN O
proteinuria NN NN B-Disease
. NN NN O
   
The NN NN O
possibility NN NN O
of NN NN O
de NN NN O
novo NN NN O
glomerular NN NN O
pathology NN NN O
under NN NN O
SRL NN NN O
treatment NN NN O
requires NN NN O
further NN NN O
investigation NN NN O
by NN NN O
renal NN NN O
biopsy NN NN O
. NN NN O
   
Long NN NN O
- NN NN O
term NN NN O
follow NN NN O
- NN NN O
up NN NN O
of NN NN O
ifosfamide NN NN O
renal NN NN B-Disease
toxicity NN NN I-Disease
in NN NN O
children NN NN O
treated NN NN O
for NN NN O
malignant NN NN B-Disease
mesenchymal NN NN I-Disease
tumors NN NN I-Disease
: NN NN O
an NN NN O
International NN NN O
Society NN NN O
of NN NN O
Pediatric NN NN O
Oncology NN NN O
report NN NN O
. NN NN O
   
The NN NN O
renal NN NN O
function NN NN O
of NN NN O
74 NN NN O
children NN NN O
with NN NN O
malignant NN NN B-Disease
mesenchymal NN NN I-Disease
tumors NN NN I-Disease
in NN NN O
complete NN NN O
remission NN NN O
and NN NN O
who NN NN O
have NN NN O
received NN NN O
the NN NN O
same NN NN O
ifosfamide NN NN O
chemotherapy NN NN O
protocol NN NN O
( NN NN O
International NN NN O
Society NN NN O
of NN NN O
Pediatric NN NN O
Oncology NN NN O
Malignant NN NN B-Disease
Mesenchymal NN NN I-Disease
Tumor NN NN I-Disease
Study NN NN O
84 NN NN O
[ NN NN O
SIOP NN NN O
MMT NN NN O
84 NN NN O
] NN NN O
) NN NN O
were NN NN O
studied NN NN O
1 NN NN O
year NN NN O
after NN NN O
the NN NN O
completion NN NN O
of NN NN O
treatment NN NN O
. NN NN O
   
Total NN NN O
cumulative NN NN O
doses NN NN O
were NN NN O
36 NN NN O
or NN NN O
60 NN NN O
g NN NN O
/ NN NN O
m2 NN NN O
of NN NN O
ifosfamide NN NN O
( NN NN O
six NN NN O
or NN NN O
10 NN NN O
cycles NN NN O
of NN NN O
ifosfamide NN NN O
, NN NN O
vincristine NN NN O
, NN NN O
and NN NN O
dactinomycin NN NN O
[ NN NN O
IVA NN NN O
] NN NN O
) NN NN O
. NN NN O
   
   O
of NN NN O
them NN NN O
had NN NN O
received NN NN O
cisplatin NN NN O
chemotherapy NN NN O
. NN NN O
   
Ages NN NN O
ranged NN NN O
from NN NN O
4 NN NN O
months NN NN O
to NN NN O
17 NN NN O
years NN NN O
; NN NN O
58 NN NN O
patients NN NN O
were NN NN O
males NN NN O
and NN NN O
42 NN NN O
females NN NN O
. NN NN O
   
The NN NN O
most NN NN O
common NN NN O
primary NN NN O
tumor NN NN B-Disease
site NN NN O
was NN NN O
the NN NN O
head NN NN O
and NN NN O
neck NN NN O
. NN NN O
   
Renal NN NN O
function NN NN O
was NN NN O
investigated NN NN O
by NN NN O
measuring NN NN O
plasma NN NN O
and NN NN O
urinary NN NN O
electrolytes NN NN O
, NN NN O
glucosuria NN NN B-Disease
, NN NN O
proteinuria NN NN B-Disease
, NN NN O
aminoaciduria NN NN B-Disease
, NN NN O
urinary NN NN O
pH NN NN O
, NN NN O
osmolarity NN NN O
, NN NN O
creatinine NN NN O
clearance NN NN O
, NN NN O
phosphate NN NN O
tubular NN NN O
reabsorption NN NN O
, NN NN O
beta NN NN O
2 NN NN O
microglobulinuria NN NN O
, NN NN O
and NN NN O
lysozymuria NN NN O
. NN NN O
   
Fifty NN NN O
- NN NN O
eight NN NN O
patients NN NN O
( NN NN O
78 NN NN O
% NN NN O
) NN NN O
had NN NN O
normal NN NN O
renal NN NN O
tests NN NN O
, NN NN O
whereas NN NN O
16 NN NN O
patients NN NN O
( NN NN O
22 NN NN O
% NN NN O
) NN NN O
had NN NN O
renal NN NN B-Disease
abnormalities NN NN I-Disease
. NN NN O
   
Two NN NN O
subsets NN NN O
of NN NN O
patients NN NN O
were NN NN O
identified NN NN O
from NN NN O
this NN NN O
latter NN NN O
group NN NN O
: NN NN O
the NN NN O
first NN NN O
included NN NN O
four NN NN O
patients NN NN O
( NN NN O
5 NN NN O
% NN NN O
of NN NN O
the NN NN O
total NN NN O
population NN NN O
) NN NN O
who NN NN O
developed NN NN O
major NN NN O
toxicity NN NN B-Disease
resulting NN NN O
in NN NN O
Fanconi NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
syndrome NN NN I-Disease
( NN NN O
TDFS NN NN B-Disease
) NN NN O
; NN NN O
and NN NN O
the NN NN O
second NN NN O
group NN NN O
included NN NN O
five NN NN O
patients NN NN O
with NN NN O
elevated NN NN O
beta NN NN O
2 NN NN O
microglobulinuria NN NN O
and NN NN O
low NN NN O
phosphate NN NN O
reabsorption NN NN O
. NN NN O
   
The NN NN O
remaining NN NN O
seven NN NN O
patients NN NN O
had NN NN O
isolated NN NN O
beta NN NN O
2 NN NN O
microglobulinuria NN NN O
. NN NN O
   
Severe NN NN O
toxicity NN NN B-Disease
was NN NN O
correlated NN NN O
with NN NN O
the NN NN O
higher NN NN O
cumulative NN NN O
dose NN NN O
of NN NN O
60 NN NN O
g NN NN O
/ NN NN O
m2 NN NN O
of NN NN O
ifosfamide NN NN O
, NN NN O
a NN NN O
younger NN NN O
age NN NN O
( NN NN O
less NN NN O
than NN NN O
2 NN NN O
1 NN NN O
/ NN NN O
2 NN NN O
years NN NN O
old NN NN O
) NN NN O
, NN NN O
and NN NN O
a NN NN O
predominance NN NN O
of NN NN O
vesicoprostatic NN NN O
tumor NN NN B-Disease
involvement NN NN O
. NN NN O
   
This NN NN O
low NN NN O
percentage NN NN O
( NN NN O
5 NN NN O
% NN NN O
) NN NN O
of NN NN O
TDFS NN NN O
must NN NN O
be NN NN O
evaluated NN NN O
with NN NN O
respect NN NN O
to NN NN O
the NN NN O
efficacy NN NN O
of NN NN O
ifosfamide NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
mesenchymal NN NN B-Disease
tumors NN NN I-Disease
in NN NN O
children NN NN O
. NN NN O
   
Progressive NN NN O
myopathy NN NN B-Disease
with NN NN O
up NN NN O
- NN NN O
regulation NN NN O
of NN NN O
MHC NN NN O
- NN NN O
I NN NN O
associated NN NN O
with NN NN O
statin NN NN O
therapy NN NN O
. NN NN O
   
Statins NN NN O
can NN NN O
cause NN NN O
a NN NN O
necrotizing NN NN O
myopathy NN NN B-Disease
and NN NN O
hyperCKaemia NN NN B-Disease
which NN NN O
is NN NN O
reversible NN NN O
on NN NN O
cessation NN NN O
of NN NN O
the NN NN O
drug NN NN O
. NN NN O
   
What NN NN O
is NN NN O
less NN NN O
well NN NN O
known NN NN O
is NN NN O
a NN NN O
phenomenon NN NN O
whereby NN NN O
statins NN NN O
may NN NN O
induce NN NN O
a NN NN O
myopathy NN NN B-Disease
, NN NN O
which NN NN O
persists NN NN O
or NN NN O
may NN NN O
progress NN NN O
after NN NN O
stopping NN NN O
the NN NN O
drug NN NN O
. NN NN O
   
We NN NN O
investigated NN NN O
the NN NN O
muscle NN NN O
pathology NN NN O
in NN NN O
8 NN NN O
such NN NN O
cases NN NN O
. NN NN O
   
All NN NN O
had NN NN O
myofibre NN NN O
necrosis NN NN B-Disease
but NN NN O
only NN NN O
3 NN NN O
had NN NN O
an NN NN O
inflammatory NN NN O
infiltrate NN NN O
. NN NN O
   
In NN NN O
all NN NN O
cases NN NN O
there NN NN O
was NN NN O
diffuse NN NN O
or NN NN O
multifocal NN NN O
up NN NN O
- NN NN O
regulation NN NN O
of NN NN O
MHC NN NN O
- NN NN O
I NN NN O
expression NN NN O
even NN NN O
in NN NN O
non NN NN O
- NN NN O
necrotic NN NN B-Disease
fibres NN NN O
. NN NN O
   
Progressive NN NN O
improvement NN NN O
occurred NN NN O
in NN NN O
7 NN NN O
cases NN NN O
after NN NN O
commencement NN NN O
of NN NN O
prednisolone NN NN O
and NN NN O
methotrexate NN NN O
, NN NN O
and NN NN O
in NN NN O
one NN NN O
case NN NN O
spontaneously NN NN O
. NN NN O
   
These NN NN O
observations NN NN O
suggest NN NN O
that NN NN O
statins NN NN O
may NN NN O
initiate NN NN O
an NN NN O
immune NN NN O
- NN NN O
mediated NN NN O
myopathy NN NN B-Disease
that NN NN O
persists NN NN O
after NN NN O
withdrawal NN NN O
of NN NN O
the NN NN O
drug NN NN O
and NN NN O
responds NN NN O
to NN NN O
immunosuppressive NN NN O
therapy NN NN O
. NN NN O
   
The NN NN O
mechanism NN NN O
of NN NN O
this NN NN O
myopathy NN NN B-Disease
is NN NN O
uncertain NN NN O
but NN NN O
may NN NN O
involve NN NN O
the NN NN O
induction NN NN O
by NN NN O
statins NN NN O
of NN NN O
an NN NN O
endoplasmic NN NN O
reticulum NN NN O
stress NN NN O
response NN NN O
with NN NN O
associated NN NN O
up NN NN O
- NN NN O
regulation NN NN O
of NN NN O
MHC NN NN O
- NN NN O
I NN NN O
expression NN NN O
and NN NN O
antigen NN NN O
presentation NN NN O
by NN NN O
muscle NN NN O
fibres NN NN O
. NN NN O
   
Use NN NN O
of NN NN O
chromosome NN NN O
substitution NN NN O
strains NN NN O
to NN NN O
identify NN NN O
seizure NN NN B-Disease
susceptibility NN NN O
loci NN NN O
in NN NN O
mice NN NN O
. NN NN O
   
Seizure NN NN B-Disease
susceptibility NN NN O
varies NN NN O
among NN NN O
inbred NN NN O
mouse NN NN O
strains NN NN O
. NN NN O
   
Chromosome NN NN O
substitution NN NN O
strains NN NN O
( NN NN O
CSS NN NN O
) NN NN O
, NN NN O
in NN NN O
which NN NN O
a NN NN O
single NN NN O
chromosome NN NN O
from NN NN O
one NN NN O
inbred NN NN O
strain NN NN O
( NN NN O
donor NN NN O
) NN NN O
has NN NN O
been NN NN O
transferred NN NN O
onto NN NN O
a NN NN O
second NN NN O
strain NN NN O
( NN NN O
host NN NN O
) NN NN O
by NN NN O
repeated NN NN O
backcrossing NN NN O
, NN NN O
may NN NN O
be NN NN O
used NN NN O
to NN NN O
identify NN NN O
quantitative NN NN O
trait NN NN O
loci NN NN O
( NN NN O
QTLs NN NN O
) NN NN O
that NN NN O
contribute NN NN O
to NN NN O
seizure NN NN B-Disease
susceptibility NN NN O
. NN NN O
   
QTLs NN NN O
for NN NN O
susceptibility NN NN O
to NN NN O
pilocarpine NN NN O
- NN NN O
induced NN NN O
seizures NN NN B-Disease
, NN NN O
a NN NN O
model NN NN O
of NN NN O
temporal NN NN B-Disease
lobe NN NN I-Disease
epilepsy NN NN I-Disease
, NN NN O
have NN NN O
not NN NN O
been NN NN O
reported NN NN O
, NN NN O
and NN NN O
CSS NN NN O
have NN NN O
not NN NN O
previously NN NN O
been NN NN O
used NN NN O
to NN NN O
localize NN NN O
seizure NN NN B-Disease
susceptibility NN NN O
genes NN NN O
. NN NN O
   
We NN NN O
report NN NN O
QTLs NN NN O
identified NN NN O
using NN NN O
a NN NN O
B6 NN NN O
( NN NN O
host NN NN O
) NN NN O
x NN NN O
A NN NN O
/ NN NN O
J NN NN O
( NN NN O
donor NN NN O
) NN NN O
CSS NN NN O
panel NN NN O
to NN NN O
localize NN NN O
genes NN NN O
involved NN NN O
in NN NN O
susceptibility NN NN O
to NN NN O
pilocarpine NN NN O
- NN NN O
induced NN NN O
seizures NN NN B-Disease
. NN NN O
   
Three NN NN O
hundred NN NN O
fifty NN NN O
- NN NN O
five NN NN O
adult NN NN O
male NN NN O
CSS NN NN O
mice NN NN O
, NN NN O
58 NN NN O
B6 NN NN O
, NN NN O
and NN NN O
39 NN NN O
A NN NN O
/ NN NN O
J NN NN O
were NN NN O
tested NN NN O
for NN NN O
susceptibility NN NN O
to NN NN O
pilocarpine NN NN O
- NN NN O
induced NN NN O
seizures NN NN B-Disease
. NN NN O
   
Highest NN NN O
stage NN NN O
reached NN NN O
and NN NN O
latency NN NN O
to NN NN O
each NN NN O
stage NN NN O
were NN NN O
recorded NN NN O
for NN NN O
all NN NN O
mice NN NN O
. NN NN O
   
B6 NN NN O
mice NN NN O
were NN NN O
resistant NN NN O
to NN NN O
seizures NN NN B-Disease
and NN NN O
slower NN NN O
to NN NN O
reach NN NN O
stages NN NN O
compared NN NN O
to NN NN O
A NN NN O
/ NN NN O
J NN NN O
mice NN NN O
. NN NN O
   
The NN NN O
CSS NN NN O
for NN NN O
Chromosomes NN NN O
10 NN NN O
and NN NN O
18 NN NN O
progressed NN NN O
to NN NN O
the NN NN O
most NN NN O
severe NN NN O
stages NN NN O
, NN NN O
diverging NN NN O
dramatically NN NN O
from NN NN O
the NN NN O
B6 NN NN O
phenotype NN NN O
. NN NN O
   
Latencies NN NN O
to NN NN O
stages NN NN O
were NN NN O
also NN NN O
significantly NN NN O
shorter NN NN O
for NN NN O
CSS10 NN NN O
and NN NN O
CSS18 NN NN O
mice NN NN O
. NN NN O
   
CSS NN NN O
mapping NN NN O
suggests NN NN O
seizure NN NN B-Disease
susceptibility NN NN O
loci NN NN O
on NN NN O
mouse NN NN O
Chromosomes NN NN O
10 NN NN O
and NN NN O
18 NN NN O
. NN NN O
   
This NN NN O
approach NN NN O
provides NN NN O
a NN NN O
framework NN NN O
for NN NN O
identifying NN NN O
potentially NN NN O
novel NN NN O
homologous NN NN O
candidate NN NN O
genes NN NN O
for NN NN O
human NN NN O
temporal NN NN B-Disease
lobe NN NN I-Disease
epilepsy NN NN I-Disease
. NN NN O
   
In NN NN O
vitro NN NN O
characterization NN NN O
of NN NN O
parasympathetic NN NN O
and NN NN O
sympathetic NN NN O
responses NN NN O
in NN NN O
cyclophosphamide NN NN O
- NN NN O
induced NN NN O
cystitis NN NN B-Disease
in NN NN O
the NN NN O
rat NN NN O
. NN NN O
   
In NN NN O
cyclophosphamide NN NN O
- NN NN O
induced NN NN O
cystitis NN NN B-Disease
in NN NN O
the NN NN O
rat NN NN O
, NN NN O
detrusor NN NN O
function NN NN O
is NN NN O
impaired NN NN O
and NN NN O
the NN NN O
expression NN NN O
and NN NN O
effects NN NN O
of NN NN O
muscarinic NN NN O
receptors NN NN O
altered NN NN O
. NN NN O
   
Whether NN NN O
or NN NN O
not NN NN O
the NN NN O
neuronal NN NN O
transmission NN NN O
may NN NN O
be NN NN O
affected NN NN O
by NN NN O
cystitis NN NN B-Disease
was NN NN O
presently NN NN O
investigated NN NN O
. NN NN O
   
Responses NN NN O
of NN NN O
urinary NN NN O
strip NN NN O
preparations NN NN O
from NN NN O
control NN NN O
and NN NN O
cyclophosphamide NN NN O
- NN NN O
pretreated NN NN O
rats NN NN O
to NN NN O
electrical NN NN O
field NN NN O
stimulation NN NN O
and NN NN O
to NN NN O
agonists NN NN O
were NN NN O
assessed NN NN O
in NN NN O
the NN NN O
absence NN NN O
and NN NN O
presence NN NN O
of NN NN O
muscarinic NN NN O
, NN NN O
adrenergic NN NN O
and NN NN O
purinergic NN NN O
receptor NN NN O
antagonists NN NN O
. NN NN O
   
Generally NN NN O
, NN NN O
atropine NN NN O
reduced NN NN O
contractions NN NN O
, NN NN O
but NN NN O
in NN NN O
contrast NN NN O
to NN NN O
controls NN NN O
, NN NN O
it NN NN O
also NN NN O
reduced NN NN O
responses NN NN O
to NN NN O
low NN NN O
electrical NN NN O
field NN NN O
stimulation NN NN O
intensity NN NN O
( NN NN O
1 NN NN O
- NN NN O
5 NN NN O
Hz NN NN O
) NN NN O
in NN NN O
inflamed NN NN O
preparations NN NN O
. NN NN O
   
In NN NN O
both NN NN O
types NN NN O
, NN NN O
purinoceptor NN NN O
desensitization NN NN O
with NN NN O
alpha NN NN O
, NN NN O
beta NN NN O
- NN NN O
methylene NN NN O
adenosine NN NN O
- NN NN O
5 NN NN O
' NN NN O
- NN NN O
triphosphate NN NN O
( NN NN O
alpha NN NN O
, NN NN O
beta NN NN O
- NN NN O
meATP NN NN O
) NN NN O
caused NN NN O
further NN NN O
reductions NN NN O
at NN NN O
low NN NN O
frequencies NN NN O
( NN NN O
< NN NN O
10 NN NN O
Hz NN NN O
) NN NN O
. NN NN O
   
The NN NN O
muscarinic NN NN O
receptor NN NN O
antagonists NN NN O
atropine NN NN O
, NN NN O
4 NN NN O
- NN NN O
diphenylacetoxy NN NN O
- NN NN O
N NN NN O
- NN NN O
methylpiperidine NN NN O
( NN NN O
4 NN NN O
- NN NN O
DAMP NN NN O
) NN NN O
( NN NN O
' NN NN O
M NN NN O
( NN NN O
1 NN NN O
) NN NN O
/ NN NN O
M NN NN O
( NN NN O
3 NN NN O
) NN NN O
/ NN NN O
M NN NN O
( NN NN O
5 NN NN O
) NN NN O
- NN NN O
selective NN NN O
' NN NN O
) NN NN O
, NN NN O
methoctramine NN NN O
( NN NN O
' NN NN O
M NN NN O
( NN NN O
2 NN NN O
) NN NN O
- NN NN O
selective NN NN O
' NN NN O
) NN NN O
and NN NN O
pirenzepine NN NN O
( NN NN O
' NN NN O
M NN NN O
( NN NN O
1 NN NN O
) NN NN O
- NN NN O
selective NN NN O
' NN NN O
) NN NN O
antagonized NN NN O
the NN NN O
tonic NN NN O
component NN NN O
of NN NN O
the NN NN O
electrical NN NN O
field NN NN O
stimulation NN NN O
- NN NN O
evoked NN NN O
contractile NN NN O
response NN NN O
more NN NN O
potently NN NN O
than NN NN O
the NN NN O
phasic NN NN O
component NN NN O
. NN NN O
   
4 NN NN O
- NN NN O
DAMP NN NN O
inhibited NN NN O
the NN NN O
tonic NN NN O
contractions NN NN O
in NN NN O
controls NN NN O
more NN NN O
potently NN NN O
than NN NN O
methoctramine NN NN O
and NN NN O
pirenzepine NN NN O
. NN NN O
   
In NN NN O
inflamed NN NN O
preparations NN NN O
, NN NN O
the NN NN O
muscarinic NN NN O
receptor NN NN O
antagonism NN NN O
on NN NN O
the NN NN O
phasic NN NN O
component NN NN O
of NN NN O
the NN NN O
electrical NN NN O
field NN NN O
stimulation NN NN O
- NN NN O
evoked NN NN O
contraction NN NN O
was NN NN O
decreased NN NN O
and NN NN O
the NN NN O
pirenzepine NN NN O
and NN NN O
4 NN NN O
- NN NN O
DAMP NN NN O
antagonism NN NN O
on NN NN O
the NN NN O
tonic NN NN O
component NN NN O
was NN NN O
much NN NN O
less NN NN O
efficient NN NN O
than NN NN O
in NN NN O
controls NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
to NN NN O
controls NN NN O
, NN NN O
methoctramine NN NN O
increased NN NN O
- NN NN O
- NN NN O
instead NN NN O
of NN NN O
decreased NN NN O
- NN NN O
- NN NN O
the NN NN O
tonic NN NN O
responses NN NN O
at NN NN O
high NN NN O
frequencies NN NN O
. NN NN O
   
While NN NN O
contractions NN NN O
to NN NN O
carbachol NN NN O
and NN NN O
ATP NN NN O
were NN NN O
the NN NN O
same NN NN O
in NN NN O
inflamed NN NN O
and NN NN O
in NN NN O
control NN NN O
strips NN NN O
when NN NN O
related NN NN O
to NN NN O
a NN NN O
reference NN NN O
potassium NN NN O
response NN NN O
, NN NN O
isoprenaline NN NN O
- NN NN O
induced NN NN O
relaxations NN NN O
were NN NN O
smaller NN NN O
in NN NN O
inflamed NN NN O
strips NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
in NN NN O
cystitis NN NN B-Disease
substantial NN NN O
changes NN NN O
of NN NN O
the NN NN O
efferent NN NN O
functional NN NN O
responses NN NN O
occur NN NN O
. NN NN O
   
While NN NN O
postjunctional NN NN O
beta NN NN O
- NN NN O
adrenoceptor NN NN O
- NN NN O
mediated NN NN O
relaxations NN NN O
are NN NN O
reduced NN NN O
, NN NN O
effects NN NN O
by NN NN O
prejunctional NN NN O
inhibitory NN NN O
muscarinic NN NN O
receptors NN NN O
may NN NN O
be NN NN O
increased NN NN O
. NN NN O
   
Direct NN NN O
inhibition NN NN O
of NN NN O
cardiac NN NN O
hyperpolarization NN NN O
- NN NN O
activated NN NN O
cyclic NN NN O
nucleotide NN NN O
- NN NN O
gated NN NN O
pacemaker NN NN O
channels NN NN O
by NN NN O
clonidine NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Inhibition NN NN O
of NN NN O
cardiac NN NN O
sympathetic NN NN O
tone NN NN O
represents NN NN O
an NN NN O
important NN NN O
strategy NN NN O
for NN NN O
treatment NN NN O
of NN NN O
cardiovascular NN NN B-Disease
disease NN NN I-Disease
, NN NN O
including NN NN O
arrhythmia NN NN B-Disease
, NN NN O
coronary NN NN B-Disease
heart NN NN I-Disease
disease NN NN I-Disease
, NN NN O
and NN NN O
chronic NN NN O
heart NN NN B-Disease
failure NN NN I-Disease
. NN NN O
   
Activation NN NN O
of NN NN O
presynaptic NN NN O
alpha2 NN NN O
- NN NN O
adrenoceptors NN NN O
is NN NN O
the NN NN O
most NN NN O
widely NN NN O
accepted NN NN O
mechanism NN NN O
of NN NN O
action NN NN O
of NN NN O
the NN NN O
antisympathetic NN NN O
drug NN NN O
clonidine NN NN O
; NN NN O
however NN NN O
, NN NN O
other NN NN O
target NN NN O
proteins NN NN O
have NN NN O
been NN NN O
postulated NN NN O
to NN NN O
contribute NN NN O
to NN NN O
the NN NN O
in NN NN O
vivo NN NN O
actions NN NN O
of NN NN O
clonidine NN NN O
. NN NN O
   
METHODS NN NN O
AND NN NN O
RESULTS NN NN O
: NN NN O
To NN NN O
test NN NN O
whether NN NN O
clonidine NN NN O
elicits NN NN O
pharmacological NN NN O
effects NN NN O
independent NN NN O
of NN NN O
alpha2 NN NN O
- NN NN O
adrenoceptors NN NN O
, NN NN O
we NN NN O
have NN NN O
generated NN NN O
mice NN NN O
with NN NN O
a NN NN O
targeted NN NN O
deletion NN NN O
of NN NN O
all NN NN O
3 NN NN O
alpha2 NN NN O
- NN NN O
adrenoceptor NN NN O
subtypes NN NN O
( NN NN O
alpha2ABC NN NN O
- NN NN O
/ NN NN O
- NN NN O
) NN NN O
. NN NN O
   
Alpha2ABC NN NN O
- NN NN O
/ NN NN O
- NN NN O
mice NN NN O
were NN NN O
completely NN NN O
unresponsive NN NN O
to NN NN O
the NN NN O
analgesic NN NN O
and NN NN O
hypnotic NN NN O
effects NN NN O
of NN NN O
clonidine NN NN O
; NN NN O
however NN NN O
, NN NN O
clonidine NN NN O
significantly NN NN O
lowered NN NN O
heart NN NN O
rate NN NN O
in NN NN O
alpha2ABC NN NN O
- NN NN O
/ NN NN O
- NN NN O
mice NN NN O
by NN NN O
up NN NN O
to NN NN O
150 NN NN O
bpm NN NN O
. NN NN O
   
Clonidine NN NN O
- NN NN O
induced NN NN O
bradycardia NN NN B-Disease
in NN NN O
conscious NN NN O
alpha2ABC NN NN O
- NN NN O
/ NN NN O
- NN NN O
mice NN NN O
was NN NN O
32 NN NN O
. NN NN O
3 NN NN O
% NN NN O
( NN NN O
10 NN NN O
microg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
and NN NN O
26 NN NN O
. NN NN O
6 NN NN O
% NN NN O
( NN NN O
100 NN NN O
microg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
of NN NN O
the NN NN O
effect NN NN O
in NN NN O
wild NN NN O
- NN NN O
type NN NN O
mice NN NN O
. NN NN O
   
A NN NN O
similar NN NN O
bradycardic NN NN O
effect NN NN O
of NN NN O
clonidine NN NN O
was NN NN O
observed NN NN O
in NN NN O
isolated NN NN O
spontaneously NN NN O
beating NN NN O
right NN NN O
atria NN NN O
from NN NN O
alpha2ABC NN NN O
- NN NN O
knockout NN NN O
and NN NN O
wild NN NN O
- NN NN O
type NN NN O
mice NN NN O
. NN NN O
   
Clonidine NN NN O
inhibited NN NN O
the NN NN O
native NN NN O
pacemaker NN NN O
current NN NN O
( NN NN O
I NN NN O
( NN NN O
f NN NN O
) NN NN O
) NN NN O
in NN NN O
isolated NN NN O
sinoatrial NN NN O
node NN NN O
pacemaker NN NN O
cells NN NN O
and NN NN O
the NN NN O
I NN NN O
( NN NN O
f NN NN O
) NN NN O
- NN NN O
generating NN NN O
hyperpolarization NN NN O
- NN NN O
activated NN NN O
cyclic NN NN O
nucleotide NN NN O
- NN NN O
gated NN NN O
( NN NN O
HCN NN NN O
) NN NN O
2 NN NN O
and NN NN O
HCN4 NN NN O
channels NN NN O
in NN NN O
transfected NN NN O
HEK293 NN NN O
cells NN NN O
. NN NN O
   
As NN NN O
a NN NN O
consequence NN NN O
of NN NN O
blocking NN NN O
I NN NN O
( NN NN O
f NN NN O
) NN NN O
, NN NN O
clonidine NN NN O
reduced NN NN O
the NN NN O
slope NN NN O
of NN NN O
the NN NN O
diastolic NN NN O
depolarization NN NN O
and NN NN O
the NN NN O
frequency NN NN O
of NN NN O
pacemaker NN NN O
potentials NN NN O
in NN NN O
sinoatrial NN NN O
node NN NN O
cells NN NN O
from NN NN O
wild NN NN O
- NN NN O
type NN NN O
and NN NN O
alpha2ABC NN NN O
- NN NN O
knockout NN NN O
mice NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Direct NN NN O
inhibition NN NN O
of NN NN O
cardiac NN NN O
HCN NN NN O
pacemaker NN NN O
channels NN NN O
contributes NN NN O
to NN NN O
the NN NN O
bradycardic NN NN O
effects NN NN O
of NN NN O
clonidine NN NN O
gene NN NN O
- NN NN O
targeted NN NN O
mice NN NN O
in NN NN O
vivo NN NN O
, NN NN O
and NN NN O
thus NN NN O
, NN NN O
clonidine NN NN O
- NN NN O
like NN NN O
drugs NN NN O
represent NN NN O
novel NN NN O
structures NN NN O
for NN NN O
future NN NN O
HCN NN NN O
channel NN NN O
inhibitors NN NN O
. NN NN O
   
Granulomatous NN NN B-Disease
hepatitis NN NN I-Disease
due NN NN O
to NN NN O
combination NN NN O
of NN NN O
amoxicillin NN NN O
and NN NN O
clavulanic NN NN O
acid NN NN O
. NN NN O
   
We NN NN O
report NN NN O
the NN NN O
case NN NN O
of NN NN O
a NN NN O
patient NN NN O
with NN NN O
amoxicillin NN NN O
- NN NN O
clavulanic NN NN O
acid NN NN O
- NN NN O
induced NN NN O
hepatitis NN NN B-Disease
with NN NN O
histologic NN NN O
multiple NN NN O
granulomas NN NN B-Disease
. NN NN O
   
This NN NN O
type NN NN O
of NN NN O
lesion NN NN O
broadens NN NN O
the NN NN O
spectrum NN NN O
of NN NN O
liver NN NN B-Disease
injury NN NN I-Disease
due NN NN O
to NN NN O
this NN NN O
drug NN NN O
combination NN NN O
, NN NN O
mainly NN NN O
represented NN NN O
by NN NN O
a NN NN O
benign NN NN O
cholestatic NN NN B-Disease
syndrome NN NN I-Disease
. NN NN O
   
The NN NN O
association NN NN O
of NN NN O
granulomas NN NN B-Disease
and NN NN O
eosinophilia NN NN B-Disease
favor NN NN O
an NN NN O
immunoallergic NN NN O
mechanism NN NN O
. NN NN O
   
As NN NN O
penicillin NN NN O
derivatives NN NN O
and NN NN O
amoxicillin NN NN O
alone NN NN O
are NN NN O
known NN NN O
to NN NN O
induce NN NN O
such NN NN O
types NN NN O
of NN NN O
lesions NN NN O
, NN NN O
the NN NN O
amoxicillin NN NN O
component NN NN O
, NN NN O
with NN NN O
or NN NN O
without NN NN O
a NN NN O
potentiating NN NN O
effect NN NN O
of NN NN O
clavulanic NN NN O
acid NN NN O
, NN NN O
might NN NN O
have NN NN O
a NN NN O
major NN NN O
role NN NN O
. NN NN O
   
Dobutamine NN NN O
stress NN NN O
echocardiography NN NN O
: NN NN O
a NN NN O
sensitive NN NN O
indicator NN NN O
of NN NN O
diminished NN NN O
myocardial NN NN O
function NN NN O
in NN NN O
asymptomatic NN NN O
doxorubicin NN NN O
- NN NN O
treated NN NN O
long NN NN O
- NN NN O
term NN NN O
survivors NN NN O
of NN NN O
childhood NN NN O
cancer NN NN B-Disease
. NN NN O
   
Doxorubicin NN NN O
is NN NN O
an NN NN O
effective NN NN O
anticancer NN NN O
chemotherapeutic NN NN O
agent NN NN O
known NN NN O
to NN NN O
cause NN NN O
acute NN NN O
and NN NN O
chronic NN NN O
cardiomyopathy NN NN B-Disease
. NN NN O
   
To NN NN O
develop NN NN O
a NN NN O
more NN NN O
sensitive NN NN O
echocardiographic NN NN O
screening NN NN O
test NN NN O
for NN NN O
cardiac NN NN B-Disease
damage NN NN I-Disease
due NN NN O
to NN NN O
doxorubicin NN NN O
, NN NN O
a NN NN O
cohort NN NN O
study NN NN O
was NN NN O
performed NN NN O
using NN NN O
dobutamine NN NN O
infusion NN NN O
to NN NN O
differentiate NN NN O
asymptomatic NN NN O
long NN NN O
- NN NN O
term NN NN O
survivors NN NN O
of NN NN O
childhood NN NN O
cancer NN NN B-Disease
treated NN NN O
with NN NN O
doxorubicin NN NN O
from NN NN O
healthy NN NN O
control NN NN O
subjects NN NN O
. NN NN O
   
Echocardiographic NN NN O
data NN NN O
from NN NN O
the NN NN O
experimental NN NN O
group NN NN O
of NN NN O
21 NN NN O
patients NN NN O
( NN NN O
mean NN NN O
age NN NN O
16 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
5 NN NN O
years NN NN O
) NN NN O
treated NN NN O
from NN NN O
1 NN NN O
. NN NN O
6 NN NN O
to NN NN O
14 NN NN O
. NN NN O
3 NN NN O
years NN NN O
( NN NN O
median NN NN O
5 NN NN O
. NN NN O
3 NN NN O
) NN NN O
before NN NN O
this NN NN O
study NN NN O
with NN NN O
27 NN NN O
to NN NN O
532 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
of NN NN O
doxorubicin NN NN O
( NN NN O
mean NN NN O
196 NN NN O
) NN NN O
were NN NN O
compared NN NN O
with NN NN O
echocardiographic NN NN O
data NN NN O
from NN NN O
12 NN NN O
normal NN NN O
age NN NN O
- NN NN O
matched NN NN O
control NN NN O
subjects NN NN O
. NN NN O
   
Graded NN NN O
dobutamine NN NN O
infusions NN NN O
of NN NN O
0 NN NN O
. NN NN O
5 NN NN O
, NN NN O
2 NN NN O
. NN NN O
5 NN NN O
, NN NN O
5 NN NN O
and NN NN O
10 NN NN O
micrograms NN NN O
/ NN NN O
kg NN NN O
per NN NN O
min NN NN O
were NN NN O
administered NN NN O
. NN NN O
   
Echocardiographic NN NN O
Doppler NN NN O
studies NN NN O
were NN NN O
performed NN NN O
before NN NN O
infusion NN NN O
and NN NN O
after NN NN O
15 NN NN O
min NN NN O
of NN NN O
infusion NN NN O
at NN NN O
each NN NN O
rate NN NN O
. NN NN O
   
Dobutamine NN NN O
infusion NN NN O
at NN NN O
10 NN NN O
micrograms NN NN O
/ NN NN O
kg NN NN O
per NN NN O
min NN NN O
was NN NN O
discontinued NN NN O
after NN NN O
six NN NN O
studies NN NN O
secondary NN NN O
to NN NN O
a NN NN O
50 NN NN O
% NN NN O
incidence NN NN O
rate NN NN O
of NN NN O
adverse NN NN O
symptoms NN NN O
. NN NN O
   
The NN NN O
most NN NN O
important NN NN O
findings NN NN O
were NN NN O
that NN NN O
compared NN NN O
with NN NN O
values NN NN O
in NN NN O
control NN NN O
subjects NN NN O
, NN NN O
end NN NN O
- NN NN O
systolic NN NN O
left NN NN O
ventricular NN NN O
posterior NN NN O
wall NN NN O
dimension NN NN O
and NN NN O
percent NN NN O
of NN NN O
left NN NN O
ventricular NN NN O
posterior NN NN O
wall NN NN O
thickening NN NN O
in NN NN O
doxorubicin NN NN O
- NN NN O
treated NN NN O
patients NN NN O
were NN NN O
decreased NN NN O
at NN NN O
baseline NN NN O
study NN NN O
and NN NN O
these NN NN O
findings NN NN O
were NN NN O
more NN NN O
clearly NN NN O
delineated NN NN O
with NN NN O
dobutamine NN NN O
stimulation NN NN O
. NN NN O
   
End NN NN O
- NN NN O
systolic NN NN O
left NN NN O
ventricular NN NN O
posterior NN NN O
wall NN NN O
dimension NN NN O
at NN NN O
baseline NN NN O
for NN NN O
the NN NN O
doxorubicin NN NN O
- NN NN O
treated NN NN O
group NN NN O
was NN NN O
11 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
9 NN NN O
mm NN NN O
versus NN NN O
13 NN NN O
. NN NN O
1 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
5 NN NN O
mm NN NN O
for NN NN O
control NN NN O
subjects NN NN O
( NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
. NN NN O
   
End NN NN O
- NN NN O
systolic NN NN O
left NN NN O
ventricular NN NN O
posterior NN NN O
wall NN NN O
dimension NN NN O
at NN NN O
the NN NN O
5 NN NN O
- NN NN O
micrograms NN NN O
/ NN NN O
kg NN NN O
per NN NN O
min NN NN O
dobutamine NN NN O
infusion NN NN O
for NN NN O
the NN NN O
doxorubicin NN NN O
- NN NN O
treated NN NN O
group NN NN O
was NN NN O
14 NN NN O
. NN NN O
1 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
. NN NN O
4 NN NN O
mm NN NN O
versus NN NN O
19 NN NN O
. NN NN O
3 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
. NN NN O
6 NN NN O
mm NN NN O
for NN NN O
control NN NN O
subjects NN NN O
( NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
. NN NN O
( NN NN O
ABSTRACT NN NN O
TRUNCATED NN NN O
AT NN NN O
250 NN NN O
WORDS NN NN O
) NN NN O
   
Influence NN NN O
of NN NN O
smoking NN NN O
on NN NN O
developing NN NN O
cochlea NN NN O
. NN NN O
   
Does NN NN O
smoking NN NN O
during NN NN O
pregnancy NN NN O
affect NN NN O
the NN NN O
amplitudes NN NN O
of NN NN O
transient NN NN O
evoked NN NN O
otoacoustic NN NN O
emissions NN NN O
in NN NN O
newborns NN NN O
? NN NN O
   
OBJECTIVE NN NN O
: NN NN O
Maternal NN NN O
tobacco NN NN O
smoking NN NN O
has NN NN O
negative NN NN O
effects NN NN O
on NN NN O
fetal NN NN O
growth NN NN O
. NN NN O
   
The NN NN O
influence NN NN O
of NN NN O
smoking NN NN O
during NN NN O
pregnancy NN NN O
on NN NN O
the NN NN O
developing NN NN O
cochlea NN NN O
has NN NN O
not NN NN O
been NN NN O
estimated NN NN O
, NN NN O
although NN NN O
smoking NN NN O
has NN NN O
been NN NN O
positively NN NN O
associated NN NN O
with NN NN O
hearing NN NN B-Disease
loss NN NN I-Disease
in NN NN O
adults NN NN O
. NN NN O
   
The NN NN O
objective NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
determine NN NN O
the NN NN O
effects NN NN O
of NN NN O
maternal NN NN O
smoking NN NN O
on NN NN O
transient NN NN O
evoked NN NN O
otoacoustic NN NN O
emissions NN NN O
( NN NN O
TEOAEs NN NN O
) NN NN O
of NN NN O
healthy NN NN O
neonates NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
This NN NN O
study NN NN O
was NN NN O
undertaken NN NN O
as NN NN O
part NN NN O
of NN NN O
neonatal NN NN O
screening NN NN O
for NN NN O
hearing NN NN B-Disease
impairment NN NN I-Disease
and NN NN O
involved NN NN O
both NN NN O
ears NN NN O
of NN NN O
200 NN NN O
newborns NN NN O
. NN NN O
   
Newborns NN NN O
whose NN NN O
mothers NN NN O
reported NN NN O
smoking NN NN O
during NN NN O
pregnancy NN NN O
( NN NN O
n NN NN O
= NN NN O
200 NN NN O
ears NN NN O
) NN NN O
were NN NN O
compared NN NN O
to NN NN O
a NN NN O
control NN NN O
group NN NN O
of NN NN O
newborns NN NN O
( NN NN O
n NN NN O
= NN NN O
200 NN NN O
ears NN NN O
) NN NN O
, NN NN O
whose NN NN O
mothers NN NN O
were NN NN O
non NN NN O
- NN NN O
smokers NN NN O
. NN NN O
   
Exposure NN NN O
to NN NN O
tobacco NN NN O
was NN NN O
characterized NN NN O
as NN NN O
low NN NN O
( NN NN O
< NN NN O
5 NN NN O
cigarettes NN NN O
per NN NN O
day NN NN O
, NN NN O
n NN NN O
= NN NN O
88 NN NN O
ears NN NN O
) NN NN O
, NN NN O
moderate NN NN O
( NN NN O
5 NN NN O
< NN NN O
or NN NN O
= NN NN O
cigarettes NN NN O
per NN NN O
day NN NN O
< NN NN O
10 NN NN O
, NN NN O
n NN NN O
= NN NN O
76 NN NN O
) NN NN O
or NN NN O
high NN NN O
( NN NN O
> NN NN O
or NN NN O
= NN NN O
10 NN NN O
cigarettes NN NN O
per NN NN O
day NN NN O
, NN NN O
n NN NN O
= NN NN O
36 NN NN O
) NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
In NN NN O
exposed NN NN O
neonates NN NN O
, NN NN O
TEOAEs NN NN O
mean NN NN O
response NN NN O
( NN NN O
across NN NN O
frequency NN NN O
) NN NN O
and NN NN O
mean NN NN O
amplitude NN NN O
at NN NN O
4000Hz NN NN O
was NN NN O
significantly NN NN O
lower NN NN O
than NN NN O
in NN NN O
non NN NN O
- NN NN O
exposed NN NN O
neonates NN NN O
. NN NN O
   
Comparisons NN NN O
between NN NN O
exposed NN NN O
newborns NN NN O
' NN NN O
subgroups NN NN O
revealed NN NN O
no NN NN O
significant NN NN O
differences NN NN O
. NN NN O
   
However NN NN O
, NN NN O
by NN NN O
comparing NN NN O
each NN NN O
subgroup NN NN O
to NN NN O
control NN NN O
group NN NN O
, NN NN O
we NN NN O
found NN NN O
statistically NN NN O
significant NN NN O
decreases NN NN B-Disease
of NN NN I-Disease
TEOAEs NN NN I-Disease
amplitudes NN NN I-Disease
at NN NN O
4000Hz NN NN O
for NN NN O
all NN NN O
three NN NN O
groups NN NN O
. NN NN O
   
Mean NN NN O
TEOAEs NN NN O
responses NN NN O
of NN NN O
highly NN NN O
exposed NN NN O
newborns NN NN O
were NN NN O
also NN NN O
significantly NN NN O
lower NN NN O
in NN NN O
comparison NN NN O
to NN NN O
our NN NN O
control NN NN O
group NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
In NN NN O
utero NN NN O
, NN NN O
exposure NN NN O
to NN NN O
tobacco NN NN O
smoking NN NN O
seems NN NN O
to NN NN O
have NN NN O
a NN NN O
small NN NN O
impact NN NN O
on NN NN O
outer NN NN O
hair NN NN O
cells NN NN O
. NN NN O
   
These NN NN O
effects NN NN O
seem NN NN O
to NN NN O
be NN NN O
equally NN NN O
true NN NN O
for NN NN O
all NN NN O
exposed NN NN O
newborns NN NN O
, NN NN O
regardless NN NN O
of NN NN O
the NN NN O
degree NN NN O
of NN NN O
exposure NN NN O
. NN NN O
   
Further NN NN O
studies NN NN O
are NN NN O
needed NN NN O
in NN NN O
order NN NN O
to NN NN O
establish NN NN O
a NN NN O
potential NN NN O
negative NN NN O
effect NN NN O
of NN NN O
maternal NN NN O
smoking NN NN O
on NN NN O
the NN NN O
neonate NN NN O
' NN NN O
s NN NN O
hearing NN NN O
acuity NN NN O
. NN NN O
   
Simvastatin NN NN O
- NN NN O
induced NN NN O
bilateral NN NN O
leg NN NN O
compartment NN NN B-Disease
syndrome NN NN I-Disease
and NN NN O
myonecrosis NN NN B-Disease
associated NN NN O
with NN NN O
hypothyroidism NN NN B-Disease
. NN NN O
   
A NN NN O
54 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
hypothyroid NN NN B-Disease
male NN NN O
taking NN NN O
thyroxine NN NN O
and NN NN O
simvastatin NN NN O
presented NN NN O
with NN NN O
bilateral NN NN O
leg NN NN O
compartment NN NN B-Disease
syndrome NN NN I-Disease
and NN NN O
myonecrosis NN NN B-Disease
. NN NN O
   
Urgent NN NN O
fasciotomies NN NN O
were NN NN O
performed NN NN O
and NN NN O
the NN NN O
patient NN NN O
made NN NN O
an NN NN O
uneventful NN NN O
recovery NN NN O
with NN NN O
the NN NN O
withdrawal NN NN O
of NN NN O
simvastatin NN NN O
. NN NN O
   
It NN NN O
is NN NN O
likely NN NN O
that NN NN O
this NN NN O
complication NN NN O
will NN NN O
be NN NN O
seen NN NN O
more NN NN O
often NN NN O
with NN NN O
the NN NN O
increased NN NN O
worldwide NN NN O
use NN NN O
of NN NN O
this NN NN O
drug NN NN O
and NN NN O
its NN NN O
approval NN NN O
for NN NN O
all NN NN O
arteriopathic NN NN B-Disease
patients NN NN O
. NN NN O
   
Neuroinflammation NN NN B-Disease
and NN NN O
behavioral NN NN B-Disease
abnormalities NN NN I-Disease
after NN NN O
neonatal NN NN O
terbutaline NN NN O
treatment NN NN O
in NN NN O
rats NN NN O
: NN NN O
implications NN NN O
for NN NN O
autism NN NN B-Disease
. NN NN O
   
Autism NN NN B-Disease
is NN NN O
a NN NN O
neurodevelopmental NN NN B-Disease
disorder NN NN I-Disease
presenting NN NN O
before NN NN O
3 NN NN O
years NN NN O
of NN NN O
age NN NN O
with NN NN O
deficits NN NN B-Disease
in NN NN I-Disease
communication NN NN I-Disease
and NN NN I-Disease
social NN NN I-Disease
skills NN NN I-Disease
and NN NN O
repetitive NN NN B-Disease
behaviors NN NN I-Disease
. NN NN O
   
In NN NN O
addition NN NN O
to NN NN O
genetic NN NN O
influences NN NN O
, NN NN O
recent NN NN O
studies NN NN O
suggest NN NN O
that NN NN O
prenatal NN NN O
drug NN NN O
or NN NN O
chemical NN NN O
exposures NN NN O
are NN NN O
risk NN NN O
factors NN NN O
for NN NN O
autism NN NN B-Disease
. NN NN O
   
Terbutaline NN NN O
, NN NN O
a NN NN O
beta2 NN NN O
- NN NN O
adrenoceptor NN NN O
agonist NN NN O
used NN NN O
to NN NN O
arrest NN NN O
preterm NN NN B-Disease
labor NN NN I-Disease
, NN NN O
has NN NN O
been NN NN O
associated NN NN O
with NN NN O
increased NN NN O
concordance NN NN O
for NN NN O
autism NN NN B-Disease
in NN NN O
dizygotic NN NN O
twins NN NN O
. NN NN O
   
We NN NN O
studied NN NN O
the NN NN O
effects NN NN O
of NN NN O
terbutaline NN NN O
on NN NN O
microglial NN NN O
activation NN NN O
in NN NN O
different NN NN O
brain NN NN O
regions NN NN O
and NN NN O
behavioral NN NN O
outcomes NN NN O
in NN NN O
developing NN NN O
rats NN NN O
. NN NN O
   
Newborn NN NN O
rats NN NN O
were NN NN O
given NN NN O
terbutaline NN NN O
( NN NN O
10 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
daily NN NN O
on NN NN O
postnatal NN NN O
days NN NN O
( NN NN O
PN NN NN O
) NN NN O
2 NN NN O
to NN NN O
5 NN NN O
or NN NN O
PN NN NN O
11 NN NN O
to NN NN O
14 NN NN O
and NN NN O
examined NN NN O
24 NN NN O
h NN NN O
after NN NN O
the NN NN O
last NN NN O
dose NN NN O
and NN NN O
at NN NN O
PN NN NN O
30 NN NN O
. NN NN O
   
Immunohistochemical NN NN O
studies NN NN O
showed NN NN O
that NN NN O
administration NN NN O
of NN NN O
terbutaline NN NN O
on NN NN O
PN NN NN O
2 NN NN O
to NN NN O
5 NN NN O
produced NN NN O
a NN NN O
robust NN NN O
increase NN NN O
in NN NN O
microglial NN NN O
activation NN NN O
on NN NN O
PN NN NN O
30 NN NN O
in NN NN O
the NN NN O
cerebral NN NN O
cortex NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
in NN NN O
cerebellar NN NN O
and NN NN O
cerebrocortical NN NN O
white NN NN O
matter NN NN O
. NN NN O
   
   O
of NN NN O
these NN NN O
effects NN NN O
occurred NN NN O
in NN NN O
animals NN NN O
given NN NN O
terbutaline NN NN O
on NN NN O
PN NN NN O
11 NN NN O
to NN NN O
14 NN NN O
. NN NN O
   
In NN NN O
behavioral NN NN O
tests NN NN O
, NN NN O
animals NN NN O
treated NN NN O
with NN NN O
terbutaline NN NN O
on NN NN O
PN NN NN O
2 NN NN O
to NN NN O
5 NN NN O
showed NN NN O
consistent NN NN O
patterns NN NN O
of NN NN O
hyper NN NN O
- NN NN O
reactivity NN NN O
to NN NN O
novelty NN NN O
and NN NN O
aversive NN NN O
stimuli NN NN O
when NN NN O
assessed NN NN O
in NN NN O
a NN NN O
novel NN NN O
open NN NN O
field NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
in NN NN O
the NN NN O
acoustic NN NN O
startle NN NN O
response NN NN O
test NN NN O
. NN NN O
   
Our NN NN O
findings NN NN O
indicate NN NN O
that NN NN O
beta2 NN NN O
- NN NN O
adrenoceptor NN NN O
overstimulation NN NN O
during NN NN O
an NN NN O
early NN NN O
critical NN NN O
period NN NN O
results NN NN O
in NN NN O
microglial NN NN O
activation NN NN O
associated NN NN O
with NN NN O
innate NN NN O
neuroinflammatory NN NN O
pathways NN NN O
and NN NN O
behavioral NN NN B-Disease
abnormalities NN NN I-Disease
, NN NN O
similar NN NN O
to NN NN O
those NN NN O
described NN NN O
in NN NN O
autism NN NN B-Disease
. NN NN O
   
This NN NN O
study NN NN O
provides NN NN O
a NN NN O
useful NN NN O
animal NN NN O
model NN NN O
for NN NN O
understanding NN NN O
the NN NN O
neuropathological NN NN O
processes NN NN O
underlying NN NN O
autism NN NN B-Disease
spectrum NN NN I-Disease
disorders NN NN I-Disease
. NN NN O
   
Upregulation NN NN O
of NN NN O
brain NN NN O
expression NN NN O
of NN NN O
P NN NN O
- NN NN O
glycoprotein NN NN O
in NN NN O
MRP2 NN NN O
- NN NN O
deficient NN NN O
TR NN NN O
( NN NN O
- NN NN O
) NN NN O
rats NN NN O
resembles NN NN O
seizure NN NN B-Disease
- NN NN O
induced NN NN O
up NN NN O
- NN NN O
regulation NN NN O
of NN NN O
this NN NN O
drug NN NN O
efflux NN NN O
transporter NN NN O
in NN NN O
normal NN NN O
rats NN NN O
. NN NN O
   
PURPOSE NN NN O
: NN NN O
The NN NN O
multidrug NN NN O
resistance NN NN O
protein NN NN O
2 NN NN O
( NN NN O
MRP2 NN NN O
) NN NN O
is NN NN O
a NN NN O
drug NN NN O
efflux NN NN O
transporter NN NN O
that NN NN O
is NN NN O
expressed NN NN O
predominantly NN NN O
at NN NN O
the NN NN O
apical NN NN O
domain NN NN O
of NN NN O
hepatocytes NN NN O
but NN NN O
seems NN NN O
also NN NN O
to NN NN O
be NN NN O
expressed NN NN O
at NN NN O
the NN NN O
apical NN NN O
membrane NN NN O
of NN NN O
brain NN NN O
capillary NN NN O
endothelial NN NN O
cells NN NN O
that NN NN O
form NN NN O
the NN NN O
blood NN NN O
- NN NN O
brain NN NN O
barrier NN NN O
( NN NN O
BBB NN NN O
) NN NN O
. NN NN O
   
MRP2 NN NN O
is NN NN O
absent NN NN O
in NN NN O
the NN NN O
transport NN NN O
- NN NN O
deficient NN NN O
( NN NN O
TR NN NN O
( NN NN O
- NN NN O
) NN NN O
) NN NN O
Wistar NN NN O
rat NN NN O
mutant NN NN O
, NN NN O
so NN NN O
that NN NN O
this NN NN O
rat NN NN O
strain NN NN O
was NN NN O
very NN NN O
helpful NN NN O
in NN NN O
defining NN NN O
substrates NN NN O
of NN NN O
MRP2 NN NN O
by NN NN O
comparing NN NN O
tissue NN NN O
concentrations NN NN O
or NN NN O
functional NN NN O
activities NN NN O
of NN NN O
compounds NN NN O
in NN NN O
MRP2 NN NN O
- NN NN O
deficient NN NN O
rats NN NN O
with NN NN O
those NN NN O
in NN NN O
transport NN NN O
- NN NN O
competent NN NN O
Wistar NN NN O
rats NN NN O
. NN NN O
   
By NN NN O
using NN NN O
this NN NN O
strategy NN NN O
to NN NN O
study NN NN O
the NN NN O
involvement NN NN O
of NN NN O
MRP2 NN NN O
in NN NN O
brain NN NN O
access NN NN O
of NN NN O
antiepileptic NN NN O
drugs NN NN O
( NN NN O
AEDs NN NN O
) NN NN O
, NN NN O
we NN NN O
recently NN NN O
reported NN NN O
that NN NN O
phenytoin NN NN O
is NN NN O
a NN NN O
substrate NN NN O
for NN NN O
MRP2 NN NN O
in NN NN O
the NN NN O
BBB NN NN O
. NN NN O
   
However NN NN O
, NN NN O
one NN NN O
drawback NN NN O
of NN NN O
such NN NN O
studies NN NN O
in NN NN O
genetically NN NN O
deficient NN NN O
rats NN NN O
is NN NN O
the NN NN O
fact NN NN O
that NN NN O
compensatory NN NN O
changes NN NN O
with NN NN O
upregulation NN NN O
of NN NN O
other NN NN O
transporters NN NN O
can NN NN O
occur NN NN O
. NN NN O
   
This NN NN O
prompted NN NN O
us NN NN O
to NN NN O
study NN NN O
the NN NN O
brain NN NN O
expression NN NN O
of NN NN O
P NN NN O
- NN NN O
glycoprotein NN NN O
( NN NN O
Pgp NN NN O
) NN NN O
, NN NN O
a NN NN O
major NN NN O
drug NN NN O
efflux NN NN O
transporter NN NN O
in NN NN O
many NN NN O
tissues NN NN O
, NN NN O
including NN NN O
the NN NN O
BBB NN NN O
, NN NN O
in NN NN O
TR NN NN O
( NN NN O
- NN NN O
) NN NN O
rats NN NN O
compared NN NN O
with NN NN O
nonmutant NN NN O
( NN NN O
wild NN NN O
- NN NN O
type NN NN O
) NN NN O
Wistar NN NN O
rats NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
The NN NN O
expression NN NN O
of NN NN O
MRP2 NN NN O
and NN NN O
Pgp NN NN O
in NN NN O
brain NN NN O
and NN NN O
liver NN NN O
sections NN NN O
of NN NN O
TR NN NN O
( NN NN O
- NN NN O
) NN NN O
rats NN NN O
and NN NN O
normal NN NN O
Wistar NN NN O
rats NN NN O
was NN NN O
determined NN NN O
with NN NN O
immunohistochemistry NN NN O
, NN NN O
by NN NN O
using NN NN O
a NN NN O
novel NN NN O
, NN NN O
highly NN NN O
selective NN NN O
monoclonal NN NN O
MRP2 NN NN O
antibody NN NN O
and NN NN O
the NN NN O
monoclonal NN NN O
Pgp NN NN O
antibody NN NN O
C219 NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Immunofluorescence NN NN O
staining NN NN O
with NN NN O
the NN NN O
MRP2 NN NN O
antibody NN NN O
was NN NN O
found NN NN O
to NN NN O
label NN NN O
a NN NN O
high NN NN O
number NN NN O
of NN NN O
microvessels NN NN O
throughout NN NN O
the NN NN O
brain NN NN O
in NN NN O
normal NN NN O
Wistar NN NN O
rats NN NN O
, NN NN O
whereas NN NN O
such NN NN O
labeling NN NN O
was NN NN O
absent NN NN O
in NN NN O
TR NN NN O
( NN NN O
- NN NN O
) NN NN O
rats NN NN O
. NN NN O
   
TR NN NN O
( NN NN O
- NN NN O
) NN NN O
rats NN NN O
exhibited NN NN O
a NN NN O
significant NN NN O
up NN NN O
- NN NN O
regulation NN NN O
of NN NN O
Pgp NN NN O
in NN NN O
brain NN NN O
capillary NN NN O
endothelial NN NN O
cells NN NN O
compared NN NN O
with NN NN O
wild NN NN O
- NN NN O
type NN NN O
controls NN NN O
. NN NN O
   
No NN NN O
such NN NN O
obvious NN NN O
upregulation NN NN O
of NN NN O
Pgp NN NN O
was NN NN O
observed NN NN O
in NN NN O
liver NN NN O
sections NN NN O
. NN NN O
   
A NN NN O
comparable NN NN O
overexpression NN NN O
of NN NN O
Pgp NN NN O
in NN NN O
the NN NN O
BBB NN NN O
was NN NN O
obtained NN NN O
after NN NN O
pilocarpine NN NN O
- NN NN O
induced NN NN O
seizures NN NN B-Disease
in NN NN O
wild NN NN O
- NN NN O
type NN NN O
Wistar NN NN O
rats NN NN O
. NN NN O
   
Experiments NN NN O
with NN NN O
systemic NN NN O
administration NN NN O
of NN NN O
the NN NN O
Pgp NN NN O
substrate NN NN O
phenobarbital NN NN O
and NN NN O
the NN NN O
selective NN NN O
Pgp NN NN O
inhibitor NN NN O
tariquidar NN NN O
in NN NN O
TR NN NN O
( NN NN O
- NN NN O
) NN NN O
rats NN NN O
substantiated NN NN O
that NN NN O
Pgp NN NN O
is NN NN O
functional NN NN O
and NN NN O
compensates NN NN O
for NN NN O
the NN NN O
lack NN NN O
of NN NN O
MRP2 NN NN O
in NN NN O
the NN NN O
BBB NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
The NN NN O
data NN NN O
on NN NN O
TR NN NN O
( NN NN O
- NN NN O
) NN NN O
rats NN NN O
indicate NN NN O
that NN NN O
Pgp NN NN O
plays NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
the NN NN O
compensation NN NN O
of NN NN O
MRP2 NN NN O
deficiency NN NN O
in NN NN O
the NN NN O
BBB NN NN O
. NN NN O
   
Because NN NN O
such NN NN O
a NN NN O
compensatory NN NN O
mechanism NN NN O
most NN NN O
likely NN NN O
occurs NN NN O
to NN NN O
reduce NN NN O
injury NN NN B-Disease
to NN NN I-Disease
the NN NN I-Disease
brain NN NN I-Disease
from NN NN O
cytotoxic NN NN O
compounds NN NN O
, NN NN O
the NN NN O
present NN NN O
data NN NN O
substantiate NN NN O
the NN NN O
concept NN NN O
that NN NN O
MRP2 NN NN O
performs NN NN O
a NN NN O
protective NN NN O
role NN NN O
in NN NN O
the NN NN O
BBB NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
our NN NN O
data NN NN O
suggest NN NN O
that NN NN O
TR NN NN O
( NN NN O
- NN NN O
) NN NN O
rats NN NN O
are NN NN O
an NN NN O
interesting NN NN O
tool NN NN O
to NN NN O
study NN NN O
consequences NN NN O
of NN NN O
overexpression NN NN O
of NN NN O
Pgp NN NN O
in NN NN O
the NN NN O
BBB NN NN O
on NN NN O
access NN NN O
of NN NN O
drugs NN NN O
in NN NN O
the NN NN O
brain NN NN O
, NN NN O
without NN NN O
the NN NN O
need NN NN O
of NN NN O
inducing NN NN O
seizures NN NN B-Disease
or NN NN O
other NN NN O
Pgp NN NN O
- NN NN O
enhancing NN NN O
events NN NN O
for NN NN O
this NN NN O
purpose NN NN O
. NN NN O
   
Role NN NN O
of NN NN O
xanthine NN NN O
oxidase NN NN O
in NN NN O
dexamethasone NN NN O
- NN NN O
induced NN NN O
hypertension NN NN B-Disease
in NN NN O
rats NN NN O
. NN NN O
   
1 NN NN O
. NN NN O
   
Glucocorticoid NN NN O
- NN NN O
induced NN NN O
hypertension NN NN B-Disease
( NN NN O
GC NN NN O
- NN NN O
HT NN NN B-Disease
) NN NN O
in NN NN O
the NN NN O
rat NN NN O
is NN NN O
associated NN NN O
with NN NN O
nitric NN NN O
oxide NN NN O
- NN NN O
redox NN NN O
imbalance NN NN O
. NN NN O
   
2 NN NN O
. NN NN O
   
We NN NN O
studied NN NN O
the NN NN O
role NN NN O
of NN NN O
xanthine NN NN O
oxidase NN NN O
( NN NN O
XO NN NN O
) NN NN O
, NN NN O
which NN NN O
is NN NN O
implicated NN NN O
in NN NN O
the NN NN O
production NN NN O
of NN NN O
reactive NN NN O
oxygen NN NN O
species NN NN O
, NN NN O
in NN NN O
dexamethasone NN NN O
- NN NN O
induced NN NN O
hypertension NN NN B-Disease
( NN NN O
dex NN NN O
- NN NN O
HT NN NN B-Disease
) NN NN O
. NN NN O
   
3 NN NN O
. NN NN O
   
Thirty NN NN O
male NN NN O
Sprague NN NN O
- NN NN O
Dawley NN NN O
rats NN NN O
were NN NN O
divided NN NN O
randomly NN NN O
into NN NN O
four NN NN O
treatment NN NN O
groups NN NN O
: NN NN O
saline NN NN O
, NN NN O
dexamethasone NN NN O
( NN NN O
dex NN NN O
) NN NN O
, NN NN O
allopurinol NN NN O
plus NN NN O
saline NN NN O
, NN NN O
and NN NN O
allopurinol NN NN O
plus NN NN O
dex NN NN O
. NN NN O
   
4 NN NN O
. NN NN O
   
Systolic NN NN O
blood NN NN O
pressures NN NN O
( NN NN O
SBP NN NN O
) NN NN O
and NN NN O
bodyweights NN NN O
were NN NN O
recorded NN NN O
each NN NN O
alternate NN NN O
day NN NN O
. NN NN O
   
Thymus NN NN O
weight NN NN O
was NN NN O
used NN NN O
as NN NN O
a NN NN O
marker NN NN O
of NN NN O
glucocorticoid NN NN O
activity NN NN O
, NN NN O
and NN NN O
serum NN NN O
urate NN NN O
to NN NN O
assess NN NN O
XO NN NN O
inhibition NN NN O
. NN NN O
   
5 NN NN O
. NN NN O
   
Dex NN NN O
increased NN NN B-Disease
SBP NN NN I-Disease
( NN NN O
110 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
- NN NN O
126 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
3 NN NN O
mmHg NN NN O
; NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
and NN NN O
decreased NN NN B-Disease
thymus NN NN I-Disease
( NN NN I-Disease
P NN NN I-Disease
< NN NN I-Disease
0 NN NN I-Disease
. NN NN I-Disease
001 NN NN I-Disease
) NN NN I-Disease
and NN NN I-Disease
bodyweights NN NN I-Disease
( NN NN O
P NN NN O
"""""""" NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
. NN NN O
   
Allopurinol NN NN O
decreased NN NN O
serum NN NN O
urate NN NN O
from NN NN O
76 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
5 NN NN O
to NN NN O
30 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
3 NN NN O
micromol NN NN O
/ NN NN O
L NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
in NN NN O
saline NN NN O
and NN NN O
from NN NN O
84 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
13 NN NN O
to NN NN O
28 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
micromol NN NN O
/ NN NN O
L NN NN O
in NN NN O
dex NN NN O
- NN NN O
treated NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
groups NN NN O
. NN NN O
   
6 NN NN O
. NN NN O
   
Allopurinol NN NN O
did NN NN O
not NN NN O
prevent NN NN O
dex NN NN O
- NN NN O
HT NN NN B-Disease
. NN NN O
   
This NN NN O
, NN NN O
together NN NN O
with NN NN O
our NN NN O
previous NN NN O
findings NN NN O
that NN NN O
allopurinol NN NN O
failed NN NN O
to NN NN O
prevent NN NN O
adrenocorticotrophic NN NN O
hormone NN NN O
induced NN NN O
hypertension NN NN B-Disease
, NN NN O
suggests NN NN O
that NN NN O
XO NN NN O
activity NN NN O
is NN NN O
not NN NN O
a NN NN O
major NN NN O
determinant NN NN O
of NN NN O
GC NN NN O
- NN NN O
HT NN NN B-Disease
in NN NN O
the NN NN O
rat NN NN O
. NN NN O
   
Side NN NN O
effects NN NN O
of NN NN O
postoperative NN NN O
administration NN NN O
of NN NN O
methylprednisolone NN NN O
and NN NN O
gentamicin NN NN O
into NN NN O
the NN NN O
posterior NN NN O
sub NN NN O
- NN NN O
Tenon NN NN O
' NN NN O
s NN NN O
space NN NN O
. NN NN O
   
PURPOSE NN NN O
: NN NN O
To NN NN O
assess NN NN O
the NN NN O
incidence NN NN O
of NN NN O
postoperative NN NN O
emetic NN NN O
side NN NN O
effects NN NN O
after NN NN O
the NN NN O
administration NN NN O
of NN NN O
methylprednisolone NN NN O
and NN NN O
gentamicin NN NN O
into NN NN O
the NN NN O
posterior NN NN O
sub NN NN O
- NN NN O
Tenon NN NN O
' NN NN O
s NN NN O
space NN NN O
at NN NN O
the NN NN O
end NN NN O
of NN NN O
routine NN NN O
cataract NN NN B-Disease
surgery NN NN O
. NN NN O
   
SETTING NN NN O
: NN NN O
St NN NN O
. NN NN O
   
Luke NN NN O
' NN NN O
s NN NN O
Hospital NN NN O
, NN NN O
Gwardamangia NN NN O
, NN NN O
Malta NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
A NN NN O
double NN NN O
- NN NN O
blind NN NN O
double NN NN O
- NN NN O
armed NN NN O
prospective NN NN O
study NN NN O
comprised NN NN O
40 NN NN O
patients NN NN O
who NN NN O
had NN NN O
uneventful NN NN O
sutureless NN NN O
phacoemulsification NN NN O
under NN NN O
sub NN NN O
- NN NN O
Tenon NN NN O
' NN NN O
s NN NN O
local NN NN O
infiltration NN NN O
of NN NN O
3 NN NN O
mL NN NN O
of NN NN O
plain NN NN O
lignocaine NN NN O
. NN NN O
   
At NN NN O
the NN NN O
end NN NN O
of NN NN O
the NN NN O
procedure NN NN O
, NN NN O
Group NN NN O
A NN NN O
( NN NN O
n NN NN O
= NN NN O
20 NN NN O
) NN NN O
had NN NN O
20 NN NN O
mg NN NN O
/ NN NN O
0 NN NN O
. NN NN O
5 NN NN O
mL NN NN O
of NN NN O
methylprednisolone NN NN O
and NN NN O
10 NN NN O
mg NN NN O
/ NN NN O
0 NN NN O
. NN NN O
5 NN NN O
mL NN NN O
of NN NN O
gentamicin NN NN O
injected NN NN O
into NN NN O
the NN NN O
posterior NN NN O
sub NN NN O
- NN NN O
Tenon NN NN O
' NN NN O
s NN NN O
space NN NN O
and NN NN O
Group NN NN O
B NN NN O
( NN NN O
n NN NN O
= NN NN O
20 NN NN O
) NN NN O
had NN NN O
the NN NN O
same NN NN O
combination NN NN O
injected NN NN O
into NN NN O
the NN NN O
anterior NN NN O
sub NN NN O
- NN NN O
Tenon NN NN O
' NN NN O
s NN NN O
space NN NN O
. NN NN O
   
Postoperatively NN NN O
, NN NN O
all NN NN O
patients NN NN O
were NN NN O
assessed NN NN O
for NN NN O
symptoms NN NN O
of NN NN O
nausea NN NN B-Disease
, NN NN I-Disease
vomiting NN NN I-Disease
, NN NN O
and NN NN O
headache NN NN B-Disease
. NN NN O
   
A NN NN O
chi NN NN O
- NN NN O
square NN NN O
test NN NN O
was NN NN O
used NN NN O
to NN NN O
assess NN NN O
the NN NN O
statistical NN NN O
significance NN NN O
of NN NN O
results NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Sixty NN NN O
percent NN NN O
in NN NN O
Group NN NN O
A NN NN O
developed NN NN O
postoperative NN NN B-Disease
emetic NN NN I-Disease
symptoms NN NN I-Disease
, NN NN O
headache NN NN B-Disease
, NN NN O
or NN NN O
both NN NN O
; NN NN O
1 NN NN O
patient NN NN O
in NN NN O
Group NN NN O
B NN NN O
developed NN NN O
symptoms NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
The NN NN O
administration NN NN O
of NN NN O
methylprednisolone NN NN O
and NN NN O
gentamicin NN NN O
in NN NN O
the NN NN O
posterior NN NN O
sub NN NN O
- NN NN O
Tenon NN NN O
' NN NN O
s NN NN O
space NN NN O
was NN NN O
related NN NN O
to NN NN O
a NN NN O
high NN NN O
incidence NN NN O
of NN NN O
side NN NN O
effects NN NN O
including NN NN O
nausea NN NN B-Disease
, NN NN I-Disease
vomiting NN NN I-Disease
, NN NN O
and NN NN O
headache NN NN B-Disease
. NN NN O
   
All NN NN O
adverse NN NN O
effects NN NN O
were NN NN O
self NN NN O
- NN NN O
limiting NN NN O
. NN NN O
   
Assessment NN NN O
of NN NN O
a NN NN O
new NN NN O
non NN NN O
- NN NN O
invasive NN NN O
index NN NN O
of NN NN O
cardiac NN NN O
performance NN NN O
for NN NN O
detection NN NN O
of NN NN O
dobutamine NN NN O
- NN NN O
induced NN NN O
myocardial NN NN B-Disease
ischemia NN NN I-Disease
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Electrocardiography NN NN O
has NN NN O
a NN NN O
very NN NN O
low NN NN O
sensitivity NN NN O
in NN NN O
detecting NN NN O
dobutamine NN NN O
- NN NN O
induced NN NN O
myocardial NN NN B-Disease
ischemia NN NN I-Disease
. NN NN O
   
OBJECTIVES NN NN O
: NN NN O
To NN NN O
assess NN NN O
the NN NN O
added NN NN O
diagnostic NN NN O
value NN NN O
of NN NN O
a NN NN O
new NN NN O
cardiac NN NN O
performance NN NN O
index NN NN O
( NN NN O
dP NN NN O
/ NN NN O
dtejc NN NN O
) NN NN O
measurement NN NN O
, NN NN O
based NN NN O
on NN NN O
brachial NN NN O
artery NN NN O
flow NN NN O
changes NN NN O
, NN NN O
as NN NN O
compared NN NN O
to NN NN O
standard NN NN O
12 NN NN O
- NN NN O
lead NN NN O
ECG NN NN O
, NN NN O
for NN NN O
detecting NN NN O
dobutamine NN NN O
- NN NN O
induced NN NN O
myocardial NN NN B-Disease
ischemia NN NN I-Disease
, NN NN O
using NN NN O
Tc99m NN NN O
- NN NN O
Sestamibi NN NN O
single NN NN O
- NN NN O
photon NN NN O
emission NN NN O
computed NN NN O
tomography NN NN O
as NN NN O
the NN NN O
gold NN NN O
standard NN NN O
of NN NN O
comparison NN NN O
to NN NN O
assess NN NN O
the NN NN O
presence NN NN O
or NN NN O
absence NN NN O
of NN NN O
ischemia NN NN B-Disease
. NN NN O
   
METHODS NN NN O
: NN NN O
The NN NN O
study NN NN O
group NN NN O
comprised NN NN O
40 NN NN O
patients NN NN O
undergoing NN NN O
Sestamibi NN NN O
- NN NN O
SPECT NN NN O
/ NN NN O
dobutamine NN NN O
stress NN NN O
test NN NN O
. NN NN O
   
Simultaneous NN NN O
measurements NN NN O
of NN NN O
ECG NN NN O
and NN NN O
brachial NN NN O
artery NN NN O
dP NN NN O
/ NN NN O
dtejc NN NN O
were NN NN O
performed NN NN O
at NN NN O
each NN NN O
dobutamine NN NN O
level NN NN O
. NN NN O
   
In NN NN O
19 NN NN O
of NN NN O
the NN NN O
40 NN NN O
patients NN NN O
perfusion NN NN O
defects NN NN O
compatible NN NN O
with NN NN O
ischemia NN NN B-Disease
were NN NN O
detected NN NN O
on NN NN O
SPECT NN NN O
. NN NN O
   
The NN NN O
increase NN NN O
in NN NN O
dP NN NN O
/ NN NN O
dtejc NN NN O
during NN NN O
infusion NN NN O
of NN NN O
dobutamine NN NN O
in NN NN O
this NN NN O
group NN NN O
was NN NN O
severely NN NN O
impaired NN NN O
as NN NN O
compared NN NN O
to NN NN O
the NN NN O
non NN NN O
- NN NN O
ischemic NN NN O
group NN NN O
. NN NN O
   
dP NN NN O
/ NN NN O
dtejc NN NN O
outcome NN NN O
was NN NN O
combined NN NN O
with NN NN O
the NN NN O
ECG NN NN O
results NN NN O
, NN NN O
giving NN NN O
an NN NN O
ECG NN NN O
- NN NN O
enhanced NN NN O
value NN NN O
, NN NN O
and NN NN O
compared NN NN O
to NN NN O
ECG NN NN O
alone NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
The NN NN O
sensitivity NN NN O
improved NN NN O
dramatically NN NN O
from NN NN O
16 NN NN O
% NN NN O
to NN NN O
79 NN NN O
% NN NN O
, NN NN O
positive NN NN O
predictive NN NN O
value NN NN O
increased NN NN O
from NN NN O
60 NN NN O
% NN NN O
to NN NN O
68 NN NN O
% NN NN O
and NN NN O
negative NN NN O
predictive NN NN O
value NN NN O
from NN NN O
54 NN NN O
% NN NN O
to NN NN O
78 NN NN O
% NN NN O
, NN NN O
and NN NN O
specificity NN NN O
decreased NN NN O
from NN NN O
90 NN NN O
% NN NN O
to NN NN O
67 NN NN O
% NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
If NN NN O
ECG NN NN O
alone NN NN O
is NN NN O
used NN NN O
for NN NN O
specificity NN NN O
, NN NN O
the NN NN O
combination NN NN O
with NN NN O
dP NN NN O
/ NN NN O
dtejc NN NN O
improved NN NN O
the NN NN O
sensitivity NN NN O
of NN NN O
the NN NN O
test NN NN O
and NN NN O
could NN NN O
be NN NN O
a NN NN O
cost NN NN O
- NN NN O
savings NN NN O
alternative NN NN O
to NN NN O
cardiac NN NN O
imaging NN NN O
or NN NN O
perfusion NN NN O
studies NN NN O
to NN NN O
detect NN NN O
myocardial NN NN B-Disease
ischemia NN NN I-Disease
, NN NN O
especially NN NN O
in NN NN O
patients NN NN O
unable NN NN O
to NN NN O
exercise NN NN O
. NN NN O
   
Cocaine NN NN O
- NN NN O
induced NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
: NN NN O
clinical NN NN O
observations NN NN O
and NN NN O
pathogenetic NN NN O
considerations NN NN O
. NN NN O
   
Clinical NN NN O
and NN NN O
experimental NN NN O
data NN NN O
published NN NN O
to NN NN O
date NN NN O
suggest NN NN O
several NN NN O
possible NN NN O
mechanisms NN NN O
by NN NN O
which NN NN O
cocaine NN NN O
may NN NN O
result NN NN O
in NN NN O
acute NN NN B-Disease
myocardial NN NN I-Disease
infarction NN NN I-Disease
. NN NN O
   
In NN NN O
individuals NN NN O
with NN NN O
preexisting NN NN O
, NN NN O
high NN NN O
- NN NN O
grade NN NN O
coronary NN NN O
arterial NN NN O
narrowing NN NN O
, NN NN O
acute NN NN B-Disease
myocardial NN NN I-Disease
infarction NN NN I-Disease
may NN NN O
result NN NN O
from NN NN O
an NN NN O
increase NN NN O
in NN NN O
myocardial NN NN O
oxygen NN NN O
demand NN NN O
associated NN NN O
with NN NN O
cocaine NN NN O
- NN NN O
induced NN NN O
increase NN NN O
in NN NN O
rate NN NN O
- NN NN O
pressure NN NN O
product NN NN O
. NN NN O
   
In NN NN O
other NN NN O
individuals NN NN O
with NN NN O
no NN NN O
underlying NN NN O
atherosclerotic NN NN B-Disease
obstruction NN NN I-Disease
, NN NN O
coronary NN NN B-Disease
occlusion NN NN I-Disease
may NN NN O
be NN NN O
due NN NN O
to NN NN O
spasm NN NN B-Disease
, NN NN O
thrombus NN NN B-Disease
, NN NN O
or NN NN O
both NN NN O
. NN NN O
   
With NN NN O
regard NN NN O
to NN NN O
spasm NN NN B-Disease
, NN NN O
the NN NN O
clinical NN NN O
findings NN NN O
are NN NN O
largely NN NN O
circumstantial NN NN O
, NN NN O
and NN NN O
the NN NN O
locus NN NN O
of NN NN O
cocaine NN NN O
- NN NN O
induced NN NN O
vasoconstriction NN NN O
remains NN NN O
speculative NN NN O
. NN NN O
   
Although NN NN O
certain NN NN O
clinical NN NN O
and NN NN O
experimental NN NN O
findings NN NN O
support NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
spasm NN NN B-Disease
involves NN NN O
the NN NN O
epicardial NN NN O
, NN NN O
medium NN NN O
- NN NN O
size NN NN O
vessels NN NN O
, NN NN O
other NN NN O
data NN NN O
suggest NN NN O
intramural NN NN O
vasoconstriction NN NN O
. NN NN O
   
Diffuse NN NN O
intramural NN NN O
vasoconstriction NN NN O
is NN NN O
not NN NN O
consistent NN NN O
with NN NN O
reports NN NN O
of NN NN O
segmental NN NN O
, NN NN O
discrete NN NN O
infarction NN NN B-Disease
. NN NN O
   
Whereas NN NN O
certain NN NN O
in NN NN O
vivo NN NN O
data NN NN O
suggest NN NN O
that NN NN O
these NN NN O
effects NN NN O
are NN NN O
alpha NN NN O
- NN NN O
mediated NN NN O
, NN NN O
other NN NN O
in NN NN O
vitro NN NN O
data NN NN O
suggest NN NN O
the NN NN O
opposite NN NN O
. NN NN O
   
The NN NN O
finding NN NN O
of NN NN O
cocaine NN NN O
- NN NN O
induced NN NN O
vasoconstriction NN NN O
in NN NN O
segments NN NN O
of NN NN O
( NN NN O
noninnervated NN NN O
) NN NN O
human NN NN O
umbilical NN NN O
artery NN NN O
suggests NN NN O
that NN NN O
the NN NN O
presence NN NN O
or NN NN O
absence NN NN O
of NN NN O
intact NN NN O
innervation NN NN O
is NN NN O
not NN NN O
sufficient NN NN O
to NN NN O
explain NN NN O
the NN NN O
discrepant NN NN O
data NN NN O
involving NN NN O
the NN NN O
possibility NN NN O
of NN NN O
alpha NN NN O
- NN NN O
mediated NN NN O
effects NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
the NN NN O
contribution NN NN O
of NN NN O
a NN NN O
primary NN NN O
, NN NN O
thrombotic NN NN B-Disease
effect NN NN O
of NN NN O
cocaine NN NN O
has NN NN O
not NN NN O
been NN NN O
excluded NN NN O
. NN NN O
   
Proteomic NN NN O
analysis NN NN O
of NN NN O
striatal NN NN O
proteins NN NN O
in NN NN O
the NN NN O
rat NN NN O
model NN NN O
of NN NN O
L NN NN O
- NN NN O
DOPA NN NN O
- NN NN O
induced NN NN O
dyskinesia NN NN B-Disease
. NN NN O
   
L NN NN O
- NN NN O
DOPA NN NN O
- NN NN O
induced NN NN O
dyskinesia NN NN B-Disease
( NN NN O
LID NN NN B-Disease
) NN NN O
is NN NN O
among NN NN O
the NN NN O
motor NN NN O
complications NN NN O
that NN NN O
arise NN NN O
in NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
( NN NN O
PD NN NN B-Disease
) NN NN O
patients NN NN O
after NN NN O
a NN NN O
prolonged NN NN O
treatment NN NN O
with NN NN O
L NN NN O
- NN NN O
DOPA NN NN O
. NN NN O
   
To NN NN O
this NN NN O
day NN NN O
, NN NN O
transcriptome NN NN O
analysis NN NN O
has NN NN O
been NN NN O
performed NN NN O
in NN NN O
a NN NN O
rat NN NN O
model NN NN O
of NN NN O
LID NN NN B-Disease
[ NN NN O
Neurobiol NN NN O
. NN NN O
Dis NN NN O
. NN NN O
, NN NN O
17 NN NN O
( NN NN O
2004 NN NN O
) NN NN O
, NN NN O
219 NN NN O
] NN NN O
but NN NN O
information NN NN O
regarding NN NN O
the NN NN O
proteome NN NN O
is NN NN O
still NN NN O
lacking NN NN O
. NN NN O
   
In NN NN O
the NN NN O
present NN NN O
study NN NN O
, NN NN O
we NN NN O
investigated NN NN O
the NN NN O
changes NN NN O
occurring NN NN O
at NN NN O
the NN NN O
protein NN NN O
level NN NN O
in NN NN O
striatal NN NN O
samples NN NN O
obtained NN NN O
from NN NN O
the NN NN O
unilaterally NN NN O
6 NN NN O
- NN NN O
hydroxydopamine NN NN O
- NN NN O
lesion NN NN O
rat NN NN O
model NN NN O
of NN NN O
PD NN NN B-Disease
treated NN NN O
with NN NN O
saline NN NN O
, NN NN O
L NN NN O
- NN NN O
DOPA NN NN O
or NN NN O
bromocriptine NN NN O
using NN NN O
two NN NN O
- NN NN O
dimensional NN NN O
difference NN NN O
gel NN NN O
electrophoresis NN NN O
and NN NN O
mass NN NN O
spectrometry NN NN O
( NN NN O
MS NN NN O
) NN NN O
. NN NN O
   
Rats NN NN O
treated NN NN O
with NN NN O
L NN NN O
- NN NN O
DOPA NN NN O
were NN NN O
allocated NN NN O
to NN NN O
two NN NN O
groups NN NN O
based NN NN O
on NN NN O
the NN NN O
presence NN NN O
or NN NN O
absence NN NN O
of NN NN O
LID NN NN B-Disease
. NN NN O
   
Among NN NN O
the NN NN O
2000 NN NN O
spots NN NN O
compared NN NN O
for NN NN O
statistical NN NN O
difference NN NN O
, NN NN O
67 NN NN O
spots NN NN O
were NN NN O
significantly NN NN O
changed NN NN O
in NN NN O
abundance NN NN O
and NN NN O
identified NN NN O
using NN NN O
matrix NN NN O
- NN NN O
assisted NN NN O
laser NN NN O
desorption NN NN O
/ NN NN O
ionization NN NN O
time NN NN O
- NN NN O
of NN NN O
- NN NN O
flight NN NN O
MS NN NN O
, NN NN O
atmospheric NN NN O
pressure NN NN O
matrix NN NN O
- NN NN O
assisted NN NN O
laser NN NN O
desorption NN NN O
/ NN NN O
ionization NN NN O
and NN NN O
HPLC NN NN O
coupled NN NN O
tandem NN NN O
MS NN NN O
( NN NN O
LC NN NN O
/ NN NN O
MS NN NN O
/ NN NN O
MS NN NN O
) NN NN O
. NN NN O
   
Out NN NN O
of NN NN O
these NN NN O
67 NN NN O
proteins NN NN O
, NN NN O
LID NN NN B-Disease
significantly NN NN O
changed NN NN O
the NN NN O
expression NN NN O
level NN NN O
of NN NN O
five NN NN O
proteins NN NN O
: NN NN O
alphabeta NN NN O
- NN NN O
crystalin NN NN O
, NN NN O
gamma NN NN O
- NN NN O
enolase NN NN O
, NN NN O
guanidoacetate NN NN O
methyltransferase NN NN O
, NN NN O
vinculin NN NN O
, NN NN O
and NN NN O
proteasome NN NN O
alpha NN NN O
- NN NN O
2 NN NN O
subunit NN NN O
. NN NN O
   
Complementary NN NN O
techniques NN NN O
such NN NN O
as NN NN O
western NN NN O
immunoblotting NN NN O
and NN NN O
immunohistochemistry NN NN O
were NN NN O
performed NN NN O
to NN NN O
investigate NN NN O
the NN NN O
validity NN NN O
of NN NN O
the NN NN O
data NN NN O
obtained NN NN O
using NN NN O
the NN NN O
proteomic NN NN O
approach NN NN O
. NN NN O
   
In NN NN O
conclusion NN NN O
, NN NN O
this NN NN O
study NN NN O
provides NN NN O
new NN NN O
insights NN NN O
into NN NN O
the NN NN O
protein NN NN O
changes NN NN O
occurring NN NN O
in NN NN O
LID NN NN B-Disease
. NN NN O
   
Cardiac NN NN O
Angiography NN NN O
in NN NN O
Renally NN NN O
Impaired NN NN O
Patients NN NN O
( NN NN O
CARE NN NN O
) NN NN O
study NN NN O
: NN NN O
a NN NN O
randomized NN NN O
double NN NN O
- NN NN O
blind NN NN O
trial NN NN O
of NN NN O
contrast NN NN O
- NN NN O
induced NN NN O
nephropathy NN NN B-Disease
in NN NN O
patients NN NN O
with NN NN O
chronic NN NN B-Disease
kidney NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
No NN NN O
direct NN NN O
comparisons NN NN O
exist NN NN O
of NN NN O
the NN NN O
renal NN NN O
tolerability NN NN O
of NN NN O
the NN NN O
low NN NN O
- NN NN O
osmolality NN NN O
contrast NN NN O
medium NN NN O
iopamidol NN NN O
with NN NN O
that NN NN O
of NN NN O
the NN NN O
iso NN NN O
- NN NN O
osmolality NN NN O
contrast NN NN O
medium NN NN O
iodixanol NN NN O
in NN NN O
high NN NN O
- NN NN O
risk NN NN O
patients NN NN O
. NN NN O
   
METHODS NN NN O
AND NN NN O
RESULTS NN NN O
: NN NN O
The NN NN O
present NN NN O
study NN NN O
is NN NN O
a NN NN O
multicenter NN NN O
, NN NN O
randomized NN NN O
, NN NN O
double NN NN O
- NN NN O
blind NN NN O
comparison NN NN O
of NN NN O
iopamidol NN NN O
and NN NN O
iodixanol NN NN O
in NN NN O
patients NN NN O
with NN NN O
chronic NN NN B-Disease
kidney NN NN I-Disease
disease NN NN I-Disease
( NN NN O
estimated NN NN O
glomerular NN NN O
filtration NN NN O
rate NN NN O
, NN NN O
20 NN NN O
to NN NN O
59 NN NN O
mL NN NN O
/ NN NN O
min NN NN O
) NN NN O
who NN NN O
underwent NN NN O
cardiac NN NN O
angiography NN NN O
or NN NN O
percutaneous NN NN O
coronary NN NN O
interventions NN NN O
. NN NN O
   
Serum NN NN O
creatinine NN NN O
( NN NN O
SCr NN NN O
) NN NN O
levels NN NN O
and NN NN O
estimated NN NN O
glomerular NN NN O
filtration NN NN O
rate NN NN O
were NN NN O
assessed NN NN O
at NN NN O
baseline NN NN O
and NN NN O
2 NN NN O
to NN NN O
5 NN NN O
days NN NN O
after NN NN O
receiving NN NN O
medications NN NN O
. NN NN O
   
The NN NN O
primary NN NN O
outcome NN NN O
was NN NN O
a NN NN O
postdose NN NN O
SCr NN NN O
increase NN NN O
> NN NN O
or NN NN O
= NN NN O
0 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
dL NN NN O
( NN NN O
44 NN NN O
. NN NN O
2 NN NN O
micromol NN NN O
/ NN NN O
L NN NN O
) NN NN O
over NN NN O
baseline NN NN O
. NN NN O
   
Secondary NN NN O
outcomes NN NN O
were NN NN O
a NN NN O
postdose NN NN O
SCr NN NN O
increase NN NN O
> NN NN O
or NN NN O
= NN NN O
25 NN NN O
% NN NN O
, NN NN O
a NN NN O
postdose NN NN O
estimated NN NN O
glomerular NN NN O
filtration NN NN O
rate NN NN O
decrease NN NN O
of NN NN O
> NN NN O
or NN NN O
= NN NN O
25 NN NN O
% NN NN O
, NN NN O
and NN NN O
the NN NN O
mean NN NN O
peak NN NN O
change NN NN O
in NN NN O
SCr NN NN O
. NN NN O
   
In NN NN O
414 NN NN O
patients NN NN O
, NN NN O
contrast NN NN O
volume NN NN O
, NN NN O
presence NN NN O
of NN NN O
diabetes NN NN B-Disease
mellitus NN NN I-Disease
, NN NN O
use NN NN O
of NN NN O
N NN NN O
- NN NN O
acetylcysteine NN NN O
, NN NN O
mean NN NN O
baseline NN NN O
SCr NN NN O
, NN NN O
and NN NN O
estimated NN NN O
glomerular NN NN O
filtration NN NN O
rate NN NN O
were NN NN O
comparable NN NN O
in NN NN O
the NN NN O
2 NN NN O
groups NN NN O
. NN NN O
   
SCr NN NN O
increases NN NN O
> NN NN O
or NN NN O
= NN NN O
0 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
dL NN NN O
occurred NN NN O
in NN NN O
4 NN NN O
. NN NN O
4 NN NN O
% NN NN O
( NN NN O
9 NN NN O
of NN NN O
204 NN NN O
patients NN NN O
) NN NN O
after NN NN O
iopamidol NN NN O
and NN NN O
6 NN NN O
. NN NN O
7 NN NN O
% NN NN O
( NN NN O
14 NN NN O
of NN NN O
210 NN NN O
patients NN NN O
) NN NN O
after NN NN O
iodixanol NN NN O
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
39 NN NN O
) NN NN O
, NN NN O
whereas NN NN O
rates NN NN O
of NN NN O
SCr NN NN O
increases NN NN O
> NN NN O
or NN NN O
= NN NN O
25 NN NN O
% NN NN O
were NN NN O
9 NN NN O
. NN NN O
8 NN NN O
% NN NN O
and NN NN O
12 NN NN O
. NN NN O
4 NN NN O
% NN NN O
, NN NN O
respectively NN NN O
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
44 NN NN O
) NN NN O
. NN NN O
   
In NN NN O
patients NN NN O
with NN NN O
diabetes NN NN B-Disease
, NN NN O
SCr NN NN O
increases NN NN O
> NN NN O
or NN NN O
= NN NN O
0 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
dL NN NN O
were NN NN O
5 NN NN O
. NN NN O
1 NN NN O
% NN NN O
( NN NN O
4 NN NN O
of NN NN O
78 NN NN O
patients NN NN O
) NN NN O
with NN NN O
iopamidol NN NN O
and NN NN O
13 NN NN O
. NN NN O
0 NN NN O
% NN NN O
( NN NN O
12 NN NN O
of NN NN O
92 NN NN O
patients NN NN O
) NN NN O
with NN NN O
iodixanol NN NN O
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
11 NN NN O
) NN NN O
, NN NN O
whereas NN NN O
SCr NN NN O
increases NN NN O
> NN NN O
or NN NN O
= NN NN O
25 NN NN O
% NN NN O
were NN NN O
10 NN NN O
. NN NN O
3 NN NN O
% NN NN O
and NN NN O
15 NN NN O
. NN NN O
2 NN NN O
% NN NN O
, NN NN O
respectively NN NN O
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
37 NN NN O
) NN NN O
. NN NN O
   
Mean NN NN O
post NN NN O
- NN NN O
SCr NN NN O
increases NN NN O
were NN NN O
significantly NN NN O
less NN NN O
with NN NN O
iopamidol NN NN O
( NN NN O
all NN NN O
patients NN NN O
: NN NN O
0 NN NN O
. NN NN O
07 NN NN O
versus NN NN O
0 NN NN O
. NN NN O
12 NN NN O
mg NN NN O
/ NN NN O
dL NN NN O
, NN NN O
6 NN NN O
. NN NN O
2 NN NN O
versus NN NN O
10 NN NN O
. NN NN O
6 NN NN O
micromol NN NN O
/ NN NN O
L NN NN O
, NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
03 NN NN O
; NN NN O
patients NN NN O
with NN NN O
diabetes NN NN B-Disease
: NN NN O
0 NN NN O
. NN NN O
07 NN NN O
versus NN NN O
0 NN NN O
. NN NN O
16 NN NN O
mg NN NN O
/ NN NN O
dL NN NN O
, NN NN O
6 NN NN O
. NN NN O
2 NN NN O
versus NN NN O
14 NN NN O
. NN NN O
1 NN NN O
micromol NN NN O
/ NN NN O
L NN NN O
, NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
The NN NN O
rate NN NN O
of NN NN O
contrast NN NN O
- NN NN O
induced NN NN O
nephropathy NN NN B-Disease
, NN NN O
defined NN NN O
by NN NN O
multiple NN NN O
end NN NN O
points NN NN O
, NN NN O
is NN NN O
not NN NN O
statistically NN NN O
different NN NN O
after NN NN O
the NN NN O
intraarterial NN NN O
administration NN NN O
of NN NN O
iopamidol NN NN O
or NN NN O
iodixanol NN NN O
to NN NN O
high NN NN O
- NN NN O
risk NN NN O
patients NN NN O
, NN NN O
with NN NN O
or NN NN O
without NN NN O
diabetes NN NN B-Disease
mellitus NN NN I-Disease
. NN NN O
   
Any NN NN O
true NN NN O
difference NN NN O
between NN NN O
the NN NN O
agents NN NN O
is NN NN O
small NN NN O
and NN NN O
not NN NN O
likely NN NN O
to NN NN O
be NN NN O
clinically NN NN O
significant NN NN O
. NN NN O
   
A NN NN O
novel NN NN O
compound NN NN O
, NN NN O
maltolyl NN NN O
p NN NN O
- NN NN O
coumarate NN NN O
, NN NN O
attenuates NN NN O
cognitive NN NN B-Disease
deficits NN NN I-Disease
and NN NN O
shows NN NN O
neuroprotective NN NN O
effects NN NN O
in NN NN O
vitro NN NN O
and NN NN O
in NN NN O
vivo NN NN O
dementia NN NN B-Disease
models NN NN O
. NN NN O
   
To NN NN O
develop NN NN O
a NN NN O
novel NN NN O
and NN NN O
effective NN NN O
drug NN NN O
that NN NN O
could NN NN O
enhance NN NN O
cognitive NN NN O
function NN NN O
and NN NN O
neuroprotection NN NN O
, NN NN O
we NN NN O
newly NN NN O
synthesized NN NN O
maltolyl NN NN O
p NN NN O
- NN NN O
coumarate NN NN O
by NN NN O
the NN NN O
esterification NN NN O
of NN NN O
maltol NN NN O
and NN NN O
p NN NN O
- NN NN O
coumaric NN NN O
acid NN NN O
. NN NN O
   
In NN NN O
the NN NN O
present NN NN O
study NN NN O
, NN NN O
we NN NN O
investigated NN NN O
whether NN NN O
maltolyl NN NN O
p NN NN O
- NN NN O
coumarate NN NN O
could NN NN O
improve NN NN O
cognitive NN NN B-Disease
decline NN NN I-Disease
in NN NN O
scopolamine NN NN O
- NN NN O
injected NN NN O
rats NN NN O
and NN NN O
in NN NN O
amyloid NN NN O
beta NN NN O
peptide NN NN O
( NN NN O
1 NN NN O
- NN NN O
42 NN NN O
) NN NN O
- NN NN O
infused NN NN O
rats NN NN O
. NN NN O
   
Maltolyl NN NN O
p NN NN O
- NN NN O
coumarate NN NN O
was NN NN O
found NN NN O
to NN NN O
attenuate NN NN O
cognitive NN NN B-Disease
deficits NN NN I-Disease
in NN NN O
both NN NN O
rat NN NN O
models NN NN O
using NN NN O
passive NN NN O
avoidance NN NN O
test NN NN O
and NN NN O
to NN NN O
reduce NN NN O
apoptotic NN NN O
cell NN NN O
death NN NN O
observed NN NN O
in NN NN O
the NN NN O
hippocampus NN NN O
of NN NN O
the NN NN O
amyloid NN NN O
beta NN NN O
peptide NN NN O
( NN NN O
1 NN NN O
- NN NN O
42 NN NN O
) NN NN O
- NN NN O
infused NN NN O
rats NN NN O
. NN NN O
   
We NN NN O
also NN NN O
examined NN NN O
the NN NN O
neuroprotective NN NN O
effects NN NN O
of NN NN O
maltolyl NN NN O
p NN NN O
- NN NN O
coumarate NN NN O
in NN NN O
vitro NN NN O
using NN NN O
SH NN NN O
- NN NN O
SY5Y NN NN O
cells NN NN O
. NN NN O
   
Cells NN NN O
were NN NN O
pretreated NN NN O
with NN NN O
maltolyl NN NN O
p NN NN O
- NN NN O
coumarate NN NN O
, NN NN O
before NN NN O
exposed NN NN O
to NN NN O
amyloid NN NN O
beta NN NN O
peptide NN NN O
( NN NN O
1 NN NN O
- NN NN O
42 NN NN O
) NN NN O
, NN NN O
glutamate NN NN O
or NN NN O
H2O2 NN NN O
. NN NN O
   
We NN NN O
found NN NN O
that NN NN O
maltolyl NN NN O
p NN NN O
- NN NN O
coumarate NN NN O
significantly NN NN O
decreased NN NN O
apoptotic NN NN O
cell NN NN O
death NN NN O
and NN NN O
reduced NN NN O
reactive NN NN O
oxygen NN NN O
species NN NN O
, NN NN O
cytochrome NN NN O
c NN NN O
release NN NN O
, NN NN O
and NN NN O
caspase NN NN O
3 NN NN O
activation NN NN O
. NN NN O
   
Taking NN NN O
these NN NN O
in NN NN O
vitro NN NN O
and NN NN O
in NN NN O
vivo NN NN O
results NN NN O
together NN NN O
, NN NN O
our NN NN O
study NN NN O
suggests NN NN O
that NN NN O
maltolyl NN NN O
p NN NN O
- NN NN O
coumarate NN NN O
is NN NN O
a NN NN O
potentially NN NN O
effective NN NN O
candidate NN NN O
against NN NN O
Alzheimer NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
that NN NN O
is NN NN O
characterized NN NN O
by NN NN O
wide NN NN O
spread NN NN O
neuronal NN NN B-Disease
death NN NN I-Disease
and NN NN O
progressive NN NN O
decline NN NN B-Disease
of NN NN I-Disease
cognitive NN NN I-Disease
function NN NN I-Disease
. NN NN O
   
Attenuation NN NN O
of NN NN O
methamphetamine NN NN O
- NN NN O
induced NN NN O
nigrostriatal NN NN O
dopaminergic NN NN O
neurotoxicity NN NN B-Disease
in NN NN O
mice NN NN O
by NN NN O
lipopolysaccharide NN NN O
pretreatment NN NN O
. NN NN O
   
Immunological NN NN O
activation NN NN O
has NN NN O
been NN NN O
proposed NN NN O
to NN NN O
play NN NN O
a NN NN O
role NN NN O
in NN NN O
methamphetamine NN NN O
- NN NN O
induced NN NN O
dopaminergic NN NN B-Disease
terminal NN NN I-Disease
damage NN NN I-Disease
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
examined NN NN O
the NN NN O
roles NN NN O
of NN NN O
lipopolysaccharide NN NN O
, NN NN O
a NN NN O
pro NN NN O
- NN NN O
inflammatory NN NN O
and NN NN O
inflammatory NN NN O
factor NN NN O
, NN NN O
treatment NN NN O
in NN NN O
modulating NN NN O
the NN NN O
methamphetamine NN NN O
- NN NN O
induced NN NN O
nigrostriatal NN NN O
dopamine NN NN O
neurotoxicity NN NN B-Disease
. NN NN O
   
Lipopolysaccharide NN NN O
pretreatment NN NN O
did NN NN O
not NN NN O
affect NN NN O
the NN NN O
basal NN NN O
body NN NN O
temperature NN NN O
or NN NN O
methamphetamine NN NN O
- NN NN O
elicited NN NN O
hyperthermia NN NN B-Disease
three NN NN O
days NN NN O
later NN NN O
. NN NN O
   
Such NN NN O
systemic NN NN O
lipopolysaccharide NN NN O
treatment NN NN O
mitigated NN NN O
methamphetamine NN NN O
- NN NN O
induced NN NN O
striatal NN NN O
dopamine NN NN O
and NN NN O
3 NN NN O
, NN NN O
4 NN NN O
- NN NN O
dihydroxyphenylacetic NN NN O
acid NN NN O
depletions NN NN O
in NN NN O
a NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
. NN NN O
   
As NN NN O
the NN NN O
most NN NN O
potent NN NN O
dose NN NN O
( NN NN O
1 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
of NN NN O
lipopolysaccharide NN NN O
was NN NN O
administered NN NN O
two NN NN O
weeks NN NN O
, NN NN O
one NN NN O
day NN NN O
before NN NN O
or NN NN O
after NN NN O
the NN NN O
methamphetamine NN NN O
dosing NN NN O
regimen NN NN O
, NN NN O
methamphetamine NN NN O
- NN NN O
induced NN NN O
striatal NN NN O
dopamine NN NN O
and NN NN O
3 NN NN O
, NN NN O
4 NN NN O
- NN NN O
dihydroxyphenylacetic NN NN O
acid NN NN O
depletions NN NN O
remained NN NN O
unaltered NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
systemic NN NN O
lipopolysaccharide NN NN O
pretreatment NN NN O
( NN NN O
1 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
attenuated NN NN O
local NN NN O
methamphetamine NN NN O
infusion NN NN O
- NN NN O
produced NN NN O
dopamine NN NN O
and NN NN O
3 NN NN O
, NN NN O
4 NN NN O
- NN NN O
dihydroxyphenylacetic NN NN O
acid NN NN O
depletions NN NN O
in NN NN O
the NN NN O
striatum NN NN O
, NN NN O
indicating NN NN O
that NN NN O
the NN NN O
protective NN NN O
effect NN NN O
of NN NN O
lipopolysaccharide NN NN O
is NN NN O
less NN NN O
likely NN NN O
due NN NN O
to NN NN O
interrupted NN NN O
peripheral NN NN O
distribution NN NN O
or NN NN O
metabolism NN NN O
of NN NN O
methamphetamine NN NN O
. NN NN O
   
We NN NN O
concluded NN NN O
a NN NN O
critical NN NN O
time NN NN O
window NN NN O
for NN NN O
systemic NN NN O
lipopolysaccharide NN NN O
pretreatment NN NN O
in NN NN O
exerting NN NN O
effective NN NN O
protection NN NN O
against NN NN O
methamphetamine NN NN O
- NN NN O
induced NN NN O
nigrostriatal NN NN O
dopamine NN NN O
neurotoxicity NN NN B-Disease
. NN NN O
   
Acute NN NN O
myocarditis NN NN B-Disease
associated NN NN O
with NN NN O
clozapine NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
A NN NN O
case NN NN O
of NN NN O
acute NN NN O
myocarditis NN NN B-Disease
associated NN NN O
with NN NN O
the NN NN O
commencement NN NN O
of NN NN O
clozapine NN NN O
is NN NN O
described NN NN O
, NN NN O
highlighting NN NN O
the NN NN O
onset NN NN O
, NN NN O
course NN NN O
and NN NN O
possible NN NN O
contributing NN NN O
factors NN NN O
. NN NN O
   
There NN NN O
is NN NN O
an NN NN O
urgent NN NN O
need NN NN O
to NN NN O
raise NN NN O
awareness NN NN O
about NN NN O
this NN NN O
potentially NN NN O
fatal NN NN O
complication NN NN O
of NN NN O
clozapine NN NN O
use NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
A NN NN O
20 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
male NN NN O
with NN NN O
schizophrenia NN NN B-Disease
developed NN NN O
a NN NN O
sudden NN NN O
onset NN NN O
of NN NN O
myocarditis NN NN B-Disease
after NN NN O
commencement NN NN O
of NN NN O
clozapine NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
recovered NN NN O
with NN NN O
intensive NN NN O
medical NN NN O
support NN NN O
. NN NN O
   
The NN NN O
symptoms NN NN O
occurred NN NN O
around NN NN O
2 NN NN O
weeks NN NN O
after NN NN O
starting NN NN O
clozapine NN NN O
in NN NN O
an NN NN O
inpatient NN NN O
setting NN NN O
. NN NN O
   
Possible NN NN O
contributing NN NN O
factors NN NN O
may NN NN O
have NN NN O
been NN NN O
concomitant NN NN O
antidepressant NN NN O
use NN NN O
and NN NN O
unaccustomed NN NN O
physical NN NN O
activity NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Myocarditis NN NN B-Disease
is NN NN O
an NN NN O
increasingly NN NN O
recognized NN NN O
complication NN NN O
associated NN NN O
with NN NN O
the NN NN O
use NN NN O
of NN NN O
clozapine NN NN O
. NN NN O
   
It NN NN O
can NN NN O
be NN NN O
fatal NN NN O
if NN NN O
not NN NN O
recognized NN NN O
and NN NN O
treated NN NN O
early NN NN O
. NN NN O
   
Considering NN NN O
that NN NN O
clozapine NN NN O
remains NN NN O
the NN NN O
gold NN NN O
standard NN NN O
in NN NN O
treatment NN NN O
of NN NN O
resistant NN NN O
psychosis NN NN B-Disease
, NN NN O
there NN NN O
is NN NN O
an NN NN O
urgent NN NN O
need NN NN O
to NN NN O
raise NN NN O
awareness NN NN O
among NN NN O
medical NN NN O
and NN NN O
paramedical NN NN O
staff NN NN O
involved NN NN O
in NN NN O
the NN NN O
care NN NN O
of NN NN O
these NN NN O
patients NN NN O
. NN NN O
   
There NN NN O
are NN NN O
also NN NN O
implications NN NN O
for NN NN O
recommendations NN NN O
and NN NN O
regulations NN NN O
regarding NN NN O
the NN NN O
use NN NN O
of NN NN O
clozapine NN NN O
. NN NN O
   
Severe NN NN O
rhabdomyolysis NN NN B-Disease
and NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
secondary NN NN O
to NN NN O
concomitant NN NN O
use NN NN O
of NN NN O
simvastatin NN NN O
, NN NN O
amiodarone NN NN O
, NN NN O
and NN NN O
atazanavir NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
To NN NN O
report NN NN O
a NN NN O
case NN NN O
of NN NN O
a NN NN O
severe NN NN O
interaction NN NN O
between NN NN O
simvastatin NN NN O
, NN NN O
amiodarone NN NN O
, NN NN O
and NN NN O
atazanavir NN NN O
resulting NN NN O
in NN NN O
rhabdomyolysis NN NN B-Disease
and NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
A NN NN O
72 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
white NN NN O
man NN NN O
with NN NN O
underlying NN NN O
human NN NN B-Disease
immunodeficiency NN NN I-Disease
virus NN NN I-Disease
, NN NN O
atrial NN NN B-Disease
fibrillation NN NN I-Disease
, NN NN O
coronary NN NN B-Disease
artery NN NN I-Disease
disease NN NN I-Disease
, NN NN O
and NN NN O
hyperlipidemia NN NN B-Disease
presented NN NN O
with NN NN O
generalized NN NN O
pain NN NN B-Disease
, NN NN O
fatigue NN NN B-Disease
, NN NN O
and NN NN O
dark NN NN O
orange NN NN O
urine NN NN O
for NN NN O
3 NN NN O
days NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
was NN NN O
taking NN NN O
80 NN NN O
mg NN NN O
simvastatin NN NN O
at NN NN O
bedtime NN NN O
( NN NN O
initiated NN NN O
27 NN NN O
days NN NN O
earlier NN NN O
) NN NN O
; NN NN O
amiodarone NN NN O
at NN NN O
a NN NN O
dose NN NN O
of NN NN O
400 NN NN O
mg NN NN O
daily NN NN O
for NN NN O
7 NN NN O
days NN NN O
, NN NN O
then NN NN O
200 NN NN O
mg NN NN O
daily NN NN O
( NN NN O
initiated NN NN O
19 NN NN O
days NN NN O
earlier NN NN O
) NN NN O
; NN NN O
and NN NN O
400 NN NN O
mg NN NN O
atazanavir NN NN O
daily NN NN O
( NN NN O
initiated NN NN O
at NN NN O
least NN NN O
2 NN NN O
years NN NN O
previously NN NN O
) NN NN O
. NN NN O
   
Laboratory NN NN O
evaluation NN NN O
revealed NN NN O
66 NN NN O
, NN NN O
680 NN NN O
U NN NN O
/ NN NN O
L NN NN O
creatine NN NN O
kinase NN NN O
, NN NN O
93 NN NN O
mg NN NN O
/ NN NN O
dL NN NN O
blood NN NN O
urea NN NN O
nitrogen NN NN O
, NN NN O
4 NN NN O
. NN NN O
6 NN NN O
mg NN NN O
/ NN NN O
dL NN NN O
creatinine NN NN O
, NN NN O
1579 NN NN O
U NN NN O
/ NN NN O
L NN NN O
aspartate NN NN O
aminotransferase NN NN O
, NN NN O
and NN NN O
738 NN NN O
U NN NN O
/ NN NN O
L NN NN O
alanine NN NN O
aminotransferase NN NN O
. NN NN O
   
Simvastatin NN NN O
, NN NN O
amiodarone NN NN O
, NN NN O
and NN NN O
the NN NN O
patient NN NN O
' NN NN O
s NN NN O
human NN NN B-Disease
immunodeficiency NN NN I-Disease
virus NN NN I-Disease
medications NN NN O
were NN NN O
all NN NN O
temporarily NN NN O
discontinued NN NN O
and NN NN O
the NN NN O
patient NN NN O
was NN NN O
given NN NN O
forced NN NN O
alkaline NN NN O
diuresis NN NN O
and NN NN O
started NN NN O
on NN NN O
dialysis NN NN O
. NN NN O
   
Nine NN NN O
days NN NN O
later NN NN O
the NN NN O
patient NN NN O
' NN NN O
s NN NN O
creatine NN NN O
kinase NN NN O
had NN NN O
dropped NN NN O
to NN NN O
1695 NN NN O
U NN NN O
/ NN NN O
L NN NN O
and NN NN O
creatinine NN NN O
was NN NN O
3 NN NN O
. NN NN O
3 NN NN O
mg NN NN O
/ NN NN O
dL NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
was NN NN O
discharged NN NN O
and NN NN O
continued NN NN O
outpatient NN NN O
dialysis NN NN O
for NN NN O
1 NN NN O
month NN NN O
until NN NN O
his NN NN O
renal NN NN O
function NN NN O
recovered NN NN O
. NN NN O
   
DISCUSSION NN NN O
: NN NN O
The NN NN O
risk NN NN O
of NN NN O
rhabdomyolysis NN NN B-Disease
is NN NN O
increased NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
concomitant NN NN O
drugs NN NN O
that NN NN O
inhibit NN NN O
simvastatin NN NN O
metabolism NN NN O
. NN NN O
   
Simvastatin NN NN O
is NN NN O
metabolized NN NN O
by NN NN O
CYP3A4 NN NN O
. NN NN O
   
Amiodarone NN NN O
and NN NN O
atazanavir NN NN O
are NN NN O
recognized NN NN O
CYP3A4 NN NN O
inhibitors NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Pharmacokinetic NN NN O
differences NN NN O
in NN NN O
statins NN NN O
are NN NN O
an NN NN O
important NN NN O
consideration NN NN O
for NN NN O
assessing NN NN O
the NN NN O
risk NN NN O
of NN NN O
potential NN NN O
drug NN NN O
interactions NN NN O
. NN NN O
   
In NN NN O
patients NN NN O
requiring NN NN O
the NN NN O
concurrent NN NN O
use NN NN O
of NN NN O
statins NN NN O
and NN NN O
CYP3A4 NN NN O
inhibitors NN NN O
, NN NN O
pravastatin NN NN O
, NN NN O
fluvastatin NN NN O
, NN NN O
and NN NN O
rosuvastatin NN NN O
carry NN NN O
the NN NN O
lowest NN NN O
risk NN NN O
of NN NN O
drug NN NN O
interactions NN NN O
; NN NN O
atorvastatin NN NN O
carries NN NN O
moderate NN NN O
risk NN NN O
, NN NN O
whereas NN NN O
simvastatin NN NN O
and NN NN O
lovastatin NN NN O
have NN NN O
the NN NN O
highest NN NN O
risk NN NN O
and NN NN O
should NN NN O
be NN NN O
avoided NN NN O
in NN NN O
patients NN NN O
taking NN NN O
concomitant NN NN O
CYP3A4 NN NN O
inhibitors NN NN O
. NN NN O
   
Interaction NN NN O
between NN NN O
warfarin NN NN O
and NN NN O
levofloxacin NN NN O
: NN NN O
case NN NN O
series NN NN O
. NN NN O
   
Warfarin NN NN O
is NN NN O
the NN NN O
most NN NN O
widely NN NN O
used NN NN O
oral NN NN O
anticoagulant NN NN O
and NN NN O
is NN NN O
indicated NN NN O
for NN NN O
many NN NN O
clinical NN NN O
conditions NN NN O
. NN NN O
   
Levofloxacin NN NN O
, NN NN O
a NN NN O
fluoroquinolone NN NN O
, NN NN O
is NN NN O
one NN NN O
of NN NN O
the NN NN O
most NN NN O
commonly NN NN O
prescribed NN NN O
antibiotics NN NN O
in NN NN O
clinical NN NN O
practice NN NN O
and NN NN O
is NN NN O
effective NN NN O
against NN NN O
Gram NN NN O
- NN NN O
positive NN NN O
, NN NN O
Gram NN NN O
- NN NN O
negative NN NN O
, NN NN O
and NN NN O
atypical NN NN O
bacteria NN NN O
. NN NN O
   
While NN NN O
small NN NN O
prospective NN NN O
studies NN NN O
have NN NN O
not NN NN O
revealed NN NN O
any NN NN O
significant NN NN O
drug NN NN O
- NN NN O
drug NN NN O
interaction NN NN O
between NN NN O
warfarin NN NN O
and NN NN O
levofloxacin NN NN O
, NN NN O
several NN NN O
case NN NN O
reports NN NN O
have NN NN O
indicated NN NN O
that NN NN O
levofloxacin NN NN O
may NN NN O
significantly NN NN O
potentiate NN NN O
the NN NN O
anticoagulation NN NN O
effect NN NN O
of NN NN O
warfarin NN NN O
. NN NN O
   
We NN NN O
report NN NN O
3 NN NN O
cases NN NN O
of NN NN O
serious NN NN O
bleeding NN NN B-Disease
complications NN NN O
that NN NN O
appear NN NN O
to NN NN O
be NN NN O
the NN NN O
result NN NN O
of NN NN O
the NN NN O
interaction NN NN O
between NN NN O
warfarin NN NN O
and NN NN O
levofloxacin NN NN O
. NN NN O
   
Physicians NN NN O
should NN NN O
be NN NN O
aware NN NN O
of NN NN O
this NN NN O
potential NN NN O
interaction NN NN O
and NN NN O
use NN NN O
caution NN NN O
when NN NN O
prescribing NN NN O
levofloxacin NN NN O
to NN NN O
patients NN NN O
taking NN NN O
warfarin NN NN O
. NN NN O
   
Mutations NN NN O
associated NN NN O
with NN NN O
lamivudine NN NN O
- NN NN O
resistance NN NN O
in NN NN O
therapy NN NN O
- NN NN O
na NN NN O
ve NN NN O
hepatitis NN NN B-Disease
B NN NN I-Disease
virus NN NN I-Disease
( NN NN I-Disease
HBV NN NN I-Disease
) NN NN I-Disease
infected NN NN I-Disease
patients NN NN O
with NN NN O
and NN NN O
without NN NN O
HIV NN NN B-Disease
co NN NN I-Disease
- NN NN I-Disease
infection NN NN I-Disease
: NN NN O
implications NN NN O
for NN NN O
antiretroviral NN NN O
therapy NN NN O
in NN NN O
HBV NN NN B-Disease
and NN NN I-Disease
HIV NN NN I-Disease
co NN NN I-Disease
- NN NN I-Disease
infected NN NN I-Disease
South NN NN O
African NN NN O
patients NN NN O
. NN NN O
   
This NN NN O
was NN NN O
an NN NN O
exploratory NN NN O
study NN NN O
to NN NN O
investigate NN NN O
lamivudine NN NN O
- NN NN O
resistant NN NN O
hepatitis NN NN B-Disease
B NN NN I-Disease
virus NN NN O
( NN NN O
HBV NN NN O
) NN NN O
strains NN NN O
in NN NN O
selected NN NN O
lamivudine NN NN O
- NN NN O
na NN NN O
ve NN NN O
HBV NN NN O
carriers NN NN O
with NN NN O
and NN NN O
without NN NN O
human NN NN B-Disease
immunodeficiency NN NN I-Disease
virus NN NN I-Disease
( NN NN I-Disease
HIV NN NN I-Disease
) NN NN I-Disease
co NN NN I-Disease
- NN NN I-Disease
infection NN NN I-Disease
in NN NN O
South NN NN O
African NN NN O
patients NN NN O
. NN NN O
   
Thirty NN NN O
- NN NN O
five NN NN O
lamivudine NN NN O
- NN NN O
na NN NN O
ve NN NN O
HBV NN NN B-Disease
infected NN NN I-Disease
patients NN NN O
with NN NN O
or NN NN O
without NN NN O
HIV NN NN B-Disease
co NN NN I-Disease
- NN NN I-Disease
infection NN NN I-Disease
were NN NN O
studied NN NN O
: NN NN O
15 NN NN O
chronic NN NN O
HBV NN NN B-Disease
mono NN NN I-Disease
- NN NN I-Disease
infected NN NN I-Disease
patients NN NN O
and NN NN O
20 NN NN O
HBV NN NN B-Disease
- NN NN I-Disease
HIV NN NN I-Disease
co NN NN I-Disease
- NN NN I-Disease
infected NN NN I-Disease
patients NN NN O
. NN NN O
   
The NN NN O
latter NN NN O
group NN NN O
was NN NN O
further NN NN O
sub NN NN O
- NN NN O
divided NN NN O
into NN NN O
13 NN NN O
occult NN NN O
HBV NN NN O
( NN NN O
HBsAg NN NN O
- NN NN O
negative NN NN O
) NN NN O
and NN NN O
7 NN NN O
overt NN NN O
HBV NN NN O
( NN NN O
HBsAg NN NN O
- NN NN O
positive NN NN O
) NN NN O
patients NN NN O
. NN NN O
   
HBsAg NN NN O
, NN NN O
anti NN NN O
- NN NN O
HBs NN NN O
, NN NN O
anti NN NN O
- NN NN O
HBc NN NN O
, NN NN O
and NN NN O
anti NN NN O
- NN NN O
HIV NN NN O
1 NN NN O
/ NN NN O
2 NN NN O
were NN NN O
determined NN NN O
as NN NN O
part NN NN O
of NN NN O
routine NN NN O
diagnosis NN NN O
using NN NN O
Axsym NN NN O
assays NN NN O
( NN NN O
Abbott NN NN O
Laboratories NN NN O
, NN NN O
North NN NN O
Chicago NN NN O
, NN NN O
IL NN NN O
) NN NN O
. NN NN O
   
Serum NN NN O
samples NN NN O
were NN NN O
PCR NN NN O
amplified NN NN O
with NN NN O
HBV NN NN O
reverse NN NN O
transcriptase NN NN O
( NN NN O
RT NN NN O
) NN NN O
primers NN NN O
, NN NN O
followed NN NN O
by NN NN O
direct NN NN O
sequencing NN NN O
across NN NN O
the NN NN O
tyrosine NN NN O
- NN NN O
methionine NN NN O
- NN NN O
aspartate NN NN O
- NN NN O
aspartate NN NN O
( NN NN O
YMDD NN NN O
) NN NN O
motif NN NN O
of NN NN O
the NN NN O
major NN NN O
catalytic NN NN O
region NN NN O
in NN NN O
the NN NN O
C NN NN O
domain NN NN O
of NN NN O
the NN NN O
HBV NN NN O
RT NN NN O
enzyme NN NN O
. NN NN O
   
HBV NN NN O
viral NN NN O
load NN NN O
was NN NN O
performed NN NN O
with NN NN O
Amplicor NN NN O
HBV NN NN O
Monitor NN NN O
test NN NN O
v2 NN NN O
. NN NN O
0 NN NN O
( NN NN O
Roche NN NN O
Diagnostics NN NN O
, NN NN O
Penzberg NN NN O
, NN NN O
Germany NN NN O
) NN NN O
. NN NN O
   
HBV NN NN O
lamivudine NN NN O
- NN NN O
resistant NN NN O
strains NN NN O
were NN NN O
detected NN NN O
in NN NN O
3 NN NN O
of NN NN O
15 NN NN O
mono NN NN O
- NN NN O
infected NN NN O
chronic NN NN O
hepatitis NN NN B-Disease
B NN NN I-Disease
patients NN NN O
and NN NN O
10 NN NN O
of NN NN O
20 NN NN O
HBV NN NN B-Disease
- NN NN I-Disease
HIV NN NN I-Disease
co NN NN I-Disease
- NN NN I-Disease
infected NN NN I-Disease
patients NN NN O
. NN NN O
   
To NN NN O
the NN NN O
best NN NN O
of NN NN O
our NN NN O
knowledge NN NN O
, NN NN O
this NN NN O
constitutes NN NN O
the NN NN O
first NN NN O
report NN NN O
of NN NN O
HBV NN NN O
lamivudine NN NN O
- NN NN O
resistant NN NN O
strains NN NN O
in NN NN O
therapy NN NN O
- NN NN O
na NN NN O
ve NN NN O
HBV NN NN B-Disease
- NN NN I-Disease
HIV NN NN I-Disease
co NN NN I-Disease
- NN NN I-Disease
infected NN NN I-Disease
patients NN NN O
. NN NN O
   
The NN NN O
HBV NN NN O
viral NN NN O
loads NN NN O
for NN NN O
mono NN NN O
- NN NN O
infected NN NN O
and NN NN O
co NN NN O
- NN NN O
infected NN NN O
patients NN NN O
ranged NN NN O
from NN NN O
3 NN NN O
. NN NN O
32 NN NN O
x NN NN O
10 NN NN O
( NN NN O
2 NN NN O
) NN NN O
to NN NN O
3 NN NN O
. NN NN O
82 NN NN O
x NN NN O
10 NN NN O
( NN NN O
7 NN NN O
) NN NN O
and NN NN O
< NN NN O
200 NN NN O
to NN NN O
4 NN NN O
. NN NN O
40 NN NN O
x NN NN O
10 NN NN O
( NN NN O
3 NN NN O
) NN NN O
copies NN NN O
/ NN NN O
ml NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
It NN NN O
remains NN NN O
to NN NN O
be NN NN O
seen NN NN O
whether NN NN O
such NN NN O
pre NN NN O
- NN NN O
existing NN NN O
antiviral NN NN O
mutations NN NN O
could NN NN O
result NN NN O
in NN NN O
widespread NN NN O
emergence NN NN O
of NN NN O
HBV NN NN O
resistant NN NN O
strains NN NN O
when NN NN O
lamivudine NN NN O
- NN NN O
containing NN NN O
highly NN NN O
active NN NN O
antiretroviral NN NN O
( NN NN O
ARV NN NN O
) NN NN O
treatment NN NN O
( NN NN O
HAART NN NN O
) NN NN O
regimens NN NN O
become NN NN O
widely NN NN O
applied NN NN O
in NN NN O
South NN NN O
Africa NN NN O
, NN NN O
as NN NN O
this NN NN O
is NN NN O
likely NN NN O
to NN NN O
have NN NN O
potential NN NN O
implications NN NN O
in NN NN O
the NN NN O
management NN NN O
of NN NN O
HBV NN NN B-Disease
- NN NN I-Disease
HIV NN NN I-Disease
co NN NN I-Disease
- NN NN I-Disease
infected NN NN I-Disease
patients NN NN O
. NN NN O
   
Rabbit NN NN B-Disease
syndrome NN NN I-Disease
, NN NN O
antidepressant NN NN O
use NN NN O
, NN NN O
and NN NN O
cerebral NN NN O
perfusion NN NN O
SPECT NN NN O
scan NN NN O
findings NN NN O
. NN NN O
   
The NN NN O
rabbit NN NN B-Disease
syndrome NN NN I-Disease
is NN NN O
an NN NN O
extrapyramidal NN NN O
side NN NN O
effect NN NN O
associated NN NN O
with NN NN O
chronic NN NN O
neuroleptic NN NN O
therapy NN NN O
. NN NN O
   
Its NN NN O
occurrence NN NN O
in NN NN O
a NN NN O
patient NN NN O
being NN NN O
treated NN NN O
with NN NN O
imipramine NN NN O
is NN NN O
described NN NN O
, NN NN O
representing NN NN O
the NN NN O
first NN NN O
reported NN NN O
case NN NN O
of NN NN O
this NN NN O
syndrome NN NN O
in NN NN O
conjunction NN NN O
with NN NN O
antidepressants NN NN O
. NN NN O
   
Repeated NN NN O
cerebral NN NN O
perfusion NN NN O
SPECT NN NN O
scans NN NN O
revealed NN NN O
decreased NN NN B-Disease
basal NN NN I-Disease
ganglia NN NN I-Disease
perfusion NN NN I-Disease
while NN NN O
the NN NN O
movement NN NN B-Disease
disorder NN NN I-Disease
was NN NN O
present NN NN O
, NN NN O
and NN NN O
a NN NN O
return NN NN O
to NN NN O
normal NN NN O
perfusion NN NN O
when NN NN O
the NN NN O
rabbit NN NN B-Disease
syndrome NN NN I-Disease
resolved NN NN O
. NN NN O
   
Estrogen NN NN O
prevents NN NN O
cholesteryl NN NN O
ester NN NN O
accumulation NN NN O
in NN NN O
macrophages NN NN O
induced NN NN O
by NN NN O
the NN NN O
HIV NN NN O
protease NN NN O
inhibitor NN NN O
ritonavir NN NN O
. NN NN O
   
Individuals NN NN O
with NN NN O
HIV NN NN O
can NN NN O
now NN NN O
live NN NN O
long NN NN O
lives NN NN O
with NN NN O
drug NN NN O
therapy NN NN O
that NN NN O
often NN NN O
includes NN NN O
protease NN NN O
inhibitors NN NN O
such NN NN O
as NN NN O
ritonavir NN NN O
. NN NN O
   
Many NN NN O
patients NN NN O
, NN NN O
however NN NN O
, NN NN O
develop NN NN O
negative NN NN O
long NN NN O
- NN NN O
term NN NN O
side NN NN O
effects NN NN O
such NN NN O
as NN NN O
premature NN NN B-Disease
atherosclerosis NN NN I-Disease
. NN NN O
   
We NN NN O
have NN NN O
previously NN NN O
demonstrated NN NN O
that NN NN O
ritonavir NN NN O
treatment NN NN O
increases NN NN O
atherosclerotic NN NN B-Disease
lesion NN NN I-Disease
formation NN NN O
in NN NN O
male NN NN O
mice NN NN O
to NN NN O
a NN NN O
greater NN NN O
extent NN NN O
than NN NN O
in NN NN O
female NN NN O
mice NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
peripheral NN NN O
blood NN NN O
monocytes NN NN O
isolated NN NN O
from NN NN O
ritonavir NN NN O
- NN NN O
treated NN NN O
females NN NN O
had NN NN O
less NN NN O
cholesteryl NN NN O
ester NN NN O
accumulation NN NN O
. NN NN O
   
In NN NN O
the NN NN O
present NN NN O
study NN NN O
, NN NN O
we NN NN O
have NN NN O
investigated NN NN O
the NN NN O
molecular NN NN O
mechanisms NN NN O
by NN NN O
which NN NN O
female NN NN O
hormones NN NN O
influence NN NN O
cholesterol NN NN O
metabolism NN NN O
in NN NN O
macrophages NN NN O
in NN NN O
response NN NN O
to NN NN O
the NN NN O
HIV NN NN O
protease NN NN O
inhibitor NN NN O
ritonavir NN NN O
. NN NN O
   
We NN NN O
have NN NN O
utilized NN NN O
the NN NN O
human NN NN O
monocyte NN NN O
cell NN NN O
line NN NN O
, NN NN O
THP NN NN O
- NN NN O
1 NN NN O
as NN NN O
a NN NN O
model NN NN O
to NN NN O
address NN NN O
this NN NN O
question NN NN O
. NN NN O
   
Briefly NN NN O
, NN NN O
cells NN NN O
were NN NN O
differentiated NN NN O
for NN NN O
72 NN NN O
h NN NN O
with NN NN O
100 NN NN O
nM NN NN O
PMA NN NN O
to NN NN O
obtain NN NN O
a NN NN O
macrophage NN NN O
- NN NN O
like NN NN O
phenotype NN NN O
in NN NN O
the NN NN O
presence NN NN O
or NN NN O
absence NN NN O
of NN NN O
1 NN NN O
nM NN NN O
17beta NN NN O
- NN NN O
estradiol NN NN O
( NN NN O
E2 NN NN O
) NN NN O
, NN NN O
100 NN NN O
nM NN NN O
progesterone NN NN O
or NN NN O
vehicle NN NN O
( NN NN O
0 NN NN O
. NN NN O
01 NN NN O
% NN NN O
ethanol NN NN O
) NN NN O
. NN NN O
   
Cells NN NN O
were NN NN O
then NN NN O
treated NN NN O
with NN NN O
30 NN NN O
ng NN NN O
/ NN NN O
ml NN NN O
ritonavir NN NN O
or NN NN O
vehicle NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
aggregated NN NN O
LDL NN NN O
for NN NN O
24 NN NN O
h NN NN O
. NN NN O
   
Cell NN NN O
extracts NN NN O
were NN NN O
harvested NN NN O
, NN NN O
and NN NN O
lipid NN NN O
or NN NN O
total NN NN O
RNA NN NN O
was NN NN O
isolated NN NN O
. NN NN O
   
E2 NN NN O
decreased NN NN O
the NN NN O
accumulation NN NN O
of NN NN O
cholesteryl NN NN O
esters NN NN O
in NN NN O
macrophages NN NN O
following NN NN O
ritonavir NN NN O
treatment NN NN O
. NN NN O
   
Ritonavir NN NN O
increased NN NN O
the NN NN O
expression NN NN O
of NN NN O
the NN NN O
scavenger NN NN O
receptor NN NN O
, NN NN O
CD36 NN NN O
mRNA NN NN O
, NN NN O
responsible NN NN O
for NN NN O
the NN NN O
uptake NN NN O
of NN NN O
LDL NN NN O
. NN NN O
   
Additionally NN NN O
, NN NN O
ritonavir NN NN O
treatment NN NN O
selectively NN NN O
increased NN NN O
the NN NN O
relative NN NN O
levels NN NN O
of NN NN O
PPARgamma NN NN O
mRNA NN NN O
, NN NN O
a NN NN O
transcription NN NN O
factor NN NN O
responsible NN NN O
for NN NN O
the NN NN O
regulation NN NN O
of NN NN O
CD36 NN NN O
mRNA NN NN O
expression NN NN O
. NN NN O
   
Treatment NN NN O
with NN NN O
E2 NN NN O
, NN NN O
however NN NN O
, NN NN O
failed NN NN O
to NN NN O
prevent NN NN O
these NN NN O
increases NN NN O
at NN NN O
the NN NN O
mRNA NN NN O
level NN NN O
. NN NN O
   
E2 NN NN O
did NN NN O
, NN NN O
however NN NN O
, NN NN O
significantly NN NN O
suppress NN NN O
CD36 NN NN O
protein NN NN O
levels NN NN O
as NN NN O
measured NN NN O
by NN NN O
fluorescent NN NN O
immunocytochemistry NN NN O
. NN NN O
   
This NN NN O
data NN NN O
suggests NN NN O
that NN NN O
E2 NN NN O
modifies NN NN O
the NN NN O
expression NN NN O
of NN NN O
CD36 NN NN O
at NN NN O
the NN NN O
level NN NN O
of NN NN O
protein NN NN O
expression NN NN O
in NN NN O
monocyte NN NN O
- NN NN O
derived NN NN O
macrophages NN NN O
resulting NN NN O
in NN NN O
reduced NN NN O
cholesteryl NN NN O
ester NN NN O
accumulation NN NN O
following NN NN O
ritonavir NN NN O
treatment NN NN O
. NN NN O
   
Acute NN NN O
hepatitis NN NN B-Disease
attack NN NN O
after NN NN O
exposure NN NN O
to NN NN O
telithromycin NN NN O
. NN NN O
   
INTRODUCTION NN NN O
: NN NN O
Antibiotic NN NN O
- NN NN O
associated NN NN O
hepatotoxicity NN NN B-Disease
is NN NN O
rare NN NN O
. NN NN O
   
With NN NN O
widespread NN NN O
use NN NN O
of NN NN O
antimicrobial NN NN O
agents NN NN O
, NN NN O
however NN NN O
, NN NN O
hepatic NN NN B-Disease
injury NN NN I-Disease
occurs NN NN O
frequently NN NN O
, NN NN O
and NN NN O
among NN NN O
adverse NN NN B-Disease
drug NN NN I-Disease
reactions NN NN I-Disease
, NN NN O
idiosyncratic NN NN O
reactions NN NN O
are NN NN O
the NN NN O
most NN NN O
serious NN NN O
. NN NN O
   
CASE NN NN O
SUMMARY NN NN O
: NN NN O
A NN NN O
25 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
male NN NN O
patient NN NN O
, NN NN O
with NN NN O
a NN NN O
height NN NN O
of NN NN O
175 NN NN O
cm NN NN O
and NN NN O
weight NN NN O
of NN NN O
72 NN NN O
kg NN NN O
presented NN NN O
to NN NN O
Marmara NN NN O
University NN NN O
Hospital NN NN O
Emergency NN NN O
Department NN NN O
, NN NN O
Istanbul NN NN O
, NN NN O
Turkey NN NN O
, NN NN O
with NN NN O
5 NN NN O
days NN NN O
' NN NN O
history NN NN O
of NN NN O
jaundice NN NN B-Disease
, NN NN O
malaise NN NN O
, NN NN O
nausea NN NN B-Disease
, NN NN O
and NN NN O
vomiting NN NN B-Disease
. NN NN O
   
He NN NN O
had NN NN O
been NN NN O
prescribed NN NN O
telithromycin NN NN O
400 NN NN O
mg NN NN O
/ NN NN O
d NN NN O
PO NN NN O
to NN NN O
treat NN NN O
an NN NN O
upper NN NN B-Disease
respiratory NN NN I-Disease
tract NN NN I-Disease
infection NN NN I-Disease
7 NN NN O
days NN NN O
prior NN NN O
. NN NN O
   
Admission NN NN O
laboratory NN NN O
tests NN NN O
were NN NN O
as NN NN O
follows NN NN O
: NN NN O
alanine NN NN O
aminotransferase NN NN O
, NN NN O
67 NN NN O
U NN NN O
/ NN NN O
L NN NN O
( NN NN O
reference NN NN O
range NN NN O
, NN NN O
10 NN NN O
- NN NN O
37 NN NN O
U NN NN O
/ NN NN O
L NN NN O
) NN NN O
; NN NN O
aspartate NN NN O
aminotransferase NN NN O
, NN NN O
98 NN NN O
U NN NN O
/ NN NN O
L NN NN O
( NN NN O
10 NN NN O
- NN NN O
40 NN NN O
U NN NN O
/ NN NN O
L NN NN O
) NN NN O
; NN NN O
alkaline NN NN O
phosphatase NN NN O
, NN NN O
513 NN NN O
U NN NN O
/ NN NN O
L NN NN O
( NN NN O
0 NN NN O
- NN NN O
270 NN NN O
U NN NN O
/ NN NN O
L NN NN O
) NN NN O
; NN NN O
gamma NN NN O
- NN NN O
glutamyltransferase NN NN O
, NN NN O
32 NN NN O
U NN NN O
/ NN NN O
L NN NN O
( NN NN O
7 NN NN O
- NN NN O
49 NN NN O
U NN NN O
/ NN NN O
L NN NN O
) NN NN O
; NN NN O
amylase NN NN O
, NN NN O
46 NN NN O
U NN NN O
/ NN NN O
L NN NN O
( NN NN O
0 NN NN O
- NN NN O
220 NN NN O
U NN NN O
/ NN NN O
L NN NN O
) NN NN O
; NN NN O
total NN NN O
bilirubin NN NN O
, NN NN O
20 NN NN O
. NN NN O
1 NN NN O
mg NN NN O
/ NN NN O
dL NN NN O
( NN NN O
0 NN NN O
. NN NN O
2 NN NN O
- NN NN O
1 NN NN O
. NN NN O
0 NN NN O
mg NN NN O
/ NN NN O
dL NN NN O
) NN NN O
; NN NN O
direct NN NN O
bilirubin NN NN O
, NN NN O
14 NN NN O
. NN NN O
8 NN NN O
mg NN NN O
/ NN NN O
dL NN NN O
( NN NN O
0 NN NN O
- NN NN O
0 NN NN O
. NN NN O
3 NN NN O
mg NN NN O
/ NN NN O
dL NN NN O
) NN NN O
; NN NN O
and NN NN O
albumin NN NN O
, NN NN O
4 NN NN O
. NN NN O
7 NN NN O
mg NN NN O
/ NN NN O
dL NN NN O
( NN NN O
3 NN NN O
. NN NN O
5 NN NN O
- NN NN O
5 NN NN O
. NN NN O
4 NN NN O
mg NN NN O
/ NN NN O
dL NN NN O
) NN NN O
. NN NN O
   
No NN NN O
toxin NN NN O
, NN NN O
alcohol NN NN O
, NN NN O
or NN NN O
other NN NN O
drugs NN NN O
were NN NN O
reported NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
had NN NN O
suffered NN NN O
a NN NN O
previous NN NN O
episode NN NN O
of NN NN O
"""""""" NN NN O
acute NN NN O
hepatitis NN NN B-Disease
of NN NN O
unknown NN NN O
origin NN NN O
, NN NN O
"""""""" NN NN O
that NN NN O
occurred NN NN O
after NN NN O
telithromycin NN NN O
usage NN NN O
. NN NN O
   
Both NN NN O
incidents NN NN O
occurred NN NN O
within NN NN O
a NN NN O
year NN NN O
. NN NN O
   
DISCUSSION NN NN O
: NN NN O
Telithromycin NN NN O
is NN NN O
the NN NN O
first NN NN O
of NN NN O
the NN NN O
ketolide NN NN O
antibacterials NN NN O
to NN NN O
receive NN NN O
US NN NN O
Food NN NN O
and NN NN O
Drug NN NN O
Administration NN NN O
approval NN NN O
for NN NN O
clinical NN NN O
use NN NN O
. NN NN O
   
It NN NN O
has NN NN O
been NN NN O
associated NN NN O
with NN NN O
infrequent NN NN O
and NN NN O
usually NN NN O
reversible NN NN O
severe NN NN O
hepatic NN NN B-Disease
dysfunction NN NN I-Disease
. NN NN O
   
Based NN NN O
on NN NN O
a NN NN O
score NN NN O
of NN NN O
8 NN NN O
on NN NN O
the NN NN O
Naranjo NN NN O
adverse NN NN B-Disease
drug NN NN I-Disease
reaction NN NN I-Disease
probability NN NN O
scale NN NN O
, NN NN O
telithromycin NN NN O
was NN NN O
the NN NN O
probable NN NN O
cause NN NN O
of NN NN O
acute NN NN O
hepatitis NN NN B-Disease
in NN NN O
this NN NN O
patient NN NN O
, NN NN O
and NN NN O
pathological NN NN O
findings NN NN O
suggested NN NN O
drug NN NN O
- NN NN O
induced NN NN O
toxic NN NN B-Disease
hepatitis NN NN I-Disease
. NN NN O
   
Recurrence NN NN O
of NN NN O
hepatitis NN NN B-Disease
attack NN NN O
might NN NN O
have NN NN O
been NN NN O
avoided NN NN O
if NN NN O
the NN NN O
initial NN NN O
incident NN NN O
had NN NN O
been NN NN O
communicated NN NN O
to NN NN O
the NN NN O
attending NN NN O
physician NN NN O
who NN NN O
prescribed NN NN O
telithromycin NN NN O
the NN NN O
second NN NN O
time NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Here NN NN O
we NN NN O
report NN NN O
a NN NN O
case NN NN O
of NN NN O
acute NN NN O
hepatitis NN NN B-Disease
probably NN NN O
associated NN NN O
with NN NN O
the NN NN O
administration NN NN O
of NN NN O
telithromycin NN NN O
. NN NN O
   
A NN NN O
study NN NN O
on NN NN O
the NN NN O
effect NN NN O
of NN NN O
the NN NN O
duration NN NN O
of NN NN O
subcutaneous NN NN O
heparin NN NN O
injection NN NN O
on NN NN O
bruising NN NN B-Disease
and NN NN O
pain NN NN B-Disease
. NN NN O
   
AIM NN NN O
: NN NN O
This NN NN O
study NN NN O
was NN NN O
carried NN NN O
out NN NN O
to NN NN O
determine NN NN O
the NN NN O
effect NN NN O
of NN NN O
injection NN NN O
duration NN NN O
on NN NN O
bruising NN NN B-Disease
and NN NN O
pain NN NN B-Disease
following NN NN O
the NN NN O
administration NN NN O
of NN NN O
the NN NN O
subcutaneous NN NN O
injection NN NN O
of NN NN O
heparin NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Although NN NN O
different NN NN O
methods NN NN O
to NN NN O
prevent NN NN O
bruising NN NN B-Disease
and NN NN O
pain NN NN B-Disease
following NN NN O
the NN NN O
subcutaneous NN NN O
injection NN NN O
of NN NN O
heparin NN NN O
have NN NN O
been NN NN O
widely NN NN O
studied NN NN O
and NN NN O
described NN NN O
, NN NN O
the NN NN O
effect NN NN O
of NN NN O
injection NN NN O
duration NN NN O
on NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
bruising NN NN B-Disease
and NN NN O
pain NN NN B-Disease
is NN NN O
little NN NN O
documented NN NN O
. NN NN O
   
DESIGN NN NN O
: NN NN O
This NN NN O
study NN NN O
was NN NN O
designed NN NN O
as NN NN O
within NN NN O
- NN NN O
subject NN NN O
, NN NN O
quasi NN NN O
- NN NN O
experimental NN NN O
research NN NN O
. NN NN O
   
METHOD NN NN O
: NN NN O
The NN NN O
sample NN NN O
for NN NN O
the NN NN O
study NN NN O
consisted NN NN O
of NN NN O
50 NN NN O
patients NN NN O
to NN NN O
whom NN NN O
subcutaneous NN NN O
heparin NN NN O
was NN NN O
administered NN NN O
. NN NN O
   
Heparin NN NN O
was NN NN O
injected NN NN O
over NN NN O
10 NN NN O
seconds NN NN O
on NN NN O
the NN NN O
right NN NN O
abdominal NN NN O
site NN NN O
and NN NN O
30 NN NN O
seconds NN NN O
on NN NN O
the NN NN O
left NN NN O
abdominal NN NN O
site NN NN O
. NN NN O
   
Injections NN NN O
areas NN NN O
were NN NN O
assessed NN NN O
for NN NN O
the NN NN O
presence NN NN O
of NN NN O
bruising NN NN B-Disease
at NN NN O
48 NN NN O
and NN NN O
72 NN NN O
hours NN NN O
after NN NN O
each NN NN O
injection NN NN O
. NN NN O
   
Dimensions NN NN O
of NN NN O
the NN NN O
bruising NN NN B-Disease
on NN NN O
the NN NN O
heparin NN NN O
applied NN NN O
areas NN NN O
were NN NN O
measured NN NN O
using NN NN O
transparent NN NN O
millimetric NN NN O
measuring NN NN O
paper NN NN O
. NN NN O
   
The NN NN O
visual NN NN O
analog NN NN O
scale NN NN O
( NN NN O
VAS NN NN O
) NN NN O
was NN NN O
used NN NN O
to NN NN O
measure NN NN O
pain NN NN B-Disease
intensity NN NN O
and NN NN O
a NN NN O
stop NN NN O
- NN NN O
watch NN NN O
was NN NN O
used NN NN O
to NN NN O
time NN NN O
the NN NN O
pain NN NN B-Disease
period NN NN O
. NN NN O
   
Data NN NN O
were NN NN O
analysed NN NN O
using NN NN O
chi NN NN O
- NN NN O
square NN NN O
test NN NN O
, NN NN O
Mann NN NN O
- NN NN O
Whitney NN NN O
U NN NN O
, NN NN O
Wilcoxon NN NN O
signed NN NN O
ranks NN NN O
tests NN NN O
and NN NN O
correlation NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
The NN NN O
percentage NN NN O
of NN NN O
bruising NN NN B-Disease
occurrence NN NN O
was NN NN O
64 NN NN O
% NN NN O
with NN NN O
the NN NN O
injection NN NN O
of NN NN O
10 NN NN O
seconds NN NN O
duration NN NN O
and NN NN O
42 NN NN O
% NN NN O
in NN NN O
the NN NN O
30 NN NN O
- NN NN O
second NN NN O
injection NN NN O
. NN NN O
   
It NN NN O
was NN NN O
determined NN NN O
that NN NN O
the NN NN O
size NN NN O
of NN NN O
the NN NN O
bruising NN NN B-Disease
was NN NN O
smaller NN NN O
in NN NN O
the NN NN O
30 NN NN O
- NN NN O
second NN NN O
injection NN NN O
. NN NN O
   
Pain NN NN B-Disease
intensity NN NN O
and NN NN O
pain NN NN B-Disease
period NN NN O
were NN NN O
statistically NN NN O
significantly NN NN O
lower NN NN O
for NN NN O
the NN NN O
30 NN NN O
- NN NN O
second NN NN O
injection NN NN O
than NN NN O
for NN NN O
the NN NN O
10 NN NN O
- NN NN O
second NN NN O
injection NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
It NN NN O
was NN NN O
determined NN NN O
that NN NN O
injection NN NN O
duration NN NN O
had NN NN O
an NN NN O
effect NN NN O
on NN NN O
bruising NN NN B-Disease
and NN NN O
pain NN NN B-Disease
following NN NN O
the NN NN O
subcutaneous NN NN O
administration NN NN O
of NN NN O
heparin NN NN O
. NN NN O
   
This NN NN O
study NN NN O
should NN NN O
be NN NN O
repeated NN NN O
on NN NN O
a NN NN O
larger NN NN O
sample NN NN O
. NN NN O
   
RELEVANCE NN NN O
TO NN NN O
CLINICAL NN NN O
PRACTICE NN NN O
: NN NN O
When NN NN O
administering NN NN O
subcutaneous NN NN O
heparin NN NN O
injections NN NN O
, NN NN O
it NN NN O
is NN NN O
important NN NN O
to NN NN O
extend NN NN O
the NN NN O
duration NN NN O
of NN NN O
the NN NN O
injection NN NN O
. NN NN O
   
Acute NN NN B-Disease
liver NN NN I-Disease
failure NN NN I-Disease
in NN NN O
two NN NN O
patients NN NN O
with NN NN O
regular NN NN O
alcohol NN NN O
consumption NN NN O
ingesting NN NN O
paracetamol NN NN O
at NN NN O
therapeutic NN NN O
dosage NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
The NN NN O
possible NN NN O
role NN NN O
of NN NN O
alcohol NN NN O
in NN NN O
the NN NN O
development NN NN O
of NN NN O
hepatotoxicity NN NN B-Disease
associated NN NN O
with NN NN O
therapeutic NN NN O
doses NN NN O
of NN NN O
paracetamol NN NN O
( NN NN O
acetaminophen NN NN O
) NN NN O
is NN NN O
currently NN NN O
debated NN NN O
. NN NN O
   
CASE NN NN O
REPORT NN NN O
: NN NN O
We NN NN O
describe NN NN O
2 NN NN O
patients NN NN O
who NN NN O
were NN NN O
regular NN NN O
consumers NN NN O
of NN NN O
alcohol NN NN O
and NN NN O
who NN NN O
developed NN NN O
liver NN NN B-Disease
failure NN NN I-Disease
within NN NN O
3 NN NN O
- NN NN O
5 NN NN O
days NN NN O
after NN NN O
hospitalization NN NN O
and NN NN O
stopping NN NN O
alcohol NN NN O
consumption NN NN O
while NN NN O
being NN NN O
treated NN NN O
with NN NN O
4 NN NN O
g NN NN O
paracetamol NN NN O
/ NN NN O
day NN NN O
. NN NN O
   
A NN NN O
paracetamol NN NN O
serum NN NN O
level NN NN O
obtained NN NN O
in NN NN O
one NN NN O
of NN NN O
these NN NN O
patients NN NN O
was NN NN O
not NN NN O
in NN NN O
the NN NN O
toxic NN NN O
range NN NN O
. NN NN O
   
Possible NN NN O
risk NN NN O
factors NN NN O
for NN NN O
the NN NN O
development NN NN O
of NN NN O
hepatotoxicity NN NN B-Disease
in NN NN O
patients NN NN O
treated NN NN O
with NN NN O
therapeutic NN NN O
doses NN NN O
of NN NN O
paracetamol NN NN O
are NN NN O
discussed NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
In NN NN O
patients NN NN O
with NN NN O
risk NN NN O
factors NN NN O
, NN NN O
e NN NN O
. NN NN O
g NN NN O
. NN NN O
regular NN NN O
consumption NN NN O
of NN NN O
alcohol NN NN O
, NN NN O
liver NN NN B-Disease
failure NN NN I-Disease
is NN NN O
possible NN NN O
when NN NN O
therapeutic NN NN O
doses NN NN O
are NN NN O
ingested NN NN O
. NN NN O
   
We NN NN O
propose NN NN O
that NN NN O
the NN NN O
paracetamol NN NN O
dose NN NN O
should NN NN O
not NN NN O
exceed NN NN O
2 NN NN O
g NN NN O
/ NN NN O
day NN NN O
in NN NN O
such NN NN O
patients NN NN O
and NN NN O
that NN NN O
their NN NN O
liver NN NN O
function NN NN O
should NN NN O
be NN NN O
monitored NN NN O
closely NN NN O
while NN NN O
being NN NN O
treated NN NN O
with NN NN O
paracetamol NN NN O
. NN NN O
   
Associations NN NN O
between NN NN O
use NN NN O
of NN NN O
benzodiazepines NN NN O
or NN NN O
related NN NN O
drugs NN NN O
and NN NN O
health NN NN O
, NN NN O
physical NN NN O
abilities NN NN O
and NN NN O
cognitive NN NN O
function NN NN O
: NN NN O
a NN NN O
non NN NN O
- NN NN O
randomised NN NN O
clinical NN NN O
study NN NN O
in NN NN O
the NN NN O
elderly NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
To NN NN O
describe NN NN O
associations NN NN O
between NN NN O
the NN NN O
use NN NN O
of NN NN O
benzodiazepines NN NN O
or NN NN O
related NN NN O
drugs NN NN O
( NN NN O
BZDs NN NN O
/ NN NN O
RDs NN NN O
) NN NN O
and NN NN O
health NN NN O
, NN NN O
functional NN NN O
abilities NN NN O
and NN NN O
cognitive NN NN O
function NN NN O
in NN NN O
the NN NN O
elderly NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
A NN NN O
non NN NN O
- NN NN O
randomised NN NN O
clinical NN NN O
study NN NN O
of NN NN O
patients NN NN O
aged NN NN O
> NN NN O
or NN NN O
= NN NN O
65 NN NN O
years NN NN O
admitted NN NN O
to NN NN O
acute NN NN O
hospital NN NN O
wards NN NN O
during NN NN O
1 NN NN O
month NN NN O
. NN NN O
   
164 NN NN O
patients NN NN O
( NN NN O
mean NN NN O
age NN NN O
+ NN NN O
/ NN NN O
- NN NN O
standard NN NN O
deviation NN NN O
[ NN NN O
SD NN NN O
] NN NN O
81 NN NN O
. NN NN O
6 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
6 NN NN O
. NN NN O
8 NN NN O
years NN NN O
) NN NN O
were NN NN O
admitted NN NN O
. NN NN O
   
Of NN NN O
these NN NN O
, NN NN O
nearly NN NN O
half NN NN O
( NN NN O
n NN NN O
= NN NN O
78 NN NN O
) NN NN O
had NN NN O
used NN NN O
BZDs NN NN O
/ NN NN O
RDs NN NN O
before NN NN O
admission NN NN O
, NN NN O
and NN NN O
the NN NN O
remainder NN NN O
( NN NN O
n NN NN O
= NN NN O
86 NN NN O
) NN NN O
were NN NN O
non NN NN O
- NN NN O
users NN NN O
. NN NN O
   
Cognitive NN NN O
ability NN NN O
was NN NN O
assessed NN NN O
by NN NN O
the NN NN O
Mini NN NN O
- NN NN O
Mental NN NN O
State NN NN O
Examination NN NN O
( NN NN O
MMSE NN NN O
) NN NN O
. NN NN O
   
Patients NN NN O
scoring NN NN O
> NN NN O
or NN NN O
= NN NN O
20 NN NN O
MMSE NN NN O
sum NN NN O
points NN NN O
were NN NN O
interviewed NN NN O
( NN NN O
n NN NN O
= NN NN O
79 NN NN O
) NN NN O
and NN NN O
questioned NN NN O
regarding NN NN O
symptoms NN NN O
and NN NN O
functional NN NN O
abilities NN NN O
during NN NN O
the NN NN O
week NN NN O
prior NN NN O
to NN NN O
admission NN NN O
. NN NN O
   
Data NN NN O
on NN NN O
use NN NN O
of NN NN O
BZDs NN NN O
/ NN NN O
RDs NN NN O
before NN NN O
admission NN NN O
, NN NN O
current NN NN O
medications NN NN O
and NN NN O
discharge NN NN O
diagnoses NN NN O
were NN NN O
collected NN NN O
from NN NN O
medical NN NN O
records NN NN O
. NN NN O
   
Health NN NN O
, NN NN O
physical NN NN O
abilities NN NN O
and NN NN O
cognitive NN NN O
function NN NN O
were NN NN O
compared NN NN O
between NN NN O
BZD NN NN O
/ NN NN O
RD NN NN O
users NN NN O
and NN NN O
non NN NN O
- NN NN O
users NN NN O
, NN NN O
and NN NN O
adjustments NN NN O
were NN NN O
made NN NN O
for NN NN O
confounding NN NN O
variables NN NN O
. NN NN O
   
The NN NN O
residual NN NN O
serum NN NN O
concentrations NN NN O
of NN NN O
oxazepam NN NN O
, NN NN O
temazepam NN NN O
and NN NN O
zopiclone NN NN O
were NN NN O
analysed NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
The NN NN O
mean NN NN O
+ NN NN O
/ NN NN O
- NN NN O
SD NN NN O
duration NN NN O
of NN NN O
BZD NN NN O
/ NN NN O
RD NN NN O
use NN NN O
was NN NN O
7 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
7 NN NN O
years NN NN O
( NN NN O
range NN NN O
1 NN NN O
- NN NN O
31 NN NN O
) NN NN O
. NN NN O
   
Two NN NN O
or NN NN O
three NN NN O
BZDs NN NN O
/ NN NN O
RDs NN NN O
were NN NN O
concomitantly NN NN O
taken NN NN O
by NN NN O
26 NN NN O
% NN NN O
of NN NN O
users NN NN O
( NN NN O
n NN NN O
= NN NN O
20 NN NN O
) NN NN O
. NN NN O
   
Long NN NN O
- NN NN O
term NN NN O
use NN NN O
of NN NN O
these NN NN O
drugs NN NN O
was NN NN O
associated NN NN O
with NN NN O
female NN NN O
sex NN NN O
and NN NN O
use NN NN O
of NN NN O
a NN NN O
higher NN NN O
number NN NN O
of NN NN O
drugs NN NN O
with NN NN O
effects NN NN O
on NN NN O
the NN NN O
CNS NN NN O
, NN NN O
which NN NN O
tended NN NN O
to NN NN O
be NN NN O
related NN NN O
to NN NN O
diagnosed NN NN O
dementia NN NN B-Disease
. NN NN O
   
After NN NN O
adjustment NN NN O
for NN NN O
these NN NN O
variables NN NN O
as NN NN O
confounders NN NN O
, NN NN O
use NN NN O
of NN NN O
BZDs NN NN O
/ NN NN O
RDs NN NN O
was NN NN O
not NN NN O
associated NN NN O
with NN NN O
cognitive NN NN O
function NN NN O
as NN NN O
measured NN NN O
by NN NN O
the NN NN O
MMSE NN NN O
. NN NN O
   
However NN NN O
, NN NN O
use NN NN O
of NN NN O
BZDs NN NN O
/ NN NN O
RDs NN NN O
was NN NN O
associated NN NN O
with NN NN O
dizziness NN NN B-Disease
, NN NN O
inability NN NN B-Disease
to NN NN I-Disease
sleep NN NN I-Disease
after NN NN O
awaking NN NN O
at NN NN O
night NN NN O
and NN NN O
tiredness NN NN B-Disease
in NN NN O
the NN NN O
mornings NN NN O
during NN NN O
the NN NN O
week NN NN O
prior NN NN O
to NN NN O
admission NN NN O
and NN NN O
with NN NN O
stronger NN NN O
depressive NN NN B-Disease
symptoms NN NN I-Disease
measured NN NN O
at NN NN O
the NN NN O
beginning NN NN O
of NN NN O
the NN NN O
hospital NN NN O
stay NN NN O
. NN NN O
   
Use NN NN O
of NN NN O
BZDs NN NN O
/ NN NN O
RDs NN NN O
tended NN NN O
to NN NN O
be NN NN O
associated NN NN O
with NN NN O
a NN NN O
reduced NN NN O
ability NN NN O
to NN NN O
walk NN NN O
and NN NN O
shorter NN NN O
night NN NN O
- NN NN O
time NN NN O
sleep NN NN O
during NN NN O
the NN NN O
week NN NN O
prior NN NN O
to NN NN O
admission NN NN O
. NN NN O
   
A NN NN O
higher NN NN O
residual NN NN O
serum NN NN O
concentration NN NN O
of NN NN O
temazepam NN NN O
correlated NN NN O
with NN NN O
a NN NN O
lower NN NN O
MMSE NN NN O
sum NN NN O
score NN NN O
after NN NN O
adjustment NN NN O
for NN NN O
confounding NN NN O
variables NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Long NN NN O
- NN NN O
term NN NN O
use NN NN O
and NN NN O
concomitant NN NN O
use NN NN O
of NN NN O
more NN NN O
than NN NN O
one NN NN O
BZD NN NN O
/ NN NN O
RD NN NN O
were NN NN O
common NN NN O
in NN NN O
elderly NN NN O
patients NN NN O
hospitalised NN NN O
because NN NN O
of NN NN O
acute NN NN O
illnesses NN NN O
. NN NN O
   
Long NN NN O
- NN NN O
term NN NN O
use NN NN O
was NN NN O
associated NN NN O
with NN NN O
daytime NN NN O
and NN NN O
night NN NN O
- NN NN O
time NN NN O
symptoms NN NN O
indicative NN NN O
of NN NN O
poorer NN NN O
health NN NN O
and NN NN O
potentially NN NN O
caused NN NN O
by NN NN O
the NN NN O
adverse NN NN O
effects NN NN O
of NN NN O
these NN NN O
drugs NN NN O
. NN NN O
   
Acute NN NN O
vocal NN NN B-Disease
fold NN NN I-Disease
palsy NN NN I-Disease
after NN NN O
acute NN NN O
disulfiram NN NN O
intoxication NN NN O
. NN NN O
   
Acute NN NN O
peripheral NN NN B-Disease
neuropathy NN NN I-Disease
caused NN NN O
by NN NN O
a NN NN O
disulfiram NN NN O
overdose NN NN B-Disease
is NN NN O
very NN NN O
rare NN NN O
and NN NN O
there NN NN O
is NN NN O
no NN NN O
report NN NN O
of NN NN O
it NN NN O
leading NN NN O
to NN NN O
vocal NN NN B-Disease
fold NN NN I-Disease
palsy NN NN I-Disease
. NN NN O
   
A NN NN O
49 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
woman NN NN O
was NN NN O
transferred NN NN O
to NN NN O
our NN NN O
department NN NN O
because NN NN O
of NN NN O
quadriparesis NN NN B-Disease
, NN NN O
lancinating NN NN O
pain NN NN B-Disease
, NN NN O
sensory NN NN B-Disease
loss NN NN I-Disease
, NN NN O
and NN NN O
paresthesia NN NN B-Disease
of NN NN O
the NN NN O
distal NN NN O
limbs NN NN O
. NN NN O
   
One NN NN O
month NN NN O
previously NN NN O
, NN NN O
she NN NN O
had NN NN O
taken NN NN O
a NN NN O
single NN NN O
high NN NN O
dose NN NN O
of NN NN O
disulfiram NN NN O
( NN NN O
130 NN NN O
tablets NN NN O
of NN NN O
ALCOHOL NN NN O
STOP NN NN O
TAB NN NN O
, NN NN O
Shin NN NN O
- NN NN O
Poong NN NN O
Pharm NN NN O
. NN NN O
Co NN NN O
. NN NN O
, NN NN O
Ansan NN NN O
, NN NN O
Korea NN NN O
) NN NN O
in NN NN O
a NN NN O
suicide NN NN O
attempt NN NN O
. NN NN O
   
She NN NN O
was NN NN O
not NN NN O
an NN NN O
alcoholic NN NN O
. NN NN O
   
For NN NN O
the NN NN O
first NN NN O
few NN NN O
days NN NN O
after NN NN O
ingestion NN NN O
, NN NN O
she NN NN O
was NN NN O
in NN NN O
a NN NN O
confused NN NN O
state NN NN O
and NN NN O
had NN NN O
mild NN NN O
to NN NN O
moderate NN NN O
ataxia NN NN B-Disease
and NN NN O
giddiness NN NN B-Disease
. NN NN O
   
She NN NN O
noticed NN NN O
hoarseness NN NN B-Disease
and NN NN O
distally NN NN O
accentuated NN NN O
motor NN NN O
and NN NN O
sensory NN NN O
dysfunction NN NN O
after NN NN O
she NN NN O
had NN NN O
recovered NN NN O
from NN NN O
this NN NN O
state NN NN O
. NN NN O
   
A NN NN O
nerve NN NN O
conduction NN NN O
study NN NN O
was NN NN O
consistent NN NN O
with NN NN O
severe NN NN O
sensorimotor NN NN O
axonal NN NN O
polyneuropathy NN NN B-Disease
. NN NN O
   
Laryngeal NN NN O
electromyography NN NN O
( NN NN O
thyroarytenoid NN NN O
muscle NN NN O
) NN NN O
showed NN NN O
ample NN NN O
denervation NN NN O
potentials NN NN O
. NN NN O
   
Laryngoscopy NN NN O
revealed NN NN O
asymmetric NN NN O
vocal NN NN O
fold NN NN O
movements NN NN O
during NN NN O
phonation NN NN O
. NN NN O
   
Her NN NN O
vocal NN NN O
change NN NN O
and NN NN O
weakness NN NN O
began NN NN O
to NN NN O
improve NN NN O
spontaneously NN NN O
about NN NN O
3 NN NN O
weeks NN NN O
after NN NN O
transfer NN NN O
. NN NN O
   
This NN NN O
was NN NN O
a NN NN O
case NN NN O
of NN NN O
acute NN NN O
palsy NN NN B-Disease
of NN NN O
the NN NN O
recurrent NN NN O
laryngeal NN NN O
nerve NN NN O
and NN NN O
superimposed NN NN O
severe NN NN O
acute NN NN O
sensorimotor NN NN O
axonal NN NN O
polyneuropathy NN NN B-Disease
caused NN NN O
by NN NN O
high NN NN O
- NN NN O
dose NN NN O
disulfiram NN NN O
intoxication NN NN O
. NN NN O
   
Encephalopathy NN NN B-Disease
induced NN NN O
by NN NN O
levetiracetam NN NN O
added NN NN O
to NN NN O
valproate NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
We NN NN O
report NN NN O
on NN NN O
the NN NN O
manifestation NN NN O
of NN NN O
a NN NN O
levetiracetam NN NN O
( NN NN O
LEV NN NN O
) NN NN O
- NN NN O
induced NN NN O
encephalopathy NN NN B-Disease
. NN NN O
   
FINDINGS NN NN O
: NN NN O
A NN NN O
28 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
man NN NN O
suffering NN NN O
from NN NN O
idiopathic NN NN B-Disease
epilepsy NN NN I-Disease
with NN NN O
generalized NN NN O
seizures NN NN B-Disease
was NN NN O
treated NN NN O
with NN NN O
LEV NN NN O
( NN NN O
3000 NN NN O
mg NN NN O
) NN NN O
added NN NN O
to NN NN O
valproate NN NN O
( NN NN O
VPA NN NN O
) NN NN O
( NN NN O
2000 NN NN O
mg NN NN O
) NN NN O
. NN NN O
   
Frequency NN NN O
of NN NN O
generalized NN NN O
tonic NN NN B-Disease
- NN NN I-Disease
clonic NN NN I-Disease
seizures NN NN I-Disease
increased NN NN O
from NN NN O
one NN NN O
per NN NN O
6 NN NN O
months NN NN O
to NN NN O
two NN NN O
per NN NN O
month NN NN O
. NN NN O
   
Neuropsychological NN NN O
testing NN NN O
showed NN NN O
impaired NN NN B-Disease
word NN NN I-Disease
fluency NN NN I-Disease
, NN NN I-Disease
psychomotor NN NN I-Disease
speed NN NN I-Disease
and NN NN I-Disease
working NN NN I-Disease
memory NN NN I-Disease
. NN NN O
   
The NN NN O
interictal NN NN O
electroencephalogram NN NN O
( NN NN O
EEG NN NN O
) NN NN O
showed NN NN O
a NN NN O
generalized NN NN O
slowing NN NN O
to NN NN O
5 NN NN O
per NN NN O
second NN NN O
theta NN NN O
rhythms NN NN O
with NN NN O
bilateral NN NN O
generalized NN NN O
high NN NN O
- NN NN O
amplitude NN NN O
discharges NN NN O
. NN NN O
   
OUTCOME NN NN O
: NN NN O
Following NN NN O
discontinuation NN NN O
of NN NN O
LEV NN NN O
, NN NN O
EEG NN NN O
and NN NN O
neuropsychological NN NN O
findings NN NN O
improved NN NN O
and NN NN O
seizure NN NN B-Disease
frequency NN NN O
decreased NN NN O
. NN NN O
   
Norepinephrine NN NN O
signaling NN NN O
through NN NN O
beta NN NN O
- NN NN O
adrenergic NN NN O
receptors NN NN O
is NN NN O
critical NN NN O
for NN NN O
expression NN NN O
of NN NN O
cocaine NN NN O
- NN NN O
induced NN NN O
anxiety NN NN B-Disease
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Cocaine NN NN O
is NN NN O
a NN NN O
widely NN NN O
abused NN NN O
psychostimulant NN NN O
that NN NN O
has NN NN O
both NN NN O
rewarding NN NN O
and NN NN O
aversive NN NN O
properties NN NN O
. NN NN O
   
While NN NN O
the NN NN O
mechanisms NN NN O
underlying NN NN O
cocaine NN NN O
' NN NN O
s NN NN O
rewarding NN NN O
effects NN NN O
have NN NN O
been NN NN O
studied NN NN O
extensively NN NN O
, NN NN O
less NN NN O
attention NN NN O
has NN NN O
been NN NN O
paid NN NN O
to NN NN O
the NN NN O
unpleasant NN NN O
behavioral NN NN O
states NN NN O
induced NN NN O
by NN NN O
cocaine NN NN O
, NN NN O
such NN NN O
as NN NN O
anxiety NN NN B-Disease
. NN NN O
   
METHODS NN NN O
: NN NN O
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
evaluated NN NN O
the NN NN O
performance NN NN O
of NN NN O
dopamine NN NN O
beta NN NN O
- NN NN O
hydroxylase NN NN O
knockout NN NN O
( NN NN O
Dbh NN NN O
- NN NN O
/ NN NN O
- NN NN O
) NN NN O
mice NN NN O
, NN NN O
which NN NN O
lack NN NN O
norepinephrine NN NN O
( NN NN O
NE NN NN O
) NN NN O
, NN NN O
in NN NN O
the NN NN O
elevated NN NN O
plus NN NN O
maze NN NN O
( NN NN O
EPM NN NN O
) NN NN O
to NN NN O
examine NN NN O
the NN NN O
contribution NN NN O
of NN NN O
noradrenergic NN NN O
signaling NN NN O
to NN NN O
cocaine NN NN O
- NN NN O
induced NN NN O
anxiety NN NN B-Disease
. NN NN O
   
RESULTS NN NN O
: NN NN O
We NN NN O
found NN NN O
that NN NN O
cocaine NN NN O
dose NN NN O
- NN NN O
dependently NN NN O
increased NN NN O
anxiety NN NN B-Disease
- NN NN O
like NN NN O
behavior NN NN O
in NN NN O
control NN NN O
( NN NN O
Dbh NN NN O
+ NN NN O
/ NN NN O
- NN NN O
) NN NN O
mice NN NN O
, NN NN O
as NN NN O
measured NN NN O
by NN NN O
a NN NN O
decrease NN NN O
in NN NN O
open NN NN O
arm NN NN O
exploration NN NN O
. NN NN O
   
The NN NN O
Dbh NN NN O
- NN NN O
/ NN NN O
- NN NN O
mice NN NN O
had NN NN O
normal NN NN O
baseline NN NN O
performance NN NN O
in NN NN O
the NN NN O
EPM NN NN O
but NN NN O
were NN NN O
completely NN NN O
resistant NN NN O
to NN NN O
the NN NN O
anxiogenic NN NN O
effects NN NN O
of NN NN O
cocaine NN NN O
. NN NN O
   
Cocaine NN NN O
- NN NN O
induced NN NN O
anxiety NN NN B-Disease
was NN NN O
also NN NN O
attenuated NN NN O
in NN NN O
Dbh NN NN O
+ NN NN O
/ NN NN O
- NN NN O
mice NN NN O
following NN NN O
administration NN NN O
of NN NN O
disulfiram NN NN O
, NN NN O
a NN NN O
dopamine NN NN O
beta NN NN O
- NN NN O
hydroxylase NN NN O
( NN NN O
DBH NN NN O
) NN NN O
inhibitor NN NN O
. NN NN O
   
In NN NN O
experiments NN NN O
using NN NN O
specific NN NN O
adrenergic NN NN O
antagonists NN NN O
, NN NN O
we NN NN O
found NN NN O
that NN NN O
pretreatment NN NN O
with NN NN O
the NN NN O
beta NN NN O
- NN NN O
adrenergic NN NN O
receptor NN NN O
antagonist NN NN O
propranolol NN NN O
blocked NN NN O
cocaine NN NN O
- NN NN O
induced NN NN O
anxiety NN NN B-Disease
- NN NN O
like NN NN O
behavior NN NN O
in NN NN O
Dbh NN NN O
+ NN NN O
/ NN NN O
- NN NN O
and NN NN O
wild NN NN O
- NN NN O
type NN NN O
C57BL6 NN NN O
/ NN NN O
J NN NN O
mice NN NN O
, NN NN O
while NN NN O
the NN NN O
alpha NN NN O
( NN NN O
1 NN NN O
) NN NN O
antagonist NN NN O
prazosin NN NN O
and NN NN O
the NN NN O
alpha NN NN O
( NN NN O
2 NN NN O
) NN NN O
antagonist NN NN O
yohimbine NN NN O
had NN NN O
no NN NN O
effect NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
noradrenergic NN NN O
signaling NN NN O
via NN NN O
beta NN NN O
- NN NN O
adrenergic NN NN O
receptors NN NN O
is NN NN O
required NN NN O
for NN NN O
cocaine NN NN O
- NN NN O
induced NN NN O
anxiety NN NN B-Disease
in NN NN O
mice NN NN O
. NN NN O
   
Hypothalamic NN NN O
prolactin NN NN O
receptor NN NN O
messenger NN NN O
ribonucleic NN NN O
acid NN NN O
levels NN NN O
, NN NN O
prolactin NN NN O
signaling NN NN O
, NN NN O
and NN NN O
hyperprolactinemic NN NN B-Disease
inhibition NN NN O
of NN NN O
pulsatile NN NN O
luteinizing NN NN O
hormone NN NN O
secretion NN NN O
are NN NN O
dependent NN NN O
on NN NN O
estradiol NN NN O
. NN NN O
   
Hyperprolactinemia NN NN B-Disease
can NN NN O
reduce NN NN O
fertility NN NN O
and NN NN O
libido NN NN O
. NN NN O
   
Although NN NN O
central NN NN O
prolactin NN NN O
actions NN NN O
are NN NN O
thought NN NN O
to NN NN O
contribute NN NN O
to NN NN O
this NN NN O
, NN NN O
the NN NN O
mechanisms NN NN O
are NN NN O
poorly NN NN O
understood NN NN O
. NN NN O
   
We NN NN O
first NN NN O
tested NN NN O
whether NN NN O
chronic NN NN O
hyperprolactinemia NN NN B-Disease
inhibited NN NN O
two NN NN O
neuroendocrine NN NN O
parameters NN NN O
necessary NN NN O
for NN NN O
female NN NN O
fertility NN NN O
: NN NN O
pulsatile NN NN O
LH NN NN O
secretion NN NN O
and NN NN O
the NN NN O
estrogen NN NN O
- NN NN O
induced NN NN O
LH NN NN O
surge NN NN O
. NN NN O
   
Chronic NN NN O
hyperprolactinemia NN NN B-Disease
induced NN NN O
by NN NN O
the NN NN O
dopamine NN NN O
antagonist NN NN O
sulpiride NN NN O
caused NN NN O
a NN NN O
40 NN NN O
% NN NN O
reduction NN NN O
LH NN NN O
pulse NN NN O
frequency NN NN O
in NN NN O
ovariectomized NN NN O
rats NN NN O
, NN NN O
but NN NN O
only NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
chronic NN NN O
low NN NN O
levels NN NN O
of NN NN O
estradiol NN NN O
. NN NN O
   
Sulpiride NN NN O
did NN NN O
not NN NN O
affect NN NN O
the NN NN O
magnitude NN NN O
of NN NN O
a NN NN O
steroid NN NN O
- NN NN O
induced NN NN O
LH NN NN O
surge NN NN O
or NN NN O
the NN NN O
percentage NN NN O
of NN NN O
GnRH NN NN O
neurons NN NN O
activated NN NN O
during NN NN O
the NN NN O
surge NN NN O
. NN NN O
   
Estradiol NN NN O
is NN NN O
known NN NN O
to NN NN O
influence NN NN O
expression NN NN O
of NN NN O
the NN NN O
long NN NN O
form NN NN O
of NN NN O
prolactin NN NN O
receptors NN NN O
( NN NN O
PRL NN NN O
- NN NN O
R NN NN O
) NN NN O
and NN NN O
components NN NN O
of NN NN O
prolactin NN NN O
' NN NN O
s NN NN O
signaling NN NN O
pathway NN NN O
. NN NN O
   
To NN NN O
test NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
estrogen NN NN O
increases NN NN O
PRL NN NN O
- NN NN O
R NN NN O
expression NN NN O
and NN NN O
sensitivity NN NN O
to NN NN O
prolactin NN NN O
, NN NN O
we NN NN O
next NN NN O
demonstrated NN NN O
that NN NN O
estradiol NN NN O
greatly NN NN O
augments NN NN O
prolactin NN NN O
- NN NN O
induced NN NN O
STAT5 NN NN O
activation NN NN O
. NN NN O
   
Lastly NN NN O
, NN NN O
we NN NN O
measured NN NN O
PRL NN NN O
- NN NN O
R NN NN O
and NN NN O
suppressor NN NN O
of NN NN O
cytokine NN NN O
signaling NN NN O
( NN NN O
SOCS NN NN O
- NN NN O
1 NN NN O
and NN NN O
- NN NN O
3 NN NN O
and NN NN O
CIS NN NN O
, NN NN O
which NN NN O
reflect NN NN O
the NN NN O
level NN NN O
of NN NN O
prolactin NN NN O
signaling NN NN O
) NN NN O
mRNAs NN NN O
in NN NN O
response NN NN O
to NN NN O
sulpiride NN NN O
and NN NN O
estradiol NN NN O
. NN NN O
   
Sulpiride NN NN O
induced NN NN O
only NN NN O
SOCS NN NN O
- NN NN O
1 NN NN O
in NN NN O
the NN NN O
medial NN NN O
preoptic NN NN O
area NN NN O
, NN NN O
where NN NN O
GnRH NN NN O
neurons NN NN O
are NN NN O
regulated NN NN O
, NN NN O
but NN NN O
in NN NN O
the NN NN O
arcuate NN NN O
nucleus NN NN O
and NN NN O
choroid NN NN O
plexus NN NN O
, NN NN O
PRL NN NN O
- NN NN O
R NN NN O
, NN NN O
SOCS NN NN O
- NN NN O
3 NN NN O
, NN NN O
and NN NN O
CIS NN NN O
mRNA NN NN O
levels NN NN O
were NN NN O
also NN NN O
induced NN NN O
. NN NN O
   
Estradiol NN NN O
enhanced NN NN O
these NN NN O
effects NN NN O
on NN NN O
SOCS NN NN O
- NN NN O
3 NN NN O
and NN NN O
CIS NN NN O
. NN NN O
   
Interestingly NN NN O
, NN NN O
estradiol NN NN O
also NN NN O
induced NN NN O
PRL NN NN O
- NN NN O
R NN NN O
, NN NN O
SOCS NN NN O
- NN NN O
3 NN NN O
, NN NN O
and NN NN O
CIS NN NN O
mRNA NN NN O
levels NN NN O
independently NN NN O
. NN NN O
   
These NN NN O
data NN NN O
show NN NN O
that NN NN O
GnRH NN NN O
pulse NN NN O
frequency NN NN O
is NN NN O
inhibited NN NN O
by NN NN O
chronic NN NN O
hyperprolactinemia NN NN B-Disease
in NN NN O
a NN NN O
steroid NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
. NN NN O
   
They NN NN O
also NN NN O
provide NN NN O
evidence NN NN O
for NN NN O
estradiol NN NN O
- NN NN O
dependent NN NN O
and NN NN O
brain NN NN O
region NN NN O
- NN NN O
specific NN NN O
regulation NN NN O
of NN NN O
PRL NN NN O
- NN NN O
R NN NN O
expression NN NN O
and NN NN O
signaling NN NN O
responses NN NN O
by NN NN O
prolactin NN NN O
. NN NN O
   
Clonidine NN NN O
for NN NN O
attention NN NN B-Disease
- NN NN I-Disease
deficit NN NN I-Disease
/ NN NN I-Disease
hyperactivity NN NN I-Disease
disorder NN NN I-Disease
: NN NN O
II NN NN O
. NN NN O
   
ECG NN NN O
changes NN NN O
and NN NN O
adverse NN NN O
events NN NN O
analysis NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
To NN NN O
examine NN NN O
the NN NN O
safety NN NN O
and NN NN O
tolerability NN NN O
of NN NN O
clonidine NN NN O
used NN NN O
alone NN NN O
or NN NN O
with NN NN O
methylphenidate NN NN O
in NN NN O
children NN NN O
with NN NN O
attention NN NN B-Disease
- NN NN I-Disease
deficit NN NN I-Disease
/ NN NN I-Disease
hyperactivity NN NN I-Disease
disorder NN NN I-Disease
( NN NN O
ADHD NN NN B-Disease
) NN NN O
. NN NN O
   
METHOD NN NN O
: NN NN O
In NN NN O
a NN NN O
16 NN NN O
- NN NN O
week NN NN O
multicenter NN NN O
, NN NN O
double NN NN O
- NN NN O
blind NN NN O
trial NN NN O
, NN NN O
122 NN NN O
children NN NN O
with NN NN O
ADHD NN NN B-Disease
were NN NN O
randomly NN NN O
assigned NN NN O
to NN NN O
clonidine NN NN O
( NN NN O
n NN NN O
= NN NN O
31 NN NN O
) NN NN O
, NN NN O
methylphenidate NN NN O
( NN NN O
n NN NN O
= NN NN O
29 NN NN O
) NN NN O
, NN NN O
clonidine NN NN O
and NN NN O
methylphenidate NN NN O
( NN NN O
n NN NN O
= NN NN O
32 NN NN O
) NN NN O
, NN NN O
or NN NN O
placebo NN NN O
( NN NN O
n NN NN O
= NN NN O
30 NN NN O
) NN NN O
. NN NN O
   
Doses NN NN O
were NN NN O
flexibly NN NN O
titrated NN NN O
up NN NN O
to NN NN O
0 NN NN O
. NN NN O
6 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
for NN NN O
clonidine NN NN O
and NN NN O
60 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
for NN NN O
methylphenidate NN NN O
( NN NN O
both NN NN O
with NN NN O
divided NN NN O
dosing NN NN O
) NN NN O
. NN NN O
   
Groups NN NN O
were NN NN O
compared NN NN O
regarding NN NN O
adverse NN NN O
events NN NN O
and NN NN O
changes NN NN O
from NN NN O
baseline NN NN O
to NN NN O
week NN NN O
16 NN NN O
in NN NN O
electrocardiograms NN NN O
and NN NN O
vital NN NN O
signs NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
There NN NN O
were NN NN O
more NN NN O
incidents NN NN O
of NN NN O
bradycardia NN NN B-Disease
in NN NN O
subjects NN NN O
treated NN NN O
with NN NN O
clonidine NN NN O
compared NN NN O
with NN NN O
those NN NN O
not NN NN O
treated NN NN O
with NN NN O
clonidine NN NN O
( NN NN O
17 NN NN O
. NN NN O
5 NN NN O
% NN NN O
versus NN NN O
3 NN NN O
. NN NN O
4 NN NN O
% NN NN O
; NN NN O
p NN NN O
= NN NN O
. NN NN O
02 NN NN O
) NN NN O
, NN NN O
but NN NN O
no NN NN O
other NN NN O
significant NN NN O
group NN NN O
differences NN NN O
regarding NN NN O
electrocardiogram NN NN O
and NN NN O
other NN NN O
cardiovascular NN NN O
outcomes NN NN O
. NN NN O
   
There NN NN O
were NN NN O
no NN NN O
suggestions NN NN O
of NN NN O
interactions NN NN O
between NN NN O
clonidine NN NN O
and NN NN O
methylphenidate NN NN O
regarding NN NN O
cardiovascular NN NN O
outcomes NN NN O
. NN NN O
   
Moderate NN NN O
or NN NN O
severe NN NN O
adverse NN NN O
events NN NN O
were NN NN O
more NN NN O
common NN NN O
in NN NN O
subjects NN NN O
on NN NN O
clonidine NN NN O
( NN NN O
79 NN NN O
. NN NN O
4 NN NN O
% NN NN O
versus NN NN O
49 NN NN O
. NN NN O
2 NN NN O
% NN NN O
; NN NN O
p NN NN O
= NN NN O
. NN NN O
0006 NN NN O
) NN NN O
but NN NN O
not NN NN O
associated NN NN O
with NN NN O
higher NN NN O
rates NN NN O
of NN NN O
early NN NN O
study NN NN O
withdrawal NN NN O
. NN NN O
   
Drowsiness NN NN B-Disease
was NN NN O
common NN NN O
on NN NN O
clonidine NN NN O
, NN NN O
but NN NN O
generally NN NN O
resolved NN NN O
by NN NN O
6 NN NN O
to NN NN O
8 NN NN O
weeks NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Clonidine NN NN O
, NN NN O
used NN NN O
alone NN NN O
or NN NN O
with NN NN O
methylphenidate NN NN O
, NN NN O
appears NN NN O
safe NN NN O
and NN NN O
well NN NN O
tolerated NN NN O
in NN NN O
childhood NN NN O
ADHD NN NN B-Disease
. NN NN O
   
Physicians NN NN O
prescribing NN NN O
clonidine NN NN O
should NN NN O
monitor NN NN O
for NN NN O
bradycardia NN NN B-Disease
and NN NN O
advise NN NN O
patients NN NN O
about NN NN O
the NN NN O
high NN NN O
likelihood NN NN O
of NN NN O
initial NN NN O
drowsiness NN NN B-Disease
. NN NN O
   
Renal NN NN B-Disease
Fanconi NN NN I-Disease
syndrome NN NN I-Disease
and NN NN O
myopathy NN NN B-Disease
after NN NN O
liver NN NN O
transplantation NN NN O
: NN NN O
drug NN NN O
- NN NN O
related NN NN O
mitochondrial NN NN B-Disease
cytopathy NN NN I-Disease
? NN NN O
   
Advances NN NN O
in NN NN O
the NN NN O
field NN NN O
of NN NN O
transplantation NN NN O
provide NN NN O
a NN NN O
better NN NN O
quality NN NN O
of NN NN O
life NN NN O
and NN NN O
allow NN NN O
more NN NN O
favorable NN NN O
conditions NN NN O
for NN NN O
growth NN NN O
and NN NN O
development NN NN O
in NN NN O
children NN NN O
. NN NN O
   
However NN NN O
, NN NN O
combinations NN NN O
of NN NN O
different NN NN O
therapeutic NN NN O
regimens NN NN O
require NN NN O
consideration NN NN O
of NN NN O
potential NN NN O
adverse NN NN O
reactions NN NN O
. NN NN O
   
We NN NN O
describe NN NN O
a NN NN O
15 NN NN O
- NN NN O
yr NN NN O
- NN NN O
old NN NN O
girl NN NN O
who NN NN O
had NN NN O
orthotopic NN NN O
liver NN NN O
transplantation NN NN O
because NN NN O
of NN NN O
Wilson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
Tacrolimus NN NN O
, NN NN O
MMF NN NN O
, NN NN O
and NN NN O
steroids NN NN O
were NN NN O
given NN NN O
as NN NN O
immunosuppressant NN NN O
. NN NN O
   
Lamivudine NN NN O
was NN NN O
added NN NN O
because NN NN O
of NN NN O
de NN NN O
nova NN NN O
hepatitis NN NN B-Disease
B NN NN I-Disease
infection NN NN I-Disease
during NN NN O
her NN NN O
follow NN NN O
- NN NN O
up NN NN O
. NN NN O
   
Three NN NN O
yr NN NN O
after NN NN O
transplantation NN NN O
she NN NN O
developed NN NN O
renal NN NN B-Disease
Fanconi NN NN I-Disease
syndrome NN NN I-Disease
with NN NN O
severe NN NN O
metabolic NN NN B-Disease
acidosis NN NN I-Disease
, NN NN O
hypophosphatemia NN NN B-Disease
, NN NN O
glycosuria NN NN B-Disease
, NN NN O
and NN NN O
aminoaciduria NN NN B-Disease
. NN NN O
   
Although NN NN O
tacrolimus NN NN O
was NN NN O
suspected NN NN O
to NN NN O
be NN NN O
the NN NN O
cause NN NN O
of NN NN O
late NN NN O
post NN NN O
- NN NN O
transplant NN NN O
renal NN NN O
acidosis NN NN B-Disease
and NN NN O
was NN NN O
replaced NN NN O
by NN NN O
sirolimus NN NN O
, NN NN O
acidosis NN NN B-Disease
, NN NN O
and NN NN O
electrolyte NN NN O
imbalance NN NN O
got NN NN O
worse NN NN O
. NN NN O
   
Proximal NN NN O
muscle NN NN B-Disease
weakness NN NN I-Disease
has NN NN O
developed NN NN O
during NN NN O
her NN NN O
follow NN NN O
- NN NN O
up NN NN O
. NN NN O
   
Fanconi NN NN B-Disease
syndrome NN NN I-Disease
, NN NN O
as NN NN O
well NN NN O
as NN NN O
myopathy NN NN B-Disease
, NN NN O
is NN NN O
well NN NN O
recognized NN NN O
in NN NN O
patients NN NN O
with NN NN O
mitochondrial NN NN B-Disease
disorders NN NN I-Disease
and NN NN O
caused NN NN O
by NN NN O
depletion NN NN O
of NN NN O
mtDNA NN NN O
. NN NN O
   
We NN NN O
suggest NN NN O
that NN NN O
our NN NN O
patient NN NN O
' NN NN O
s NN NN O
tubular NN NN B-Disease
dysfunction NN NN I-Disease
and NN NN O
myopathy NN NN B-Disease
may NN NN O
have NN NN O
resulted NN NN O
from NN NN O
mitochondrial NN NN B-Disease
dysfunction NN NN I-Disease
which NN NN O
is NN NN O
triggered NN NN O
by NN NN O
tacrolimus NN NN O
and NN NN O
augmented NN NN O
by NN NN O
lamivudine NN NN O
. NN NN O
   
Higher NN NN O
optical NN NN O
density NN NN O
of NN NN O
an NN NN O
antigen NN NN O
assay NN NN O
predicts NN NN O
thrombosis NN NN B-Disease
in NN NN O
patients NN NN O
with NN NN O
heparin NN NN O
- NN NN O
induced NN NN O
thrombocytopenia NN NN B-Disease
. NN NN O
   
OBJECTIVES NN NN O
: NN NN O
To NN NN O
correlate NN NN O
optical NN NN O
density NN NN O
and NN NN O
percent NN NN O
inhibition NN NN O
of NN NN O
a NN NN O
two NN NN O
- NN NN O
step NN NN O
heparin NN NN O
- NN NN O
induced NN NN O
thrombocytopenia NN NN B-Disease
( NN NN O
HIT NN NN B-Disease
) NN NN O
antigen NN NN O
assay NN NN O
with NN NN O
thrombosis NN NN B-Disease
; NN NN O
the NN NN O
assay NN NN O
utilizes NN NN O
reaction NN NN O
inhibition NN NN O
characteristics NN NN O
of NN NN O
a NN NN O
high NN NN O
heparin NN NN O
concentration NN NN O
. NN NN O
   
PATIENTS NN NN O
AND NN NN O
METHODS NN NN O
: NN NN O
Patients NN NN O
with NN NN O
more NN NN O
than NN NN O
50 NN NN O
% NN NN O
decrease NN NN O
in NN NN O
platelet NN NN O
count NN NN O
or NN NN O
thrombocytopenia NN NN B-Disease
( NN NN O
< NN NN O
150 NN NN O
x NN NN O
10 NN NN O
( NN NN O
9 NN NN O
) NN NN O
/ NN NN O
L NN NN O
) NN NN O
after NN NN O
exposure NN NN O
to NN NN O
heparin NN NN O
, NN NN O
who NN NN O
had NN NN O
a NN NN O
positive NN NN O
two NN NN O
- NN NN O
step NN NN O
antigen NN NN O
assay NN NN O
[ NN NN O
optical NN NN O
density NN NN O
( NN NN O
OD NN NN O
) NN NN O
> NN NN O
0 NN NN O
. NN NN O
4 NN NN O
and NN NN O
> NN NN O
50 NN NN O
inhibition NN NN O
with NN NN O
high NN NN O
concentration NN NN O
of NN NN O
heparin NN NN O
] NN NN O
were NN NN O
included NN NN O
in NN NN O
the NN NN O
study NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Forty NN NN O
of NN NN O
94 NN NN O
HIT NN NN B-Disease
patients NN NN O
had NN NN O
thrombosis NN NN B-Disease
at NN NN O
diagnosis NN NN O
; NN NN O
54 NN NN O
/ NN NN O
94 NN NN O
had NN NN O
isolated NN NN O
- NN NN O
HIT NN NN B-Disease
without NN NN O
thrombosis NN NN B-Disease
. NN NN O
   
Eight NN NN O
of NN NN O
the NN NN O
isolated NN NN O
- NN NN O
HIT NN NN B-Disease
patients NN NN O
developed NN NN O
thrombosis NN NN B-Disease
within NN NN O
the NN NN O
next NN NN O
30 NN NN O
d NN NN O
; NN NN O
thus NN NN O
, NN NN O
a NN NN O
total NN NN O
of NN NN O
48 NN NN O
patients NN NN O
had NN NN O
thrombosis NN NN B-Disease
at NN NN O
day NN NN O
30 NN NN O
. NN NN O
   
At NN NN O
diagnosis NN NN O
there NN NN O
was NN NN O
no NN NN O
significant NN NN O
difference NN NN O
in NN NN O
OD NN NN O
between NN NN O
HIT NN NN B-Disease
patients NN NN O
with NN NN O
thrombosis NN NN B-Disease
and NN NN O
those NN NN O
with NN NN O
isolated NN NN O
- NN NN O
HIT NN NN B-Disease
. NN NN O
   
However NN NN O
, NN NN O
OD NN NN O
was NN NN O
significantly NN NN O
higher NN NN O
in NN NN O
all NN NN O
patients NN NN O
with NN NN O
thrombosis NN NN B-Disease
( NN NN O
n NN NN O
= NN NN O
48 NN NN O
, NN NN O
1 NN NN O
. NN NN O
34 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
89 NN NN O
) NN NN O
, NN NN O
including NN NN O
isolated NN NN O
- NN NN O
HIT NN NN B-Disease
patients NN NN O
who NN NN O
later NN NN O
developed NN NN O
thrombosis NN NN B-Disease
within NN NN O
30 NN NN O
d NN NN O
( NN NN O
n NN NN O
= NN NN O
8 NN NN O
, NN NN O
1 NN NN O
. NN NN O
84 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
64 NN NN O
) NN NN O
as NN NN O
compared NN NN O
to NN NN O
isolated NN NN O
- NN NN O
HIT NN NN B-Disease
patients NN NN O
who NN NN O
did NN NN O
not NN NN O
develop NN NN O
thrombosis NN NN B-Disease
( NN NN O
0 NN NN O
. NN NN O
96 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
75 NN NN O
; NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
011 NN NN O
and NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
008 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
Receiver NN NN O
Operative NN NN O
Characteristic NN NN O
Curve NN NN O
showed NN NN O
that NN NN O
OD NN NN O
> NN NN O
1 NN NN O
. NN NN O
27 NN NN O
in NN NN O
the NN NN O
isolated NN NN O
- NN NN O
HIT NN NN B-Disease
group NN NN O
had NN NN O
a NN NN O
significantly NN NN O
higher NN NN O
chance NN NN O
of NN NN O
developing NN NN O
thrombosis NN NN B-Disease
by NN NN O
day NN NN O
30 NN NN O
. NN NN O
   
   O
of NN NN O
these NN NN O
groups NN NN O
showed NN NN O
significant NN NN O
difference NN NN O
in NN NN O
percent NN NN O
inhibition NN NN O
. NN NN O
   
Multivariate NN NN O
analysis NN NN O
showed NN NN O
a NN NN O
2 NN NN O
. NN NN O
8 NN NN O
- NN NN O
fold NN NN O
increased NN NN O
risk NN NN O
of NN NN O
thrombosis NN NN B-Disease
in NN NN O
females NN NN O
. NN NN O
   
Similarly NN NN O
, NN NN O
thrombotic NN NN B-Disease
risk NN NN O
increased NN NN O
with NN NN O
age NN NN O
and NN NN O
OD NN NN O
values NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Higher NN NN O
OD NN NN O
is NN NN O
associated NN NN O
with NN NN O
significant NN NN O
risk NN NN O
of NN NN O
subsequent NN NN O
thrombosis NN NN B-Disease
in NN NN O
patients NN NN O
with NN NN O
isolated NN NN O
- NN NN O
HIT NN NN B-Disease
; NN NN O
percent NN NN O
inhibition NN NN O
, NN NN O
however NN NN O
, NN NN O
was NN NN O
not NN NN O
predictive NN NN O
. NN NN O
   
Thalidomide NN NN O
has NN NN O
limited NN NN O
single NN NN O
- NN NN O
agent NN NN O
activity NN NN O
in NN NN O
relapsed NN NN O
or NN NN O
refractory NN NN O
indolent NN NN O
non NN NN B-Disease
- NN NN I-Disease
Hodgkin NN NN I-Disease
lymphomas NN NN I-Disease
: NN NN O
a NN NN O
phase NN NN O
II NN NN O
trial NN NN O
of NN NN O
the NN NN O
Cancer NN NN B-Disease
and NN NN O
Leukemia NN NN B-Disease
Group NN NN O
B NN NN O
. NN NN O
   
Thalidomide NN NN O
is NN NN O
an NN NN O
immunomodulatory NN NN O
agent NN NN O
with NN NN O
demonstrated NN NN O
activity NN NN O
in NN NN O
multiple NN NN B-Disease
myeloma NN NN I-Disease
, NN NN O
mantle NN NN B-Disease
cell NN NN I-Disease
lymphoma NN NN I-Disease
and NN NN O
lymphoplasmacytic NN NN B-Disease
lymphoma NN NN I-Disease
. NN NN O
   
Its NN NN O
activity NN NN O
is NN NN O
believed NN NN O
to NN NN O
be NN NN O
due NN NN O
modulation NN NN O
of NN NN O
the NN NN O
tumour NN NN B-Disease
milieu NN NN O
, NN NN O
including NN NN O
downregulation NN NN O
of NN NN O
angiogenesis NN NN O
and NN NN O
inflammatory NN NN O
cytokines NN NN O
. NN NN O
   
Between NN NN O
July NN NN O
2001 NN NN O
and NN NN O
April NN NN O
2004 NN NN O
, NN NN O
24 NN NN O
patients NN NN O
with NN NN O
relapsed NN NN O
/ NN NN O
refractory NN NN O
indolent NN NN O
lymphomas NN NN B-Disease
received NN NN O
thalidomide NN NN O
200 NN NN O
mg NN NN O
daily NN NN O
with NN NN O
escalation NN NN O
by NN NN O
100 NN NN O
mg NN NN O
daily NN NN O
every NN NN O
1 NN NN O
- NN NN O
2 NN NN O
weeks NN NN O
as NN NN O
tolerated NN NN O
, NN NN O
up NN NN O
to NN NN O
a NN NN O
maximum NN NN O
of NN NN O
800 NN NN O
mg NN NN O
daily NN NN O
. NN NN O
   
Patients NN NN O
had NN NN O
received NN NN O
a NN NN O
median NN NN O
of NN NN O
2 NN NN O
( NN NN O
range NN NN O
, NN NN O
1 NN NN O
- NN NN O
4 NN NN O
) NN NN O
prior NN NN O
regimens NN NN O
. NN NN O
   
Of NN NN O
24 NN NN O
evaluable NN NN O
patients NN NN O
, NN NN O
two NN NN O
achieved NN NN O
a NN NN O
complete NN NN O
remission NN NN O
and NN NN O
one NN NN O
achieved NN NN O
a NN NN O
partial NN NN O
remission NN NN O
for NN NN O
an NN NN O
overall NN NN O
response NN NN O
rate NN NN O
of NN NN O
12 NN NN O
. NN NN O
5 NN NN O
% NN NN O
( NN NN O
95 NN NN O
% NN NN O
confidence NN NN O
interval NN NN O
: NN NN O
2 NN NN O
. NN NN O
6 NN NN O
- NN NN O
32 NN NN O
. NN NN O
4 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
Eleven NN NN O
patients NN NN O
progressed NN NN O
during NN NN O
therapy NN NN O
. NN NN O
   
Grade NN NN O
3 NN NN O
- NN NN O
4 NN NN O
adverse NN NN O
effects NN NN O
included NN NN O
myelosuppression NN NN B-Disease
, NN NN O
fatigue NN NN B-Disease
, NN NN O
somnolence NN NN B-Disease
/ NN NN O
depressed NN NN B-Disease
mood NN NN I-Disease
, NN NN O
neuropathy NN NN B-Disease
and NN NN O
dyspnea NN NN B-Disease
. NN NN O
   
Of NN NN O
concern NN NN O
was NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
four NN NN O
thromboembolic NN NN B-Disease
events NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
failed NN NN O
to NN NN O
demonstrate NN NN O
an NN NN O
important NN NN O
response NN NN O
rate NN NN O
to NN NN O
single NN NN O
agent NN NN O
thalidomide NN NN O
in NN NN O
indolent NN NN O
lymphomas NN NN B-Disease
and NN NN O
contrast NN NN O
with NN NN O
the NN NN O
higher NN NN O
activity NN NN O
level NN NN O
reported NN NN O
with NN NN O
the NN NN O
second NN NN O
generation NN NN O
immunomodulatory NN NN O
agent NN NN O
, NN NN O
lenalidomide NN NN O
. NN NN O
   
Sex NN NN O
differences NN NN O
in NN NN O
NMDA NN NN O
antagonist NN NN O
enhancement NN NN O
of NN NN O
morphine NN NN O
antihyperalgesia NN NN O
in NN NN O
a NN NN O
capsaicin NN NN O
model NN NN O
of NN NN O
persistent NN NN O
pain NN NN B-Disease
: NN NN O
comparisons NN NN O
to NN NN O
two NN NN O
models NN NN O
of NN NN O
acute NN NN B-Disease
pain NN NN I-Disease
. NN NN O
   
In NN NN O
acute NN NN B-Disease
pain NN NN I-Disease
models NN NN O
, NN NN O
N NN NN O
- NN NN O
methyl NN NN O
- NN NN O
D NN NN O
- NN NN O
aspartate NN NN O
( NN NN O
NMDA NN NN O
) NN NN O
antagonists NN NN O
enhance NN NN O
the NN NN O
antinociceptive NN NN O
effects NN NN O
of NN NN O
morphine NN NN O
to NN NN O
a NN NN O
greater NN NN O
extent NN NN O
in NN NN O
males NN NN O
than NN NN O
females NN NN O
. NN NN O
   
The NN NN O
purpose NN NN O
of NN NN O
this NN NN O
investigation NN NN O
was NN NN O
to NN NN O
extend NN NN O
these NN NN O
findings NN NN O
to NN NN O
a NN NN O
persistent NN NN O
pain NN NN B-Disease
model NN NN O
which NN NN O
could NN NN O
be NN NN O
distinguished NN NN O
from NN NN O
acute NN NN B-Disease
pain NN NN I-Disease
models NN NN O
on NN NN O
the NN NN O
basis NN NN O
of NN NN O
the NN NN O
nociceptive NN NN O
fibers NN NN O
activated NN NN O
, NN NN O
neurochemical NN NN O
substrates NN NN O
, NN NN O
and NN NN O
duration NN NN O
of NN NN O
the NN NN O
nociceptive NN NN O
stimulus NN NN O
. NN NN O
   
To NN NN O
this NN NN O
end NN NN O
, NN NN O
persistent NN NN O
hyperalgesia NN NN B-Disease
was NN NN O
induced NN NN O
by NN NN O
administration NN NN O
of NN NN O
capsaicin NN NN O
in NN NN O
the NN NN O
tail NN NN O
of NN NN O
gonadally NN NN O
intact NN NN O
F344 NN NN O
rats NN NN O
, NN NN O
following NN NN O
which NN NN O
the NN NN O
tail NN NN O
was NN NN O
immersed NN NN O
in NN NN O
a NN NN O
mildly NN NN O
noxious NN NN O
thermal NN NN O
stimulus NN NN O
, NN NN O
and NN NN O
tail NN NN O
- NN NN O
withdrawal NN NN O
latencies NN NN O
measured NN NN O
. NN NN O
   
For NN NN O
comparison NN NN O
, NN NN O
tests NN NN O
were NN NN O
conducted NN NN O
in NN NN O
two NN NN O
acute NN NN B-Disease
pain NN NN I-Disease
models NN NN O
, NN NN O
the NN NN O
hotplate NN NN O
and NN NN O
warm NN NN O
water NN NN O
tail NN NN O
- NN NN O
withdrawal NN NN O
procedures NN NN O
. NN NN O
   
In NN NN O
males NN NN O
, NN NN O
the NN NN O
non NN NN O
- NN NN O
competitive NN NN O
NMDA NN NN O
antagonist NN NN O
dextromethorphan NN NN O
enhanced NN NN O
the NN NN O
antihyperalgesic NN NN O
effect NN NN O
of NN NN O
low NN NN O
to NN NN O
moderate NN NN O
doses NN NN O
of NN NN O
morphine NN NN O
in NN NN O
a NN NN O
dose NN NN O
- NN NN O
and NN NN O
time NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
. NN NN O
   
Across NN NN O
the NN NN O
doses NN NN O
and NN NN O
pretreatment NN NN O
times NN NN O
examined NN NN O
, NN NN O
enhancement NN NN O
was NN NN O
not NN NN O
observed NN NN O
in NN NN O
females NN NN O
. NN NN O
   
Enhancement NN NN O
of NN NN O
morphine NN NN O
antinociception NN NN O
by NN NN O
dextromethorphan NN NN O
was NN NN O
seen NN NN O
in NN NN O
both NN NN O
males NN NN O
and NN NN O
females NN NN O
in NN NN O
the NN NN O
acute NN NN B-Disease
pain NN NN I-Disease
models NN NN O
, NN NN O
with NN NN O
the NN NN O
magnitude NN NN O
of NN NN O
this NN NN O
effect NN NN O
being NN NN O
greater NN NN O
in NN NN O
males NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
demonstrate NN NN O
a NN NN O
sexually NN NN O
- NN NN O
dimorphic NN NN O
interaction NN NN O
between NN NN O
NMDA NN NN O
antagonists NN NN O
and NN NN O
morphine NN NN O
in NN NN O
a NN NN O
persistent NN NN O
pain NN NN B-Disease
model NN NN O
that NN NN O
can NN NN O
be NN NN O
distinguished NN NN O
from NN NN O
those NN NN O
observed NN NN O
in NN NN O
acute NN NN B-Disease
pain NN NN I-Disease
models NN NN O
. NN NN O
   
Development NN NN O
of NN NN O
proteinuria NN NN B-Disease
after NN NN O
switch NN NN O
to NN NN O
sirolimus NN NN O
- NN NN O
based NN NN O
immunosuppression NN NN O
in NN NN O
long NN NN O
- NN NN O
term NN NN O
cardiac NN NN O
transplant NN NN O
patients NN NN O
. NN NN O
   
Calcineurin NN NN O
- NN NN O
inhibitor NN NN O
therapy NN NN O
can NN NN O
lead NN NN O
to NN NN O
renal NN NN B-Disease
dysfunction NN NN I-Disease
in NN NN O
heart NN NN O
transplantation NN NN O
patients NN NN O
. NN NN O
   
The NN NN O
novel NN NN O
immunosuppressive NN NN O
( NN NN O
IS NN NN O
) NN NN O
drug NN NN O
sirolmus NN NN O
( NN NN O
Srl NN NN O
) NN NN O
lacks NN NN O
nephrotoxic NN NN B-Disease
effects NN NN O
; NN NN O
however NN NN O
, NN NN O
proteinuria NN NN B-Disease
associated NN NN O
with NN NN O
Srl NN NN O
has NN NN O
been NN NN O
reported NN NN O
following NN NN O
renal NN NN O
transplantation NN NN O
. NN NN O
   
In NN NN O
cardiac NN NN O
transplantation NN NN O
, NN NN O
the NN NN O
incidence NN NN O
of NN NN O
proteinuria NN NN B-Disease
associated NN NN O
with NN NN O
Srl NN NN O
is NN NN O
unknown NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
long NN NN O
- NN NN O
term NN NN O
cardiac NN NN O
transplant NN NN O
patients NN NN O
were NN NN O
switched NN NN O
from NN NN O
cyclosporine NN NN O
to NN NN O
Srl NN NN O
- NN NN O
based NN NN O
IS NN NN O
. NN NN O
   
Concomitant NN NN O
IS NN NN O
consisted NN NN O
of NN NN O
mycophenolate NN NN O
mofetil NN NN O
+ NN NN O
/ NN NN O
- NN NN O
steroids NN NN O
. NN NN O
   
Proteinuria NN NN O
increased NN NN O
significantly NN NN O
from NN NN O
a NN NN O
median NN NN O
of NN NN O
0 NN NN O
. NN NN O
13 NN NN O
g NN NN O
/ NN NN O
day NN NN O
( NN NN O
range NN NN O
0 NN NN O
- NN NN O
5 NN NN O
. NN NN O
7 NN NN O
) NN NN O
preswitch NN NN O
to NN NN O
0 NN NN O
. NN NN O
23 NN NN O
g NN NN O
/ NN NN O
day NN NN O
( NN NN O
0 NN NN O
- NN NN O
9 NN NN O
. NN NN O
88 NN NN O
) NN NN O
at NN NN O
24 NN NN O
months NN NN O
postswitch NN NN O
( NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
0024 NN NN O
) NN NN O
. NN NN O
   
Before NN NN O
the NN NN O
switch NN NN O
, NN NN O
11 NN NN O
. NN NN O
5 NN NN O
% NN NN O
of NN NN O
patients NN NN O
had NN NN O
high NN NN O
- NN NN O
grade NN NN O
proteinuria NN NN B-Disease
( NN NN O
> NN NN O
1 NN NN O
. NN NN O
0 NN NN O
g NN NN O
/ NN NN O
day NN NN O
) NN NN O
; NN NN O
this NN NN O
increased NN NN O
to NN NN O
22 NN NN O
. NN NN O
9 NN NN O
% NN NN O
postswitch NN NN O
( NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
006 NN NN O
) NN NN O
. NN NN O
   
ACE NN NN O
inhibitor NN NN O
and NN NN O
angiotensin NN NN O
- NN NN O
releasing NN NN O
blocker NN NN O
( NN NN O
ARB NN NN O
) NN NN O
therapy NN NN O
reduced NN NN O
proteinuria NN NN B-Disease
development NN NN O
. NN NN O
   
Patients NN NN O
without NN NN O
proteinuria NN NN B-Disease
had NN NN O
increased NN NN O
renal NN NN O
function NN NN O
( NN NN O
median NN NN O
42 NN NN O
. NN NN O
5 NN NN O
vs NN NN O
. NN NN O
64 NN NN O
. NN NN O
1 NN NN O
, NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
25 NN NN O
) NN NN O
, NN NN O
whereas NN NN O
patients NN NN O
who NN NN O
developed NN NN O
high NN NN O
- NN NN O
grade NN NN O
proteinuria NN NN B-Disease
showed NN NN O
decreased NN NN O
renal NN NN O
function NN NN O
at NN NN O
the NN NN O
end NN NN O
of NN NN O
follow NN NN O
- NN NN O
up NN NN O
( NN NN O
median NN NN O
39 NN NN O
. NN NN O
6 NN NN O
vs NN NN O
. NN NN O
29 NN NN O
. NN NN O
2 NN NN O
, NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
125 NN NN O
) NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
proteinuria NN NN B-Disease
may NN NN O
develop NN NN O
in NN NN O
cardiac NN NN O
transplant NN NN O
patients NN NN O
after NN NN O
switch NN NN O
to NN NN O
Srl NN NN O
, NN NN O
which NN NN O
may NN NN O
have NN NN O
an NN NN O
adverse NN NN O
effect NN NN O
on NN NN O
renal NN NN O
function NN NN O
in NN NN O
these NN NN O
patients NN NN O
. NN NN O
   
Srl NN NN O
should NN NN O
be NN NN O
used NN NN O
with NN NN O
ACEi NN NN O
/ NN NN O
ARB NN NN O
therapy NN NN O
and NN NN O
patients NN NN O
monitored NN NN O
for NN NN O
proteinuria NN NN B-Disease
and NN NN O
increased NN NN O
renal NN NN B-Disease
dysfunction NN NN I-Disease
. NN NN O
   
Ginsenoside NN NN O
Rg1 NN NN O
restores NN NN O
the NN NN O
impairment NN NN B-Disease
of NN NN I-Disease
learning NN NN I-Disease
induced NN NN O
by NN NN O
chronic NN NN O
morphine NN NN O
administration NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
Rg1 NN NN O
, NN NN O
as NN NN O
a NN NN O
ginsenoside NN NN O
extracted NN NN O
from NN NN O
Panax NN NN O
ginseng NN NN O
, NN NN O
could NN NN O
ameliorate NN NN O
spatial NN NN O
learning NN NN B-Disease
impairment NN NN I-Disease
. NN NN O
   
Previous NN NN O
studies NN NN O
have NN NN O
demonstrated NN NN O
that NN NN O
Rg1 NN NN O
might NN NN O
be NN NN O
a NN NN O
useful NN NN O
agent NN NN O
for NN NN O
the NN NN O
prevention NN NN O
and NN NN O
treatment NN NN O
of NN NN O
the NN NN O
adverse NN NN O
effects NN NN O
of NN NN O
morphine NN NN O
. NN NN O
   
The NN NN O
aim NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
investigate NN NN O
the NN NN O
effect NN NN O
of NN NN O
Rg1 NN NN O
on NN NN O
learning NN NN B-Disease
impairment NN NN I-Disease
by NN NN O
chronic NN NN O
morphine NN NN O
administration NN NN O
and NN NN O
the NN NN O
mechanism NN NN O
responsible NN NN O
for NN NN O
this NN NN O
effect NN NN O
. NN NN O
   
Male NN NN O
rats NN NN O
were NN NN O
subcutaneously NN NN O
injected NN NN O
with NN NN O
morphine NN NN O
( NN NN O
10 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
twice NN NN O
a NN NN O
day NN NN O
at NN NN O
12 NN NN O
hour NN NN O
intervals NN NN O
for NN NN O
10 NN NN O
days NN NN O
, NN NN O
and NN NN O
Rg1 NN NN O
( NN NN O
30 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
was NN NN O
intraperitoneally NN NN O
injected NN NN O
2 NN NN O
hours NN NN O
after NN NN O
the NN NN O
second NN NN O
injection NN NN O
of NN NN O
morphine NN NN O
once NN NN O
a NN NN O
day NN NN O
for NN NN O
10 NN NN O
days NN NN O
. NN NN O
   
Spatial NN NN O
learning NN NN O
capacity NN NN O
was NN NN O
assessed NN NN O
in NN NN O
the NN NN O
Morris NN NN O
water NN NN O
maze NN NN O
. NN NN O
   
The NN NN O
results NN NN O
showed NN NN O
that NN NN O
rats NN NN O
treated NN NN O
with NN NN O
Morphine NN NN O
/ NN NN O
Rg1 NN NN O
decreased NN NN O
escape NN NN O
latency NN NN O
and NN NN O
increased NN NN O
the NN NN O
time NN NN O
spent NN NN O
in NN NN O
platform NN NN O
quadrant NN NN O
and NN NN O
entering NN NN O
frequency NN NN O
. NN NN O
   
By NN NN O
implantation NN NN O
of NN NN O
electrodes NN NN O
and NN NN O
electrophysiological NN NN O
recording NN NN O
in NN NN O
vivo NN NN O
, NN NN O
the NN NN O
results NN NN O
showed NN NN O
that NN NN O
Rg1 NN NN O
restored NN NN O
the NN NN O
long NN NN O
- NN NN O
term NN NN O
potentiation NN NN O
( NN NN O
LTP NN NN O
) NN NN O
impaired NN NN O
by NN NN O
morphine NN NN O
in NN NN O
both NN NN O
freely NN NN O
moving NN NN O
and NN NN O
anaesthetised NN NN O
rats NN NN O
. NN NN O
   
The NN NN O
electrophysiological NN NN O
recording NN NN O
in NN NN O
vitro NN NN O
showed NN NN O
that NN NN O
Rg1 NN NN O
restored NN NN O
the NN NN O
LTP NN NN O
in NN NN O
slices NN NN O
from NN NN O
the NN NN O
rats NN NN O
treated NN NN O
with NN NN O
morphine NN NN O
, NN NN O
but NN NN O
not NN NN O
changed NN NN O
LTP NN NN O
in NN NN O
the NN NN O
slices NN NN O
from NN NN O
normal NN NN O
saline NN NN O
- NN NN O
or NN NN O
morphine NN NN O
/ NN NN O
Rg1 NN NN O
- NN NN O
treated NN NN O
rats NN NN O
; NN NN O
this NN NN O
restoration NN NN O
could NN NN O
be NN NN O
inhibited NN NN O
by NN NN O
N NN NN O
- NN NN O
methyl NN NN O
- NN NN O
D NN NN O
- NN NN O
aspartate NN NN O
( NN NN O
NMDA NN NN O
) NN NN O
receptor NN NN O
antagonist NN NN O
MK801 NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
Rg1 NN NN O
may NN NN O
significantly NN NN O
improve NN NN O
the NN NN O
spatial NN NN O
learning NN NN O
capacity NN NN O
impaired NN NN O
by NN NN O
chonic NN NN O
morphine NN NN O
administration NN NN O
and NN NN O
restore NN NN O
the NN NN O
morphine NN NN O
- NN NN O
inhibited NN NN O
LTP NN NN O
. NN NN O
   
This NN NN O
effect NN NN O
is NN NN O
NMDA NN NN O
receptor NN NN O
dependent NN NN O
. NN NN O
   
Synthesis NN NN O
of NN NN O
N NN NN O
- NN NN O
pyrimidinyl NN NN O
- NN NN O
2 NN NN O
- NN NN O
phenoxyacetamides NN NN O
as NN NN O
adenosine NN NN O
A2A NN NN O
receptor NN NN O
antagonists NN NN O
. NN NN O
   
A NN NN O
series NN NN O
of NN NN O
N NN NN O
- NN NN O
pyrimidinyl NN NN O
- NN NN O
2 NN NN O
- NN NN O
phenoxyacetamide NN NN O
adenosine NN NN O
A NN NN O
( NN NN O
2A NN NN O
) NN NN O
antagonists NN NN O
is NN NN O
described NN NN O
. NN NN O
   
SAR NN NN O
studies NN NN O
led NN NN O
to NN NN O
compound NN NN O
14 NN NN O
with NN NN O
excellent NN NN O
potency NN NN O
( NN NN O
K NN NN O
( NN NN O
i NN NN O
) NN NN O
= NN NN O
0 NN NN O
. NN NN O
4 NN NN O
nM NN NN O
) NN NN O
, NN NN O
selectivity NN NN O
( NN NN O
A NN NN O
( NN NN O
1 NN NN O
) NN NN O
/ NN NN O
A NN NN O
( NN NN O
2A NN NN O
) NN NN O
> NN NN O
100 NN NN O
) NN NN O
, NN NN O
and NN NN O
efficacy NN NN O
( NN NN O
MED NN NN O
10 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
p NN NN O
. NN NN O
o NN NN O
. NN NN O
) NN NN O
in NN NN O
the NN NN O
rat NN NN O
haloperidol NN NN O
- NN NN O
induced NN NN O
catalepsy NN NN B-Disease
model NN NN O
for NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
Evidence NN NN O
for NN NN O
an NN NN O
involvement NN NN O
of NN NN O
D1 NN NN O
and NN NN O
D2 NN NN O
dopamine NN NN O
receptors NN NN O
in NN NN O
mediating NN NN O
nicotine NN NN O
- NN NN O
induced NN NN O
hyperactivity NN NN B-Disease
in NN NN O
rats NN NN O
. NN NN O
   
Previous NN NN O
studies NN NN O
have NN NN O
suggested NN NN O
that NN NN O
repeated NN NN O
exposure NN NN O
of NN NN O
rats NN NN O
to NN NN O
the NN NN O
drug NN NN O
or NN NN O
to NN NN O
the NN NN O
experimental NN NN O
environment NN NN O
is NN NN O
necessary NN NN O
to NN NN O
observe NN NN O
nicotine NN NN O
- NN NN O
induced NN NN O
locomotor NN NN O
stimulation NN NN O
. NN NN O
   
In NN NN O
the NN NN O
present NN NN O
study NN NN O
the NN NN O
role NN NN O
of NN NN O
habituation NN NN O
to NN NN O
the NN NN O
experimental NN NN O
environment NN NN O
on NN NN O
the NN NN O
stimulant NN NN O
effect NN NN O
of NN NN O
nicotine NN NN O
in NN NN O
rats NN NN O
was NN NN O
examined NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
the NN NN O
role NN NN O
of NN NN O
dopamine NN NN O
receptors NN NN O
in NN NN O
mediating NN NN O
nicotine NN NN O
- NN NN O
induced NN NN O
locomotor NN NN O
stimulation NN NN O
was NN NN O
investigated NN NN O
by NN NN O
examining NN NN O
the NN NN O
effects NN NN O
of NN NN O
selective NN NN O
D1 NN NN O
and NN NN O
D2 NN NN O
dopamine NN NN O
receptor NN NN O
antagonists NN NN O
on NN NN O
activity NN NN O
induced NN NN O
by NN NN O
nicotine NN NN O
. NN NN O
   
Locomotor NN NN O
activity NN NN O
was NN NN O
assessed NN NN O
in NN NN O
male NN NN O
Sprague NN NN O
- NN NN O
Dawley NN NN O
rats NN NN O
tested NN NN O
in NN NN O
photocell NN NN O
cages NN NN O
. NN NN O
   
Nicotine NN NN O
( NN NN O
1 NN NN O
. NN NN O
0 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
caused NN NN O
a NN NN O
significant NN NN O
increase NN NN B-Disease
in NN NN I-Disease
locomotor NN NN I-Disease
activity NN NN I-Disease
in NN NN O
rats NN NN O
that NN NN O
were NN NN O
habituated NN NN O
to NN NN O
the NN NN O
test NN NN O
environment NN NN O
, NN NN O
but NN NN O
had NN NN O
only NN NN O
a NN NN O
weak NN NN O
and NN NN O
delayed NN NN O
stimulant NN NN O
action NN NN O
in NN NN O
rats NN NN O
that NN NN O
were NN NN O
unfamiliar NN NN O
with NN NN O
the NN NN O
test NN NN O
environment NN NN O
. NN NN O
   
The NN NN O
stimulant NN NN O
action NN NN O
of NN NN O
nicotine NN NN O
was NN NN O
blocked NN NN O
by NN NN O
the NN NN O
central NN NN O
nicotinic NN NN O
antagonist NN NN O
mecamylamine NN NN O
but NN NN O
not NN NN O
by NN NN O
the NN NN O
peripheral NN NN O
nicotinic NN NN O
blocker NN NN O
hexamethonium NN NN O
, NN NN O
indicating NN NN O
that NN NN O
the NN NN O
response NN NN O
is NN NN O
probably NN NN O
mediated NN NN O
by NN NN O
central NN NN O
nicotinic NN NN O
receptors NN NN O
. NN NN O
   
Nicotine NN NN O
- NN NN O
induced NN NN O
hyperactivity NN NN B-Disease
was NN NN O
blocked NN NN O
by NN NN O
the NN NN O
selective NN NN O
D1 NN NN O
antagonist NN NN O
SCH NN NN O
23390 NN NN O
, NN NN O
the NN NN O
selective NN NN O
D2 NN NN O
antagonist NN NN O
raclopride NN NN O
and NN NN O
the NN NN O
D1 NN NN O
/ NN NN O
D2 NN NN O
antagonist NN NN O
fluphenazine NN NN O
. NN NN O
   
Pretreatment NN NN O
with NN NN O
the NN NN O
D2 NN NN O
agonist NN NN O
PHNO NN NN O
enhanced NN NN O
nicotine NN NN O
- NN NN O
induced NN NN O
hyperactivity NN NN B-Disease
, NN NN O
whereas NN NN O
the NN NN O
D1 NN NN O
agonist NN NN O
SKF NN NN O
38393 NN NN O
had NN NN O
no NN NN O
effect NN NN O
. NN NN O
   
The NN NN O
results NN NN O
indicate NN NN O
that NN NN O
acute NN NN O
nicotine NN NN O
injection NN NN O
induces NN NN O
a NN NN O
pronounced NN NN O
hyperactivity NN NN B-Disease
in NN NN O
rats NN NN O
habituated NN NN O
to NN NN O
the NN NN O
test NN NN O
environment NN NN O
. NN NN O
   
The NN NN O
effect NN NN O
appears NN NN O
to NN NN O
be NN NN O
mediated NN NN O
by NN NN O
central NN NN O
nicotine NN NN O
receptors NN NN O
, NN NN O
possibly NN NN O
located NN NN O
on NN NN O
dopaminergic NN NN O
neurons NN NN O
, NN NN O
and NN NN O
also NN NN O
requires NN NN O
the NN NN O
activation NN NN O
of NN NN O
both NN NN O
D1 NN NN O
and NN NN O
D2 NN NN O
dopamine NN NN O
receptors NN NN O
. NN NN O
   
Central NN NN O
retinal NN NN B-Disease
vein NN NN I-Disease
occlusion NN NN I-Disease
associated NN NN O
with NN NN O
clomiphene NN NN O
- NN NN O
induced NN NN O
ovulation NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
To NN NN O
report NN NN O
a NN NN O
case NN NN O
of NN NN O
central NN NN O
retinal NN NN B-Disease
vein NN NN I-Disease
occlusion NN NN I-Disease
associated NN NN O
with NN NN O
clomiphene NN NN O
citrate NN NN O
( NN NN O
CC NN NN O
) NN NN O
. NN NN O
   
DESIGN NN NN O
: NN NN O
Case NN NN O
study NN NN O
. NN NN O
   
SETTING NN NN O
: NN NN O
Ophthalmology NN NN O
clinic NN NN O
of NN NN O
an NN NN O
academic NN NN O
hospital NN NN O
. NN NN O
   
PATIENT NN NN O
( NN NN O
S NN NN O
) NN NN O
: NN NN O
A NN NN O
36 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
woman NN NN O
referred NN NN O
from NN NN O
the NN NN O
infertility NN NN B-Disease
clinic NN NN O
for NN NN O
blurred NN NN B-Disease
vision NN NN I-Disease
. NN NN O
   
INTERVENTION NN NN O
( NN NN O
S NN NN O
) NN NN O
: NN NN O
Ophthalmic NN NN O
examination NN NN O
after NN NN O
CC NN NN O
therapy NN NN O
. NN NN O
   
MAIN NN NN O
OUTCOME NN NN O
MEASURE NN NN O
( NN NN O
S NN NN O
) NN NN O
: NN NN O
Central NN NN O
retinal NN NN B-Disease
vein NN NN I-Disease
occlusion NN NN I-Disease
after NN NN O
ovulation NN NN O
induction NN NN O
with NN NN O
CC NN NN O
. NN NN O
   
RESULT NN NN O
( NN NN O
S NN NN O
) NN NN O
: NN NN O
A NN NN O
36 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
Chinese NN NN O
woman NN NN O
developed NN NN O
central NN NN O
retinal NN NN B-Disease
vein NN NN I-Disease
occlusion NN NN I-Disease
after NN NN O
eight NN NN O
courses NN NN O
of NN NN O
CC NN NN O
. NN NN O
   
A NN NN O
search NN NN O
of NN NN O
the NN NN O
literature NN NN O
on NN NN O
the NN NN O
thromboembolic NN NN B-Disease
complications NN NN O
of NN NN O
CC NN NN O
does NN NN O
not NN NN O
include NN NN O
this NN NN O
severe NN NN O
ophthalmic NN NN O
complication NN NN O
, NN NN O
although NN NN O
mild NN NN O
visual NN NN B-Disease
disturbance NN NN I-Disease
after NN NN O
CC NN NN O
intake NN NN O
is NN NN O
not NN NN O
uncommon NN NN O
. NN NN O
   
CONCLUSION NN NN O
( NN NN O
S NN NN O
) NN NN O
: NN NN O
This NN NN O
is NN NN O
the NN NN O
first NN NN O
reported NN NN O
case NN NN O
of NN NN O
central NN NN O
retinal NN NN B-Disease
vein NN NN I-Disease
occlusion NN NN I-Disease
after NN NN O
treatment NN NN O
with NN NN O
CC NN NN O
. NN NN O
   
Extra NN NN O
caution NN NN O
is NN NN O
warranted NN NN O
in NN NN O
treating NN NN O
infertility NN NN B-Disease
patients NN NN O
with NN NN O
CC NN NN O
, NN NN O
and NN NN O
patients NN NN O
should NN NN O
be NN NN O
well NN NN O
informed NN NN O
of NN NN O
this NN NN O
side NN NN O
effect NN NN O
before NN NN O
commencement NN NN O
of NN NN O
therapy NN NN O
. NN NN O
   
Acute NN NN O
bronchodilating NN NN O
effects NN NN O
of NN NN O
ipratropium NN NN O
bromide NN NN O
and NN NN O
theophylline NN NN O
in NN NN O
chronic NN NN B-Disease
obstructive NN NN I-Disease
pulmonary NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
The NN NN O
bronchodilator NN NN O
effects NN NN O
of NN NN O
a NN NN O
single NN NN O
dose NN NN O
of NN NN O
ipratropium NN NN O
bromide NN NN O
aerosol NN NN O
( NN NN O
36 NN NN O
micrograms NN NN O
) NN NN O
and NN NN O
short NN NN O
- NN NN O
acting NN NN O
theophylline NN NN O
tablets NN NN O
( NN NN O
dose NN NN O
titrated NN NN O
to NN NN O
produce NN NN O
serum NN NN O
levels NN NN O
of NN NN O
10 NN NN O
- NN NN O
20 NN NN O
micrograms NN NN O
/ NN NN O
mL NN NN O
) NN NN O
were NN NN O
compared NN NN O
in NN NN O
a NN NN O
double NN NN O
- NN NN O
blind NN NN O
, NN NN O
placebo NN NN O
- NN NN O
controlled NN NN O
crossover NN NN O
study NN NN O
in NN NN O
21 NN NN O
patients NN NN O
with NN NN O
stable NN NN O
, NN NN O
chronic NN NN B-Disease
obstructive NN NN I-Disease
pulmonary NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
Mean NN NN O
peak NN NN O
forced NN NN O
expiratory NN NN O
volume NN NN O
in NN NN O
1 NN NN O
second NN NN O
( NN NN O
FEV1 NN NN O
) NN NN O
increases NN NN O
over NN NN O
baseline NN NN O
and NN NN O
the NN NN O
proportion NN NN O
of NN NN O
patients NN NN O
attaining NN NN O
at NN NN O
least NN NN O
a NN NN O
15 NN NN O
% NN NN O
increase NN NN O
in NN NN O
the NN NN O
FEV1 NN NN O
( NN NN O
responders NN NN O
) NN NN O
were NN NN O
31 NN NN O
% NN NN O
and NN NN O
90 NN NN O
% NN NN O
, NN NN O
respectively NN NN O
, NN NN O
for NN NN O
ipratropium NN NN O
and NN NN O
17 NN NN O
% NN NN O
and NN NN O
50 NN NN O
% NN NN O
, NN NN O
respectively NN NN O
, NN NN O
for NN NN O
theophylline NN NN O
. NN NN O
   
The NN NN O
average NN NN O
FEV1 NN NN O
increases NN NN O
during NN NN O
the NN NN O
6 NN NN O
- NN NN O
hour NN NN O
observation NN NN O
period NN NN O
were NN NN O
18 NN NN O
% NN NN O
for NN NN O
ipratropium NN NN O
and NN NN O
8 NN NN O
% NN NN O
for NN NN O
theophylline NN NN O
. NN NN O
   
The NN NN O
mean NN NN O
duration NN NN O
of NN NN O
action NN NN O
was NN NN O
3 NN NN O
. NN NN O
8 NN NN O
hours NN NN O
with NN NN O
ipratropium NN NN O
and NN NN O
2 NN NN O
. NN NN O
4 NN NN O
hours NN NN O
with NN NN O
theophylline NN NN O
. NN NN O
   
While NN NN O
side NN NN O
effects NN NN O
were NN NN O
rare NN NN O
, NN NN O
those NN NN O
experienced NN NN O
after NN NN O
theophylline NN NN O
use NN NN O
did NN NN O
involve NN NN O
the NN NN O
cardiovascular NN NN B-Disease
and NN NN I-Disease
gastrointestinal NN NN I-Disease
systems NN NN I-Disease
. NN NN O
   
These NN NN O
results NN NN O
show NN NN O
that NN NN O
ipratropium NN NN O
is NN NN O
a NN NN O
more NN NN O
potent NN NN O
bronchodilator NN NN O
than NN NN O
oral NN NN O
theophylline NN NN O
in NN NN O
patients NN NN O
with NN NN O
chronic NN NN B-Disease
airflow NN NN I-Disease
obstruction NN NN I-Disease
. NN NN O
   
Methamphetamine NN NN O
- NN NN O
induced NN NN O
neurotoxicity NN NN B-Disease
and NN NN O
microglial NN NN O
activation NN NN O
are NN NN O
not NN NN O
mediated NN NN O
by NN NN O
fractalkine NN NN O
receptor NN NN O
signaling NN NN O
. NN NN O
   
Methamphetamine NN NN O
( NN NN O
METH NN NN O
) NN NN O
damages NN NN O
dopamine NN NN O
( NN NN O
DA NN NN O
) NN NN O
nerve NN NN O
endings NN NN O
by NN NN O
a NN NN O
process NN NN O
that NN NN O
has NN NN O
been NN NN O
linked NN NN O
to NN NN O
microglial NN NN O
activation NN NN O
but NN NN O
the NN NN O
signaling NN NN O
pathways NN NN O
that NN NN O
mediate NN NN O
this NN NN O
response NN NN O
have NN NN O
not NN NN O
yet NN NN O
been NN NN O
delineated NN NN O
. NN NN O
   
Cardona NN NN O
et NN NN O
al NN NN O
. NN NN O
   
[ NN NN O
Nat NN NN O
. NN NN O
Neurosci NN NN O
. NN NN O
9 NN NN O
( NN NN O
2006 NN NN O
) NN NN O
, NN NN O
917 NN NN O
] NN NN O
recently NN NN O
identified NN NN O
the NN NN O
microglial NN NN O
- NN NN O
specific NN NN O
fractalkine NN NN O
receptor NN NN O
( NN NN O
CX3CR1 NN NN O
) NN NN O
as NN NN O
an NN NN O
important NN NN O
mediator NN NN O
of NN NN O
MPTP NN NN O
- NN NN O
induced NN NN O
neurodegeneration NN NN B-Disease
of NN NN O
DA NN NN O
neurons NN NN O
. NN NN O
   
Because NN NN O
the NN NN O
CNS NN NN B-Disease
damage NN NN I-Disease
caused NN NN O
by NN NN O
METH NN NN O
and NN NN O
MPTP NN NN O
is NN NN O
highly NN NN O
selective NN NN O
for NN NN O
the NN NN O
DA NN NN O
neuronal NN NN O
system NN NN O
in NN NN O
mouse NN NN O
models NN NN O
of NN NN O
neurotoxicity NN NN B-Disease
, NN NN O
we NN NN O
hypothesized NN NN O
that NN NN O
the NN NN O
CX3CR1 NN NN O
plays NN NN O
a NN NN O
role NN NN O
in NN NN O
METH NN NN O
- NN NN O
induced NN NN O
neurotoxicity NN NN B-Disease
and NN NN O
microglial NN NN O
activation NN NN O
. NN NN O
   
Mice NN NN O
in NN NN O
which NN NN O
the NN NN O
CX3CR1 NN NN O
gene NN NN O
has NN NN O
been NN NN O
deleted NN NN O
and NN NN O
replaced NN NN O
with NN NN O
a NN NN O
cDNA NN NN O
encoding NN NN O
enhanced NN NN O
green NN NN O
fluorescent NN NN O
protein NN NN O
( NN NN O
eGFP NN NN O
) NN NN O
were NN NN O
treated NN NN O
with NN NN O
METH NN NN O
and NN NN O
examined NN NN O
for NN NN O
striatal NN NN O
neurotoxicity NN NN B-Disease
. NN NN O
   
METH NN NN O
depleted NN NN O
DA NN NN O
, NN NN O
caused NN NN O
microglial NN NN O
activation NN NN O
, NN NN O
and NN NN O
increased NN NN O
body NN NN O
temperature NN NN O
in NN NN O
CX3CR1 NN NN O
knockout NN NN O
mice NN NN O
to NN NN O
the NN NN O
same NN NN O
extent NN NN O
and NN NN O
over NN NN O
the NN NN O
same NN NN O
time NN NN O
course NN NN O
seen NN NN O
in NN NN O
wild NN NN O
- NN NN O
type NN NN O
controls NN NN O
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
METH NN NN O
in NN NN O
CX3CR1 NN NN O
knockout NN NN O
mice NN NN O
were NN NN O
not NN NN O
gender NN NN O
- NN NN O
dependent NN NN O
and NN NN O
did NN NN O
not NN NN O
extend NN NN O
beyond NN NN O
the NN NN O
striatum NN NN O
. NN NN O
   
Striatal NN NN O
microglia NN NN O
expressing NN NN O
eGFP NN NN O
constitutively NN NN O
show NN NN O
morphological NN NN O
changes NN NN O
after NN NN O
METH NN NN O
that NN NN O
are NN NN O
characteristic NN NN O
of NN NN O
activation NN NN O
. NN NN O
   
This NN NN O
response NN NN O
was NN NN O
restricted NN NN O
to NN NN O
the NN NN O
striatum NN NN O
and NN NN O
contrasted NN NN O
sharply NN NN O
with NN NN O
unresponsive NN NN O
eGFP NN NN O
- NN NN O
microglia NN NN O
in NN NN O
surrounding NN NN O
brain NN NN O
areas NN NN O
that NN NN O
are NN NN O
not NN NN O
damaged NN NN O
by NN NN O
METH NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
from NN NN O
these NN NN O
studies NN NN O
that NN NN O
CX3CR1 NN NN O
signaling NN NN O
does NN NN O
not NN NN O
modulate NN NN O
METH NN NN O
neurotoxicity NN NN B-Disease
or NN NN O
microglial NN NN O
activation NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
it NN NN O
appears NN NN O
that NN NN O
striatal NN NN O
- NN NN O
resident NN NN O
microglia NN NN O
respond NN NN O
to NN NN O
METH NN NN O
with NN NN O
an NN NN O
activation NN NN O
cascade NN NN O
and NN NN O
then NN NN O
return NN NN O
to NN NN O
a NN NN O
surveying NN NN O
state NN NN O
without NN NN O
undergoing NN NN O
apoptosis NN NN O
or NN NN O
migration NN NN O
. NN NN O
   
Nicotine NN NN O
- NN NN O
induced NN NN O
nystagmus NN NN B-Disease
correlates NN NN O
with NN NN O
midpontine NN NN O
activation NN NN O
. NN NN O
   
The NN NN O
pathomechanism NN NN O
of NN NN O
nicotine NN NN O
- NN NN O
induced NN NN O
nystagmus NN NN B-Disease
( NN NN O
NIN NN NN B-Disease
) NN NN O
is NN NN O
unknown NN NN O
. NN NN O
   
The NN NN O
aim NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
delineate NN NN O
brain NN NN O
structures NN NN O
that NN NN O
are NN NN O
involved NN NN O
in NN NN O
NIN NN NN B-Disease
generation NN NN O
. NN NN O
   
Eight NN NN O
healthy NN NN O
volunteers NN NN O
inhaled NN NN O
nicotine NN NN O
in NN NN O
darkness NN NN O
during NN NN O
a NN NN O
functional NN NN O
magnetic NN NN O
resonance NN NN O
imaging NN NN O
( NN NN O
fMRI NN NN O
) NN NN O
experiment NN NN O
; NN NN O
eye NN NN O
movements NN NN O
were NN NN O
registered NN NN O
using NN NN O
video NN NN O
- NN NN O
oculography NN NN O
. NN NN O
   
NIN NN NN B-Disease
correlated NN NN O
with NN NN O
blood NN NN O
oxygen NN NN O
level NN NN O
- NN NN O
dependent NN NN O
( NN NN O
BOLD NN NN O
) NN NN O
activity NN NN O
levels NN NN O
in NN NN O
a NN NN O
midpontine NN NN O
site NN NN O
in NN NN O
the NN NN O
posterior NN NN O
basis NN NN O
pontis NN NN O
. NN NN O
   
NIN NN NN B-Disease
- NN NN O
induced NN NN O
midpontine NN NN O
activation NN NN O
may NN NN O
correspond NN NN O
to NN NN O
activation NN NN O
of NN NN O
the NN NN O
dorsomedial NN NN O
pontine NN NN O
nuclei NN NN O
and NN NN O
the NN NN O
nucleus NN NN O
reticularis NN NN O
tegmenti NN NN O
pontis NN NN O
, NN NN O
structures NN NN O
known NN NN O
to NN NN O
participate NN NN O
in NN NN O
the NN NN O
generation NN NN O
of NN NN O
multidirectional NN NN O
saccades NN NN O
and NN NN O
smooth NN NN O
pursuit NN NN O
eye NN NN O
movements NN NN O
. NN NN O
   
Acute NN NN O
effects NN NN O
of NN NN O
N NN NN O
- NN NN O
( NN NN O
2 NN NN O
- NN NN O
propylpentanoyl NN NN O
) NN NN O
urea NN NN O
on NN NN O
hippocampal NN NN O
amino NN NN O
acid NN NN O
neurotransmitters NN NN O
in NN NN O
pilocarpine NN NN O
- NN NN O
induced NN NN O
seizure NN NN B-Disease
in NN NN O
rats NN NN O
. NN NN O
   
The NN NN O
present NN NN O
study NN NN O
aimed NN NN O
to NN NN O
investigate NN NN O
the NN NN O
anticonvulsant NN NN O
activity NN NN O
as NN NN O
well NN NN O
as NN NN O
the NN NN O
effects NN NN O
on NN NN O
the NN NN O
level NN NN O
of NN NN O
hippocampal NN NN O
amino NN NN O
acid NN NN O
neurotransmitters NN NN O
( NN NN O
glutamate NN NN O
, NN NN O
aspartate NN NN O
, NN NN O
glycine NN NN O
and NN NN O
GABA NN NN O
) NN NN O
of NN NN O
N NN NN O
- NN NN O
( NN NN O
2 NN NN O
- NN NN O
propylpentanoyl NN NN O
) NN NN O
urea NN NN O
( NN NN O
VPU NN NN O
) NN NN O
in NN NN O
comparison NN NN O
to NN NN O
its NN NN O
parent NN NN O
compound NN NN O
, NN NN O
valproic NN NN O
acid NN NN O
( NN NN O
VPA NN NN O
) NN NN O
. NN NN O
   
VPU NN NN O
was NN NN O
more NN NN O
potent NN NN O
than NN NN O
VPA NN NN O
, NN NN O
exhibiting NN NN O
the NN NN O
median NN NN O
effective NN NN O
dose NN NN O
( NN NN O
ED NN NN O
( NN NN O
50 NN NN O
) NN NN O
) NN NN O
of NN NN O
49 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
in NN NN O
protecting NN NN O
rats NN NN O
against NN NN O
pilocarpine NN NN O
- NN NN O
induced NN NN O
seizure NN NN B-Disease
whereas NN NN O
the NN NN O
corresponding NN NN O
value NN NN O
for NN NN O
VPA NN NN O
was NN NN O
322 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
. NN NN O
   
In NN NN O
vivo NN NN O
microdialysis NN NN O
demonstrated NN NN O
that NN NN O
an NN NN O
intraperitoneal NN NN O
administration NN NN O
of NN NN O
pilocarpine NN NN O
induced NN NN O
a NN NN O
pronounced NN NN O
increment NN NN O
of NN NN O
hippocampal NN NN O
glutamate NN NN O
and NN NN O
aspartate NN NN O
whereas NN NN O
no NN NN O
significant NN NN O
change NN NN O
was NN NN O
observed NN NN O
on NN NN O
the NN NN O
level NN NN O
of NN NN O
glycine NN NN O
and NN NN O
GABA NN NN O
. NN NN O
   
Pretreatment NN NN O
with NN NN O
either NN NN O
VPU NN NN O
( NN NN O
50 NN NN O
and NN NN O
100 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
or NN NN O
VPA NN NN O
( NN NN O
300 NN NN O
and NN NN O
600 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
completely NN NN O
abolished NN NN O
pilocarpine NN NN O
- NN NN O
evoked NN NN O
increases NN NN O
in NN NN O
extracellular NN NN O
glutamate NN NN O
and NN NN O
aspartate NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
a NN NN O
statistically NN NN O
significant NN NN O
reduction NN NN O
was NN NN O
also NN NN O
observed NN NN O
on NN NN O
the NN NN O
level NN NN O
of NN NN O
GABA NN NN O
and NN NN O
glycine NN NN O
but NN NN O
less NN NN O
than NN NN O
a NN NN O
drastic NN NN O
reduction NN NN O
of NN NN O
glutamate NN NN O
and NN NN O
aspartate NN NN O
level NN NN O
. NN NN O
   
Based NN NN O
on NN NN O
the NN NN O
finding NN NN O
that NN NN O
VPU NN NN O
and NN NN O
VPA NN NN O
could NN NN O
protect NN NN O
the NN NN O
animals NN NN O
against NN NN O
pilocarpine NN NN O
- NN NN O
induced NN NN O
seizure NN NN B-Disease
it NN NN O
is NN NN O
suggested NN NN O
that NN NN O
the NN NN O
reduction NN NN O
of NN NN O
inhibitory NN NN O
amino NN NN O
acid NN NN O
neurotransmitters NN NN O
was NN NN O
comparatively NN NN O
minor NN NN O
and NN NN O
offset NN NN O
by NN NN O
a NN NN O
pronounced NN NN O
reduction NN NN O
of NN NN O
glutamate NN NN O
and NN NN O
aspartate NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
like NN NN O
VPA NN NN O
, NN NN O
the NN NN O
finding NN NN O
that NN NN O
VPU NN NN O
could NN NN O
drastically NN NN O
reduce NN NN O
pilocarpine NN NN O
- NN NN O
induced NN NN O
increases NN NN O
in NN NN O
glutamate NN NN O
and NN NN O
aspartate NN NN O
should NN NN O
account NN NN O
, NN NN O
at NN NN O
least NN NN O
partly NN NN O
, NN NN O
for NN NN O
its NN NN O
anticonvulsant NN NN O
activity NN NN O
observed NN NN O
in NN NN O
pilocarpine NN NN O
- NN NN O
induced NN NN O
seizure NN NN B-Disease
in NN NN O
experimental NN NN O
animals NN NN O
. NN NN O
   
Some NN NN O
other NN NN O
mechanism NN NN O
than NN NN O
those NN NN O
being NN NN O
reported NN NN O
herein NN NN O
should NN NN O
be NN NN O
further NN NN O
investigated NN NN O
. NN NN O
   
Protective NN NN O
effect NN NN O
of NN NN O
verapamil NN NN O
on NN NN O
gastric NN NN B-Disease
hemorrhagic NN NN I-Disease
ulcers NN NN B-Disease
in NN NN O
severe NN NN O
atherosclerotic NN NN B-Disease
rats NN NN O
. NN NN O
   
Studies NN NN O
concerning NN NN O
with NN NN O
pathogenesis NN NN O
of NN NN O
gastric NN NN B-Disease
hemorrhage NN NN I-Disease
and NN NN O
mucosal NN NN O
ulceration NN NN O
produced NN NN O
in NN NN O
atherosclerotic NN NN B-Disease
rats NN NN O
are NN NN O
lacking NN NN O
. NN NN O
   
The NN NN O
aim NN NN O
of NN NN O
this NN NN O
study NN NN O
is NN NN O
to NN NN O
examine NN NN O
the NN NN O
role NN NN O
of NN NN O
gastric NN NN O
acid NN NN O
back NN NN O
- NN NN O
diffusion NN NN O
, NN NN O
mast NN NN O
cell NN NN O
histamine NN NN O
release NN NN O
, NN NN O
lipid NN NN O
peroxide NN NN O
( NN NN O
LPO NN NN O
) NN NN O
generation NN NN O
and NN NN O
mucosal NN NN O
microvascular NN NN O
permeability NN NN O
in NN NN O
modulating NN NN O
gastric NN NN B-Disease
hemorrhage NN NN I-Disease
and NN NN O
ulcer NN NN B-Disease
in NN NN O
rats NN NN O
with NN NN O
atherosclerosis NN NN B-Disease
induced NN NN O
by NN NN O
coadministration NN NN O
of NN NN O
vitamin NN NN O
D2 NN NN O
and NN NN O
cholesterol NN NN O
. NN NN O
   
Additionally NN NN O
, NN NN O
the NN NN O
protective NN NN O
effect NN NN O
of NN NN O
verapamil NN NN O
on NN NN O
this NN NN O
ulcer NN NN B-Disease
model NN NN O
was NN NN O
evaluated NN NN O
. NN NN O
   
Male NN NN O
Wistar NN NN O
rats NN NN O
were NN NN O
challenged NN NN O
intragastrically NN NN O
once NN NN O
daily NN NN O
for NN NN O
9 NN NN O
days NN NN O
with NN NN O
1 NN NN O
. NN NN O
0 NN NN O
ml NN NN O
/ NN NN O
kg NN NN O
of NN NN O
corn NN NN O
oil NN NN O
containing NN NN O
vitamin NN NN O
D2 NN NN O
and NN NN O
cholesterol NN NN O
to NN NN O
induce NN NN O
atherosclerosis NN NN B-Disease
. NN NN O
   
Control NN NN O
rats NN NN O
received NN NN O
corn NN NN O
oil NN NN O
only NN NN O
. NN NN O
   
After NN NN O
gastric NN NN O
surgery NN NN O
, NN NN O
rat NN NN O
stomachs NN NN O
were NN NN O
irrigated NN NN O
for NN NN O
3 NN NN O
h NN NN O
with NN NN O
either NN NN O
simulated NN NN O
gastric NN NN O
juice NN NN O
or NN NN O
normal NN NN O
saline NN NN O
. NN NN O
   
Gastric NN NN O
acid NN NN O
back NN NN O
- NN NN O
diffusion NN NN O
, NN NN O
mucosal NN NN O
LPO NN NN O
generation NN NN O
, NN NN O
histamine NN NN O
concentration NN NN O
, NN NN O
microvascular NN NN O
permeability NN NN O
, NN NN O
luminal NN NN O
hemoglobin NN NN O
content NN NN O
and NN NN O
ulcer NN NN B-Disease
areas NN NN O
were NN NN O
determined NN NN O
. NN NN O
   
Elevated NN NN O
atherosclerotic NN NN B-Disease
parameters NN NN O
, NN NN O
such NN NN O
as NN NN O
serum NN NN O
calcium NN NN O
, NN NN O
total NN NN O
cholesterol NN NN O
and NN NN O
low NN NN O
- NN NN O
density NN NN O
lipoprotein NN NN O
concentration NN NN O
were NN NN O
obtained NN NN O
in NN NN O
atherosclerotic NN NN B-Disease
rats NN NN O
. NN NN O
   
Severe NN NN O
gastric NN NN O
ulcers NN NN B-Disease
accompanied NN NN O
with NN NN O
increased NN NN O
ulcerogenic NN NN O
factors NN NN O
, NN NN O
including NN NN O
gastric NN NN O
acid NN NN O
back NN NN O
- NN NN O
diffusion NN NN O
, NN NN O
histamine NN NN O
release NN NN O
, NN NN O
LPO NN NN O
generation NN NN O
and NN NN O
luminal NN NN O
hemoglobin NN NN O
content NN NN O
were NN NN O
also NN NN O
observed NN NN O
in NN NN O
these NN NN O
rats NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
a NN NN O
positive NN NN O
correlation NN NN O
of NN NN O
histamine NN NN O
to NN NN O
gastric NN NN B-Disease
hemorrhage NN NN I-Disease
and NN NN O
to NN NN O
ulcer NN NN B-Disease
was NN NN O
found NN NN O
in NN NN O
those NN NN O
atherosclerotic NN NN B-Disease
rats NN NN O
. NN NN O
   
This NN NN O
hemorrhagic NN NN B-Disease
ulcer NN NN B-Disease
and NN NN O
various NN NN O
ulcerogenic NN NN O
parameters NN NN O
were NN NN O
dose NN NN O
- NN NN O
dependently NN NN O
ameliorated NN NN O
by NN NN O
daily NN NN O
intragastric NN NN O
verapamil NN NN O
. NN NN O
   
Atherosclerosis NN NN B-Disease
could NN NN O
produce NN NN O
gastric NN NN B-Disease
hemorrhagic NN NN I-Disease
ulcer NN NN B-Disease
via NN NN O
aggravation NN NN O
of NN NN O
gastric NN NN O
acid NN NN O
back NN NN O
- NN NN O
diffusion NN NN O
, NN NN O
LPO NN NN O
generation NN NN O
, NN NN O
histamine NN NN O
release NN NN O
and NN NN O
microvascular NN NN O
permeability NN NN O
that NN NN O
could NN NN O
be NN NN O
ameliorated NN NN O
by NN NN O
verapamil NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
Lamivudine NN NN O
for NN NN O
the NN NN O
prevention NN NN O
of NN NN O
hepatitis NN NN B-Disease
B NN NN I-Disease
virus NN NN O
reactivation NN NN O
in NN NN O
hepatitis NN NN O
- NN NN O
B NN NN O
surface NN NN O
antigen NN NN O
( NN NN O
HBSAG NN NN O
) NN NN O
seropositive NN NN O
cancer NN NN B-Disease
patients NN NN O
undergoing NN NN O
cytotoxic NN NN O
chemotherapy NN NN O
. NN NN O
   
Hepatitis NN NN B-Disease
B NN NN I-Disease
virus NN NN O
( NN NN O
HBV NN NN O
) NN NN O
is NN NN O
one NN NN O
of NN NN O
the NN NN O
major NN NN O
causes NN NN O
of NN NN O
chronic NN NN O
liver NN NN B-Disease
disease NN NN I-Disease
worldwide NN NN O
. NN NN O
   
Cancer NN NN B-Disease
patients NN NN O
who NN NN O
are NN NN O
chronic NN NN O
carriers NN NN O
of NN NN O
HBV NN NN O
have NN NN O
a NN NN O
higher NN NN O
hepatic NN NN B-Disease
complication NN NN I-Disease
rate NN NN O
while NN NN O
receiving NN NN O
cytotoxic NN NN O
chemotherapy NN NN O
( NN NN O
CT NN NN O
) NN NN O
and NN NN O
this NN NN O
has NN NN O
mainly NN NN O
been NN NN O
attributed NN NN O
to NN NN O
HBV NN NN O
reactivation NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
cancer NN NN B-Disease
patients NN NN O
who NN NN O
have NN NN O
solid NN NN O
and NN NN O
hematological NN NN B-Disease
malignancies NN NN I-Disease
with NN NN O
chronic NN NN O
HBV NN NN B-Disease
infection NN NN I-Disease
received NN NN O
the NN NN O
antiviral NN NN O
agent NN NN O
lamivudine NN NN O
prior NN NN O
and NN NN O
during NN NN O
CT NN NN O
compared NN NN O
with NN NN O
historical NN NN O
control NN NN O
group NN NN O
who NN NN O
did NN NN O
not NN NN O
receive NN NN O
lamivudine NN NN O
. NN NN O
   
The NN NN O
objectives NN NN O
were NN NN O
to NN NN O
assess NN NN O
the NN NN O
efficacy NN NN O
of NN NN O
lamivudine NN NN O
in NN NN O
reducing NN NN O
the NN NN O
incidence NN NN O
of NN NN O
HBV NN NN O
reactivation NN NN O
, NN NN O
and NN NN O
diminishing NN NN O
morbidity NN NN O
and NN NN O
mortality NN NN O
during NN NN O
CT NN NN O
. NN NN O
   
Two NN NN O
groups NN NN O
were NN NN O
compared NN NN O
in NN NN O
this NN NN O
study NN NN O
. NN NN O
   
The NN NN O
prophylactic NN NN O
lamivudin NN NN O
group NN NN O
consisted NN NN O
of NN NN O
37 NN NN O
patients NN NN O
who NN NN O
received NN NN O
prophylactic NN NN O
lamivudine NN NN O
treatment NN NN O
. NN NN O
   
The NN NN O
historical NN NN O
controls NN NN O
consisted NN NN O
of NN NN O
50 NN NN O
consecutive NN NN O
patients NN NN O
who NN NN O
underwent NN NN O
CT NN NN O
without NN NN O
prophylactic NN NN O
lamivudine NN NN O
. NN NN O
   
They NN NN O
were NN NN O
followed NN NN O
up NN NN O
during NN NN O
and NN NN O
for NN NN O
8 NN NN O
weeks NN NN O
after NN NN O
CT NN NN O
. NN NN O
   
The NN NN O
outcomes NN NN O
were NN NN O
compared NN NN O
for NN NN O
both NN NN O
groups NN NN O
. NN NN O
   
Of NN NN O
our NN NN O
control NN NN O
group NN NN O
( NN NN O
n NN NN O
= NN NN O
50 NN NN O
) NN NN O
, NN NN O
21 NN NN O
patients NN NN O
( NN NN O
42 NN NN O
% NN NN O
) NN NN O
were NN NN O
established NN NN O
hepatitis NN NN B-Disease
. NN NN O
   
Twelve NN NN O
( NN NN O
24 NN NN O
% NN NN O
) NN NN O
of NN NN O
them NN NN O
were NN NN O
evaluated NN NN O
as NN NN O
severe NN NN O
hepatitis NN NN B-Disease
. NN NN O
   
In NN NN O
the NN NN O
prophylactic NN NN O
lamivudine NN NN O
group NN NN O
severe NN NN O
hepatitis NN NN B-Disease
were NN NN O
observed NN NN O
only NN NN O
in NN NN O
1 NN NN O
patient NN NN O
( NN NN O
2 NN NN O
. NN NN O
7 NN NN O
% NN NN O
) NN NN O
of NN NN O
37 NN NN O
patients NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
006 NN NN O
) NN NN O
. NN NN O
   
Comparison NN NN O
of NN NN O
the NN NN O
mean NN NN O
ALT NN NN O
values NN NN O
revealed NN NN O
significantly NN NN O
higher NN NN O
mean NN NN O
alanine NN NN O
aminotransferase NN NN O
( NN NN O
ALT NN NN O
) NN NN O
values NN NN O
in NN NN O
the NN NN O
control NN NN O
group NN NN O
than NN NN O
the NN NN O
prophylactic NN NN O
lamivudine NN NN O
group NN NN O
; NN NN O
154 NN NN O
: NN NN O
64 NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
32 NN NN O
) NN NN O
. NN NN O
   
Our NN NN O
study NN NN O
suggests NN NN O
that NN NN O
prophylactic NN NN O
lamivudine NN NN O
significantly NN NN O
decreases NN NN O
the NN NN O
incidence NN NN O
of NN NN O
HBV NN NN O
reactivation NN NN O
and NN NN O
overall NN NN O
morbidity NN NN O
in NN NN O
cancer NN NN B-Disease
patients NN NN O
during NN NN O
and NN NN O
after NN NN O
immunosuppressive NN NN O
therapy NN NN O
. NN NN O
   
Further NN NN O
studies NN NN O
are NN NN O
needed NN NN O
to NN NN O
determine NN NN O
the NN NN O
most NN NN O
appropriate NN NN O
nucleoside NN NN O
or NN NN O
nucleotide NN NN O
analogue NN NN O
for NN NN O
antiviral NN NN O
prophylaxis NN NN O
during NN NN O
CT NN NN O
and NN NN O
the NN NN O
optimal NN NN O
duration NN NN O
of NN NN O
administration NN NN O
after NN NN O
completion NN NN O
of NN NN O
CT NN NN O
. NN NN O
   
Recovery NN NN O
of NN NN O
tacrolimus NN NN O
- NN NN O
associated NN NN O
brachial NN NN B-Disease
neuritis NN NN I-Disease
after NN NN O
conversion NN NN O
to NN NN O
everolimus NN NN O
in NN NN O
a NN NN O
pediatric NN NN O
renal NN NN O
transplant NN NN O
recipient NN NN O
- NN NN O
- NN NN O
case NN NN O
report NN NN O
and NN NN O
review NN NN O
of NN NN O
the NN NN O
literature NN NN O
. NN NN O
   
TAC NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
be NN NN O
a NN NN O
potent NN NN O
immunosuppressive NN NN O
agent NN NN O
for NN NN O
solid NN NN O
organ NN NN O
transplantation NN NN O
in NN NN O
pediatrics NN NN O
. NN NN O
   
Neurotoxicity NN NN B-Disease
is NN NN O
a NN NN O
potentially NN NN O
serious NN NN O
toxic NN NN O
effect NN NN O
. NN NN O
   
It NN NN O
is NN NN O
characterized NN NN O
by NN NN O
encephalopathy NN NN B-Disease
, NN NN O
headaches NN NN B-Disease
, NN NN O
seizures NN NN B-Disease
, NN NN O
or NN NN O
neurological NN NN B-Disease
deficits NN NN I-Disease
. NN NN O
   
Here NN NN O
, NN NN O
we NN NN O
describe NN NN O
an NN NN O
eight NN NN O
- NN NN O
and NN NN O
- NN NN O
a NN NN O
- NN NN O
half NN NN O
- NN NN O
yr NN NN O
- NN NN O
old NN NN O
male NN NN O
renal NN NN O
transplant NN NN O
recipient NN NN O
with NN NN O
right NN NN O
BN NN NN O
. NN NN O
   
MRI NN NN O
demonstrated NN NN O
hyperintense NN NN O
T2 NN NN O
signals NN NN O
in NN NN O
the NN NN O
cervical NN NN O
cord NN NN O
and NN NN O
right NN NN O
brachial NN NN O
plexus NN NN O
roots NN NN O
indicative NN NN O
of NN NN O
both NN NN O
myelitis NN NN B-Disease
and NN NN O
right NN NN O
brachial NN NN B-Disease
plexitis NN NN I-Disease
. NN NN O
   
Symptoms NN NN O
persisted NN NN O
for NN NN O
three NN NN O
months NN NN O
despite NN NN O
TAC NN NN O
dose NN NN O
reduction NN NN O
, NN NN O
administration NN NN O
of NN NN O
IVIG NN NN O
and NN NN O
four NN NN O
doses NN NN O
of NN NN O
methylprednisolone NN NN O
pulse NN NN O
therapy NN NN O
. NN NN O
   
Improvement NN NN O
and NN NN O
eventually NN NN O
full NN NN O
recovery NN NN O
only NN NN O
occurred NN NN O
after NN NN O
TAC NN NN O
was NN NN O
completely NN NN O
discontinued NN NN O
and NN NN O
successfully NN NN O
replaced NN NN O
by NN NN O
everolimus NN NN O
. NN NN O
   
Omitting NN NN O
fentanyl NN NN O
reduces NN NN O
nausea NN NN B-Disease
and NN NN O
vomiting NN NN B-Disease
, NN NN O
without NN NN O
increasing NN NN O
pain NN NN B-Disease
, NN NN O
after NN NN O
sevoflurane NN NN O
for NN NN O
day NN NN O
surgery NN NN O
. NN NN O
   
BACKGROUND NN NN O
AND NN NN O
OBJECTIVE NN NN O
: NN NN O
Despite NN NN O
advantages NN NN O
of NN NN O
induction NN NN O
and NN NN O
maintenance NN NN O
of NN NN O
anaesthesia NN NN O
with NN NN O
sevoflurane NN NN O
, NN NN O
postoperative NN NN B-Disease
nausea NN NN I-Disease
and NN NN I-Disease
vomiting NN NN I-Disease
occurs NN NN O
frequently NN NN O
. NN NN O
   
Fentanyl NN NN O
is NN NN O
a NN NN O
commonly NN NN O
used NN NN O
supplement NN NN O
that NN NN O
may NN NN O
contribute NN NN O
to NN NN O
this NN NN O
, NN NN O
although NN NN O
it NN NN O
may NN NN O
also NN NN O
improve NN NN O
analgesia NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
This NN NN O
double NN NN O
- NN NN O
blind NN NN O
study NN NN O
examined NN NN O
the NN NN O
incidence NN NN O
and NN NN O
severity NN NN O
of NN NN O
postoperative NN NN B-Disease
nausea NN NN I-Disease
and NN NN I-Disease
vomiting NN NN I-Disease
and NN NN O
pain NN NN B-Disease
in NN NN O
the NN NN O
first NN NN O
24 NN NN O
h NN NN O
after NN NN O
sevoflurane NN NN O
anaesthesia NN NN O
in NN NN O
216 NN NN O
adult NN NN O
day NN NN O
surgery NN NN O
patients NN NN O
. NN NN O
   
Patients NN NN O
were NN NN O
randomly NN NN O
allocated NN NN O
to NN NN O
either NN NN O
receive NN NN O
or NN NN O
not NN NN O
receive NN NN O
1 NN NN O
1 NN NN O
fentanyl NN NN O
, NN NN O
while NN NN O
a NN NN O
third NN NN O
group NN NN O
received NN NN O
dexamethasone NN NN O
in NN NN O
addition NN NN O
to NN NN O
fentanyl NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Omission NN NN O
of NN NN O
fentanyl NN NN O
did NN NN O
not NN NN O
reduce NN NN O
the NN NN O
overall NN NN O
incidence NN NN O
of NN NN O
postoperative NN NN B-Disease
nausea NN NN I-Disease
and NN NN I-Disease
vomiting NN NN I-Disease
, NN NN O
but NN NN O
did NN NN O
reduce NN NN O
the NN NN O
incidence NN NN O
of NN NN O
vomiting NN NN B-Disease
and NN NN O
/ NN NN O
or NN NN O
moderate NN NN O
to NN NN O
severe NN NN O
nausea NN NN B-Disease
prior NN NN O
to NN NN O
discharge NN NN O
from NN NN O
20 NN NN O
% NN NN O
and NN NN O
17 NN NN O
% NN NN O
with NN NN O
fentanyl NN NN O
and NN NN O
fentanyl NN NN O
- NN NN O
dexamethasone NN NN O
, NN NN O
respectively NN NN O
, NN NN O
to NN NN O
5 NN NN O
% NN NN O
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
013 NN NN O
) NN NN O
. NN NN O
   
Antiemetic NN NN O
requirements NN NN O
were NN NN O
reduced NN NN O
from NN NN O
24 NN NN O
% NN NN O
and NN NN O
31 NN NN O
% NN NN O
to NN NN O
7 NN NN O
% NN NN O
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
0012 NN NN O
) NN NN O
. NN NN O
   
Dexamethasone NN NN O
had NN NN O
no NN NN O
significant NN NN O
effect NN NN O
on NN NN O
the NN NN O
incidence NN NN O
or NN NN O
severity NN NN O
of NN NN O
postoperative NN NN B-Disease
nausea NN NN I-Disease
and NN NN I-Disease
vomiting NN NN I-Disease
. NN NN O
   
Combining NN NN O
the NN NN O
two NN NN O
fentanyl NN NN O
groups NN NN O
revealed NN NN O
further NN NN O
significant NN NN O
benefits NN NN O
from NN NN O
the NN NN O
avoidance NN NN O
of NN NN O
opioids NN NN O
, NN NN O
reducing NN NN O
postoperative NN NN B-Disease
nausea NN NN I-Disease
and NN NN I-Disease
vomiting NN NN I-Disease
and NN NN O
nausea NN NN B-Disease
prior NN NN O
to NN NN O
discharge NN NN O
from NN NN O
35 NN NN O
% NN NN O
and NN NN O
33 NN NN O
% NN NN O
to NN NN O
22 NN NN O
% NN NN O
and NN NN O
19 NN NN O
% NN NN O
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
049 NN NN O
and NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
035 NN NN O
) NN NN O
, NN NN O
respectively NN NN O
, NN NN O
while NN NN O
nausea NN NN B-Disease
in NN NN O
the NN NN O
first NN NN O
24 NN NN O
h NN NN O
was NN NN O
decreased NN NN O
from NN NN O
42 NN NN O
% NN NN O
to NN NN O
27 NN NN O
% NN NN O
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
034 NN NN O
) NN NN O
. NN NN O
   
Pain NN NN B-Disease
severity NN NN O
and NN NN O
analgesic NN NN O
requirements NN NN O
were NN NN O
unaffected NN NN O
by NN NN O
the NN NN O
omission NN NN O
of NN NN O
fentanyl NN NN O
. NN NN O
   
Fentanyl NN NN O
did NN NN O
reduce NN NN O
minor NN NN O
intraoperative NN NN O
movement NN NN O
but NN NN O
had NN NN O
no NN NN O
sevoflurane NN NN O
- NN NN O
sparing NN NN O
effect NN NN O
and NN NN O
increased NN NN O
respiratory NN NN B-Disease
depression NN NN I-Disease
, NN NN O
hypotension NN NN B-Disease
and NN NN O
bradycardia NN NN B-Disease
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
As NN NN O
fentanyl NN NN O
exacerbated NN NN O
postoperative NN NN B-Disease
nausea NN NN I-Disease
and NN NN I-Disease
vomiting NN NN I-Disease
without NN NN O
an NN NN O
improvement NN NN O
in NN NN O
postoperative NN NN B-Disease
pain NN NN I-Disease
and NN NN O
also NN NN O
had NN NN O
adverse NN NN O
cardiorespiratory NN NN O
effects NN NN O
, NN NN O
it NN NN O
appears NN NN O
to NN NN O
be NN NN O
an NN NN O
unnecessary NN NN O
and NN NN O
possibly NN NN O
detrimental NN NN O
supplement NN NN O
to NN NN O
sevoflurane NN NN O
in NN NN O
day NN NN O
surgery NN NN O
. NN NN O
   
Valvular NN NN B-Disease
heart NN NN I-Disease
disease NN NN I-Disease
in NN NN O
patients NN NN O
with NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
treated NN NN O
with NN NN O
pergolide NN NN O
. NN NN O
   
Course NN NN O
following NN NN O
treatment NN NN O
modifications NN NN O
. NN NN O
   
Valvular NN NN B-Disease
heart NN NN I-Disease
abnormalities NN NN I-Disease
have NN NN O
been NN NN O
reported NN NN O
in NN NN O
patients NN NN O
with NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
( NN NN O
PD NN NN B-Disease
) NN NN O
treated NN NN O
with NN NN O
pergolide NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
incidence NN NN O
and NN NN O
severity NN NN O
of NN NN O
these NN NN O
abnormalities NN NN O
vary NN NN O
from NN NN O
study NN NN O
to NN NN O
study NN NN O
and NN NN O
their NN NN O
course NN NN O
after NN NN O
drug NN NN O
withdrawal NN NN O
has NN NN O
not NN NN O
been NN NN O
systematically NN NN O
assessed NN NN O
. NN NN O
   
OBJECTIVES NN NN O
: NN NN O
To NN NN O
estimate NN NN O
the NN NN O
frequency NN NN O
and NN NN O
severity NN NN O
of NN NN O
valvular NN NN B-Disease
heart NN NN I-Disease
abnormality NN NN I-Disease
and NN NN O
its NN NN O
possible NN NN O
reversibility NN NN O
after NN NN O
drug NN NN O
withdrawal NN NN O
in NN NN O
a NN NN O
case NN NN O
- NN NN O
control NN NN O
study NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
All NN NN O
PD NN NN B-Disease
patients NN NN O
in NN NN O
the NN NN O
Amiens NN NN O
area NN NN O
treated NN NN O
with NN NN O
pergolide NN NN O
were NN NN O
invited NN NN O
to NN NN O
attend NN NN O
a NN NN O
cardiologic NN NN O
assessment NN NN O
including NN NN O
transthoracic NN NN O
echocardiography NN NN O
. NN NN O
   
Thirty NN NN O
PD NN NN B-Disease
patients NN NN O
participated NN NN O
in NN NN O
the NN NN O
study NN NN O
. NN NN O
   
A NN NN O
second NN NN O
echocardiography NN NN O
was NN NN O
performed NN NN O
( NN NN O
median NN NN O
interval NN NN O
: NN NN O
13 NN NN O
months NN NN O
) NN NN O
after NN NN O
pergolide NN NN O
withdrawal NN NN O
( NN NN O
n NN NN O
= NN NN O
10 NN NN O
patients NN NN O
) NN NN O
. NN NN O
   
Controls NN NN O
were NN NN O
age NN NN O
- NN NN O
and NN NN O
sex NN NN O
- NN NN O
matched NN NN O
non NN NN O
- NN NN O
PD NN NN B-Disease
patients NN NN O
referred NN NN O
to NN NN O
the NN NN O
cardiology NN NN O
department NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Compared NN NN O
to NN NN O
controls NN NN O
, NN NN O
aortic NN NN B-Disease
regurgitation NN NN I-Disease
( NN NN O
OR NN NN O
: NN NN O
3 NN NN O
. NN NN O
1 NN NN O
; NN NN O
95 NN NN O
% NN NN O
IC NN NN O
: NN NN O
1 NN NN O
. NN NN O
1 NN NN O
- NN NN O
8 NN NN O
. NN NN O
8 NN NN O
) NN NN O
and NN NN O
mitral NN NN B-Disease
regurgitation NN NN I-Disease
( NN NN O
OR NN NN O
: NN NN O
10 NN NN O
. NN NN O
7 NN NN O
; NN NN O
95 NN NN O
% NN NN O
IC NN NN O
: NN NN O
2 NN NN O
. NN NN O
1 NN NN O
- NN NN O
53 NN NN O
) NN NN O
were NN NN O
more NN NN O
frequent NN NN O
in NN NN O
PD NN NN B-Disease
patients NN NN O
( NN NN O
tricuspid NN NN O
: NN NN O
NS NN NN O
) NN NN O
. NN NN O
   
The NN NN O
number NN NN O
of NN NN O
affected NN NN O
valves NN NN O
( NN NN O
n NN NN O
= NN NN O
2 NN NN O
. NN NN O
4 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
7 NN NN O
) NN NN O
and NN NN O
the NN NN O
sum NN NN O
of NN NN O
regurgitation NN NN O
grades NN NN O
( NN NN O
n NN NN O
= NN NN O
2 NN NN O
. NN NN O
8 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
09 NN NN O
) NN NN O
were NN NN O
higher NN NN O
( NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
008 NN NN O
and NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
006 NN NN O
, NN NN O
respectively NN NN O
) NN NN O
in NN NN O
the NN NN O
pergolide NN NN O
group NN NN O
. NN NN O
   
Severity NN NN O
of NN NN O
regurgitation NN NN O
was NN NN O
not NN NN O
correlated NN NN O
with NN NN O
pergolide NN NN O
cumulative NN NN O
dose NN NN O
. NN NN O
   
A NN NN O
restrictive NN NN O
pattern NN NN O
of NN NN O
valvular NN NN B-Disease
regurgitation NN NN I-Disease
, NN NN O
suggestive NN NN O
of NN NN O
the NN NN O
role NN NN O
of NN NN O
pergolide NN NN O
, NN NN O
was NN NN O
observed NN NN O
in NN NN O
12 NN NN O
/ NN NN O
30 NN NN O
( NN NN O
40 NN NN O
% NN NN O
) NN NN O
patients NN NN O
including NN NN O
two NN NN O
with NN NN O
heart NN NN B-Disease
failure NN NN I-Disease
. NN NN O
   
Pergolide NN NN O
was NN NN O
discontinued NN NN O
in NN NN O
10 NN NN O
patients NN NN O
with NN NN O
valvular NN NN B-Disease
heart NN NN I-Disease
disease NN NN I-Disease
, NN NN O
resulting NN NN O
in NN NN O
a NN NN O
lower NN NN O
regurgitation NN NN O
grade NN NN O
( NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
at NN NN O
the NN NN O
second NN NN O
transthoracic NN NN O
echocardiography NN NN O
and NN NN O
the NN NN O
two NN NN O
patients NN NN O
with NN NN O
heart NN NN B-Disease
failure NN NN I-Disease
returned NN NN O
to NN NN O
nearly NN NN O
normal NN NN O
clinical NN NN O
examination NN NN O
. NN NN O
   
This NN NN O
study NN NN O
supports NN NN O
the NN NN O
high NN NN O
frequency NN NN O
of NN NN O
restrictive NN NN O
valve NN NN B-Disease
regurgitation NN NN I-Disease
in NN NN O
PD NN NN B-Disease
patients NN NN O
treated NN NN O
with NN NN O
pergolide NN NN O
and NN NN O
reveals NN NN O
that NN NN O
a NN NN O
significant NN NN O
improvement NN NN O
is NN NN O
usual NN NN O
when NN NN O
the NN NN O
treatment NN NN O
is NN NN O
converted NN NN O
to NN NN O
non NN NN O
- NN NN O
ergot NN NN O
dopamine NN NN O
agonists NN NN O
. NN NN O
   
Adriamycin NN NN O
- NN NN O
induced NN NN O
autophagic NN NN O
cardiomyocyte NN NN O
death NN NN B-Disease
plays NN NN O
a NN NN O
pathogenic NN NN O
role NN NN O
in NN NN O
a NN NN O
rat NN NN O
model NN NN O
of NN NN O
heart NN NN B-Disease
failure NN NN I-Disease
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
The NN NN O
mechanisms NN NN O
underlying NN NN O
heart NN NN B-Disease
failure NN NN I-Disease
induced NN NN O
by NN NN O
adriamycin NN NN O
are NN NN O
very NN NN O
complicated NN NN O
and NN NN O
still NN NN O
unclear NN NN O
. NN NN O
   
The NN NN O
aim NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
investigate NN NN O
whether NN NN O
autophagy NN NN O
was NN NN O
involved NN NN O
in NN NN O
the NN NN O
progression NN NN O
of NN NN O
heart NN NN B-Disease
failure NN NN I-Disease
induced NN NN O
by NN NN O
adriamycin NN NN O
, NN NN O
so NN NN O
that NN NN O
we NN NN O
can NN NN O
develop NN NN O
a NN NN O
novel NN NN O
treatment NN NN O
strategy NN NN O
for NN NN O
heart NN NN B-Disease
failure NN NN I-Disease
. NN NN O
   
METHODS NN NN O
: NN NN O
3 NN NN O
- NN NN O
methyladenine NN NN O
( NN NN O
3MA NN NN O
) NN NN O
, NN NN O
a NN NN O
specific NN NN O
inhibitor NN NN O
on NN NN O
autophagy NN NN O
was NN NN O
used NN NN O
in NN NN O
a NN NN O
heart NN NN B-Disease
failure NN NN I-Disease
model NN NN O
of NN NN O
rats NN NN O
induced NN NN O
by NN NN O
adriamycin NN NN O
. NN NN O
   
Neonatal NN NN O
cardiomyocytes NN NN O
were NN NN O
isolated NN NN O
from NN NN O
Sprague NN NN O
- NN NN O
Dawley NN NN O
rat NN NN O
hearts NN NN O
and NN NN O
randomly NN NN O
divided NN NN O
into NN NN O
controls NN NN O
, NN NN O
an NN NN O
adriamycin NN NN O
- NN NN O
treated NN NN O
group NN NN O
, NN NN O
and NN NN O
a NN NN O
3MA NN NN O
plus NN NN O
adriamycin NN NN O
- NN NN O
treated NN NN O
group NN NN O
. NN NN O
   
We NN NN O
then NN NN O
examined NN NN O
the NN NN O
morphology NN NN O
, NN NN O
expression NN NN O
of NN NN O
beclin NN NN O
1 NN NN O
gene NN NN O
, NN NN O
mitochondrial NN NN O
permeability NN NN O
transition NN NN O
( NN NN O
MPT NN NN O
) NN NN O
, NN NN O
and NN NN O
Na NN NN O
+ NN NN O
- NN NN O
K NN NN O
+ NN NN O
ATPase NN NN O
activity NN NN O
in NN NN O
vivo NN NN O
. NN NN O
   
We NN NN O
also NN NN O
assessed NN NN O
cell NN NN O
viability NN NN O
, NN NN O
mitochondrial NN NN O
membrane NN NN O
potential NN NN O
changes NN NN O
and NN NN O
counted NN NN O
autophagic NN NN O
vacuoles NN NN O
in NN NN O
cultured NN NN O
cardiomyocytes NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
we NN NN O
analyzed NN NN O
the NN NN O
expression NN NN O
of NN NN O
autophagy NN NN O
associated NN NN O
gene NN NN O
, NN NN O
beclin NN NN O
1 NN NN O
using NN NN O
RT NN NN O
- NN NN O
PCR NN NN O
and NN NN O
Western NN NN O
blotting NN NN O
in NN NN O
an NN NN O
animal NN NN O
model NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
3MA NN NN O
significantly NN NN O
improved NN NN O
cardiac NN NN O
function NN NN O
and NN NN O
reduced NN NN O
mitochondrial NN NN O
injury NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
adriamycin NN NN O
induced NN NN O
the NN NN O
formation NN NN O
of NN NN O
autophagic NN NN O
vacuoles NN NN O
, NN NN O
and NN NN O
3MA NN NN O
strongly NN NN O
downregulated NN NN O
the NN NN O
expression NN NN O
of NN NN O
beclin NN NN O
1 NN NN O
in NN NN O
adriamycin NN NN O
- NN NN O
induced NN NN O
failing NN NN O
heart NN NN O
and NN NN O
inhibited NN NN O
the NN NN O
formation NN NN O
of NN NN O
autophagic NN NN O
vacuoles NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Autophagic NN NN O
cardiomyocyte NN NN O
death NN NN B-Disease
plays NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
heart NN NN B-Disease
failure NN NN I-Disease
in NN NN O
rats NN NN O
induced NN NN O
by NN NN O
adriamycin NN NN O
. NN NN O
   
Mitochondrial NN NN O
injury NN NN O
may NN NN O
be NN NN O
involved NN NN O
in NN NN O
the NN NN O
progression NN NN O
of NN NN O
heart NN NN B-Disease
failure NN NN I-Disease
caused NN NN O
by NN NN O
adriamycin NN NN O
via NN NN O
the NN NN O
autophagy NN NN O
pathway NN NN O
. NN NN O
   
mToR NN NN O
inhibitors NN NN O
- NN NN O
induced NN NN O
proteinuria NN NN B-Disease
: NN NN O
mechanisms NN NN O
, NN NN O
significance NN NN O
, NN NN O
and NN NN O
management NN NN O
. NN NN O
   
Massive NN NN O
urinary NN NN O
protein NN NN O
excretion NN NN O
has NN NN O
been NN NN O
observed NN NN O
after NN NN O
conversion NN NN O
from NN NN O
calcineurin NN NN O
inhibitors NN NN O
to NN NN O
mammalian NN NN O
target NN NN O
of NN NN O
rapamycin NN NN O
( NN NN O
mToR NN NN O
) NN NN O
inhibitors NN NN O
, NN NN O
especially NN NN O
sirolimus NN NN O
, NN NN O
in NN NN O
renal NN NN O
transplant NN NN O
recipients NN NN O
with NN NN O
chronic NN NN B-Disease
allograft NN NN I-Disease
nephropathy NN NN I-Disease
. NN NN O
   
Because NN NN O
proteinuria NN NN B-Disease
is NN NN O
a NN NN O
major NN NN O
predictive NN NN O
factor NN NN O
of NN NN O
poor NN NN O
transplantation NN NN O
outcome NN NN O
, NN NN O
many NN NN O
studies NN NN O
focused NN NN O
on NN NN O
this NN NN O
adverse NN NN O
event NN NN O
during NN NN O
the NN NN O
past NN NN O
years NN NN O
. NN NN O
   
Whether NN NN O
proteinuria NN NN B-Disease
was NN NN O
due NN NN O
to NN NN O
sirolimus NN NN O
or NN NN O
only NN NN O
a NN NN O
consequence NN NN O
of NN NN O
calcineurin NN NN O
inhibitors NN NN O
withdrawal NN NN O
remained NN NN O
unsolved NN NN O
until NN NN O
high NN NN O
range NN NN O
proteinuria NN NN B-Disease
has NN NN O
been NN NN O
observed NN NN O
during NN NN O
sirolimus NN NN O
therapy NN NN O
in NN NN O
islet NN NN O
transplantation NN NN O
and NN NN O
in NN NN O
patients NN NN O
who NN NN O
received NN NN O
sirolimus NN NN O
de NN NN O
novo NN NN O
. NN NN O
   
Podocyte NN NN O
injury NN NN O
and NN NN O
focal NN NN O
segmental NN NN O
glomerulosclerosis NN NN B-Disease
have NN NN O
been NN NN O
related NN NN O
to NN NN O
mToR NN NN O
inhibition NN NN O
in NN NN O
some NN NN O
patients NN NN O
, NN NN O
but NN NN O
the NN NN O
pathways NN NN O
underlying NN NN O
these NN NN O
lesions NN NN O
remain NN NN O
hypothetic NN NN O
. NN NN O
   
We NN NN O
discuss NN NN O
herein NN NN O
the NN NN O
possible NN NN O
mechanisms NN NN O
and NN NN O
the NN NN O
significance NN NN O
of NN NN O
mToR NN NN O
blockade NN NN O
- NN NN O
induced NN NN O
proteinuria NN NN B-Disease
. NN NN O
   
Neuropsychiatric NN NN O
side NN NN O
effects NN NN O
after NN NN O
the NN NN O
use NN NN O
of NN NN O
mefloquine NN NN O
. NN NN O
   
This NN NN O
study NN NN O
describes NN NN O
neuropsychiatric NN NN O
side NN NN O
effects NN NN O
in NN NN O
patients NN NN O
after NN NN O
treatment NN NN O
with NN NN O
mefloquine NN NN O
. NN NN O
   
Reactions NN NN O
consisted NN NN O
mainly NN NN O
of NN NN O
seizures NN NN B-Disease
, NN NN O
acute NN NN O
psychoses NN NN B-Disease
, NN NN O
anxiety NN NN B-Disease
neurosis NN NN I-Disease
, NN NN O
and NN NN O
major NN NN O
disturbances NN NN B-Disease
of NN NN I-Disease
sleep NN NN I-Disease
- NN NN I-Disease
wake NN NN I-Disease
rhythm NN NN I-Disease
. NN NN O
   
Side NN NN O
effects NN NN O
occurred NN NN O
after NN NN O
both NN NN O
therapeutic NN NN O
and NN NN O
prophylactic NN NN O
intake NN NN O
and NN NN O
were NN NN O
graded NN NN O
from NN NN O
moderate NN NN O
to NN NN O
severe NN NN O
. NN NN O
   
In NN NN O
a NN NN O
risk NN NN O
analysis NN NN O
of NN NN O
neuropsychiatric NN NN O
side NN NN O
effects NN NN O
in NN NN O
Germany NN NN O
, NN NN O
it NN NN O
is NN NN O
estimated NN NN O
that NN NN O
one NN NN O
of NN NN O
8 NN NN O
, NN NN O
000 NN NN O
mefloquine NN NN O
users NN NN O
suffers NN NN O
from NN NN O
such NN NN O
reactions NN NN O
. NN NN O
   
The NN NN O
incidence NN NN O
calculation NN NN O
revealed NN NN O
that NN NN O
one NN NN O
of NN NN O
215 NN NN O
therapeutic NN NN O
users NN NN O
had NN NN O
reactions NN NN O
, NN NN O
compared NN NN O
with NN NN O
one NN NN O
of NN NN O
13 NN NN O
, NN NN O
000 NN NN O
in NN NN O
the NN NN O
prophylaxis NN NN O
group NN NN O
, NN NN O
making NN NN O
the NN NN O
risk NN NN O
of NN NN O
neuropsychiatric NN NN O
reactions NN NN O
after NN NN O
mefloquine NN NN O
treatment NN NN O
60 NN NN O
times NN NN O
higher NN NN O
than NN NN O
after NN NN O
prophylaxis NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
certain NN NN O
limitations NN NN O
for NN NN O
malaria NN NN B-Disease
prophylaxis NN NN O
and NN NN O
treatment NN NN O
with NN NN O
mefloquine NN NN O
are NN NN O
recommended NN NN O
. NN NN O
   
Prenatal NN NN O
protein NN NN O
deprivation NN NN O
alters NN NN O
dopamine NN NN O
- NN NN O
mediated NN NN O
behaviors NN NN O
and NN NN O
dopaminergic NN NN O
and NN NN O
glutamatergic NN NN O
receptor NN NN O
binding NN NN O
. NN NN O
   
Epidemiological NN NN O
evidence NN NN O
indicates NN NN O
that NN NN O
prenatal NN NN O
nutritional NN NN O
deprivation NN NN O
may NN NN O
increase NN NN O
the NN NN O
risk NN NN O
of NN NN O
schizophrenia NN NN B-Disease
. NN NN O
   
The NN NN O
goal NN NN O
of NN NN O
these NN NN O
studies NN NN O
was NN NN O
to NN NN O
use NN NN O
an NN NN O
animal NN NN O
model NN NN O
to NN NN O
examine NN NN O
the NN NN O
effects NN NN O
of NN NN O
prenatal NN NN O
protein NN NN O
deprivation NN NN O
on NN NN O
behaviors NN NN O
and NN NN O
receptor NN NN O
binding NN NN O
with NN NN O
relevance NN NN O
to NN NN O
schizophrenia NN NN B-Disease
. NN NN O
   
We NN NN O
report NN NN O
that NN NN O
prenatally NN NN O
protein NN NN O
deprived NN NN O
( NN NN O
PD NN NN O
) NN NN O
female NN NN O
rats NN NN O
showed NN NN O
an NN NN O
increased NN NN O
stereotypic NN NN O
response NN NN O
to NN NN O
apomorphine NN NN O
and NN NN O
an NN NN O
increased NN NN O
locomotor NN NN O
response NN NN O
to NN NN O
amphetamine NN NN O
in NN NN O
adulthood NN NN O
. NN NN O
   
These NN NN O
differences NN NN O
were NN NN O
not NN NN O
observed NN NN O
during NN NN O
puberty NN NN O
. NN NN O
   
No NN NN O
changes NN NN O
in NN NN O
haloperidol NN NN O
- NN NN O
induced NN NN O
catalepsy NN NN B-Disease
or NN NN O
MK NN NN O
- NN NN O
801 NN NN O
- NN NN O
induced NN NN O
locomotion NN NN O
were NN NN O
seen NN NN O
following NN NN O
PD NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
PD NN NN O
female NN NN O
rats NN NN O
showed NN NN O
increased NN NN O
( NN NN O
3 NN NN O
) NN NN O
H NN NN O
- NN NN O
MK NN NN O
- NN NN O
801 NN NN O
binding NN NN O
in NN NN O
the NN NN O
striatum NN NN O
and NN NN O
hippocampus NN NN O
, NN NN O
but NN NN O
not NN NN O
in NN NN O
the NN NN O
cortex NN NN O
. NN NN O
   
PD NN NN O
female NN NN O
rats NN NN O
also NN NN O
showed NN NN O
increased NN NN O
( NN NN O
3 NN NN O
) NN NN O
H NN NN O
- NN NN O
haloperidol NN NN O
binding NN NN O
and NN NN O
decreased NN NN O
dopamine NN NN O
transporter NN NN O
binding NN NN O
in NN NN O
striatum NN NN O
. NN NN O
   
No NN NN O
statistically NN NN O
significant NN NN O
changes NN NN O
in NN NN O
behavior NN NN O
or NN NN O
receptor NN NN O
binding NN NN O
were NN NN O
found NN NN O
in NN NN O
PD NN NN O
males NN NN O
with NN NN O
the NN NN O
exception NN NN O
of NN NN O
increased NN NN O
( NN NN O
3 NN NN O
) NN NN O
H NN NN O
- NN NN O
MK NN NN O
- NN NN O
801 NN NN O
binding NN NN O
in NN NN O
cortex NN NN O
. NN NN O
   
This NN NN O
animal NN NN O
model NN NN O
may NN NN O
be NN NN O
useful NN NN O
to NN NN O
explore NN NN O
the NN NN O
mechanisms NN NN O
by NN NN O
which NN NN O
prenatal NN NN O
nutritional NN NN B-Disease
deficiency NN NN I-Disease
enhances NN NN O
risk NN NN O
for NN NN O
schizophrenia NN NN B-Disease
in NN NN O
humans NN NN O
and NN NN O
may NN NN O
also NN NN O
have NN NN O
implications NN NN O
for NN NN O
developmental NN NN O
processes NN NN O
leading NN NN O
to NN NN O
differential NN NN O
sensitivity NN NN O
to NN NN O
drugs NN NN O
of NN NN O
abuse NN NN O
. NN NN O
   
Adverse NN NN O
effects NN NN O
of NN NN O
topical NN NN O
papaverine NN NN O
on NN NN O
auditory NN NN O
nerve NN NN O
function NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Papaverine NN NN O
hydrochloride NN NN O
is NN NN O
a NN NN O
direct NN NN O
- NN NN O
acting NN NN O
vasodilator NN NN O
used NN NN O
to NN NN O
manage NN NN O
vasospasm NN NN B-Disease
during NN NN O
various NN NN O
neurosurgical NN NN O
operations NN NN O
. NN NN O
   
Transient NN NN O
cranial NN NN B-Disease
nerve NN NN I-Disease
dysfunction NN NN I-Disease
has NN NN O
been NN NN O
described NN NN O
in NN NN O
a NN NN O
few NN NN O
cases NN NN O
with NN NN O
topical NN NN O
papaverine NN NN O
. NN NN O
   
This NN NN O
study NN NN O
supports NN NN O
previous NN NN O
reports NN NN O
and NN NN O
provides NN NN O
neurophysiological NN NN O
evidence NN NN O
of NN NN O
an NN NN O
adverse NN NN O
effect NN NN O
on NN NN O
the NN NN O
auditory NN NN O
nerve NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
We NN NN O
conducted NN NN O
a NN NN O
retrospective NN NN O
review NN NN O
of NN NN O
70 NN NN O
consecutive NN NN O
microvascular NN NN O
decompression NN NN O
operations NN NN O
and NN NN O
studied NN NN O
those NN NN O
patients NN NN O
who NN NN O
received NN NN O
topical NN NN O
papaverine NN NN O
for NN NN O
vasospasm NN NN B-Disease
. NN NN O
   
Topical NN NN O
papaverine NN NN O
was NN NN O
used NN NN O
as NN NN O
a NN NN O
direct NN NN O
therapeutic NN NN O
action NN NN O
to NN NN O
manage NN NN O
vasospasm NN NN B-Disease
in NN NN O
a NN NN O
total NN NN O
of NN NN O
11 NN NN O
patients NN NN O
. NN NN O
   
The NN NN O
timing NN NN O
of NN NN O
papaverine NN NN O
application NN NN O
and NN NN O
ongoing NN NN O
operative NN NN O
events NN NN O
was NN NN O
reviewed NN NN O
relative NN NN O
to NN NN O
changes NN NN O
in NN NN O
neurophysiological NN NN O
recordings NN NN O
. NN NN O
   
Brainstem NN NN O
auditory NN NN O
evoked NN NN O
potentials NN NN O
( NN NN O
BAEPs NN NN O
) NN NN O
were NN NN O
routinely NN NN O
used NN NN O
to NN NN O
monitor NN NN O
cochlear NN NN O
nerve NN NN O
function NN NN O
during NN NN O
these NN NN O
operations NN NN O
. NN NN O
   
FINDINGS NN NN O
: NN NN O
A NN NN O
temporal NN NN O
relationship NN NN O
was NN NN O
found NN NN O
between NN NN O
topical NN NN O
papaverine NN NN O
and NN NN O
BAEP NN NN O
changes NN NN O
leading NN NN O
to NN NN O
complete NN NN O
waveform NN NN O
loss NN NN O
. NN NN O
   
The NN NN O
average NN NN O
temporal NN NN O
delay NN NN O
between NN NN O
papaverine NN NN O
and NN NN O
the NN NN O
onset NN NN O
of NN NN O
an NN NN O
adverse NN NN O
BAEP NN NN O
change NN NN O
was NN NN O
5 NN NN O
min NN NN O
. NN NN O
   
In NN NN O
10 NN NN O
of NN NN O
11 NN NN O
patients NN NN O
, NN NN O
BAEP NN NN O
waves NN NN O
II NN NN O
/ NN NN O
III NN NN O
- NN NN O
V NN NN O
completely NN NN O
disappeared NN NN O
within NN NN O
2 NN NN O
to NN NN O
25 NN NN O
min NN NN O
after NN NN O
papaverine NN NN O
. NN NN O
   
Eight NN NN O
of NN NN O
these NN NN O
10 NN NN O
patients NN NN O
had NN NN O
complete NN NN O
loss NN NN O
of NN NN O
BAEP NN NN O
waveforms NN NN O
within NN NN O
10 NN NN O
min NN NN O
. NN NN O
   
One NN NN O
patient NN NN O
showed NN NN O
no NN NN O
recovery NN NN O
of NN NN O
later NN NN O
waves NN NN O
and NN NN O
a NN NN O
delayed NN NN O
profound NN NN O
sensorineural NN NN B-Disease
hearing NN NN I-Disease
loss NN NN I-Disease
. NN NN O
   
The NN NN O
average NN NN O
recovery NN NN O
time NN NN O
of NN NN O
BAEP NN NN O
waveforms NN NN O
to NN NN O
pre NN NN O
- NN NN O
papaverine NN NN O
baseline NN NN O
values NN NN O
was NN NN O
39 NN NN O
min NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Topical NN NN O
papaverine NN NN O
for NN NN O
the NN NN O
treatment NN NN O
of NN NN O
vasospasm NN NN B-Disease
was NN NN O
associated NN NN O
with NN NN O
the NN NN O
onset NN NN O
of NN NN O
a NN NN O
transient NN NN O
disturbance NN NN O
in NN NN O
neurophysiological NN NN O
function NN NN O
of NN NN O
the NN NN O
ascending NN NN O
auditory NN NN O
brainstem NN NN O
pathway NN NN O
. NN NN O
   
The NN NN O
complete NN NN O
disappearance NN NN O
of NN NN O
BAEP NN NN O
waveforms NN NN O
with NN NN O
a NN NN O
consistent NN NN O
temporal NN NN O
delay NN NN O
suggests NN NN O
a NN NN O
possible NN NN O
adverse NN NN B-Disease
effect NN NN I-Disease
on NN NN I-Disease
the NN NN I-Disease
proximal NN NN I-Disease
eighth NN NN I-Disease
nerve NN NN I-Disease
. NN NN O
   
Recommendations NN NN O
to NN NN O
avoid NN NN O
potential NN NN O
cranial NN NN B-Disease
nerve NN NN I-Disease
deficits NN NN I-Disease
from NN NN O
papaverine NN NN O
are NN NN O
provided NN NN O
. NN NN O
   
Simvastatin NN NN O
- NN NN O
ezetimibe NN NN O
- NN NN O
induced NN NN O
hepatic NN NN B-Disease
failure NN NN I-Disease
necessitating NN NN O
liver NN NN O
transplantation NN NN O
. NN NN O
   
Abstract NN NN O
Serum NN NN O
aminotransferase NN NN O
elevations NN NN O
are NN NN O
a NN NN O
commonly NN NN O
known NN NN O
adverse NN NN O
effect NN NN O
of NN NN O
3 NN NN O
- NN NN O
hydroxy NN NN O
- NN NN O
3 NN NN O
- NN NN O
methylglutaryl NN NN O
coenzyme NN NN O
A NN NN O
reductase NN NN O
inhibitor NN NN O
( NN NN O
statin NN NN O
) NN NN O
therapy NN NN O
. NN NN O
   
However NN NN O
, NN NN O
hepatotoxic NN NN B-Disease
events NN NN O
have NN NN O
not NN NN O
been NN NN O
widely NN NN O
published NN NN O
with NN NN O
ezetimibe NN NN O
or NN NN O
the NN NN O
combination NN NN O
agent NN NN O
simvastatin NN NN O
- NN NN O
ezetimibe NN NN O
. NN NN O
   
We NN NN O
describe NN NN O
a NN NN O
70 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
Hispanic NN NN O
woman NN NN O
who NN NN O
developed NN NN O
fulminant NN NN B-Disease
hepatic NN NN I-Disease
failure NN NN I-Disease
necessitating NN NN O
liver NN NN O
transplantation NN NN O
10 NN NN O
weeks NN NN O
after NN NN O
conversion NN NN O
from NN NN O
simvastatin NN NN O
40 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
to NN NN O
simvastatin NN NN O
10 NN NN O
mg NN NN O
- NN NN O
ezetimibe NN NN O
40 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
' NN NN O
s NN NN O
lipid NN NN O
panel NN NN O
had NN NN O
been NN NN O
maintained NN NN O
with NN NN O
simvastatin NN NN O
for NN NN O
18 NN NN O
months NN NN O
before NN NN O
the NN NN O
conversion NN NN O
without NN NN O
evidence NN NN O
of NN NN O
hepatotoxicity NN NN B-Disease
. NN NN O
   
A NN NN O
routine NN NN O
laboratory NN NN O
work NN NN O
- NN NN O
up NN NN O
10 NN NN O
weeks NN NN O
after NN NN O
conversion NN NN O
revealed NN NN O
elevated NN NN O
serum NN NN O
aminotransferase NN NN O
levels NN NN O
. NN NN O
   
Simvastatinezetimibe NN NN O
and NN NN O
escitalopram NN NN O
( NN NN O
which NN NN O
she NN NN O
was NN NN O
taking NN NN O
for NN NN O
depression NN NN B-Disease
) NN NN O
were NN NN O
discontinued NN NN O
, NN NN O
and NN NN O
other NN NN O
potential NN NN O
causes NN NN O
of NN NN O
hepatotoxicity NN NN B-Disease
were NN NN O
excluded NN NN O
. NN NN O
   
A NN NN O
repeat NN NN O
work NN NN O
- NN NN O
up NN NN O
revealed NN NN O
further NN NN O
elevations NN NN O
in NN NN O
aminotransferase NN NN O
levels NN NN O
, NN NN O
and NN NN O
liver NN NN O
biopsy NN NN O
revealed NN NN O
evidence NN NN O
of NN NN O
moderate NN NN O
- NN NN O
to NN NN O
- NN NN O
severe NN NN O
drug NN NN B-Disease
toxicity NN NN I-Disease
. NN NN O
   
She NN NN O
underwent NN NN O
liver NN NN O
transplantation NN NN O
with NN NN O
an NN NN O
uneventful NN NN O
postoperative NN NN O
course NN NN O
. NN NN O
   
Her NN NN O
aminotransferase NN NN O
levels NN NN O
returned NN NN O
to NN NN O
normal NN NN O
by NN NN O
postoperative NN NN O
day NN NN O
23 NN NN O
, NN NN O
and NN NN O
her NN NN O
2 NN NN O
- NN NN O
year NN NN O
follow NN NN O
- NN NN O
up NN NN O
showed NN NN O
no NN NN O
adverse NN NN O
events NN NN O
. NN NN O
   
Ezetimibe NN NN O
undergoes NN NN O
extensive NN NN O
glucuronidation NN NN O
by NN NN O
uridine NN NN O
diphosphate NN NN O
glucoronosyltransferases NN NN O
( NN NN O
UGT NN NN O
) NN NN O
in NN NN O
the NN NN O
intestine NN NN O
and NN NN O
liver NN NN O
and NN NN O
may NN NN O
have NN NN O
inhibited NN NN O
the NN NN O
glucuronidation NN NN O
of NN NN O
simvastatin NN NN O
hydroxy NN NN O
acid NN NN O
, NN NN O
resulting NN NN O
in NN NN O
increased NN NN O
simvastatin NN NN O
exposure NN NN O
and NN NN O
subsequent NN NN O
hepatotoxicity NN NN B-Disease
. NN NN O
   
To NN NN O
our NN NN O
knowledge NN NN O
, NN NN O
this NN NN O
is NN NN O
the NN NN O
first NN NN O
case NN NN O
report NN NN O
of NN NN O
simvastatin NN NN O
- NN NN O
ezetimibe NN NN O
- NN NN O
induced NN NN O
liver NN NN B-Disease
failure NN NN I-Disease
that NN NN O
resulted NN NN O
in NN NN O
liver NN NN O
transplantation NN NN O
. NN NN O
   
We NN NN O
postulate NN NN O
that NN NN O
the NN NN O
mechanism NN NN O
of NN NN O
the NN NN O
simvastatinezetimibe NN NN O
- NN NN O
induced NN NN O
hepatotoxicity NN NN B-Disease
is NN NN O
the NN NN O
increased NN NN O
simvastatin NN NN O
exposure NN NN O
by NN NN O
ezetimibe NN NN O
inhibition NN NN O
of NN NN O
UGT NN NN O
enzymes NN NN O
. NN NN O
   
Clinicians NN NN O
should NN NN O
be NN NN O
aware NN NN O
of NN NN O
potential NN NN O
hepatotoxicity NN NN B-Disease
with NN NN O
simvastatin NN NN O
- NN NN O
ezetimibe NN NN O
especially NN NN O
in NN NN O
elderly NN NN O
patients NN NN O
and NN NN O
should NN NN O
carefully NN NN O
monitor NN NN O
serum NN NN O
aminotransferase NN NN O
levels NN NN O
when NN NN O
starting NN NN O
therapy NN NN O
and NN NN O
titrating NN NN O
the NN NN O
dosage NN NN O
. NN NN O
   
Massive NN NN O
proteinuria NN NN B-Disease
and NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
after NN NN O
oral NN NN O
bisphosphonate NN NN O
( NN NN O
alendronate NN NN O
) NN NN O
administration NN NN O
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
focal NN NN B-Disease
segmental NN NN I-Disease
glomerulosclerosis NN NN I-Disease
. NN NN O
   
A NN NN O
61 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
Japanese NN NN O
man NN NN O
with NN NN O
nephrotic NN NN B-Disease
syndrome NN NN I-Disease
due NN NN O
to NN NN O
focal NN NN B-Disease
segmental NN NN I-Disease
glomerulosclerosis NN NN I-Disease
was NN NN O
initially NN NN O
responding NN NN O
well NN NN O
to NN NN O
steroid NN NN O
therapy NN NN O
. NN NN O
   
The NN NN O
amount NN NN O
of NN NN O
daily NN NN O
urinary NN NN O
protein NN NN O
decreased NN NN O
from NN NN O
15 NN NN O
. NN NN O
6 NN NN O
to NN NN O
2 NN NN O
. NN NN O
8 NN NN O
g NN NN O
. NN NN O
   
Within NN NN O
14 NN NN O
days NN NN O
of NN NN O
the NN NN O
oral NN NN O
bisphosphonate NN NN O
( NN NN O
alendronate NN NN O
sodium NN NN O
) NN NN O
administration NN NN O
, NN NN O
the NN NN O
amount NN NN O
of NN NN O
daily NN NN O
urinary NN NN O
protein NN NN O
increased NN NN O
rapidly NN NN O
up NN NN O
to NN NN O
12 NN NN O
. NN NN O
8 NN NN O
g NN NN O
with NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
. NN NN O
   
After NN NN O
discontinuing NN NN O
the NN NN O
oral NN NN O
alendronate NN NN O
, NN NN O
the NN NN O
patient NN NN O
underwent NN NN O
six NN NN O
cycles NN NN O
of NN NN O
hemodialysis NN NN O
and NN NN O
four NN NN O
cycles NN NN O
of NN NN O
LDL NN NN O
apheresis NN NN O
. NN NN O
   
Urinary NN NN O
volume NN NN O
and NN NN O
serum NN NN O
creatinine NN NN O
levels NN NN O
recovered NN NN O
to NN NN O
the NN NN O
normal NN NN O
range NN NN O
, NN NN O
with NN NN O
urinary NN NN O
protein NN NN O
disappearing NN NN O
completely NN NN O
within NN NN O
40 NN NN O
days NN NN O
. NN NN O
   
This NN NN O
report NN NN O
demonstrates NN NN O
that NN NN O
not NN NN O
only NN NN O
intravenous NN NN O
, NN NN O
but NN NN O
also NN NN O
oral NN NN O
bisphosphonates NN NN O
can NN NN O
aggravate NN NN O
proteinuria NN NN B-Disease
and NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
. NN NN O
   
Serum NN NN O
- NN NN O
and NN NN O
glucocorticoid NN NN O
- NN NN O
inducible NN NN O
kinase NN NN O
1 NN NN O
in NN NN O
doxorubicin NN NN O
- NN NN O
induced NN NN O
nephrotic NN NN B-Disease
syndrome NN NN I-Disease
. NN NN O
   
Doxorubicin NN NN O
- NN NN O
induced NN NN O
nephropathy NN NN B-Disease
leads NN NN O
to NN NN O
epithelial NN NN O
sodium NN NN O
channel NN NN O
( NN NN O
ENaC NN NN O
) NN NN O
- NN NN O
dependent NN NN O
volume NN NN B-Disease
retention NN NN I-Disease
and NN NN O
renal NN NN O
fibrosis NN NN B-Disease
. NN NN O
   
The NN NN O
aldosterone NN NN O
- NN NN O
sensitive NN NN O
serum NN NN O
- NN NN O
and NN NN O
glucocorticoid NN NN O
- NN NN O
inducible NN NN O
kinase NN NN O
SGK1 NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
participate NN NN O
in NN NN O
the NN NN O
stimulation NN NN O
of NN NN O
ENaC NN NN O
and NN NN O
to NN NN O
mediate NN NN O
renal NN NN O
fibrosis NN NN B-Disease
following NN NN O
mineralocorticoid NN NN O
and NN NN O
salt NN NN O
excess NN NN O
. NN NN O
   
The NN NN O
present NN NN O
study NN NN O
was NN NN O
performed NN NN O
to NN NN O
elucidate NN NN O
the NN NN O
role NN NN O
of NN NN O
SGK1 NN NN O
in NN NN O
the NN NN O
volume NN NN B-Disease
retention NN NN I-Disease
and NN NN O
fibrosis NN NN B-Disease
during NN NN O
nephrotic NN NN B-Disease
syndrome NN NN I-Disease
. NN NN O
   
To NN NN O
this NN NN O
end NN NN O
, NN NN O
doxorubicin NN NN O
( NN NN O
15 NN NN O
mug NN NN O
/ NN NN O
g NN NN O
body NN NN O
wt NN NN O
) NN NN O
was NN NN O
injected NN NN O
intravenously NN NN O
into NN NN O
gene NN NN O
- NN NN O
targeted NN NN O
mice NN NN O
lacking NN NN O
SGK1 NN NN O
( NN NN O
sgk1 NN NN O
( NN NN O
- NN NN O
/ NN NN O
- NN NN O
) NN NN O
) NN NN O
and NN NN O
their NN NN O
wild NN NN O
- NN NN O
type NN NN O
littermates NN NN O
( NN NN O
sgk1 NN NN O
( NN NN O
+ NN NN O
/ NN NN O
+ NN NN O
) NN NN O
) NN NN O
. NN NN O
   
Doxorubicin NN NN O
treatment NN NN O
resulted NN NN O
in NN NN O
heavy NN NN O
proteinuria NN NN B-Disease
( NN NN O
> NN NN O
100 NN NN O
mg NN NN O
protein NN NN O
/ NN NN O
mg NN NN O
crea NN NN O
) NN NN O
in NN NN O
15 NN NN O
/ NN NN O
44 NN NN O
of NN NN O
sgk1 NN NN O
( NN NN O
+ NN NN O
/ NN NN O
+ NN NN O
) NN NN O
and NN NN O
15 NN NN O
/ NN NN O
44 NN NN O
of NN NN O
sgk1 NN NN O
( NN NN O
- NN NN O
/ NN NN O
- NN NN O
) NN NN O
mice NN NN O
leading NN NN O
to NN NN O
severe NN NN O
nephrotic NN NN B-Disease
syndrome NN NN I-Disease
with NN NN O
ascites NN NN B-Disease
, NN NN O
lipidemia NN NN B-Disease
, NN NN O
and NN NN O
hypoalbuminemia NN NN B-Disease
in NN NN O
both NN NN O
genotypes NN NN O
. NN NN O
   
Plasma NN NN O
aldosterone NN NN O
levels NN NN O
increased NN NN O
in NN NN O
nephrotic NN NN B-Disease
mice NN NN O
of NN NN O
both NN NN O
genotypes NN NN O
and NN NN O
was NN NN O
followed NN NN O
by NN NN O
increased NN NN O
SGK1 NN NN O
protein NN NN O
expression NN NN O
in NN NN O
sgk1 NN NN O
( NN NN O
+ NN NN O
/ NN NN O
+ NN NN O
) NN NN O
mice NN NN O
. NN NN O
   
Urinary NN NN O
sodium NN NN O
excretion NN NN O
reached NN NN O
signficantly NN NN O
lower NN NN O
values NN NN O
in NN NN O
sgk1 NN NN O
( NN NN O
+ NN NN O
/ NN NN O
+ NN NN O
) NN NN O
mice NN NN O
( NN NN O
15 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
5 NN NN O
mumol NN NN O
/ NN NN O
mg NN NN O
crea NN NN O
) NN NN O
than NN NN O
in NN NN O
sgk1 NN NN O
( NN NN O
- NN NN O
/ NN NN O
- NN NN O
) NN NN O
mice NN NN O
( NN NN O
35 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
5 NN NN O
mumol NN NN O
/ NN NN O
mg NN NN O
crea NN NN O
) NN NN O
and NN NN O
was NN NN O
associated NN NN O
with NN NN O
a NN NN O
significantly NN NN O
higher NN NN O
body NN NN O
weight NN NN B-Disease
gain NN NN I-Disease
in NN NN O
sgk1 NN NN O
( NN NN O
+ NN NN O
/ NN NN O
+ NN NN O
) NN NN O
compared NN NN O
with NN NN O
sgk1 NN NN O
( NN NN O
- NN NN O
/ NN NN O
- NN NN O
) NN NN O
mice NN NN O
( NN NN O
+ NN NN O
6 NN NN O
. NN NN O
6 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
7 NN NN O
vs NN NN O
. NN NN O
+ NN NN O
4 NN NN O
. NN NN O
1 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
8 NN NN O
g NN NN O
) NN NN O
. NN NN O
   
During NN NN O
the NN NN O
course NN NN O
of NN NN O
nephrotic NN NN B-Disease
syndrome NN NN I-Disease
, NN NN O
serum NN NN O
urea NN NN O
concentrations NN NN O
increased NN NN O
significantly NN NN O
faster NN NN O
in NN NN O
sgk1 NN NN O
( NN NN O
- NN NN O
/ NN NN O
- NN NN O
) NN NN O
mice NN NN O
than NN NN O
in NN NN O
sgk1 NN NN O
( NN NN O
+ NN NN O
/ NN NN O
+ NN NN O
) NN NN O
mice NN NN O
leading NN NN O
to NN NN O
uremia NN NN B-Disease
and NN NN O
a NN NN O
reduced NN NN O
median NN NN O
survival NN NN O
in NN NN O
sgk1 NN NN O
( NN NN O
- NN NN O
/ NN NN O
- NN NN O
) NN NN O
mice NN NN O
( NN NN O
29 NN NN O
vs NN NN O
. NN NN O
40 NN NN O
days NN NN O
in NN NN O
sgk1 NN NN O
( NN NN O
+ NN NN O
/ NN NN O
+ NN NN O
) NN NN O
mice NN NN O
) NN NN O
. NN NN O
   
In NN NN O
conclusion NN NN O
, NN NN O
gene NN NN O
- NN NN O
targeted NN NN O
mice NN NN O
lacking NN NN O
SGK1 NN NN O
showed NN NN O
blunted NN NN O
volume NN NN B-Disease
retention NN NN I-Disease
, NN NN O
yet NN NN O
were NN NN O
not NN NN O
protected NN NN O
against NN NN O
renal NN NN O
fibrosis NN NN B-Disease
during NN NN O
experimental NN NN O
nephrotic NN NN B-Disease
syndrome NN NN I-Disease
. NN NN O
   
Severe NN NN O
thrombocytopenia NN NN B-Disease
and NN NN O
haemolytic NN NN B-Disease
anaemia NN NN I-Disease
associated NN NN O
with NN NN O
ciprofloxacin NN NN O
: NN NN O
a NN NN O
case NN NN O
report NN NN O
with NN NN O
fatal NN NN O
outcome NN NN O
. NN NN O
   
Haematological NN NN O
adverse NN NN O
reactions NN NN O
associated NN NN O
with NN NN O
fatal NN NN O
outcome NN NN O
are NN NN O
rare NN NN O
during NN NN O
treatment NN NN O
with NN NN O
ciprofloxacin NN NN O
. NN NN O
   
A NN NN O
30 NN NN O
- NN NN O
year NN NN O
old NN NN O
Caucasian NN NN O
man NN NN O
reported NN NN O
with NN NN O
abdominal NN NN B-Disease
pain NN NN I-Disease
and NN NN O
jaundice NN NN B-Disease
after NN NN O
3 NN NN O
- NN NN O
day NN NN O
administration NN NN O
of NN NN O
oral NN NN O
ciprofloxacin NN NN O
for NN NN O
a NN NN O
suspect NN NN O
of NN NN O
urinary NN NN B-Disease
tract NN NN I-Disease
infection NN NN I-Disease
. NN NN O
   
Clinical NN NN O
evaluations NN NN O
suggested NN NN O
an NN NN O
initial NN NN O
diagnosis NN NN O
of NN NN O
severe NN NN O
thrombocytopenia NN NN B-Disease
and NN NN O
haemolysis NN NN B-Disease
. NN NN O
   
The NN NN O
patient NN NN O
progressively NN NN O
developed NN NN O
petechiae NN NN B-Disease
and NN NN O
purpura NN NN B-Disease
on NN NN O
thorax NN NN O
and NN NN O
lower NN NN O
limbs NN NN O
. NN NN O
   
Despite NN NN O
pharmacological NN NN O
and NN NN O
supportive NN NN O
interventions NN NN O
, NN NN O
laboratory NN NN O
parameters NN NN O
worsened NN NN O
and NN NN O
the NN NN O
patient NN NN O
died NN NN O
17 NN NN O
hours NN NN O
after NN NN O
admission NN NN O
. NN NN O
   
An NN NN O
accurate NN NN O
autopsy NN NN O
revealed NN NN O
most NN NN O
organs NN NN O
with NN NN O
diffuse NN NN O
petechial NN NN O
haemorrhages NN NN B-Disease
. NN NN O
   
No NN NN O
signs NN NN O
of NN NN O
bone NN NN B-Disease
marrow NN NN I-Disease
depression NN NN I-Disease
were NN NN O
found NN NN O
. NN NN O
   
No NN NN O
thrombi NN NN B-Disease
or NN NN O
signs NN NN O
of NN NN O
microangiopathies NN NN B-Disease
were NN NN O
observed NN NN O
in NN NN O
arterial NN NN O
vessels NN NN O
. NN NN O
   
Blood NN NN O
and NN NN O
urine NN NN O
cultures NN NN O
did NN NN O
not NN NN O
show NN NN O
any NN NN O
bacterial NN NN O
growth NN NN O
. NN NN O
   
This NN NN O
case NN NN O
report NN NN O
shows NN NN O
that NN NN O
ciprofloxacin NN NN O
may NN NN O
precipitate NN NN O
life NN NN O
- NN NN O
threatening NN NN O
thrombocytopenia NN NN B-Disease
and NN NN O
haemolytic NN NN B-Disease
anaemia NN NN I-Disease
, NN NN O
even NN NN O
in NN NN O
the NN NN O
early NN NN O
phases NN NN O
of NN NN O
treatment NN NN O
and NN NN O
without NN NN O
apparent NN NN O
previous NN NN O
exposures NN NN O
. NN NN O
   
Alpha NN NN O
- NN NN O
lipoic NN NN O
acid NN NN O
prevents NN NN O
mitochondrial NN NN B-Disease
damage NN NN I-Disease
and NN NN O
neurotoxicity NN NN B-Disease
in NN NN O
experimental NN NN O
chemotherapy NN NN O
neuropathy NN NN B-Disease
. NN NN O
   
The NN NN O
study NN NN O
investigates NN NN O
if NN NN O
alpha NN NN O
- NN NN O
lipoic NN NN O
acid NN NN O
is NN NN O
neuroprotective NN NN O
against NN NN O
chemotherapy NN NN O
induced NN NN O
neurotoxicity NN NN B-Disease
, NN NN O
if NN NN O
mitochondrial NN NN B-Disease
damage NN NN I-Disease
plays NN NN O
a NN NN O
critical NN NN O
role NN NN O
in NN NN O
toxic NN NN B-Disease
neurodegenerative NN NN I-Disease
cascade NN NN I-Disease
, NN NN O
and NN NN O
if NN NN O
neuroprotective NN NN O
effects NN NN O
of NN NN O
alpha NN NN O
- NN NN O
lipoic NN NN O
acid NN NN O
depend NN NN O
on NN NN O
mitochondria NN NN O
protection NN NN O
. NN NN O
   
We NN NN O
used NN NN O
an NN NN O
in NN NN O
vitro NN NN O
model NN NN O
of NN NN O
chemotherapy NN NN O
induced NN NN O
peripheral NN NN B-Disease
neuropathy NN NN I-Disease
that NN NN O
closely NN NN O
mimic NN NN O
the NN NN O
in NN NN O
vivo NN NN O
condition NN NN O
by NN NN O
exposing NN NN O
primary NN NN O
cultures NN NN O
of NN NN O
dorsal NN NN O
root NN NN O
ganglion NN NN O
( NN NN O
DRG NN NN O
) NN NN O
sensory NN NN O
neurons NN NN O
to NN NN O
paclitaxel NN NN O
and NN NN O
cisplatin NN NN O
, NN NN O
two NN NN O
widely NN NN O
used NN NN O
and NN NN O
highly NN NN O
effective NN NN O
chemotherapeutic NN NN O
drugs NN NN O
. NN NN O
   
This NN NN O
approach NN NN O
allowed NN NN O
investigating NN NN O
the NN NN O
efficacy NN NN O
of NN NN O
alpha NN NN O
- NN NN O
lipoic NN NN O
acid NN NN O
in NN NN O
preventing NN NN O
axonal NN NN B-Disease
damage NN NN I-Disease
and NN NN O
apoptosis NN NN O
and NN NN O
the NN NN O
function NN NN O
and NN NN O
ultrastructural NN NN O
morphology NN NN O
of NN NN O
mitochondria NN NN O
after NN NN O
exposure NN NN O
to NN NN O
toxic NN NN O
agents NN NN O
and NN NN O
alpha NN NN O
- NN NN O
lipoic NN NN O
acid NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
demonstrate NN NN O
that NN NN O
both NN NN O
cisplatin NN NN O
and NN NN O
paclitaxel NN NN O
cause NN NN O
early NN NN O
mitochondrial NN NN B-Disease
impairment NN NN I-Disease
with NN NN O
loss NN NN O
of NN NN O
membrane NN NN O
potential NN NN O
and NN NN O
induction NN NN O
of NN NN O
autophagic NN NN O
vacuoles NN NN O
in NN NN O
neurons NN NN O
. NN NN O
   
Alpha NN NN O
- NN NN O
lipoic NN NN O
acid NN NN O
exerts NN NN O
neuroprotective NN NN O
effects NN NN O
against NN NN O
chemotherapy NN NN O
induced NN NN O
neurotoxicity NN NN B-Disease
in NN NN O
sensory NN NN O
neurons NN NN O
: NN NN O
it NN NN O
rescues NN NN O
the NN NN O
mitochondrial NN NN B-Disease
toxicity NN NN I-Disease
and NN NN O
induces NN NN O
the NN NN O
expression NN NN O
of NN NN O
frataxin NN NN O
, NN NN O
an NN NN O
essential NN NN O
mitochondrial NN NN O
protein NN NN O
with NN NN O
anti NN NN O
- NN NN O
oxidant NN NN O
and NN NN O
chaperone NN NN O
properties NN NN O
. NN NN O
   
In NN NN O
conclusion NN NN O
mitochondrial NN NN B-Disease
toxicity NN NN I-Disease
is NN NN O
an NN NN O
early NN NN O
common NN NN O
event NN NN O
both NN NN O
in NN NN O
paclitaxel NN NN O
and NN NN O
cisplatin NN NN O
induced NN NN O
neurotoxicity NN NN B-Disease
. NN NN O
   
Alpha NN NN O
- NN NN O
lipoic NN NN O
acid NN NN O
protects NN NN O
sensory NN NN O
neurons NN NN O
through NN NN O
its NN NN O
anti NN NN O
- NN NN O
oxidant NN NN O
and NN NN O
mitochondrial NN NN O
regulatory NN NN O
functions NN NN O
, NN NN O
possibly NN NN O
inducing NN NN O
the NN NN O
expression NN NN O
of NN NN O
frataxin NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
alpha NN NN O
- NN NN O
lipoic NN NN O
acid NN NN O
might NN NN O
reduce NN NN O
the NN NN O
risk NN NN O
of NN NN O
developing NN NN O
peripheral NN NN B-Disease
nerve NN NN I-Disease
toxicity NN NN I-Disease
in NN NN O
patients NN NN O
undergoing NN NN O
chemotherapy NN NN O
and NN NN O
encourage NN NN O
further NN NN O
confirmatory NN NN O
clinical NN NN O
trials NN NN O
. NN NN O
   
Toxicity NN NN B-Disease
in NN NN O
rhesus NN NN O
monkeys NN NN O
following NN NN O
administration NN NN O
of NN NN O
the NN NN O
8 NN NN O
- NN NN O
aminoquinoline NN NN O
8 NN NN O
- NN NN O
[ NN NN O
( NN NN O
4 NN NN O
- NN NN O
amino NN NN O
- NN NN O
l NN NN O
- NN NN O
methylbutyl NN NN O
) NN NN O
amino NN NN O
] NN NN O
- NN NN O
5 NN NN O
- NN NN O
( NN NN O
l NN NN O
- NN NN O
hexyloxy NN NN O
) NN NN O
- NN NN O
6 NN NN O
- NN NN O
methoxy NN NN O
- NN NN O
4 NN NN O
- NN NN O
methylquinoline NN NN O
( NN NN O
WR242511 NN NN O
) NN NN O
. NN NN O
   
INTRODUCTION NN NN O
: NN NN O
Many NN NN O
substances NN NN O
that NN NN O
form NN NN O
methemoglobin NN NN O
( NN NN O
MHb NN NN O
) NN NN O
effectively NN NN O
counter NN NN O
cyanide NN NN O
( NN NN O
CN NN NN O
) NN NN O
toxicity NN NN B-Disease
. NN NN O
   
Although NN NN O
MHb NN NN O
formers NN NN O
are NN NN O
generally NN NN O
applied NN NN O
as NN NN O
treatments NN NN O
for NN NN O
CN NN NN O
poisoning NN NN B-Disease
, NN NN O
it NN NN O
has NN NN O
been NN NN O
proposed NN NN O
that NN NN O
a NN NN O
stable NN NN O
, NN NN O
long NN NN O
- NN NN O
acting NN NN O
MHb NN NN O
former NN NN O
could NN NN O
serve NN NN O
as NN NN O
a NN NN O
CN NN NN O
pretreatment NN NN O
. NN NN O
   
Using NN NN O
this NN NN O
rationale NN NN O
, NN NN O
the NN NN O
8 NN NN O
- NN NN O
aminoquinoline NN NN O
WR242511 NN NN O
, NN NN O
a NN NN O
potent NN NN O
long NN NN O
- NN NN O
lasting NN NN O
MHb NN NN O
former NN NN O
in NN NN O
rodents NN NN O
and NN NN O
beagle NN NN O
dogs NN NN O
, NN NN O
was NN NN O
studied NN NN O
in NN NN O
the NN NN O
rhesus NN NN O
monkey NN NN O
for NN NN O
advanced NN NN O
development NN NN O
as NN NN O
a NN NN O
potential NN NN O
CN NN NN O
pretreatment NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
In NN NN O
this NN NN O
study NN NN O
, NN NN O
WR242511 NN NN O
was NN NN O
administered NN NN O
intravenously NN NN O
( NN NN O
IV NN NN O
) NN NN O
in NN NN O
2 NN NN O
female NN NN O
and NN NN O
4 NN NN O
male NN NN O
rhesus NN NN O
monkeys NN NN O
in NN NN O
doses NN NN O
of NN NN O
3 NN NN O
. NN NN O
5 NN NN O
and NN NN O
/ NN NN O
or NN NN O
7 NN NN O
. NN NN O
0 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
; NN NN O
a NN NN O
single NN NN O
male NN NN O
also NN NN O
received NN NN O
WR242511 NN NN O
orally NN NN O
( NN NN O
PO NN NN O
) NN NN O
at NN NN O
7 NN NN O
. NN NN O
0 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
. NN NN O
   
Health NN NN O
status NN NN O
and NN NN O
MHb NN NN O
levels NN NN O
were NN NN O
monitored NN NN O
following NN NN O
exposure NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
The NN NN O
selected NN NN O
doses NN NN O
of NN NN O
WR242511 NN NN O
, NN NN O
which NN NN O
produced NN NN O
significant NN NN O
methemoglobinemia NN NN B-Disease
in NN NN O
beagle NN NN O
dogs NN NN O
in NN NN O
earlier NN NN O
studies NN NN O
conducted NN NN O
elsewhere NN NN O
, NN NN O
produced NN NN O
very NN NN O
little NN NN O
MHb NN NN O
( NN NN O
mean NN NN O
< NN NN O
2 NN NN O
. NN NN O
0 NN NN O
% NN NN O
) NN NN O
in NN NN O
the NN NN O
rhesus NN NN O
monkey NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
transient NN NN O
hemoglobinuria NN NN B-Disease
was NN NN O
noted NN NN O
approximately NN NN O
60 NN NN O
minutes NN NN O
postinjection NN NN O
of NN NN O
WR242511 NN NN O
( NN NN O
3 NN NN O
. NN NN O
5 NN NN O
or NN NN O
7 NN NN O
. NN NN O
0 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
, NN NN O
and NN NN O
2 NN NN O
lethalities NN NN O
occurred NN NN O
( NN NN O
one NN NN O
IV NN NN O
and NN NN O
one NN NN O
PO NN NN O
) NN NN O
following NN NN O
the NN NN O
7 NN NN O
. NN NN O
0 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
dose NN NN O
. NN NN O
   
Myoglobinuria NN NN B-Disease
was NN NN O
also NN NN O
observed NN NN O
following NN NN O
the NN NN O
7 NN NN O
. NN NN O
0 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
dose NN NN O
. NN NN O
   
Histopathology NN NN O
analyses NN NN O
in NN NN O
the NN NN O
2 NN NN O
animals NN NN O
that NN NN O
died NN NN O
revealed NN NN O
liver NN NN B-Disease
and NN NN I-Disease
kidney NN NN I-Disease
toxicity NN NN I-Disease
, NN NN O
with NN NN O
greater NN NN O
severity NN NN O
in NN NN O
the NN NN O
orally NN NN O
- NN NN O
treated NN NN O
animal NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
These NN NN O
data NN NN O
demonstrate NN NN O
direct NN NN O
and NN NN O
/ NN NN O
or NN NN O
indirect NN NN O
drug NN NN O
- NN NN O
induced NN NN O
toxicity NN NN B-Disease
. NN NN O
   
It NN NN O
is NN NN O
concluded NN NN O
that NN NN O
WR242511 NN NN O
should NN NN O
not NN NN O
be NN NN O
pursued NN NN O
as NN NN O
a NN NN O
pretreatment NN NN O
for NN NN O
CN NN NN O
poisoning NN NN B-Disease
unless NN NN O
the NN NN O
anti NN NN O
- NN NN O
CN NN NN O
characteristics NN NN O
of NN NN O
this NN NN O
compound NN NN O
can NN NN O
be NN NN O
successfully NN NN O
dissociated NN NN O
from NN NN O
those NN NN O
producing NN NN O
undesirable NN NN O
toxicity NN NN B-Disease
. NN NN O
   
Repetitive NN NN O
transcranial NN NN O
magnetic NN NN O
stimulation NN NN O
for NN NN O
levodopa NN NN O
- NN NN O
induced NN NN O
dyskinesias NN NN B-Disease
in NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
In NN NN O
a NN NN O
placebo NN NN O
- NN NN O
controlled NN NN O
, NN NN O
single NN NN O
- NN NN O
blinded NN NN O
, NN NN O
crossover NN NN O
study NN NN O
, NN NN O
we NN NN O
assessed NN NN O
the NN NN O
effect NN NN O
of NN NN O
"""""""" NN NN O
real NN NN O
"""""""" NN NN O
repetitive NN NN O
transcranial NN NN O
magnetic NN NN O
stimulation NN NN O
( NN NN O
rTMS NN NN O
) NN NN O
versus NN NN O
"""""""" NN NN O
sham NN NN O
"""""""" NN NN O
rTMS NN NN O
( NN NN O
placebo NN NN O
) NN NN O
on NN NN O
peak NN NN O
dose NN NN O
dyskinesias NN NN B-Disease
in NN NN O
patients NN NN O
with NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
( NN NN O
PD NN NN B-Disease
) NN NN O
. NN NN O
   
Ten NN NN O
patients NN NN O
with NN NN O
PD NN NN B-Disease
and NN NN O
prominent NN NN O
dyskinesias NN NN B-Disease
had NN NN O
rTMS NN NN O
( NN NN O
1 NN NN O
, NN NN O
800 NN NN O
pulses NN NN O
; NN NN O
1 NN NN O
Hz NN NN O
rate NN NN O
) NN NN O
delivered NN NN O
over NN NN O
the NN NN O
motor NN NN O
cortex NN NN O
for NN NN O
4 NN NN O
consecutive NN NN O
days NN NN O
twice NN NN O
, NN NN O
once NN NN O
real NN NN O
stimuli NN NN O
and NN NN O
once NN NN O
sham NN NN O
stimulation NN NN O
were NN NN O
used NN NN O
; NN NN O
evaluations NN NN O
were NN NN O
done NN NN O
at NN NN O
the NN NN O
baseline NN NN O
and NN NN O
1 NN NN O
day NN NN O
after NN NN O
the NN NN O
end NN NN O
of NN NN O
each NN NN O
of NN NN O
the NN NN O
treatment NN NN O
series NN NN O
. NN NN O
   
Direct NN NN O
comparison NN NN O
between NN NN O
sham NN NN O
and NN NN O
real NN NN O
rTMS NN NN O
effects NN NN O
showed NN NN O
no NN NN O
significant NN NN O
difference NN NN O
in NN NN O
clinician NN NN O
- NN NN O
assessed NN NN O
dyskinesia NN NN B-Disease
severity NN NN O
. NN NN O
   
However NN NN O
, NN NN O
comparison NN NN O
with NN NN O
the NN NN O
baseline NN NN O
showed NN NN O
small NN NN O
but NN NN O
significant NN NN O
reduction NN NN O
in NN NN O
dyskinesia NN NN B-Disease
severity NN NN O
following NN NN O
real NN NN O
rTMS NN NN O
but NN NN O
not NN NN O
placebo NN NN O
. NN NN O
   
The NN NN O
major NN NN O
effect NN NN O
was NN NN O
on NN NN O
dystonia NN NN B-Disease
subscore NN NN O
. NN NN O
   
Similarly NN NN O
, NN NN O
in NN NN O
patient NN NN O
diaries NN NN O
, NN NN O
although NN NN O
both NN NN O
treatments NN NN O
caused NN NN O
reduction NN NN O
in NN NN O
subjective NN NN O
dyskinesia NN NN B-Disease
scores NN NN O
during NN NN O
the NN NN O
days NN NN O
of NN NN O
intervention NN NN O
, NN NN O
the NN NN O
effect NN NN O
was NN NN O
sustained NN NN O
for NN NN O
3 NN NN O
days NN NN O
after NN NN O
the NN NN O
intervention NN NN O
for NN NN O
the NN NN O
real NN NN O
rTMS NN NN O
only NN NN O
. NN NN O
   
Following NN NN O
rTMS NN NN O
, NN NN O
no NN NN O
side NN NN O
effects NN NN O
and NN NN O
no NN NN O
adverse NN NN O
effects NN NN O
on NN NN O
motor NN NN O
function NN NN O
and NN NN O
PD NN NN B-Disease
symptoms NN NN O
were NN NN O
noted NN NN O
. NN NN O
   
The NN NN O
results NN NN O
suggest NN NN O
the NN NN O
existence NN NN O
of NN NN O
residual NN NN O
beneficial NN NN O
clinical NN NN O
aftereffects NN NN O
of NN NN O
consecutive NN NN O
daily NN NN O
applications NN NN O
of NN NN O
low NN NN O
- NN NN O
frequency NN NN O
rTMS NN NN O
on NN NN O
dyskinesias NN NN B-Disease
in NN NN O
PD NN NN B-Disease
. NN NN O
   
The NN NN O
effects NN NN O
may NN NN O
be NN NN O
further NN NN O
exploited NN NN O
for NN NN O
potential NN NN O
therapeutic NN NN O
uses NN NN O
. NN NN O
   
Intracavernous NN NN O
epinephrine NN NN O
: NN NN O
a NN NN O
minimally NN NN O
invasive NN NN O
treatment NN NN O
for NN NN O
priapism NN NN B-Disease
in NN NN O
the NN NN O
emergency NN NN O
department NN NN O
. NN NN O
   
Priapism NN NN B-Disease
is NN NN O
the NN NN O
prolonged NN NN O
erection NN NN O
of NN NN O
the NN NN O
penis NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
sexual NN NN O
arousal NN NN O
. NN NN O
   
A NN NN O
45 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
man NN NN O
, NN NN O
an NN NN O
admitted NN NN O
frequent NN NN O
cocaine NN NN O
user NN NN O
, NN NN O
presented NN NN O
to NN NN O
the NN NN O
Emergency NN NN O
Department NN NN O
( NN NN O
ED NN NN O
) NN NN O
on NN NN O
two NN NN O
separate NN NN O
occasions NN NN O
with NN NN O
a NN NN O
history NN NN O
of NN NN O
priapism NN NN B-Disease
after NN NN O
cocaine NN NN O
use NN NN O
. NN NN O
   
The NN NN O
management NN NN O
options NN NN O
in NN NN O
the NN NN O
ED NN NN O
, NN NN O
as NN NN O
exemplified NN NN O
by NN NN O
four NN NN O
individual NN NN O
case NN NN O
reports NN NN O
, NN NN O
in NN NN O
particular NN NN O
the NN NN O
use NN NN O
of NN NN O
a NN NN O
minimally NN NN O
invasive NN NN O
method NN NN O
of NN NN O
intracorporal NN NN O
epinephrine NN NN O
instillation NN NN O
, NN NN O
are NN NN O
discussed NN NN O
. NN NN O
   
Prophylactic NN NN O
use NN NN O
of NN NN O
lamivudine NN NN O
with NN NN O
chronic NN NN O
immunosuppressive NN NN O
therapy NN NN O
for NN NN O
rheumatologic NN NN B-Disease
disorders NN NN I-Disease
. NN NN O
   
The NN NN O
objective NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
report NN NN O
our NN NN O
experience NN NN O
concerning NN NN O
the NN NN O
effectiveness NN NN O
of NN NN O
the NN NN O
prophylactic NN NN O
administration NN NN O
of NN NN O
lamivudine NN NN O
in NN NN O
hepatitis NN NN O
B NN NN O
virus NN NN O
surface NN NN O
antigen NN NN O
( NN NN O
HBs NN NN O
Ag NN NN O
) NN NN O
positive NN NN O
patients NN NN O
with NN NN O
rheumatologic NN NN B-Disease
disease NN NN I-Disease
. NN NN O
   
From NN NN O
June NN NN O
2004 NN NN O
to NN NN O
October NN NN O
2006 NN NN O
, NN NN O
11 NN NN O
HBs NN NN O
Ag NN NN O
positive NN NN O
patients NN NN O
with NN NN O
rheumatologic NN NN B-Disease
diseases NN NN I-Disease
, NN NN O
who NN NN O
were NN NN O
on NN NN O
both NN NN O
immunosuppressive NN NN O
and NN NN O
prophylactic NN NN O
lamivudine NN NN O
therapies NN NN O
, NN NN O
were NN NN O
retrospectively NN NN O
assessed NN NN O
. NN NN O
   
Liver NN NN O
function NN NN O
tests NN NN O
, NN NN O
hepatitis NN NN B-Disease
B NN NN I-Disease
virus NN NN O
( NN NN O
HBV NN NN O
) NN NN O
serologic NN NN O
markers NN NN O
, NN NN O
and NN NN O
HBV NN NN O
DNA NN NN O
levels NN NN O
of NN NN O
the NN NN O
patients NN NN O
during NN NN O
follow NN NN O
- NN NN O
up NN NN O
were NN NN O
obtained NN NN O
from NN NN O
hospital NN NN O
file NN NN O
records NN NN O
. NN NN O
   
Eleven NN NN O
patients NN NN O
( NN NN O
six NN NN O
male NN NN O
) NN NN O
with NN NN O
median NN NN O
age NN NN O
47 NN NN O
years NN NN O
( NN NN O
range NN NN O
27 NN NN O
- NN NN O
73 NN NN O
) NN NN O
, NN NN O
median NN NN O
disease NN NN O
duration NN NN O
50 NN NN O
months NN NN O
( NN NN O
range NN NN O
9 NN NN O
- NN NN O
178 NN NN O
) NN NN O
and NN NN O
median NN NN O
follow NN NN O
- NN NN O
up NN NN O
period NN NN O
of NN NN O
patients NN NN O
13 NN NN O
. NN NN O
8 NN NN O
months NN NN O
( NN NN O
range NN NN O
5 NN NN O
- NN NN O
27 NN NN O
) NN NN O
were NN NN O
enrolled NN NN O
in NN NN O
this NN NN O
study NN NN O
. NN NN O
   
Lamivudine NN NN O
therapy NN NN O
was NN NN O
started NN NN O
3 NN NN O
- NN NN O
7 NN NN O
days NN NN O
prior NN NN O
to NN NN O
immunosuppressive NN NN O
therapy NN NN O
in NN NN O
all NN NN O
patients NN NN O
. NN NN O
   
Baseline NN NN O
, NN NN O
liver NN NN O
function NN NN O
tests NN NN O
were NN NN O
elevated NN NN O
in NN NN O
two NN NN O
patients NN NN O
( NN NN O
fourth NN NN O
patient NN NN O
: NN NN O
ALT NN NN O
: NN NN O
122 NN NN O
IU NN NN O
/ NN NN O
l NN NN O
, NN NN O
AST NN NN O
: NN NN O
111 NN NN O
IU NN NN O
/ NN NN O
l NN NN O
, NN NN O
tenth NN NN O
patient NN NN O
: NN NN O
ALT NN NN O
: NN NN O
294 NN NN O
IU NN NN O
/ NN NN O
l NN NN O
, NN NN O
AST NN NN O
: NN NN O
274 NN NN O
IU NN NN O
/ NN NN O
l NN NN O
, NN NN O
with NN NN O
minimal NN NN O
changes NN NN O
in NN NN O
the NN NN O
liver NN NN O
biopsy NN NN O
in NN NN O
both NN NN O
) NN NN O
. NN NN O
   
Shortly NN NN O
after NN NN O
treatment NN NN O
their NN NN O
tests NN NN O
normalized NN NN O
and NN NN O
during NN NN O
follow NN NN O
- NN NN O
up NN NN O
period NN NN O
none NN NN O
of NN NN O
the NN NN O
patients NN NN O
had NN NN O
abnormal NN NN B-Disease
liver NN NN I-Disease
function NN NN I-Disease
tests NN NN O
. NN NN O
   
In NN NN O
four NN NN O
patients NN NN O
HBV NN NN O
DNA NN NN O
levels NN NN O
were NN NN O
higher NN NN O
than NN NN O
normal NN NN O
at NN NN O
baseline NN NN O
. NN NN O
   
Two NN NN O
of NN NN O
these NN NN O
normalized NN NN O
and NN NN O
the NN NN O
others NN NN O
increased NN NN O
later NN NN O
. NN NN O
   
In NN NN O
three NN NN O
additional NN NN O
patients NN NN O
, NN NN O
HBV NN NN O
DNA NN NN O
levels NN NN O
were NN NN O
increased NN NN O
during NN NN O
follow NN NN O
- NN NN O
up NN NN O
. NN NN O
   
   O
of NN NN O
the NN NN O
patients NN NN O
had NN NN O
significant NN NN O
clinical NN NN O
sings NN NN O
of NN NN O
HBV NN NN O
activation NN NN O
. NN NN O
   
Lamivudine NN NN O
was NN NN O
well NN NN O
tolerated NN NN O
and NN NN O
was NN NN O
continued NN NN O
in NN NN O
all NN NN O
patients NN NN O
. NN NN O
   
Prophylactic NN NN O
administration NN NN O
of NN NN O
lamivudine NN NN O
in NN NN O
patients NN NN O
who NN NN O
required NN NN O
immunosuppressive NN NN O
therapy NN NN O
seems NN NN O
to NN NN O
be NN NN O
safe NN NN O
, NN NN O
well NN NN O
tolerated NN NN O
and NN NN O
effective NN NN O
in NN NN O
preventing NN NN O
HBV NN NN O
reactivation NN NN O
. NN NN O
   
Effect NN NN O
of NN NN O
green NN NN O
tea NN NN O
and NN NN O
vitamin NN NN O
E NN NN O
combination NN NN O
in NN NN O
isoproterenol NN NN O
induced NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
in NN NN O
rats NN NN O
. NN NN O
   
The NN NN O
present NN NN O
study NN NN O
was NN NN O
aimed NN NN O
to NN NN O
investigate NN NN O
the NN NN O
combined NN NN O
effects NN NN O
of NN NN O
green NN NN O
tea NN NN O
and NN NN O
vitamin NN NN O
E NN NN O
on NN NN O
heart NN NN O
weight NN NN O
, NN NN O
body NN NN O
weight NN NN O
, NN NN O
serum NN NN O
marker NN NN O
enzymes NN NN O
, NN NN O
lipid NN NN O
peroxidation NN NN O
, NN NN O
endogenous NN NN O
antioxidants NN NN O
and NN NN O
membrane NN NN O
bound NN NN O
ATPases NN NN O
in NN NN O
isoproterenol NN NN O
( NN NN O
ISO NN NN O
) NN NN O
- NN NN O
induced NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
in NN NN O
rats NN NN O
. NN NN O
   
Adult NN NN O
male NN NN O
albino NN NN O
rats NN NN O
, NN NN O
treated NN NN O
with NN NN O
ISO NN NN O
( NN NN O
200 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
s NN NN O
. NN NN O
c NN NN O
. NN NN O
) NN NN O
for NN NN O
2 NN NN O
days NN NN O
at NN NN O
an NN NN O
interval NN NN O
of NN NN O
24 NN NN O
h NN NN O
caused NN NN O
a NN NN O
significant NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
elevation NN NN O
of NN NN O
heart NN NN O
weight NN NN O
, NN NN O
serum NN NN O
marker NN NN O
enzymes NN NN O
, NN NN O
lipid NN NN O
peroxidation NN NN O
and NN NN O
Ca NN NN O
+ NN NN O
2 NN NN O
ATPase NN NN O
level NN NN O
whereas NN NN O
there NN NN O
was NN NN O
a NN NN O
significant NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
decrease NN NN O
in NN NN O
body NN NN O
weight NN NN O
, NN NN O
endogenous NN NN O
antioxidants NN NN O
, NN NN O
Na NN NN O
+ NN NN O
/ NN NN O
K NN NN O
+ NN NN O
ATPase NN NN O
and NN NN O
Mg NN NN O
+ NN NN O
2 NN NN O
ATPase NN NN O
levels NN NN O
. NN NN O
   
Administration NN NN O
of NN NN O
green NN NN O
tea NN NN O
( NN NN O
100 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
, NN NN O
p NN NN O
. NN NN O
o NN NN O
. NN NN O
) NN NN O
and NN NN O
vitamin NN NN O
E NN NN O
( NN NN O
100 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
, NN NN O
p NN NN O
. NN NN O
o NN NN O
. NN NN O
) NN NN O
together NN NN O
for NN NN O
30 NN NN O
consecutive NN NN O
days NN NN O
and NN NN O
challenged NN NN O
with NN NN O
ISO NN NN O
on NN NN O
the NN NN O
day NN NN O
29th NN NN O
and NN NN O
30th NN NN O
, NN NN O
showed NN NN O
a NN NN O
significant NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
decrease NN NN O
in NN NN O
heart NN NN O
weight NN NN O
, NN NN O
serum NN NN O
marker NN NN O
enzymes NN NN O
, NN NN O
lipid NN NN O
peroxidation NN NN O
, NN NN O
Ca NN NN O
+ NN NN O
2 NN NN O
ATPase NN NN O
and NN NN O
a NN NN O
significant NN NN O
increase NN NN O
in NN NN O
the NN NN O
body NN NN O
weight NN NN O
, NN NN O
endogenous NN NN O
antioxidants NN NN O
, NN NN O
Na NN NN O
+ NN NN O
/ NN NN O
K NN NN O
+ NN NN O
ATPase NN NN O
and NN NN O
Mg NN NN O
+ NN NN O
2 NN NN O
ATPase NN NN O
when NN NN O
compared NN NN O
with NN NN O
ISO NN NN O
treated NN NN O
group NN NN O
and NN NN O
green NN NN O
tea NN NN O
or NN NN O
vitamin NN NN O
E NN NN O
alone NN NN O
treated NN NN O
groups NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
indicate NN NN O
the NN NN O
synergistic NN NN O
protective NN NN O
effect NN NN O
of NN NN O
green NN NN O
tea NN NN O
and NN NN O
vitamin NN NN O
E NN NN O
during NN NN O
ISO NN NN O
induced NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
in NN NN O
rats NN NN O
. NN NN O
   
Irreversible NN NN O
damage NN NN O
to NN NN O
the NN NN O
medullary NN NN O
interstitium NN NN O
in NN NN O
experimental NN NN O
analgesic NN NN O
nephropathy NN NN B-Disease
in NN NN O
F344 NN NN O
rats NN NN O
. NN NN O
   
Renal NN NN B-Disease
papillary NN NN I-Disease
necrosis NN NN I-Disease
( NN NN O
RPN NN NN B-Disease
) NN NN O
and NN NN O
a NN NN O
decreased NN NN O
urinary NN NN O
concentrating NN NN O
ability NN NN O
developed NN NN O
during NN NN O
continuous NN NN O
long NN NN O
- NN NN O
term NN NN O
treatment NN NN O
with NN NN O
aspirin NN NN O
and NN NN O
paracetamol NN NN O
in NN NN O
female NN NN O
Fischer NN NN O
344 NN NN O
rats NN NN O
. NN NN O
   
Renal NN NN O
structure NN NN O
and NN NN O
concentrating NN NN O
ability NN NN O
were NN NN O
examined NN NN O
after NN NN O
a NN NN O
recovery NN NN O
period NN NN O
of NN NN O
up NN NN O
to NN NN O
18 NN NN O
weeks NN NN O
, NN NN O
when NN NN O
no NN NN O
analgesics NN NN O
were NN NN O
given NN NN O
, NN NN O
to NN NN O
investigate NN NN O
whether NN NN O
the NN NN O
analgesic NN NN O
- NN NN O
induced NN NN O
changes NN NN O
were NN NN O
reversible NN NN O
. NN NN O
   
There NN NN O
was NN NN O
no NN NN O
evidence NN NN O
of NN NN O
repair NN NN O
to NN NN O
the NN NN O
damaged NN NN O
medullary NN NN O
interstitial NN NN O
matrix NN NN O
, NN NN O
or NN NN O
proliferation NN NN O
of NN NN O
remaining NN NN O
undamaged NN NN O
type NN NN O
1 NN NN O
medullary NN NN O
interstitial NN NN O
cells NN NN O
after NN NN O
the NN NN O
recovery NN NN O
period NN NN O
following NN NN O
analgesic NN NN O
treatment NN NN O
. NN NN O
   
The NN NN O
recovery NN NN O
of NN NN O
urinary NN NN O
concentrating NN NN O
ability NN NN O
was NN NN O
related NN NN O
to NN NN O
the NN NN O
length NN NN O
of NN NN O
analgesic NN NN O
treatment NN NN O
and NN NN O
the NN NN O
extent NN NN O
of NN NN O
the NN NN O
resulting NN NN O
inner NN NN O
medullary NN NN O
structural NN NN O
damage NN NN O
. NN NN O
   
During NN NN O
the NN NN O
early NN NN O
stages NN NN O
of NN NN O
analgesic NN NN O
treatment NN NN O
, NN NN O
the NN NN O
changes NN NN O
in NN NN O
urinary NN NN O
concentrating NN NN O
ability NN NN O
were NN NN O
reversible NN NN O
, NN NN O
but NN NN O
after NN NN O
prolonged NN NN O
analgesic NN NN O
treatment NN NN O
, NN NN O
maximum NN NN O
urinary NN NN O
concentrating NN NN O
ability NN NN O
failed NN NN O
to NN NN O
recover NN NN O
. NN NN O
   
This NN NN O
study NN NN O
shows NN NN O
that NN NN O
prolonged NN NN O
analgesic NN NN O
treatment NN NN O
in NN NN O
Fischer NN NN O
344 NN NN O
rats NN NN O
causes NN NN O
progressive NN NN O
and NN NN O
irreversible NN NN O
damage NN NN O
to NN NN O
the NN NN O
interstitial NN NN O
matrix NN NN O
and NN NN O
type NN NN O
1 NN NN O
interstitial NN NN O
cells NN NN O
leading NN NN O
to NN NN O
RPN NN NN B-Disease
. NN NN O
   
The NN NN O
associated NN NN O
urinary NN NN O
concentrating NN NN O
defect NN NN O
is NN NN O
reversible NN NN O
only NN NN O
during NN NN O
the NN NN O
early NN NN O
stages NN NN O
of NN NN O
structural NN NN O
damage NN NN O
to NN NN O
the NN NN O
inner NN NN O
medulla NN NN O
. NN NN O
   
Testosterone NN NN O
- NN NN O
dependent NN NN O
hypertension NN NN B-Disease
and NN NN O
upregulation NN NN O
of NN NN O
intrarenal NN NN O
angiotensinogen NN NN O
in NN NN O
Dahl NN NN O
salt NN NN O
- NN NN O
sensitive NN NN O
rats NN NN O
. NN NN O
   
Blood NN NN O
pressure NN NN O
( NN NN O
BP NN NN O
) NN NN O
is NN NN O
more NN NN O
salt NN NN O
sensitive NN NN O
in NN NN O
men NN NN O
than NN NN O
in NN NN O
premenopausal NN NN O
women NN NN O
. NN NN O
   
In NN NN O
Dahl NN NN O
salt NN NN O
- NN NN O
sensitive NN NN O
rats NN NN O
( NN NN O
DS NN NN O
) NN NN O
, NN NN O
high NN NN O
- NN NN O
salt NN NN O
( NN NN O
HS NN NN O
) NN NN O
diet NN NN O
increases NN NN O
BP NN NN O
more NN NN O
in NN NN O
males NN NN O
than NN NN O
females NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
to NN NN O
the NN NN O
systemic NN NN O
renin NN NN O
- NN NN O
angiotensin NN NN O
system NN NN O
, NN NN O
which NN NN O
is NN NN O
suppressed NN NN O
in NN NN O
response NN NN O
to NN NN O
HS NN NN O
in NN NN O
male NN NN O
DS NN NN O
, NN NN O
intrarenal NN NN O
angiotensinogen NN NN O
expression NN NN O
is NN NN O
increased NN NN O
, NN NN O
and NN NN O
intrarenal NN NN O
levels NN NN O
of NN NN O
ANG NN NN O
II NN NN O
are NN NN O
not NN NN O
suppressed NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
the NN NN O
hypothesis NN NN O
was NN NN O
tested NN NN O
that NN NN O
there NN NN O
is NN NN O
a NN NN O
sexual NN NN O
dimorphism NN NN O
in NN NN O
HS NN NN O
- NN NN O
induced NN NN O
upregulation NN NN O
of NN NN O
intrarenal NN NN O
angiotensinogen NN NN O
mediated NN NN O
by NN NN O
testosterone NN NN O
that NN NN O
also NN NN O
causes NN NN O
increases NN NN O
in NN NN O
BP NN NN O
and NN NN O
renal NN NN B-Disease
injury NN NN I-Disease
. NN NN O
   
On NN NN O
a NN NN O
low NN NN O
- NN NN O
salt NN NN O
( NN NN O
LS NN NN O
) NN NN O
diet NN NN O
, NN NN O
male NN NN O
DS NN NN O
had NN NN O
higher NN NN O
levels NN NN O
of NN NN O
intrarenal NN NN O
angiotensinogen NN NN O
mRNA NN NN O
than NN NN O
females NN NN O
. NN NN O
   
HS NN NN O
diet NN NN O
for NN NN O
4 NN NN O
wk NN NN O
increased NN NN O
renal NN NN O
cortical NN NN O
angiotensinogen NN NN O
mRNA NN NN O
and NN NN O
protein NN NN O
only NN NN O
in NN NN O
male NN NN O
DS NN NN O
, NN NN O
which NN NN O
was NN NN O
prevented NN NN O
by NN NN O
castration NN NN O
. NN NN O
   
Ovariectomy NN NN O
of NN NN O
female NN NN O
DS NN NN O
had NN NN O
no NN NN O
effect NN NN O
on NN NN O
intrarenal NN NN O
angiotensinogen NN NN O
expression NN NN O
on NN NN O
either NN NN O
diet NN NN O
. NN NN O
   
Radiotelemetric NN NN O
BP NN NN O
was NN NN O
similar NN NN O
between NN NN O
males NN NN O
and NN NN O
castrated NN NN O
rats NN NN O
on NN NN O
LS NN NN O
diet NN NN O
. NN NN O
   
HS NN NN O
diet NN NN O
for NN NN O
4 NN NN O
wk NN NN O
caused NN NN O
a NN NN O
progressive NN NN O
increase NN NN O
in NN NN O
BP NN NN O
, NN NN O
protein NN NN O
and NN NN O
albumin NN NN O
excretion NN NN O
, NN NN O
and NN NN O
glomerular NN NN B-Disease
sclerosis NN NN I-Disease
in NN NN O
male NN NN O
DS NN NN O
rats NN NN O
, NN NN O
which NN NN O
were NN NN O
attenuated NN NN O
by NN NN O
castration NN NN O
. NN NN O
   
Testosterone NN NN O
replacement NN NN O
in NN NN O
castrated NN NN O
DS NN NN O
rats NN NN O
increased NN NN O
BP NN NN O
, NN NN O
renal NN NN B-Disease
injury NN NN I-Disease
, NN NN O
and NN NN O
upregulation NN NN O
of NN NN O
renal NN NN O
angiotensinogen NN NN O
associated NN NN O
with NN NN O
HS NN NN O
diet NN NN O
. NN NN O
   
Testosterone NN NN O
contributes NN NN O
to NN NN O
the NN NN O
development NN NN O
of NN NN O
hypertension NN NN B-Disease
and NN NN O
renal NN NN B-Disease
injury NN NN I-Disease
in NN NN O
male NN NN O
DS NN NN O
rats NN NN O
on NN NN O
HS NN NN O
diet NN NN O
possibly NN NN O
through NN NN O
upregulation NN NN O
of NN NN O
the NN NN O
intrarenal NN NN O
renin NN NN O
- NN NN O
angiotensin NN NN O
system NN NN O
. NN NN O
   
Explicit NN NN O
episodic NN NN O
memory NN NN O
for NN NN O
sensory NN NN O
- NN NN O
discriminative NN NN O
components NN NN O
of NN NN O
capsaicin NN NN O
- NN NN O
induced NN NN O
pain NN NN B-Disease
: NN NN O
immediate NN NN O
and NN NN O
delayed NN NN O
ratings NN NN O
. NN NN O
   
Pain NN NN B-Disease
memory NN NN O
is NN NN O
thought NN NN O
to NN NN O
affect NN NN O
future NN NN O
pain NN NN B-Disease
sensitivity NN NN O
and NN NN O
thus NN NN O
contribute NN NN O
to NN NN O
clinical NN NN O
pain NN NN B-Disease
conditions NN NN O
. NN NN O
   
Systematic NN NN O
investigations NN NN O
of NN NN O
the NN NN O
human NN NN O
capacity NN NN O
to NN NN O
remember NN NN O
sensory NN NN O
features NN NN O
of NN NN O
experimental NN NN O
pain NN NN B-Disease
are NN NN O
sparse NN NN O
. NN NN O
   
In NN NN O
order NN NN O
to NN NN O
address NN NN O
long NN NN O
- NN NN O
term NN NN O
pain NN NN B-Disease
memory NN NN O
, NN NN O
nine NN NN O
healthy NN NN O
male NN NN O
volunteers NN NN O
received NN NN O
intradermal NN NN O
injections NN NN O
of NN NN O
three NN NN O
doses NN NN O
of NN NN O
capsaicin NN NN O
( NN NN O
0 NN NN O
. NN NN O
05 NN NN O
, NN NN O
1 NN NN O
and NN NN O
20 NN NN O
microg NN NN O
, NN NN O
separated NN NN O
by NN NN O
15 NN NN O
min NN NN O
breaks NN NN O
) NN NN O
, NN NN O
each NN NN O
given NN NN O
three NN NN O
times NN NN O
in NN NN O
a NN NN O
balanced NN NN O
design NN NN O
across NN NN O
three NN NN O
sessions NN NN O
at NN NN O
one NN NN O
week NN NN O
intervals NN NN O
. NN NN O
   
Pain NN NN B-Disease
rating NN NN O
was NN NN O
performed NN NN O
using NN NN O
a NN NN O
computerized NN NN O
visual NN NN O
analogue NN NN O
scale NN NN O
( NN NN O
0 NN NN O
- NN NN O
100 NN NN O
) NN NN O
digitized NN NN O
at NN NN O
1 NN NN O
/ NN NN O
s NN NN O
, NN NN O
either NN NN O
immediately NN NN O
online NN NN O
or NN NN O
one NN NN O
hour NN NN O
or NN NN O
one NN NN O
day NN NN O
after NN NN O
injection NN NN O
. NN NN O
   
Subjects NN NN O
also NN NN O
recalled NN NN O
their NN NN O
pains NN NN B-Disease
one NN NN O
week NN NN O
later NN NN O
. NN NN O
   
Capsaicin NN NN O
injection NN NN O
reliably NN NN O
induced NN NN O
a NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
flare NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
without NN NN O
any NN NN O
difference NN NN O
within NN NN O
or NN NN O
across NN NN O
sessions NN NN O
. NN NN O
   
The NN NN O
strong NN NN O
burning NN NN O
pain NN NN B-Disease
decayed NN NN O
exponentially NN NN O
within NN NN O
a NN NN O
few NN NN O
minutes NN NN O
. NN NN O
   
Subjects NN NN O
were NN NN O
able NN NN O
to NN NN O
reliably NN NN O
discriminate NN NN O
pain NN NN B-Disease
magnitude NN NN O
and NN NN O
duration NN NN O
across NN NN O
capsaicin NN NN O
doses NN NN O
( NN NN O
both NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
, NN NN O
regardless NN NN O
of NN NN O
whether NN NN O
first NN NN O
- NN NN O
time NN NN O
ratings NN NN O
were NN NN O
requested NN NN O
immediately NN NN O
, NN NN O
after NN NN O
one NN NN O
hour NN NN O
or NN NN O
after NN NN O
one NN NN O
day NN NN O
. NN NN O
   
Pain NN NN B-Disease
recall NN NN O
after NN NN O
one NN NN O
week NN NN O
was NN NN O
similarly NN NN O
precise NN NN O
( NN NN O
magnitude NN NN O
: NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
, NN NN O
duration NN NN O
: NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
Correlation NN NN O
with NN NN O
rating NN NN O
recall NN NN O
after NN NN O
one NN NN O
week NN NN O
was NN NN O
best NN NN O
when NN NN O
first NN NN O
- NN NN O
time NN NN O
ratings NN NN O
were NN NN O
requested NN NN O
as NN NN O
late NN NN O
as NN NN O
one NN NN O
day NN NN O
after NN NN O
injection NN NN O
( NN NN O
R NN NN O
( NN NN O
2 NN NN O
) NN NN O
= NN NN O
0 NN NN O
. NN NN O
79 NN NN O
) NN NN O
indicating NN NN O
that NN NN O
both NN NN O
rating NN NN O
retrievals NN NN O
utilized NN NN O
similar NN NN O
memory NN NN O
traces NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicate NN NN O
a NN NN O
reliable NN NN O
memory NN NN O
for NN NN O
magnitude NN NN O
and NN NN O
duration NN NN O
of NN NN O
experimentally NN NN O
induced NN NN O
pain NN NN B-Disease
. NN NN O
   
The NN NN O
data NN NN O
further NN NN O
suggest NN NN O
that NN NN O
the NN NN O
consolidation NN NN O
of NN NN O
this NN NN O
memory NN NN O
is NN NN O
an NN NN O
important NN NN O
interim NN NN O
stage NN NN O
, NN NN O
and NN NN O
may NN NN O
take NN NN O
up NN NN O
to NN NN O
one NN NN O
day NN NN O
. NN NN O
   
Severe NN NN O
and NN NN O
long NN NN O
lasting NN NN O
cholestasis NN NN B-Disease
after NN NN O
high NN NN O
- NN NN O
dose NN NN O
co NN NN O
- NN NN O
trimoxazole NN NN O
treatment NN NN O
for NN NN O
Pneumocystis NN NN B-Disease
pneumonia NN NN I-Disease
in NN NN O
HIV NN NN B-Disease
- NN NN I-Disease
infected NN NN I-Disease
patients NN NN O
- NN NN O
- NN NN O
a NN NN O
report NN NN O
of NN NN O
two NN NN O
cases NN NN O
. NN NN O
   
Pneumocystis NN NN B-Disease
pneumonia NN NN I-Disease
( NN NN O
PCP NN NN B-Disease
) NN NN O
, NN NN O
a NN NN O
common NN NN O
opportunistic NN NN B-Disease
infection NN NN I-Disease
in NN NN O
HIV NN NN B-Disease
- NN NN I-Disease
infected NN NN I-Disease
individuals NN NN O
, NN NN O
is NN NN O
generally NN NN O
treated NN NN O
with NN NN O
high NN NN O
doses NN NN O
of NN NN O
co NN NN O
- NN NN O
trimoxazole NN NN O
. NN NN O
   
However NN NN O
, NN NN O
treatment NN NN O
is NN NN O
often NN NN O
limited NN NN O
by NN NN O
adverse NN NN O
effects NN NN O
. NN NN O
   
Here NN NN O
, NN NN O
we NN NN O
report NN NN O
two NN NN O
cases NN NN O
of NN NN O
severely NN NN O
immunocompromised NN NN O
HIV NN NN B-Disease
- NN NN I-Disease
infected NN NN I-Disease
patients NN NN O
who NN NN O
developed NN NN O
severe NN NN O
intrahepatic NN NN B-Disease
cholestasis NN NN I-Disease
, NN NN O
and NN NN O
in NN NN O
one NN NN O
patient NN NN O
lesions NN NN O
mimicking NN NN O
liver NN NN B-Disease
abscess NN NN I-Disease
formation NN NN O
on NN NN O
radiologic NN NN O
exams NN NN O
, NN NN O
during NN NN O
co NN NN O
- NN NN O
trimoxazole NN NN O
treatment NN NN O
for NN NN O
PCP NN NN B-Disease
. NN NN O
   
Whereas NN NN O
patient NN NN O
1 NN NN O
showed NN NN O
lesions NN NN O
of NN NN O
up NN NN O
to NN NN O
1 NN NN O
cm NN NN O
readily NN NN O
detectable NN NN O
on NN NN O
magnetic NN NN O
resonance NN NN O
imaging NN NN O
under NN NN O
prolonged NN NN O
co NN NN O
- NN NN O
trimoxazole NN NN O
treatment NN NN O
, NN NN O
therapy NN NN O
of NN NN O
patient NN NN O
2 NN NN O
was NN NN O
switched NN NN O
early NN NN O
. NN NN O
   
Bradykinin NN NN O
receptors NN NN O
antagonists NN NN O
and NN NN O
nitric NN NN O
oxide NN NN O
synthase NN NN O
inhibitors NN NN O
in NN NN O
vincristine NN NN O
and NN NN O
streptozotocin NN NN O
induced NN NN O
hyperalgesia NN NN B-Disease
in NN NN O
chemotherapy NN NN O
and NN NN O
diabetic NN NN B-Disease
neuropathy NN NN I-Disease
rat NN NN O
model NN NN O
. NN NN O
   
PURPOSE NN NN O
: NN NN O
The NN NN O
influence NN NN O
of NN NN O
an NN NN O
irreversible NN NN O
inhibitor NN NN O
of NN NN O
constitutive NN NN O
NO NN NN O
synthase NN NN O
( NN NN O
L NN NN O
- NN NN O
NOArg NN NN O
; NN NN O
1 NN NN O
. NN NN O
0 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
ip NN NN O
) NN NN O
, NN NN O
a NN NN O
relatively NN NN O
selective NN NN O
inhibitor NN NN O
of NN NN O
inducible NN NN O
NO NN NN O
synthase NN NN O
( NN NN O
L NN NN O
- NN NN O
NIL NN NN O
; NN NN O
1 NN NN O
. NN NN O
0 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
ip NN NN O
) NN NN O
and NN NN O
a NN NN O
relatively NN NN O
specific NN NN O
inhibitor NN NN O
of NN NN O
neuronal NN NN O
NO NN NN O
synthase NN NN O
( NN NN O
7 NN NN O
- NN NN O
NI NN NN O
; NN NN O
0 NN NN O
. NN NN O
1 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
ip NN NN O
) NN NN O
, NN NN O
on NN NN O
antihyperalgesic NN NN O
action NN NN O
of NN NN O
selective NN NN O
antagonists NN NN O
of NN NN O
B2 NN NN O
and NN NN O
B1 NN NN O
receptors NN NN O
: NN NN O
D NN NN O
- NN NN O
Arg NN NN O
- NN NN O
[ NN NN O
Hyp3 NN NN O
, NN NN O
Thi5 NN NN O
, NN NN O
D NN NN O
- NN NN O
Tic7 NN NN O
, NN NN O
Oic8 NN NN O
] NN NN O
bradykinin NN NN O
( NN NN O
HOE NN NN O
140 NN NN O
; NN NN O
70 NN NN O
nmol NN NN O
/ NN NN O
kg NN NN O
ip NN NN O
) NN NN O
or NN NN O
des NN NN O
Arg10 NN NN O
HOE NN NN O
140 NN NN O
( NN NN O
70 NN NN O
nmol NN NN O
/ NN NN O
kg NN NN O
ip NN NN O
) NN NN O
respectively NN NN O
, NN NN O
in NN NN O
model NN NN O
of NN NN O
diabetic NN NN B-Disease
( NN NN I-Disease
streptozotocin NN NN I-Disease
- NN NN I-Disease
induced NN NN I-Disease
) NN NN I-Disease
and NN NN I-Disease
toxic NN NN I-Disease
( NN NN I-Disease
vincristine NN NN I-Disease
- NN NN I-Disease
induced NN NN I-Disease
) NN NN I-Disease
neuropathy NN NN I-Disease
was NN NN O
investigated NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
The NN NN O
changes NN NN O
in NN NN O
pain NN NN B-Disease
thresholds NN NN O
were NN NN O
determined NN NN O
using NN NN O
mechanical NN NN O
stimuli NN NN O
- NN NN O
- NN NN O
the NN NN O
modification NN NN O
of NN NN O
the NN NN O
classic NN NN O
paw NN NN O
withdrawal NN NN O
test NN NN O
described NN NN O
by NN NN O
Randall NN NN O
- NN NN O
Selitto NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
The NN NN O
results NN NN O
of NN NN O
this NN NN O
paper NN NN O
confirm NN NN O
that NN NN O
inhibition NN NN O
of NN NN O
bradykinin NN NN O
receptors NN NN O
and NN NN O
inducible NN NN O
NO NN NN O
synthase NN NN O
but NN NN O
not NN NN O
neuronal NN NN O
NO NN NN O
synthase NN NN O
activity NN NN O
reduces NN NN O
diabetic NN NN B-Disease
hyperalgesia NN NN I-Disease
. NN NN O
   
Pretreatment NN NN O
with NN NN O
L NN NN O
- NN NN O
NOArg NN NN O
and NN NN O
L NN NN O
- NN NN O
NIL NN NN O
but NN NN O
not NN NN O
7 NN NN O
- NN NN O
NI NN NN O
, NN NN O
significantly NN NN O
increases NN NN O
antihyperalgesic NN NN O
activity NN NN O
both NN NN O
HOE NN NN O
140 NN NN O
and NN NN O
des NN NN O
Arg10 NN NN O
HOE NN NN O
140 NN NN O
. NN NN O
   
It NN NN O
was NN NN O
also NN NN O
shown NN NN O
that NN NN O
both NN NN O
products NN NN O
of NN NN O
inducible NN NN O
NO NN NN O
synthase NN NN O
and NN NN O
neuronal NN NN O
NO NN NN O
synthase NN NN O
activation NN NN O
as NN NN O
well NN NN O
as NN NN O
bradykinin NN NN O
are NN NN O
involved NN NN O
in NN NN O
hyperalgesia NN NN B-Disease
produced NN NN O
by NN NN O
vincristine NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
L NN NN O
- NN NN O
NOArg NN NN O
and NN NN O
7 NN NN O
- NN NN O
NI NN NN O
but NN NN O
not NN NN O
L NN NN O
- NN NN O
NIL NN NN O
intensify NN NN O
antihyperalgesic NN NN O
activity NN NN O
of NN NN O
HOE NN NN O
140 NN NN O
or NN NN O
des NN NN O
- NN NN O
Arg10HOE NN NN O
140 NN NN O
in NN NN O
toxic NN NN B-Disease
neuropathy NN NN I-Disease
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Results NN NN O
of NN NN O
these NN NN O
studies NN NN O
suggest NN NN O
that NN NN O
B1 NN NN O
and NN NN O
B2 NN NN O
receptors NN NN O
are NN NN O
engaged NN NN O
in NN NN O
transmission NN NN O
of NN NN O
nociceptive NN NN O
stimuli NN NN O
in NN NN O
both NN NN O
diabetic NN NN B-Disease
and NN NN I-Disease
toxic NN NN I-Disease
neuropathy NN NN I-Disease
. NN NN O
   
In NN NN O
streptozotocin NN NN O
- NN NN O
induced NN NN O
hyperalgesia NN NN B-Disease
, NN NN O
inducible NN NN O
NO NN NN O
synthase NN NN O
participates NN NN O
in NN NN O
pronociceptive NN NN O
activity NN NN O
of NN NN O
bradykinin NN NN O
, NN NN O
whereas NN NN O
in NN NN O
vincristine NN NN O
- NN NN O
induced NN NN O
hyperalgesia NN NN B-Disease
bradykinin NN NN O
seemed NN NN O
to NN NN O
activate NN NN O
neuronal NN NN O
NO NN NN O
synthase NN NN O
pathway NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
concomitant NN NN O
administration NN NN O
of NN NN O
small NN NN O
doses NN NN O
of NN NN O
bradykinin NN NN O
receptor NN NN O
antagonists NN NN O
and NN NN O
NO NN NN O
synthase NN NN O
inhibitors NN NN O
can NN NN O
be NN NN O
effective NN NN O
in NN NN O
alleviation NN NN O
of NN NN O
neuropathic NN NN B-Disease
pain NN NN I-Disease
, NN NN O
even NN NN O
in NN NN O
hospital NN NN O
care NN NN O
. NN NN O
   
Confusion NN NN B-Disease
, NN NN O
a NN NN O
rather NN NN O
serious NN NN O
adverse NN NN O
drug NN NN O
reaction NN NN O
with NN NN O
valproic NN NN O
acid NN NN O
: NN NN O
a NN NN O
review NN NN O
of NN NN O
the NN NN O
French NN NN O
Pharmacovigilance NN NN O
database NN NN O
. NN NN O
   
INTRODUCTION NN NN O
: NN NN O
Confusion NN NN B-Disease
is NN NN O
an NN NN O
adverse NN NN O
drug NN NN O
reaction NN NN O
frequently NN NN O
observed NN NN O
with NN NN O
valproic NN NN O
acid NN NN O
. NN NN O
   
Some NN NN O
case NN NN O
reports NN NN O
are NN NN O
published NN NN O
in NN NN O
the NN NN O
literature NN NN O
but NN NN O
no NN NN O
systematic NN NN O
study NN NN O
from NN NN O
a NN NN O
sample NN NN O
of NN NN O
patients NN NN O
has NN NN O
been NN NN O
published NN NN O
. NN NN O
   
We NN NN O
performed NN NN O
this NN NN O
study NN NN O
in NN NN O
order NN NN O
to NN NN O
describe NN NN O
the NN NN O
main NN NN O
characteristics NN NN O
of NN NN O
this NN NN O
adverse NN NN O
drug NN NN O
reaction NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Using NN NN O
the NN NN O
French NN NN O
Pharmacovigilance NN NN O
database NN NN O
, NN NN O
we NN NN O
selected NN NN O
the NN NN O
cases NN NN O
of NN NN O
confusion NN NN B-Disease
reported NN NN O
since NN NN O
1985 NN NN O
with NN NN O
valproic NN NN O
acid NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
272 NN NN O
cases NN NN O
of NN NN O
confusion NN NN B-Disease
were NN NN O
reported NN NN O
with NN NN O
valproic NN NN O
acid NN NN O
: NN NN O
153 NN NN O
women NN NN O
and NN NN O
119 NN NN O
men NN NN O
. NN NN O
   
Confusion NN NN B-Disease
mostly NN NN O
occurred NN NN O
during NN NN O
the NN NN O
two NN NN O
first NN NN O
weeks NN NN O
following NN NN O
valproic NN NN O
acid NN NN O
exposure NN NN O
( NN NN O
39 NN NN O
. NN NN O
7 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
It NN NN O
was NN NN O
"""""""" NN NN O
serious NN NN O
"""""""" NN NN O
for NN NN O
almost NN NN O
2 NN NN O
/ NN NN O
3 NN NN O
of NN NN O
the NN NN O
patients NN NN O
( NN NN O
62 NN NN O
. NN NN O
5 NN NN O
% NN NN O
) NN NN O
and NN NN O
its NN NN O
outcome NN NN O
favourable NN NN O
in NN NN O
most NN NN O
of NN NN O
the NN NN O
cases NN NN O
( NN NN O
82 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
The NN NN O
occurrence NN NN O
of NN NN O
this NN NN O
ADR NN NN O
was NN NN O
more NN NN O
frequent NN NN O
in NN NN O
patients NN NN O
aged NN NN O
between NN NN O
61 NN NN O
and NN NN O
80 NN NN O
years NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
This NN NN O
work NN NN O
shows NN NN O
that NN NN O
confusion NN NN B-Disease
with NN NN O
valproic NN NN O
acid NN NN O
is NN NN O
a NN NN O
serious NN NN O
, NN NN O
rather NN NN O
frequent NN NN O
but NN NN O
reversible NN NN O
adverse NN NN O
drug NN NN O
reaction NN NN O
. NN NN O
   
It NN NN O
occurs NN NN O
especially NN NN O
in NN NN O
older NN NN O
patients NN NN O
and NN NN O
during NN NN O
the NN NN O
first NN NN O
two NN NN O
weeks NN NN O
of NN NN O
treatment NN NN O
. NN NN O
   
Reversible NN NN O
inferior NN NN B-Disease
colliculus NN NN I-Disease
lesion NN NN I-Disease
in NN NN O
metronidazole NN NN O
- NN NN O
induced NN NN O
encephalopathy NN NN B-Disease
: NN NN O
magnetic NN NN O
resonance NN NN O
findings NN NN O
on NN NN O
diffusion NN NN O
- NN NN O
weighted NN NN O
and NN NN O
fluid NN NN O
attenuated NN NN O
inversion NN NN O
recovery NN NN O
imaging NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
This NN NN O
is NN NN O
to NN NN O
present NN NN O
reversible NN NN O
inferior NN NN B-Disease
colliculus NN NN I-Disease
lesions NN NN I-Disease
in NN NN O
metronidazole NN NN O
- NN NN O
induced NN NN O
encephalopathy NN NN B-Disease
, NN NN O
to NN NN O
focus NN NN O
on NN NN O
the NN NN O
diffusion NN NN O
- NN NN O
weighted NN NN O
imaging NN NN O
( NN NN O
DWI NN NN O
) NN NN O
and NN NN O
fluid NN NN O
attenuated NN NN O
inversion NN NN O
recovery NN NN O
( NN NN O
FLAIR NN NN O
) NN NN O
imaging NN NN O
. NN NN O
   
MATERIALS NN NN O
AND NN NN O
METHODS NN NN O
: NN NN O
From NN NN O
November NN NN O
2005 NN NN O
to NN NN O
September NN NN O
2007 NN NN O
, NN NN O
8 NN NN O
patients NN NN O
( NN NN O
5 NN NN O
men NN NN O
and NN NN O
3 NN NN O
women NN NN O
) NN NN O
were NN NN O
diagnosed NN NN O
as NN NN O
having NN NN O
metronidazole NN NN O
- NN NN O
induced NN NN O
encephalopathy NN NN B-Disease
( NN NN O
age NN NN O
range NN NN O
; NN NN O
43 NN NN O
- NN NN O
78 NN NN O
years NN NN O
) NN NN O
. NN NN O
   
They NN NN O
had NN NN O
been NN NN O
taking NN NN O
metronidazole NN NN O
( NN NN O
total NN NN O
dosage NN NN O
, NN NN O
45 NN NN O
- NN NN O
120 NN NN O
g NN NN O
; NN NN O
duration NN NN O
, NN NN O
30 NN NN O
days NN NN O
to NN NN O
2 NN NN O
months NN NN O
) NN NN O
to NN NN O
treat NN NN O
the NN NN O
infection NN NN B-Disease
in NN NN O
various NN NN O
organs NN NN O
. NN NN O
   
Initial NN NN O
brain NN NN O
magnetic NN NN O
resonance NN NN O
imaging NN NN O
( NN NN O
MRI NN NN O
) NN NN O
were NN NN O
obtained NN NN O
after NN NN O
the NN NN O
hospitalization NN NN O
, NN NN O
including NN NN O
DWI NN NN O
( NN NN O
8 NN NN O
/ NN NN O
8 NN NN O
) NN NN O
, NN NN O
apparent NN NN O
diffusion NN NN O
coefficient NN NN O
( NN NN O
ADC NN NN O
) NN NN O
map NN NN O
( NN NN O
4 NN NN O
/ NN NN O
8 NN NN O
) NN NN O
, NN NN O
FLAIR NN NN O
( NN NN O
7 NN NN O
/ NN NN O
8 NN NN O
) NN NN O
, NN NN O
and NN NN O
T2 NN NN O
- NN NN O
weighted NN NN O
image NN NN O
( NN NN O
8 NN NN O
/ NN NN O
8 NN NN O
) NN NN O
. NN NN O
   
Follow NN NN O
- NN NN O
up NN NN O
MRIs NN NN O
were NN NN O
performed NN NN O
on NN NN O
5 NN NN O
patients NN NN O
from NN NN O
third NN NN O
to NN NN O
14th NN NN O
days NN NN O
after NN NN O
discontinuation NN NN O
of NN NN O
metronidazole NN NN O
administration NN NN O
. NN NN O
   
Findings NN NN O
of NN NN O
initial NN NN O
and NN NN O
follow NN NN O
- NN NN O
up NN NN O
MRIs NN NN O
were NN NN O
retrospectively NN NN O
evaluated NN NN O
by NN NN O
2 NN NN O
neuroradiologists NN NN O
by NN NN O
consensus NN NN O
, NN NN O
to NN NN O
analyze NN NN O
the NN NN O
presence NN NN O
of NN NN O
abnormal NN NN O
signal NN NN O
intensities NN NN O
, NN NN O
their NN NN O
locations NN NN O
, NN NN O
and NN NN O
signal NN NN O
changes NN NN O
on NN NN O
follow NN NN O
- NN NN O
up NN NN O
images NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Initial NN NN O
MRIs NN NN O
showed NN NN O
abnormal NN NN O
high NN NN O
signal NN NN O
intensities NN NN O
on NN NN O
DWI NN NN O
and NN NN O
FLAIR NN NN O
( NN NN O
or NN NN O
T2 NN NN O
- NN NN O
weighted NN NN O
image NN NN O
) NN NN O
at NN NN O
the NN NN O
dentate NN NN O
nucleus NN NN O
( NN NN O
8 NN NN O
/ NN NN O
8 NN NN O
) NN NN O
, NN NN O
inferior NN NN O
colliculus NN NN O
( NN NN O
6 NN NN O
/ NN NN O
8 NN NN O
) NN NN O
, NN NN O
corpus NN NN O
callosum NN NN O
( NN NN O
2 NN NN O
/ NN NN O
8 NN NN O
) NN NN O
, NN NN O
pons NN NN O
( NN NN O
2 NN NN O
/ NN NN O
8 NN NN O
) NN NN O
, NN NN O
medulla NN NN O
( NN NN O
1 NN NN O
/ NN NN O
8 NN NN O
) NN NN O
, NN NN O
and NN NN O
bilateral NN NN O
cerebral NN NN O
white NN NN O
matter NN NN O
( NN NN O
1 NN NN O
/ NN NN O
8 NN NN O
) NN NN O
. NN NN O
   
High NN NN O
- NN NN O
signal NN NN O
intensity NN NN O
lesions NN NN O
on NN NN O
DWI NN NN O
tended NN NN O
to NN NN O
show NN NN O
low NN NN O
signal NN NN O
intensity NN NN O
on NN NN O
ADC NN NN O
map NN NN O
( NN NN O
3 NN NN O
/ NN NN O
4 NN NN O
) NN NN O
, NN NN O
but NN NN O
in NN NN O
one NN NN O
patient NN NN O
, NN NN O
high NN NN O
signal NN NN O
intensity NN NN O
was NN NN O
shown NN NN O
at NN NN O
bilateral NN NN O
dentate NN NN O
nuclei NN NN O
on NN NN O
not NN NN O
only NN NN O
DWI NN NN O
but NN NN O
also NN NN O
ADC NN NN O
map NN NN O
. NN NN O
   
All NN NN O
the NN NN O
lesions NN NN O
in NN NN O
dentate NN NN O
, NN NN O
inferior NN NN O
colliculus NN NN O
, NN NN O
pons NN NN O
, NN NN O
and NN NN O
medullas NN NN O
had NN NN O
been NN NN O
resolved NN NN O
completely NN NN O
on NN NN O
follow NN NN O
- NN NN O
up NN NN O
MRIs NN NN O
in NN NN O
5 NN NN O
patients NN NN O
, NN NN O
but NN NN O
in NN NN O
1 NN NN O
patient NN NN O
of NN NN O
them NN NN O
, NN NN O
corpus NN NN O
callosal NN NN B-Disease
lesion NN NN I-Disease
persisted NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Reversible NN NN O
inferior NN NN B-Disease
colliculus NN NN I-Disease
lesions NN NN I-Disease
could NN NN O
be NN NN O
considered NN NN O
as NN NN O
the NN NN O
characteristic NN NN O
for NN NN O
metronidazole NN NN O
- NN NN O
induced NN NN O
encephalopathy NN NN B-Disease
, NN NN O
next NN NN O
to NN NN O
the NN NN O
dentate NN NN O
nucleus NN NN O
involvement NN NN O
. NN NN O
   
Clinically NN NN O
significant NN NN O
proteinuria NN NN B-Disease
following NN NN O
the NN NN O
administration NN NN O
of NN NN O
sirolimus NN NN O
to NN NN O
renal NN NN O
transplant NN NN O
recipients NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Sirolimus NN NN O
is NN NN O
the NN NN O
latest NN NN O
immunosuppressive NN NN O
agent NN NN O
used NN NN O
to NN NN O
prevent NN NN O
rejection NN NN O
, NN NN O
and NN NN O
may NN NN O
have NN NN O
less NN NN O
nephrotoxicity NN NN B-Disease
than NN NN O
calcineurin NN NN O
inhibitor NN NN O
( NN NN O
CNI NN NN O
) NN NN O
- NN NN O
based NN NN O
regimens NN NN O
. NN NN O
   
To NN NN O
date NN NN O
there NN NN O
has NN NN O
been NN NN O
little NN NN O
documentation NN NN O
of NN NN O
clinically NN NN O
significant NN NN O
proteinuria NN NN B-Disease
linked NN NN O
with NN NN O
the NN NN O
use NN NN O
of NN NN O
sirolimus NN NN O
. NN NN O
   
We NN NN O
have NN NN O
encountered NN NN O
several NN NN O
patients NN NN O
who NN NN O
developed NN NN O
substantial NN NN O
proteinuria NN NN B-Disease
associated NN NN O
with NN NN O
sirolimus NN NN O
use NN NN O
. NN NN O
   
In NN NN O
each NN NN O
patient NN NN O
, NN NN O
the NN NN O
close NN NN O
temporal NN NN O
association NN NN O
between NN NN O
the NN NN O
commencement NN NN O
of NN NN O
sirolimus NN NN O
therapy NN NN O
and NN NN O
proteinuria NN NN B-Disease
implicated NN NN O
sirolimus NN NN O
as NN NN O
the NN NN O
most NN NN O
likely NN NN O
etiology NN NN O
of NN NN O
the NN NN O
proteinuria NN NN B-Disease
. NN NN O
   
METHODS NN NN O
: NN NN O
We NN NN O
analyzed NN NN O
the NN NN O
clinical NN NN O
and NN NN O
laboratory NN NN O
information NN NN O
available NN NN O
for NN NN O
all NN NN O
119 NN NN O
patients NN NN O
transplanted NN NN O
at NN NN O
the NN NN O
Washington NN NN O
Hospital NN NN O
Center NN NN O
between NN NN O
1999 NN NN O
- NN NN O
2003 NN NN O
for NN NN O
whom NN NN O
sirolimus NN NN O
was NN NN O
a NN NN O
component NN NN O
of NN NN O
their NN NN O
immunosuppressant NN NN O
regimen NN NN O
. NN NN O
   
In NN NN O
these NN NN O
patients NN NN O
, NN NN O
the NN NN O
magnitude NN NN O
of NN NN O
proteinuria NN NN B-Disease
was NN NN O
assessed NN NN O
on NN NN O
morning NN NN O
urine NN NN O
samples NN NN O
by NN NN O
turbidometric NN NN O
measurement NN NN O
or NN NN O
random NN NN O
urine NN NN O
protein NN NN O
: NN NN O
creatinine NN NN O
ratios NN NN O
, NN NN O
an NN NN O
estimate NN NN O
of NN NN O
grams NN NN O
of NN NN O
proteinuria NN NN B-Disease
/ NN NN O
day NN NN O
. NN NN O
   
Laboratory NN NN O
results NN NN O
were NN NN O
compared NN NN O
between NN NN O
prior NN NN O
, NN NN O
during NN NN O
and NN NN O
following NN NN O
sirolimus NN NN O
use NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Twenty NN NN O
- NN NN O
eight NN NN O
patients NN NN O
( NN NN O
24 NN NN O
% NN NN O
) NN NN O
developed NN NN O
increased NN NN O
proteinuria NN NN B-Disease
from NN NN O
baseline NN NN O
during NN NN O
their NN NN O
post NN NN O
- NN NN O
transplantation NN NN O
course NN NN O
. NN NN O
   
In NN NN O
21 NN NN O
patients NN NN O
an NN NN O
alternative NN NN O
cause NN NN O
of NN NN O
proteinuria NN NN B-Disease
was NN NN O
either NN NN O
obvious NN NN O
or NN NN O
insufficient NN NN O
data NN NN O
was NN NN O
available NN NN O
to NN NN O
be NN NN O
conclusive NN NN O
. NN NN O
   
In NN NN O
7 NN NN O
of NN NN O
the NN NN O
28 NN NN O
patients NN NN O
there NN NN O
was NN NN O
a NN NN O
striking NN NN O
temporal NN NN O
association NN NN O
between NN NN O
the NN NN O
initiation NN NN O
of NN NN O
sirolimus NN NN O
and NN NN O
the NN NN O
development NN NN O
of NN NN O
nephrotic NN NN B-Disease
- NN NN O
range NN NN O
proteinuria NN NN B-Disease
. NN NN O
   
Proteinuria NN NN B-Disease
correlated NN NN O
most NN NN O
strongly NN NN O
with NN NN O
sirolimus NN NN O
therapy NN NN O
when NN NN O
compared NN NN O
to NN NN O
other NN NN O
demographic NN NN O
and NN NN O
clinical NN NN O
variables NN NN O
. NN NN O
   
In NN NN O
most NN NN O
patients NN NN O
, NN NN O
discontinuation NN NN O
of NN NN O
sirolimus NN NN O
resulted NN NN O
in NN NN O
a NN NN O
decrease NN NN O
, NN NN O
but NN NN O
not NN NN O
resolution NN NN O
, NN NN O
of NN NN O
proteinuria NN NN B-Disease
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Sirolimus NN NN O
induces NN NN O
or NN NN O
aggravates NN NN O
pre NN NN O
- NN NN O
existing NN NN O
proteinuria NN NN B-Disease
in NN NN O
an NN NN O
unpredictable NN NN O
subset NN NN O
of NN NN O
renal NN NN O
allograft NN NN O
recipients NN NN O
. NN NN O
   
Proteinuria NN NN B-Disease
may NN NN O
improve NN NN O
, NN NN O
but NN NN O
does NN NN O
not NN NN O
resolve NN NN O
, NN NN O
when NN NN O
sirolimus NN NN O
is NN NN O
withdrawn NN NN O
. NN NN O
   
Components NN NN O
of NN NN O
lemon NN NN O
essential NN NN O
oil NN NN O
attenuate NN NN O
dementia NN NN B-Disease
induced NN NN O
by NN NN O
scopolamine NN NN O
. NN NN O
   
The NN NN O
anti NN NN O
- NN NN O
dementia NN NN B-Disease
effects NN NN O
of NN NN O
s NN NN O
- NN NN O
limonene NN NN O
and NN NN O
s NN NN O
- NN NN O
perillyl NN NN O
alcohol NN NN O
were NN NN O
observed NN NN O
using NN NN O
the NN NN O
passive NN NN O
avoidance NN NN O
test NN NN O
( NN NN O
PA NN NN O
) NN NN O
and NN NN O
the NN NN O
open NN NN O
field NN NN O
habituation NN NN O
test NN NN O
( NN NN O
OFH NN NN O
) NN NN O
. NN NN O
   
These NN NN O
lemon NN NN O
essential NN NN O
oils NN NN O
showed NN NN O
strong NN NN O
ability NN NN O
to NN NN O
improve NN NN O
memory NN NN B-Disease
impaired NN NN I-Disease
by NN NN O
scopolamine NN NN O
; NN NN O
however NN NN O
, NN NN O
s NN NN O
- NN NN O
perillyl NN NN O
alcohol NN NN O
relieved NN NN O
the NN NN O
deficit NN NN B-Disease
of NN NN I-Disease
associative NN NN I-Disease
memory NN NN I-Disease
in NN NN O
PA NN NN O
only NN NN O
, NN NN O
and NN NN O
did NN NN O
not NN NN O
improve NN NN O
non NN NN O
- NN NN O
associative NN NN O
memory NN NN O
significantly NN NN O
in NN NN O
OFH NN NN O
. NN NN O
   
Analysis NN NN O
of NN NN O
neurotransmitter NN NN O
concentration NN NN O
in NN NN O
some NN NN O
brain NN NN O
regions NN NN O
on NN NN O
the NN NN O
test NN NN O
day NN NN O
showed NN NN O
that NN NN O
dopamine NN NN O
concentration NN NN O
of NN NN O
the NN NN O
vehicle NN NN O
/ NN NN O
scopolamine NN NN O
group NN NN O
was NN NN O
significantly NN NN O
lower NN NN O
than NN NN O
that NN NN O
of NN NN O
the NN NN O
vehicle NN NN O
/ NN NN O
vehicle NN NN O
group NN NN O
, NN NN O
but NN NN O
this NN NN O
phenomenon NN NN O
was NN NN O
reversed NN NN O
when NN NN O
s NN NN O
- NN NN O
limonene NN NN O
or NN NN O
s NN NN O
- NN NN O
perillyl NN NN O
alcohol NN NN O
were NN NN O
administered NN NN O
before NN NN O
the NN NN O
injection NN NN O
of NN NN O
scopolamine NN NN O
. NN NN O
   
Simultaneously NN NN O
, NN NN O
we NN NN O
found NN NN O
that NN NN O
these NN NN O
two NN NN O
lemon NN NN O
essential NN NN O
oil NN NN O
components NN NN O
could NN NN O
inhibit NN NN O
acetylcholinesterase NN NN O
activity NN NN O
in NN NN O
vitro NN NN O
using NN NN O
the NN NN O
Ellman NN NN O
method NN NN O
. NN NN O
   
Attentional NN NN O
modulation NN NN O
of NN NN O
perceived NN NN O
pain NN NN B-Disease
intensity NN NN O
in NN NN O
capsaicin NN NN O
- NN NN O
induced NN NN O
secondary NN NN O
hyperalgesia NN NN B-Disease
. NN NN O
   
Perceived NN NN O
pain NN NN B-Disease
intensity NN NN O
is NN NN O
modulated NN NN O
by NN NN O
attention NN NN O
. NN NN O
   
However NN NN O
, NN NN O
it NN NN O
is NN NN O
not NN NN O
known NN NN O
that NN NN O
how NN NN O
pain NN NN B-Disease
intensity NN NN O
ratings NN NN O
are NN NN O
affected NN NN O
by NN NN O
attention NN NN O
in NN NN O
capsaicin NN NN O
- NN NN O
induced NN NN O
secondary NN NN O
hyperalgesia NN NN B-Disease
. NN NN O
   
Here NN NN O
we NN NN O
show NN NN O
that NN NN O
perceived NN NN O
pain NN NN B-Disease
intensity NN NN O
in NN NN O
secondary NN NN O
hyperalgesia NN NN B-Disease
is NN NN O
decreased NN NN O
when NN NN O
attention NN NN O
is NN NN O
distracted NN NN O
away NN NN O
from NN NN O
the NN NN O
painful NN NN O
pinprick NN NN O
stimulus NN NN O
with NN NN O
a NN NN O
visual NN NN O
task NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
it NN NN O
was NN NN O
found NN NN O
that NN NN O
the NN NN O
magnitude NN NN O
of NN NN O
attentional NN NN O
modulation NN NN O
in NN NN O
secondary NN NN O
hyperalgesia NN NN B-Disease
is NN NN O
very NN NN O
similar NN NN O
to NN NN O
that NN NN O
of NN NN O
capsaicin NN NN O
- NN NN O
untreated NN NN O
, NN NN O
control NN NN O
condition NN NN O
. NN NN O
   
Our NN NN O
findings NN NN O
, NN NN O
showing NN NN O
no NN NN O
interaction NN NN O
between NN NN O
capsaicin NN NN O
treatment NN NN O
and NN NN O
attentional NN NN O
modulation NN NN O
suggest NN NN O
that NN NN O
capsaicin NN NN O
- NN NN O
induced NN NN O
secondary NN NN O
hyperalgesia NN NN B-Disease
and NN NN O
attention NN NN O
might NN NN O
affect NN NN O
mechanical NN NN O
pain NN NN B-Disease
through NN NN O
independent NN NN O
mechanisms NN NN O
. NN NN O
   
Cardioprotective NN NN O
effect NN NN O
of NN NN O
salvianolic NN NN O
acid NN NN O
A NN NN O
on NN NN O
isoproterenol NN NN O
- NN NN O
induced NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
in NN NN O
rats NN NN O
. NN NN O
   
The NN NN O
present NN NN O
study NN NN O
was NN NN O
designed NN NN O
to NN NN O
evaluate NN NN O
the NN NN O
cardioprotective NN NN O
potential NN NN O
of NN NN O
salvianolic NN NN O
acid NN NN O
A NN NN O
on NN NN O
isoproterenol NN NN O
- NN NN O
induced NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
in NN NN O
rats NN NN O
. NN NN O
   
Hemodynamic NN NN O
parameters NN NN O
and NN NN O
lead NN NN O
II NN NN O
electrocardiograph NN NN O
were NN NN O
monitored NN NN O
and NN NN O
recorded NN NN O
continuously NN NN O
. NN NN O
   
Cardiac NN NN O
marker NN NN O
enzymes NN NN O
and NN NN O
antioxidative NN NN O
parameters NN NN O
in NN NN O
serum NN NN O
and NN NN O
heart NN NN O
tissues NN NN O
were NN NN O
measured NN NN O
. NN NN O
   
Assay NN NN O
for NN NN O
mitochondrial NN NN O
respiratory NN NN O
function NN NN O
and NN NN O
histopathological NN NN O
examination NN NN O
of NN NN O
heart NN NN O
tissues NN NN O
were NN NN O
performed NN NN O
. NN NN O
   
Isoproterenol NN NN O
- NN NN O
treated NN NN O
rats NN NN O
showed NN NN O
significant NN NN O
increases NN NN O
in NN NN O
the NN NN O
levels NN NN O
of NN NN O
lactate NN NN O
dehydrogenase NN NN O
, NN NN O
aspartate NN NN O
transaminase NN NN O
, NN NN O
creatine NN NN O
kinase NN NN O
and NN NN O
malondialdehyde NN NN O
and NN NN O
significant NN NN O
decreases NN NN O
in NN NN O
the NN NN O
activities NN NN O
of NN NN O
superoxide NN NN O
dismutase NN NN O
, NN NN O
catalase NN NN O
and NN NN O
glutathione NN NN O
peroxidase NN NN O
in NN NN O
serum NN NN O
and NN NN O
heart NN NN O
. NN NN O
   
These NN NN O
rats NN NN O
also NN NN O
showed NN NN O
declines NN NN O
in NN NN O
left NN NN O
ventricular NN NN O
systolic NN NN O
pressure NN NN O
, NN NN O
maximum NN NN O
and NN NN O
minimum NN NN O
rate NN NN O
of NN NN O
developed NN NN O
left NN NN O
ventricular NN NN O
pressure NN NN O
, NN NN O
and NN NN O
elevation NN NN O
of NN NN O
left NN NN O
ventricular NN NN O
end NN NN O
- NN NN O
diastolic NN NN O
pressure NN NN O
and NN NN O
ST NN NN O
- NN NN O
segment NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
mitochondrial NN NN O
respiratory NN NN B-Disease
dysfunction NN NN I-Disease
characterized NN NN O
by NN NN O
decreased NN NN O
respiratory NN NN O
control NN NN O
ratio NN NN O
and NN NN O
ADP NN NN O
/ NN NN O
O NN NN O
was NN NN O
observed NN NN O
in NN NN O
isoproterenol NN NN O
- NN NN O
treated NN NN O
rats NN NN O
. NN NN O
   
Administration NN NN O
of NN NN O
salvianolic NN NN O
acid NN NN O
A NN NN O
for NN NN O
a NN NN O
period NN NN O
of NN NN O
8 NN NN O
days NN NN O
significantly NN NN O
attenuated NN NN O
isoproterenol NN NN O
- NN NN O
induced NN NN O
cardiac NN NN B-Disease
dysfunction NN NN I-Disease
and NN NN O
myocardial NN NN B-Disease
injury NN NN I-Disease
and NN NN O
improved NN NN O
mitochondrial NN NN O
respiratory NN NN O
function NN NN O
. NN NN O
   
The NN NN O
protective NN NN O
role NN NN O
of NN NN O
salvianolic NN NN O
acid NN NN O
A NN NN O
against NN NN O
isoproterenol NN NN O
- NN NN O
induced NN NN O
myocardial NN NN B-Disease
damage NN NN I-Disease
was NN NN O
further NN NN O
confirmed NN NN O
by NN NN O
histopathological NN NN O
examination NN NN O
. NN NN O
   
The NN NN O
results NN NN O
of NN NN O
our NN NN O
study NN NN O
suggest NN NN O
that NN NN O
salvianolic NN NN O
acid NN NN O
A NN NN O
possessing NN NN O
antioxidant NN NN O
activity NN NN O
has NN NN O
a NN NN O
significant NN NN O
protective NN NN O
effect NN NN O
against NN NN O
isoproterenol NN NN O
- NN NN O
induced NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
. NN NN O
   
Long NN NN O
- NN NN O
term NN NN O
glutamate NN NN O
supplementation NN NN O
failed NN NN O
to NN NN O
protect NN NN O
against NN NN O
peripheral NN NN B-Disease
neurotoxicity NN NN I-Disease
of NN NN O
paclitaxel NN NN O
. NN NN O
   
Toxic NN NN O
peripheral NN NN B-Disease
neuropathy NN NN I-Disease
is NN NN O
still NN NN O
a NN NN O
significant NN NN O
limiting NN NN O
factor NN NN O
for NN NN O
chemotherapy NN NN O
with NN NN O
paclitaxel NN NN O
( NN NN O
PAC NN NN O
) NN NN O
, NN NN O
although NN NN O
glutamate NN NN O
and NN NN O
its NN NN O
closely NN NN O
related NN NN O
amino NN NN O
acid NN NN O
glutamine NN NN O
were NN NN O
claimed NN NN O
to NN NN O
ameliorate NN NN O
PAC NN NN O
neurotoxicity NN NN B-Disease
. NN NN O
   
This NN NN O
pilot NN NN O
trial NN NN O
aimed NN NN O
to NN NN O
evaluate NN NN O
the NN NN O
role NN NN O
of NN NN O
glutamate NN NN O
supplementation NN NN O
for NN NN O
preventing NN NN O
PAC NN NN O
- NN NN O
induced NN NN O
peripheral NN NN B-Disease
neuropathy NN NN I-Disease
in NN NN O
a NN NN O
randomized NN NN O
, NN NN O
placebo NN NN O
- NN NN O
controlled NN NN O
, NN NN O
double NN NN O
- NN NN O
blinded NN NN O
clinical NN NN O
and NN NN O
electro NN NN O
- NN NN O
diagnostic NN NN O
study NN NN O
. NN NN O
   
Forty NN NN O
- NN NN O
three NN NN O
ovarian NN NN B-Disease
cancer NN NN I-Disease
patients NN NN O
were NN NN O
available NN NN O
for NN NN O
analysis NN NN O
following NN NN O
six NN NN O
cycles NN NN O
of NN NN O
the NN NN O
same NN NN O
PAC NN NN O
- NN NN O
containing NN NN O
regimen NN NN O
: NN NN O
23 NN NN O
had NN NN O
been NN NN O
supplemented NN NN O
by NN NN O
glutamate NN NN O
all NN NN O
along NN NN O
the NN NN O
treatment NN NN O
period NN NN O
, NN NN O
at NN NN O
a NN NN O
daily NN NN O
dose NN NN O
of NN NN O
three NN NN O
times NN NN O
500 NN NN O
mg NN NN O
( NN NN O
group NN NN O
G NN NN O
) NN NN O
, NN NN O
and NN NN O
20 NN NN O
had NN NN O
received NN NN O
a NN NN O
placebo NN NN O
( NN NN O
group NN NN O
P NN NN O
) NN NN O
. NN NN O
   
Patients NN NN O
were NN NN O
evaluated NN NN O
by NN NN O
neurological NN NN O
examinations NN NN O
, NN NN O
questionnaires NN NN O
and NN NN O
sensory NN NN O
- NN NN O
motor NN NN O
nerve NN NN O
conduction NN NN O
studies NN NN O
. NN NN O
   
There NN NN O
was NN NN O
no NN NN O
significant NN NN O
difference NN NN O
in NN NN O
the NN NN O
frequency NN NN O
of NN NN O
signs NN NN O
or NN NN O
symptoms NN NN O
between NN NN O
the NN NN O
two NN NN O
groups NN NN O
although NN NN O
neurotoxicity NN NN B-Disease
symptoms NN NN O
presented NN NN O
mostly NN NN O
with NN NN O
lower NN NN O
scores NN NN O
of NN NN O
severity NN NN O
in NN NN O
group NN NN O
G NN NN O
. NN NN O
   
However NN NN O
, NN NN O
this NN NN O
difference NN NN O
reached NN NN O
statistical NN NN O
significance NN NN O
only NN NN O
with NN NN O
regard NN NN O
to NN NN O
reported NN NN O
pain NN NN B-Disease
sensation NN NN O
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
011 NN NN O
) NN NN O
. NN NN O
   
Also NN NN O
the NN NN O
frequency NN NN O
of NN NN O
abnormal NN NN O
electro NN NN O
- NN NN O
diagnostic NN NN O
findings NN NN O
showed NN NN O
similarity NN NN O
between NN NN O
the NN NN O
two NN NN O
groups NN NN O
( NN NN O
G NN NN O
: NN NN O
7 NN NN O
/ NN NN O
23 NN NN O
= NN NN O
30 NN NN O
. NN NN O
4 NN NN O
% NN NN O
; NN NN O
P NN NN O
: NN NN O
6 NN NN O
/ NN NN O
20 NN NN O
= NN NN O
30 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
This NN NN O
pilot NN NN O
study NN NN O
leads NN NN O
to NN NN O
the NN NN O
conclusion NN NN O
that NN NN O
glutamate NN NN O
supplementation NN NN O
at NN NN O
the NN NN O
chosen NN NN O
regimen NN NN O
fails NN NN O
to NN NN O
protect NN NN O
against NN NN O
peripheral NN NN B-Disease
neurotoxicity NN NN I-Disease
of NN NN O
PAC NN NN O
. NN NN O
   
Development NN NN O
of NN NN O
ocular NN NN B-Disease
myasthenia NN NN I-Disease
during NN NN O
pegylated NN NN O
interferon NN NN O
and NN NN O
ribavirin NN NN O
treatment NN NN O
for NN NN O
chronic NN NN B-Disease
hepatitis NN NN I-Disease
C NN NN I-Disease
. NN NN O
   
A NN NN O
63 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
male NN NN O
experienced NN NN O
sudden NN NN O
diplopia NN NN B-Disease
after NN NN O
9 NN NN O
weeks NN NN O
of NN NN O
administration NN NN O
of NN NN O
pegylated NN NN O
interferon NN NN O
( NN NN O
IFN NN NN O
) NN NN O
alpha NN NN O
- NN NN O
2b NN NN O
and NN NN O
ribavirin NN NN O
for NN NN O
chronic NN NN B-Disease
hepatitis NN NN I-Disease
C NN NN I-Disease
( NN NN O
CHC NN NN B-Disease
) NN NN O
. NN NN O
   
Ophthalmologic NN NN O
examinations NN NN O
showed NN NN O
ptosis NN NN B-Disease
on NN NN I-Disease
the NN NN I-Disease
right NN NN I-Disease
upper NN NN I-Disease
lid NN NN I-Disease
and NN NN O
restricted NN NN B-Disease
right NN NN I-Disease
eye NN NN I-Disease
movement NN NN I-Disease
without NN NN O
any NN NN O
other NN NN O
neurological NN NN O
signs NN NN O
. NN NN O
   
A NN NN O
brain NN NN O
imaging NN NN O
study NN NN O
and NN NN O
repetitive NN NN O
nerve NN NN O
stimulation NN NN O
test NN NN O
indicated NN NN O
no NN NN O
abnormality NN NN O
. NN NN O
   
The NN NN O
acetylcholine NN NN O
receptor NN NN O
antibody NN NN O
titer NN NN O
and NN NN O
response NN NN O
to NN NN O
acetylcholinesterase NN NN O
inhibitors NN NN O
were NN NN O
negative NN NN O
, NN NN O
and NN NN O
the NN NN O
results NN NN O
of NN NN O
thyroid NN NN O
function NN NN O
tests NN NN O
were NN NN O
normal NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
' NN NN O
s NN NN O
ophthalmological NN NN O
symptoms NN NN O
improved NN NN O
rapidly NN NN O
3 NN NN O
weeks NN NN O
after NN NN O
discontinuation NN NN O
of NN NN O
pegylated NN NN O
IFN NN NN O
alpha NN NN O
- NN NN O
2b NN NN O
and NN NN O
ribavirin NN NN O
. NN NN O
   
The NN NN O
ocular NN NN B-Disease
myasthenia NN NN I-Disease
associated NN NN O
with NN NN O
combination NN NN O
therapy NN NN O
of NN NN O
pegylated NN NN O
IFN NN NN O
alpha NN NN O
- NN NN O
2b NN NN O
and NN NN O
ribavirin NN NN O
for NN NN O
CHC NN NN B-Disease
is NN NN O
very NN NN O
rarely NN NN O
reported NN NN O
; NN NN O
therefore NN NN O
, NN NN O
we NN NN O
present NN NN O
this NN NN O
case NN NN O
with NN NN O
a NN NN O
review NN NN O
of NN NN O
the NN NN O
various NN NN O
eye NN NN O
complications NN NN O
of NN NN O
IFN NN NN O
therapy NN NN O
. NN NN O
   
Learning NN NN B-Disease
and NN NN I-Disease
memory NN NN I-Disease
deficits NN NN I-Disease
in NN NN O
ecstasy NN NN O
users NN NN O
and NN NN O
their NN NN O
neural NN NN O
correlates NN NN O
during NN NN O
a NN NN O
face NN NN O
- NN NN O
learning NN NN O
task NN NN O
. NN NN O
   
It NN NN O
has NN NN O
been NN NN O
consistently NN NN O
shown NN NN O
that NN NN O
ecstasy NN NN O
users NN NN O
display NN NN O
impairments NN NN B-Disease
in NN NN I-Disease
learning NN NN I-Disease
and NN NN I-Disease
memory NN NN I-Disease
performance NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
working NN NN O
memory NN NN O
processing NN NN O
in NN NN O
ecstasy NN NN O
users NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
be NN NN O
associated NN NN O
with NN NN O
neural NN NN O
alterations NN NN O
in NN NN O
hippocampal NN NN O
and NN NN O
/ NN NN O
or NN NN O
cortical NN NN O
regions NN NN O
as NN NN O
measured NN NN O
by NN NN O
functional NN NN O
magnetic NN NN O
resonance NN NN O
imaging NN NN O
( NN NN O
fMRI NN NN O
) NN NN O
. NN NN O
   
Using NN NN O
functional NN NN O
imaging NN NN O
and NN NN O
a NN NN O
face NN NN O
- NN NN O
learning NN NN O
task NN NN O
, NN NN O
we NN NN O
investigated NN NN O
neural NN NN O
correlates NN NN O
of NN NN O
encoding NN NN O
and NN NN O
recalling NN NN O
face NN NN O
- NN NN O
name NN NN O
associations NN NN O
in NN NN O
20 NN NN O
recreational NN NN O
drug NN NN O
users NN NN O
whose NN NN O
predominant NN NN O
drug NN NN O
use NN NN O
was NN NN O
ecstasy NN NN O
and NN NN O
20 NN NN O
controls NN NN O
. NN NN O
   
To NN NN O
address NN NN O
the NN NN O
potential NN NN O
confounding NN NN O
effects NN NN O
of NN NN O
the NN NN O
cannabis NN NN O
use NN NN O
of NN NN O
the NN NN O
ecstasy NN NN O
using NN NN O
group NN NN O
, NN NN O
a NN NN O
second NN NN O
analysis NN NN O
included NN NN O
14 NN NN O
previously NN NN O
tested NN NN O
cannabis NN NN O
users NN NN O
( NN NN O
Nestor NN NN O
, NN NN O
L NN NN O
. NN NN O
, NN NN O
Roberts NN NN O
, NN NN O
G NN NN O
. NN NN O
, NN NN O
Garavan NN NN O
, NN NN O
H NN NN O
. NN NN O
, NN NN O
Hester NN NN O
, NN NN O
R NN NN O
. NN NN O
, NN NN O
2008 NN NN O
. NN NN O
Deficits NN NN B-Disease
in NN NN I-Disease
learning NN NN I-Disease
and NN NN I-Disease
memory NN NN I-Disease
: NN NN O
parahippocampal NN NN O
hyperactivity NN NN B-Disease
and NN NN O
frontocortical NN NN O
hypoactivity NN NN O
in NN NN O
cannabis NN NN O
users NN NN O
. NN NN O
Neuroimage NN NN O
40 NN NN O
, NN NN O
1328 NN NN O
- NN NN O
1339 NN NN O
) NN NN O
. NN NN O
   
Ecstasy NN NN O
users NN NN O
performed NN NN O
significantly NN NN O
worse NN NN O
in NN NN O
learning NN NN O
and NN NN O
memory NN NN O
compared NN NN O
to NN NN O
controls NN NN O
and NN NN O
cannabis NN NN O
users NN NN O
. NN NN O
   
A NN NN O
conjunction NN NN O
analysis NN NN O
of NN NN O
the NN NN O
encode NN NN O
and NN NN O
recall NN NN O
phases NN NN O
of NN NN O
the NN NN O
task NN NN O
revealed NN NN O
ecstasy NN NN O
- NN NN O
specific NN NN O
hyperactivity NN NN B-Disease
in NN NN O
bilateral NN NN O
frontal NN NN O
regions NN NN O
, NN NN O
left NN NN O
temporal NN NN O
, NN NN O
right NN NN O
parietal NN NN O
, NN NN O
bilateral NN NN O
temporal NN NN O
, NN NN O
and NN NN O
bilateral NN NN O
occipital NN NN O
brain NN NN O
regions NN NN O
. NN NN O
   
Ecstasy NN NN O
- NN NN O
specific NN NN O
hypoactivity NN NN O
was NN NN O
evident NN NN O
in NN NN O
the NN NN O
right NN NN O
dorsal NN NN O
anterior NN NN O
cingulated NN NN O
cortex NN NN O
( NN NN O
ACC NN NN O
) NN NN O
and NN NN O
left NN NN O
posterior NN NN O
cingulated NN NN O
cortex NN NN O
. NN NN O
   
In NN NN O
both NN NN O
ecstasy NN NN O
and NN NN O
cannabis NN NN O
groups NN NN O
brain NN NN O
activation NN NN O
was NN NN O
decreased NN NN O
in NN NN O
the NN NN O
right NN NN O
medial NN NN O
frontal NN NN O
gyrus NN NN O
, NN NN O
left NN NN O
parahippocampal NN NN O
gyrus NN NN O
, NN NN O
left NN NN O
dorsal NN NN O
cingulate NN NN O
gyrus NN NN O
, NN NN O
and NN NN O
left NN NN O
caudate NN NN O
. NN NN O
   
These NN NN O
results NN NN O
elucidated NN NN O
ecstasy NN NN O
- NN NN O
related NN NN O
deficits NN NN O
, NN NN O
only NN NN O
some NN NN O
of NN NN O
which NN NN O
might NN NN O
be NN NN O
attributed NN NN O
to NN NN O
cannabis NN NN O
use NN NN O
. NN NN O
   
These NN NN O
ecstasy NN NN O
- NN NN O
specific NN NN O
effects NN NN O
may NN NN O
be NN NN O
related NN NN O
to NN NN O
the NN NN O
vulnerability NN NN O
of NN NN O
isocortical NN NN O
and NN NN O
allocortical NN NN O
regions NN NN O
to NN NN O
the NN NN O
neurotoxic NN NN B-Disease
effects NN NN O
of NN NN O
ecstasy NN NN O
. NN NN O
   
Disulfiram NN NN O
- NN NN O
like NN NN O
syndrome NN NN O
after NN NN O
hydrogen NN NN O
cyanamide NN NN O
professional NN NN O
skin NN NN O
exposure NN NN O
: NN NN O
two NN NN O
case NN NN O
reports NN NN O
in NN NN O
France NN NN O
. NN NN O
   
Hydrogen NN NN O
cyanamide NN NN O
is NN NN O
a NN NN O
plant NN NN O
growth NN NN O
regulator NN NN O
used NN NN O
in NN NN O
agriculture NN NN O
to NN NN O
induce NN NN O
bud NN NN O
break NN NN O
in NN NN O
fruit NN NN O
trees NN NN O
. NN NN O
   
Contact NN NN O
with NN NN O
the NN NN O
skin NN NN O
can NN NN O
result NN NN O
in NN NN O
percutaneous NN NN O
absorption NN NN O
of NN NN O
the NN NN O
substance NN NN O
that NN NN O
inhibits NN NN O
aldehyde NN NN O
dehydrogenase NN NN O
and NN NN O
can NN NN O
induce NN NN O
acetaldehyde NN NN O
syndrome NN NN O
in NN NN O
case NN NN O
of NN NN O
alcohol NN NN O
use NN NN O
. NN NN O
   
The NN NN O
purpose NN NN O
of NN NN O
this NN NN O
report NN NN O
is NN NN O
to NN NN O
describe NN NN O
two NN NN O
cases NN NN O
of NN NN O
a NN NN O
disulfiram NN NN O
- NN NN O
like NN NN O
syndrome NN NN O
following NN NN O
occupational NN NN O
exposure NN NN O
to NN NN O
hydrogen NN NN O
cyanamide NN NN O
. NN NN O
   
The NN NN O
first NN NN O
case NN NN O
involved NN NN O
a NN NN O
59 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
man NN NN O
who NN NN O
used NN NN O
Dormex NN NN O
, NN NN O
which NN NN O
contains NN NN O
hydrogen NN NN O
cyanamide NN NN O
, NN NN O
without NN NN O
protection NN NN O
after NN NN O
consuming NN NN O
a NN NN O
large NN NN O
amount NN NN O
of NN NN O
alcohol NN NN O
during NN NN O
a NN NN O
meal NN NN O
. NN NN O
   
In NN NN O
less NN NN O
than NN NN O
1 NN NN O
hour NN NN O
after NN NN O
the NN NN O
ingestion NN NN O
of NN NN O
alcohol NN NN O
, NN NN O
he NN NN O
developed NN NN O
malaise NN NN O
with NN NN O
flushing NN NN B-Disease
of NN NN I-Disease
the NN NN I-Disease
face NN NN I-Disease
, NN NN O
tachycardia NN NN B-Disease
, NN NN O
and NN NN O
dyspnea NN NN B-Disease
. NN NN O
   
Manifestations NN NN O
regressed NN NN O
spontaneously NN NN O
under NN NN O
surveillance NN NN O
in NN NN O
the NN NN O
hospital NN NN O
. NN NN O
   
The NN NN O
second NN NN O
case NN NN O
occurred NN NN O
in NN NN O
a NN NN O
55 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
farmer NN NN O
following NN NN O
cutaneous NN NN O
contact NN NN O
with NN NN O
Dormex NN NN O
. NN NN O
   
Five NN NN O
hours NN NN O
after NN NN O
exposure NN NN O
, NN NN O
he NN NN O
developed NN NN O
disulfiram NN NN O
- NN NN O
like NN NN O
syndrome NN NN O
with NN NN O
flushing NN NN B-Disease
, NN NN O
tachycardia NN NN B-Disease
, NN NN O
and NN NN O
arterial NN NN B-Disease
hypotension NN NN I-Disease
after NN NN O
consuming NN NN O
three NN NN O
glasses NN NN O
of NN NN O
wine NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
recovered NN NN O
spontaneously NN NN O
in NN NN O
3 NN NN O
hours NN NN O
under NN NN O
surveillance NN NN O
in NN NN O
the NN NN O
hospital NN NN O
. NN NN O
   
These NN NN O
cases NN NN O
confirm NN NN O
the NN NN O
necessity NN NN O
of NN NN O
avoiding NN NN O
alcohol NN NN O
consumption NN NN O
as NN NN O
recommended NN NN O
in NN NN O
the NN NN O
instructions NN NN O
for NN NN O
use NN NN O
of NN NN O
Dormex NN NN O
and NN NN O
of NN NN O
preventing NN NN O
cutaneous NN NN O
contact NN NN O
during NN NN O
use NN NN O
. NN NN O
   
Sulpiride NN NN O
- NN NN O
induced NN NN O
tardive NN NN B-Disease
dystonia NN NN I-Disease
. NN NN O
   
Sulpiride NN NN O
is NN NN O
a NN NN O
selective NN NN O
D2 NN NN O
- NN NN O
receptor NN NN O
antagonist NN NN O
with NN NN O
antipsychotic NN NN O
and NN NN O
antidepressant NN NN O
properties NN NN O
. NN NN O
   
Although NN NN O
initially NN NN O
thought NN NN O
to NN NN O
be NN NN O
free NN NN O
of NN NN O
extrapyramidal NN NN O
side NN NN O
effects NN NN O
, NN NN O
sulpiride NN NN O
- NN NN O
induced NN NN O
tardive NN NN B-Disease
dyskinesia NN NN I-Disease
and NN NN O
parkinsonism NN NN B-Disease
have NN NN O
been NN NN O
reported NN NN O
occasionally NN NN O
. NN NN O
   
We NN NN O
studied NN NN O
a NN NN O
37 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
man NN NN O
who NN NN O
developed NN NN O
persistent NN NN O
segmental NN NN O
dystonia NN NN B-Disease
within NN NN O
2 NN NN O
months NN NN O
after NN NN O
starting NN NN O
sulpiride NN NN O
therapy NN NN O
. NN NN O
   
We NN NN O
could NN NN O
not NN NN O
find NN NN O
any NN NN O
previous NN NN O
reports NN NN O
of NN NN O
sulpiride NN NN O
- NN NN O
induced NN NN O
tardive NN NN B-Disease
dystonia NN NN I-Disease
. NN NN O
   
Comparative NN NN O
cognitive NN NN O
and NN NN O
subjective NN NN O
side NN NN O
effects NN NN O
of NN NN O
immediate NN NN O
- NN NN O
release NN NN O
oxycodone NN NN O
in NN NN O
healthy NN NN O
middle NN NN O
- NN NN O
aged NN NN O
and NN NN O
older NN NN O
adults NN NN O
. NN NN O
   
This NN NN O
study NN NN O
measured NN NN O
the NN NN O
objective NN NN O
and NN NN O
subjective NN NN O
neurocognitive NN NN O
effects NN NN O
of NN NN O
a NN NN O
single NN NN O
10 NN NN O
- NN NN O
mg NN NN O
dose NN NN O
of NN NN O
immediate NN NN O
- NN NN O
release NN NN O
oxycodone NN NN O
in NN NN O
healthy NN NN O
, NN NN O
older NN NN O
( NN NN O
> NN NN O
65 NN NN O
years NN NN O
) NN NN O
, NN NN O
and NN NN O
middle NN NN O
- NN NN O
aged NN NN O
( NN NN O
35 NN NN O
to NN NN O
55 NN NN O
years NN NN O
) NN NN O
adults NN NN O
who NN NN O
were NN NN O
not NN NN O
suffering NN NN O
from NN NN O
chronic NN NN O
or NN NN O
significant NN NN O
daily NN NN O
pain NN NN B-Disease
. NN NN O
   
Seventy NN NN O
- NN NN O
one NN NN O
participants NN NN O
completed NN NN O
2 NN NN O
separate NN NN O
study NN NN O
days NN NN O
and NN NN O
were NN NN O
blind NN NN O
to NN NN O
medication NN NN O
condition NN NN O
( NN NN O
placebo NN NN O
, NN NN O
10 NN NN O
- NN NN O
mg NN NN O
oxycodone NN NN O
) NN NN O
. NN NN O
   
Plasma NN NN O
oxycodone NN NN O
concentration NN NN O
peaked NN NN O
between NN NN O
60 NN NN O
and NN NN O
90 NN NN O
minutes NN NN O
postdose NN NN O
( NN NN O
P NN NN O
< NN NN O
. NN NN O
01 NN NN O
) NN NN O
and NN NN O
pupil NN NN O
size NN NN O
, NN NN O
an NN NN O
indication NN NN O
of NN NN O
physiological NN NN O
effects NN NN O
of NN NN O
the NN NN O
medication NN NN O
, NN NN O
peaked NN NN O
at NN NN O
approximately NN NN O
90 NN NN O
to NN NN O
120 NN NN O
minutes NN NN O
postdose NN NN O
( NN NN O
P NN NN O
< NN NN O
. NN NN O
01 NN NN O
) NN NN O
. NN NN O
   
Significant NN NN O
declines NN NN B-Disease
in NN NN I-Disease
simple NN NN I-Disease
and NN NN I-Disease
sustained NN NN I-Disease
attention NN NN I-Disease
, NN NN I-Disease
working NN NN I-Disease
memory NN NN I-Disease
, NN NN I-Disease
and NN NN I-Disease
verbal NN NN I-Disease
memory NN NN I-Disease
were NN NN O
observed NN NN O
at NN NN O
1 NN NN O
hour NN NN O
postdose NN NN O
compared NN NN O
to NN NN O
baseline NN NN O
for NN NN O
both NN NN O
age NN NN O
groups NN NN O
with NN NN O
a NN NN O
trend NN NN O
toward NN NN O
return NN NN O
to NN NN O
baseline NN NN O
by NN NN O
5 NN NN O
hours NN NN O
postdose NN NN O
. NN NN O
   
For NN NN O
almost NN NN O
all NN NN O
cognitive NN NN O
measures NN NN O
, NN NN O
there NN NN O
were NN NN O
no NN NN O
medication NN NN O
by NN NN O
age NN NN O
- NN NN O
interaction NN NN O
effects NN NN O
, NN NN O
which NN NN O
indicates NN NN O
that NN NN O
the NN NN O
2 NN NN O
age NN NN O
groups NN NN O
exhibited NN NN O
similar NN NN O
responses NN NN O
to NN NN O
the NN NN O
medication NN NN O
challenge NN NN O
. NN NN O
   
This NN NN O
study NN NN O
suggests NN NN O
that NN NN O
for NN NN O
healthy NN NN O
older NN NN O
adults NN NN O
who NN NN O
are NN NN O
not NN NN O
suffering NN NN O
from NN NN O
chronic NN NN B-Disease
pain NN NN I-Disease
, NN NN O
neurocognitive NN NN O
and NN NN O
pharmacodynamic NN NN O
changes NN NN O
in NN NN O
response NN NN O
to NN NN O
a NN NN O
10 NN NN O
- NN NN O
mg NN NN O
dose NN NN O
of NN NN O
immediate NN NN O
- NN NN O
release NN NN O
oxycodone NN NN O
are NN NN O
similar NN NN O
to NN NN O
those NN NN O
observed NN NN O
for NN NN O
middle NN NN O
- NN NN O
aged NN NN O
adults NN NN O
. NN NN O
   
PERSPECTIVE NN NN O
: NN NN O
Study NN NN O
findings NN NN O
indicate NN NN O
that NN NN O
the NN NN O
metabolism NN NN O
, NN NN O
neurocognitive NN NN O
effects NN NN O
, NN NN O
and NN NN O
physical NN NN O
side NN NN O
effects NN NN O
of NN NN O
oral NN NN O
oxycodone NN NN O
are NN NN O
similar NN NN O
for NN NN O
healthy NN NN O
middle NN NN O
- NN NN O
aged NN NN O
and NN NN O
older NN NN O
adults NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
clinicians NN NN O
should NN NN O
not NN NN O
avoid NN NN O
prescribing NN NN O
oral NN NN O
opioids NN NN O
to NN NN O
older NN NN O
adults NN NN O
based NN NN O
on NN NN O
the NN NN O
belief NN NN O
that NN NN O
older NN NN O
adults NN NN O
are NN NN O
at NN NN O
higher NN NN O
risk NN NN O
for NN NN O
side NN NN O
effects NN NN O
than NN NN O
younger NN NN O
adults NN NN O
. NN NN O
   
The NN NN O
glycine NN NN O
transporter NN NN O
- NN NN O
1 NN NN O
inhibitor NN NN O
SSR103800 NN NN O
displays NN NN O
a NN NN O
selective NN NN O
and NN NN O
specific NN NN O
antipsychotic NN NN O
- NN NN O
like NN NN O
profile NN NN O
in NN NN O
normal NN NN O
and NN NN O
transgenic NN NN O
mice NN NN O
. NN NN O
   
Schizophrenia NN NN B-Disease
has NN NN O
been NN NN O
initially NN NN O
associated NN NN O
with NN NN O
dysfunction NN NN O
in NN NN O
dopamine NN NN O
neurotransmission NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
observation NN NN O
that NN NN O
antagonists NN NN O
of NN NN O
the NN NN O
glutamate NN NN O
N NN NN O
- NN NN O
methyl NN NN O
- NN NN O
D NN NN O
- NN NN O
aspartate NN NN O
( NN NN O
NMDA NN NN O
) NN NN O
receptor NN NN O
produce NN NN O
schizophrenic NN NN B-Disease
- NN NN O
like NN NN O
symptoms NN NN O
in NN NN O
humans NN NN O
has NN NN O
led NN NN O
to NN NN O
the NN NN O
idea NN NN O
of NN NN O
a NN NN O
dysfunctioning NN NN O
of NN NN O
the NN NN O
glutamatergic NN NN O
system NN NN O
via NN NN O
its NN NN O
NMDA NN NN O
receptor NN NN O
. NN NN O
   
As NN NN O
a NN NN O
result NN NN O
, NN NN O
there NN NN O
is NN NN O
a NN NN O
growing NN NN O
interest NN NN O
in NN NN O
the NN NN O
development NN NN O
of NN NN O
pharmacological NN NN O
agents NN NN O
with NN NN O
potential NN NN O
antipsychotic NN NN O
properties NN NN O
that NN NN O
enhance NN NN O
the NN NN O
activity NN NN O
of NN NN O
the NN NN O
glutamatergic NN NN O
system NN NN O
via NN NN O
a NN NN O
modulation NN NN O
of NN NN O
the NN NN O
NMDA NN NN O
receptor NN NN O
. NN NN O
   
Among NN NN O
them NN NN O
are NN NN O
glycine NN NN O
transporter NN NN O
- NN NN O
1 NN NN O
( NN NN O
GlyT1 NN NN O
) NN NN O
inhibitors NN NN O
such NN NN O
as NN NN O
SSR103800 NN NN O
, NN NN O
which NN NN O
indirectly NN NN O
enhance NN NN O
NMDA NN NN O
receptor NN NN O
function NN NN O
by NN NN O
increasing NN NN O
the NN NN O
glycine NN NN O
( NN NN O
a NN NN O
co NN NN O
- NN NN O
agonist NN NN O
for NN NN O
the NN NN O
NMDA NN NN O
receptor NN NN O
) NN NN O
levels NN NN O
in NN NN O
the NN NN O
synapse NN NN O
. NN NN O
   
This NN NN O
study NN NN O
aimed NN NN O
at NN NN O
investigating NN NN O
the NN NN O
potential NN NN O
antipsychotic NN NN O
- NN NN O
like NN NN O
properties NN NN O
of NN NN O
SSR103800 NN NN O
, NN NN O
with NN NN O
a NN NN O
particular NN NN O
focus NN NN O
on NN NN O
models NN NN O
of NN NN O
hyperactivity NN NN B-Disease
, NN NN O
involving NN NN O
either NN NN O
drug NN NN O
challenge NN NN O
( NN NN O
ie NN NN O
, NN NN O
amphetamine NN NN O
and NN NN O
MK NN NN O
- NN NN O
801 NN NN O
) NN NN O
or NN NN O
transgenic NN NN O
mice NN NN O
( NN NN O
ie NN NN O
, NN NN O
NMDA NN NN O
Nr1 NN NN O
( NN NN O
neo NN NN O
- NN NN O
/ NN NN O
- NN NN O
) NN NN O
and NN NN O
DAT NN NN O
( NN NN O
- NN NN O
/ NN NN O
- NN NN O
) NN NN O
) NN NN O
. NN NN O
   
Results NN NN O
showed NN NN O
that NN NN O
SSR103800 NN NN O
( NN NN O
10 NN NN O
- NN NN O
30 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
p NN NN O
. NN NN O
o NN NN O
. NN NN O
) NN NN O
blocked NN NN O
hyperactivity NN NN B-Disease
induced NN NN O
by NN NN O
the NN NN O
non NN NN O
- NN NN O
competitive NN NN O
NMDA NN NN O
receptor NN NN O
antagonist NN NN O
, NN NN O
MK NN NN O
- NN NN O
801 NN NN O
and NN NN O
partially NN NN O
reversed NN NN O
spontaneous NN NN O
hyperactivity NN NN B-Disease
of NN NN O
NMDA NN NN O
Nr1 NN NN O
( NN NN O
neo NN NN O
- NN NN O
/ NN NN O
- NN NN O
) NN NN O
mice NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
SSR103800 NN NN O
failed NN NN O
to NN NN O
affect NN NN O
hyperactivity NN NN B-Disease
induced NN NN O
by NN NN O
amphetamine NN NN O
or NN NN O
naturally NN NN O
observed NN NN O
in NN NN O
dopamine NN NN O
transporter NN NN O
( NN NN O
DAT NN NN O
( NN NN O
- NN NN O
/ NN NN O
- NN NN O
) NN NN O
) NN NN O
knockout NN NN O
mice NN NN O
( NN NN O
10 NN NN O
- NN NN O
30 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
p NN NN O
. NN NN O
o NN NN O
. NN NN O
) NN NN O
. NN NN O
   
Importantly NN NN O
, NN NN O
both NN NN O
classical NN NN O
( NN NN O
haloperidol NN NN O
) NN NN O
and NN NN O
atypical NN NN O
( NN NN O
olanzapine NN NN O
, NN NN O
clozapine NN NN O
and NN NN O
aripiprazole NN NN O
) NN NN O
antipsychotics NN NN O
were NN NN O
effective NN NN O
in NN NN O
all NN NN O
these NN NN O
models NN NN O
of NN NN O
hyperactivity NN NN B-Disease
. NN NN O
   
However NN NN O
, NN NN O
unlike NN NN O
these NN NN O
latter NN NN O
, NN NN O
SSR103800 NN NN O
did NN NN O
not NN NN O
produce NN NN O
catalepsy NN NN B-Disease
( NN NN O
retention NN NN O
on NN NN O
the NN NN O
bar NN NN O
test NN NN O
) NN NN O
up NN NN O
to NN NN O
30 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
p NN NN O
. NN NN O
o NN NN O
. NN NN O
   
Together NN NN O
these NN NN O
findings NN NN O
show NN NN O
that NN NN O
the NN NN O
GlyT1 NN NN O
inhibitor NN NN O
, NN NN O
SSR103800 NN NN O
, NN NN O
produces NN NN O
antipsychotic NN NN O
- NN NN O
like NN NN O
effects NN NN O
, NN NN O
which NN NN O
differ NN NN O
from NN NN O
those NN NN O
observed NN NN O
with NN NN O
compounds NN NN O
primarily NN NN O
targeting NN NN O
the NN NN O
dopaminergic NN NN O
system NN NN O
, NN NN O
and NN NN O
has NN NN O
a NN NN O
reduced NN NN O
side NN NN O
- NN NN O
effect NN NN O
potential NN NN O
as NN NN O
compared NN NN O
with NN NN O
these NN NN O
latter NN NN O
drugs NN NN O
. NN NN O
   
Pyrrolidine NN NN O
dithiocarbamate NN NN O
protects NN NN O
the NN NN O
piriform NN NN O
cortex NN NN O
in NN NN O
the NN NN O
pilocarpine NN NN O
status NN NN B-Disease
epilepticus NN NN I-Disease
model NN NN O
. NN NN O
   
Pyrrolidine NN NN O
dithiocarbamate NN NN O
( NN NN O
PDTC NN NN O
) NN NN O
has NN NN O
a NN NN O
dual NN NN O
mechanism NN NN O
of NN NN O
action NN NN O
as NN NN O
an NN NN O
antioxidant NN NN O
and NN NN O
an NN NN O
inhibitor NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
kappa NN NN O
- NN NN O
beta NN NN O
. NN NN O
   
Both NN NN O
, NN NN O
production NN NN O
of NN NN O
reactive NN NN O
oxygen NN NN O
species NN NN O
as NN NN O
well NN NN O
as NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
have NN NN O
been NN NN O
implicated NN NN O
in NN NN O
severe NN NN O
neuronal NN NN B-Disease
damage NN NN I-Disease
in NN NN O
different NN NN O
sub NN NN O
- NN NN O
regions NN NN O
of NN NN O
the NN NN O
hippocampus NN NN O
as NN NN O
well NN NN O
as NN NN O
in NN NN O
the NN NN O
surrounding NN NN O
cortices NN NN O
. NN NN O
   
The NN NN O
effect NN NN O
of NN NN O
PDTC NN NN O
on NN NN O
status NN NN B-Disease
epilepticus NN NN I-Disease
- NN NN O
associated NN NN O
cell NN NN O
loss NN NN O
in NN NN O
the NN NN O
hippocampus NN NN O
and NN NN O
piriform NN NN O
cortex NN NN O
was NN NN O
evaluated NN NN O
in NN NN O
the NN NN O
rat NN NN O
fractionated NN NN O
pilocarpine NN NN O
model NN NN O
. NN NN O
   
Treatment NN NN O
with NN NN O
150 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
PDTC NN NN O
before NN NN O
and NN NN O
following NN NN O
status NN NN B-Disease
epilepticus NN NN I-Disease
significantly NN NN O
increased NN NN O
the NN NN O
mortality NN NN O
rate NN NN O
to NN NN O
100 NN NN O
% NN NN O
. NN NN O
   
Administration NN NN O
of NN NN O
50 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
PDTC NN NN O
( NN NN O
low NN NN O
- NN NN O
dose NN NN O
) NN NN O
did NN NN O
not NN NN O
exert NN NN O
major NN NN O
effects NN NN O
on NN NN O
the NN NN O
development NN NN O
of NN NN O
a NN NN O
status NN NN B-Disease
epilepticus NN NN I-Disease
or NN NN O
the NN NN O
mortality NN NN O
rate NN NN O
. NN NN O
   
In NN NN O
vehicle NN NN O
- NN NN O
treated NN NN O
rats NN NN O
, NN NN O
status NN NN B-Disease
epilepticus NN NN I-Disease
caused NN NN O
pronounced NN NN O
neuronal NN NN B-Disease
damage NN NN I-Disease
in NN NN O
the NN NN O
piriform NN NN O
cortex NN NN O
comprising NN NN O
both NN NN O
pyramidal NN NN O
cells NN NN O
and NN NN O
interneurons NN NN O
. NN NN O
   
Low NN NN O
- NN NN O
dose NN NN O
PDTC NN NN O
treatment NN NN O
almost NN NN O
completely NN NN O
protected NN NN O
from NN NN O
lesions NN NN O
in NN NN O
the NN NN O
piriform NN NN O
cortex NN NN O
. NN NN O
   
A NN NN O
significant NN NN O
decrease NN NN O
in NN NN O
neuronal NN NN O
density NN NN O
of NN NN O
the NN NN O
hippocampal NN NN O
hilar NN NN O
formation NN NN O
was NN NN O
identified NN NN O
in NN NN O
vehicle NN NN O
- NN NN O
and NN NN O
PDTC NN NN O
- NN NN O
treated NN NN O
rats NN NN O
following NN NN O
status NN NN B-Disease
epilepticus NN NN I-Disease
. NN NN O
   
In NN NN O
conclusion NN NN O
, NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
inhibitor NN NN O
and NN NN O
antioxidant NN NN O
PDTC NN NN O
protected NN NN O
the NN NN O
piriform NN NN O
cortex NN NN O
, NN NN O
whereas NN NN O
it NN NN O
did NN NN O
not NN NN O
affect NN NN O
hilar NN NN O
neuronal NN NN B-Disease
loss NN NN I-Disease
. NN NN O
   
These NN NN O
data NN NN O
might NN NN O
indicate NN NN O
that NN NN O
the NN NN O
generation NN NN O
of NN NN O
reactive NN NN O
oxygen NN NN O
species NN NN O
and NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
plays NN NN O
a NN NN O
more NN NN O
central NN NN O
role NN NN O
in NN NN O
seizure NN NN B-Disease
- NN NN O
associated NN NN O
neuronal NN NN B-Disease
damage NN NN I-Disease
in NN NN O
the NN NN O
temporal NN NN O
cortex NN NN O
as NN NN O
compared NN NN O
to NN NN O
the NN NN O
hippocampal NN NN O
hilus NN NN O
. NN NN O
   
However NN NN O
, NN NN O
future NN NN O
investigations NN NN O
are NN NN O
necessary NN NN O
to NN NN O
exactly NN NN O
analyze NN NN O
the NN NN O
biochemical NN NN O
mechanisms NN NN O
by NN NN O
which NN NN O
PDTC NN NN O
exerted NN NN O
its NN NN O
beneficial NN NN O
effects NN NN O
in NN NN O
the NN NN O
piriform NN NN O
cortex NN NN O
. NN NN O
   
Anaesthetists NN NN O
' NN NN O
nightmare NN NN O
: NN NN O
masseter NN NN B-Disease
spasm NN NN I-Disease
after NN NN O
induction NN NN O
in NN NN O
an NN NN O
undiagnosed NN NN O
case NN NN O
of NN NN O
myotonia NN NN B-Disease
congenita NN NN I-Disease
. NN NN O
   
We NN NN O
report NN NN O
an NN NN O
undiagnosed NN NN O
case NN NN O
of NN NN O
myotonia NN NN B-Disease
congenita NN NN I-Disease
in NN NN O
a NN NN O
24 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
previously NN NN O
healthy NN NN O
primigravida NN NN O
, NN NN O
who NN NN O
developed NN NN O
life NN NN O
threatening NN NN O
masseter NN NN B-Disease
spasm NN NN I-Disease
following NN NN O
a NN NN O
standard NN NN O
dose NN NN O
of NN NN O
intravenous NN NN O
suxamethonium NN NN O
for NN NN O
induction NN NN O
of NN NN O
anaesthesia NN NN O
. NN NN O
   
Neither NN NN O
the NN NN O
patient NN NN O
nor NN NN O
the NN NN O
anaesthetist NN NN O
was NN NN O
aware NN NN O
of NN NN O
the NN NN O
diagnosis NN NN O
before NN NN O
this NN NN O
potentially NN NN O
lethal NN NN O
complication NN NN O
occurred NN NN O
. NN NN O
   
Twin NN NN O
preterm NN NN O
neonates NN NN O
with NN NN O
cardiac NN NN B-Disease
toxicity NN NN I-Disease
related NN NN O
to NN NN O
lopinavir NN NN O
/ NN NN O
ritonavir NN NN O
therapy NN NN O
. NN NN O
   
We NN NN O
report NN NN O
twin NN NN O
neonates NN NN O
who NN NN O
were NN NN O
born NN NN O
prematurely NN NN O
at NN NN O
32 NN NN O
weeks NN NN O
of NN NN O
gestation NN NN O
to NN NN O
a NN NN O
mother NN NN O
with NN NN O
human NN NN B-Disease
immunodeficiency NN NN I-Disease
virus NN NN I-Disease
infection NN NN I-Disease
. NN NN O
   
One NN NN O
of NN NN O
the NN NN O
twins NN NN O
developed NN NN O
complete NN NN O
heart NN NN B-Disease
block NN NN I-Disease
and NN NN O
dilated NN NN B-Disease
cardiomyopathy NN NN I-Disease
related NN NN O
to NN NN O
lopinavir NN NN O
/ NN NN O
ritonavir NN NN O
therapy NN NN O
, NN NN O
a NN NN O
boosted NN NN O
protease NN NN O
- NN NN O
inhibitor NN NN O
agent NN NN O
, NN NN O
while NN NN O
the NN NN O
other NN NN O
twin NN NN O
developed NN NN O
mild NN NN O
bradycardia NN NN B-Disease
. NN NN O
   
We NN NN O
recommend NN NN O
caution NN NN O
in NN NN O
the NN NN O
use NN NN O
of NN NN O
lopinavir NN NN O
/ NN NN O
ritonavir NN NN O
in NN NN O
the NN NN O
immediate NN NN O
neonatal NN NN O
period NN NN O
. NN NN O
   
When NN NN O
drugs NN NN O
disappear NN NN O
from NN NN O
the NN NN O
patient NN NN O
: NN NN O
elimination NN NN O
of NN NN O
intravenous NN NN O
medication NN NN O
by NN NN O
hemodiafiltration NN NN O
. NN NN O
   
Twenty NN NN O
- NN NN O
three NN NN O
hours NN NN O
after NN NN O
heart NN NN O
transplantation NN NN O
, NN NN O
life NN NN O
- NN NN O
threatening NN NN O
acute NN NN O
right NN NN B-Disease
heart NN NN I-Disease
failure NN NN I-Disease
was NN NN O
diagnosed NN NN O
in NN NN O
a NN NN O
patient NN NN O
requiring NN NN O
continuous NN NN O
venovenous NN NN O
hemodiafiltration NN NN O
( NN NN O
CVVHDF NN NN O
) NN NN O
. NN NN O
   
Increasing NN NN O
doses NN NN O
of NN NN O
catecholamines NN NN O
, NN NN O
sedatives NN NN O
, NN NN O
and NN NN O
muscle NN NN O
relaxants NN NN O
administered NN NN O
through NN NN O
a NN NN O
central NN NN O
venous NN NN O
catheter NN NN O
were NN NN O
ineffective NN NN O
. NN NN O
   
However NN NN O
, NN NN O
a NN NN O
bolus NN NN O
of NN NN O
epinephrine NN NN O
injected NN NN O
through NN NN O
an NN NN O
alternative NN NN O
catheter NN NN O
provoked NN NN O
a NN NN O
hypertensive NN NN B-Disease
crisis NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
interference NN NN O
with NN NN O
the NN NN O
central NN NN O
venous NN NN O
infusion NN NN O
by NN NN O
the NN NN O
dialysis NN NN O
catheter NN NN O
was NN NN O
suspected NN NN O
. NN NN O
   
The NN NN O
catheters NN NN O
were NN NN O
changed NN NN O
, NN NN O
and NN NN O
hemodynamics NN NN O
stabilized NN NN O
at NN NN O
lower NN NN O
catecholamine NN NN O
doses NN NN O
. NN NN O
   
When NN NN O
the NN NN O
effects NN NN O
of NN NN O
IV NN NN O
drugs NN NN O
are NN NN O
inadequate NN NN O
in NN NN O
patients NN NN O
receiving NN NN O
CVVHDF NN NN O
, NN NN O
interference NN NN O
with NN NN O
adjacent NN NN O
catheters NN NN O
resulting NN NN O
in NN NN O
elimination NN NN O
of NN NN O
the NN NN O
drug NN NN O
by NN NN O
CVVHDF NN NN O
should NN NN O
be NN NN O
suspected NN NN O
. NN NN O
   
Less NN NN O
frequent NN NN O
lithium NN NN O
administration NN NN O
and NN NN O
lower NN NN O
urine NN NN O
volume NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
This NN NN O
study NN NN O
was NN NN O
designed NN NN O
to NN NN O
determine NN NN O
whether NN NN O
patients NN NN O
maintained NN NN O
on NN NN O
a NN NN O
regimen NN NN O
of NN NN O
lithium NN NN O
on NN NN O
a NN NN O
once NN NN O
- NN NN O
per NN NN O
- NN NN O
day NN NN O
schedule NN NN O
have NN NN O
lower NN NN O
urine NN NN O
volumes NN NN O
than NN NN O
do NN NN O
patients NN NN O
receiving NN NN O
multiple NN NN O
doses NN NN O
per NN NN O
day NN NN O
. NN NN O
   
METHOD NN NN O
: NN NN O
This NN NN O
was NN NN O
a NN NN O
cross NN NN O
- NN NN O
sectional NN NN O
study NN NN O
of NN NN O
85 NN NN O
patients NN NN O
from NN NN O
a NN NN O
lithium NN NN O
clinic NN NN O
who NN NN O
received NN NN O
different NN NN O
dose NN NN O
schedules NN NN O
. NN NN O
   
Patients NN NN O
were NN NN O
admitted NN NN O
to NN NN O
the NN NN O
hospital NN NN O
for NN NN O
measurement NN NN O
of NN NN O
lithium NN NN O
level NN NN O
, NN NN O
creatinine NN NN O
clearance NN NN O
, NN NN O
urine NN NN O
volume NN NN O
, NN NN O
and NN NN O
maximum NN NN O
osmolality NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Multiple NN NN O
daily NN NN O
doses NN NN O
of NN NN O
lithium NN NN O
were NN NN O
associated NN NN O
with NN NN O
higher NN NN O
urine NN NN O
volumes NN NN O
. NN NN O
   
The NN NN O
dosing NN NN O
schedule NN NN O
, NN NN O
duration NN NN O
of NN NN O
lithium NN NN O
treatment NN NN O
, NN NN O
and NN NN O
daily NN NN O
dose NN NN O
of NN NN O
lithium NN NN O
did NN NN O
not NN NN O
affect NN NN O
maximum NN NN O
osmolality NN NN O
or NN NN O
creatinine NN NN O
clearance NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Urine NN NN O
volume NN NN O
can NN NN O
be NN NN O
reduced NN NN O
by NN NN O
giving NN NN O
lithium NN NN O
once NN NN O
daily NN NN O
and NN NN O
/ NN NN O
or NN NN O
by NN NN O
lowering NN NN O
the NN NN O
total NN NN O
daily NN NN O
dose NN NN O
. NN NN O
   
Lithium NN NN O
- NN NN O
induced NN NN O
polyuria NN NN B-Disease
seems NN NN O
to NN NN O
be NN NN O
related NN NN O
to NN NN O
extrarenal NN NN O
as NN NN O
well NN NN O
as NN NN O
to NN NN O
renal NN NN O
effects NN NN O
. NN NN O
   
Antibacterial NN NN O
medication NN NN O
use NN NN O
during NN NN O
pregnancy NN NN O
and NN NN O
risk NN NN O
of NN NN O
birth NN NN B-Disease
defects NN NN I-Disease
: NN NN O
National NN NN O
Birth NN NN B-Disease
Defects NN NN I-Disease
Prevention NN NN O
Study NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
To NN NN O
estimate NN NN O
the NN NN O
association NN NN O
between NN NN O
antibacterial NN NN O
medications NN NN O
and NN NN O
selected NN NN O
birth NN NN B-Disease
defects NN NN I-Disease
. NN NN O
   
DESIGN NN NN O
, NN NN O
SETTING NN NN O
, NN NN O
AND NN NN O
PARTICIPANTS NN NN O
: NN NN O
Population NN NN O
- NN NN O
based NN NN O
, NN NN O
multisite NN NN O
, NN NN O
case NN NN O
- NN NN O
control NN NN O
study NN NN O
of NN NN O
women NN NN O
who NN NN O
had NN NN O
pregnancies NN NN O
affected NN NN O
by NN NN O
1 NN NN O
of NN NN O
more NN NN O
than NN NN O
30 NN NN O
eligible NN NN O
major NN NN O
birth NN NN B-Disease
defects NN NN I-Disease
identified NN NN O
via NN NN O
birth NN NN B-Disease
defect NN NN I-Disease
surveillance NN NN O
programs NN NN O
in NN NN O
10 NN NN O
states NN NN O
( NN NN O
n NN NN O
= NN NN O
13 NN NN O
155 NN NN O
) NN NN O
and NN NN O
control NN NN O
women NN NN O
randomly NN NN O
selected NN NN O
from NN NN O
the NN NN O
same NN NN O
geographical NN NN O
regions NN NN O
( NN NN O
n NN NN O
= NN NN O
4941 NN NN O
) NN NN O
. NN NN O
   
MAIN NN NN O
EXPOSURE NN NN O
: NN NN O
Reported NN NN O
maternal NN NN O
use NN NN O
of NN NN O
antibacterials NN NN O
( NN NN O
1 NN NN O
month NN NN O
before NN NN O
pregnancy NN NN O
through NN NN O
the NN NN O
end NN NN O
of NN NN O
the NN NN O
first NN NN O
trimester NN NN O
) NN NN O
. NN NN O
   
MAIN NN NN O
OUTCOME NN NN O
MEASURE NN NN O
: NN NN O
Odds NN NN O
ratios NN NN O
( NN NN O
ORs NN NN O
) NN NN O
measuring NN NN O
the NN NN O
association NN NN O
between NN NN O
antibacterial NN NN O
use NN NN O
and NN NN O
selected NN NN O
birth NN NN B-Disease
defects NN NN I-Disease
adjusted NN NN O
for NN NN O
potential NN NN O
confounders NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
The NN NN O
reported NN NN O
use NN NN O
of NN NN O
antibacterials NN NN O
increased NN NN O
during NN NN O
pregnancy NN NN O
, NN NN O
peaking NN NN O
during NN NN O
the NN NN O
third NN NN O
month NN NN O
. NN NN O
   
Sulfonamides NN NN O
were NN NN O
associated NN NN O
with NN NN O
anencephaly NN NN B-Disease
( NN NN O
adjusted NN NN O
OR NN NN O
[ NN NN O
AOR NN NN O
] NN NN O
= NN NN O
3 NN NN O
. NN NN O
4 NN NN O
; NN NN O
95 NN NN O
% NN NN O
confidence NN NN O
interval NN NN O
[ NN NN O
CI NN NN O
] NN NN O
, NN NN O
1 NN NN O
. NN NN O
3 NN NN O
- NN NN O
8 NN NN O
. NN NN O
8 NN NN O
) NN NN O
, NN NN O
hypoplastic NN NN B-Disease
left NN NN I-Disease
heart NN NN I-Disease
syndrome NN NN I-Disease
( NN NN O
AOR NN NN O
= NN NN O
3 NN NN O
. NN NN O
2 NN NN O
; NN NN O
95 NN NN O
% NN NN O
CI NN NN O
, NN NN O
1 NN NN O
. NN NN O
3 NN NN O
- NN NN O
7 NN NN O
. NN NN O
6 NN NN O
) NN NN O
, NN NN O
coarctation NN NN B-Disease
of NN NN I-Disease
the NN NN I-Disease
aorta NN NN I-Disease
( NN NN O
AOR NN NN O
= NN NN O
2 NN NN O
. NN NN O
7 NN NN O
; NN NN O
95 NN NN O
% NN NN O
CI NN NN O
, NN NN O
1 NN NN O
. NN NN O
3 NN NN O
- NN NN O
5 NN NN O
. NN NN O
6 NN NN O
) NN NN O
, NN NN O
choanal NN NN B-Disease
atresia NN NN I-Disease
( NN NN O
AOR NN NN O
= NN NN O
8 NN NN O
. NN NN O
0 NN NN O
; NN NN O
95 NN NN O
% NN NN O
CI NN NN O
, NN NN O
2 NN NN O
. NN NN O
7 NN NN O
- NN NN O
23 NN NN O
. NN NN O
5 NN NN O
) NN NN O
, NN NN O
transverse NN NN B-Disease
limb NN NN I-Disease
deficiency NN NN I-Disease
( NN NN O
AOR NN NN O
= NN NN O
2 NN NN O
. NN NN O
5 NN NN O
; NN NN O
95 NN NN O
% NN NN O
CI NN NN O
, NN NN O
1 NN NN O
. NN NN O
0 NN NN O
- NN NN O
5 NN NN O
. NN NN O
9 NN NN O
) NN NN O
, NN NN O
and NN NN O
diaphragmatic NN NN B-Disease
hernia NN NN I-Disease
( NN NN O
AOR NN NN O
= NN NN O
2 NN NN O
. NN NN O
4 NN NN O
; NN NN O
95 NN NN O
% NN NN O
CI NN NN O
, NN NN O
1 NN NN O
. NN NN O
1 NN NN O
- NN NN O
5 NN NN O
. NN NN O
4 NN NN O
) NN NN O
. NN NN O
   
Nitrofurantoins NN NN O
were NN NN O
associated NN NN O
with NN NN O
anophthalmia NN NN B-Disease
or NN NN O
microphthalmos NN NN B-Disease
( NN NN O
AOR NN NN O
= NN NN O
3 NN NN O
. NN NN O
7 NN NN O
; NN NN O
95 NN NN O
% NN NN O
CI NN NN O
, NN NN O
1 NN NN O
. NN NN O
1 NN NN O
- NN NN O
12 NN NN O
. NN NN O
2 NN NN O
) NN NN O
, NN NN O
hypoplastic NN NN B-Disease
left NN NN I-Disease
heart NN NN I-Disease
syndrome NN NN I-Disease
( NN NN O
AOR NN NN O
= NN NN O
4 NN NN O
. NN NN O
2 NN NN O
; NN NN O
95 NN NN O
% NN NN O
CI NN NN O
, NN NN O
1 NN NN O
. NN NN O
9 NN NN O
- NN NN O
9 NN NN O
. NN NN O
1 NN NN O
) NN NN O
, NN NN O
atrial NN NN B-Disease
septal NN NN I-Disease
defects NN NN I-Disease
( NN NN O
AOR NN NN O
= NN NN O
1 NN NN O
. NN NN O
9 NN NN O
; NN NN O
95 NN NN O
% NN NN O
CI NN NN O
, NN NN O
1 NN NN O
. NN NN O
1 NN NN O
- NN NN O
3 NN NN O
. NN NN O
4 NN NN O
) NN NN O
, NN NN O
and NN NN O
cleft NN NN B-Disease
lip NN NN I-Disease
with NN NN O
cleft NN NN B-Disease
palate NN NN I-Disease
( NN NN O
AOR NN NN O
= NN NN O
2 NN NN O
. NN NN O
1 NN NN O
; NN NN O
95 NN NN O
% NN NN O
CI NN NN O
, NN NN O
1 NN NN O
. NN NN O
2 NN NN O
- NN NN O
3 NN NN O
. NN NN O
9 NN NN O
) NN NN O
. NN NN O
   
Other NN NN O
antibacterial NN NN O
agents NN NN O
that NN NN O
showed NN NN O
associations NN NN O
included NN NN O
erythromycins NN NN O
( NN NN O
2 NN NN O
defects NN NN O
) NN NN O
, NN NN O
penicillins NN NN O
( NN NN O
1 NN NN O
defect NN NN O
) NN NN O
, NN NN O
cephalosporins NN NN O
( NN NN O
1 NN NN O
defect NN NN O
) NN NN O
, NN NN O
and NN NN O
quinolones NN NN O
( NN NN O
1 NN NN O
defect NN NN O
) NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Reassuringly NN NN O
, NN NN O
penicillins NN NN O
, NN NN O
erythromycins NN NN O
, NN NN O
and NN NN O
cephalosporins NN NN O
, NN NN O
although NN NN O
used NN NN O
commonly NN NN O
by NN NN O
pregnant NN NN O
women NN NN O
, NN NN O
were NN NN O
not NN NN O
associated NN NN O
with NN NN O
many NN NN O
birth NN NN B-Disease
defects NN NN I-Disease
. NN NN O
   
Sulfonamides NN NN O
and NN NN O
nitrofurantoins NN NN O
were NN NN O
associated NN NN O
with NN NN O
several NN NN O
birth NN NN B-Disease
defects NN NN I-Disease
, NN NN O
indicating NN NN O
a NN NN O
need NN NN O
for NN NN O
additional NN NN O
scrutiny NN NN O
. NN NN O
   
Differential NN NN O
impact NN NN O
of NN NN O
immune NN NN O
escape NN NN O
mutations NN NN O
G145R NN NN O
and NN NN O
P120T NN NN O
on NN NN O
the NN NN O
replication NN NN O
of NN NN O
lamivudine NN NN O
- NN NN O
resistant NN NN O
hepatitis NN NN O
B NN NN O
virus NN NN O
e NN NN O
antigen NN NN O
- NN NN O
positive NN NN O
and NN NN O
- NN NN O
negative NN NN O
strains NN NN O
. NN NN O
   
Immune NN NN O
escape NN NN O
variants NN NN O
of NN NN O
the NN NN O
hepatitis NN NN B-Disease
B NN NN I-Disease
virus NN NN O
( NN NN O
HBV NN NN O
) NN NN O
represent NN NN O
an NN NN O
emerging NN NN O
clinical NN NN O
challenge NN NN O
, NN NN O
because NN NN O
they NN NN O
can NN NN O
be NN NN O
associated NN NN O
with NN NN O
vaccine NN NN O
escape NN NN O
, NN NN O
HBV NN NN O
reactivation NN NN O
, NN NN O
and NN NN O
failure NN NN O
of NN NN O
diagnostic NN NN O
tests NN NN O
. NN NN O
   
Recent NN NN O
data NN NN O
suggest NN NN O
a NN NN O
preferential NN NN O
selection NN NN O
of NN NN O
immune NN NN O
escape NN NN O
mutants NN NN O
in NN NN O
distinct NN NN O
peripheral NN NN O
blood NN NN O
leukocyte NN NN O
compartments NN NN O
of NN NN O
infected NN NN O
individuals NN NN O
. NN NN O
   
We NN NN O
therefore NN NN O
systematically NN NN O
analyzed NN NN O
the NN NN O
functional NN NN O
impact NN NN O
of NN NN O
the NN NN O
most NN NN O
prevalent NN NN O
immune NN NN O
escape NN NN O
variants NN NN O
, NN NN O
the NN NN O
sG145R NN NN O
and NN NN O
sP120T NN NN O
mutants NN NN O
, NN NN O
on NN NN O
the NN NN O
viral NN NN O
replication NN NN O
efficacy NN NN O
and NN NN O
antiviral NN NN O
drug NN NN O
susceptibility NN NN O
of NN NN O
common NN NN O
treatment NN NN O
- NN NN O
associated NN NN O
mutants NN NN O
with NN NN O
resistance NN NN O
to NN NN O
lamivudine NN NN O
( NN NN O
LAM NN NN O
) NN NN O
and NN NN O
/ NN NN O
or NN NN O
HBeAg NN NN O
negativity NN NN O
. NN NN O
   
Replication NN NN O
- NN NN O
competent NN NN O
HBV NN NN O
strains NN NN O
with NN NN O
sG145R NN NN O
or NN NN O
sP120T NN NN O
and NN NN O
LAM NN NN O
resistance NN NN O
( NN NN O
rtM204I NN NN O
or NN NN O
rtL180M NN NN O
/ NN NN O
rtM204V NN NN O
) NN NN O
were NN NN O
generated NN NN O
on NN NN O
an NN NN O
HBeAg NN NN O
- NN NN O
positive NN NN O
and NN NN O
an NN NN O
HBeAg NN NN O
- NN NN O
negative NN NN O
background NN NN O
with NN NN O
precore NN NN O
( NN NN O
PC NN NN O
) NN NN O
and NN NN O
basal NN NN O
core NN NN O
promoter NN NN O
( NN NN O
BCP NN NN O
) NN NN O
mutants NN NN O
. NN NN O
   
The NN NN O
sG145R NN NN O
mutation NN NN O
strongly NN NN O
reduced NN NN O
HBsAg NN NN O
levels NN NN O
and NN NN O
was NN NN O
able NN NN O
to NN NN O
fully NN NN O
restore NN NN O
the NN NN O
impaired NN NN O
replication NN NN O
of NN NN O
LAM NN NN O
- NN NN O
resistant NN NN O
HBV NN NN O
mutants NN NN O
to NN NN O
the NN NN O
levels NN NN O
of NN NN O
wild NN NN O
- NN NN O
type NN NN O
HBV NN NN O
, NN NN O
and NN NN O
PC NN NN O
or NN NN O
BCP NN NN O
mutations NN NN O
further NN NN O
enhanced NN NN O
viral NN NN O
replication NN NN O
. NN NN O
   
Although NN NN O
the NN NN O
sP120T NN NN O
substitution NN NN O
also NN NN O
impaired NN NN O
HBsAg NN NN O
secretion NN NN O
, NN NN O
it NN NN O
did NN NN O
not NN NN O
enhance NN NN O
the NN NN O
replication NN NN O
of NN NN O
LAM NN NN O
- NN NN O
resistant NN NN O
clones NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
concomitant NN NN O
occurrence NN NN O
of NN NN O
HBeAg NN NN O
negativity NN NN O
( NN NN O
PC NN NN O
/ NN NN O
BCP NN NN O
) NN NN O
, NN NN O
sP120T NN NN O
, NN NN O
and NN NN O
LAM NN NN O
resistance NN NN O
resulted NN NN O
in NN NN O
the NN NN O
restoration NN NN O
of NN NN O
replication NN NN O
to NN NN O
levels NN NN O
of NN NN O
wild NN NN O
- NN NN O
type NN NN O
HBV NN NN O
. NN NN O
   
In NN NN O
all NN NN O
clones NN NN O
with NN NN O
combined NN NN O
immune NN NN O
escape NN NN O
and NN NN O
LAM NN NN O
resistance NN NN O
mutations NN NN O
, NN NN O
the NN NN O
nucleotide NN NN O
analogues NN NN O
adefovir NN NN O
and NN NN O
tenofovir NN NN O
remained NN NN O
effective NN NN O
in NN NN O
suppressing NN NN O
viral NN NN O
replication NN NN O
in NN NN O
vitro NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
reveal NN NN O
the NN NN O
differential NN NN O
impact NN NN O
of NN NN O
immune NN NN O
escape NN NN O
variants NN NN O
on NN NN O
the NN NN O
replication NN NN O
and NN NN O
drug NN NN O
susceptibility NN NN O
of NN NN O
complex NN NN O
HBV NN NN O
mutants NN NN O
, NN NN O
supporting NN NN O
the NN NN O
need NN NN O
of NN NN O
close NN NN O
surveillance NN NN O
and NN NN O
treatment NN NN O
adjustment NN NN O
in NN NN O
response NN NN O
to NN NN O
the NN NN O
selection NN NN O
of NN NN O
distinct NN NN O
mutational NN NN O
patterns NN NN O
. NN NN O
   
Hemolytic NN NN B-Disease
anemia NN NN I-Disease
associated NN NN O
with NN NN O
the NN NN O
use NN NN O
of NN NN O
omeprazole NN NN O
. NN NN O
   
Omeprazole NN NN O
is NN NN O
the NN NN O
first NN NN O
drug NN NN O
designed NN NN O
to NN NN O
block NN NN O
the NN NN O
final NN NN O
step NN NN O
in NN NN O
the NN NN O
acid NN NN O
secretory NN NN O
process NN NN O
within NN NN O
the NN NN O
parietal NN NN O
cell NN NN O
. NN NN O
   
It NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
be NN NN O
extremely NN NN O
effective NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
peptic NN NN B-Disease
ulcer NN NN I-Disease
disease NN NN I-Disease
, NN NN O
reflux NN NN B-Disease
esophagitis NN NN I-Disease
, NN NN O
and NN NN O
the NN NN O
Zollinger NN NN B-Disease
- NN NN I-Disease
Ellison NN NN I-Disease
syndrome NN NN I-Disease
. NN NN O
   
Although NN NN O
clinical NN NN O
experience NN NN O
with NN NN O
omeprazole NN NN O
is NN NN O
still NN NN O
limited NN NN O
, NN NN O
many NN NN O
controlled NN NN O
studies NN NN O
have NN NN O
established NN NN O
the NN NN O
short NN NN O
- NN NN O
term NN NN O
safety NN NN O
of NN NN O
this NN NN O
drug NN NN O
. NN NN O
   
We NN NN O
report NN NN O
the NN NN O
first NN NN O
case NN NN O
of NN NN O
a NN NN O
serious NN NN O
short NN NN O
- NN NN O
term NN NN O
adverse NN NN O
reaction NN NN O
with NN NN O
the NN NN O
use NN NN O
of NN NN O
omeprazole NN NN O
: NN NN O
hemolytic NN NN B-Disease
anemia NN NN I-Disease
. NN NN O
   
The NN NN O
patient NN NN O
developed NN NN O
weakness NN NN O
, NN NN O
lethargy NN NN B-Disease
, NN NN O
and NN NN O
shortness NN NN B-Disease
of NN NN I-Disease
breath NN NN I-Disease
2 NN NN O
days NN NN O
after NN NN O
starting NN NN O
therapy NN NN O
with NN NN O
omeprazole NN NN O
. NN NN O
   
Two NN NN O
weeks NN NN O
after NN NN O
the NN NN O
initiation NN NN O
of NN NN O
therapy NN NN O
, NN NN O
her NN NN O
hematocrit NN NN O
had NN NN O
decreased NN NN O
from NN NN O
44 NN NN O
. NN NN O
1 NN NN O
% NN NN O
to NN NN O
20 NN NN O
. NN NN O
4 NN NN O
% NN NN O
, NN NN O
and NN NN O
she NN NN O
had NN NN O
a NN NN O
positive NN NN O
direct NN NN O
Coombs NN NN O
antiglobulin NN NN O
test NN NN O
and NN NN O
an NN NN O
elevated NN NN O
indirect NN NN O
bilirubin NN NN O
. NN NN O
   
After NN NN O
she NN NN O
discontinued NN NN O
the NN NN O
omeprazole NN NN O
, NN NN O
her NN NN O
hemoglobin NN NN O
and NN NN O
hematocrit NN NN O
gradually NN NN O
returned NN NN O
to NN NN O
normal NN NN O
. NN NN O
   
The NN NN O
mechanism NN NN O
by NN NN O
which NN NN O
omeprazole NN NN O
caused NN NN O
the NN NN O
patient NN NN O
' NN NN O
s NN NN O
hemolytic NN NN B-Disease
anemia NN NN I-Disease
is NN NN O
uncertain NN NN O
, NN NN O
but NN NN O
physicians NN NN O
should NN NN O
be NN NN O
alerted NN NN O
to NN NN O
this NN NN O
possible NN NN O
adverse NN NN O
effect NN NN O
. NN NN O
   
Phenylephrine NN NN O
but NN NN O
not NN NN O
ephedrine NN NN O
reduces NN NN B-Disease
frontal NN NN I-Disease
lobe NN NN I-Disease
oxygenation NN NN I-Disease
following NN NN O
anesthesia NN NN O
- NN NN O
induced NN NN O
hypotension NN NN B-Disease
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Vasopressor NN NN O
agents NN NN O
are NN NN O
used NN NN O
to NN NN O
correct NN NN O
anesthesia NN NN O
- NN NN O
induced NN NN O
hypotension NN NN B-Disease
. NN NN O
   
We NN NN O
describe NN NN O
the NN NN O
effect NN NN O
of NN NN O
phenylephrine NN NN O
and NN NN O
ephedrine NN NN O
on NN NN O
frontal NN NN O
lobe NN NN O
oxygenation NN NN O
( NN NN O
S NN NN O
( NN NN O
c NN NN O
) NN NN O
O NN NN O
( NN NN O
2 NN NN O
) NN NN O
) NN NN O
following NN NN O
anesthesia NN NN O
- NN NN O
induced NN NN O
hypotension NN NN B-Disease
. NN NN O
   
METHODS NN NN O
: NN NN O
Following NN NN O
induction NN NN O
of NN NN O
anesthesia NN NN O
by NN NN O
fentanyl NN NN O
( NN NN O
0 NN NN O
. NN NN O
15 NN NN O
mg NN NN O
kg NN NN O
( NN NN O
- NN NN O
1 NN NN O
) NN NN O
) NN NN O
and NN NN O
propofol NN NN O
( NN NN O
2 NN NN O
. NN NN O
0 NN NN O
mg NN NN O
kg NN NN O
( NN NN O
- NN NN O
1 NN NN O
) NN NN O
) NN NN O
, NN NN O
13 NN NN O
patients NN NN O
received NN NN O
phenylephrine NN NN O
( NN NN O
0 NN NN O
. NN NN O
1 NN NN O
mg NN NN O
iv NN NN O
) NN NN O
and NN NN O
12 NN NN O
patients NN NN O
received NN NN O
ephedrine NN NN O
( NN NN O
10 NN NN O
mg NN NN O
iv NN NN O
) NN NN O
to NN NN O
restore NN NN O
mean NN NN O
arterial NN NN O
pressure NN NN O
( NN NN O
MAP NN NN O
) NN NN O
. NN NN O
   
Heart NN NN O
rate NN NN O
( NN NN O
HR NN NN O
) NN NN O
, NN NN O
MAP NN NN O
, NN NN O
stroke NN NN B-Disease
volume NN NN O
( NN NN O
SV NN NN O
) NN NN O
, NN NN O
cardiac NN NN O
output NN NN O
( NN NN O
CO NN NN O
) NN NN O
, NN NN O
and NN NN O
frontal NN NN O
lobe NN NN O
oxygenation NN NN O
( NN NN O
S NN NN O
( NN NN O
c NN NN O
) NN NN O
O NN NN O
( NN NN O
2 NN NN O
) NN NN O
) NN NN O
were NN NN O
registered NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Induction NN NN O
of NN NN O
anesthesia NN NN O
was NN NN O
followed NN NN O
by NN NN O
a NN NN B-Disease
decrease NN NN I-Disease
in NN NN I-Disease
MAP NN NN I-Disease
, NN NN I-Disease
HR NN NN I-Disease
, NN NN I-Disease
SV NN NN I-Disease
, NN NN I-Disease
and NN NN I-Disease
CO NN NN I-Disease
concomitant NN NN O
with NN NN O
an NN NN O
elevation NN NN O
in NN NN O
S NN NN O
( NN NN O
c NN NN O
) NN NN O
O NN NN O
( NN NN O
2 NN NN O
) NN NN O
. NN NN O
   
After NN NN O
administration NN NN O
of NN NN O
phenylephrine NN NN O
, NN NN O
MAP NN NN O
increased NN NN O
( NN NN O
51 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
12 NN NN O
to NN NN O
81 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
13 NN NN O
mmHg NN NN O
; NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
; NN NN O
mean NN NN O
+ NN NN O
/ NN NN O
- NN NN O
SD NN NN O
) NN NN O
. NN NN O
   
However NN NN O
, NN NN O
a NN NN O
14 NN NN O
% NN NN O
( NN NN O
from NN NN O
70 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
8 NN NN O
% NN NN O
to NN NN O
60 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
7 NN NN O
% NN NN O
) NN NN O
reduction NN NN O
in NN NN O
S NN NN O
( NN NN O
c NN NN O
) NN NN O
O NN NN O
( NN NN O
2 NN NN O
) NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
followed NN NN O
with NN NN O
no NN NN O
change NN NN O
in NN NN O
CO NN NN O
( NN NN O
3 NN NN O
. NN NN O
7 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
1 NN NN O
to NN NN O
3 NN NN O
. NN NN O
4 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
9 NN NN O
l NN NN O
min NN NN O
( NN NN O
- NN NN O
1 NN NN O
) NN NN O
) NN NN O
. NN NN O
   
The NN NN O
administration NN NN O
of NN NN O
ephedrine NN NN O
led NN NN O
to NN NN O
a NN NN O
similar NN NN O
increase NN NN O
in NN NN O
MAP NN NN O
( NN NN O
53 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
9 NN NN O
to NN NN O
79 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
8 NN NN O
mmHg NN NN O
; NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
, NN NN O
restored NN NN O
CO NN NN O
( NN NN O
3 NN NN O
. NN NN O
2 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
2 NN NN O
to NN NN O
5 NN NN O
. NN NN O
0 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
3 NN NN O
l NN NN O
min NN NN O
( NN NN O
- NN NN O
1 NN NN O
) NN NN O
) NN NN O
, NN NN O
and NN NN O
preserved NN NN O
S NN NN O
( NN NN O
c NN NN O
) NN NN O
O NN NN O
( NN NN O
2 NN NN O
) NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
The NN NN O
utilization NN NN O
of NN NN O
phenylephrine NN NN O
to NN NN O
correct NN NN O
hypotension NN NN B-Disease
induced NN NN O
by NN NN O
anesthesia NN NN O
has NN NN O
a NN NN O
negative NN NN O
impact NN NN O
on NN NN O
S NN NN O
( NN NN O
c NN NN O
) NN NN O
O NN NN O
( NN NN O
2 NN NN O
) NN NN O
while NN NN O
ephedrine NN NN O
maintains NN NN O
frontal NN NN O
lobe NN NN O
oxygenation NN NN O
potentially NN NN O
related NN NN O
to NN NN O
an NN NN O
increase NN NN O
in NN NN O
CO NN NN O
. NN NN O
   
Prolonged NN NN O
elevation NN NN O
of NN NN O
plasma NN NN O
argatroban NN NN O
in NN NN O
a NN NN O
cardiac NN NN O
transplant NN NN O
patient NN NN O
with NN NN O
a NN NN O
suspected NN NN O
history NN NN O
of NN NN O
heparin NN NN O
- NN NN O
induced NN NN O
thrombocytopenia NN NN B-Disease
with NN NN O
thrombosis NN NN B-Disease
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Direct NN NN O
thrombin NN NN O
inhibitors NN NN O
( NN NN O
DTIs NN NN O
) NN NN O
provide NN NN O
an NN NN O
alternative NN NN O
method NN NN O
of NN NN O
anticoagulation NN NN O
for NN NN O
patients NN NN O
with NN NN O
a NN NN O
history NN NN O
of NN NN O
heparin NN NN O
- NN NN O
induced NN NN O
thrombocytopenia NN NN B-Disease
( NN NN O
HIT NN NN B-Disease
) NN NN O
or NN NN O
HIT NN NN B-Disease
with NN NN O
thrombosis NN NN B-Disease
( NN NN O
HITT NN NN B-Disease
) NN NN O
undergoing NN NN O
cardiopulmonary NN NN O
bypass NN NN O
( NN NN O
CPB NN NN O
) NN NN O
. NN NN O
   
In NN NN O
the NN NN O
following NN NN O
report NN NN O
, NN NN O
a NN NN O
65 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
critically NN NN B-Disease
ill NN NN I-Disease
patient NN NN O
with NN NN O
a NN NN O
suspected NN NN O
history NN NN O
of NN NN O
HITT NN NN B-Disease
was NN NN O
administered NN NN O
argatroban NN NN O
for NN NN O
anticoagulation NN NN O
on NN NN O
bypass NN NN O
during NN NN O
heart NN NN O
transplantation NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
required NN NN O
massive NN NN O
transfusion NN NN O
support NN NN O
( NN NN O
55 NN NN O
units NN NN O
of NN NN O
red NN NN O
blood NN NN O
cells NN NN O
, NN NN O
42 NN NN O
units NN NN O
of NN NN O
fresh NN NN O
- NN NN O
frozen NN NN O
plasma NN NN O
, NN NN O
40 NN NN O
units NN NN O
of NN NN O
cryoprecipitate NN NN O
, NN NN O
40 NN NN O
units NN NN O
of NN NN O
platelets NN NN O
, NN NN O
and NN NN O
three NN NN O
doses NN NN O
of NN NN O
recombinant NN NN O
Factor NN NN O
VIIa NN NN O
) NN NN O
for NN NN O
severe NN NN O
intraoperative NN NN B-Disease
and NN NN I-Disease
postoperative NN NN I-Disease
bleeding NN NN I-Disease
. NN NN O
   
STUDY NN NN O
DESIGN NN NN O
AND NN NN O
METHODS NN NN O
: NN NN O
Plasma NN NN O
samples NN NN O
from NN NN O
before NN NN O
and NN NN O
after NN NN O
CPB NN NN O
were NN NN O
analyzed NN NN O
postoperatively NN NN O
for NN NN O
argatroban NN NN O
concentration NN NN O
using NN NN O
a NN NN O
modified NN NN O
ecarin NN NN O
clotting NN NN O
time NN NN O
( NN NN O
ECT NN NN O
) NN NN O
assay NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Unexpectedly NN NN O
high NN NN O
concentrations NN NN O
of NN NN O
argatroban NN NN O
were NN NN O
measured NN NN O
in NN NN O
these NN NN O
samples NN NN O
( NN NN O
range NN NN O
, NN NN O
0 NN NN O
- NN NN O
32 NN NN O
microg NN NN O
/ NN NN O
mL NN NN O
) NN NN O
, NN NN O
and NN NN O
a NN NN O
prolonged NN NN O
plasma NN NN O
argatroban NN NN O
half NN NN O
life NN NN O
( NN NN O
t NN NN O
( NN NN O
1 NN NN O
/ NN NN O
2 NN NN O
) NN NN O
) NN NN O
of NN NN O
514 NN NN O
minutes NN NN O
was NN NN O
observed NN NN O
( NN NN O
published NN NN O
elimination NN NN O
t NN NN O
( NN NN O
1 NN NN O
/ NN NN O
2 NN NN O
) NN NN O
is NN NN O
39 NN NN O
- NN NN O
51 NN NN O
minutes NN NN O
[ NN NN O
< NN NN O
or NN NN O
= NN NN O
181 NN NN O
minutes NN NN O
with NN NN O
hepatic NN NN B-Disease
impairment NN NN I-Disease
] NN NN O
) NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Correlation NN NN O
of NN NN O
plasma NN NN O
argatroban NN NN O
concentration NN NN O
versus NN NN O
the NN NN O
patient NN NN O
' NN NN O
s NN NN O
coagulation NN NN O
variables NN NN O
and NN NN O
clinical NN NN O
course NN NN O
suggest NN NN O
that NN NN O
prolonged NN NN O
elevated NN NN O
levels NN NN O
of NN NN O
plasma NN NN O
argatroban NN NN O
may NN NN O
have NN NN O
contributed NN NN O
to NN NN O
the NN NN O
patient NN NN O
' NN NN O
s NN NN O
extended NN NN O
coagulopathy NN NN B-Disease
. NN NN O
   
Because NN NN O
DTIs NN NN O
do NN NN O
not NN NN O
have NN NN O
reversal NN NN O
agents NN NN O
, NN NN O
surgical NN NN O
teams NN NN O
and NN NN O
transfusion NN NN O
services NN NN O
should NN NN O
remain NN NN O
aware NN NN O
of NN NN O
the NN NN O
possibility NN NN O
of NN NN O
massive NN NN O
transfusion NN NN O
events NN NN O
during NN NN O
anticoagulation NN NN O
with NN NN O
these NN NN O
agents NN NN O
. NN NN O
   
This NN NN O
is NN NN O
the NN NN O
first NN NN O
report NN NN O
to NN NN O
measure NN NN O
plasma NN NN O
argatroban NN NN O
concentration NN NN O
in NN NN O
the NN NN O
context NN NN O
of NN NN O
CPB NN NN O
and NN NN O
extended NN NN O
coagulopathy NN NN B-Disease
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
the NN NN O
adjunctive NN NN O
bupropion NN NN O
on NN NN O
male NN NN O
sexual NN NN B-Disease
dysfunction NN NN I-Disease
induced NN NN O
by NN NN O
a NN NN O
selective NN NN O
serotonin NN NN O
reuptake NN NN O
inhibitor NN NN O
: NN NN O
a NN NN O
double NN NN O
- NN NN O
blind NN NN O
placebo NN NN O
- NN NN O
controlled NN NN O
and NN NN O
randomized NN NN O
study NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
To NN NN O
determine NN NN O
the NN NN O
safety NN NN O
and NN NN O
efficacy NN NN O
of NN NN O
adjunctive NN NN O
bupropion NN NN O
sustained NN NN O
- NN NN O
release NN NN O
( NN NN O
SR NN NN O
) NN NN O
on NN NN O
male NN NN O
sexual NN NN B-Disease
dysfunction NN NN I-Disease
( NN NN O
SD NN NN B-Disease
) NN NN O
induced NN NN O
by NN NN O
a NN NN O
selective NN NN O
serotonin NN NN O
reuptake NN NN O
inhibitor NN NN O
( NN NN O
SSRI NN NN O
) NN NN O
, NN NN O
as NN NN O
SD NN NN B-Disease
is NN NN O
a NN NN O
common NN NN O
side NN NN O
- NN NN O
effect NN NN O
of NN NN O
SSRIs NN NN O
and NN NN O
the NN NN O
most NN NN O
effective NN NN O
treatments NN NN O
have NN NN O
yet NN NN O
to NN NN O
be NN NN O
determined NN NN O
. NN NN O
   
PATIENTS NN NN O
AND NN NN O
METHODS NN NN O
: NN NN O
The NN NN O
randomized NN NN O
sample NN NN O
consisted NN NN O
of NN NN O
234 NN NN O
euthymic NN NN O
men NN NN O
who NN NN O
were NN NN O
receiving NN NN O
some NN NN O
type NN NN O
of NN NN O
SSRI NN NN O
. NN NN O
   
The NN NN O
men NN NN O
were NN NN O
randomly NN NN O
assigned NN NN O
to NN NN O
bupropion NN NN O
SR NN NN O
( NN NN O
150 NN NN O
mg NN NN O
twice NN NN O
daily NN NN O
, NN NN O
117 NN NN O
) NN NN O
or NN NN O
placebo NN NN O
( NN NN O
twice NN NN O
daily NN NN O
, NN NN O
117 NN NN O
) NN NN O
for NN NN O
12 NN NN O
weeks NN NN O
. NN NN O
   
Efficacy NN NN O
was NN NN O
evaluated NN NN O
using NN NN O
the NN NN O
Clinical NN NN O
Global NN NN O
Impression NN NN O
- NN NN O
Sexual NN NN O
Function NN NN O
( NN NN O
CGI NN NN O
- NN NN O
SF NN NN O
; NN NN O
the NN NN O
primary NN NN O
outcome NN NN O
measure NN NN O
) NN NN O
, NN NN O
the NN NN O
International NN NN O
Index NN NN O
of NN NN O
Erectile NN NN O
Function NN NN O
( NN NN O
IIEF NN NN O
) NN NN O
, NN NN O
Arizona NN NN O
Sexual NN NN O
Experience NN NN O
Scale NN NN O
( NN NN O
ASEX NN NN O
) NN NN O
, NN NN O
and NN NN O
Erectile NN NN B-Disease
Dysfunction NN NN I-Disease
Inventory NN NN O
of NN NN O
Treatment NN NN O
Satisfaction NN NN O
( NN NN O
EDITS NN NN O
) NN NN O
( NN NN O
secondary NN NN O
outcome NN NN O
measures NN NN O
) NN NN O
. NN NN O
   
Participants NN NN O
were NN NN O
followed NN NN O
biweekly NN NN O
during NN NN O
study NN NN O
period NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
After NN NN O
12 NN NN O
weeks NN NN O
of NN NN O
treatment NN NN O
, NN NN O
the NN NN O
mean NN NN O
( NN NN O
sd NN NN O
) NN NN O
scores NN NN O
for NN NN O
CGI NN NN O
- NN NN O
SF NN NN O
were NN NN O
significantly NN NN O
lower NN NN O
, NN NN O
i NN NN O
. NN NN O
e NN NN O
. NN NN O
better NN NN O
, NN NN O
in NN NN O
patients NN NN O
on NN NN O
bupropion NN NN O
SR NN NN O
, NN NN O
at NN NN O
2 NN NN O
. NN NN O
4 NN NN O
( NN NN O
1 NN NN O
. NN NN O
2 NN NN O
) NN NN O
, NN NN O
than NN NN O
in NN NN O
the NN NN O
placebo NN NN O
group NN NN O
, NN NN O
at NN NN O
3 NN NN O
. NN NN O
9 NN NN O
( NN NN O
1 NN NN O
. NN NN O
1 NN NN O
) NN NN O
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
. NN NN O
   
Men NN NN O
who NN NN O
received NN NN O
bupropion NN NN O
had NN NN O
a NN NN O
significant NN NN O
increase NN NN O
in NN NN O
the NN NN O
total NN NN O
IIEF NN NN O
score NN NN O
( NN NN O
54 NN NN O
. NN NN O
4 NN NN O
% NN NN O
vs NN NN O
1 NN NN O
. NN NN O
2 NN NN O
% NN NN O
; NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
003 NN NN O
) NN NN O
, NN NN O
and NN NN O
in NN NN O
the NN NN O
five NN NN O
different NN NN O
domains NN NN O
of NN NN O
the NN NN O
IIEF NN NN O
. NN NN O
   
Total NN NN O
ASEX NN NN O
scores NN NN O
were NN NN O
significantly NN NN O
lower NN NN O
, NN NN O
i NN NN O
. NN NN O
e NN NN O
. NN NN O
better NN NN O
, NN NN O
among NN NN O
men NN NN O
who NN NN O
received NN NN O
bupropion NN NN O
than NN NN O
placebo NN NN O
, NN NN O
at NN NN O
15 NN NN O
. NN NN O
5 NN NN O
( NN NN O
4 NN NN O
. NN NN O
3 NN NN O
) NN NN O
vs NN NN O
21 NN NN O
. NN NN O
5 NN NN O
( NN NN O
4 NN NN O
. NN NN O
7 NN NN O
) NN NN O
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
002 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
EDITS NN NN O
scores NN NN O
were NN NN O
67 NN NN O
. NN NN O
4 NN NN O
( NN NN O
10 NN NN O
. NN NN O
2 NN NN O
) NN NN O
for NN NN O
the NN NN O
bupropion NN NN O
and NN NN O
36 NN NN O
. NN NN O
3 NN NN O
( NN NN O
11 NN NN O
. NN NN O
7 NN NN O
) NN NN O
for NN NN O
the NN NN O
placebo NN NN O
group NN NN O
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
ASEX NN NN O
score NN NN O
and NN NN O
CGI NN NN O
- NN NN O
SF NN NN O
score NN NN O
were NN NN O
correlated NN NN O
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
003 NN NN O
) NN NN O
. NN NN O
   
In NN NN O
linear NN NN O
regression NN NN O
analyses NN NN O
the NN NN O
CGI NN NN O
- NN NN O
SF NN NN O
score NN NN O
was NN NN O
not NN NN O
affected NN NN O
significantly NN NN O
by NN NN O
the NN NN O
duration NN NN O
of NN NN O
SD NN NN B-Disease
, NN NN O
type NN NN O
of NN NN O
SSRI NN NN O
used NN NN O
and NN NN O
age NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Bupropion NN NN O
is NN NN O
an NN NN O
effective NN NN O
treatment NN NN O
for NN NN O
male NN NN O
SD NN NN B-Disease
induced NN NN O
by NN NN O
SSRIs NN NN O
. NN NN O
   
These NN NN O
results NN NN O
provide NN NN O
empirical NN NN O
support NN NN O
for NN NN O
conducting NN NN O
a NN NN O
further NN NN O
study NN NN O
of NN NN O
bupropion NN NN O
. NN NN O
   
Prevention NN NN O
of NN NN O
seizures NN NN B-Disease
and NN NN O
reorganization NN NN O
of NN NN O
hippocampal NN NN O
functions NN NN O
by NN NN O
transplantation NN NN O
of NN NN O
bone NN NN O
marrow NN NN O
cells NN NN O
in NN NN O
the NN NN O
acute NN NN O
phase NN NN O
of NN NN O
experimental NN NN O
epilepsy NN NN B-Disease
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
investigated NN NN O
the NN NN O
therapeutic NN NN O
potential NN NN O
of NN NN O
bone NN NN O
marrow NN NN O
mononuclear NN NN O
cells NN NN O
( NN NN O
BMCs NN NN O
) NN NN O
in NN NN O
a NN NN O
model NN NN O
of NN NN O
epilepsy NN NN B-Disease
induced NN NN O
by NN NN O
pilocarpine NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
BMCs NN NN O
obtained NN NN O
from NN NN O
green NN NN O
fluorescent NN NN O
protein NN NN O
( NN NN O
GFP NN NN O
) NN NN O
transgenic NN NN O
mice NN NN O
or NN NN O
rats NN NN O
were NN NN O
transplanted NN NN O
intravenously NN NN O
after NN NN O
induction NN NN O
of NN NN O
status NN NN B-Disease
epilepticus NN NN I-Disease
( NN NN O
SE NN NN B-Disease
) NN NN O
. NN NN O
   
Spontaneous NN NN B-Disease
recurrent NN NN I-Disease
seizures NN NN I-Disease
( NN NN O
SRS NN NN B-Disease
) NN NN O
were NN NN O
monitored NN NN O
using NN NN O
Racine NN NN O
' NN NN O
s NN NN O
seizure NN NN B-Disease
severity NN NN O
scale NN NN O
. NN NN O
   
All NN NN O
of NN NN O
the NN NN O
rats NN NN O
in NN NN O
the NN NN O
saline NN NN O
- NN NN O
treated NN NN O
epileptic NN NN B-Disease
control NN NN O
group NN NN O
developed NN NN O
SRS NN NN B-Disease
, NN NN O
whereas NN NN O
none NN NN O
of NN NN O
the NN NN O
BMC NN NN O
- NN NN O
treated NN NN O
epileptic NN NN B-Disease
animals NN NN O
had NN NN O
seizures NN NN B-Disease
in NN NN O
the NN NN O
short NN NN O
term NN NN O
( NN NN O
15 NN NN O
days NN NN O
after NN NN O
transplantation NN NN O
) NN NN O
, NN NN O
regardless NN NN O
of NN NN O
the NN NN O
BMC NN NN O
source NN NN O
. NN NN O
   
Over NN NN O
the NN NN O
long NN NN O
- NN NN O
term NN NN O
chronic NN NN O
phase NN NN O
( NN NN O
120 NN NN O
days NN NN O
after NN NN O
transplantation NN NN O
) NN NN O
, NN NN O
only NN NN O
25 NN NN O
% NN NN O
of NN NN O
BMC NN NN O
- NN NN O
treated NN NN O
epileptic NN NN B-Disease
animals NN NN O
had NN NN O
seizures NN NN B-Disease
, NN NN O
but NN NN O
with NN NN O
a NN NN O
lower NN NN O
frequency NN NN O
and NN NN O
duration NN NN O
compared NN NN O
to NN NN O
the NN NN O
epileptic NN NN B-Disease
control NN NN O
group NN NN O
. NN NN O
   
The NN NN O
density NN NN O
of NN NN O
hippocampal NN NN O
neurons NN NN O
in NN NN O
the NN NN O
brains NN NN O
of NN NN O
animals NN NN O
treated NN NN O
with NN NN O
BMCs NN NN O
was NN NN O
markedly NN NN O
preserved NN NN O
. NN NN O
   
At NN NN O
hippocampal NN NN O
Schaeffer NN NN O
collateral NN NN O
- NN NN O
CA1 NN NN O
synapses NN NN O
, NN NN O
long NN NN O
- NN NN O
term NN NN O
potentiation NN NN O
was NN NN O
preserved NN NN O
in NN NN O
BMC NN NN O
- NN NN O
transplanted NN NN O
rats NN NN O
compared NN NN O
to NN NN O
epileptic NN NN B-Disease
controls NN NN O
. NN NN O
   
The NN NN O
donor NN NN O
- NN NN O
derived NN NN O
GFP NN NN O
( NN NN O
+ NN NN O
) NN NN O
cells NN NN O
were NN NN O
rarely NN NN O
found NN NN O
in NN NN O
the NN NN O
brains NN NN O
of NN NN O
transplanted NN NN O
epileptic NN NN B-Disease
rats NN NN O
. NN NN O
   
In NN NN O
conclusion NN NN O
, NN NN O
treatment NN NN O
with NN NN O
BMCs NN NN O
can NN NN O
prevent NN NN O
the NN NN O
development NN NN O
of NN NN O
chronic NN NN O
seizures NN NN B-Disease
, NN NN O
reduce NN NN O
neuronal NN NN B-Disease
loss NN NN I-Disease
, NN NN O
and NN NN O
influence NN NN O
the NN NN O
reorganization NN NN O
of NN NN O
the NN NN O
hippocampal NN NN O
neuronal NN NN O
network NN NN O
. NN NN O
   
Normalizing NN NN O
effects NN NN O
of NN NN O
modafinil NN NN O
on NN NN O
sleep NN NN O
in NN NN O
chronic NN NN O
cocaine NN NN O
users NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
The NN NN O
purpose NN NN O
of NN NN O
the NN NN O
present NN NN O
study NN NN O
was NN NN O
to NN NN O
determine NN NN O
the NN NN O
effect NN NN O
of NN NN O
morning NN NN O
- NN NN O
dosed NN NN O
modafinil NN NN O
on NN NN O
sleep NN NN O
and NN NN O
daytime NN NN B-Disease
sleepiness NN NN I-Disease
in NN NN O
chronic NN NN O
cocaine NN NN O
users NN NN O
. NN NN O
   
METHOD NN NN O
: NN NN O
Twenty NN NN O
cocaine NN NN O
- NN NN O
dependent NN NN O
participants NN NN O
were NN NN O
randomly NN NN O
assigned NN NN O
to NN NN O
receive NN NN O
modafinil NN NN O
, NN NN O
400 NN NN O
mg NN NN O
( NN NN O
N NN NN O
= NN NN O
10 NN NN O
) NN NN O
, NN NN O
or NN NN O
placebo NN NN O
( NN NN O
N NN NN O
= NN NN O
10 NN NN O
) NN NN O
every NN NN O
morning NN NN O
at NN NN O
7 NN NN O
: NN NN O
30 NN NN O
a NN NN O
. NN NN O
m NN NN O
. NN NN O
for NN NN O
16 NN NN O
days NN NN O
in NN NN O
an NN NN O
inpatient NN NN O
, NN NN O
double NN NN O
- NN NN O
blind NN NN O
randomized NN NN O
trial NN NN O
. NN NN O
   
Participants NN NN O
underwent NN NN O
polysomnographic NN NN O
sleep NN NN O
recordings NN NN O
on NN NN O
days NN NN O
1 NN NN O
to NN NN O
3 NN NN O
, NN NN O
7 NN NN O
to NN NN O
9 NN NN O
, NN NN O
and NN NN O
14 NN NN O
to NN NN O
16 NN NN O
( NN NN O
first NN NN O
, NN NN O
second NN NN O
, NN NN O
and NN NN O
third NN NN O
weeks NN NN O
of NN NN O
abstinence NN NN O
) NN NN O
. NN NN O
   
The NN NN O
Multiple NN NN O
Sleep NN NN O
Latency NN NN O
Test NN NN O
was NN NN O
performed NN NN O
at NN NN O
11 NN NN O
: NN NN O
30 NN NN O
a NN NN O
. NN NN O
m NN NN O
. NN NN O
, NN NN O
2 NN NN O
: NN NN O
00 NN NN O
p NN NN O
. NN NN O
m NN NN O
. NN NN O
, NN NN O
and NN NN O
4 NN NN O
: NN NN O
30 NN NN O
p NN NN O
. NN NN O
m NN NN O
. NN NN O
on NN NN O
days NN NN O
2 NN NN O
, NN NN O
8 NN NN O
, NN NN O
and NN NN O
15 NN NN O
. NN NN O
   
For NN NN O
comparison NN NN O
of NN NN O
sleep NN NN O
architecture NN NN O
variables NN NN O
, NN NN O
12 NN NN O
healthy NN NN O
comparison NN NN O
participants NN NN O
underwent NN NN O
a NN NN O
single NN NN O
night NN NN O
of NN NN O
experimental NN NN O
polysomnography NN NN O
that NN NN O
followed NN NN O
1 NN NN O
night NN NN O
of NN NN O
accommodation NN NN O
polysomnography NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Progressive NN NN O
abstinence NN NN O
from NN NN O
cocaine NN NN O
was NN NN O
associated NN NN O
with NN NN O
worsening NN NN O
of NN NN O
all NN NN O
measured NN NN O
polysomnographic NN NN O
sleep NN NN O
outcomes NN NN O
. NN NN O
   
Compared NN NN O
with NN NN O
placebo NN NN O
, NN NN O
modafinil NN NN O
decreased NN NN O
nighttime NN NN O
sleep NN NN O
latency NN NN O
and NN NN O
increased NN NN O
slow NN NN O
- NN NN O
wave NN NN O
sleep NN NN O
time NN NN O
in NN NN O
cocaine NN NN O
- NN NN O
dependent NN NN O
participants NN NN O
. NN NN O
   
The NN NN O
effect NN NN O
of NN NN O
modafinil NN NN O
interacted NN NN O
with NN NN O
the NN NN O
abstinence NN NN O
week NN NN O
and NN NN O
was NN NN O
associated NN NN O
with NN NN O
longer NN NN O
total NN NN O
sleep NN NN O
time NN NN O
and NN NN O
shorter NN NN O
REM NN NN O
sleep NN NN O
latency NN NN O
in NN NN O
the NN NN O
third NN NN O
week NN NN O
of NN NN O
abstinence NN NN O
. NN NN O
   
Comparison NN NN O
of NN NN O
slow NN NN O
- NN NN O
wave NN NN O
sleep NN NN O
time NN NN O
, NN NN O
total NN NN O
sleep NN NN O
time NN NN O
, NN NN O
and NN NN O
sleep NN NN O
latency NN NN O
in NN NN O
cocaine NN NN O
- NN NN O
dependent NN NN O
and NN NN O
healthy NN NN O
participants NN NN O
revealed NN NN O
a NN NN O
normalizing NN NN O
effect NN NN O
of NN NN O
modafinil NN NN O
in NN NN O
cocaine NN NN O
- NN NN O
dependent NN NN O
participants NN NN O
. NN NN O
   
Modafinil NN NN O
was NN NN O
associated NN NN O
with NN NN O
increased NN NN O
daytime NN NN O
sleep NN NN O
latency NN NN O
, NN NN O
as NN NN O
measured NN NN O
by NN NN O
the NN NN O
Multiple NN NN O
Sleep NN NN O
Latency NN NN O
Test NN NN O
, NN NN O
and NN NN O
a NN NN O
nearly NN NN O
significant NN NN O
decrease NN NN O
in NN NN O
subjective NN NN O
daytime NN NN B-Disease
sleepiness NN NN I-Disease
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Morning NN NN O
- NN NN O
dosed NN NN O
modafinil NN NN O
promotes NN NN O
nocturnal NN NN O
sleep NN NN O
, NN NN O
normalizes NN NN O
sleep NN NN O
architecture NN NN O
, NN NN O
and NN NN O
decreases NN NN O
daytime NN NN B-Disease
sleepiness NN NN I-Disease
in NN NN O
abstinent NN NN O
cocaine NN NN O
users NN NN O
. NN NN O
   
These NN NN O
effects NN NN O
may NN NN O
be NN NN O
relevant NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
cocaine NN NN O
dependence NN NN O
. NN NN O
   
Safety NN NN O
of NN NN O
transesophageal NN NN O
echocardiography NN NN O
in NN NN O
adults NN NN O
: NN NN O
study NN NN O
in NN NN O
a NN NN O
multidisciplinary NN NN O
hospital NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
TEE NN NN O
is NN NN O
a NN NN O
semi NN NN O
- NN NN O
invasive NN NN O
tool NN NN O
broadly NN NN O
used NN NN O
and NN NN O
its NN NN O
utilization NN NN O
associated NN NN O
to NN NN O
sedatives NN NN O
drugs NN NN O
might NN NN O
to NN NN O
affect NN NN O
the NN NN O
procedure NN NN O
safety NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
to NN NN O
analyze NN NN O
aspects NN NN O
of NN NN O
TEE NN NN O
safety NN NN O
associated NN NN O
to NN NN O
the NN NN O
use NN NN O
of NN NN O
Midazolan NN NN O
( NN NN O
MZ NN NN O
) NN NN O
and NN NN O
Flumazenil NN NN O
( NN NN O
FL NN NN O
) NN NN O
and NN NN O
the NN NN O
influence NN NN O
of NN NN O
the NN NN O
clinical NN NN O
variables NN NN O
on NN NN O
the NN NN O
event NN NN O
rate NN NN O
. NN NN O
   
METHOD NN NN O
: NN NN O
prospective NN NN O
study NN NN O
with NN NN O
137 NN NN O
patients NN NN O
that NN NN O
underwent NN NN O
TEE NN NN O
with NN NN O
MZ NN NN O
associated NN NN O
to NN NN O
moderate NN NN O
sedation NN NN O
. NN NN O
   
We NN NN O
analyzed NN NN O
the NN NN O
following NN NN O
events NN NN O
: NN NN O
complications NN NN O
related NN NN O
with NN NN O
the NN NN O
topical NN NN O
anesthesia NN NN O
, NN NN O
with NN NN O
MZ NN NN O
use NN NN O
and NN NN O
with NN NN O
the NN NN O
procedure NN NN O
. NN NN O
   
Uni NN NN O
- NN NN O
and NN NN O
multivariate NN NN O
analyses NN NN O
were NN NN O
used NN NN O
to NN NN O
test NN NN O
the NN NN O
influence NN NN O
of NN NN O
the NN NN O
clinical NN NN O
variables NN NN O
: NN NN O
age NN NN O
, NN NN O
sex NN NN O
, NN NN O
stroke NN NN B-Disease
, NN NN O
myocardiopathy NN NN B-Disease
( NN NN O
MP NN NN B-Disease
) NN NN O
, NN NN O
duration NN NN O
of NN NN O
the NN NN O
test NN NN O
, NN NN O
mitral NN NN B-Disease
regurgitation NN NN I-Disease
( NN NN O
MR NN NN B-Disease
) NN NN O
and NN NN O
the NN NN O
MZ NN NN O
dose NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
All NN NN O
patients NN NN O
( NN NN O
65 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
16 NN NN O
yrs NN NN O
; NN NN O
58 NN NN O
% NN NN O
males NN NN O
) NN NN O
finished NN NN O
the NN NN O
examination NN NN O
. NN NN O
   
The NN NN O
mean NN NN O
doses NN NN O
of NN NN O
MZ NN NN O
and NN NN O
FL NN NN O
were NN NN O
4 NN NN O
. NN NN O
3 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
9 NN NN O
mg NN NN O
and NN NN O
0 NN NN O
. NN NN O
28 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
2 NN NN O
mg NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
The NN NN O
duration NN NN O
of NN NN O
the NN NN O
examination NN NN O
and NN NN O
the NN NN O
mean NN NN O
ejection NN NN O
fraction NN NN O
( NN NN O
EF NN NN O
) NN NN O
were NN NN O
16 NN NN O
. NN NN O
4 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
6 NN NN O
. NN NN O
1 NN NN O
minutes NN NN O
and NN NN O
60 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
9 NN NN O
% NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
Mild NN NN O
hypoxia NN NN B-Disease
( NN NN O
SO2 NN NN O
< NN NN O
90 NN NN O
% NN NN O
) NN NN O
was NN NN O
the NN NN O
most NN NN O
common NN NN O
event NN NN O
( NN NN O
11 NN NN O
patients NN NN O
) NN NN O
; NN NN O
3 NN NN O
patients NN NN O
( NN NN O
2 NN NN O
% NN NN O
) NN NN O
presented NN NN O
transient NN NN O
hypoxia NN NN B-Disease
due NN NN O
to NN NN O
upper NN NN O
airway NN NN B-Disease
obstruction NN NN I-Disease
by NN NN O
probe NN NN O
introduction NN NN O
and NN NN O
8 NN NN O
( NN NN O
5 NN NN O
. NN NN O
8 NN NN O
% NN NN O
) NN NN O
due NN NN O
to NN NN O
hypoxia NN NN B-Disease
caused NN NN O
by NN NN O
MZ NN NN O
use NN NN O
. NN NN O
   
Transient NN NN O
hypotension NN NN B-Disease
( NN NN O
SAP NN NN O
< NN NN O
90mmHg NN NN O
) NN NN O
occurred NN NN O
in NN NN O
1 NN NN O
patient NN NN O
( NN NN O
0 NN NN O
. NN NN O
7 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
The NN NN O
multivariate NN NN O
analysis NN NN O
showed NN NN O
that NN NN O
severe NN NN O
MR NN NN B-Disease
, NN NN O
MP NN NN B-Disease
( NN NN O
EF NN NN O
< NN NN O
45 NN NN O
% NN NN O
) NN NN O
and NN NN O
high NN NN O
doses NN NN O
of NN NN O
MZ NN NN O
( NN NN O
> NN NN O
5mg NN NN O
) NN NN O
were NN NN O
associated NN NN O
with NN NN O
events NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
EF NN NN O
was NN NN O
40 NN NN O
% NN NN O
, NN NN O
in NN NN O
the NN NN O
group NN NN O
with NN NN O
MP NN NN B-Disease
and NN NN O
44 NN NN O
% NN NN O
in NN NN O
the NN NN O
group NN NN O
with NN NN O
severe NN NN O
MR NN NN B-Disease
and NN NN O
it NN NN O
can NN NN O
be NN NN O
a NN NN O
factor NN NN O
associated NN NN O
with NN NN O
clinical NN NN O
events NN NN O
in NN NN O
the NN NN O
last NN NN O
group NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
TEE NN NN O
with NN NN O
sedation NN NN O
presents NN NN O
a NN NN O
low NN NN O
rate NN NN O
of NN NN O
events NN NN O
. NN NN O
   
There NN NN O
were NN NN O
no NN NN O
severe NN NN O
events NN NN O
and NN NN O
there NN NN O
was NN NN O
no NN NN O
need NN NN O
to NN NN O
interrupt NN NN O
the NN NN O
examinations NN NN O
. NN NN O
   
Effect NN NN O
of NN NN O
direct NN NN O
intracoronary NN NN O
administration NN NN O
of NN NN O
methylergonovine NN NN O
in NN NN O
patients NN NN O
with NN NN O
and NN NN O
without NN NN O
variant NN NN B-Disease
angina NN NN I-Disease
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
intracoronary NN NN O
administration NN NN O
of NN NN O
methylergonovine NN NN O
were NN NN O
studied NN NN O
in NN NN O
21 NN NN O
patients NN NN O
with NN NN O
variant NN NN B-Disease
angina NN NN I-Disease
and NN NN O
22 NN NN O
patients NN NN O
with NN NN O
atypical NN NN O
chest NN NN B-Disease
pain NN NN I-Disease
and NN NN O
in NN NN O
others NN NN O
without NN NN O
angina NN NN B-Disease
pectoris NN NN I-Disease
( NN NN O
control NN NN O
group NN NN O
) NN NN O
. NN NN O
   
Methylergonovine NN NN O
was NN NN O
administered NN NN O
continuously NN NN O
at NN NN O
a NN NN O
rate NN NN O
of NN NN O
10 NN NN O
micrograms NN NN O
/ NN NN O
min NN NN O
up NN NN O
to NN NN O
50 NN NN O
micrograms NN NN O
. NN NN O
   
In NN NN O
all NN NN O
patients NN NN O
with NN NN O
variant NN NN B-Disease
angina NN NN I-Disease
, NN NN O
coronary NN NN B-Disease
spasm NN NN I-Disease
was NN NN O
provoked NN NN O
at NN NN O
a NN NN O
mean NN NN O
dose NN NN O
of NN NN O
28 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
13 NN NN O
micrograms NN NN O
( NN NN O
mean NN NN O
+ NN NN O
/ NN NN O
- NN NN O
SD NN NN O
) NN NN O
. NN NN O
   
In NN NN O
the NN NN O
control NN NN O
group NN NN O
neither NN NN O
ischemic NN NN O
ST NN NN O
change NN NN O
nor NN NN O
localized NN NN O
spasm NN NN B-Disease
occurred NN NN O
. NN NN O
   
The NN NN O
basal NN NN O
tone NN NN O
of NN NN O
the NN NN O
right NN NN O
coronary NN NN O
artery NN NN O
was NN NN O
significantly NN NN O
lower NN NN O
than NN NN O
that NN NN O
of NN NN O
the NN NN O
left NN NN O
coronary NN NN O
artery NN NN O
. NN NN O
   
The NN NN O
percentage NN NN O
of NN NN O
vasoconstriction NN NN O
of NN NN O
the NN NN O
right NN NN O
coronary NN NN O
artery NN NN O
was NN NN O
significantly NN NN O
higher NN NN O
than NN NN O
that NN NN O
of NN NN O
the NN NN O
left NN NN O
coronary NN NN O
artery NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
spasm NN NN B-Disease
provocation NN NN O
tests NN NN O
, NN NN O
which NN NN O
use NN NN O
an NN NN O
intracoronary NN NN O
injection NN NN O
of NN NN O
a NN NN O
relatively NN NN O
low NN NN O
dose NN NN O
of NN NN O
methylergonovine NN NN O
, NN NN O
have NN NN O
a NN NN O
high NN NN O
sensitivity NN NN O
in NN NN O
variant NN NN B-Disease
angina NN NN I-Disease
and NN NN O
the NN NN O
vasoreactivity NN NN O
of NN NN O
the NN NN O
right NN NN O
coronary NN NN O
artery NN NN O
may NN NN O
be NN NN O
greater NN NN O
than NN NN O
that NN NN O
of NN NN O
the NN NN O
other NN NN O
coronary NN NN O
arteries NN NN O
. NN NN O
   
Oral NN NN O
manifestations NN NN O
of NN NN O
"""""""" NN NN O
meth NN NN B-Disease
mouth NN NN I-Disease
"""""""" NN NN O
: NN NN O
a NN NN O
case NN NN O
report NN NN O
. NN NN O
   
AIM NN NN O
: NN NN O
The NN NN O
aim NN NN O
of NN NN O
the NN NN O
documentation NN NN O
of NN NN O
this NN NN O
clinical NN NN O
case NN NN O
is NN NN O
to NN NN O
make NN NN O
clinicians NN NN O
aware NN NN O
of NN NN O
"""""""" NN NN O
meth NN NN B-Disease
mouth NN NN I-Disease
"""""""" NN NN O
and NN NN O
the NN NN O
medical NN NN O
risks NN NN O
associated NN NN O
with NN NN O
this NN NN O
serious NN NN O
condition NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Methamphetamine NN NN O
is NN NN O
a NN NN O
very NN NN O
addictive NN NN O
, NN NN O
powerful NN NN O
stimulant NN NN O
that NN NN O
increases NN NN O
wakefulness NN NN O
and NN NN O
physical NN NN O
activity NN NN O
and NN NN O
can NN NN O
produce NN NN O
other NN NN O
effects NN NN O
such NN NN O
as NN NN O
cardiac NN NN B-Disease
dysrhythmias NN NN I-Disease
, NN NN O
hypertension NN NN B-Disease
, NN NN O
hallucinations NN NN B-Disease
, NN NN O
and NN NN O
violent NN NN B-Disease
behavior NN NN I-Disease
. NN NN O
   
Dental NN NN O
patients NN NN O
abusing NN NN O
methamphetamine NN NN O
can NN NN O
present NN NN O
with NN NN O
poor NN NN O
oral NN NN O
hygiene NN NN O
, NN NN O
xerostomia NN NN B-Disease
, NN NN O
rampant NN NN O
caries NN NN B-Disease
( NN NN O
"""""""" NN NN O
meth NN NN B-Disease
mouth NN NN I-Disease
"""""""" NN NN O
) NN NN O
, NN NN O
and NN NN O
excessive NN NN O
tooth NN NN B-Disease
wear NN NN I-Disease
. NN NN O
   
Oral NN NN O
rehabilitation NN NN O
of NN NN O
patients NN NN O
using NN NN O
methamphetamine NN NN O
can NN NN O
be NN NN O
challenging NN NN O
. NN NN O
   
CASE NN NN O
DESCRIPTION NN NN O
: NN NN O
A NN NN O
30 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
Caucasian NN NN O
woman NN NN O
presented NN NN O
with NN NN O
dental NN NN O
pain NN NN B-Disease
, NN NN O
bad NN NN B-Disease
breath NN NN I-Disease
, NN NN O
and NN NN O
self NN NN O
- NN NN O
reported NN NN O
poor NN NN O
esthetics NN NN O
. NN NN O
   
A NN NN O
comprehensive NN NN O
examination NN NN O
including NN NN O
her NN NN O
medical NN NN O
history NN NN O
, NN NN O
panoramic NN NN O
radiograph NN NN O
, NN NN O
and NN NN O
intraoral NN NN O
examination NN NN O
revealed NN NN O
19 NN NN O
carious NN NN B-Disease
lesions NN NN I-Disease
, NN NN O
which NN NN O
is NN NN O
not NN NN O
very NN NN O
common NN NN O
for NN NN O
a NN NN O
healthy NN NN O
adult NN NN O
. NN NN O
   
She NN NN O
reported NN NN O
her NN NN O
use NN NN O
of NN NN O
methamphetamine NN NN O
for NN NN O
five NN NN O
years NN NN O
and NN NN O
had NN NN O
not NN NN O
experienced NN NN O
any NN NN O
major NN NN O
carious NN NN B-Disease
episodes NN NN I-Disease
before NN NN O
she NN NN O
started NN NN O
using NN NN O
the NN NN O
drug NN NN O
. NN NN O
   
SUMMARY NN NN O
: NN NN O
The NN NN O
patient NN NN O
' NN NN O
s NN NN O
medical NN NN O
and NN NN O
dental NN NN O
histories NN NN O
along NN NN O
with NN NN O
radiographic NN NN O
and NN NN O
clinical NN NN O
findings NN NN O
lead NN NN O
to NN NN O
a NN NN O
diagnosis NN NN O
of NN NN O
"""""""" NN NN O
meth NN NN B-Disease
mouth NN NN I-Disease
. NN NN O
"""""""" NN NN O
Although NN NN O
three NN NN O
different NN NN O
dental NN NN O
treatment NN NN O
modalities NN NN O
( NN NN O
either NN NN O
conventional NN NN O
or NN NN O
implant NN NN O
- NN NN O
supported NN NN O
) NN NN O
have NN NN O
been NN NN O
offered NN NN O
to NN NN O
the NN NN O
patient NN NN O
since NN NN O
August NN NN O
2007 NN NN O
, NN NN O
the NN NN O
patient NN NN O
has NN NN O
yet NN NN O
to NN NN O
initiate NN NN O
any NN NN O
treatment NN NN O
. NN NN O
   
CLINICAL NN NN O
SIGNIFICANCE NN NN O
: NN NN O
This NN NN O
clinical NN NN O
case NN NN O
showing NN NN O
oral NN NN O
manifestations NN NN O
of NN NN O
meth NN NN B-Disease
mouth NN NN I-Disease
was NN NN O
presented NN NN O
to NN NN O
help NN NN O
dental NN NN O
practitioners NN NN O
recognize NN NN O
and NN NN O
manage NN NN O
patients NN NN O
who NN NN O
may NN NN O
be NN NN O
abusing NN NN O
methamphetamines NN NN O
. NN NN O
   
Dental NN NN O
practitioners NN NN O
also NN NN O
may NN NN O
be NN NN O
skeptical NN NN O
about NN NN O
the NN NN O
reliability NN NN O
of NN NN O
appointment NN NN O
keeping NN NN O
by NN NN O
these NN NN O
patients NN NN O
, NN NN O
as NN NN O
they NN NN O
frequently NN NN O
miss NN NN O
their NN NN O
appointments NN NN O
without NN NN O
reasonable NN NN O
justification NN NN O
. NN NN O
   
Antituberculosis NN NN O
therapy NN NN O
- NN NN O
induced NN NN O
acute NN NN B-Disease
liver NN NN I-Disease
failure NN NN I-Disease
: NN NN O
magnitude NN NN O
, NN NN O
profile NN NN O
, NN NN O
prognosis NN NN O
, NN NN O
and NN NN O
predictors NN NN O
of NN NN O
outcome NN NN O
. NN NN O
   
Antituberculosis NN NN O
therapy NN NN O
( NN NN O
ATT NN NN O
) NN NN O
- NN NN O
associated NN NN O
acute NN NN B-Disease
liver NN NN I-Disease
failure NN NN I-Disease
( NN NN O
ATT NN NN O
- NN NN O
ALF NN NN B-Disease
) NN NN O
is NN NN O
the NN NN O
commonest NN NN O
drug NN NN O
- NN NN O
induced NN NN O
ALF NN NN B-Disease
in NN NN O
South NN NN O
Asia NN NN O
. NN NN O
   
Prospective NN NN O
studies NN NN O
on NN NN O
ATT NN NN O
- NN NN O
ALF NN NN B-Disease
are NN NN O
lacking NN NN O
. NN NN O
   
The NN NN O
current NN NN O
study NN NN O
prospectively NN NN O
evaluated NN NN O
the NN NN O
magnitude NN NN O
, NN NN O
clinical NN NN O
course NN NN O
, NN NN O
outcome NN NN O
, NN NN O
and NN NN O
prognostic NN NN O
factors NN NN O
in NN NN O
ATT NN NN O
- NN NN O
ALF NN NN B-Disease
. NN NN O
   
From NN NN O
January NN NN O
1986 NN NN O
to NN NN O
January NN NN O
2009 NN NN O
, NN NN O
1223 NN NN O
consecutive NN NN O
ALF NN NN B-Disease
patients NN NN O
were NN NN O
evaluated NN NN O
: NN NN O
ATT NN NN O
alone NN NN O
was NN NN O
the NN NN O
cause NN NN O
in NN NN O
70 NN NN O
( NN NN O
5 NN NN O
. NN NN O
7 NN NN O
% NN NN O
) NN NN O
patients NN NN O
. NN NN O
   
Another NN NN O
15 NN NN O
( NN NN O
1 NN NN O
. NN NN O
2 NN NN O
% NN NN O
) NN NN O
had NN NN O
ATT NN NN O
and NN NN O
simultaneous NN NN O
hepatitis NN NN B-Disease
virus NN NN I-Disease
infection NN NN I-Disease
. NN NN O
   
In NN NN O
44 NN NN O
( NN NN O
62 NN NN O
. NN NN O
8 NN NN O
% NN NN O
) NN NN O
patients NN NN O
, NN NN O
ATT NN NN O
was NN NN O
prescribed NN NN O
empirically NN NN O
without NN NN O
definitive NN NN O
evidence NN NN O
of NN NN O
tuberculosis NN NN B-Disease
. NN NN O
   
ATT NN NN O
- NN NN O
ALF NN NN B-Disease
patients NN NN O
were NN NN O
younger NN NN O
( NN NN O
32 NN NN O
. NN NN O
87 NN NN O
[ NN NN O
+ NN NN O
/ NN NN O
- NN NN O
15 NN NN O
. NN NN O
8 NN NN O
] NN NN O
years NN NN O
) NN NN O
, NN NN O
and NN NN O
49 NN NN O
( NN NN O
70 NN NN O
% NN NN O
) NN NN O
of NN NN O
them NN NN O
were NN NN O
women NN NN O
. NN NN O
   
Most NN NN O
had NN NN O
hyperacute NN NN O
presentation NN NN O
; NN NN O
the NN NN O
median NN NN O
icterus NN NN B-Disease
encephalopathy NN NN B-Disease
interval NN NN O
was NN NN O
4 NN NN O
. NN NN O
5 NN NN O
( NN NN O
0 NN NN O
- NN NN O
30 NN NN O
) NN NN O
days NN NN O
. NN NN O
   
The NN NN O
median NN NN O
duration NN NN O
of NN NN O
ATT NN NN O
before NN NN O
ALF NN NN B-Disease
was NN NN O
30 NN NN O
( NN NN O
7 NN NN O
- NN NN O
350 NN NN O
) NN NN O
days NN NN O
. NN NN O
   
At NN NN O
presentation NN NN O
, NN NN O
advanced NN NN O
encephalopathy NN NN B-Disease
and NN NN O
cerebral NN NN B-Disease
edema NN NN I-Disease
were NN NN O
present NN NN O
in NN NN O
51 NN NN O
( NN NN O
76 NN NN O
% NN NN O
) NN NN O
and NN NN O
29 NN NN O
( NN NN O
41 NN NN O
. NN NN O
4 NN NN O
% NN NN O
) NN NN O
patients NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
Gastrointestinal NN NN B-Disease
bleed NN NN I-Disease
, NN NN O
seizures NN NN B-Disease
, NN NN O
infection NN NN B-Disease
, NN NN O
and NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
were NN NN O
documented NN NN O
in NN NN O
seven NN NN O
( NN NN O
10 NN NN O
% NN NN O
) NN NN O
, NN NN O
five NN NN O
( NN NN O
7 NN NN O
. NN NN O
1 NN NN O
% NN NN O
) NN NN O
, NN NN O
26 NN NN O
( NN NN O
37 NN NN O
. NN NN O
1 NN NN O
% NN NN O
) NN NN O
, NN NN O
and NN NN O
seven NN NN O
( NN NN O
10 NN NN O
% NN NN O
) NN NN O
patients NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
Compared NN NN O
with NN NN O
hepatitis NN NN B-Disease
E NN NN I-Disease
virus NN NN O
( NN NN O
HEV NN NN O
) NN NN O
and NN NN O
non NN NN O
- NN NN O
A NN NN O
non NN NN O
- NN NN O
E NN NN O
- NN NN O
induced NN NN O
ALF NN NN B-Disease
, NN NN O
ATT NN NN O
- NN NN O
ALF NN NN B-Disease
patients NN NN O
had NN NN O
nearly NN NN O
similar NN NN O
presentations NN NN O
except NN NN O
for NN NN O
older NN NN O
age NN NN O
and NN NN O
less NN NN O
elevation NN NN O
of NN NN O
liver NN NN O
enzymes NN NN O
. NN NN O
   
The NN NN O
mortality NN NN O
rate NN NN O
among NN NN O
patients NN NN O
with NN NN O
ATT NN NN O
- NN NN O
ALF NN NN B-Disease
was NN NN O
high NN NN O
( NN NN O
67 NN NN O
. NN NN O
1 NN NN O
% NN NN O
, NN NN O
n NN NN O
= NN NN O
47 NN NN O
) NN NN O
, NN NN O
and NN NN O
only NN NN O
23 NN NN O
( NN NN O
32 NN NN O
. NN NN O
9 NN NN O
% NN NN O
) NN NN O
patients NN NN O
recovered NN NN O
with NN NN O
medical NN NN O
treatment NN NN O
. NN NN O
   
In NN NN O
multivariate NN NN O
analysis NN NN O
, NN NN O
three NN NN O
factors NN NN O
independently NN NN O
predicted NN NN O
mortality NN NN O
: NN NN O
serum NN NN O
bilirubin NN NN O
( NN NN O
> NN NN O
or NN NN O
= NN NN O
10 NN NN O
. NN NN O
8 NN NN O
mg NN NN O
/ NN NN O
dL NN NN O
) NN NN O
, NN NN O
prothrombin NN NN O
time NN NN O
( NN NN O
PT NN NN O
) NN NN O
prolongation NN NN O
( NN NN O
> NN NN O
or NN NN O
= NN NN O
26 NN NN O
seconds NN NN O
) NN NN O
, NN NN O
and NN NN O
grade NN NN O
III NN NN O
/ NN NN O
IV NN NN O
encephalopathy NN NN B-Disease
at NN NN O
presentation NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
ATT NN NN O
- NN NN O
ALF NN NN B-Disease
constituted NN NN O
5 NN NN O
. NN NN O
7 NN NN O
% NN NN O
of NN NN O
ALF NN NN B-Disease
at NN NN O
our NN NN O
center NN NN O
and NN NN O
had NN NN O
a NN NN O
high NN NN O
mortality NN NN O
rate NN NN O
. NN NN O
   
Because NN NN O
the NN NN O
mortality NN NN O
rate NN NN O
is NN NN O
so NN NN O
high NN NN O
, NN NN O
determining NN NN O
which NN NN O
factors NN NN O
are NN NN O
predictors NN NN O
is NN NN O
less NN NN O
important NN NN O
. NN NN O
   
A NN NN O
high NN NN O
proportion NN NN O
of NN NN O
patients NN NN O
had NN NN O
consumed NN NN O
ATT NN NN O
empirically NN NN O
, NN NN O
which NN NN O
could NN NN O
have NN NN O
been NN NN O
prevented NN NN O
. NN NN O
   
Design NN NN O
and NN NN O
analysis NN NN O
of NN NN O
the NN NN O
HYPREN NN NN O
- NN NN O
trial NN NN O
: NN NN O
safety NN NN O
of NN NN O
enalapril NN NN O
and NN NN O
prazosin NN NN O
in NN NN O
the NN NN O
initial NN NN O
treatment NN NN O
phase NN NN O
of NN NN O
patients NN NN O
with NN NN O
congestive NN NN B-Disease
heart NN NN I-Disease
failure NN NN I-Disease
. NN NN O
   
Since NN NN O
the NN NN O
introduction NN NN O
of NN NN O
angiotensin NN NN O
converting NN NN O
enzyme NN NN O
( NN NN O
ACE NN NN O
) NN NN O
inhibitors NN NN O
into NN NN O
the NN NN O
adjunctive NN NN O
treatment NN NN O
of NN NN O
patients NN NN O
with NN NN O
congestive NN NN B-Disease
heart NN NN I-Disease
failure NN NN I-Disease
, NN NN O
cases NN NN O
of NN NN O
severe NN NN O
hypotension NN NN B-Disease
, NN NN O
especially NN NN O
on NN NN O
the NN NN O
first NN NN O
day NN NN O
of NN NN O
treatment NN NN O
, NN NN O
have NN NN O
occasionally NN NN O
been NN NN O
reported NN NN O
. NN NN O
   
To NN NN O
assess NN NN O
the NN NN O
safety NN NN O
of NN NN O
the NN NN O
ACE NN NN O
inhibitor NN NN O
enalapril NN NN O
a NN NN O
multicenter NN NN O
, NN NN O
randomized NN NN O
, NN NN O
prazosin NN NN O
- NN NN O
controlled NN NN O
trial NN NN O
was NN NN O
designed NN NN O
that NN NN O
compared NN NN O
the NN NN O
incidence NN NN O
and NN NN O
severity NN NN O
of NN NN O
symptomatic NN NN O
hypotension NN NN B-Disease
on NN NN O
the NN NN O
first NN NN O
day NN NN O
of NN NN O
treatment NN NN O
. NN NN O
   
Trial NN NN O
medication NN NN O
was NN NN O
2 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
enalapril NN NN O
or NN NN O
0 NN NN O
. NN NN O
5 NN NN O
prazosin NN NN O
. NN NN O
   
Subjects NN NN O
were NN NN O
1210 NN NN O
inpatients NN NN O
with NN NN O
New NN NN O
York NN NN O
Heart NN NN O
Association NN NN O
( NN NN O
NYHA NN NN O
) NN NN O
functional NN NN O
class NN NN O
II NN NN O
and NN NN O
III NN NN O
. NN NN O
   
Patients NN NN O
who NN NN O
received NN NN O
enalapril NN NN O
experienced NN NN O
clinically NN NN O
and NN NN O
statistically NN NN O
significantly NN NN O
less NN NN O
symptomatic NN NN O
hypotension NN NN B-Disease
( NN NN O
5 NN NN O
. NN NN O
2 NN NN O
% NN NN O
) NN NN O
than NN NN O
the NN NN O
patients NN NN O
who NN NN O
received NN NN O
prazosin NN NN O
( NN NN O
12 NN NN O
. NN NN O
9 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
All NN NN O
patients NN NN O
recovered NN NN O
. NN NN O
   
It NN NN O
was NN NN O
concluded NN NN O
that NN NN O
treatment NN NN O
with NN NN O
enalapril NN NN O
was NN NN O
well NN NN O
tolerated NN NN O
and NN NN O
it NN NN O
is NN NN O
, NN NN O
therefore NN NN O
, NN NN O
unreasonable NN NN O
to NN NN O
restrict NN NN O
the NN NN O
initiation NN NN O
of NN NN O
treatment NN NN O
with NN NN O
enalapril NN NN O
to NN NN O
inpatients NN NN O
. NN NN O
   
Central NN NN B-Disease
nervous NN NN I-Disease
system NN NN I-Disease
complications NN NN I-Disease
during NN NN O
treatment NN NN O
of NN NN O
acute NN NN B-Disease
lymphoblastic NN NN I-Disease
leukemia NN NN I-Disease
in NN NN O
a NN NN O
single NN NN O
pediatric NN NN O
institution NN NN O
. NN NN O
   
Central NN NN B-Disease
nervous NN NN I-Disease
system NN NN I-Disease
( NN NN I-Disease
CNS NN NN I-Disease
) NN NN I-Disease
complications NN NN I-Disease
during NN NN O
treatment NN NN O
of NN NN O
childhood NN NN O
acute NN NN B-Disease
lymphoblastic NN NN I-Disease
leukemia NN NN I-Disease
( NN NN O
ALL NN NN B-Disease
) NN NN O
remain NN NN O
a NN NN O
challenging NN NN O
clinical NN NN O
problem NN NN O
. NN NN O
   
Outcome NN NN O
improvement NN NN O
with NN NN O
more NN NN O
intensive NN NN O
chemotherapy NN NN O
has NN NN O
significantly NN NN O
increased NN NN O
the NN NN O
incidence NN NN O
and NN NN O
severity NN NN O
of NN NN O
adverse NN NN O
events NN NN O
. NN NN O
   
This NN NN O
study NN NN O
analyzed NN NN O
the NN NN O
incidence NN NN O
of NN NN O
neurological NN NN B-Disease
complications NN NN I-Disease
during NN NN O
ALL NN NN B-Disease
treatment NN NN O
in NN NN O
a NN NN O
single NN NN O
pediatric NN NN O
institution NN NN O
, NN NN O
focusing NN NN O
on NN NN O
clinical NN NN O
, NN NN O
radiological NN NN O
, NN NN O
and NN NN O
electrophysiological NN NN O
findings NN NN O
. NN NN O
   
Exclusion NN NN O
criteria NN NN O
included NN NN O
CNS NN NN O
leukemic NN NN B-Disease
infiltration NN NN I-Disease
at NN NN O
diagnosis NN NN O
, NN NN O
therapy NN NN O
- NN NN O
related NN NN O
peripheral NN NN B-Disease
neuropathy NN NN I-Disease
, NN NN O
late NN NN O
- NN NN O
onset NN NN O
encephalopathy NN NN B-Disease
, NN NN O
or NN NN O
long NN NN O
- NN NN O
term NN NN O
neurocognitive NN NN B-Disease
defects NN NN I-Disease
. NN NN O
   
During NN NN O
a NN NN O
9 NN NN O
- NN NN O
year NN NN O
period NN NN O
, NN NN O
we NN NN O
retrospectively NN NN O
collected NN NN O
27 NN NN O
neurological NN NN O
events NN NN O
( NN NN O
11 NN NN O
% NN NN O
) NN NN O
in NN NN O
as NN NN O
many NN NN O
patients NN NN O
, NN NN O
from NN NN O
253 NN NN O
children NN NN O
enrolled NN NN O
in NN NN O
the NN NN O
ALL NN NN B-Disease
front NN NN O
- NN NN O
line NN NN O
protocol NN NN O
. NN NN O
   
CNS NN NN O
complications NN NN O
included NN NN O
posterior NN NN O
reversible NN NN O
leukoencephalopathy NN NN B-Disease
syndrome NN NN O
( NN NN O
n NN NN O
= NN NN O
10 NN NN O
) NN NN O
, NN NN O
stroke NN NN B-Disease
( NN NN O
n NN NN O
= NN NN O
5 NN NN O
) NN NN O
, NN NN O
temporal NN NN B-Disease
lobe NN NN I-Disease
epilepsy NN NN I-Disease
( NN NN O
n NN NN O
= NN NN O
2 NN NN O
) NN NN O
, NN NN O
high NN NN O
- NN NN O
dose NN NN O
methotrexate NN NN O
toxicity NN NN B-Disease
( NN NN O
n NN NN O
= NN NN O
2 NN NN O
) NN NN O
, NN NN O
syndrome NN NN O
of NN NN O
inappropriate NN NN B-Disease
antidiuretic NN NN I-Disease
hormone NN NN I-Disease
secretion NN NN I-Disease
( NN NN O
n NN NN O
= NN NN O
1 NN NN O
) NN NN O
, NN NN O
and NN NN O
other NN NN O
unclassified NN NN O
events NN NN O
( NN NN O
n NN NN O
= NN NN O
7 NN NN O
) NN NN O
. NN NN O
   
In NN NN O
conclusion NN NN O
, NN NN O
CNS NN NN O
complications NN NN O
are NN NN O
frequent NN NN O
events NN NN O
during NN NN O
ALL NN NN B-Disease
therapy NN NN O
, NN NN O
and NN NN O
require NN NN O
rapid NN NN O
detection NN NN O
and NN NN O
prompt NN NN O
treatment NN NN O
to NN NN O
limit NN NN O
permanent NN NN O
damage NN NN O
. NN NN O
   
Cocaine NN NN O
causes NN NN O
memory NN NN B-Disease
and NN NN I-Disease
learning NN NN I-Disease
impairments NN NN I-Disease
in NN NN O
rats NN NN O
: NN NN O
involvement NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
kappa NN NN O
B NN NN O
and NN NN O
oxidative NN NN O
stress NN NN O
, NN NN O
and NN NN O
prevention NN NN O
by NN NN O
topiramate NN NN O
. NN NN O
   
Different NN NN O
mechanisms NN NN O
have NN NN O
been NN NN O
suggested NN NN O
for NN NN O
cocaine NN NN O
toxicity NN NN B-Disease
including NN NN O
an NN NN O
increase NN NN O
in NN NN O
oxidative NN NN O
stress NN NN O
but NN NN O
the NN NN O
association NN NN O
between NN NN O
oxidative NN NN O
status NN NN O
in NN NN O
the NN NN O
brain NN NN O
and NN NN O
cocaine NN NN O
induced NN NN O
- NN NN O
behaviour NN NN O
is NN NN O
poorly NN NN O
understood NN NN O
. NN NN O
   
Nuclear NN NN O
factor NN NN O
kappa NN NN O
B NN NN O
( NN NN O
NFkappaB NN NN O
) NN NN O
is NN NN O
a NN NN O
sensor NN NN O
of NN NN O
oxidative NN NN O
stress NN NN O
and NN NN O
participates NN NN O
in NN NN O
memory NN NN O
formation NN NN O
that NN NN O
could NN NN O
be NN NN O
involved NN NN O
in NN NN O
drug NN NN O
toxicity NN NN B-Disease
and NN NN O
addiction NN NN O
mechanisms NN NN O
. NN NN O
   
Therefore NN NN O
NFkappaB NN NN O
activity NN NN O
, NN NN O
oxidative NN NN O
stress NN NN O
, NN NN O
neuronal NN NN O
nitric NN NN O
oxide NN NN O
synthase NN NN O
( NN NN O
nNOS NN NN O
) NN NN O
activity NN NN O
, NN NN O
spatial NN NN O
learning NN NN O
and NN NN O
memory NN NN O
as NN NN O
well NN NN O
as NN NN O
the NN NN O
effect NN NN O
of NN NN O
topiramate NN NN O
, NN NN O
a NN NN O
previously NN NN O
proposed NN NN O
therapy NN NN O
for NN NN O
cocaine NN NN B-Disease
addiction NN NN I-Disease
, NN NN O
were NN NN O
evaluated NN NN O
in NN NN O
an NN NN O
experimental NN NN O
model NN NN O
of NN NN O
cocaine NN NN O
administration NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
NFkappaB NN NN O
activity NN NN O
was NN NN O
decreased NN NN O
in NN NN O
the NN NN O
frontal NN NN O
cortex NN NN O
of NN NN O
cocaine NN NN O
treated NN NN O
rats NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
GSH NN NN O
concentration NN NN O
and NN NN O
glutathione NN NN O
peroxidase NN NN O
activity NN NN O
in NN NN O
the NN NN O
hippocampus NN NN O
, NN NN O
whereas NN NN O
nNOS NN NN O
activity NN NN O
in NN NN O
the NN NN O
hippocampus NN NN O
was NN NN O
increased NN NN O
. NN NN O
   
Memory NN NN O
retrieval NN NN O
of NN NN O
experiences NN NN O
acquired NN NN O
prior NN NN O
to NN NN O
cocaine NN NN O
administration NN NN O
was NN NN O
impaired NN NN O
and NN NN O
negatively NN NN O
correlated NN NN O
with NN NN O
NFkappaB NN NN O
activity NN NN O
in NN NN O
the NN NN O
frontal NN NN O
cortex NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
learning NN NN O
of NN NN O
new NN NN O
tasks NN NN O
was NN NN O
enhanced NN NN O
and NN NN O
correlated NN NN O
with NN NN O
the NN NN O
increase NN NN O
of NN NN O
nNOS NN NN O
activity NN NN O
and NN NN O
the NN NN O
decrease NN NN O
of NN NN O
glutathione NN NN O
peroxidase NN NN O
. NN NN O
   
These NN NN O
results NN NN O
provide NN NN O
evidence NN NN O
for NN NN O
a NN NN O
possible NN NN O
mechanistic NN NN O
role NN NN O
of NN NN O
oxidative NN NN O
and NN NN O
nitrosative NN NN O
stress NN NN O
and NN NN O
NFkappaB NN NN O
in NN NN O
the NN NN O
alterations NN NN O
induced NN NN O
by NN NN O
cocaine NN NN O
. NN NN O
   
Topiramate NN NN O
prevented NN NN O
all NN NN O
the NN NN O
alterations NN NN O
observed NN NN O
, NN NN O
showing NN NN O
novel NN NN O
neuroprotective NN NN O
properties NN NN O
. NN NN O
   
Efficacy NN NN O
and NN NN O
safety NN NN O
of NN NN O
asenapine NN NN O
in NN NN O
a NN NN O
placebo NN NN O
- NN NN O
and NN NN O
haloperidol NN NN O
- NN NN O
controlled NN NN O
trial NN NN O
in NN NN O
patients NN NN O
with NN NN O
acute NN NN O
exacerbation NN NN O
of NN NN O
schizophrenia NN NN B-Disease
. NN NN O
   
Asenapine NN NN O
is NN NN O
approved NN NN O
by NN NN O
the NN NN O
Food NN NN O
and NN NN O
Drugs NN NN O
Administration NN NN O
in NN NN O
adults NN NN O
for NN NN O
acute NN NN O
treatment NN NN O
of NN NN O
schizophrenia NN NN B-Disease
or NN NN O
of NN NN O
manic NN NN B-Disease
or NN NN O
mixed NN NN O
episodes NN NN O
associated NN NN O
with NN NN O
bipolar NN NN B-Disease
I NN NN I-Disease
disorder NN NN I-Disease
with NN NN O
or NN NN O
without NN NN O
psychotic NN NN B-Disease
features NN NN O
. NN NN O
   
In NN NN O
a NN NN O
double NN NN O
- NN NN O
blind NN NN O
6 NN NN O
- NN NN O
week NN NN O
trial NN NN O
, NN NN O
458 NN NN O
patients NN NN O
with NN NN O
acute NN NN O
schizophrenia NN NN B-Disease
were NN NN O
randomly NN NN O
assigned NN NN O
to NN NN O
fixed NN NN O
- NN NN O
dose NN NN O
treatment NN NN O
with NN NN O
asenapine NN NN O
at NN NN O
5 NN NN O
mg NN NN O
twice NN NN O
daily NN NN O
( NN NN O
BID NN NN O
) NN NN O
, NN NN O
asenapine NN NN O
at NN NN O
10 NN NN O
mg NN NN O
BID NN NN O
, NN NN O
placebo NN NN O
, NN NN O
or NN NN O
haloperidol NN NN O
at NN NN O
4 NN NN O
mg NN NN O
BID NN NN O
( NN NN O
to NN NN O
verify NN NN O
assay NN NN O
sensitivity NN NN O
) NN NN O
. NN NN O
   
With NN NN O
last NN NN O
observations NN NN O
carried NN NN O
forward NN NN O
( NN NN O
LOCF NN NN O
) NN NN O
, NN NN O
mean NN NN O
Positive NN NN O
and NN NN O
Negative NN NN O
Syndrome NN NN O
Scale NN NN O
total NN NN O
score NN NN O
reductions NN NN O
from NN NN O
baseline NN NN O
to NN NN O
endpoint NN NN O
were NN NN O
significantly NN NN O
greater NN NN O
with NN NN O
asenapine NN NN O
at NN NN O
5 NN NN O
mg NN NN O
BID NN NN O
( NN NN O
- NN NN O
16 NN NN O
. NN NN O
2 NN NN O
) NN NN O
and NN NN O
haloperidol NN NN O
( NN NN O
- NN NN O
15 NN NN O
. NN NN O
4 NN NN O
) NN NN O
than NN NN O
placebo NN NN O
( NN NN O
- NN NN O
10 NN NN O
. NN NN O
7 NN NN O
; NN NN O
both NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
; NN NN O
using NN NN O
mixed NN NN O
model NN NN O
for NN NN O
repeated NN NN O
measures NN NN O
( NN NN O
MMRM NN NN O
) NN NN O
, NN NN O
changes NN NN O
at NN NN O
day NN NN O
42 NN NN O
were NN NN O
significantly NN NN O
greater NN NN O
with NN NN O
asenapine NN NN O
at NN NN O
5 NN NN O
and NN NN O
10 NN NN O
mg NN NN O
BID NN NN O
( NN NN O
- NN NN O
21 NN NN O
. NN NN O
3 NN NN O
and NN NN O
- NN NN O
19 NN NN O
. NN NN O
4 NN NN O
, NN NN O
respectively NN NN O
) NN NN O
and NN NN O
haloperidol NN NN O
( NN NN O
- NN NN O
20 NN NN O
. NN NN O
0 NN NN O
) NN NN O
than NN NN O
placebo NN NN O
( NN NN O
- NN NN O
14 NN NN O
. NN NN O
6 NN NN O
; NN NN O
all NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
On NN NN O
the NN NN O
Positive NN NN O
and NN NN O
Negative NN NN O
Syndrome NN NN O
Scale NN NN O
positive NN NN O
subscale NN NN O
, NN NN O
all NN NN O
treatments NN NN O
were NN NN O
superior NN NN O
to NN NN O
placebo NN NN O
with NN NN O
LOCF NN NN O
and NN NN O
MMRM NN NN O
; NN NN O
asenapine NN NN O
at NN NN O
5 NN NN O
mg NN NN O
BID NN NN O
was NN NN O
superior NN NN O
to NN NN O
placebo NN NN O
on NN NN O
the NN NN O
negative NN NN O
subscale NN NN O
with NN NN O
MMRM NN NN O
and NN NN O
on NN NN O
the NN NN O
general NN NN O
psychopathology NN NN O
subscale NN NN O
with NN NN O
LOCF NN NN O
and NN NN O
MMRM NN NN O
. NN NN O
   
Treatment NN NN O
- NN NN O
related NN NN O
adverse NN NN O
events NN NN O
( NN NN O
AEs NN NN O
) NN NN O
occurred NN NN O
in NN NN O
44 NN NN O
% NN NN O
and NN NN O
52 NN NN O
% NN NN O
, NN NN O
57 NN NN O
% NN NN O
, NN NN O
and NN NN O
41 NN NN O
% NN NN O
of NN NN O
the NN NN O
asenapine NN NN O
at NN NN O
5 NN NN O
and NN NN O
10 NN NN O
mg NN NN O
BID NN NN O
, NN NN O
haloperidol NN NN O
, NN NN O
and NN NN O
placebo NN NN O
groups NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
Extrapyramidal NN NN B-Disease
symptoms NN NN I-Disease
reported NN NN O
as NN NN O
AEs NN NN O
occurred NN NN O
in NN NN O
15 NN NN O
% NN NN O
and NN NN O
18 NN NN O
% NN NN O
, NN NN O
34 NN NN O
% NN NN O
, NN NN O
and NN NN O
10 NN NN O
% NN NN O
of NN NN O
the NN NN O
asenapine NN NN O
at NN NN O
5 NN NN O
and NN NN O
10 NN NN O
mg NN NN O
BID NN NN O
, NN NN O
haloperidol NN NN O
, NN NN O
and NN NN O
placebo NN NN O
groups NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
Across NN NN O
all NN NN O
groups NN NN O
, NN NN O
no NN NN O
more NN NN O
than NN NN O
5 NN NN O
% NN NN O
of NN NN O
patients NN NN O
had NN NN O
clinically NN NN O
significant NN NN O
weight NN NN O
change NN NN O
. NN NN O
   
Post NN NN O
hoc NN NN O
analyses NN NN O
indicated NN NN O
that NN NN O
efficacy NN NN O
was NN NN O
similar NN NN O
with NN NN O
asenapine NN NN O
and NN NN O
haloperidol NN NN O
; NN NN O
greater NN NN O
contrasts NN NN O
were NN NN O
seen NN NN O
in NN NN O
AEs NN NN O
, NN NN O
especially NN NN O
extrapyramidal NN NN B-Disease
symptoms NN NN I-Disease
. NN NN O
   
Salvage NN NN O
therapy NN NN O
with NN NN O
nelarabine NN NN O
, NN NN O
etoposide NN NN O
, NN NN O
and NN NN O
cyclophosphamide NN NN O
in NN NN O
relapsed NN NN O
/ NN NN O
refractory NN NN O
paediatric NN NN O
T NN NN B-Disease
- NN NN I-Disease
cell NN NN I-Disease
lymphoblastic NN NN I-Disease
leukaemia NN NN I-Disease
and NN NN I-Disease
lymphoma NN NN I-Disease
. NN NN O
   
A NN NN O
combination NN NN O
of NN NN O
5 NN NN O
d NN NN O
of NN NN O
nelarabine NN NN O
( NN NN O
AraG NN NN O
) NN NN O
with NN NN O
5 NN NN O
d NN NN O
of NN NN O
etoposide NN NN O
( NN NN O
VP NN NN O
) NN NN O
and NN NN O
cyclophosphamide NN NN O
( NN NN O
CPM NN NN O
) NN NN O
and NN NN O
prophylactic NN NN O
intrathecal NN NN O
chemotherapy NN NN O
was NN NN O
used NN NN O
as NN NN O
salvage NN NN O
therapy NN NN O
in NN NN O
seven NN NN O
children NN NN O
with NN NN O
refractory NN NN O
or NN NN O
relapsed NN NN O
T NN NN B-Disease
- NN NN I-Disease
cell NN NN I-Disease
leukaemia NN NN I-Disease
or NN NN I-Disease
lymphoma NN NN I-Disease
. NN NN O
   
The NN NN O
most NN NN O
common NN NN O
side NN NN O
effects NN NN O
attributable NN NN O
to NN NN O
the NN NN O
AraG NN NN O
included NN NN O
Grade NN NN O
2 NN NN O
and NN NN O
3 NN NN O
sensory NN NN O
and NN NN O
motor NN NN O
neuropathy NN NN B-Disease
and NN NN O
musculoskeletal NN NN B-Disease
pain NN NN I-Disease
. NN NN O
   
Haematological NN NN B-Disease
toxicity NN NN I-Disease
was NN NN O
greater NN NN O
for NN NN O
the NN NN O
combination NN NN O
than NN NN O
AraG NN NN O
alone NN NN O
, NN NN O
although NN NN O
median NN NN O
time NN NN O
to NN NN O
neutrophil NN NN O
and NN NN O
platelet NN NN O
recovery NN NN O
was NN NN O
consistent NN NN O
with NN NN O
other NN NN O
salvage NN NN O
therapies NN NN O
. NN NN O
   
All NN NN O
patients NN NN O
had NN NN O
some NN NN O
response NN NN O
to NN NN O
the NN NN O
combined NN NN O
therapy NN NN O
and NN NN O
five NN NN O
of NN NN O
the NN NN O
seven NN NN O
went NN NN O
into NN NN O
complete NN NN O
remission NN NN O
after NN NN O
one NN NN O
or NN NN O
two NN NN O
courses NN NN O
of NN NN O
AraG NN NN O
/ NN NN O
VP NN NN O
/ NN NN O
CPM NN NN O
. NN NN O
   
Our NN NN O
experience NN NN O
supports NN NN O
the NN NN O
safety NN NN O
of NN NN O
giving NN NN O
AraG NN NN O
as NN NN O
salvage NN NN O
therapy NN NN O
in NN NN O
synchrony NN NN O
with NN NN O
etoposide NN NN O
and NN NN O
cyclophosphamide NN NN O
, NN NN O
although NN NN O
neurological NN NN B-Disease
toxicity NN NN I-Disease
must NN NN O
be NN NN O
closely NN NN O
monitored NN NN O
. NN NN O
   
Effect NN NN O
of NN NN O
adriamycin NN NN O
combined NN NN O
with NN NN O
whole NN NN O
body NN NN O
hyperthermia NN NN B-Disease
on NN NN O
tumor NN NN B-Disease
and NN NN O
normal NN NN O
tissues NN NN O
. NN NN O
   
Thermal NN NN O
enhancement NN NN O
of NN NN O
Adriamycin NN NN O
- NN NN O
mediated NN NN O
antitumor NN NN O
activity NN NN O
and NN NN O
normal NN NN O
tissue NN NN O
toxicities NN NN B-Disease
by NN NN O
whole NN NN O
body NN NN O
hyperthermia NN NN B-Disease
were NN NN O
compared NN NN O
using NN NN O
a NN NN O
F344 NN NN O
rat NN NN O
model NN NN O
. NN NN O
   
Antitumor NN NN O
activity NN NN O
was NN NN O
studied NN NN O
using NN NN O
a NN NN O
tumor NN NN B-Disease
growth NN NN O
delay NN NN O
assay NN NN O
. NN NN O
   
Acute NN NN O
normal NN NN O
tissue NN NN O
toxicities NN NN B-Disease
( NN NN O
i NN NN O
. NN NN O
e NN NN O
. NN NN O
, NN NN O
leukopenia NN NN B-Disease
and NN NN O
thrombocytopenia NN NN B-Disease
) NN NN O
and NN NN O
late NN NN O
normal NN NN O
tissue NN NN O
toxicities NN NN B-Disease
( NN NN O
i NN NN O
. NN NN O
e NN NN O
. NN NN O
, NN NN O
myocardial NN NN B-Disease
and NN NN I-Disease
kidney NN NN I-Disease
injury NN NN I-Disease
) NN NN O
were NN NN O
evaluated NN NN O
by NN NN O
functional NN NN O
/ NN NN O
physiological NN NN O
assays NN NN O
and NN NN O
by NN NN O
morphological NN NN O
techniques NN NN O
. NN NN O
   
Whole NN NN O
body NN NN O
hyperthermia NN NN B-Disease
( NN NN O
120 NN NN O
min NN NN O
at NN NN O
41 NN NN O
. NN NN O
5 NN NN O
degrees NN NN O
C NN NN O
) NN NN O
enhanced NN NN O
both NN NN O
Adriamycin NN NN O
- NN NN O
mediated NN NN O
antitumor NN NN O
activity NN NN O
and NN NN O
toxic NN NN O
side NN NN O
effects NN NN O
. NN NN O
   
The NN NN O
thermal NN NN O
enhancement NN NN O
ratio NN NN O
calculated NN NN O
for NN NN O
antitumor NN NN O
activity NN NN O
was NN NN O
1 NN NN O
. NN NN O
6 NN NN O
. NN NN O
   
Thermal NN NN O
enhancement NN NN O
ratios NN NN O
estimated NN NN O
for NN NN O
"""""""" NN NN O
acute NN NN O
"""""""" NN NN O
hematological NN NN O
changes NN NN O
were NN NN O
1 NN NN O
. NN NN O
3 NN NN O
, NN NN O
whereas NN NN O
those NN NN O
estimated NN NN O
for NN NN O
"""""""" NN NN O
late NN NN O
"""""""" NN NN O
damage NN NN O
( NN NN O
based NN NN O
on NN NN O
morphological NN NN O
cardiac NN NN B-Disease
and NN NN I-Disease
renal NN NN I-Disease
lesions NN NN I-Disease
) NN NN O
varied NN NN O
between NN NN O
2 NN NN O
. NN NN O
4 NN NN O
and NN NN O
4 NN NN O
. NN NN O
3 NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
while NN NN O
whole NN NN O
body NN NN O
hyperthermia NN NN B-Disease
enhances NN NN O
Adriamycin NN NN O
- NN NN O
mediated NN NN O
antitumor NN NN O
effect NN NN O
, NN NN O
normal NN NN O
tissue NN NN O
toxicity NN NN B-Disease
is NN NN O
also NN NN O
increased NN NN O
, NN NN O
and NN NN O
the NN NN O
potential NN NN O
therapeutic NN NN O
gain NN NN O
of NN NN O
the NN NN O
combined NN NN O
modality NN NN O
treatment NN NN O
is NN NN O
eroded NN NN O
. NN NN O
   
Permeability NN NN O
, NN NN O
ultrastructural NN NN O
changes NN NN O
, NN NN O
and NN NN O
distribution NN NN O
of NN NN O
novel NN NN O
proteins NN NN O
in NN NN O
the NN NN O
glomerular NN NN O
barrier NN NN O
in NN NN O
early NN NN O
puromycin NN NN O
aminonucleoside NN NN O
nephrosis NN NN B-Disease
. NN NN O
   
BACKGROUND NN NN O
/ NN NN O
AIMS NN NN O
: NN NN O
It NN NN O
is NN NN O
still NN NN O
unclear NN NN O
what NN NN O
happens NN NN O
in NN NN O
the NN NN O
glomerulus NN NN O
when NN NN O
proteinuria NN NN B-Disease
starts NN NN O
. NN NN O
   
Using NN NN O
puromycin NN NN O
aminonucleoside NN NN O
nephrosis NN NN B-Disease
( NN NN O
PAN NN NN O
) NN NN O
rats NN NN O
, NN NN O
we NN NN O
studied NN NN O
early NN NN O
ultrastructural NN NN O
and NN NN O
permeability NN NN O
changes NN NN O
in NN NN O
relation NN NN O
to NN NN O
the NN NN O
expression NN NN O
of NN NN O
the NN NN O
podocyte NN NN O
- NN NN O
associated NN NN O
molecules NN NN O
nephrin NN NN O
, NN NN O
a NN NN O
- NN NN O
actinin NN NN O
, NN NN O
dendrin NN NN O
, NN NN O
and NN NN O
plekhh2 NN NN O
, NN NN O
the NN NN O
last NN NN O
two NN NN O
of NN NN O
which NN NN O
were NN NN O
only NN NN O
recently NN NN O
discovered NN NN O
in NN NN O
podocytes NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Using NN NN O
immune NN NN O
stainings NN NN O
, NN NN O
semiquantitative NN NN O
measurement NN NN O
was NN NN O
performed NN NN O
under NN NN O
the NN NN O
electron NN NN O
microscope NN NN O
. NN NN O
   
Permeability NN NN O
was NN NN O
assessed NN NN O
using NN NN O
isolated NN NN O
kidney NN NN O
perfusion NN NN O
with NN NN O
tracers NN NN O
. NN NN O
   
Possible NN NN O
effects NN NN O
of NN NN O
ACE NN NN O
inhibition NN NN O
were NN NN O
tested NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
By NN NN O
day NN NN O
2 NN NN O
, NN NN O
some NN NN O
patchy NN NN O
foot NN NN O
process NN NN O
effacement NN NN O
, NN NN O
but NN NN O
no NN NN O
proteinuria NN NN B-Disease
, NN NN O
appeared NN NN O
. NN NN O
   
The NN NN O
amount NN NN O
of NN NN O
nephrin NN NN O
was NN NN O
reduced NN NN O
in NN NN O
both NN NN O
diseased NN NN O
and NN NN O
normal NN NN O
areas NN NN O
. NN NN O
   
The NN NN O
other NN NN O
proteins NN NN O
showed NN NN O
few NN NN O
changes NN NN O
, NN NN O
which NN NN O
were NN NN O
limited NN NN O
to NN NN O
diseased NN NN O
areas NN NN O
. NN NN O
   
By NN NN O
day NN NN O
4 NN NN O
, NN NN O
foot NN NN O
process NN NN O
effacement NN NN O
was NN NN O
complete NN NN O
and NN NN O
proteinuria NN NN B-Disease
appeared NN NN O
in NN NN O
parallel NN NN O
with NN NN O
signs NN NN O
of NN NN O
size NN NN O
barrier NN NN O
damage NN NN O
. NN NN O
   
Nephrin NN NN O
decreased NN NN O
further NN NN O
, NN NN O
while NN NN O
dendrin NN NN O
and NN NN O
plekhh2 NN NN O
also NN NN O
decreased NN NN O
but NN NN O
a NN NN O
- NN NN O
actinin NN NN O
remained NN NN O
unchanged NN NN O
. NN NN O
   
ACE NN NN O
inhibition NN NN O
had NN NN O
no NN NN O
significant NN NN O
protective NN NN O
effect NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
PAN NN NN O
glomeruli NN NN O
already NN NN O
showed NN NN O
significant NN NN O
pathology NN NN O
by NN NN O
day NN NN O
4 NN NN O
, NN NN O
despite NN NN O
relatively NN NN O
mild NN NN O
proteinuria NN NN B-Disease
. NN NN O
   
This NN NN O
was NN NN O
preceded NN NN O
by NN NN O
altered NN NN O
nephrin NN NN O
expression NN NN O
, NN NN O
supporting NN NN O
its NN NN O
pivotal NN NN O
role NN NN O
in NN NN O
podocyte NN NN O
morphology NN NN O
. NN NN O
   
The NN NN O
novel NN NN O
proteins NN NN O
dendrin NN NN O
and NN NN O
plekhh2 NN NN O
were NN NN O
both NN NN O
reduced NN NN O
, NN NN O
suggesting NN NN O
roles NN NN O
in NN NN O
PAN NN NN O
, NN NN O
whereas NN NN O
a NN NN O
- NN NN O
actinin NN NN O
was NN NN O
unchanged NN NN O
. NN NN O
   
A NN NN O
novel NN NN O
, NN NN O
multiple NN NN O
symptom NN NN O
model NN NN O
of NN NN O
obsessive NN NN B-Disease
- NN NN I-Disease
compulsive NN NN I-Disease
- NN NN I-Disease
like NN NN I-Disease
behaviors NN NN I-Disease
in NN NN O
animals NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Current NN NN O
animal NN NN O
models NN NN O
of NN NN O
obsessive NN NN B-Disease
- NN NN I-Disease
compulsive NN NN I-Disease
disorder NN NN I-Disease
( NN NN O
OCD NN NN B-Disease
) NN NN O
typically NN NN O
involve NN NN O
acute NN NN O
, NN NN O
drug NN NN O
- NN NN O
induced NN NN O
symptom NN NN O
provocation NN NN O
or NN NN O
a NN NN O
genetic NN NN O
association NN NN O
with NN NN O
stereotypies NN NN O
or NN NN O
anxiety NN NN B-Disease
. NN NN O
   
   O
of NN NN O
these NN NN O
current NN NN O
models NN NN O
demonstrate NN NN O
multiple NN NN O
OCD NN NN B-Disease
- NN NN O
like NN NN O
behaviors NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Neonatal NN NN O
rats NN NN O
were NN NN O
treated NN NN O
with NN NN O
the NN NN O
tricyclic NN NN O
antidepressant NN NN O
clomipramine NN NN O
or NN NN O
vehicle NN NN O
between NN NN O
days NN NN O
9 NN NN O
and NN NN O
16 NN NN O
twice NN NN O
daily NN NN O
and NN NN O
behaviorally NN NN O
tested NN NN O
in NN NN O
adulthood NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Clomipramine NN NN O
exposure NN NN O
in NN NN O
immature NN NN O
rats NN NN O
produced NN NN O
significant NN NN O
behavioral NN NN O
and NN NN O
biochemical NN NN O
changes NN NN O
that NN NN O
include NN NN O
enhanced NN NN O
anxiety NN NN B-Disease
( NN NN O
elevated NN NN O
plus NN NN O
maze NN NN O
and NN NN O
marble NN NN O
burying NN NN O
) NN NN O
, NN NN O
behavioral NN NN B-Disease
inflexibility NN NN I-Disease
( NN NN O
perseveration NN NN O
in NN NN O
the NN NN O
spontaneous NN NN O
alternation NN NN O
task NN NN O
and NN NN O
impaired NN NN O
reversal NN NN O
learning NN NN O
) NN NN O
, NN NN O
working NN NN O
memory NN NN B-Disease
impairment NN NN I-Disease
( NN NN O
e NN NN O
. NN NN O
g NN NN O
. NN NN O
, NN NN O
win NN NN O
- NN NN O
shift NN NN O
paradigm NN NN O
) NN NN O
, NN NN O
hoarding NN NN B-Disease
, NN NN O
and NN NN O
corticostriatal NN NN B-Disease
dysfunction NN NN I-Disease
. NN NN O
   
Dopamine NN NN O
D2 NN NN O
receptors NN NN O
were NN NN O
elevated NN NN O
in NN NN O
the NN NN O
striatum NN NN O
, NN NN O
whereas NN NN O
serotonin NN NN O
2C NN NN O
, NN NN O
but NN NN O
not NN NN O
serotonin NN NN O
1A NN NN O
, NN NN O
receptors NN NN O
were NN NN O
elevated NN NN O
in NN NN O
the NN NN O
orbital NN NN O
frontal NN NN O
cortex NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
This NN NN O
is NN NN O
the NN NN O
first NN NN O
demonstration NN NN O
of NN NN O
multiple NN NN O
symptoms NN NN O
consistent NN NN O
with NN NN O
an NN NN O
OCD NN NN B-Disease
- NN NN O
like NN NN O
profile NN NN O
in NN NN O
animals NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
these NN NN O
behaviors NN NN O
are NN NN O
accompanied NN NN O
by NN NN O
biochemical NN NN O
changes NN NN O
in NN NN O
brain NN NN O
regions NN NN O
previously NN NN O
identified NN NN O
as NN NN O
relevant NN NN O
to NN NN O
OCD NN NN B-Disease
. NN NN O
   
This NN NN O
novel NN NN O
model NN NN O
of NN NN O
OCD NN NN B-Disease
demonstrates NN NN O
that NN NN O
drug NN NN O
exposure NN NN O
during NN NN O
a NN NN O
sensitive NN NN O
period NN NN O
can NN NN O
program NN NN O
disease NN NN O
- NN NN O
like NN NN O
systems NN NN O
permanently NN NN O
, NN NN O
which NN NN O
could NN NN O
have NN NN O
implications NN NN O
for NN NN O
current NN NN O
and NN NN O
future NN NN O
therapeutic NN NN O
strategies NN NN O
for NN NN O
this NN NN O
and NN NN O
other NN NN O
psychiatric NN NN B-Disease
disorders NN NN I-Disease
. NN NN O
   
Elevation NN NN O
of NN NN O
ADAM10 NN NN O
, NN NN O
ADAM17 NN NN O
, NN NN O
MMP NN NN O
- NN NN O
2 NN NN O
and NN NN O
MMP NN NN O
- NN NN O
9 NN NN O
expression NN NN O
with NN NN O
media NN NN O
degeneration NN NN O
features NN NN O
CaCl2 NN NN O
- NN NN O
induced NN NN O
thoracic NN NN B-Disease
aortic NN NN I-Disease
aneurysm NN NN I-Disease
in NN NN O
a NN NN O
rat NN NN O
model NN NN O
. NN NN O
   
PURPOSE NN NN O
: NN NN O
This NN NN O
study NN NN O
was NN NN O
designed NN NN O
to NN NN O
establish NN NN O
a NN NN O
rat NN NN O
model NN NN O
of NN NN O
thoracic NN NN B-Disease
aortic NN NN I-Disease
aneurysm NN NN I-Disease
( NN NN O
TAA NN NN B-Disease
) NN NN O
by NN NN O
calcium NN NN O
chloride NN NN O
( NN NN O
CaCl NN NN O
( NN NN O
2 NN NN O
) NN NN O
) NN NN O
- NN NN O
induced NN NN O
arterial NN NN B-Disease
injury NN NN I-Disease
and NN NN O
to NN NN O
explore NN NN O
the NN NN O
potential NN NN O
role NN NN O
of NN NN O
a NN NN O
disintegrin NN NN O
and NN NN O
metalloproteinase NN NN O
( NN NN O
ADAM NN NN O
) NN NN O
, NN NN O
matrix NN NN O
metalloproteinases NN NN O
( NN NN O
MMPs NN NN O
) NN NN O
and NN NN O
their NN NN O
endogenous NN NN O
inhibitors NN NN O
( NN NN O
TIMPs NN NN O
) NN NN O
in NN NN O
TAA NN NN B-Disease
formation NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Thoracic NN NN O
aorta NN NN O
of NN NN O
male NN NN O
Sprague NN NN O
- NN NN O
Dawley NN NN O
rats NN NN O
was NN NN O
exposed NN NN O
to NN NN O
0 NN NN O
. NN NN O
5M NN NN O
CaCl NN NN O
( NN NN O
2 NN NN O
) NN NN O
or NN NN O
normal NN NN O
saline NN NN O
( NN NN O
NaCl NN NN O
) NN NN O
. NN NN O
   
After NN NN O
12weeks NN NN O
, NN NN O
animals NN NN O
were NN NN O
euthanized NN NN O
, NN NN O
and NN NN O
CaCl NN NN O
( NN NN O
2 NN NN O
) NN NN O
- NN NN O
treated NN NN O
, NN NN O
CaCl NN NN O
( NN NN O
2 NN NN O
) NN NN O
- NN NN O
untreated NN NN O
( NN NN O
n NN NN O
= NN NN O
12 NN NN O
) NN NN O
and NN NN O
NaCl NN NN O
- NN NN O
treated NN NN O
aortic NN NN O
segments NN NN O
( NN NN O
n NN NN O
= NN NN O
12 NN NN O
) NN NN O
were NN NN O
collected NN NN O
for NN NN O
histological NN NN O
and NN NN O
molecular NN NN O
assessments NN NN O
. NN NN O
   
MMP NN NN O
- NN NN O
TIMP NN NN O
and NN NN O
ADAM NN NN O
mRNAs NN NN O
were NN NN O
semi NN NN O
- NN NN O
quantitatively NN NN O
analyzed NN NN O
and NN NN O
protein NN NN O
expressions NN NN O
were NN NN O
determined NN NN O
by NN NN O
immunohistochemistry NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Despite NN NN O
similar NN NN O
external NN NN O
diameters NN NN O
among NN NN O
CaCl NN NN O
( NN NN O
2 NN NN O
) NN NN O
- NN NN O
treated NN NN O
, NN NN O
non NN NN O
- NN NN O
CaCl NN NN O
( NN NN O
2 NN NN O
) NN NN O
- NN NN O
treated NN NN O
and NN NN O
NaCl NN NN O
- NN NN O
treated NN NN O
segments NN NN O
, NN NN O
aneurymal NN NN O
alteration NN NN O
( NN NN O
n NN NN O
= NN NN O
6 NN NN O
, NN NN O
50 NN NN O
% NN NN O
) NN NN O
, NN NN O
media NN NN O
degeneration NN NN O
with NN NN O
regional NN NN O
disruption NN NN O
, NN NN O
fragmentation NN NN O
of NN NN O
elastic NN NN O
fiber NN NN O
, NN NN O
and NN NN O
increased NN NN O
collagen NN NN O
deposition NN NN O
( NN NN O
n NN NN O
= NN NN O
12 NN NN O
, NN NN O
100 NN NN O
% NN NN O
) NN NN O
were NN NN O
demonstrated NN NN O
in NN NN O
CaCl NN NN O
( NN NN O
2 NN NN O
) NN NN O
- NN NN O
treated NN NN O
segments NN NN O
. NN NN O
   
MMP NN NN O
- NN NN O
2 NN NN O
, NN NN O
MMP NN NN O
- NN NN O
9 NN NN O
, NN NN O
ADAM NN NN O
- NN NN O
10 NN NN O
and NN NN O
ADAM NN NN O
- NN NN O
17 NN NN O
mRNA NN NN O
levels NN NN O
were NN NN O
increased NN NN O
in NN NN O
CaCl NN NN O
( NN NN O
2 NN NN O
) NN NN O
- NN NN O
treated NN NN O
segments NN NN O
( NN NN O
all NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
, NN NN O
with NN NN O
trends NN NN O
of NN NN O
elevation NN NN O
in NN NN O
CaCl NN NN O
( NN NN O
2 NN NN O
) NN NN O
- NN NN O
untreated NN NN O
segments NN NN O
, NN NN O
as NN NN O
compared NN NN O
with NN NN O
NaCl NN NN O
- NN NN O
treated NN NN O
segments NN NN O
. NN NN O
   
Immunohistochemistry NN NN O
displayed NN NN O
significantly NN NN O
increased NN NN O
expressions NN NN O
of NN NN O
MMP NN NN O
- NN NN O
2 NN NN O
, NN NN O
MMP NN NN O
- NN NN O
9 NN NN O
, NN NN O
ADAM NN NN O
- NN NN O
10 NN NN O
and NN NN O
ADAM NN NN O
- NN NN O
17 NN NN O
( NN NN O
all NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
in NN NN O
intima NN NN O
and NN NN O
media NN NN O
for NN NN O
CaCl NN NN O
( NN NN O
2 NN NN O
) NN NN O
- NN NN O
treated NN NN O
segments NN NN O
. NN NN O
   
TIMP NN NN O
mRNA NN NN O
and NN NN O
tissue NN NN O
levels NN NN O
did NN NN O
not NN NN O
differ NN NN O
obviously NN NN O
among NN NN O
the NN NN O
three NN NN O
aortic NN NN O
segments NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
This NN NN O
study NN NN O
establishes NN NN O
a NN NN O
TAA NN NN B-Disease
model NN NN O
by NN NN O
periarterial NN NN O
CaCl NN NN O
( NN NN O
2 NN NN O
) NN NN O
exposure NN NN O
in NN NN O
rats NN NN O
, NN NN O
and NN NN O
demonstrates NN NN O
a NN NN O
significant NN NN O
elevation NN NN O
of NN NN O
expression NN NN O
of NN NN O
MMP NN NN O
- NN NN O
2 NN NN O
, NN NN O
MMP NN NN O
- NN NN O
9 NN NN O
, NN NN O
ADAM10 NN NN O
and NN NN O
ADAM17 NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
vascular NN NN O
remodeling NN NN O
. NN NN O
   
Suxamethonium NN NN O
induced NN NN O
prolonged NN NN O
apnea NN NN B-Disease
in NN NN O
a NN NN O
patient NN NN O
receiving NN NN O
electroconvulsive NN NN O
therapy NN NN O
. NN NN O
   
Suxamethonium NN NN O
causes NN NN O
prolonged NN NN O
apnea NN NN B-Disease
in NN NN O
patients NN NN O
in NN NN O
whom NN NN O
pseudocholinesterase NN NN O
enzyme NN NN O
gets NN NN O
deactivated NN NN O
by NN NN O
organophosphorus NN NN O
( NN NN O
OP NN NN O
) NN NN O
poisons NN NN O
. NN NN O
   
Here NN NN O
, NN NN O
we NN NN O
present NN NN O
a NN NN O
similar NN NN O
incident NN NN O
in NN NN O
a NN NN O
severely NN NN O
depressed NN NN B-Disease
patient NN NN O
who NN NN O
received NN NN O
electroconvulsive NN NN O
therapy NN NN O
( NN NN O
ECT NN NN O
) NN NN O
. NN NN O
   
Prolonged NN NN O
apnea NN NN B-Disease
in NN NN O
our NN NN O
case NN NN O
ensued NN NN O
because NN NN O
the NN NN O
information NN NN O
about NN NN O
suicidal NN NN O
attempt NN NN O
by NN NN O
OP NN NN O
compound NN NN O
was NN NN O
concealed NN NN O
from NN NN O
the NN NN O
treating NN NN O
team NN NN O
. NN NN O
   
Curcumin NN NN O
ameliorates NN NN O
cognitive NN NN B-Disease
dysfunction NN NN I-Disease
and NN NN O
oxidative NN NN O
damage NN NN O
in NN NN O
phenobarbitone NN NN O
and NN NN O
carbamazepine NN NN O
administered NN NN O
rats NN NN O
. NN NN O
   
The NN NN O
antiepileptic NN NN O
drugs NN NN O
, NN NN O
phenobarbitone NN NN O
and NN NN O
carbamazepine NN NN O
are NN NN O
well NN NN O
known NN NN O
to NN NN O
cause NN NN O
cognitive NN NN B-Disease
impairment NN NN I-Disease
on NN NN O
chronic NN NN O
use NN NN O
. NN NN O
   
The NN NN O
increase NN NN O
in NN NN O
free NN NN O
radical NN NN O
generation NN NN O
has NN NN O
been NN NN O
implicated NN NN O
as NN NN O
one NN NN O
of NN NN O
the NN NN O
important NN NN O
mechanisms NN NN O
of NN NN O
cognitive NN NN B-Disease
impairment NN NN I-Disease
by NN NN O
antiepileptic NN NN O
drugs NN NN O
. NN NN O
   
Curcumin NN NN O
has NN NN O
shown NN NN O
antioxidant NN NN O
, NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
and NN NN O
neuro NN NN O
- NN NN O
protective NN NN O
properties NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
the NN NN O
present NN NN O
study NN NN O
was NN NN O
carried NN NN O
out NN NN O
to NN NN O
investigate NN NN O
the NN NN O
effect NN NN O
of NN NN O
chronic NN NN O
curcumin NN NN O
administration NN NN O
on NN NN O
phenobarbitone NN NN O
- NN NN O
and NN NN O
carbamazepine NN NN O
- NN NN O
induced NN NN O
cognitive NN NN B-Disease
impairment NN NN I-Disease
and NN NN O
oxidative NN NN O
stress NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
Pharmacokinetic NN NN O
interactions NN NN O
of NN NN O
curcumin NN NN O
with NN NN O
phenobarbitone NN NN O
and NN NN O
carbamazepine NN NN O
were NN NN O
also NN NN O
studied NN NN O
. NN NN O
   
Vehicle NN NN O
/ NN NN O
drugs NN NN O
were NN NN O
administered NN NN O
daily NN NN O
for NN NN O
21days NN NN O
to NN NN O
male NN NN O
Wistar NN NN O
rats NN NN O
. NN NN O
   
Passive NN NN O
avoidance NN NN O
paradigm NN NN O
and NN NN O
elevated NN NN O
plus NN NN O
maze NN NN O
test NN NN O
were NN NN O
used NN NN O
to NN NN O
assess NN NN O
cognitive NN NN O
function NN NN O
. NN NN O
   
At NN NN O
the NN NN O
end NN NN O
of NN NN O
study NN NN O
period NN NN O
, NN NN O
serum NN NN O
phenobarbitone NN NN O
and NN NN O
carbamazepine NN NN O
, NN NN O
whole NN NN O
brain NN NN O
malondialdehyde NN NN O
and NN NN O
reduced NN NN O
glutathione NN NN O
levels NN NN O
were NN NN O
estimated NN NN O
. NN NN O
   
The NN NN O
administration NN NN O
of NN NN O
phenobarbitone NN NN O
and NN NN O
carbamazepine NN NN O
for NN NN O
21days NN NN O
caused NN NN O
a NN NN O
significant NN NN O
impairment NN NN B-Disease
of NN NN I-Disease
learning NN NN I-Disease
and NN NN I-Disease
memory NN NN I-Disease
as NN NN O
well NN NN O
as NN NN O
an NN NN O
increased NN NN O
oxidative NN NN O
stress NN NN O
. NN NN O
   
Concomitant NN NN O
curcumin NN NN O
administration NN NN O
prevented NN NN O
the NN NN O
cognitive NN NN B-Disease
impairment NN NN I-Disease
and NN NN O
decreased NN NN O
the NN NN O
increased NN NN O
oxidative NN NN O
stress NN NN O
induced NN NN O
by NN NN O
these NN NN O
antiepileptic NN NN O
drugs NN NN O
. NN NN O
   
Curcumin NN NN O
co NN NN O
- NN NN O
administration NN NN O
did NN NN O
not NN NN O
cause NN NN O
any NN NN O
significant NN NN O
alteration NN NN O
in NN NN O
the NN NN O
serum NN NN O
concentrations NN NN O
of NN NN O
both NN NN O
phenobarbitone NN NN O
as NN NN O
well NN NN O
as NN NN O
carbamazepine NN NN O
. NN NN O
   
These NN NN O
results NN NN O
show NN NN O
that NN NN O
curcumin NN NN O
has NN NN O
beneficial NN NN O
effect NN NN O
in NN NN O
mitigating NN NN O
the NN NN O
deterioration NN NN B-Disease
of NN NN I-Disease
cognitive NN NN I-Disease
functions NN NN I-Disease
and NN NN O
oxidative NN NN O
damage NN NN O
in NN NN O
rats NN NN O
treated NN NN O
with NN NN O
phenobarbitone NN NN O
and NN NN O
carbamazepine NN NN O
without NN NN O
significantly NN NN O
altering NN NN O
their NN NN O
serum NN NN O
concentrations NN NN O
. NN NN O
   
The NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
curcumin NN NN O
can NN NN O
be NN NN O
considered NN NN O
as NN NN O
a NN NN O
potential NN NN O
safe NN NN O
and NN NN O
effective NN NN O
adjuvant NN NN O
to NN NN O
phenobarbitone NN NN O
and NN NN O
carbamazepine NN NN O
therapy NN NN O
in NN NN O
preventing NN NN O
cognitive NN NN B-Disease
impairment NN NN I-Disease
associated NN NN O
with NN NN O
these NN NN O
drugs NN NN O
. NN NN O
   
Can NN NN O
angiogenesis NN NN O
be NN NN O
a NN NN O
target NN NN O
of NN NN O
treatment NN NN O
for NN NN O
ribavirin NN NN O
associated NN NN O
hemolytic NN NN B-Disease
anemia NN NN I-Disease
? NN NN O
   
BACKGROUND NN NN O
/ NN NN O
AIMS NN NN O
: NN NN O
Recently NN NN O
ribavirin NN NN O
has NN NN O
been NN NN O
found NN NN O
to NN NN O
inhibit NN NN O
angiogenesis NN NN O
and NN NN O
a NN NN O
number NN NN O
of NN NN O
angiogenesis NN NN O
inhibitors NN NN O
such NN NN O
as NN NN O
sunitinib NN NN O
and NN NN O
sorafenib NN NN O
have NN NN O
been NN NN O
found NN NN O
to NN NN O
cause NN NN O
acute NN NN O
hemolysis NN NN B-Disease
. NN NN O
   
We NN NN O
aimed NN NN O
to NN NN O
investigate NN NN O
whether NN NN O
there NN NN O
is NN NN O
a NN NN O
relation NN NN O
between NN NN O
hemoglobin NN NN O
, NN NN O
haptoglobin NN NN O
and NN NN O
angiogenesis NN NN O
soluble NN NN O
markers NN NN O
which NN NN O
are NN NN O
modifiable NN NN O
and NN NN O
can NN NN O
help NN NN O
in NN NN O
developing NN NN O
strategies NN NN O
against NN NN O
anemia NN NN B-Disease
. NN NN O
   
METHODS NN NN O
: NN NN O
Fourteen NN NN O
patients NN NN O
chronically NN NN B-Disease
infected NN NN I-Disease
with NN NN I-Disease
hepatitis NN NN I-Disease
C NN NN I-Disease
virus NN NN I-Disease
were NN NN O
treated NN NN O
by NN NN O
pegylated NN NN O
interferon NN NN O
alpha NN NN O
2a NN NN O
and NN NN O
ribavirin NN NN O
. NN NN O
   
Serum NN NN O
hemoglobin NN NN O
, NN NN O
haptoglobin NN NN O
and NN NN O
angiogenesis NN NN O
markers NN NN O
of NN NN O
vascular NN NN O
endothelial NN NN O
growth NN NN O
factor NN NN O
and NN NN O
angiopoetin NN NN O
- NN NN O
2 NN NN O
were NN NN O
investigated NN NN O
before NN NN O
and NN NN O
after NN NN O
therapy NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
We NN NN O
observed NN NN O
a NN NN O
significant NN NN O
decrease NN NN O
in NN NN O
haptoglobin NN NN O
levels NN NN O
at NN NN O
the NN NN O
end NN NN O
of NN NN O
the NN NN O
treatment NN NN O
period NN NN O
. NN NN O
   
Hemoglobin NN NN O
levels NN NN O
also NN NN O
decreased NN NN O
but NN NN O
insignificantly NN NN O
by NN NN O
treatment NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
with NN NN O
the NN NN O
literature NN NN O
, NN NN O
serum NN NN O
levels NN NN O
of NN NN O
angiogenesis NN NN O
factors NN NN O
did NN NN O
not NN NN O
change NN NN O
significantly NN NN O
by NN NN O
pegylated NN NN O
interferon NN NN O
and NN NN O
ribavirin NN NN O
therapy NN NN O
. NN NN O
   
We NN NN O
found NN NN O
no NN NN O
correlation NN NN O
of NN NN O
angiogenesis NN NN O
soluble NN NN O
markers NN NN O
with NN NN O
either NN NN O
hemoglobin NN NN O
or NN NN O
haptoglobin NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
This NN NN O
is NN NN O
the NN NN O
first NN NN O
study NN NN O
in NN NN O
the NN NN O
literature NN NN O
investigating NN NN O
a NN NN O
link NN NN O
between NN NN O
angiogenesis NN NN O
soluble NN NN O
markers NN NN O
and NN NN O
ribavirin NN NN O
induced NN NN O
anemia NN NN B-Disease
in NN NN O
patients NN NN O
with NN NN O
hepatitis NN NN B-Disease
C NN NN I-Disease
and NN NN O
we NN NN O
could NN NN O
not NN NN O
find NN NN O
any NN NN O
relation NN NN O
. NN NN O
   
Future NN NN O
research NN NN O
with NN NN O
larger NN NN O
number NN NN O
of NN NN O
patients NN NN O
is NN NN O
needed NN NN O
to NN NN O
find NN NN O
out NN NN O
modifiable NN NN O
factors NN NN O
that NN NN O
will NN NN O
improve NN NN O
the NN NN O
safety NN NN O
of NN NN O
ribavirin NN NN O
therapy NN NN O
. NN NN O
   
Reduction NN NN O
in NN NN O
injection NN NN O
pain NN NN B-Disease
using NN NN O
buffered NN NN O
lidocaine NN NN O
as NN NN O
a NN NN O
local NN NN O
anesthetic NN NN O
before NN NN O
cardiac NN NN O
catheterization NN NN O
. NN NN O
   
Previous NN NN O
reports NN NN O
have NN NN O
suggested NN NN O
that NN NN O
pain NN NN B-Disease
associated NN NN O
with NN NN O
the NN NN O
injection NN NN O
of NN NN O
lidocaine NN NN O
is NN NN O
related NN NN O
to NN NN O
the NN NN O
acidic NN NN O
pH NN NN O
of NN NN O
the NN NN O
solution NN NN O
. NN NN O
   
To NN NN O
determine NN NN O
if NN NN O
the NN NN O
addition NN NN O
of NN NN O
a NN NN O
buffering NN NN O
solution NN NN O
to NN NN O
adjust NN NN O
the NN NN O
pH NN NN O
of NN NN O
lidocaine NN NN O
into NN NN O
the NN NN O
physiologic NN NN O
range NN NN O
would NN NN O
reduce NN NN O
pain NN NN B-Disease
during NN NN O
injection NN NN O
, NN NN O
we NN NN O
performed NN NN O
a NN NN O
blinded NN NN O
randomized NN NN O
study NN NN O
in NN NN O
patients NN NN O
undergoing NN NN O
cardiac NN NN O
catheterization NN NN O
. NN NN O
   
Twenty NN NN O
patients NN NN O
were NN NN O
asked NN NN O
to NN NN O
quantify NN NN O
the NN NN O
severity NN NN O
of NN NN O
pain NN NN B-Disease
after NN NN O
receiving NN NN O
standard NN NN O
lidocaine NN NN O
in NN NN O
one NN NN O
femoral NN NN O
area NN NN O
and NN NN O
buffered NN NN O
lidocaine NN NN O
in NN NN O
the NN NN O
opposite NN NN O
femoral NN NN O
area NN NN O
. NN NN O
   
The NN NN O
mean NN NN O
pain NN NN B-Disease
score NN NN O
for NN NN O
buffered NN NN O
lidocaine NN NN O
was NN NN O
significantly NN NN O
lower NN NN O
than NN NN O
the NN NN O
mean NN NN O
score NN NN O
for NN NN O
standard NN NN O
lidocaine NN NN O
( NN NN O
2 NN NN O
. NN NN O
7 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
9 NN NN O
vs NN NN O
. NN NN O
3 NN NN O
. NN NN O
8 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
. NN NN O
2 NN NN O
, NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
03 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
pH NN NN O
adjustment NN NN O
of NN NN O
standard NN NN O
lidocaine NN NN O
can NN NN O
be NN NN O
accomplished NN NN O
easily NN NN O
in NN NN O
the NN NN O
catheterization NN NN O
laboratory NN NN O
before NN NN O
injection NN NN O
and NN NN O
results NN NN O
in NN NN O
a NN NN O
reduction NN NN O
of NN NN O
the NN NN O
pain NN NN B-Disease
occurring NN NN O
during NN NN O
the NN NN O
infiltration NN NN O
of NN NN O
tissues NN NN O
. NN NN O
   
Effect NN NN O
of NN NN O
L NN NN O
- NN NN O
alpha NN NN O
- NN NN O
glyceryl NN NN O
- NN NN O
phosphorylcholine NN NN O
on NN NN O
amnesia NN NN B-Disease
caused NN NN O
by NN NN O
scopolamine NN NN O
. NN NN O
   
The NN NN O
present NN NN O
study NN NN O
was NN NN O
carried NN NN O
out NN NN O
to NN NN O
test NN NN O
the NN NN O
effects NN NN O
of NN NN O
L NN NN O
- NN NN O
alpha NN NN O
- NN NN O
glycerylphosphorylcholine NN NN O
( NN NN O
L NN NN O
- NN NN O
alpha NN NN O
- NN NN O
GFC NN NN O
) NN NN O
on NN NN O
memory NN NN B-Disease
impairment NN NN I-Disease
induced NN NN O
by NN NN O
scopolamine NN NN O
in NN NN O
man NN NN O
. NN NN O
   
Thirty NN NN O
- NN NN O
two NN NN O
healthy NN NN O
young NN NN O
volunteers NN NN O
were NN NN O
randomly NN NN O
allocated NN NN O
to NN NN O
four NN NN O
different NN NN O
groups NN NN O
. NN NN O
   
They NN NN O
were NN NN O
given NN NN O
a NN NN O
ten NN NN O
day NN NN O
pretreatment NN NN O
with NN NN O
either NN NN O
L NN NN O
- NN NN O
alpha NN NN O
- NN NN O
GFC NN NN O
or NN NN O
placebo NN NN O
, NN NN O
p NN NN O
. NN NN O
o NN NN O
. NN NN O
, NN NN O
and NN NN O
on NN NN O
the NN NN O
eleventh NN NN O
day NN NN O
either NN NN O
scopolamine NN NN O
or NN NN O
placebo NN NN O
, NN NN O
i NN NN O
. NN NN O
m NN NN O
. NN NN O
   
Before NN NN O
and NN NN O
0 NN NN O
. NN NN O
5 NN NN O
, NN NN O
1 NN NN O
, NN NN O
2 NN NN O
, NN NN O
3 NN NN O
, NN NN O
and NN NN O
6 NN NN O
h NN NN O
after NN NN O
injection NN NN O
the NN NN O
subjects NN NN O
were NN NN O
given NN NN O
attention NN NN O
and NN NN O
mnemonic NN NN O
tests NN NN O
. NN NN O
   
The NN NN O
findings NN NN O
of NN NN O
this NN NN O
study NN NN O
indicate NN NN O
that NN NN O
the NN NN O
drug NN NN O
is NN NN O
able NN NN O
to NN NN O
antagonize NN NN O
impairment NN NN B-Disease
of NN NN I-Disease
attention NN NN I-Disease
and NN NN I-Disease
memory NN NN I-Disease
induced NN NN O
by NN NN O
scopolamine NN NN O
. NN NN O
   
Safety NN NN O
of NN NN O
capecitabine NN NN O
: NN NN O
a NN NN O
review NN NN O
. NN NN O
   
IMPORTANCE NN NN O
OF NN NN O
THE NN NN O
FIELD NN NN O
: NN NN O
Fluoropyrimidines NN NN O
, NN NN O
in NN NN O
particular NN NN O
5 NN NN O
- NN NN O
fluorouracil NN NN O
( NN NN O
5 NN NN O
- NN NN O
FU NN NN O
) NN NN O
, NN NN O
have NN NN O
been NN NN O
the NN NN O
mainstay NN NN O
of NN NN O
treatment NN NN O
for NN NN O
several NN NN O
solid NN NN O
tumors NN NN B-Disease
, NN NN O
including NN NN O
colorectal NN NN B-Disease
, NN NN I-Disease
breast NN NN I-Disease
and NN NN I-Disease
head NN NN I-Disease
and NN NN I-Disease
neck NN NN I-Disease
cancers NN NN I-Disease
, NN NN O
for NN NN O
> NN NN O
40 NN NN O
years NN NN O
. NN NN O
   
AREAS NN NN O
COVERED NN NN O
IN NN NN O
THIS NN NN O
REVIEW NN NN O
: NN NN O
This NN NN O
article NN NN O
reviews NN NN O
the NN NN O
pharmacology NN NN O
and NN NN O
efficacy NN NN O
of NN NN O
capecitabine NN NN O
with NN NN O
a NN NN O
special NN NN O
emphasis NN NN O
on NN NN O
its NN NN O
safety NN NN O
. NN NN O
   
WHAT NN NN O
THE NN NN O
READER NN NN O
WILL NN NN O
GAIN NN NN O
: NN NN O
The NN NN O
reader NN NN O
will NN NN O
gain NN NN O
better NN NN O
insight NN NN O
into NN NN O
the NN NN O
safety NN NN O
of NN NN O
capecitabine NN NN O
in NN NN O
special NN NN O
populations NN NN O
such NN NN O
as NN NN O
patients NN NN O
with NN NN O
advanced NN NN O
age NN NN O
, NN NN O
renal NN NN B-Disease
and NN NN I-Disease
kidney NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
We NN NN O
also NN NN O
explore NN NN O
different NN NN O
dosing NN NN O
and NN NN O
schedules NN NN O
of NN NN O
capecitabine NN NN O
administration NN NN O
. NN NN O
   
TAKE NN NN O
HOME NN NN O
MESSAGE NN NN O
: NN NN O
Capecitabine NN NN O
is NN NN O
an NN NN O
oral NN NN O
prodrug NN NN O
of NN NN O
5 NN NN O
- NN NN O
FU NN NN O
and NN NN O
was NN NN O
developed NN NN O
to NN NN O
fulfill NN NN O
the NN NN O
need NN NN O
for NN NN O
a NN NN O
more NN NN O
convenient NN NN O
therapy NN NN O
and NN NN O
provide NN NN O
an NN NN O
improved NN NN O
safety NN NN O
/ NN NN O
efficacy NN NN O
profile NN NN O
. NN NN O
   
It NN NN O
has NN NN O
shown NN NN O
promising NN NN O
results NN NN O
alone NN NN O
or NN NN O
in NN NN O
combination NN NN O
with NN NN O
other NN NN O
chemotherapeutic NN NN O
agents NN NN O
in NN NN O
colorectal NN NN B-Disease
, NN NN I-Disease
breast NN NN I-Disease
, NN NN I-Disease
pancreaticobiliary NN NN I-Disease
, NN NN I-Disease
gastric NN NN I-Disease
, NN NN I-Disease
renal NN NN I-Disease
cell NN NN I-Disease
and NN NN I-Disease
head NN NN I-Disease
and NN NN I-Disease
neck NN NN I-Disease
cancers NN NN I-Disease
. NN NN O
   
The NN NN O
most NN NN O
commonly NN NN O
reported NN NN O
toxic NN NN O
effects NN NN O
of NN NN O
capecitabine NN NN O
are NN NN O
diarrhea NN NN B-Disease
, NN NN O
nausea NN NN B-Disease
, NN NN O
vomiting NN NN B-Disease
, NN NN O
stomatitis NN NN B-Disease
and NN NN O
hand NN NN B-Disease
- NN NN I-Disease
foot NN NN I-Disease
syndrome NN NN I-Disease
. NN NN O
   
Capecitabine NN NN O
has NN NN O
a NN NN O
well NN NN O
- NN NN O
established NN NN O
safety NN NN O
profile NN NN O
and NN NN O
can NN NN O
be NN NN O
given NN NN O
safely NN NN O
to NN NN O
patients NN NN O
with NN NN O
advanced NN NN O
age NN NN O
, NN NN O
hepatic NN NN B-Disease
and NN NN I-Disease
renal NN NN I-Disease
dysfunctions NN NN I-Disease
. NN NN O
   
Levodopa NN NN O
- NN NN O
induced NN NN O
dyskinesias NN NN B-Disease
in NN NN O
patients NN NN O
with NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
: NN NN O
filling NN NN O
the NN NN O
bench NN NN O
- NN NN O
to NN NN O
- NN NN O
bedside NN NN O
gap NN NN O
. NN NN O
   
Levodopa NN NN O
is NN NN O
the NN NN O
most NN NN O
effective NN NN O
drug NN NN O
for NN NN O
the NN NN O
treatment NN NN O
of NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
long NN NN O
- NN NN O
term NN NN O
use NN NN O
of NN NN O
this NN NN O
dopamine NN NN O
precursor NN NN O
is NN NN O
complicated NN NN O
by NN NN O
highly NN NN O
disabling NN NN O
fluctuations NN NN O
and NN NN O
dyskinesias NN NN B-Disease
. NN NN O
   
Although NN NN O
preclinical NN NN O
and NN NN O
clinical NN NN O
findings NN NN O
suggest NN NN O
pulsatile NN NN O
stimulation NN NN O
of NN NN O
striatal NN NN O
postsynaptic NN NN O
receptors NN NN O
as NN NN O
a NN NN O
key NN NN O
mechanism NN NN O
underlying NN NN O
levodopa NN NN O
- NN NN O
induced NN NN O
dyskinesias NN NN B-Disease
, NN NN O
their NN NN O
pathogenesis NN NN O
is NN NN O
still NN NN O
unclear NN NN O
. NN NN O
   
In NN NN O
recent NN NN O
years NN NN O
, NN NN O
evidence NN NN O
from NN NN O
animal NN NN O
models NN NN O
of NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
has NN NN O
provided NN NN O
important NN NN O
information NN NN O
to NN NN O
understand NN NN O
the NN NN O
effect NN NN O
of NN NN O
specific NN NN O
receptor NN NN O
and NN NN O
post NN NN O
- NN NN O
receptor NN NN O
molecular NN NN O
mechanisms NN NN O
underlying NN NN O
the NN NN O
development NN NN O
of NN NN O
dyskinetic NN NN B-Disease
movements NN NN I-Disease
. NN NN O
   
Recent NN NN O
preclinical NN NN O
and NN NN O
clinical NN NN O
data NN NN O
from NN NN O
promising NN NN O
lines NN NN O
of NN NN O
research NN NN O
focus NN NN O
on NN NN O
the NN NN O
differential NN NN O
role NN NN O
of NN NN O
presynaptic NN NN O
versus NN NN O
postsynaptic NN NN O
mechanisms NN NN O
, NN NN O
dopamine NN NN O
receptor NN NN O
subtypes NN NN O
, NN NN O
ionotropic NN NN O
and NN NN O
metabotropic NN NN O
glutamate NN NN O
receptors NN NN O
, NN NN O
and NN NN O
non NN NN O
- NN NN O
dopaminergic NN NN O
neurotransmitter NN NN O
systems NN NN O
in NN NN O
the NN NN O
pathophysiology NN NN O
of NN NN O
levodopa NN NN O
- NN NN O
induced NN NN O
dyskinesias NN NN B-Disease
. NN NN O
   
Effects NN NN O
of NN NN O
pallidal NN NN O
neurotensin NN NN O
on NN NN O
haloperidol NN NN O
- NN NN O
induced NN NN O
parkinsonian NN NN B-Disease
catalepsy NN NN I-Disease
: NN NN O
behavioral NN NN O
and NN NN O
electrophysiological NN NN O
studies NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
The NN NN O
globus NN NN O
pallidus NN NN O
plays NN NN O
a NN NN O
critical NN NN O
role NN NN O
in NN NN O
movement NN NN O
regulation NN NN O
. NN NN O
   
Previous NN NN O
studies NN NN O
have NN NN O
indicated NN NN O
that NN NN O
the NN NN O
globus NN NN O
pallidus NN NN O
receives NN NN O
neurotensinergic NN NN O
innervation NN NN O
from NN NN O
the NN NN O
striatum NN NN O
, NN NN O
and NN NN O
systemic NN NN O
administration NN NN O
of NN NN O
a NN NN O
neurotensin NN NN O
analog NN NN O
could NN NN O
produce NN NN O
antiparkinsonian NN NN O
effects NN NN O
. NN NN O
   
The NN NN O
present NN NN O
study NN NN O
aimed NN NN O
to NN NN O
investigate NN NN O
the NN NN O
effects NN NN O
of NN NN O
pallidal NN NN O
neurotensin NN NN O
on NN NN O
haloperidol NN NN O
- NN NN O
induced NN NN O
parkinsonian NN NN B-Disease
symptoms NN NN I-Disease
. NN NN O
   
METHODS NN NN O
: NN NN O
Behavioral NN NN O
experiments NN NN O
and NN NN O
electrophysiological NN NN O
recordings NN NN O
were NN NN O
performed NN NN O
in NN NN O
the NN NN O
present NN NN O
study NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Bilateral NN NN O
infusions NN NN O
of NN NN O
neurotensin NN NN O
into NN NN O
the NN NN O
globus NN NN O
pallidus NN NN O
reversed NN NN O
haloperidol NN NN O
- NN NN O
induced NN NN O
parkinsonian NN NN B-Disease
catalepsy NN NN I-Disease
in NN NN O
rats NN NN O
. NN NN O
   
Electrophysiological NN NN O
recordings NN NN O
showed NN NN O
that NN NN O
microinjection NN NN O
of NN NN O
neurotensin NN NN O
induced NN NN O
excitation NN NN O
of NN NN O
pallidal NN NN O
neurons NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
systemic NN NN O
haloperidol NN NN O
administration NN NN O
. NN NN O
   
The NN NN O
neurotensin NN NN O
type NN NN O
- NN NN O
1 NN NN O
receptor NN NN O
antagonist NN NN O
SR48692 NN NN O
blocked NN NN O
both NN NN O
the NN NN O
behavioral NN NN O
and NN NN O
the NN NN O
electrophysiological NN NN O
effects NN NN O
induced NN NN O
by NN NN O
neurotensin NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Activation NN NN O
of NN NN O
pallidal NN NN O
neurotensin NN NN O
receptors NN NN O
may NN NN O
be NN NN O
involved NN NN O
in NN NN O
neurotensin NN NN O
- NN NN O
induced NN NN O
antiparkinsonian NN NN O
effects NN NN O
. NN NN O
   
Carmofur NN NN O
- NN NN O
induced NN NN O
organic NN NN B-Disease
mental NN NN I-Disease
disorders NN NN I-Disease
. NN NN O
   
Organic NN NN B-Disease
mental NN NN I-Disease
disorder NN NN I-Disease
was NN NN O
observed NN NN O
in NN NN O
a NN NN O
29 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
female NN NN O
in NN NN O
the NN NN O
prognostic NN NN O
period NN NN O
after NN NN O
the NN NN O
onset NN NN O
of NN NN O
carmofur NN NN O
- NN NN O
induced NN NN O
leukoencephalopathy NN NN B-Disease
. NN NN O
   
Symptoms NN NN O
such NN NN O
as NN NN O
euphoria NN NN O
, NN NN O
emotional NN NN O
lability NN NN O
and NN NN O
puerile NN NN O
attitude NN NN O
noted NN NN O
in NN NN O
the NN NN O
patient NN NN O
were NN NN O
diagnosed NN NN O
as NN NN O
organic NN NN B-Disease
personality NN NN I-Disease
syndrome NN NN I-Disease
according NN NN O
to NN NN O
the NN NN O
criteria NN NN O
defined NN NN O
in NN NN O
the NN NN O
DSM NN NN O
- NN NN O
III NN NN O
- NN NN O
R NN NN O
. NN NN O
   
It NN NN O
is NN NN O
referred NN NN O
to NN NN O
as NN NN O
a NN NN O
frontal NN NN B-Disease
lobe NN NN I-Disease
syndrome NN NN I-Disease
. NN NN O
   
Brain NN NN O
CT NN NN O
revealed NN NN O
a NN NN O
periventricular NN NN O
low NN NN O
density NN NN O
area NN NN O
in NN NN O
the NN NN O
frontal NN NN O
white NN NN O
matter NN NN O
and NN NN O
moderate NN NN O
dilatation NN NN O
of NN NN O
the NN NN O
lateral NN NN O
ventricles NN NN O
especially NN NN O
at NN NN O
the NN NN O
bilateral NN NN O
anterior NN NN O
horns NN NN O
. NN NN O
   
Consequently NN NN O
, NN NN O
carmofur NN NN O
- NN NN O
induced NN NN O
leukoencephalopathy NN NN B-Disease
may NN NN O
uncommonly NN NN O
result NN NN O
in NN NN O
organic NN NN B-Disease
personality NN NN I-Disease
syndrome NN NN I-Disease
in NN NN O
the NN NN O
residual NN NN O
state NN NN O
. NN NN O
   
It NN NN O
may NN NN O
be NN NN O
attributed NN NN O
to NN NN O
the NN NN O
structural NN NN B-Disease
damage NN NN I-Disease
to NN NN I-Disease
the NN NN I-Disease
frontal NN NN I-Disease
lobe NN NN I-Disease
. NN NN O
   
Butyrylcholinesterase NN NN O
gene NN NN O
mutations NN NN O
in NN NN O
patients NN NN O
with NN NN O
prolonged NN NN O
apnea NN NN B-Disease
after NN NN O
succinylcholine NN NN O
for NN NN O
electroconvulsive NN NN O
therapy NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
patients NN NN O
undergoing NN NN O
electroconvulsive NN NN O
therapy NN NN O
( NN NN O
ECT NN NN O
) NN NN O
often NN NN O
receive NN NN O
succinylcholine NN NN O
as NN NN O
part NN NN O
of NN NN O
the NN NN O
anesthetic NN NN O
procedure NN NN O
. NN NN O
   
The NN NN O
duration NN NN O
of NN NN O
action NN NN O
may NN NN O
be NN NN O
prolonged NN NN O
in NN NN O
patients NN NN O
with NN NN O
genetic NN NN O
variants NN NN O
of NN NN O
the NN NN O
butyrylcholinesterase NN NN O
enzyme NN NN O
( NN NN O
BChE NN NN O
) NN NN O
, NN NN O
the NN NN O
most NN NN O
common NN NN O
being NN NN O
the NN NN O
K NN NN O
- NN NN O
and NN NN O
the NN NN O
A NN NN O
- NN NN O
variants NN NN O
. NN NN O
   
The NN NN O
aim NN NN O
of NN NN O
the NN NN O
study NN NN O
was NN NN O
to NN NN O
assess NN NN O
the NN NN O
clinical NN NN O
significance NN NN O
of NN NN O
genetic NN NN O
variants NN NN O
in NN NN O
butyrylcholinesterase NN NN O
gene NN NN O
( NN NN O
BCHE NN NN O
) NN NN O
in NN NN O
patients NN NN O
with NN NN O
a NN NN O
suspected NN NN O
prolonged NN NN O
duration NN NN O
of NN NN O
action NN NN O
of NN NN O
succinylcholine NN NN O
after NN NN O
ECT NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
a NN NN O
total NN NN O
of NN NN O
13 NN NN O
patients NN NN O
were NN NN O
referred NN NN O
to NN NN O
the NN NN O
Danish NN NN O
Cholinesterase NN NN O
Research NN NN O
Unit NN NN O
after NN NN O
ECT NN NN O
during NN NN O
38 NN NN O
months NN NN O
. NN NN O
   
We NN NN O
determined NN NN O
the NN NN O
BChE NN NN O
activity NN NN O
and NN NN O
the NN NN O
BCHE NN NN O
genotype NN NN O
using NN NN O
molecular NN NN O
genetic NN NN O
methods NN NN O
, NN NN O
the NN NN O
duration NN NN O
of NN NN O
apnea NN NN B-Disease
, NN NN O
time NN NN O
to NN NN O
sufficient NN NN O
spontaneous NN NN O
ventilation NN NN O
and NN NN O
whether NN NN O
neuromuscular NN NN O
monitoring NN NN O
was NN NN O
used NN NN O
. NN NN O
   
The NN NN O
duration NN NN O
of NN NN O
apnea NN NN B-Disease
was NN NN O
compared NN NN O
with NN NN O
published NN NN O
data NN NN O
on NN NN O
normal NN NN O
subjects NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
in NN NN O
11 NN NN O
patients NN NN O
, NN NN O
mutations NN NN O
were NN NN O
found NN NN O
in NN NN O
the NN NN O
BCHE NN NN O
gene NN NN O
, NN NN O
the NN NN O
K NN NN O
- NN NN O
variant NN NN O
being NN NN O
the NN NN O
most NN NN O
frequent NN NN O
. NN NN O
   
The NN NN O
duration NN NN O
of NN NN O
apnea NN NN B-Disease
was NN NN O
5 NN NN O
- NN NN O
15 NN NN O
min NN NN O
compared NN NN O
with NN NN O
3 NN NN O
- NN NN O
5 NN NN O
. NN NN O
3 NN NN O
min NN NN O
from NN NN O
the NN NN O
literature NN NN O
. NN NN O
   
Severe NN NN O
distress NN NN O
was NN NN O
noted NN NN O
in NN NN O
the NN NN O
recovery NN NN O
phase NN NN O
in NN NN O
two NN NN O
patients NN NN O
. NN NN O
   
Neuromuscular NN NN O
monitoring NN NN O
was NN NN O
used NN NN O
in NN NN O
two NN NN O
patients NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
eleven NN NN O
of NN NN O
13 NN NN O
patients NN NN O
with NN NN O
a NN NN O
prolonged NN NN O
duration NN NN O
of NN NN O
action NN NN O
of NN NN O
succinylcholine NN NN O
had NN NN O
mutations NN NN O
in NN NN O
BCHE NN NN O
, NN NN O
indicating NN NN O
that NN NN O
this NN NN O
is NN NN O
the NN NN O
possible NN NN O
reason NN NN O
for NN NN O
a NN NN O
prolonged NN NN O
period NN NN O
of NN NN O
apnea NN NN B-Disease
. NN NN O
   
We NN NN O
recommend NN NN O
objective NN NN O
neuromuscular NN NN O
monitoring NN NN O
during NN NN O
the NN NN O
first NN NN O
ECT NN NN O
. NN NN O
   
Perhexiline NN NN O
maleate NN NN O
and NN NN O
peripheral NN NN B-Disease
neuropathy NN NN I-Disease
. NN NN O
   
Peripheral NN NN B-Disease
neuropathy NN NN I-Disease
has NN NN O
been NN NN O
noted NN NN O
as NN NN O
a NN NN O
complication NN NN O
of NN NN O
therapy NN NN O
with NN NN O
perhexiline NN NN O
maleate NN NN O
, NN NN O
a NN NN O
drug NN NN O
widely NN NN O
used NN NN O
in NN NN O
France NN NN O
( NN NN O
and NN NN O
in NN NN O
clinical NN NN O
trials NN NN O
in NN NN O
the NN NN O
United NN NN O
States NN NN O
) NN NN O
for NN NN O
the NN NN O
prophylactic NN NN O
treatment NN NN O
of NN NN O
angina NN NN B-Disease
pectoris NN NN I-Disease
. NN NN O
   
In NN NN O
24 NN NN O
patients NN NN O
with NN NN O
this NN NN O
complication NN NN O
, NN NN O
the NN NN O
marked NN NN O
slowing NN NN O
of NN NN O
motor NN NN O
nerve NN NN O
conduction NN NN O
velocity NN NN O
and NN NN O
the NN NN O
electromyographic NN NN O
changes NN NN O
imply NN NN O
mainly NN NN O
a NN NN O
demyelinating NN NN B-Disease
disorder NN NN I-Disease
. NN NN O
   
Improvement NN NN O
was NN NN O
noted NN NN O
with NN NN O
cessation NN NN O
of NN NN O
therapy NN NN O
. NN NN O
   
In NN NN O
a NN NN O
few NN NN O
cases NN NN O
the NN NN O
presence NN NN O
of NN NN O
active NN NN O
denervation NN NN O
signified NN NN O
a NN NN O
poor NN NN O
prognosis NN NN O
, NN NN O
with NN NN O
only NN NN O
slight NN NN O
improvement NN NN O
. NN NN O
   
The NN NN O
underlying NN NN O
mechanism NN NN O
causing NN NN O
the NN NN O
neuropathy NN NN B-Disease
is NN NN O
not NN NN O
yet NN NN O
fully NN NN O
known NN NN O
, NN NN O
although NN NN O
some NN NN O
evidence NN NN O
indicates NN NN O
that NN NN O
it NN NN O
may NN NN O
be NN NN O
a NN NN O
lipid NN NN O
storage NN NN O
process NN NN O
. NN NN O
   
A NN NN O
phase NN NN O
I NN NN O
study NN NN O
of NN NN O
4 NN NN O
' NN NN O
- NN NN O
0 NN NN O
- NN NN O
tetrahydropyranyladriamycin NN NN O
. NN NN O
   
Clinical NN NN O
pharmacology NN NN O
and NN NN O
pharmacokinetics NN NN O
. NN NN O
   
A NN NN O
Phase NN NN O
I NN NN O
study NN NN O
of NN NN O
intravenous NN NN O
( NN NN O
IV NN NN O
) NN NN O
bolus NN NN O
4 NN NN O
' NN NN O
- NN NN O
0 NN NN O
- NN NN O
tetrahydropyranyladriamycin NN NN O
( NN NN O
Pirarubicin NN NN O
) NN NN O
was NN NN O
done NN NN O
in NN NN O
55 NN NN O
patients NN NN O
in NN NN O
good NN NN O
performance NN NN O
status NN NN O
with NN NN O
refractory NN NN O
tumors NN NN B-Disease
. NN NN O
   
Twenty NN NN O
- NN NN O
six NN NN O
had NN NN O
minimal NN NN O
prior NN NN O
therapy NN NN O
( NN NN O
good NN NN O
risk NN NN O
) NN NN O
, NN NN O
23 NN NN O
had NN NN O
extensive NN NN O
prior NN NN O
therapy NN NN O
( NN NN O
poor NN NN O
risk NN NN O
) NN NN O
, NN NN O
and NN NN O
six NN NN O
had NN NN O
renal NN NN B-Disease
and NN NN I-Disease
/ NN NN I-Disease
or NN NN I-Disease
hepatic NN NN I-Disease
dysfunction NN NN I-Disease
. NN NN O
   
A NN NN O
total NN NN O
of NN NN O
167 NN NN O
courses NN NN O
at NN NN O
doses NN NN O
of NN NN O
15 NN NN O
to NN NN O
70 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
were NN NN O
evaluable NN NN O
. NN NN O
   
Maximum NN NN O
tolerated NN NN O
dose NN NN O
in NN NN O
good NN NN O
- NN NN O
risk NN NN O
patients NN NN O
was NN NN O
70 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
, NN NN O
and NN NN O
in NN NN O
poor NN NN O
- NN NN O
risk NN NN O
patients NN NN O
, NN NN O
60 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
. NN NN O
   
The NN NN O
dose NN NN O
- NN NN O
limiting NN NN O
toxic NN NN O
effect NN NN O
was NN NN O
transient NN NN O
noncumulative NN NN O
granulocytopenia NN NN B-Disease
. NN NN O
   
Granulocyte NN NN O
nadir NN NN O
was NN NN O
on NN NN O
day NN NN O
14 NN NN O
( NN NN O
range NN NN O
, NN NN O
4 NN NN O
- NN NN O
22 NN NN O
) NN NN O
. NN NN O
   
Less NN NN O
frequent NN NN O
toxic NN NN O
effects NN NN O
included NN NN O
thrombocytopenia NN NN B-Disease
, NN NN O
anemia NN NN B-Disease
, NN NN O
nausea NN NN B-Disease
, NN NN O
mild NN NN O
alopecia NN NN B-Disease
, NN NN O
phlebitis NN NN B-Disease
, NN NN O
and NN NN O
mucositis NN NN B-Disease
. NN NN O
   
Myelosuppression NN NN B-Disease
was NN NN O
more NN NN O
in NN NN O
patients NN NN O
with NN NN O
hepatic NN NN B-Disease
dysfunction NN NN I-Disease
. NN NN O
   
Pharmacokinetic NN NN O
analyses NN NN O
in NN NN O
21 NN NN O
patients NN NN O
revealed NN NN O
Pirarubicin NN NN O
plasma NN NN O
T NN NN O
1 NN NN O
/ NN NN O
2 NN NN O
alpha NN NN O
( NN NN O
+ NN NN O
/ NN NN O
- NN NN O
SE NN NN O
) NN NN O
of NN NN O
2 NN NN O
. NN NN O
5 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
85 NN NN O
minutes NN NN O
, NN NN O
T NN NN O
beta NN NN O
1 NN NN O
/ NN NN O
2 NN NN O
of NN NN O
25 NN NN O
. NN NN O
6 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
6 NN NN O
. NN NN O
5 NN NN O
minutes NN NN O
, NN NN O
and NN NN O
T NN NN O
1 NN NN O
/ NN NN O
2 NN NN O
gamma NN NN O
of NN NN O
23 NN NN O
. NN NN O
6 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
7 NN NN O
. NN NN O
6 NN NN O
hours NN NN O
. NN NN O
   
The NN NN O
area NN NN O
under NN NN O
the NN NN O
curve NN NN O
was NN NN O
537 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
149 NN NN O
ng NN NN O
/ NN NN O
ml NN NN O
x NN NN O
hours NN NN O
, NN NN O
volume NN NN O
of NN NN O
distribution NN NN O
( NN NN O
Vd NN NN O
) NN NN O
3504 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
644 NN NN O
l NN NN O
/ NN NN O
m2 NN NN O
, NN NN O
and NN NN O
total NN NN O
clearance NN NN O
( NN NN O
ClT NN NN O
) NN NN O
was NN NN O
204 NN NN O
+ NN NN O
39 NN NN O
. NN NN O
3 NN NN O
l NN NN O
/ NN NN O
hour NN NN O
/ NN NN O
m2 NN NN O
. NN NN O
   
Adriamycinol NN NN O
, NN NN O
doxorubicin NN NN O
, NN NN O
adriamycinone NN NN O
, NN NN O
and NN NN O
tetrahydropyranyladriamycinol NN NN O
were NN NN O
the NN NN O
metabolites NN NN O
detected NN NN O
in NN NN O
plasma NN NN O
and NN NN O
the NN NN O
amount NN NN O
of NN NN O
doxorubicin NN NN O
was NN NN O
less NN NN O
than NN NN O
or NN NN O
equal NN NN O
to NN NN O
10 NN NN O
% NN NN O
of NN NN O
the NN NN O
total NN NN O
metabolites NN NN O
. NN NN O
   
Urinary NN NN O
excretion NN NN O
of NN NN O
Pirarubicin NN NN O
in NN NN O
the NN NN O
first NN NN O
24 NN NN O
hours NN NN O
was NN NN O
less NN NN O
than NN NN O
or NN NN O
equal NN NN O
to NN NN O
10 NN NN O
% NN NN O
. NN NN O
   
Activity NN NN O
was NN NN O
noted NN NN O
in NN NN O
mesothelioma NN NN B-Disease
, NN NN O
leiomyosarcoma NN NN B-Disease
, NN NN O
and NN NN O
basal NN NN B-Disease
cell NN NN I-Disease
carcinoma NN NN I-Disease
. NN NN O
   
The NN NN O
recommended NN NN O
starting NN NN O
dose NN NN O
for NN NN O
Phase NN NN O
II NN NN O
trials NN NN O
is NN NN O
60 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
IV NN NN O
bolus NN NN O
every NN NN O
3 NN NN O
weeks NN NN O
. NN NN O
   
Ocular NN NN B-Disease
and NN NN I-Disease
auditory NN NN I-Disease
toxicity NN NN I-Disease
in NN NN O
hemodialyzed NN NN O
patients NN NN O
receiving NN NN O
desferrioxamine NN NN O
. NN NN O
   
During NN NN O
an NN NN O
18 NN NN O
- NN NN O
month NN NN O
period NN NN O
of NN NN O
study NN NN O
41 NN NN O
hemodialyzed NN NN O
patients NN NN O
receiving NN NN O
desferrioxamine NN NN O
( NN NN O
10 NN NN O
- NN NN O
40 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
BW NN NN O
/ NN NN O
3 NN NN O
times NN NN O
weekly NN NN O
) NN NN O
for NN NN O
the NN NN O
first NN NN O
time NN NN O
were NN NN O
monitored NN NN O
for NN NN O
detection NN NN O
of NN NN O
audiovisual NN NN B-Disease
toxicity NN NN I-Disease
. NN NN O
   
6 NN NN O
patients NN NN O
presented NN NN O
clinical NN NN O
symptoms NN NN O
of NN NN O
visual NN NN B-Disease
or NN NN I-Disease
auditory NN NN I-Disease
toxicity NN NN I-Disease
. NN NN O
   
Moreover NN NN O
, NN NN O
detailed NN NN O
ophthalmologic NN NN O
and NN NN O
audiologic NN NN O
studies NN NN O
disclosed NN NN O
abnormalities NN NN O
in NN NN O
7 NN NN O
more NN NN O
asymptomatic NN NN O
patients NN NN O
. NN NN O
   
Visual NN NN B-Disease
toxicity NN NN I-Disease
was NN NN O
of NN NN O
retinal NN NN O
origin NN NN O
and NN NN O
was NN NN O
characterized NN NN O
by NN NN O
a NN NN O
tritan NN NN O
- NN NN O
type NN NN O
dyschromatopsy NN NN B-Disease
, NN NN O
sometimes NN NN O
associated NN NN O
with NN NN O
a NN NN B-Disease
loss NN NN I-Disease
of NN NN I-Disease
visual NN NN I-Disease
acuity NN NN I-Disease
and NN NN O
pigmentary NN NN B-Disease
retinal NN NN I-Disease
deposits NN NN I-Disease
. NN NN O
   
Auditory NN NN B-Disease
toxicity NN NN I-Disease
was NN NN O
characterized NN NN O
by NN NN O
a NN NN O
mid NN NN O
- NN NN O
to NN NN O
high NN NN O
- NN NN O
frequency NN NN O
neurosensorial NN NN B-Disease
hearing NN NN I-Disease
loss NN NN I-Disease
and NN NN O
the NN NN O
lesion NN NN O
was NN NN O
of NN NN O
the NN NN O
cochlear NN NN O
type NN NN O
. NN NN O
   
Desferrioxamine NN NN O
withdrawal NN NN O
resulted NN NN O
in NN NN O
a NN NN O
complete NN NN O
recovery NN NN O
of NN NN O
visual NN NN O
function NN NN O
in NN NN O
1 NN NN O
patient NN NN O
and NN NN O
partial NN NN O
recovery NN NN O
in NN NN O
3 NN NN O
, NN NN O
and NN NN O
a NN NN O
complete NN NN O
reversal NN NN O
of NN NN O
hearing NN NN B-Disease
loss NN NN I-Disease
in NN NN O
3 NN NN O
patients NN NN O
and NN NN O
partial NN NN O
recovery NN NN O
in NN NN O
3 NN NN O
. NN NN O
   
This NN NN O
toxicity NN NN B-Disease
appeared NN NN O
in NN NN O
patients NN NN O
receiving NN NN O
the NN NN O
higher NN NN O
doses NN NN O
of NN NN O
desferrioxamine NN NN O
or NN NN O
coincided NN NN O
with NN NN O
the NN NN O
normalization NN NN O
of NN NN O
ferritin NN NN O
or NN NN O
aluminium NN NN O
serum NN NN O
levels NN NN O
. NN NN O
   
The NN NN O
data NN NN O
indicate NN NN O
that NN NN O
audiovisual NN NN B-Disease
toxicity NN NN I-Disease
is NN NN O
not NN NN O
an NN NN O
infrequent NN NN O
complication NN NN O
in NN NN O
hemodialyzed NN NN O
patients NN NN O
receiving NN NN O
desferrioxamine NN NN O
. NN NN O
   
Periodical NN NN O
audiovisual NN NN O
monitoring NN NN O
should NN NN O
be NN NN O
performed NN NN O
on NN NN O
hemodialyzed NN NN O
patients NN NN O
receiving NN NN O
the NN NN O
drug NN NN O
in NN NN O
order NN NN O
to NN NN O
detect NN NN O
adverse NN NN O
effects NN NN O
as NN NN O
early NN NN O
as NN NN O
possible NN NN O
. NN NN O
   
Serial NN NN O
epilepsy NN NN B-Disease
caused NN NN O
by NN NN O
levodopa NN NN O
/ NN NN O
carbidopa NN NN O
administration NN NN O
in NN NN O
two NN NN O
patients NN NN O
on NN NN O
hemodialysis NN NN O
. NN NN O
   
Two NN NN O
patients NN NN O
with NN NN O
similar NN NN O
clinical NN NN O
features NN NN O
are NN NN O
presented NN NN O
: NN NN O
both NN NN O
patients NN NN O
had NN NN O
chronic NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
, NN NN O
on NN NN O
hemodialysis NN NN O
for NN NN O
many NN NN O
years NN NN O
but NN NN O
recently NN NN O
begun NN NN O
on NN NN O
a NN NN O
high NN NN O
- NN NN O
flux NN NN O
dialyzer NN NN O
; NN NN O
both NN NN O
had NN NN O
been NN NN O
receiving NN NN O
a NN NN O
carbidopa NN NN O
/ NN NN O
levodopa NN NN O
preparation NN NN O
; NN NN O
and NN NN O
both NN NN O
had NN NN O
the NN NN O
onset NN NN O
of NN NN O
hallucinosis NN NN B-Disease
and NN NN O
recurrent NN NN O
seizures NN NN B-Disease
, NN NN O
which NN NN O
were NN NN O
refractory NN NN O
to NN NN O
anticonvulsants NN NN O
. NN NN O
   
The NN NN O
first NN NN O
patient NN NN O
died NN NN O
without NN NN O
a NN NN O
diagnosis NN NN O
; NN NN O
the NN NN O
second NN NN O
patient NN NN O
had NN NN O
a NN NN O
dramatic NN NN O
recovery NN NN O
following NN NN O
the NN NN O
administration NN NN O
of NN NN O
vitamin NN NN O
B6 NN NN O
. NN NN O
   
Neither NN NN O
patient NN NN O
was NN NN O
considered NN NN O
to NN NN O
have NN NN O
a NN NN O
renal NN NN O
state NN NN O
sufficiently NN NN O
severe NN NN O
enough NN NN O
to NN NN O
explain NN NN O
their NN NN O
presentation NN NN O
. NN NN O
   
Randomized NN NN O
, NN NN O
double NN NN O
- NN NN O
blind NN NN O
trial NN NN O
of NN NN O
mazindol NN NN O
in NN NN O
Duchenne NN NN B-Disease
dystrophy NN NN I-Disease
. NN NN O
   
There NN NN O
is NN NN O
evidence NN NN O
that NN NN O
growth NN NN O
hormone NN NN O
may NN NN O
be NN NN O
related NN NN O
to NN NN O
the NN NN O
progression NN NN O
of NN NN O
weakness NN NN B-Disease
in NN NN O
Duchenne NN NN B-Disease
dystrophy NN NN I-Disease
. NN NN O
   
We NN NN O
conducted NN NN O
a NN NN O
12 NN NN O
- NN NN O
month NN NN O
controlled NN NN O
trial NN NN O
of NN NN O
mazindol NN NN O
, NN NN O
a NN NN O
putative NN NN O
growth NN NN O
hormone NN NN O
secretion NN NN O
inhibitor NN NN O
, NN NN O
in NN NN O
83 NN NN O
boys NN NN O
with NN NN O
Duchenne NN NN B-Disease
dystrophy NN NN I-Disease
. NN NN O
   
Muscle NN NN O
strength NN NN O
, NN NN O
contractures NN NN O
, NN NN O
functional NN NN O
ability NN NN O
and NN NN O
pulmonary NN NN O
function NN NN O
were NN NN O
tested NN NN O
at NN NN O
baseline NN NN O
, NN NN O
and NN NN O
6 NN NN O
and NN NN O
12 NN NN O
months NN NN O
after NN NN O
treatment NN NN O
with NN NN O
mazindol NN NN O
( NN NN O
3 NN NN O
mg NN NN O
/ NN NN O
d NN NN O
) NN NN O
or NN NN O
placebo NN NN O
. NN NN O
   
The NN NN O
study NN NN O
was NN NN O
designed NN NN O
to NN NN O
have NN NN O
a NN NN O
power NN NN O
of NN NN O
greater NN NN O
than NN NN O
0 NN NN O
. NN NN O
90 NN NN O
to NN NN O
detect NN NN O
a NN NN O
slowing NN NN O
to NN NN O
25 NN NN O
% NN NN O
of NN NN O
the NN NN O
expected NN NN O
rate NN NN O
of NN NN O
progression NN NN O
of NN NN O
weakness NN NN B-Disease
at NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
05 NN NN O
. NN NN O
   
Mazindol NN NN O
did NN NN O
not NN NN O
benefit NN NN O
strength NN NN O
at NN NN O
any NN NN O
point NN NN O
in NN NN O
the NN NN O
study NN NN O
. NN NN O
   
Side NN NN O
effects NN NN O
attributable NN NN O
to NN NN O
mazindol NN NN O
included NN NN O
decreased NN NN B-Disease
appetite NN NN I-Disease
( NN NN O
36 NN NN O
% NN NN O
) NN NN O
, NN NN O
dry NN NN B-Disease
mouth NN NN I-Disease
( NN NN O
10 NN NN O
% NN NN O
) NN NN O
, NN NN O
behavioral NN NN O
change NN NN O
( NN NN O
22 NN NN O
% NN NN O
) NN NN O
, NN NN O
and NN NN O
gastrointestinal NN NN B-Disease
symptoms NN NN I-Disease
( NN NN O
18 NN NN O
% NN NN O
) NN NN O
; NN NN O
mazindol NN NN O
dosage NN NN O
was NN NN O
reduced NN NN O
in NN NN O
43 NN NN O
% NN NN O
of NN NN O
patients NN NN O
. NN NN O
   
The NN NN O
effect NN NN O
of NN NN O
mazindol NN NN O
on NN NN O
GH NN NN O
secretion NN NN O
was NN NN O
estimated NN NN O
indirectly NN NN O
by NN NN O
comparing NN NN O
the NN NN O
postabsorptive NN NN O
IGF NN NN O
- NN NN O
I NN NN O
levels NN NN O
obtained NN NN O
following NN NN O
3 NN NN O
, NN NN O
6 NN NN O
, NN NN O
9 NN NN O
, NN NN O
and NN NN O
12 NN NN O
months NN NN O
in NN NN O
the NN NN O
mazindol NN NN O
treated NN NN O
to NN NN O
those NN NN O
in NN NN O
the NN NN O
placebo NN NN O
groups NN NN O
. NN NN O
   
Although NN NN O
mazindol NN NN O
- NN NN O
treated NN NN O
patients NN NN O
gained NN NN O
less NN NN O
weight NN NN O
and NN NN O
height NN NN O
than NN NN O
placebo NN NN O
- NN NN O
treated NN NN O
patients NN NN O
, NN NN O
no NN NN O
significant NN NN O
effect NN NN O
on NN NN O
IGF NN NN O
- NN NN O
I NN NN O
levels NN NN O
was NN NN O
observed NN NN O
. NN NN O
   
Mazindol NN NN O
doses NN NN O
not NN NN O
slow NN NN O
the NN NN O
progression NN NN O
of NN NN O
weakness NN NN B-Disease
in NN NN O
Duchenne NN NN B-Disease
dystrophy NN NN I-Disease
. NN NN O
   
Facilitation NN NN O
of NN NN O
memory NN NN O
retrieval NN NN O
by NN NN O
pre NN NN O
- NN NN O
test NN NN O
morphine NN NN O
and NN NN O
its NN NN O
state NN NN O
dependency NN NN O
in NN NN O
the NN NN O
step NN NN O
- NN NN O
through NN NN O
type NN NN O
passive NN NN O
avoidance NN NN O
learning NN NN O
test NN NN O
in NN NN O
mice NN NN O
. NN NN O
   
Amnesia NN NN B-Disease
produced NN NN O
by NN NN O
scopolamine NN NN O
and NN NN O
cycloheximide NN NN O
were NN NN O
reversed NN NN O
by NN NN O
morphine NN NN O
given NN NN O
30 NN NN O
min NN NN O
before NN NN O
the NN NN O
test NN NN O
trial NN NN O
( NN NN O
pre NN NN O
- NN NN O
test NN NN O
) NN NN O
, NN NN O
and NN NN O
pre NN NN O
- NN NN O
test NN NN O
morphine NN NN O
also NN NN O
facilitated NN NN O
the NN NN O
memory NN NN O
retrieval NN NN O
in NN NN O
the NN NN O
animals NN NN O
administered NN NN O
naloxone NN NN O
during NN NN O
the NN NN O
training NN NN O
trial NN NN O
. NN NN O
   
Similarly NN NN O
, NN NN O
pre NN NN O
- NN NN O
test NN NN O
scopolamine NN NN O
partially NN NN O
reversed NN NN O
the NN NN O
scopolamine NN NN O
- NN NN O
induced NN NN O
amnesia NN NN B-Disease
, NN NN O
but NN NN O
not NN NN O
significantly NN NN O
; NN NN O
and NN NN O
pre NN NN O
- NN NN O
test NN NN O
cycloheximide NN NN O
failed NN NN O
to NN NN O
reverse NN NN O
the NN NN O
cycloheximide NN NN O
- NN NN O
induced NN NN O
amnesia NN NN B-Disease
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
the NN NN O
facilitation NN NN O
of NN NN O
memory NN NN O
retrieval NN NN O
by NN NN O
pre NN NN O
- NN NN O
test NN NN O
morphine NN NN O
might NN NN O
be NN NN O
the NN NN O
direct NN NN O
action NN NN O
of NN NN O
morphine NN NN O
rather NN NN O
than NN NN O
a NN NN O
state NN NN O
dependent NN NN O
effect NN NN O
. NN NN O
   
Naloxone NN NN O
reverses NN NN O
the NN NN O
antihypertensive NN NN O
effect NN NN O
of NN NN O
clonidine NN NN O
. NN NN O
   
In NN NN O
unanesthetized NN NN O
, NN NN O
spontaneously NN NN O
hypertensive NN NN B-Disease
rats NN NN O
the NN NN O
decrease NN NN O
in NN NN O
blood NN NN O
pressure NN NN O
and NN NN O
heart NN NN O
rate NN NN O
produced NN NN O
by NN NN O
intravenous NN NN O
clonidine NN NN O
, NN NN O
5 NN NN O
to NN NN O
20 NN NN O
micrograms NN NN O
/ NN NN O
kg NN NN O
, NN NN O
was NN NN O
inhibited NN NN O
or NN NN O
reversed NN NN O
by NN NN O
nalozone NN NN O
, NN NN O
0 NN NN O
. NN NN O
2 NN NN O
to NN NN O
2 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
. NN NN O
   
The NN NN O
hypotensive NN NN B-Disease
effect NN NN O
of NN NN O
100 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
alpha NN NN O
- NN NN O
methyldopa NN NN O
was NN NN O
also NN NN O
partially NN NN O
reversed NN NN O
by NN NN O
naloxone NN NN O
. NN NN O
   
Naloxone NN NN O
alone NN NN O
did NN NN O
not NN NN O
affect NN NN O
either NN NN O
blood NN NN O
pressure NN NN O
or NN NN O
heart NN NN O
rate NN NN O
. NN NN O
   
In NN NN O
brain NN NN O
membranes NN NN O
from NN NN O
spontaneously NN NN O
hypertensive NN NN B-Disease
rats NN NN O
clonidine NN NN O
, NN NN O
10 NN NN O
( NN NN O
- NN NN O
8 NN NN O
) NN NN O
to NN NN O
10 NN NN O
( NN NN O
- NN NN O
5 NN NN O
) NN NN O
M NN NN O
, NN NN O
did NN NN O
not NN NN O
influence NN NN O
stereoselective NN NN O
binding NN NN O
of NN NN O
[ NN NN O
3H NN NN O
] NN NN O
- NN NN O
naloxone NN NN O
( NN NN O
8 NN NN O
nM NN NN O
) NN NN O
, NN NN O
and NN NN O
naloxone NN NN O
, NN NN O
10 NN NN O
( NN NN O
- NN NN O
8 NN NN O
) NN NN O
to NN NN O
10 NN NN O
( NN NN O
- NN NN O
4 NN NN O
) NN NN O
M NN NN O
, NN NN O
did NN NN O
not NN NN O
influence NN NN O
clonidine NN NN O
- NN NN O
suppressible NN NN O
binding NN NN O
of NN NN O
[ NN NN O
3H NN NN O
] NN NN O
- NN NN O
dihydroergocryptine NN NN O
( NN NN O
1 NN NN O
nM NN NN O
) NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
indicate NN NN O
that NN NN O
in NN NN O
spontaneously NN NN O
hypertensive NN NN B-Disease
rats NN NN O
the NN NN O
effects NN NN O
of NN NN O
central NN NN O
alpha NN NN O
- NN NN O
adrenoceptor NN NN O
stimulation NN NN O
involve NN NN O
activation NN NN O
of NN NN O
opiate NN NN O
receptors NN NN O
. NN NN O
   
As NN NN O
naloxone NN NN O
and NN NN O
clonidine NN NN O
do NN NN O
not NN NN O
appear NN NN O
to NN NN O
interact NN NN O
with NN NN O
the NN NN O
same NN NN O
receptor NN NN O
site NN NN O
, NN NN O
the NN NN O
observed NN NN O
functional NN NN O
antagonism NN NN O
suggests NN NN O
the NN NN O
release NN NN O
of NN NN O
an NN NN O
endogenous NN NN O
opiate NN NN O
by NN NN O
clonidine NN NN O
or NN NN O
alpha NN NN O
- NN NN O
methyldopa NN NN O
and NN NN O
the NN NN O
possible NN NN O
role NN NN O
of NN NN O
the NN NN O
opiate NN NN O
in NN NN O
the NN NN O
central NN NN O
control NN NN O
of NN NN O
sympathetic NN NN O
tone NN NN O
. NN NN O
   
Neurotoxicity NN NN B-Disease
of NN NN O
halogenated NN NN O
hydroxyquinolines NN NN O
: NN NN O
clinical NN NN O
analysis NN NN O
of NN NN O
cases NN NN O
reported NN NN O
outside NN NN O
Japan NN NN O
. NN NN O
   
An NN NN O
analysis NN NN O
is NN NN O
presented NN NN O
of NN NN O
220 NN NN O
cases NN NN O
of NN NN O
possible NN NN O
neurotoxic NN NN B-Disease
reactions NN NN O
to NN NN O
halogenated NN NN O
hydroxyquinolines NN NN O
reported NN NN O
from NN NN O
outside NN NN O
Japan NN NN O
. NN NN O
   
In NN NN O
80 NN NN O
cases NN NN O
insufficient NN NN O
information NN NN O
was NN NN O
available NN NN O
for NN NN O
adequate NN NN O
comment NN NN O
and NN NN O
in NN NN O
29 NN NN O
a NN NN O
relationship NN NN O
to NN NN O
the NN NN O
administration NN NN O
of NN NN O
clioquinol NN NN O
could NN NN O
be NN NN O
excluded NN NN O
. NN NN O
   
Of NN NN O
the NN NN O
remainder NN NN O
, NN NN O
a NN NN O
relationship NN NN O
to NN NN O
clioquinol NN NN O
was NN NN O
considered NN NN O
probable NN NN O
in NN NN O
42 NN NN O
and NN NN O
possible NN NN O
in NN NN O
69 NN NN O
cases NN NN O
. NN NN O
   
In NN NN O
six NN NN O
of NN NN O
the NN NN O
probable NN NN O
cases NN NN O
the NN NN O
neurological NN NN B-Disease
disturbance NN NN I-Disease
consisted NN NN O
of NN NN O
an NN NN O
acute NN NN O
reversible NN NN O
encephalopathy NN NN B-Disease
usually NN NN O
related NN NN O
to NN NN O
the NN NN O
ingestion NN NN O
of NN NN O
a NN NN O
high NN NN O
dose NN NN O
of NN NN O
clioquinol NN NN O
over NN NN O
a NN NN O
short NN NN O
period NN NN O
. NN NN O
   
The NN NN O
most NN NN O
common NN NN O
manifestation NN NN O
, NN NN O
observed NN NN O
in NN NN O
15 NN NN O
further NN NN O
cases NN NN O
, NN NN O
was NN NN O
isolated NN NN O
optic NN NN B-Disease
atrophy NN NN I-Disease
. NN NN O
   
This NN NN O
was NN NN O
most NN NN O
frequently NN NN O
found NN NN O
in NN NN O
children NN NN O
, NN NN O
many NN NN O
of NN NN O
whom NN NN O
had NN NN O
received NN NN O
clioquinol NN NN O
as NN NN O
treatment NN NN O
for NN NN O
acrodermatitis NN NN B-Disease
enteropathica NN NN I-Disease
. NN NN O
   
In NN NN O
the NN NN O
remaining NN NN O
cases NN NN O
, NN NN O
a NN NN O
combination NN NN O
of NN NN O
myelopathy NN NN B-Disease
, NN NN O
visual NN NN B-Disease
disturbance NN NN I-Disease
, NN NN O
and NN NN O
peripheral NN NN B-Disease
neuropathy NN NN I-Disease
was NN NN O
the NN NN O
most NN NN O
common NN NN O
manifestation NN NN O
. NN NN O
   
Isolated NN NN O
myelopathy NN NN B-Disease
or NN NN O
peripheral NN NN B-Disease
neuropathy NN NN I-Disease
, NN NN O
or NN NN O
these NN NN O
manifestations NN NN O
occurring NN NN O
together NN NN O
, NN NN O
were NN NN O
infrequent NN NN O
. NN NN O
   
The NN NN O
onset NN NN O
of NN NN O
all NN NN O
manifestations NN NN O
( NN NN O
except NN NN O
toxic NN NN O
encephalopathy NN NN B-Disease
) NN NN O
was NN NN O
usually NN NN O
subacute NN NN O
, NN NN O
with NN NN O
subsequent NN NN O
partial NN NN O
recovery NN NN O
. NN NN O
   
Older NN NN O
subjects NN NN O
tended NN NN O
to NN NN O
display NN NN O
more NN NN O
side NN NN O
effects NN NN O
. NN NN O
   
The NN NN O
full NN NN O
syndrome NN NN O
of NN NN O
subacute NN NN O
myelo NN NN B-Disease
- NN NN I-Disease
optic NN NN I-Disease
neuropathy NN NN I-Disease
was NN NN O
more NN NN O
frequent NN NN O
in NN NN O
women NN NN O
, NN NN O
but NN NN O
they NN NN O
tended NN NN O
to NN NN O
have NN NN O
taken NN NN O
greater NN NN O
quantities NN NN O
of NN NN O
the NN NN O
drug NN NN O
. NN NN O
   
Prazosin NN NN O
- NN NN O
induced NN NN O
stress NN NN B-Disease
incontinence NN NN I-Disease
. NN NN O
   
A NN NN O
case NN NN O
of NN NN O
genuine NN NN O
stress NN NN B-Disease
incontinence NN NN I-Disease
due NN NN O
to NN NN O
prazosin NN NN O
, NN NN O
a NN NN O
common NN NN O
antihypertensive NN NN O
drug NN NN O
, NN NN O
is NN NN O
presented NN NN O
. NN NN O
   
Prazosin NN NN O
exerts NN NN O
its NN NN O
antihypertensive NN NN O
effects NN NN O
through NN NN O
vasodilatation NN NN O
caused NN NN O
by NN NN O
selective NN NN O
blockade NN NN O
of NN NN O
postsynaptic NN NN O
alpha NN NN O
- NN NN O
1 NN NN O
adrenergic NN NN O
receptors NN NN O
. NN NN O
   
As NN NN O
an NN NN O
alpha NN NN O
- NN NN O
blocker NN NN O
, NN NN O
it NN NN O
also NN NN O
exerts NN NN O
a NN NN O
significant NN NN O
relaxant NN NN O
effect NN NN O
on NN NN O
the NN NN O
bladder NN NN O
neck NN NN O
and NN NN O
urethra NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
' NN NN O
s NN NN O
clinical NN NN O
course NN NN O
is NN NN O
described NN NN O
and NN NN O
correlated NN NN O
with NN NN O
initial NN NN O
urodynamic NN NN O
studies NN NN O
while NN NN O
on NN NN O
prazosin NN NN O
and NN NN O
subsequent NN NN O
studies NN NN O
while NN NN O
taking NN NN O
verapamil NN NN O
. NN NN O
   
Her NN NN O
incontinence NN NN B-Disease
resolved NN NN O
with NN NN O
the NN NN O
change NN NN O
of NN NN O
medication NN NN O
. NN NN O
   
The NN NN O
restoration NN NN O
of NN NN O
continence NN NN O
was NN NN O
accompanied NN NN O
by NN NN O
a NN NN O
substantial NN NN O
rise NN NN O
in NN NN O
maximum NN NN O
urethral NN NN O
pressure NN NN O
, NN NN O
maximum NN NN O
urethral NN NN O
closure NN NN O
pressure NN NN O
, NN NN O
and NN NN O
functional NN NN O
urethral NN NN O
length NN NN O
. NN NN O
   
Patients NN NN O
who NN NN O
present NN NN O
with NN NN O
stress NN NN B-Disease
incontinence NN NN I-Disease
while NN NN O
taking NN NN O
prazosin NN NN O
should NN NN O
change NN NN O
their NN NN O
antihypertensive NN NN O
medication NN NN O
before NN NN O
considering NN NN O
surgery NN NN O
, NN NN O
because NN NN O
their NN NN O
incontinence NN NN B-Disease
may NN NN O
resolve NN NN O
spontaneously NN NN O
with NN NN O
a NN NN O
change NN NN O
in NN NN O
drug NN NN O
therapy NN NN O
. NN NN O
   
Myocardial NN NN B-Disease
infarction NN NN I-Disease
following NN NN O
sublingual NN NN O
administration NN NN O
of NN NN O
isosorbide NN NN O
dinitrate NN NN O
. NN NN O
   
A NN NN O
78 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
with NN NN O
healed NN NN O
septal NN NN O
necrosis NN NN B-Disease
suffered NN NN O
a NN NN O
recurrent NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
of NN NN O
the NN NN O
anterior NN NN O
wall NN NN O
following NN NN O
the NN NN O
administration NN NN O
of NN NN O
isosorbide NN NN O
dinitrate NN NN O
5 NN NN O
mg NN NN O
sublingually NN NN O
. NN NN O
   
After NN NN O
detailing NN NN O
the NN NN O
course NN NN O
of NN NN O
events NN NN O
, NN NN O
we NN NN O
discuss NN NN O
the NN NN O
role NN NN O
of NN NN O
paradoxical NN NN O
coronary NN NN O
spasm NN NN B-Disease
and NN NN O
hypotension NN NN B-Disease
- NN NN O
mediated NN NN O
myocardial NN NN B-Disease
ischemia NN NN I-Disease
occurring NN NN O
downstream NN NN O
to NN NN O
significant NN NN O
coronary NN NN B-Disease
arterial NN NN I-Disease
stenosis NN NN I-Disease
in NN NN O
the NN NN O
pathophysiology NN NN O
of NN NN O
acute NN NN B-Disease
coronary NN NN I-Disease
insufficiency NN NN I-Disease
. NN NN O
   
Comparison NN NN O
of NN NN O
the NN NN O
respiratory NN NN O
effects NN NN O
of NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
infusions NN NN O
of NN NN O
morphine NN NN O
and NN NN O
regional NN NN O
analgesia NN NN O
by NN NN O
extradural NN NN O
block NN NN O
. NN NN O
   
The NN NN O
incidence NN NN O
of NN NN O
postoperative NN NN O
respiratory NN NN O
apnoea NN NN B-Disease
was NN NN O
compared NN NN O
between NN NN O
five NN NN O
patients NN NN O
receiving NN NN O
a NN NN O
continuous NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
infusion NN NN O
of NN NN O
morphine NN NN O
( NN NN O
mean NN NN O
73 NN NN O
. NN NN O
6 NN NN O
mg NN NN O
) NN NN O
and NN NN O
five NN NN O
patients NN NN O
receiving NN NN O
a NN NN O
continuous NN NN O
extradural NN NN O
infusion NN NN O
of NN NN O
0 NN NN O
. NN NN O
25 NN NN O
% NN NN O
bupivacaine NN NN O
( NN NN O
mean NN NN O
192 NN NN O
mg NN NN O
) NN NN O
in NN NN O
the NN NN O
24 NN NN O
- NN NN O
h NN NN O
period NN NN O
following NN NN O
upper NN NN O
abdominal NN NN O
surgery NN NN O
. NN NN O
   
Monitoring NN NN O
consisted NN NN O
of NN NN O
airflow NN NN O
detection NN NN O
by NN NN O
a NN NN O
carbon NN NN O
dioxide NN NN O
analyser NN NN O
, NN NN O
chest NN NN O
wall NN NN O
movement NN NN O
detected NN NN O
by NN NN O
pneumatic NN NN O
capsules NN NN O
, NN NN O
and NN NN O
continuous NN NN O
electrocardiograph NN NN O
recorded NN NN O
with NN NN O
a NN NN O
Holter NN NN O
ambulatory NN NN O
monitor NN NN O
. NN NN O
   
Both NN NN O
obstructive NN NN B-Disease
( NN NN I-Disease
P NN NN I-Disease
less NN NN I-Disease
than NN NN I-Disease
0 NN NN I-Disease
. NN NN I-Disease
05 NN NN I-Disease
) NN NN I-Disease
and NN NN I-Disease
central NN NN I-Disease
apnoea NN NN I-Disease
( NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
occurred NN NN O
more NN NN O
frequently NN NN O
in NN NN O
patients NN NN O
who NN NN O
had NN NN O
a NN NN O
morphine NN NN O
infusion NN NN O
. NN NN O
   
There NN NN O
was NN NN O
also NN NN O
a NN NN O
higher NN NN O
incidence NN NN O
of NN NN O
tachyarrhythmias NN NN B-Disease
( NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
and NN NN O
ventricular NN NN B-Disease
ectopic NN NN I-Disease
beats NN NN I-Disease
( NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
in NN NN O
the NN NN O
morphine NN NN O
infusion NN NN O
group NN NN O
. NN NN O
   
Effects NN NN O
of NN NN O
aminophylline NN NN O
on NN NN O
the NN NN O
threshold NN NN O
for NN NN O
initiating NN NN O
ventricular NN NN B-Disease
fibrillation NN NN I-Disease
during NN NN O
respiratory NN NN B-Disease
failure NN NN I-Disease
. NN NN O
   
Cardiac NN NN B-Disease
arrhythmias NN NN I-Disease
have NN NN O
frequently NN NN O
been NN NN O
reported NN NN O
in NN NN O
association NN NN O
with NN NN O
respiratory NN NN B-Disease
failure NN NN I-Disease
. NN NN O
   
The NN NN O
possible NN NN O
additive NN NN O
role NN NN O
of NN NN O
pharmacologic NN NN O
agents NN NN O
in NN NN O
precipitating NN NN O
cardiac NN NN B-Disease
disturbances NN NN I-Disease
in NN NN O
patients NN NN O
with NN NN O
respiratory NN NN B-Disease
failure NN NN I-Disease
has NN NN O
only NN NN O
recently NN NN O
been NN NN O
emphasized NN NN O
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
aminophylline NN NN O
on NN NN O
the NN NN O
ventricular NN NN B-Disease
fibrillation NN NN I-Disease
threshold NN NN O
during NN NN O
normal NN NN O
acid NN NN O
- NN NN O
base NN NN O
conditions NN NN O
and NN NN O
during NN NN O
respiratory NN NN B-Disease
failure NN NN I-Disease
were NN NN O
studied NN NN O
in NN NN O
anesthetized NN NN O
open NN NN O
chest NN NN O
dogs NN NN O
. NN NN O
   
The NN NN O
ventricular NN NN B-Disease
fibrillation NN NN I-Disease
threshold NN NN O
was NN NN O
measured NN NN O
by NN NN O
passing NN NN O
a NN NN O
gated NN NN O
train NN NN O
of NN NN O
12 NN NN O
constant NN NN O
current NN NN O
pulses NN NN O
through NN NN O
the NN NN O
ventricular NN NN O
myocardium NN NN O
during NN NN O
the NN NN O
vulnerable NN NN O
period NN NN O
of NN NN O
the NN NN O
cardiac NN NN O
cycle NN NN O
. NN NN O
   
During NN NN O
the NN NN O
infusion NN NN O
of NN NN O
aminophylline NN NN O
, NN NN O
the NN NN O
ventricular NN NN B-Disease
fibrillation NN NN I-Disease
threshold NN NN O
was NN NN O
reduced NN NN O
by NN NN O
30 NN NN O
to NN NN O
40 NN NN O
percent NN NN O
of NN NN O
the NN NN O
control NN NN O
when NN NN O
pH NN NN O
and NN NN O
partial NN NN O
pressures NN NN O
of NN NN O
oxygen NN NN O
( NN NN O
PO2 NN NN O
) NN NN O
and NN NN O
carbon NN NN O
dioxide NN NN O
( NN NN O
CO2 NN NN O
) NN NN O
were NN NN O
kept NN NN O
within NN NN O
normal NN NN O
limits NN NN O
. NN NN O
   
When NN NN O
respiratory NN NN B-Disease
failure NN NN I-Disease
was NN NN O
produced NN NN O
by NN NN O
hypoventilation NN NN B-Disease
( NN NN O
pH NN NN O
7 NN NN O
. NN NN O
05 NN NN O
to NN NN O
7 NN NN O
. NN NN O
25 NN NN O
; NN NN O
PC02 NN NN O
70 NN NN O
to NN NN O
100 NN NN O
mm NN NN O
Hg NN NN O
: NN NN O
P02 NN NN O
20 NN NN O
to NN NN O
40 NN NN O
mm NN NN O
Hg NN NN O
) NN NN O
, NN NN O
infusion NN NN O
of NN NN O
aminophylline NN NN O
resulted NN NN O
in NN NN O
an NN NN O
even NN NN O
greater NN NN O
decrease NN NN O
in NN NN O
ventricular NN NN B-Disease
fibrillation NN NN I-Disease
threshold NN NN O
to NN NN O
60 NN NN O
percent NN NN O
of NN NN O
the NN NN O
control NN NN O
level NN NN O
. NN NN O
   
These NN NN O
experiments NN NN O
suggest NN NN O
that NN NN O
although NN NN O
many NN NN O
factors NN NN O
may NN NN O
contribute NN NN O
to NN NN O
the NN NN O
increased NN NN O
incidence NN NN O
of NN NN O
ventricular NN NN B-Disease
arrhythmias NN NN I-Disease
in NN NN O
respiratory NN NN B-Disease
failure NN NN I-Disease
, NN NN O
pharmacologic NN NN O
agents NN NN O
, NN NN O
particularly NN NN O
aminophylline NN NN O
, NN NN O
may NN NN O
play NN NN O
a NN NN O
significant NN NN O
role NN NN O
. NN NN O
   
Pentoxifylline NN NN O
( NN NN O
Trental NN NN O
) NN NN O
does NN NN O
not NN NN O
inhibit NN NN O
dipyridamole NN NN O
- NN NN O
induced NN NN O
coronary NN NN O
hyperemia NN NN B-Disease
: NN NN O
implications NN NN O
for NN NN O
dipyridamole NN NN O
- NN NN O
thallium NN NN O
- NN NN O
201 NN NN O
myocardial NN NN O
imaging NN NN O
. NN NN O
   
Dipyridamole NN NN O
- NN NN O
thallium NN NN O
- NN NN O
201 NN NN O
imaging NN NN O
is NN NN O
often NN NN O
performed NN NN O
in NN NN O
patients NN NN O
unable NN NN O
to NN NN O
exercise NN NN O
because NN NN O
of NN NN O
peripheral NN NN B-Disease
vascular NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
Many NN NN O
of NN NN O
these NN NN O
patients NN NN O
are NN NN O
taking NN NN O
pentoxifylline NN NN O
( NN NN O
Trental NN NN O
) NN NN O
, NN NN O
a NN NN O
methylxanthine NN NN O
derivative NN NN O
which NN NN O
may NN NN O
improve NN NN O
intermittent NN NN B-Disease
claudication NN NN I-Disease
. NN NN O
   
Whether NN NN O
pentoxifylline NN NN O
inhibits NN NN O
dipyridamole NN NN O
- NN NN O
induced NN NN O
coronary NN NN O
hyperemia NN NN B-Disease
like NN NN O
other NN NN O
methylxanthines NN NN O
such NN NN O
as NN NN O
theophylline NN NN O
and NN NN O
should NN NN O
be NN NN O
stopped NN NN O
prior NN NN O
to NN NN O
dipyridamole NN NN O
- NN NN O
thallium NN NN O
- NN NN O
201 NN NN O
imaging NN NN O
is NN NN O
unknown NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
we NN NN O
studied NN NN O
the NN NN O
hyperemic NN NN O
response NN NN O
to NN NN O
dipyridamole NN NN O
in NN NN O
seven NN NN O
open NN NN O
- NN NN O
chest NN NN O
anesthetized NN NN O
dogs NN NN O
after NN NN O
pretreatment NN NN O
with NN NN O
either NN NN O
pentoxifylline NN NN O
( NN NN O
0 NN NN O
, NN NN O
7 NN NN O
. NN NN O
5 NN NN O
, NN NN O
or NN NN O
15 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
) NN NN O
or NN NN O
theophylline NN NN O
( NN NN O
3 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
) NN NN O
. NN NN O
   
Baseline NN NN O
circumflex NN NN O
coronary NN NN O
blood NN NN O
flows NN NN O
did NN NN O
not NN NN O
differ NN NN O
significantly NN NN O
among NN NN O
treatment NN NN O
groups NN NN O
. NN NN O
   
Dipyridamole NN NN O
significantly NN NN O
increased NN NN O
coronary NN NN O
blood NN NN O
flow NN NN O
before NN NN O
and NN NN O
after NN NN O
7 NN NN O
. NN NN O
5 NN NN O
or NN NN O
15 NN NN O
mm NN NN O
/ NN NN O
kg NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
pentoxifylline NN NN O
( NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
002 NN NN O
) NN NN O
. NN NN O
   
Neither NN NN O
dose NN NN O
of NN NN O
pentoxifylline NN NN O
significantly NN NN O
decreased NN NN O
the NN NN O
dipyridamole NN NN O
- NN NN O
induced NN NN O
hyperemia NN NN B-Disease
, NN NN O
while NN NN O
peak NN NN O
coronary NN NN O
blood NN NN O
flow NN NN O
was NN NN O
significantly NN NN O
lower NN NN O
after NN NN O
theophylline NN NN O
( NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
pentoxyifylline NN NN O
does NN NN O
not NN NN O
inhibit NN NN O
dipyridamole NN NN O
- NN NN O
induced NN NN O
coronary NN NN O
hyperemia NN NN B-Disease
even NN NN O
at NN NN O
high NN NN O
doses NN NN O
. NN NN O
   
Cause NN NN O
of NN NN O
death NN NN B-Disease
among NN NN O
patients NN NN O
with NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
: NN NN O
a NN NN O
rare NN NN O
mortality NN NN O
due NN NN O
to NN NN O
cerebral NN NN B-Disease
haemorrhage NN NN I-Disease
. NN NN O
   
Causes NN NN O
of NN NN O
death NN NN B-Disease
, NN NN O
with NN NN O
special NN NN O
reference NN NN O
to NN NN O
cerebral NN NN B-Disease
haemorrhage NN NN I-Disease
, NN NN O
among NN NN O
240 NN NN O
patients NN NN O
with NN NN O
pathologically NN NN O
verified NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
were NN NN O
investigated NN NN O
using NN NN O
the NN NN O
Annuals NN NN O
of NN NN O
the NN NN O
Pathological NN NN O
Autopsy NN NN O
Cases NN NN O
in NN NN O
Japan NN NN O
from NN NN O
1981 NN NN O
to NN NN O
1985 NN NN O
. NN NN O
   
The NN NN O
leading NN NN O
causes NN NN O
of NN NN O
death NN NN B-Disease
were NN NN O
pneumonia NN NN B-Disease
and NN NN O
bronchitis NN NN B-Disease
( NN NN O
44 NN NN O
. NN NN O
1 NN NN O
% NN NN O
) NN NN O
, NN NN O
malignant NN NN O
neoplasms NN NN B-Disease
( NN NN O
11 NN NN O
. NN NN O
6 NN NN O
% NN NN O
) NN NN O
, NN NN O
heart NN NN B-Disease
diseases NN NN I-Disease
( NN NN O
4 NN NN O
. NN NN O
1 NN NN O
% NN NN O
) NN NN O
, NN NN O
cerebral NN NN B-Disease
infarction NN NN I-Disease
( NN NN O
3 NN NN O
. NN NN O
7 NN NN O
% NN NN O
) NN NN O
and NN NN O
septicaemia NN NN B-Disease
( NN NN O
3 NN NN O
. NN NN O
3 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
Cerebral NN NN B-Disease
haemorrhage NN NN I-Disease
was NN NN O
the NN NN O
11th NN NN O
most NN NN O
frequent NN NN O
cause NN NN O
of NN NN O
death NN NN B-Disease
, NN NN O
accounting NN NN O
for NN NN O
only NN NN O
0 NN NN O
. NN NN O
8 NN NN O
% NN NN O
of NN NN O
deaths NN NN B-Disease
among NN NN O
the NN NN O
patients NN NN O
, NN NN O
whereas NN NN O
it NN NN O
was NN NN O
the NN NN O
5th NN NN O
most NN NN O
common NN NN O
cause NN NN O
of NN NN O
death NN NN B-Disease
among NN NN O
the NN NN O
Japanese NN NN O
general NN NN O
population NN NN O
in NN NN O
1985 NN NN O
. NN NN O
   
The NN NN O
low NN NN O
incidence NN NN O
of NN NN O
cerebral NN NN B-Disease
haemorrhage NN NN I-Disease
as NN NN O
a NN NN O
cause NN NN O
of NN NN O
death NN NN B-Disease
in NN NN O
patients NN NN O
with NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
may NN NN O
reflect NN NN O
the NN NN O
hypotensive NN NN B-Disease
effect NN NN O
of NN NN O
levodopa NN NN O
and NN NN O
a NN NN O
hypotensive NN NN B-Disease
mechanism NN NN O
due NN NN O
to NN NN O
reduced NN NN O
noradrenaline NN NN O
levels NN NN O
in NN NN O
the NN NN O
parkinsonian NN NN B-Disease
brain NN NN O
. NN NN O
   
Possible NN NN O
intramuscular NN NN O
midazolam NN NN O
- NN NN O
associated NN NN O
cardiorespiratory NN NN B-Disease
arrest NN NN I-Disease
and NN NN O
death NN NN B-Disease
. NN NN O
   
Midazolam NN NN O
hydrochloride NN NN O
is NN NN O
commonly NN NN O
used NN NN O
for NN NN O
dental NN NN O
or NN NN O
endoscopic NN NN O
procedures NN NN O
. NN NN O
   
Although NN NN O
generally NN NN O
consisted NN NN O
safe NN NN O
when NN NN O
given NN NN O
intramuscularly NN NN O
, NN NN O
intravenous NN NN O
administration NN NN O
is NN NN O
known NN NN O
to NN NN O
cause NN NN O
respiratory NN NN B-Disease
and NN NN I-Disease
cardiovascular NN NN I-Disease
depression NN NN I-Disease
. NN NN O
   
This NN NN O
report NN NN O
describes NN NN O
the NN NN O
first NN NN O
published NN NN O
case NN NN O
of NN NN O
cardiorespiratory NN NN B-Disease
arrest NN NN I-Disease
and NN NN O
death NN NN B-Disease
associated NN NN O
with NN NN O
intramuscular NN NN O
administration NN NN O
of NN NN O
midazolam NN NN O
. NN NN O
   
Information NN NN O
regarding NN NN O
midazolam NN NN O
use NN NN O
is NN NN O
reviewed NN NN O
to NN NN O
provide NN NN O
recommendation NN NN O
for NN NN O
safe NN NN O
administration NN NN O
. NN NN O
   
Myasthenia NN NN B-Disease
gravis NN NN I-Disease
presenting NN NN O
as NN NN O
weakness NN NN O
after NN NN O
magnesium NN NN O
administration NN NN O
. NN NN O
   
We NN NN O
studied NN NN O
a NN NN O
patient NN NN O
with NN NN O
no NN NN O
prior NN NN O
history NN NN O
of NN NN O
neuromuscular NN NN B-Disease
disease NN NN I-Disease
who NN NN O
became NN NN O
virtually NN NN O
quadriplegic NN NN B-Disease
after NN NN O
parenteral NN NN O
magnesium NN NN O
administration NN NN O
for NN NN O
preeclampsia NN NN B-Disease
. NN NN O
   
The NN NN O
serum NN NN O
magnesium NN NN O
concentration NN NN O
was NN NN O
3 NN NN O
. NN NN O
0 NN NN O
mEq NN NN O
/ NN NN O
L NN NN O
, NN NN O
which NN NN O
is NN NN O
usually NN NN O
well NN NN O
tolerated NN NN O
. NN NN O
   
The NN NN O
magnesium NN NN O
was NN NN O
stopped NN NN O
and NN NN O
she NN NN O
recovered NN NN O
over NN NN O
a NN NN O
few NN NN O
days NN NN O
. NN NN O
   
While NN NN O
she NN NN O
was NN NN O
weak NN NN O
, NN NN O
2 NN NN O
- NN NN O
Hz NN NN O
repetitive NN NN O
stimulation NN NN O
revealed NN NN O
a NN NN O
decrement NN NN O
without NN NN O
significant NN NN O
facilitation NN NN O
at NN NN O
rapid NN NN O
rates NN NN O
or NN NN O
after NN NN O
exercise NN NN O
, NN NN O
suggesting NN NN O
postsynaptic NN NN B-Disease
neuromuscular NN NN I-Disease
blockade NN NN I-Disease
. NN NN O
   
After NN NN O
her NN NN O
strength NN NN O
returned NN NN O
, NN NN O
repetitive NN NN O
stimulation NN NN O
was NN NN O
normal NN NN O
, NN NN O
but NN NN O
single NN NN O
fiber NN NN O
EMG NN NN O
revealed NN NN O
increased NN NN O
jitter NN NN O
and NN NN O
blocking NN NN O
. NN NN O
   
Her NN NN O
acetylcholine NN NN O
receptor NN NN O
antibody NN NN O
level NN NN O
was NN NN O
markedly NN NN O
elevated NN NN O
. NN NN O
   
Although NN NN O
paralysis NN NN B-Disease
after NN NN O
magnesium NN NN O
administration NN NN O
has NN NN O
been NN NN O
described NN NN O
in NN NN O
patients NN NN O
with NN NN O
known NN NN O
myasthenia NN NN B-Disease
gravis NN NN I-Disease
, NN NN O
it NN NN O
has NN NN O
not NN NN O
previously NN NN O
been NN NN O
reported NN NN O
to NN NN O
be NN NN O
the NN NN O
initial NN NN O
or NN NN O
only NN NN O
manifestation NN NN O
of NN NN O
the NN NN O
disease NN NN O
. NN NN O
   
Patients NN NN O
who NN NN O
are NN NN O
unusually NN NN O
sensitive NN NN O
to NN NN O
the NN NN O
neuromuscular NN NN O
effects NN NN O
of NN NN O
magnesium NN NN O
should NN NN O
be NN NN O
suspected NN NN O
of NN NN O
having NN NN O
an NN NN O
underlying NN NN O
disorder NN NN B-Disease
of NN NN I-Disease
neuromuscular NN NN I-Disease
transmission NN NN I-Disease
. NN NN O
   
No NN NN O
enhancement NN NN O
by NN NN O
phenobarbital NN NN O
of NN NN O
the NN NN O
hepatocarcinogenicity NN NN O
of NN NN O
a NN NN O
choline NN NN O
- NN NN O
devoid NN NN O
diet NN NN O
in NN NN O
the NN NN O
rat NN NN O
. NN NN O
   
An NN NN O
experiment NN NN O
was NN NN O
performed NN NN O
to NN NN O
test NN NN O
whether NN NN O
inclusion NN NN O
of NN NN O
phenobarbital NN NN O
in NN NN O
a NN NN O
choline NN NN O
- NN NN O
devoid NN NN O
diet NN NN O
would NN NN O
increase NN NN O
the NN NN O
hepatocarcinogenicity NN NN O
of NN NN O
the NN NN O
diet NN NN O
. NN NN O
   
Groups NN NN O
of NN NN O
5 NN NN O
- NN NN O
week NN NN O
old NN NN O
male NN NN O
Fischer NN NN O
- NN NN O
344 NN NN O
rats NN NN O
were NN NN O
fed NN NN O
for NN NN O
7 NN NN O
- NN NN O
25 NN NN O
months NN NN O
semipurified NN NN O
choline NN NN O
- NN NN O
devoid NN NN O
or NN NN O
choline NN NN O
- NN NN O
supplemented NN NN O
diets NN NN O
, NN NN O
containing NN NN O
or NN NN O
not NN NN O
0 NN NN O
. NN NN O
06 NN NN O
% NN NN O
phenobarbital NN NN O
. NN NN O
   
No NN NN O
hepatic NN NN O
preneoplastic NN NN O
nodules NN NN O
or NN NN O
hepatocellular NN NN B-Disease
carcinomas NN NN I-Disease
developed NN NN O
in NN NN O
rats NN NN O
fed NN NN O
the NN NN O
plain NN NN O
choline NN NN O
- NN NN O
supplemented NN NN O
diet NN NN O
, NN NN O
while NN NN O
one NN NN O
preneoplastic NN NN O
nodule NN NN O
and NN NN O
one NN NN O
hepatocellular NN NN B-Disease
carcinoma NN NN I-Disease
developed NN NN O
in NN NN O
two NN NN O
rats NN NN O
fed NN NN O
the NN NN O
same NN NN O
diet NN NN O
containing NN NN O
phenobarbital NN NN O
. NN NN O
   
The NN NN O
incidence NN NN O
of NN NN O
preneoplastic NN NN O
nodules NN NN O
and NN NN O
of NN NN O
hepatocellular NN NN B-Disease
carcinomas NN NN I-Disease
was NN NN O
10 NN NN O
% NN NN O
and NN NN O
37 NN NN O
% NN NN O
, NN NN O
respectively NN NN O
, NN NN O
in NN NN O
rats NN NN O
fed NN NN O
the NN NN O
plain NN NN O
choline NN NN O
- NN NN O
devoid NN NN O
diet NN NN O
, NN NN O
and NN NN O
17 NN NN O
% NN NN O
and NN NN O
30 NN NN O
% NN NN O
, NN NN O
in NN NN O
rats NN NN O
fed NN NN O
the NN NN O
phenobarbital NN NN O
- NN NN O
containing NN NN O
choline NN NN O
- NN NN O
devoid NN NN O
diet NN NN O
. NN NN O
   
The NN NN O
results NN NN O
evinced NN NN O
no NN NN O
enhancement NN NN O
of NN NN O
the NN NN O
hepatocarcinogenicity NN NN O
of NN NN O
the NN NN O
choline NN NN O
- NN NN O
devoid NN NN O
diet NN NN O
by NN NN O
phenobarbital NN NN O
. NN NN O
   
Sporadic NN NN O
neoplastic NN NN O
lesions NN NN O
were NN NN O
observed NN NN O
in NN NN O
organs NN NN O
other NN NN O
than NN NN O
the NN NN O
liver NN NN O
of NN NN O
some NN NN O
of NN NN O
the NN NN O
animals NN NN O
, NN NN O
irrespective NN NN O
of NN NN O
the NN NN O
diet NN NN O
fed NN NN O
. NN NN O
   
On NN NN O
two NN NN O
paradoxical NN NN O
side NN NN O
- NN NN O
effects NN NN O
of NN NN O
prednisolone NN NN O
in NN NN O
rats NN NN O
, NN NN O
ribosomal NN NN O
RNA NN NN O
biosyntheses NN NN O
, NN NN O
and NN NN O
a NN NN O
mechanism NN NN O
of NN NN O
action NN NN O
. NN NN O
   
Liver NN NN B-Disease
enlargement NN NN I-Disease
and NN NN O
muscle NN NN B-Disease
wastage NN NN I-Disease
occurred NN NN O
in NN NN O
Wistar NN NN O
rats NN NN O
following NN NN O
the NN NN O
subcutaneous NN NN O
administration NN NN O
of NN NN O
prednisolone NN NN O
. NN NN O
   
In NN NN O
the NN NN O
liver NN NN O
both NN NN O
the NN NN O
content NN NN O
of NN NN O
RNA NN NN O
and NN NN O
the NN NN O
biosynthesis NN NN O
of NN NN O
ribosomal NN NN O
RNA NN NN O
increased NN NN O
while NN NN O
both NN NN O
the NN NN O
RNA NN NN O
content NN NN O
and NN NN O
ribosomal NN NN O
RNA NN NN O
biosynthesis NN NN O
were NN NN O
reduced NN NN O
in NN NN O
the NN NN O
gastrocnemius NN NN O
muscle NN NN O
. NN NN O
   
It NN NN O
is NN NN O
suggested NN NN O
that NN NN O
the NN NN O
drug NN NN O
acted NN NN O
in NN NN O
a NN NN O
selective NN NN O
and NN NN O
tissue NN NN O
- NN NN O
specific NN NN O
manner NN NN O
to NN NN O
enhance NN NN O
ribosomal NN NN O
RNA NN NN O
synthesis NN NN O
in NN NN O
the NN NN O
liver NN NN O
and NN NN O
depress NN NN O
such NN NN O
synthesis NN NN O
in NN NN O
the NN NN O
muscle NN NN O
. NN NN O
   
This NN NN O
view NN NN O
supports NN NN O
the NN NN O
contention NN NN O
that NN NN O
the NN NN O
liver NN NN O
and NN NN O
muscle NN NN O
are NN NN O
independent NN NN O
sites NN NN O
of NN NN O
prednisolone NN NN O
action NN NN O
. NN NN O
   
Differential NN NN O
effects NN NN O
of NN NN O
gamma NN NN O
- NN NN O
hexachlorocyclohexane NN NN O
( NN NN O
lindane NN NN O
) NN NN O
on NN NN O
pharmacologically NN NN O
- NN NN O
induced NN NN O
seizures NN NN B-Disease
. NN NN O
   
Gamma NN NN O
- NN NN O
hexachlorocyclohexane NN NN O
( NN NN O
gamma NN NN O
- NN NN O
HCH NN NN O
) NN NN O
, NN NN O
the NN NN O
active NN NN O
ingredient NN NN O
of NN NN O
the NN NN O
insecticide NN NN O
lindane NN NN O
, NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
decrease NN NN O
seizure NN NN B-Disease
threshold NN NN O
to NN NN O
pentylenetrazol NN NN O
( NN NN O
PTZ NN NN O
) NN NN O
3 NN NN O
h NN NN O
after NN NN O
exposure NN NN O
to NN NN O
gamma NN NN O
- NN NN O
HCH NN NN O
and NN NN O
conversely NN NN O
increase NN NN O
threshold NN NN O
to NN NN O
PTZ NN NN O
- NN NN O
induced NN NN O
seizures NN NN B-Disease
24 NN NN O
h NN NN O
after NN NN O
exposure NN NN O
to NN NN O
gamma NN NN O
- NN NN O
HCH NN NN O
( NN NN O
Vohland NN NN O
et NN NN O
al NN NN O
. NN NN O
1981 NN NN O
) NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
the NN NN O
severity NN NN O
of NN NN O
response NN NN O
to NN NN O
other NN NN O
seizure NN NN B-Disease
- NN NN O
inducing NN NN O
agents NN NN O
was NN NN O
tested NN NN O
in NN NN O
mice NN NN O
1 NN NN O
and NN NN O
24 NN NN O
h NN NN O
after NN NN O
intraperitoneal NN NN O
administration NN NN O
of NN NN O
80 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
gamma NN NN O
- NN NN O
HCH NN NN O
. NN NN O
   
One NN NN O
hour NN NN O
after NN NN O
the NN NN O
administration NN NN O
of NN NN O
gamma NN NN O
- NN NN O
HCH NN NN O
, NN NN O
the NN NN O
activity NN NN O
of NN NN O
seizure NN NN B-Disease
- NN NN O
inducing NN NN O
agents NN NN O
was NN NN O
increased NN NN O
, NN NN O
regardless NN NN O
of NN NN O
their NN NN O
mechanism NN NN O
, NN NN O
while NN NN O
24 NN NN O
h NN NN O
after NN NN O
gamma NN NN O
- NN NN O
HCH NN NN O
a NN NN O
differential NN NN O
response NN NN O
was NN NN O
observed NN NN O
. NN NN O
   
Seizure NN NN B-Disease
activity NN NN O
due NN NN O
to NN NN O
PTZ NN NN O
and NN NN O
picrotoxin NN NN O
( NN NN O
PTX NN NN O
) NN NN O
was NN NN O
significantly NN NN O
decreased NN NN O
; NN NN O
however NN NN O
, NN NN O
seizure NN NN B-Disease
activity NN NN O
due NN NN O
to NN NN O
3 NN NN O
- NN NN O
mercaptopropionic NN NN O
acid NN NN O
( NN NN O
MPA NN NN O
) NN NN O
, NN NN O
bicuculline NN NN O
( NN NN O
BCC NN NN O
) NN NN O
, NN NN O
methyl NN NN O
6 NN NN O
, NN NN O
7 NN NN O
- NN NN O
dimethoxy NN NN O
- NN NN O
4 NN NN O
- NN NN O
ethyl NN NN O
- NN NN O
B NN NN O
- NN NN O
carboline NN NN O
- NN NN O
3 NN NN O
- NN NN O
carboxylate NN NN O
( NN NN O
DMCM NN NN O
) NN NN O
, NN NN O
or NN NN O
strychnine NN NN O
( NN NN O
STR NN NN O
) NN NN O
was NN NN O
not NN NN O
different NN NN O
from NN NN O
control NN NN O
. NN NN O
   
In NN NN O
vitro NN NN O
, NN NN O
gamma NN NN O
- NN NN O
HCH NN NN O
, NN NN O
pentylenetetrazol NN NN O
and NN NN O
picrotoxin NN NN O
were NN NN O
shown NN NN O
to NN NN O
inhibit NN NN O
3H NN NN O
- NN NN O
TBOB NN NN O
binding NN NN O
in NN NN O
mouse NN NN O
whole NN NN O
brain NN NN O
, NN NN O
with NN NN O
IC50 NN NN O
values NN NN O
of NN NN O
4 NN NN O
. NN NN O
6 NN NN O
, NN NN O
404 NN NN O
and NN NN O
9 NN NN O
. NN NN O
4 NN NN O
microM NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
MPA NN NN O
, NN NN O
BCC NN NN O
, NN NN O
DMCM NN NN O
, NN NN O
and NN NN O
STR NN NN O
showed NN NN O
no NN NN O
inhibition NN NN O
of NN NN O
3H NN NN O
- NN NN O
TBOB NN NN O
( NN NN O
t NN NN O
- NN NN O
butyl NN NN O
bicyclo NN NN O
- NN NN O
orthobenzoate NN NN O
) NN NN O
binding NN NN O
at NN NN O
concentrations NN NN O
of NN NN O
100 NN NN O
micron NN NN O
. NN NN O
   
The NN NN O
pharmacological NN NN O
challenge NN NN O
data NN NN O
suggest NN NN O
that NN NN O
tolerance NN NN O
may NN NN O
occur NN NN O
to NN NN O
seizure NN NN B-Disease
activity NN NN O
induced NN NN O
by NN NN O
PTZ NN NN O
and NN NN O
PTX NN NN O
24 NN NN O
h NN NN O
after NN NN O
gamma NN NN O
- NN NN O
HCH NN NN O
, NN NN O
since NN NN O
the NN NN O
response NN NN O
to NN NN O
only NN NN O
these NN NN O
two NN NN O
seizure NN NN B-Disease
- NN NN O
inducing NN NN O
agents NN NN O
is NN NN O
decreased NN NN O
. NN NN O
   
The NN NN O
in NN NN O
vitro NN NN O
data NN NN O
suggest NN NN O
that NN NN O
the NN NN O
site NN NN O
responsible NN NN O
for NN NN O
the NN NN O
decrease NN NN O
in NN NN O
seizure NN NN B-Disease
activity NN NN O
24 NN NN O
h NN NN O
after NN NN O
gamma NN NN O
- NN NN O
HCH NN NN O
may NN NN O
be NN NN O
the NN NN O
GABA NN NN O
- NN NN O
A NN NN O
receptor NN NN O
- NN NN O
linked NN NN O
chloride NN NN O
channel NN NN O
. NN NN O
   
Tolerance NN NN O
and NN NN O
antiviral NN NN O
effect NN NN O
of NN NN O
ribavirin NN NN O
in NN NN O
patients NN NN O
with NN NN O
Argentine NN NN B-Disease
hemorrhagic NN NN I-Disease
fever NN NN I-Disease
. NN NN O
   
Tolerance NN NN O
and NN NN O
antiviral NN NN O
effect NN NN O
of NN NN O
ribavirin NN NN O
was NN NN O
studied NN NN O
in NN NN O
6 NN NN O
patients NN NN O
with NN NN O
Argentine NN NN B-Disease
hemorrhagic NN NN I-Disease
fever NN NN I-Disease
( NN NN O
AHF NN NN B-Disease
) NN NN O
of NN NN O
more NN NN O
than NN NN O
8 NN NN O
days NN NN O
of NN NN O
evolution NN NN O
. NN NN O
   
Administration NN NN O
of NN NN O
ribavirin NN NN O
resulted NN NN O
in NN NN O
a NN NN O
neutralization NN NN O
of NN NN O
viremia NN NN B-Disease
and NN NN O
a NN NN O
drop NN NN O
of NN NN O
endogenous NN NN O
interferon NN NN O
titers NN NN O
. NN NN O
   
The NN NN O
average NN NN O
time NN NN O
of NN NN O
death NN NN B-Disease
was NN NN O
delayed NN NN O
. NN NN O
   
A NN NN O
reversible NN NN O
anemia NN NN B-Disease
was NN NN O
the NN NN O
only NN NN O
adverse NN NN O
effect NN NN O
observed NN NN O
. NN NN O
   
From NN NN O
these NN NN O
results NN NN O
, NN NN O
we NN NN O
conclude NN NN O
that NN NN O
ribavirin NN NN O
has NN NN O
an NN NN O
antiviral NN NN O
effect NN NN O
in NN NN O
advanced NN NN O
cases NN NN O
of NN NN O
AHF NN NN B-Disease
, NN NN O
and NN NN O
that NN NN O
anemia NN NN B-Disease
, NN NN O
the NN NN O
only NN NN O
secondary NN NN O
reaction NN NN O
observed NN NN O
, NN NN O
can NN NN O
be NN NN O
easily NN NN O
managed NN NN O
. NN NN O
   
The NN NN O
possible NN NN O
beneficial NN NN O
effect NN NN O
of NN NN O
ribavirin NN NN O
during NN NN O
the NN NN O
initial NN NN O
days NN NN O
of NN NN O
AHF NN NN B-Disease
is NN NN O
discussed NN NN O
. NN NN O
   
Is NN NN O
the NN NN O
treatment NN NN O
of NN NN O
scabies NN NN B-Disease
hazardous NN NN O
? NN NN O
   
Treatment NN NN O
for NN NN O
scabies NN NN B-Disease
is NN NN O
usually NN NN O
initiated NN NN O
by NN NN O
general NN NN O
practitioners NN NN O
; NN NN O
most NN NN O
consider NN NN O
lindane NN NN O
( NN NN O
gamma NN NN O
benzene NN NN O
hexachloride NN NN O
) NN NN O
the NN NN O
treatment NN NN O
of NN NN O
choice NN NN O
. NN NN O
   
Lindane NN NN O
is NN NN O
also NN NN O
widely NN NN O
used NN NN O
as NN NN O
an NN NN O
agricultural NN NN O
and NN NN O
industrial NN NN O
pesticide NN NN O
, NN NN O
and NN NN O
as NN NN O
a NN NN O
result NN NN O
the NN NN O
toxic NN NN O
profile NN NN O
of NN NN O
this NN NN O
insecticide NN NN O
is NN NN O
well NN NN O
understood NN NN O
. NN NN O
   
Evidence NN NN O
is NN NN O
accumulating NN NN O
that NN NN O
lindane NN NN O
can NN NN O
be NN NN O
toxic NN NN B-Disease
to NN NN I-Disease
the NN NN I-Disease
central NN NN I-Disease
nervous NN NN I-Disease
system NN NN I-Disease
and NN NN O
may NN NN O
be NN NN O
associated NN NN O
with NN NN O
aplastic NN NN B-Disease
anaemia NN NN I-Disease
. NN NN O
   
Preparations NN NN O
containing NN NN O
lindane NN NN O
continue NN NN O
to NN NN O
be NN NN O
sold NN NN O
over NN NN O
the NN NN O
counter NN NN O
and NN NN O
may NN NN O
represent NN NN O
a NN NN O
hazard NN NN O
to NN NN O
poorly NN NN O
informed NN NN O
patients NN NN O
. NN NN O
   
This NN NN O
literature NN NN O
review NN NN O
suggests NN NN O
that NN NN O
general NN NN O
practitioners NN NN O
should NN NN O
prescribe NN NN O
scabicides NN NN O
with NN NN O
increased NN NN O
caution NN NN O
for NN NN O
certain NN NN O
at NN NN O
- NN NN O
risk NN NN O
groups NN NN O
, NN NN O
and NN NN O
give NN NN O
adequate NN NN O
warnings NN NN O
regarding NN NN O
potential NN NN O
toxicity NN NN B-Disease
. NN NN O
   
Mouse NN NN O
strain NN NN O
- NN NN O
dependent NN NN O
effect NN NN O
of NN NN O
amantadine NN NN O
on NN NN O
motility NN NN O
and NN NN O
brain NN NN O
biogenic NN NN O
amines NN NN O
. NN NN O
   
The NN NN O
effect NN NN O
of NN NN O
amantadine NN NN O
hydrochloride NN NN O
, NN NN O
injected NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
in NN NN O
6 NN NN O
increments NN NN O
of NN NN O
100 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
each NN NN O
over NN NN O
30 NN NN O
hr NN NN O
, NN NN O
on NN NN O
mouse NN NN O
motility NN NN O
and NN NN O
whole NN NN O
brain NN NN O
content NN NN O
of NN NN O
selected NN NN O
biogenic NN NN O
amines NN NN O
and NN NN O
major NN NN O
metabolites NN NN O
was NN NN O
studied NN NN O
in NN NN O
4 NN NN O
strains NN NN O
of NN NN O
mice NN NN O
. NN NN O
   
These NN NN O
were NN NN O
the NN NN O
albino NN NN O
Sprague NN NN O
- NN NN O
Dawley NN NN O
ICR NN NN O
and NN NN O
BALB NN NN O
/ NN NN O
C NN NN O
, NN NN O
the NN NN O
black NN NN O
C57BL NN NN O
/ NN NN O
6 NN NN O
and NN NN O
the NN NN O
brown NN NN O
CDF NN NN O
- NN NN O
I NN NN O
mouse NN NN O
strains NN NN O
. NN NN O
   
Amantadine NN NN O
treatment NN NN O
produced NN NN O
a NN NN O
biphasic NN NN O
effect NN NN O
on NN NN O
mouse NN NN O
motility NN NN O
. NN NN O
   
The NN NN O
initial NN NN O
dose NN NN O
of NN NN O
amantadine NN NN O
depressed NN NN B-Disease
locomotor NN NN O
activity NN NN O
in NN NN O
all NN NN O
mouse NN NN O
strains NN NN O
studied NN NN O
with NN NN O
the NN NN O
BALB NN NN O
/ NN NN O
C NN NN O
mice NN NN O
being NN NN O
the NN NN O
most NN NN O
sensitive NN NN O
. NN NN O
   
Subsequent NN NN O
amantadine NN NN O
treatments NN NN O
produced NN NN O
enhancement NN NN O
of NN NN O
motility NN NN O
from NN NN O
corresponding NN NN O
control NN NN O
in NN NN O
all NN NN O
mouse NN NN O
strains NN NN O
with NN NN O
the NN NN O
BALB NN NN O
/ NN NN O
C NN NN O
mice NN NN O
being NN NN O
the NN NN O
least NN NN O
sensitive NN NN O
. NN NN O
   
The NN NN O
locomotor NN NN O
activity NN NN O
was NN NN O
decreased NN NN O
from NN NN O
corresponding NN NN O
controls NN NN O
in NN NN O
all NN NN O
strains NN NN O
studied NN NN O
, NN NN O
except NN NN O
for NN NN O
the NN NN O
ICR NN NN O
mice NN NN O
, NN NN O
during NN NN O
an NN NN O
overnight NN NN O
drug NN NN O
- NN NN O
free NN NN O
period NN NN O
following NN NN O
the NN NN O
fourth NN NN O
amantadine NN NN O
treatment NN NN O
. NN NN O
   
Readministration NN NN O
of NN NN O
amantadine NN NN O
, NN NN O
after NN NN O
a NN NN O
drug NN NN O
- NN NN O
free NN NN O
overnight NN NN O
period NN NN O
, NN NN O
increased NN NN O
motility NN NN O
from NN NN O
respective NN NN O
saline NN NN O
control NN NN O
in NN NN O
all NN NN O
strains NN NN O
with NN NN O
exception NN NN O
of NN NN O
the NN NN O
BALB NN NN O
/ NN NN O
C NN NN O
mice NN NN O
where NN NN O
suppression NN NN B-Disease
of NN NN I-Disease
motility NN NN I-Disease
occurred NN NN O
. NN NN O
   
Treatment NN NN O
with NN NN O
amantadine NN NN O
did NN NN O
not NN NN O
alter NN NN O
whole NN NN O
brain NN NN O
dopamine NN NN O
levels NN NN O
but NN NN O
decreased NN NN O
the NN NN O
amounts NN NN O
of NN NN O
3 NN NN O
, NN NN O
4 NN NN O
- NN NN O
dihydroxyphenylacetic NN NN O
acid NN NN O
in NN NN O
the NN NN O
BALB NN NN O
/ NN NN O
C NN NN O
mice NN NN O
compared NN NN O
to NN NN O
saline NN NN O
control NN NN O
. NN NN O
   
Conversely NN NN O
, NN NN O
brain NN NN O
normetanephrine NN NN O
concentration NN NN O
was NN NN O
increased NN NN O
from NN NN O
saline NN NN O
control NN NN O
by NN NN O
amantadine NN NN O
in NN NN O
the NN NN O
BALB NN NN O
/ NN NN O
C NN NN O
mice NN NN O
. NN NN O
   
The NN NN O
results NN NN O
suggest NN NN O
a NN NN O
strain NN NN O
- NN NN O
dependent NN NN O
effect NN NN O
of NN NN O
amantadine NN NN O
on NN NN O
motility NN NN O
and NN NN O
indicate NN NN O
a NN NN O
differential NN NN O
response NN NN O
to NN NN O
the NN NN O
acute NN NN O
and NN NN O
multiple NN NN O
dose NN NN O
regimens NN NN O
used NN NN O
. NN NN O
   
The NN NN O
BALB NN NN O
/ NN NN O
C NN NN O
mouse NN NN O
was NN NN O
the NN NN O
most NN NN O
sensitive NN NN O
strain NN NN O
and NN NN O
could NN NN O
serve NN NN O
as NN NN O
the NN NN O
strain NN NN O
of NN NN O
choice NN NN O
for NN NN O
evaluating NN NN O
the NN NN O
side NN NN O
effects NN NN O
of NN NN O
amantadine NN NN O
. NN NN O
   
The NN NN O
biochemical NN NN O
results NN NN O
of NN NN O
brain NN NN O
biogenic NN NN O
amines NN NN O
of NN NN O
BALB NN NN O
/ NN NN O
C NN NN O
mouse NN NN O
strain NN NN O
suggest NN NN O
a NN NN O
probable NN NN O
decrease NN NN O
of NN NN O
catecholamine NN NN O
turnover NN NN O
rate NN NN O
and NN NN O
/ NN NN O
or NN NN O
metabolism NN NN O
by NN NN O
monoamine NN NN O
oxidase NN NN O
and NN NN O
a NN NN O
resulting NN NN O
increase NN NN O
in NN NN O
O NN NN O
- NN NN O
methylation NN NN O
of NN NN O
norepinephrine NN NN O
which NN NN O
may NN NN O
account NN NN O
for NN NN O
a NN NN O
behavioral NN NN B-Disease
depression NN NN I-Disease
caused NN NN O
by NN NN O
amantadine NN NN O
in NN NN O
the NN NN O
BALB NN NN O
/ NN NN O
C NN NN O
mice NN NN O
. NN NN O
   
Chloroacetaldehyde NN NN O
and NN NN O
its NN NN O
contribution NN NN O
to NN NN O
urotoxicity NN NN O
during NN NN O
treatment NN NN O
with NN NN O
cyclophosphamide NN NN O
or NN NN O
ifosfamide NN NN O
. NN NN O
   
An NN NN O
experimental NN NN O
study NN NN O
/ NN NN O
short NN NN O
communication NN NN O
. NN NN O
   
Based NN NN O
on NN NN O
clinical NN NN O
data NN NN O
, NN NN O
indicating NN NN O
that NN NN O
chloroacetaldehyde NN NN O
( NN NN O
CAA NN NN O
) NN NN O
is NN NN O
an NN NN O
important NN NN O
metabolite NN NN O
of NN NN O
oxazaphosphorine NN NN O
cytostatics NN NN O
, NN NN O
an NN NN O
experimental NN NN O
study NN NN O
was NN NN O
carried NN NN O
out NN NN O
in NN NN O
order NN NN O
to NN NN O
elucidate NN NN O
the NN NN O
role NN NN O
of NN NN O
CAA NN NN O
in NN NN O
the NN NN O
development NN NN O
of NN NN O
hemorrhagic NN NN B-Disease
cystitis NN NN I-Disease
. NN NN O
   
The NN NN O
data NN NN O
demonstrate NN NN O
that NN NN O
CAA NN NN O
after NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
administration NN NN O
does NN NN O
not NN NN O
contribute NN NN O
to NN NN O
bladder NN NN B-Disease
damage NN NN I-Disease
. NN NN O
   
When NN NN O
instilled NN NN O
directly NN NN O
into NN NN O
the NN NN O
bladder NN NN O
, NN NN O
CAA NN NN O
exerts NN NN O
urotoxic NN NN O
effects NN NN O
, NN NN O
it NN NN O
is NN NN O
, NN NN O
however NN NN O
, NN NN O
susceptible NN NN O
to NN NN O
detoxification NN NN O
with NN NN O
mesna NN NN O
. NN NN O
   
Source NN NN O
of NN NN O
pain NN NN B-Disease
and NN NN O
primitive NN NN O
dysfunction NN NN O
in NN NN O
migraine NN NN B-Disease
: NN NN O
an NN NN O
identical NN NN O
site NN NN O
? NN NN O
   
Twenty NN NN O
common NN NN O
migraine NN NN B-Disease
patients NN NN O
received NN NN O
a NN NN O
one NN NN O
sided NN NN O
frontotemporal NN NN O
application NN NN O
of NN NN O
nitroglycerin NN NN O
( NN NN O
10 NN NN O
patients NN NN O
) NN NN O
or NN NN O
placebo NN NN O
ointment NN NN O
( NN NN O
10 NN NN O
patients NN NN O
) NN NN O
in NN NN O
a NN NN O
double NN NN O
blind NN NN O
study NN NN O
. NN NN O
   
Early NN NN O
onset NN NN O
migraine NN NN B-Disease
attacks NN NN O
were NN NN O
induced NN NN O
by NN NN O
nitroglycerin NN NN O
in NN NN O
seven NN NN O
out NN NN O
of NN NN O
10 NN NN O
patients NN NN O
versus NN NN O
no NN NN O
patient NN NN O
in NN NN O
the NN NN O
placebo NN NN O
group NN NN O
. NN NN O
   
Subsequently NN NN O
20 NN NN O
migraine NN NN B-Disease
patients NN NN O
, NN NN O
who NN NN O
developed NN NN O
an NN NN O
early NN NN O
onset NN NN O
attack NN NN O
with NN NN O
frontotemporal NN NN O
nitroglycerin NN NN O
, NN NN O
received NN NN O
the NN NN O
drug NN NN O
in NN NN O
a NN NN O
second NN NN O
induction NN NN O
test NN NN O
at NN NN O
other NN NN O
body NN NN O
areas NN NN O
. NN NN O
   
No NN NN O
early NN NN O
onset NN NN O
migraine NN NN B-Disease
was NN NN O
observed NN NN O
. NN NN O
   
Thus NN NN O
the NN NN O
migraine NN NN B-Disease
- NN NN O
inducing NN NN O
effect NN NN O
of NN NN O
nitroglycerin NN NN O
seems NN NN O
to NN NN O
depend NN NN O
on NN NN O
direct NN NN O
stimulation NN NN O
of NN NN O
the NN NN O
habitual NN NN O
site NN NN O
of NN NN O
pain NN NN B-Disease
, NN NN O
suggesting NN NN O
that NN NN O
the NN NN O
frontotemporal NN NN O
region NN NN O
is NN NN O
of NN NN O
crucial NN NN O
importance NN NN O
in NN NN O
the NN NN O
development NN NN O
of NN NN O
a NN NN O
migraine NN NN B-Disease
crisis NN NN O
. NN NN O
   
This NN NN O
is NN NN O
not NN NN O
consistent NN NN O
with NN NN O
a NN NN O
CNS NN NN O
origin NN NN O
of NN NN O
migraine NN NN B-Disease
attack NN NN O
. NN NN O
   
Hypersensitivity NN NN B-Disease
to NN NN O
carbamazepine NN NN O
presenting NN NN O
with NN NN O
a NN NN O
leukemoid NN NN B-Disease
reaction NN NN I-Disease
, NN NN O
eosinophilia NN NN B-Disease
, NN NN O
erythroderma NN NN B-Disease
, NN NN O
and NN NN O
renal NN NN B-Disease
failure NN NN I-Disease
. NN NN O
   
We NN NN O
report NN NN O
a NN NN O
patient NN NN O
in NN NN O
whom NN NN O
hypersensitivity NN NN B-Disease
to NN NN O
carbamazepine NN NN O
presented NN NN O
with NN NN O
generalized NN NN O
erythroderma NN NN B-Disease
, NN NN O
a NN NN O
severe NN NN O
leukemoid NN NN B-Disease
reaction NN NN I-Disease
, NN NN O
eosinophilia NN NN B-Disease
, NN NN O
hyponatremia NN NN B-Disease
, NN NN O
and NN NN O
renal NN NN B-Disease
failure NN NN I-Disease
. NN NN O
   
This NN NN O
is NN NN O
the NN NN O
first NN NN O
report NN NN O
of NN NN O
such NN NN O
an NN NN O
unusual NN NN O
reaction NN NN O
to NN NN O
carbamazepine NN NN O
. NN NN O
   
Fluoxetine NN NN O
- NN NN O
induced NN NN O
akathisia NN NN B-Disease
: NN NN O
clinical NN NN O
and NN NN O
theoretical NN NN O
implications NN NN O
. NN NN O
   
Five NN NN O
patients NN NN O
receiving NN NN O
fluoxetine NN NN O
for NN NN O
the NN NN O
treatment NN NN O
of NN NN O
obsessive NN NN B-Disease
compulsive NN NN I-Disease
disorder NN NN I-Disease
or NN NN O
major NN NN B-Disease
depression NN NN I-Disease
developed NN NN O
akathisia NN NN B-Disease
. NN NN O
   
The NN NN O
typical NN NN O
fluoxetine NN NN O
- NN NN O
induced NN NN O
symptoms NN NN O
of NN NN O
restlessness NN NN O
, NN NN O
constant NN NN O
pacing NN NN O
, NN NN O
purposeless NN NN O
movements NN NN O
of NN NN O
the NN NN O
feet NN NN O
and NN NN O
legs NN NN O
, NN NN O
and NN NN O
marked NN NN O
anxiety NN NN B-Disease
were NN NN O
indistinguishable NN NN O
from NN NN O
those NN NN O
of NN NN O
neuroleptic NN NN O
- NN NN O
induced NN NN O
akathisia NN NN B-Disease
. NN NN O
   
Three NN NN O
patients NN NN O
who NN NN O
had NN NN O
experienced NN NN O
neuroleptic NN NN O
- NN NN O
induced NN NN O
akathisia NN NN B-Disease
in NN NN O
the NN NN O
past NN NN O
reported NN NN O
that NN NN O
the NN NN O
symptoms NN NN O
of NN NN O
fluoxetine NN NN O
- NN NN O
induced NN NN O
akathisia NN NN B-Disease
were NN NN O
identical NN NN O
, NN NN O
although NN NN O
somewhat NN NN O
milder NN NN O
. NN NN O
   
Akathisia NN NN B-Disease
appeared NN NN O
to NN NN O
be NN NN O
a NN NN O
common NN NN O
side NN NN O
effect NN NN O
of NN NN O
fluoxetine NN NN O
and NN NN O
generally NN NN O
responded NN NN O
well NN NN O
to NN NN O
treatment NN NN O
with NN NN O
the NN NN O
beta NN NN O
- NN NN O
adrenergic NN NN O
antagonist NN NN O
propranolol NN NN O
, NN NN O
dose NN NN O
reduction NN NN O
, NN NN O
or NN NN O
both NN NN O
. NN NN O
   
The NN NN O
authors NN NN O
suggest NN NN O
that NN NN O
fluoxetine NN NN O
- NN NN O
induced NN NN O
akathisia NN NN B-Disease
may NN NN O
be NN NN O
caused NN NN O
by NN NN O
serotonergically NN NN O
mediated NN NN O
inhibition NN NN O
of NN NN O
dopaminergic NN NN O
neurotransmission NN NN O
and NN NN O
that NN NN O
the NN NN O
pathophysiology NN NN O
of NN NN O
fluoxetine NN NN O
- NN NN O
induced NN NN O
akathisia NN NN B-Disease
and NN NN O
tricyclic NN NN O
antidepressant NN NN O
- NN NN O
induced NN NN O
"""""""" NN NN O
jitteriness NN NN O
"""""""" NN NN O
may NN NN O
be NN NN O
identical NN NN O
. NN NN O
   
Effect NN NN O
of NN NN O
converting NN NN O
enzyme NN NN O
inhibition NN NN O
on NN NN O
the NN NN O
course NN NN O
of NN NN O
adriamycin NN NN O
- NN NN O
induced NN NN O
nephropathy NN NN B-Disease
. NN NN O
   
The NN NN O
effect NN NN O
of NN NN O
the NN NN O
converting NN NN O
enzyme NN NN O
inhibitor NN NN O
( NN NN O
CEI NN NN O
) NN NN O
enalapril NN NN O
was NN NN O
assessed NN NN O
in NN NN O
Munich NN NN O
- NN NN O
Wistar NN NN O
rats NN NN O
with NN NN O
established NN NN O
adriamycin NN NN O
nephrosis NN NN B-Disease
. NN NN O
   
Rats NN NN O
were NN NN O
given NN NN O
a NN NN O
single NN NN O
dose NN NN O
of NN NN O
adriamycin NN NN O
and NN NN O
one NN NN O
month NN NN O
later NN NN O
divided NN NN O
into NN NN O
four NN NN O
groups NN NN O
matched NN NN O
for NN NN O
albuminuria NN NN B-Disease
, NN NN O
blood NN NN O
pressure NN NN O
, NN NN O
and NN NN O
plasma NN NN O
albumin NN NN O
concentration NN NN O
. NN NN O
   
Groups NN NN O
1 NN NN O
and NN NN O
3 NN NN O
remained NN NN O
untreated NN NN O
while NN NN O
groups NN NN O
2 NN NN O
and NN NN O
4 NN NN O
received NN NN O
enalapril NN NN O
. NN NN O
   
Groups NN NN O
1 NN NN O
and NN NN O
2 NN NN O
underwent NN NN O
micropuncture NN NN O
studies NN NN O
after NN NN O
10 NN NN O
days NN NN O
. NN NN O
   
These NN NN O
short NN NN O
- NN NN O
term NN NN O
studies NN NN O
showed NN NN O
that NN NN O
enalapril NN NN O
reduced NN NN O
arterial NN NN O
blood NN NN O
pressure NN NN O
( NN NN O
101 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
vs NN NN O
. NN NN O
124 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
3 NN NN O
mm NN NN O
Hg NN NN O
, NN NN O
group NN NN O
2 NN NN O
vs NN NN O
. NN NN O
1 NN NN O
, NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
and NN NN O
glomerular NN NN O
capillary NN NN O
pressure NN NN O
( NN NN O
54 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
vs NN NN O
. NN NN O
61 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
mm NN NN O
Hg NN NN O
, NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
without NN NN O
reducing NN NN O
albuminuria NN NN B-Disease
( NN NN O
617 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
50 NN NN O
vs NN NN O
. NN NN O
570 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
47 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
) NN NN O
or NN NN O
GFR NN NN O
( NN NN O
1 NN NN O
. NN NN O
03 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
04 NN NN O
vs NN NN O
. NN NN O
1 NN NN O
. NN NN O
04 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
11 NN NN O
ml NN NN O
/ NN NN O
min NN NN O
) NN NN O
. NN NN O
   
Groups NN NN O
3 NN NN O
and NN NN O
4 NN NN O
were NN NN O
studied NN NN O
at NN NN O
four NN NN O
and NN NN O
at NN NN O
six NN NN O
months NN NN O
to NN NN O
assess NN NN O
the NN NN O
effect NN NN O
of NN NN O
enalapril NN NN O
on NN NN O
progression NN NN O
of NN NN O
renal NN NN B-Disease
injury NN NN I-Disease
in NN NN O
adriamycin NN NN O
nephrosis NN NN B-Disease
. NN NN O
   
Chronic NN NN O
enalapril NN NN O
treatment NN NN O
reduced NN NN O
blood NN NN O
pressure NN NN O
without NN NN O
reducing NN NN O
albuminuria NN NN B-Disease
in NN NN O
group NN NN O
4 NN NN O
. NN NN O
   
Untreated NN NN O
group NN NN O
3 NN NN O
rats NN NN O
exhibited NN NN O
a NN NN O
progressive NN NN O
reduction NN NN O
in NN NN O
GFR NN NN O
( NN NN O
0 NN NN O
. NN NN O
35 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
08 NN NN O
ml NN NN O
/ NN NN O
min NN NN O
at NN NN O
4 NN NN O
months NN NN O
, NN NN O
0 NN NN O
. NN NN O
27 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
07 NN NN O
ml NN NN O
/ NN NN O
min NN NN O
at NN NN O
6 NN NN O
months NN NN O
) NN NN O
. NN NN O
   
Enalapril NN NN O
treatment NN NN O
blunted NN NN O
but NN NN O
did NN NN O
not NN NN O
prevent NN NN O
reduction NN NN O
in NN NN O
GFR NN NN O
in NN NN O
group NN NN O
4 NN NN O
( NN NN O
0 NN NN O
. NN NN O
86 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
15 NN NN O
ml NN NN O
/ NN NN O
min NN NN O
at NN NN O
4 NN NN O
months NN NN O
, NN NN O
0 NN NN O
. NN NN O
69 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
13 NN NN O
ml NN NN O
/ NN NN O
min NN NN O
at NN NN O
6 NN NN O
months NN NN O
, NN NN O
both NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
05 NN NN O
vs NN NN O
. NN NN O
group NN NN O
3 NN NN O
) NN NN O
. NN NN O
   
Reduction NN NN O
in NN NN O
GFR NN NN O
was NN NN O
associated NN NN O
with NN NN O
the NN NN O
development NN NN O
of NN NN O
glomerular NN NN B-Disease
sclerosis NN NN I-Disease
in NN NN O
both NN NN O
treated NN NN O
and NN NN O
untreated NN NN O
rats NN NN O
. NN NN O
( NN NN O
ABSTRACT NN NN O
TRUNCATED NN NN O
AT NN NN O
250 NN NN O
WORDS NN NN O
) NN NN O
   
Clotiazepam NN NN O
- NN NN O
induced NN NN O
acute NN NN O
hepatitis NN NN B-Disease
. NN NN O
   
We NN NN O
report NN NN O
the NN NN O
case NN NN O
of NN NN O
a NN NN O
patient NN NN O
who NN NN O
developed NN NN O
acute NN NN O
hepatitis NN NN B-Disease
with NN NN O
extensive NN NN B-Disease
hepatocellular NN NN I-Disease
necrosis NN NN I-Disease
, NN NN O
7 NN NN O
months NN NN O
after NN NN O
the NN NN O
onset NN NN O
of NN NN O
administration NN NN O
of NN NN O
clotiazepam NN NN O
, NN NN O
a NN NN O
thienodiazepine NN NN O
derivative NN NN O
. NN NN O
   
Clotiazepam NN NN O
withdrawal NN NN O
was NN NN O
followed NN NN O
by NN NN O
prompt NN NN O
recovery NN NN O
. NN NN O
   
The NN NN O
administration NN NN O
of NN NN O
several NN NN O
benzodiazepines NN NN O
, NN NN O
chemically NN NN O
related NN NN O
to NN NN O
clotiazepam NN NN O
, NN NN O
did NN NN O
not NN NN O
interfere NN NN O
with NN NN O
recovery NN NN O
and NN NN O
did NN NN O
not NN NN O
induce NN NN O
any NN NN O
relapse NN NN O
of NN NN O
hepatitis NN NN B-Disease
. NN NN O
   
This NN NN O
observation NN NN O
shows NN NN O
that NN NN O
clotiazepam NN NN O
can NN NN O
induce NN NN O
acute NN NN O
hepatitis NN NN B-Disease
and NN NN O
suggests NN NN O
that NN NN O
there NN NN O
is NN NN O
no NN NN O
cross NN NN O
hepatotoxicity NN NN B-Disease
between NN NN O
clotiazepam NN NN O
and NN NN O
several NN NN O
benzodiazepines NN NN O
. NN NN O
   
5 NN NN O
- NN NN O
azacytidine NN NN O
potentiates NN NN O
initiation NN NN B-Disease
induced NN NN I-Disease
by NN NN I-Disease
carcinogens NN NN I-Disease
in NN NN O
rat NN NN O
liver NN NN O
. NN NN O
   
To NN NN O
test NN NN O
the NN NN O
validity NN NN O
of NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
hypomethylation NN NN O
of NN NN O
DNA NN NN O
plays NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
the NN NN O
initiation NN NN B-Disease
of NN NN I-Disease
carcinogenic NN NN I-Disease
process NN NN I-Disease
, NN NN O
5 NN NN O
- NN NN O
azacytidine NN NN O
( NN NN O
5 NN NN O
- NN NN O
AzC NN NN O
) NN NN O
( NN NN O
10 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
, NN NN O
an NN NN O
inhibitor NN NN O
of NN NN O
DNA NN NN O
methylation NN NN O
, NN NN O
was NN NN O
given NN NN O
to NN NN O
rats NN NN O
during NN NN O
the NN NN O
phase NN NN O
of NN NN O
repair NN NN O
synthesis NN NN O
induced NN NN O
by NN NN O
the NN NN O
three NN NN O
carcinogens NN NN O
, NN NN O
benzo NN NN O
[ NN NN O
a NN NN O
] NN NN O
- NN NN O
pyrene NN NN O
( NN NN O
200 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
, NN NN O
N NN NN O
- NN NN O
methyl NN NN O
- NN NN O
N NN NN O
- NN NN O
nitrosourea NN NN O
( NN NN O
60 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
and NN NN O
1 NN NN O
, NN NN O
2 NN NN O
- NN NN O
dimethylhydrazine NN NN O
( NN NN O
1 NN NN O
, NN NN O
2 NN NN O
- NN NN O
DMH NN NN O
) NN NN O
( NN NN O
100 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
. NN NN O
   
The NN NN O
initiated NN NN O
hepatocytes NN NN O
in NN NN O
the NN NN O
liver NN NN O
were NN NN O
assayed NN NN O
as NN NN O
the NN NN O
gamma NN NN O
- NN NN O
glutamyltransferase NN NN O
( NN NN O
gamma NN NN O
- NN NN O
GT NN NN O
) NN NN O
positive NN NN O
foci NN NN O
formed NN NN O
following NN NN O
a NN NN O
2 NN NN O
- NN NN O
week NN NN O
selection NN NN O
regimen NN NN O
consisting NN NN O
of NN NN O
dietary NN NN O
0 NN NN O
. NN NN O
02 NN NN O
% NN NN O
2 NN NN O
- NN NN O
acetylaminofluorene NN NN O
coupled NN NN O
with NN NN O
a NN NN O
necrogenic NN NN O
dose NN NN O
of NN NN O
CCl4 NN NN O
. NN NN O
   
The NN NN O
results NN NN O
obtained NN NN O
indicate NN NN O
that NN NN O
with NN NN O
all NN NN O
three NN NN O
carcinogens NN NN O
, NN NN O
administration NN NN O
of NN NN O
5 NN NN O
- NN NN O
AzC NN NN O
during NN NN O
repair NN NN O
synthesis NN NN O
increased NN NN O
the NN NN O
incidence NN NN O
of NN NN O
initiated NN NN O
hepatocytes NN NN O
, NN NN O
for NN NN O
example NN NN O
10 NN NN O
- NN NN O
20 NN NN O
foci NN NN O
/ NN NN O
cm2 NN NN O
in NN NN O
5 NN NN O
- NN NN O
AzC NN NN O
and NN NN O
carcinogen NN NN O
- NN NN O
treated NN NN O
rats NN NN O
compared NN NN O
with NN NN O
3 NN NN O
- NN NN O
5 NN NN O
foci NN NN O
/ NN NN O
cm2 NN NN O
in NN NN O
rats NN NN O
treated NN NN O
with NN NN O
carcinogen NN NN O
only NN NN O
. NN NN O
   
Administration NN NN O
of NN NN O
[ NN NN O
3H NN NN O
] NN NN O
- NN NN O
5 NN NN O
- NN NN O
azadeoxycytidine NN NN O
during NN NN O
the NN NN O
repair NN NN O
synthesis NN NN O
induced NN NN O
by NN NN O
1 NN NN O
, NN NN O
2 NN NN O
- NN NN O
DMH NN NN O
further NN NN O
showed NN NN O
that NN NN O
0 NN NN O
. NN NN O
019 NN NN O
mol NN NN O
% NN NN O
of NN NN O
cytosine NN NN O
residues NN NN O
in NN NN O
DNA NN NN O
were NN NN O
substituted NN NN O
by NN NN O
the NN NN O
analogue NN NN O
, NN NN O
indicating NN NN O
that NN NN O
incorporation NN NN O
of NN NN O
5 NN NN O
- NN NN O
AzC NN NN O
occurs NN NN O
during NN NN O
repair NN NN O
synthesis NN NN O
. NN NN O
   
In NN NN O
the NN NN O
absence NN NN O
of NN NN O
the NN NN O
carcinogen NN NN O
, NN NN O
5 NN NN O
- NN NN O
AzC NN NN O
given NN NN O
after NN NN O
a NN NN O
two NN NN O
thirds NN NN O
partial NN NN O
hepatectomy NN NN O
, NN NN O
when NN NN O
its NN NN O
incorporation NN NN O
should NN NN O
be NN NN O
maximum NN NN O
, NN NN O
failed NN NN O
to NN NN O
induce NN NN O
any NN NN O
gamma NN NN O
- NN NN O
GT NN NN O
positive NN NN O
foci NN NN O
. NN NN O
   
The NN NN O
results NN NN O
suggest NN NN O
that NN NN O
hypomethylation NN NN O
of NN NN O
DNA NN NN O
per NN NN O
se NN NN O
may NN NN O
not NN NN O
be NN NN O
sufficient NN NN O
for NN NN O
initiation NN NN O
. NN NN O
   
Perhaps NN NN O
two NN NN O
events NN NN O
might NN NN O
be NN NN O
necessary NN NN O
for NN NN O
initiation NN NN O
, NN NN O
the NN NN O
first NN NN O
caused NN NN O
by NN NN O
the NN NN O
carcinogen NN NN O
and NN NN O
a NN NN O
second NN NN O
involving NN NN O
hypomethylation NN NN O
of NN NN O
DNA NN NN O
. NN NN O
   
Antihypertensive NN NN O
drugs NN NN O
and NN NN O
depression NN NN B-Disease
: NN NN O
a NN NN O
reappraisal NN NN O
. NN NN O
   
Eighty NN NN O
- NN NN O
nine NN NN O
new NN NN O
referral NN NN O
hypertensive NN NN B-Disease
out NN NN O
- NN NN O
patients NN NN O
and NN NN O
46 NN NN O
new NN NN O
referral NN NN O
non NN NN O
- NN NN O
hypertensive NN NN B-Disease
chronically NN NN O
physically NN NN O
ill NN NN O
out NN NN O
- NN NN O
patients NN NN O
completed NN NN O
a NN NN O
mood NN NN O
rating NN NN O
scale NN NN O
at NN NN O
regular NN NN O
intervals NN NN O
for NN NN O
one NN NN O
year NN NN O
. NN NN O
   
The NN NN O
results NN NN O
showed NN NN O
a NN NN O
high NN NN O
prevalence NN NN O
of NN NN O
depression NN NN B-Disease
in NN NN O
both NN NN O
groups NN NN O
of NN NN O
patients NN NN O
, NN NN O
with NN NN O
no NN NN O
preponderance NN NN O
in NN NN O
the NN NN O
hypertensive NN NN B-Disease
group NN NN O
. NN NN O
   
Hypertensive NN NN B-Disease
patients NN NN O
with NN NN O
psychiatric NN NN B-Disease
histories NN NN O
had NN NN O
a NN NN O
higher NN NN O
prevalence NN NN O
of NN NN O
depression NN NN B-Disease
than NN NN O
the NN NN O
comparison NN NN O
patients NN NN O
. NN NN O
   
This NN NN O
was NN NN O
accounted NN NN O
for NN NN O
by NN NN O
a NN NN O
significant NN NN O
number NN NN O
of NN NN O
depressions NN NN B-Disease
occurring NN NN O
in NN NN O
methyl NN NN O
dopa NN NN O
treated NN NN O
patients NN NN O
with NN NN O
psychiatric NN NN B-Disease
histories NN NN O
. NN NN O
   
Chronic NN NN B-Disease
active NN NN I-Disease
hepatitis NN NN I-Disease
associated NN NN O
with NN NN O
diclofenac NN NN O
sodium NN NN O
therapy NN NN O
. NN NN O
   
Diclofenac NN NN O
sodium NN NN O
( NN NN O
Voltarol NN NN O
, NN NN O
Geigy NN NN O
Pharmaceuticals NN NN O
) NN NN O
is NN NN O
a NN NN O
non NN NN O
- NN NN O
steroidal NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
derivative NN NN O
of NN NN O
phenylacetic NN NN O
acid NN NN O
. NN NN O
   
Although NN NN O
generally NN NN O
well NN NN O
- NN NN O
tolerated NN NN O
, NN NN O
asymptomatic NN NN O
abnormalities NN NN B-Disease
of NN NN I-Disease
liver NN NN I-Disease
function NN NN I-Disease
have NN NN O
been NN NN O
recorded NN NN O
and NN NN O
, NN NN O
less NN NN O
commonly NN NN O
, NN NN O
severe NN NN O
hepatitis NN NN B-Disease
induced NN NN O
by NN NN O
diclofenac NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
described NN NN O
developed NN NN O
chronic NN NN B-Disease
active NN NN I-Disease
hepatitis NN NN I-Disease
after NN NN O
six NN NN O
months NN NN O
therapy NN NN O
with NN NN O
diclofenac NN NN O
sodium NN NN O
which NN NN O
progressed NN NN O
despite NN NN O
the NN NN O
withdrawal NN NN O
of NN NN O
the NN NN O
drug NN NN O
, NN NN O
a NN NN O
finding NN NN O
not NN NN O
previously NN NN O
reported NN NN O
. NN NN O
   
Arterial NN NN O
hypertension NN NN B-Disease
as NN NN O
a NN NN O
complication NN NN O
of NN NN O
prolonged NN NN O
ketoconazole NN NN O
treatment NN NN O
. NN NN O
   
Two NN NN O
of NN NN O
14 NN NN O
patients NN NN O
with NN NN O
Cushing NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
syndrome NN NN I-Disease
treated NN NN O
on NN NN O
a NN NN O
long NN NN O
- NN NN O
term NN NN O
basis NN NN O
with NN NN O
ketoconazole NN NN O
developed NN NN O
sustained NN NN O
hypertension NN NN B-Disease
. NN NN O
   
In NN NN O
both NN NN O
cases NN NN O
normal NN NN O
plasma NN NN O
and NN NN O
urinary NN NN O
free NN NN O
cortisol NN NN O
levels NN NN O
had NN NN O
been NN NN O
achieved NN NN O
following NN NN O
ketoconazole NN NN O
therapy NN NN O
, NN NN O
yet NN NN O
continuous NN NN O
blood NN NN O
pressure NN NN O
monitoring NN NN O
demonstrated NN NN O
hypertension NN NN B-Disease
31 NN NN O
( NN NN O
patient NN NN O
1 NN NN O
) NN NN O
and NN NN O
52 NN NN O
weeks NN NN O
( NN NN O
patient NN NN O
2 NN NN O
) NN NN O
after NN NN O
treatment NN NN O
. NN NN O
   
In NN NN O
patient NN NN O
1 NN NN O
, NN NN O
plasma NN NN O
levels NN NN O
of NN NN O
deoxycorticosterone NN NN O
and NN NN O
11 NN NN O
- NN NN O
deoxycortisol NN NN O
were NN NN O
elevated NN NN O
. NN NN O
   
In NN NN O
patient NN NN O
2 NN NN O
, NN NN O
in NN NN O
addition NN NN O
to NN NN O
an NN NN O
increase NN NN O
in NN NN O
both NN NN O
deoxycorticosterone NN NN O
and NN NN O
11 NN NN O
- NN NN O
deoxycortisol NN NN O
levels NN NN O
, NN NN O
plasma NN NN O
aldosterone NN NN O
values NN NN O
were NN NN O
raised NN NN O
, NN NN O
with NN NN O
a NN NN O
concomitant NN NN O
suppression NN NN O
of NN NN O
renin NN NN O
levels NN NN O
. NN NN O
   
Our NN NN O
findings NN NN O
show NN NN O
that NN NN O
long NN NN O
- NN NN O
term NN NN O
treatment NN NN O
with NN NN O
high NN NN O
doses NN NN O
of NN NN O
ketoconazole NN NN O
may NN NN O
induce NN NN O
enzyme NN NN O
blockade NN NN O
leading NN NN O
to NN NN O
mineralocorticoid NN NN O
- NN NN O
related NN NN O
hypertension NN NN B-Disease
. NN NN O
   
Effects NN NN O
of NN NN O
an NN NN O
inhibitor NN NN O
of NN NN O
angiotensin NN NN O
converting NN NN O
enzyme NN NN O
( NN NN O
Captopril NN NN O
) NN NN O
on NN NN O
pulmonary NN NN B-Disease
and NN NN I-Disease
renal NN NN I-Disease
insufficiency NN NN I-Disease
due NN NN O
to NN NN O
intravascular NN NN B-Disease
coagulation NN NN I-Disease
in NN NN O
the NN NN O
rat NN NN O
. NN NN O
   
Induction NN NN O
of NN NN O
intravascular NN NN B-Disease
coagulation NN NN I-Disease
and NN NN O
inhibition NN NN O
of NN NN O
fibrinolysis NN NN O
by NN NN O
injection NN NN O
of NN NN O
thrombin NN NN O
and NN NN O
tranexamic NN NN O
acid NN NN O
( NN NN O
AMCA NN NN O
) NN NN O
in NN NN O
the NN NN O
rat NN NN O
gives NN NN O
rise NN NN O
to NN NN O
pulmonary NN NN B-Disease
and NN NN I-Disease
renal NN NN I-Disease
insufficiency NN NN I-Disease
resembling NN NN O
that NN NN O
occurring NN NN O
after NN NN O
trauma NN NN B-Disease
or NN NN O
sepsis NN NN B-Disease
in NN NN O
man NN NN O
. NN NN O
   
Injection NN NN O
of NN NN O
Captopril NN NN O
( NN NN O
1 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
, NN NN O
an NN NN O
inhibitor NN NN O
of NN NN O
angiotensin NN NN O
converting NN NN O
enzyme NN NN O
( NN NN O
ACE NN NN O
) NN NN O
, NN NN O
reduced NN NN O
both NN NN O
pulmonary NN NN B-Disease
and NN NN I-Disease
renal NN NN I-Disease
insufficiency NN NN I-Disease
in NN NN O
this NN NN O
rat NN NN O
model NN NN O
. NN NN O
   
The NN NN O
lung NN NN O
weights NN NN O
were NN NN O
lower NN NN O
and NN NN O
PaO2 NN NN O
was NN NN O
improved NN NN O
in NN NN O
rats NN NN O
given NN NN O
this NN NN O
enzyme NN NN O
- NN NN O
blocking NN NN O
agent NN NN O
. NN NN O
   
The NN NN O
contents NN NN O
of NN NN O
albumin NN NN O
in NN NN O
the NN NN O
lungs NN NN O
were NN NN O
not NN NN O
changed NN NN O
, NN NN O
indicating NN NN O
that NN NN O
Captopril NN NN O
did NN NN O
not NN NN O
influence NN NN O
the NN NN O
extravasation NN NN O
of NN NN O
protein NN NN O
. NN NN O
   
Renal NN NN B-Disease
damage NN NN I-Disease
as NN NN O
reflected NN NN O
by NN NN O
an NN NN O
increase NN NN O
in NN NN O
serum NN NN O
urea NN NN O
and NN NN O
in NN NN O
kidney NN NN O
weight NN NN O
was NN NN O
prevented NN NN O
by NN NN O
Captopril NN NN O
. NN NN O
   
The NN NN O
amount NN NN O
of NN NN O
fibrin NN NN O
in NN NN O
the NN NN O
kidneys NN NN O
was NN NN O
also NN NN O
considerably NN NN O
lower NN NN O
than NN NN O
in NN NN O
animals NN NN O
which NN NN O
received NN NN O
thrombin NN NN O
and NN NN O
AMCA NN NN O
alone NN NN O
. NN NN O
   
It NN NN O
is NN NN O
suggested NN NN O
that NN NN O
the NN NN O
effects NN NN O
of NN NN O
Captopril NN NN O
on NN NN O
the NN NN O
lungs NN NN O
may NN NN O
be NN NN O
attributable NN NN O
to NN NN O
a NN NN O
vasodilatory NN NN O
effect NN NN O
due NN NN O
to NN NN O
a NN NN O
reduction NN NN O
in NN NN O
the NN NN O
circulating NN NN O
level NN NN O
of NN NN O
Angiotension NN NN O
II NN NN O
and NN NN O
an NN NN O
increase NN NN O
in NN NN O
prostacyclin NN NN O
( NN NN O
secondary NN NN O
to NN NN O
an NN NN O
increase NN NN O
in NN NN O
bradykinin NN NN O
) NN NN O
. NN NN O
   
Captopril NN NN O
may NN NN O
, NN NN O
by NN NN O
the NN NN O
same NN NN O
mechanism NN NN O
, NN NN O
reduce NN NN O
the NN NN O
increase NN NN O
in NN NN O
glomerular NN NN O
filtration NN NN O
that NN NN O
is NN NN O
known NN NN O
to NN NN O
occur NN NN O
after NN NN O
an NN NN O
injection NN NN O
of NN NN O
thrombin NN NN O
, NN NN O
thereby NN NN O
diminishing NN NN O
the NN NN O
aggregation NN NN O
of NN NN O
fibrin NN NN O
monomers NN NN O
in NN NN O
the NN NN O
glomeruli NN NN O
, NN NN O
with NN NN O
the NN NN O
result NN NN O
that NN NN O
less NN NN O
fibrin NN NN O
will NN NN O
be NN NN O
deposited NN NN O
and NN NN O
thus NN NN O
less NN NN O
kidney NN NN B-Disease
damage NN NN I-Disease
will NN NN O
be NN NN O
produced NN NN O
. NN NN O
   
Stroke NN NN B-Disease
associated NN NN O
with NN NN O
cocaine NN NN O
use NN NN O
. NN NN O
   
We NN NN O
describe NN NN O
eight NN NN O
patients NN NN O
in NN NN O
whom NN NN O
cocaine NN NN O
use NN NN O
was NN NN O
related NN NN O
to NN NN O
stroke NN NN B-Disease
and NN NN O
review NN NN O
39 NN NN O
cases NN NN O
from NN NN O
the NN NN O
literature NN NN O
. NN NN O
   
Among NN NN O
these NN NN O
47 NN NN O
patients NN NN O
the NN NN O
mean NN NN O
( NN NN O
+ NN NN O
/ NN NN O
- NN NN O
SD NN NN O
) NN NN O
age NN NN O
was NN NN O
32 NN NN O
. NN NN O
5 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
12 NN NN O
. NN NN O
1 NN NN O
years NN NN O
; NN NN O
76 NN NN O
% NN NN O
( NN NN O
34 NN NN O
/ NN NN O
45 NN NN O
) NN NN O
were NN NN O
men NN NN O
. NN NN O
   
Stroke NN NN B-Disease
followed NN NN O
cocaine NN NN O
use NN NN O
by NN NN O
inhalation NN NN O
, NN NN O
intranasal NN NN O
, NN NN O
intravenous NN NN O
, NN NN O
and NN NN O
intramuscular NN NN O
routes NN NN O
. NN NN O
   
Intracranial NN NN B-Disease
aneurysms NN NN I-Disease
or NN NN O
arteriovenous NN NN B-Disease
malformations NN NN I-Disease
were NN NN O
present NN NN O
in NN NN O
17 NN NN O
of NN NN O
32 NN NN O
patients NN NN O
studied NN NN O
angiographically NN NN O
or NN NN O
at NN NN O
autopsy NN NN O
; NN NN O
cerebral NN NN B-Disease
vasculitis NN NN I-Disease
was NN NN O
present NN NN O
in NN NN O
two NN NN O
patients NN NN O
. NN NN O
   
Cerebral NN NN B-Disease
infarction NN NN I-Disease
occurred NN NN O
in NN NN O
10 NN NN O
patients NN NN O
( NN NN O
22 NN NN O
% NN NN O
) NN NN O
, NN NN O
intracerebral NN NN B-Disease
hemorrhage NN NN I-Disease
in NN NN O
22 NN NN O
( NN NN O
49 NN NN O
% NN NN O
) NN NN O
, NN NN O
and NN NN O
subarachnoid NN NN B-Disease
hemorrhage NN NN I-Disease
in NN NN O
13 NN NN O
( NN NN O
29 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
These NN NN O
data NN NN O
indicate NN NN O
that NN NN O
( NN NN O
1 NN NN O
) NN NN O
the NN NN O
apparent NN NN O
incidence NN NN O
of NN NN O
stroke NN NN B-Disease
related NN NN O
to NN NN O
cocaine NN NN O
use NN NN O
is NN NN O
increasing NN NN O
; NN NN O
( NN NN O
2 NN NN O
) NN NN O
cocaine NN NN O
- NN NN O
associated NN NN O
stroke NN NN B-Disease
occurs NN NN O
primarily NN NN O
in NN NN O
young NN NN O
adults NN NN O
; NN NN O
( NN NN O
3 NN NN O
) NN NN O
stroke NN NN B-Disease
may NN NN O
follow NN NN O
any NN NN O
route NN NN O
of NN NN O
cocaine NN NN O
administration NN NN O
; NN NN O
( NN NN O
4 NN NN O
) NN NN O
stroke NN NN B-Disease
after NN NN O
cocaine NN NN O
use NN NN O
is NN NN O
frequently NN NN O
associated NN NN O
with NN NN O
intracranial NN NN B-Disease
aneurysms NN NN I-Disease
and NN NN O
arteriovenous NN NN B-Disease
malformations NN NN I-Disease
; NN NN O
and NN NN O
( NN NN O
5 NN NN O
) NN NN O
in NN NN O
cocaine NN NN O
- NN NN O
associated NN NN O
stroke NN NN B-Disease
, NN NN O
the NN NN O
frequency NN NN O
of NN NN O
intracranial NN NN B-Disease
hemorrhage NN NN I-Disease
exceeds NN NN O
that NN NN O
of NN NN O
cerebral NN NN B-Disease
infarction NN NN I-Disease
. NN NN O
   
A NN NN O
randomized NN NN O
comparison NN NN O
of NN NN O
labetalol NN NN O
and NN NN O
nitroprusside NN NN O
for NN NN O
induced NN NN O
hypotension NN NN B-Disease
. NN NN O
   
In NN NN O
a NN NN O
randomized NN NN O
study NN NN O
, NN NN O
labetalol NN NN O
- NN NN O
induced NN NN O
hypotension NN NN B-Disease
and NN NN O
nitroprusside NN NN O
- NN NN O
induced NN NN O
hypotension NN NN B-Disease
were NN NN O
compared NN NN O
in NN NN O
20 NN NN O
patients NN NN O
( NN NN O
10 NN NN O
in NN NN O
each NN NN O
group NN NN O
) NN NN O
scheduled NN NN O
for NN NN O
major NN NN O
orthopedic NN NN O
procedures NN NN O
. NN NN O
   
Each NN NN O
patient NN NN O
was NN NN O
subjected NN NN O
to NN NN O
an NN NN O
identical NN NN O
anesthetic NN NN O
protocol NN NN O
and NN NN O
similar NN NN O
drug NN NN O
- NN NN O
induced NN NN O
reductions NN NN B-Disease
in NN NN I-Disease
mean NN NN I-Disease
arterial NN NN I-Disease
blood NN NN I-Disease
pressure NN NN I-Disease
( NN NN O
BP NN NN O
) NN NN O
( NN NN O
50 NN NN O
to NN NN O
55 NN NN O
mmHg NN NN O
) NN NN O
. NN NN O
   
Nitroprusside NN NN O
infusion NN NN O
was NN NN O
associated NN NN O
with NN NN O
a NN NN O
significant NN NN O
( NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
increase NN NN B-Disease
in NN NN I-Disease
heart NN NN I-Disease
rate NN NN I-Disease
and NN NN I-Disease
cardiac NN NN I-Disease
output NN NN I-Disease
; NN NN O
rebound NN NN O
hypertension NN NN B-Disease
was NN NN O
observed NN NN O
in NN NN O
three NN NN O
patients NN NN O
after NN NN O
discontinuation NN NN O
of NN NN O
nitroprusside NN NN O
. NN NN O
   
Labetalol NN NN O
administration NN NN O
was NN NN O
not NN NN O
associated NN NN O
with NN NN O
any NN NN O
of NN NN O
these NN NN O
findings NN NN O
. NN NN O
   
Arterial NN NN O
PO2 NN NN O
decreased NN NN O
in NN NN O
both NN NN O
groups NN NN O
. NN NN O
   
It NN NN O
was NN NN O
concluded NN NN O
that NN NN O
labetalol NN NN O
offers NN NN O
advantages NN NN O
over NN NN O
nitroprusside NN NN O
. NN NN O
   
Sodium NN NN O
status NN NN O
influences NN NN O
chronic NN NN O
amphotericin NN NN O
B NN NN O
nephrotoxicity NN NN B-Disease
in NN NN O
rats NN NN O
. NN NN O
   
The NN NN O
nephrotoxic NN NN B-Disease
potential NN NN O
of NN NN O
amphotericin NN NN O
B NN NN O
( NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
per NN NN O
day NN NN O
intraperitoneally NN NN O
for NN NN O
3 NN NN O
weeks NN NN O
) NN NN O
has NN NN O
been NN NN O
investigated NN NN O
in NN NN O
salt NN NN O
- NN NN O
depleted NN NN O
, NN NN O
normal NN NN O
- NN NN O
salt NN NN O
, NN NN O
and NN NN O
salt NN NN O
- NN NN O
loaded NN NN O
rats NN NN O
. NN NN O
   
In NN NN O
salt NN NN O
- NN NN O
depleted NN NN O
rats NN NN O
, NN NN O
amphotericin NN NN O
B NN NN O
decreased NN NN O
creatinine NN NN O
clearance NN NN O
linearly NN NN O
with NN NN O
time NN NN O
, NN NN O
with NN NN O
an NN NN O
85 NN NN O
% NN NN O
reduction NN NN O
by NN NN O
week NN NN O
3 NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
in NN NN O
normal NN NN O
- NN NN O
salt NN NN O
rats NN NN O
creatinine NN NN O
clearance NN NN O
was NN NN O
decreased NN NN O
but NN NN O
to NN NN O
a NN NN O
lesser NN NN O
extent NN NN O
at NN NN O
week NN NN O
2 NN NN O
and NN NN O
3 NN NN O
, NN NN O
and NN NN O
in NN NN O
salt NN NN O
- NN NN O
loaded NN NN O
rats NN NN O
creatinine NN NN O
clearance NN NN O
did NN NN O
not NN NN O
change NN NN O
for NN NN O
2 NN NN O
weeks NN NN O
and NN NN O
was NN NN O
decreased NN NN O
by NN NN O
43 NN NN O
% NN NN O
at NN NN O
week NN NN O
3 NN NN O
. NN NN O
   
All NN NN O
rats NN NN O
in NN NN O
the NN NN O
sodium NN NN O
- NN NN O
depleted NN NN O
group NN NN O
had NN NN O
histopathological NN NN O
evidence NN NN O
of NN NN O
patchy NN NN O
tubular NN NN O
cytoplasmic NN NN O
degeneration NN NN O
in NN NN O
tubules NN NN O
that NN NN O
was NN NN O
not NN NN O
observed NN NN O
in NN NN O
any NN NN O
normal NN NN O
- NN NN O
salt NN NN O
or NN NN O
salt NN NN O
- NN NN O
loaded NN NN O
rat NN NN O
. NN NN O
   
Concentrations NN NN O
of NN NN O
amphotericin NN NN O
B NN NN O
in NN NN O
plasma NN NN O
were NN NN O
not NN NN O
significantly NN NN O
different NN NN O
among NN NN O
the NN NN O
three NN NN O
groups NN NN O
at NN NN O
any NN NN O
time NN NN O
during NN NN O
the NN NN O
study NN NN O
. NN NN O
   
However NN NN O
, NN NN O
at NN NN O
the NN NN O
end NN NN O
of NN NN O
3 NN NN O
weeks NN NN O
, NN NN O
amphotericin NN NN O
B NN NN O
levels NN NN O
in NN NN O
the NN NN O
kidneys NN NN O
and NN NN O
liver NN NN O
were NN NN O
significantly NN NN O
higher NN NN O
in NN NN O
salt NN NN O
- NN NN O
depleted NN NN O
and NN NN O
normal NN NN O
- NN NN O
salt NN NN O
rats NN NN O
than NN NN O
those NN NN O
in NN NN O
salt NN NN O
- NN NN O
loaded NN NN O
rats NN NN O
, NN NN O
with NN NN O
plasma NN NN O
/ NN NN O
kidney NN NN O
ratios NN NN O
of NN NN O
21 NN NN O
, NN NN O
14 NN NN O
, NN NN O
and NN NN O
8 NN NN O
in NN NN O
salt NN NN O
- NN NN O
depleted NN NN O
, NN NN O
normal NN NN O
- NN NN O
salt NN NN O
, NN NN O
and NN NN O
salt NN NN O
- NN NN O
loaded NN NN O
rats NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
In NN NN O
conclusion NN NN O
, NN NN O
reductions NN NN O
in NN NN O
creatinine NN NN O
clearance NN NN O
and NN NN O
renal NN NN O
amphotericin NN NN O
B NN NN O
accumulation NN NN O
after NN NN O
chronic NN NN O
amphotericin NN NN O
B NN NN O
administration NN NN O
were NN NN O
enhanced NN NN O
by NN NN O
salt NN NN O
depletion NN NN O
and NN NN O
attenuated NN NN O
by NN NN O
sodium NN NN O
loading NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
Flestolol NN NN O
: NN NN O
an NN NN O
ultra NN NN O
- NN NN O
short NN NN O
- NN NN O
acting NN NN O
beta NN NN O
- NN NN O
adrenergic NN NN O
blocking NN NN O
agent NN NN O
. NN NN O
   
Flestolol NN NN O
( NN NN O
ACC NN NN O
- NN NN O
9089 NN NN O
) NN NN O
is NN NN O
a NN NN O
nonselective NN NN O
, NN NN O
competitive NN NN O
, NN NN O
ultra NN NN O
- NN NN O
short NN NN O
- NN NN O
acting NN NN O
beta NN NN O
- NN NN O
adrenergic NN NN O
blocking NN NN O
agent NN NN O
, NN NN O
without NN NN O
any NN NN O
intrinsic NN NN O
sympathomimetic NN NN O
activity NN NN O
. NN NN O
   
Flestolol NN NN O
is NN NN O
metabolized NN NN O
by NN NN O
plasma NN NN O
esterases NN NN O
and NN NN O
has NN NN O
an NN NN O
elimination NN NN O
half NN NN O
- NN NN O
life NN NN O
of NN NN O
approximately NN NN O
6 NN NN O
. NN NN O
5 NN NN O
minutes NN NN O
. NN NN O
   
This NN NN O
agent NN NN O
was NN NN O
well NN NN O
tolerated NN NN O
in NN NN O
healthy NN NN O
volunteers NN NN O
at NN NN O
doses NN NN O
up NN NN O
to NN NN O
100 NN NN O
micrograms NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
. NN NN O
   
In NN NN O
long NN NN O
- NN NN O
term NN NN O
infusion NN NN O
studies NN NN O
, NN NN O
flestolol NN NN O
was NN NN O
well NN NN O
tolerated NN NN O
at NN NN O
the NN NN O
effective NN NN O
beta NN NN O
- NN NN O
blocking NN NN O
dose NN NN O
( NN NN O
5 NN NN O
micrograms NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
) NN NN O
for NN NN O
up NN NN O
to NN NN O
seven NN NN O
days NN NN O
. NN NN O
   
Flestolol NN NN O
blood NN NN O
concentrations NN NN O
increased NN NN O
linearly NN NN O
with NN NN O
increasing NN NN O
dose NN NN O
and NN NN O
good NN NN O
correlation NN NN O
exists NN NN O
between NN NN O
blood NN NN O
concentrations NN NN O
of NN NN O
flestolol NN NN O
and NN NN O
beta NN NN O
- NN NN O
adrenergic NN NN O
blockade NN NN O
. NN NN O
   
Flestolol NN NN O
produced NN NN O
a NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
attenuation NN NN O
of NN NN O
isoproterenol NN NN O
- NN NN O
induced NN NN O
tachycardia NN NN B-Disease
. NN NN O
   
Electrophysiologic NN NN O
and NN NN O
hemodynamic NN NN O
effects NN NN O
of NN NN O
flestolol NN NN O
are NN NN O
similar NN NN O
to NN NN O
those NN NN O
of NN NN O
other NN NN O
beta NN NN O
blockers NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
with NN NN O
other NN NN O
beta NN NN O
blockers NN NN O
, NN NN O
flestolol NN NN O
- NN NN O
induced NN NN O
effects NN NN O
reverse NN NN O
rapidly NN NN O
( NN NN O
within NN NN O
30 NN NN O
minutes NN NN O
) NN NN O
following NN NN O
discontinuation NN NN O
because NN NN O
of NN NN O
its NN NN O
short NN NN O
half NN NN O
- NN NN O
life NN NN O
. NN NN O
   
Flestolol NN NN O
effectively NN NN O
reduced NN NN O
heart NN NN O
rate NN NN O
in NN NN O
patients NN NN O
with NN NN O
supraventricular NN NN B-Disease
tachyarrhythmia NN NN I-Disease
. NN NN O
   
In NN NN O
patients NN NN O
with NN NN O
unstable NN NN B-Disease
angina NN NN I-Disease
, NN NN O
flestolol NN NN O
infusion NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
safe NN NN O
and NN NN O
effective NN NN O
in NN NN O
controlling NN NN O
chest NN NN B-Disease
pain NN NN I-Disease
. NN NN O
   
It NN NN O
is NN NN O
concluded NN NN O
that NN NN O
flestolol NN NN O
is NN NN O
a NN NN O
potent NN NN O
, NN NN O
well NN NN O
- NN NN O
tolerated NN NN O
, NN NN O
ultra NN NN O
- NN NN O
short NN NN O
- NN NN O
acting NN NN O
beta NN NN O
- NN NN O
adrenergic NN NN O
blocking NN NN O
agent NN NN O
. NN NN O
   
Use NN NN O
of NN NN O
flestolol NN NN O
in NN NN O
the NN NN O
critical NN NN O
care NN NN O
setting NN NN O
is NN NN O
currently NN NN O
undergoing NN NN O
investigation NN NN O
. NN NN O
   
Immunohistochemical NN NN O
, NN NN O
electron NN NN O
microscopic NN NN O
and NN NN O
morphometric NN NN O
studies NN NN O
of NN NN O
estrogen NN NN O
- NN NN O
induced NN NN O
rat NN NN O
prolactinomas NN NN B-Disease
after NN NN O
bromocriptine NN NN O
treatment NN NN O
. NN NN O
   
To NN NN O
clarify NN NN O
the NN NN O
effects NN NN O
of NN NN O
bromocriptine NN NN O
on NN NN O
prolactinoma NN NN B-Disease
cells NN NN O
in NN NN O
vivo NN NN O
, NN NN O
immunohistochemical NN NN O
, NN NN O
ultrastructural NN NN O
and NN NN O
morphometrical NN NN O
analyses NN NN O
were NN NN O
applied NN NN O
to NN NN O
estrogen NN NN O
- NN NN O
induced NN NN O
rat NN NN O
prolactinoma NN NN B-Disease
cells NN NN O
1 NN NN O
h NN NN O
and NN NN O
6 NN NN O
h NN NN O
after NN NN O
injection NN NN O
of NN NN O
bromocriptine NN NN O
( NN NN O
3 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
of NN NN O
body NN NN O
weight NN NN O
) NN NN O
. NN NN O
   
One NN NN O
h NN NN O
after NN NN O
treatment NN NN O
, NN NN O
serum NN NN O
prolactin NN NN O
levels NN NN O
decreased NN NN O
markedly NN NN O
. NN NN O
   
Electron NN NN O
microscopy NN NN O
disclosed NN NN O
many NN NN O
secretory NN NN O
granules NN NN O
, NN NN O
slightly NN NN O
distorted NN NN O
rough NN NN O
endoplasmic NN NN O
reticulum NN NN O
, NN NN O
and NN NN O
partially NN NN O
dilated NN NN O
Golgi NN NN O
cisternae NN NN O
in NN NN O
the NN NN O
prolactinoma NN NN B-Disease
cells NN NN O
. NN NN O
   
Morphometric NN NN O
analysis NN NN O
revealed NN NN O
that NN NN O
the NN NN O
volume NN NN O
density NN NN O
of NN NN O
secretory NN NN O
granules NN NN O
increased NN NN O
, NN NN O
while NN NN O
the NN NN O
volume NN NN O
density NN NN O
of NN NN O
cytoplasmic NN NN O
microtubules NN NN O
decreased NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
lowered NN NN O
serum NN NN O
prolactin NN NN O
levels NN NN O
in NN NN O
the NN NN O
early NN NN O
phase NN NN O
of NN NN O
bromocriptine NN NN O
treatment NN NN O
may NN NN O
result NN NN O
from NN NN O
an NN NN O
impaired NN NN O
secretion NN NN O
of NN NN O
prolactin NN NN O
due NN NN O
to NN NN O
decreasing NN NN O
numbers NN NN O
of NN NN O
cytoplasmic NN NN O
microtubules NN NN O
. NN NN O
   
At NN NN O
6 NN NN O
h NN NN O
after NN NN O
injection NN NN O
, NN NN O
serum NN NN O
prolactin NN NN O
levels NN NN O
were NN NN O
still NN NN O
considerably NN NN O
lower NN NN O
than NN NN O
in NN NN O
controls NN NN O
. NN NN O
   
The NN NN O
prolactinoma NN NN B-Disease
cells NN NN O
at NN NN O
this NN NN O
time NN NN O
were NN NN O
well NN NN O
granulated NN NN O
, NN NN O
with NN NN O
vesiculated NN NN O
rough NN NN O
endoplasmic NN NN O
reticulum NN NN O
and NN NN O
markedly NN NN O
dilated NN NN O
Golgi NN NN O
cisternae NN NN O
. NN NN O
   
Electron NN NN O
microscopical NN NN O
immunohistochemistry NN NN O
revealed NN NN O
positive NN NN O
reaction NN NN O
products NN NN O
noted NN NN O
on NN NN O
the NN NN O
secretory NN NN O
granules NN NN O
, NN NN O
Golgi NN NN O
cisternae NN NN O
, NN NN O
and NN NN O
endoplasmic NN NN O
reticulum NN NN O
of NN NN O
the NN NN O
untreated NN NN O
rat NN NN O
prolactinoma NN NN B-Disease
cells NN NN O
. NN NN O
   
However NN NN O
, NN NN O
only NN NN O
secretory NN NN O
granules NN NN O
showed NN NN O
the NN NN O
positive NN NN O
reaction NN NN O
products NN NN O
for NN NN O
prolactin NN NN O
6 NN NN O
h NN NN O
after NN NN O
bromocriptine NN NN O
treatment NN NN O
of NN NN O
the NN NN O
adenoma NN NN B-Disease
cells NN NN O
. NN NN O
   
An NN NN O
increase NN NN O
in NN NN O
the NN NN O
volume NN NN O
density NN NN O
of NN NN O
secretory NN NN O
granules NN NN O
and NN NN O
a NN NN O
decrease NN NN O
in NN NN O
the NN NN O
volume NN NN O
densities NN NN O
of NN NN O
rough NN NN O
endoplasmic NN NN O
reticulum NN NN O
and NN NN O
microtubules NN NN O
was NN NN O
determined NN NN O
by NN NN O
morphometric NN NN O
analysis NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
bromocriptine NN NN O
inhibits NN NN O
protein NN NN O
synthesis NN NN O
as NN NN O
well NN NN O
as NN NN O
bringing NN NN O
about NN NN O
a NN NN O
disturbance NN NN O
of NN NN O
the NN NN O
prolactin NN NN O
secretion NN NN O
. NN NN O
   
Sulfasalazine NN NN O
- NN NN O
induced NN NN O
lupus NN NN B-Disease
erythematosus NN NN I-Disease
. NN NN O
   
Pneumonitis NN NN B-Disease
, NN NN O
bilateral NN NN O
pleural NN NN B-Disease
effusions NN NN I-Disease
, NN NN O
echocardiographic NN NN O
evidence NN NN O
of NN NN O
cardiac NN NN B-Disease
tamponade NN NN I-Disease
, NN NN O
and NN NN O
positive NN NN O
autoantibodies NN NN O
developed NN NN O
in NN NN O
a NN NN O
43 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
man NN NN O
, NN NN O
who NN NN O
was NN NN O
receiving NN NN O
long NN NN O
- NN NN O
term NN NN O
sulfasalazine NN NN O
therapy NN NN O
for NN NN O
chronic NN NN O
ulcerative NN NN B-Disease
colitis NN NN I-Disease
. NN NN O
   
After NN NN O
cessation NN NN O
of NN NN O
the NN NN O
sulfasalazine NN NN O
and NN NN O
completion NN NN O
of NN NN O
a NN NN O
six NN NN O
- NN NN O
week NN NN O
course NN NN O
of NN NN O
corticosteroids NN NN O
, NN NN O
these NN NN O
problems NN NN O
resolved NN NN O
over NN NN O
a NN NN O
period NN NN O
of NN NN O
four NN NN O
to NN NN O
six NN NN O
months NN NN O
. NN NN O
   
It NN NN O
is NN NN O
suggested NN NN O
that NN NN O
the NN NN O
patient NN NN O
had NN NN O
sulfasalazine NN NN O
- NN NN O
induced NN NN O
lupus NN NN B-Disease
, NN NN O
which NN NN O
manifested NN NN O
with NN NN O
serositis NN NN B-Disease
and NN NN O
pulmonary NN NN O
parenchymal NN NN O
involvement NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
joint NN NN O
symptoms NN NN O
. NN NN O
   
Physicians NN NN O
who NN NN O
use NN NN O
sulfasalazine NN NN O
to NN NN O
treat NN NN O
patients NN NN O
with NN NN O
inflammatory NN NN B-Disease
bowel NN NN I-Disease
disease NN NN I-Disease
should NN NN O
be NN NN O
aware NN NN O
of NN NN O
the NN NN O
signs NN NN O
of NN NN O
sulfasalazine NN NN O
- NN NN O
induced NN NN O
lupus NN NN B-Disease
syndrome NN NN I-Disease
. NN NN O
   
Chronic NN NN O
carbamazepine NN NN O
treatment NN NN O
in NN NN O
the NN NN O
rat NN NN O
: NN NN O
efficacy NN NN O
, NN NN O
toxicity NN NN B-Disease
, NN NN O
and NN NN O
effect NN NN O
on NN NN O
plasma NN NN O
and NN NN O
tissue NN NN O
folate NN NN O
concentrations NN NN O
. NN NN O
   
Folate NN NN O
depletion NN NN O
has NN NN O
often NN NN O
been NN NN O
a NN NN O
problem NN NN O
in NN NN O
chronic NN NN O
antiepileptic NN NN O
drug NN NN O
( NN NN O
AED NN NN O
) NN NN O
therapy NN NN O
. NN NN O
   
Carbamazepine NN NN O
( NN NN O
CBZ NN NN O
) NN NN O
, NN NN O
a NN NN O
commonly NN NN O
used NN NN O
AED NN NN O
, NN NN O
has NN NN O
been NN NN O
implicated NN NN O
in NN NN O
some NN NN O
clinical NN NN O
studies NN NN O
. NN NN O
   
A NN NN O
rat NN NN O
model NN NN O
was NN NN O
developed NN NN O
to NN NN O
examine NN NN O
the NN NN O
effects NN NN O
of NN NN O
chronic NN NN O
CBZ NN NN O
treatment NN NN O
on NN NN O
folate NN NN O
concentrations NN NN O
in NN NN O
the NN NN O
rat NN NN O
. NN NN O
   
In NN NN O
the NN NN O
course NN NN O
of NN NN O
developing NN NN O
this NN NN O
model NN NN O
, NN NN O
a NN NN O
common NN NN O
vehicle NN NN O
, NN NN O
propylene NN NN O
glycol NN NN O
, NN NN O
by NN NN O
itself NN NN O
in NN NN O
high NN NN O
doses NN NN O
, NN NN O
was NN NN O
found NN NN O
to NN NN O
exhibit NN NN O
protective NN NN O
properties NN NN O
against NN NN O
induced NN NN O
seizures NN NN B-Disease
and NN NN O
inhibited NN NN O
weight NN NN B-Disease
gain NN NN I-Disease
. NN NN O
   
Seizures NN NN B-Disease
induced NN NN O
by NN NN O
hexafluorodiethyl NN NN O
ether NN NN O
( NN NN O
HFDE NN NN O
) NN NN O
were NN NN O
also NN NN O
found NN NN O
to NN NN O
be NN NN O
a NN NN O
more NN NN O
sensitive NN NN O
measure NN NN O
of NN NN O
protection NN NN O
by NN NN O
CBZ NN NN O
than NN NN O
seizures NN NN B-Disease
induced NN NN O
by NN NN O
maximal NN NN O
electroshock NN NN O
( NN NN O
MES NN NN O
) NN NN O
. NN NN O
   
Oral NN NN O
administration NN NN O
of NN NN O
CBZ NN NN O
as NN NN O
an NN NN O
aqueous NN NN O
suspension NN NN O
every NN NN O
8 NN NN O
h NN NN O
at NN NN O
a NN NN O
dose NN NN O
of NN NN O
250 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
was NN NN O
continuously NN NN O
protective NN NN O
against NN NN O
HFDE NN NN O
- NN NN O
induced NN NN O
seizures NN NN B-Disease
and NN NN O
was NN NN O
minimally NN NN O
toxic NN NN O
as NN NN O
measured NN NN O
by NN NN O
weight NN NN B-Disease
gain NN NN I-Disease
over NN NN O
8 NN NN O
weeks NN NN O
of NN NN O
treatment NN NN O
. NN NN O
   
The NN NN O
CBZ NN NN O
levels NN NN O
measured NN NN O
in NN NN O
plasma NN NN O
and NN NN O
brain NN NN O
of NN NN O
these NN NN O
animals NN NN O
, NN NN O
however NN NN O
, NN NN O
were NN NN O
below NN NN O
those NN NN O
normally NN NN O
considered NN NN O
protective NN NN O
. NN NN O
   
This NN NN O
treatment NN NN O
with NN NN O
CBZ NN NN O
had NN NN O
no NN NN O
apparent NN NN O
adverse NN NN O
effect NN NN O
on NN NN O
folate NN NN O
concentrations NN NN O
in NN NN O
the NN NN O
rat NN NN O
, NN NN O
and NN NN O
, NN NN O
indeed NN NN O
, NN NN O
the NN NN O
folate NN NN O
concentration NN NN O
increased NN NN O
in NN NN O
liver NN NN O
after NN NN O
6 NN NN O
weeks NN NN O
of NN NN O
treatment NN NN O
and NN NN O
in NN NN O
plasma NN NN O
at NN NN O
8 NN NN O
weeks NN NN O
of NN NN O
treatment NN NN O
. NN NN O
   
Dipyridamole NN NN O
- NN NN O
induced NN NN O
myocardial NN NN B-Disease
ischemia NN NN I-Disease
. NN NN O
   
Angina NN NN B-Disease
and NN NN O
ischemic NN NN O
electrocardiographic NN NN O
changes NN NN O
occurred NN NN O
after NN NN O
administration NN NN O
of NN NN O
oral NN NN O
dipyridamole NN NN O
in NN NN O
four NN NN O
patients NN NN O
awaiting NN NN O
urgent NN NN O
myocardial NN NN O
revascularization NN NN O
procedures NN NN O
. NN NN O
   
To NN NN O
our NN NN O
knowledge NN NN O
, NN NN O
this NN NN O
has NN NN O
not NN NN O
previously NN NN O
been NN NN O
reported NN NN O
as NN NN O
a NN NN O
side NN NN O
effect NN NN O
of NN NN O
preoperative NN NN O
dipyridamole NN NN O
therapy NN NN O
, NN NN O
although NN NN O
dipyridamole NN NN O
- NN NN O
induced NN NN O
myocardial NN NN B-Disease
ischemia NN NN I-Disease
has NN NN O
been NN NN O
demonstrated NN NN O
to NN NN O
occur NN NN O
in NN NN O
animals NN NN O
and NN NN O
humans NN NN O
with NN NN O
coronary NN NN B-Disease
artery NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
Epicardial NN NN O
coronary NN NN O
collateral NN NN O
vessels NN NN O
were NN NN O
demonstrated NN NN O
in NN NN O
all NN NN O
four NN NN O
patients NN NN O
; NN NN O
a NN NN O
coronary NN NN O
"""""""" NN NN O
steal NN NN O
"""""""" NN NN O
phenomenon NN NN O
may NN NN O
be NN NN O
the NN NN O
mechanism NN NN O
of NN NN O
the NN NN O
dipyridamole NN NN O
- NN NN O
induced NN NN O
ischemia NN NN B-Disease
observed NN NN O
. NN NN O
   
Inhibition NN NN O
of NN NN O
sympathoadrenal NN NN O
activity NN NN O
by NN NN O
atrial NN NN O
natriuretic NN NN O
factor NN NN O
in NN NN O
dogs NN NN O
. NN NN O
   
In NN NN O
six NN NN O
conscious NN NN O
, NN NN O
trained NN NN O
dogs NN NN O
, NN NN O
maintained NN NN O
on NN NN O
a NN NN O
normal NN NN O
sodium NN NN O
intake NN NN O
of NN NN O
2 NN NN O
to NN NN O
4 NN NN O
mEq NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
, NN NN O
sympathetic NN NN O
activity NN NN O
was NN NN O
assessed NN NN O
as NN NN O
the NN NN O
release NN NN O
rate NN NN O
of NN NN O
norepinephrine NN NN O
and NN NN O
epinephrine NN NN O
during NN NN O
15 NN NN O
- NN NN O
minute NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
infusions NN NN O
of NN NN O
human NN NN O
alpha NN NN O
- NN NN O
atrial NN NN O
natriuretic NN NN O
factor NN NN O
. NN NN O
   
Mean NN NN O
arterial NN NN O
pressure NN NN O
( NN NN O
as NN NN O
a NN NN O
percentage NN NN O
of NN NN O
control NN NN O
+ NN NN O
/ NN NN O
- NN NN O
SEM NN NN O
) NN NN O
during NN NN O
randomized NN NN O
infusions NN NN O
of NN NN O
0 NN NN O
. NN NN O
03 NN NN O
, NN NN O
0 NN NN O
. NN NN O
1 NN NN O
, NN NN O
0 NN NN O
. NN NN O
3 NN NN O
, NN NN O
or NN NN O
1 NN NN O
. NN NN O
0 NN NN O
microgram NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
was NN NN O
99 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
, NN NN O
95 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
( NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
, NN NN O
93 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
( NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
, NN NN O
or NN NN O
79 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
6 NN NN O
% NN NN O
( NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
, NN NN O
respectively NN NN O
, NN NN O
but NN NN O
no NN NN O
tachycardia NN NN B-Disease
and NN NN O
no NN NN O
augmentation NN NN O
of NN NN O
the NN NN O
norepinephrine NN NN O
release NN NN O
rate NN NN O
( NN NN O
up NN NN O
to NN NN O
0 NN NN O
. NN NN O
3 NN NN O
microgram NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
) NN NN O
were NN NN O
observed NN NN O
, NN NN O
which NN NN O
is NN NN O
in NN NN O
contrast NN NN O
to NN NN O
comparable NN NN O
hypotension NN NN B-Disease
induced NN NN O
by NN NN O
hydralazine NN NN O
or NN NN O
nitroglycerin NN NN O
. NN NN O
   
The NN NN O
release NN NN O
rate NN NN O
of NN NN O
epinephrine NN NN O
( NN NN O
control NN NN O
, NN NN O
6 NN NN O
. NN NN O
7 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
6 NN NN O
ng NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
) NN NN O
declined NN NN O
immediately NN NN O
during NN NN O
infusions NN NN O
of NN NN O
atrial NN NN O
natriuretic NN NN O
factor NN NN O
to NN NN O
a NN NN O
minimum NN NN O
of NN NN O
49 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
5 NN NN O
% NN NN O
of NN NN O
control NN NN O
( NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
during NN NN O
0 NN NN O
. NN NN O
1 NN NN O
microgram NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
and NN NN O
to NN NN O
63 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
5 NN NN O
% NN NN O
( NN NN O
0 NN NN O
. NN NN O
1 NN NN O
greater NN NN O
than NN NN O
p NN NN O
greater NN NN O
than NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
or NN NN O
95 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
13 NN NN O
% NN NN O
( NN NN O
not NN NN O
significant NN NN O
) NN NN O
during NN NN O
0 NN NN O
. NN NN O
3 NN NN O
or NN NN O
1 NN NN O
. NN NN O
0 NN NN O
microgram NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
. NN NN O
   
Steady NN NN O
state NN NN O
arterial NN NN O
plasma NN NN O
concentrations NN NN O
of NN NN O
atrial NN NN O
natriuretic NN NN O
factor NN NN O
were NN NN O
39 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
10 NN NN O
pg NN NN O
/ NN NN O
ml NN NN O
( NN NN O
n NN NN O
= NN NN O
6 NN NN O
) NN NN O
during NN NN O
infusions NN NN O
of NN NN O
saline NN NN O
and NN NN O
284 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
24 NN NN O
pg NN NN O
/ NN NN O
ml NN NN O
( NN NN O
n NN NN O
= NN NN O
6 NN NN O
) NN NN O
and NN NN O
1520 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
300 NN NN O
pg NN NN O
/ NN NN O
ml NN NN O
( NN NN O
n NN NN O
= NN NN O
9 NN NN O
) NN NN O
during NN NN O
0 NN NN O
. NN NN O
03 NN NN O
and NN NN O
0 NN NN O
. NN NN O
1 NN NN O
microgram NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
infusions NN NN O
of NN NN O
the NN NN O
factor NN NN O
. NN NN O
( NN NN O
ABSTRACT NN NN O
TRUNCATED NN NN O
AT NN NN O
250 NN NN O
WORDS NN NN O
) NN NN O
   
Inhibition NN NN O
of NN NN O
immunoreactive NN NN O
corticotropin NN NN O
- NN NN O
releasing NN NN O
factor NN NN O
secretion NN NN O
into NN NN O
the NN NN O
hypophysial NN NN O
- NN NN O
portal NN NN O
circulation NN NN O
by NN NN O
delayed NN NN O
glucocorticoid NN NN O
feedback NN NN O
. NN NN O
   
Nitroprusside NN NN O
- NN NN O
induced NN NN O
hypotension NN NN B-Disease
evokes NN NN O
ACTH NN NN O
secretion NN NN O
which NN NN O
is NN NN O
primarily NN NN O
mediated NN NN O
by NN NN O
enhanced NN NN O
secretion NN NN O
of NN NN O
immunoreactive NN NN O
corticotropin NN NN O
- NN NN O
releasing NN NN O
factor NN NN O
( NN NN O
irCRF NN NN O
) NN NN O
into NN NN O
the NN NN O
hypophysial NN NN O
- NN NN O
portal NN NN O
circulation NN NN O
. NN NN O
   
Portal NN NN O
plasma NN NN O
concentrations NN NN O
of NN NN O
neither NN NN O
arginine NN NN O
vasopressin NN NN O
nor NN NN O
oxytocin NN NN O
are NN NN O
significantly NN NN O
altered NN NN O
in NN NN O
this NN NN O
paradigm NN NN O
. NN NN O
   
Application NN NN O
of NN NN O
a NN NN O
delayed NN NN O
feedback NN NN O
signal NN NN O
, NN NN O
in NN NN O
the NN NN O
form NN NN O
of NN NN O
a NN NN O
2 NN NN O
- NN NN O
h NN NN O
systemic NN NN O
corticosterone NN NN O
infusion NN NN O
in NN NN O
urethane NN NN O
- NN NN O
anesthetized NN NN O
rats NN NN O
with NN NN O
pharmacological NN NN O
blockade NN NN O
of NN NN O
glucocorticoid NN NN O
synthesis NN NN O
, NN NN O
is NN NN O
without NN NN O
effect NN NN O
on NN NN O
the NN NN O
resting NN NN O
secretion NN NN O
of NN NN O
arginine NN NN O
vasopressin NN NN O
and NN NN O
oxytocin NN NN O
at NN NN O
any NN NN O
corticosterone NN NN O
feedback NN NN O
dose NN NN O
tested NN NN O
. NN NN O
   
Resting NN NN O
irCRF NN NN O
levels NN NN O
are NN NN O
suppressed NN NN O
only NN NN O
at NN NN O
the NN NN O
highest NN NN O
corticosterone NN NN O
infusion NN NN O
rate NN NN O
, NN NN O
which NN NN O
resulted NN NN O
in NN NN O
systemic NN NN O
corticosterone NN NN O
levels NN NN O
of NN NN O
40 NN NN O
micrograms NN NN O
/ NN NN O
dl NN NN O
. NN NN O
   
Suppression NN NN O
of NN NN O
irCRF NN NN O
secretion NN NN O
in NN NN O
response NN NN O
to NN NN O
nitroprusside NN NN O
- NN NN O
induced NN NN O
hypotension NN NN B-Disease
is NN NN O
observed NN NN O
and NN NN O
occurs NN NN O
at NN NN O
a NN NN O
plasma NN NN O
corticosterone NN NN O
level NN NN O
between NN NN O
8 NN NN O
- NN NN O
12 NN NN O
micrograms NN NN O
/ NN NN O
dl NN NN O
. NN NN O
   
These NN NN O
studies NN NN O
provide NN NN O
further NN NN O
evidence NN NN O
for NN NN O
a NN NN O
strong NN NN O
central NN NN O
component NN NN O
of NN NN O
the NN NN O
delayed NN NN O
feedback NN NN O
process NN NN O
which NN NN O
is NN NN O
mediated NN NN O
by NN NN O
modulation NN NN O
of NN NN O
irCRF NN NN O
release NN NN O
. NN NN O
   
Noradrenergic NN NN O
involvement NN NN O
in NN NN O
catalepsy NN NN B-Disease
induced NN NN O
by NN NN O
delta NN NN O
9 NN NN O
- NN NN O
tetrahydrocannabinol NN NN O
. NN NN O
   
In NN NN O
order NN NN O
to NN NN O
elucidate NN NN O
the NN NN O
role NN NN O
of NN NN O
the NN NN O
catecholaminergic NN NN O
system NN NN O
in NN NN O
the NN NN O
cataleptogenic NN NN O
effect NN NN O
of NN NN O
delta NN NN O
9 NN NN O
- NN NN O
tetrahydrocannabinol NN NN O
( NN NN O
THC NN NN O
) NN NN O
, NN NN O
the NN NN O
effect NN NN O
of NN NN O
pretreatment NN NN O
with NN NN O
6 NN NN O
- NN NN O
hydroxydopamine NN NN O
( NN NN O
6 NN NN O
- NN NN O
OHDA NN NN O
) NN NN O
or NN NN O
with NN NN O
desipramine NN NN O
and NN NN O
6 NN NN O
- NN NN O
OHDA NN NN O
and NN NN O
lesions NN NN O
of NN NN O
the NN NN O
locus NN NN O
coeruleus NN NN O
were NN NN O
investigated NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
The NN NN O
cataleptogenic NN NN O
effect NN NN O
of NN NN O
THC NN NN O
was NN NN O
significantly NN NN O
reduced NN NN O
in NN NN O
rats NN NN O
treated NN NN O
with NN NN O
6 NN NN O
- NN NN O
OHDA NN NN O
and NN NN O
in NN NN O
rats NN NN O
with NN NN O
lesions NN NN O
of NN NN O
the NN NN O
locus NN NN O
coeruleus NN NN O
but NN NN O
not NN NN O
in NN NN O
rats NN NN O
treated NN NN O
with NN NN O
desipramine NN NN O
and NN NN O
6 NN NN O
- NN NN O
OHDA NN NN O
, NN NN O
as NN NN O
compared NN NN O
with NN NN O
control NN NN O
rats NN NN O
. NN NN O
   
On NN NN O
the NN NN O
contrary NN NN O
, NN NN O
the NN NN O
cataleptogenic NN NN O
effect NN NN O
of NN NN O
haloperidol NN NN O
was NN NN O
significantly NN NN O
reduced NN NN O
in NN NN O
rats NN NN O
treated NN NN O
with NN NN O
desipramine NN NN O
and NN NN O
6 NN NN O
- NN NN O
OHDA NN NN O
but NN NN O
not NN NN O
in NN NN O
rats NN NN O
treated NN NN O
with NN NN O
6 NN NN O
- NN NN O
OHDA NN NN O
or NN NN O
in NN NN O
rats NN NN O
with NN NN O
lesions NN NN O
of NN NN O
the NN NN O
locus NN NN O
coeruleus NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
noradrenergic NN NN O
neurons NN NN O
have NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
the NN NN O
manifestation NN NN O
of NN NN O
catalepsy NN NN B-Disease
induced NN NN O
by NN NN O
THC NN NN O
, NN NN O
whereas NN NN O
dopaminergic NN NN O
neurons NN NN O
are NN NN O
important NN NN O
in NN NN O
catalepsy NN NN B-Disease
induced NN NN O
by NN NN O
haloperidol NN NN O
. NN NN O
   
Reversibility NN NN O
of NN NN O
captopril NN NN O
- NN NN O
induced NN NN O
renal NN NN B-Disease
insufficiency NN NN I-Disease
after NN NN O
prolonged NN NN O
use NN NN O
in NN NN O
an NN NN O
unusual NN NN O
case NN NN O
of NN NN O
renovascular NN NN B-Disease
hypertension NN NN I-Disease
. NN NN O
   
We NN NN O
report NN NN O
a NN NN O
case NN NN O
of NN NN O
severe NN NN O
hypertension NN NN B-Disease
with NN NN O
an NN NN O
occluded NN NN O
renal NN NN O
artery NN NN O
to NN NN O
a NN NN O
solitary NN NN O
kidney NN NN O
, NN NN O
who NN NN O
developed NN NN O
sudden NN NN B-Disease
deterioration NN NN I-Disease
of NN NN I-Disease
renal NN NN I-Disease
function NN NN I-Disease
following NN NN O
treatment NN NN O
with NN NN O
captopril NN NN O
. NN NN O
   
His NN NN O
renal NN NN O
function NN NN O
remained NN NN O
impaired NN NN O
but NN NN O
stable NN NN O
during NN NN O
2 NN NN O
years NN NN O
' NN NN O
treatment NN NN O
with NN NN O
captopril NN NN O
but NN NN O
returned NN NN O
to NN NN O
pre NN NN O
- NN NN O
treatment NN NN O
levels NN NN O
soon NN NN O
after NN NN O
cessation NN NN O
of NN NN O
the NN NN O
drug NN NN O
. NN NN O
   
This NN NN O
indicates NN NN O
reversibility NN NN O
in NN NN O
captopril NN NN O
- NN NN O
induced NN NN O
renal NN NN B-Disease
failure NN NN I-Disease
even NN NN O
after NN NN O
its NN NN O
prolonged NN NN O
use NN NN O
and NN NN O
suggests NN NN O
that NN NN O
no NN NN O
organic NN NN O
damage NN NN O
occurs NN NN O
to NN NN O
glomerular NN NN O
arterioles NN NN O
following NN NN O
chronic NN NN O
ACE NN NN O
inhibition NN NN O
. NN NN O
   
HMG NN NN O
CoA NN NN O
reductase NN NN O
inhibitors NN NN O
. NN NN O
   
Current NN NN O
clinical NN NN O
experience NN NN O
. NN NN O
   
Lovastatin NN NN O
and NN NN O
simvastatin NN NN O
are NN NN O
the NN NN O
2 NN NN O
best NN NN O
- NN NN O
known NN NN O
members NN NN O
of NN NN O
the NN NN O
class NN NN O
of NN NN O
hypolipidaemic NN NN O
agents NN NN O
known NN NN O
as NN NN O
HMG NN NN O
CoA NN NN O
reductase NN NN O
inhibitors NN NN O
. NN NN O
   
Clinical NN NN O
experience NN NN O
with NN NN O
lovastatin NN NN O
includes NN NN O
over NN NN O
5000 NN NN O
patients NN NN O
, NN NN O
700 NN NN O
of NN NN O
whom NN NN O
have NN NN O
been NN NN O
treated NN NN O
for NN NN O
2 NN NN O
years NN NN O
or NN NN O
more NN NN O
, NN NN O
and NN NN O
experience NN NN O
with NN NN O
simvastatin NN NN O
includes NN NN O
over NN NN O
3500 NN NN O
patients NN NN O
, NN NN O
of NN NN O
whom NN NN O
350 NN NN O
have NN NN O
been NN NN O
treated NN NN O
for NN NN O
18 NN NN O
months NN NN O
or NN NN O
more NN NN O
. NN NN O
   
Lovastatin NN NN O
has NN NN O
been NN NN O
marketed NN NN O
in NN NN O
the NN NN O
United NN NN O
States NN NN O
for NN NN O
over NN NN O
6 NN NN O
months NN NN O
. NN NN O
   
Both NN NN O
agents NN NN O
show NN NN O
substantial NN NN O
clinical NN NN O
efficacy NN NN O
, NN NN O
with NN NN O
reductions NN NN O
in NN NN O
total NN NN O
cholesterol NN NN O
of NN NN O
over NN NN O
30 NN NN O
% NN NN O
and NN NN O
in NN NN O
LDL NN NN O
- NN NN O
cholesterol NN NN O
of NN NN O
40 NN NN O
% NN NN O
in NN NN O
clinical NN NN O
studies NN NN O
. NN NN O
   
Modest NN NN O
increases NN NN O
in NN NN O
HDL NN NN O
- NN NN O
cholesterol NN NN O
levels NN NN O
of NN NN O
about NN NN O
10 NN NN O
% NN NN O
are NN NN O
also NN NN O
reported NN NN O
. NN NN O
   
Clinical NN NN O
tolerability NN NN O
of NN NN O
both NN NN O
agents NN NN O
has NN NN O
been NN NN O
good NN NN O
, NN NN O
with NN NN O
fewer NN NN O
than NN NN O
3 NN NN O
% NN NN O
of NN NN O
patients NN NN O
withdrawn NN NN O
from NN NN O
treatment NN NN O
because NN NN O
of NN NN O
clinical NN NN O
adverse NN NN O
experiences NN NN O
. NN NN O
   
Ophthalmological NN NN O
examinations NN NN O
in NN NN O
over NN NN O
1100 NN NN O
patients NN NN O
treated NN NN O
with NN NN O
one NN NN O
or NN NN O
the NN NN O
other NN NN O
agent NN NN O
have NN NN O
revealed NN NN O
no NN NN O
evidence NN NN O
of NN NN O
significant NN NN O
short NN NN O
term NN NN O
( NN NN O
up NN NN O
to NN NN O
2 NN NN O
years NN NN O
) NN NN O
cataractogenic NN NN O
potential NN NN O
. NN NN O
   
One NN NN O
to NN NN O
2 NN NN O
% NN NN O
of NN NN O
patients NN NN O
have NN NN O
elevations NN NN O
of NN NN O
serum NN NN O
transaminases NN NN O
to NN NN O
greater NN NN O
than NN NN O
3 NN NN O
times NN NN O
the NN NN O
upper NN NN O
limit NN NN O
of NN NN O
normal NN NN O
. NN NN O
   
These NN NN O
episodes NN NN O
are NN NN O
asymptomatic NN NN O
and NN NN O
reversible NN NN O
when NN NN O
therapy NN NN O
is NN NN O
discontinued NN NN O
. NN NN O
   
Minor NN NN O
elevations NN NN O
of NN NN O
creatine NN NN O
kinase NN NN O
levels NN NN O
are NN NN O
reported NN NN O
in NN NN O
about NN NN O
5 NN NN O
% NN NN O
of NN NN O
patients NN NN O
. NN NN O
   
Myopathy NN NN B-Disease
, NN NN O
associated NN NN O
in NN NN O
some NN NN O
cases NN NN O
with NN NN O
myoglobinuria NN NN B-Disease
, NN NN O
and NN NN O
in NN NN O
2 NN NN O
cases NN NN O
with NN NN O
transient NN NN O
renal NN NN B-Disease
failure NN NN I-Disease
, NN NN O
has NN NN O
been NN NN O
rarely NN NN O
reported NN NN O
with NN NN O
lovastatin NN NN O
, NN NN O
especially NN NN O
in NN NN O
patients NN NN O
concomitantly NN NN O
treated NN NN O
with NN NN O
cyclosporin NN NN O
, NN NN O
gemfibrozil NN NN O
or NN NN O
niacin NN NN O
. NN NN O
   
Lovastatin NN NN O
and NN NN O
simvastatin NN NN O
are NN NN O
both NN NN O
effective NN NN O
and NN NN O
well NN NN O
- NN NN O
tolerated NN NN O
agents NN NN O
for NN NN O
lowering NN NN O
elevated NN NN O
levels NN NN O
of NN NN O
serum NN NN O
cholesterol NN NN O
. NN NN O
   
As NN NN O
wider NN NN O
use NN NN O
confirms NN NN O
their NN NN O
safety NN NN O
profile NN NN O
, NN NN O
they NN NN O
will NN NN O
gain NN NN O
increasing NN NN O
importance NN NN O
in NN NN O
the NN NN O
therapeutic NN NN O
approach NN NN O
to NN NN O
hypercholesterolaemia NN NN B-Disease
and NN NN O
its NN NN O
consequences NN NN O
. NN NN O
   
Hepatic NN NN O
reactions NN NN O
associated NN NN O
with NN NN O
ketoconazole NN NN O
in NN NN O
the NN NN O
United NN NN O
Kingdom NN NN O
. NN NN O
   
Ketoconazole NN NN O
was NN NN O
introduced NN NN O
in NN NN O
the NN NN O
United NN NN O
Kingdom NN NN O
in NN NN O
1981 NN NN O
. NN NN O
   
By NN NN O
November NN NN O
1984 NN NN O
the NN NN O
Committee NN NN O
on NN NN O
Safety NN NN O
of NN NN O
Medicines NN NN O
had NN NN O
received NN NN O
82 NN NN O
reports NN NN O
of NN NN O
possible NN NN O
hepatotoxicity NN NN B-Disease
associated NN NN O
with NN NN O
the NN NN O
drug NN NN O
, NN NN O
including NN NN O
five NN NN O
deaths NN NN B-Disease
. NN NN O
   
An NN NN O
analysis NN NN O
of NN NN O
the NN NN O
75 NN NN O
cases NN NN O
that NN NN O
had NN NN O
been NN NN O
adequately NN NN O
followed NN NN O
up NN NN O
suggested NN NN O
that NN NN O
16 NN NN O
, NN NN O
including NN NN O
three NN NN O
deaths NN NN B-Disease
, NN NN O
were NN NN O
probably NN NN O
related NN NN O
to NN NN O
treatment NN NN O
with NN NN O
the NN NN O
drug NN NN O
. NN NN O
   
Of NN NN O
the NN NN O
remainder NN NN O
, NN NN O
48 NN NN O
were NN NN O
possibly NN NN O
related NN NN O
to NN NN O
treatment NN NN O
, NN NN O
five NN NN O
were NN NN O
unlikely NN NN O
to NN NN O
be NN NN O
so NN NN O
, NN NN O
and NN NN O
six NN NN O
were NN NN O
unclassifiable NN NN O
. NN NN O
   
The NN NN O
mean NN NN O
age NN NN O
of NN NN O
patients NN NN O
in NN NN O
the NN NN O
16 NN NN O
probable NN NN O
cases NN NN O
was NN NN O
57 NN NN O
. NN NN O
9 NN NN O
, NN NN O
with NN NN O
hepatotoxicity NN NN B-Disease
being NN NN O
more NN NN O
common NN NN O
in NN NN O
women NN NN O
. NN NN O
   
The NN NN O
average NN NN O
duration NN NN O
of NN NN O
treatment NN NN O
before NN NN O
the NN NN O
onset NN NN O
of NN NN O
jaundice NN NN B-Disease
was NN NN O
61 NN NN O
days NN NN O
. NN NN O
   
   O
of NN NN O
these NN NN O
well NN NN O
validated NN NN O
cases NN NN O
occurred NN NN O
within NN NN O
the NN NN O
first NN NN O
10 NN NN O
days NN NN O
after NN NN O
treatment NN NN O
. NN NN O
   
The NN NN O
results NN NN O
of NN NN O
serum NN NN O
liver NN NN O
function NN NN O
tests NN NN O
suggested NN NN O
hepatocellular NN NN B-Disease
injury NN NN I-Disease
in NN NN O
10 NN NN O
( NN NN O
63 NN NN O
% NN NN O
) NN NN O
; NN NN O
the NN NN O
rest NN NN O
showed NN NN O
a NN NN O
mixed NN NN O
pattern NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
the NN NN O
results NN NN O
of NN NN O
histological NN NN O
examination NN NN O
of NN NN O
the NN NN O
liver NN NN O
often NN NN O
showed NN NN O
evidence NN NN O
of NN NN O
cholestasis NN NN B-Disease
. NN NN O
   
The NN NN O
characteristics NN NN O
of NN NN O
the NN NN O
48 NN NN O
patients NN NN O
in NN NN O
the NN NN O
possible NN NN O
cases NN NN O
were NN NN O
similar NN NN O
. NN NN O
   
Allergic NN NN O
manifestations NN NN O
such NN NN O
as NN NN O
rash NN NN B-Disease
and NN NN O
eosinophilia NN NN B-Disease
were NN NN O
rare NN NN O
. NN NN O
   
Hepatitis NN NN B-Disease
was NN NN O
usually NN NN O
reversible NN NN O
when NN NN O
treatment NN NN O
was NN NN O
stopped NN NN O
, NN NN O
with NN NN O
the NN NN O
results NN NN O
of NN NN O
liver NN NN O
function NN NN O
tests NN NN O
returning NN NN O
to NN NN O
normal NN NN O
after NN NN O
an NN NN O
average NN NN O
of NN NN O
3 NN NN O
. NN NN O
1 NN NN O
months NN NN O
. NN NN O
   
In NN NN O
two NN NN O
of NN NN O
the NN NN O
three NN NN O
deaths NN NN B-Disease
probably NN NN O
associated NN NN O
with NN NN O
ketoconazole NN NN O
treatment NN NN O
the NN NN O
drug NN NN O
had NN NN O
been NN NN O
continued NN NN O
after NN NN O
the NN NN O
onset NN NN O
of NN NN O
jaundice NN NN B-Disease
and NN NN O
other NN NN O
symptoms NN NN O
of NN NN O
hepatitis NN NN B-Disease
. NN NN O
   
Clinical NN NN O
and NN NN O
biochemical NN NN O
monitoring NN NN O
at NN NN O
regular NN NN O
intervals NN NN O
for NN NN O
evidence NN NN O
of NN NN O
hepatitis NN NN B-Disease
is NN NN O
advised NN NN O
during NN NN O
long NN NN O
term NN NN O
treatment NN NN O
with NN NN O
ketoconazole NN NN O
to NN NN O
prevent NN NN O
possible NN NN O
serious NN NN O
hepatic NN NN B-Disease
injury NN NN I-Disease
. NN NN O
   
Glyburide NN NN O
- NN NN O
induced NN NN O
hepatitis NN NN B-Disease
. NN NN O
   
Drug NN NN O
- NN NN O
induced NN NN O
hepatotoxicity NN NN B-Disease
, NN NN O
although NN NN O
common NN NN O
, NN NN O
has NN NN O
been NN NN O
reported NN NN O
only NN NN O
infrequently NN NN O
with NN NN O
sulfonylureas NN NN O
. NN NN O
   
For NN NN O
glyburide NN NN O
, NN NN O
a NN NN O
second NN NN O
- NN NN O
generation NN NN O
sulfonylurea NN NN O
, NN NN O
only NN NN O
two NN NN O
brief NN NN O
reports NN NN O
of NN NN O
hepatotoxicity NN NN B-Disease
exist NN NN O
. NN NN O
   
Two NN NN O
patients NN NN O
with NN NN O
type NN NN B-Disease
II NN NN I-Disease
diabetes NN NN I-Disease
mellitus NN NN I-Disease
developed NN NN O
an NN NN O
acute NN NN B-Disease
hepatitis NN NN I-Disease
- NN NN I-Disease
like NN NN I-Disease
syndrome NN NN I-Disease
soon NN NN O
after NN NN O
initiation NN NN O
of NN NN O
glyburide NN NN O
therapy NN NN O
. NN NN O
   
There NN NN O
was NN NN O
no NN NN O
serologic NN NN O
evidence NN NN O
of NN NN O
viral NN NN B-Disease
infection NN NN I-Disease
, NN NN O
and NN NN O
a NN NN O
liver NN NN O
biopsy NN NN O
sample NN NN O
showed NN NN O
a NN NN O
histologic NN NN O
pattern NN NN O
consistent NN NN O
with NN NN O
drug NN NN B-Disease
- NN NN I-Disease
induced NN NN I-Disease
hepatitis NN NN I-Disease
. NN NN O
   
Both NN NN O
patients NN NN O
recovered NN NN O
quickly NN NN O
after NN NN O
stopping NN NN O
glyburide NN NN O
therapy NN NN O
and NN NN O
have NN NN O
remained NN NN O
well NN NN O
for NN NN O
a NN NN O
follow NN NN O
- NN NN O
up NN NN O
period NN NN O
of NN NN O
1 NN NN O
year NN NN O
. NN NN O
   
Glyburide NN NN O
can NN NN O
produce NN NN O
an NN NN O
acute NN NN B-Disease
hepatitis NN NN I-Disease
- NN NN I-Disease
like NN NN I-Disease
illness NN NN I-Disease
in NN NN O
some NN NN O
persons NN NN O
. NN NN O
   
Intracranial NN NN O
pressure NN NN O
increases NN NN O
during NN NN O
alfentanil NN NN O
- NN NN O
induced NN NN O
rigidity NN NN B-Disease
. NN NN O
   
Intracranial NN NN O
pressure NN NN O
( NN NN O
ICP NN NN O
) NN NN O
was NN NN O
measured NN NN O
during NN NN O
alfentanil NN NN O
- NN NN O
induced NN NN O
rigidity NN NN B-Disease
in NN NN O
rats NN NN O
. NN NN O
   
Ten NN NN O
rats NN NN O
had NN NN O
arterial NN NN O
, NN NN O
central NN NN O
venous NN NN O
( NN NN O
CVP NN NN O
) NN NN O
, NN NN O
and NN NN O
subdural NN NN O
cannulae NN NN O
inserted NN NN O
under NN NN O
halothane NN NN O
anesthesia NN NN O
. NN NN O
   
The NN NN O
animals NN NN O
were NN NN O
mechanically NN NN O
ventilated NN NN O
to NN NN O
achieve NN NN O
normocarbia NN NN O
( NN NN O
PCO2 NN NN O
= NN NN O
42 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
mmHg NN NN O
, NN NN O
mean NN NN O
+ NN NN O
/ NN NN O
- NN NN O
SE NN NN O
) NN NN O
. NN NN O
   
Following NN NN O
instrumentation NN NN O
, NN NN O
halothane NN NN O
was NN NN O
discontinued NN NN O
and NN NN O
alfentanil NN NN O
( NN NN O
125 NN NN O
mu NN NN O
/ NN NN O
kg NN NN O
) NN NN O
administered NN NN O
iv NN NN O
during NN NN O
emergence NN NN O
from NN NN O
halothane NN NN O
anesthesia NN NN O
. NN NN O
   
In NN NN O
the NN NN O
five NN NN O
rats NN NN O
that NN NN O
developed NN NN O
somatic NN NN B-Disease
rigidity NN NN I-Disease
, NN NN O
ICP NN NN O
and NN NN O
CVP NN NN O
increased NN NN O
significantly NN NN O
above NN NN O
baseline NN NN O
( NN NN O
delta NN NN O
ICP NN NN O
7 NN NN O
. NN NN O
5 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
0 NN NN O
mmHg NN NN O
, NN NN O
delta NN NN O
CVP NN NN O
5 NN NN O
. NN NN O
9 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
3 NN NN O
mmHg NN NN O
) NN NN O
. NN NN O
   
These NN NN O
variables NN NN O
returned NN NN O
to NN NN O
baseline NN NN O
when NN NN O
rigidity NN NN B-Disease
was NN NN O
abolished NN NN O
with NN NN O
metocurine NN NN O
. NN NN O
   
In NN NN O
five NN NN O
rats NN NN O
that NN NN O
did NN NN O
not NN NN O
become NN NN O
rigid NN NN O
, NN NN O
ICP NN NN O
and NN NN O
CVP NN NN O
did NN NN O
not NN NN O
change NN NN O
following NN NN O
alfentanil NN NN O
. NN NN O
   
These NN NN O
observations NN NN O
suggest NN NN O
that NN NN O
rigidity NN NN B-Disease
should NN NN O
be NN NN O
prevented NN NN O
when NN NN O
alfentanil NN NN O
, NN NN O
and NN NN O
, NN NN O
presumably NN NN O
, NN NN O
other NN NN O
opiates NN NN O
, NN NN O
are NN NN O
used NN NN O
in NN NN O
the NN NN O
anesthetic NN NN O
management NN NN O
of NN NN O
patients NN NN O
with NN NN O
ICP NN NN O
problems NN NN O
. NN NN O
   
Verapamil NN NN O
withdrawal NN NN O
as NN NN O
a NN NN O
possible NN NN O
cause NN NN O
of NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
in NN NN O
a NN NN O
hypertensive NN NN B-Disease
woman NN NN O
with NN NN O
a NN NN O
normal NN NN O
coronary NN NN O
angiogram NN NN O
. NN NN O
   
Verapamil NN NN O
is NN NN O
an NN NN O
effective NN NN O
and NN NN O
relatively NN NN O
- NN NN O
safe NN NN O
antihypertensive NN NN O
drug NN NN O
. NN NN O
   
Serious NN NN O
adverse NN NN O
effects NN NN O
are NN NN O
uncommon NN NN O
and NN NN O
mainly NN NN O
have NN NN O
been NN NN O
related NN NN O
to NN NN O
the NN NN O
depression NN NN B-Disease
of NN NN O
cardiac NN NN O
contractility NN NN O
and NN NN O
conduction NN NN O
, NN NN O
especially NN NN O
when NN NN O
the NN NN O
drug NN NN O
is NN NN O
combined NN NN O
with NN NN O
beta NN NN O
- NN NN O
blocking NN NN O
agents NN NN O
. NN NN O
   
We NN NN O
report NN NN O
a NN NN O
case NN NN O
in NN NN O
which NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
coincided NN NN O
with NN NN O
the NN NN O
introduction NN NN O
of NN NN O
captopril NN NN O
and NN NN O
the NN NN O
withdrawal NN NN O
of NN NN O
verapamil NN NN O
in NN NN O
a NN NN O
previously NN NN O
asymptomatic NN NN O
woman NN NN O
with NN NN O
severe NN NN O
hypertension NN NN B-Disease
. NN NN O
   
Possible NN NN O
mechanisms NN NN O
that NN NN O
involve NN NN O
a NN NN O
verapamil NN NN O
- NN NN O
related NN NN O
increase NN NN O
in NN NN O
platelet NN NN O
and NN NN O
/ NN NN O
or NN NN O
vascular NN NN O
alpha NN NN O
2 NN NN O
- NN NN O
adrenoreceptor NN NN O
affinity NN NN O
for NN NN O
catecholamines NN NN O
are NN NN O
discussed NN NN O
. NN NN O
   
Haemolytic NN NN B-Disease
- NN NN I-Disease
uraemic NN NN I-Disease
syndrome NN NN I-Disease
after NN NN O
treatment NN NN O
with NN NN O
metronidazole NN NN O
. NN NN O
   
This NN NN O
paper NN NN O
describes NN NN O
the NN NN O
clinical NN NN O
features NN NN O
of NN NN O
six NN NN O
children NN NN O
who NN NN O
developed NN NN O
the NN NN O
haemolytic NN NN B-Disease
- NN NN I-Disease
uraemic NN NN I-Disease
syndrome NN NN I-Disease
after NN NN O
treatment NN NN O
with NN NN O
metronidazole NN NN O
. NN NN O
   
These NN NN O
children NN NN O
were NN NN O
older NN NN O
and NN NN O
were NN NN O
more NN NN O
likely NN NN O
to NN NN O
have NN NN O
undergone NN NN O
recent NN NN O
bowel NN NN O
surgery NN NN O
than NN NN O
are NN NN O
other NN NN O
children NN NN O
with NN NN O
this NN NN O
condition NN NN O
. NN NN O
   
While NN NN O
the NN NN O
involvement NN NN O
of NN NN O
metronidazole NN NN O
in NN NN O
the NN NN O
aetiology NN NN O
of NN NN O
the NN NN O
haemolytic NN NN B-Disease
- NN NN I-Disease
uraemic NN NN I-Disease
syndrome NN NN I-Disease
is NN NN O
not NN NN O
established NN NN O
firmly NN NN O
, NN NN O
the NN NN O
action NN NN O
of NN NN O
this NN NN O
drug NN NN O
in NN NN O
sensitizing NN NN O
tissues NN NN O
to NN NN O
oxidation NN NN O
injury NN NN O
and NN NN O
the NN NN O
reported NN NN O
evidence NN NN O
of NN NN O
oxidation NN NN O
changes NN NN O
in NN NN O
the NN NN O
haemolytic NN NN B-Disease
- NN NN I-Disease
uraemic NN NN I-Disease
syndrome NN NN I-Disease
suggest NN NN O
a NN NN O
possible NN NN O
link NN NN O
between NN NN O
metronidazole NN NN O
treatment NN NN O
and NN NN O
some NN NN O
cases NN NN O
of NN NN O
the NN NN O
haemolytic NN NN B-Disease
- NN NN I-Disease
uraemic NN NN I-Disease
syndrome NN NN I-Disease
. NN NN O
   
Adverse NN NN O
cardiac NN NN O
effects NN NN O
during NN NN O
induction NN NN O
chemotherapy NN NN O
treatment NN NN O
with NN NN O
cis NN NN O
- NN NN O
platin NN NN O
and NN NN O
5 NN NN O
- NN NN O
fluorouracil NN NN O
. NN NN O
   
Survival NN NN O
for NN NN O
patients NN NN O
with NN NN O
advanced NN NN O
head NN NN B-Disease
and NN NN I-Disease
neck NN NN I-Disease
carcinoma NN NN I-Disease
and NN NN O
esophageal NN NN B-Disease
carcinoma NN NN I-Disease
is NN NN O
poor NN NN O
with NN NN O
radiotherapy NN NN O
and NN NN O
/ NN NN O
or NN NN O
surgery NN NN O
. NN NN O
   
Obviously NN NN O
, NN NN O
there NN NN O
is NN NN O
a NN NN O
need NN NN O
for NN NN O
effective NN NN O
chemotherapy NN NN O
. NN NN O
   
In NN NN O
the NN NN O
present NN NN O
study NN NN O
, NN NN O
cis NN NN O
- NN NN O
platin NN NN O
( NN NN O
80 NN NN O
- NN NN O
120 NN NN O
mg NN NN O
/ NN NN O
m2BSA NN NN O
) NN NN O
and NN NN O
5 NN NN O
- NN NN O
FU NN NN O
( NN NN O
1000 NN NN O
mg NN NN O
/ NN NN O
m2BSA NN NN O
daily NN NN O
as NN NN O
a NN NN O
continuous NN NN O
infusion NN NN O
during NN NN O
5 NN NN O
days NN NN O
) NN NN O
were NN NN O
given NN NN O
to NN NN O
76 NN NN O
patients NN NN O
before NN NN O
radiotherapy NN NN O
and NN NN O
surgery NN NN O
. NN NN O
   
The NN NN O
aim NN NN O
of NN NN O
the NN NN O
study NN NN O
was NN NN O
to NN NN O
clarify NN NN O
the NN NN O
incidence NN NN O
and NN NN O
severity NN NN O
of NN NN O
adverse NN NN O
cardiac NN NN O
effects NN NN O
to NN NN O
this NN NN O
treatment NN NN O
. NN NN O
   
Before NN NN O
treatment NN NN O
all NN NN O
patients NN NN O
had NN NN O
a NN NN O
cardiac NN NN O
evaluation NN NN O
and NN NN O
during NN NN O
treatment NN NN O
serial NN NN O
ECG NN NN O
recordings NN NN O
were NN NN O
performed NN NN O
. NN NN O
   
In NN NN O
the NN NN O
pre NN NN O
- NN NN O
treatment NN NN O
evaluation NN NN O
, NN NN O
signs NN NN O
of NN NN O
cardiovascular NN NN B-Disease
disease NN NN I-Disease
were NN NN O
found NN NN O
in NN NN O
33 NN NN O
patients NN NN O
( NN NN O
43 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
During NN NN O
treatment NN NN O
, NN NN O
adverse NN NN O
cardiac NN NN O
effects NN NN O
were NN NN O
observed NN NN O
in NN NN O
14 NN NN O
patients NN NN O
( NN NN O
18 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
The NN NN O
mean NN NN O
age NN NN O
of NN NN O
these NN NN O
patients NN NN O
was NN NN O
the NN NN O
same NN NN O
as NN NN O
for NN NN O
the NN NN O
entire NN NN O
group NN NN O
, NN NN O
64 NN NN O
years NN NN O
. NN NN O
   
The NN NN O
incidence NN NN O
of NN NN O
cardiotoxicity NN NN B-Disease
was NN NN O
not NN NN O
higher NN NN O
in NN NN O
patients NN NN O
with NN NN O
signs NN NN O
of NN NN O
cardiovascular NN NN B-Disease
disease NN NN I-Disease
than NN NN O
in NN NN O
those NN NN O
without NN NN O
in NN NN O
the NN NN O
pre NN NN O
- NN NN O
treatment NN NN O
evaluation NN NN O
. NN NN O
   
The NN NN O
most NN NN O
common NN NN O
signs NN NN O
of NN NN O
cardiotoxicity NN NN B-Disease
were NN NN O
chest NN NN B-Disease
pain NN NN I-Disease
, NN NN O
ST NN NN O
- NN NN O
T NN NN O
wave NN NN O
changes NN NN O
and NN NN O
atrial NN NN B-Disease
fibrillation NN NN I-Disease
. NN NN O
   
This NN NN O
was NN NN O
followed NN NN O
by NN NN O
ventricular NN NN B-Disease
fibrillation NN NN I-Disease
in NN NN O
one NN NN O
patient NN NN O
and NN NN O
sudden NN NN B-Disease
death NN NN I-Disease
in NN NN O
another NN NN O
. NN NN O
   
It NN NN O
is NN NN O
concluded NN NN O
that NN NN O
patients NN NN O
on NN NN O
5 NN NN O
- NN NN O
FU NN NN O
treatment NN NN O
should NN NN O
be NN NN O
under NN NN O
close NN NN O
supervision NN NN O
and NN NN O
that NN NN O
the NN NN O
treatment NN NN O
should NN NN O
be NN NN O
discontinued NN NN O
if NN NN O
chest NN NN B-Disease
pain NN NN I-Disease
or NN NN O
tachyarrhythmia NN NN B-Disease
is NN NN O
observed NN NN O
. NN NN O
   
Death NN NN B-Disease
from NN NN O
chemotherapy NN NN O
in NN NN O
gestational NN NN B-Disease
trophoblastic NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
Multiple NN NN O
cytotoxic NN NN O
drug NN NN O
administration NN NN O
is NN NN O
the NN NN O
generally NN NN O
accepted NN NN O
treatment NN NN O
of NN NN O
patients NN NN O
with NN NN O
a NN NN O
high NN NN O
- NN NN O
risk NN NN O
stage NN NN O
of NN NN O
choriocarcinoma NN NN B-Disease
. NN NN O
   
Based NN NN O
on NN NN O
this NN NN O
principle NN NN O
a NN NN O
27 NN NN O
- NN NN O
year NN NN O
old NN NN O
woman NN NN O
, NN NN O
classified NN NN O
as NN NN O
being NN NN O
in NN NN O
the NN NN O
high NN NN O
- NN NN O
risk NN NN O
group NN NN O
( NN NN O
Goldstein NN NN O
and NN NN O
Berkowitz NN NN O
score NN NN O
: NN NN O
11 NN NN O
) NN NN O
, NN NN O
was NN NN O
treated NN NN O
with NN NN O
multiple NN NN O
cytotoxic NN NN O
drugs NN NN O
. NN NN O
   
The NN NN O
multiple NN NN O
drug NN NN O
schema NN NN O
consisted NN NN O
of NN NN O
: NN NN O
Etoposide NN NN O
16 NN NN O
. NN NN O
213 NN NN O
, NN NN O
Methotrexate NN NN O
, NN NN O
Cyclophosphamide NN NN O
, NN NN O
Actomycin NN NN O
- NN NN O
D NN NN O
, NN NN O
and NN NN O
Cisplatin NN NN O
. NN NN O
   
On NN NN O
the NN NN O
first NN NN O
day NN NN O
of NN NN O
the NN NN O
schedule NN NN O
, NN NN O
moderate NN NN O
high NN NN O
doses NN NN O
of NN NN O
Methotrexate NN NN O
, NN NN O
Etoposide NN NN O
and NN NN O
Cyclophosphamide NN NN O
were NN NN O
administered NN NN O
. NN NN O
   
Within NN NN O
8 NN NN O
hours NN NN O
after NN NN O
initiation NN NN O
of NN NN O
therapy NN NN O
the NN NN O
patient NN NN O
died NN NN O
with NN NN O
a NN NN O
clinical NN NN O
picture NN NN O
resembling NN NN O
massive NN NN O
pulmonary NN NN B-Disease
obstruction NN NN I-Disease
due NN NN O
to NN NN O
choriocarcinomic NN NN O
tissue NN NN O
plugs NN NN O
, NN NN O
probably NN NN O
originating NN NN O
from NN NN O
the NN NN O
uterus NN NN O
. NN NN O
   
Formation NN NN O
of NN NN O
these NN NN O
plugs NN NN O
was NN NN O
probably NN NN O
due NN NN O
to NN NN O
extensive NN NN O
tumor NN NN B-Disease
necrosis NN NN B-Disease
at NN NN O
the NN NN O
level NN NN O
of NN NN O
the NN NN O
walls NN NN O
of NN NN O
the NN NN O
major NN NN O
uterine NN NN O
veins NN NN O
, NN NN O
which NN NN O
resulted NN NN O
in NN NN O
an NN NN O
open NN NN O
exchange NN NN O
of NN NN O
tumor NN NN B-Disease
plugs NN NN O
to NN NN O
the NN NN O
vascular NN NN O
spaces NN NN O
; NN NN O
decrease NN NN O
in NN NN O
tumor NN NN B-Disease
tissue NN NN O
coherence NN NN O
secondary NN NN O
to NN NN O
chemotherapy NN NN O
may NN NN O
have NN NN O
further NN NN O
contributed NN NN O
to NN NN O
the NN NN O
formation NN NN O
of NN NN O
tumor NN NN B-Disease
emboli NN NN O
. NN NN O
   
In NN NN O
view NN NN O
of NN NN O
the NN NN O
close NN NN O
time NN NN O
association NN NN O
between NN NN O
the NN NN O
start NN NN O
of NN NN O
chemotherapy NN NN O
and NN NN O
the NN NN O
acute NN NN O
onset NN NN O
of NN NN O
massive NN NN O
embolism NN NN B-Disease
other NN NN O
explanations NN NN O
, NN NN O
such NN NN O
as NN NN O
spontaneous NN NN O
necrosis NN NN B-Disease
, NN NN O
must NN NN O
be NN NN O
considered NN NN O
less NN NN O
likely NN NN O
. NN NN O
   
Patients NN NN O
with NN NN O
large NN NN O
pelvic NN NN B-Disease
tumor NN NN I-Disease
loads NN NN O
are NN NN O
, NN NN O
according NN NN O
to NN NN O
existing NN NN O
classifications NN NN O
, NN NN O
at NN NN O
high NN NN O
risk NN NN O
to NN NN O
die NN NN O
and NN NN O
to NN NN O
develop NN NN O
drug NN NN O
resistance NN NN O
. NN NN O
   
Notwithstanding NN NN O
these NN NN O
facts NN NN O
our NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
these NN NN O
patients NN NN O
might NN NN O
benefit NN NN O
from NN NN O
relatively NN NN O
mild NN NN O
initial NN NN O
treatment NN NN O
, NN NN O
especially NN NN O
true NN NN O
for NN NN O
patients NN NN O
not NN NN O
previously NN NN O
exposed NN NN O
to NN NN O
this NN NN O
drug NN NN O
. NN NN O
   
Close NN NN O
observation NN NN O
of NN NN O
the NN NN O
response NN NN O
status NN NN O
both NN NN O
clinically NN NN O
and NN NN O
with NN NN O
beta NN NN O
- NN NN O
hCG NN NN O
values NN NN O
may NN NN O
indicate NN NN O
whether NN NN O
and NN NN O
when NN NN O
more NN NN O
agressive NN NN O
combination NN NN O
chemotherapy NN NN O
should NN NN O
be NN NN O
started NN NN O
. NN NN O
( NN NN O
ABSTRACT NN NN O
TRUNCATED NN NN O
AT NN NN O
250 NN NN O
WORDS NN NN O
) NN NN O
   
Pulmonary NN NN O
shunt NN NN O
and NN NN O
cardiovascular NN NN O
responses NN NN O
to NN NN O
CPAP NN NN O
during NN NN O
nitroprusside NN NN O
- NN NN O
induced NN NN O
hypotension NN NN B-Disease
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
continuous NN NN O
positive NN NN O
airway NN NN O
pressure NN NN O
( NN NN O
CPAP NN NN O
) NN NN O
on NN NN O
cardiovascular NN NN O
dynamics NN NN O
and NN NN O
pulmonary NN NN O
shunt NN NN O
( NN NN O
QS NN NN O
/ NN NN O
QT NN NN O
) NN NN O
were NN NN O
investigated NN NN O
in NN NN O
12 NN NN O
dogs NN NN O
before NN NN O
and NN NN O
during NN NN O
sodium NN NN O
nitroprusside NN NN O
infusion NN NN O
that NN NN O
decreased NN NN O
mean NN NN O
arterial NN NN O
blood NN NN O
pressure NN NN O
40 NN NN O
- NN NN O
50 NN NN O
per NN NN O
cent NN NN O
. NN NN O
   
Before NN NN O
nitroprusside NN NN O
infusion NN NN O
, NN NN O
5 NN NN O
cm NN NN O
H2O NN NN O
CPAP NN NN O
significantly NN NN O
, NN NN O
P NN NN O
less NN NN O
than NN NN O
. NN NN O
05 NN NN O
, NN NN O
decreased NN NN O
arterial NN NN O
blood NN NN O
pressure NN NN O
, NN NN O
but NN NN O
did NN NN O
not NN NN O
significantly NN NN O
alter NN NN O
heart NN NN O
rate NN NN O
, NN NN O
cardiac NN NN O
output NN NN O
, NN NN O
systemic NN NN O
vascular NN NN O
resistance NN NN O
, NN NN O
or NN NN O
QS NN NN O
/ NN NN O
QT NN NN O
. NN NN O
   
Ten NN NN O
cm NN NN O
H2O NN NN O
CPAP NN NN O
before NN NN O
nitroprusside NN NN O
infusion NN NN O
produced NN NN O
a NN NN O
further NN NN O
decrease NN NN B-Disease
in NN NN I-Disease
arterial NN NN I-Disease
blood NN NN I-Disease
pressure NN NN I-Disease
and NN NN O
significantly NN NN O
increased NN NN O
heart NN NN O
rate NN NN O
and NN NN O
decreased NN NN B-Disease
cardiac NN NN I-Disease
output NN NN I-Disease
and NN NN O
QS NN NN O
/ NN NN O
QT NN NN O
. NN NN O
   
Nitroprusside NN NN O
caused NN NN O
significant NN NN O
decreases NN NN B-Disease
in NN NN I-Disease
arterial NN NN I-Disease
blood NN NN I-Disease
pressure NN NN I-Disease
and NN NN O
systemic NN NN O
vascular NN NN O
resistance NN NN O
and NN NN O
increases NN NN O
in NN NN O
heart NN NN O
rate NN NN O
, NN NN O
but NN NN O
did NN NN O
not NN NN O
change NN NN O
cardiac NN NN O
output NN NN O
or NN NN O
QS NN NN O
/ NN NN O
QT NN NN O
. NN NN O
   
Five NN NN O
cm NN NN O
H2O NN NN O
CPAP NN NN O
during NN NN O
nitroprusside NN NN O
did NN NN O
not NN NN O
further NN NN O
alter NN NN O
any NN NN O
of NN NN O
the NN NN O
above NN NN O
- NN NN O
mentioned NN NN O
variables NN NN O
. NN NN O
   
However NN NN O
, NN NN O
10 NN NN O
cm NN NN O
H2O NN NN O
CPAP NN NN O
decreased NN NN O
arterial NN NN O
blood NN NN O
pressure NN NN O
, NN NN O
cardiac NN NN O
output NN NN O
, NN NN O
and NN NN O
QS NN NN O
/ NN NN O
QT NN NN O
. NN NN O
   
These NN NN O
data NN NN O
indicate NN NN O
that NN NN O
nitroprusside NN NN O
infusion NN NN O
rates NN NN O
that NN NN O
decrease NN NN O
mean NN NN O
arterial NN NN O
blood NN NN O
pressure NN NN O
by NN NN O
40 NN NN O
- NN NN O
50 NN NN O
per NN NN O
cent NN NN O
do NN NN O
not NN NN O
change NN NN O
cardiac NN NN O
output NN NN O
or NN NN O
QS NN NN O
/ NN NN O
QT NN NN O
. NN NN O
   
During NN NN O
nitroprusside NN NN O
infusion NN NN O
low NN NN O
levels NN NN O
of NN NN O
CPAP NN NN O
do NN NN O
not NN NN O
markedly NN NN O
alter NN NN O
cardiovascular NN NN O
dynamics NN NN O
, NN NN O
but NN NN O
high NN NN O
levels NN NN O
of NN NN O
CPAP NN NN O
( NN NN O
10 NN NN O
cm NN NN O
H2O NN NN O
) NN NN O
, NN NN O
while NN NN O
decreasing NN NN O
QS NN NN O
/ NN NN O
QT NN NN O
, NN NN O
produce NN NN O
marked NN NN O
decreases NN NN B-Disease
in NN NN I-Disease
arterial NN NN I-Disease
blood NN NN I-Disease
pressure NN NN I-Disease
and NN NN I-Disease
cardiac NN NN I-Disease
output NN NN I-Disease
. NN NN O
   
Systolic NN NN O
pressure NN NN O
variation NN NN O
is NN NN O
greater NN NN O
during NN NN O
hemorrhage NN NN B-Disease
than NN NN O
during NN NN O
sodium NN NN O
nitroprusside NN NN O
- NN NN O
induced NN NN O
hypotension NN NN B-Disease
in NN NN O
ventilated NN NN O
dogs NN NN O
. NN NN O
   
The NN NN O
systolic NN NN O
pressure NN NN O
variation NN NN O
( NN NN O
SPV NN NN O
) NN NN O
, NN NN O
which NN NN O
is NN NN O
the NN NN O
difference NN NN O
between NN NN O
the NN NN O
maximal NN NN O
and NN NN O
minimal NN NN O
values NN NN O
of NN NN O
the NN NN O
systolic NN NN O
blood NN NN O
pressure NN NN O
( NN NN O
SBP NN NN O
) NN NN O
after NN NN O
one NN NN O
positive NN NN O
- NN NN O
pressure NN NN O
breath NN NN O
, NN NN O
was NN NN O
studied NN NN O
in NN NN O
ventilated NN NN O
dogs NN NN O
subjected NN NN O
to NN NN O
hypotension NN NN B-Disease
. NN NN O
   
Mean NN NN O
arterial NN NN O
pressure NN NN O
was NN NN O
decreased NN NN O
to NN NN O
50 NN NN O
mm NN NN O
Hg NN NN O
for NN NN O
30 NN NN O
minutes NN NN O
either NN NN O
by NN NN O
hemorrhage NN NN B-Disease
( NN NN O
HEM NN NN B-Disease
, NN NN O
n NN NN O
= NN NN O
7 NN NN O
) NN NN O
or NN NN O
by NN NN O
continuous NN NN O
infusion NN NN O
of NN NN O
sodium NN NN O
nitroprusside NN NN O
( NN NN O
SNP NN NN O
, NN NN O
n NN NN O
= NN NN O
7 NN NN O
) NN NN O
. NN NN O
   
During NN NN O
HEM NN NN B-Disease
- NN NN O
induced NN NN O
hypotension NN NN B-Disease
the NN NN O
cardiac NN NN O
output NN NN O
was NN NN O
significantly NN NN O
lower NN NN O
and NN NN O
systemic NN NN O
vascular NN NN O
resistance NN NN O
higher NN NN O
compared NN NN O
with NN NN O
that NN NN O
in NN NN O
the NN NN O
SNP NN NN O
group NN NN O
. NN NN O
   
The NN NN O
systemic NN NN O
, NN NN O
central NN NN O
venous NN NN O
, NN NN O
pulmonary NN NN O
capillary NN NN O
wedge NN NN O
pressures NN NN O
, NN NN O
and NN NN O
heart NN NN O
rates NN NN O
, NN NN O
were NN NN O
similar NN NN O
in NN NN O
the NN NN O
two NN NN O
groups NN NN O
. NN NN O
   
Analysis NN NN O
of NN NN O
the NN NN O
respiratory NN NN O
changes NN NN O
in NN NN O
the NN NN O
arterial NN NN O
pressure NN NN O
waveform NN NN O
enabled NN NN O
differentiation NN NN O
between NN NN O
the NN NN O
two NN NN O
groups NN NN O
. NN NN O
   
The NN NN O
SPV NN NN O
during NN NN O
hypotension NN NN B-Disease
was NN NN O
15 NN NN O
. NN NN O
7 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
6 NN NN O
. NN NN O
7 NN NN O
mm NN NN O
Hg NN NN O
in NN NN O
the NN NN O
HEM NN NN B-Disease
group NN NN O
, NN NN O
compared NN NN O
with NN NN O
9 NN NN O
. NN NN O
1 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
. NN NN O
0 NN NN O
mm NN NN O
Hg NN NN O
in NN NN O
the NN NN O
SNP NN NN O
group NN NN O
( NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
02 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
delta NN NN O
down NN NN O
, NN NN O
which NN NN O
is NN NN O
the NN NN O
measure NN NN O
of NN NN O
decrease NN NN O
of NN NN O
SBP NN NN O
after NN NN O
a NN NN O
mechanical NN NN O
breath NN NN O
, NN NN O
was NN NN O
20 NN NN O
. NN NN O
3 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
8 NN NN O
. NN NN O
4 NN NN O
and NN NN O
10 NN NN O
. NN NN O
1 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
3 NN NN O
. NN NN O
8 NN NN O
mm NN NN O
Hg NN NN O
in NN NN O
the NN NN O
HEM NN NN B-Disease
and NN NN O
SNP NN NN O
groups NN NN O
, NN NN O
respectively NN NN O
, NN NN O
during NN NN O
hypotension NN NN B-Disease
( NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
02 NN NN O
) NN NN O
. NN NN O
   
It NN NN O
is NN NN O
concluded NN NN O
that NN NN O
increases NN NN O
in NN NN O
the NN NN O
SPV NN NN O
and NN NN O
the NN NN O
delta NN NN O
down NN NN O
are NN NN O
characteristic NN NN O
of NN NN O
a NN NN O
hypotensive NN NN B-Disease
state NN NN O
due NN NN O
to NN NN O
a NN NN O
predominant NN NN O
decrease NN NN O
in NN NN O
preload NN NN O
. NN NN O
   
They NN NN O
are NN NN O
thus NN NN O
more NN NN O
important NN NN O
during NN NN O
absolute NN NN O
hypovolemia NN NN B-Disease
than NN NN O
during NN NN O
deliberate NN NN O
hypotension NN NN B-Disease
. NN NN O
   
Ventricular NN NN B-Disease
tachyarrhythmias NN NN I-Disease
during NN NN O
cesarean NN NN O
section NN NN O
after NN NN O
ritodrine NN NN O
therapy NN NN O
: NN NN O
interaction NN NN O
with NN NN O
anesthetics NN NN O
. NN NN O
   
This NN NN O
case NN NN O
illustrates NN NN O
that NN NN O
patients NN NN O
receiving NN NN O
ritodrine NN NN O
for NN NN O
preterm NN NN B-Disease
labor NN NN I-Disease
may NN NN O
risk NN NN O
interactions NN NN O
between NN NN O
the NN NN O
residual NN NN O
betamimetic NN NN O
effects NN NN O
of NN NN O
ritodrine NN NN O
and NN NN O
the NN NN O
effects NN NN O
of NN NN O
anesthetics NN NN O
during NN NN O
cesarean NN NN O
section NN NN O
. NN NN O
   
Such NN NN O
interactions NN NN O
may NN NN O
result NN NN O
in NN NN O
serious NN NN O
cardiovascular NN NN B-Disease
complications NN NN I-Disease
even NN NN O
after NN NN O
cessation NN NN O
of NN NN O
an NN NN O
infusion NN NN O
of NN NN O
ritodrine NN NN O
. NN NN O
   
Preoperative NN NN O
assessment NN NN O
should NN NN O
focus NN NN O
on NN NN O
cardiovascular NN NN O
status NN NN O
and NN NN O
serum NN NN O
potassium NN NN O
level NN NN O
. NN NN O
   
Delaying NN NN O
induction NN NN O
of NN NN O
anesthesia NN NN O
should NN NN O
be NN NN O
considered NN NN O
whenever NN NN O
possible NN NN O
. NN NN O
   
Careful NN NN O
fluid NN NN O
administration NN NN O
and NN NN O
cautious NN NN O
use NN NN O
of NN NN O
titrated NN NN O
doses NN NN O
of NN NN O
ephedrine NN NN O
are NN NN O
advised NN NN O
. NN NN O
   
After NN NN O
delivery NN NN O
of NN NN O
the NN NN O
infant NN NN O
, NN NN O
there NN NN O
should NN NN O
be NN NN O
no NN NN O
contraindication NN NN O
to NN NN O
the NN NN O
use NN NN O
of NN NN O
an NN NN O
alpha NN NN O
- NN NN O
adrenergic NN NN O
vasopressor NN NN O
such NN NN O
as NN NN O
phenylephrine NN NN O
to NN NN O
treat NN NN O
hypotensive NN NN B-Disease
patients NN NN O
with NN NN O
tachycardia NN NN B-Disease
. NN NN O
   
Verapamil NN NN O
- NN NN O
induced NN NN O
carbamazepine NN NN O
neurotoxicity NN NN B-Disease
. NN NN O
   
A NN NN O
report NN NN O
of NN NN O
two NN NN O
cases NN NN O
. NN NN O
   
Two NN NN O
patients NN NN O
with NN NN O
signs NN NN O
of NN NN O
carbamazepine NN NN O
neurotoxicity NN NN B-Disease
after NN NN O
combined NN NN O
treatment NN NN O
with NN NN O
verapamil NN NN O
showed NN NN O
complete NN NN O
recovery NN NN O
after NN NN O
discontinuation NN NN O
of NN NN O
the NN NN O
calcium NN NN O
entry NN NN O
blocker NN NN O
. NN NN O
   
Use NN NN O
of NN NN O
verapamil NN NN O
in NN NN O
combination NN NN O
with NN NN O
carbamazepine NN NN O
should NN NN O
either NN NN O
be NN NN O
avoided NN NN O
or NN NN O
prescribed NN NN O
only NN NN O
with NN NN O
appropriate NN NN O
adjustment NN NN O
of NN NN O
the NN NN O
carbamazepine NN NN O
dose NN NN O
( NN NN O
usually NN NN O
reduction NN NN O
of NN NN O
the NN NN O
carbamazepine NN NN O
dose NN NN O
by NN NN O
one NN NN O
half NN NN O
) NN NN O
. NN NN O
   
Paracetamol NN NN O
- NN NN O
associated NN NN O
coma NN NN B-Disease
, NN NN O
metabolic NN NN B-Disease
acidosis NN NN I-Disease
, NN NN O
renal NN NN B-Disease
and NN NN I-Disease
hepatic NN NN I-Disease
failure NN NN I-Disease
. NN NN O
   
A NN NN O
case NN NN O
of NN NN O
metabolic NN NN B-Disease
acidosis NN NN I-Disease
, NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
and NN NN I-Disease
hepatic NN NN I-Disease
failure NN NN I-Disease
following NN NN O
paracetamol NN NN O
ingestion NN NN O
is NN NN O
presented NN NN O
. NN NN O
   
The NN NN O
diagnostic NN NN O
difficulty NN NN O
at NN NN O
presentation NN NN O
is NN NN O
highlighted NN NN O
. NN NN O
   
Continuous NN NN O
arteriovenous NN NN O
haemofiltration NN NN O
proved NN NN O
a NN NN O
valuable NN NN O
means NN NN O
of NN NN O
maintaining NN NN O
fluid NN NN O
and NN NN O
electrolyte NN NN O
balance NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
recovered NN NN O
. NN NN O
   
Sexual NN NN B-Disease
dysfunction NN NN I-Disease
among NN NN O
patients NN NN O
with NN NN O
arthritis NN NN B-Disease
. NN NN O
   
The NN NN O
relationship NN NN O
of NN NN O
arthritis NN NN B-Disease
and NN NN O
sexual NN NN B-Disease
dysfunction NN NN I-Disease
was NN NN O
investigated NN NN O
among NN NN O
169 NN NN O
patients NN NN O
with NN NN O
rheumatoid NN NN B-Disease
arthritis NN NN I-Disease
, NN NN O
osteoarthritis NN NN B-Disease
and NN NN O
spondyloarthropathy NN NN B-Disease
, NN NN O
130 NN NN O
of NN NN O
whom NN NN O
were NN NN O
pair NN NN O
- NN NN O
matched NN NN O
to NN NN O
controls NN NN O
. NN NN O
   
Assessments NN NN O
of NN NN O
marital NN NN O
happiness NN NN O
and NN NN O
depressed NN NN B-Disease
mood NN NN I-Disease
were NN NN O
also NN NN O
made NN NN O
using NN NN O
the NN NN O
CES NN NN O
- NN NN O
D NN NN O
and NN NN O
the NN NN O
Azrin NN NN O
Marital NN NN O
Happiness NN NN O
Scale NN NN O
( NN NN O
AMHS NN NN O
) NN NN O
. NN NN O
   
Sexual NN NN B-Disease
dysfunctions NN NN I-Disease
were NN NN O
found NN NN O
to NN NN O
be NN NN O
common NN NN O
among NN NN O
patients NN NN O
and NN NN O
controls NN NN O
, NN NN O
the NN NN O
majority NN NN O
in NN NN O
both NN NN O
groups NN NN O
reporting NN NN O
one NN NN O
or NN NN O
more NN NN O
dysfunctions NN NN O
. NN NN O
   
Impotence NN NN B-Disease
was NN NN O
more NN NN O
common NN NN O
among NN NN O
male NN NN O
patients NN NN O
than NN NN O
controls NN NN O
and NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
associated NN NN O
with NN NN O
co NN NN O
- NN NN O
morbidity NN NN O
and NN NN O
the NN NN O
taking NN NN O
of NN NN O
methotrexate NN NN O
. NN NN O
   
Depressed NN NN B-Disease
mood NN NN I-Disease
was NN NN O
more NN NN O
common NN NN O
among NN NN O
patients NN NN O
and NN NN O
was NN NN O
associated NN NN O
with NN NN O
certain NN NN O
sexual NN NN O
difficulties NN NN O
, NN NN O
but NN NN O
not NN NN O
with NN NN O
impotence NN NN B-Disease
. NN NN O
   
Marital NN NN O
unhappiness NN NN O
, NN NN O
as NN NN O
indicated NN NN O
by NN NN O
AMHS NN NN O
scores NN NN O
, NN NN O
was NN NN O
not NN NN O
associated NN NN O
with NN NN O
arthritis NN NN B-Disease
but NN NN O
was NN NN O
associated NN NN O
with NN NN O
sexual NN NN B-Disease
dysfunction NN NN I-Disease
, NN NN O
sexual NN NN O
dissatisfaction NN NN O
and NN NN O
being NN NN O
female NN NN O
. NN NN O
   
Does NN NN O
paracetamol NN NN O
cause NN NN O
urothelial NN NN B-Disease
cancer NN NN I-Disease
or NN NN O
renal NN NN B-Disease
papillary NN NN I-Disease
necrosis NN NN I-Disease
? NN NN O
   
The NN NN O
risk NN NN O
of NN NN O
developing NN NN O
renal NN NN B-Disease
papillary NN NN I-Disease
necrosis NN NN I-Disease
or NN NN O
cancer NN NN B-Disease
of NN NN I-Disease
the NN NN I-Disease
renal NN NN I-Disease
pelvis NN NN I-Disease
, NN NN I-Disease
ureter NN NN I-Disease
or NN NN I-Disease
bladder NN NN I-Disease
associated NN NN O
with NN NN O
consumption NN NN O
of NN NN O
either NN NN O
phenacetin NN NN O
or NN NN O
paracetamol NN NN O
was NN NN O
calculated NN NN O
from NN NN O
data NN NN O
acquired NN NN O
by NN NN O
questionnaire NN NN O
from NN NN O
381 NN NN O
cases NN NN O
and NN NN O
808 NN NN O
controls NN NN O
. NN NN O
   
The NN NN O
risk NN NN O
of NN NN O
renal NN NN B-Disease
papillary NN NN I-Disease
necrosis NN NN I-Disease
was NN NN O
increased NN NN O
nearly NN NN O
20 NN NN O
- NN NN O
fold NN NN O
by NN NN O
consumption NN NN O
of NN NN O
phenacetin NN NN O
, NN NN O
which NN NN O
also NN NN O
increased NN NN O
the NN NN O
risk NN NN O
for NN NN O
cancer NN NN B-Disease
of NN NN I-Disease
the NN NN I-Disease
renal NN NN I-Disease
pelvis NN NN I-Disease
and NN NN I-Disease
bladder NN NN I-Disease
but NN NN O
not NN NN O
for NN NN O
ureteric NN NN B-Disease
cancer NN NN I-Disease
. NN NN O
   
By NN NN O
contrast NN NN O
, NN NN O
we NN NN O
were NN NN O
unable NN NN O
to NN NN O
substantiate NN NN O
an NN NN O
increased NN NN O
risk NN NN O
from NN NN O
paracetamol NN NN O
consumption NN NN O
for NN NN O
renal NN NN B-Disease
papillary NN NN I-Disease
necrosis NN NN I-Disease
or NN NN O
any NN NN O
of NN NN O
these NN NN O
cancers NN NN B-Disease
although NN NN O
there NN NN O
was NN NN O
a NN NN O
suggestion NN NN O
of NN NN O
an NN NN O
association NN NN O
with NN NN O
cancer NN NN B-Disease
of NN NN I-Disease
the NN NN I-Disease
ureter NN NN I-Disease
. NN NN O
   
Dapsone NN NN O
- NN NN O
associated NN NN O
Heinz NN NN O
body NN NN O
hemolytic NN NN B-Disease
anemia NN NN I-Disease
in NN NN O
a NN NN O
Cambodian NN NN O
woman NN NN O
with NN NN O
hemoglobin NN NN O
E NN NN O
trait NN NN O
. NN NN O
   
A NN NN O
Cambodian NN NN O
woman NN NN O
with NN NN O
hemoglobin NN NN O
E NN NN O
trait NN NN O
( NN NN O
AE NN NN O
) NN NN O
and NN NN O
leprosy NN NN B-Disease
developed NN NN O
a NN NN O
Heinz NN NN O
body NN NN O
hemolytic NN NN B-Disease
anemia NN NN I-Disease
while NN NN O
taking NN NN O
a NN NN O
dose NN NN O
of NN NN O
dapsone NN NN O
( NN NN O
50 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
) NN NN O
not NN NN O
usually NN NN O
associated NN NN O
with NN NN O
clinical NN NN O
hemolysis NN NN B-Disease
. NN NN O
   
Her NN NN O
red NN NN O
blood NN NN O
cells NN NN O
( NN NN O
RBCs NN NN O
) NN NN O
had NN NN O
increased NN NN O
incubated NN NN O
Heinz NN NN O
body NN NN O
formation NN NN O
, NN NN O
decreased NN NN O
reduced NN NN O
glutathione NN NN O
( NN NN O
GSH NN NN O
) NN NN O
, NN NN O
and NN NN O
decreased NN NN O
GSH NN NN O
stability NN NN O
. NN NN O
   
The NN NN O
pentose NN NN O
phosphate NN NN O
shunt NN NN O
activity NN NN O
of NN NN O
the NN NN O
dapsone NN NN O
- NN NN O
exposed NN NN O
AE NN NN O
RBCs NN NN O
was NN NN O
increased NN NN O
compared NN NN O
to NN NN O
normal NN NN O
RBCs NN NN O
. NN NN O
   
Although NN NN O
the NN NN O
AE NN NN O
RBCs NN NN O
from NN NN O
an NN NN O
individual NN NN O
not NN NN O
taking NN NN O
dapsone NN NN O
had NN NN O
increased NN NN O
incubated NN NN O
Heinz NN NN O
body NN NN O
formation NN NN O
, NN NN O
the NN NN O
GSH NN NN O
content NN NN O
and NN NN O
GSH NN NN O
stability NN NN O
were NN NN O
normal NN NN O
. NN NN O
   
The NN NN O
pentose NN NN O
phosphate NN NN O
shunt NN NN O
activity NN NN O
of NN NN O
the NN NN O
non NN NN O
- NN NN O
dapsone NN NN O
- NN NN O
exposed NN NN O
AE NN NN O
RBCs NN NN O
was NN NN O
decreased NN NN O
compared NN NN O
to NN NN O
normal NN NN O
RBCs NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
AE NN NN O
RBCs NN NN O
appear NN NN O
to NN NN O
have NN NN O
an NN NN O
increased NN NN O
sensitivity NN NN O
to NN NN O
oxidant NN NN O
stress NN NN O
both NN NN O
in NN NN O
vitro NN NN O
and NN NN O
in NN NN O
vivo NN NN O
, NN NN O
since NN NN O
dapsone NN NN O
does NN NN O
not NN NN O
cause NN NN O
hemolytic NN NN B-Disease
anemia NN NN I-Disease
at NN NN O
this NN NN O
dose NN NN O
in NN NN O
hematologically NN NN O
normal NN NN O
individuals NN NN O
. NN NN O
   
Given NN NN O
the NN NN O
influx NN NN O
of NN NN O
Southeast NN NN O
Asians NN NN O
into NN NN O
the NN NN O
United NN NN O
States NN NN O
, NN NN O
oxidant NN NN O
medications NN NN O
should NN NN O
be NN NN O
used NN NN O
with NN NN O
caution NN NN O
, NN NN O
especially NN NN O
if NN NN O
an NN NN O
infection NN NN B-Disease
is NN NN O
present NN NN O
, NN NN O
in NN NN O
individuals NN NN O
of NN NN O
ethnic NN NN O
backgrounds NN NN O
that NN NN O
have NN NN O
an NN NN O
increased NN NN O
prevalence NN NN O
of NN NN O
hemoglobin NN NN O
E NN NN O
. NN NN O
   
Severe NN NN O
complications NN NN O
of NN NN O
antianginal NN NN O
drug NN NN O
therapy NN NN O
in NN NN O
a NN NN O
patient NN NN O
identified NN NN O
as NN NN O
a NN NN O
poor NN NN O
metabolizer NN NN O
of NN NN O
metoprolol NN NN O
, NN NN O
propafenone NN NN O
, NN NN O
diltiazem NN NN O
, NN NN O
and NN NN O
sparteine NN NN O
. NN NN O
   
A NN NN O
47 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
patient NN NN O
suffering NN NN O
from NN NN O
coronary NN NN B-Disease
artery NN NN I-Disease
disease NN NN I-Disease
was NN NN O
admitted NN NN O
to NN NN O
the NN NN O
CCU NN NN O
in NN NN O
shock NN NN B-Disease
with NN NN O
III NN NN O
. NN NN O
   
AV NN NN B-Disease
block NN NN I-Disease
, NN NN O
severe NN NN O
hypotension NN NN B-Disease
, NN NN O
and NN NN O
impairment NN NN B-Disease
of NN NN I-Disease
ventricular NN NN I-Disease
function NN NN I-Disease
. NN NN O
   
One NN NN O
week NN NN O
prior NN NN O
to NN NN O
admission NN NN O
a NN NN O
therapy NN NN O
with NN NN O
standard NN NN O
doses NN NN O
of NN NN O
metoprolol NN NN O
( NN NN O
100 NN NN O
mg NN NN O
t NN NN O
. NN NN O
i NN NN O
. NN NN O
d NN NN O
. NN NN O
and NN NN O
then NN NN O
100 NN NN O
mg NN NN O
b NN NN O
. NN NN O
i NN NN O
. NN NN O
d NN NN O
. NN NN O
) NN NN O
had NN NN O
been NN NN O
initiated NN NN O
. NN NN O
   
Two NN NN O
days NN NN O
before NN NN O
admission NN NN O
diltiazem NN NN O
( NN NN O
60 NN NN O
mg NN NN O
b NN NN O
. NN NN O
i NN NN O
. NN NN O
d NN NN O
. NN NN O
) NN NN O
was NN NN O
prescribed NN NN O
in NN NN O
addition NN NN O
. NN NN O
   
Analyses NN NN O
of NN NN O
a NN NN O
blood NN NN O
sample NN NN O
revealed NN NN O
unusually NN NN O
high NN NN O
plasma NN NN O
concentrations NN NN O
of NN NN O
metoprolol NN NN O
( NN NN O
greater NN NN O
than NN NN O
3000 NN NN O
ng NN NN O
/ NN NN O
ml NN NN O
) NN NN O
and NN NN O
diltiazem NN NN O
( NN NN O
526 NN NN O
ng NN NN O
/ NN NN O
ml NN NN O
) NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
recovered NN NN O
within NN NN O
1 NN NN O
week NN NN O
following NN NN O
discontinuation NN NN O
of NN NN O
antianginal NN NN O
therapy NN NN O
. NN NN O
   
Three NN NN O
months NN NN O
later NN NN O
the NN NN O
patient NN NN O
was NN NN O
exposed NN NN O
to NN NN O
a NN NN O
single NN NN O
dose NN NN O
of NN NN O
metoprolol NN NN O
, NN NN O
diltiazem NN NN O
, NN NN O
propafenone NN NN O
( NN NN O
since NN NN O
he NN NN O
had NN NN O
received NN NN O
this NN NN O
drug NN NN O
in NN NN O
the NN NN O
past NN NN O
) NN NN O
, NN NN O
and NN NN O
sparteine NN NN O
( NN NN O
as NN NN O
a NN NN O
probe NN NN O
for NN NN O
the NN NN O
debrisoquine NN NN O
/ NN NN O
sparteine NN NN O
type NN NN O
polymorphism NN NN O
of NN NN O
oxidative NN NN O
drug NN NN O
metabolism NN NN O
) NN NN O
. NN NN O
   
It NN NN O
was NN NN O
found NN NN O
that NN NN O
he NN NN O
was NN NN O
a NN NN O
poor NN NN O
metabolizer NN NN O
of NN NN O
all NN NN O
four NN NN O
drugs NN NN O
, NN NN O
indicating NN NN O
that NN NN O
their NN NN O
metabolism NN NN O
is NN NN O
under NN NN O
the NN NN O
same NN NN O
genetic NN NN O
control NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
patients NN NN O
belonging NN NN O
to NN NN O
the NN NN O
poor NN NN O
- NN NN O
metabolizer NN NN O
phenotype NN NN O
of NN NN O
sparteine NN NN O
/ NN NN O
debrisoquine NN NN O
polymorphism NN NN O
in NN NN O
drug NN NN O
metabolism NN NN O
, NN NN O
which NN NN O
constitutes NN NN O
6 NN NN O
. NN NN O
4 NN NN O
% NN NN O
of NN NN O
the NN NN O
German NN NN O
population NN NN O
, NN NN O
may NN NN O
experience NN NN O
adverse NN NN B-Disease
drug NN NN I-Disease
reactions NN NN I-Disease
when NN NN O
treated NN NN O
with NN NN O
standard NN NN O
doses NN NN O
of NN NN O
one NN NN O
of NN NN O
these NN NN O
drugs NN NN O
alone NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
the NN NN O
coadministration NN NN O
of NN NN O
these NN NN O
frequently NN NN O
used NN NN O
drugs NN NN O
is NN NN O
expected NN NN O
to NN NN O
be NN NN O
especially NN NN O
harmful NN NN O
in NN NN O
this NN NN O
subgroup NN NN O
of NN NN O
patients NN NN O
. NN NN O
   
Clinical NN NN O
experiences NN NN O
in NN NN O
an NN NN O
open NN NN O
and NN NN O
a NN NN O
double NN NN O
- NN NN O
blind NN NN O
trial NN NN O
. NN NN O
   
A NN NN O
total NN NN O
of NN NN O
sixty NN NN O
patients NN NN O
were NN NN O
trated NN NN O
with NN NN O
bromperidol NN NN O
first NN NN O
in NN NN O
open NN NN O
conditions NN NN O
( NN NN O
20 NN NN O
patients NN NN O
) NN NN O
, NN NN O
then NN NN O
on NN NN O
a NN NN O
double NN NN O
blind NN NN O
basis NN NN O
( NN NN O
40 NN NN O
patients NN NN O
) NN NN O
with NN NN O
haloperidol NN NN O
as NN NN O
the NN NN O
reference NN NN O
substance NN NN O
. NN NN O
   
The NN NN O
open NN NN O
study NN NN O
lasted NN NN O
for NN NN O
four NN NN O
weeks NN NN O
; NN NN O
the NN NN O
drug NN NN O
was NN NN O
administrated NN NN O
in NN NN O
the NN NN O
form NN NN O
of NN NN O
1 NN NN O
mg NN NN O
tablets NN NN O
. NN NN O
   
The NN NN O
daily NN NN O
dose NN NN O
( NN NN O
initial NN NN O
dose NN NN O
: NN NN O
1 NN NN O
mg NN NN O
; NN NN O
mean NN NN O
dose NN NN O
at NN NN O
the NN NN O
end NN NN O
of NN NN O
the NN NN O
trial NN NN O
: NN NN O
4 NN NN O
. NN NN O
47 NN NN O
mg NN NN O
) NN NN O
was NN NN O
always NN NN O
administered NN NN O
in NN NN O
one NN NN O
single NN NN O
dose NN NN O
. NN NN O
   
Nineteen NN NN O
patients NN NN O
finished NN NN O
the NN NN O
trial NN NN O
, NN NN O
and NN NN O
in NN NN O
18 NN NN O
cases NN NN O
the NN NN O
therapeutic NN NN O
result NN NN O
was NN NN O
considered NN NN O
very NN NN O
good NN NN O
to NN NN O
good NN NN O
. NN NN O
   
These NN NN O
results NN NN O
were NN NN O
confirmed NN NN O
by NN NN O
statistical NN NN O
analysis NN NN O
. NN NN O
   
Nine NN NN O
patients NN NN O
exhibited NN NN O
mild NN NN O
to NN NN O
moderate NN NN O
extrapyramidal NN NN B-Disease
concomitant NN NN I-Disease
symptoms NN NN I-Disease
; NN NN O
no NN NN O
other NN NN O
side NN NN O
effects NN NN O
were NN NN O
observed NN NN O
. NN NN O
   
The NN NN O
results NN NN O
of NN NN O
detailed NN NN O
laboratory NN NN O
tests NN NN O
and NN NN O
evaluations NN NN O
of NN NN O
various NN NN O
quantitative NN NN O
and NN NN O
qualitative NN NN O
tolerability NN NN O
parameters NN NN O
were NN NN O
not NN NN O
indicative NN NN O
of NN NN O
toxic NN NN O
effects NN NN O
. NN NN O
   
In NN NN O
the NN NN O
double NN NN O
blind NN NN O
study NN NN O
with NN NN O
haloperidol NN NN O
, NN NN O
both NN NN O
substances NN NN O
were NN NN O
found NN NN O
to NN NN O
be NN NN O
highly NN NN O
effective NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
psychotic NN NN B-Disease
syndromes NN NN I-Disease
belonging NN NN I-Disease
predominantly NN NN I-Disease
to NN NN I-Disease
the NN NN I-Disease
schizophrenia NN NN I-Disease
group NN NN I-Disease
. NN NN O
   
Certain NN NN O
clues NN NN O
, NN NN O
including NN NN O
the NN NN O
onset NN NN O
of NN NN O
action NN NN O
, NN NN O
seem NN NN O
to NN NN O
be NN NN O
indicative NN NN O
of NN NN O
the NN NN O
superiority NN NN O
of NN NN O
bromperidol NN NN O
. NN NN O
   
No NN NN O
differences NN NN O
were NN NN O
observed NN NN O
with NN NN O
respect NN NN O
to NN NN O
side NN NN O
effects NN NN O
and NN NN O
general NN NN O
tolerability NN NN O
. NN NN O
   
Prolonged NN NN O
cholestasis NN NN B-Disease
after NN NN O
troleandomycin NN NN O
- NN NN O
induced NN NN O
acute NN NN O
hepatitis NN NN B-Disease
. NN NN O
   
We NN NN O
report NN NN O
the NN NN O
case NN NN O
of NN NN O
a NN NN O
patient NN NN O
in NN NN O
whom NN NN O
troleandomycin NN NN O
- NN NN O
induced NN NN O
hepatitis NN NN B-Disease
was NN NN O
followed NN NN O
by NN NN O
prolonged NN NN O
anicteric NN NN O
cholestasis NN NN B-Disease
. NN NN O
   
Jaundice NN NN B-Disease
occurred NN NN O
after NN NN O
administration NN NN O
of NN NN O
troleandomycin NN NN O
for NN NN O
7 NN NN O
days NN NN O
and NN NN O
was NN NN O
associated NN NN O
with NN NN O
hypereosinophilia NN NN B-Disease
. NN NN O
   
Jaundice NN NN B-Disease
disappeared NN NN O
within NN NN O
3 NN NN O
months NN NN O
but NN NN O
was NN NN O
followed NN NN O
by NN NN O
prolonged NN NN O
anicteric NN NN O
cholestasis NN NN B-Disease
marked NN NN O
by NN NN O
pruritus NN NN B-Disease
and NN NN O
high NN NN O
levels NN NN O
of NN NN O
alkaline NN NN O
phosphatase NN NN O
and NN NN O
gammaglutamyltransferase NN NN O
activities NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
pruritus NN NN B-Disease
disappeared NN NN O
within NN NN O
19 NN NN O
months NN NN O
, NN NN O
and NN NN O
liver NN NN O
tests NN NN O
returned NN NN O
to NN NN O
normal NN NN O
27 NN NN O
months NN NN O
after NN NN O
the NN NN O
onset NN NN O
of NN NN O
hepatitis NN NN B-Disease
. NN NN O
   
This NN NN O
observation NN NN O
demonstrates NN NN O
that NN NN O
prolonged NN NN O
cholestasis NN NN B-Disease
can NN NN O
follow NN NN O
troleandomycin NN NN O
- NN NN O
induced NN NN O
acute NN NN O
hepatitis NN NN B-Disease
. NN NN O
   
Serial NN NN O
studies NN NN O
of NN NN O
auditory NN NN B-Disease
neurotoxicity NN NN I-Disease
in NN NN O
patients NN NN O
receiving NN NN O
deferoxamine NN NN O
therapy NN NN O
. NN NN O
   
Visual NN NN B-Disease
and NN NN I-Disease
auditory NN NN I-Disease
neurotoxicity NN NN I-Disease
was NN NN O
previously NN NN O
documented NN NN O
in NN NN O
42 NN NN O
of NN NN O
89 NN NN O
patients NN NN O
with NN NN O
transfusion NN NN O
- NN NN O
dependent NN NN O
anemia NN NN B-Disease
who NN NN O
were NN NN O
receiving NN NN O
iron NN NN O
chelation NN NN O
therapy NN NN O
with NN NN O
daily NN NN O
subcutaneous NN NN O
deferoxamine NN NN O
. NN NN O
   
Twenty NN NN O
- NN NN O
two NN NN O
patients NN NN O
in NN NN O
the NN NN O
affected NN NN O
group NN NN O
had NN NN O
abnormal NN NN B-Disease
audiograms NN NN I-Disease
with NN NN I-Disease
deficits NN NN I-Disease
mostly NN NN I-Disease
in NN NN I-Disease
the NN NN I-Disease
high NN NN I-Disease
frequency NN NN I-Disease
range NN NN I-Disease
of NN NN I-Disease
4 NN NN I-Disease
, NN NN I-Disease
000 NN NN I-Disease
to NN NN I-Disease
8 NN NN I-Disease
, NN NN I-Disease
000 NN NN I-Disease
Hz NN NN I-Disease
and NN NN O
in NN NN O
the NN NN O
hearing NN NN O
threshold NN NN O
levels NN NN O
of NN NN O
30 NN NN O
to NN NN O
100 NN NN O
decibels NN NN O
. NN NN O
   
When NN NN O
deferoxamine NN NN O
therapy NN NN O
was NN NN O
discontinued NN NN O
and NN NN O
serial NN NN O
studies NN NN O
were NN NN O
performed NN NN O
, NN NN O
audiograms NN NN O
in NN NN O
seven NN NN O
cases NN NN O
reverted NN NN O
to NN NN O
normal NN NN O
or NN NN O
near NN NN O
normal NN NN O
within NN NN O
two NN NN O
to NN NN O
three NN NN O
weeks NN NN O
, NN NN O
and NN NN O
nine NN NN O
of NN NN O
13 NN NN O
patients NN NN O
with NN NN O
symptoms NN NN O
became NN NN O
asymptomatic NN NN O
. NN NN O
   
Audiograms NN NN O
from NN NN O
15 NN NN O
patients NN NN O
remained NN NN O
abnormal NN NN O
and NN NN O
four NN NN O
patients NN NN O
required NN NN O
hearing NN NN O
aids NN NN O
because NN NN O
of NN NN O
permanent NN NN B-Disease
disability NN NN I-Disease
. NN NN O
   
Since NN NN O
18 NN NN O
of NN NN O
the NN NN O
22 NN NN O
patients NN NN O
were NN NN O
initially NN NN O
receiving NN NN O
deferoxamine NN NN O
doses NN NN O
in NN NN O
excess NN NN O
of NN NN O
the NN NN O
commonly NN NN O
recommended NN NN O
50 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
per NN NN O
dose NN NN O
, NN NN O
therapy NN NN O
was NN NN O
restarted NN NN O
with NN NN O
lower NN NN O
doses NN NN O
, NN NN O
usually NN NN O
50 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
per NN NN O
dose NN NN O
or NN NN O
less NN NN O
depending NN NN O
on NN NN O
the NN NN O
degree NN NN O
of NN NN O
auditory NN NN B-Disease
abnormality NN NN I-Disease
, NN NN O
and NN NN O
with NN NN O
the NN NN O
exception NN NN O
of NN NN O
two NN NN O
cases NN NN O
no NN NN O
further NN NN O
toxicity NN NN B-Disease
was NN NN O
demonstrated NN NN O
. NN NN O
   
Auditory NN NN O
deterioration NN NN O
and NN NN O
improvement NN NN O
, NN NN O
demonstrated NN NN O
serially NN NN O
in NN NN O
individual NN NN O
patients NN NN O
receiving NN NN O
and NN NN O
not NN NN O
receiving NN NN O
deferoxamine NN NN O
, NN NN O
respectively NN NN O
, NN NN O
provided NN NN O
convincing NN NN O
evidence NN NN O
for NN NN O
a NN NN O
cause NN NN O
- NN NN O
and NN NN O
- NN NN O
effect NN NN O
relation NN NN O
between NN NN O
deferoxamine NN NN O
administration NN NN O
and NN NN O
ototoxicity NN NN B-Disease
. NN NN O
   
Based NN NN O
on NN NN O
these NN NN O
data NN NN O
, NN NN O
a NN NN O
plan NN NN O
of NN NN O
management NN NN O
was NN NN O
developed NN NN O
that NN NN O
allows NN NN O
effective NN NN O
yet NN NN O
safe NN NN O
administration NN NN O
of NN NN O
deferoxamine NN NN O
. NN NN O
   
A NN NN O
dose NN NN O
of NN NN O
50 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
is NN NN O
recommended NN NN O
in NN NN O
those NN NN O
without NN NN O
audiogram NN NN O
abnormalities NN NN O
. NN NN O
   
With NN NN O
mild NN NN O
toxicity NN NN B-Disease
, NN NN O
a NN NN O
reduction NN NN O
to NN NN O
30 NN NN O
or NN NN O
40 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
per NN NN O
dose NN NN O
should NN NN O
result NN NN O
in NN NN O
a NN NN O
reversal NN NN O
of NN NN O
the NN NN O
abnormal NN NN O
results NN NN O
to NN NN O
normal NN NN O
within NN NN O
four NN NN O
weeks NN NN O
. NN NN O
   
Moderate NN NN O
abnormalities NN NN O
require NN NN O
a NN NN O
reduction NN NN O
of NN NN O
deferoxamine NN NN O
to NN NN O
25 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
per NN NN O
dose NN NN O
with NN NN O
careful NN NN O
monitoring NN NN O
. NN NN O
   
In NN NN O
those NN NN O
with NN NN O
symptoms NN NN O
of NN NN O
hearing NN NN B-Disease
loss NN NN I-Disease
, NN NN O
the NN NN O
drug NN NN O
should NN NN O
be NN NN O
stopped NN NN O
for NN NN O
four NN NN O
weeks NN NN O
, NN NN O
and NN NN O
when NN NN O
the NN NN O
audiogram NN NN O
is NN NN O
stable NN NN O
or NN NN O
improved NN NN O
, NN NN O
therapy NN NN O
should NN NN O
be NN NN O
restarted NN NN O
at NN NN O
10 NN NN O
to NN NN O
25 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
per NN NN O
dose NN NN O
. NN NN O
   
Serial NN NN O
audiograms NN NN O
should NN NN O
be NN NN O
performed NN NN O
every NN NN O
six NN NN O
months NN NN O
in NN NN O
those NN NN O
without NN NN O
problems NN NN O
and NN NN O
more NN NN O
frequently NN NN O
in NN NN O
young NN NN O
patients NN NN O
with NN NN O
normal NN NN O
serum NN NN O
ferritin NN NN O
values NN NN O
and NN NN O
in NN NN O
those NN NN O
with NN NN O
auditory NN NN B-Disease
dysfunction NN NN I-Disease
. NN NN O
   
Lidocaine NN NN O
- NN NN O
induced NN NN O
cardiac NN NN B-Disease
asystole NN NN I-Disease
. NN NN O
   
Intravenous NN NN O
administration NN NN O
of NN NN O
a NN NN O
single NN NN O
50 NN NN O
- NN NN O
mg NN NN O
bolus NN NN O
of NN NN O
lidocaine NN NN O
in NN NN O
a NN NN O
67 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
man NN NN O
resulted NN NN O
in NN NN O
profound NN NN O
depression NN NN B-Disease
of NN NN O
the NN NN O
activity NN NN O
of NN NN O
the NN NN O
sinoatrial NN NN O
and NN NN O
atrioventricular NN NN O
nodal NN NN O
pacemakers NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
had NN NN O
no NN NN O
apparent NN NN O
associated NN NN O
conditions NN NN O
which NN NN O
might NN NN O
have NN NN O
predisposed NN NN O
him NN NN O
to NN NN O
the NN NN O
development NN NN O
of NN NN O
bradyarrhythmias NN NN B-Disease
; NN NN O
and NN NN O
, NN NN O
thus NN NN O
, NN NN O
this NN NN O
probably NN NN O
represented NN NN O
a NN NN O
true NN NN O
idiosyncrasy NN NN O
to NN NN O
lidocaine NN NN O
. NN NN O
   
Flurbiprofen NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
juvenile NN NN B-Disease
rheumatoid NN NN I-Disease
arthritis NN NN I-Disease
. NN NN O
   
Thirty NN NN O
- NN NN O
four NN NN O
patients NN NN O
with NN NN O
juvenile NN NN B-Disease
rheumatoid NN NN I-Disease
arthritis NN NN I-Disease
, NN NN O
who NN NN O
were NN NN O
treated NN NN O
with NN NN O
flurbiprofen NN NN O
at NN NN O
a NN NN O
maximum NN NN O
dose NN NN O
of NN NN O
4 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
, NN NN O
had NN NN O
statistically NN NN O
significant NN NN O
decreases NN NN O
from NN NN O
baseline NN NN O
in NN NN O
6 NN NN O
arthritis NN NN B-Disease
indices NN NN O
after NN NN O
12 NN NN O
weeks NN NN O
of NN NN O
treatment NN NN O
. NN NN O
   
Improvements NN NN O
were NN NN O
seen NN NN O
in NN NN O
the NN NN O
number NN NN O
of NN NN O
tender NN NN B-Disease
joints NN NN I-Disease
, NN NN O
the NN NN O
severity NN NN O
of NN NN O
swelling NN NN B-Disease
and NN NN O
tenderness NN NN B-Disease
, NN NN O
the NN NN O
time NN NN O
of NN NN O
walk NN NN O
50 NN NN O
feet NN NN O
, NN NN O
the NN NN O
duration NN NN O
of NN NN O
morning NN NN B-Disease
stiffness NN NN I-Disease
and NN NN O
the NN NN O
circumference NN NN O
of NN NN O
the NN NN O
left NN NN O
knee NN NN O
. NN NN O
   
The NN NN O
most NN NN O
frequently NN NN O
observed NN NN O
side NN NN O
effect NN NN O
was NN NN O
fecal NN NN B-Disease
occult NN NN I-Disease
blood NN NN I-Disease
( NN NN O
25 NN NN O
% NN NN O
of NN NN O
patients NN NN O
) NN NN O
; NN NN O
however NN NN O
, NN NN O
there NN NN O
was NN NN O
no NN NN O
other NN NN O
evidence NN NN O
of NN NN O
gastrointestinal NN NN B-Disease
( NN NN I-Disease
GI NN NN I-Disease
) NN NN I-Disease
bleeding NN NN I-Disease
in NN NN O
these NN NN O
patients NN NN O
. NN NN O
   
One NN NN O
patient NN NN O
was NN NN O
prematurely NN NN O
discontinued NN NN O
from NN NN O
the NN NN O
study NN NN O
for NN NN O
severe NN NN O
headache NN NN B-Disease
and NN NN O
abdominal NN NN B-Disease
pain NN NN I-Disease
. NN NN O
   
Most NN NN O
side NN NN O
effects NN NN O
were NN NN O
mild NN NN O
and NN NN O
related NN NN O
to NN NN O
the NN NN O
GI NN NN O
tract NN NN O
. NN NN O
   
Hyperkalemia NN NN B-Disease
associated NN NN O
with NN NN O
sulindac NN NN O
therapy NN NN O
. NN NN O
   
Hyperkalemia NN NN B-Disease
has NN NN O
recently NN NN O
been NN NN O
recognized NN NN O
as NN NN O
a NN NN O
complication NN NN O
of NN NN O
nonsteroidal NN NN O
antiinflammatory NN NN O
agents NN NN O
( NN NN O
NSAID NN NN O
) NN NN O
such NN NN O
as NN NN O
indomethacin NN NN O
. NN NN O
   
Several NN NN O
recent NN NN O
studies NN NN O
have NN NN O
stressed NN NN O
the NN NN O
renal NN NN O
sparing NN NN O
features NN NN O
of NN NN O
sulindac NN NN O
, NN NN O
owing NN NN O
to NN NN O
its NN NN O
lack NN NN O
of NN NN O
interference NN NN O
with NN NN O
renal NN NN O
prostacyclin NN NN O
synthesis NN NN O
. NN NN O
   
We NN NN O
describe NN NN O
4 NN NN O
patients NN NN O
in NN NN O
whom NN NN O
hyperkalemia NN NN B-Disease
ranging NN NN O
from NN NN O
6 NN NN O
. NN NN O
1 NN NN O
to NN NN O
6 NN NN O
. NN NN O
9 NN NN O
mEq NN NN O
/ NN NN O
l NN NN O
developed NN NN O
within NN NN O
3 NN NN O
to NN NN O
8 NN NN O
days NN NN O
of NN NN O
sulindac NN NN O
administration NN NN O
. NN NN O
   
In NN NN O
all NN NN O
of NN NN O
them NN NN O
normal NN NN O
serum NN NN O
potassium NN NN O
levels NN NN O
reached NN NN O
within NN NN O
2 NN NN O
to NN NN O
4 NN NN O
days NN NN O
of NN NN O
stopping NN NN O
sulindac NN NN O
. NN NN O
   
As NN NN O
no NN NN O
other NN NN O
medications NN NN O
known NN NN O
to NN NN O
effect NN NN O
serum NN NN O
potassium NN NN O
had NN NN O
been NN NN O
given NN NN O
concomitantly NN NN O
, NN NN O
this NN NN O
course NN NN O
of NN NN O
events NN NN O
is NN NN O
suggestive NN NN O
of NN NN O
a NN NN O
cause NN NN O
- NN NN O
and NN NN O
- NN NN O
effect NN NN O
relationship NN NN O
between NN NN O
sulindac NN NN O
and NN NN O
hyperkalemia NN NN B-Disease
. NN NN O
   
These NN NN O
observations NN NN O
indicate NN NN O
that NN NN O
initial NN NN O
hopes NN NN O
that NN NN O
sulindac NN NN O
may NN NN O
not NN NN O
be NN NN O
associated NN NN O
with NN NN O
the NN NN O
adverse NN NN O
renal NN NN O
effects NN NN O
of NN NN O
other NN NN O
NSAID NN NN O
are NN NN O
probably NN NN O
not NN NN O
justified NN NN O
. NN NN O
   
Drug NN NN O
- NN NN O
induced NN NN O
arterial NN NN O
spasm NN NN B-Disease
relieved NN NN O
by NN NN O
lidocaine NN NN O
. NN NN O
   
Case NN NN O
report NN NN O
. NN NN O
   
Following NN NN O
major NN NN O
intracranial NN NN O
surgery NN NN O
in NN NN O
a NN NN O
35 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
man NN NN O
, NN NN O
sodium NN NN O
pentothal NN NN O
was NN NN O
intravenously NN NN O
infused NN NN O
to NN NN O
minimize NN NN O
cerebral NN NN B-Disease
ischaemia NN NN I-Disease
. NN NN O
   
Intense NN NN O
vasospasm NN NN B-Disease
with NN NN O
threatened NN NN O
gangrene NN NN B-Disease
arose NN NN O
in NN NN O
the NN NN O
arm NN NN O
used NN NN O
for NN NN O
the NN NN O
infusion NN NN O
. NN NN O
   
Since NN NN O
the NN NN O
cranial NN NN O
condition NN NN O
precluded NN NN O
use NN NN O
of NN NN O
more NN NN O
usual NN NN O
methods NN NN O
, NN NN O
lidocaine NN NN O
was NN NN O
given NN NN O
intra NN NN O
- NN NN O
arterially NN NN O
, NN NN O
with NN NN O
careful NN NN O
cardiovascular NN NN O
monitoring NN NN O
, NN NN O
to NN NN O
counteract NN NN O
the NN NN O
vasospasm NN NN B-Disease
. NN NN O
   
The NN NN O
treatment NN NN O
was NN NN O
rapidly NN NN O
successful NN NN O
. NN NN O
   
Regional NN NN O
localization NN NN O
of NN NN O
the NN NN O
antagonism NN NN O
of NN NN O
amphetamine NN NN O
- NN NN O
induced NN NN O
hyperactivity NN NN B-Disease
by NN NN O
intracerebral NN NN O
calcitonin NN NN O
injections NN NN O
. NN NN O
   
Calcitonin NN NN O
receptors NN NN O
are NN NN O
found NN NN O
in NN NN O
the NN NN O
brain NN NN O
, NN NN O
and NN NN O
intracerebral NN NN O
infusions NN NN O
of NN NN O
calcitonin NN NN O
can NN NN O
produce NN NN O
behavioral NN NN O
effects NN NN O
. NN NN O
   
Among NN NN O
these NN NN O
behavioral NN NN O
effects NN NN O
are NN NN O
decreases NN NN O
in NN NN O
food NN NN O
intake NN NN O
and NN NN O
decreases NN NN O
in NN NN O
amphetamine NN NN O
- NN NN O
induced NN NN O
locomotor NN NN O
activity NN NN O
. NN NN O
   
In NN NN O
previous NN NN O
experiments NN NN O
we NN NN O
found NN NN O
that NN NN O
decreases NN NN O
in NN NN O
food NN NN O
intake NN NN O
were NN NN O
induced NN NN O
by NN NN O
local NN NN O
administration NN NN O
of NN NN O
calcitonin NN NN O
into NN NN O
several NN NN O
hypothalamic NN NN O
sites NN NN O
and NN NN O
into NN NN O
the NN NN O
nucleus NN NN O
accumbens NN NN O
. NN NN O
   
In NN NN O
the NN NN O
present NN NN O
experiment NN NN O
calcitonin NN NN O
decreased NN NN O
locomotor NN NN O
activity NN NN O
when NN NN O
locally NN NN O
injected NN NN O
into NN NN O
the NN NN O
same NN NN O
sites NN NN O
where NN NN O
it NN NN O
decreases NN NN O
food NN NN O
intake NN NN O
. NN NN O
   
The NN NN O
areas NN NN O
where NN NN O
calcitonin NN NN O
is NN NN O
most NN NN O
effective NN NN O
in NN NN O
decreasing NN NN O
locomotor NN NN O
activity NN NN O
are NN NN O
located NN NN O
in NN NN O
the NN NN O
hypothalamus NN NN O
and NN NN O
nucleus NN NN O
accumbens NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
these NN NN O
areas NN NN O
are NN NN O
the NN NN O
major NN NN O
sites NN NN O
of NN NN O
action NN NN O
of NN NN O
calcitonin NN NN O
in NN NN O
inhibiting NN NN O
amphetamine NN NN O
- NN NN O
induced NN NN O
locomotor NN NN O
activity NN NN O
. NN NN O
   
The NN NN O
hematologic NN NN O
effects NN NN O
of NN NN O
cefonicid NN NN O
and NN NN O
cefazedone NN NN O
in NN NN O
the NN NN O
dog NN NN O
: NN NN O
a NN NN O
potential NN NN O
model NN NN O
of NN NN O
cephalosporin NN NN O
hematotoxicity NN NN B-Disease
in NN NN O
man NN NN O
. NN NN O
   
Cephalosporin NN NN O
antibiotics NN NN O
cause NN NN O
a NN NN O
variety NN NN O
of NN NN O
hematologic NN NN B-Disease
disturbances NN NN I-Disease
in NN NN O
man NN NN O
, NN NN O
the NN NN O
pathogeneses NN NN O
and NN NN O
hematopathology NN NN O
of NN NN O
which NN NN O
remain NN NN O
poorly NN NN O
characterized NN NN O
. NN NN O
   
There NN NN O
is NN NN O
a NN NN O
need NN NN O
for NN NN O
a NN NN O
well NN NN O
- NN NN O
defined NN NN O
animal NN NN O
model NN NN O
in NN NN O
which NN NN O
these NN NN O
blood NN NN B-Disease
dyscrasias NN NN I-Disease
can NN NN O
be NN NN O
studied NN NN O
. NN NN O
   
In NN NN O
four NN NN O
subacute NN NN O
toxicity NN NN B-Disease
studies NN NN O
, NN NN O
the NN NN O
intravenous NN NN O
administration NN NN O
of NN NN O
cefonicid NN NN O
or NN NN O
cefazedone NN NN O
to NN NN O
beagle NN NN O
dogs NN NN O
caused NN NN O
a NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
incidence NN NN O
of NN NN O
anemia NN NN B-Disease
, NN NN O
neutropenia NN NN B-Disease
, NN NN O
and NN NN O
thrombocytopenia NN NN B-Disease
after NN NN O
1 NN NN O
- NN NN O
3 NN NN O
months NN NN O
of NN NN O
treatment NN NN O
. NN NN O
   
A NN NN O
nonregenerative NN NN O
anemia NN NN B-Disease
was NN NN O
the NN NN O
most NN NN O
compromising NN NN O
of NN NN O
the NN NN O
cytopenias NN NN B-Disease
and NN NN O
occurred NN NN O
in NN NN O
approximately NN NN O
50 NN NN O
% NN NN O
of NN NN O
dogs NN NN O
receiving NN NN O
400 NN NN O
- NN NN O
500 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
cefonicid NN NN O
or NN NN O
540 NN NN O
- NN NN O
840 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
cefazedone NN NN O
. NN NN O
   
All NN NN O
three NN NN O
cytopenias NN NN B-Disease
were NN NN O
completely NN NN O
reversible NN NN O
following NN NN O
cessation NN NN O
of NN NN O
treatment NN NN O
; NN NN O
the NN NN O
time NN NN O
required NN NN O
for NN NN O
recovery NN NN O
of NN NN O
the NN NN O
erythron NN NN O
( NN NN O
approximately NN NN O
1 NN NN O
month NN NN O
) NN NN O
was NN NN O
considerably NN NN O
longer NN NN O
than NN NN O
that NN NN O
of NN NN O
the NN NN O
granulocytes NN NN O
and NN NN O
platelets NN NN O
( NN NN O
hours NN NN O
to NN NN O
a NN NN O
few NN NN O
days NN NN O
) NN NN O
. NN NN O
   
Upon NN NN O
rechallenge NN NN O
with NN NN O
either NN NN O
cephalosporin NN NN O
, NN NN O
the NN NN O
hematologic NN NN B-Disease
syndrome NN NN I-Disease
was NN NN O
reproduced NN NN O
in NN NN O
most NN NN O
dogs NN NN O
tested NN NN O
; NN NN O
cefonicid NN NN O
( NN NN O
but NN NN O
not NN NN O
cefazedone NN NN O
) NN NN O
- NN NN O
treated NN NN O
dogs NN NN O
showed NN NN O
a NN NN O
substantially NN NN O
reduced NN NN O
induction NN NN O
period NN NN O
( NN NN O
15 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
5 NN NN O
days NN NN O
) NN NN O
compared NN NN O
to NN NN O
that NN NN O
of NN NN O
the NN NN O
first NN NN O
exposure NN NN O
to NN NN O
the NN NN O
drug NN NN O
( NN NN O
61 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
24 NN NN O
days NN NN O
) NN NN O
. NN NN O
   
This NN NN O
observation NN NN O
, NN NN O
along NN NN O
with NN NN O
the NN NN O
rapid NN NN O
rate NN NN O
of NN NN O
decline NN NN O
in NN NN O
red NN NN O
cell NN NN O
mass NN NN O
parameters NN NN O
of NN NN O
affected NN NN O
dogs NN NN O
, NN NN O
suggests NN NN O
that NN NN O
a NN NN O
hemolytic NN NN B-Disease
component NN NN O
complicated NN NN O
the NN NN O
red NN NN O
cell NN NN O
production NN NN O
problem NN NN O
and NN NN O
that NN NN O
multiple NN NN O
toxicologic NN NN O
mechanisms NN NN O
contributed NN NN O
to NN NN O
the NN NN O
cytopenia NN NN B-Disease
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
the NN NN O
administration NN NN O
of NN NN O
high NN NN O
doses NN NN O
of NN NN O
cefonicid NN NN O
or NN NN O
cefazedone NN NN O
to NN NN O
dogs NN NN O
can NN NN O
induce NN NN O
hematotoxicity NN NN B-Disease
similar NN NN O
to NN NN O
the NN NN O
cephalosporin NN NN O
- NN NN O
induced NN NN O
blood NN NN B-Disease
dyscrasias NN NN I-Disease
described NN NN O
in NN NN O
man NN NN O
and NN NN O
thus NN NN O
provides NN NN O
a NN NN O
useful NN NN O
model NN NN O
for NN NN O
studying NN NN O
the NN NN O
mechanisms NN NN O
of NN NN O
these NN NN O
disorders NN NN O
. NN NN O
   
Cerebral NN NN O
blood NN NN O
flow NN NN O
and NN NN O
metabolism NN NN O
during NN NN O
isoflurane NN NN O
- NN NN O
induced NN NN O
hypotension NN NN B-Disease
in NN NN O
patients NN NN O
subjected NN NN O
to NN NN O
surgery NN NN O
for NN NN O
cerebral NN NN B-Disease
aneurysms NN NN I-Disease
. NN NN O
   
Cerebral NN NN O
blood NN NN O
flow NN NN O
and NN NN O
cerebral NN NN O
metabolic NN NN O
rate NN NN O
for NN NN O
oxygen NN NN O
were NN NN O
measured NN NN O
during NN NN O
isoflurane NN NN O
- NN NN O
induced NN NN O
hypotension NN NN B-Disease
in NN NN O
10 NN NN O
patients NN NN O
subjected NN NN O
to NN NN O
craniotomy NN NN O
for NN NN O
clipping NN NN O
of NN NN O
a NN NN O
cerebral NN NN B-Disease
aneurysm NN NN I-Disease
. NN NN O
   
Flow NN NN O
and NN NN O
metabolism NN NN O
were NN NN O
measured NN NN O
5 NN NN O
- NN NN O
13 NN NN O
days NN NN O
after NN NN O
the NN NN O
subarachnoid NN NN B-Disease
haemorrhage NN NN I-Disease
by NN NN O
a NN NN O
modification NN NN O
of NN NN O
the NN NN O
classical NN NN O
Kety NN NN O
- NN NN O
Schmidt NN NN O
technique NN NN O
using NN NN O
xenon NN NN O
- NN NN O
133 NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
Anaesthesia NN NN O
was NN NN O
maintained NN NN O
with NN NN O
an NN NN O
inspired NN NN O
isoflurane NN NN O
concentration NN NN O
of NN NN O
0 NN NN O
. NN NN O
75 NN NN O
% NN NN O
( NN NN O
plus NN NN O
67 NN NN O
% NN NN O
nitrous NN NN O
oxide NN NN O
in NN NN O
oxygen NN NN O
) NN NN O
, NN NN O
during NN NN O
which NN NN O
CBF NN NN O
and NN NN O
CMRO2 NN NN O
were NN NN O
34 NN NN O
. NN NN O
3 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
. NN NN O
1 NN NN O
ml NN NN O
/ NN NN O
100 NN NN O
g NN NN O
min NN NN O
- NN NN O
1 NN NN O
and NN NN O
2 NN NN O
. NN NN O
32 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
16 NN NN O
ml NN NN O
/ NN NN O
100 NN NN O
g NN NN O
min NN NN O
- NN NN O
1 NN NN O
at NN NN O
PaCO2 NN NN O
4 NN NN O
. NN NN O
1 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
1 NN NN O
kPa NN NN O
( NN NN O
mean NN NN O
+ NN NN O
/ NN NN O
- NN NN O
SEM NN NN O
) NN NN O
. NN NN O
   
Controlled NN NN O
hypotension NN NN B-Disease
to NN NN O
an NN NN O
average NN NN O
MAP NN NN O
of NN NN O
50 NN NN O
- NN NN O
55 NN NN O
mm NN NN O
Hg NN NN O
was NN NN O
induced NN NN O
by NN NN O
increasing NN NN O
the NN NN O
dose NN NN O
of NN NN O
isoflurane NN NN O
, NN NN O
and NN NN O
maintained NN NN O
at NN NN O
an NN NN O
inspired NN NN O
concentration NN NN O
of NN NN O
2 NN NN O
. NN NN O
2 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
2 NN NN O
% NN NN O
. NN NN O
   
This NN NN O
resulted NN NN O
in NN NN O
a NN NN O
significant NN NN O
decrease NN NN O
in NN NN O
CMRO2 NN NN O
( NN NN O
to NN NN O
1 NN NN O
. NN NN O
73 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
16 NN NN O
ml NN NN O
/ NN NN O
100 NN NN O
g NN NN O
min NN NN O
- NN NN O
1 NN NN O
) NN NN O
, NN NN O
while NN NN O
CBF NN NN O
was NN NN O
unchanged NN NN O
. NN NN O
   
After NN NN O
the NN NN O
clipping NN NN O
of NN NN O
the NN NN O
aneurysm NN NN B-Disease
the NN NN O
isoflurane NN NN O
concentration NN NN O
was NN NN O
reduced NN NN O
to NN NN O
0 NN NN O
. NN NN O
75 NN NN O
% NN NN O
. NN NN O
   
There NN NN O
was NN NN O
a NN NN O
significant NN NN O
increase NN NN O
in NN NN O
CBF NN NN O
, NN NN O
although NN NN O
CMRO2 NN NN O
was NN NN O
unchanged NN NN O
, NN NN O
compared NN NN O
with NN NN O
pre NN NN O
- NN NN O
hypotensive NN NN B-Disease
values NN NN O
. NN NN O
   
These NN NN O
changes NN NN O
might NN NN O
offer NN NN O
protection NN NN O
to NN NN O
brain NN NN O
tissue NN NN O
during NN NN O
periods NN NN O
of NN NN O
induced NN NN O
hypotension NN NN B-Disease
. NN NN O
   
Triazolam NN NN O
- NN NN O
induced NN NN O
brief NN NN O
episodes NN NN O
of NN NN O
secondary NN NN O
mania NN NN B-Disease
in NN NN O
a NN NN O
depressed NN NN B-Disease
patient NN NN O
. NN NN O
   
Large NN NN O
doses NN NN O
of NN NN O
triazolam NN NN O
repeatedly NN NN O
induced NN NN O
brief NN NN O
episodes NN NN O
of NN NN O
mania NN NN B-Disease
in NN NN O
a NN NN O
depressed NN NN B-Disease
elderly NN NN O
woman NN NN O
. NN NN O
   
Features NN NN O
of NN NN O
organic NN NN B-Disease
mental NN NN I-Disease
disorder NN NN I-Disease
( NN NN O
delirium NN NN B-Disease
) NN NN O
were NN NN O
not NN NN O
present NN NN O
. NN NN O
   
Manic NN NN B-Disease
excitement NN NN O
was NN NN O
coincident NN NN O
with NN NN O
the NN NN O
duration NN NN O
of NN NN O
action NN NN O
of NN NN O
triazolam NN NN O
. NN NN O
   
The NN NN O
possible NN NN O
contribution NN NN O
of NN NN O
the NN NN O
triazolo NN NN O
group NN NN O
to NN NN O
changes NN NN O
in NN NN O
affective NN NN O
status NN NN O
is NN NN O
discussed NN NN O
. NN NN O
   
The NN NN O
correlation NN NN O
between NN NN O
neurotoxic NN NN B-Disease
esterase NN NN O
inhibition NN NN O
and NN NN O
mipafox NN NN O
- NN NN O
induced NN NN O
neuropathic NN NN B-Disease
damage NN NN I-Disease
in NN NN O
rats NN NN O
. NN NN O
   
The NN NN O
correlation NN NN O
between NN NN O
neuropathic NN NN B-Disease
damage NN NN I-Disease
and NN NN O
inhibition NN NN O
of NN NN O
neurotoxic NN NN B-Disease
esterase NN NN O
or NN NN O
neuropathy NN NN B-Disease
target NN NN O
enzyme NN NN O
( NN NN O
NTE NN NN O
) NN NN O
was NN NN O
examined NN NN O
in NN NN O
rats NN NN O
acutely NN NN O
exposed NN NN O
to NN NN O
Mipafox NN NN O
( NN NN O
N NN NN O
, NN NN O
N NN NN O
' NN NN O
- NN NN O
diisopropylphosphorodiamidofluoridate NN NN O
) NN NN O
, NN NN O
a NN NN O
neurotoxic NN NN B-Disease
organophosphate NN NN O
. NN NN O
   
Brain NN NN O
and NN NN O
spinal NN NN O
cord NN NN O
NTE NN NN O
activities NN NN O
were NN NN O
measured NN NN O
in NN NN O
Long NN NN O
- NN NN O
Evans NN NN O
male NN NN O
rats NN NN O
1 NN NN O
hr NN NN O
post NN NN O
- NN NN O
exposure NN NN O
to NN NN O
various NN NN O
dosages NN NN O
of NN NN O
Mipafox NN NN O
( NN NN O
ip NN NN O
, NN NN O
1 NN NN O
- NN NN O
15 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
. NN NN O
   
These NN NN O
data NN NN O
were NN NN O
correlated NN NN O
with NN NN O
histologically NN NN O
scored NN NN O
cervical NN NN O
cord NN NN B-Disease
damage NN NN I-Disease
in NN NN O
a NN NN O
separate NN NN O
group NN NN O
of NN NN O
similarly NN NN O
dosed NN NN O
rats NN NN O
sampled NN NN O
14 NN NN O
- NN NN O
21 NN NN O
days NN NN O
post NN NN O
- NN NN O
exposure NN NN O
. NN NN O
   
Those NN NN O
dosages NN NN O
( NN NN O
greater NN NN O
than NN NN O
or NN NN O
equal NN NN O
to NN NN O
10 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
that NN NN O
inhibited NN NN O
mean NN NN O
NTE NN NN O
activity NN NN O
in NN NN O
the NN NN O
spinal NN NN O
cord NN NN O
greater NN NN O
than NN NN O
or NN NN O
equal NN NN O
to NN NN O
73 NN NN O
% NN NN O
and NN NN O
brain NN NN O
greater NN NN O
than NN NN O
or NN NN O
equal NN NN O
to NN NN O
67 NN NN O
% NN NN O
of NN NN O
control NN NN O
values NN NN O
produced NN NN O
severe NN NN O
( NN NN O
greater NN NN O
than NN NN O
or NN NN O
equal NN NN O
to NN NN O
3 NN NN O
) NN NN O
cervical NN NN O
cord NN NN O
pathology NN NN O
in NN NN O
85 NN NN O
% NN NN O
of NN NN O
the NN NN O
rats NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
dosages NN NN O
of NN NN O
Mipafox NN NN O
( NN NN O
less NN NN O
than NN NN O
or NN NN O
equal NN NN O
to NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
which NN NN O
inhibited NN NN O
mean NN NN O
NTE NN NN O
activity NN NN O
in NN NN O
spinal NN NN O
cord NN NN O
less NN NN O
than NN NN O
or NN NN O
equal NN NN O
to NN NN O
61 NN NN O
% NN NN O
and NN NN O
brain NN NN O
less NN NN O
than NN NN O
or NN NN O
equal NN NN O
to NN NN O
60 NN NN O
% NN NN O
produced NN NN O
this NN NN O
degree NN NN O
of NN NN O
cord NN NN B-Disease
damage NN NN I-Disease
in NN NN O
only NN NN O
9 NN NN O
% NN NN O
of NN NN O
the NN NN O
animals NN NN O
. NN NN O
   
These NN NN O
data NN NN O
indicate NN NN O
that NN NN O
a NN NN O
critical NN NN O
percentage NN NN O
of NN NN O
NTE NN NN O
inhibition NN NN O
in NN NN O
brain NN NN O
and NN NN O
spinal NN NN O
cord NN NN O
sampled NN NN O
shortly NN NN O
after NN NN O
Mipafox NN NN O
exposure NN NN O
can NN NN O
predict NN NN O
neuropathic NN NN B-Disease
damage NN NN I-Disease
in NN NN O
rats NN NN O
several NN NN O
weeks NN NN O
later NN NN O
. NN NN O
   
Allergic NN NN B-Disease
reaction NN NN I-Disease
to NN NN O
5 NN NN O
- NN NN O
fluorouracil NN NN O
infusion NN NN O
. NN NN O
   
An NN NN O
allergic NN NN B-Disease
reaction NN NN I-Disease
consisting NN NN O
of NN NN O
angioneurotic NN NN B-Disease
edema NN NN I-Disease
secondary NN NN O
to NN NN O
continuous NN NN O
infusion NN NN O
5 NN NN O
- NN NN O
fluorouracil NN NN O
occurred NN NN O
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
recurrent NN NN O
carcinoma NN NN B-Disease
of NN NN I-Disease
the NN NN I-Disease
oral NN NN I-Disease
cavity NN NN I-Disease
, NN NN O
cirrhosis NN NN B-Disease
, NN NN O
and NN NN O
cisplatin NN NN O
- NN NN O
induced NN NN O
impaired NN NN B-Disease
renal NN NN I-Disease
function NN NN I-Disease
. NN NN O
   
This NN NN O
reaction NN NN O
occurred NN NN O
during NN NN O
the NN NN O
sixth NN NN O
and NN NN O
seventh NN NN O
courses NN NN O
of NN NN O
infusional NN NN O
chemotherapy NN NN O
. NN NN O
   
Oral NN NN O
diphenhydramine NN NN O
and NN NN O
prednisone NN NN O
were NN NN O
ineffective NN NN O
in NN NN O
preventing NN NN O
the NN NN O
recurrence NN NN O
of NN NN O
the NN NN O
allergic NN NN B-Disease
reaction NN NN I-Disease
. NN NN O
   
Discontinuance NN NN O
of NN NN O
effective NN NN O
chemotherapy NN NN O
in NN NN O
this NN NN O
patient NN NN O
during NN NN O
partial NN NN O
remission NN NN O
resulted NN NN O
in NN NN O
fatal NN NN O
disease NN NN O
progression NN NN O
. NN NN O
   
Myasthenia NN NN B-Disease
gravis NN NN I-Disease
caused NN NN O
by NN NN O
penicillamine NN NN O
and NN NN O
chloroquine NN NN O
therapy NN NN O
for NN NN O
rheumatoid NN NN B-Disease
arthritis NN NN I-Disease
. NN NN O
   
We NN NN O
have NN NN O
described NN NN O
a NN NN O
unique NN NN O
patient NN NN O
who NN NN O
had NN NN O
reversible NN NN O
and NN NN O
dose NN NN O
- NN NN O
related NN NN O
myasthenia NN NN B-Disease
gravis NN NN I-Disease
after NN NN O
penicillamine NN NN O
and NN NN O
chloroquine NN NN O
therapy NN NN O
for NN NN O
rheumatoid NN NN B-Disease
arthritis NN NN I-Disease
. NN NN O
   
Although NN NN O
acetylcholine NN NN O
receptor NN NN O
antibodies NN NN O
were NN NN O
not NN NN O
detectable NN NN O
, NN NN O
the NN NN O
time NN NN O
course NN NN O
was NN NN O
consistent NN NN O
with NN NN O
an NN NN O
autoimmune NN NN O
process NN NN O
. NN NN O
   
On NN NN O
the NN NN O
mechanisms NN NN O
of NN NN O
the NN NN O
development NN NN O
of NN NN O
tolerance NN NN O
to NN NN O
the NN NN O
muscular NN NN B-Disease
rigidity NN NN I-Disease
produced NN NN O
by NN NN O
morphine NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
The NN NN O
development NN NN O
of NN NN O
tolerance NN NN O
to NN NN O
the NN NN O
muscular NN NN B-Disease
rigidity NN NN I-Disease
produced NN NN O
by NN NN O
morphine NN NN O
was NN NN O
studied NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
Saline NN NN O
- NN NN O
pretreated NN NN O
controls NN NN O
given NN NN O
a NN NN O
test NN NN O
dose NN NN O
of NN NN O
morphine NN NN O
( NN NN O
20 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
showed NN NN O
a NN NN O
pronounced NN NN O
rigidity NN NN B-Disease
recorded NN NN O
as NN NN O
tonic NN NN O
activity NN NN O
in NN NN O
the NN NN O
electromyogram NN NN O
. NN NN O
   
Rats NN NN O
treated NN NN O
for NN NN O
11 NN NN O
days NN NN O
with NN NN O
morphine NN NN O
and NN NN O
withdrawn NN NN O
for NN NN O
36 NN NN O
- NN NN O
40 NN NN O
h NN NN O
showed NN NN O
differences NN NN O
in NN NN O
the NN NN O
development NN NN O
of NN NN O
tolerance NN NN O
: NN NN O
about NN NN O
half NN NN O
of NN NN O
the NN NN O
animals NN NN O
showed NN NN O
a NN NN O
rigidity NN NN B-Disease
after NN NN O
the NN NN O
test NN NN O
dose NN NN O
of NN NN O
morphine NN NN O
that NN NN O
was NN NN O
not NN NN O
significantly NN NN O
less NN NN O
than NN NN O
in NN NN O
the NN NN O
controls NN NN O
and NN NN O
were NN NN O
akinetic NN NN B-Disease
( NN NN O
A NN NN O
group NN NN O
) NN NN O
. NN NN O
   
The NN NN O
other NN NN O
rats NN NN O
showed NN NN O
a NN NN O
strong NN NN O
decrease NN NN O
in NN NN O
the NN NN O
rigidity NN NN B-Disease
and NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
stereotyped NN NN O
( NN NN O
S NN NN O
) NN NN O
licking NN NN O
and NN NN O
/ NN NN O
or NN NN O
gnawing NN NN O
in NN NN O
presence NN NN O
of NN NN O
akinetic NN NN B-Disease
or NN NN O
hyperkinetic NN NN B-Disease
( NN NN O
K NN NN O
) NN NN O
behaviour NN NN O
( NN NN O
AS NN NN O
/ NN NN O
KS NN NN O
group NN NN O
) NN NN O
, NN NN O
suggesting NN NN O
signs NN NN O
of NN NN O
dopaminergic NN NN O
activation NN NN O
. NN NN O
   
The NN NN O
rigidity NN NN B-Disease
was NN NN O
considerably NN NN O
decreased NN NN O
in NN NN O
both NN NN O
groups NN NN O
after NN NN O
20 NN NN O
days NN NN O
' NN NN O
treatment NN NN O
. NN NN O
   
In NN NN O
a NN NN O
further NN NN O
series NN NN O
of NN NN O
experiments NN NN O
, NN NN O
haloperidol NN NN O
( NN NN O
0 NN NN O
. NN NN O
2 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
was NN NN O
used NN NN O
in NN NN O
order NN NN O
to NN NN O
block NN NN O
the NN NN O
dopaminergic NN NN O
activation NN NN O
and NN NN O
to NN NN O
estimate NN NN O
the NN NN O
real NN NN O
degree NN NN O
of NN NN O
the NN NN O
tolerance NN NN O
to NN NN O
the NN NN O
rigidity NN NN B-Disease
without NN NN O
any NN NN O
dopaminergic NN NN O
interference NN NN O
. NN NN O
   
Haloperidol NN NN O
enhanced NN NN O
the NN NN O
rigidity NN NN B-Disease
in NN NN O
the NN NN O
A NN NN O
group NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
level NN NN O
in NN NN O
the NN NN O
AS NN NN O
/ NN NN O
KS NN NN O
group NN NN O
remained NN NN O
considerably NN NN O
lower NN NN O
than NN NN O
in NN NN O
the NN NN O
A NN NN O
group NN NN O
. NN NN O
   
The NN NN O
results NN NN O
suggest NN NN O
that NN NN O
rigidity NN NN B-Disease
, NN NN O
which NN NN O
is NN NN O
assumed NN NN O
to NN NN O
be NN NN O
due NN NN O
to NN NN O
an NN NN O
action NN NN O
of NN NN O
morphine NN NN O
in NN NN O
the NN NN O
striatum NN NN O
, NN NN O
can NN NN O
be NN NN O
antagonized NN NN O
by NN NN O
another NN NN O
process NN NN O
leading NN NN O
to NN NN O
dopaminergic NN NN O
activation NN NN O
in NN NN O
the NN NN O
striatum NN NN O
. NN NN O
   
Nevertheless NN NN O
, NN NN O
there NN NN O
occurs NN NN O
some NN NN O
real NN NN O
tolerance NN NN O
to NN NN O
this NN NN O
effect NN NN O
. NN NN O
   
The NN NN O
rapid NN NN O
alternations NN NN O
of NN NN O
rigidity NN NN B-Disease
and NN NN O
the NN NN O
signs NN NN O
of NN NN O
dopaminergic NN NN O
activation NN NN O
observed NN NN O
in NN NN O
the NN NN O
animals NN NN O
of NN NN O
the NN NN O
AS NN NN O
/ NN NN O
KS NN NN O
group NN NN O
might NN NN O
be NN NN O
due NN NN O
to NN NN O
rapid NN NN O
shifts NN NN O
in NN NN O
the NN NN O
predominance NN NN O
of NN NN O
various NN NN O
DA NN NN O
- NN NN O
innervated NN NN O
structures NN NN O
. NN NN O
   
A NN NN O
case NN NN O
of NN NN O
massive NN NN O
rhabdomyolysis NN NN B-Disease
following NN NN O
molindone NN NN O
administration NN NN O
. NN NN O
   
Rhabdomyolysis NN NN B-Disease
is NN NN O
a NN NN O
potentially NN NN O
lethal NN NN O
syndrome NN NN O
that NN NN O
psychiatric NN NN B-Disease
patients NN NN O
seem NN NN O
predisposed NN NN O
to NN NN O
develop NN NN O
. NN NN O
   
The NN NN O
clinical NN NN O
signs NN NN O
and NN NN O
symptoms NN NN O
, NN NN O
typical NN NN O
laboratory NN NN O
features NN NN O
, NN NN O
and NN NN O
complications NN NN O
of NN NN O
rhabdomyolysis NN NN B-Disease
are NN NN O
presented NN NN O
. NN NN O
   
The NN NN O
case NN NN O
of NN NN O
a NN NN O
schizophrenic NN NN B-Disease
patient NN NN O
is NN NN O
reported NN NN O
to NN NN O
illustrate NN NN O
massive NN NN O
rhabdomyolysis NN NN B-Disease
and NN NN O
subsequent NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
following NN NN O
molindone NN NN O
administration NN NN O
. NN NN O
   
Physicians NN NN O
who NN NN O
prescribe NN NN O
molindone NN NN O
should NN NN O
be NN NN O
aware NN NN O
of NN NN O
this NN NN O
reaction NN NN O
. NN NN O
   
Compression NN NN B-Disease
neuropathy NN NN I-Disease
of NN NN I-Disease
the NN NN I-Disease
radial NN NN I-Disease
nerve NN NN I-Disease
due NN NN O
to NN NN O
pentazocine NN NN O
- NN NN O
induced NN NN O
fibrous NN NN B-Disease
myopathy NN NN I-Disease
. NN NN O
   
Fibrous NN NN B-Disease
myopathy NN NN I-Disease
is NN NN O
a NN NN O
common NN NN O
, NN NN O
well NN NN O
- NN NN O
known NN NN O
side NN NN O
effect NN NN O
of NN NN O
repeated NN NN O
pentazocine NN NN O
injection NN NN O
. NN NN O
   
However NN NN O
, NN NN O
compression NN NN B-Disease
neuropathy NN NN I-Disease
due NN NN O
to NN NN O
fibrotic NN NN O
muscle NN NN O
affected NN NN O
by NN NN O
pentazocine NN NN O
- NN NN O
induced NN NN O
myopathy NN NN B-Disease
has NN NN O
not NN NN O
previously NN NN O
been NN NN O
reported NN NN O
. NN NN O
   
In NN NN O
a NN NN O
37 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
woman NN NN O
with NN NN O
documented NN NN O
pentazocine NN NN O
- NN NN O
induced NN NN O
fibrous NN NN B-Disease
myopathy NN NN I-Disease
of NN NN O
triceps NN NN O
and NN NN O
deltoid NN NN O
muscles NN NN O
bilaterally NN NN O
and NN NN O
a NN NN O
three NN NN O
- NN NN O
week NN NN O
history NN NN O
of NN NN O
right NN NN O
wrist NN NN O
drop NN NN O
, NN NN O
electrodiagnostic NN NN O
examination NN NN O
showed NN NN O
a NN NN O
severe NN NN O
but NN NN O
partial NN NN O
lesion NN NN O
of NN NN O
the NN NN O
right NN NN O
radial NN NN O
nerve NN NN O
distal NN NN O
to NN NN O
the NN NN O
branches NN NN O
to NN NN O
the NN NN O
triceps NN NN O
, NN NN O
in NN NN O
addition NN NN O
to NN NN O
the NN NN O
fibrous NN NN B-Disease
myopathy NN NN I-Disease
. NN NN O
   
Surgery NN NN O
revealed NN NN O
the NN NN O
right NN NN O
radial NN NN O
nerve NN NN O
to NN NN O
be NN NN O
severely NN NN O
compressed NN NN O
by NN NN O
the NN NN O
densely NN NN O
fibrotic NN NN O
lateral NN NN O
head NN NN O
of NN NN O
the NN NN O
triceps NN NN O
. NN NN O
   
Decompression NN NN O
and NN NN O
neurolysis NN NN O
were NN NN O
performed NN NN O
with NN NN O
good NN NN O
subsequent NN NN O
recovery NN NN O
of NN NN O
function NN NN O
. NN NN O
   
Recurrent NN NN O
reversible NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
from NN NN O
amphotericin NN NN O
. NN NN O
   
A NN NN O
patient NN NN O
with NN NN O
cryptogenic NN NN O
cirrhosis NN NN B-Disease
and NN NN O
disseminated NN NN O
sporotrichosis NN NN B-Disease
developed NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
immediately NN NN O
following NN NN O
the NN NN O
administration NN NN O
of NN NN O
amphotericin NN NN O
B NN NN O
on NN NN O
four NN NN O
separate NN NN O
occasions NN NN O
. NN NN O
   
The NN NN O
abruptness NN NN O
of NN NN O
the NN NN O
renal NN NN B-Disease
failure NN NN I-Disease
and NN NN O
its NN NN O
reversibility NN NN O
within NN NN O
days NN NN O
suggests NN NN O
that NN NN O
there NN NN O
was NN NN O
a NN NN O
functional NN NN O
component NN NN O
to NN NN O
the NN NN O
renal NN NN B-Disease
dysfunction NN NN I-Disease
. NN NN O
   
We NN NN O
propose NN NN O
that NN NN O
amphotericin NN NN O
, NN NN O
in NN NN O
the NN NN O
setting NN NN O
of NN NN O
reduced NN NN O
effective NN NN O
arterial NN NN O
volume NN NN O
, NN NN O
may NN NN O
activate NN NN O
tubuloglomerular NN NN O
feedback NN NN O
, NN NN O
thereby NN NN O
contributing NN NN O
to NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
. NN NN O
   
Cerebral NN NN B-Disease
infarction NN NN I-Disease
with NN NN O
a NN NN O
single NN NN O
oral NN NN O
dose NN NN O
of NN NN O
phenylpropanolamine NN NN O
. NN NN O
   
Phenylpropanolamine NN NN O
( NN NN O
PPA NN NN O
) NN NN O
, NN NN O
a NN NN O
synthetic NN NN O
sympathomimetic NN NN O
that NN NN O
is NN NN O
structurally NN NN O
similar NN NN O
to NN NN O
amphetamine NN NN O
, NN NN O
is NN NN O
available NN NN O
over NN NN O
the NN NN O
counter NN NN O
in NN NN O
anorectics NN NN O
, NN NN O
nasal NN NN O
congestants NN NN O
, NN NN O
and NN NN O
cold NN NN O
preparations NN NN O
. NN NN O
   
Its NN NN O
prolonged NN NN O
use NN NN O
or NN NN O
overuse NN NN O
has NN NN O
been NN NN O
associated NN NN O
with NN NN O
seizures NN NN B-Disease
, NN NN O
intracerebral NN NN B-Disease
hemorrhage NN NN I-Disease
, NN NN O
neuropsychiatric NN NN B-Disease
symptoms NN NN I-Disease
, NN NN O
and NN NN O
nonhemorrhagic NN NN O
cerebral NN NN B-Disease
infarction NN NN I-Disease
. NN NN O
   
We NN NN O
report NN NN O
the NN NN O
case NN NN O
of NN NN O
a NN NN O
young NN NN O
woman NN NN O
who NN NN O
suffered NN NN O
a NN NN O
cerebral NN NN B-Disease
infarction NN NN I-Disease
after NN NN O
taking NN NN O
a NN NN O
single NN NN O
oral NN NN O
dose NN NN O
of NN NN O
PPA NN NN O
. NN NN O
   
Remission NN NN O
induction NN NN O
of NN NN O
meningeal NN NN B-Disease
leukemia NN NN I-Disease
with NN NN O
high NN NN O
- NN NN O
dose NN NN O
intravenous NN NN O
methotrexate NN NN O
. NN NN O
   
Twenty NN NN O
children NN NN O
with NN NN O
acute NN NN B-Disease
lymphoblastic NN NN I-Disease
leukemia NN NN I-Disease
who NN NN O
developed NN NN O
meningeal NN NN B-Disease
disease NN NN I-Disease
were NN NN O
treated NN NN O
with NN NN O
a NN NN O
high NN NN O
- NN NN O
dose NN NN O
intravenous NN NN O
methotrexate NN NN O
regimen NN NN O
that NN NN O
was NN NN O
designed NN NN O
to NN NN O
achieve NN NN O
and NN NN O
maintain NN NN O
CSF NN NN O
methotrexate NN NN O
concentrations NN NN O
of NN NN O
10 NN NN O
( NN NN O
- NN NN O
5 NN NN O
) NN NN O
mol NN NN O
/ NN NN O
L NN NN O
without NN NN O
the NN NN O
need NN NN O
for NN NN O
concomitant NN NN O
intrathecal NN NN O
dosing NN NN O
. NN NN O
   
The NN NN O
methotrexate NN NN O
was NN NN O
administered NN NN O
as NN NN O
a NN NN O
loading NN NN O
dose NN NN O
of NN NN O
6 NN NN O
, NN NN O
000 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
for NN NN O
a NN NN O
period NN NN O
of NN NN O
one NN NN O
hour NN NN O
followed NN NN O
by NN NN O
an NN NN O
infusion NN NN O
of NN NN O
1 NN NN O
, NN NN O
200 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
/ NN NN O
h NN NN O
for NN NN O
23 NN NN O
hours NN NN O
. NN NN O
   
Leucovorin NN NN O
rescue NN NN O
was NN NN O
initiated NN NN O
12 NN NN O
hours NN NN O
after NN NN O
the NN NN O
end NN NN O
of NN NN O
the NN NN O
infusion NN NN O
with NN NN O
a NN NN O
loading NN NN O
dose NN NN O
of NN NN O
200 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
followed NN NN O
by NN NN O
12 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
every NN NN O
three NN NN O
hours NN NN O
for NN NN O
six NN NN O
doses NN NN O
and NN NN O
then NN NN O
every NN NN O
six NN NN O
hours NN NN O
until NN NN O
the NN NN O
plasma NN NN O
methotrexate NN NN O
level NN NN O
decreased NN NN O
to NN NN O
less NN NN O
than NN NN O
1 NN NN O
X NN NN O
10 NN NN O
( NN NN O
- NN NN O
7 NN NN O
) NN NN O
mol NN NN O
/ NN NN O
L NN NN O
. NN NN O
   
The NN NN O
mean NN NN O
steady NN NN O
- NN NN O
state NN NN O
plasma NN NN O
and NN NN O
CSF NN NN O
methotrexate NN NN O
concentrations NN NN O
achieved NN NN O
were NN NN O
1 NN NN O
. NN NN O
1 NN NN O
X NN NN O
10 NN NN O
( NN NN O
- NN NN O
3 NN NN O
) NN NN O
mol NN NN O
/ NN NN O
L NN NN O
and NN NN O
3 NN NN O
. NN NN O
6 NN NN O
X NN NN O
10 NN NN O
( NN NN O
- NN NN O
5 NN NN O
) NN NN O
mol NN NN O
/ NN NN O
L NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
All NN NN O
20 NN NN O
patients NN NN O
responded NN NN O
to NN NN O
this NN NN O
regimen NN NN O
, NN NN O
16 NN NN O
/ NN NN O
20 NN NN O
( NN NN O
80 NN NN O
% NN NN O
) NN NN O
achieved NN NN O
a NN NN O
complete NN NN O
remission NN NN O
, NN NN O
and NN NN O
20 NN NN O
% NN NN O
obtained NN NN O
a NN NN O
partial NN NN O
remission NN NN O
. NN NN O
   
The NN NN O
most NN NN O
common NN NN O
toxicities NN NN B-Disease
encountered NN NN O
were NN NN O
transient NN NN O
serum NN NN O
transaminase NN NN O
and NN NN O
bilirubin NN NN O
elevations NN NN O
, NN NN O
neutropenia NN NN B-Disease
, NN NN O
and NN NN O
mucositis NN NN B-Disease
. NN NN O
   
One NN NN O
patient NN NN O
had NN NN O
focal NN NN O
seizures NN NN B-Disease
and NN NN O
transient NN NN B-Disease
hemiparesis NN NN I-Disease
but NN NN O
recovered NN NN O
completely NN NN O
. NN NN O
   
High NN NN O
- NN NN O
dose NN NN O
intravenous NN NN O
methotrexate NN NN O
is NN NN O
an NN NN O
effective NN NN O
treatment NN NN O
for NN NN O
the NN NN O
induction NN NN O
of NN NN O
remission NN NN O
after NN NN O
meningeal NN NN O
relapse NN NN O
in NN NN O
acute NN NN B-Disease
lymphoblastic NN NN I-Disease
leukemia NN NN I-Disease
. NN NN O
   
Interaction NN NN O
of NN NN O
cyclosporin NN NN O
A NN NN O
with NN NN O
antineoplastic NN NN O
agents NN NN O
. NN NN O
   
A NN NN O
synergistic NN NN O
effect NN NN O
of NN NN O
etoposide NN NN O
and NN NN O
cyclosporin NN NN O
A NN NN O
was NN NN O
observed NN NN O
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
acute NN NN B-Disease
T NN NN I-Disease
- NN NN I-Disease
lymphocytic NN NN I-Disease
leukemia NN NN I-Disease
in NN NN O
relapse NN NN O
. NN NN O
   
The NN NN O
concomitant NN NN O
administration NN NN O
of NN NN O
etoposide NN NN O
and NN NN O
cyclosporin NN NN O
A NN NN O
resulted NN NN O
in NN NN O
eradication NN NN O
of NN NN O
hitherto NN NN O
refractory NN NN O
leukemic NN NN B-Disease
infiltration NN NN I-Disease
of NN NN O
bone NN NN O
marrow NN NN O
. NN NN O
   
Severe NN NN O
side NN NN O
effects NN NN O
in NN NN O
terms NN NN O
of NN NN O
mental NN NN O
confusion NN NN B-Disease
and NN NN O
progressive NN NN O
hyperbilirubinemia NN NN B-Disease
, NN NN O
however NN NN O
, NN NN O
point NN NN O
to NN NN O
an NN NN O
enhancement NN NN O
not NN NN O
only NN NN O
of NN NN O
antineoplastic NN NN O
effects NN NN O
but NN NN O
also NN NN O
of NN NN O
toxicity NN NN B-Disease
in NN NN O
normal NN NN O
tissues NN NN O
. NN NN O
   
This NN NN O
report NN NN O
demonstrates NN NN O
for NN NN O
the NN NN O
first NN NN O
time NN NN O
that NN NN O
the NN NN O
pharmacodynamic NN NN O
properties NN NN O
of NN NN O
cyclosporin NN NN O
A NN NN O
may NN NN O
not NN NN O
be NN NN O
confined NN NN O
strictly NN NN O
to NN NN O
suppression NN NN O
of NN NN O
normal NN NN O
T NN NN O
- NN NN O
cell NN NN O
functions NN NN O
. NN NN O
   
Incidence NN NN O
of NN NN O
neoplasms NN NN B-Disease
in NN NN O
patients NN NN O
with NN NN O
rheumatoid NN NN B-Disease
arthritis NN NN I-Disease
exposed NN NN O
to NN NN O
different NN NN O
treatment NN NN O
regimens NN NN O
. NN NN O
   
Immunosuppressive NN NN O
drugs NN NN O
have NN NN O
been NN NN O
used NN NN O
during NN NN O
the NN NN O
last NN NN O
30 NN NN O
years NN NN O
in NN NN O
treatment NN NN O
of NN NN O
patients NN NN O
with NN NN O
severe NN NN O
rheumatoid NN NN B-Disease
arthritis NN NN I-Disease
. NN NN O
   
The NN NN O
drugs NN NN O
commonly NN NN O
used NN NN O
are NN NN O
cyclophosphamide NN NN O
and NN NN O
chlorambucil NN NN O
( NN NN O
alkylating NN NN O
agents NN NN O
) NN NN O
, NN NN O
azathioprine NN NN O
( NN NN O
purine NN NN O
analogue NN NN O
) NN NN O
, NN NN O
and NN NN O
methotrexate NN NN O
( NN NN O
folic NN NN O
acid NN NN O
analogue NN NN O
) NN NN O
. NN NN O
   
There NN NN O
is NN NN O
evidence NN NN O
that NN NN O
all NN NN O
four NN NN O
immunosuppressive NN NN O
drugs NN NN O
can NN NN O
reduce NN NN O
synovitis NN NN B-Disease
, NN NN O
but NN NN O
disease NN NN O
activity NN NN O
almost NN NN O
always NN NN O
recurs NN NN O
after NN NN O
therapy NN NN O
is NN NN O
stopped NN NN O
. NN NN O
   
Since NN NN O
adverse NN NN O
reactions NN NN O
are NN NN O
frequent NN NN O
, NN NN O
less NN NN O
than NN NN O
50 NN NN O
percent NN NN O
of NN NN O
patients NN NN O
are NN NN O
able NN NN O
to NN NN O
continue NN NN O
a NN NN O
particular NN NN O
drug NN NN O
for NN NN O
more NN NN O
than NN NN O
one NN NN O
year NN NN O
. NN NN O
   
Since NN NN O
it NN NN O
takes NN NN O
three NN NN O
to NN NN O
12 NN NN O
months NN NN O
to NN NN O
achieve NN NN O
maximal NN NN O
effects NN NN O
, NN NN O
those NN NN O
patients NN NN O
who NN NN O
are NN NN O
unable NN NN O
to NN NN O
continue NN NN O
the NN NN O
drug NN NN O
receive NN NN O
little NN NN O
benefit NN NN O
from NN NN O
it NN NN O
. NN NN O
   
Patients NN NN O
treated NN NN O
with NN NN O
alkylating NN NN O
agents NN NN O
have NN NN O
an NN NN O
increased NN NN O
risk NN NN O
of NN NN O
development NN NN O
of NN NN O
acute NN NN B-Disease
nonlymphocytic NN NN I-Disease
leukemia NN NN I-Disease
, NN NN O
and NN NN O
both NN NN O
alkylating NN NN O
agents NN NN O
and NN NN O
azathioprine NN NN O
are NN NN O
associated NN NN O
with NN NN O
the NN NN O
development NN NN O
of NN NN O
non NN NN B-Disease
- NN NN I-Disease
Hodgkin NN NN I-Disease
' NN NN I-Disease
s NN NN I-Disease
lymphoma NN NN I-Disease
. NN NN O
   
Cyclophosphamide NN NN O
therapy NN NN O
increases NN NN O
the NN NN O
risk NN NN O
of NN NN O
carcinoma NN NN B-Disease
of NN NN I-Disease
the NN NN I-Disease
bladder NN NN I-Disease
. NN NN O
   
There NN NN O
have NN NN O
been NN NN O
several NN NN O
long NN NN O
- NN NN O
term NN NN O
studies NN NN O
of NN NN O
patients NN NN O
with NN NN O
rheumatoid NN NN B-Disease
arthritis NN NN I-Disease
treated NN NN O
with NN NN O
azathioprine NN NN O
and NN NN O
cyclophosphamide NN NN O
and NN NN O
the NN NN O
incidence NN NN O
of NN NN O
most NN NN O
of NN NN O
the NN NN O
common NN NN O
cancers NN NN B-Disease
is NN NN O
not NN NN O
increased NN NN O
. NN NN O
   
Data NN NN O
on NN NN O
the NN NN O
possible NN NN O
increased NN NN O
risk NN NN O
of NN NN O
malignancy NN NN B-Disease
in NN NN O
rheumatoid NN NN B-Disease
arthritis NN NN I-Disease
are NN NN O
still NN NN O
being NN NN O
collected NN NN O
, NN NN O
and NN NN O
until NN NN O
further NN NN O
information NN NN O
is NN NN O
available NN NN O
, NN NN O
the NN NN O
use NN NN O
of NN NN O
immunosuppressive NN NN O
drugs NN NN O
, NN NN O
particularly NN NN O
alkylating NN NN O
agents NN NN O
, NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
rheumatoid NN NN B-Disease
arthritis NN NN I-Disease
should NN NN O
be NN NN O
reserved NN NN O
for NN NN O
patients NN NN O
with NN NN O
severe NN NN O
progressive NN NN O
disease NN NN O
or NN NN O
life NN NN O
- NN NN O
threatening NN NN O
complications NN NN O
. NN NN O
   
Warfarin NN NN O
- NN NN O
induced NN NN O
iliopsoas NN NN O
hemorrhage NN NN B-Disease
with NN NN O
subsequent NN NN O
femoral NN NN B-Disease
nerve NN NN I-Disease
palsy NN NN I-Disease
. NN NN O
   
We NN NN O
present NN NN O
the NN NN O
case NN NN O
of NN NN O
a NN NN O
28 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
man NN NN O
on NN NN O
chronic NN NN O
warfarin NN NN O
therapy NN NN O
who NN NN O
sustained NN NN O
a NN NN O
minor NN NN O
muscle NN NN B-Disease
tear NN NN I-Disease
and NN NN O
developed NN NN O
increasing NN NN O
pain NN NN B-Disease
and NN NN O
a NN NN O
flexure NN NN O
contracture NN NN B-Disease
of NN NN O
the NN NN O
right NN NN O
hip NN NN O
. NN NN O
   
Surgical NN NN O
exploration NN NN O
revealed NN NN O
an NN NN O
iliopsoas NN NN O
hematoma NN NN B-Disease
and NN NN O
femoral NN NN O
nerve NN NN B-Disease
entrapment NN NN I-Disease
, NN NN O
resulting NN NN O
in NN NN O
a NN NN O
femoral NN NN B-Disease
nerve NN NN I-Disease
palsy NN NN I-Disease
and NN NN O
partial NN NN B-Disease
loss NN NN I-Disease
of NN NN I-Disease
quadriceps NN NN I-Disease
functions NN NN I-Disease
. NN NN O
   
Anticoagulant NN NN O
- NN NN O
induced NN NN O
femoral NN NN B-Disease
nerve NN NN I-Disease
palsy NN NN I-Disease
represents NN NN O
the NN NN O
most NN NN O
common NN NN O
form NN NN O
of NN NN O
warfarin NN NN O
- NN NN O
induced NN NN O
peripheral NN NN B-Disease
neuropathy NN NN I-Disease
; NN NN O
it NN NN O
is NN NN O
characterized NN NN O
by NN NN O
severe NN NN O
pain NN NN B-Disease
in NN NN O
the NN NN O
inguinal NN NN O
region NN NN O
, NN NN O
varying NN NN O
degrees NN NN O
of NN NN O
motor NN NN B-Disease
and NN NN I-Disease
sensory NN NN I-Disease
impairment NN NN I-Disease
, NN NN O
and NN NN O
flexure NN NN O
contracture NN NN B-Disease
of NN NN O
the NN NN O
involved NN NN O
extremity NN NN O
. NN NN O
   
Pneumonitis NN NN O
with NN NN O
pleural NN NN B-Disease
and NN NN I-Disease
pericardial NN NN I-Disease
effusion NN NN I-Disease
and NN NN O
neuropathy NN NN B-Disease
during NN NN O
amiodarone NN NN O
therapy NN NN O
. NN NN O
   
A NN NN O
patient NN NN O
with NN NN O
sinuatrial NN NN B-Disease
disease NN NN I-Disease
and NN NN O
implanted NN NN O
pacemaker NN NN O
was NN NN O
treated NN NN O
with NN NN O
amiodarone NN NN O
( NN NN O
maximum NN NN O
dose NN NN O
1000 NN NN O
mg NN NN O
, NN NN O
maintenance NN NN O
dose NN NN O
800 NN NN O
mg NN NN O
daily NN NN O
) NN NN O
for NN NN O
10 NN NN O
months NN NN O
, NN NN O
for NN NN O
control NN NN O
of NN NN O
supraventricular NN NN B-Disease
tachyarrhythmias NN NN I-Disease
. NN NN O
   
He NN NN O
developed NN NN O
pneumonitis NN NN B-Disease
, NN NN O
pleural NN NN B-Disease
and NN NN I-Disease
pericardial NN NN I-Disease
effusions NN NN I-Disease
, NN NN O
and NN NN O
a NN NN O
predominantly NN NN O
proximal NN NN B-Disease
motor NN NN I-Disease
neuropathy NN NN I-Disease
. NN NN O
   
Immediate NN NN O
but NN NN O
gradual NN NN O
improvement NN NN O
followed NN NN O
withdrawal NN NN O
of NN NN O
amiodarone NN NN O
and NN NN O
treatment NN NN O
with NN NN O
prednisolone NN NN O
. NN NN O
   
Review NN NN O
of NN NN O
this NN NN O
and NN NN O
previously NN NN O
reported NN NN O
cases NN NN O
indicates NN NN O
the NN NN O
need NN NN O
for NN NN O
early NN NN O
diagnosis NN NN O
of NN NN O
amiodarone NN NN O
pneumonitis NN NN B-Disease
, NN NN O
immediate NN NN O
withdrawal NN NN O
of NN NN O
amiodarone NN NN O
, NN NN O
and NN NN O
prompt NN NN O
but NN NN O
continued NN NN O
steroid NN NN O
therapy NN NN O
to NN NN O
ensure NN NN O
full NN NN O
recovery NN NN O
. NN NN O
   
Amiodarone NN NN O
- NN NN O
induced NN NN O
sinoatrial NN NN B-Disease
block NN NN I-Disease
. NN NN O
   
We NN NN O
observed NN NN O
sinoatrial NN NN B-Disease
block NN NN I-Disease
due NN NN O
to NN NN O
chronic NN NN O
amiodarone NN NN O
administration NN NN O
in NN NN O
a NN NN O
5 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
boy NN NN O
with NN NN O
primary NN NN B-Disease
cardiomyopathy NN NN I-Disease
, NN NN O
Wolff NN NN B-Disease
- NN NN I-Disease
Parkinson NN NN I-Disease
- NN NN I-Disease
White NN NN I-Disease
syndrome NN NN I-Disease
and NN NN O
supraventricular NN NN B-Disease
tachycardia NN NN I-Disease
. NN NN O
   
Reduction NN NN O
in NN NN O
the NN NN O
dosage NN NN O
of NN NN O
amiodarone NN NN O
resulted NN NN O
in NN NN O
the NN NN O
disappearance NN NN O
of NN NN O
the NN NN O
sinoatrial NN NN B-Disease
block NN NN I-Disease
and NN NN O
the NN NN O
persistence NN NN O
of NN NN O
asymptomatic NN NN O
sinus NN NN B-Disease
bradycardia NN NN I-Disease
. NN NN O
   
Desipramine NN NN O
- NN NN O
induced NN NN O
delirium NN NN B-Disease
at NN NN O
"""""""" NN NN O
subtherapeutic NN NN O
"""""""" NN NN O
concentrations NN NN O
: NN NN O
a NN NN O
case NN NN O
report NN NN O
. NN NN O
   
An NN NN O
elderly NN NN O
patient NN NN O
treated NN NN O
with NN NN O
low NN NN O
dose NN NN O
Desipramine NN NN O
developed NN NN O
a NN NN O
delirium NN NN B-Disease
while NN NN O
her NN NN O
plasma NN NN O
level NN NN O
was NN NN O
in NN NN O
the NN NN O
"""""""" NN NN O
subtherapeutic NN NN O
"""""""" NN NN O
range NN NN O
. NN NN O
   
Delirium NN NN B-Disease
, NN NN O
which NN NN O
may NN NN O
be NN NN O
induced NN NN O
by NN NN O
tricyclic NN NN O
drug NN NN O
therapy NN NN O
in NN NN O
the NN NN O
elderly NN NN O
, NN NN O
can NN NN O
be NN NN O
caused NN NN O
by NN NN O
tricyclics NN NN O
with NN NN O
low NN NN O
anticholinergic NN NN O
potency NN NN O
. NN NN O
   
Therapeutic NN NN O
ranges NN NN O
for NN NN O
antidepressants NN NN O
that NN NN O
have NN NN O
been NN NN O
derived NN NN O
from NN NN O
general NN NN O
adult NN NN O
population NN NN O
studies NN NN O
may NN NN O
not NN NN O
be NN NN O
appropriate NN NN O
for NN NN O
the NN NN O
elderly NN NN O
. NN NN O
   
Further NN NN O
studies NN NN O
of NN NN O
specifically NN NN O
elderly NN NN O
patients NN NN O
are NN NN O
now NN NN O
required NN NN O
to NN NN O
establish NN NN O
safer NN NN O
and NN NN O
more NN NN O
appropriate NN NN O
guidelines NN NN O
for NN NN O
drug NN NN O
therapy NN NN O
. NN NN O
   
Indomethacin NN NN O
- NN NN O
induced NN NN O
renal NN NN B-Disease
insufficiency NN NN I-Disease
: NN NN O
recurrence NN NN O
on NN NN O
rechallenge NN NN O
. NN NN O
   
We NN NN O
have NN NN O
reported NN NN O
a NN NN O
case NN NN O
of NN NN O
acute NN NN O
oliguric NN NN O
renal NN NN B-Disease
failure NN NN I-Disease
with NN NN O
hyperkalemia NN NN B-Disease
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
cirrhosis NN NN B-Disease
, NN NN O
ascites NN NN B-Disease
, NN NN O
and NN NN O
cor NN NN B-Disease
pulmonale NN NN I-Disease
after NN NN O
indomethacin NN NN O
therapy NN NN O
. NN NN O
   
Prompt NN NN O
restoration NN NN O
of NN NN O
renal NN NN O
function NN NN O
followed NN NN O
drug NN NN O
withdrawal NN NN O
, NN NN O
while NN NN O
re NN NN O
- NN NN O
exposure NN NN O
to NN NN O
a NN NN O
single NN NN O
dose NN NN O
of NN NN O
indomethacin NN NN O
caused NN NN O
recurrence NN NN O
of NN NN O
acute NN NN O
reversible NN NN O
oliguria NN NN B-Disease
. NN NN O
   
Our NN NN O
case NN NN O
supports NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
endogenous NN NN O
renal NN NN O
prostaglandins NN NN O
play NN NN O
a NN NN O
role NN NN O
in NN NN O
the NN NN O
maintenance NN NN O
of NN NN O
renal NN NN O
blood NN NN O
flow NN NN O
when NN NN O
circulating NN NN O
plasma NN NN O
volume NN NN O
is NN NN O
diminished NN NN O
. NN NN O
   
Since NN NN O
nonsteroidal NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
agents NN NN O
interfere NN NN O
with NN NN O
this NN NN O
compensatory NN NN O
mechanism NN NN O
and NN NN O
may NN NN O
cause NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
, NN NN O
they NN NN O
should NN NN O
be NN NN O
used NN NN O
with NN NN O
caution NN NN O
in NN NN O
such NN NN O
patients NN NN O
. NN NN O
   
Patterns NN NN O
of NN NN O
hepatic NN NN B-Disease
injury NN NN I-Disease
induced NN NN O
by NN NN O
methyldopa NN NN O
. NN NN O
   
Twelve NN NN O
patients NN NN O
with NN NN O
liver NN NN B-Disease
disease NN NN I-Disease
related NN NN O
to NN NN O
methyldopa NN NN O
were NN NN O
seen NN NN O
between NN NN O
1967 NN NN O
and NN NN O
1977 NN NN O
. NN NN O
   
Illness NN NN O
occurred NN NN O
within NN NN O
1 NN NN O
- NN NN O
- NN NN O
9 NN NN O
weeks NN NN O
of NN NN O
commencement NN NN O
of NN NN O
therapy NN NN O
in NN NN O
9 NN NN O
patients NN NN O
, NN NN O
the NN NN O
remaining NN NN O
3 NN NN O
patients NN NN O
having NN NN O
received NN NN O
the NN NN O
drug NN NN O
for NN NN O
13 NN NN O
months NN NN O
, NN NN O
15 NN NN O
months NN NN O
and NN NN O
7 NN NN O
years NN NN O
before NN NN O
experiencing NN NN O
symptoms NN NN O
. NN NN O
   
Jaundice NN NN B-Disease
with NN NN O
tender NN NN O
hepatomegaly NN NN B-Disease
, NN NN O
usually NN NN O
preceded NN NN O
by NN NN O
symptoms NN NN O
of NN NN O
malaise NN NN O
, NN NN O
anorexia NN NN B-Disease
, NN NN O
nausea NN NN B-Disease
and NN NN O
vomiting NN NN B-Disease
, NN NN O
and NN NN O
associated NN NN O
with NN NN O
upper NN NN O
abdominal NN NN B-Disease
pain NN NN I-Disease
, NN NN O
was NN NN O
an NN NN O
invariable NN NN O
finding NN NN O
in NN NN O
all NN NN O
patients NN NN O
. NN NN O
   
Biochemical NN NN O
liver NN NN O
function NN NN O
tests NN NN O
indicated NN NN O
hepatocellular NN NN O
necrosis NN NN B-Disease
and NN NN O
correlated NN NN O
with NN NN O
histopathological NN NN O
evidence NN NN O
of NN NN O
hepatic NN NN B-Disease
injury NN NN I-Disease
, NN NN O
the NN NN O
spectrum NN NN O
of NN NN O
which NN NN O
ranged NN NN O
from NN NN O
fatty NN NN B-Disease
change NN NN I-Disease
and NN NN O
focal NN NN O
hepatocellular NN NN O
necrosis NN NN B-Disease
to NN NN O
massive NN NN B-Disease
hepatic NN NN I-Disease
necrosis NN NN I-Disease
. NN NN O
   
Most NN NN O
patients NN NN O
showed NN NN O
moderate NN NN O
to NN NN O
severe NN NN O
acute NN NN B-Disease
hepatitis NN NN I-Disease
or NN NN O
chronic NN NN B-Disease
active NN NN I-Disease
hepatitis NN NN I-Disease
with NN NN O
associated NN NN O
cholestasis NN NN B-Disease
. NN NN O
   
The NN NN O
drug NN NN O
was NN NN O
withdrawn NN NN O
on NN NN O
presentation NN NN O
to NN NN O
hospital NN NN O
in NN NN O
11 NN NN O
patients NN NN O
, NN NN O
with NN NN O
rapid NN NN O
clinical NN NN O
improvement NN NN O
in NN NN O
9 NN NN O
. NN NN O
   
One NN NN O
patient NN NN O
died NN NN O
, NN NN O
having NN NN O
presented NN NN O
in NN NN O
hepatic NN NN B-Disease
failure NN NN I-Disease
, NN NN O
and NN NN O
another NN NN O
, NN NN O
who NN NN O
had NN NN O
been NN NN O
taking NN NN O
methyldopa NN NN O
for NN NN O
7 NN NN O
years NN NN O
, NN NN O
showed NN NN O
slower NN NN O
clinical NN NN O
and NN NN O
biochemical NN NN O
resolution NN NN O
over NN NN O
a NN NN O
period NN NN O
of NN NN O
several NN NN O
months NN NN O
. NN NN O
   
The NN NN O
remaining NN NN O
patient NN NN O
in NN NN O
the NN NN O
series NN NN O
developed NN NN O
fulminant NN NN B-Disease
hepatitis NN NN I-Disease
when NN NN O
the NN NN O
drug NN NN O
was NN NN O
accidentally NN NN O
recommenced NN NN O
1 NN NN O
year NN NN O
after NN NN O
a NN NN O
prior NN NN O
episode NN NN O
of NN NN O
methyldopa NN NN O
- NN NN O
induced NN NN O
hepatitis NN NN B-Disease
. NN NN O
   
In NN NN O
this NN NN O
latter NN NN O
patient NN NN O
, NN NN O
and NN NN O
in NN NN O
2 NN NN O
others NN NN O
, NN NN O
the NN NN O
causal NN NN O
relationship NN NN O
between NN NN O
methyldopa NN NN O
and NN NN O
hepatic NN NN B-Disease
dysfunction NN NN I-Disease
was NN NN O
proved NN NN O
with NN NN O
the NN NN O
recurrence NN NN O
of NN NN O
hepatitis NN NN B-Disease
within NN NN O
2 NN NN O
weeks NN NN O
of NN NN O
re NN NN O
- NN NN O
exposure NN NN O
to NN NN O
the NN NN O
drug NN NN O
. NN NN O
   
Suxamethonium NN NN O
infusion NN NN O
rate NN NN O
and NN NN O
observed NN NN O
fasciculations NN NN B-Disease
. NN NN O
   
A NN NN O
dose NN NN O
- NN NN O
response NN NN O
study NN NN O
. NN NN O
   
Suxamethonium NN NN O
chloride NN NN O
( NN NN O
Sch NN NN O
) NN NN O
was NN NN O
administered NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
to NN NN O
36 NN NN O
adult NN NN O
males NN NN O
at NN NN O
six NN NN O
rates NN NN O
: NN NN O
0 NN NN O
. NN NN O
25 NN NN O
mg NN NN O
s NN NN O
- NN NN O
1 NN NN O
to NN NN O
20 NN NN O
mg NN NN O
s NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
The NN NN O
infusion NN NN O
was NN NN O
discontinued NN NN O
either NN NN O
when NN NN O
there NN NN O
was NN NN O
no NN NN O
muscular NN NN O
response NN NN O
to NN NN O
tetanic NN NN B-Disease
stimulation NN NN O
of NN NN O
the NN NN O
ulnar NN NN O
nerve NN NN O
or NN NN O
when NN NN O
Sch NN NN O
120 NN NN O
mg NN NN O
was NN NN O
exceeded NN NN O
. NN NN O
   
Six NN NN O
additional NN NN O
patients NN NN O
received NN NN O
a NN NN O
30 NN NN O
- NN NN O
mg NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
bolus NN NN O
dose NN NN O
. NN NN O
   
Fasciculations NN NN B-Disease
in NN NN O
six NN NN O
areas NN NN O
of NN NN O
the NN NN O
body NN NN O
were NN NN O
scored NN NN O
from NN NN O
0 NN NN O
to NN NN O
3 NN NN O
and NN NN O
summated NN NN O
as NN NN O
a NN NN O
total NN NN O
fasciculation NN NN B-Disease
score NN NN O
. NN NN O
   
The NN NN O
times NN NN O
to NN NN O
first NN NN O
fasciculation NN NN B-Disease
, NN NN O
twitch NN NN B-Disease
suppression NN NN O
and NN NN O
tetanus NN NN B-Disease
suppression NN NN O
were NN NN O
inversely NN NN O
related NN NN O
to NN NN O
the NN NN O
infusion NN NN O
rates NN NN O
. NN NN O
   
Fasciculations NN NN B-Disease
in NN NN O
the NN NN O
six NN NN O
areas NN NN O
and NN NN O
the NN NN O
total NN NN O
fasciculation NN NN B-Disease
score NN NN O
were NN NN O
related NN NN O
directly NN NN O
to NN NN O
the NN NN O
rate NN NN O
of NN NN O
infusion NN NN O
. NN NN O
   
Total NN NN O
fasciculation NN NN B-Disease
scores NN NN O
in NN NN O
the NN NN O
30 NN NN O
- NN NN O
mg NN NN O
bolus NN NN O
group NN NN O
and NN NN O
the NN NN O
5 NN NN O
- NN NN O
mg NN NN O
s NN NN O
- NN NN O
1 NN NN O
and NN NN O
20 NN NN O
- NN NN O
mg NN NN O
s NN NN O
- NN NN O
1 NN NN O
infusion NN NN O
groups NN NN O
were NN NN O
not NN NN O
significantly NN NN O
different NN NN O
. NN NN O
   
Treatment NN NN O
of NN NN O
psoriasis NN NN B-Disease
with NN NN O
azathioprine NN NN O
. NN NN O
   
Azathioprine NN NN O
treatment NN NN O
benefited NN NN O
19 NN NN O
( NN NN O
66 NN NN O
% NN NN O
) NN NN O
out NN NN O
of NN NN O
29 NN NN O
patients NN NN O
suffering NN NN O
from NN NN O
severe NN NN O
psoriasis NN NN B-Disease
. NN NN O
   
Haematological NN NN O
complications NN NN O
were NN NN O
not NN NN O
troublesome NN NN O
and NN NN O
results NN NN O
of NN NN O
biochemical NN NN O
liver NN NN O
function NN NN O
tests NN NN O
remained NN NN O
normal NN NN O
. NN NN O
   
Minimal NN NN O
cholestasis NN NN B-Disease
was NN NN O
seen NN NN O
in NN NN O
two NN NN O
cases NN NN O
and NN NN O
portal NN NN O
fibrosis NN NN B-Disease
of NN NN O
a NN NN O
reversible NN NN O
degree NN NN O
in NN NN O
eight NN NN O
. NN NN O
   
Liver NN NN O
biopsies NN NN O
should NN NN O
be NN NN O
undertaken NN NN O
at NN NN O
regular NN NN O
intervals NN NN O
if NN NN O
azathioprine NN NN O
therapy NN NN O
is NN NN O
continued NN NN O
so NN NN O
that NN NN O
structural NN NN O
liver NN NN B-Disease
damage NN NN I-Disease
may NN NN O
be NN NN O
detected NN NN O
at NN NN O
an NN NN O
early NN NN O
and NN NN O
reversible NN NN O
stage NN NN O
. NN NN O
   
Angiosarcoma NN NN B-Disease
of NN NN I-Disease
the NN NN I-Disease
liver NN NN I-Disease
associated NN NN O
with NN NN O
diethylstilbestrol NN NN O
. NN NN O
   
Angiosarcoma NN NN B-Disease
of NN NN I-Disease
the NN NN I-Disease
liver NN NN I-Disease
occurred NN NN O
in NN NN O
a NN NN O
76 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
man NN NN O
who NN NN O
had NN NN O
been NN NN O
treated NN NN O
for NN NN O
a NN NN O
well NN NN O
- NN NN O
differentiated NN NN O
adenocarcinoma NN NN B-Disease
of NN NN I-Disease
the NN NN I-Disease
liver NN NN I-Disease
with NN NN O
diethylstilbestrol NN NN O
for NN NN O
13 NN NN O
years NN NN O
. NN NN O
   
Angiosarcoma NN NN B-Disease
was NN NN O
also NN NN O
present NN NN O
within NN NN O
pulmonary NN NN O
and NN NN O
renal NN NN O
arteries NN NN O
. NN NN O
   
The NN NN O
possibility NN NN O
that NN NN O
the NN NN O
intraarterial NN NN B-Disease
lesions NN NN I-Disease
might NN NN O
represent NN NN O
independent NN NN O
primary NN NN O
tumors NN NN B-Disease
is NN NN O
considered NN NN O
. NN NN O
   
Galanthamine NN NN O
hydrobromide NN NN O
, NN NN O
a NN NN O
longer NN NN O
acting NN NN O
anticholinesterase NN NN O
drug NN NN O
, NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
the NN NN O
central NN NN O
effects NN NN O
of NN NN O
scopolamine NN NN O
( NN NN O
Hyoscine NN NN O
) NN NN O
. NN NN O
   
Galanthamine NN NN O
hydrobromide NN NN O
, NN NN O
an NN NN O
anticholinesterase NN NN O
drug NN NN O
capable NN NN O
of NN NN O
penetrating NN NN O
the NN NN O
blood NN NN O
- NN NN O
brain NN NN O
barrier NN NN O
, NN NN O
was NN NN O
used NN NN O
in NN NN O
a NN NN O
patient NN NN O
demonstrating NN NN O
central NN NN O
effects NN NN O
of NN NN O
scopolamine NN NN O
( NN NN O
hyoscine NN NN O
) NN NN O
overdosage NN NN B-Disease
. NN NN O
   
It NN NN O
is NN NN O
longer NN NN O
acting NN NN O
than NN NN O
physostigmine NN NN O
and NN NN O
is NN NN O
used NN NN O
in NN NN O
anaesthesia NN NN O
to NN NN O
reverse NN NN O
the NN NN O
non NN NN O
- NN NN O
depolarizing NN NN O
neuromuscular NN NN O
block NN NN O
. NN NN O
   
However NN NN O
, NN NN O
studies NN NN O
into NN NN O
the NN NN O
dose NN NN O
necessary NN NN O
to NN NN O
combating NN NN O
scopolamine NN NN O
intoxication NN NN O
are NN NN O
indicated NN NN O
. NN NN O
   
Comparison NN NN O
of NN NN O
the NN NN O
subjective NN NN O
effects NN NN O
and NN NN O
plasma NN NN O
concentrations NN NN O
following NN NN O
oral NN NN O
and NN NN O
i NN NN O
. NN NN O
m NN NN O
. NN NN O
administration NN NN O
of NN NN O
flunitrazepam NN NN O
in NN NN O
volunteers NN NN O
. NN NN O
   
Flunitrazepam NN NN O
0 NN NN O
. NN NN O
5 NN NN O
, NN NN O
1 NN NN O
. NN NN O
0 NN NN O
or NN NN O
2 NN NN O
. NN NN O
0 NN NN O
mg NN NN O
was NN NN O
given NN NN O
by NN NN O
the NN NN O
oral NN NN O
or NN NN O
i NN NN O
. NN NN O
m NN NN O
. NN NN O
routes NN NN O
to NN NN O
groups NN NN O
of NN NN O
volunteers NN NN O
and NN NN O
its NN NN O
effects NN NN O
compared NN NN O
. NN NN O
   
Plasma NN NN O
concentrations NN NN O
of NN NN O
the NN NN O
drug NN NN O
were NN NN O
estimated NN NN O
by NN NN O
gas NN NN O
- NN NN O
liquid NN NN O
chromatography NN NN O
, NN NN O
in NN NN O
a NN NN O
smaller NN NN O
number NN NN O
of NN NN O
the NN NN O
subjects NN NN O
. NN NN O
   
The NN NN O
most NN NN O
striking NN NN O
effect NN NN O
was NN NN O
sedation NN NN O
which NN NN O
increased NN NN O
with NN NN O
the NN NN O
dose NN NN O
, NN NN O
2 NN NN O
mg NN NN O
producing NN NN O
deep NN NN O
sleep NN NN O
although NN NN O
the NN NN O
subjects NN NN O
could NN NN O
still NN NN O
be NN NN O
aroused NN NN O
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
i NN NN O
. NN NN O
m NN NN O
. NN NN O
administration NN NN O
were NN NN O
apparent NN NN O
earlier NN NN O
and NN NN O
sometimes NN NN O
lasted NN NN O
longer NN NN O
than NN NN O
those NN NN O
following NN NN O
oral NN NN O
administration NN NN O
. NN NN O
   
Dizziness NN NN B-Disease
was NN NN O
less NN NN O
marked NN NN O
than NN NN O
sedation NN NN O
, NN NN O
but NN NN O
increased NN NN O
with NN NN O
the NN NN O
dose NN NN O
. NN NN O
   
There NN NN O
was NN NN O
pain NN NN B-Disease
on NN NN O
i NN NN O
. NN NN O
m NN NN O
. NN NN O
injection NN NN O
of NN NN O
flunitrazepam NN NN O
significantly NN NN O
more NN NN O
often NN NN O
than NN NN O
with NN NN O
isotonic NN NN O
saline NN NN O
. NN NN O
   
Plasma NN NN O
concentrations NN NN O
varied NN NN O
with NN NN O
dose NN NN O
and NN NN O
route NN NN O
and NN NN O
corresponded NN NN O
qualitatively NN NN O
with NN NN O
the NN NN O
subjective NN NN O
effects NN NN O
. NN NN O
   
The NN NN O
drug NN NN O
was NN NN O
still NN NN O
present NN NN O
in NN NN O
measurable NN NN O
quantities NN NN O
after NN NN O
24 NN NN O
h NN NN O
even NN NN O
with NN NN O
the NN NN O
smallest NN NN O
dose NN NN O
. NN NN O
   
Possible NN NN O
teratogenicity NN NN O
of NN NN O
sulphasalazine NN NN O
. NN NN O
   
Three NN NN O
infants NN NN O
, NN NN O
born NN NN O
of NN NN O
two NN NN O
mothers NN NN O
with NN NN O
inflammatory NN NN B-Disease
bowel NN NN I-Disease
disease NN NN I-Disease
who NN NN O
received NN NN O
treatment NN NN O
with NN NN O
sulphasalazine NN NN O
throughout NN NN O
pregnancy NN NN O
, NN NN O
were NN NN O
found NN NN O
to NN NN O
have NN NN O
major NN NN O
congenital NN NN B-Disease
anomalies NN NN I-Disease
. NN NN O
   
In NN NN O
the NN NN O
singleton NN NN O
pregnancy NN NN O
, NN NN O
the NN NN O
mother NN NN O
had NN NN O
ulcerative NN NN B-Disease
colitis NN NN I-Disease
, NN NN O
and NN NN O
the NN NN O
infant NN NN O
, NN NN O
a NN NN O
male NN NN O
, NN NN O
had NN NN O
coarctation NN NN B-Disease
of NN NN I-Disease
the NN NN I-Disease
aorta NN NN I-Disease
and NN NN O
a NN NN O
ventricular NN NN B-Disease
septal NN NN I-Disease
defect NN NN I-Disease
. NN NN O
   
In NN NN O
the NN NN O
twin NN NN O
pregnancy NN NN O
, NN NN O
the NN NN O
mother NN NN O
had NN NN O
Crohn NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
The NN NN O
first NN NN O
twin NN NN O
, NN NN O
a NN NN O
female NN NN O
, NN NN O
had NN NN O
a NN NN O
left NN NN O
Potter NN NN B-Disease
- NN NN I-Disease
type NN NN I-Disease
IIa NN NN I-Disease
polycystic NN NN I-Disease
kidney NN NN I-Disease
and NN NN O
a NN NN O
rudimentary NN NN B-Disease
left NN NN I-Disease
uterine NN NN I-Disease
cornu NN NN I-Disease
. NN NN O
   
The NN NN O
second NN NN O
twin NN NN O
, NN NN O
a NN NN O
male NN NN O
, NN NN O
had NN NN O
some NN NN O
features NN NN O
of NN NN O
Potter NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
facies NN NN I-Disease
, NN NN O
hypoplastic NN NN B-Disease
lungs NN NN I-Disease
, NN NN O
absent NN NN B-Disease
kidneys NN NN I-Disease
and NN NN I-Disease
ureters NN NN I-Disease
, NN NN O
and NN NN O
talipes NN NN B-Disease
equinovarus NN NN I-Disease
. NN NN O
   
Despite NN NN O
reports NN NN O
to NN NN O
the NN NN O
contrary NN NN O
, NN NN O
it NN NN O
is NN NN O
suggested NN NN O
that NN NN O
sulphasalazine NN NN O
may NN NN O
be NN NN O
teratogenic NN NN O
. NN NN O
   
Thrombotic NN NN B-Disease
microangiopathy NN NN I-Disease
and NN NN O
renal NN NN B-Disease
failure NN NN I-Disease
associated NN NN O
with NN NN O
antineoplastic NN NN O
chemotherapy NN NN O
. NN NN O
   
Five NN NN O
patients NN NN O
with NN NN O
carcinoma NN NN B-Disease
developed NN NN O
thrombotic NN NN B-Disease
microangiopathy NN NN I-Disease
( NN NN O
characterized NN NN O
by NN NN O
renal NN NN B-Disease
insufficiency NN NN I-Disease
, NN NN O
microangiopathic NN NN B-Disease
hemolytic NN NN I-Disease
anemia NN NN I-Disease
, NN NN O
and NN NN O
usually NN NN O
thrombocytopenia NN NN B-Disease
) NN NN O
after NN NN O
treatment NN NN O
with NN NN O
cisplatin NN NN O
, NN NN O
bleomycin NN NN O
, NN NN O
and NN NN O
a NN NN O
vinca NN NN O
alkaloid NN NN O
. NN NN O
   
One NN NN O
patient NN NN O
had NN NN O
thrombotic NN NN B-Disease
thrombocytopenic NN NN I-Disease
purpura NN NN I-Disease
, NN NN O
three NN NN O
the NN NN O
hemolytic NN NN B-Disease
- NN NN I-Disease
uremic NN NN I-Disease
syndrome NN NN I-Disease
, NN NN O
and NN NN O
one NN NN O
an NN NN O
apparent NN NN O
forme NN NN O
fruste NN NN O
of NN NN O
one NN NN O
of NN NN O
these NN NN O
disorders NN NN O
. NN NN O
   
Histologic NN NN O
examination NN NN O
of NN NN O
the NN NN O
renal NN NN O
tissue NN NN O
showed NN NN O
evidence NN NN O
of NN NN O
intravascular NN NN B-Disease
coagulation NN NN I-Disease
, NN NN O
primarily NN NN O
affecting NN NN O
the NN NN O
small NN NN O
arteries NN NN O
, NN NN O
arterioles NN NN O
, NN NN O
and NN NN O
glomeruli NN NN O
. NN NN O
   
Because NN NN O
each NN NN O
patient NN NN O
was NN NN O
tumor NN NN B-Disease
- NN NN O
free NN NN O
or NN NN O
had NN NN O
only NN NN O
a NN NN O
small NN NN O
tumor NN NN B-Disease
at NN NN O
the NN NN O
onset NN NN O
of NN NN O
this NN NN O
syndrome NN NN O
, NN NN O
the NN NN O
thrombotic NN NN B-Disease
microangiopathy NN NN I-Disease
may NN NN O
have NN NN O
been NN NN O
induced NN NN O
by NN NN O
chemotherapy NN NN O
. NN NN O
   
Diagnosis NN NN O
of NN NN O
this NN NN O
potentially NN NN O
fatal NN NN O
complication NN NN O
may NN NN O
be NN NN O
delayed NN NN O
or NN NN O
missed NN NN O
if NN NN O
renal NN NN O
tissue NN NN O
or NN NN O
the NN NN O
peripheral NN NN O
blood NN NN O
smear NN NN O
is NN NN O
not NN NN O
examined NN NN O
, NN NN O
because NN NN O
renal NN NN B-Disease
failure NN NN I-Disease
may NN NN O
be NN NN O
ascribed NN NN O
to NN NN O
cisplatin NN NN O
nephrotoxicity NN NN B-Disease
and NN NN O
the NN NN O
anemia NN NN B-Disease
and NN NN O
thrombocytopenia NN NN B-Disease
to NN NN O
drug NN NN O
- NN NN O
induced NN NN O
bone NN NN B-Disease
marrow NN NN I-Disease
suppression NN NN I-Disease
. NN NN O
   
International NN NN O
mexiletine NN NN O
and NN NN O
placebo NN NN O
antiarrhythmic NN NN O
coronary NN NN O
trial NN NN O
: NN NN O
I NN NN O
. NN NN O
   
Report NN NN O
on NN NN O
arrhythmia NN NN B-Disease
and NN NN O
other NN NN O
findings NN NN O
. NN NN O
   
Impact NN NN O
Research NN NN O
Group NN NN O
. NN NN O
   
The NN NN O
antiarrhythmic NN NN O
effects NN NN O
of NN NN O
the NN NN O
sustained NN NN O
release NN NN O
form NN NN O
of NN NN O
mexiletine NN NN O
( NN NN O
Mexitil NN NN O
- NN NN O
Perlongets NN NN O
) NN NN O
were NN NN O
evaluated NN NN O
in NN NN O
a NN NN O
double NN NN O
- NN NN O
blind NN NN O
placebo NN NN O
trial NN NN O
in NN NN O
630 NN NN O
patients NN NN O
with NN NN O
recent NN NN O
documented NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
. NN NN O
   
The NN NN O
primary NN NN O
response NN NN O
variable NN NN O
was NN NN O
based NN NN O
on NN NN O
central NN NN O
reading NN NN O
of NN NN O
24 NN NN O
hour NN NN O
ambulatory NN NN O
electrocardiographic NN NN O
recordings NN NN O
and NN NN O
was NN NN O
defined NN NN O
as NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
30 NN NN O
or NN NN O
more NN NN O
single NN NN O
premature NN NN O
ventricular NN NN O
complexes NN NN O
in NN NN O
any NN NN O
two NN NN O
consecutive NN NN O
30 NN NN O
minute NN NN O
blocks NN NN O
or NN NN O
one NN NN O
or NN NN O
more NN NN O
runs NN NN O
of NN NN O
two NN NN O
or NN NN O
more NN NN O
premature NN NN O
ventricular NN NN O
complexes NN NN O
in NN NN O
the NN NN O
entire NN NN O
24 NN NN O
hour NN NN O
electrocardiographic NN NN O
recording NN NN O
. NN NN O
   
Large NN NN O
differences NN NN O
, NN NN O
regarded NN NN O
as NN NN O
statistically NN NN O
significant NN NN O
, NN NN O
between NN NN O
the NN NN O
mexiletine NN NN O
and NN NN O
placebo NN NN O
groups NN NN O
were NN NN O
noted NN NN O
in NN NN O
that NN NN O
end NN NN O
point NN NN O
at NN NN O
months NN NN O
1 NN NN O
and NN NN O
4 NN NN O
, NN NN O
but NN NN O
only NN NN O
trends NN NN O
were NN NN O
observed NN NN O
at NN NN O
month NN NN O
12 NN NN O
. NN NN O
   
These NN NN O
differences NN NN O
were NN NN O
observed NN NN O
even NN NN O
though NN NN O
the NN NN O
serum NN NN O
mexiletine NN NN O
levels NN NN O
obtained NN NN O
in NN NN O
this NN NN O
study NN NN O
were NN NN O
generally NN NN O
lower NN NN O
than NN NN O
those NN NN O
observed NN NN O
in NN NN O
studies NN NN O
that NN NN O
have NN NN O
used NN NN O
the NN NN O
regular NN NN O
form NN NN O
of NN NN O
the NN NN O
drug NN NN O
. NN NN O
   
There NN NN O
were NN NN O
more NN NN O
deaths NN NN B-Disease
in NN NN O
the NN NN O
mexiletine NN NN O
group NN NN O
( NN NN O
7 NN NN O
. NN NN O
6 NN NN O
% NN NN O
) NN NN O
than NN NN O
in NN NN O
the NN NN O
placebo NN NN O
group NN NN O
( NN NN O
4 NN NN O
. NN NN O
8 NN NN O
% NN NN O
) NN NN O
; NN NN O
the NN NN O
difference NN NN O
was NN NN O
not NN NN O
statistically NN NN O
significant NN NN O
. NN NN O
   
The NN NN O
incidence NN NN O
of NN NN O
coronary NN NN O
events NN NN O
was NN NN O
similar NN NN O
in NN NN O
both NN NN O
groups NN NN O
. NN NN O
   
Previously NN NN O
recognized NN NN O
side NN NN O
effects NN NN O
, NN NN O
particularly NN NN O
tremor NN NN B-Disease
and NN NN O
gastrointestinal NN NN B-Disease
problems NN NN I-Disease
, NN NN O
were NN NN O
more NN NN O
frequent NN NN O
in NN NN O
the NN NN O
mexiletine NN NN O
group NN NN O
than NN NN O
in NN NN O
the NN NN O
placebo NN NN O
group NN NN O
. NN NN O
   
Changes NN NN O
in NN NN O
heart NN NN O
size NN NN O
during NN NN O
long NN NN O
- NN NN O
term NN NN O
timolol NN NN O
treatment NN NN O
after NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
. NN NN O
   
The NN NN O
effect NN NN O
of NN NN O
long NN NN O
- NN NN O
term NN NN O
timolol NN NN O
treatment NN NN O
on NN NN O
heart NN NN O
size NN NN O
after NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
was NN NN O
evaluated NN NN O
by NN NN O
X NN NN O
- NN NN O
ray NN NN O
in NN NN O
a NN NN O
double NN NN O
- NN NN O
blind NN NN O
study NN NN O
including NN NN O
241 NN NN O
patients NN NN O
( NN NN O
placebo NN NN O
126 NN NN O
, NN NN O
timolol NN NN O
115 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
follow NN NN O
- NN NN O
up NN NN O
period NN NN O
was NN NN O
12 NN NN O
months NN NN O
. NN NN O
   
The NN NN O
timolol NN NN O
- NN NN O
treated NN NN O
patients NN NN O
showed NN NN O
a NN NN O
small NN NN O
but NN NN O
significant NN NN O
increase NN NN O
in NN NN O
heart NN NN O
size NN NN O
from NN NN O
baseline NN NN O
in NN NN O
contrast NN NN O
to NN NN O
a NN NN O
decrease NN NN O
in NN NN O
the NN NN O
placebo NN NN O
group NN NN O
. NN NN O
   
These NN NN O
differences NN NN O
may NN NN O
be NN NN O
caused NN NN O
by NN NN O
timolol NN NN O
- NN NN O
induced NN NN O
bradycardia NN NN B-Disease
and NN NN O
a NN NN O
compensatory NN NN O
increase NN NN O
in NN NN O
end NN NN O
- NN NN O
diastolic NN NN O
volume NN NN O
. NN NN O
   
The NN NN O
timolol NN NN O
- NN NN O
related NN NN O
increase NN NN O
in NN NN O
heart NN NN O
size NN NN O
was NN NN O
observed NN NN O
only NN NN O
in NN NN O
patients NN NN O
with NN NN O
normal NN NN O
and NN NN O
borderline NN NN O
heart NN NN O
size NN NN O
. NN NN O
   
In NN NN O
patients NN NN O
with NN NN O
cardiomegaly NN NN B-Disease
, NN NN O
the NN NN O
increase NN NN O
in NN NN O
heart NN NN O
size NN NN O
was NN NN O
similar NN NN O
in NN NN O
both NN NN O
groups NN NN O
. NN NN O
   
After NN NN O
re NN NN O
- NN NN O
infarction NN NN B-Disease
, NN NN O
heart NN NN O
size NN NN O
increased NN NN O
in NN NN O
the NN NN O
placebo NN NN O
group NN NN O
and NN NN O
remained NN NN O
unchanged NN NN O
in NN NN O
the NN NN O
timolol NN NN O
group NN NN O
. NN NN O
   
Vitamin NN NN O
D3 NN NN O
toxicity NN NN B-Disease
in NN NN O
dairy NN NN O
cows NN NN O
. NN NN O
   
Large NN NN O
parenteral NN NN O
doses NN NN O
of NN NN O
vitamin NN NN O
D3 NN NN O
( NN NN O
15 NN NN O
to NN NN O
17 NN NN O
. NN NN O
5 NN NN O
x NN NN O
10 NN NN O
( NN NN O
6 NN NN O
) NN NN O
IU NN NN O
vitamin NN NN O
D3 NN NN O
) NN NN O
were NN NN O
associated NN NN O
with NN NN O
prolonged NN NN O
hypercalcemia NN NN B-Disease
, NN NN O
hyperphosphatemia NN NN B-Disease
, NN NN O
and NN NN O
large NN NN O
increases NN NN O
of NN NN O
vitamin NN NN O
D3 NN NN O
and NN NN O
its NN NN O
metabolites NN NN O
in NN NN O
the NN NN O
blood NN NN O
plasma NN NN O
of NN NN O
nonlactating NN NN O
nonpregnant NN NN O
and NN NN O
pregnant NN NN O
Jersey NN NN O
cows NN NN O
. NN NN O
   
Calcium NN NN O
concentrations NN NN O
1 NN NN O
day NN NN O
postpartum NN NN O
were NN NN O
higher NN NN O
in NN NN O
cows NN NN O
treated NN NN O
with NN NN O
vitamin NN NN O
D3 NN NN O
about NN NN O
32 NN NN O
days NN NN O
prepartum NN NN O
( NN NN O
8 NN NN O
. NN NN O
8 NN NN O
mg NN NN O
/ NN NN O
100 NN NN O
ml NN NN O
) NN NN O
than NN NN O
in NN NN O
control NN NN O
cows NN NN O
( NN NN O
5 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
100 NN NN O
ml NN NN O
) NN NN O
. NN NN O
   
   O
of NN NN O
the NN NN O
cows NN NN O
treated NN NN O
with NN NN O
vitamin NN NN O
D3 NN NN O
showed NN NN O
signs NN NN O
of NN NN O
milk NN NN B-Disease
fever NN NN I-Disease
during NN NN O
the NN NN O
peripartal NN NN O
period NN NN O
; NN NN O
however NN NN O
, NN NN O
22 NN NN O
% NN NN O
of NN NN O
the NN NN O
control NN NN O
cows NN NN O
developed NN NN O
clinical NN NN O
signs NN NN O
of NN NN O
milk NN NN B-Disease
fever NN NN I-Disease
during NN NN O
this NN NN O
period NN NN O
. NN NN O
   
Signs NN NN O
of NN NN O
vitamin NN NN O
D3 NN NN O
toxicity NN NN B-Disease
were NN NN O
not NN NN O
observed NN NN O
in NN NN O
nonlactating NN NN O
nonpregnant NN NN O
cows NN NN O
; NN NN O
however NN NN O
, NN NN O
pregnant NN NN O
cows NN NN O
commonly NN NN O
developed NN NN O
severe NN NN O
signs NN NN O
of NN NN O
vitamin NN NN O
D3 NN NN O
toxicity NN NN B-Disease
and NN NN O
10 NN NN O
of NN NN O
17 NN NN O
cows NN NN O
died NN NN O
. NN NN O
   
There NN NN O
was NN NN O
widespread NN NN O
metastatic NN NN O
calcification NN NN O
in NN NN O
the NN NN O
cows NN NN O
that NN NN O
died NN NN O
. NN NN O
   
Because NN NN O
of NN NN O
the NN NN O
extreme NN NN O
toxicity NN NN B-Disease
of NN NN O
vitamin NN NN O
D3 NN NN O
in NN NN O
pregnant NN NN O
Jersey NN NN O
cows NN NN O
and NN NN O
the NN NN O
low NN NN O
margin NN NN O
of NN NN O
safety NN NN O
between NN NN O
doses NN NN O
of NN NN O
vitamin NN NN O
D3 NN NN O
that NN NN O
prevent NN NN O
milk NN NN B-Disease
fever NN NN I-Disease
and NN NN O
doses NN NN O
that NN NN O
induce NN NN O
milk NN NN B-Disease
fever NN NN I-Disease
, NN NN O
we NN NN O
concluded NN NN O
that NN NN O
vitamin NN NN O
D3 NN NN O
cannot NN NN O
be NN NN O
used NN NN O
practically NN NN O
to NN NN O
prevent NN NN O
milk NN NN B-Disease
fever NN NN I-Disease
when NN NN O
injected NN NN O
several NN NN O
weeks NN NN O
prepartum NN NN O
. NN NN O
   
Diseases NN NN B-Disease
of NN NN I-Disease
peripheral NN NN I-Disease
nerves NN NN I-Disease
as NN NN O
seen NN NN O
in NN NN O
the NN NN O
Nigerian NN NN O
African NN NN O
. NN NN O
   
The NN NN O
anatomical NN NN O
and NN NN O
aetiological NN NN O
diagnoses NN NN O
of NN NN O
peripheral NN NN B-Disease
nerve NN NN I-Disease
disease NN NN I-Disease
excluding NN NN O
its NN NN O
primary NN NN O
benign NN NN O
and NN NN O
malignant NN NN O
disorders NN NN O
, NN NN O
as NN NN O
seen NN NN O
in NN NN O
358 NN NN O
Nigerians NN NN O
are NN NN O
presented NN NN O
. NN NN O
   
There NN NN O
is NN NN O
a NN NN O
male NN NN O
preponderance NN NN O
and NN NN O
the NN NN O
peak NN NN O
incidence NN NN O
is NN NN O
in NN NN O
the NN NN O
fourth NN NN O
decade NN NN O
. NN NN O
   
Sensori NN NN B-Disease
- NN NN I-Disease
motor NN NN I-Disease
neuropathy NN NN I-Disease
was NN NN O
the NN NN O
commonest NN NN O
presentation NN NN O
( NN NN O
50 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
Guillain NN NN B-Disease
- NN NN I-Disease
Barr NN NN I-Disease
syndrome NN NN I-Disease
was NN NN O
the NN NN O
commonest NN NN O
identifiable NN NN O
cause NN NN O
( NN NN O
15 NN NN O
. NN NN O
6 NN NN O
% NN NN O
) NN NN O
, NN NN O
accounting NN NN O
for NN NN O
half NN NN O
of NN NN O
the NN NN O
cases NN NN O
with NN NN O
motor NN NN B-Disease
neuropathy NN NN I-Disease
. NN NN O
   
Peripheral NN NN B-Disease
neuropathy NN NN I-Disease
due NN NN O
to NN NN O
nutritional NN NN B-Disease
deficiency NN NN I-Disease
of NN NN O
thiamine NN NN O
and NN NN O
riboflavin NN NN O
was NN NN O
common NN NN O
( NN NN O
10 NN NN O
. NN NN O
1 NN NN O
% NN NN O
) NN NN O
and NN NN O
presented NN NN O
mainly NN NN O
as NN NN O
sensory NN NN O
and NN NN O
sensori NN NN B-Disease
- NN NN I-Disease
motor NN NN I-Disease
neuropathy NN NN I-Disease
. NN NN O
   
Diabetes NN NN B-Disease
mellitus NN NN I-Disease
was NN NN O
the NN NN O
major NN NN O
cause NN NN O
of NN NN O
autonomic NN NN B-Disease
neuropathy NN NN I-Disease
. NN NN O
   
Isoniazid NN NN O
was NN NN O
the NN NN O
most NN NN O
frequent NN NN O
agent NN NN O
in NN NN O
drug NN NN O
- NN NN O
induced NN NN O
neuropathy NN NN B-Disease
. NN NN O
   
Migraine NN NN B-Disease
( NN NN O
20 NN NN O
% NN NN O
) NN NN O
was NN NN O
not NN NN O
an NN NN O
uncommon NN NN O
cause NN NN O
of NN NN O
cranial NN NN B-Disease
neuropathy NN NN I-Disease
although NN NN O
malignancies NN NN B-Disease
arising NN NN O
from NN NN O
the NN NN O
reticuloendothelial NN NN O
system NN NN O
or NN NN O
related NN NN O
structures NN NN O
of NN NN O
the NN NN O
head NN NN O
and NN NN O
neck NN NN O
were NN NN O
more NN NN O
frequent NN NN O
( NN NN O
26 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
In NN NN O
26 NN NN O
. NN NN O
5 NN NN O
% NN NN O
of NN NN O
all NN NN O
the NN NN O
cases NN NN O
, NN NN O
the NN NN O
aetiology NN NN O
of NN NN O
the NN NN O
neuropathy NN NN B-Disease
was NN NN O
undetermined NN NN O
. NN NN O
   
Heredofamilial NN NN O
and NN NN O
connective NN NN B-Disease
tissue NN NN I-Disease
disorders NN NN I-Disease
were NN NN O
rare NN NN O
. NN NN O
   
Some NN NN O
of NN NN O
the NN NN O
factors NN NN O
related NN NN O
to NN NN O
the NN NN O
clinical NN NN O
presentation NN NN O
and NN NN O
pathogenesis NN NN O
of NN NN O
the NN NN O
neuropathies NN NN B-Disease
are NN NN O
briefly NN NN O
discussed NN NN O
. NN NN O
   
Reduction NN NN O
in NN NN O
caffeine NN NN O
toxicity NN NN B-Disease
by NN NN O
acetaminophen NN NN O
. NN NN O
   
A NN NN O
patient NN NN O
who NN NN O
allegedly NN NN O
consumed NN NN O
100 NN NN O
tablets NN NN O
of NN NN O
an NN NN O
over NN NN O
- NN NN O
the NN NN O
- NN NN O
counter NN NN O
analgesic NN NN O
containing NN NN O
sodium NN NN O
acetylsalicylate NN NN O
, NN NN O
caffeine NN NN O
, NN NN O
and NN NN O
acetaminophen NN NN O
displayed NN NN O
no NN NN O
significant NN NN O
CNS NN NN O
stimulation NN NN O
despite NN NN O
the NN NN O
presence NN NN O
of NN NN O
175 NN NN O
micrograms NN NN O
of NN NN O
caffeine NN NN O
per NN NN O
mL NN NN O
of NN NN O
serum NN NN O
. NN NN O
   
Because NN NN O
salicylates NN NN O
have NN NN O
been NN NN O
reported NN NN O
to NN NN O
augment NN NN O
the NN NN O
stimulatory NN NN O
effects NN NN O
of NN NN O
caffeine NN NN O
on NN NN O
the NN NN O
CNS NN NN O
, NN NN O
attention NN NN O
was NN NN O
focused NN NN O
on NN NN O
the NN NN O
possibility NN NN O
that NN NN O
the NN NN O
presence NN NN O
of NN NN O
acetaminophen NN NN O
( NN NN O
52 NN NN O
micrograms NN NN O
/ NN NN O
mL NN NN O
) NN NN O
reduced NN NN O
the NN NN O
CNS NN NN O
toxicity NN NN B-Disease
of NN NN O
caffeine NN NN O
. NN NN O
   
Studies NN NN O
in NN NN O
DBA NN NN O
/ NN NN O
2J NN NN O
mice NN NN O
showed NN NN O
that NN NN O
: NN NN O
1 NN NN O
) NN NN O
pretreatment NN NN O
with NN NN O
acetaminophen NN NN O
( NN NN O
100 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
increased NN NN O
the NN NN O
interval NN NN O
between NN NN O
the NN NN O
administration NN NN O
of NN NN O
caffeine NN NN O
( NN NN O
300 NN NN O
to NN NN O
450 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
IP NN NN O
) NN NN O
and NN NN O
the NN NN O
onset NN NN O
of NN NN O
fatal NN NN O
convulsions NN NN B-Disease
by NN NN O
a NN NN O
factor NN NN O
of NN NN O
about NN NN O
two NN NN O
; NN NN O
and NN NN O
2 NN NN O
) NN NN O
pretreatment NN NN O
with NN NN O
acetaminophen NN NN O
( NN NN O
75 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
reduced NN NN O
the NN NN O
incidence NN NN O
of NN NN O
audiogenic NN NN O
seizures NN NN B-Disease
produced NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
caffeine NN NN O
( NN NN O
12 NN NN O
. NN NN O
5 NN NN O
to NN NN O
75 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
IP NN NN O
) NN NN O
. NN NN O
   
The NN NN O
frequency NN NN O
of NN NN O
sound NN NN O
- NN NN O
induced NN NN O
seizures NN NN B-Disease
after NN NN O
12 NN NN O
. NN NN O
5 NN NN O
or NN NN O
25 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
caffeine NN NN O
was NN NN O
reduced NN NN O
from NN NN O
50 NN NN O
to NN NN O
5 NN NN O
% NN NN O
by NN NN O
acetaminophen NN NN O
. NN NN O
   
In NN NN O
the NN NN O
absence NN NN O
of NN NN O
caffeine NN NN O
, NN NN O
acetaminophen NN NN O
( NN NN O
up NN NN O
to NN NN O
300 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
did NN NN O
not NN NN O
modify NN NN O
the NN NN O
seizures NN NN B-Disease
induced NN NN O
by NN NN O
maximal NN NN O
electroshock NN NN O
and NN NN O
did NN NN O
not NN NN O
alter NN NN O
the NN NN O
convulsant NN NN O
dose NN NN O
of NN NN O
pentylenetetrezol NN NN O
in NN NN O
mice NN NN O
( NN NN O
tests NN NN O
performed NN NN O
by NN NN O
the NN NN O
Anticonvulsant NN NN O
Screening NN NN O
Project NN NN O
of NN NN O
NINCDS NN NN O
) NN NN O
. NN NN O
   
Acetaminophen NN NN O
( NN NN O
up NN NN O
to NN NN O
150 NN NN O
micrograms NN NN O
/ NN NN O
mL NN NN O
) NN NN O
did NN NN O
not NN NN O
retard NN NN O
the NN NN O
incorporation NN NN O
of NN NN O
radioactive NN NN O
adenosine NN NN O
into NN NN O
ATP NN NN O
in NN NN O
slices NN NN O
of NN NN O
rat NN NN O
cerebral NN NN O
cortex NN NN O
. NN NN O
   
Thus NN NN O
the NN NN O
mechanism NN NN O
by NN NN O
which NN NN O
acetaminophen NN NN O
antagonizes NN NN O
the NN NN O
actions NN NN O
of NN NN O
caffeine NN NN O
in NN NN O
the NN NN O
CNS NN NN O
remains NN NN O
unknown NN NN O
. NN NN O
   
A NN NN O
double NN NN O
- NN NN O
blind NN NN O
study NN NN O
of NN NN O
the NN NN O
efficacy NN NN O
and NN NN O
safety NN NN O
of NN NN O
dothiepin NN NN O
hydrochloride NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
major NN NN O
depressive NN NN B-Disease
disorder NN NN I-Disease
. NN NN O
   
In NN NN O
a NN NN O
6 NN NN O
- NN NN O
week NN NN O
double NN NN O
- NN NN O
blind NN NN O
parallel NN NN O
treatment NN NN O
study NN NN O
, NN NN O
dothiepin NN NN O
and NN NN O
amitriptyline NN NN O
were NN NN O
compared NN NN O
to NN NN O
placebo NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
33 NN NN O
depressed NN NN B-Disease
outpatients NN NN O
. NN NN O
   
Dothiepin NN NN O
and NN NN O
amitriptyline NN NN O
were NN NN O
equally NN NN O
effective NN NN O
in NN NN O
alleviating NN NN O
the NN NN O
symptoms NN NN O
of NN NN O
depressive NN NN B-Disease
illness NN NN I-Disease
, NN NN O
and NN NN O
both NN NN O
were NN NN O
significantly NN NN O
superior NN NN O
to NN NN O
placebo NN NN O
. NN NN O
   
The NN NN O
overall NN NN O
incidence NN NN O
of NN NN O
side NN NN O
effects NN NN O
and NN NN O
the NN NN O
frequency NN NN O
and NN NN O
severity NN NN O
of NN NN O
blurred NN NN B-Disease
vision NN NN I-Disease
, NN NN O
dry NN NN B-Disease
mouth NN NN I-Disease
, NN NN O
and NN NN O
drowsiness NN NN O
were NN NN O
significantly NN NN O
less NN NN O
with NN NN O
dothiepin NN NN O
than NN NN O
with NN NN O
amitriptyline NN NN O
. NN NN O
   
Dothiepin NN NN O
also NN NN O
produced NN NN O
fewer NN NN O
CNS NN NN O
and NN NN O
cardiovascular NN NN O
effects NN NN O
. NN NN O
   
There NN NN O
were NN NN O
no NN NN O
clinically NN NN O
important NN NN O
changes NN NN O
in NN NN O
laboratory NN NN O
parameters NN NN O
. NN NN O
   
Dothiepin NN NN O
thus NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
an NN NN O
effective NN NN O
antidepressant NN NN O
drug NN NN O
associated NN NN O
with NN NN O
fewer NN NN O
side NN NN O
effects NN NN O
than NN NN O
amitriptyline NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
depressed NN NN B-Disease
outpatients NN NN O
. NN NN O
   
Behavioral NN NN O
effects NN NN O
of NN NN O
diazepam NN NN O
and NN NN O
propranolol NN NN O
in NN NN O
patients NN NN O
with NN NN O
panic NN NN B-Disease
disorder NN NN I-Disease
and NN NN O
agoraphobia NN NN B-Disease
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
oral NN NN O
doses NN NN O
of NN NN O
diazepam NN NN O
( NN NN O
single NN NN O
dose NN NN O
of NN NN O
10 NN NN O
mg NN NN O
and NN NN O
a NN NN O
median NN NN O
dose NN NN O
of NN NN O
30 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
for NN NN O
2 NN NN O
weeks NN NN O
) NN NN O
and NN NN O
propranolol NN NN O
( NN NN O
single NN NN O
dose NN NN O
of NN NN O
80 NN NN O
mg NN NN O
and NN NN O
a NN NN O
median NN NN O
dose NN NN O
of NN NN O
240 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
for NN NN O
2 NN NN O
weeks NN NN O
) NN NN O
on NN NN O
psychological NN NN O
performance NN NN O
of NN NN O
patients NN NN O
with NN NN O
panic NN NN B-Disease
disorders NN NN I-Disease
and NN NN O
agoraphobia NN NN B-Disease
were NN NN O
investigated NN NN O
in NN NN O
a NN NN O
double NN NN O
- NN NN O
blind NN NN O
, NN NN O
randomized NN NN O
and NN NN O
crossover NN NN O
design NN NN O
. NN NN O
   
Both NN NN O
drugs NN NN O
impaired NN NN B-Disease
immediate NN NN I-Disease
free NN NN I-Disease
recall NN NN I-Disease
but NN NN O
the NN NN O
decrease NN NN O
was NN NN O
greater NN NN O
for NN NN O
diazepam NN NN O
than NN NN O
propranolol NN NN O
. NN NN O
   
Delayed NN NN B-Disease
free NN NN I-Disease
recall NN NN I-Disease
was NN NN I-Disease
also NN NN I-Disease
impaired NN NN I-Disease
but NN NN O
the NN NN O
two NN NN O
drugs NN NN O
did NN NN O
not NN NN O
differ NN NN O
. NN NN O
   
Patients NN NN O
tapped NN NN O
faster NN NN O
after NN NN O
propranolol NN NN O
than NN NN O
diazepam NN NN O
and NN NN O
they NN NN O
were NN NN O
more NN NN O
sedated NN NN O
after NN NN O
diazepam NN NN O
than NN NN O
propranolol NN NN O
. NN NN O
   
After NN NN O
2 NN NN O
weeks NN NN O
of NN NN O
treatment NN NN O
, NN NN O
patients NN NN O
tested NN NN O
5 NN NN O
- NN NN O
8 NN NN O
h NN NN O
after NN NN O
the NN NN O
last NN NN O
dose NN NN O
of NN NN O
medication NN NN O
did NN NN O
not NN NN O
show NN NN O
any NN NN O
decrement NN NN O
of NN NN O
performance NN NN O
. NN NN O
   
These NN NN O
results NN NN O
are NN NN O
similar NN NN O
to NN NN O
those NN NN O
previously NN NN O
found NN NN O
in NN NN O
healthy NN NN O
subjects NN NN O
. NN NN O
   
Accumulation NN NN O
of NN NN O
drugs NN NN O
was NN NN O
not NN NN O
reflected NN NN O
in NN NN O
prolonged NN NN O
behavioral NN NN B-Disease
impairment NN NN I-Disease
. NN NN O
   
Comparison NN NN O
of NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
glycopyrrolate NN NN O
and NN NN O
atropine NN NN O
in NN NN O
the NN NN O
prevention NN NN O
of NN NN O
bradycardia NN NN B-Disease
and NN NN O
arrhythmias NN NN B-Disease
following NN NN O
repeated NN NN O
doses NN NN O
of NN NN O
suxamethonium NN NN O
in NN NN O
children NN NN O
. NN NN O
   
The NN NN O
effectiveness NN NN O
of NN NN O
administration NN NN O
of NN NN O
glycopyrrolate NN NN O
5 NN NN O
and NN NN O
10 NN NN O
micrograms NN NN O
kg NN NN O
- NN NN O
1 NN NN O
and NN NN O
atropine NN NN O
10 NN NN O
and NN NN O
20 NN NN O
micrograms NN NN O
kg NN NN O
- NN NN O
1 NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
immediately NN NN O
before NN NN O
the NN NN O
induction NN NN O
of NN NN O
anaesthesia NN NN O
, NN NN O
to NN NN O
prevent NN NN O
arrhythmia NN NN B-Disease
and NN NN O
bradycardia NN NN B-Disease
following NN NN O
repeated NN NN O
doses NN NN O
of NN NN O
suxamethonium NN NN O
in NN NN O
children NN NN O
, NN NN O
was NN NN O
studied NN NN O
. NN NN O
   
A NN NN O
control NN NN O
group NN NN O
was NN NN O
included NN NN O
for NN NN O
comparison NN NN O
with NN NN O
the NN NN O
lower NN NN O
dose NN NN O
range NN NN O
of NN NN O
glycopyrrolate NN NN O
and NN NN O
atropine NN NN O
. NN NN O
   
A NN NN O
frequency NN NN O
of NN NN O
bradycardia NN NN B-Disease
of NN NN O
50 NN NN O
% NN NN O
was NN NN O
noted NN NN O
in NN NN O
the NN NN O
control NN NN O
group NN NN O
, NN NN O
but NN NN O
this NN NN O
was NN NN O
not NN NN O
significantly NN NN O
different NN NN O
from NN NN O
the NN NN O
frequency NN NN O
with NN NN O
the NN NN O
active NN NN O
drugs NN NN O
. NN NN O
   
Bradycardia NN NN B-Disease
( NN NN O
defined NN NN O
as NN NN O
a NN NN O
decrease NN NN O
in NN NN O
heart NN NN O
rate NN NN O
to NN NN O
less NN NN O
than NN NN O
50 NN NN O
beat NN NN O
min NN NN O
- NN NN O
1 NN NN O
) NN NN O
was NN NN O
prevented NN NN O
when NN NN O
the NN NN O
larger NN NN O
dose NN NN O
of NN NN O
either NN NN O
active NN NN O
drug NN NN O
was NN NN O
used NN NN O
. NN NN O
   
It NN NN O
is NN NN O
recommended NN NN O
that NN NN O
either NN NN O
glycopyrrolate NN NN O
10 NN NN O
micrograms NN NN O
kg NN NN O
- NN NN O
1 NN NN O
or NN NN O
atropine NN NN O
20 NN NN O
micrograms NN NN O
kg NN NN O
- NN NN O
1 NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
should NN NN O
immediately NN NN O
precede NN NN O
induction NN NN O
of NN NN O
anaesthesia NN NN O
, NN NN O
in NN NN O
children NN NN O
, NN NN O
if NN NN O
the NN NN O
repeated NN NN O
administration NN NN O
of NN NN O
suxamethonium NN NN O
is NN NN O
anticipated NN NN O
. NN NN O
   
Veno NN NN B-Disease
- NN NN I-Disease
occlusive NN NN I-Disease
liver NN NN I-Disease
disease NN NN I-Disease
after NN NN O
dacarbazine NN NN O
therapy NN NN O
( NN NN O
DTIC NN NN O
) NN NN O
for NN NN O
melanoma NN NN B-Disease
. NN NN O
   
A NN NN O
case NN NN O
of NN NN O
veno NN NN B-Disease
- NN NN I-Disease
occlusive NN NN I-Disease
disease NN NN I-Disease
of NN NN I-Disease
the NN NN I-Disease
liver NN NN I-Disease
with NN NN O
fatal NN NN O
outcome NN NN O
after NN NN O
dacarbazine NN NN O
( NN NN O
DTIC NN NN O
) NN NN O
therapy NN NN O
for NN NN O
melanoma NN NN B-Disease
is NN NN O
reported NN NN O
. NN NN O
   
There NN NN O
was NN NN O
a NN NN O
fulminant NN NN O
clinical NN NN O
course NN NN O
from NN NN O
start NN NN O
of NN NN O
symptoms NN NN O
until NN NN O
death NN NN B-Disease
. NN NN O
   
At NN NN O
autopsy NN NN O
the NN NN O
liver NN NN O
was NN NN O
enlarged NN NN O
and NN NN O
firm NN NN O
with NN NN O
signs NN NN O
of NN NN O
venous NN NN B-Disease
congestion NN NN I-Disease
. NN NN O
   
Small NN NN O
- NN NN O
and NN NN O
medium NN NN O
- NN NN O
sized NN NN O
hepatic NN NN O
veins NN NN O
were NN NN O
blocked NN NN O
by NN NN O
thrombosis NN NN B-Disease
. NN NN O
   
Eosinophilic NN NN O
infiltrations NN NN O
were NN NN O
found NN NN O
around NN NN O
the NN NN O
vessels NN NN O
. NN NN O
   
Published NN NN O
cases NN NN O
from NN NN O
the NN NN O
literature NN NN O
are NN NN O
reviewed NN NN O
and NN NN O
pertinent NN NN O
features NN NN O
discussed NN NN O
. NN NN O
   
Maternal NN NN O
lithium NN NN O
and NN NN O
neonatal NN NN O
Ebstein NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
anomaly NN NN I-Disease
: NN NN O
evaluation NN NN O
with NN NN O
cross NN NN O
- NN NN O
sectional NN NN O
echocardiography NN NN O
. NN NN O
   
Cross NN NN O
- NN NN O
sectional NN NN O
echocardiography NN NN O
was NN NN O
used NN NN O
to NN NN O
evaluate NN NN O
two NN NN O
neonates NN NN O
whose NN NN O
mothers NN NN O
ingested NN NN O
lithium NN NN O
during NN NN O
pregnancy NN NN O
. NN NN O
   
In NN NN O
one NN NN O
infant NN NN O
, NN NN O
Ebstein NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
anomaly NN NN I-Disease
of NN NN O
the NN NN O
tricuspid NN NN O
valve NN NN O
was NN NN O
identified NN NN O
. NN NN O
   
In NN NN O
the NN NN O
other NN NN O
infant NN NN O
cross NN NN O
- NN NN O
sectional NN NN O
echocardiography NN NN O
provided NN NN O
reassurance NN NN O
that NN NN O
the NN NN O
infant NN NN O
did NN NN O
not NN NN O
have NN NN O
Ebstein NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
anomaly NN NN I-Disease
. NN NN O
   
Cross NN NN O
- NN NN O
sectional NN NN O
echocardiographic NN NN O
screening NN NN O
of NN NN O
newborns NN NN O
exposed NN NN O
to NN NN O
lithium NN NN O
during NN NN O
gestation NN NN O
can NN NN O
provide NN NN O
highly NN NN O
accurate NN NN O
, NN NN O
noninvasive NN NN O
assessment NN NN O
of NN NN O
the NN NN O
presence NN NN O
or NN NN O
absence NN NN O
of NN NN O
lithium NN NN O
- NN NN O
induced NN NN O
cardiac NN NN B-Disease
malformations NN NN I-Disease
. NN NN O
   
Effects NN NN O
of NN NN O
training NN NN O
on NN NN O
the NN NN O
extent NN NN O
of NN NN O
experimental NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
in NN NN O
aging NN NN O
rats NN NN O
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
exercise NN NN O
on NN NN O
the NN NN O
severity NN NN O
of NN NN O
isoproterenol NN NN O
- NN NN O
induced NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
were NN NN O
studied NN NN O
in NN NN O
female NN NN O
albino NN NN O
rats NN NN O
of NN NN O
20 NN NN O
, NN NN O
40 NN NN O
, NN NN O
60 NN NN O
and NN NN O
80 NN NN O
weeks NN NN O
of NN NN O
age NN NN O
. NN NN O
   
The NN NN O
rats NN NN O
were NN NN O
trained NN NN O
to NN NN O
swim NN NN O
for NN NN O
a NN NN O
specific NN NN O
duration NN NN O
and NN NN O
for NN NN O
a NN NN O
particular NN NN O
period NN NN O
. NN NN O
   
The NN NN O
occurrence NN NN O
of NN NN O
infarcts NN NN B-Disease
were NN NN O
confirmed NN NN O
by NN NN O
histological NN NN O
methods NN NN O
. NN NN O
   
Elevations NN NN O
in NN NN O
the NN NN O
serum NN NN O
GOT NN NN O
and NN NN O
GPT NN NN O
were NN NN O
maximum NN NN O
in NN NN O
the NN NN O
sedentary NN NN O
- NN NN O
isoproterenols NN NN O
and NN NN O
minimum NN NN O
in NN NN O
the NN NN O
exercise NN NN O
- NN NN O
controls NN NN O
. NN NN O
   
These NN NN O
changes NN NN O
in NN NN O
the NN NN O
serum NN NN O
transaminases NN NN O
were NN NN O
associated NN NN O
with NN NN O
corresponding NN NN O
depletions NN NN O
in NN NN O
the NN NN O
cardiac NN NN O
GOT NN NN O
and NN NN O
GPT NN NN O
. NN NN O
   
However NN NN O
, NN NN O
age NN NN O
was NN NN O
seen NN NN O
to NN NN O
interfere NN NN O
with NN NN O
the NN NN O
responses NN NN O
exhibited NN NN O
by NN NN O
the NN NN O
young NN NN O
and NN NN O
old NN NN O
rats NN NN O
. NN NN O
   
Studies NN NN O
dealing NN NN O
with NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
are NN NN O
more NN NN O
informative NN NN O
when NN NN O
dealt NN NN O
with NN NN O
age NN NN O
. NN NN O
   
Effect NN NN O
of NN NN O
polyethylene NN NN O
glycol NN NN O
400 NN NN O
on NN NN O
adriamycin NN NN O
toxicity NN NN B-Disease
in NN NN O
mice NN NN O
. NN NN O
   
The NN NN O
effect NN NN O
of NN NN O
a NN NN O
widely NN NN O
used NN NN O
organic NN NN O
solvent NN NN O
, NN NN O
polyethylene NN NN O
glycol NN NN O
400 NN NN O
( NN NN O
PEG NN NN O
400 NN NN O
) NN NN O
, NN NN O
on NN NN O
the NN NN O
toxic NN NN O
action NN NN O
of NN NN O
an NN NN O
acute NN NN O
or NN NN O
chronic NN NN O
treatment NN NN O
with NN NN O
adriamycin NN NN O
( NN NN O
ADR NN NN O
) NN NN O
was NN NN O
evaluated NN NN O
in NN NN O
mice NN NN O
. NN NN O
   
PEG NN NN O
400 NN NN O
impressively NN NN O
decreased NN NN O
both NN NN O
acute NN NN O
high NN NN O
- NN NN O
dose NN NN O
and NN NN O
chronic NN NN O
low NN NN O
- NN NN O
dose NN NN O
- NN NN O
ADR NN NN O
- NN NN O
associated NN NN O
lethality NN NN O
. NN NN O
   
Light NN NN O
microscopic NN NN O
analysis NN NN O
showed NN NN O
a NN NN O
significant NN NN O
protection NN NN O
against NN NN O
ADR NN NN O
- NN NN O
induced NN NN O
cardiac NN NN B-Disease
morphological NN NN I-Disease
alterations NN NN I-Disease
. NN NN O
   
Such NN NN O
treatment NN NN O
did NN NN O
not NN NN O
diminish NN NN O
the NN NN O
ADR NN NN O
antitumor NN NN O
activity NN NN O
in NN NN O
L1210 NN NN B-Disease
leukemia NN NN I-Disease
and NN NN O
in NN NN O
Ehrlich NN NN B-Disease
ascites NN NN I-Disease
tumor NN NN I-Disease
. NN NN O
   
Sublingual NN NN O
absorption NN NN O
of NN NN O
the NN NN O
quaternary NN NN O
ammonium NN NN O
antiarrhythmic NN NN O
agent NN NN O
, NN NN O
UM NN NN O
- NN NN O
272 NN NN O
. NN NN O
   
UM NN NN O
- NN NN O
272 NN NN O
( NN NN O
N NN NN O
, NN NN O
N NN NN O
- NN NN O
dimethylpropranolol NN NN O
) NN NN O
, NN NN O
a NN NN O
quaternary NN NN O
antiarrhythmic NN NN O
agent NN NN O
, NN NN O
was NN NN O
administered NN NN O
sublingually NN NN O
to NN NN O
dogs NN NN O
with NN NN O
ouabain NN NN O
- NN NN O
induced NN NN O
ventricular NN NN B-Disease
tachycardias NN NN I-Disease
. NN NN O
   
Both NN NN O
anti NN NN O
- NN NN O
arrhythmic NN NN O
efficacy NN NN O
and NN NN O
bioavailability NN NN O
were NN NN O
compared NN NN O
to NN NN O
oral NN NN O
drug NN NN O
. NN NN O
   
Sublingual NN NN O
UM NN NN O
- NN NN O
272 NN NN O
converted NN NN O
ventricular NN NN B-Disease
tachycardia NN NN I-Disease
to NN NN O
sinus NN NN O
rhythm NN NN O
in NN NN O
all NN NN O
5 NN NN O
dogs NN NN O
. NN NN O
   
The NN NN O
area NN NN O
under NN NN O
the NN NN O
plasma NN NN O
concentration NN NN O
time NN NN O
curve NN NN O
at NN NN O
90 NN NN O
min NN NN O
was NN NN O
4 NN NN O
- NN NN O
12 NN NN O
times NN NN O
greater NN NN O
than NN NN O
for NN NN O
oral NN NN O
drug NN NN O
, NN NN O
suggesting NN NN O
the NN NN O
existence NN NN O
of NN NN O
an NN NN O
absorption NN NN O
- NN NN O
limiting NN NN O
process NN NN O
in NN NN O
the NN NN O
intestine NN NN O
, NN NN O
and NN NN O
providing NN NN O
an NN NN O
alternate NN NN O
form NN NN O
of NN NN O
administration NN NN O
for NN NN O
quaternary NN NN O
drugs NN NN O
. NN NN O
   
Early NN NN O
adjuvant NN NN O
adriamycin NN NN O
in NN NN O
superficial NN NN O
bladder NN NN B-Disease
carcinoma NN NN I-Disease
. NN NN O
   
A NN NN O
multicenter NN NN O
study NN NN O
was NN NN O
performed NN NN O
in NN NN O
110 NN NN O
patients NN NN O
with NN NN O
superficial NN NN O
transitional NN NN O
cell NN NN O
carcinoma NN NN B-Disease
of NN NN I-Disease
the NN NN I-Disease
bladder NN NN I-Disease
. NN NN O
   
Adriamycin NN NN O
( NN NN O
50 NN NN O
mg NN NN O
/ NN NN O
50 NN NN O
ml NN NN O
) NN NN O
was NN NN O
administered NN NN O
intravesically NN NN O
within NN NN O
24 NN NN O
h NN NN O
after NN NN O
transurethral NN NN O
resection NN NN O
of NN NN O
TA NN NN O
- NN NN O
T1 NN NN O
( NN NN O
O NN NN O
- NN NN O
A NN NN O
) NN NN O
bladder NN NN B-Disease
tumors NN NN I-Disease
. NN NN O
   
Instillation NN NN O
was NN NN O
repeated NN NN O
twice NN NN O
during NN NN O
the NN NN O
first NN NN O
week NN NN O
, NN NN O
then NN NN O
weekly NN NN O
during NN NN O
the NN NN O
first NN NN O
month NN NN O
and NN NN O
afterwards NN NN O
monthly NN NN O
for NN NN O
1 NN NN O
year NN NN O
. NN NN O
   
The NN NN O
tolerance NN NN O
was NN NN O
evaluated NN NN O
in NN NN O
these NN NN O
110 NN NN O
patients NN NN O
, NN NN O
and NN NN O
29 NN NN O
patients NN NN O
presented NN NN O
with NN NN O
local NN NN O
side NN NN O
- NN NN O
effects NN NN O
. NN NN O
   
In NN NN O
24 NN NN O
of NN NN O
these NN NN O
patients NN NN O
chemical NN NN O
cystitis NN NN B-Disease
was NN NN O
severe NN NN O
enough NN NN O
for NN NN O
them NN NN O
to NN NN O
drop NN NN O
out NN NN O
of NN NN O
the NN NN O
study NN NN O
. NN NN O
   
No NN NN O
systemic NN NN O
side NN NN O
- NN NN O
effects NN NN O
were NN NN O
observed NN NN O
. NN NN O
   
Recurrence NN NN O
was NN NN O
studied NN NN O
in NN NN O
82 NN NN O
evaluable NN NN O
patients NN NN O
after NN NN O
1 NN NN O
year NN NN O
of NN NN O
follow NN NN O
- NN NN O
up NN NN O
and NN NN O
in NN NN O
72 NN NN O
patients NN NN O
followed NN NN O
for NN NN O
2 NN NN O
- NN NN O
3 NN NN O
years NN NN O
( NN NN O
mean NN NN O
32 NN NN O
months NN NN O
) NN NN O
. NN NN O
   
Of NN NN O
the NN NN O
82 NN NN O
patients NN NN O
studied NN NN O
after NN NN O
1 NN NN O
year NN NN O
, NN NN O
23 NN NN O
had NN NN O
primary NN NN O
and NN NN O
59 NN NN O
recurrent NN NN O
disease NN NN O
. NN NN O
   
Of NN NN O
the NN NN O
82 NN NN O
evaluable NN NN O
patients NN NN O
, NN NN O
50 NN NN O
did NN NN O
not NN NN O
show NN NN O
any NN NN O
recurrence NN NN O
after NN NN O
1 NN NN O
year NN NN O
( NN NN O
61 NN NN O
% NN NN O
) NN NN O
, NN NN O
while NN NN O
32 NN NN O
presented NN NN O
with NN NN O
one NN NN O
or NN NN O
more NN NN O
recurrences NN NN O
( NN NN O
39 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
Of NN NN O
these NN NN O
recurrences NN NN O
, NN NN O
27 NN NN O
were NN NN O
T1 NN NN O
tumors NN NN B-Disease
while NN NN O
five NN NN O
progressed NN NN O
to NN NN O
more NN NN O
highly NN NN O
invasive NN NN O
lesions NN NN O
. NN NN O
   
In NN NN O
patients NN NN O
that NN NN O
were NN NN O
free NN NN O
of NN NN O
recurrence NN NN O
during NN NN O
the NN NN O
first NN NN O
year NN NN O
, NN NN O
80 NN NN O
% NN NN O
remained NN NN O
tumor NN NN B-Disease
- NN NN O
free NN NN O
during NN NN O
the NN NN O
2 NN NN O
- NN NN O
to NN NN O
3 NN NN O
- NN NN O
year NN NN O
follow NN NN O
- NN NN O
up NN NN O
period NN NN O
. NN NN O
   
Of NN NN O
the NN NN O
patients NN NN O
developing NN NN O
one NN NN O
or NN NN O
more NN NN O
recurrences NN NN O
during NN NN O
the NN NN O
first NN NN O
year NN NN O
, NN NN O
only NN NN O
50 NN NN O
% NN NN O
presented NN NN O
with NN NN O
further NN NN O
recurrence NN NN O
once NN NN O
the NN NN O
instillations NN NN O
were NN NN O
stopped NN NN O
. NN NN O
   
The NN NN O
beneficial NN NN O
effect NN NN O
of NN NN O
Adriamycin NN NN O
appears NN NN O
obvious NN NN O
and NN NN O
might NN NN O
be NN NN O
related NN NN O
to NN NN O
the NN NN O
drug NN NN O
itself NN NN O
, NN NN O
the NN NN O
early NN NN O
and NN NN O
repeated NN NN O
instillations NN NN O
after NN NN O
TUR NN NN O
, NN NN O
or NN NN O
both NN NN O
. NN NN O
   
D NN NN O
- NN NN O
penicillamine NN NN O
- NN NN O
induced NN NN O
angiopathy NN NN B-Disease
in NN NN O
rats NN NN O
. NN NN O
   
The NN NN O
effect NN NN O
of NN NN O
high NN NN O
dose NN NN O
D NN NN O
- NN NN O
penicillamine NN NN O
treatment NN NN O
on NN NN O
aortic NN NN O
permeability NN NN O
to NN NN O
albumin NN NN O
and NN NN O
on NN NN O
the NN NN O
ultrastructure NN NN O
of NN NN O
the NN NN O
vessel NN NN O
. NN NN O
   
Male NN NN O
Sprague NN NN O
- NN NN O
Dawley NN NN O
rats NN NN O
were NN NN O
treated NN NN O
with NN NN O
D NN NN O
- NN NN O
penicillamine NN NN O
( NN NN O
D NN NN O
- NN NN O
pen NN NN O
) NN NN O
500 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
for NN NN O
10 NN NN O
or NN NN O
42 NN NN O
days NN NN O
. NN NN O
   
Pair NN NN O
fed NN NN O
rats NN NN O
served NN NN O
as NN NN O
controls NN NN O
. NN NN O
   
Changes NN NN O
in NN NN O
aortic NN NN O
morphology NN NN O
were NN NN O
examined NN NN O
by NN NN O
light NN NN O
- NN NN O
and NN NN O
transmission NN NN O
- NN NN O
electron NN NN O
microscopy NN NN O
( NN NN O
TEM NN NN O
) NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
the NN NN O
endothelial NN NN O
permeability NN NN O
and NN NN O
the NN NN O
penetration NN NN O
through NN NN O
the NN NN O
aortic NN NN O
wall NN NN O
of NN NN O
albumin NN NN O
were NN NN O
studied NN NN O
10 NN NN O
minutes NN NN O
, NN NN O
24 NN NN O
and NN NN O
48 NN NN O
hours NN NN O
after NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
injection NN NN O
of NN NN O
human NN NN O
serum NN NN O
131I NN NN O
- NN NN O
albumin NN NN O
( NN NN O
131I NN NN O
- NN NN O
HSA NN NN O
) NN NN O
. NN NN O
   
TEM NN NN O
revealed NN NN O
extensive NN NN O
elastolysis NN NN O
in NN NN O
the NN NN O
arterial NN NN O
wall NN NN O
of NN NN O
D NN NN O
- NN NN O
pen NN NN O
- NN NN O
treated NN NN O
rats NN NN O
, NN NN O
consistent NN NN O
with NN NN O
an NN NN O
inhibitory NN NN O
effect NN NN O
on NN NN O
crosslink NN NN O
formation NN NN O
. NN NN O
   
In NN NN O
experimental NN NN O
animals NN NN O
excess NN NN O
deposition NN NN O
of NN NN O
collagen NN NN O
and NN NN O
glycoaminoglycans NN NN O
was NN NN O
observed NN NN O
in NN NN O
the NN NN O
subendothelial NN NN O
and NN NN O
medial NN NN O
layer NN NN O
of NN NN O
the NN NN O
aortic NN NN O
wall NN NN O
, NN NN O
together NN NN O
with NN NN O
prominent NN NN O
basal NN NN O
membrane NN NN O
substance NN NN O
around NN NN O
aortic NN NN O
smooth NN NN O
muscle NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
aorta NN NN O
/ NN NN O
serum NN NN O
- NN NN O
ratio NN NN O
and NN NN O
the NN NN O
radioactive NN NN O
build NN NN O
- NN NN O
up NN NN O
24 NN NN O
and NN NN O
48 NN NN O
hours NN NN O
after NN NN O
injection NN NN O
of NN NN O
131I NN NN O
- NN NN O
HSA NN NN O
was NN NN O
reduced NN NN O
in NN NN O
animals NN NN O
treated NN NN O
with NN NN O
D NN NN O
- NN NN O
pen NN NN O
for NN NN O
42 NN NN O
days NN NN O
, NN NN O
indicating NN NN O
an NN NN O
impeded NN NN O
transmural NN NN O
transport NN NN O
of NN NN O
tracer NN NN O
which NN NN O
may NN NN O
be NN NN O
caused NN NN O
by NN NN O
a NN NN O
steric NN NN O
exclusion NN NN O
effect NN NN O
of NN NN O
abundant NN NN O
hyaluronate NN NN O
. NN NN O
   
The NN NN O
endothelial NN NN O
ultrastructure NN NN O
was NN NN O
unaffected NN NN O
by NN NN O
D NN NN O
- NN NN O
pen NN NN O
, NN NN O
and NN NN O
no NN NN O
differences NN NN O
in NN NN O
aortic NN NN O
131I NN NN O
- NN NN O
HSA NN NN O
radioactivity NN NN O
or NN NN O
aorta NN NN O
/ NN NN O
serum NN NN O
- NN NN O
ratio NN NN O
were NN NN O
recorded NN NN O
between NN NN O
experimental NN NN O
and NN NN O
control NN NN O
groups NN NN O
10 NN NN O
minutes NN NN O
after NN NN O
tracer NN NN O
injection NN NN O
, NN NN O
indicating NN NN O
that NN NN O
the NN NN O
permeability NN NN O
of NN NN O
the NN NN O
endothelial NN NN O
barrier NN NN O
to NN NN O
albumin NN NN O
remained NN NN O
unaffected NN NN O
by NN NN O
D NN NN O
- NN NN O
pen NN NN O
treatment NN NN O
. NN NN O
   
These NN NN O
observations NN NN O
support NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
treatment NN NN O
with NN NN O
high NN NN O
doses NN NN O
of NN NN O
D NN NN O
- NN NN O
pen NN NN O
may NN NN O
induce NN NN O
a NN NN O
fibroproliferative NN NN O
response NN NN O
in NN NN O
rat NN NN O
aorta NN NN O
, NN NN O
possibly NN NN O
by NN NN O
an NN NN O
inhibitory NN NN O
effect NN NN O
on NN NN O
the NN NN O
cross NN NN O
- NN NN O
linking NN NN O
of NN NN O
collagen NN NN O
and NN NN O
elastin NN NN O
. NN NN O
   
Effect NN NN O
of NN NN O
aspirin NN NN O
on NN NN O
N NN NN O
- NN NN O
[ NN NN O
4 NN NN O
- NN NN O
( NN NN O
5 NN NN O
- NN NN O
nitro NN NN O
- NN NN O
2 NN NN O
- NN NN O
furyl NN NN O
) NN NN O
- NN NN O
2 NN NN O
- NN NN O
thiazolyl NN NN O
] NN NN O
- NN NN O
formamide NN NN O
- NN NN O
induced NN NN O
epithelial NN NN O
proliferation NN NN O
in NN NN O
the NN NN O
urinary NN NN O
bladder NN NN O
and NN NN O
forestomach NN NN O
of NN NN O
the NN NN O
rat NN NN O
. NN NN O
   
The NN NN O
co NN NN O
- NN NN O
administration NN NN O
of NN NN O
aspirin NN NN O
with NN NN O
N NN NN O
- NN NN O
[ NN NN O
4 NN NN O
- NN NN O
( NN NN O
5 NN NN O
- NN NN O
nitro NN NN O
- NN NN O
2 NN NN O
- NN NN O
furyl NN NN O
) NN NN O
- NN NN O
2 NN NN O
- NN NN O
thiazolyl NN NN O
] NN NN O
- NN NN O
formamide NN NN O
( NN NN O
FANFT NN NN O
) NN NN O
to NN NN O
rats NN NN O
resulted NN NN O
in NN NN O
a NN NN O
reduced NN NN O
incidence NN NN O
of NN NN O
FANFT NN NN O
- NN NN O
induced NN NN O
bladder NN NN B-Disease
carcinomas NN NN I-Disease
but NN NN O
a NN NN O
concomitant NN NN O
induction NN NN O
of NN NN O
forestomach NN NN B-Disease
tumors NN NN I-Disease
. NN NN O
   
An NN NN O
autoradiographic NN NN O
study NN NN O
was NN NN O
performed NN NN O
on NN NN O
male NN NN O
F NN NN O
- NN NN O
344 NN NN O
rats NN NN O
fed NN NN O
diet NN NN O
containing NN NN O
FANFT NN NN O
at NN NN O
a NN NN O
level NN NN O
of NN NN O
0 NN NN O
. NN NN O
2 NN NN O
% NN NN O
and NN NN O
/ NN NN O
or NN NN O
aspirin NN NN O
at NN NN O
a NN NN O
level NN NN O
of NN NN O
0 NN NN O
. NN NN O
5 NN NN O
% NN NN O
to NN NN O
evaluate NN NN O
the NN NN O
effect NN NN O
of NN NN O
aspirin NN NN O
on NN NN O
the NN NN O
increased NN NN O
cell NN NN O
proliferation NN NN O
induced NN NN O
by NN NN O
FANFT NN NN O
in NN NN O
the NN NN O
forestomach NN NN O
and NN NN O
bladder NN NN O
. NN NN O
   
FANFT NN NN O
- NN NN O
induced NN NN O
cell NN NN O
proliferation NN NN O
in NN NN O
the NN NN O
bladder NN NN O
was NN NN O
significantly NN NN O
suppressed NN NN O
by NN NN O
aspirin NN NN O
co NN NN O
- NN NN O
administration NN NN O
after NN NN O
4 NN NN O
weeks NN NN O
but NN NN O
not NN NN O
after NN NN O
12 NN NN O
weeks NN NN O
. NN NN O
   
In NN NN O
the NN NN O
forestomach NN NN O
, NN NN O
and NN NN O
also NN NN O
in NN NN O
the NN NN O
liver NN NN O
, NN NN O
aspirin NN NN O
did NN NN O
not NN NN O
affect NN NN O
the NN NN O
FANFT NN NN O
- NN NN O
induced NN NN O
increase NN NN O
in NN NN O
labeling NN NN O
index NN NN O
. NN NN O
   
The NN NN O
present NN NN O
results NN NN O
are NN NN O
consistent NN NN O
with NN NN O
the NN NN O
carcinogenicity NN NN O
experiment NN NN O
suggesting NN NN O
that NN NN O
different NN NN O
mechanisms NN NN O
are NN NN O
involved NN NN O
in NN NN O
FANFT NN NN O
carcinogenesis NN NN B-Disease
in NN NN O
the NN NN O
bladder NN NN O
and NN NN O
forestomach NN NN O
, NN NN O
and NN NN O
that NN NN O
aspirin NN NN O
' NN NN O
s NN NN O
effect NN NN O
on NN NN O
FANFT NN NN O
in NN NN O
the NN NN O
forestomach NN NN O
is NN NN O
not NN NN O
due NN NN O
to NN NN O
an NN NN O
irritant NN NN O
effect NN NN O
associated NN NN O
with NN NN O
increased NN NN O
cell NN NN O
proliferation NN NN O
. NN NN O
   
Also NN NN O
, NN NN O
there NN NN O
appears NN NN O
to NN NN O
be NN NN O
an NN NN O
adaptation NN NN O
by NN NN O
the NN NN O
rats NN NN O
to NN NN O
the NN NN O
chronic NN NN O
ingestion NN NN O
of NN NN O
aspirin NN NN O
. NN NN O
   
A NN NN O
case NN NN O
of NN NN O
tardive NN NN B-Disease
dyskinesia NN NN I-Disease
caused NN NN O
by NN NN O
metoclopramide NN NN O
. NN NN O
   
Abnormal NN NN B-Disease
involuntary NN NN I-Disease
movements NN NN I-Disease
appeared NN NN O
in NN NN O
the NN NN O
mouth NN NN O
, NN NN O
tongue NN NN O
, NN NN O
neck NN NN O
and NN NN O
abdomen NN NN O
of NN NN O
a NN NN O
64 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
male NN NN O
patient NN NN O
after NN NN O
he NN NN O
took NN NN O
metoclopramide NN NN O
for NN NN O
gastrointestinal NN NN B-Disease
disorder NN NN I-Disease
in NN NN O
a NN NN O
regimen NN NN O
of NN NN O
30 NN NN O
mg NN NN O
per NN NN O
day NN NN O
for NN NN O
a NN NN O
total NN NN O
of NN NN O
about NN NN O
260 NN NN O
days NN NN O
. NN NN O
   
The NN NN O
symptoms NN NN O
exacerbated NN NN O
to NN NN O
a NN NN O
maximum NN NN O
in NN NN O
a NN NN O
month NN NN O
. NN NN O
   
When NN NN O
the NN NN O
metoclopramide NN NN O
administration NN NN O
was NN NN O
discontinued NN NN O
, NN NN O
the NN NN O
abnormal NN NN B-Disease
movements NN NN I-Disease
gradually NN NN O
improved NN NN O
to NN NN O
a NN NN O
considerable NN NN O
extent NN NN O
. NN NN O
   
Attention NN NN O
to NN NN O
the NN NN O
possible NN NN O
induction NN NN O
of NN NN O
specific NN NN O
tardive NN NN B-Disease
dyskinesia NN NN I-Disease
is NN NN O
called NN NN O
for NN NN O
in NN NN O
the NN NN O
use NN NN O
of NN NN O
this NN NN O
drug NN NN O
. NN NN O
   
Intra NN NN O
- NN NN O
arterial NN NN O
BCNU NN NN O
chemotherapy NN NN O
for NN NN O
treatment NN NN O
of NN NN O
malignant NN NN B-Disease
gliomas NN NN I-Disease
of NN NN O
the NN NN O
central NN NN O
nervous NN NN O
system NN NN O
. NN NN O
   
Because NN NN O
of NN NN O
the NN NN O
rapid NN NN O
systemic NN NN O
clearance NN NN O
of NN NN O
BCNU NN NN O
( NN NN O
1 NN NN O
, NN NN O
3 NN NN O
- NN NN O
bis NN NN O
- NN NN O
( NN NN O
2 NN NN O
- NN NN O
chloroethyl NN NN O
) NN NN O
- NN NN O
1 NN NN O
- NN NN O
nitrosourea NN NN O
) NN NN O
, NN NN O
intra NN NN O
- NN NN O
arterial NN NN O
administration NN NN O
should NN NN O
provide NN NN O
a NN NN O
substantial NN NN O
advantage NN NN O
over NN NN O
intravenous NN NN O
administration NN NN O
for NN NN O
the NN NN O
treatment NN NN O
of NN NN O
malignant NN NN B-Disease
gliomas NN NN I-Disease
. NN NN O
   
Thirty NN NN O
- NN NN O
six NN NN O
patients NN NN O
were NN NN O
treated NN NN O
with NN NN O
BCNU NN NN O
every NN NN O
6 NN NN O
to NN NN O
8 NN NN O
weeks NN NN O
, NN NN O
either NN NN O
by NN NN O
transfemoral NN NN O
catheterization NN NN O
of NN NN O
the NN NN O
internal NN NN O
carotid NN NN O
or NN NN O
vertebral NN NN O
artery NN NN O
or NN NN O
through NN NN O
a NN NN O
fully NN NN O
implantable NN NN O
intracarotid NN NN O
drug NN NN O
delivery NN NN O
system NN NN O
, NN NN O
beginning NN NN O
with NN NN O
a NN NN O
dose NN NN O
of NN NN O
200 NN NN O
mg NN NN O
/ NN NN O
sq NN NN O
m NN NN O
body NN NN O
surface NN NN O
area NN NN O
. NN NN O
   
Twelve NN NN O
patients NN NN O
with NN NN O
Grade NN NN O
III NN NN O
or NN NN O
IV NN NN O
astrocytomas NN NN B-Disease
were NN NN O
treated NN NN O
after NN NN O
partial NN NN O
resection NN NN O
of NN NN O
the NN NN O
tumor NN NN B-Disease
without NN NN O
prior NN NN O
radiation NN NN O
therapy NN NN O
. NN NN O
   
After NN NN O
two NN NN O
to NN NN O
seven NN NN O
cycles NN NN O
of NN NN O
chemotherapy NN NN O
, NN NN O
nine NN NN O
patients NN NN O
showed NN NN O
a NN NN O
decrease NN NN O
in NN NN O
tumor NN NN B-Disease
size NN NN O
and NN NN O
surrounding NN NN O
edema NN NN B-Disease
on NN NN O
contrast NN NN O
- NN NN O
enhanced NN NN O
computerized NN NN O
tomography NN NN O
scans NN NN O
. NN NN O
   
In NN NN O
the NN NN O
nine NN NN O
responders NN NN O
, NN NN O
median NN NN O
duration NN NN O
of NN NN O
chemotherapy NN NN O
response NN NN O
from NN NN O
the NN NN O
time NN NN O
of NN NN O
operation NN NN O
was NN NN O
25 NN NN O
weeks NN NN O
( NN NN O
range NN NN O
12 NN NN O
to NN NN O
more NN NN O
than NN NN O
91 NN NN O
weeks NN NN O
) NN NN O
. NN NN O
   
The NN NN O
median NN NN O
duration NN NN O
of NN NN O
survival NN NN O
in NN NN O
the NN NN O
12 NN NN O
patients NN NN O
was NN NN O
54 NN NN O
weeks NN NN O
( NN NN O
range NN NN O
21 NN NN O
to NN NN O
more NN NN O
than NN NN O
156 NN NN O
weeks NN NN O
) NN NN O
, NN NN O
with NN NN O
an NN NN O
18 NN NN O
- NN NN O
month NN NN O
survival NN NN O
rate NN NN O
of NN NN O
42 NN NN O
% NN NN O
. NN NN O
   
Twenty NN NN O
- NN NN O
four NN NN O
patients NN NN O
with NN NN O
recurrent NN NN O
Grade NN NN O
I NN NN O
to NN NN O
IV NN NN O
astrocytomas NN NN B-Disease
, NN NN O
whose NN NN O
resection NN NN O
and NN NN O
irradiation NN NN O
therapy NN NN O
had NN NN O
failed NN NN O
, NN NN O
received NN NN O
two NN NN O
to NN NN O
eight NN NN O
courses NN NN O
of NN NN O
intra NN NN O
- NN NN O
arterial NN NN O
BCNU NN NN O
therapy NN NN O
. NN NN O
   
Seventeen NN NN O
of NN NN O
these NN NN O
had NN NN O
a NN NN O
response NN NN O
or NN NN O
were NN NN O
stable NN NN O
for NN NN O
a NN NN O
median NN NN O
of NN NN O
20 NN NN O
weeks NN NN O
( NN NN O
range NN NN O
6 NN NN O
to NN NN O
more NN NN O
than NN NN O
66 NN NN O
weeks NN NN O
) NN NN O
. NN NN O
   
The NN NN O
catheterization NN NN O
procedure NN NN O
is NN NN O
safe NN NN O
, NN NN O
with NN NN O
no NN NN O
immediate NN NN O
complication NN NN O
in NN NN O
111 NN NN O
infusions NN NN O
of NN NN O
BCNU NN NN O
. NN NN O
   
A NN NN O
delayed NN NN O
complication NN NN O
in NN NN O
nine NN NN O
patients NN NN O
has NN NN O
been NN NN O
unilateral NN NN O
loss NN NN B-Disease
of NN NN I-Disease
vision NN NN I-Disease
secondary NN NN O
to NN NN O
a NN NN O
retinal NN NN B-Disease
vasculitis NN NN I-Disease
. NN NN O
   
The NN NN O
frequency NN NN O
of NN NN O
visual NN NN B-Disease
loss NN NN I-Disease
decreased NN NN O
after NN NN O
the NN NN O
concentration NN NN O
of NN NN O
the NN NN O
ethanol NN NN O
diluent NN NN O
was NN NN O
lowered NN NN O
. NN NN O
   
Provocation NN NN O
of NN NN O
postural NN NN O
hypotension NN NN B-Disease
by NN NN O
nitroglycerin NN NN O
in NN NN O
diabetic NN NN B-Disease
autonomic NN NN I-Disease
neuropathy NN NN I-Disease
? NN NN O
   
The NN NN O
effect NN NN O
of NN NN O
nitroglycerin NN NN O
on NN NN O
heart NN NN O
rate NN NN O
and NN NN O
systolic NN NN O
blood NN NN O
pressure NN NN O
was NN NN O
compared NN NN O
in NN NN O
5 NN NN O
normal NN NN O
subjects NN NN O
, NN NN O
12 NN NN O
diabetic NN NN B-Disease
subjects NN NN O
without NN NN O
autonomic NN NN B-Disease
neuropathy NN NN I-Disease
, NN NN O
and NN NN O
5 NN NN O
diabetic NN NN B-Disease
subjects NN NN O
with NN NN O
autonomic NN NN B-Disease
neuropathy NN NN I-Disease
. NN NN O
   
The NN NN O
magnitude NN NN O
and NN NN O
time NN NN O
course NN NN O
of NN NN O
the NN NN O
increase NN NN O
in NN NN O
heart NN NN O
rate NN NN O
and NN NN O
the NN NN O
decrease NN NN O
in NN NN O
systolic NN NN O
blood NN NN O
pressure NN NN O
after NN NN O
nitroglycerin NN NN O
were NN NN O
similar NN NN O
in NN NN O
the NN NN O
normal NN NN O
and NN NN O
diabetic NN NN B-Disease
subjects NN NN O
without NN NN O
autonomic NN NN B-Disease
neuropathy NN NN I-Disease
, NN NN O
whereas NN NN O
a NN NN O
lesser NN NN O
increase NN NN O
in NN NN O
heart NN NN O
rate NN NN O
and NN NN O
a NN NN O
greater NN NN O
decrease NN NN O
in NN NN O
systolic NN NN O
blood NN NN O
pressure NN NN O
occurred NN NN O
in NN NN O
the NN NN O
diabetic NN NN B-Disease
subjects NN NN O
with NN NN O
autonomic NN NN B-Disease
neuropathy NN NN I-Disease
. NN NN O
   
It NN NN O
is NN NN O
therefore NN NN O
suggested NN NN O
that NN NN O
caution NN NN O
should NN NN O
be NN NN O
exercised NN NN O
when NN NN O
prescribing NN NN O
vasodilator NN NN O
drugs NN NN O
in NN NN O
diabetic NN NN B-Disease
patients NN NN O
, NN NN O
particularly NN NN O
those NN NN O
with NN NN O
autonomic NN NN B-Disease
neuropathy NN NN I-Disease
. NN NN O
   
Blood NN NN O
pressure NN NN O
response NN NN O
to NN NN O
chronic NN NN O
low NN NN O
- NN NN O
dose NN NN O
intrarenal NN NN O
noradrenaline NN NN O
infusion NN NN O
in NN NN O
conscious NN NN O
rats NN NN O
. NN NN O
   
Sodium NN NN O
chloride NN NN O
solution NN NN O
( NN NN O
0 NN NN O
. NN NN O
9 NN NN O
% NN NN O
) NN NN O
or NN NN O
noradrenaline NN NN O
in NN NN O
doses NN NN O
of NN NN O
4 NN NN O
, NN NN O
12 NN NN O
and NN NN O
36 NN NN O
micrograms NN NN O
h NN NN O
- NN NN O
1 NN NN O
kg NN NN O
- NN NN O
1 NN NN O
was NN NN O
infused NN NN O
for NN NN O
five NN NN O
consecutive NN NN O
days NN NN O
, NN NN O
either NN NN O
intrarenally NN NN O
( NN NN O
by NN NN O
a NN NN O
new NN NN O
technique NN NN O
) NN NN O
or NN NN O
intravenously NN NN O
into NN NN O
rats NN NN O
with NN NN O
one NN NN O
kidney NN NN O
removed NN NN O
. NN NN O
   
Intrarenal NN NN O
infusion NN NN O
of NN NN O
noradrenaline NN NN O
caused NN NN O
hypertension NN NN B-Disease
at NN NN O
doses NN NN O
which NN NN O
did NN NN O
not NN NN O
do NN NN O
so NN NN O
when NN NN O
infused NN NN O
intravenously NN NN O
. NN NN O
   
Intrarenal NN NN O
compared NN NN O
with NN NN O
intravenous NN NN O
infusion NN NN O
of NN NN O
noradrenaline NN NN O
caused NN NN O
higher NN NN O
plasma NN NN O
noradrenaline NN NN O
concentrations NN NN O
and NN NN O
a NN NN O
shift NN NN O
of NN NN O
the NN NN O
plasma NN NN O
noradrenaline NN NN O
concentration NN NN O
- NN NN O
blood NN NN O
pressure NN NN O
effect NN NN O
curve NN NN O
towards NN NN O
lower NN NN O
plasma NN NN O
noradrenaline NN NN O
levels NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
hypertension NN NN B-Disease
after NN NN O
chronic NN NN O
intrarenal NN NN O
noradrenaline NN NN O
infusion NN NN O
is NN NN O
produced NN NN O
by NN NN O
relatively NN NN O
higher NN NN O
levels NN NN O
of NN NN O
circulating NN NN O
noradrenaline NN NN O
and NN NN O
by NN NN O
triggering NN NN O
of NN NN O
an NN NN O
additional NN NN O
intrarenal NN NN O
pressor NN NN O
mechanism NN NN O
. NN NN O
   
Characterization NN NN O
of NN NN O
estrogen NN NN O
- NN NN O
induced NN NN O
adenohypophyseal NN NN B-Disease
tumors NN NN I-Disease
in NN NN O
the NN NN O
Fischer NN NN O
344 NN NN O
rat NN NN O
. NN NN O
   
Pituitary NN NN B-Disease
tumors NN NN I-Disease
were NN NN O
induced NN NN O
in NN NN O
F344 NN NN O
female NN NN O
rats NN NN O
by NN NN O
chronic NN NN O
treatment NN NN O
with NN NN O
diethylstilbestrol NN NN O
( NN NN O
DES NN NN O
, NN NN O
8 NN NN O
- NN NN O
10 NN NN O
mg NN NN O
) NN NN O
implanted NN NN O
subcutaneously NN NN O
in NN NN O
silastic NN NN O
capsules NN NN O
. NN NN O
   
Over NN NN O
a NN NN O
range NN NN O
of NN NN O
1 NN NN O
- NN NN O
150 NN NN O
days NN NN O
of NN NN O
DES NN NN O
treatment NN NN O
, NN NN O
pairs NN NN O
of NN NN O
control NN NN O
and NN NN O
DES NN NN O
- NN NN O
treated NN NN O
rats NN NN O
were NN NN O
sacrificed NN NN O
, NN NN O
and NN NN O
their NN NN O
pituitaries NN NN O
dissociated NN NN O
enzymatically NN NN O
into NN NN O
single NN NN O
- NN NN O
cell NN NN O
preparations NN NN O
. NN NN O
   
The NN NN O
cell NN NN O
populations NN NN O
were NN NN O
examined NN NN O
regarding NN NN O
total NN NN O
cell NN NN O
recovery NN NN O
correlated NN NN O
with NN NN O
gland NN NN O
weight NN NN O
, NN NN O
intracellular NN NN O
prolactin NN NN O
( NN NN O
PRL NN NN O
) NN NN O
content NN NN O
and NN NN O
subsequent NN NN O
release NN NN O
in NN NN O
primary NN NN O
culture NN NN O
, NN NN O
immunocytochemical NN NN O
PRL NN NN O
staining NN NN O
, NN NN O
density NN NN O
and NN NN O
/ NN NN O
or NN NN O
size NN NN O
alterations NN NN O
via NN NN O
separation NN NN O
on NN NN O
Ficoll NN NN O
- NN NN O
Hypaque NN NN O
and NN NN O
by NN NN O
unit NN NN O
gravity NN NN O
sedimentation NN NN O
, NN NN O
and NN NN O
cell NN NN O
cycle NN NN O
analysis NN NN O
, NN NN O
after NN NN O
acriflavine NN NN O
DNA NN NN O
staining NN NN O
, NN NN O
by NN NN O
laser NN NN O
flow NN NN O
cytometry NN NN O
. NN NN O
   
Total NN NN O
cell NN NN O
yields NN NN O
from NN NN O
DES NN NN O
- NN NN O
treated NN NN O
pituitaries NN NN O
increased NN NN O
from NN NN O
1 NN NN O
. NN NN O
3 NN NN O
times NN NN O
control NN NN O
yields NN NN O
at NN NN O
8 NN NN O
days NN NN O
of NN NN O
treatment NN NN O
to NN NN O
58 NN NN O
. NN NN O
9 NN NN O
times NN NN O
control NN NN O
values NN NN O
by NN NN O
day NN NN O
150 NN NN O
. NN NN O
   
Intracellular NN NN O
PRL NN NN O
content NN NN O
ranged NN NN O
from NN NN O
1 NN NN O
. NN NN O
9 NN NN O
to NN NN O
9 NN NN O
. NN NN O
4 NN NN O
times NN NN O
control NN NN O
levels NN NN O
, NN NN O
and NN NN O
PRL NN NN O
release NN NN O
in NN NN O
vitro NN NN O
was NN NN O
significantly NN NN O
and NN NN O
consistently NN NN O
higher NN NN O
than NN NN O
controls NN NN O
, NN NN O
after NN NN O
at NN NN O
least NN NN O
8 NN NN O
days NN NN O
of NN NN O
DES NN NN O
exposure NN NN O
. NN NN O
   
Beyond NN NN O
8 NN NN O
days NN NN O
of NN NN O
DES NN NN O
exposure NN NN O
, NN NN O
the NN NN O
immunochemically NN NN O
PRL NN NN O
- NN NN O
positive NN NN O
proportion NN NN O
of NN NN O
cells NN NN O
increased NN NN O
to NN NN O
over NN NN O
50 NN NN O
% NN NN O
of NN NN O
the NN NN O
total NN NN O
population NN NN O
. NN NN O
   
Increased NN NN O
density NN NN O
and NN NN O
/ NN NN O
or NN NN O
size NN NN O
and NN NN O
PRL NN NN O
content NN NN O
were NN NN O
indicated NN NN O
for NN NN O
the NN NN O
majority NN NN O
of NN NN O
the NN NN O
PRL NN NN O
cell NN NN O
population NN NN O
in NN NN O
both NN NN O
types NN NN O
of NN NN O
separation NN NN O
protocols NN NN O
. NN NN O
   
All NN NN O
these NN NN O
effects NN NN O
of NN NN O
DES NN NN O
were NN NN O
more NN NN O
pronounced NN NN O
among NN NN O
previously NN NN O
ovariectomized NN NN O
animals NN NN O
. NN NN O
   
The NN NN O
data NN NN O
extend NN NN O
the NN NN O
findings NN NN O
of NN NN O
other NN NN O
investigators NN NN O
, NN NN O
further NN NN O
establishing NN NN O
the NN NN O
DES NN NN O
- NN NN O
induced NN NN O
tumor NN NN B-Disease
as NN NN O
a NN NN O
model NN NN O
for NN NN O
study NN NN O
of NN NN O
PRL NN NN O
cellular NN NN O
control NN NN O
mechanisms NN NN O
. NN NN O
   
Age NN NN O
and NN NN O
renal NN NN O
clearance NN NN O
of NN NN O
cimetidine NN NN O
. NN NN O
   
In NN NN O
35 NN NN O
patients NN NN O
( NN NN O
ages NN NN O
20 NN NN O
to NN NN O
86 NN NN O
yr NN NN O
) NN NN O
receiving NN NN O
cimetidine NN NN O
therapeutically NN NN O
two NN NN O
serum NN NN O
samples NN NN O
and NN NN O
all NN NN O
urine NN NN O
formed NN NN O
in NN NN O
the NN NN O
interim NN NN O
were NN NN O
collected NN NN O
for NN NN O
analysis NN NN O
of NN NN O
cimetidine NN NN O
by NN NN O
high NN NN O
- NN NN O
pressure NN NN O
liquid NN NN O
chromatography NN NN O
and NN NN O
for NN NN O
creatinine NN NN O
. NN NN O
   
Cimetidine NN NN O
clearance NN NN O
decreased NN NN O
with NN NN O
age NN NN O
. NN NN O
   
The NN NN O
extrapolated NN NN O
6 NN NN O
- NN NN O
hr NN NN O
serum NN NN O
concentration NN NN O
of NN NN O
cimetidine NN NN O
per NN NN O
unit NN NN O
dose NN NN O
, NN NN O
after NN NN O
intravenous NN NN O
cimetidine NN NN O
, NN NN O
increased NN NN O
with NN NN O
age NN NN O
of NN NN O
the NN NN O
patients NN NN O
. NN NN O
   
The NN NN O
ratio NN NN O
of NN NN O
cimetidine NN NN O
clearance NN NN O
to NN NN O
creatinine NN NN O
clearance NN NN O
( NN NN O
Rc NN NN O
) NN NN O
averaged NN NN O
4 NN NN O
. NN NN O
8 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
. NN NN O
0 NN NN O
, NN NN O
indicating NN NN O
net NN NN O
tubular NN NN O
secretion NN NN O
for NN NN O
cimetidine NN NN O
. NN NN O
   
Rc NN NN O
seemed NN NN O
to NN NN O
be NN NN O
independent NN NN O
of NN NN O
age NN NN O
and NN NN O
decreased NN NN O
with NN NN O
increasing NN NN O
serum NN NN O
concentration NN NN O
of NN NN O
cimetidine NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
secretion NN NN O
of NN NN O
cimetidine NN NN O
is NN NN O
a NN NN O
saturable NN NN O
process NN NN O
. NN NN O
   
There NN NN O
was NN NN O
only NN NN O
one NN NN O
case NN NN O
of NN NN O
dementia NN NN B-Disease
possibly NN NN O
due NN NN O
to NN NN O
cimetidine NN NN O
( NN NN O
with NN NN O
a NN NN O
drug NN NN O
level NN NN O
of NN NN O
1 NN NN O
. NN NN O
9 NN NN O
microgram NN NN O
/ NN NN O
ml NN NN O
6 NN NN O
hr NN NN O
after NN NN O
a NN NN O
dose NN NN O
) NN NN O
in NN NN O
a NN NN O
group NN NN O
of NN NN O
13 NN NN O
patients NN NN O
without NN NN O
liver NN NN B-Disease
or NN NN I-Disease
kidney NN NN I-Disease
disease NN NN I-Disease
who NN NN O
had NN NN O
cimetidine NN NN O
levels NN NN O
above NN NN O
1 NN NN O
. NN NN O
25 NN NN O
microgram NN NN O
/ NN NN O
ml NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
high NN NN O
cimetidine NN NN O
levels NN NN O
alone NN NN O
do NN NN O
not NN NN O
always NN NN O
induce NN NN O
dementia NN NN B-Disease
. NN NN O
   
Further NN NN O
observations NN NN O
on NN NN O
the NN NN O
electrophysiologic NN NN O
effects NN NN O
of NN NN O
oral NN NN O
amiodarone NN NN O
therapy NN NN O
. NN NN O
   
A NN NN O
case NN NN O
is NN NN O
presented NN NN O
of NN NN O
a NN NN O
reversible NN NN O
intra NN NN B-Disease
- NN NN I-Disease
Hisian NN NN I-Disease
block NN NN I-Disease
occurring NN NN O
under NN NN O
amiodarone NN NN O
treatment NN NN O
for NN NN O
atrial NN NN B-Disease
tachycardia NN NN I-Disease
in NN NN O
a NN NN O
patient NN NN O
without NN NN O
clear NN NN O
intraventricular NN NN B-Disease
conduction NN NN I-Disease
abnormalities NN NN I-Disease
. NN NN O
   
His NN NN O
bundle NN NN O
recordings NN NN O
showed NN NN O
an NN NN O
atrial NN NN B-Disease
tachycardia NN NN I-Disease
with NN NN O
intermittent NN NN O
exit NN NN O
block NN NN O
and NN NN O
greatly NN NN O
prolonged NN NN O
BH NN NN O
and NN NN O
HV NN NN O
intervals NN NN O
( NN NN O
40 NN NN O
and NN NN O
100 NN NN O
msec NN NN O
, NN NN O
respectively NN NN O
) NN NN O
. NN NN O
   
Thirty NN NN O
days NN NN O
after NN NN O
amiodarone NN NN O
discontinuation NN NN O
, NN NN O
His NN NN O
bundle NN NN O
electrograms NN NN O
showed NN NN O
atrial NN NN B-Disease
flutter NN NN I-Disease
without NN NN O
intra NN NN O
- NN NN O
Hisian NN NN O
or NN NN O
infra NN NN O
- NN NN O
Hisian NN NN O
delay NN NN O
. NN NN O
   
Amiodarone NN NN O
should NN NN O
be NN NN O
used NN NN O
with NN NN O
caution NN NN O
during NN NN O
long NN NN O
- NN NN O
term NN NN O
oral NN NN O
therapy NN NN O
in NN NN O
patients NN NN O
with NN NN O
or NN NN O
without NN NN O
clear NN NN O
intraventricular NN NN O
conduction NN NN O
defects NN NN O
. NN NN O
   
Development NN NN O
of NN NN O
clear NN NN B-Disease
cell NN NN I-Disease
adenocarcinoma NN NN I-Disease
in NN NN O
DES NN NN O
- NN NN O
exposed NN NN O
offspring NN NN O
under NN NN O
observation NN NN O
. NN NN O
   
Two NN NN O
cases NN NN O
of NN NN O
clear NN NN B-Disease
cell NN NN I-Disease
adenocarcinoma NN NN I-Disease
of NN NN I-Disease
the NN NN I-Disease
vagina NN NN I-Disease
detected NN NN O
at NN NN O
follow NN NN O
- NN NN O
up NN NN O
in NN NN O
young NN NN O
women NN NN O
exposed NN NN O
in NN NN O
utero NN NN O
to NN NN O
diethylstilbestrol NN NN O
are NN NN O
reported NN NN O
. NN NN O
   
One NN NN O
patient NN NN O
, NN NN O
aged NN NN O
23 NN NN O
, NN NN O
had NN NN O
been NN NN O
followed NN NN O
for NN NN O
2 NN NN O
years NN NN O
before NN NN O
carcinoma NN NN B-Disease
was NN NN O
diagnosed NN NN O
; NN NN O
the NN NN O
second NN NN O
patient NN NN O
, NN NN O
aged NN NN O
22 NN NN O
, NN NN O
had NN NN O
been NN NN O
seen NN NN O
on NN NN O
a NN NN O
regular NN NN O
basis NN NN O
for NN NN O
5 NN NN O
years NN NN O
, NN NN O
8 NN NN O
months NN NN O
. NN NN O
   
In NN NN O
both NN NN O
instances NN NN O
, NN NN O
suspicion NN NN O
of NN NN O
the NN NN O
presence NN NN O
of NN NN O
carcinoma NN NN B-Disease
was NN NN O
aroused NN NN O
by NN NN O
the NN NN O
palpation NN NN O
of NN NN O
a NN NN O
small NN NN O
nodule NN NN O
in NN NN O
the NN NN O
vaginal NN NN O
fornix NN NN O
. NN NN O
   
Hysterosalpingography NN NN O
was NN NN O
performed NN NN O
on NN NN O
both NN NN O
patients NN NN O
and NN NN O
, NN NN O
in NN NN O
1 NN NN O
instance NN NN O
, NN NN O
an NN NN O
abnormal NN NN O
x NN NN O
- NN NN O
ray NN NN O
film NN NN O
was NN NN O
reflected NN NN O
by NN NN O
the NN NN O
gross NN NN O
appearance NN NN O
of NN NN O
the NN NN O
uterine NN NN O
cavity NN NN O
found NN NN O
in NN NN O
the NN NN O
surgical NN NN O
specimen NN NN O
. NN NN O
   
Neurologic NN NN O
effects NN NN O
of NN NN O
subarachnoid NN NN O
administration NN NN O
of NN NN O
2 NN NN O
- NN NN O
chloroprocaine NN NN O
- NN NN O
CE NN NN O
, NN NN O
bupivacaine NN NN O
, NN NN O
and NN NN O
low NN NN O
pH NN NN O
normal NN NN O
saline NN NN O
in NN NN O
dogs NN NN O
. NN NN O
   
The NN NN O
purpose NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
evaluate NN NN O
the NN NN O
neurologic NN NN O
consequences NN NN O
of NN NN O
deliberate NN NN O
subarachnoid NN NN O
injection NN NN O
of NN NN O
large NN NN O
volumes NN NN O
of NN NN O
2 NN NN O
- NN NN O
chloroprocaine NN NN O
- NN NN O
CE NN NN O
in NN NN O
experimental NN NN O
animals NN NN O
. NN NN O
   
The NN NN O
possible NN NN O
role NN NN O
of NN NN O
low NN NN O
pH NN NN O
as NN NN O
well NN NN O
as NN NN O
total NN NN O
volume NN NN O
as NN NN O
potential NN NN O
factors NN NN O
in NN NN O
causing NN NN O
neurotoxicity NN NN B-Disease
was NN NN O
evaluated NN NN O
. NN NN O
   
The NN NN O
65 NN NN O
dogs NN NN O
in NN NN O
the NN NN O
study NN NN O
received NN NN O
injections NN NN O
in NN NN O
the NN NN O
subarachnoid NN NN O
space NN NN O
as NN NN O
follows NN NN O
: NN NN O
6 NN NN O
to NN NN O
8 NN NN O
ml NN NN O
of NN NN O
bupivacaine NN NN O
( NN NN O
N NN NN O
= NN NN O
15 NN NN O
) NN NN O
, NN NN O
2 NN NN O
- NN NN O
chloroprocaine NN NN O
- NN NN O
CE NN NN O
( NN NN O
N NN NN O
= NN NN O
20 NN NN O
) NN NN O
, NN NN O
low NN NN O
pH NN NN O
normal NN NN O
saline NN NN O
( NN NN O
pH NN NN O
3 NN NN O
. NN NN O
0 NN NN O
) NN NN O
( NN NN O
N NN NN O
= NN NN O
20 NN NN O
) NN NN O
, NN NN O
or NN NN O
normal NN NN O
saline NN NN O
( NN NN O
N NN NN O
= NN NN O
10 NN NN O
) NN NN O
. NN NN O
   
Of NN NN O
the NN NN O
20 NN NN O
animals NN NN O
that NN NN O
received NN NN O
subarachnoid NN NN O
injection NN NN O
of NN NN O
2 NN NN O
- NN NN O
chloroprocaine NN NN O
- NN NN O
CE NN NN O
seven NN NN O
( NN NN O
35 NN NN O
% NN NN O
) NN NN O
developed NN NN O
hind NN NN O
- NN NN O
limb NN NN O
paralysis NN NN B-Disease
. NN NN O
   
   O
of NN NN O
the NN NN O
animals NN NN O
that NN NN O
received NN NN O
bupivacaine NN NN O
, NN NN O
normal NN NN O
saline NN NN O
, NN NN O
or NN NN O
normal NN NN O
saline NN NN O
titrated NN NN O
to NN NN O
a NN NN O
pH NN NN O
3 NN NN O
. NN NN O
0 NN NN O
developed NN NN O
hind NN NN O
- NN NN O
limb NN NN O
paralysis NN NN B-Disease
. NN NN O
   
Of NN NN O
the NN NN O
15 NN NN O
spinal NN NN O
cords NN NN O
of NN NN O
the NN NN O
animals NN NN O
that NN NN O
received NN NN O
2 NN NN O
- NN NN O
chloroprocaine NN NN O
- NN NN O
CE NN NN O
, NN NN O
13 NN NN O
showed NN NN O
subpial NN NN B-Disease
necrosis NN NN I-Disease
; NN NN O
the NN NN O
nerve NN NN O
roots NN NN O
and NN NN O
subarachnoid NN NN O
vessels NN NN O
were NN NN O
normal NN NN O
. NN NN O
   
The NN NN O
spinal NN NN O
cords NN NN O
of NN NN O
the NN NN O
animals NN NN O
that NN NN O
received NN NN O
bupivacaine NN NN O
, NN NN O
low NN NN O
pH NN NN O
normal NN NN O
saline NN NN O
( NN NN O
pH NN NN O
3 NN NN O
. NN NN O
0 NN NN O
) NN NN O
, NN NN O
or NN NN O
normal NN NN O
saline NN NN O
did NN NN O
not NN NN O
show NN NN O
abnormal NN NN O
findings NN NN O
. NN NN O
   
Procainamide NN NN O
- NN NN O
induced NN NN O
polymorphous NN NN O
ventricular NN NN B-Disease
tachycardia NN NN I-Disease
. NN NN O
   
Seven NN NN O
cases NN NN O
of NN NN O
procainamide NN NN O
- NN NN O
induced NN NN O
polymorphous NN NN O
ventricular NN NN B-Disease
tachycardia NN NN I-Disease
are NN NN O
presented NN NN O
. NN NN O
   
In NN NN O
four NN NN O
patients NN NN O
, NN NN O
polymorphous NN NN O
ventricular NN NN B-Disease
tachycardia NN NN I-Disease
appeared NN NN O
after NN NN O
intravenous NN NN O
administration NN NN O
of NN NN O
200 NN NN O
to NN NN O
400 NN NN O
mg NN NN O
of NN NN O
procainamide NN NN O
for NN NN O
the NN NN O
treatment NN NN O
of NN NN O
sustained NN NN O
ventricular NN NN B-Disease
tachycardia NN NN I-Disease
. NN NN O
   
In NN NN O
the NN NN O
remaining NN NN O
three NN NN O
patients NN NN O
, NN NN O
procainamide NN NN O
was NN NN O
administered NN NN O
orally NN NN O
for NN NN O
treatment NN NN O
of NN NN O
chronic NN NN O
premature NN NN B-Disease
ventricular NN NN I-Disease
contractions NN NN I-Disease
or NN NN O
atrial NN NN B-Disease
flutter NN NN I-Disease
. NN NN O
   
These NN NN O
patients NN NN O
had NN NN O
Q NN NN B-Disease
- NN NN I-Disease
T NN NN I-Disease
prolongation NN NN I-Disease
and NN NN O
recurrent NN NN O
syncope NN NN B-Disease
due NN NN O
to NN NN O
polymorphous NN NN O
ventricular NN NN B-Disease
tachycardia NN NN I-Disease
. NN NN O
   
In NN NN O
four NN NN O
patients NN NN O
, NN NN O
the NN NN O
arrhythmia NN NN B-Disease
was NN NN O
rapidly NN NN O
diagnosed NN NN O
and NN NN O
treated NN NN O
with NN NN O
disappearance NN NN O
of NN NN O
further NN NN O
episodes NN NN O
of NN NN O
the NN NN O
arrhythmia NN NN B-Disease
. NN NN O
   
In NN NN O
two NN NN O
patients NN NN O
, NN NN O
the NN NN O
arrhythmia NN NN B-Disease
degenerated NN NN O
into NN NN O
irreversible NN NN O
ventricular NN NN B-Disease
fibrillation NN NN I-Disease
and NN NN O
both NN NN O
patients NN NN O
died NN NN O
. NN NN O
   
In NN NN O
the NN NN O
seventh NN NN O
patient NN NN O
, NN NN O
a NN NN O
permanent NN NN O
ventricular NN NN O
pacemaker NN NN O
was NN NN O
inserted NN NN O
and NN NN O
, NN NN O
despite NN NN O
continuation NN NN O
of NN NN O
procainamide NN NN O
therapy NN NN O
, NN NN O
polymorphous NN NN O
ventricular NN NN B-Disease
tachycardia NN NN I-Disease
did NN NN O
not NN NN O
reoccur NN NN O
. NN NN O
   
These NN NN O
seven NN NN O
cases NN NN O
demonstrate NN NN O
that NN NN O
procainamide NN NN O
can NN NN O
produce NN NN O
an NN NN O
acquired NN NN O
prolonged NN NN B-Disease
Q NN NN I-Disease
- NN NN I-Disease
T NN NN I-Disease
syndrome NN NN I-Disease
with NN NN O
polymorphous NN NN O
ventricular NN NN B-Disease
tachycardia NN NN I-Disease
. NN NN O
   
Phenobarbitone NN NN O
- NN NN O
induced NN NN O
enlargement NN NN B-Disease
of NN NN I-Disease
the NN NN I-Disease
liver NN NN I-Disease
in NN NN O
the NN NN O
rat NN NN O
: NN NN O
its NN NN O
relationship NN NN O
to NN NN O
carbon NN NN O
tetrachloride NN NN O
- NN NN O
induced NN NN O
cirrhosis NN NN B-Disease
. NN NN O
   
The NN NN O
yield NN NN O
of NN NN O
severe NN NN O
cirrhosis NN NN B-Disease
of NN NN I-Disease
the NN NN I-Disease
liver NN NN I-Disease
( NN NN O
defined NN NN O
as NN NN O
a NN NN O
shrunken NN NN O
finely NN NN O
nodular NN NN O
liver NN NN O
with NN NN O
micronodular NN NN O
histology NN NN O
, NN NN O
ascites NN NN B-Disease
greater NN NN O
than NN NN O
30 NN NN O
ml NN NN O
, NN NN O
plasma NN NN O
albumin NN NN O
less NN NN O
than NN NN O
2 NN NN O
. NN NN O
2 NN NN O
g NN NN O
/ NN NN O
dl NN NN O
, NN NN O
splenomegaly NN NN B-Disease
2 NN NN O
- NN NN O
3 NN NN O
times NN NN O
normal NN NN O
, NN NN O
and NN NN O
testicular NN NN O
atrophy NN NN B-Disease
approximately NN NN O
half NN NN O
normal NN NN O
weight NN NN O
) NN NN O
after NN NN O
12 NN NN O
doses NN NN O
of NN NN O
carbon NN NN O
tetrachloride NN NN O
given NN NN O
intragastrically NN NN O
in NN NN O
the NN NN O
phenobarbitone NN NN O
- NN NN O
primed NN NN O
rat NN NN O
was NN NN O
increased NN NN O
from NN NN O
25 NN NN O
% NN NN O
to NN NN O
56 NN NN O
% NN NN O
by NN NN O
giving NN NN O
the NN NN O
initial NN NN O
"""""""" NN NN O
calibrating NN NN O
"""""""" NN NN O
dose NN NN O
of NN NN O
carbon NN NN O
tetrachloride NN NN O
at NN NN O
the NN NN O
peak NN NN O
of NN NN O
the NN NN O
phenobarbitone NN NN O
- NN NN O
induced NN NN O
enlargement NN NN B-Disease
of NN NN I-Disease
the NN NN I-Disease
liver NN NN I-Disease
. NN NN O
   
At NN NN O
this NN NN O
point NN NN O
it NN NN O
was NN NN O
assumed NN NN O
that NN NN O
the NN NN O
cytochrome NN NN O
P450 NN NN O
/ NN NN O
CCl4 NN NN O
toxic NN NN O
state NN NN O
was NN NN O
both NN NN O
maximal NN NN O
and NN NN O
stable NN NN O
. NN NN O
   
The NN NN O
optimal NN NN O
rat NN NN O
size NN NN O
to NN NN O
begin NN NN O
phenobarbitone NN NN O
was NN NN O
determined NN NN O
as NN NN O
100 NN NN O
g NN NN O
, NN NN O
and NN NN O
this NN NN O
size NN NN O
as NN NN O
a NN NN O
group NN NN O
had NN NN O
a NN NN O
mean NN NN O
maximum NN NN O
relative NN NN O
liver NN NN O
weight NN NN O
increase NN NN O
47 NN NN O
% NN NN O
greater NN NN O
than NN NN O
normal NN NN O
rats NN NN O
of NN NN O
the NN NN O
same NN NN O
body NN NN O
weight NN NN O
. NN NN O
   
The NN NN O
optimal NN NN O
time NN NN O
for NN NN O
the NN NN O
initial NN NN O
dose NN NN O
of NN NN O
carbon NN NN O
tetrachloride NN NN O
was NN NN O
after NN NN O
14 NN NN O
days NN NN O
on NN NN O
phenobarbitone NN NN O
. NN NN O
   
Triamterene NN NN O
nephrolithiasis NN NN B-Disease
complicating NN NN O
dyazide NN NN O
therapy NN NN O
. NN NN O
   
A NN NN O
case NN NN O
of NN NN O
triamterene NN NN O
nephrolithiasis NN NN B-Disease
is NN NN O
reported NN NN O
in NN NN O
a NN NN O
man NN NN O
after NN NN O
4 NN NN O
years NN NN O
of NN NN O
hydrochlorothiazide NN NN O
- NN NN O
triamterene NN NN O
therapy NN NN O
for NN NN O
hypertension NN NN B-Disease
. NN NN O
   
The NN NN O
stone NN NN O
passed NN NN O
spontaneously NN NN O
and NN NN O
was NN NN O
found NN NN O
to NN NN O
contain NN NN O
a NN NN O
triamterene NN NN O
metabolite NN NN O
admixed NN NN O
with NN NN O
uric NN NN O
acid NN NN O
salts NN NN O
. NN NN O
   
Factors NN NN O
affecting NN NN O
triamterene NN NN O
nephrolithiasis NN NN B-Disease
are NN NN O
discussed NN NN O
and NN NN O
2 NN NN O
previously NN NN O
reported NN NN O
cases NN NN O
are NN NN O
reviewed NN NN O
. NN NN O
   
Busulfan NN NN O
- NN NN O
induced NN NN O
hemorrhagic NN NN B-Disease
cystitis NN NN I-Disease
. NN NN O
   
A NN NN O
case NN NN O
of NN NN O
a NN NN O
busulfan NN NN O
- NN NN O
induced NN NN O
hemorrhage NN NN B-Disease
cystitis NN NN I-Disease
is NN NN O
reported NN NN O
. NN NN O
   
Spontaneous NN NN O
resolution NN NN O
occurred NN NN O
following NN NN O
cessation NN NN O
of NN NN O
the NN NN O
drug NN NN O
. NN NN O
   
The NN NN O
similarity NN NN O
between NN NN O
the NN NN O
histologic NN NN O
appearances NN NN O
of NN NN O
busulfan NN NN O
cystitis NN NN B-Disease
and NN NN O
both NN NN O
radiation NN NN O
and NN NN O
cyclophosphamide NN NN O
- NN NN O
induced NN NN O
cystitis NN NN B-Disease
is NN NN O
discussed NN NN O
and NN NN O
the NN NN O
world NN NN O
literature NN NN O
reviewed NN NN O
. NN NN O
   
In NN NN O
view NN NN O
of NN NN O
the NN NN O
known NN NN O
tendency NN NN O
of NN NN O
busulfan NN NN O
to NN NN O
induce NN NN O
cellular NN NN O
atypia NN NN O
and NN NN O
carcinoma NN NN B-Disease
in NN NN O
other NN NN O
sites NN NN O
, NN NN O
periodic NN NN O
urinary NN NN O
cytology NN NN O
is NN NN O
suggested NN NN O
in NN NN O
patients NN NN O
on NN NN O
long NN NN O
- NN NN O
term NN NN O
therapy NN NN O
. NN NN O
   
Variant NN NN O
ventricular NN NN B-Disease
tachycardia NN NN I-Disease
in NN NN O
desipramine NN NN O
toxicity NN NN B-Disease
. NN NN O
   
We NN NN O
report NN NN O
a NN NN O
case NN NN O
of NN NN O
variant NN NN O
ventricular NN NN B-Disease
tachycardia NN NN I-Disease
induced NN NN O
by NN NN O
desipramine NN NN O
toxicity NN NN B-Disease
. NN NN O
   
Unusual NN NN O
features NN NN O
of NN NN O
the NN NN O
arrhythmia NN NN B-Disease
are NN NN O
repetitive NN NN O
group NN NN O
beating NN NN O
, NN NN O
progressive NN NN O
shortening NN NN O
of NN NN O
the NN NN O
R NN NN O
- NN NN O
R NN NN O
interval NN NN O
, NN NN O
progressive NN NN O
widening NN NN O
of NN NN O
the NN NN O
QRS NN NN O
complex NN NN O
with NN NN O
eventual NN NN O
failure NN NN O
of NN NN O
intraventricular NN NN O
conduction NN NN O
, NN NN O
and NN NN O
changes NN NN O
in NN NN O
direction NN NN O
of NN NN O
the NN NN O
QRS NN NN O
axis NN NN O
. NN NN O
   
Recognition NN NN O
of NN NN O
variant NN NN O
ventricular NN NN B-Disease
tachycardia NN NN I-Disease
is NN NN O
important NN NN O
because NN NN O
therapy NN NN O
differs NN NN O
from NN NN O
that NN NN O
of NN NN O
classic NN NN O
ventricular NN NN B-Disease
tachycardia NN NN I-Disease
. NN NN O
   
Rebound NN NN O
hypertensive NN NN B-Disease
after NN NN O
sodium NN NN O
nitroprusside NN NN O
prevented NN NN O
by NN NN O
saralasin NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
The NN NN O
role NN NN O
of NN NN O
the NN NN O
renin NN NN O
- NN NN O
- NN NN O
angiotensin NN NN O
system NN NN O
in NN NN O
the NN NN O
maintenance NN NN O
of NN NN O
blood NN NN O
pressure NN NN O
during NN NN O
halothane NN NN O
anesthesia NN NN O
and NN NN O
sodium NN NN O
nitroprusside NN NN O
( NN NN O
SNP NN NN O
) NN NN O
- NN NN O
induced NN NN O
hypotension NN NN B-Disease
was NN NN O
evaluated NN NN O
. NN NN O
   
Control NN NN O
rats NN NN O
received NN NN O
halothane NN NN O
anesthesia NN NN O
( NN NN O
1 NN NN O
MAC NN NN O
) NN NN O
for NN NN O
one NN NN O
hour NN NN O
, NN NN O
followed NN NN O
by NN NN O
SNP NN NN O
infusion NN NN O
, NN NN O
40 NN NN O
microgram NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
, NN NN O
for NN NN O
30 NN NN O
min NN NN O
, NN NN O
followed NN NN O
by NN NN O
a NN NN O
30 NN NN O
- NN NN O
min NN NN O
recovery NN NN O
period NN NN O
. NN NN O
   
A NN NN O
second NN NN O
group NN NN O
of NN NN O
rats NN NN O
was NN NN O
treated NN NN O
identically NN NN O
and NN NN O
, NN NN O
in NN NN O
addition NN NN O
, NN NN O
received NN NN O
an NN NN O
infusion NN NN O
of NN NN O
saralasin NN NN O
( NN NN O
a NN NN O
competitive NN NN O
inhibitor NN NN O
of NN NN O
angiotensin NN NN O
II NN NN O
) NN NN O
throughout NN NN O
the NN NN O
experimental NN NN O
period NN NN O
. NN NN O
   
In NN NN O
each NN NN O
group NN NN O
, NN NN O
SNP NN NN O
infusion NN NN O
resulted NN NN O
in NN NN O
an NN NN O
initial NN NN O
decrease NN NN O
in NN NN O
blood NN NN O
pressure NN NN O
from NN NN O
86 NN NN O
torr NN NN O
and NN NN O
83 NN NN O
torr NN NN O
, NN NN O
respectively NN NN O
, NN NN O
to NN NN O
48 NN NN O
torr NN NN O
. NN NN O
   
During NN NN O
the NN NN O
SNP NN NN O
infusion NN NN O
the NN NN O
control NN NN O
animals NN NN O
demonstrated NN NN O
a NN NN O
progressive NN NN O
increase NN NN B-Disease
in NN NN I-Disease
blood NN NN I-Disease
pressure NN NN I-Disease
to NN NN O
61 NN NN O
torr NN NN O
, NN NN O
whereas NN NN O
the NN NN O
saralasin NN NN O
- NN NN O
treated NN NN O
animals NN NN O
showed NN NN O
no NN NN O
change NN NN O
. NN NN O
   
Following NN NN O
discontinuation NN NN O
of NN NN O
SNP NN NN O
, NN NN O
blood NN NN O
pressure NN NN O
in NN NN O
the NN NN O
control NN NN O
animals NN NN O
rebounded NN NN O
to NN NN O
94 NN NN O
torr NN NN O
, NN NN O
as NN NN O
compared NN NN O
with NN NN O
78 NN NN O
torr NN NN O
in NN NN O
the NN NN O
saralasin NN NN O
- NN NN O
treated NN NN O
rats NN NN O
. NN NN O
   
This NN NN O
study NN NN O
indicates NN NN O
that NN NN O
with NN NN O
stable NN NN O
halothane NN NN O
anesthesia NN NN O
, NN NN O
the NN NN O
partial NN NN O
recovery NN NN O
of NN NN O
blood NN NN O
pressure NN NN O
during NN NN O
SNP NN NN O
infusion NN NN O
and NN NN O
the NN NN O
post NN NN O
- NN NN O
SNP NN NN O
rebound NN NN O
of NN NN O
blood NN NN O
pressure NN NN O
can NN NN O
be NN NN O
completely NN NN O
blocked NN NN O
by NN NN O
saralasin NN NN O
. NN NN O
   
This NN NN O
demonstrates NN NN O
the NN NN O
participation NN NN O
of NN NN O
the NN NN O
renin NN NN O
- NN NN O
- NN NN O
angiotensin NN NN O
system NN NN O
in NN NN O
antagonizing NN NN O
the NN NN O
combined NN NN O
hypotensive NN NN B-Disease
effects NN NN O
of NN NN O
halothane NN NN O
and NN NN O
SNP NN NN O
. NN NN O
   
Clinical NN NN O
nephrotoxicity NN NN B-Disease
of NN NN O
tobramycin NN NN O
and NN NN O
gentamicin NN NN O
. NN NN O
   
A NN NN O
prospective NN NN O
study NN NN O
. NN NN O
   
Nearly NN NN O
3 NN NN O
. NN NN O
2 NN NN O
million NN NN O
people NN NN O
in NN NN O
this NN NN O
country NN NN O
receive NN NN O
aminoglycoside NN NN O
antibiotics NN NN O
annually NN NN O
. NN NN O
   
Gentamicin NN NN O
sulfate NN NN O
and NN NN O
tobramycin NN NN O
sulfate NN NN O
continue NN NN O
to NN NN O
demonstrate NN NN O
ototoxicity NN NN B-Disease
and NN NN O
nephrotoxicity NN NN B-Disease
in NN NN O
both NN NN O
animal NN NN O
and NN NN O
clinical NN NN O
studies NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
62 NN NN O
patients NN NN O
with NN NN O
confirmed NN NN O
initial NN NN O
normal NN NN O
renal NN NN O
function NN NN O
and NN NN O
treated NN NN O
with NN NN O
2 NN NN O
to NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
of NN NN O
gentamicin NN NN O
sulfate NN NN O
or NN NN O
tobramycin NN NN O
sulfate NN NN O
for NN NN O
a NN NN O
minimum NN NN O
of NN NN O
seven NN NN O
days NN NN O
were NN NN O
followed NN NN O
up NN NN O
prospectively NN NN O
for NN NN O
the NN NN O
development NN NN O
of NN NN O
aminoglycoside NN NN O
- NN NN O
related NN NN O
renal NN NN B-Disease
failure NN NN I-Disease
, NN NN O
defined NN NN O
as NN NN O
at NN NN O
least NN NN O
a NN NN O
one NN NN O
- NN NN O
third NN NN O
reduction NN NN O
in NN NN O
renal NN NN O
function NN NN O
. NN NN O
   
In NN NN O
these NN NN O
62 NN NN O
patients NN NN O
, NN NN O
no NN NN O
other NN NN O
causes NN NN O
for NN NN O
renal NN NN B-Disease
failure NN NN I-Disease
could NN NN O
be NN NN O
identified NN NN O
. NN NN O
   
Five NN NN O
of NN NN O
33 NN NN O
( NN NN O
15 NN NN O
% NN NN O
) NN NN O
of NN NN O
the NN NN O
tobramycin NN NN O
- NN NN O
treated NN NN O
patients NN NN O
and NN NN O
16 NN NN O
of NN NN O
29 NN NN O
( NN NN O
55 NN NN O
. NN NN O
2 NN NN O
% NN NN O
) NN NN O
of NN NN O
the NN NN O
gentamicin NN NN O
- NN NN O
treated NN NN O
patients NN NN O
had NN NN O
renal NN NN B-Disease
failure NN NN I-Disease
. NN NN O
   
Thus NN NN O
, NN NN O
gentamicin NN NN O
was NN NN O
associated NN NN O
with NN NN O
renal NN NN B-Disease
failure NN NN I-Disease
more NN NN O
than NN NN O
three NN NN O
times NN NN O
as NN NN O
often NN NN O
as NN NN O
was NN NN O
tobramycin NN NN O
. NN NN O
   
Metabolic NN NN O
involvement NN NN O
in NN NN O
adriamycin NN NN O
cardiotoxicity NN NN B-Disease
. NN NN O
   
The NN NN O
cardiotoxic NN NN B-Disease
effects NN NN O
of NN NN O
adriamycin NN NN O
were NN NN O
studied NN NN O
in NN NN O
mammalian NN NN O
myocardial NN NN O
cells NN NN O
in NN NN O
culture NN NN O
as NN NN O
a NN NN O
model NN NN O
system NN NN O
. NN NN O
   
Adriamycin NN NN O
inhibited NN NN O
cell NN NN O
growth NN NN O
and NN NN O
the NN NN O
rhythmic NN NN O
contractions NN NN O
characteristic NN NN O
of NN NN O
myocardial NN NN O
cells NN NN O
in NN NN O
culture NN NN O
. NN NN O
   
A NN NN O
possible NN NN O
involvement NN NN O
of NN NN O
energy NN NN O
metabolism NN NN O
was NN NN O
suggested NN NN O
previously NN NN O
, NN NN O
and NN NN O
in NN NN O
this NN NN O
study NN NN O
the NN NN O
adenylate NN NN O
energy NN NN O
charge NN NN O
and NN NN O
phosphorylcreatine NN NN O
mole NN NN O
fraction NN NN O
were NN NN O
determined NN NN O
in NN NN O
the NN NN O
adriamycin NN NN O
- NN NN O
treated NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
adenylate NN NN O
energy NN NN O
charge NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
significantly NN NN O
decreased NN NN O
, NN NN O
while NN NN O
the NN NN O
phophorylcreatine NN NN O
mole NN NN O
fraction NN NN O
was NN NN O
unchanged NN NN O
. NN NN O
   
Such NN NN O
disparity NN NN O
suggests NN NN O
an NN NN O
inhibition NN NN O
of NN NN O
creatine NN NN O
phosphokinase NN NN O
. NN NN O
   
The NN NN O
addition NN NN O
of NN NN O
1 NN NN O
mM NN NN O
adenosine NN NN O
to NN NN O
the NN NN O
myocardial NN NN O
cell NN NN O
cultures NN NN O
markedly NN NN O
increases NN NN O
the NN NN O
ATP NN NN O
concentration NN NN O
through NN NN O
a NN NN O
pathway NN NN O
reportedly NN NN O
leading NN NN O
to NN NN O
a NN NN O
compartmentalized NN NN O
ATP NN NN O
pool NN NN O
. NN NN O
   
In NN NN O
the NN NN O
adriamycin NN NN O
- NN NN O
treated NN NN O
cells NN NN O
, NN NN O
the NN NN O
addition NN NN O
of NN NN O
adenosine NN NN O
increased NN NN O
the NN NN O
adenylate NN NN O
charge NN NN O
and NN NN O
, NN NN O
concomitant NN NN O
with NN NN O
this NN NN O
inrcease NN NN O
, NN NN O
the NN NN O
cells NN NN O
' NN NN O
functional NN NN O
integrity NN NN O
, NN NN O
in NN NN O
terms NN NN O
of NN NN O
percentage NN NN O
of NN NN O
beating NN NN O
cells NN NN O
and NN NN O
rate NN NN O
of NN NN O
contractions NN NN O
, NN NN O
was NN NN O
maintained NN NN O
. NN NN O
   
Age NN NN O
- NN NN O
dependent NN NN O
sensitivity NN NN O
of NN NN O
the NN NN O
rat NN NN O
to NN NN O
neurotoxic NN NN B-Disease
effects NN NN O
of NN NN O
streptomycin NN NN O
. NN NN O
   
Streptomycin NN NN O
sulfate NN NN O
( NN NN O
300 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
s NN NN O
. NN NN O
c NN NN O
. NN NN O
) NN NN O
was NN NN O
injected NN NN O
for NN NN O
various NN NN O
periods NN NN O
into NN NN O
preweanling NN NN O
rats NN NN O
and NN NN O
for NN NN O
3 NN NN O
weeks NN NN O
into NN NN O
weanling NN NN O
rats NN NN O
. NN NN O
   
Beginning NN NN O
at NN NN O
8 NN NN O
days NN NN O
of NN NN O
age NN NN O
, NN NN O
body NN NN O
movement NN NN O
and NN NN O
hearing NN NN O
were NN NN O
examined NN NN O
for NN NN O
6 NN NN O
and NN NN O
up NN NN O
to NN NN O
17 NN NN O
weeks NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
Abnormal NN NN B-Disease
movements NN NN I-Disease
and NN NN O
deafness NN NN B-Disease
occurred NN NN O
only NN NN O
in NN NN O
rats NN NN O
treated NN NN O
during NN NN O
the NN NN O
preweaning NN NN O
period NN NN O
; NN NN O
within NN NN O
this NN NN O
period NN NN O
the NN NN O
greatest NN NN O
sensitivities NN NN O
for NN NN O
these NN NN O
abnormalities NN NN O
occurred NN NN O
from NN NN O
2 NN NN O
to NN NN O
11 NN NN O
- NN NN O
17 NN NN O
and NN NN O
5 NN NN O
to NN NN O
11 NN NN O
days NN NN O
of NN NN O
age NN NN O
, NN NN O
respectively NN NN O
, NN NN O
indicating NN NN O
that NN NN O
the NN NN O
cochlea NN NN O
is NN NN O
more NN NN O
sensitive NN NN O
to NN NN O
streptomycin NN NN O
than NN NN O
the NN NN O
site NN NN O
( NN NN O
vestibular NN NN O
or NN NN O
central NN NN O
) NN NN O
responsible NN NN O
for NN NN O
the NN NN O
dyskinesias NN NN B-Disease
. NN NN O
   
Late NN NN O
, NN NN O
late NN NN O
doxorubicin NN NN O
cardiotoxicity NN NN B-Disease
. NN NN O
   
Cardiac NN NN B-Disease
toxicity NN NN I-Disease
is NN NN O
a NN NN O
major NN NN O
complication NN NN O
which NN NN O
limits NN NN O
the NN NN O
use NN NN O
of NN NN O
adriamycin NN NN O
as NN NN O
a NN NN O
chemotherapeutic NN NN O
agent NN NN O
. NN NN O
   
Cardiomyopathy NN NN B-Disease
is NN NN O
frequent NN NN O
when NN NN O
the NN NN O
total NN NN O
dose NN NN O
exceeds NN NN O
600 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
and NN NN O
occurs NN NN O
within NN NN O
one NN NN O
to NN NN O
six NN NN O
months NN NN O
after NN NN O
cessation NN NN O
of NN NN O
therapy NN NN O
. NN NN O
   
A NN NN O
patient NN NN O
is NN NN O
reported NN NN O
who NN NN O
developed NN NN O
progressive NN NN O
cardiomyopathy NN NN B-Disease
two NN NN O
and NN NN O
one NN NN O
- NN NN O
half NN NN O
years NN NN O
after NN NN O
receiving NN NN O
580 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
which NN NN O
apparently NN NN O
represents NN NN O
late NN NN O
, NN NN O
late NN NN O
cardiotoxicity NN NN B-Disease
. NN NN O
   
Attenuation NN NN O
of NN NN O
the NN NN O
lithium NN NN O
- NN NN O
induced NN NN O
diabetes NN NN B-Disease
- NN NN I-Disease
insipidus NN NN I-Disease
- NN NN I-Disease
like NN NN I-Disease
syndrome NN NN I-Disease
by NN NN O
amiloride NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
The NN NN O
effect NN NN O
of NN NN O
amiloride NN NN O
on NN NN O
lithium NN NN O
- NN NN O
induced NN NN O
polydipsia NN NN B-Disease
and NN NN O
polyuria NN NN B-Disease
and NN NN O
on NN NN O
the NN NN O
lithium NN NN O
concentration NN NN O
in NN NN O
the NN NN O
plasma NN NN O
, NN NN O
brain NN NN O
, NN NN O
kidney NN NN O
, NN NN O
thyroid NN NN O
and NN NN O
red NN NN O
blood NN NN O
cells NN NN O
was NN NN O
investigated NN NN O
in NN NN O
rats NN NN O
, NN NN O
chronically NN NN O
treated NN NN O
with NN NN O
LiCl NN NN O
. NN NN O
   
Amiloride NN NN O
reduced NN NN O
the NN NN O
drinking NN NN O
and NN NN O
urine NN NN O
volume NN NN O
of NN NN O
rats NN NN O
in NN NN O
an NN NN O
acute NN NN O
( NN NN O
6 NN NN O
or NN NN O
12 NN NN O
h NN NN O
) NN NN O
and NN NN O
a NN NN O
subacute NN NN O
( NN NN O
3 NN NN O
days NN NN O
) NN NN O
experiment NN NN O
. NN NN O
   
6 NN NN O
h NN NN O
after NN NN O
the NN NN O
administration NN NN O
of NN NN O
amiloride NN NN O
, NN NN O
a NN NN O
reduction NN NN O
was NN NN O
observed NN NN O
in NN NN O
the NN NN O
lithium NN NN O
content NN NN O
of NN NN O
the NN NN O
renal NN NN O
medulla NN NN O
but NN NN O
not NN NN O
in NN NN O
the NN NN O
other NN NN O
organs NN NN O
studied NN NN O
. NN NN O
   
At NN NN O
12 NN NN O
h NN NN O
, NN NN O
all NN NN O
the NN NN O
tissues NN NN O
showed NN NN O
a NN NN O
slight NN NN O
increase NN NN O
in NN NN O
lithium NN NN O
levels NN NN O
. NN NN O
   
After NN NN O
3 NN NN O
days NN NN O
of NN NN O
combined NN NN O
treatment NN NN O
, NN NN O
a NN NN O
marked NN NN O
elevation NN NN O
in NN NN O
plasma NN NN O
and NN NN O
tissue NN NN O
lithium NN NN O
levels NN NN O
accompanied NN NN O
a NN NN O
reduction NN NN O
in NN NN O
water NN NN O
intake NN NN O
. NN NN O
   
In NN NN O
all NN NN O
the NN NN O
experiments NN NN O
, NN NN O
the NN NN O
attenuation NN NN O
of NN NN O
the NN NN O
lithium NN NN O
- NN NN O
induced NN NN O
diabetes NN NN B-Disease
- NN NN I-Disease
insipidus NN NN I-Disease
- NN NN I-Disease
like NN NN I-Disease
syndrome NN NN I-Disease
by NN NN O
amiloride NN NN O
was NN NN O
accompanied NN NN O
by NN NN O
a NN NN O
reduction NN NN O
of NN NN O
the NN NN O
ratio NN NN O
between NN NN O
the NN NN O
lithium NN NN O
concentration NN NN O
in NN NN O
the NN NN O
renal NN NN O
medulla NN NN O
and NN NN O
its NN NN O
levels NN NN O
in NN NN O
the NN NN O
blood NN NN O
and NN NN O
an NN NN O
elevation NN NN O
in NN NN O
the NN NN O
plasma NN NN O
potassium NN NN O
level NN NN O
. NN NN O
   
It NN NN O
is NN NN O
concluded NN NN O
that NN NN O
acute NN NN O
amiloride NN NN O
administration NN NN O
to NN NN O
lithium NN NN O
- NN NN O
treated NN NN O
patients NN NN O
suffering NN NN O
from NN NN O
polydipsia NN NN B-Disease
and NN NN O
polyuria NN NN B-Disease
might NN NN O
relieve NN NN O
these NN NN O
patients NN NN O
but NN NN O
prolonged NN NN O
amiloride NN NN O
supplementation NN NN O
would NN NN O
result NN NN O
in NN NN O
elevated NN NN O
lithium NN NN O
levels NN NN O
and NN NN O
might NN NN O
be NN NN O
hazardous NN NN O
. NN NN O
   
Cardiovascular NN NN B-Disease
complications NN NN I-Disease
associated NN NN O
with NN NN O
terbutaline NN NN O
treatment NN NN O
for NN NN O
preterm NN NN B-Disease
labor NN NN I-Disease
. NN NN O
   
Severe NN NN O
cardiovascular NN NN B-Disease
complications NN NN I-Disease
occurred NN NN O
in NN NN O
eight NN NN O
of NN NN O
160 NN NN O
patients NN NN O
treated NN NN O
with NN NN O
terbutaline NN NN O
for NN NN O
preterm NN NN B-Disease
labor NN NN I-Disease
. NN NN O
   
Associated NN NN O
corticosteroid NN NN O
therapy NN NN O
and NN NN O
twin NN NN O
gestations NN NN O
appear NN NN O
to NN NN O
be NN NN O
predisposing NN NN O
factors NN NN O
. NN NN O
   
Potential NN NN O
mechanisms NN NN O
of NN NN O
the NN NN O
pathophysiology NN NN O
are NN NN O
briefly NN NN O
discussed NN NN O
. NN NN O
   
Toxic NN NN B-Disease
hepatitis NN NN I-Disease
induced NN NN O
by NN NN O
antithyroid NN NN O
drugs NN NN O
: NN NN O
four NN NN O
cases NN NN O
including NN NN O
one NN NN O
with NN NN O
cross NN NN O
- NN NN O
reactivity NN NN O
between NN NN O
carbimazole NN NN O
and NN NN O
benzylthiouracil NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
This NN NN O
study NN NN O
was NN NN O
conducted NN NN O
to NN NN O
assess NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
hepatic NN NN B-Disease
adverse NN NN I-Disease
effects NN NN I-Disease
encountered NN NN O
with NN NN O
antithyroid NN NN O
drugs NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Retrospective NN NN O
review NN NN O
of NN NN O
medical NN NN O
records NN NN O
of NN NN O
236 NN NN O
patients NN NN O
with NN NN O
hyperthyroidism NN NN B-Disease
admitted NN NN O
in NN NN O
our NN NN O
department NN NN O
( NN NN O
in NN NN O
- NN NN O
or NN NN O
out NN NN O
- NN NN O
patients NN NN O
) NN NN O
from NN NN O
1986 NN NN O
to NN NN O
1992 NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Four NN NN O
patients NN NN O
( NN NN O
1 NN NN O
. NN NN O
7 NN NN O
% NN NN O
) NN NN O
were NN NN O
identified NN NN O
with NN NN O
toxic NN NN B-Disease
hepatitis NN NN I-Disease
which NN NN O
could NN NN O
reasonably NN NN O
be NN NN O
attributed NN NN O
to NN NN O
the NN NN O
use NN NN O
of NN NN O
antithyroid NN NN O
agent NN NN O
. NN NN O
   
Two NN NN O
patients NN NN O
had NN NN O
a NN NN O
cholestatic NN NN B-Disease
hepatitis NN NN I-Disease
induced NN NN O
by NN NN O
carbimazole NN NN O
( NN NN O
N NN NN O
omercazole NN NN O
) NN NN O
. NN NN O
   
Two NN NN O
others NN NN O
had NN NN O
a NN NN O
mixed NN NN O
( NN NN O
cholestatic NN NN B-Disease
and NN NN O
cytolytic NN NN O
) NN NN O
hepatitis NN NN B-Disease
following NN NN O
carbimazole NN NN O
. NN NN O
   
One NN NN O
of NN NN O
the NN NN O
latter NN NN O
two NN NN O
patients NN NN O
further NN NN O
experienced NN NN O
a NN NN O
cytolytic NN NN O
hepatitis NN NN B-Disease
which NN NN O
appeared NN NN O
after NN NN O
Benzylthiouracil NN NN O
( NN NN O
Basd NN NN O
ne NN NN O
) NN NN O
had NN NN O
replaced NN NN O
carbimazole NN NN O
. NN NN O
   
Biological NN NN O
features NN NN O
of NN NN O
hepatitis NN NN B-Disease
disappeared NN NN O
in NN NN O
all NN NN O
cases NN NN O
after NN NN O
cessation NN NN O
of NN NN O
the NN NN O
incriminated NN NN O
drug NN NN O
, NN NN O
while NN NN O
biliary NN NN O
, NN NN O
viral NN NN O
and NN NN O
immunological NN NN O
searches NN NN O
were NN NN O
negative NN NN O
. NN NN O
   
Only NN NN O
2 NN NN O
patients NN NN O
of NN NN O
our NN NN O
retrospective NN NN O
study NN NN O
experienced NN NN O
a NN NN O
mild NN NN O
or NN NN O
severe NN NN O
neutropenia NN NN B-Disease
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Toxic NN NN B-Disease
hepatitis NN NN I-Disease
is NN NN O
a NN NN O
potential NN NN O
adverse NN NN O
effect NN NN O
of NN NN O
antithyroid NN NN O
drugs NN NN O
which NN NN O
warrants NN NN O
, NN NN O
as NN NN O
for NN NN O
haematological NN NN O
disturbances NN NN O
, NN NN O
a NN NN O
pre NN NN O
- NN NN O
therapeutic NN NN O
determination NN NN O
and NN NN O
a NN NN O
careful NN NN O
follow NN NN O
- NN NN O
up NN NN O
of NN NN O
relevant NN NN O
biological NN NN O
markers NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
hepatotoxicity NN NN B-Disease
may NN NN O
not NN NN O
be NN NN O
restricted NN NN O
to NN NN O
one NN NN O
class NN NN O
of NN NN O
antithyroid NN NN O
agents NN NN O
. NN NN O
   
Interactive NN NN O
effects NN NN O
of NN NN O
variations NN NN O
in NN NN O
[ NN NN O
Na NN NN O
] NN NN O
o NN NN O
and NN NN O
[ NN NN O
Ca NN NN O
] NN NN O
o NN NN O
on NN NN O
rat NN NN O
atrial NN NN O
spontaneous NN NN O
frequency NN NN O
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
varying NN NN O
the NN NN O
extracellular NN NN O
concentrations NN NN O
of NN NN O
Na NN NN O
and NN NN O
Ca NN NN O
( NN NN O
[ NN NN O
Na NN NN O
] NN NN O
o NN NN O
and NN NN O
[ NN NN O
Ca NN NN O
] NN NN O
o NN NN O
) NN NN O
on NN NN O
both NN NN O
, NN NN O
the NN NN O
spontaneous NN NN O
beating NN NN O
and NN NN O
the NN NN O
negative NN NN O
chronotropic NN NN O
action NN NN O
of NN NN O
verapamil NN NN O
, NN NN O
were NN NN O
studied NN NN O
in NN NN O
the NN NN O
isolated NN NN O
rat NN NN O
atria NN NN O
. NN NN O
   
Basal NN NN O
frequency NN NN O
( NN NN O
BF NN NN O
) NN NN O
evaluated NN NN O
by NN NN O
surface NN NN O
electrogram NN NN O
was NN NN O
223 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
4 NN NN O
beats NN NN O
/ NN NN O
min NN NN O
. NN NN O
in NN NN O
control NN NN O
Krebs NN NN O
- NN NN O
Ringer NN NN O
containing NN NN O
137 NN NN O
mM NN NN O
Na NN NN O
and NN NN O
1 NN NN O
. NN NN O
35 NN NN O
mM NN NN O
Ca NN NN O
( NN NN O
N NN NN O
) NN NN O
. NN NN O
   
It NN NN O
decreased NN NN O
by NN NN O
16 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
3 NN NN O
% NN NN O
by NN NN O
lowering NN NN O
[ NN NN O
Na NN NN O
] NN NN O
o NN NN O
to NN NN O
78 NN NN O
mM NN NN O
( NN NN O
LNa NN NN O
) NN NN O
, NN NN O
23 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
% NN NN O
by NN NN O
lowering NN NN O
simultaneously NN NN O
[ NN NN O
Na NN NN O
] NN NN O
o NN NN O
to NN NN O
78 NN NN O
mM NN NN O
and NN NN O
[ NN NN O
Ca NN NN O
] NN NN O
o NN NN O
to NN NN O
0 NN NN O
. NN NN O
675 NN NN O
mM NN NN O
( NN NN O
LNa NN NN O
+ NN NN O
LCa NN NN O
) NN NN O
and NN NN O
31 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
5 NN NN O
% NN NN O
by NN NN O
lowering NN NN O
[ NN NN O
Na NN NN O
] NN NN O
o NN NN O
to NN NN O
78 NN NN O
mM NN NN O
plus NN NN O
increasing NN NN O
[ NN NN O
Ca NN NN O
] NN NN O
o NN NN O
to NN NN O
3 NN NN O
. NN NN O
6 NN NN O
mM NN NN O
( NN NN O
LNa NN NN O
+ NN NN O
HCa NN NN O
) NN NN O
. NN NN O
   
At NN NN O
normal NN NN O
[ NN NN O
Na NN NN O
] NN NN O
o NN NN O
, NN NN O
decrease NN NN O
( NN NN O
0 NN NN O
. NN NN O
675 NN NN O
mM NN NN O
) NN NN O
or NN NN O
increase NN NN O
( NN NN O
3 NN NN O
. NN NN O
6 NN NN O
mM NN NN O
) NN NN O
of NN NN O
[ NN NN O
Ca NN NN O
] NN NN O
o NN NN O
did NN NN O
not NN NN O
modify NN NN O
BF NN NN O
; NN NN O
a NN NN O
reduction NN NN O
of NN NN O
ten NN NN O
times NN NN O
( NN NN O
0 NN NN O
. NN NN O
135 NN NN O
mM NN NN O
of NN NN O
normal NN NN O
[ NN NN O
Ca NN NN O
] NN NN O
o NN NN O
was NN NN O
effective NN NN O
to NN NN O
reduce NN NN O
BF NN NN O
by NN NN O
40 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
13 NN NN O
% NN NN O
. NN NN O
   
All NN NN O
negative NN NN O
chronotropic NN NN O
effects NN NN O
were NN NN O
BF NN NN O
- NN NN O
dependent NN NN O
. NN NN O
   
Dose NN NN O
- NN NN O
dependent NN NN O
bradycardia NN NN B-Disease
induced NN NN O
by NN NN O
verapamil NN NN O
was NN NN O
potentiated NN NN O
by NN NN O
LNa NN NN O
, NN NN O
LCa NN NN O
, NN NN O
and NN NN O
HCa NN NN O
. NN NN O
   
Independent NN NN O
but NN NN O
not NN NN O
additive NN NN O
effects NN NN O
of NN NN O
Na NN NN O
and NN NN O
Ca NN NN O
are NN NN O
shown NN NN O
by NN NN O
decreases NN NN O
in NN NN O
the NN NN O
values NN NN O
of NN NN O
[ NN NN O
verapamil NN NN O
] NN NN O
o NN NN O
needed NN NN O
to NN NN O
reduce NN NN O
BF NN NN O
by NN NN O
30 NN NN O
% NN NN O
( NN NN O
IC30 NN NN O
) NN NN O
with NN NN O
the NN NN O
following NN NN O
order NN NN O
of NN NN O
inhibitory NN NN O
potency NN NN O
: NN NN O
LNa NN NN O
> NN NN O
LCa NN NN O
> NN NN O
HCa NN NN O
> NN NN O
N NN NN O
, NN NN O
resulting NN NN O
LNa NN NN O
+ NN NN O
HCa NN NN O
similar NN NN O
to NN NN O
LNa NN NN O
. NN NN O
   
The NN NN O
[ NN NN O
verapamil NN NN O
] NN NN O
o NN NN O
that NN NN O
arrested NN NN O
atrial NN NN O
beating NN NN O
( NN NN O
AC NN NN O
) NN NN O
was NN NN O
also NN NN O
potentiated NN NN O
with NN NN O
the NN NN O
order NN NN O
LNa NN NN O
= NN NN O
LNa NN NN O
+ NN NN O
LCa NN NN O
= NN NN O
LNa NN NN O
+ NN NN O
HCa NN NN O
= NN NN O
LCa NN NN O
> NN NN O
HCa NN NN O
= NN NN O
N NN NN O
. NN NN O
   
The NN NN O
results NN NN O
indicate NN NN O
that NN NN O
rat NN NN O
atrial NN NN O
spontaneous NN NN O
beating NN NN O
is NN NN O
more NN NN O
dependent NN NN O
on NN NN O
[ NN NN O
Na NN NN O
] NN NN O
o NN NN O
than NN NN O
on NN NN O
[ NN NN O
Ca NN NN O
] NN NN O
o NN NN O
in NN NN O
a NN NN O
range NN NN O
of NN NN O
+ NN NN O
/ NN NN O
- NN NN O
50 NN NN O
% NN NN O
of NN NN O
their NN NN O
normal NN NN O
concentration NN NN O
. NN NN O
   
Also NN NN O
the NN NN O
enhancement NN NN O
of NN NN O
verapamil NN NN O
effects NN NN O
on NN NN O
atrial NN NN O
beating NN NN O
was NN NN O
more NN NN O
pronounced NN NN O
at NN NN O
LNa NN NN O
than NN NN O
at NN NN O
LCa NN NN O
. NN NN O
( NN NN O
ABSTRACT NN NN O
TRUNCATED NN NN O
AT NN NN O
250 NN NN O
WORDS NN NN O
) NN NN O
   
Pseudo NN NN O
- NN NN O
allergic NN NN B-Disease
reactions NN NN I-Disease
to NN NN O
corticosteroids NN NN O
: NN NN O
diagnosis NN NN O
and NN NN O
alternatives NN NN O
. NN NN O
   
Two NN NN O
patients NN NN O
treated NN NN O
with NN NN O
parenteral NN NN O
paramethasone NN NN O
( NN NN O
Triniol NN NN O
) NN NN O
and NN NN O
dexamethasone NN NN O
( NN NN O
Sedionbel NN NN O
) NN NN O
are NN NN O
described NN NN O
. NN NN O
   
A NN NN O
few NN NN O
minutes NN NN O
after NN NN O
administration NN NN O
of NN NN O
the NN NN O
drugs NN NN O
, NN NN O
they NN NN O
presented NN NN O
urticaria NN NN B-Disease
( NN NN O
patients NN NN O
1 NN NN O
and NN NN O
2 NN NN O
) NN NN O
and NN NN O
conjunctivitis NN NN B-Disease
( NN NN O
patient NN NN O
1 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
purpose NN NN O
of NN NN O
our NN NN O
study NN NN O
was NN NN O
to NN NN O
determine NN NN O
the NN NN O
cause NN NN O
of NN NN O
the NN NN O
patients NN NN O
' NN NN O
reactions NN NN O
, NN NN O
the NN NN O
immunological NN NN O
mechanisms NN NN O
involved NN NN O
and NN NN O
whether NN NN O
these NN NN O
patients NN NN O
would NN NN O
be NN NN O
able NN NN O
to NN NN O
tolerate NN NN O
any NN NN O
kind NN NN O
of NN NN O
corticoid NN NN O
. NN NN O
   
Clinical NN NN O
examinations NN NN O
and NN NN O
skin NN NN O
, NN NN O
oral NN NN O
and NN NN O
parenteral NN NN O
challenges NN NN O
with NN NN O
different NN NN O
corticosteroids NN NN O
and NN NN O
ELISA NN NN O
tests NN NN O
were NN NN O
performed NN NN O
. NN NN O
   
In NN NN O
the NN NN O
two NN NN O
patients NN NN O
, NN NN O
skin NN NN O
and NN NN O
ELISA NN NN O
tests NN NN O
with NN NN O
paramethasone NN NN O
were NN NN O
negative NN NN O
, NN NN O
as NN NN O
was NN NN O
the NN NN O
prick NN NN O
test NN NN O
with NN NN O
each NN NN O
of NN NN O
its NN NN O
excipients NN NN O
. NN NN O
   
A NN NN O
single NN NN O
- NN NN O
blind NN NN O
parenteral NN NN O
challenge NN NN O
with NN NN O
Triniol NN NN O
was NN NN O
positive NN NN O
in NN NN O
both NN NN O
patients NN NN O
after NN NN O
the NN NN O
administration NN NN O
of NN NN O
1 NN NN O
ml NN NN O
of NN NN O
the NN NN O
drug NN NN O
, NN NN O
and NN NN O
negative NN NN O
with NN NN O
its NN NN O
excipients NN NN O
. NN NN O
   
We NN NN O
also NN NN O
carried NN NN O
out NN NN O
oral NN NN O
and NN NN O
parenteral NN NN O
challenges NN NN O
with NN NN O
other NN NN O
corticosteroids NN NN O
and NN NN O
found NN NN O
intolerance NN NN O
to NN NN O
some NN NN O
of NN NN O
them NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
paramethasone NN NN O
caused NN NN O
pseudoallergic NN NN O
reactions NN NN O
in NN NN O
our NN NN O
patients NN NN O
. NN NN O
   
Corticosteroids NN NN O
different NN NN O
from NN NN O
paramethasone NN NN O
also NN NN O
produced NN NN O
hypersensitivity NN NN B-Disease
reactions NN NN O
in NN NN O
these NN NN O
patients NN NN O
; NN NN O
however NN NN O
, NN NN O
a NN NN O
few NN NN O
of NN NN O
them NN NN O
were NN NN O
tolerated NN NN O
. NN NN O
   
The NN NN O
basic NN NN O
mechanisms NN NN O
of NN NN O
those NN NN O
reactions NN NN O
are NN NN O
not NN NN O
yet NN NN O
fully NN NN O
understood NN NN O
. NN NN O
   
To NN NN O
our NN NN O
knowledge NN NN O
, NN NN O
this NN NN O
is NN NN O
the NN NN O
first NN NN O
report NN NN O
of NN NN O
a NN NN O
pseudo NN NN O
- NN NN O
allergy NN NN B-Disease
caused NN NN O
by NN NN O
paramethasone NN NN O
. NN NN O
   
Study NN NN O
of NN NN O
the NN NN O
role NN NN O
of NN NN O
vitamin NN NN O
B12 NN NN O
and NN NN O
folinic NN NN O
acid NN NN O
supplementation NN NN O
in NN NN O
preventing NN NN O
hematologic NN NN O
toxicity NN NN B-Disease
of NN NN O
zidovudine NN NN O
. NN NN O
   
A NN NN O
prospective NN NN O
, NN NN O
randomized NN NN O
study NN NN O
was NN NN O
conducted NN NN O
to NN NN O
evaluate NN NN O
the NN NN O
role NN NN O
of NN NN O
vitamin NN NN O
B12 NN NN O
and NN NN O
folinic NN NN O
acid NN NN O
supplementation NN NN O
in NN NN O
preventing NN NN O
zidovudine NN NN O
( NN NN O
ZDV NN NN O
) NN NN O
- NN NN O
induced NN NN O
bone NN NN B-Disease
marrow NN NN I-Disease
suppression NN NN I-Disease
. NN NN O
   
Seventy NN NN O
- NN NN O
five NN NN O
human NN NN B-Disease
immunodeficiency NN NN I-Disease
virus NN NN I-Disease
( NN NN I-Disease
HIV NN NN I-Disease
) NN NN I-Disease
- NN NN I-Disease
infected NN NN I-Disease
patients NN NN O
with NN NN O
CD4 NN NN O
+ NN NN O
cell NN NN O
counts NN NN O
< NN NN O
500 NN NN O
/ NN NN O
mm3 NN NN O
were NN NN O
randomized NN NN O
to NN NN O
receive NN NN O
either NN NN O
ZDV NN NN O
( NN NN O
500 NN NN O
mg NN NN O
daily NN NN O
) NN NN O
alone NN NN O
( NN NN O
group NN NN O
I NN NN O
, NN NN O
n NN NN O
= NN NN O
38 NN NN O
) NN NN O
or NN NN O
in NN NN O
combination NN NN O
with NN NN O
folinic NN NN O
acid NN NN O
( NN NN O
15 NN NN O
mg NN NN O
daily NN NN O
) NN NN O
and NN NN O
intramascular NN NN O
vitamin NN NN O
B12 NN NN O
( NN NN O
1000 NN NN O
micrograms NN NN O
monthly NN NN O
) NN NN O
( NN NN O
group NN NN O
II NN NN O
, NN NN O
n NN NN O
= NN NN O
37 NN NN O
) NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
15 NN NN O
patients NN NN O
were NN NN O
excluded NN NN O
from NN NN O
the NN NN O
study NN NN O
( NN NN O
noncompliance NN NN O
14 NN NN O
, NN NN O
death NN NN B-Disease
1 NN NN O
) NN NN O
; NN NN O
thus NN NN O
, NN NN O
60 NN NN O
patients NN NN O
( NN NN O
31 NN NN O
in NN NN O
group NN NN O
I NN NN O
and NN NN O
29 NN NN O
in NN NN O
group NN NN O
II NN NN O
) NN NN O
were NN NN O
eligible NN NN O
for NN NN O
analysis NN NN O
. NN NN O
   
No NN NN O
significant NN NN O
differences NN NN O
between NN NN O
groups NN NN O
were NN NN O
found NN NN O
at NN NN O
enrollment NN NN O
. NN NN O
   
During NN NN O
the NN NN O
study NN NN O
, NN NN O
vitamin NN NN O
B12 NN NN O
and NN NN O
folate NN NN O
levels NN NN O
were NN NN O
significantly NN NN O
higher NN NN O
in NN NN O
group NN NN O
II NN NN O
patients NN NN O
; NN NN O
however NN NN O
, NN NN O
no NN NN O
differences NN NN O
in NN NN O
hemoglobin NN NN O
, NN NN O
hematocrit NN NN O
, NN NN O
mean NN NN O
corpuscular NN NN O
volume NN NN O
, NN NN O
and NN NN O
white NN NN O
- NN NN O
cell NN NN O
, NN NN O
neutrophil NN NN O
and NN NN O
platelet NN NN O
counts NN NN O
were NN NN O
observed NN NN O
between NN NN O
groups NN NN O
at NN NN O
3 NN NN O
, NN NN O
6 NN NN O
, NN NN O
9 NN NN O
and NN NN O
12 NN NN O
months NN NN O
. NN NN O
   
Severe NN NN O
hematologic NN NN O
toxicity NN NN B-Disease
( NN NN O
neutrophil NN NN O
count NN NN O
< NN NN O
1000 NN NN O
/ NN NN O
mm3 NN NN O
and NN NN O
/ NN NN O
or NN NN O
hemoglobin NN NN O
< NN NN O
8 NN NN O
g NN NN O
/ NN NN O
dl NN NN O
) NN NN O
occurred NN NN O
in NN NN O
4 NN NN O
patients NN NN O
assigned NN NN O
to NN NN O
group NN NN O
I NN NN O
and NN NN O
7 NN NN O
assigned NN NN O
to NN NN O
group NN NN O
II NN NN O
. NN NN O
   
There NN NN O
was NN NN O
no NN NN O
correlation NN NN O
between NN NN O
vitamin NN NN O
B12 NN NN O
or NN NN O
folate NN NN O
levels NN NN O
and NN NN O
development NN NN O
of NN NN O
myelosuppression NN NN B-Disease
. NN NN O
   
Vitamin NN NN O
B12 NN NN O
and NN NN O
folinic NN NN O
acid NN NN O
supplementation NN NN O
of NN NN O
ZDV NN NN O
therapy NN NN O
does NN NN O
not NN NN O
seem NN NN O
useful NN NN O
in NN NN O
preventing NN NN O
or NN NN O
reducing NN NN O
ZDV NN NN O
- NN NN O
induced NN NN O
myelotoxicity NN NN B-Disease
in NN NN O
the NN NN O
overall NN NN O
treated NN NN O
population NN NN O
, NN NN O
although NN NN O
a NN NN O
beneficial NN NN O
effect NN NN O
in NN NN O
certain NN NN O
subgroups NN NN O
of NN NN O
patients NN NN O
cannot NN NN O
be NN NN O
excluded NN NN O
. NN NN O
   
Safety NN NN O
and NN NN O
side NN NN O
- NN NN O
effects NN NN O
of NN NN O
alprazolam NN NN O
. NN NN O
   
Controlled NN NN O
study NN NN O
in NN NN O
agoraphobia NN NN B-Disease
with NN NN O
panic NN NN B-Disease
disorder NN NN I-Disease
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
The NN NN O
widespread NN NN O
use NN NN O
of NN NN O
benzodiazepines NN NN O
has NN NN O
led NN NN O
to NN NN O
increasing NN NN O
recognition NN NN O
of NN NN O
their NN NN O
unwanted NN NN O
effects NN NN O
. NN NN O
   
The NN NN O
efficacy NN NN O
of NN NN O
alprazolam NN NN O
and NN NN O
placebo NN NN O
in NN NN O
panic NN NN B-Disease
disorder NN NN I-Disease
with NN NN O
agoraphobia NN NN B-Disease
, NN NN O
and NN NN O
the NN NN O
side NN NN O
- NN NN O
effect NN NN O
and NN NN O
adverse NN NN O
effect NN NN O
profiles NN NN O
of NN NN O
both NN NN O
drug NN NN O
groups NN NN O
were NN NN O
measured NN NN O
. NN NN O
   
METHOD NN NN O
: NN NN O
In NN NN O
London NN NN O
and NN NN O
Toronto NN NN O
154 NN NN O
patients NN NN O
who NN NN O
met NN NN O
DSM NN NN O
- NN NN O
III NN NN O
criteria NN NN O
for NN NN O
panic NN NN B-Disease
disorder NN NN I-Disease
with NN NN O
agoraphobia NN NN B-Disease
were NN NN O
randomised NN NN O
to NN NN O
alprazolam NN NN O
or NN NN O
placebo NN NN O
. NN NN O
   
Subjects NN NN O
in NN NN O
each NN NN O
drug NN NN O
group NN NN O
also NN NN O
received NN NN O
either NN NN O
exposure NN NN O
or NN NN O
relaxation NN NN O
. NN NN O
   
Treatment NN NN O
was NN NN O
from NN NN O
weeks NN NN O
0 NN NN O
to NN NN O
8 NN NN O
and NN NN O
was NN NN O
then NN NN O
tapered NN NN O
from NN NN O
weeks NN NN O
8 NN NN O
to NN NN O
16 NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Mean NN NN O
alprazolam NN NN O
dose NN NN O
was NN NN O
5 NN NN O
mg NN NN O
daily NN NN O
. NN NN O
   
Compared NN NN O
with NN NN O
placebo NN NN O
subjects NN NN O
, NN NN O
alprazolam NN NN O
patients NN NN O
developed NN NN O
more NN NN O
adverse NN NN O
reactions NN NN O
( NN NN O
21 NN NN O
% NN NN O
v NN NN O
. NN NN O
0 NN NN O
% NN NN O
) NN NN O
of NN NN O
depression NN NN B-Disease
, NN NN O
enuresis NN NN B-Disease
, NN NN O
disinhibition NN NN O
and NN NN O
aggression NN NN B-Disease
; NN NN O
and NN NN O
more NN NN O
side NN NN O
- NN NN O
effects NN NN O
, NN NN O
particularly NN NN O
sedation NN NN O
, NN NN O
irritability NN NN B-Disease
, NN NN O
impaired NN NN B-Disease
memory NN NN I-Disease
, NN NN O
weight NN NN B-Disease
loss NN NN I-Disease
and NN NN O
ataxia NN NN B-Disease
. NN NN O
   
Side NN NN O
- NN NN O
effects NN NN O
tended NN NN O
to NN NN O
diminish NN NN O
during NN NN O
treatment NN NN O
but NN NN O
remained NN NN O
significant NN NN O
at NN NN O
week NN NN O
8 NN NN O
. NN NN O
   
Despite NN NN O
this NN NN O
, NN NN O
the NN NN O
drop NN NN O
- NN NN O
out NN NN O
rate NN NN O
was NN NN O
low NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Alprazolam NN NN O
caused NN NN O
side NN NN O
- NN NN O
effects NN NN O
and NN NN O
adverse NN NN O
effects NN NN O
during NN NN O
treatment NN NN O
but NN NN O
many NN NN O
patients NN NN O
were NN NN O
willing NN NN O
to NN NN O
accept NN NN O
these NN NN O
. NN NN O
   
Crescentic NN NN O
fibrillary NN NN O
glomerulonephritis NN NN B-Disease
associated NN NN O
with NN NN O
intermittent NN NN O
rifampin NN NN O
therapy NN NN O
for NN NN O
pulmonary NN NN B-Disease
tuberculosis NN NN I-Disease
. NN NN O
   
This NN NN O
case NN NN O
study NN NN O
reveals NN NN O
an NN NN O
unusual NN NN O
finding NN NN O
of NN NN O
rapidly NN NN O
proliferative NN NN O
crescentic NN NN O
glomerulonephritis NN NN B-Disease
in NN NN O
a NN NN O
patient NN NN O
treated NN NN O
with NN NN O
rifampin NN NN O
who NN NN O
had NN NN O
no NN NN O
other NN NN O
identifiable NN NN O
causes NN NN O
for NN NN O
developing NN NN O
this NN NN O
disease NN NN O
. NN NN O
   
This NN NN O
patient NN NN O
underwent NN NN O
a NN NN O
10 NN NN O
- NN NN O
month NN NN O
regimen NN NN O
of NN NN O
rifampin NN NN O
and NN NN O
isoniazid NN NN O
for NN NN O
pulmonary NN NN B-Disease
tuberculosis NN NN I-Disease
and NN NN O
was NN NN O
discovered NN NN O
to NN NN O
have NN NN O
developed NN NN O
signs NN NN O
of NN NN O
severe NN NN O
renal NN NN B-Disease
failure NN NN I-Disease
five NN NN O
weeks NN NN O
after NN NN O
completion NN NN O
of NN NN O
therapy NN NN O
. NN NN O
   
Renal NN NN O
biopsy NN NN O
revealed NN NN O
severe NN NN O
glomerulonephritis NN NN B-Disease
with NN NN O
crescents NN NN O
, NN NN O
electron NN NN O
dense NN NN O
fibrillar NN NN O
deposits NN NN O
and NN NN O
moderate NN NN O
lymphocytic NN NN O
interstitial NN NN O
infiltrate NN NN O
. NN NN O
   
Other NN NN O
possible NN NN O
causes NN NN O
of NN NN O
rapidly NN NN O
progressive NN NN O
glomerulonephritis NN NN B-Disease
were NN NN O
investigated NN NN O
and NN NN O
ruled NN NN O
out NN NN O
. NN NN O
   
This NN NN O
report NN NN O
documents NN NN O
the NN NN O
unusual NN NN O
occurrence NN NN O
of NN NN O
rapidly NN NN O
progressive NN NN O
glomerulonephritis NN NN B-Disease
with NN NN O
crescents NN NN O
and NN NN O
fibrillar NN NN O
glomerulonephritis NN NN B-Disease
in NN NN O
a NN NN O
patient NN NN O
treated NN NN O
with NN NN O
rifampin NN NN O
. NN NN O
   
Acute NN NN O
confusion NN NN B-Disease
induced NN NN O
by NN NN O
a NN NN O
high NN NN O
- NN NN O
dose NN NN O
infusion NN NN O
of NN NN O
5 NN NN O
- NN NN O
fluorouracil NN NN O
and NN NN O
folinic NN NN O
acid NN NN O
. NN NN O
   
A NN NN O
61 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
man NN NN O
was NN NN O
treated NN NN O
with NN NN O
combination NN NN O
chemotherapy NN NN O
incorporating NN NN O
cisplatinum NN NN O
, NN NN O
etoposide NN NN O
, NN NN O
high NN NN O
- NN NN O
dose NN NN O
5 NN NN O
- NN NN O
fluorouracil NN NN O
( NN NN O
2 NN NN O
, NN NN O
250 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
/ NN NN O
24 NN NN O
hours NN NN O
) NN NN O
and NN NN O
folinic NN NN O
acid NN NN O
for NN NN O
an NN NN O
inoperable NN NN O
gastric NN NN B-Disease
adenocarcinoma NN NN I-Disease
. NN NN O
   
He NN NN O
developed NN NN O
acute NN NN O
neurologic NN NN O
symptoms NN NN O
of NN NN O
mental NN NN O
confusion NN NN B-Disease
, NN NN O
disorientation NN NN B-Disease
and NN NN O
irritability NN NN B-Disease
, NN NN O
and NN NN O
then NN NN O
lapsed NN NN O
into NN NN O
a NN NN O
deep NN NN O
coma NN NN B-Disease
, NN NN O
lasting NN NN O
for NN NN O
approximately NN NN O
40 NN NN O
hours NN NN O
during NN NN O
the NN NN O
first NN NN O
dose NN NN O
( NN NN O
day NN NN O
2 NN NN O
) NN NN O
of NN NN O
5 NN NN O
- NN NN O
fluorouracil NN NN O
and NN NN O
folinic NN NN O
acid NN NN O
infusion NN NN O
. NN NN O
   
This NN NN O
complication NN NN O
reappeared NN NN O
on NN NN O
day NN NN O
25 NN NN O
during NN NN O
the NN NN O
second NN NN O
dose NN NN O
of NN NN O
5 NN NN O
- NN NN O
fluorouracil NN NN O
and NN NN O
folinic NN NN O
acid NN NN O
, NN NN O
which NN NN O
were NN NN O
then NN NN O
the NN NN O
only NN NN O
drugs NN NN O
given NN NN O
. NN NN O
   
Because NN NN O
folinic NN NN O
acid NN NN O
was NN NN O
unlikely NN NN O
to NN NN O
be NN NN O
associated NN NN O
with NN NN O
this NN NN O
condition NN NN O
, NN NN O
neurotoxicity NN NN B-Disease
due NN NN O
to NN NN O
high NN NN O
- NN NN O
dose NN NN O
5 NN NN O
- NN NN O
fluorouracil NN NN O
was NN NN O
highly NN NN O
suspected NN NN O
. NN NN O
   
The NN NN O
pathogenesis NN NN O
of NN NN O
5 NN NN O
- NN NN O
fluorouracil NN NN O
neurotoxicity NN NN B-Disease
may NN NN O
be NN NN O
due NN NN O
to NN NN O
a NN NN O
Krebs NN NN O
cycle NN NN O
blockade NN NN O
by NN NN O
fluoroacetate NN NN O
and NN NN O
fluorocitrate NN NN O
, NN NN O
thiamine NN NN O
deficiency NN NN O
, NN NN O
or NN NN O
dihydrouracil NN NN O
dehydrogenase NN NN O
deficiency NN NN O
. NN NN O
   
High NN NN O
- NN NN O
dose NN NN O
5 NN NN O
- NN NN O
fluorouracil NN NN O
/ NN NN O
folinic NN NN O
acid NN NN O
infusion NN NN O
therapy NN NN O
has NN NN O
recently NN NN O
become NN NN O
a NN NN O
popular NN NN O
regimen NN NN O
for NN NN O
various NN NN O
cancers NN NN B-Disease
. NN NN O
   
It NN NN O
is NN NN O
necessary NN NN O
that NN NN O
both NN NN O
oncologists NN NN O
and NN NN O
neurologists NN NN O
be NN NN O
fully NN NN O
aware NN NN O
of NN NN O
this NN NN O
unusual NN NN O
complication NN NN O
. NN NN O
   
Effect NN NN O
of NN NN O
switching NN NN O
carbamazepine NN NN O
to NN NN O
oxcarbazepine NN NN O
on NN NN O
the NN NN O
plasma NN NN O
levels NN NN O
of NN NN O
neuroleptics NN NN O
. NN NN O
   
A NN NN O
case NN NN O
report NN NN O
. NN NN O
   
Carbamazepine NN NN O
was NN NN O
switched NN NN O
to NN NN O
its NN NN O
10 NN NN O
- NN NN O
keto NN NN O
analogue NN NN O
oxcarbazepine NN NN O
among NN NN O
six NN NN O
difficult NN NN O
- NN NN O
to NN NN O
- NN NN O
treat NN NN O
schizophrenic NN NN B-Disease
or NN NN O
organic NN NN B-Disease
psychotic NN NN I-Disease
patients NN NN O
using NN NN O
concomitantly NN NN O
haloperidol NN NN O
, NN NN O
chlorpromazine NN NN O
or NN NN O
clozapine NN NN O
. NN NN O
   
This NN NN O
change NN NN O
resulted NN NN O
within NN NN O
2 NN NN O
- NN NN O
4 NN NN O
weeks NN NN O
in NN NN O
the NN NN O
50 NN NN O
- NN NN O
200 NN NN O
% NN NN O
increase NN NN O
in NN NN O
the NN NN O
plasma NN NN O
levels NN NN O
of NN NN O
these NN NN O
neuroleptics NN NN O
and NN NN O
the NN NN O
appearance NN NN O
of NN NN O
extrapyramidal NN NN B-Disease
symptoms NN NN I-Disease
. NN NN O
   
   O
of NN NN O
the NN NN O
patients NN NN O
showed NN NN O
any NN NN O
clinical NN NN O
deteriotation NN NN O
during NN NN O
the NN NN O
following NN NN O
3 NN NN O
- NN NN O
6 NN NN O
months NN NN O
. NN NN O
   
The NN NN O
results NN NN O
of NN NN O
this NN NN O
case NN NN O
report NN NN O
support NN NN O
the NN NN O
idea NN NN O
that NN NN O
in NN NN O
contrast NN NN O
with NN NN O
carbamazepine NN NN O
oxcarbazepine NN NN O
does NN NN O
not NN NN O
induce NN NN O
the NN NN O
hepatic NN NN O
microsomal NN NN O
enzyme NN NN O
systems NN NN O
regulating NN NN O
the NN NN O
inactivation NN NN O
of NN NN O
antipsychotic NN NN O
drugs NN NN O
. NN NN O
   
Time NN NN O
course NN NN O
of NN NN O
lipid NN NN O
peroxidation NN NN O
in NN NN O
puromycin NN NN O
aminonucleoside NN NN O
- NN NN O
induced NN NN O
nephropathy NN NN B-Disease
. NN NN O
   
Reactive NN NN O
oxygen NN NN O
species NN NN O
have NN NN O
been NN NN O
implicated NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
acute NN NN O
puromycin NN NN O
aminonucleoside NN NN O
( NN NN O
PAN NN NN O
) NN NN O
- NN NN O
induced NN NN O
nephropathy NN NN B-Disease
, NN NN O
with NN NN O
antioxidants NN NN O
significantly NN NN O
reducing NN NN O
the NN NN O
proteinuria NN NN B-Disease
. NN NN O
   
The NN NN O
temporal NN NN O
relationship NN NN O
between NN NN O
lipid NN NN O
peroxidation NN NN O
in NN NN O
the NN NN O
kidney NN NN O
and NN NN O
proteinuria NN NN B-Disease
was NN NN O
examined NN NN O
in NN NN O
this NN NN O
study NN NN O
. NN NN O
   
Rats NN NN O
were NN NN O
treated NN NN O
with NN NN O
a NN NN O
single NN NN O
IV NN NN O
injection NN NN O
of NN NN O
puromycin NN NN O
aminonucleoside NN NN O
, NN NN O
( NN NN O
PAN NN NN O
, NN NN O
7 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
and NN NN O
24 NN NN O
hour NN NN O
urine NN NN O
samples NN NN O
were NN NN O
obtained NN NN O
prior NN NN O
to NN NN O
sacrifice NN NN O
on NN NN O
days NN NN O
3 NN NN O
, NN NN O
5 NN NN O
, NN NN O
7 NN NN O
, NN NN O
10 NN NN O
, NN NN O
17 NN NN O
, NN NN O
27 NN NN O
, NN NN O
41 NN NN O
( NN NN O
N NN NN O
= NN NN O
5 NN NN O
- NN NN O
10 NN NN O
per NN NN O
group NN NN O
) NN NN O
. NN NN O
   
The NN NN O
kidneys NN NN O
were NN NN O
removed NN NN O
, NN NN O
flushed NN NN O
with NN NN O
ice NN NN O
cold NN NN O
TRIS NN NN O
buffer NN NN O
. NN NN O
   
Kidney NN NN O
cortices NN NN O
from NN NN O
each NN NN O
animal NN NN O
were NN NN O
used NN NN O
to NN NN O
prepare NN NN O
homogenates NN NN O
. NN NN O
   
Tissue NN NN O
lipid NN NN O
peroxidation NN NN O
was NN NN O
measured NN NN O
in NN NN O
whole NN NN O
homogenates NN NN O
as NN NN O
well NN NN O
as NN NN O
in NN NN O
lipid NN NN O
extracts NN NN O
from NN NN O
homogenates NN NN O
as NN NN O
thiobarbituric NN NN O
acid NN NN O
reactive NN NN O
substances NN NN O
. NN NN O
   
Proteinuria NN NN B-Disease
was NN NN O
evident NN NN O
at NN NN O
day NN NN O
5 NN NN O
, NN NN O
peaked NN NN O
at NN NN O
day NN NN O
7 NN NN O
and NN NN O
persisted NN NN O
to NN NN O
day NN NN O
27 NN NN O
. NN NN O
   
Lipid NN NN O
peroxidation NN NN O
in NN NN O
homogenates NN NN O
was NN NN O
maximal NN NN O
at NN NN O
day NN NN O
3 NN NN O
and NN NN O
declined NN NN O
rapidly NN NN O
to NN NN O
control NN NN O
levels NN NN O
by NN NN O
day NN NN O
17 NN NN O
. NN NN O
   
This NN NN O
study NN NN O
supports NN NN O
the NN NN O
role NN NN O
of NN NN O
lipid NN NN O
peroxidation NN NN O
in NN NN O
mediating NN NN O
the NN NN O
proteinuric NN NN B-Disease
injury NN NN I-Disease
in NN NN O
PAN NN NN O
nephropathy NN NN B-Disease
. NN NN O
   
Composition NN NN O
of NN NN O
gall NN NN B-Disease
bladder NN NN I-Disease
stones NN NN I-Disease
associated NN NN O
with NN NN O
octreotide NN NN O
: NN NN O
response NN NN O
to NN NN O
oral NN NN O
ursodeoxycholic NN NN O
acid NN NN O
. NN NN O
   
Octreotide NN NN O
, NN NN O
an NN NN O
effective NN NN O
treatment NN NN O
for NN NN O
acromegaly NN NN B-Disease
, NN NN O
induces NN NN O
gall NN NN B-Disease
bladder NN NN I-Disease
stones NN NN I-Disease
in NN NN O
13 NN NN O
- NN NN O
60 NN NN O
% NN NN O
of NN NN O
patients NN NN O
. NN NN O
   
Because NN NN O
knowledge NN NN O
of NN NN O
stone NN NN O
composition NN NN O
is NN NN O
essential NN NN O
for NN NN O
studies NN NN O
of NN NN O
their NN NN O
pathogenesis NN NN O
, NN NN O
treatment NN NN O
, NN NN O
and NN NN O
prevention NN NN O
, NN NN O
this NN NN O
was NN NN O
investigated NN NN O
by NN NN O
direct NN NN O
and NN NN O
indirect NN NN O
methods NN NN O
in NN NN O
14 NN NN O
octreotide NN NN O
treated NN NN O
acromegalic NN NN B-Disease
patients NN NN O
with NN NN O
gall NN NN B-Disease
stones NN NN I-Disease
. NN NN O
   
Chemical NN NN O
analysis NN NN O
of NN NN O
gall NN NN B-Disease
stones NN NN I-Disease
retrieved NN NN O
at NN NN O
cholecystectomy NN NN O
from NN NN O
two NN NN O
patients NN NN O
, NN NN O
showed NN NN O
that NN NN O
they NN NN O
contained NN NN O
71 NN NN O
% NN NN O
and NN NN O
87 NN NN O
% NN NN O
cholesterol NN NN O
by NN NN O
weight NN NN O
. NN NN O
   
In NN NN O
the NN NN O
remaining NN NN O
12 NN NN O
patients NN NN O
, NN NN O
localised NN NN O
computed NN NN O
tomography NN NN O
of NN NN O
the NN NN O
gall NN NN O
bladder NN NN O
showed NN NN O
that NN NN O
eight NN NN O
had NN NN O
stones NN NN O
with NN NN O
maximum NN NN O
attenuation NN NN O
scores NN NN O
of NN NN O
< NN NN O
100 NN NN O
Hounsfield NN NN O
units NN NN O
( NN NN O
values NN NN O
of NN NN O
< NN NN O
100 NN NN O
HU NN NN O
predict NN NN O
cholesterol NN NN O
rich NN NN O
, NN NN O
dissolvable NN NN O
stones NN NN O
) NN NN O
. NN NN O
   
Gall NN NN O
bladder NN NN O
bile NN NN O
was NN NN O
obtained NN NN O
by NN NN O
ultrasound NN NN O
guided NN NN O
, NN NN O
fine NN NN O
needle NN NN O
puncture NN NN O
from NN NN O
six NN NN O
patients NN NN O
. NN NN O
   
All NN NN O
six NN NN O
patients NN NN O
had NN NN O
supersaturated NN NN O
bile NN NN O
( NN NN O
mean NN NN O
( NN NN O
SEM NN NN O
) NN NN O
cholesterol NN NN O
saturation NN NN O
index NN NN O
of NN NN O
1 NN NN O
. NN NN O
19 NN NN O
( NN NN O
0 NN NN O
. NN NN O
08 NN NN O
) NN NN O
( NN NN O
range NN NN O
1 NN NN O
. NN NN O
01 NN NN O
- NN NN O
1 NN NN O
. NN NN O
53 NN NN O
) NN NN O
) NN NN O
and NN NN O
all NN NN O
had NN NN O
abnormally NN NN O
rapid NN NN O
cholesterol NN NN O
microcrystal NN NN O
nucleation NN NN O
times NN NN O
( NN NN O
< NN NN O
4 NN NN O
days NN NN O
( NN NN O
range NN NN O
1 NN NN O
- NN NN O
4 NN NN O
) NN NN O
) NN NN O
, NN NN O
whilst NN NN O
in NN NN O
four NN NN O
, NN NN O
the NN NN O
bile NN NN O
contained NN NN O
cholesterol NN NN O
microcrystals NN NN O
immediately NN NN O
after NN NN O
sampling NN NN O
. NN NN O
   
Of NN NN O
the NN NN O
12 NN NN O
patients NN NN O
considered NN NN O
for NN NN O
oral NN NN O
ursodeoxycholic NN NN O
acid NN NN O
( NN NN O
UDCA NN NN O
) NN NN O
treatment NN NN O
, NN NN O
two NN NN O
had NN NN O
a NN NN O
blocked NN NN O
cystic NN NN O
duct NN NN O
and NN NN O
were NN NN O
not NN NN O
started NN NN O
on NN NN O
UDCA NN NN O
while NN NN O
one NN NN O
was NN NN O
lost NN NN O
to NN NN O
follow NN NN O
up NN NN O
. NN NN O
   
After NN NN O
one NN NN O
year NN NN O
of NN NN O
treatment NN NN O
, NN NN O
five NN NN O
of NN NN O
the NN NN O
remaining NN NN O
nine NN NN O
patients NN NN O
showed NN NN O
either NN NN O
partial NN NN O
( NN NN O
n NN NN O
= NN NN O
3 NN NN O
) NN NN O
or NN NN O
complete NN NN O
( NN NN O
n NN NN O
= NN NN O
2 NN NN O
) NN NN O
gall NN NN B-Disease
stone NN NN I-Disease
dissolution NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
their NN NN O
stones NN NN O
were NN NN O
cholesterol NN NN O
rich NN NN O
. NN NN O
   
This NN NN O
corresponds NN NN O
, NN NN O
by NN NN O
actuarial NN NN O
( NN NN O
life NN NN O
table NN NN O
) NN NN O
analysis NN NN O
, NN NN O
to NN NN O
a NN NN O
combined NN NN O
gall NN NN B-Disease
stone NN NN I-Disease
dissolution NN NN O
rate NN NN O
of NN NN O
58 NN NN O
. NN NN O
3 NN NN O
( NN NN O
15 NN NN O
. NN NN O
9 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
In NN NN O
conclusion NN NN O
, NN NN O
octreotide NN NN O
induced NN NN O
gall NN NN B-Disease
stones NN NN I-Disease
are NN NN O
generally NN NN O
small NN NN O
, NN NN O
multiple NN NN O
, NN NN O
and NN NN O
cholesterol NN NN O
rich NN NN O
although NN NN O
, NN NN O
in NN NN O
common NN NN O
with NN NN O
spontaneous NN NN O
gall NN NN B-Disease
stone NN NN I-Disease
disease NN NN I-Disease
, NN NN O
at NN NN O
presentation NN NN O
some NN NN O
patients NN NN O
will NN NN O
have NN NN O
a NN NN O
blocked NN NN O
cystic NN NN O
duct NN NN O
and NN NN O
some NN NN O
gall NN NN B-Disease
stones NN NN I-Disease
containing NN NN O
calcium NN NN O
. NN NN O
   
Erythema NN NN B-Disease
multiforme NN NN I-Disease
and NN NN O
hypersensitivity NN NN B-Disease
myocarditis NN NN I-Disease
caused NN NN O
by NN NN O
ampicillin NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
To NN NN O
report NN NN O
a NN NN O
case NN NN O
of NN NN O
erythema NN NN B-Disease
multiforme NN NN I-Disease
and NN NN O
hypersensitivity NN NN B-Disease
myocarditis NN NN I-Disease
caused NN NN O
by NN NN O
ampicillin NN NN O
. NN NN O
   
CASE NN NN O
SUMMARY NN NN O
: NN NN O
A NN NN O
13 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
boy NN NN O
was NN NN O
treated NN NN O
with NN NN O
ampicillin NN NN O
and NN NN O
gentamicin NN NN O
because NN NN O
of NN NN O
suspected NN NN O
septicemia NN NN B-Disease
. NN NN O
   
Medications NN NN O
were NN NN O
discontinued NN NN O
when NN NN O
erythema NN NN B-Disease
multiforme NN NN I-Disease
and NN NN O
congestive NN NN B-Disease
heart NN NN I-Disease
failure NN NN I-Disease
caused NN NN O
by NN NN O
myocarditis NN NN B-Disease
occurred NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
was NN NN O
treated NN NN O
with NN NN O
methylprednisolone NN NN O
and NN NN O
gradually NN NN O
improved NN NN O
. NN NN O
   
Macrophage NN NN O
- NN NN O
migration NN NN O
inhibition NN NN O
( NN NN O
MIF NN NN O
) NN NN O
test NN NN O
with NN NN O
ampicillin NN NN O
was NN NN O
positive NN NN O
. NN NN O
   
DISCUSSION NN NN O
: NN NN O
After NN NN O
most NN NN O
infections NN NN B-Disease
causing NN NN O
erythema NN NN B-Disease
multiforme NN NN I-Disease
and NN NN O
myocarditis NN NN B-Disease
were NN NN O
ruled NN NN O
out NN NN O
, NN NN O
a NN NN O
drug NN NN B-Disease
- NN NN I-Disease
induced NN NN I-Disease
allergic NN NN I-Disease
reaction NN NN I-Disease
was NN NN O
suspected NN NN O
. NN NN O
   
Positive NN NN O
MIF NN NN O
test NN NN O
for NN NN O
ampicillin NN NN O
showed NN NN O
sensitization NN NN O
of NN NN O
the NN NN O
patient NN NN O
' NN NN O
s NN NN O
lymphocytes NN NN O
to NN NN O
ampicillin NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Hypersensitivity NN NN B-Disease
myocarditis NN NN I-Disease
is NN NN O
a NN NN O
rare NN NN O
and NN NN O
dangerous NN NN O
manifestation NN NN O
of NN NN O
allergy NN NN B-Disease
to NN NN O
penicillins NN NN O
. NN NN O
   
Clomipramine NN NN O
- NN NN O
induced NN NN O
sleep NN NN B-Disease
disturbance NN NN I-Disease
does NN NN O
not NN NN O
impair NN NN O
its NN NN O
prolactin NN NN O
- NN NN O
releasing NN NN O
action NN NN O
. NN NN O
   
The NN NN O
present NN NN O
study NN NN O
was NN NN O
undertaken NN NN O
to NN NN O
examine NN NN O
the NN NN O
role NN NN O
of NN NN O
sleep NN NN B-Disease
disturbance NN NN I-Disease
, NN NN O
induced NN NN O
by NN NN O
clomipramine NN NN O
administration NN NN O
, NN NN O
on NN NN O
the NN NN O
secretory NN NN O
rate NN NN O
of NN NN O
prolactin NN NN O
( NN NN O
PRL NN NN O
) NN NN O
in NN NN O
addition NN NN O
to NN NN O
the NN NN O
direct NN NN O
drug NN NN O
effect NN NN O
. NN NN O
   
Two NN NN O
groups NN NN O
of NN NN O
supine NN NN O
subjects NN NN O
were NN NN O
studied NN NN O
under NN NN O
placebo NN NN O
- NN NN O
controlled NN NN O
conditions NN NN O
, NN NN O
one NN NN O
during NN NN O
the NN NN O
night NN NN O
, NN NN O
when NN NN O
sleeping NN NN O
( NN NN O
n NN NN O
= NN NN O
7 NN NN O
) NN NN O
and NN NN O
the NN NN O
other NN NN O
at NN NN O
daytime NN NN O
, NN NN O
when NN NN O
awake NN NN O
( NN NN O
n NN NN O
= NN NN O
6 NN NN O
) NN NN O
. NN NN O
   
Each NN NN O
subject NN NN O
received NN NN O
a NN NN O
single NN NN O
50 NN NN O
mg NN NN O
dose NN NN O
of NN NN O
clomipramine NN NN O
given NN NN O
orally NN NN O
2 NN NN O
hours NN NN O
before NN NN O
blood NN NN O
collection NN NN O
. NN NN O
   
Plasma NN NN O
PRL NN NN O
concentrations NN NN O
were NN NN O
analysed NN NN O
at NN NN O
10 NN NN O
min NN NN O
intervals NN NN O
and NN NN O
underlying NN NN O
secretory NN NN O
rates NN NN O
calculated NN NN O
by NN NN O
a NN NN O
deconvolution NN NN O
procedure NN NN O
. NN NN O
   
For NN NN O
both NN NN O
experiments NN NN O
the NN NN O
drug NN NN O
intake NN NN O
led NN NN O
to NN NN O
significant NN NN O
increases NN NN O
in NN NN O
PRL NN NN O
secretion NN NN O
, NN NN O
acting NN NN O
preferentially NN NN O
on NN NN O
tonic NN NN O
secretion NN NN O
as NN NN O
pulse NN NN O
amplitude NN NN O
and NN NN O
frequency NN NN O
did NN NN O
not NN NN O
differ NN NN O
significantly NN NN O
from NN NN O
corresponding NN NN O
control NN NN O
values NN NN O
. NN NN O
   
During NN NN O
the NN NN O
night NN NN O
clomipramine NN NN O
ingestion NN NN O
altered NN NN O
the NN NN O
complete NN NN O
sleep NN NN O
architecture NN NN O
in NN NN O
that NN NN O
it NN NN O
suppressed NN NN O
REM NN NN O
sleep NN NN O
and NN NN O
the NN NN O
sleep NN NN O
cycles NN NN O
and NN NN O
induced NN NN O
increased NN NN O
wakefulness NN NN O
. NN NN O
   
As NN NN O
the NN NN O
relative NN NN O
increase NN NN O
in NN NN O
PRL NN NN O
secretion NN NN O
expressed NN NN O
as NN NN O
a NN NN O
percentage NN NN O
of NN NN O
the NN NN O
mean NN NN O
did NN NN O
not NN NN O
significantly NN NN O
differ NN NN O
between NN NN O
the NN NN O
night NN NN O
and NN NN O
day NN NN O
time NN NN O
studies NN NN O
( NN NN O
46 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
19 NN NN O
% NN NN O
vs NN NN O
34 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
10 NN NN O
% NN NN O
) NN NN O
, NN NN O
it NN NN O
can NN NN O
be NN NN O
concluded NN NN O
that NN NN O
the NN NN O
observed NN NN O
sleep NN NN B-Disease
disturbance NN NN I-Disease
did NN NN O
not NN NN O
interfere NN NN O
with NN NN O
the NN NN O
drug NN NN O
action NN NN O
per NN NN O
se NN NN O
. NN NN O
   
The NN NN O
presence NN NN O
of NN NN O
REM NN NN O
sleep NN NN O
was NN NN O
shown NN NN O
not NN NN O
to NN NN O
be NN NN O
a NN NN O
determining NN NN O
factor NN NN O
either NN NN O
for NN NN O
secretory NN NN O
pulse NN NN O
amplitude NN NN O
and NN NN O
frequency NN NN O
, NN NN O
as NN NN O
, NN NN O
for NN NN O
both NN NN O
, NN NN O
mean NN NN O
nocturnal NN NN O
values NN NN O
were NN NN O
similar NN NN O
with NN NN O
and NN NN O
without NN NN O
prior NN NN O
clomipramine NN NN O
ingestion NN NN O
. NN NN O
   
Survey NN NN O
of NN NN O
complications NN NN O
of NN NN O
indocyanine NN NN O
green NN NN O
angiography NN NN O
in NN NN O
Japan NN NN O
. NN NN O
   
PURPOSE NN NN O
: NN NN O
We NN NN O
evaluated NN NN O
the NN NN O
safety NN NN O
of NN NN O
indocyanine NN NN O
green NN NN O
for NN NN O
use NN NN O
in NN NN O
fundus NN NN O
angiography NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
We NN NN O
sent NN NN O
a NN NN O
questionnaire NN NN O
concerning NN NN O
complications NN NN O
of NN NN O
indocyanine NN NN O
green NN NN O
to NN NN O
32 NN NN O
institutions NN NN O
in NN NN O
Japan NN NN O
, NN NN O
which NN NN O
were NN NN O
selected NN NN O
on NN NN O
the NN NN O
basis NN NN O
of NN NN O
the NN NN O
client NN NN O
list NN NN O
from NN NN O
the NN NN O
Topcon NN NN O
Company NN NN O
, NN NN O
which NN NN O
manufactures NN NN O
the NN NN O
indocyanine NN NN O
green NN NN O
fundus NN NN O
camera NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Ophthalmologists NN NN O
at NN NN O
15 NN NN O
institutions NN NN O
responded NN NN O
, NN NN O
reporting NN NN O
a NN NN O
total NN NN O
of NN NN O
3 NN NN O
, NN NN O
774 NN NN O
indocyanine NN NN O
green NN NN O
angiograms NN NN O
performed NN NN O
on NN NN O
2 NN NN O
, NN NN O
820 NN NN O
patients NN NN O
between NN NN O
June NN NN O
1984 NN NN O
and NN NN O
September NN NN O
1992 NN NN O
. NN NN O
   
Before NN NN O
angiography NN NN O
, NN NN O
intradermal NN NN O
or NN NN O
intravenous NN NN O
indocyanine NN NN O
green NN NN O
testing NN NN O
, NN NN O
or NN NN O
both NN NN O
was NN NN O
performed NN NN O
at NN NN O
13 NN NN O
of NN NN O
15 NN NN O
institutions NN NN O
. NN NN O
   
For NN NN O
three NN NN O
patients NN NN O
, NN NN O
the NN NN O
decision NN NN O
was NN NN O
made NN NN O
not NN NN O
to NN NN O
proceed NN NN O
with NN NN O
angiography NN NN O
after NN NN O
positive NN NN O
preangiographic NN NN O
testing NN NN O
. NN NN O
   
The NN NN O
dosage NN NN O
of NN NN O
indocyanine NN NN O
green NN NN O
used NN NN O
for NN NN O
angiography NN NN O
varied NN NN O
from NN NN O
25 NN NN O
to NN NN O
75 NN NN O
mg NN NN O
, NN NN O
depending NN NN O
upon NN NN O
the NN NN O
institution NN NN O
. NN NN O
   
There NN NN O
were NN NN O
13 NN NN O
cases NN NN O
of NN NN O
adverse NN NN O
reactions NN NN O
( NN NN O
0 NN NN O
. NN NN O
34 NN NN O
% NN NN O
) NN NN O
, NN NN O
ten NN NN O
of NN NN O
which NN NN O
were NN NN O
mild NN NN O
reactions NN NN O
such NN NN O
as NN NN O
nausea NN NN B-Disease
, NN NN O
exanthema NN NN B-Disease
, NN NN O
urtication NN NN B-Disease
, NN NN O
itchiness NN NN B-Disease
, NN NN O
and NN NN O
urgency NN NN O
to NN NN O
defecate NN NN O
, NN NN O
and NN NN O
did NN NN O
not NN NN O
require NN NN O
treatment NN NN O
. NN NN O
   
Also NN NN O
recorded NN NN O
were NN NN O
one NN NN O
case NN NN O
of NN NN O
pain NN NN B-Disease
of NN NN O
the NN NN O
vein NN NN O
, NN NN O
which NN NN O
required NN NN O
treatment NN NN O
, NN NN O
and NN NN O
two NN NN O
cases NN NN O
of NN NN O
hypotension NN NN B-Disease
. NN NN O
   
The NN NN O
two NN NN O
hypotensive NN NN B-Disease
patients NN NN O
required NN NN O
treatment NN NN O
for NN NN O
shock NN NN B-Disease
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
A NN NN O
comparison NN NN O
of NN NN O
frequency NN NN O
of NN NN O
adverse NN NN O
reactions NN NN O
to NN NN O
indocyanine NN NN O
green NN NN O
with NN NN O
the NN NN O
previously NN NN O
reported NN NN O
frequency NN NN O
of NN NN O
such NN NN O
reactions NN NN O
to NN NN O
fluorescein NN NN O
sodium NN NN O
indicated NN NN O
that NN NN O
indocyanine NN NN O
green NN NN O
is NN NN O
a NN NN O
safe NN NN O
as NN NN O
fluorescein NN NN O
for NN NN O
use NN NN O
in NN NN O
angiography NN NN O
. NN NN O
   
Angioedema NN NN B-Disease
following NN NN O
the NN NN O
intravenous NN NN O
administration NN NN O
of NN NN O
metoprolol NN NN O
. NN NN O
   
A NN NN O
72 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
woman NN NN O
was NN NN O
admitted NN NN O
to NN NN O
the NN NN O
hospital NN NN O
with NN NN O
"""""""" NN NN O
flash NN NN O
"""""""" NN NN O
pulmonary NN NN B-Disease
edema NN NN I-Disease
, NN NN O
preceded NN NN O
by NN NN O
chest NN NN B-Disease
pain NN NN I-Disease
, NN NN O
requiring NN NN O
intubation NN NN O
. NN NN O
   
Her NN NN O
medical NN NN O
history NN NN O
included NN NN O
coronary NN NN B-Disease
artery NN NN I-Disease
disease NN NN I-Disease
with NN NN O
previous NN NN O
myocardial NN NN B-Disease
infarctions NN NN I-Disease
, NN NN O
hypertension NN NN B-Disease
, NN NN O
and NN NN O
diabetes NN NN B-Disease
mellitus NN NN I-Disease
. NN NN O
   
A NN NN O
history NN NN O
of NN NN O
angioedema NN NN B-Disease
secondary NN NN O
to NN NN O
lisinopril NN NN O
therapy NN NN O
was NN NN O
elicited NN NN O
. NN NN O
   
Current NN NN O
medications NN NN O
did NN NN O
not NN NN O
include NN NN O
angiotensin NN NN O
- NN NN O
converting NN NN O
enzyme NN NN O
inhibitors NN NN O
or NN NN O
beta NN NN O
- NN NN O
blockers NN NN O
. NN NN O
   
She NN NN O
had NN NN O
no NN NN O
previous NN NN O
beta NN NN O
- NN NN O
blocking NN NN O
drug NN NN O
exposure NN NN O
. NN NN O
   
During NN NN O
the NN NN O
first NN NN O
day NN NN O
of NN NN O
hospitalization NN NN O
( NN NN O
while NN NN O
intubated NN NN O
) NN NN O
, NN NN O
intravenous NN NN O
metoprolol NN NN O
was NN NN O
given NN NN O
, NN NN O
resulting NN NN O
in NN NN O
severe NN NN O
angioedema NN NN B-Disease
. NN NN O
   
The NN NN O
angioedema NN NN B-Disease
resolved NN NN O
after NN NN O
therapy NN NN O
with NN NN O
intravenous NN NN O
steroids NN NN O
and NN NN O
diphenhydramine NN NN O
hydrochloride NN NN O
. NN NN O
   
Effect NN NN O
of NN NN O
coniine NN NN O
on NN NN O
the NN NN O
developing NN NN O
chick NN NN O
embryo NN NN O
. NN NN O
   
Coniine NN NN O
, NN NN O
an NN NN O
alkaloid NN NN O
from NN NN O
Conium NN NN O
maculatum NN NN O
( NN NN O
poison NN NN O
hemlock NN NN O
) NN NN O
, NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
be NN NN O
teratogenic NN NN O
in NN NN O
livestock NN NN O
. NN NN O
   
The NN NN O
major NN NN O
teratogenic NN NN O
outcome NN NN O
is NN NN O
arthrogryposis NN NN B-Disease
, NN NN O
presumably NN NN O
due NN NN O
to NN NN O
nicotinic NN NN O
receptor NN NN O
blockade NN NN O
. NN NN O
   
However NN NN O
, NN NN O
coniine NN NN O
has NN NN O
failed NN NN O
to NN NN O
produce NN NN O
arthrogryposis NN NN B-Disease
in NN NN O
rats NN NN O
or NN NN O
mice NN NN O
and NN NN O
is NN NN O
only NN NN O
weakly NN NN O
teratogenic NN NN O
in NN NN O
rabbits NN NN O
. NN NN O
   
The NN NN O
purpose NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
evaluate NN NN O
and NN NN O
compare NN NN O
the NN NN O
effects NN NN O
of NN NN O
coniine NN NN O
and NN NN O
nicotine NN NN O
in NN NN O
the NN NN O
developing NN NN O
chick NN NN O
. NN NN O
   
Concentrations NN NN O
of NN NN O
coniine NN NN O
and NN NN O
nicotine NN NN O
sulfate NN NN O
were NN NN O
0 NN NN O
. NN NN O
015 NN NN O
% NN NN O
, NN NN O
0 NN NN O
. NN NN O
03 NN NN O
% NN NN O
, NN NN O
0 NN NN O
. NN NN O
075 NN NN O
% NN NN O
, NN NN O
0 NN NN O
. NN NN O
15 NN NN O
% NN NN O
, NN NN O
0 NN NN O
. NN NN O
75 NN NN O
% NN NN O
, NN NN O
1 NN NN O
. NN NN O
5 NN NN O
% NN NN O
, NN NN O
3 NN NN O
% NN NN O
, NN NN O
and NN NN O
6 NN NN O
% NN NN O
and NN NN O
1 NN NN O
% NN NN O
, NN NN O
5 NN NN O
% NN NN O
, NN NN O
and NN NN O
10 NN NN O
% NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
Both NN NN O
compounds NN NN O
caused NN NN O
deformations NN NN B-Disease
and NN NN O
lethality NN NN O
in NN NN O
a NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
. NN NN O
   
All NN NN O
concentrations NN NN O
of NN NN O
nicotine NN NN O
sulfate NN NN O
caused NN NN O
some NN NN O
lethality NN NN O
but NN NN O
a NN NN O
no NN NN O
effect NN NN O
level NN NN O
for NN NN O
coniine NN NN O
lethality NN NN O
was NN NN O
0 NN NN O
. NN NN O
75 NN NN O
% NN NN O
. NN NN O
   
The NN NN O
deformations NN NN B-Disease
caused NN NN O
by NN NN O
both NN NN O
coniine NN NN O
and NN NN O
nicotine NN NN O
sulfate NN NN O
were NN NN O
excessive NN NN B-Disease
flexion NN NN I-Disease
or NN NN I-Disease
extension NN NN I-Disease
of NN NN I-Disease
one NN NN I-Disease
or NN NN I-Disease
more NN NN I-Disease
toes NN NN I-Disease
. NN NN O
   
No NN NN O
histopathological NN NN O
alterations NN NN O
or NN NN O
differences NN NN O
in NN NN O
bone NN NN O
formation NN NN O
were NN NN O
seen NN NN O
in NN NN O
the NN NN O
limbs NN NN O
or NN NN O
toes NN NN O
of NN NN O
any NN NN O
chicks NN NN O
from NN NN O
any NN NN O
group NN NN O
; NN NN O
however NN NN O
, NN NN O
extensive NN NN O
cranial NN NN B-Disease
hemorrhage NN NN I-Disease
occurred NN NN O
in NN NN O
all NN NN O
nicotine NN NN O
sulfate NN NN O
- NN NN O
treated NN NN O
chicks NN NN O
. NN NN O
   
There NN NN O
was NN NN O
a NN NN O
statistically NN NN O
significant NN NN O
( NN NN O
P NN NN O
< NN NN O
or NN NN O
= NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
decrease NN NN O
in NN NN O
movement NN NN O
in NN NN O
coniine NN NN O
and NN NN O
nicotine NN NN O
sulfate NN NN O
treated NN NN O
chicks NN NN O
as NN NN O
determined NN NN O
by NN NN O
ultrasound NN NN O
. NN NN O
   
Control NN NN O
chicks NN NN O
were NN NN O
in NN NN O
motion NN NN O
an NN NN O
average NN NN O
of NN NN O
33 NN NN O
. NN NN O
67 NN NN O
% NN NN O
of NN NN O
the NN NN O
time NN NN O
, NN NN O
while NN NN O
coniine NN NN O
- NN NN O
treated NN NN O
chicks NN NN O
were NN NN O
only NN NN O
moving NN NN O
8 NN NN O
. NN NN O
95 NN NN O
% NN NN O
of NN NN O
a NN NN O
5 NN NN O
- NN NN O
min NN NN O
interval NN NN O
, NN NN O
and NN NN O
no NN NN O
movement NN NN O
was NN NN O
observed NN NN O
for NN NN O
nicotine NN NN O
sulfate NN NN O
treated NN NN O
chicks NN NN O
. NN NN O
   
In NN NN O
summary NN NN O
, NN NN O
the NN NN O
chick NN NN O
embryo NN NN O
provides NN NN O
a NN NN O
reliable NN NN O
and NN NN O
simple NN NN O
experimental NN NN O
animal NN NN O
model NN NN O
of NN NN O
coniine NN NN O
- NN NN O
induced NN NN O
arthrogryposis NN NN B-Disease
. NN NN O
   
Data NN NN O
from NN NN O
this NN NN O
model NN NN O
support NN NN O
a NN NN O
mechanism NN NN O
involving NN NN O
nicotinic NN NN O
receptor NN NN O
blockade NN NN O
with NN NN O
subsequent NN NN O
decreased NN NN O
fetal NN NN O
movement NN NN O
. NN NN O
   
Immediate NN NN O
allergic NN NN B-Disease
reactions NN NN I-Disease
to NN NN O
amoxicillin NN NN O
. NN NN O
   
A NN NN O
large NN NN O
group NN NN O
of NN NN O
patients NN NN O
with NN NN O
suspected NN NN O
allergic NN NN B-Disease
reactions NN NN I-Disease
to NN NN O
beta NN NN O
- NN NN O
lactam NN NN O
antibiotics NN NN O
was NN NN O
evaluated NN NN O
. NN NN O
   
A NN NN O
detailed NN NN O
clinical NN NN O
history NN NN O
, NN NN O
together NN NN O
with NN NN O
skin NN NN O
tests NN NN O
, NN NN O
RAST NN NN O
( NN NN O
radioallergosorbent NN NN O
test NN NN O
) NN NN O
, NN NN O
and NN NN O
controlled NN NN O
challenge NN NN O
tests NN NN O
, NN NN O
was NN NN O
used NN NN O
to NN NN O
establish NN NN O
whether NN NN O
patients NN NN O
allergic NN NN B-Disease
to NN NN O
beta NN NN O
- NN NN O
lactam NN NN O
antibiotics NN NN O
had NN NN O
selective NN NN O
immediate NN NN O
allergic NN NN B-Disease
responses NN NN O
to NN NN O
amoxicillin NN NN O
( NN NN O
AX NN NN O
) NN NN O
or NN NN O
were NN NN O
cross NN NN O
- NN NN O
reacting NN NN O
with NN NN O
other NN NN O
penicillin NN NN O
derivatives NN NN O
. NN NN O
   
Skin NN NN O
tests NN NN O
were NN NN O
performed NN NN O
with NN NN O
benzylpenicilloyl NN NN O
- NN NN O
poly NN NN O
- NN NN O
L NN NN O
- NN NN O
lysine NN NN O
( NN NN O
BPO NN NN O
- NN NN O
PLL NN NN O
) NN NN O
, NN NN O
benzylpenicilloate NN NN O
, NN NN O
benzylpenicillin NN NN O
( NN NN O
PG NN NN O
) NN NN O
, NN NN O
ampicillin NN NN O
( NN NN O
AMP NN NN O
) NN NN O
, NN NN O
and NN NN O
AX NN NN O
. NN NN O
   
RAST NN NN O
for NN NN O
BPO NN NN O
- NN NN O
PLL NN NN O
and NN NN O
AX NN NN O
- NN NN O
PLL NN NN O
was NN NN O
done NN NN O
. NN NN O
   
When NN NN O
both NN NN O
skin NN NN O
test NN NN O
and NN NN O
RAST NN NN O
for NN NN O
BPO NN NN O
were NN NN O
negative NN NN O
, NN NN O
single NN NN O
- NN NN O
blind NN NN O
, NN NN O
placebo NN NN O
- NN NN O
controlled NN NN O
challenge NN NN O
tests NN NN O
were NN NN O
done NN NN O
to NN NN O
ensure NN NN O
tolerance NN NN O
of NN NN O
PG NN NN O
or NN NN O
sensitivity NN NN O
to NN NN O
AX NN NN O
. NN NN O
   
A NN NN O
total NN NN O
of NN NN O
177 NN NN O
patients NN NN O
were NN NN O
diagnosed NN NN O
as NN NN O
allergic NN NN B-Disease
to NN NN O
beta NN NN O
- NN NN O
lactam NN NN O
antibiotics NN NN O
. NN NN O
   
We NN NN O
selected NN NN O
the NN NN O
54 NN NN O
( NN NN O
30 NN NN O
. NN NN O
5 NN NN O
% NN NN O
) NN NN O
cases NN NN O
of NN NN O
immediate NN NN O
AX NN NN O
allergy NN NN B-Disease
with NN NN O
good NN NN O
tolerance NN NN O
of NN NN O
PG NN NN O
. NN NN O
   
Anaphylaxis NN NN B-Disease
was NN NN O
seen NN NN O
in NN NN O
37 NN NN O
patients NN NN O
( NN NN O
69 NN NN O
% NN NN O
) NN NN O
, NN NN O
the NN NN O
other NN NN O
17 NN NN O
( NN NN O
31 NN NN O
% NN NN O
) NN NN O
having NN NN O
urticaria NN NN B-Disease
and NN NN O
/ NN NN O
or NN NN O
angioedema NN NN B-Disease
. NN NN O
   
All NN NN O
the NN NN O
patients NN NN O
were NN NN O
skin NN NN O
test NN NN O
negative NN NN O
to NN NN O
BPO NN NN O
; NN NN O
49 NN NN O
of NN NN O
51 NN NN O
( NN NN O
96 NN NN O
% NN NN O
) NN NN O
were NN NN O
also NN NN O
negative NN NN O
to NN NN O
MDM NN NN B-Disease
, NN NN O
and NN NN O
44 NN NN O
of NN NN O
46 NN NN O
( NN NN O
96 NN NN O
% NN NN O
) NN NN O
to NN NN O
PG NN NN O
. NN NN O
   
Skin NN NN O
tests NN NN O
with NN NN O
AX NN NN O
were NN NN O
positive NN NN O
in NN NN O
34 NN NN O
( NN NN O
63 NN NN O
% NN NN O
) NN NN O
patients NN NN O
. NN NN O
   
RAST NN NN O
was NN NN O
positive NN NN O
for NN NN O
AX NN NN O
in NN NN O
22 NN NN O
patients NN NN O
( NN NN O
41 NN NN O
% NN NN O
) NN NN O
and NN NN O
to NN NN O
BPO NN NN O
in NN NN O
just NN NN O
5 NN NN O
( NN NN O
9 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
   O
of NN NN O
the NN NN O
sera NN NN O
with NN NN O
negative NN NN O
RAST NN NN O
for NN NN O
AX NN NN O
were NN NN O
positive NN NN O
to NN NN O
BPO NN NN O
. NN NN O
   
Challenge NN NN O
tests NN NN O
with NN NN O
AX NN NN O
were NN NN O
performed NN NN O
in NN NN O
23 NN NN O
subjects NN NN O
( NN NN O
43 NN NN O
% NN NN O
) NN NN O
to NN NN O
establish NN NN O
the NN NN O
diagnosis NN NN O
of NN NN O
immediate NN NN O
allergic NN NN B-Disease
reaction NN NN I-Disease
to NN NN O
AX NN NN O
, NN NN O
and NN NN O
in NN NN O
15 NN NN O
cases NN NN O
( NN NN O
28 NN NN O
% NN NN O
) NN NN O
both NN NN O
skin NN NN O
test NN NN O
and NN NN O
RAST NN NN O
for NN NN O
AX NN NN O
were NN NN O
negative NN NN O
. NN NN O
   
PG NN NN O
was NN NN O
well NN NN O
tolerated NN NN O
by NN NN O
all NN NN O
54 NN NN O
patients NN NN O
. NN NN O
   
We NN NN O
describe NN NN O
the NN NN O
largest NN NN O
group NN NN O
of NN NN O
AX NN NN O
- NN NN O
allergic NN NN B-Disease
patients NN NN O
who NN NN O
have NN NN O
tolerated NN NN O
PG NN NN O
reported NN NN O
so NN NN O
far NN NN O
. NN NN O
   
Diagnosis NN NN O
of NN NN O
these NN NN O
patients NN NN O
can NN NN O
be NN NN O
achieved NN NN O
only NN NN O
if NN NN O
specific NN NN O
AX NN NN O
- NN NN O
related NN NN O
reagents NN NN O
are NN NN O
employed NN NN O
. NN NN O
   
Further NN NN O
studies NN NN O
are NN NN O
necessary NN NN O
to NN NN O
determine NN NN O
the NN NN O
exact NN NN O
extent NN NN O
of NN NN O
this NN NN O
problem NN NN O
and NN NN O
to NN NN O
improve NN NN O
the NN NN O
efficacy NN NN O
of NN NN O
diagnostic NN NN O
methods NN NN O
. NN NN O
   
Reversal NN NN O
by NN NN O
phenylephrine NN NN O
of NN NN O
the NN NN O
beneficial NN NN O
effects NN NN O
of NN NN O
intravenous NN NN O
nitroglycerin NN NN O
in NN NN O
patients NN NN O
with NN NN O
acute NN NN B-Disease
myocardial NN NN I-Disease
infarction NN NN I-Disease
. NN NN O
   
Nitroglycerin NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
reduce NN NN O
ST NN NN O
- NN NN O
segment NN NN O
elevation NN NN O
during NN NN O
acute NN NN B-Disease
myocardial NN NN I-Disease
infarction NN NN I-Disease
, NN NN O
an NN NN O
effect NN NN O
potentiated NN NN O
in NN NN O
the NN NN O
dog NN NN O
by NN NN O
agents NN NN O
that NN NN O
reverse NN NN O
nitroglycerin NN NN O
- NN NN O
induced NN NN O
hypotension NN NN B-Disease
. NN NN O
   
Our NN NN O
study NN NN O
was NN NN O
designed NN NN O
to NN NN O
determine NN NN O
the NN NN O
effects NN NN O
of NN NN O
combined NN NN O
nitroglycerin NN NN O
and NN NN O
phenylephrine NN NN O
therapy NN NN O
. NN NN O
   
Ten NN NN O
patients NN NN O
with NN NN O
acute NN NN O
transmural NN NN O
myocardial NN NN B-Disease
infarctions NN NN I-Disease
received NN NN O
intravenous NN NN O
nitroglycerin NN NN O
, NN NN O
sufficient NN NN O
to NN NN O
reduce NN NN O
mean NN NN O
arterial NN NN O
pressure NN NN O
from NN NN O
107 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
6 NN NN O
to NN NN O
85 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
6 NN NN O
mm NN NN O
Hg NN NN O
( NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
, NN NN O
for NN NN O
60 NN NN O
minutes NN NN O
. NN NN O
   
Left NN NN O
ventricular NN NN O
filling NN NN O
pressure NN NN O
decreased NN NN O
from NN NN O
19 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
to NN NN O
11 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
mm NN NN O
Hg NN NN O
( NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
. NN NN O
   
SigmaST NN NN O
, NN NN O
the NN NN O
sum NN NN O
of NN NN O
ST NN NN O
- NN NN O
segment NN NN O
elevations NN NN O
in NN NN O
16 NN NN O
precordial NN NN O
leads NN NN O
, NN NN O
decreased NN NN O
( NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
02 NN NN O
) NN NN O
with NN NN O
intravenous NN NN O
nitroglycerin NN NN O
. NN NN O
   
Subsequent NN NN O
addition NN NN O
of NN NN O
phenylephrine NN NN O
infusion NN NN O
, NN NN O
sufficient NN NN O
to NN NN O
re NN NN O
- NN NN O
elevate NN NN O
mean NN NN O
arterial NN NN O
pressure NN NN O
to NN NN O
106 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
4 NN NN O
mm NN NN O
Hg NN NN O
( NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
for NN NN O
30 NN NN O
minutes NN NN O
, NN NN O
increased NN NN O
left NN NN O
ventricular NN NN O
filling NN NN O
pressure NN NN O
to NN NN O
17 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
mm NN NN O
Hg NN NN O
( NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
and NN NN O
also NN NN O
significantly NN NN O
increased NN NN O
sigmaST NN NN O
( NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
suggest NN NN O
that NN NN O
addition NN NN O
of NN NN O
phenylephrine NN NN O
to NN NN O
nitroglycerin NN NN O
is NN NN O
not NN NN O
beneficial NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
patients NN NN O
with NN NN O
acute NN NN B-Disease
myocardial NN NN I-Disease
infarction NN NN I-Disease
. NN NN O
   
Acetazolamide NN NN O
- NN NN O
induced NN NN O
nephrolithiasis NN NN B-Disease
: NN NN O
implications NN NN O
for NN NN O
treatment NN NN O
of NN NN O
neuromuscular NN NN B-Disease
disorders NN NN I-Disease
. NN NN O
   
Carbonic NN NN O
anhydrase NN NN O
inhibitors NN NN O
can NN NN O
cause NN NN O
nephrolithiasis NN NN B-Disease
. NN NN O
   
We NN NN O
studied NN NN O
20 NN NN O
patients NN NN O
receiving NN NN O
long NN NN O
- NN NN O
term NN NN O
carbonic NN NN O
anhydrase NN NN O
inhibitor NN NN O
treatment NN NN O
for NN NN O
periodic NN NN O
paralysis NN NN B-Disease
and NN NN O
myotonia NN NN B-Disease
. NN NN O
   
Three NN NN O
patients NN NN O
on NN NN O
acetazolamide NN NN O
( NN NN O
15 NN NN O
% NN NN O
) NN NN O
developed NN NN O
renal NN NN B-Disease
calculi NN NN I-Disease
. NN NN O
   
Extracorporeal NN NN O
lithotripsy NN NN O
successfully NN NN O
removed NN NN O
a NN NN O
renal NN NN B-Disease
calculus NN NN I-Disease
in NN NN O
one NN NN O
patient NN NN O
and NN NN O
surgery NN NN O
removed NN NN O
a NN NN O
staghorn NN NN O
calculus NN NN B-Disease
in NN NN O
another NN NN O
, NN NN O
permitting NN NN O
continued NN NN O
treatment NN NN O
. NN NN O
   
Renal NN NN O
function NN NN O
remained NN NN O
normal NN NN O
in NN NN O
all NN NN O
patients NN NN O
. NN NN O
   
Nephrolithiasis NN NN B-Disease
is NN NN O
a NN NN O
complication NN NN O
of NN NN O
acetazolamide NN NN O
but NN NN O
does NN NN O
not NN NN O
preclude NN NN O
its NN NN O
use NN NN O
. NN NN O
   
Effects NN NN O
of NN NN O
calcium NN NN O
channel NN NN O
blockers NN NN O
on NN NN O
bupivacaine NN NN O
- NN NN O
induced NN NN O
toxicity NN NN B-Disease
. NN NN O
   
The NN NN O
purpose NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
investigate NN NN O
the NN NN O
influence NN NN O
of NN NN O
calcium NN NN O
channel NN NN O
blockers NN NN O
on NN NN O
bupivacaine NN NN O
- NN NN O
induced NN NN O
acute NN NN O
toxicity NN NN B-Disease
. NN NN O
   
For NN NN O
each NN NN O
of NN NN O
the NN NN O
three NN NN O
tested NN NN O
calcium NN NN O
channel NN NN O
blockers NN NN O
( NN NN O
diltiazem NN NN O
, NN NN O
verapamil NN NN O
and NN NN O
bepridil NN NN O
) NN NN O
6 NN NN O
groups NN NN O
of NN NN O
mice NN NN O
were NN NN O
treated NN NN O
by NN NN O
two NN NN O
different NN NN O
doses NN NN O
, NN NN O
i NN NN O
. NN NN O
e NN NN O
. NN NN O
2 NN NN O
and NN NN O
10 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
, NN NN O
or NN NN O
an NN NN O
equal NN NN O
volume NN NN O
of NN NN O
saline NN NN O
for NN NN O
the NN NN O
control NN NN O
group NN NN O
( NN NN O
n NN NN O
= NN NN O
20 NN NN O
) NN NN O
; NN NN O
15 NN NN O
minutes NN NN O
later NN NN O
, NN NN O
all NN NN O
the NN NN O
animals NN NN O
were NN NN O
injected NN NN O
with NN NN O
a NN NN O
single NN NN O
50 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
dose NN NN O
of NN NN O
bupivacaine NN NN O
. NN NN O
   
The NN NN O
convulsant NN NN O
activity NN NN O
, NN NN O
the NN NN O
time NN NN O
of NN NN O
latency NN NN O
to NN NN O
convulse NN NN O
and NN NN O
the NN NN O
mortality NN NN O
rate NN NN O
were NN NN O
assessed NN NN O
in NN NN O
each NN NN O
group NN NN O
. NN NN O
   
The NN NN O
local NN NN O
anesthetic NN NN O
- NN NN O
induced NN NN O
mortality NN NN O
was NN NN O
significantly NN NN O
increased NN NN O
by NN NN O
the NN NN O
three NN NN O
different NN NN O
calcium NN NN O
channel NN NN O
blockers NN NN O
. NN NN O
   
The NN NN O
convulsant NN NN O
activity NN NN O
of NN NN O
bupivacaine NN NN O
was NN NN O
not NN NN O
significantly NN NN O
modified NN NN O
but NN NN O
calcium NN NN O
channel NN NN O
blockers NN NN O
decreased NN NN O
the NN NN O
time NN NN O
of NN NN O
latency NN NN O
to NN NN O
obtain NN NN O
bupivacaine NN NN O
- NN NN O
induced NN NN O
convulsions NN NN B-Disease
; NN NN O
this NN NN O
effect NN NN O
was NN NN O
less NN NN O
pronounced NN NN O
with NN NN O
bepridil NN NN O
. NN NN O
   
Epidural NN NN O
blood NN NN O
flow NN NN O
during NN NN O
prostaglandin NN NN O
E1 NN NN O
or NN NN O
trimethaphan NN NN O
induced NN NN O
hypotension NN NN B-Disease
. NN NN O
   
To NN NN O
evaluate NN NN O
the NN NN O
effect NN NN O
of NN NN O
prostaglandin NN NN O
E1 NN NN O
( NN NN O
PGE1 NN NN O
) NN NN O
or NN NN O
trimethaphan NN NN O
( NN NN O
TMP NN NN O
) NN NN O
induced NN NN O
hypotension NN NN B-Disease
on NN NN O
epidural NN NN O
blood NN NN O
flow NN NN O
( NN NN O
EBF NN NN O
) NN NN O
during NN NN O
spinal NN NN O
surgery NN NN O
, NN NN O
EBF NN NN O
was NN NN O
measured NN NN O
using NN NN O
the NN NN O
heat NN NN O
clearance NN NN O
method NN NN O
in NN NN O
30 NN NN O
patients NN NN O
who NN NN O
underwent NN NN O
postero NN NN O
- NN NN O
lateral NN NN O
interbody NN NN O
fusion NN NN O
under NN NN O
isoflurane NN NN O
anaesthesia NN NN O
. NN NN O
   
An NN NN O
initial NN NN O
dose NN NN O
of NN NN O
0 NN NN O
. NN NN O
1 NN NN O
microgram NN NN O
. NN NN O
kg NN NN O
- NN NN O
1 NN NN O
. NN NN O
min NN NN O
- NN NN O
1 NN NN O
of NN NN O
PGE1 NN NN O
( NN NN O
15 NN NN O
patients NN NN O
) NN NN O
, NN NN O
or NN NN O
10 NN NN O
micrograms NN NN O
. NN NN O
kg NN NN O
- NN NN O
1 NN NN O
. NN NN O
min NN NN O
- NN NN O
1 NN NN O
of NN NN O
TMP NN NN O
( NN NN O
15 NN NN O
patients NN NN O
) NN NN O
was NN NN O
administered NN NN O
intravenously NN NN O
after NN NN O
the NN NN O
dural NN NN O
opening NN NN O
and NN NN O
the NN NN O
dose NN NN O
was NN NN O
adjusted NN NN O
to NN NN O
maintain NN NN O
the NN NN O
mean NN NN O
arterial NN NN O
blood NN NN O
pressure NN NN O
( NN NN O
MAP NN NN O
) NN NN O
at NN NN O
about NN NN O
60 NN NN O
mmHg NN NN O
. NN NN O
   
The NN NN O
hypotensive NN NN B-Disease
drug NN NN O
was NN NN O
discontinued NN NN O
at NN NN O
the NN NN O
completion NN NN O
of NN NN O
the NN NN O
operative NN NN O
procedure NN NN O
. NN NN O
   
After NN NN O
starting NN NN O
PGE1 NN NN O
or NN NN O
TMP NN NN O
, NN NN O
MAP NN NN O
and NN NN O
rate NN NN O
pressure NN NN O
product NN NN O
( NN NN O
RPP NN NN O
) NN NN O
decreased NN NN O
significantly NN NN O
compared NN NN O
with NN NN O
preinfusion NN NN O
values NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
, NN NN O
and NN NN O
the NN NN O
degree NN NN O
of NN NN O
hypotension NN NN B-Disease
due NN NN O
to NN NN O
PGE1 NN NN O
remained NN NN O
constant NN NN O
until NN NN O
60 NN NN O
min NN NN O
after NN NN O
its NN NN O
discontinuation NN NN O
. NN NN O
   
Heart NN NN O
rate NN NN O
( NN NN O
HR NN NN O
) NN NN O
did NN NN O
not NN NN O
change NN NN O
in NN NN O
either NN NN O
group NN NN O
. NN NN O
   
EBFF NN NN O
did NN NN O
not NN NN O
change NN NN O
during NN NN O
PGE1 NN NN O
infusion NN NN O
whereas NN NN O
in NN NN O
the NN NN O
TMP NN NN O
group NN NN O
, NN NN O
EBF NN NN O
decreased NN NN O
significantly NN NN O
at NN NN O
30 NN NN O
and NN NN O
60 NN NN O
min NN NN O
after NN NN O
the NN NN O
start NN NN O
of NN NN O
TMP NN NN O
( NN NN O
preinfusion NN NN O
: NN NN O
45 NN NN O
. NN NN O
9 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
13 NN NN O
. NN NN O
9 NN NN O
ml NN NN O
/ NN NN O
100g NN NN O
/ NN NN O
min NN NN O
. NN NN O
30 NN NN O
min NN NN O
: NN NN O
32 NN NN O
. NN NN O
3 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
9 NN NN O
. NN NN O
9 NN NN O
ml NN NN O
/ NN NN O
100 NN NN O
g NN NN O
/ NN NN O
min NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
60 NN NN O
min NN NN O
: NN NN O
30 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
7 NN NN O
. NN NN O
5 NN NN O
ml NN NN O
/ NN NN O
100 NN NN O
g NN NN O
/ NN NN O
min NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
) NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
PGE1 NN NN O
may NN NN O
be NN NN O
preferable NN NN O
to NN NN O
TMP NN NN O
for NN NN O
hypotensive NN NN B-Disease
anaesthesia NN NN O
in NN NN O
spinal NN NN O
surgery NN NN O
because NN NN O
TMP NN NN O
decreased NN NN O
EBF NN NN O
. NN NN O
   
Dup NN NN O
753 NN NN O
prevents NN NN O
the NN NN O
development NN NN O
of NN NN O
puromycin NN NN O
aminonucleoside NN NN O
- NN NN O
induced NN NN O
nephrosis NN NN B-Disease
. NN NN O
   
The NN NN O
appearance NN NN O
of NN NN O
nephrotic NN NN B-Disease
syndromes NN NN I-Disease
such NN NN O
as NN NN O
proteinuria NN NN B-Disease
, NN NN O
hypoalbuminemia NN NN B-Disease
, NN NN O
hypercholesterolemia NN NN B-Disease
and NN NN O
increase NN NN O
in NN NN O
blood NN NN O
nitrogen NN NN O
urea NN NN O
, NN NN O
induced NN NN O
in NN NN O
rats NN NN O
by NN NN O
injection NN NN O
of NN NN O
puromycin NN NN O
aminonucleoside NN NN O
was NN NN O
markedly NN NN O
inhibited NN NN O
by NN NN O
oral NN NN O
administration NN NN O
of NN NN O
Dup NN NN O
753 NN NN O
( NN NN O
losartan NN NN O
) NN NN O
, NN NN O
a NN NN O
novel NN NN O
angiotensin NN NN O
II NN NN O
receptor NN NN O
antagonist NN NN O
, NN NN O
at NN NN O
a NN NN O
dose NN NN O
of NN NN O
1 NN NN O
or NN NN O
2 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
per NN NN O
day NN NN O
. NN NN O
   
The NN NN O
results NN NN O
suggest NN NN O
a NN NN O
possible NN NN O
involvement NN NN O
of NN NN O
the NN NN O
renin NN NN O
- NN NN O
angiotensin NN NN O
system NN NN O
in NN NN O
the NN NN O
development NN NN O
of NN NN O
puromycin NN NN O
aminonucleoside NN NN O
- NN NN O
induced NN NN O
nephrosis NN NN B-Disease
. NN NN O
   
Neuroplasticity NN NN O
of NN NN O
the NN NN O
adult NN NN O
primate NN NN O
auditory NN NN O
cortex NN NN O
following NN NN O
cochlear NN NN O
hearing NN NN B-Disease
loss NN NN I-Disease
. NN NN O
   
Tonotopic NN NN O
organization NN NN O
is NN NN O
an NN NN O
essential NN NN O
feature NN NN O
of NN NN O
the NN NN O
primary NN NN O
auditory NN NN O
area NN NN O
( NN NN O
A1 NN NN O
) NN NN O
of NN NN O
primate NN NN O
cortex NN NN O
. NN NN O
   
In NN NN O
A1 NN NN O
of NN NN O
macaque NN NN O
monkeys NN NN O
, NN NN O
low NN NN O
frequencies NN NN O
are NN NN O
represented NN NN O
rostrolaterally NN NN O
and NN NN O
high NN NN O
frequencies NN NN O
are NN NN O
represented NN NN O
caudomedially NN NN O
. NN NN O
   
The NN NN O
purpose NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
determine NN NN O
if NN NN O
changes NN NN O
occur NN NN O
in NN NN O
this NN NN O
tonotopic NN NN O
organization NN NN O
following NN NN O
cochlear NN NN O
hearing NN NN B-Disease
loss NN NN I-Disease
. NN NN O
   
Under NN NN O
anesthesia NN NN O
, NN NN O
the NN NN O
superior NN NN O
temporal NN NN O
gyrus NN NN O
of NN NN O
adult NN NN O
macaque NN NN O
monkeys NN NN O
was NN NN O
exposed NN NN O
, NN NN O
and NN NN O
the NN NN O
tonotopic NN NN O
organization NN NN O
of NN NN O
A1 NN NN O
was NN NN O
mapped NN NN O
using NN NN O
conventional NN NN O
microelectrode NN NN O
recording NN NN O
techniques NN NN O
. NN NN O
   
Following NN NN O
recovery NN NN O
, NN NN O
the NN NN O
monkeys NN NN O
were NN NN O
selectively NN NN O
deafened NN NN O
for NN NN O
high NN NN O
frequencies NN NN O
using NN NN O
kanamycin NN NN O
and NN NN O
furosemide NN NN O
. NN NN O
   
The NN NN O
actual NN NN O
frequencies NN NN O
deafened NN NN O
were NN NN O
determined NN NN O
by NN NN O
the NN NN O
loss NN NN O
of NN NN O
tone NN NN O
- NN NN O
burst NN NN O
elicited NN NN O
auditory NN NN O
brainstem NN NN O
responses NN NN O
. NN NN O
   
Three NN NN O
months NN NN O
after NN NN O
deafening NN NN O
, NN NN O
A1 NN NN O
was NN NN O
remapped NN NN O
. NN NN O
   
Postmortem NN NN O
cytoarchitectural NN NN O
features NN NN O
identifying NN NN O
A1 NN NN O
were NN NN O
correlated NN NN O
with NN NN O
the NN NN O
electrophysiologic NN NN O
data NN NN O
. NN NN O
   
The NN NN O
results NN NN O
indicate NN NN O
that NN NN O
the NN NN O
deprived NN NN O
area NN NN O
of NN NN O
A1 NN NN O
undergoes NN NN O
extensive NN NN O
reorganization NN NN O
and NN NN O
becomes NN NN O
responsive NN NN O
to NN NN O
intact NN NN O
cochlear NN NN O
frequencies NN NN O
. NN NN O
   
The NN NN O
region NN NN O
of NN NN O
cortex NN NN O
that NN NN O
represents NN NN O
the NN NN O
low NN NN O
frequencies NN NN O
was NN NN O
not NN NN O
obviously NN NN O
affected NN NN O
by NN NN O
the NN NN O
cochlear NN NN O
hearing NN NN B-Disease
loss NN NN I-Disease
. NN NN O
   
Sodium NN NN O
bicarbonate NN NN O
alleviates NN NN O
penile NN NN B-Disease
pain NN NN I-Disease
induced NN NN O
by NN NN O
intracavernous NN NN O
injections NN NN O
for NN NN O
erectile NN NN B-Disease
dysfunction NN NN I-Disease
. NN NN O
   
In NN NN O
an NN NN O
attempt NN NN O
to NN NN O
determine NN NN O
whether NN NN O
penile NN NN B-Disease
pain NN NN I-Disease
associated NN NN O
with NN NN O
intracorporeal NN NN O
injections NN NN O
could NN NN O
be NN NN O
due NN NN O
to NN NN O
the NN NN O
acidity NN NN O
of NN NN O
the NN NN O
medication NN NN O
, NN NN O
we NN NN O
performed NN NN O
a NN NN O
randomized NN NN O
study NN NN O
comparing NN NN O
the NN NN O
incidence NN NN O
of NN NN O
penile NN NN B-Disease
pain NN NN I-Disease
following NN NN O
intracorporeal NN NN O
injections NN NN O
with NN NN O
or NN NN O
without NN NN O
the NN NN O
addition NN NN O
of NN NN O
sodium NN NN O
bicarbonate NN NN O
to NN NN O
the NN NN O
intracorporeal NN NN O
medications NN NN O
. NN NN O
   
A NN NN O
total NN NN O
of NN NN O
38 NN NN O
consecutive NN NN O
patients NN NN O
who NN NN O
presented NN NN O
to NN NN O
our NN NN O
clinic NN NN O
with NN NN O
impotence NN NN B-Disease
received NN NN O
0 NN NN O
. NN NN O
2 NN NN O
ml NN NN O
. NN NN O
of NN NN O
a NN NN O
combination NN NN O
of NN NN O
3 NN NN O
drugs NN NN O
: NN NN O
6 NN NN O
mg NN NN O
. NN NN O
papaverine NN NN O
, NN NN O
100 NN NN O
micrograms NN NN O
. NN NN O
phentolamine NN NN O
and NN NN O
10 NN NN O
micrograms NN NN O
. NN NN O
prostaglandin NN NN O
E1 NN NN O
with NN NN O
( NN NN O
pH NN NN O
7 NN NN O
. NN NN O
05 NN NN O
) NN NN O
or NN NN O
without NN NN O
( NN NN O
pH NN NN O
4 NN NN O
. NN NN O
17 NN NN O
) NN NN O
the NN NN O
addition NN NN O
of NN NN O
sodium NN NN O
bicarbonate NN NN O
( NN NN O
0 NN NN O
. NN NN O
03 NN NN O
mEq NN NN O
. NN NN O
) NN NN O
. NN NN O
   
Of NN NN O
the NN NN O
19 NN NN O
patients NN NN O
without NN NN O
sodium NN NN O
bicarbonate NN NN O
added NN NN O
to NN NN O
the NN NN O
medication NN NN O
11 NN NN O
( NN NN O
58 NN NN O
% NN NN O
) NN NN O
complained NN NN O
of NN NN O
penile NN NN B-Disease
pain NN NN I-Disease
due NN NN O
to NN NN O
the NN NN O
medication NN NN O
, NN NN O
while NN NN O
only NN NN O
1 NN NN O
of NN NN O
the NN NN O
19 NN NN O
men NN NN O
( NN NN O
5 NN NN O
% NN NN O
) NN NN O
who NN NN O
received NN NN O
sodium NN NN O
bicarbonate NN NN O
complained NN NN O
of NN NN O
penile NN NN B-Disease
pain NN NN I-Disease
. NN NN O
   
From NN NN O
these NN NN O
data NN NN O
we NN NN O
conclude NN NN O
that NN NN O
the NN NN O
penile NN NN B-Disease
pain NN NN I-Disease
following NN NN O
intracorporeal NN NN O
injections NN NN O
is NN NN O
most NN NN O
likely NN NN O
due NN NN O
to NN NN O
the NN NN O
acidity NN NN O
of NN NN O
the NN NN O
medication NN NN O
, NN NN O
which NN NN O
can NN NN O
be NN NN O
overcome NN NN O
by NN NN O
elevating NN NN O
the NN NN O
pH NN NN O
to NN NN O
a NN NN O
neutral NN NN O
level NN NN O
. NN NN O
   
The NN NN O
use NN NN O
and NN NN O
toxicity NN NN B-Disease
of NN NN O
didanosine NN NN O
( NN NN O
ddI NN NN O
) NN NN O
in NN NN O
HIV NN NN B-Disease
antibody NN NN I-Disease
- NN NN I-Disease
positive NN NN I-Disease
individuals NN NN O
intolerant NN NN O
to NN NN O
zidovudine NN NN O
( NN NN O
AZT NN NN O
) NN NN O
   
One NN NN O
hundred NN NN O
and NN NN O
fifty NN NN O
- NN NN O
one NN NN O
patients NN NN O
intolerant NN NN O
to NN NN O
zidovudine NN NN O
( NN NN O
AZT NN NN O
) NN NN O
received NN NN O
didanosine NN NN O
( NN NN O
ddI NN NN O
) NN NN O
to NN NN O
a NN NN O
maximum NN NN O
dose NN NN O
of NN NN O
12 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
. NN NN O
   
Patient NN NN O
response NN NN O
was NN NN O
assessed NN NN O
using NN NN O
changes NN NN O
in NN NN O
CD4 NN NN O
+ NN NN O
lymphocyte NN NN O
subset NN NN O
count NN NN O
, NN NN O
HIV NN NN O
p24 NN NN O
antigen NN NN O
, NN NN O
weight NN NN O
, NN NN O
and NN NN O
quality NN NN O
of NN NN O
life NN NN O
. NN NN O
   
Seventy NN NN O
patients NN NN O
developed NN NN O
major NN NN O
opportunistic NN NN B-Disease
infections NN NN I-Disease
whilst NN NN O
on NN NN O
therapy NN NN O
; NN NN O
this NN NN O
was NN NN O
the NN NN O
first NN NN O
AIDS NN NN B-Disease
diagnosis NN NN O
in NN NN O
17 NN NN O
. NN NN O
   
Only NN NN O
minor NN NN O
changes NN NN O
in NN NN O
CD4 NN NN O
+ NN NN O
lymphocyte NN NN O
subset NN NN O
count NN NN O
were NN NN O
observed NN NN O
in NN NN O
AIDS NN NN B-Disease
patients NN NN O
, NN NN O
although NN NN O
a NN NN O
more NN NN O
significant NN NN O
rise NN NN O
occurred NN NN O
in NN NN O
those NN NN O
with NN NN O
earlier NN NN O
stages NN NN O
of NN NN O
disease NN NN O
. NN NN O
   
Of NN NN O
those NN NN O
positive NN NN O
for NN NN O
p24 NN NN O
antigen NN NN O
at NN NN O
the NN NN O
commencement NN NN O
of NN NN O
the NN NN O
study NN NN O
67 NN NN O
% NN NN O
showed NN NN O
a NN NN O
positive NN NN O
response NN NN O
, NN NN O
and NN NN O
this NN NN O
was NN NN O
most NN NN O
likely NN NN O
in NN NN O
those NN NN O
with NN NN O
CD4 NN NN O
+ NN NN O
lymphocyte NN NN O
subset NN NN O
counts NN NN O
above NN NN O
100 NN NN O
mm3 NN NN O
. NN NN O
   
A NN NN O
positive NN NN O
weight NN NN O
response NN NN O
was NN NN O
seen NN NN O
in NN NN O
16 NN NN O
% NN NN O
of NN NN O
patients NN NN O
. NN NN O
   
Most NN NN O
patients NN NN O
showed NN NN O
improvement NN NN O
in NN NN O
individual NN NN O
parameters NN NN O
and NN NN O
global NN NN O
score NN NN O
of NN NN O
quality NN NN O
of NN NN O
life NN NN O
. NN NN O
   
Adverse NN NN O
reactions NN NN O
possibly NN NN O
attributable NN NN O
to NN NN O
didanosine NN NN O
were NN NN O
common NN NN O
. NN NN O
   
The NN NN O
most NN NN O
common NN NN O
side NN NN O
- NN NN O
effect NN NN O
was NN NN O
diarrhoea NN NN B-Disease
, NN NN O
which NN NN O
resulted NN NN O
in NN NN O
cessation NN NN O
of NN NN O
therapy NN NN O
in NN NN O
19 NN NN O
individuals NN NN O
. NN NN O
   
Peripheral NN NN B-Disease
neuropathy NN NN I-Disease
occurred NN NN O
in NN NN O
12 NN NN O
patients NN NN O
and NN NN O
pancreatitis NN NN B-Disease
in NN NN O
six NN NN O
. NN NN O
   
Thirteen NN NN O
patients NN NN O
developed NN NN O
a NN NN O
raised NN NN O
serum NN NN O
amylase NN NN O
without NN NN O
abdominal NN NN B-Disease
pain NN NN I-Disease
. NN NN O
   
Seven NN NN O
patients NN NN O
developed NN NN O
glucose NN NN B-Disease
tolerance NN NN I-Disease
curves NN NN I-Disease
characteristic NN NN O
of NN NN O
diabetes NN NN B-Disease
but NN NN O
these NN NN O
were NN NN O
mild NN NN O
, NN NN O
did NN NN O
not NN NN O
require NN NN O
treatment NN NN O
and NN NN O
returned NN NN O
to NN NN O
normal NN NN O
on NN NN O
ceasing NN NN O
didanosine NN NN O
. NN NN O
   
Immunohistochemical NN NN O
studies NN NN O
with NN NN O
antibodies NN NN O
to NN NN O
neurofilament NN NN O
proteins NN NN O
on NN NN O
axonal NN NN B-Disease
damage NN NN I-Disease
in NN NN O
experimental NN NN O
focal NN NN O
lesions NN NN O
in NN NN O
rat NN NN O
. NN NN O
   
Immunohistochemistry NN NN O
with NN NN O
monoclonal NN NN O
antibodies NN NN O
against NN NN O
neurofilament NN NN O
( NN NN O
NF NN NN O
) NN NN O
proteins NN NN O
of NN NN O
middle NN NN O
and NN NN O
high NN NN O
molecular NN NN O
weight NN NN O
class NN NN O
, NN NN O
NF NN NN O
- NN NN O
M NN NN O
and NN NN O
NF NN NN O
- NN NN O
H NN NN O
, NN NN O
was NN NN O
used NN NN O
to NN NN O
study NN NN O
axonal NN NN B-Disease
injury NN NN I-Disease
in NN NN O
the NN NN O
borderzone NN NN O
of NN NN O
focal NN NN O
lesions NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
Focal NN NN O
injury NN NN B-Disease
in NN NN I-Disease
the NN NN I-Disease
cortex NN NN I-Disease
was NN NN O
produced NN NN O
by NN NN O
infusion NN NN O
of NN NN O
lactate NN NN O
at NN NN O
acid NN NN O
pH NN NN O
or NN NN O
by NN NN O
stab NN NN O
caused NN NN O
by NN NN O
needle NN NN O
insertion NN NN O
. NN NN O
   
Infarcts NN NN B-Disease
in NN NN I-Disease
substantia NN NN I-Disease
nigra NN NN I-Disease
pars NN NN I-Disease
reticulata NN NN I-Disease
were NN NN O
evoked NN NN O
by NN NN O
prolonged NN NN O
pilocarpine NN NN O
- NN NN O
induced NN NN O
status NN NN B-Disease
epilepticus NN NN I-Disease
. NN NN O
   
Immunohistochemical NN NN O
staining NN NN O
for NN NN O
NFs NN NN O
showed NN NN O
characteristic NN NN O
terminal NN NN O
clubs NN NN O
of NN NN O
axons NN NN O
in NN NN O
the NN NN O
borderzone NN NN O
of NN NN O
lesions NN NN O
. NN NN O
   
Differences NN NN O
in NN NN O
the NN NN O
labelling NN NN O
pattern NN NN O
occurred NN NN O
with NN NN O
different NN NN O
antibodies NN NN O
which NN NN O
apparently NN NN O
depended NN NN O
on NN NN O
molecular NN NN O
weight NN NN O
class NN NN O
of NN NN O
NFs NN NN O
and NN NN O
phosphorylation NN NN O
state NN NN O
. NN NN O
   
These NN NN O
immunohistochemical NN NN O
changes NN NN O
of NN NN O
NFs NN NN O
can NN NN O
serve NN NN O
as NN NN O
a NN NN O
marker NN NN O
for NN NN O
axonal NN NN B-Disease
damage NN NN I-Disease
in NN NN O
various NN NN O
experimental NN NN O
traumatic NN NN B-Disease
or NN NN O
ischemic NN NN O
lesions NN NN O
. NN NN O
   
Pharmacokinetic NN NN O
and NN NN O
clinical NN NN O
studies NN NN O
in NN NN O
patients NN NN O
with NN NN O
cimetidine NN NN O
- NN NN O
associated NN NN O
mental NN NN O
confusion NN NN B-Disease
. NN NN O
   
15 NN NN O
cases NN NN O
of NN NN O
cimetidine NN NN O
- NN NN O
associated NN NN O
mental NN NN O
confusion NN NN B-Disease
have NN NN O
been NN NN O
reported NN NN O
. NN NN O
   
In NN NN O
order NN NN O
that NN NN O
this NN NN O
syndrome NN NN O
might NN NN O
be NN NN O
investigated NN NN O
changes NN NN O
in NN NN O
mental NN NN O
status NN NN O
( NN NN O
M NN NN O
. NN NN O
S NN NN O
. NN NN O
) NN NN O
were NN NN O
correlated NN NN O
with NN NN O
serum NN NN O
concentrations NN NN O
and NN NN O
renal NN NN O
and NN NN O
hepatic NN NN O
function NN NN O
in NN NN O
36 NN NN O
patients NN NN O
, NN NN O
30 NN NN O
patients NN NN O
had NN NN O
no NN NN O
M NN NN O
. NN NN O
S NN NN O
. NN NN O
change NN NN O
on NN NN O
cimetidine NN NN O
and NN NN O
6 NN NN O
had NN NN O
moderate NN NN O
to NN NN O
severe NN NN O
changes NN NN O
. NN NN O
   
These NN NN O
6 NN NN O
patients NN NN O
had NN NN O
both NN NN O
renal NN NN B-Disease
and NN NN I-Disease
liver NN NN I-Disease
dysfunction NN NN I-Disease
( NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
cimetidine NN NN O
trough NN NN O
- NN NN O
concentrations NN NN O
of NN NN O
more NN NN O
than NN NN O
1 NN NN O
. NN NN O
25 NN NN O
microgram NN NN O
/ NN NN O
ml NN NN O
( NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
severity NN NN O
of NN NN O
M NN NN O
. NN NN O
S NN NN O
. NN NN O
changes NN NN O
increased NN NN O
as NN NN O
trough NN NN O
- NN NN O
concentrations NN NN O
rose NN NN O
, NN NN O
5 NN NN O
patients NN NN O
had NN NN O
lumbar NN NN O
puncture NN NN O
. NN NN O
   
The NN NN O
cerebrospinal NN NN O
fluid NN NN O
: NN NN O
serum NN NN O
ratio NN NN O
of NN NN O
cimetidine NN NN O
concentrations NN NN O
was NN NN O
0 NN NN O
. NN NN O
24 NN NN O
: NN NN O
1 NN NN O
and NN NN O
indicates NN NN O
that NN NN O
cimetidine NN NN O
passes NN NN O
the NN NN O
blood NN NN O
- NN NN O
brain NN NN O
barrier NN NN O
; NN NN O
it NN NN O
also NN NN O
raises NN NN O
the NN NN O
possibility NN NN O
that NN NN O
M NN NN O
. NN NN O
S NN NN O
. NN NN O
changes NN NN O
are NN NN O
due NN NN O
to NN NN O
blockade NN NN O
of NN NN O
histamine NN NN O
H2 NN NN O
- NN NN O
receptors NN NN O
in NN NN O
the NN NN O
central NN NN O
nervous NN NN O
system NN NN O
. NN NN O
   
Patients NN NN O
likely NN NN O
to NN NN O
have NN NN O
both NN NN O
raised NN NN O
trough NN NN O
- NN NN O
concentrations NN NN O
and NN NN O
mental NN NN O
confusion NN NN B-Disease
are NN NN O
those NN NN O
with NN NN O
both NN NN O
severe NN NN O
renal NN NN B-Disease
and NN NN I-Disease
hepatic NN NN I-Disease
dysfunction NN NN I-Disease
. NN NN O
   
They NN NN O
should NN NN O
be NN NN O
closely NN NN O
observed NN NN O
and NN NN O
should NN NN O
be NN NN O
given NN NN O
reduced NN NN O
doses NN NN O
of NN NN O
cimetidine NN NN O
. NN NN O
   
Prospective NN NN O
study NN NN O
of NN NN O
the NN NN O
long NN NN O
- NN NN O
term NN NN O
effects NN NN O
of NN NN O
somatostatin NN NN O
analog NN NN O
( NN NN O
octreotide NN NN O
) NN NN O
on NN NN O
gallbladder NN NN O
function NN NN O
and NN NN O
gallstone NN NN B-Disease
formation NN NN O
in NN NN O
Chinese NN NN O
acromegalic NN NN B-Disease
patients NN NN O
. NN NN O
   
This NN NN O
article NN NN O
reports NN NN O
the NN NN O
changes NN NN O
in NN NN O
gallbladder NN NN O
function NN NN O
examined NN NN O
by NN NN O
ultrasonography NN NN O
in NN NN O
20 NN NN O
Chinese NN NN O
patients NN NN O
with NN NN O
active NN NN O
acromegaly NN NN B-Disease
treated NN NN O
with NN NN O
sc NN NN O
injection NN NN O
of NN NN O
the NN NN O
somatostatin NN NN O
analog NN NN O
octreotide NN NN O
in NN NN O
dosages NN NN O
of NN NN O
300 NN NN O
- NN NN O
1500 NN NN O
micrograms NN NN O
/ NN NN O
day NN NN O
for NN NN O
a NN NN O
mean NN NN O
of NN NN O
24 NN NN O
. NN NN O
2 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
13 NN NN O
. NN NN O
9 NN NN O
months NN NN O
. NN NN O
   
During NN NN O
treatment NN NN O
with NN NN O
octreotide NN NN O
, NN NN O
17 NN NN O
patients NN NN O
developed NN NN O
sludge NN NN O
, NN NN O
10 NN NN O
had NN NN O
gallstones NN NN B-Disease
, NN NN O
and NN NN O
1 NN NN O
developed NN NN O
acute NN NN B-Disease
cholecystitis NN NN I-Disease
requiring NN NN O
surgery NN NN O
. NN NN O
   
In NN NN O
all NN NN O
of NN NN O
7 NN NN O
patients NN NN O
examined NN NN O
acutely NN NN O
, NN NN O
gallbladder NN NN O
contractility NN NN O
was NN NN O
inhibited NN NN O
after NN NN O
a NN NN O
single NN NN O
100 NN NN O
- NN NN O
micrograms NN NN O
injection NN NN O
. NN NN O
   
In NN NN O
8 NN NN O
patients NN NN O
followed NN NN O
for NN NN O
24 NN NN O
weeks NN NN O
, NN NN O
gallbladder NN NN O
contractility NN NN O
remained NN NN O
depressed NN NN B-Disease
throughout NN NN O
therapy NN NN O
. NN NN O
   
After NN NN O
withdrawal NN NN O
of NN NN O
octreotide NN NN O
in NN NN O
10 NN NN O
patients NN NN O
without NN NN O
gallstones NN NN B-Disease
, NN NN O
8 NN NN O
patients NN NN O
assessed NN NN O
had NN NN O
return NN NN O
of NN NN O
normal NN NN O
gallbladder NN NN O
contractility NN NN O
within NN NN O
1 NN NN O
month NN NN O
. NN NN O
   
In NN NN O
8 NN NN O
of NN NN O
the NN NN O
remaining NN NN O
10 NN NN O
patients NN NN O
who NN NN O
developed NN NN O
gallstones NN NN B-Disease
during NN NN O
treatment NN NN O
, NN NN O
gallbladder NN NN O
contractility NN NN O
normalized NN NN O
in NN NN O
5 NN NN O
patients NN NN O
( NN NN O
3 NN NN O
of NN NN O
whom NN NN O
has NN NN O
disappearance NN NN O
of NN NN O
their NN NN O
stones NN NN O
within NN NN O
3 NN NN O
weeks NN NN O
) NN NN O
, NN NN O
and NN NN O
remained NN NN O
depressed NN NN B-Disease
in NN NN O
3 NN NN O
( NN NN O
2 NN NN O
of NN NN O
whom NN NN O
had NN NN O
stones NN NN O
present NN NN O
at NN NN O
6 NN NN O
months NN NN O
) NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
suggest NN NN O
that NN NN O
the NN NN O
suppression NN NN O
of NN NN O
gallbladder NN NN O
contractility NN NN O
is NN NN O
the NN NN O
cause NN NN O
of NN NN O
the NN NN O
successive NN NN O
formation NN NN O
of NN NN O
bile NN NN O
sludge NN NN O
, NN NN O
gallstones NN NN B-Disease
, NN NN O
and NN NN O
cholecystitis NN NN B-Disease
during NN NN O
octreotide NN NN O
therapy NN NN O
in NN NN O
Chinese NN NN O
acromegalic NN NN B-Disease
patients NN NN O
. NN NN O
   
It NN NN O
is NN NN O
therefore NN NN O
very NN NN O
important NN NN O
to NN NN O
follow NN NN O
the NN NN O
changes NN NN O
of NN NN O
gallbladder NN NN O
function NN NN O
during NN NN O
long NN NN O
- NN NN O
term NN NN O
octreotide NN NN O
therapy NN NN O
of NN NN O
acromegalic NN NN B-Disease
patients NN NN O
. NN NN O
   
Increase NN NN O
of NN NN O
Parkinson NN NN B-Disease
disability NN NN I-Disease
after NN NN O
fluoxetine NN NN O
medication NN NN O
. NN NN O
   
Depression NN NN B-Disease
is NN NN O
a NN NN O
major NN NN O
clinical NN NN O
feature NN NN O
of NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
We NN NN O
report NN NN O
the NN NN O
increased NN NN O
amount NN NN O
of NN NN O
motor NN NN B-Disease
disability NN NN I-Disease
in NN NN O
four NN NN O
patients NN NN O
with NN NN O
idiopathic NN NN B-Disease
Parkinson NN NN I-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
after NN NN O
exposure NN NN O
to NN NN O
the NN NN O
antidepressant NN NN O
fluoxetine NN NN O
. NN NN O
   
The NN NN O
possibility NN NN O
of NN NN O
a NN NN O
clinically NN NN O
relevant NN NN O
dopamine NN NN O
- NN NN O
antagonistic NN NN O
capacity NN NN O
of NN NN O
fluoxetine NN NN O
in NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
patients NN NN O
must NN NN O
be NN NN O
considered NN NN O
. NN NN O
   
Sinus NN NN B-Disease
arrest NN NN I-Disease
associated NN NN O
with NN NN O
continuous NN NN O
- NN NN O
infusion NN NN O
cimetidine NN NN O
. NN NN O
   
The NN NN O
administration NN NN O
of NN NN O
intermittent NN NN O
intravenous NN NN O
infusions NN NN O
of NN NN O
cimetidine NN NN O
is NN NN O
infrequently NN NN O
associated NN NN O
with NN NN O
the NN NN O
development NN NN O
of NN NN O
bradyarrhythmias NN NN B-Disease
. NN NN O
   
A NN NN O
40 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
man NN NN O
with NN NN O
leukemia NN NN B-Disease
and NN NN O
no NN NN O
history NN NN O
of NN NN O
cardiac NN NN B-Disease
disease NN NN I-Disease
developed NN NN O
recurrent NN NN O
, NN NN O
brief NN NN O
episodes NN NN O
of NN NN O
apparent NN NN O
sinus NN NN B-Disease
arrest NN NN I-Disease
while NN NN O
receiving NN NN O
continuous NN NN O
- NN NN O
infusion NN NN O
cimetidine NN NN O
50 NN NN O
mg NN NN O
/ NN NN O
hour NN NN O
. NN NN O
   
The NN NN O
arrhythmias NN NN B-Disease
were NN NN O
temporally NN NN O
related NN NN O
to NN NN O
cimetidine NN NN O
administration NN NN O
, NN NN O
disappeared NN NN O
after NN NN O
dechallenge NN NN O
, NN NN O
and NN NN O
did NN NN O
not NN NN O
recur NN NN O
during NN NN O
ranitidine NN NN O
treatment NN NN O
. NN NN O
   
This NN NN O
is NN NN O
the NN NN O
first NN NN O
reported NN NN O
case NN NN O
of NN NN O
sinus NN NN B-Disease
arrest NN NN I-Disease
associated NN NN O
with NN NN O
continuous NN NN O
- NN NN O
infusion NN NN O
cimetidine NN NN O
. NN NN O
   
Phase NN NN O
II NN NN O
trial NN NN O
of NN NN O
vinorelbine NN NN O
in NN NN O
metastatic NN NN O
squamous NN NN B-Disease
cell NN NN I-Disease
esophageal NN NN I-Disease
carcinoma NN NN I-Disease
. NN NN O
   
European NN NN O
Organization NN NN O
for NN NN O
Research NN NN O
and NN NN O
Treatment NN NN O
of NN NN O
Cancer NN NN B-Disease
Gastrointestinal NN NN O
Treat NN NN O
Cancer NN NN B-Disease
Cooperative NN NN O
Group NN NN O
. NN NN O
   
PURPOSE NN NN O
: NN NN O
To NN NN O
evaluate NN NN O
the NN NN O
response NN NN O
rate NN NN O
and NN NN O
toxic NN NN O
effects NN NN O
of NN NN O
vinorelbine NN NN O
( NN NN O
VNB NN NN O
) NN NN O
administered NN NN O
as NN NN O
a NN NN O
single NN NN O
agent NN NN O
in NN NN O
metastatic NN NN O
squamous NN NN B-Disease
cell NN NN I-Disease
esophageal NN NN I-Disease
carcinoma NN NN I-Disease
. NN NN O
   
PATIENTS NN NN O
AND NN NN O
METHODS NN NN O
: NN NN O
Forty NN NN O
- NN NN O
six NN NN O
eligible NN NN O
patients NN NN O
with NN NN O
measurable NN NN O
lesions NN NN O
were NN NN O
included NN NN O
and NN NN O
were NN NN O
stratified NN NN O
according NN NN O
to NN NN O
previous NN NN O
chemotherapy NN NN O
. NN NN O
   
Thirty NN NN O
patients NN NN O
without NN NN O
prior NN NN O
chemotherapy NN NN O
and NN NN O
16 NN NN O
pretreated NN NN O
with NN NN O
cisplatin NN NN O
- NN NN O
based NN NN O
chemotherapy NN NN O
were NN NN O
assessable NN NN O
for NN NN O
toxicity NN NN B-Disease
and NN NN O
response NN NN O
. NN NN O
   
VNB NN NN O
was NN NN O
administered NN NN O
weekly NN NN O
as NN NN O
a NN NN O
25 NN NN O
- NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
short NN NN O
intravenous NN NN O
( NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
) NN NN O
infusion NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Six NN NN O
of NN NN O
30 NN NN O
patients NN NN O
( NN NN O
20 NN NN O
% NN NN O
) NN NN O
without NN NN O
prior NN NN O
chemotherapy NN NN O
achieved NN NN O
a NN NN O
partial NN NN O
response NN NN O
( NN NN O
PR NN NN O
) NN NN O
( NN NN O
95 NN NN O
% NN NN O
confidence NN NN O
interval NN NN O
[ NN NN O
CI NN NN O
] NN NN O
, NN NN O
8 NN NN O
% NN NN O
to NN NN O
39 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
The NN NN O
median NN NN O
duration NN NN O
of NN NN O
response NN NN O
was NN NN O
21 NN NN O
weeks NN NN O
( NN NN O
range NN NN O
, NN NN O
17 NN NN O
to NN NN O
28 NN NN O
) NN NN O
. NN NN O
   
One NN NN O
of NN NN O
16 NN NN O
patients NN NN O
( NN NN O
6 NN NN O
% NN NN O
) NN NN O
with NN NN O
prior NN NN O
chemotherapy NN NN O
had NN NN O
a NN NN O
complete NN NN O
response NN NN O
( NN NN O
CR NN NN O
) NN NN O
of NN NN O
31 NN NN O
weeks NN NN O
' NN NN O
duration NN NN O
( NN NN O
95 NN NN O
% NN NN O
CI NN NN O
, NN NN O
0 NN NN O
% NN NN O
to NN NN O
30 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
The NN NN O
overall NN NN O
response NN NN O
rate NN NN O
( NN NN O
World NN NN O
Health NN NN O
Organization NN NN O
[ NN NN O
WHO NN NN O
] NN NN O
criteria NN NN O
) NN NN O
was NN NN O
15 NN NN O
% NN NN O
( NN NN O
CR NN NN O
, NN NN O
2 NN NN O
% NN NN O
; NN NN O
PR NN NN O
13 NN NN O
% NN NN O
; NN NN O
95 NN NN O
% NN NN O
CI NN NN O
, NN NN O
6 NN NN O
% NN NN O
to NN NN O
29 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
The NN NN O
median NN NN O
dose NN NN O
- NN NN O
intensity NN NN O
( NN NN O
DI NN NN O
) NN NN O
was NN NN O
20 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
/ NN NN O
wk NN NN O
. NN NN O
   
VNB NN NN O
was NN NN O
well NN NN O
tolerated NN NN O
and NN NN O
zero NN NN O
instances NN NN O
of NN NN O
WHO NN NN O
grade NN NN O
4 NN NN O
nonhematologic NN NN O
toxicity NN NN B-Disease
occurred NN NN O
. NN NN O
   
At NN NN O
least NN NN O
one NN NN O
episode NN NN O
of NN NN O
grade NN NN O
3 NN NN O
or NN NN O
4 NN NN O
granulocytopenia NN NN B-Disease
was NN NN O
seen NN NN O
in NN NN O
59 NN NN O
% NN NN O
of NN NN O
patients NN NN O
. NN NN O
   
A NN NN O
grade NN NN O
2 NN NN O
or NN NN O
3 NN NN O
infection NN NN B-Disease
occurred NN NN O
in NN NN O
16 NN NN O
% NN NN O
of NN NN O
patients NN NN O
, NN NN O
but NN NN O
no NN NN O
toxic NN NN O
deaths NN NN B-Disease
occurred NN NN O
. NN NN O
   
Other NN NN O
side NN NN O
effects NN NN O
were NN NN O
rare NN NN O
, NN NN O
and NN NN O
peripheral NN NN B-Disease
neurotoxicity NN NN I-Disease
has NN NN O
been NN NN O
minor NN NN O
( NN NN O
26 NN NN O
% NN NN O
grade NN NN O
1 NN NN O
) NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
These NN NN O
data NN NN O
indicate NN NN O
that NN NN O
VNB NN NN O
is NN NN O
an NN NN O
active NN NN O
agent NN NN O
in NN NN O
metastatic NN NN O
esophageal NN NN B-Disease
squamous NN NN I-Disease
cell NN NN I-Disease
carcinoma NN NN I-Disease
. NN NN O
   
Given NN NN O
its NN NN O
excellent NN NN O
tolerance NN NN O
profile NN NN O
and NN NN O
low NN NN O
toxicity NN NN B-Disease
, NN NN O
further NN NN O
evaluation NN NN O
of NN NN O
VNB NN NN O
in NN NN O
combination NN NN O
therapy NN NN O
is NN NN O
warranted NN NN O
. NN NN O
   
Evaluation NN NN O
of NN NN O
adverse NN NN O
reactions NN NN O
of NN NN O
aponidine NN NN O
hydrochloride NN NN O
ophthalmic NN NN O
solution NN NN O
. NN NN O
   
We NN NN O
prospectively NN NN O
evaluated NN NN O
the NN NN O
adverse NN NN O
reactions NN NN O
of NN NN O
apraclonidine NN NN O
in NN NN O
20 NN NN O
normal NN NN O
volunteers NN NN O
by NN NN O
instilling NN NN O
a NN NN O
single NN NN O
drop NN NN O
of NN NN O
1 NN NN O
% NN NN O
apraclonidine NN NN O
in NN NN O
their NN NN O
right NN NN O
eyes NN NN O
. NN NN O
   
Examinations NN NN O
, NN NN O
including NN NN O
blood NN NN O
pressure NN NN O
, NN NN O
pulse NN NN O
rate NN NN O
, NN NN O
conjunctiva NN NN O
and NN NN O
cornea NN NN O
, NN NN O
intraocular NN NN O
pressure NN NN O
( NN NN O
IOP NN NN O
) NN NN O
, NN NN O
pupil NN NN O
diameter NN NN O
, NN NN O
basal NN NN O
tear NN NN O
secretion NN NN O
and NN NN O
margin NN NN O
reflex NN NN O
distance NN NN O
of NN NN O
both NN NN O
upper NN NN O
and NN NN O
lower NN NN O
eyelids NN NN O
, NN NN O
were NN NN O
performed NN NN O
prior NN NN O
to NN NN O
entry NN NN O
and NN NN O
at NN NN O
1 NN NN O
, NN NN O
3 NN NN O
, NN NN O
5 NN NN O
and NN NN O
7 NN NN O
hours NN NN O
after NN NN O
instillation NN NN O
. NN NN O
   
The NN NN O
ocular NN NN B-Disease
hypotensive NN NN I-Disease
effects NN NN O
were NN NN O
statistically NN NN O
significant NN NN O
for NN NN O
apraclonidine NN NN O
- NN NN O
treated NN NN O
eyes NN NN O
throughout NN NN O
the NN NN O
study NN NN O
and NN NN O
also NN NN O
statistically NN NN O
significant NN NN O
for NN NN O
contralateral NN NN O
eyes NN NN O
from NN NN O
three NN NN O
hours NN NN O
after NN NN O
topical NN NN O
administration NN NN O
of NN NN O
1 NN NN O
% NN NN O
apraclonidine NN NN O
. NN NN O
   
Decreases NN NN B-Disease
in NN NN I-Disease
systolic NN NN I-Disease
blood NN NN I-Disease
pressure NN NN I-Disease
were NN NN O
statistically NN NN O
, NN NN O
but NN NN O
not NN NN O
clinically NN NN O
, NN NN O
significant NN NN O
. NN NN O
   
No NN NN O
significant NN NN O
changes NN NN O
in NN NN O
diastolic NN NN O
blood NN NN O
pressure NN NN O
, NN NN O
pulse NN NN O
rate NN NN O
and NN NN O
basal NN NN O
tear NN NN O
secretion NN NN O
were NN NN O
noted NN NN O
. NN NN O
   
Conjunctival NN NN B-Disease
blanching NN NN I-Disease
and NN NN O
mydriasis NN NN B-Disease
were NN NN O
commonly NN NN O
found NN NN O
. NN NN O
   
Upper NN NN O
lid NN NN O
retraction NN NN O
was NN NN O
frequently NN NN O
noted NN NN O
. NN NN O
   
While NN NN O
the NN NN O
elevations NN NN O
of NN NN O
the NN NN O
upper NN NN O
lid NN NN O
margin NN NN O
in NN NN O
most NN NN O
subjects NN NN O
were NN NN O
not NN NN O
more NN NN O
than NN NN O
2 NN NN O
mm NN NN O
and NN NN O
did NN NN O
not NN NN O
cause NN NN O
noticeable NN NN O
change NN NN O
in NN NN O
appearance NN NN O
, NN NN O
one NN NN O
subject NN NN O
suffered NN NN O
from NN NN O
mechanical NN NN O
entropion NN NN B-Disease
and NN NN O
marked NN NN O
corneal NN NN B-Disease
abrasion NN NN I-Disease
3 NN NN O
hours NN NN O
after NN NN O
instillation NN NN O
of NN NN O
the NN NN O
medication NN NN O
. NN NN O
   
This NN NN O
may NN NN O
well NN NN O
be NN NN O
a NN NN O
particularly NN NN O
notable NN NN O
finding NN NN O
in NN NN O
Asian NN NN O
people NN NN O
. NN NN O
   
Thiopentone NN NN O
pretreatment NN NN O
for NN NN O
propofol NN NN O
injection NN NN O
pain NN NN B-Disease
in NN NN O
ambulatory NN NN O
patients NN NN O
. NN NN O
   
This NN NN O
study NN NN O
investigated NN NN O
propofol NN NN O
injection NN NN O
pain NN NN B-Disease
in NN NN O
patients NN NN O
undergoing NN NN O
ambulatory NN NN O
anaesthesia NN NN O
. NN NN O
   
In NN NN O
a NN NN O
randomized NN NN O
, NN NN O
double NN NN O
- NN NN O
blind NN NN O
trial NN NN O
, NN NN O
90 NN NN O
women NN NN O
were NN NN O
allocated NN NN O
to NN NN O
receive NN NN O
one NN NN O
of NN NN O
three NN NN O
treatments NN NN O
prior NN NN O
to NN NN O
induction NN NN O
of NN NN O
anaesthesia NN NN O
with NN NN O
propofol NN NN O
. NN NN O
   
Patients NN NN O
in NN NN O
Group NN NN O
C NN NN O
received NN NN O
2 NN NN O
ml NN NN O
normal NN NN O
saline NN NN O
, NN NN O
Group NN NN O
L NN NN O
, NN NN O
2 NN NN O
ml NN NN O
, NN NN O
lidocaine NN NN O
2 NN NN O
% NN NN O
( NN NN O
40 NN NN O
mg NN NN O
) NN NN O
and NN NN O
Group NN NN O
T NN NN O
, NN NN O
2 NN NN O
ml NN NN O
thiopentone NN NN O
2 NN NN O
. NN NN O
5 NN NN O
% NN NN O
( NN NN O
50 NN NN O
mg NN NN O
) NN NN O
. NN NN O
   
Venous NN NN O
discomfort NN NN O
was NN NN O
assessed NN NN O
with NN NN O
a NN NN O
visual NN NN O
analogue NN NN O
scale NN NN O
( NN NN O
VAS NN NN O
) NN NN O
5 NN NN O
- NN NN O
15 NN NN O
sec NN NN O
after NN NN O
commencing NN NN O
propofol NN NN O
administration NN NN O
using NN NN O
an NN NN O
infusion NN NN O
pump NN NN O
( NN NN O
rate NN NN O
1000 NN NN O
micrograms NN NN O
. NN NN O
kg NN NN O
- NN NN O
1 NN NN O
. NN NN O
min NN NN O
- NN NN O
1 NN NN O
) NN NN O
. NN NN O
   
Loss NN NN B-Disease
of NN NN I-Disease
consciousness NN NN I-Disease
occurred NN NN O
in NN NN O
60 NN NN O
- NN NN O
90 NN NN O
sec NN NN O
. NN NN O
   
Visual NN NN O
analogue NN NN O
scores NN NN O
( NN NN O
mean NN NN O
+ NN NN O
/ NN NN O
- NN NN O
SD NN NN O
) NN NN O
during NN NN O
induction NN NN O
were NN NN O
lower NN NN O
in NN NN O
Groups NN NN O
L NN NN O
( NN NN O
3 NN NN O
. NN NN O
3 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
. NN NN O
5 NN NN O
) NN NN O
and NN NN O
T NN NN O
( NN NN O
4 NN NN O
. NN NN O
1 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
. NN NN O
7 NN NN O
) NN NN O
than NN NN O
in NN NN O
Group NN NN O
C NN NN O
( NN NN O
5 NN NN O
. NN NN O
6 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
. NN NN O
3 NN NN O
) NN NN O
; NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
0031 NN NN O
. NN NN O
   
The NN NN O
incidence NN NN O
of NN NN O
venous NN NN O
discomfort NN NN O
was NN NN O
lower NN NN O
in NN NN O
Group NN NN O
L NN NN O
( NN NN O
76 NN NN O
. NN NN O
6 NN NN O
% NN NN O
; NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
than NN NN O
in NN NN O
Group NN NN O
C NN NN O
( NN NN O
100 NN NN O
% NN NN O
) NN NN O
but NN NN O
not NN NN O
different NN NN O
from NN NN O
Group NN NN O
T NN NN O
( NN NN O
90 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
The NN NN O
VAS NN NN O
scores NN NN O
for NN NN O
recall NN NN O
of NN NN O
pain NN NN B-Disease
in NN NN O
the NN NN O
recovery NN NN O
room NN NN O
were NN NN O
correlated NN NN O
with NN NN O
the NN NN O
VAS NN NN O
scores NN NN O
during NN NN O
induction NN NN O
( NN NN O
r NN NN O
= NN NN O
0 NN NN O
. NN NN O
7045 NN NN O
; NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
0001 NN NN O
) NN NN O
. NN NN O
   
Recovery NN NN O
room NN NN O
discharge NN NN O
times NN NN O
were NN NN O
similar NN NN O
: NN NN O
C NN NN O
( NN NN O
75 NN NN O
. NN NN O
9 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
19 NN NN O
. NN NN O
4 NN NN O
min NN NN O
) NN NN O
; NN NN O
L NN NN O
73 NN NN O
. NN NN O
6 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
21 NN NN O
. NN NN O
6 NN NN O
min NN NN O
) NN NN O
; NN NN O
T NN NN O
( NN NN O
77 NN NN O
. NN NN O
1 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
18 NN NN O
. NN NN O
9 NN NN O
min NN NN O
) NN NN O
. NN NN O
   
Assessing NN NN O
their NN NN O
overall NN NN O
satisfaction NN NN O
, NN NN O
89 NN NN O
. NN NN O
7 NN NN O
% NN NN O
would NN NN O
choose NN NN O
propofol NN NN O
anaesthesia NN NN O
again NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
lidocaine NN NN O
reduces NN NN O
the NN NN O
incidence NN NN O
and NN NN O
severity NN NN O
of NN NN O
propofol NN NN O
injection NN NN O
pain NN NN B-Disease
in NN NN O
ambulatory NN NN O
patients NN NN O
whereas NN NN O
thiopentone NN NN O
only NN NN O
reduces NN NN O
its NN NN O
severity NN NN O
. NN NN O
   
Persistent NN NN O
paralysis NN NN B-Disease
after NN NN O
prolonged NN NN O
use NN NN O
of NN NN O
atracurium NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
corticosteroids NN NN O
. NN NN O
   
Neuromuscular NN NN O
blocking NN NN O
agents NN NN O
( NN NN O
NMBAs NN NN O
) NN NN O
are NN NN O
often NN NN O
used NN NN O
for NN NN O
patients NN NN O
requiring NN NN O
prolonged NN NN O
mechanical NN NN O
ventilation NN NN O
. NN NN O
   
Reports NN NN O
of NN NN O
persistent NN NN O
paralysis NN NN B-Disease
after NN NN O
the NN NN O
discontinuance NN NN O
of NN NN O
these NN NN O
drugs NN NN O
have NN NN O
most NN NN O
often NN NN O
involved NN NN O
aminosteroid NN NN O
- NN NN O
based NN NN O
NMBAs NN NN O
such NN NN O
as NN NN O
vecuronium NN NN O
bromide NN NN O
, NN NN O
especially NN NN O
when NN NN O
used NN NN O
in NN NN O
conjunction NN NN O
with NN NN O
corticosteroids NN NN O
. NN NN O
   
Atracurium NN NN O
besylate NN NN O
, NN NN O
a NN NN O
short NN NN O
- NN NN O
acting NN NN O
benzylisoquinolinium NN NN O
NMBA NN NN O
that NN NN O
is NN NN O
eliminated NN NN O
independently NN NN O
of NN NN O
renal NN NN O
or NN NN O
hepatic NN NN O
function NN NN O
, NN NN O
has NN NN O
also NN NN O
been NN NN O
associated NN NN O
with NN NN O
persistent NN NN O
paralysis NN NN B-Disease
, NN NN O
but NN NN O
only NN NN O
when NN NN O
used NN NN O
with NN NN O
corticosteroids NN NN O
. NN NN O
   
We NN NN O
report NN NN O
a NN NN O
case NN NN O
of NN NN O
atracurium NN NN O
- NN NN O
related NN NN O
paralysis NN NN B-Disease
persisting NN NN O
for NN NN O
approximately NN NN O
50 NN NN O
hours NN NN O
in NN NN O
a NN NN O
patient NN NN O
who NN NN O
was NN NN O
not NN NN O
treated NN NN O
with NN NN O
corticosteroids NN NN O
. NN NN O
   
A NN NN O
phase NN NN O
I NN NN O
/ NN NN O
II NN NN O
study NN NN O
of NN NN O
paclitaxel NN NN O
plus NN NN O
cisplatin NN NN O
as NN NN O
first NN NN O
- NN NN O
line NN NN O
therapy NN NN O
for NN NN O
head NN NN B-Disease
and NN NN I-Disease
neck NN NN I-Disease
cancers NN NN I-Disease
: NN NN O
preliminary NN NN O
results NN NN O
. NN NN O
   
Improved NN NN O
outcomes NN NN O
among NN NN O
patients NN NN O
with NN NN O
head NN NN B-Disease
and NN NN I-Disease
neck NN NN I-Disease
carcinomas NN NN I-Disease
require NN NN O
investigations NN NN O
of NN NN O
new NN NN O
drugs NN NN O
for NN NN O
induction NN NN O
therapy NN NN O
. NN NN O
   
Preliminary NN NN O
results NN NN O
of NN NN O
an NN NN O
Eastern NN NN O
Cooperative NN NN O
Oncology NN NN O
Group NN NN O
study NN NN O
of NN NN O
single NN NN O
- NN NN O
agent NN NN O
paclitaxel NN NN O
( NN NN O
Taxol NN NN O
; NN NN O
Bristol NN NN O
- NN NN O
Myers NN NN O
Squibb NN NN O
Company NN NN O
, NN NN O
Princeton NN NN O
, NN NN O
NJ NN NN O
) NN NN O
reported NN NN O
a NN NN O
37 NN NN O
% NN NN O
response NN NN O
rate NN NN O
in NN NN O
patients NN NN O
with NN NN O
head NN NN B-Disease
and NN NN I-Disease
neck NN NN I-Disease
cancer NN NN I-Disease
, NN NN O
and NN NN O
the NN NN O
paclitaxel NN NN O
/ NN NN O
cisplatin NN NN O
combination NN NN O
has NN NN O
been NN NN O
used NN NN O
successfully NN NN O
and NN NN O
has NN NN O
significantly NN NN O
improved NN NN O
median NN NN O
response NN NN O
duration NN NN O
in NN NN O
ovarian NN NN B-Disease
cancer NN NN I-Disease
patients NN NN O
. NN NN O
   
We NN NN O
initiated NN NN O
a NN NN O
phase NN NN O
I NN NN O
/ NN NN O
II NN NN O
trial NN NN O
to NN NN O
determine NN NN O
the NN NN O
response NN NN O
and NN NN O
toxicity NN NN B-Disease
of NN NN O
escalating NN NN O
paclitaxel NN NN O
doses NN NN O
combined NN NN O
with NN NN O
fixed NN NN O
- NN NN O
dose NN NN O
cisplatin NN NN O
with NN NN O
granulocyte NN NN O
colony NN NN O
- NN NN O
stimulating NN NN O
factor NN NN O
support NN NN O
in NN NN O
patients NN NN O
with NN NN O
untreated NN NN O
locally NN NN O
advanced NN NN O
inoperable NN NN O
head NN NN B-Disease
and NN NN I-Disease
neck NN NN I-Disease
carcinoma NN NN I-Disease
. NN NN O
   
To NN NN O
date NN NN O
, NN NN O
23 NN NN O
men NN NN O
with NN NN O
a NN NN O
median NN NN O
age NN NN O
of NN NN O
50 NN NN O
years NN NN O
and NN NN O
good NN NN O
performance NN NN O
status NN NN O
have NN NN O
entered NN NN O
the NN NN O
trial NN NN O
. NN NN O
   
Primary NN NN O
tumor NN NN B-Disease
sites NN NN O
were NN NN O
oropharynx NN NN O
, NN NN O
10 NN NN O
patients NN NN O
; NN NN O
hypopharynx NN NN O
, NN NN O
four NN NN O
; NN NN O
larynx NN NN O
, NN NN O
two NN NN O
; NN NN O
oral NN NN O
cavity NN NN O
, NN NN O
three NN NN O
; NN NN O
unknown NN NN O
primary NN NN O
, NN NN O
two NN NN O
; NN NN O
and NN NN O
nasal NN NN O
cavity NN NN O
and NN NN O
parotid NN NN O
gland NN NN O
, NN NN O
one NN NN O
each NN NN O
. NN NN O
   
Of NN NN O
20 NN NN O
patients NN NN O
evaluable NN NN O
for NN NN O
toxicity NN NN B-Disease
, NN NN O
four NN NN O
had NN NN O
stage NN NN O
III NN NN O
and NN NN O
16 NN NN O
had NN NN O
stage NN NN O
IV NN NN O
disease NN NN O
. NN NN O
   
Treatment NN NN O
, NN NN O
given NN NN O
every NN NN O
21 NN NN O
days NN NN O
for NN NN O
a NN NN O
maximum NN NN O
of NN NN O
three NN NN O
cycles NN NN O
, NN NN O
consisted NN NN O
of NN NN O
paclitaxel NN NN O
by NN NN O
3 NN NN O
- NN NN O
hour NN NN O
infusion NN NN O
followed NN NN O
the NN NN O
next NN NN O
day NN NN O
by NN NN O
a NN NN O
fixed NN NN O
dose NN NN O
of NN NN O
cisplatin NN NN O
( NN NN O
75 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
dose NN NN O
levels NN NN O
incorporate NN NN O
escalating NN NN O
paclitaxel NN NN O
doses NN NN O
, NN NN O
and NN NN O
intrapatient NN NN O
escalations NN NN O
within NN NN O
a NN NN O
given NN NN O
dose NN NN O
level NN NN O
are NN NN O
permitted NN NN O
if NN NN O
toxicity NN NN B-Disease
permits NN NN O
. NN NN O
   
At NN NN O
the NN NN O
time NN NN O
of NN NN O
this NN NN O
writing NN NN O
, NN NN O
dose NN NN O
level NN NN O
4 NN NN O
( NN NN O
260 NN NN O
, NN NN O
270 NN NN O
, NN NN O
and NN NN O
280 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
) NN NN O
is NN NN O
being NN NN O
evaluated NN NN O
; NN NN O
three NN NN O
patients NN NN O
from NN NN O
this NN NN O
level NN NN O
are NN NN O
evaluable NN NN O
. NN NN O
   
With NN NN O
paclitaxel NN NN O
doses NN NN O
of NN NN O
200 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
and NN NN O
higher NN NN O
, NN NN O
granulocyte NN NN O
colony NN NN O
- NN NN O
stimulating NN NN O
factor NN NN O
5 NN NN O
micrograms NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
d NN NN O
is NN NN O
given NN NN O
( NN NN O
days NN NN O
4 NN NN O
through NN NN O
12 NN NN O
) NN NN O
. NN NN O
   
Of NN NN O
18 NN NN O
patients NN NN O
evaluable NN NN O
for NN NN O
response NN NN O
, NN NN O
seven NN NN O
( NN NN O
39 NN NN O
% NN NN O
) NN NN O
achieved NN NN O
a NN NN O
complete NN NN O
response NN NN O
and NN NN O
six NN NN O
( NN NN O
33 NN NN O
% NN NN O
) NN NN O
achieved NN NN O
a NN NN O
partial NN NN O
response NN NN O
. NN NN O
   
Three NN NN O
patients NN NN O
had NN NN O
no NN NN O
change NN NN O
and NN NN O
disease NN NN O
progressed NN NN O
in NN NN O
two NN NN O
. NN NN O
   
The NN NN O
overall NN NN O
response NN NN O
rate NN NN O
is NN NN O
72 NN NN O
% NN NN O
. NN NN O
   
Eleven NN NN O
responding NN NN O
patients NN NN O
had NN NN O
subsequent NN NN O
surgery NN NN O
/ NN NN O
radiotherapy NN NN O
or NN NN O
radical NN NN O
radiotherapy NN NN O
. NN NN O
   
Two NN NN O
pathologic NN NN O
complete NN NN O
responses NN NN O
were NN NN O
observed NN NN O
in NN NN O
patients NN NN O
who NN NN O
had NN NN O
achieved NN NN O
clinical NN NN O
complete NN NN O
responses NN NN O
. NN NN O
   
Alopecia NN NN B-Disease
, NN NN O
paresthesias NN NN B-Disease
, NN NN O
and NN NN O
arthralgias NN NN B-Disease
/ NN NN O
myalgias NN NN B-Disease
have NN NN O
occurred NN NN O
frequently NN NN O
, NN NN O
but NN NN O
with NN NN O
one NN NN O
exception NN NN O
( NN NN O
a NN NN O
grade NN NN O
3 NN NN O
myalgia NN NN B-Disease
) NN NN O
they NN NN O
have NN NN O
been NN NN O
grade NN NN O
1 NN NN O
or NN NN O
2 NN NN O
. NN NN O
   
No NN NN O
dose NN NN O
- NN NN O
limiting NN NN O
hematologic NN NN O
toxicity NN NN B-Disease
has NN NN O
been NN NN O
seen NN NN O
. NN NN O
   
Paclitaxel NN NN O
/ NN NN O
cisplatin NN NN O
is NN NN O
an NN NN O
effective NN NN O
first NN NN O
- NN NN O
line NN NN O
regimen NN NN O
for NN NN O
locoregionally NN NN O
advanced NN NN O
head NN NN B-Disease
and NN NN I-Disease
neck NN NN I-Disease
cancer NN NN I-Disease
and NN NN O
continued NN NN O
study NN NN O
is NN NN O
warranted NN NN O
. NN NN O
   
Results NN NN O
thus NN NN O
far NN NN O
suggest NN NN O
no NN NN O
dose NN NN O
- NN NN O
response NN NN O
effect NN NN O
for NN NN O
paclitaxel NN NN O
doses NN NN O
above NN NN O
200 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
. NN NN O
   
Improvement NN NN O
of NN NN O
levodopa NN NN O
- NN NN O
induced NN NN O
dyskinesia NN NN B-Disease
by NN NN O
propranolol NN NN O
in NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
Seven NN NN O
patients NN NN O
suffering NN NN O
from NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
( NN NN O
PD NN NN B-Disease
) NN NN O
with NN NN O
severely NN NN O
disabling NN NN O
dyskinesia NN NN B-Disease
received NN NN O
low NN NN O
- NN NN O
dose NN NN O
propranolol NN NN O
as NN NN O
an NN NN O
adjunct NN NN O
to NN NN O
the NN NN O
currently NN NN O
used NN NN O
medical NN NN O
treatment NN NN O
. NN NN O
   
There NN NN O
was NN NN O
a NN NN O
significant NN NN O
40 NN NN O
% NN NN O
improvement NN NN O
in NN NN O
the NN NN O
dyskinesia NN NN B-Disease
score NN NN O
without NN NN O
increase NN NN O
of NN NN O
parkinsonian NN NN B-Disease
motor NN NN B-Disease
disability NN NN I-Disease
. NN NN O
   
Ballistic NN NN O
and NN NN O
choreic NN NN O
dyskinesia NN NN B-Disease
were NN NN O
markedly NN NN O
ameliorated NN NN O
, NN NN O
whereas NN NN O
dystonia NN NN B-Disease
was NN NN O
not NN NN O
. NN NN O
   
This NN NN O
study NN NN O
suggests NN NN O
that NN NN O
administration NN NN O
of NN NN O
low NN NN O
doses NN NN O
of NN NN O
beta NN NN O
- NN NN O
blockers NN NN O
may NN NN O
improve NN NN O
levodopa NN NN O
- NN NN O
induced NN NN O
ballistic NN NN O
and NN NN O
choreic NN NN O
dyskinesia NN NN B-Disease
in NN NN O
PD NN NN B-Disease
. NN NN O
   
Habitual NN NN O
use NN NN O
of NN NN O
acetaminophen NN NN O
as NN NN O
a NN NN O
risk NN NN O
factor NN NN O
for NN NN O
chronic NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
: NN NN O
a NN NN O
comparison NN NN O
with NN NN O
phenacetin NN NN O
. NN NN O
   
Six NN NN O
epidemiologic NN NN O
studies NN NN O
in NN NN O
the NN NN O
United NN NN O
States NN NN O
and NN NN O
Europe NN NN O
indicate NN NN O
that NN NN O
habitual NN NN O
use NN NN O
of NN NN O
phenacetin NN NN O
is NN NN O
associated NN NN O
with NN NN O
the NN NN O
development NN NN O
of NN NN O
chronic NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
and NN NN O
end NN NN B-Disease
- NN NN I-Disease
stage NN NN I-Disease
renal NN NN I-Disease
disease NN NN I-Disease
( NN NN O
ESRD NN NN B-Disease
) NN NN O
, NN NN O
with NN NN O
a NN NN O
relative NN NN O
risk NN NN O
in NN NN O
the NN NN O
range NN NN O
of NN NN O
4 NN NN O
to NN NN O
19 NN NN O
. NN NN O
   
As NN NN O
a NN NN O
result NN NN O
of NN NN O
these NN NN O
and NN NN O
other NN NN O
studies NN NN O
, NN NN O
phenacetin NN NN O
has NN NN O
now NN NN O
been NN NN O
withdrawn NN NN O
from NN NN O
the NN NN O
market NN NN O
in NN NN O
most NN NN O
countries NN NN O
. NN NN O
   
However NN NN O
, NN NN O
three NN NN O
case NN NN O
control NN NN O
studies NN NN O
, NN NN O
one NN NN O
each NN NN O
in NN NN O
North NN NN O
Carolina NN NN O
, NN NN O
northern NN NN O
Maryland NN NN O
, NN NN O
and NN NN O
West NN NN O
Berlin NN NN O
, NN NN O
Germany NN NN O
, NN NN O
showed NN NN O
that NN NN O
habitual NN NN O
use NN NN O
of NN NN O
acetaminophen NN NN O
is NN NN O
also NN NN O
associated NN NN O
with NN NN O
chronic NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
and NN NN O
ESRD NN NN B-Disease
, NN NN O
with NN NN O
a NN NN O
relative NN NN O
risk NN NN O
in NN NN O
the NN NN O
range NN NN O
of NN NN O
2 NN NN O
to NN NN O
4 NN NN O
. NN NN O
   
These NN NN O
studies NN NN O
suggest NN NN O
that NN NN O
both NN NN O
phenacetin NN NN O
and NN NN O
acetaminophen NN NN O
may NN NN O
contribute NN NN O
to NN NN O
the NN NN O
burden NN NN O
of NN NN O
ESRD NN NN B-Disease
, NN NN O
with NN NN O
the NN NN O
risk NN NN O
of NN NN O
the NN NN O
latter NN NN O
being NN NN O
somewhat NN NN O
less NN NN O
than NN NN O
that NN NN O
of NN NN O
the NN NN O
former NN NN O
. NN NN O
   
This NN NN O
apparent NN NN O
difference NN NN O
in NN NN O
risk NN NN O
may NN NN O
not NN NN O
be NN NN O
due NN NN O
to NN NN O
differences NN NN O
in NN NN O
nephrotoxic NN NN B-Disease
potential NN NN O
of NN NN O
the NN NN O
drugs NN NN O
themselves NN NN O
. NN NN O
   
A NN NN O
lower NN NN O
relative NN NN O
risk NN NN O
would NN NN O
be NN NN O
expected NN NN O
for NN NN O
acetaminophen NN NN O
if NN NN O
the NN NN O
risk NN NN O
of NN NN O
both NN NN O
drugs NN NN O
in NN NN O
combination NN NN O
with NN NN O
other NN NN O
analgesics NN NN O
was NN NN O
higher NN NN O
than NN NN O
the NN NN O
risk NN NN O
of NN NN O
either NN NN O
agent NN NN O
alone NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
acetaminophen NN NN O
has NN NN O
been NN NN O
used NN NN O
both NN NN O
as NN NN O
a NN NN O
single NN NN O
agent NN NN O
and NN NN O
in NN NN O
combination NN NN O
with NN NN O
other NN NN O
analgesics NN NN O
, NN NN O
whereas NN NN O
phenacetin NN NN O
was NN NN O
available NN NN O
only NN NN O
in NN NN O
combinations NN NN O
. NN NN O
   
The NN NN O
possibility NN NN O
that NN NN O
habitual NN NN O
use NN NN O
of NN NN O
acetaminophen NN NN O
alone NN NN O
increases NN NN O
the NN NN O
risk NN NN O
of NN NN O
ESRD NN NN B-Disease
has NN NN O
not NN NN O
been NN NN O
clearly NN NN O
demonstrated NN NN O
, NN NN O
but NN NN O
cannot NN NN O
be NN NN O
dismissed NN NN O
. NN NN O
   
Acetaminophen NN NN O
- NN NN O
induced NN NN O
hypotension NN NN B-Disease
. NN NN O
   
Through NN NN O
30 NN NN O
years NN NN O
of NN NN O
widespread NN NN O
use NN NN O
, NN NN O
acetaminophen NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
be NN NN O
a NN NN O
remarkably NN NN O
safe NN NN O
medication NN NN O
in NN NN O
therapeutic NN NN O
dosages NN NN O
. NN NN O
   
The NN NN O
potential NN NN O
for NN NN O
acetaminophen NN NN O
to NN NN O
produce NN NN O
cardiovascular NN NN B-Disease
toxicities NN NN I-Disease
is NN NN O
very NN NN O
low NN NN O
. NN NN O
   
However NN NN O
, NN NN O
acetaminophen NN NN O
has NN NN O
been NN NN O
demonstrated NN NN O
to NN NN O
produce NN NN O
symptoms NN NN O
of NN NN O
anaphylaxis NN NN B-Disease
, NN NN O
including NN NN O
hypotension NN NN B-Disease
, NN NN O
in NN NN O
sensitive NN NN O
individuals NN NN O
. NN NN O
   
This NN NN O
article NN NN O
describes NN NN O
two NN NN O
critically NN NN B-Disease
ill NN NN I-Disease
patients NN NN O
in NN NN O
whom NN NN O
transient NN NN O
episodes NN NN O
of NN NN O
hypotension NN NN B-Disease
reproducibly NN NN O
developed NN NN O
after NN NN O
administration NN NN O
of NN NN O
acetaminophen NN NN O
. NN NN O
   
Other NN NN O
symptoms NN NN O
of NN NN O
allergic NN NN B-Disease
reactions NN NN I-Disease
were NN NN O
not NN NN O
clinically NN NN O
detectable NN NN O
. NN NN O
   
The NN NN O
hypotensive NN NN B-Disease
episodes NN NN O
were NN NN O
severe NN NN O
enough NN NN O
to NN NN O
require NN NN O
vasopressor NN NN O
administration NN NN O
. NN NN O
   
The NN NN O
reports NN NN O
illustrate NN NN O
the NN NN O
need NN NN O
for NN NN O
clinicians NN NN O
to NN NN O
consider NN NN O
acetaminophen NN NN O
in NN NN O
patients NN NN O
with NN NN O
hypotension NN NN B-Disease
of NN NN O
unknown NN NN O
origin NN NN O
. NN NN O
   
Reduction NN NN O
of NN NN O
heparan NN NN O
sulphate NN NN O
- NN NN O
associated NN NN O
anionic NN NN O
sites NN NN O
in NN NN O
the NN NN O
glomerular NN NN O
basement NN NN O
membrane NN NN O
of NN NN O
rats NN NN O
with NN NN O
streptozotocin NN NN O
- NN NN O
induced NN NN O
diabetic NN NN B-Disease
nephropathy NN NN I-Disease
. NN NN O
   
Heparan NN NN O
sulphate NN NN O
- NN NN O
associated NN NN O
anionic NN NN O
sites NN NN O
in NN NN O
the NN NN O
glomerular NN NN O
basement NN NN O
membrane NN NN O
were NN NN O
studied NN NN O
in NN NN O
rats NN NN O
8 NN NN O
months NN NN O
after NN NN O
induction NN NN O
of NN NN O
diabetes NN NN B-Disease
by NN NN O
streptozotocin NN NN O
and NN NN O
in NN NN O
age NN NN O
- NN NN O
adn NN NN O
sex NN NN O
- NN NN O
matched NN NN O
control NN NN O
rats NN NN O
, NN NN O
employing NN NN O
the NN NN O
cationic NN NN O
dye NN NN O
cuprolinic NN NN O
blue NN NN O
. NN NN O
   
Morphometric NN NN O
analysis NN NN O
at NN NN O
the NN NN O
ultrastructural NN NN O
level NN NN O
was NN NN O
performed NN NN O
using NN NN O
a NN NN O
computerized NN NN O
image NN NN O
processor NN NN O
. NN NN O
   
The NN NN O
heparan NN NN O
sulphate NN NN O
specificity NN NN O
of NN NN O
the NN NN O
cuprolinic NN NN O
blue NN NN O
staining NN NN O
was NN NN O
demonstrated NN NN O
by NN NN O
glycosaminoglycan NN NN O
- NN NN O
degrading NN NN O
enzymes NN NN O
, NN NN O
showing NN NN O
that NN NN O
pretreatment NN NN O
of NN NN O
the NN NN O
sections NN NN O
with NN NN O
heparitinase NN NN O
abolished NN NN O
all NN NN O
staining NN NN O
, NN NN O
whereas NN NN O
chondroitinase NN NN O
ABC NN NN O
had NN NN O
no NN NN O
effect NN NN O
. NN NN O
   
The NN NN O
majority NN NN O
of NN NN O
anionic NN NN O
sites NN NN O
( NN NN O
74 NN NN O
% NN NN O
in NN NN O
diabetic NN NN B-Disease
and NN NN O
81 NN NN O
% NN NN O
in NN NN O
control NN NN O
rats NN NN O
) NN NN O
were NN NN O
found NN NN O
within NN NN O
the NN NN O
lamina NN NN O
rara NN NN O
externa NN NN O
of NN NN O
the NN NN O
glomerular NN NN O
basement NN NN O
membrane NN NN O
. NN NN O
   
A NN NN O
minority NN NN O
of NN NN O
anionic NN NN O
sites NN NN O
were NN NN O
scattered NN NN O
throughout NN NN O
the NN NN O
lamina NN NN O
densa NN NN O
and NN NN O
lamina NN NN O
rara NN NN O
interna NN NN O
, NN NN O
and NN NN O
were NN NN O
significantly NN NN O
smaller NN NN O
than NN NN O
those NN NN O
in NN NN O
the NN NN O
lamina NN NN O
rara NN NN O
externa NN NN O
of NN NN O
the NN NN O
glomerular NN NN O
basement NN NN O
membrane NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
and NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
for NN NN O
diabetic NN NN B-Disease
and NN NN O
control NN NN O
rats NN NN O
, NN NN O
respectively NN NN O
) NN NN O
. NN NN O
   
Diabetic NN NN B-Disease
rats NN NN O
progressively NN NN O
developed NN NN O
albuminuria NN NN B-Disease
reaching NN NN O
40 NN NN O
. NN NN O
3 NN NN O
( NN NN O
32 NN NN O
. NN NN O
2 NN NN O
- NN NN O
62 NN NN O
. NN NN O
0 NN NN O
) NN NN O
mg NN NN O
/ NN NN O
24 NN NN O
h NN NN O
after NN NN O
8 NN NN O
months NN NN O
in NN NN O
contrast NN NN O
to NN NN O
the NN NN O
control NN NN O
animals NN NN O
( NN NN O
0 NN NN O
. NN NN O
8 NN NN O
( NN NN O
0 NN NN O
. NN NN O
2 NN NN O
- NN NN O
0 NN NN O
. NN NN O
9 NN NN O
) NN NN O
mg NN NN O
/ NN NN O
24 NN NN O
h NN NN O
, NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
002 NN NN O
) NN NN O
. NN NN O
   
At NN NN O
the NN NN O
same NN NN O
time NN NN O
, NN NN O
the NN NN O
number NN NN O
of NN NN O
heparan NN NN O
sulphate NN NN O
anionic NN NN O
sites NN NN O
and NN NN O
the NN NN O
total NN NN O
anionic NN NN O
site NN NN O
surface NN NN O
( NN NN O
number NN NN O
of NN NN O
anionic NN NN O
sites NN NN O
x NN NN O
mean NN NN O
anionic NN NN O
site NN NN O
surface NN NN O
) NN NN O
in NN NN O
the NN NN O
lamina NN NN O
rara NN NN O
externa NN NN O
of NN NN O
the NN NN O
glomerular NN NN O
basement NN NN O
membrane NN NN O
was NN NN O
reduced NN NN O
by NN NN O
19 NN NN O
% NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
021 NN NN O
) NN NN O
and NN NN O
by NN NN O
26 NN NN O
% NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
02 NN NN O
) NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
Number NN NN O
and NN NN O
total NN NN O
anionic NN NN O
site NN NN O
surface NN NN O
in NN NN O
the NN NN O
remaining NN NN O
part NN NN O
of NN NN O
the NN NN O
glomerular NN NN O
basement NN NN O
membrane NN NN O
( NN NN O
lamina NN NN O
densa NN NN O
and NN NN O
lamina NN NN O
rara NN NN O
interna NN NN O
) NN NN O
were NN NN O
not NN NN O
significantly NN NN O
changed NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
in NN NN O
streptozotocin NN NN O
- NN NN O
diabetic NN NN B-Disease
rats NN NN O
with NN NN O
an NN NN O
increased NN NN O
urinary NN NN O
albumin NN NN O
excretion NN NN O
, NN NN O
a NN NN O
reduced NN NN O
heparan NN NN O
sulphate NN NN O
charge NN NN O
barrier NN NN O
/ NN NN O
density NN NN O
is NN NN O
found NN NN O
at NN NN O
the NN NN O
lamina NN NN O
rara NN NN O
externa NN NN O
of NN NN O
the NN NN O
glomerular NN NN O
basement NN NN O
membrane NN NN O
. NN NN O
   
Mediation NN NN O
of NN NN O
enhanced NN NN O
reflex NN NN O
vagal NN NN O
bradycardia NN NN B-Disease
by NN NN O
L NN NN O
- NN NN O
dopa NN NN O
via NN NN O
central NN NN O
dopamine NN NN O
formation NN NN O
in NN NN O
dogs NN NN O
. NN NN O
   
L NN NN O
- NN NN O
Dopa NN NN O
( NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
) NN NN O
decreased NN NN O
blood NN NN O
pressure NN NN O
and NN NN O
heart NN NN O
rate NN NN O
after NN NN O
extracerebral NN NN O
decarboxylase NN NN O
inhibition NN NN O
with NN NN O
MK NN NN O
- NN NN O
486 NN NN O
( NN NN O
25 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
) NN NN O
in NN NN O
anesthetize NN NN O
MAO NN NN O
- NN NN O
inhibited NN NN O
dogs NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
reflex NN NN O
bradycardia NN NN B-Disease
caused NN NN O
by NN NN O
injected NN NN O
norepinephrine NN NN O
was NN NN O
significantly NN NN O
enhanced NN NN O
by NN NN O
L NN NN O
- NN NN O
dopa NN NN O
, NN NN O
DL NN NN O
- NN NN O
Threo NN NN O
- NN NN O
dihydroxyphenylserine NN NN O
had NN NN O
no NN NN O
effect NN NN O
on NN NN O
blood NN NN O
pressure NN NN O
, NN NN O
heart NN NN O
rate NN NN O
or NN NN O
reflex NN NN O
responses NN NN O
to NN NN O
norepinephrine NN NN O
. NN NN O
   
FLA NN NN O
- NN NN O
63 NN NN O
, NN NN O
a NN NN O
dopamine NN NN O
- NN NN O
beta NN NN O
- NN NN O
oxidase NN NN O
inhibitor NN NN O
, NN NN O
did NN NN O
not NN NN O
have NN NN O
any NN NN O
effect NN NN O
on NN NN O
the NN NN O
hypotension NN NN B-Disease
, NN NN O
bradycardia NN NN B-Disease
or NN NN O
reflex NN NN O
- NN NN O
enhancing NN NN O
effect NN NN O
of NN NN O
L NN NN O
- NN NN O
dopa NN NN O
. NN NN O
   
Pimozide NN NN O
did NN NN O
not NN NN O
affect NN NN O
the NN NN O
actions NN NN O
of NN NN O
L NN NN O
- NN NN O
dopa NN NN O
on NN NN O
blood NN NN O
pressure NN NN O
and NN NN O
heart NN NN O
rate NN NN O
but NN NN O
completely NN NN O
blocked NN NN O
the NN NN O
enhancement NN NN O
of NN NN O
reflexes NN NN O
. NN NN O
   
Removal NN NN O
of NN NN O
the NN NN O
carotid NN NN O
sinuses NN NN O
caused NN NN O
an NN NN O
elevation NN NN O
blood NN NN O
pressure NN NN O
and NN NN O
heart NN NN O
rate NN NN O
and NN NN O
abolished NN NN O
the NN NN O
negative NN NN O
chronotropic NN NN O
effect NN NN O
of NN NN O
norepinephrine NN NN O
. NN NN O
   
However NN NN O
, NN NN O
L NN NN O
- NN NN O
dopa NN NN O
restored NN NN O
the NN NN O
bradycardia NN NN B-Disease
caused NN NN O
by NN NN O
norepinephrine NN NN O
in NN NN O
addition NN NN O
to NN NN O
decreasing NN NN O
blood NN NN O
pressure NN NN O
and NN NN O
heart NN NN O
rate NN NN O
. NN NN O
   
5 NN NN O
- NN NN O
HTP NN NN O
( NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
) NN NN O
decreased NN NN O
blood NN NN O
pressure NN NN O
and NN NN O
heart NN NN O
rate NN NN O
and NN NN O
decreased NN NN O
the NN NN O
reflex NN NN O
bradycardia NN NN B-Disease
to NN NN O
norepinephrine NN NN O
. NN NN O
   
It NN NN O
is NN NN O
concluded NN NN O
that NN NN O
L NN NN O
- NN NN O
dopa NN NN O
enhances NN NN O
reflex NN NN O
bradycardia NN NN B-Disease
through NN NN O
central NN NN O
alpha NN NN O
- NN NN O
receptor NN NN O
stimulation NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
the NN NN O
effects NN NN O
are NN NN O
mediated NN NN O
through NN NN O
dopamine NN NN O
rather NN NN O
than NN NN O
norepinephrine NN NN O
and NN NN O
do NN NN O
not NN NN O
require NN NN O
the NN NN O
carotid NN NN O
sinus NN NN O
baroreceptors NN NN O
. NN NN O
   
Microangiopathic NN NN B-Disease
hemolytic NN NN I-Disease
anemia NN NN I-Disease
complicating NN NN O
FK506 NN NN O
( NN NN O
tacrolimus NN NN O
) NN NN O
therapy NN NN O
. NN NN O
   
We NN NN O
describe NN NN O
3 NN NN O
episodes NN NN O
of NN NN O
microangiopathic NN NN B-Disease
hemolytic NN NN I-Disease
anemia NN NN I-Disease
( NN NN O
MAHA NN NN B-Disease
) NN NN O
in NN NN O
2 NN NN O
solid NN NN O
organ NN NN O
recipients NN NN O
under NN NN O
FK506 NN NN O
( NN NN O
tacrolimus NN NN O
) NN NN O
therapy NN NN O
. NN NN O
   
In NN NN O
both NN NN O
cases NN NN O
, NN NN O
discontinuation NN NN O
of NN NN O
FK506 NN NN O
and NN NN O
treatment NN NN O
with NN NN O
plasma NN NN O
exchange NN NN O
, NN NN O
fresh NN NN O
frozen NN NN O
plasma NN NN O
replacement NN NN O
, NN NN O
corticosteroids NN NN O
, NN NN O
aspirin NN NN O
, NN NN O
and NN NN O
dipyridamole NN NN O
led NN NN O
to NN NN O
resolution NN NN O
of NN NN O
MAHA NN NN B-Disease
. NN NN O
   
In NN NN O
one NN NN O
patient NN NN O
, NN NN O
reintroduction NN NN O
of NN NN O
FK506 NN NN O
led NN NN O
to NN NN O
rapid NN NN O
recurrence NN NN O
of NN NN O
MAHA NN NN B-Disease
. NN NN O
   
FK506 NN NN O
- NN NN O
associated NN NN O
MAHA NN NN B-Disease
is NN NN O
probably NN NN O
rare NN NN O
but NN NN O
physicians NN NN O
must NN NN O
be NN NN O
aware NN NN O
of NN NN O
this NN NN O
severe NN NN O
complication NN NN O
. NN NN O
   
In NN NN O
our NN NN O
experience NN NN O
and NN NN O
according NN NN O
to NN NN O
the NN NN O
literature NN NN O
, NN NN O
FK506 NN NN O
does NN NN O
not NN NN O
seem NN NN O
to NN NN O
cross NN NN O
- NN NN O
react NN NN O
with NN NN O
cyclosporin NN NN O
A NN NN O
( NN NN O
CyA NN NN O
) NN NN O
, NN NN O
an NN NN O
immuno NN NN O
- NN NN O
suppressive NN NN O
drug NN NN O
already NN NN O
known NN NN O
to NN NN O
induce NN NN O
MAHA NN NN B-Disease
. NN NN O
   
Effect NN NN O
of NN NN O
some NN NN O
anticancer NN NN O
drugs NN NN O
and NN NN O
combined NN NN O
chemotherapy NN NN O
on NN NN O
renal NN NN B-Disease
toxicity NN NN I-Disease
. NN NN O
   
The NN NN O
nephrotoxic NN NN B-Disease
action NN NN O
of NN NN O
anticancer NN NN O
drugs NN NN O
such NN NN O
as NN NN O
nitrogranulogen NN NN O
( NN NN O
NG NN NN O
) NN NN O
, NN NN O
methotrexate NN NN O
( NN NN O
MTX NN NN O
) NN NN O
, NN NN O
5 NN NN O
- NN NN O
fluorouracil NN NN O
( NN NN O
5 NN NN O
- NN NN O
FU NN NN O
) NN NN O
and NN NN O
cyclophosphamide NN NN O
( NN NN O
CY NN NN O
) NN NN O
administered NN NN O
alone NN NN O
or NN NN O
in NN NN O
combination NN NN O
[ NN NN O
MTX NN NN O
+ NN NN O
5 NN NN O
- NN NN O
FU NN NN O
+ NN NN O
CY NN NN O
( NN NN O
CMF NN NN O
) NN NN O
] NN NN O
was NN NN O
evaluated NN NN O
in NN NN O
experiments NN NN O
on NN NN O
Wistar NN NN O
rats NN NN O
. NN NN O
   
After NN NN O
drug NN NN O
administration NN NN O
, NN NN O
creatinine NN NN O
concentrations NN NN O
in NN NN O
the NN NN O
plasma NN NN O
and NN NN O
in NN NN O
the NN NN O
urine NN NN O
of NN NN O
the NN NN O
rats NN NN O
were NN NN O
determined NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
creatinine NN NN O
clearance NN NN O
. NN NN O
   
Histopathologic NN NN O
evaluation NN NN O
of NN NN O
the NN NN O
kidneys NN NN O
was NN NN O
also NN NN O
performed NN NN O
. NN NN O
   
After NN NN O
MTX NN NN O
administration NN NN O
a NN NN O
significant NN NN O
increase NN NN O
( NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
0228 NN NN O
) NN NN O
in NN NN O
the NN NN O
plasma NN NN O
creatinine NN NN O
concentration NN NN O
and NN NN O
a NN NN O
significant NN NN O
( NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
0001 NN NN O
) NN NN O
decrease NN NN O
in NN NN O
creatinine NN NN O
clearance NN NN O
was NN NN O
noted NN NN O
compared NN NN O
to NN NN O
controls NN NN O
. NN NN O
   
After NN NN O
the NN NN O
administration NN NN O
of NN NN O
NG NN NN O
, NN NN O
5 NN NN O
- NN NN O
FU NN NN O
and NN NN O
CY NN NN O
neither NN NN O
a NN NN O
statistically NN NN O
significant NN NN O
increase NN NN O
in NN NN O
creatinine NN NN O
concentration NN NN O
nor NN NN O
an NN NN O
increase NN NN O
in NN NN O
creatinine NN NN O
clearance NN NN O
was NN NN O
observed NN NN O
compared NN NN O
to NN NN O
the NN NN O
group NN NN O
receiving NN NN O
no NN NN O
cytostatics NN NN O
. NN NN O
   
Following NN NN O
polytherapy NN NN O
according NN NN O
to NN NN O
the NN NN O
CMF NN NN O
regimen NN NN O
, NN NN O
a NN NN O
statistically NN NN O
significant NN NN O
decrease NN NN O
( NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
0343 NN NN O
) NN NN O
in NN NN O
creatinine NN NN O
clearance NN NN O
was NN NN O
found NN NN O
, NN NN O
but NN NN O
creatinine NN NN O
concentration NN NN O
did NN NN O
not NN NN O
increase NN NN O
significantly NN NN O
compared NN NN O
to NN NN O
controls NN NN O
. NN NN O
   
CY NN NN O
caused NN NN O
hemorrhagic NN NN B-Disease
cystitis NN NN I-Disease
in NN NN O
40 NN NN O
% NN NN O
of NN NN O
rats NN NN O
, NN NN O
but NN NN O
it NN NN O
did NN NN O
not NN NN O
cause NN NN O
this NN NN O
complication NN NN O
when NN NN O
combined NN NN O
with NN NN O
5 NN NN O
- NN NN O
FU NN NN O
and NN NN O
MTX NN NN O
. NN NN O
   
Histologic NN NN O
changes NN NN O
were NN NN O
found NN NN O
in NN NN O
rat NN NN O
kidneys NN NN O
after NN NN O
administration NN NN O
of NN NN O
MTX NN NN O
, NN NN O
CY NN NN O
and NN NN O
NG NN NN O
, NN NN O
while NN NN O
no NN NN O
such NN NN O
change NN NN O
was NN NN O
observed NN NN O
after NN NN O
5 NN NN O
- NN NN O
FU NN NN O
and NN NN O
joint NN NN O
administration NN NN O
of NN NN O
MTX NN NN O
+ NN NN O
5 NN NN O
- NN NN O
FU NN NN O
+ NN NN O
CY NN NN O
compared NN NN O
to NN NN O
controls NN NN O
. NN NN O
   
Our NN NN O
studies NN NN O
indicate NN NN O
that NN NN O
nephrotoxicity NN NN B-Disease
of NN NN O
MTX NN NN O
+ NN NN O
5 NN NN O
- NN NN O
FU NN NN O
+ NN NN O
CY NN NN O
administered NN NN O
jointly NN NN O
is NN NN O
lower NN NN O
than NN NN O
in NN NN O
monotherapy NN NN O
. NN NN O
   
The NN NN O
interpeduncular NN NN O
nucleus NN NN O
regulates NN NN O
nicotine NN NN O
' NN NN O
s NN NN O
effects NN NN O
on NN NN O
free NN NN O
- NN NN O
field NN NN O
activity NN NN O
. NN NN O
   
Partial NN NN O
lesions NN NN O
were NN NN O
made NN NN O
with NN NN O
kainic NN NN O
acid NN NN O
in NN NN O
the NN NN O
interpeduncular NN NN O
nucleus NN NN O
of NN NN O
the NN NN O
ventral NN NN O
midbrain NN NN O
of NN NN O
the NN NN O
rat NN NN O
. NN NN O
   
Compared NN NN O
with NN NN O
sham NN NN O
- NN NN O
operated NN NN O
controls NN NN O
, NN NN O
lesions NN NN O
significantly NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
25 NN NN O
) NN NN O
blunted NN NN O
the NN NN O
early NN NN O
( NN NN O
< NN NN O
60 NN NN O
min NN NN O
) NN NN O
free NN NN O
- NN NN O
field NN NN O
locomotor NN NN B-Disease
hypoactivity NN NN I-Disease
caused NN NN O
by NN NN O
nicotine NN NN O
( NN NN O
0 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
kg NN NN O
( NN NN O
- NN NN O
1 NN NN O
) NN NN O
, NN NN O
i NN NN O
. NN NN O
m NN NN O
. NN NN O
) NN NN O
, NN NN O
enhanced NN NN O
the NN NN O
later NN NN O
( NN NN O
60 NN NN O
- NN NN O
120 NN NN O
min NN NN O
) NN NN O
nicotine NN NN O
- NN NN O
induced NN NN O
hyperactivity NN NN B-Disease
, NN NN O
and NN NN O
raised NN NN O
spontaneous NN NN O
nocturnal NN NN O
activity NN NN O
. NN NN O
   
Lesions NN NN O
reduced NN NN O
the NN NN O
extent NN NN O
of NN NN O
immunohistological NN NN O
staining NN NN O
for NN NN O
choline NN NN O
acetyltransferase NN NN O
in NN NN O
the NN NN O
interpeduncular NN NN O
nucleus NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
025 NN NN O
) NN NN O
, NN NN O
but NN NN O
not NN NN O
for NN NN O
tyrosine NN NN O
hydroxylase NN NN O
in NN NN O
the NN NN O
surrounding NN NN O
catecholaminergic NN NN O
A10 NN NN O
region NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
the NN NN O
interpeduncular NN NN O
nucleus NN NN O
mediates NN NN O
nicotinic NN NN O
depression NN NN B-Disease
of NN NN O
locomotor NN NN O
activity NN NN O
and NN NN O
dampens NN NN O
nicotinic NN NN O
arousal NN NN O
mechanisms NN NN O
located NN NN O
elsewhere NN NN O
in NN NN O
the NN NN O
brain NN NN O
. NN NN O
   
Lithium NN NN O
- NN NN O
associated NN NN O
cognitive NN NN B-Disease
and NN NN I-Disease
functional NN NN I-Disease
deficits NN NN I-Disease
reduced NN NN O
by NN NN O
a NN NN O
switch NN NN O
to NN NN O
divalproex NN NN O
sodium NN NN O
: NN NN O
a NN NN O
case NN NN O
series NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Lithium NN NN O
remains NN NN O
a NN NN O
first NN NN O
- NN NN O
line NN NN O
treatment NN NN O
for NN NN O
the NN NN O
acute NN NN O
and NN NN O
maintenance NN NN O
treatment NN NN O
of NN NN O
bipolar NN NN B-Disease
disorder NN NN I-Disease
. NN NN O
   
Although NN NN O
much NN NN O
has NN NN O
been NN NN O
written NN NN O
about NN NN O
the NN NN O
management NN NN O
of NN NN O
the NN NN O
more NN NN O
common NN NN O
adverse NN NN O
effects NN NN O
of NN NN O
lithium NN NN O
, NN NN O
such NN NN O
as NN NN O
polyuria NN NN B-Disease
and NN NN O
tremor NN NN B-Disease
, NN NN O
more NN NN O
subtle NN NN O
lithium NN NN O
side NN NN O
effects NN NN O
such NN NN O
as NN NN O
cognitive NN NN B-Disease
deficits NN NN I-Disease
, NN NN O
loss NN NN B-Disease
of NN NN I-Disease
creativity NN NN I-Disease
, NN NN O
and NN NN O
functional NN NN B-Disease
impairments NN NN I-Disease
remain NN NN O
understudied NN NN O
. NN NN O
   
This NN NN O
report NN NN O
summarizes NN NN O
our NN NN O
experience NN NN O
in NN NN O
switching NN NN O
bipolar NN NN B-Disease
patients NN NN O
from NN NN O
lithium NN NN O
to NN NN O
divalproex NN NN O
sodium NN NN O
to NN NN O
alleviate NN NN O
such NN NN O
cognitive NN NN B-Disease
and NN NN I-Disease
functional NN NN I-Disease
impairments NN NN I-Disease
. NN NN O
   
METHOD NN NN O
: NN NN O
Open NN NN O
, NN NN O
case NN NN O
series NN NN O
design NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
We NN NN O
report NN NN O
seven NN NN O
cases NN NN O
where NN NN O
substitution NN NN O
of NN NN O
lithium NN NN O
, NN NN O
either NN NN O
fully NN NN O
or NN NN O
partially NN NN O
, NN NN O
with NN NN O
divalproex NN NN O
sodium NN NN O
was NN NN O
extremely NN NN O
helpful NN NN O
in NN NN O
reducing NN NN O
the NN NN O
cognitive NN NN B-Disease
, NN NN I-Disease
motivational NN NN I-Disease
, NN NN I-Disease
or NN NN I-Disease
creative NN NN I-Disease
deficits NN NN I-Disease
attributed NN NN O
to NN NN O
lithium NN NN O
in NN NN O
our NN NN O
bipolar NN NN B-Disease
patients NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
In NN NN O
this NN NN O
preliminary NN NN O
report NN NN O
, NN NN O
divalproex NN NN O
sodium NN NN O
was NN NN O
a NN NN O
superior NN NN O
alternative NN NN O
to NN NN O
lithium NN NN O
in NN NN O
bipolar NN NN B-Disease
patients NN NN O
experiencing NN NN O
cognitive NN NN B-Disease
deficits NN NN I-Disease
, NN NN O
loss NN NN B-Disease
of NN NN I-Disease
creativity NN NN I-Disease
, NN NN O
and NN NN O
functional NN NN B-Disease
impairments NN NN I-Disease
. NN NN O
   
Effect NN NN O
of NN NN O
nifedipine NN NN O
on NN NN O
renal NN NN O
function NN NN O
in NN NN O
liver NN NN O
transplant NN NN O
recipients NN NN O
receiving NN NN O
tacrolimus NN NN O
. NN NN O
   
The NN NN O
effect NN NN O
of NN NN O
nifedipine NN NN O
on NN NN O
renal NN NN O
function NN NN O
in NN NN O
liver NN NN O
transplant NN NN O
recipients NN NN O
who NN NN O
were NN NN O
receiving NN NN O
tacrolimus NN NN O
was NN NN O
evaluated NN NN O
between NN NN O
January NN NN O
1992 NN NN O
and NN NN O
January NN NN O
1996 NN NN O
. NN NN O
   
Two NN NN O
groups NN NN O
of NN NN O
patients NN NN O
receiving NN NN O
tacrolimus NN NN O
were NN NN O
compared NN NN O
over NN NN O
a NN NN O
period NN NN O
of NN NN O
1 NN NN O
year NN NN O
, NN NN O
one NN NN O
group NN NN O
comprising NN NN O
hypertensive NN NN B-Disease
patients NN NN O
who NN NN O
were NN NN O
receiving NN NN O
nifedipine NN NN O
, NN NN O
and NN NN O
the NN NN O
other NN NN O
comprising NN NN O
nonhypertensive NN NN O
patients NN NN O
not NN NN O
receiving NN NN O
nifedipine NN NN O
. NN NN O
   
The NN NN O
time NN NN O
from NN NN O
transplant NN NN O
to NN NN O
baseline NN NN O
was NN NN O
similar NN NN O
in NN NN O
all NN NN O
patients NN NN O
. NN NN O
   
Nifedipine NN NN O
significantly NN NN O
improved NN NN O
kidney NN NN O
function NN NN O
as NN NN O
indicated NN NN O
by NN NN O
a NN NN O
significant NN NN O
lowering NN NN O
of NN NN O
serum NN NN O
creatinine NN NN O
levels NN NN O
at NN NN O
6 NN NN O
and NN NN O
12 NN NN O
months NN NN O
. NN NN O
   
The NN NN O
observed NN NN O
positive NN NN O
impact NN NN O
of NN NN O
nifedipine NN NN O
on NN NN O
reducing NN NN O
the NN NN O
nephrotoxicity NN NN B-Disease
associated NN NN O
with NN NN O
tacrolimus NN NN O
in NN NN O
liver NN NN O
transplant NN NN O
recipients NN NN O
should NN NN O
be NN NN O
an NN NN O
important NN NN O
factor NN NN O
in NN NN O
selecting NN NN O
an NN NN O
agent NN NN O
to NN NN O
treat NN NN O
hypertension NN NN B-Disease
in NN NN O
this NN NN O
population NN NN O
. NN NN O
   
Alpha NN NN O
and NN NN O
beta NN NN O
coma NN NN B-Disease
in NN NN O
drug NN NN O
intoxication NN NN O
uncomplicated NN NN O
by NN NN O
cerebral NN NN B-Disease
hypoxia NN NN I-Disease
. NN NN O
   
Four NN NN O
patients NN NN O
who NN NN O
were NN NN O
rendered NN NN O
comatose NN NN B-Disease
or NN NN O
stuporous NN NN B-Disease
by NN NN O
drug NN NN O
intoxication NN NN O
, NN NN O
but NN NN O
who NN NN O
were NN NN O
not NN NN O
hypoxic NN NN O
, NN NN O
are NN NN O
described NN NN O
. NN NN O
   
Three NN NN O
patients NN NN O
received NN NN O
high NN NN O
doses NN NN O
of NN NN O
chlormethiazole NN NN O
for NN NN O
alcohol NN NN O
withdrawal NN NN B-Disease
symptoms NN NN I-Disease
, NN NN O
and NN NN O
one NN NN O
took NN NN O
a NN NN O
suicidal NN NN O
overdose NN NN B-Disease
of NN NN O
nitrazepam NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
with NN NN O
nitrazepam NN NN O
overdose NN NN B-Disease
and NN NN O
two NN NN O
of NN NN O
those NN NN O
with NN NN O
chlormethiazole NN NN O
intoxication NN NN O
conformed NN NN O
to NN NN O
the NN NN O
criteria NN NN O
of NN NN O
' NN NN O
alpha NN NN O
coma NN NN B-Disease
' NN NN O
, NN NN O
showing NN NN O
non NN NN O
- NN NN O
reactive NN NN O
generalized NN NN O
or NN NN O
frontally NN NN O
predominant NN NN O
alpha NN NN O
activity NN NN O
in NN NN O
the NN NN O
EEG NN NN O
. NN NN O
   
The NN NN O
fourth NN NN O
patient NN NN O
who NN NN O
was NN NN O
unconscious NN NN O
after NN NN O
chlormethiazole NN NN O
administration NN NN O
exhibite NN NN O
generalized NN NN O
non NN NN O
- NN NN O
reactive NN NN O
activity NN NN O
in NN NN O
the NN NN O
slow NN NN O
beta NN NN O
range NN NN O
. NN NN O
   
All NN NN O
four NN NN O
recovered NN NN O
completely NN NN O
without NN NN O
neurological NN NN B-Disease
sequelae NN NN I-Disease
following NN NN O
the NN NN O
withdrawal NN NN O
of NN NN O
the NN NN O
offending NN NN O
agents NN NN O
. NN NN O
   
The NN NN O
similarities NN NN O
between NN NN O
the NN NN O
effects NN NN O
of NN NN O
structural NN NN O
lesions NN NN O
and NN NN O
pharmacological NN NN O
depression NN NN B-Disease
of NN NN O
the NN NN O
brain NN NN O
stem NN NN O
reticular NN NN O
formation NN NN O
are NN NN O
discussed NN NN O
. NN NN O
   
It NN NN O
is NN NN O
suggested NN NN O
that NN NN O
in NN NN O
both NN NN O
situations NN NN O
disturbed NN NN O
reticulo NN NN O
- NN NN O
thalamic NN NN O
interactions NN NN O
are NN NN O
important NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
alpha NN NN O
coma NN NN B-Disease
. NN NN O
   
It NN NN O
is NN NN O
concluded NN NN O
that NN NN O
when NN NN O
this NN NN O
electroencephalographic NN NN O
and NN NN O
behavioural NN NN O
picture NN NN O
is NN NN O
seen NN NN O
in NN NN O
drug NN NN O
intoxication NN NN O
, NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
significant NN NN O
hypoxaemia NN NN B-Disease
, NN NN O
a NN NN O
favourable NN NN O
outcome NN NN O
may NN NN O
be NN NN O
anticipated NN NN O
. NN NN O
   
Magnetic NN NN O
resonance NN NN O
volumetry NN NN O
of NN NN O
the NN NN O
cerebellum NN NN O
in NN NN O
epileptic NN NN B-Disease
patients NN NN O
after NN NN O
phenytoin NN NN O
overdosages NN NN B-Disease
. NN NN O
   
The NN NN O
aim NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
evaluate NN NN O
the NN NN O
relationship NN NN O
between NN NN O
phenytoin NN NN O
medication NN NN O
and NN NN O
cerebellar NN NN B-Disease
atrophy NN NN I-Disease
in NN NN O
patients NN NN O
who NN NN O
had NN NN O
experienced NN NN O
clinical NN NN O
intoxication NN NN O
. NN NN O
   
Five NN NN O
females NN NN O
and NN NN O
6 NN NN O
males NN NN O
, NN NN O
21 NN NN O
- NN NN O
59 NN NN O
years NN NN O
of NN NN O
age NN NN O
, NN NN O
were NN NN O
examined NN NN O
with NN NN O
a NN NN O
1 NN NN O
. NN NN O
5 NN NN O
- NN NN O
T NN NN O
whole NN NN O
- NN NN O
body NN NN O
system NN NN O
using NN NN O
a NN NN O
circular NN NN O
polarized NN NN O
head NN NN O
coil NN NN O
. NN NN O
   
Conventional NN NN O
spin NN NN O
echo NN NN O
images NN NN O
were NN NN O
acquired NN NN O
in NN NN O
the NN NN O
sagittal NN NN O
and NN NN O
transverse NN NN O
orientation NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
we NN NN O
performed NN NN O
a NN NN O
high NN NN O
- NN NN O
resolution NN NN O
3D NN NN O
gradient NN NN O
echo NN NN O
, NN NN O
T1 NN NN O
- NN NN O
weighted NN NN O
sequences NN NN O
at NN NN O
a NN NN O
1 NN NN O
- NN NN O
mm NN NN O
slice NN NN O
thickness NN NN O
. NN NN O
   
The NN NN O
images NN NN O
were NN NN O
subsequently NN NN O
processed NN NN O
to NN NN O
obtain NN NN O
volumetric NN NN O
data NN NN O
for NN NN O
the NN NN O
cerebellum NN NN O
. NN NN O
   
Cerebellar NN NN O
volume NN NN O
for NN NN O
the NN NN O
patient NN NN O
group NN NN O
ranged NN NN O
between NN NN O
67 NN NN O
. NN NN O
66 NN NN O
and NN NN O
131 NN NN O
. NN NN O
08 NN NN O
ml NN NN O
( NN NN O
mean NN NN O
108 NN NN O
. NN NN O
9 NN NN O
ml NN NN O
) NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
3D NN NN O
gradient NN NN O
echo NN NN O
data NN NN O
sets NN NN O
from NN NN O
10 NN NN O
healthy NN NN O
male NN NN O
and NN NN O
10 NN NN O
healthy NN NN O
female NN NN O
age NN NN O
- NN NN O
matched NN NN O
volunteers NN NN O
were NN NN O
used NN NN O
to NN NN O
compare NN NN O
cerebellar NN NN O
volumes NN NN O
. NN NN O
   
Using NN NN O
linear NN NN O
regression NN NN O
we NN NN O
found NN NN O
that NN NN O
no NN NN O
correlation NN NN O
exists NN NN O
between NN NN O
seizure NN NN B-Disease
duration NN NN O
, NN NN O
elevation NN NN O
of NN NN O
phenytoin NN NN O
serum NN NN O
levels NN NN O
and NN NN O
cerebellar NN NN O
volume NN NN O
. NN NN O
   
However NN NN O
, NN NN O
multiple NN NN O
regression NN NN O
for NN NN O
the NN NN O
daily NN NN O
dosage NN NN O
, NN NN O
duration NN NN O
of NN NN O
phenytoin NN NN O
treatment NN NN O
and NN NN O
cerebellar NN NN O
volume NN NN O
revealed NN NN O
a NN NN O
correlation NN NN O
of NN NN O
these NN NN O
parameters NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
phenytoin NN NN O
overdosage NN NN B-Disease
does NN NN O
not NN NN O
necessarily NN NN O
result NN NN O
in NN NN O
cerebellar NN NN B-Disease
atrophy NN NN I-Disease
and NN NN O
it NN NN O
is NN NN O
unlikely NN NN O
that NN NN O
phenytoin NN NN O
medication NN NN O
was NN NN O
the NN NN O
only NN NN O
cause NN NN O
of NN NN O
cerebellar NN NN B-Disease
atrophy NN NN I-Disease
in NN NN O
the NN NN O
remaining NN NN O
patients NN NN O
. NN NN O
   
Quantitative NN NN O
morphometric NN NN O
studies NN NN O
of NN NN O
the NN NN O
cerebellum NN NN O
provide NN NN O
valuable NN NN O
insights NN NN O
into NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
cerebellar NN NN B-Disease
disorders NN NN I-Disease
. NN NN O
   
Late NN NN O
recovery NN NN O
of NN NN O
renal NN NN O
function NN NN O
in NN NN O
a NN NN O
woman NN NN O
with NN NN O
the NN NN O
hemolytic NN NN B-Disease
uremic NN NN I-Disease
syndrome NN NN I-Disease
. NN NN O
   
A NN NN O
case NN NN O
is NN NN O
reported NN NN O
of NN NN O
the NN NN O
hemolytic NN NN B-Disease
uremic NN NN I-Disease
syndrome NN NN I-Disease
( NN NN O
HUS NN NN B-Disease
) NN NN O
in NN NN O
a NN NN O
woman NN NN O
taking NN NN O
oral NN NN O
contraceptives NN NN O
. NN NN O
   
She NN NN O
was NN NN O
treated NN NN O
with NN NN O
heparin NN NN O
, NN NN O
dipyridamole NN NN O
and NN NN O
hemodialysis NN NN O
; NN NN O
and NN NN O
after NN NN O
more NN NN O
than NN NN O
three NN NN O
months NN NN O
, NN NN O
her NN NN O
urinary NN NN O
output NN NN O
rose NN NN O
above NN NN O
500 NN NN O
ml NN NN O
; NN NN O
and NN NN O
six NN NN O
months NN NN O
after NN NN O
the NN NN O
onset NN NN O
of NN NN O
anuria NN NN B-Disease
, NN NN O
dialysis NN NN O
treatment NN NN O
was NN NN O
stopped NN NN O
. NN NN O
   
This NN NN O
case NN NN O
emphasizes NN NN O
the NN NN O
possibility NN NN O
that NN NN O
HUS NN NN B-Disease
in NN NN O
adults NN NN O
is NN NN O
not NN NN O
invariably NN NN O
irreversible NN NN O
and NN NN O
that NN NN O
, NN NN O
despite NN NN O
prolonged NN NN O
oliguria NN NN B-Disease
, NN NN O
recovery NN NN O
of NN NN O
renal NN NN O
function NN NN O
can NN NN O
be NN NN O
obtained NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
in NN NN O
adult NN NN O
patients NN NN O
affected NN NN O
by NN NN O
HUS NN NN B-Disease
, NN NN O
dialysis NN NN O
should NN NN O
not NN NN O
be NN NN O
discontinued NN NN O
prematurely NN NN O
; NN NN O
moreover NN NN O
, NN NN O
bilateral NN NN O
nephrectomy NN NN O
, NN NN O
for NN NN O
treatment NN NN O
of NN NN O
severe NN NN O
hypertension NN NN B-Disease
and NN NN O
microangiopathic NN NN B-Disease
hemolytic NN NN I-Disease
anemia NN NN I-Disease
, NN NN O
should NN NN O
be NN NN O
performed NN NN O
with NN NN O
caution NN NN O
. NN NN O
   
Morphological NN NN O
features NN NN O
of NN NN O
encephalopathy NN NN B-Disease
after NN NN O
chronic NN NN O
administration NN NN O
of NN NN O
the NN NN O
antiepileptic NN NN O
drug NN NN O
valproate NN NN O
to NN NN O
rats NN NN O
. NN NN O
   
A NN NN O
transmission NN NN O
electron NN NN O
microscopic NN NN O
study NN NN O
of NN NN O
capillaries NN NN O
in NN NN O
the NN NN O
cerebellar NN NN O
cortex NN NN O
. NN NN O
   
Long NN NN O
- NN NN O
term NN NN O
intragastric NN NN O
application NN NN O
of NN NN O
the NN NN O
antiepileptic NN NN O
drug NN NN O
sodium NN NN O
valproate NN NN O
( NN NN O
Vupral NN NN O
"""""""" NN NN O
Polfa NN NN O
"""""""" NN NN O
) NN NN O
at NN NN O
the NN NN O
effective NN NN O
dose NN NN O
of NN NN O
200 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
b NN NN O
. NN NN O
   
w NN NN O
. NN NN O
once NN NN O
daily NN NN O
to NN NN O
rats NN NN O
for NN NN O
1 NN NN O
, NN NN O
3 NN NN O
, NN NN O
6 NN NN O
, NN NN O
9 NN NN O
and NN NN O
12 NN NN O
months NN NN O
revealed NN NN O
neurological NN NN B-Disease
disorders NN NN I-Disease
indicating NN NN O
cerebellum NN NN B-Disease
damage NN NN I-Disease
( NN NN O
"""""""" NN NN O
valproate NN NN O
encephalopathy NN NN B-Disease
"""""""" NN NN O
) NN NN O
. NN NN O
   
The NN NN O
first NN NN O
ultrastructural NN NN O
changes NN NN O
in NN NN O
structural NN NN O
elements NN NN O
of NN NN O
the NN NN O
blood NN NN O
- NN NN O
brain NN NN O
- NN NN O
barrier NN NN O
( NN NN O
BBB NN NN O
) NN NN O
in NN NN O
the NN NN O
cerebellar NN NN O
cortex NN NN O
were NN NN O
detectable NN NN O
after NN NN O
3 NN NN O
months NN NN O
of NN NN O
the NN NN O
experiment NN NN O
. NN NN O
   
They NN NN O
became NN NN O
more NN NN O
severe NN NN O
in NN NN O
the NN NN O
later NN NN O
months NN NN O
of NN NN O
the NN NN O
experiment NN NN O
, NN NN O
and NN NN O
were NN NN O
most NN NN O
severe NN NN O
after NN NN O
12 NN NN O
months NN NN O
, NN NN O
located NN NN O
mainly NN NN O
in NN NN O
the NN NN O
molecular NN NN O
layer NN NN O
of NN NN O
the NN NN O
cerebellar NN NN O
cortex NN NN O
. NN NN O
   
Lesions NN NN O
of NN NN O
the NN NN O
capillary NN NN O
included NN NN O
necrosis NN NN B-Disease
of NN NN O
endothelial NN NN O
cells NN NN O
. NN NN O
   
Organelles NN NN O
of NN NN O
these NN NN O
cells NN NN O
, NN NN O
in NN NN O
particular NN NN O
the NN NN O
mitochondria NN NN O
( NN NN O
increased NN NN O
number NN NN O
and NN NN O
size NN NN O
, NN NN O
distinct NN NN O
degeneration NN NN O
of NN NN O
their NN NN O
matrix NN NN O
and NN NN O
cristae NN NN O
) NN NN O
and NN NN O
Golgi NN NN O
apparatus NN NN O
were NN NN O
altered NN NN O
. NN NN O
   
Reduced NN NN O
size NN NN O
of NN NN O
capillary NN NN O
lumen NN NN O
and NN NN O
occlusion NN NN O
were NN NN O
caused NN NN O
by NN NN O
swollen NN NN O
endothelial NN NN O
cells NN NN O
which NN NN O
had NN NN O
luminal NN NN O
protrusions NN NN O
and NN NN O
swollen NN NN O
microvilli NN NN O
. NN NN O
   
Pressure NN NN O
on NN NN O
the NN NN O
vessel NN NN O
wall NN NN O
was NN NN O
produced NN NN O
by NN NN O
enlarged NN NN O
perivascular NN NN O
astrocytic NN NN O
processes NN NN O
. NN NN O
   
Fragments NN NN O
of NN NN O
necrotic NN NN B-Disease
endothelial NN NN O
cells NN NN O
were NN NN O
in NN NN O
the NN NN O
vascular NN NN O
lumens NN NN O
and NN NN O
in NN NN O
these NN NN O
there NN NN O
was NN NN O
loosening NN NN O
and NN NN O
breaking NN NN O
of NN NN O
tight NN NN O
cellular NN NN O
junctions NN NN O
. NN NN O
   
Damage NN NN O
to NN NN O
the NN NN O
vascular NN NN O
basement NN NN O
lamina NN NN O
was NN NN O
also NN NN O
observed NN NN O
. NN NN O
   
Damage NN NN O
to NN NN O
the NN NN O
capillary NN NN O
was NN NN O
accompanied NN NN O
by NN NN O
marked NN NN O
damage NN NN O
to NN NN O
neuroglial NN NN O
cells NN NN O
, NN NN O
mainly NN NN O
to NN NN O
perivascular NN NN O
processes NN NN O
of NN NN O
astrocytes NN NN O
. NN NN O
   
The NN NN O
proliferation NN NN O
of NN NN O
astrocytes NN NN O
( NN NN O
Bergmann NN NN O
' NN NN O
s NN NN O
in NN NN O
particular NN NN O
) NN NN O
and NN NN O
occasionally NN NN O
of NN NN O
oligodendrocytes NN NN O
was NN NN O
found NN NN O
. NN NN O
   
Alterations NN NN O
in NN NN O
the NN NN O
structural NN NN O
elements NN NN O
of NN NN O
the NN NN O
BBB NN NN O
coexisted NN NN O
with NN NN O
marked NN NN O
lesions NN NN O
of NN NN O
neurons NN NN O
of NN NN O
the NN NN O
cerebellum NN NN O
( NN NN O
Purkinje NN NN O
cells NN NN O
are NN NN O
earliest NN NN O
) NN NN O
. NN NN O
   
In NN NN O
electron NN NN O
micrographs NN NN O
both NN NN O
luminal NN NN O
and NN NN O
antiluminal NN NN O
sides NN NN O
of NN NN O
the NN NN O
BBB NN NN O
of NN NN O
the NN NN O
cerebellar NN NN O
cortex NN NN O
had NN NN O
similar NN NN O
lesions NN NN O
. NN NN O
   
The NN NN O
possible NN NN O
influence NN NN O
of NN NN O
the NN NN O
hepatic NN NN B-Disease
damage NN NN I-Disease
, NN NN O
mainly NN NN O
hyperammonemia NN NN B-Disease
, NN NN O
upon NN NN O
the NN NN O
development NN NN O
of NN NN O
valproate NN NN O
encephalopathy NN NN B-Disease
is NN NN O
discussed NN NN O
. NN NN O
   
Fatal NN NN O
intracranial NN NN B-Disease
bleeding NN NN I-Disease
associated NN NN O
with NN NN O
prehospital NN NN O
use NN NN O
of NN NN O
epinephrine NN NN O
. NN NN O
   
We NN NN O
present NN NN O
a NN NN O
case NN NN O
of NN NN O
paramedic NN NN O
misjudgment NN NN O
in NN NN O
the NN NN O
execution NN NN O
of NN NN O
a NN NN O
protocol NN NN O
for NN NN O
the NN NN O
treatment NN NN O
of NN NN O
allergic NN NN B-Disease
reaction NN NN I-Disease
in NN NN O
a NN NN O
case NN NN O
of NN NN O
pulmonary NN NN B-Disease
edema NN NN I-Disease
with NN NN O
wheezing NN NN B-Disease
. NN NN O
   
The NN NN O
sudden NN NN O
onset NN NN O
of NN NN O
respiratory NN NN B-Disease
distress NN NN I-Disease
, NN NN O
rash NN NN B-Disease
, NN NN O
and NN NN O
a NN NN O
history NN NN O
of NN NN O
a NN NN O
new NN NN O
medicine NN NN O
led NN NN O
the NN NN O
two NN NN O
paramedics NN NN O
on NN NN O
the NN NN O
scene NN NN O
to NN NN O
administer NN NN O
subcutaneous NN NN O
epinephrine NN NN O
. NN NN O
   
Subsequently NN NN O
, NN NN O
acute NN NN O
cardiac NN NN B-Disease
arrest NN NN I-Disease
and NN NN O
fatal NN NN O
subarachnoid NN NN B-Disease
hemorrhage NN NN I-Disease
occurred NN NN O
. NN NN O
   
Epinephrine NN NN O
has NN NN O
a NN NN O
proven NN NN O
role NN NN O
in NN NN O
cardiac NN NN B-Disease
arrest NN NN I-Disease
in NN NN O
prehospital NN NN O
care NN NN O
; NN NN O
however NN NN O
, NN NN O
use NN NN O
by NN NN O
paramedics NN NN O
in NN NN O
patients NN NN O
with NN NN O
suspected NN NN O
allergic NN NN B-Disease
reaction NN NN I-Disease
and NN NN O
severe NN NN O
hypertension NN NN B-Disease
should NN NN O
be NN NN O
viewed NN NN O
with NN NN O
caution NN NN O
. NN NN O
   
Role NN NN O
of NN NN O
activation NN NN O
of NN NN O
bradykinin NN NN O
B2 NN NN O
receptors NN NN O
in NN NN O
disruption NN NN O
of NN NN O
the NN NN O
blood NN NN O
- NN NN O
brain NN NN O
barrier NN NN O
during NN NN O
acute NN NN O
hypertension NN NN B-Disease
. NN NN O
   
Cellular NN NN O
mechanisms NN NN O
which NN NN O
account NN NN O
for NN NN O
disruption NN NN O
the NN NN O
blood NN NN O
- NN NN O
brain NN NN O
barrier NN NN O
during NN NN O
acute NN NN O
hypertension NN NN B-Disease
are NN NN O
not NN NN O
clear NN NN O
. NN NN O
   
The NN NN O
goal NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
determine NN NN O
the NN NN O
role NN NN O
of NN NN O
synthesis NN NN O
/ NN NN O
release NN NN O
of NN NN O
bradykinin NN NN O
to NN NN O
activate NN NN O
B2 NN NN O
receptors NN NN O
in NN NN O
disruption NN NN O
of NN NN O
the NN NN O
blood NN NN O
- NN NN O
brain NN NN O
barrier NN NN O
during NN NN O
acute NN NN O
hypertension NN NN B-Disease
. NN NN O
   
Permeability NN NN O
of NN NN O
the NN NN O
blood NN NN O
- NN NN O
brain NN NN O
barrier NN NN O
was NN NN O
quantitated NN NN O
by NN NN O
clearance NN NN O
of NN NN O
fluorescent NN NN O
- NN NN O
labeled NN NN O
dextran NN NN O
before NN NN O
and NN NN O
during NN NN O
phenylephrine NN NN O
- NN NN O
induced NN NN O
acute NN NN O
hypertension NN NN B-Disease
in NN NN O
rats NN NN O
treated NN NN O
with NN NN O
vehicle NN NN O
and NN NN O
Hoe NN NN O
- NN NN O
140 NN NN O
( NN NN O
0 NN NN O
. NN NN O
1 NN NN O
microM NN NN O
) NN NN O
. NN NN O
   
Phenylephrine NN NN O
infusion NN NN O
increased NN NN O
arterial NN NN O
pressure NN NN O
, NN NN O
arteriolar NN NN O
diameter NN NN O
and NN NN O
clearance NN NN O
of NN NN O
fluorescent NN NN O
dextran NN NN O
by NN NN O
a NN NN O
similar NN NN O
magnitude NN NN O
in NN NN O
both NN NN O
groups NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
disruption NN NN O
of NN NN O
the NN NN O
blood NN NN O
- NN NN O
brain NN NN O
barrier NN NN O
during NN NN O
acute NN NN O
hypertension NN NN B-Disease
is NN NN O
not NN NN O
related NN NN O
to NN NN O
the NN NN O
synthesis NN NN O
/ NN NN O
release NN NN O
of NN NN O
bradykinin NN NN O
to NN NN O
activate NN NN O
B2 NN NN O
receptors NN NN O
. NN NN O
   
Risk NN NN O
factors NN NN O
of NN NN O
sensorineural NN NN B-Disease
hearing NN NN I-Disease
loss NN NN I-Disease
in NN NN O
preterm NN NN O
infants NN NN O
. NN NN O
   
Among NN NN O
547 NN NN O
preterm NN NN O
infants NN NN O
of NN NN O
< NN NN O
or NN NN O
= NN NN O
34 NN NN O
weeks NN NN O
gestation NN NN O
born NN NN O
between NN NN O
1987 NN NN O
and NN NN O
1991 NN NN O
, NN NN O
8 NN NN O
children NN NN O
( NN NN O
1 NN NN O
. NN NN O
46 NN NN O
% NN NN O
) NN NN O
developed NN NN O
severe NN NN O
progressive NN NN O
and NN NN O
bilateral NN NN O
sensorineural NN NN B-Disease
hearing NN NN I-Disease
loss NN NN I-Disease
. NN NN O
   
Perinatal NN NN O
risk NN NN O
factors NN NN O
of NN NN O
infants NN NN O
with NN NN O
hearing NN NN B-Disease
loss NN NN I-Disease
were NN NN O
compared NN NN O
with NN NN O
those NN NN O
of NN NN O
two NN NN O
control NN NN O
groups NN NN O
matched NN NN O
for NN NN O
gestation NN NN O
and NN NN O
birth NN NN O
weight NN NN O
and NN NN O
for NN NN O
perinatal NN NN O
complications NN NN O
. NN NN O
   
Our NN NN O
observations NN NN O
demonstrated NN NN O
an NN NN O
association NN NN O
of NN NN O
hearing NN NN B-Disease
loss NN NN I-Disease
with NN NN O
a NN NN O
higher NN NN O
incidence NN NN O
of NN NN O
perinatal NN NN O
complications NN NN O
. NN NN O
   
Ototoxicity NN NN B-Disease
appeared NN NN O
closely NN NN O
related NN NN O
to NN NN O
a NN NN O
prolonged NN NN O
administration NN NN O
and NN NN O
higher NN NN O
total NN NN O
dose NN NN O
of NN NN O
ototoxic NN NN B-Disease
drugs NN NN O
, NN NN O
particularly NN NN O
aminoglycosides NN NN O
and NN NN O
furosemide NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
we NN NN O
strongly NN NN O
recommend NN NN O
to NN NN O
prospectively NN NN O
and NN NN O
regularly NN NN O
perform NN NN O
audiologic NN NN O
assessment NN NN O
in NN NN O
sick NN NN O
preterm NN NN O
children NN NN O
as NN NN O
hearing NN NN B-Disease
loss NN NN I-Disease
is NN NN O
of NN NN O
delayed NN NN O
onset NN NN O
and NN NN O
in NN NN O
most NN NN O
cases NN NN O
bilateral NN NN O
and NN NN O
severe NN NN O
. NN NN O
   
Seizure NN NN B-Disease
resulting NN NN O
from NN NN O
a NN NN O
venlafaxine NN NN O
overdose NN NN B-Disease
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
To NN NN O
report NN NN O
a NN NN O
case NN NN O
of NN NN O
venlafaxine NN NN O
overdose NN NN B-Disease
. NN NN O
   
CASE NN NN O
SUMMARY NN NN O
: NN NN O
A NN NN O
40 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
woman NN NN O
with NN NN O
major NN NN B-Disease
depression NN NN I-Disease
took NN NN O
an NN NN O
overdose NN NN B-Disease
of NN NN O
venlafaxine NN NN O
in NN NN O
an NN NN O
apparent NN NN O
suicide NN NN O
attempt NN NN O
. NN NN O
   
After NN NN O
the NN NN O
ingestion NN NN O
of NN NN O
26 NN NN O
venlafaxine NN NN O
50 NN NN O
- NN NN O
mg NN NN O
tablets NN NN O
, NN NN O
the NN NN O
patient NN NN O
experienced NN NN O
a NN NN O
witnessed NN NN O
generalized NN NN O
seizure NN NN B-Disease
. NN NN O
   
She NN NN O
was NN NN O
admitted NN NN O
to NN NN O
the NN NN O
medical NN NN O
intensive NN NN O
care NN NN O
unit NN NN O
, NN NN O
venlafaxine NN NN O
was NN NN O
discontinued NN NN O
, NN NN O
and NN NN O
no NN NN O
further NN NN O
sequelae NN NN O
were NN NN O
seen NN NN O
. NN NN O
   
DISCUSSION NN NN O
: NN NN O
To NN NN O
our NN NN O
knowledge NN NN O
, NN NN O
this NN NN O
is NN NN O
the NN NN O
first NN NN O
reported NN NN O
case NN NN O
of NN NN O
venlafaxine NN NN O
overdose NN NN B-Disease
that NN NN O
resulted NN NN O
in NN NN O
a NN NN O
generalized NN NN O
seizure NN NN B-Disease
. NN NN O
   
Based NN NN O
on NN NN O
nonoverdose NN NN O
pharmacokinetics NN NN O
and NN NN O
pharmacodynamics NN NN O
of NN NN O
venlafaxine NN NN O
and NN NN O
the NN NN O
potential NN NN O
risks NN NN O
of NN NN O
available NN NN O
interventions NN NN O
, NN NN O
no NN NN O
emergent NN NN O
therapy NN NN O
was NN NN O
instituted NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
The NN NN O
venlafaxine NN NN O
overdose NN NN B-Disease
in NN NN O
our NN NN O
patient NN NN O
resulted NN NN O
in NN NN O
a NN NN O
single NN NN O
episode NN NN O
of NN NN O
generalized NN NN O
seizure NN NN B-Disease
but NN NN O
elicited NN NN O
no NN NN O
further NN NN O
sequelae NN NN O
. NN NN O
   
Combined NN NN O
effects NN NN O
of NN NN O
prolonged NN NN O
prostaglandin NN NN O
E1 NN NN O
- NN NN O
induced NN NN O
hypotension NN NN B-Disease
and NN NN O
haemodilution NN NN B-Disease
on NN NN O
human NN NN O
hepatic NN NN O
function NN NN O
. NN NN O
   
Combined NN NN O
effects NN NN O
of NN NN O
prolonged NN NN O
prostaglandin NN NN O
E1 NN NN O
( NN NN O
PGE1 NN NN O
) NN NN O
- NN NN O
induced NN NN O
hypotension NN NN B-Disease
and NN NN O
haemodilution NN NN B-Disease
on NN NN O
hepatic NN NN O
function NN NN O
were NN NN O
studied NN NN O
in NN NN O
30 NN NN O
patients NN NN O
undergoing NN NN O
hip NN NN O
surgery NN NN O
. NN NN O
   
The NN NN O
patients NN NN O
were NN NN O
randomly NN NN O
allocated NN NN O
to NN NN O
one NN NN O
of NN NN O
three NN NN O
groups NN NN O
; NN NN O
those NN NN O
in NN NN O
group NN NN O
A NN NN O
( NN NN O
n NN NN O
= NN NN O
10 NN NN O
) NN NN O
were NN NN O
subjected NN NN O
to NN NN O
controlled NN NN O
hypotension NN NN B-Disease
alone NN NN O
, NN NN O
those NN NN O
in NN NN O
group NN NN O
B NN NN O
( NN NN O
n NN NN O
= NN NN O
10 NN NN O
) NN NN O
to NN NN O
haemodilution NN NN B-Disease
alone NN NN O
and NN NN O
those NN NN O
in NN NN O
group NN NN O
C NN NN O
( NN NN O
n NN NN O
= NN NN O
10 NN NN O
) NN NN O
to NN NN O
both NN NN O
controlled NN NN O
hypotension NN NN B-Disease
and NN NN O
haemodilution NN NN B-Disease
. NN NN O
   
Haemodilution NN NN B-Disease
in NN NN O
groups NN NN O
B NN NN O
and NN NN O
C NN NN O
was NN NN O
produced NN NN O
by NN NN O
withdrawing NN NN O
approximately NN NN O
1000 NN NN O
mL NN NN O
of NN NN O
blood NN NN O
and NN NN O
replacing NN NN O
it NN NN O
with NN NN O
the NN NN O
same NN NN O
amount NN NN O
of NN NN O
dextran NN NN O
solution NN NN O
, NN NN O
and NN NN O
final NN NN O
haematocrit NN NN O
values NN NN O
were NN NN O
21 NN NN O
or NN NN O
22 NN NN O
% NN NN O
. NN NN O
   
Controlled NN NN O
hypotension NN NN B-Disease
in NN NN O
groups NN NN O
A NN NN O
and NN NN O
C NN NN O
was NN NN O
induced NN NN O
with NN NN O
PGE1 NN NN O
to NN NN O
maintain NN NN O
mean NN NN O
arterial NN NN O
blood NN NN O
pressure NN NN O
at NN NN O
55 NN NN O
mmHg NN NN O
for NN NN O
180 NN NN O
min NN NN O
. NN NN O
   
Measurements NN NN O
included NN NN O
arterial NN NN O
ketone NN NN O
body NN NN O
ratio NN NN O
( NN NN O
AKBR NN NN O
, NN NN O
aceto NN NN O
- NN NN O
acetate NN NN O
/ NN NN O
3 NN NN O
- NN NN O
hydroxybutyrate NN NN O
) NN NN O
and NN NN O
clinical NN NN O
hepatic NN NN O
function NN NN O
parameters NN NN O
. NN NN O
   
AKBR NN NN O
and NN NN O
biological NN NN O
hepatic NN NN O
function NN NN O
tests NN NN O
showed NN NN O
no NN NN O
change NN NN O
throughout NN NN O
the NN NN O
time NN NN O
course NN NN O
in NN NN O
groups NN NN O
A NN NN O
and NN NN O
B NN NN O
. NN NN O
   
In NN NN O
group NN NN O
C NN NN O
, NN NN O
AKBR NN NN O
showed NN NN O
a NN NN O
significant NN NN O
decrease NN NN O
at NN NN O
120 NN NN O
min NN NN O
( NN NN O
- NN NN O
40 NN NN O
% NN NN O
) NN NN O
and NN NN O
at NN NN O
180 NN NN O
min NN NN O
( NN NN O
- NN NN O
49 NN NN O
% NN NN O
) NN NN O
after NN NN O
the NN NN O
start NN NN O
of NN NN O
hypotension NN NN B-Disease
and NN NN O
at NN NN O
60 NN NN O
min NN NN O
( NN NN O
- NN NN O
32 NN NN O
% NN NN O
) NN NN O
after NN NN O
recovery NN NN O
of NN NN O
normotension NN NN O
, NN NN O
and NN NN O
SGOT NN NN O
, NN NN O
SGPT NN NN O
, NN NN O
LDH NN NN O
and NN NN O
total NN NN O
bilirubin NN NN O
showed NN NN O
significant NN NN O
increases NN NN O
after NN NN O
operation NN NN O
. NN NN O
   
The NN NN O
results NN NN O
suggest NN NN O
that NN NN O
a NN NN O
prolonged NN NN O
combination NN NN O
of NN NN O
more NN NN O
than NN NN O
120 NN NN O
min NN NN O
of NN NN O
PGE1 NN NN O
- NN NN O
induced NN NN O
hypotension NN NN B-Disease
and NN NN O
moderate NN NN O
haemodilution NN NN B-Disease
would NN NN O
cause NN NN O
impairment NN NN B-Disease
of NN NN I-Disease
hepatic NN NN I-Disease
function NN NN I-Disease
. NN NN O
   
Cardiovascular NN NN B-Disease
alterations NN NN I-Disease
in NN NN O
rat NN NN O
fetuses NN NN O
exposed NN NN O
to NN NN O
calcium NN NN O
channel NN NN O
blockers NN NN O
. NN NN O
   
Preclinical NN NN O
toxicologic NN NN O
investigation NN NN O
suggested NN NN O
that NN NN O
a NN NN O
new NN NN O
calcium NN NN O
channel NN NN O
blocker NN NN O
, NN NN O
Ro NN NN O
40 NN NN O
- NN NN O
5967 NN NN O
, NN NN O
induced NN NN O
cardiovascular NN NN B-Disease
alterations NN NN I-Disease
in NN NN O
rat NN NN O
fetuses NN NN O
exposed NN NN O
to NN NN O
this NN NN O
agent NN NN O
during NN NN O
organogenesis NN NN O
. NN NN O
   
The NN NN O
present NN NN O
study NN NN O
was NN NN O
designed NN NN O
to NN NN O
investigate NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
calcium NN NN O
channel NN NN O
blockers NN NN O
in NN NN O
general NN NN O
induce NN NN O
cardiovascular NN NN B-Disease
malformations NN NN I-Disease
indicating NN NN O
a NN NN O
pharmacologic NN NN O
class NN NN O
effect NN NN O
. NN NN O
   
We NN NN O
studied NN NN O
three NN NN O
calcium NN NN O
channel NN NN O
blockers NN NN O
of NN NN O
different NN NN O
structure NN NN O
, NN NN O
nifedipine NN NN O
, NN NN O
diltiazem NN NN O
, NN NN O
and NN NN O
verapamil NN NN O
, NN NN O
along NN NN O
with NN NN O
the NN NN O
new NN NN O
agent NN NN O
. NN NN O
   
Pregnant NN NN O
rats NN NN O
were NN NN O
administered NN NN O
one NN NN O
of NN NN O
these NN NN O
calcium NN NN O
channel NN NN O
blockers NN NN O
during NN NN O
the NN NN O
period NN NN O
of NN NN O
cardiac NN NN O
morphogenesis NN NN O
and NN NN O
the NN NN O
offspring NN NN O
examined NN NN O
on NN NN O
day NN NN O
20 NN NN O
of NN NN O
gestation NN NN O
for NN NN O
cardiovascular NN NN B-Disease
malformations NN NN I-Disease
. NN NN O
   
A NN NN O
low NN NN O
incidence NN NN O
of NN NN O
cardiovascular NN NN B-Disease
malformations NN NN I-Disease
was NN NN O
observed NN NN O
after NN NN O
exposure NN NN O
to NN NN O
each NN NN O
of NN NN O
the NN NN O
four NN NN O
calcium NN NN O
channel NN NN O
blockers NN NN O
, NN NN O
but NN NN O
this NN NN O
incidence NN NN O
was NN NN O
statistically NN NN O
significant NN NN O
only NN NN O
for NN NN O
verapamil NN NN O
and NN NN O
nifedipine NN NN O
. NN NN O
   
All NN NN O
four NN NN O
agents NN NN O
were NN NN O
associated NN NN O
with NN NN O
aortic NN NN O
arch NN NN O
branching NN NN O
variants NN NN O
, NN NN O
although NN NN O
significantly NN NN O
increased NN NN O
only NN NN O
for NN NN O
Ro NN NN O
40 NN NN O
- NN NN O
5967 NN NN O
and NN NN O
verapamil NN NN O
. NN NN O
   
The NN NN O
site NN NN O
of NN NN O
common NN NN O
side NN NN O
effects NN NN O
of NN NN O
sumatriptan NN NN O
. NN NN O
   
Atypical NN NN B-Disease
sensations NN NN I-Disease
following NN NN O
the NN NN O
use NN NN O
of NN NN O
subcutaneous NN NN O
sumatriptan NN NN O
are NN NN O
common NN NN O
, NN NN O
but NN NN O
of NN NN O
uncertain NN NN O
origin NN NN O
. NN NN O
   
They NN NN O
are NN NN O
almost NN NN O
always NN NN O
benign NN NN O
, NN NN O
but NN NN O
can NN NN O
be NN NN O
mistaken NN NN O
for NN NN O
a NN NN O
serious NN NN O
adverse NN NN O
event NN NN O
by NN NN O
the NN NN O
patient NN NN O
. NN NN O
   
Two NN NN O
patients NN NN O
are NN NN O
presented NN NN O
with NN NN O
tingling NN NN B-Disease
or NN NN I-Disease
burning NN NN I-Disease
sensations NN NN I-Disease
limited NN NN O
to NN NN O
areas NN NN O
of NN NN O
heat NN NN O
exposure NN NN O
or NN NN O
sunburn NN NN B-Disease
. NN NN O
   
In NN NN O
these NN NN O
individuals NN NN O
, NN NN O
side NN NN O
effects NN NN O
are NN NN O
most NN NN O
likely NN NN O
generated NN NN O
superficially NN NN O
in NN NN O
the NN NN O
skin NN NN O
. NN NN O
   
Macula NN NN O
toxicity NN NN B-Disease
after NN NN O
intravitreal NN NN O
amikacin NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Although NN NN O
intravitreal NN NN O
aminoglycosides NN NN O
have NN NN O
substantially NN NN O
improved NN NN O
visual NN NN O
prognosis NN NN O
in NN NN O
endophthalmitis NN NN B-Disease
, NN NN O
macular NN NN O
infarction NN NN B-Disease
may NN NN O
impair NN NN O
full NN NN O
visual NN NN O
recovery NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
We NN NN O
present NN NN O
a NN NN O
case NN NN O
of NN NN O
presumed NN NN O
amikacin NN NN O
retinal NN NN B-Disease
toxicity NN NN I-Disease
following NN NN O
treatment NN NN O
with NN NN O
amikacin NN NN O
and NN NN O
vancomycin NN NN O
for NN NN O
alpha NN NN O
- NN NN O
haemolytic NN NN O
streptococcal NN NN B-Disease
endophthalmitis NN NN I-Disease
. NN NN O
   
RESULTS NN NN O
: NN NN O
Endophthalmitis NN NN B-Disease
resolved NN NN O
with NN NN O
improvement NN NN O
in NN NN O
visual NN NN O
acuity NN NN O
to NN NN O
6 NN NN O
/ NN NN O
24 NN NN O
at NN NN O
three NN NN O
months NN NN O
. NN NN O
   
Fundus NN NN O
fluorescein NN NN O
angiography NN NN O
confirmed NN NN O
macular NN NN O
capillary NN NN O
closure NN NN O
and NN NN O
telangiectasis NN NN B-Disease
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Currently NN NN O
accepted NN NN O
intravitreal NN NN O
antibiotic NN NN O
regimens NN NN O
may NN NN O
cause NN NN O
retinal NN NN B-Disease
toxicity NN NN I-Disease
and NN NN O
macular NN NN O
ischaemia NN NN B-Disease
. NN NN O
   
Treatment NN NN O
strategies NN NN O
aimed NN NN O
at NN NN O
avoiding NN NN O
retinal NN NN B-Disease
toxicity NN NN I-Disease
are NN NN O
discussed NN NN O
. NN NN O
   
The NN NN O
role NN NN O
of NN NN O
nicotine NN NN O
in NN NN O
smoking NN NN O
- NN NN O
related NN NN O
cardiovascular NN NN B-Disease
disease NN NN I-Disease
. NN NN O
   
Nicotine NN NN O
activates NN NN O
the NN NN O
sympathetic NN NN O
nervous NN NN O
system NN NN O
and NN NN O
in NN NN O
this NN NN O
way NN NN O
could NN NN O
contribute NN NN O
to NN NN O
cardiovascular NN NN B-Disease
disease NN NN I-Disease
. NN NN O
   
Animal NN NN O
studies NN NN O
and NN NN O
mechanistic NN NN O
studies NN NN O
indicate NN NN O
that NN NN O
nicotine NN NN O
could NN NN O
play NN NN O
a NN NN O
role NN NN O
in NN NN O
accelerating NN NN O
atherosclerosis NN NN B-Disease
, NN NN O
but NN NN O
evidence NN NN O
among NN NN O
humans NN NN O
is NN NN O
too NN NN O
inadequate NN NN O
to NN NN O
be NN NN O
definitive NN NN O
about NN NN O
such NN NN O
an NN NN O
effect NN NN O
. NN NN O
   
Almost NN NN O
certainly NN NN O
, NN NN O
nicotine NN NN O
via NN NN O
its NN NN O
hemodynamic NN NN O
effects NN NN O
contributes NN NN O
to NN NN O
acute NN NN O
cardiovascular NN NN O
events NN NN O
, NN NN O
although NN NN O
current NN NN O
evidence NN NN O
suggests NN NN O
that NN NN O
the NN NN O
effects NN NN O
of NN NN O
nicotine NN NN O
are NN NN O
much NN NN O
less NN NN O
important NN NN O
than NN NN O
are NN NN O
the NN NN O
prothrombotic NN NN O
effects NN NN O
of NN NN O
cigarette NN NN O
smoking NN NN O
or NN NN O
the NN NN O
effects NN NN O
of NN NN O
carbon NN NN O
monoxide NN NN O
. NN NN O
   
Nicotine NN NN O
does NN NN O
not NN NN O
appear NN NN O
to NN NN O
enhance NN NN O
thrombosis NN NN B-Disease
among NN NN O
humans NN NN O
. NN NN O
   
Clinical NN NN O
studies NN NN O
of NN NN O
pipe NN NN O
smokers NN NN O
and NN NN O
people NN NN O
using NN NN O
transdermal NN NN O
nicotine NN NN O
support NN NN O
the NN NN O
idea NN NN O
that NN NN O
toxins NN NN O
other NN NN O
than NN NN O
nicotine NN NN O
are NN NN O
the NN NN O
most NN NN O
important NN NN O
causes NN NN O
of NN NN O
acute NN NN O
cardiovascular NN NN O
events NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
the NN NN O
dose NN NN O
response NN NN O
for NN NN O
cardiovascular NN NN O
events NN NN O
of NN NN O
nicotine NN NN O
appears NN NN O
to NN NN O
be NN NN O
flat NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
if NN NN O
nicotine NN NN O
is NN NN O
involved NN NN O
, NN NN O
adverse NN NN O
effects NN NN O
might NN NN O
be NN NN O
seen NN NN O
with NN NN O
relatively NN NN O
low NN NN O
- NN NN O
level NN NN O
cigarette NN NN O
exposures NN NN O
. NN NN O
   
Iatrogenically NN NN O
induced NN NN O
intractable NN NN O
atrioventricular NN NN B-Disease
reentrant NN NN I-Disease
tachycardia NN NN I-Disease
after NN NN O
verapamil NN NN O
and NN NN O
catheter NN NN O
ablation NN NN O
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
Wolff NN NN B-Disease
- NN NN I-Disease
Parkinson NN NN I-Disease
- NN NN I-Disease
White NN NN I-Disease
syndrome NN NN I-Disease
and NN NN O
idiopathic NN NN B-Disease
dilated NN NN I-Disease
cardiomyopathy NN NN I-Disease
. NN NN O
   
In NN NN O
a NN NN O
patient NN NN O
with NN NN O
WPW NN NN B-Disease
syndrome NN NN I-Disease
and NN NN O
idiopathic NN NN B-Disease
dilated NN NN I-Disease
cardiomyopathy NN NN I-Disease
, NN NN O
intractable NN NN O
atrioventricular NN NN B-Disease
reentrant NN NN I-Disease
tachycardia NN NN I-Disease
( NN NN O
AVRT NN NN B-Disease
) NN NN O
was NN NN O
iatrogenically NN NN O
induced NN NN O
. NN NN O
   
QRS NN NN O
without NN NN O
preexcitation NN NN O
, NN NN O
caused NN NN O
by NN NN O
junctional NN NN O
escape NN NN O
beats NN NN O
after NN NN O
verapamil NN NN O
or NN NN O
unidirectional NN NN O
antegrade NN NN O
block NN NN O
of NN NN O
accessory NN NN O
pathway NN NN O
after NN NN O
catheter NN NN O
ablation NN NN O
, NN NN O
established NN NN O
frequent NN NN O
AVRT NN NN B-Disease
attack NN NN O
. NN NN O
   
Epidemic NN NN O
of NN NN O
liver NN NN B-Disease
disease NN NN I-Disease
caused NN NN O
by NN NN O
hydrochlorofluorocarbons NN NN O
used NN NN O
as NN NN O
ozone NN NN O
- NN NN O
sparing NN NN O
substitutes NN NN O
of NN NN O
chlorofluorocarbons NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Hydrochlorofluorocarbons NN NN O
( NN NN O
HCFCs NN NN O
) NN NN O
are NN NN O
used NN NN O
increasingly NN NN O
in NN NN O
industry NN NN O
as NN NN O
substitutes NN NN O
for NN NN O
ozone NN NN O
- NN NN O
depleting NN NN O
chlorofluorocarbons NN NN O
( NN NN O
CFCs NN NN O
) NN NN O
. NN NN O
   
Limited NN NN O
studies NN NN O
in NN NN O
animals NN NN O
indicate NN NN O
potential NN NN O
hepatotoxicity NN NN B-Disease
of NN NN O
some NN NN O
of NN NN O
these NN NN O
compounds NN NN O
. NN NN O
   
We NN NN O
investigated NN NN O
an NN NN O
epidemic NN NN O
of NN NN O
liver NN NN B-Disease
disease NN NN I-Disease
in NN NN O
nine NN NN O
industrial NN NN O
workers NN NN O
who NN NN O
had NN NN O
had NN NN O
repeated NN NN O
accidental NN NN O
exposure NN NN O
to NN NN O
a NN NN O
mixture NN NN O
of NN NN O
1 NN NN O
, NN NN O
1 NN NN O
- NN NN O
dichloro NN NN O
- NN NN O
2 NN NN O
, NN NN O
2 NN NN O
, NN NN O
2 NN NN O
- NN NN O
trifluoroethane NN NN O
( NN NN O
HCFC NN NN O
123 NN NN O
) NN NN O
and NN NN O
1 NN NN O
- NN NN O
chloro NN NN O
- NN NN O
1 NN NN O
, NN NN O
2 NN NN O
, NN NN O
2 NN NN O
, NN NN O
2 NN NN O
- NN NN O
tetrafluoroethane NN NN O
( NN NN O
HCFC NN NN O
124 NN NN O
) NN NN O
. NN NN O
   
All NN NN O
nine NN NN O
exposed NN NN O
workers NN NN O
were NN NN O
affected NN NN O
to NN NN O
various NN NN O
degrees NN NN O
. NN NN O
   
Both NN NN O
compounds NN NN O
are NN NN O
metabolised NN NN O
in NN NN O
the NN NN O
same NN NN O
way NN NN O
as NN NN O
1 NN NN O
- NN NN O
bromo NN NN O
- NN NN O
1 NN NN O
- NN NN O
chloro NN NN O
- NN NN O
2 NN NN O
, NN NN O
2 NN NN O
, NN NN O
2 NN NN O
- NN NN O
trifluoroethane NN NN O
( NN NN O
halothane NN NN O
) NN NN O
to NN NN O
form NN NN O
reactive NN NN O
trifluoroacetyl NN NN O
halide NN NN O
intermediates NN NN O
, NN NN O
which NN NN O
have NN NN O
been NN NN O
implicated NN NN O
in NN NN O
the NN NN O
hepatotoxicity NN NN B-Disease
of NN NN O
halothane NN NN O
. NN NN O
   
We NN NN O
aimed NN NN O
to NN NN O
test NN NN O
whether NN NN O
HCFCs NN NN O
123 NN NN O
and NN NN O
124 NN NN O
can NN NN O
result NN NN O
in NN NN O
serious NN NN O
liver NN NN B-Disease
disease NN NN I-Disease
. NN NN O
   
METHODS NN NN O
: NN NN O
For NN NN O
one NN NN O
severely NN NN O
affected NN NN O
worker NN NN O
liver NN NN O
biopsy NN NN O
and NN NN O
immunohistochemical NN NN O
stainings NN NN O
for NN NN O
the NN NN O
presence NN NN O
of NN NN O
trifluoroacetyl NN NN O
protein NN NN O
adducts NN NN O
were NN NN O
done NN NN O
. NN NN O
   
The NN NN O
serum NN NN O
of NN NN O
six NN NN O
affected NN NN O
workers NN NN O
and NN NN O
five NN NN O
controls NN NN O
was NN NN O
tested NN NN O
for NN NN O
autoantibodies NN NN O
that NN NN O
react NN NN O
with NN NN O
human NN NN O
liver NN NN O
cytochrome NN NN O
- NN NN O
P450 NN NN O
2E1 NN NN O
( NN NN O
P450 NN NN O
2E1 NN NN O
) NN NN O
and NN NN O
P58 NN NN O
protein NN NN O
disulphide NN NN O
isomerase NN NN O
isoform NN NN O
( NN NN O
P58 NN NN O
) NN NN O
. NN NN O
   
FINDINGS NN NN O
: NN NN O
The NN NN O
liver NN NN O
biopsy NN NN O
sample NN NN O
showed NN NN O
hepatocellular NN NN O
necrosis NN NN B-Disease
which NN NN O
was NN NN O
prominent NN NN O
in NN NN O
perivenular NN NN O
zone NN NN O
three NN NN O
and NN NN O
extended NN NN O
focally NN NN O
from NN NN O
portal NN NN O
tracts NN NN O
to NN NN O
portal NN NN O
tracts NN NN O
and NN NN O
centrilobular NN NN O
areas NN NN O
( NN NN O
bridging NN NN O
necrosis NN NN B-Disease
) NN NN O
. NN NN O
   
Trifluoroacetyl NN NN O
- NN NN O
adducted NN NN O
proteins NN NN O
were NN NN O
detected NN NN O
in NN NN O
surviving NN NN O
hepatocytes NN NN O
. NN NN O
   
Autoantibodies NN NN O
against NN NN O
P450 NN NN O
2E1 NN NN O
or NN NN O
P58 NN NN O
, NN NN O
previously NN NN O
associated NN NN O
with NN NN O
halothane NN NN B-Disease
hepatitis NN NN I-Disease
, NN NN O
were NN NN O
detected NN NN O
in NN NN O
the NN NN O
serum NN NN O
of NN NN O
five NN NN O
affected NN NN O
workers NN NN O
. NN NN O
   
INTERPRETATION NN NN O
: NN NN O
Repeated NN NN O
exposure NN NN O
of NN NN O
human NN NN O
beings NN NN O
to NN NN O
HCFCs NN NN O
123 NN NN O
and NN NN O
124 NN NN O
can NN NN O
result NN NN O
in NN NN O
serious NN NN O
liver NN NN B-Disease
injury NN NN I-Disease
in NN NN O
a NN NN O
large NN NN O
proportion NN NN O
of NN NN O
the NN NN O
exposed NN NN O
population NN NN O
. NN NN O
   
Although NN NN O
the NN NN O
exact NN NN O
mechanism NN NN O
of NN NN O
hepatotoxicity NN NN B-Disease
of NN NN O
these NN NN O
agents NN NN O
is NN NN O
not NN NN O
known NN NN O
, NN NN O
the NN NN O
results NN NN O
suggest NN NN O
that NN NN O
trifluoroacetyl NN NN O
- NN NN O
altered NN NN O
liver NN NN O
proteins NN NN O
are NN NN O
involved NN NN O
. NN NN O
   
In NN NN O
view NN NN O
of NN NN O
the NN NN O
potentially NN NN O
widespread NN NN O
use NN NN O
of NN NN O
these NN NN O
compounds NN NN O
, NN NN O
there NN NN O
is NN NN O
an NN NN O
urgent NN NN O
need NN NN O
to NN NN O
develop NN NN O
safer NN NN O
alternatives NN NN O
. NN NN O
   
Bile NN NN B-Disease
duct NN NN I-Disease
hamartoma NN NN I-Disease
occurring NN NN O
in NN NN O
association NN NN O
with NN NN O
long NN NN O
- NN NN O
term NN NN O
treatment NN NN O
with NN NN O
danazol NN NN O
. NN NN O
   
We NN NN O
report NN NN O
a NN NN O
case NN NN O
of NN NN O
bile NN NN B-Disease
duct NN NN I-Disease
hamartoma NN NN I-Disease
which NN NN O
developed NN NN O
in NN NN O
a NN NN O
patient NN NN O
who NN NN O
had NN NN O
been NN NN O
on NN NN O
long NN NN O
- NN NN O
term NN NN O
danazol NN NN O
treatment NN NN O
. NN NN O
   
Such NN NN O
patients NN NN O
should NN NN O
be NN NN O
under NN NN O
close NN NN O
follow NN NN O
- NN NN O
up NN NN O
, NN NN O
preferably NN NN O
with NN NN O
periodic NN NN O
ultrasound NN NN O
examination NN NN O
of NN NN O
the NN NN O
liver NN NN O
. NN NN O
   
If NN NN O
the NN NN O
patient NN NN O
develops NN NN O
a NN NN O
liver NN NN B-Disease
mass NN NN I-Disease
, NN NN O
because NN NN O
of NN NN O
non NN NN O
- NN NN O
specific NN NN O
clinical NN NN O
features NN NN O
and NN NN O
imaging NN NN O
appearances NN NN O
, NN NN O
biopsy NN NN O
may NN NN O
be NN NN O
the NN NN O
only NN NN O
way NN NN O
to NN NN O
achieve NN NN O
a NN NN O
definitive NN NN O
diagnosis NN NN O
. NN NN O
   
Endocrine NN NN O
screening NN NN O
in NN NN O
1 NN NN O
, NN NN O
022 NN NN O
men NN NN O
with NN NN O
erectile NN NN B-Disease
dysfunction NN NN I-Disease
: NN NN O
clinical NN NN O
significance NN NN O
and NN NN O
cost NN NN O
- NN NN O
effective NN NN O
strategy NN NN O
. NN NN O
   
PURPOSE NN NN O
: NN NN O
We NN NN O
reviewed NN NN O
the NN NN O
results NN NN O
of NN NN O
serum NN NN O
testosterone NN NN O
and NN NN O
prolactin NN NN O
determination NN NN O
in NN NN O
1 NN NN O
, NN NN O
022 NN NN O
patients NN NN O
referred NN NN O
because NN NN O
of NN NN O
erectile NN NN B-Disease
dysfunction NN NN I-Disease
and NN NN O
compared NN NN O
the NN NN O
data NN NN O
with NN NN O
history NN NN O
, NN NN O
results NN NN O
of NN NN O
physical NN NN O
examination NN NN O
, NN NN O
other NN NN O
etiological NN NN O
investigations NN NN O
and NN NN O
effects NN NN O
of NN NN O
endocrine NN NN O
therapy NN NN O
to NN NN O
refine NN NN O
the NN NN O
rules NN NN O
of NN NN O
cost NN NN O
- NN NN O
effective NN NN O
endocrine NN NN O
screening NN NN O
and NN NN O
to NN NN O
pinpoint NN NN O
actual NN NN O
responsibility NN NN O
for NN NN O
hormonal NN NN O
abnormalities NN NN O
. NN NN O
   
MATERIALS NN NN O
AND NN NN O
METHODS NN NN O
: NN NN O
Testosterone NN NN O
and NN NN O
prolactin NN NN O
were NN NN O
determined NN NN O
by NN NN O
radioimmunoassay NN NN O
. NN NN O
   
Every NN NN O
patient NN NN O
was NN NN O
screened NN NN O
for NN NN O
testosterone NN NN O
and NN NN O
451 NN NN O
were NN NN O
screened NN NN O
for NN NN O
prolactin NN NN O
on NN NN O
the NN NN O
basis NN NN O
of NN NN O
low NN NN B-Disease
sexual NN NN I-Disease
desire NN NN I-Disease
, NN NN O
gynecomastia NN NN B-Disease
or NN NN O
testosterone NN NN O
less NN NN O
than NN NN O
4 NN NN O
ng NN NN O
. NN NN O
/ NN NN O
ml NN NN O
. NN NN O
   
Determination NN NN O
was NN NN O
repeated NN NN O
in NN NN O
case NN NN O
of NN NN O
abnormal NN NN O
first NN NN O
results NN NN O
. NN NN O
   
Prolactin NN NN O
results NN NN O
were NN NN O
compared NN NN O
with NN NN O
those NN NN O
of NN NN O
a NN NN O
previous NN NN O
personal NN NN O
cohort NN NN O
of NN NN O
1 NN NN O
, NN NN O
340 NN NN O
patients NN NN O
with NN NN O
erectile NN NN B-Disease
dysfunction NN NN I-Disease
and NN NN O
systematic NN NN O
prolactin NN NN O
determination NN NN O
. NN NN O
   
Main NN NN O
clinical NN NN O
criteria NN NN O
tested NN NN O
regarding NN NN O
efficiency NN NN O
in NN NN O
hormone NN NN O
determination NN NN O
were NN NN O
low NN NN B-Disease
sexual NN NN I-Disease
desire NN NN I-Disease
, NN NN O
small NN NN O
testes NN NN O
and NN NN O
gynecomastia NN NN B-Disease
. NN NN O
   
Endocrine NN NN O
therapy NN NN O
consisted NN NN O
of NN NN O
testosterone NN NN O
heptylate NN NN O
or NN NN O
human NN NN O
chorionic NN NN O
gonadotropin NN NN O
for NN NN O
hypogonadism NN NN B-Disease
and NN NN O
bromocriptine NN NN O
for NN NN O
hyperprolactinemia NN NN B-Disease
. NN NN O
   
RESULTS NN NN O
: NN NN O
Testosterone NN NN O
was NN NN O
less NN NN O
than NN NN O
3 NN NN O
ng NN NN O
. NN NN O
/ NN NN O
ml NN NN O
. NN NN O
in NN NN O
107 NN NN O
patients NN NN O
but NN NN O
normal NN NN O
in NN NN O
40 NN NN O
% NN NN O
at NN NN O
repeat NN NN O
determination NN NN O
. NN NN O
   
The NN NN O
prevalence NN NN O
of NN NN O
repeatedly NN NN O
low NN NN O
testosterone NN NN O
increased NN NN O
with NN NN O
age NN NN O
( NN NN O
4 NN NN O
% NN NN O
before NN NN O
age NN NN O
50 NN NN O
years NN NN O
and NN NN O
9 NN NN O
% NN NN O
50 NN NN O
years NN NN O
or NN NN O
older NN NN O
) NN NN O
. NN NN O
   
Two NN NN O
pituitary NN NN B-Disease
tumors NN NN I-Disease
were NN NN O
discovered NN NN O
after NN NN O
testosterone NN NN O
determination NN NN O
. NN NN O
   
Most NN NN O
of NN NN O
the NN NN O
other NN NN O
low NN NN O
testosterone NN NN O
levels NN NN O
seemed NN NN O
to NN NN O
result NN NN O
from NN NN O
nonorganic NN NN O
hypothalamic NN NN B-Disease
dysfunction NN NN I-Disease
because NN NN O
of NN NN O
normal NN NN O
serum NN NN O
luteinizing NN NN O
hormone NN NN O
and NN NN O
prolactin NN NN O
and NN NN O
to NN NN O
have NN NN O
only NN NN O
a NN NN O
small NN NN O
role NN NN O
in NN NN O
erectile NN NN B-Disease
dysfunction NN NN I-Disease
( NN NN O
definite NN NN O
improvement NN NN O
in NN NN O
only NN NN O
16 NN NN O
of NN NN O
44 NN NN O
[ NN NN O
36 NN NN O
% NN NN O
] NN NN O
after NN NN O
androgen NN NN O
therapy NN NN O
, NN NN O
normal NN NN O
morning NN NN O
or NN NN O
nocturnal NN NN O
erections NN NN O
in NN NN O
30 NN NN O
% NN NN O
and NN NN O
definite NN NN O
vasculogenic NN NN O
contributions NN NN O
in NN NN O
42 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
Determining NN NN O
testosterone NN NN O
only NN NN O
in NN NN O
cases NN NN O
of NN NN O
low NN NN B-Disease
sexual NN NN I-Disease
desire NN NN I-Disease
or NN NN O
abnormal NN NN O
physical NN NN O
examination NN NN O
would NN NN O
have NN NN O
missed NN NN O
40 NN NN O
% NN NN O
of NN NN O
the NN NN O
cases NN NN O
with NN NN O
low NN NN O
testosterone NN NN O
, NN NN O
including NN NN O
37 NN NN O
% NN NN O
of NN NN O
those NN NN O
subsequently NN NN O
improved NN NN O
by NN NN O
androgen NN NN O
therapy NN NN O
. NN NN O
   
Prolactin NN NN O
exceeded NN NN O
20 NN NN O
ng NN NN O
. NN NN O
/ NN NN O
ml NN NN O
. NN NN O
in NN NN O
5 NN NN O
men NN NN O
and NN NN O
was NN NN O
normal NN NN O
in NN NN O
2 NN NN O
at NN NN O
repeat NN NN O
determination NN NN O
. NN NN O
   
Only NN NN O
1 NN NN O
prolactinoma NN NN B-Disease
was NN NN O
discovered NN NN O
. NN NN O
   
These NN NN O
data NN NN O
are NN NN O
lower NN NN O
than NN NN O
those NN NN O
we NN NN O
found NN NN O
during NN NN O
the NN NN O
last NN NN O
2 NN NN O
decades NN NN O
( NN NN O
overall NN NN O
prolactin NN NN O
greater NN NN O
than NN NN O
20 NN NN O
ng NN NN O
. NN NN O
/ NN NN O
ml NN NN O
. NN NN O
in NN NN O
1 NN NN O
. NN NN O
86 NN NN O
% NN NN O
of NN NN O
1 NN NN O
, NN NN O
821 NN NN O
patients NN NN O
, NN NN O
prolactinomas NN NN B-Disease
in NN NN O
7 NN NN O
, NN NN O
0 NN NN O
. NN NN O
38 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
Bromocriptine NN NN O
was NN NN O
definitely NN NN O
effective NN NN O
in NN NN O
cases NN NN O
with NN NN O
prolactin NN NN O
greater NN NN O
than NN NN O
35 NN NN O
ng NN NN O
. NN NN O
/ NN NN O
ml NN NN O
. NN NN O
   
( NN NN O
8 NN NN O
of NN NN O
12 NN NN O
compared NN NN O
to NN NN O
only NN NN O
9 NN NN O
of NN NN O
22 NN NN O
cases NN NN O
with NN NN O
prolactin NN NN O
between NN NN O
20 NN NN O
and NN NN O
35 NN NN O
ng NN NN O
. NN NN O
/ NN NN O
ml NN NN O
. NN NN O
) NN NN O
. NN NN O
   
Testosterone NN NN O
was NN NN O
low NN NN O
in NN NN O
less NN NN O
than NN NN O
50 NN NN O
% NN NN O
of NN NN O
cases NN NN O
with NN NN O
prolactin NN NN O
greater NN NN O
than NN NN O
35 NN NN O
ng NN NN O
. NN NN O
/ NN NN O
ml NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Low NN NN O
prevalences NN NN O
and NN NN O
effects NN NN O
of NN NN O
low NN NN O
testosterone NN NN O
and NN NN O
high NN NN O
prolactin NN NN O
in NN NN O
erectile NN NN B-Disease
dysfunction NN NN I-Disease
cannot NN NN O
justify NN NN O
their NN NN O
routine NN NN O
determination NN NN O
. NN NN O
   
However NN NN O
, NN NN O
cost NN NN O
- NN NN O
effective NN NN O
screening NN NN O
strategies NN NN O
recommended NN NN O
so NN NN O
far NN NN O
missed NN NN O
40 NN NN O
to NN NN O
50 NN NN O
% NN NN O
of NN NN O
cases NN NN O
improved NN NN O
with NN NN O
endocrine NN NN O
therapy NN NN O
and NN NN O
the NN NN O
pituitary NN NN B-Disease
tumors NN NN I-Disease
. NN NN O
   
We NN NN O
now NN NN O
advocate NN NN O
that NN NN O
before NN NN O
age NN NN O
50 NN NN O
years NN NN O
testosterone NN NN O
be NN NN O
determined NN NN O
only NN NN O
in NN NN O
cases NN NN O
of NN NN O
low NN NN B-Disease
sexual NN NN I-Disease
desire NN NN I-Disease
and NN NN O
abnormal NN NN O
physical NN NN O
examination NN NN O
but NN NN O
that NN NN O
it NN NN O
be NN NN O
measured NN NN O
in NN NN O
all NN NN O
men NN NN O
older NN NN O
than NN NN O
50 NN NN O
years NN NN O
. NN NN O
   
Prolactin NN NN O
should NN NN O
be NN NN O
determined NN NN O
only NN NN O
in NN NN O
cases NN NN O
of NN NN O
low NN NN B-Disease
sexual NN NN I-Disease
desire NN NN I-Disease
, NN NN O
gynecomastia NN NN B-Disease
and NN NN O
/ NN NN O
or NN NN O
testosterone NN NN O
less NN NN O
than NN NN O
4 NN NN O
ng NN NN O
. NN NN O
/ NN NN O
ml NN NN O
. NN NN O
   
Extrapyramidal NN NN O
side NN NN O
effects NN NN O
with NN NN O
risperidone NN NN O
and NN NN O
haloperidol NN NN O
at NN NN O
comparable NN NN O
D2 NN NN O
receptor NN NN O
occupancy NN NN O
levels NN NN O
. NN NN O
   
Risperidone NN NN O
is NN NN O
an NN NN O
antipsychotic NN NN O
drug NN NN O
with NN NN O
high NN NN O
affinity NN NN O
at NN NN O
dopamine NN NN O
D2 NN NN O
and NN NN O
serotonin NN NN O
5 NN NN O
- NN NN O
HT2 NN NN O
receptors NN NN O
. NN NN O
   
Previous NN NN O
clinical NN NN O
studies NN NN O
have NN NN O
proposed NN NN O
that NN NN O
risperidone NN NN O
' NN NN O
s NN NN O
pharmacologic NN NN O
profile NN NN O
may NN NN O
produce NN NN O
improved NN NN O
efficacy NN NN O
for NN NN O
negative NN NN O
psychotic NN NN B-Disease
symptoms NN NN I-Disease
and NN NN O
decreased NN NN O
propensity NN NN O
for NN NN O
extrapyramidal NN NN O
side NN NN O
effects NN NN O
; NN NN O
features NN NN O
shared NN NN O
by NN NN O
so NN NN O
- NN NN O
called NN NN O
' NN NN O
atypical NN NN O
' NN NN O
neuroleptics NN NN O
. NN NN O
   
To NN NN O
determine NN NN O
if NN NN O
routine NN NN O
risperidone NN NN O
treatment NN NN O
is NN NN O
associated NN NN O
with NN NN O
a NN NN O
unique NN NN O
degree NN NN O
of NN NN O
D2 NN NN O
receptor NN NN O
occupancy NN NN O
and NN NN O
pattern NN NN O
of NN NN O
clinical NN NN O
effects NN NN O
, NN NN O
we NN NN O
used NN NN O
[ NN NN O
123I NN NN O
] NN NN O
IBZM NN NN O
SPECT NN NN O
to NN NN O
determine NN NN O
D2 NN NN O
occupancy NN NN O
in NN NN O
subjects NN NN O
treated NN NN O
with NN NN O
routine NN NN O
clinical NN NN O
doses NN NN O
of NN NN O
risperidone NN NN O
( NN NN O
n NN NN O
= NN NN O
12 NN NN O
) NN NN O
or NN NN O
haloperidol NN NN O
( NN NN O
n NN NN O
= NN NN O
7 NN NN O
) NN NN O
. NN NN O
   
Both NN NN O
risperidone NN NN O
and NN NN O
haloperidol NN NN O
produced NN NN O
D2 NN NN O
occupancy NN NN O
levels NN NN O
between NN NN O
approximately NN NN O
60 NN NN O
and NN NN O
90 NN NN O
% NN NN O
at NN NN O
standard NN NN O
clinical NN NN O
doses NN NN O
. NN NN O
   
There NN NN O
was NN NN O
no NN NN O
significant NN NN O
difference NN NN O
between NN NN O
occupancy NN NN O
levels NN NN O
obtained NN NN O
with NN NN O
haloperidol NN NN O
or NN NN O
risperidone NN NN O
. NN NN O
   
Drug NN NN B-Disease
- NN NN I-Disease
induced NN NN I-Disease
parkinsonism NN NN I-Disease
was NN NN O
observed NN NN O
in NN NN O
subjects NN NN O
treated NN NN O
with NN NN O
risperidone NN NN O
( NN NN O
42 NN NN O
% NN NN O
) NN NN O
and NN NN O
haloperidol NN NN O
( NN NN O
29 NN NN O
% NN NN O
) NN NN O
and NN NN O
was NN NN O
observed NN NN O
at NN NN O
occupancy NN NN O
levels NN NN O
above NN NN O
60 NN NN O
% NN NN O
. NN NN O
   
Based NN NN O
on NN NN O
these NN NN O
observations NN NN O
, NN NN O
it NN NN O
is NN NN O
concluded NN NN O
that NN NN O
5 NN NN O
- NN NN O
HT2 NN NN O
blockade NN NN O
obtained NN NN O
with NN NN O
risperidone NN NN O
at NN NN O
D2 NN NN O
occupancy NN NN O
rates NN NN O
of NN NN O
60 NN NN O
% NN NN O
and NN NN O
above NN NN O
does NN NN O
not NN NN O
appear NN NN O
to NN NN O
protect NN NN O
against NN NN O
the NN NN O
risk NN NN O
for NN NN O
extrapyramidal NN NN O
side NN NN O
effects NN NN O
. NN NN O
   
Treatment NN NN O
of NN NN O
previously NN NN O
treated NN NN O
metastatic NN NN O
breast NN NN B-Disease
cancer NN NN I-Disease
by NN NN O
mitoxantrone NN NN O
and NN NN O
48 NN NN O
- NN NN O
hour NN NN O
continuous NN NN O
infusion NN NN O
of NN NN O
high NN NN O
- NN NN O
dose NN NN O
5 NN NN O
- NN NN O
FU NN NN O
and NN NN O
leucovorin NN NN O
( NN NN O
MFL NN NN O
) NN NN O
: NN NN O
low NN NN O
palliative NN NN O
benefit NN NN O
and NN NN O
high NN NN O
treatment NN NN O
- NN NN O
related NN NN O
toxicity NN NN B-Disease
. NN NN O
   
For NN NN O
previously NN NN O
treated NN NN O
advanced NN NN O
breast NN NN B-Disease
cancer NN NN I-Disease
, NN NN O
there NN NN O
is NN NN O
no NN NN O
standard NN NN O
second NN NN O
- NN NN O
line NN NN O
therapy NN NN O
. NN NN O
   
Combination NN NN O
chemotherapy NN NN O
with NN NN O
mitoxantrone NN NN O
, NN NN O
high NN NN O
- NN NN O
dose NN NN O
5 NN NN O
- NN NN O
fluorouracil NN NN O
( NN NN O
5 NN NN O
- NN NN O
FU NN NN O
) NN NN O
and NN NN O
leucovorin NN NN O
( NN NN O
MFL NN NN O
regimen NN NN O
) NN NN O
had NN NN O
been NN NN O
reported NN NN O
as NN NN O
an NN NN O
effective NN NN O
and NN NN O
well NN NN O
tolerated NN NN O
regimen NN NN O
. NN NN O
   
From NN NN O
October NN NN O
1993 NN NN O
to NN NN O
November NN NN O
1995 NN NN O
, NN NN O
we NN NN O
treated NN NN O
13 NN NN O
patients NN NN O
with NN NN O
previously NN NN O
chemotherapy NN NN O
- NN NN O
treated NN NN O
metastatic NN NN O
breast NN NN B-Disease
cancer NN NN I-Disease
by NN NN O
mitoxantrone NN NN O
, NN NN O
12 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
, NN NN O
on NN NN O
day NN NN O
1 NN NN O
and NN NN O
continuous NN NN O
infusion NN NN O
of NN NN O
5 NN NN O
- NN NN O
FU NN NN O
, NN NN O
3000 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
, NN NN O
together NN NN O
with NN NN O
leucovorin NN NN O
, NN NN O
300 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
, NN NN O
for NN NN O
48 NN NN O
h NN NN O
from NN NN O
day NN NN O
1 NN NN O
to NN NN O
2 NN NN O
. NN NN O
   
Each NN NN O
course NN NN O
of NN NN O
chemotherapy NN NN O
was NN NN O
given NN NN O
every NN NN O
4 NN NN O
weeks NN NN O
. NN NN O
   
Most NN NN O
of NN NN O
these NN NN O
patients NN NN O
had NN NN O
more NN NN O
than NN NN O
two NN NN O
metastatic NN NN O
sites NN NN O
, NN NN O
with NN NN O
lung NN NN O
metastasis NN NN O
predominant NN NN O
. NN NN O
   
Seven NN NN O
patients NN NN O
had NN NN O
been NN NN O
treated NN NN O
with NN NN O
anthracycline NN NN O
. NN NN O
   
Seven NN NN O
patients NN NN O
had NN NN O
previously NN NN O
received NN NN O
radiotherapy NN NN O
and NN NN O
seven NN NN O
had NN NN O
received NN NN O
hormone NN NN O
therapy NN NN O
. NN NN O
   
Median NN NN O
number NN NN O
of NN NN O
courses NN NN O
of NN NN O
MFL NN NN O
regimen NN NN O
given NN NN O
was NN NN O
six NN NN O
and NN NN O
the NN NN O
median NN NN O
cumulative NN NN O
dose NN NN O
of NN NN O
mitoxantrone NN NN O
was NN NN O
68 NN NN O
. NN NN O
35 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
. NN NN O
   
One NN NN O
patient NN NN O
had NN NN O
complete NN NN O
response NN NN O
, NN NN O
seven NN NN O
had NN NN O
stable NN NN O
disease NN NN O
, NN NN O
none NN NN O
had NN NN O
partial NN NN O
response NN NN O
and NN NN O
five NN NN O
had NN NN O
progressive NN NN O
disease NN NN O
. NN NN O
   
The NN NN O
overall NN NN O
objective NN NN O
response NN NN O
rate NN NN O
was NN NN O
7 NN NN O
. NN NN O
6 NN NN O
% NN NN O
. NN NN O
   
The NN NN O
median NN NN O
follow NN NN O
- NN NN O
up NN NN O
period NN NN O
was NN NN O
14 NN NN O
months NN NN O
. NN NN O
   
Median NN NN O
survival NN NN O
was NN NN O
16 NN NN O
months NN NN O
. NN NN O
   
Median NN NN O
progression NN NN O
- NN NN O
free NN NN O
survival NN NN O
was NN NN O
5 NN NN O
months NN NN O
. NN NN O
   
A NN NN O
complete NN NN O
responder NN NN O
had NN NN O
relapse NN NN O
- NN NN O
free NN NN O
survival NN NN O
up NN NN O
to NN NN O
17 NN NN O
months NN NN O
. NN NN O
   
Major NN NN O
toxicities NN NN B-Disease
were NN NN O
cardiotoxicity NN NN B-Disease
and NN NN O
leukopenia NN NN B-Disease
. NN NN O
   
Eight NN NN O
patients NN NN O
were NN NN O
dead NN NN O
in NN NN O
the NN NN O
last NN NN O
follow NN NN O
- NN NN O
up NN NN O
; NN NN O
two NN NN O
of NN NN O
them NN NN O
died NN NN O
of NN NN O
treatment NN NN O
- NN NN O
related NN NN O
toxicity NN NN B-Disease
. NN NN O
   
The NN NN O
MFL NN NN O
regimen NN NN O
achieves NN NN O
little NN NN O
palliative NN NN O
benefit NN NN O
and NN NN O
induces NN NN O
severe NN NN O
toxicity NN NN B-Disease
at NN NN O
a NN NN O
fairly NN NN O
high NN NN O
rate NN NN O
. NN NN O
   
Administration NN NN O
of NN NN O
this NN NN O
regimen NN NN O
to NN NN O
breast NN NN B-Disease
cancer NN NN I-Disease
patients NN NN O
who NN NN O
have NN NN O
been NN NN O
treated NN NN O
by NN NN O
chemotherapy NN NN O
and NN NN O
those NN NN O
with NN NN O
impaired NN NN B-Disease
heart NN NN I-Disease
function NN NN I-Disease
requires NN NN O
careful NN NN O
attention NN NN O
. NN NN O
   
Ticlopidine NN NN O
- NN NN O
induced NN NN O
aplastic NN NN B-Disease
anemia NN NN I-Disease
: NN NN O
report NN NN O
of NN NN O
three NN NN O
Chinese NN NN O
patients NN NN O
and NN NN O
review NN NN O
of NN NN O
the NN NN O
literature NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
three NN NN O
Chinese NN NN O
patients NN NN O
with NN NN O
ticlopidine NN NN O
- NN NN O
induced NN NN O
aplastic NN NN B-Disease
anemia NN NN I-Disease
were NN NN O
reported NN NN O
and NN NN O
another NN NN O
13 NN NN O
patients NN NN O
in NN NN O
the NN NN O
English NN NN O
literature NN NN O
were NN NN O
reviewed NN NN O
. NN NN O
   
We NN NN O
attempted NN NN O
to NN NN O
find NN NN O
underlying NN NN O
similarities NN NN O
, NN NN O
evaluate NN NN O
the NN NN O
risk NN NN O
factors NN NN O
, NN NN O
and NN NN O
identify NN NN O
appropriate NN NN O
treatment NN NN O
for NN NN O
this NN NN O
complication NN NN O
. NN NN O
   
All NN NN O
but NN NN O
one NN NN O
of NN NN O
the NN NN O
patients NN NN O
were NN NN O
over NN NN O
60 NN NN O
years NN NN O
old NN NN O
, NN NN O
and NN NN O
the NN NN O
6 NN NN O
who NN NN O
died NN NN O
were NN NN O
all NN NN O
older NN NN O
than NN NN O
65 NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
old NN NN O
age NN NN O
may NN NN O
be NN NN O
a NN NN O
risk NN NN O
factor NN NN O
for NN NN O
developing NN NN O
this NN NN O
complication NN NN O
. NN NN O
   
Agranulocytosis NN NN B-Disease
occurred NN NN O
3 NN NN O
- NN NN O
20 NN NN O
weeks NN NN O
after NN NN O
initiation NN NN O
of NN NN O
ticlopidine NN NN O
, NN NN O
so NN NN O
frequent NN NN O
examination NN NN O
of NN NN O
white NN NN O
cell NN NN O
count NN NN O
during NN NN O
treatment NN NN O
is NN NN O
recommended NN NN O
. NN NN O
   
There NN NN O
seemed NN NN O
to NN NN O
be NN NN O
no NN NN O
direct NN NN O
correlation NN NN O
between NN NN O
the NN NN O
dose NN NN O
or NN NN O
duration NN NN O
used NN NN O
and NN NN O
the NN NN O
severity NN NN O
of NN NN O
bone NN NN B-Disease
marrow NN NN I-Disease
suppression NN NN I-Disease
. NN NN O
   
Treatment NN NN O
for NN NN O
ticlopidine NN NN O
- NN NN O
induced NN NN O
aplastic NN NN B-Disease
anemia NN NN I-Disease
with NN NN O
colony NN NN O
- NN NN O
stimulating NN NN O
factors NN NN O
seemed NN NN O
to NN NN O
have NN NN O
little NN NN O
effect NN NN O
. NN NN O
   
The NN NN O
fact NN NN O
that NN NN O
5 NN NN O
of NN NN O
the NN NN O
6 NN NN O
patients NN NN O
who NN NN O
received NN NN O
concurrent NN NN O
calcium NN NN O
channel NN NN O
blockers NN NN O
died NN NN O
, NN NN O
should NN NN O
alert NN NN O
clinicians NN NN O
to NN NN O
be NN NN O
more NN NN O
cautious NN NN O
when NN NN O
using NN NN O
these NN NN O
two NN NN O
drugs NN NN O
simultaneously NN NN O
. NN NN O
   
Upregulation NN NN O
of NN NN O
the NN NN O
expression NN NN O
of NN NN O
vasopressin NN NN O
gene NN NN O
in NN NN O
the NN NN O
paraventricular NN NN O
and NN NN O
supraoptic NN NN O
nuclei NN NN O
of NN NN O
the NN NN O
lithium NN NN O
- NN NN O
induced NN NN O
diabetes NN NN B-Disease
insipidus NN NN I-Disease
rat NN NN O
. NN NN O
   
The NN NN O
expression NN NN O
of NN NN O
arginine NN NN O
vasopressin NN NN O
( NN NN O
AVP NN NN O
) NN NN O
gene NN NN O
in NN NN O
the NN NN O
paraventricular NN NN O
( NN NN O
PVN NN NN O
) NN NN O
and NN NN O
supraoptic NN NN O
nuclei NN NN O
( NN NN O
SON NN NN O
) NN NN O
was NN NN O
investigated NN NN O
in NN NN O
rats NN NN O
with NN NN O
lithium NN NN O
( NN NN O
Li NN NN O
) NN NN O
- NN NN O
induced NN NN O
polyuria NN NN B-Disease
, NN NN O
using NN NN O
in NN NN O
situ NN NN O
hybridization NN NN O
histochemistry NN NN O
and NN NN O
radioimmunoassay NN NN O
. NN NN O
   
The NN NN O
male NN NN O
Wistar NN NN O
rats NN NN O
consuming NN NN O
a NN NN O
diet NN NN O
that NN NN O
contained NN NN O
LiCl NN NN O
( NN NN O
60 NN NN O
mmol NN NN O
/ NN NN O
kg NN NN O
) NN NN O
for NN NN O
4 NN NN O
weeks NN NN O
developed NN NN O
marked NN NN O
polyuria NN NN B-Disease
. NN NN O
   
The NN NN O
Li NN NN O
- NN NN O
treated NN NN O
rats NN NN O
produced NN NN O
a NN NN O
large NN NN O
volume NN NN O
of NN NN O
hypotonic NN NN O
urine NN NN O
with NN NN O
low NN NN O
ionic NN NN O
concentrations NN NN O
. NN NN O
   
Plasma NN NN O
sodium NN NN O
concentrations NN NN O
were NN NN O
found NN NN O
to NN NN O
be NN NN O
slightly NN NN O
increased NN NN O
in NN NN O
the NN NN O
Li NN NN O
- NN NN O
treated NN NN O
rats NN NN O
compared NN NN O
with NN NN O
those NN NN O
in NN NN O
controls NN NN O
. NN NN O
   
Plasma NN NN O
concentration NN NN O
of NN NN O
AVP NN NN O
and NN NN O
transcripts NN NN O
of NN NN O
AVP NN NN O
gene NN NN O
in NN NN O
the NN NN O
PVN NN NN O
and NN NN O
SON NN NN O
were NN NN O
significantly NN NN O
increased NN NN O
in NN NN O
the NN NN O
Li NN NN O
- NN NN O
treated NN NN O
rats NN NN O
compared NN NN O
with NN NN O
controls NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
dehydration NN NN B-Disease
and NN NN O
/ NN NN O
or NN NN O
the NN NN O
activation NN NN O
of NN NN O
visceral NN NN O
afferent NN NN O
inputs NN NN O
may NN NN O
contribute NN NN O
to NN NN O
the NN NN O
elevation NN NN O
of NN NN O
plasma NN NN O
AVP NN NN O
and NN NN O
the NN NN O
upregulation NN NN O
of NN NN O
AVP NN NN O
gene NN NN O
expression NN NN O
in NN NN O
the NN NN O
PVN NN NN O
and NN NN O
the NN NN O
SON NN NN O
of NN NN O
the NN NN O
Li NN NN O
- NN NN O
induced NN NN O
diabetes NN NN B-Disease
insipidus NN NN I-Disease
rat NN NN O
. NN NN O
   
Antinociceptive NN NN O
and NN NN O
antiamnesic NN NN O
properties NN NN O
of NN NN O
the NN NN O
presynaptic NN NN O
cholinergic NN NN O
amplifier NN NN O
PG NN NN O
- NN NN O
9 NN NN O
. NN NN O
   
The NN NN O
antinociceptive NN NN O
effect NN NN O
of NN NN O
3 NN NN O
alpha NN NN O
- NN NN O
tropyl NN NN O
2 NN NN O
- NN NN O
( NN NN O
p NN NN O
- NN NN O
bromophenyl NN NN O
) NN NN O
propionate NN NN O
[ NN NN O
( NN NN O
+ NN NN O
/ NN NN O
- NN NN O
) NN NN O
- NN NN O
PG NN NN O
- NN NN O
9 NN NN O
] NN NN O
( NN NN O
10 NN NN O
- NN NN O
40 NN NN O
mg NN NN O
kg NN NN O
- NN NN O
1 NN NN O
s NN NN O
. NN NN O
c NN NN O
. NN NN O
; NN NN O
30 NN NN O
- NN NN O
60 NN NN O
mg NN NN O
kg NN NN O
- NN NN O
1 NN NN O
p NN NN O
. NN NN O
o NN NN O
. NN NN O
; NN NN O
10 NN NN O
- NN NN O
30 NN NN O
mg NN NN O
kg NN NN O
- NN NN O
1 NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
; NN NN O
10 NN NN O
- NN NN O
30 NN NN O
micrograms NN NN O
/ NN NN O
mouse NN NN O
i NN NN O
. NN NN O
c NN NN O
. NN NN O
v NN NN O
. NN NN O
) NN NN O
was NN NN O
examined NN NN O
in NN NN O
mice NN NN O
, NN NN O
rats NN NN O
and NN NN O
guinea NN NN O
pigs NN NN O
by NN NN O
use NN NN O
of NN NN O
the NN NN O
hot NN NN O
- NN NN O
plate NN NN O
, NN NN O
abdominal NN NN O
- NN NN O
constriction NN NN O
, NN NN O
tail NN NN O
- NN NN O
flick NN NN O
and NN NN O
paw NN NN O
- NN NN O
pressure NN NN O
tests NN NN O
. NN NN O
   
( NN NN O
+ NN NN O
/ NN NN O
- NN NN O
) NN NN O
- NN NN O
PG NN NN O
- NN NN O
9 NN NN O
antinociception NN NN O
peaked NN NN O
15 NN NN O
min NN NN O
after NN NN O
injection NN NN O
and NN NN O
then NN NN O
slowly NN NN O
diminished NN NN O
. NN NN O
   
The NN NN O
antinociception NN NN O
produced NN NN O
by NN NN O
( NN NN O
+ NN NN O
/ NN NN O
- NN NN O
) NN NN O
- NN NN O
PG NN NN O
- NN NN O
9 NN NN O
was NN NN O
prevented NN NN O
by NN NN O
the NN NN O
unselective NN NN O
muscarinic NN NN O
antagonist NN NN O
atropine NN NN O
, NN NN O
the NN NN O
M1 NN NN O
- NN NN O
selective NN NN O
antagonists NN NN O
pirenzepine NN NN O
and NN NN O
dicyclomine NN NN O
and NN NN O
the NN NN O
acetylcholine NN NN O
depletor NN NN O
hemicholinium NN NN O
- NN NN O
3 NN NN O
, NN NN O
but NN NN O
not NN NN O
by NN NN O
the NN NN O
opioid NN NN O
antagonist NN NN O
naloxone NN NN O
, NN NN O
the NN NN O
gamma NN NN O
- NN NN O
aminobutyric NN NN O
acidB NN NN O
antagonist NN NN O
3 NN NN O
- NN NN O
aminopropyl NN NN O
- NN NN O
diethoxy NN NN O
- NN NN O
methyl NN NN O
- NN NN O
phosphinic NN NN O
acid NN NN O
, NN NN O
the NN NN O
H3 NN NN O
agonist NN NN O
R NN NN O
- NN NN O
( NN NN O
alpha NN NN O
) NN NN O
- NN NN O
methylhistamine NN NN O
, NN NN O
the NN NN O
D2 NN NN O
antagonist NN NN O
quinpirole NN NN O
, NN NN O
the NN NN O
5 NN NN O
- NN NN O
hydroxytryptamine4 NN NN O
antagonist NN NN O
2 NN NN O
- NN NN O
methoxy NN NN O
- NN NN O
4 NN NN O
- NN NN O
amino NN NN O
- NN NN O
5 NN NN O
- NN NN O
chlorobenzoic NN NN O
acid NN NN O
2 NN NN O
- NN NN O
( NN NN O
diethylamino NN NN O
) NN NN O
ethyl NN NN O
ester NN NN O
hydrochloride NN NN O
, NN NN O
the NN NN O
5 NN NN O
- NN NN O
hydroxytryptamin1A NN NN O
antagonist NN NN O
1 NN NN O
- NN NN O
( NN NN O
2 NN NN O
- NN NN O
methoxyphenyl NN NN O
) NN NN O
- NN NN O
4 NN NN O
- NN NN O
[ NN NN O
4 NN NN O
- NN NN O
( NN NN O
2 NN NN O
- NN NN O
phthalimido NN NN O
) NN NN O
butyl NN NN O
] NN NN O
piperazine NN NN O
hydrobromide NN NN O
and NN NN O
the NN NN O
polyamines NN NN O
depletor NN NN O
reserpine NN NN O
. NN NN O
   
Based NN NN O
on NN NN O
these NN NN O
data NN NN O
, NN NN O
it NN NN O
can NN NN O
be NN NN O
postulated NN NN O
that NN NN O
( NN NN O
+ NN NN O
/ NN NN O
- NN NN O
) NN NN O
- NN NN O
PG NN NN O
- NN NN O
9 NN NN O
exerted NN NN O
an NN NN O
antinociceptive NN NN O
effect NN NN O
mediated NN NN O
by NN NN O
a NN NN O
central NN NN O
potentiation NN NN O
of NN NN O
cholinergic NN NN O
transmission NN NN O
. NN NN O
   
( NN NN O
+ NN NN O
/ NN NN O
- NN NN O
) NN NN O
- NN NN O
PG NN NN O
- NN NN O
9 NN NN O
( NN NN O
10 NN NN O
- NN NN O
40 NN NN O
mg NN NN O
kg NN NN O
- NN NN O
1 NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
was NN NN O
able NN NN O
to NN NN O
prevent NN NN O
amnesia NN NN B-Disease
induced NN NN O
by NN NN O
scopolamine NN NN O
( NN NN O
1 NN NN O
mg NN NN O
kg NN NN O
- NN NN O
1 NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
and NN NN O
dicyclomine NN NN O
( NN NN O
2 NN NN O
mg NN NN O
kg NN NN O
- NN NN O
1 NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
in NN NN O
the NN NN O
mouse NN NN O
passive NN NN O
- NN NN O
avoidance NN NN O
test NN NN O
. NN NN O
   
Affinity NN NN O
profiles NN NN O
of NN NN O
( NN NN O
+ NN NN O
/ NN NN O
- NN NN O
) NN NN O
- NN NN O
PG NN NN O
- NN NN O
9 NN NN O
for NN NN O
muscarinic NN NN O
receptor NN NN O
subtypes NN NN O
, NN NN O
determined NN NN O
by NN NN O
functional NN NN O
studies NN NN O
( NN NN O
rabbit NN NN O
vas NN NN O
deferens NN NN O
for NN NN O
M1 NN NN O
, NN NN O
guinea NN NN O
pig NN NN O
atrium NN NN O
for NN NN O
M2 NN NN O
, NN NN O
guinea NN NN O
pig NN NN O
ileum NN NN O
for NN NN O
M3 NN NN O
and NN NN O
immature NN NN O
guinea NN NN O
pig NN NN O
uterus NN NN O
for NN NN O
putative NN NN O
M4 NN NN O
) NN NN O
, NN NN O
have NN NN O
shown NN NN O
an NN NN O
M4 NN NN O
/ NN NN O
M1 NN NN O
selectivity NN NN O
ratio NN NN O
of NN NN O
10 NN NN O
. NN NN O
2 NN NN O
that NN NN O
might NN NN O
be NN NN O
responsible NN NN O
for NN NN O
the NN NN O
antinociception NN NN O
and NN NN O
the NN NN O
anti NN NN O
- NN NN O
amnesic NN NN B-Disease
effect NN NN O
induced NN NN O
by NN NN O
( NN NN O
+ NN NN O
/ NN NN O
- NN NN O
) NN NN O
- NN NN O
PG NN NN O
- NN NN O
9 NN NN O
through NN NN O
an NN NN O
increase NN NN O
in NN NN O
acetylcholine NN NN O
extracellular NN NN O
levels NN NN O
. NN NN O
   
In NN NN O
the NN NN O
antinociceptive NN NN O
and NN NN O
antiamnesic NN NN O
dose NN NN O
range NN NN O
, NN NN O
( NN NN O
+ NN NN O
/ NN NN O
- NN NN O
) NN NN O
- NN NN O
PG NN NN O
- NN NN O
9 NN NN O
did NN NN O
not NN NN O
impair NN NN O
mouse NN NN O
performance NN NN O
evaluated NN NN O
by NN NN O
the NN NN O
rota NN NN O
- NN NN O
rod NN NN O
test NN NN O
and NN NN O
Animex NN NN O
apparatus NN NN O
. NN NN O
   
The NN NN O
effect NN NN O
of NN NN O
different NN NN O
anaesthetic NN NN O
agents NN NN O
in NN NN O
hearing NN NN B-Disease
loss NN NN I-Disease
following NN NN O
spinal NN NN O
anaesthesia NN NN O
. NN NN O
   
The NN NN O
cause NN NN O
of NN NN O
hearing NN NN B-Disease
loss NN NN I-Disease
after NN NN O
spinal NN NN O
anaesthesia NN NN O
is NN NN O
unknown NN NN O
. NN NN O
   
Up NN NN O
until NN NN O
now NN NN O
, NN NN O
the NN NN O
only NN NN O
factor NN NN O
studied NN NN O
has NN NN O
been NN NN O
the NN NN O
effect NN NN O
of NN NN O
the NN NN O
diameter NN NN O
of NN NN O
the NN NN O
spinal NN NN O
needle NN NN O
on NN NN O
post NN NN O
- NN NN O
operative NN NN O
sensorineural NN NN B-Disease
hearing NN NN I-Disease
loss NN NN I-Disease
. NN NN O
   
The NN NN O
aim NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
describe NN NN O
this NN NN O
hearing NN NN B-Disease
loss NN NN I-Disease
and NN NN O
to NN NN O
investigate NN NN O
other NN NN O
factors NN NN O
influencing NN NN O
the NN NN O
degree NN NN O
of NN NN O
hearing NN NN B-Disease
loss NN NN I-Disease
. NN NN O
   
Two NN NN O
groups NN NN O
of NN NN O
22 NN NN O
similar NN NN O
patients NN NN O
were NN NN O
studied NN NN O
: NN NN O
one NN NN O
group NN NN O
received NN NN O
6 NN NN O
mL NN NN O
prilocaine NN NN O
2 NN NN O
% NN NN O
; NN NN O
and NN NN O
the NN NN O
other NN NN O
received NN NN O
3 NN NN O
mL NN NN O
bupivacaine NN NN O
0 NN NN O
. NN NN O
5 NN NN O
% NN NN O
. NN NN O
   
Patients NN NN O
given NN NN O
prilocaine NN NN O
were NN NN O
more NN NN O
likely NN NN O
to NN NN O
develop NN NN O
hearing NN NN B-Disease
loss NN NN I-Disease
( NN NN O
10 NN NN O
out NN NN O
of NN NN O
22 NN NN O
) NN NN O
than NN NN O
those NN NN O
given NN NN O
bupivacaine NN NN O
( NN NN O
4 NN NN O
out NN NN O
of NN NN O
22 NN NN O
) NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
average NN NN O
hearing NN NN B-Disease
loss NN NN I-Disease
for NN NN O
speech NN NN O
frequencies NN NN O
was NN NN O
about NN NN O
10 NN NN O
dB NN NN O
after NN NN O
prilocaine NN NN O
and NN NN O
15 NN NN O
dB NN NN O
after NN NN O
bupivacaine NN NN O
. NN NN O
   
   O
of NN NN O
the NN NN O
patients NN NN O
complained NN NN O
of NN NN O
subjective NN NN O
hearing NN NN B-Disease
loss NN NN I-Disease
. NN NN O
   
Long NN NN O
- NN NN O
term NN NN O
follow NN NN O
- NN NN O
up NN NN O
of NN NN O
the NN NN O
patients NN NN O
was NN NN O
not NN NN O
possible NN NN O
. NN NN O
   
A NN NN O
transient NN NN O
neurological NN NN B-Disease
deficit NN NN I-Disease
following NN NN O
intrathecal NN NN O
injection NN NN O
of NN NN O
1 NN NN O
% NN NN O
hyperbaric NN NN O
bupivacaine NN NN O
for NN NN O
unilateral NN NN O
spinal NN NN O
anaesthesia NN NN O
. NN NN O
   
We NN NN O
describe NN NN O
a NN NN O
case NN NN O
of NN NN O
transient NN NN O
neurological NN NN B-Disease
deficit NN NN I-Disease
that NN NN O
occurred NN NN O
after NN NN O
unilateral NN NN O
spinal NN NN O
anaesthesia NN NN O
with NN NN O
8 NN NN O
mg NN NN O
of NN NN O
1 NN NN O
% NN NN O
hyperbaric NN NN O
bupivacaine NN NN O
slowly NN NN O
injected NN NN O
through NN NN O
a NN NN O
25 NN NN O
- NN NN O
gauge NN NN O
pencil NN NN O
- NN NN O
point NN NN O
spinal NN NN O
needle NN NN O
. NN NN O
   
The NN NN O
surgery NN NN O
and NN NN O
anaesthesia NN NN O
were NN NN O
uneventful NN NN O
, NN NN O
but NN NN O
3 NN NN O
days NN NN O
after NN NN O
surgery NN NN O
, NN NN O
the NN NN O
patient NN NN O
reported NN NN O
an NN NN O
area NN NN O
of NN NN O
hypoaesthesia NN NN O
over NN NN O
L3 NN NN O
- NN NN O
L4 NN NN O
dermatomes NN NN O
of NN NN O
the NN NN O
leg NN NN O
which NN NN O
had NN NN O
been NN NN O
operated NN NN O
on NN NN O
( NN NN O
loss NN NN B-Disease
of NN NN I-Disease
pinprick NN NN I-Disease
sensation NN NN I-Disease
) NN NN O
without NN NN O
reduction NN NN O
in NN NN O
muscular NN NN O
strength NN NN O
. NN NN O
   
Sensation NN NN O
in NN NN O
this NN NN O
area NN NN O
returned NN NN O
to NN NN O
normal NN NN O
over NN NN O
the NN NN O
following NN NN O
2 NN NN O
weeks NN NN O
. NN NN O
   
Prospective NN NN O
multicentre NN NN O
studies NN NN O
with NN NN O
a NN NN O
large NN NN O
population NN NN O
and NN NN O
a NN NN O
long NN NN O
follow NN NN O
- NN NN O
up NN NN O
should NN NN O
be NN NN O
performed NN NN O
in NN NN O
order NN NN O
to NN NN O
evaluate NN NN O
the NN NN O
incidence NN NN O
of NN NN O
this NN NN O
unusual NN NN O
side NN NN O
effect NN NN O
. NN NN O
   
However NN NN O
, NN NN O
we NN NN O
suggest NN NN O
that NN NN O
a NN NN O
low NN NN O
solution NN NN O
concentration NN NN O
should NN NN O
be NN NN O
preferred NN NN O
for NN NN O
unilateral NN NN O
spinal NN NN O
anaesthesia NN NN O
with NN NN O
a NN NN O
hyperbaric NN NN O
anaesthetic NN NN O
solution NN NN O
( NN NN O
if NN NN O
pencil NN NN O
- NN NN O
point NN NN O
needle NN NN O
and NN NN O
slow NN NN O
injection NN NN O
rate NN NN O
are NN NN O
employed NN NN O
) NN NN O
, NN NN O
in NN NN O
order NN NN O
to NN NN O
minimize NN NN O
the NN NN O
risk NN NN O
of NN NN O
a NN NN O
localized NN NN O
high NN NN O
peak NN NN O
anaesthetic NN NN O
concentration NN NN O
, NN NN O
which NN NN O
might NN NN O
lead NN NN O
to NN NN O
a NN NN O
transient NN NN O
neurological NN NN B-Disease
deficit NN NN I-Disease
. NN NN O
   
Transient NN NN B-Disease
neurologic NN NN I-Disease
symptoms NN NN I-Disease
after NN NN O
spinal NN NN O
anesthesia NN NN O
: NN NN O
a NN NN O
lower NN NN O
incidence NN NN O
with NN NN O
prilocaine NN NN O
and NN NN O
bupivacaine NN NN O
than NN NN O
with NN NN O
lidocaine NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Recent NN NN O
evidence NN NN O
suggests NN NN O
that NN NN O
transient NN NN B-Disease
neurologic NN NN I-Disease
symptoms NN NN I-Disease
( NN NN O
TNSs NN NN B-Disease
) NN NN O
frequently NN NN O
follow NN NN O
lidocaine NN NN O
spinal NN NN O
anesthesia NN NN O
but NN NN O
are NN NN O
infrequent NN NN O
with NN NN O
bupivacaine NN NN O
. NN NN O
   
However NN NN O
, NN NN O
identification NN NN O
of NN NN O
a NN NN O
short NN NN O
- NN NN O
acting NN NN O
local NN NN O
anesthetic NN NN O
to NN NN O
substitute NN NN O
for NN NN O
lidocaine NN NN O
for NN NN O
brief NN NN O
surgical NN NN O
procedures NN NN O
remains NN NN O
an NN NN O
important NN NN O
goal NN NN O
. NN NN O
   
Prilocaine NN NN O
is NN NN O
an NN NN O
amide NN NN O
local NN NN O
anesthetic NN NN O
with NN NN O
a NN NN O
duration NN NN O
of NN NN O
action NN NN O
similar NN NN O
to NN NN O
that NN NN O
of NN NN O
lidocaine NN NN O
. NN NN O
   
Accordingly NN NN O
, NN NN O
the NN NN O
present NN NN O
, NN NN O
prospective NN NN O
double NN NN O
- NN NN O
blind NN NN O
study NN NN O
compares NN NN O
prilocaine NN NN O
with NN NN O
lidocaine NN NN O
and NN NN O
bupivacaine NN NN O
with NN NN O
respect NN NN O
to NN NN O
duration NN NN O
of NN NN O
action NN NN O
and NN NN O
relative NN NN O
risk NN NN O
of NN NN O
TNSs NN NN B-Disease
. NN NN O
   
METHODS NN NN O
: NN NN O
Ninety NN NN O
patients NN NN O
classified NN NN O
as NN NN O
American NN NN O
Society NN NN O
of NN NN O
Anesthesiologists NN NN O
physical NN NN O
status NN NN O
I NN NN O
or NN NN O
II NN NN O
who NN NN O
were NN NN O
scheduled NN NN O
for NN NN O
short NN NN O
gynecologic NN NN O
procedures NN NN O
under NN NN O
spinal NN NN O
anesthesia NN NN O
were NN NN O
randomly NN NN O
allocated NN NN O
to NN NN O
receive NN NN O
2 NN NN O
. NN NN O
5 NN NN O
ml NN NN O
2 NN NN O
% NN NN O
lidocaine NN NN O
in NN NN O
7 NN NN O
. NN NN O
5 NN NN O
% NN NN O
glucose NN NN O
, NN NN O
2 NN NN O
% NN NN O
prilocaine NN NN O
in NN NN O
7 NN NN O
. NN NN O
5 NN NN O
% NN NN O
glucose NN NN O
, NN NN O
or NN NN O
0 NN NN O
. NN NN O
5 NN NN O
% NN NN O
bupivacaine NN NN O
in NN NN O
7 NN NN O
. NN NN O
5 NN NN O
% NN NN O
glucose NN NN O
. NN NN O
   
All NN NN O
solutions NN NN O
were NN NN O
provided NN NN O
in NN NN O
blinded NN NN O
vials NN NN O
by NN NN O
the NN NN O
hospital NN NN O
pharmacy NN NN O
. NN NN O
   
Details NN NN O
of NN NN O
spinal NN NN O
puncture NN NN O
, NN NN O
extension NN NN O
and NN NN O
regression NN NN O
of NN NN O
spinal NN NN O
block NN NN O
, NN NN O
and NN NN O
the NN NN O
times NN NN O
to NN NN O
reach NN NN O
discharge NN NN O
criteria NN NN O
were NN NN O
noted NN NN O
. NN NN O
   
In NN NN O
the NN NN O
evening NN NN O
of NN NN O
postoperative NN NN O
day NN NN O
1 NN NN O
, NN NN O
patients NN NN O
were NN NN O
evaluated NN NN O
for NN NN O
TNSs NN NN B-Disease
by NN NN O
a NN NN O
physician NN NN O
unaware NN NN O
of NN NN O
the NN NN O
drug NN NN O
administered NN NN O
and NN NN O
the NN NN O
details NN NN O
of NN NN O
the NN NN O
anesthetic NN NN O
procedure NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Nine NN NN O
of NN NN O
30 NN NN O
patients NN NN O
receiving NN NN O
lidocaine NN NN O
experienced NN NN O
TNSs NN NN B-Disease
, NN NN O
1 NN NN O
of NN NN O
30 NN NN O
patients NN NN O
receiving NN NN O
prilocaine NN NN O
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
03 NN NN O
) NN NN O
had NN NN O
them NN NN O
, NN NN O
and NN NN O
none NN NN O
of NN NN O
30 NN NN O
patients NN NN O
receiving NN NN O
bupivacaine NN NN O
had NN NN O
TNSs NN NN B-Disease
. NN NN O
   
Times NN NN O
to NN NN O
ambulate NN NN O
and NN NN O
to NN NN O
void NN NN O
were NN NN O
similar NN NN O
after NN NN O
lidocaine NN NN O
and NN NN O
prilocaine NN NN O
( NN NN O
150 NN NN O
vs NN NN O
. NN NN O
165 NN NN O
min NN NN O
and NN NN O
238 NN NN O
vs NN NN O
. NN NN O
253 NN NN O
min NN NN O
, NN NN O
respectively NN NN O
) NN NN O
but NN NN O
prolonged NN NN O
after NN NN O
bupivacaine NN NN O
( NN NN O
200 NN NN O
and NN NN O
299 NN NN O
min NN NN O
, NN NN O
respectively NN NN O
; NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Prilocaine NN NN O
may NN NN O
be NN NN O
preferable NN NN O
to NN NN O
lidocaine NN NN O
for NN NN O
short NN NN O
surgical NN NN O
procedures NN NN O
because NN NN O
it NN NN O
has NN NN O
a NN NN O
similar NN NN O
duration NN NN O
of NN NN O
action NN NN O
but NN NN O
a NN NN O
lower NN NN O
incidence NN NN O
of NN NN O
TNSs NN NN B-Disease
. NN NN O
   
Suxamethonium NN NN O
- NN NN O
induced NN NN O
cardiac NN NN B-Disease
arrest NN NN I-Disease
and NN NN O
death NN NN B-Disease
following NN NN O
5 NN NN O
days NN NN O
of NN NN O
immobilization NN NN O
. NN NN O
   
The NN NN O
present NN NN O
report NN NN O
describes NN NN O
a NN NN O
case NN NN O
of NN NN O
cardiac NN NN B-Disease
arrest NN NN I-Disease
and NN NN O
subsequent NN NN O
death NN NN B-Disease
as NN NN O
a NN NN O
result NN NN O
of NN NN O
hyperkalaemia NN NN B-Disease
following NN NN O
the NN NN O
use NN NN O
of NN NN O
suxamethonium NN NN O
in NN NN O
a NN NN O
23 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
Malawian NN NN O
woman NN NN O
. NN NN O
   
Five NN NN O
days NN NN O
after NN NN O
the NN NN O
onset NN NN O
of NN NN O
the NN NN O
symptoms NN NN O
of NN NN O
meningitis NN NN B-Disease
, NN NN O
the NN NN O
patient NN NN O
aspirated NN NN O
stomach NN NN O
contents NN NN O
and NN NN O
needed NN NN O
endotracheal NN NN O
intubation NN NN O
. NN NN O
   
Forty NN NN O
seconds NN NN O
after NN NN O
injection NN NN O
of NN NN O
suxamethonium NN NN O
, NN NN O
bradycardia NN NN B-Disease
and NN NN O
cardiac NN NN B-Disease
arrest NN NN I-Disease
occurred NN NN O
. NN NN O
   
Attempts NN NN O
to NN NN O
resuscitate NN NN O
the NN NN O
patient NN NN O
were NN NN O
not NN NN O
successful NN NN O
. NN NN O
   
The NN NN O
serum NN NN O
level NN NN O
of NN NN O
potassium NN NN O
was NN NN O
observed NN NN O
to NN NN O
be NN NN O
8 NN NN O
. NN NN O
4 NN NN O
mequiv NN NN O
L NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
Apart NN NN O
from NN NN O
the NN NN O
reduction NN NN O
in NN NN O
the NN NN O
patient NN NN O
' NN NN O
s NN NN O
level NN NN O
of NN NN O
consciousness NN NN O
, NN NN O
there NN NN O
were NN NN O
no NN NN O
signs NN NN O
of NN NN O
motor NN NN O
neurone NN NN O
damage NN NN O
or NN NN O
of NN NN O
any NN NN O
of NN NN O
the NN NN O
other NN NN O
known NN NN O
predisposing NN NN O
conditions NN NN O
for NN NN O
hyperkalaemia NN NN B-Disease
following NN NN O
the NN NN O
administration NN NN O
of NN NN O
suxamethonium NN NN O
. NN NN O
   
It NN NN O
is NN NN O
postulated NN NN O
that NN NN O
her NN NN O
death NN NN B-Disease
was NN NN O
caused NN NN O
by NN NN O
hypersensitivity NN NN B-Disease
to NN NN O
suxamethonium NN NN O
, NN NN O
associated NN NN O
with NN NN O
her NN NN O
5 NN NN O
- NN NN O
day NN NN O
immobilization NN NN O
. NN NN O
   
Acute NN NN O
hepatitis NN NN B-Disease
, NN NN O
autoimmune NN NN B-Disease
hemolytic NN NN I-Disease
anemia NN NN I-Disease
, NN NN O
and NN NN O
erythroblastocytopenia NN NN B-Disease
induced NN NN O
by NN NN O
ceftriaxone NN NN O
. NN NN O
   
An NN NN O
80 NN NN O
- NN NN O
yr NN NN O
- NN NN O
old NN NN O
man NN NN O
developed NN NN O
acute NN NN O
hepatitis NN NN B-Disease
shortly NN NN O
after NN NN O
ingesting NN NN O
oral NN NN O
ceftriaxone NN NN O
. NN NN O
   
Although NN NN O
the NN NN O
transaminases NN NN O
gradually NN NN O
returned NN NN O
to NN NN O
baseline NN NN O
after NN NN O
withholding NN NN O
the NN NN O
beta NN NN O
lactam NN NN O
antibiotic NN NN O
, NN NN O
there NN NN O
was NN NN O
a NN NN O
gradual NN NN O
increase NN NN O
in NN NN O
serum NN NN O
bilirubin NN NN O
and NN NN O
a NN NN O
decrease NN NN O
in NN NN O
hemoglobin NN NN O
concentration NN NN O
caused NN NN O
by NN NN O
an NN NN O
autoimmune NN NN B-Disease
hemolytic NN NN I-Disease
anemia NN NN I-Disease
and NN NN O
erythroblastocytopenia NN NN B-Disease
. NN NN O
   
These NN NN O
responded NN NN O
to NN NN O
systemic NN NN O
steroids NN NN O
and NN NN O
immunoglobulins NN NN O
. NN NN O
   
Despite NN NN O
the NN NN O
widespread NN NN O
use NN NN O
of NN NN O
these NN NN O
agents NN NN O
this NN NN O
triad NN NN O
of NN NN O
side NN NN O
effects NN NN O
has NN NN O
not NN NN O
previously NN NN O
been NN NN O
reported NN NN O
in NN NN O
connection NN NN O
with NN NN O
beta NN NN O
lactam NN NN O
antibiotics NN NN O
. NN NN O
   
Thyroxine NN NN O
abuse NN NN O
: NN NN O
an NN NN O
unusual NN NN O
case NN NN O
of NN NN O
thyrotoxicosis NN NN B-Disease
in NN NN O
pregnancy NN NN O
. NN NN O
   
Eating NN NN B-Disease
disorders NN NN I-Disease
and NN NN O
the NN NN O
associated NN NN O
behavioural NN NN O
problems NN NN O
and NN NN O
drug NN NN B-Disease
abuse NN NN I-Disease
are NN NN O
uncommon NN NN O
in NN NN O
pregnancy NN NN O
. NN NN O
   
When NN NN O
they NN NN O
do NN NN O
occur NN NN O
they NN NN O
are NN NN O
often NN NN O
unrecognized NN NN O
because NN NN O
of NN NN O
denial NN NN O
but NN NN O
when NN NN O
significant NN NN O
may NN NN O
pose NN NN O
a NN NN O
risk NN NN O
to NN NN O
both NN NN O
the NN NN O
mother NN NN O
and NN NN O
her NN NN O
fetus NN NN O
. NN NN O
   
This NN NN O
case NN NN O
illustrates NN NN O
a NN NN O
number NN NN O
of NN NN O
problems NN NN O
that NN NN O
may NN NN O
be NN NN O
encountered NN NN O
in NN NN O
women NN NN O
with NN NN O
eating NN NN B-Disease
disorders NN NN I-Disease
in NN NN O
pregnancy NN NN O
, NN NN O
including NN NN O
prolonged NN NN O
and NN NN O
recurrent NN NN O
metabolic NN NN O
disturbances NN NN O
and NN NN O
diuretic NN NN O
abuse NN NN O
. NN NN O
   
In NN NN O
particular NN NN O
it NN NN O
illustrates NN NN O
the NN NN O
derangements NN NN O
of NN NN O
thyroid NN NN O
function NN NN O
seen NN NN O
in NN NN O
pregnant NN NN O
women NN NN O
with NN NN O
eating NN NN B-Disease
disorders NN NN I-Disease
and NN NN O
reminds NN NN O
us NN NN O
that NN NN O
when NN NN O
a NN NN O
cause NN NN O
for NN NN O
thyrotoxicosis NN NN B-Disease
remains NN NN O
obscure NN NN O
, NN NN O
thyroxine NN NN O
abuse NN NN O
should NN NN O
be NN NN O
considered NN NN O
and NN NN O
explored NN NN O
. NN NN O
   
Repeated NN NN O
trimipramine NN NN O
induces NN NN O
dopamine NN NN O
D2 NN NN O
/ NN NN O
D3 NN NN O
and NN NN O
alpha1 NN NN O
- NN NN O
adrenergic NN NN O
up NN NN O
- NN NN O
regulation NN NN O
. NN NN O
   
Trimipramine NN NN O
( NN NN O
TRI NN NN O
) NN NN O
, NN NN O
which NN NN O
shows NN NN O
a NN NN O
clinical NN NN O
antidepressant NN NN O
activity NN NN O
, NN NN O
is NN NN O
chemically NN NN O
related NN NN O
to NN NN O
imipramine NN NN O
but NN NN O
does NN NN O
not NN NN O
inhibit NN NN O
the NN NN O
reuptake NN NN O
of NN NN O
noradrenaline NN NN O
and NN NN O
5 NN NN O
- NN NN O
hydroxytryptamine NN NN O
, NN NN O
nor NN NN O
does NN NN O
it NN NN O
induce NN NN O
beta NN NN O
- NN NN O
adrenergic NN NN O
down NN NN O
- NN NN O
regulation NN NN O
. NN NN O
   
The NN NN O
mechanism NN NN O
of NN NN O
its NN NN O
antidepressant NN NN O
activity NN NN O
is NN NN O
still NN NN O
unknown NN NN O
. NN NN O
   
The NN NN O
aim NN NN O
of NN NN O
the NN NN O
present NN NN O
study NN NN O
was NN NN O
to NN NN O
find NN NN O
out NN NN O
whether NN NN O
TRI NN NN O
given NN NN O
repeatedly NN NN O
was NN NN O
able NN NN O
to NN NN O
induce NN NN O
adaptive NN NN O
changes NN NN O
in NN NN O
the NN NN O
dopaminergic NN NN O
and NN NN O
alpha1 NN NN O
- NN NN O
adrenergic NN NN O
systems NN NN O
, NN NN O
demonstrated NN NN O
by NN NN O
us NN NN O
previously NN NN O
for NN NN O
various NN NN O
antidepressants NN NN O
. NN NN O
   
TRI NN NN O
was NN NN O
given NN NN O
to NN NN O
male NN NN O
Wistar NN NN O
rats NN NN O
and NN NN O
male NN NN O
Albino NN NN O
Swiss NN NN O
mice NN NN O
perorally NN NN O
twice NN NN O
daily NN NN O
for NN NN O
14 NN NN O
days NN NN O
. NN NN O
   
In NN NN O
the NN NN O
acute NN NN O
experiment NN NN O
TRI NN NN O
( NN NN O
given NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
does NN NN O
not NN NN O
antagonize NN NN O
the NN NN O
reserpine NN NN O
hypothermia NN NN B-Disease
in NN NN O
mice NN NN O
and NN NN O
does NN NN O
not NN NN O
potentiate NN NN O
the NN NN O
5 NN NN O
- NN NN O
hydroxytryptophan NN NN O
head NN NN O
twitches NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
TRI NN NN O
given NN NN O
repeatedly NN NN O
to NN NN O
rats NN NN O
increases NN NN O
the NN NN O
locomotor NN NN O
hyperactivity NN NN B-Disease
induced NN NN O
by NN NN O
d NN NN O
- NN NN O
amphetamine NN NN O
, NN NN O
quinpirole NN NN O
and NN NN O
( NN NN O
+ NN NN O
) NN NN O
- NN NN O
7 NN NN O
- NN NN O
hydroxy NN NN O
- NN NN O
dipropyloaminotetralin NN NN O
( NN NN O
dopamine NN NN O
D2 NN NN O
and NN NN O
D3 NN NN O
effects NN NN O
) NN NN O
. NN NN O
   
The NN NN O
stereotypies NN NN O
induced NN NN O
by NN NN O
d NN NN O
- NN NN O
amphetamine NN NN O
or NN NN O
apomorphine NN NN O
are NN NN O
not NN NN O
potentiated NN NN O
by NN NN O
TRI NN NN O
. NN NN O
   
It NN NN O
increases NN NN O
the NN NN O
behaviour NN NN O
stimulation NN NN O
evoked NN NN O
by NN NN O
phenylephrine NN NN O
( NN NN O
given NN NN O
intraventricularly NN NN O
) NN NN O
in NN NN O
rats NN NN O
, NN NN O
evaluated NN NN O
in NN NN O
the NN NN O
open NN NN O
field NN NN O
test NN NN O
as NN NN O
well NN NN O
as NN NN O
the NN NN O
aggressiveness NN NN B-Disease
evoked NN NN O
by NN NN O
clonidine NN NN O
in NN NN O
mice NN NN O
, NN NN O
both NN NN O
these NN NN O
effects NN NN O
being NN NN O
mediated NN NN O
by NN NN O
an NN NN O
alpha1 NN NN O
- NN NN O
adrenergic NN NN O
receptor NN NN O
. NN NN O
   
It NN NN O
may NN NN O
be NN NN O
concluded NN NN O
that NN NN O
, NN NN O
like NN NN O
other NN NN O
tricyclic NN NN O
antidepressants NN NN O
studied NN NN O
previously NN NN O
, NN NN O
TRI NN NN O
given NN NN O
repeatedly NN NN O
increases NN NN O
the NN NN O
responsiveness NN NN O
of NN NN O
brain NN NN O
dopamine NN NN O
D2 NN NN O
and NN NN O
D3 NN NN O
( NN NN O
locomotor NN NN O
activity NN NN O
but NN NN O
not NN NN O
stereotypy NN NN O
) NN NN O
as NN NN O
well NN NN O
as NN NN O
alpha1 NN NN O
- NN NN O
adrenergic NN NN O
receptors NN NN O
to NN NN O
their NN NN O
agonists NN NN O
. NN NN O
   
A NN NN O
question NN NN O
arises NN NN O
whether NN NN O
the NN NN O
reuptake NN NN O
inhibition NN NN O
is NN NN O
of NN NN O
any NN NN O
importance NN NN O
to NN NN O
the NN NN O
adaptive NN NN O
changes NN NN O
induced NN NN O
by NN NN O
repeated NN NN O
antidepressants NN NN O
, NN NN O
suggested NN NN O
to NN NN O
be NN NN O
responsible NN NN O
for NN NN O
the NN NN O
antidepressant NN NN O
activity NN NN O
. NN NN O
   
Pethidine NN NN O
- NN NN O
associated NN NN O
seizure NN NN B-Disease
in NN NN O
a NN NN O
healthy NN NN O
adolescent NN NN O
receiving NN NN O
pethidine NN NN O
for NN NN O
postoperative NN NN B-Disease
pain NN NN I-Disease
control NN NN O
. NN NN O
   
A NN NN O
healthy NN NN O
17 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
male NN NN O
received NN NN O
standard NN NN O
intermittent NN NN O
doses NN NN O
of NN NN O
pethidine NN NN O
via NN NN O
a NN NN O
patient NN NN O
- NN NN O
controlled NN NN O
analgesia NN NN O
( NN NN O
PCA NN NN O
) NN NN O
pump NN NN O
for NN NN O
management NN NN O
of NN NN O
postoperative NN NN B-Disease
pain NN NN I-Disease
control NN NN O
. NN NN O
   
Twenty NN NN O
- NN NN O
three NN NN O
h NN NN O
postoperatively NN NN O
he NN NN O
developed NN NN O
a NN NN O
brief NN NN O
self NN NN O
- NN NN O
limited NN NN O
seizure NN NN B-Disease
. NN NN O
   
Both NN NN O
plasma NN NN O
pethidine NN NN O
and NN NN O
norpethidine NN NN O
were NN NN O
elevated NN NN O
in NN NN O
the NN NN O
range NN NN O
associated NN NN O
with NN NN O
clinical NN NN O
manifestations NN NN O
of NN NN O
central NN NN O
nervous NN NN O
system NN NN O
excitation NN NN O
. NN NN O
   
No NN NN O
other NN NN O
risk NN NN O
factors NN NN O
for NN NN O
CNS NN NN O
toxicity NN NN B-Disease
were NN NN O
identified NN NN O
. NN NN O
   
This NN NN O
method NN NN O
allowed NN NN O
frequent NN NN O
self NN NN O
- NN NN O
dosing NN NN O
of NN NN O
pethidine NN NN O
at NN NN O
short NN NN O
time NN NN O
intervals NN NN O
and NN NN O
rapid NN NN O
accumulation NN NN O
of NN NN O
pethidine NN NN O
and NN NN O
norpethidine NN NN O
. NN NN O
   
The NN NN O
routine NN NN O
use NN NN O
of NN NN O
pethidine NN NN O
via NN NN O
PCA NN NN O
even NN NN O
for NN NN O
a NN NN O
brief NN NN O
postoperative NN NN O
analgesia NN NN O
should NN NN O
be NN NN O
reconsidered NN NN O
. NN NN O
   
An NN NN O
unusual NN NN O
toxic NN NN O
reaction NN NN O
to NN NN O
axillary NN NN O
block NN NN O
by NN NN O
mepivacaine NN NN O
with NN NN O
adrenaline NN NN O
. NN NN O
   
An NN NN O
increase NN NN B-Disease
in NN NN I-Disease
blood NN NN I-Disease
pressure NN NN I-Disease
, NN NN O
accompanied NN NN O
by NN NN O
atrial NN NN B-Disease
fibrillation NN NN I-Disease
, NN NN O
agitation NN NN B-Disease
, NN NN O
incomprehensible NN NN B-Disease
shouts NN NN I-Disease
and NN NN O
loss NN NN B-Disease
of NN NN I-Disease
consciousness NN NN I-Disease
, NN NN O
was NN NN O
observed NN NN O
in NN NN O
an NN NN O
elderly NN NN O
, NN NN O
ASA NN NN O
classification NN NN O
group NN NN O
II NN NN O
, NN NN O
cardiovascularly NN NN O
medicated NN NN O
male NN NN O
, NN NN O
12 NN NN O
min NN NN O
after NN NN O
performance NN NN O
of NN NN O
axillary NN NN O
block NN NN O
with NN NN O
mepivacaine NN NN O
850 NN NN O
mg NN NN O
containing NN NN O
adrenaline NN NN O
0 NN NN O
. NN NN O
225 NN NN O
mg NN NN O
, NN NN O
for NN NN O
correction NN NN O
of NN NN O
Dupuytren NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
contracture NN NN I-Disease
. NN NN O
   
After NN NN O
intravenous NN NN O
administration NN NN O
of NN NN O
labetalol NN NN O
, NN NN O
metoprolol NN NN O
and NN NN O
midazolam NN NN O
the NN NN O
patient NN NN O
' NN NN O
s NN NN O
condition NN NN O
improved NN NN O
, NN NN O
and NN NN O
15 NN NN O
min NN NN O
later NN NN O
he NN NN O
woke NN NN O
up NN NN O
. NN NN O
   
The NN NN O
block NN NN O
was NN NN O
successful NN NN O
and NN NN O
surgery NN NN O
was NN NN O
conducted NN NN O
as NN NN O
scheduled NN NN O
despite NN NN O
persisting NN NN O
atrial NN NN B-Disease
fibrillation NN NN I-Disease
. NN NN O
   
Postoperatively NN NN O
, NN NN O
the NN NN O
patient NN NN O
refused NN NN O
DC NN NN O
cardioversion NN NN O
and NN NN O
was NN NN O
treated NN NN O
medically NN NN O
. NN NN O
   
Both NN NN O
the NN NN O
temporal NN NN O
relationship NN NN O
of NN NN O
events NN NN O
and NN NN O
the NN NN O
response NN NN O
to NN NN O
treatment NN NN O
suggest NN NN O
that NN NN O
a NN NN O
rapid NN NN O
systemic NN NN O
absorption NN NN O
of NN NN O
mepivacaine NN NN O
with NN NN O
adrenaline NN NN O
and NN NN O
/ NN NN O
or NN NN O
interaction NN NN O
of NN NN O
these NN NN O
drugs NN NN O
with NN NN O
the NN NN O
patient NN NN O
' NN NN O
s NN NN O
cardiovascular NN NN O
medications NN NN O
were NN NN O
responsible NN NN O
for NN NN O
the NN NN O
perioperative NN NN O
complications NN NN O
. NN NN O
   
Drug NN NN O
- NN NN O
associated NN NN O
acute NN NN O
- NN NN O
onset NN NN O
vanishing NN NN B-Disease
bile NN NN I-Disease
duct NN NN I-Disease
and NN NN O
Stevens NN NN B-Disease
- NN NN I-Disease
Johnson NN NN I-Disease
syndromes NN NN I-Disease
in NN NN O
a NN NN O
child NN NN O
. NN NN O
   
Acute NN NN O
vanishing NN NN B-Disease
bile NN NN I-Disease
duct NN NN I-Disease
syndrome NN NN O
is NN NN O
a NN NN O
rare NN NN O
but NN NN O
established NN NN O
cause NN NN O
of NN NN O
progressive NN NN O
cholestasis NN NN B-Disease
in NN NN O
adults NN NN O
, NN NN O
is NN NN O
most NN NN O
often NN NN O
drug NN NN O
or NN NN O
toxin NN NN O
related NN NN O
, NN NN O
and NN NN O
is NN NN O
of NN NN O
unknown NN NN O
pathogenesis NN NN O
. NN NN O
   
It NN NN O
has NN NN O
not NN NN O
been NN NN O
reported NN NN O
previously NN NN O
in NN NN O
children NN NN O
. NN NN O
   
Stevens NN NN B-Disease
- NN NN I-Disease
Johnson NN NN I-Disease
syndrome NN NN I-Disease
is NN NN O
a NN NN O
well NN NN O
- NN NN O
recognized NN NN O
immune NN NN O
complex NN NN O
- NN NN O
mediated NN NN O
hypersensitivity NN NN B-Disease
reaction NN NN O
that NN NN O
affects NN NN O
all NN NN O
age NN NN O
groups NN NN O
, NN NN O
is NN NN O
drug NN NN O
or NN NN O
infection NN NN B-Disease
induced NN NN O
, NN NN O
and NN NN O
has NN NN O
classic NN NN O
systemic NN NN O
, NN NN O
mucosal NN NN O
, NN NN O
and NN NN O
dermatologic NN NN O
manifestations NN NN O
. NN NN O
   
A NN NN O
previously NN NN O
healthy NN NN O
child NN NN O
who NN NN O
developed NN NN O
acute NN NN O
, NN NN O
severe NN NN O
, NN NN O
rapidly NN NN O
progressive NN NN O
vanishing NN NN B-Disease
bile NN NN I-Disease
duct NN NN I-Disease
syndrome NN NN I-Disease
shortly NN NN O
after NN NN O
Stevens NN NN B-Disease
- NN NN I-Disease
Johnson NN NN I-Disease
syndrome NN NN I-Disease
is NN NN O
described NN NN O
; NN NN O
this NN NN O
was NN NN O
temporally NN NN O
associated NN NN O
with NN NN O
ibuprofen NN NN O
use NN NN O
. NN NN O
   
Despite NN NN O
therapy NN NN O
with NN NN O
ursodeoxycholic NN NN O
acid NN NN O
, NN NN O
prednisone NN NN O
, NN NN O
and NN NN O
then NN NN O
tacrolimus NN NN O
, NN NN O
her NN NN O
cholestatic NN NN B-Disease
disease NN NN I-Disease
was NN NN O
unrelenting NN NN O
, NN NN O
with NN NN O
cirrhosis NN NN B-Disease
shown NN NN O
by NN NN O
biopsy NN NN O
6 NN NN O
months NN NN O
after NN NN O
presentation NN NN O
. NN NN O
   
This NN NN O
case NN NN O
documents NN NN O
acute NN NN O
drug NN NN O
- NN NN O
related NN NN O
vanishing NN NN B-Disease
bile NN NN I-Disease
duct NN NN I-Disease
syndrome NN NN I-Disease
in NN NN O
the NN NN O
pediatric NN NN O
age NN NN O
group NN NN O
and NN NN O
suggests NN NN O
shared NN NN O
immune NN NN O
mechanisms NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
both NN NN O
Stevens NN NN B-Disease
- NN NN I-Disease
Johnson NN NN I-Disease
syndrome NN NN I-Disease
and NN NN O
vanishing NN NN B-Disease
bile NN NN I-Disease
duct NN NN I-Disease
syndrome NN NN I-Disease
. NN NN O
   
High NN NN O
incidence NN NN O
of NN NN O
primary NN NN B-Disease
pulmonary NN NN I-Disease
hypertension NN NN I-Disease
associated NN NN O
with NN NN O
appetite NN NN O
suppressants NN NN O
in NN NN O
Belgium NN NN O
. NN NN O
   
Primary NN NN B-Disease
pulmonary NN NN I-Disease
hypertension NN NN I-Disease
is NN NN O
a NN NN O
rare NN NN O
, NN NN O
progressive NN NN O
and NN NN O
incurable NN NN O
disease NN NN O
, NN NN O
which NN NN O
has NN NN O
been NN NN O
associated NN NN O
with NN NN O
the NN NN O
intake NN NN O
of NN NN O
appetite NN NN O
suppressant NN NN O
drugs NN NN O
. NN NN O
   
The NN NN O
importance NN NN O
of NN NN O
this NN NN O
association NN NN O
was NN NN O
evaluated NN NN O
in NN NN O
Belgium NN NN O
while NN NN O
this NN NN O
country NN NN O
still NN NN O
had NN NN O
no NN NN O
restriction NN NN O
on NN NN O
the NN NN O
prescription NN NN O
of NN NN O
appetite NN NN O
suppressants NN NN O
. NN NN O
   
Thirty NN NN O
- NN NN O
five NN NN O
patients NN NN O
with NN NN O
primary NN NN B-Disease
pulmonary NN NN I-Disease
hypertension NN NN I-Disease
and NN NN O
85 NN NN O
matched NN NN O
controls NN NN O
were NN NN O
recruited NN NN O
over NN NN O
32 NN NN O
months NN NN O
( NN NN O
1992 NN NN O
- NN NN O
1994 NN NN O
) NN NN O
in NN NN O
Belgium NN NN O
. NN NN O
   
Exposure NN NN O
to NN NN O
appetite NN NN O
- NN NN O
suppressants NN NN O
was NN NN O
assessed NN NN O
on NN NN O
the NN NN O
basis NN NN O
of NN NN O
hospital NN NN O
records NN NN O
and NN NN O
standardized NN NN O
interview NN NN O
. NN NN O
   
Twenty NN NN O
- NN NN O
three NN NN O
of NN NN O
the NN NN O
patients NN NN O
had NN NN O
previously NN NN O
taken NN NN O
appetite NN NN O
suppressants NN NN O
, NN NN O
mainly NN NN O
fenfluramines NN NN O
, NN NN O
as NN NN O
compared NN NN O
with NN NN O
only NN NN O
5 NN NN O
of NN NN O
the NN NN O
controls NN NN O
( NN NN O
66 NN NN O
versus NN NN O
6 NN NN O
% NN NN O
, NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
0001 NN NN O
) NN NN O
. NN NN O
   
Five NN NN O
patients NN NN O
died NN NN O
before NN NN O
the NN NN O
interview NN NN O
, NN NN O
all NN NN O
of NN NN O
them NN NN O
had NN NN O
taken NN NN O
appetite NN NN O
suppressants NN NN O
. NN NN O
   
In NN NN O
8 NN NN O
patients NN NN O
the NN NN O
diagnosis NN NN O
of NN NN O
primary NN NN B-Disease
pulmonary NN NN I-Disease
hypertension NN NN I-Disease
was NN NN O
uncertain NN NN O
, NN NN O
5 NN NN O
of NN NN O
them NN NN O
had NN NN O
taken NN NN O
appetite NN NN O
suppressants NN NN O
. NN NN O
   
The NN NN O
patients NN NN O
who NN NN O
had NN NN O
been NN NN O
exposed NN NN O
to NN NN O
appetite NN NN O
suppressants NN NN O
tended NN NN O
to NN NN O
be NN NN O
on NN NN O
average NN NN O
more NN NN O
severely NN NN O
ill NN NN O
, NN NN O
and NN NN O
to NN NN O
have NN NN O
a NN NN O
shorter NN NN O
median NN NN O
delay NN NN O
between NN NN O
onset NN NN O
of NN NN O
symptoms NN NN O
and NN NN O
diagnosis NN NN O
. NN NN O
   
A NN NN O
policy NN NN O
of NN NN O
unrestricted NN NN O
prescription NN NN O
of NN NN O
appetite NN NN O
suppressants NN NN O
may NN NN O
lead NN NN O
to NN NN O
a NN NN O
high NN NN O
incidence NN NN O
of NN NN O
associated NN NN O
primary NN NN B-Disease
pulmonary NN NN I-Disease
hypertension NN NN I-Disease
. NN NN O
   
Intake NN NN O
of NN NN O
appetite NN NN O
suppressants NN NN O
may NN NN O
accelerate NN NN O
the NN NN O
progression NN NN O
of NN NN O
the NN NN O
disease NN NN O
. NN NN O
   
Inappropriate NN NN O
use NN NN O
of NN NN O
carbamazepine NN NN O
and NN NN O
vigabatrin NN NN O
in NN NN O
typical NN NN O
absence NN NN B-Disease
seizures NN NN I-Disease
. NN NN O
   
Carbamazepine NN NN O
and NN NN O
vigabatrin NN NN O
are NN NN O
contraindicated NN NN O
in NN NN O
typical NN NN O
absence NN NN B-Disease
seizures NN NN I-Disease
. NN NN O
   
Of NN NN O
18 NN NN O
consecutive NN NN O
referrals NN NN O
of NN NN O
children NN NN O
with NN NN O
resistant NN NN O
typical NN NN O
absences NN NN O
only NN NN O
, NN NN O
eight NN NN O
were NN NN O
erroneously NN NN O
treated NN NN O
with NN NN O
carbamazepine NN NN O
either NN NN O
as NN NN O
monotherapy NN NN O
or NN NN O
as NN NN O
an NN NN O
add NN NN O
- NN NN O
on NN NN O
. NN NN O
   
Vigabatrin NN NN O
was NN NN O
also NN NN O
used NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
two NN NN O
children NN NN O
. NN NN O
   
Frequency NN NN O
of NN NN O
absences NN NN O
increased NN NN O
in NN NN O
four NN NN O
children NN NN O
treated NN NN O
with NN NN O
carbamazepine NN NN O
and NN NN O
two NN NN O
of NN NN O
these NN NN O
developed NN NN O
myoclonic NN NN B-Disease
jerks NN NN I-Disease
, NN NN O
which NN NN O
resolved NN NN O
on NN NN O
withdrawal NN NN O
of NN NN O
carbamazepine NN NN O
. NN NN O
   
Absences NN NN O
were NN NN O
aggravated NN NN O
in NN NN O
both NN NN O
cases NN NN O
where NN NN O
vigabatrin NN NN O
was NN NN O
added NN NN O
on NN NN O
to NN NN O
concurrent NN NN O
treatment NN NN O
. NN NN O
   
Optimal NN NN O
control NN NN O
of NN NN O
the NN NN O
absences NN NN O
was NN NN O
achieved NN NN O
with NN NN O
sodium NN NN O
valproate NN NN O
, NN NN O
lamotrigine NN NN O
, NN NN O
or NN NN O
ethosuximide NN NN O
alone NN NN O
or NN NN O
in NN NN O
combination NN NN O
. NN NN O
   
Choreoathetoid NN NN B-Disease
movements NN NN I-Disease
associated NN NN O
with NN NN O
rapid NN NN O
adjustment NN NN O
to NN NN O
methadone NN NN O
. NN NN O
   
Choreatiform NN NN B-Disease
hyperkinesias NN NN I-Disease
are NN NN O
known NN NN O
to NN NN O
be NN NN O
occasional NN NN O
movement NN NN B-Disease
abnormalities NN NN I-Disease
during NN NN O
intoxications NN NN O
with NN NN O
cocaine NN NN O
but NN NN O
not NN NN O
opiates NN NN O
. NN NN O
   
This NN NN O
is NN NN O
a NN NN O
case NN NN O
report NN NN O
of NN NN O
euphoria NN NN O
and NN NN O
choreoathetoid NN NN B-Disease
movements NN NN I-Disease
both NN NN O
transiently NN NN O
induced NN NN O
by NN NN O
rapid NN NN O
adjustment NN NN O
to NN NN O
the NN NN O
selective NN NN O
mu NN NN O
- NN NN O
opioid NN NN O
receptor NN NN O
agonist NN NN O
methadone NN NN O
in NN NN O
an NN NN O
inpatient NN NN O
previously NN NN O
abusing NN NN O
heroine NN NN O
and NN NN O
cocaine NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
minor NN NN O
EEG NN NN O
abnormalities NN NN O
occurred NN NN O
. NN NN O
   
Possible NN NN O
underlying NN NN O
neurobiological NN NN O
phenomena NN NN O
are NN NN O
discussed NN NN O
. NN NN O
   
Adverse NN NN O
effects NN NN O
of NN NN O
the NN NN O
atypical NN NN O
antipsychotics NN NN O
. NN NN O
   
Collaborative NN NN O
Working NN NN O
Group NN NN O
on NN NN O
Clinical NN NN O
Trial NN NN O
Evaluations NN NN O
. NN NN O
   
Adverse NN NN O
effects NN NN O
of NN NN O
antipsychotics NN NN O
often NN NN O
lead NN NN O
to NN NN O
noncompliance NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
clinicians NN NN O
should NN NN O
address NN NN O
patients NN NN O
' NN NN O
concerns NN NN O
about NN NN O
adverse NN NN O
effects NN NN O
and NN NN O
attempt NN NN O
to NN NN O
choose NN NN O
medications NN NN O
that NN NN O
will NN NN O
improve NN NN O
their NN NN O
patients NN NN O
' NN NN O
quality NN NN O
of NN NN O
life NN NN O
as NN NN O
well NN NN O
as NN NN O
overall NN NN O
health NN NN O
. NN NN O
   
The NN NN O
side NN NN O
effect NN NN O
profiles NN NN O
of NN NN O
the NN NN O
atypical NN NN O
antipsychotics NN NN O
are NN NN O
more NN NN O
advantageous NN NN O
than NN NN O
those NN NN O
of NN NN O
the NN NN O
conventional NN NN O
neuroleptics NN NN O
. NN NN O
   
Conventional NN NN O
agents NN NN O
are NN NN O
associated NN NN O
with NN NN O
unwanted NN NN O
central NN NN O
nervous NN NN O
system NN NN O
effects NN NN O
, NN NN O
including NN NN O
extrapyramidal NN NN B-Disease
symptoms NN NN I-Disease
( NN NN O
EPS NN NN B-Disease
) NN NN O
, NN NN O
tardive NN NN B-Disease
dyskinesia NN NN I-Disease
, NN NN O
sedation NN NN O
, NN NN O
and NN NN O
possible NN NN O
impairment NN NN O
of NN NN O
some NN NN O
cognitive NN NN O
measures NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
cardiac NN NN O
effects NN NN O
, NN NN O
orthostatic NN NN B-Disease
hypotension NN NN I-Disease
, NN NN O
hepatic NN NN O
changes NN NN O
, NN NN O
anticholinergic NN NN O
side NN NN O
effects NN NN O
, NN NN O
sexual NN NN B-Disease
dysfunction NN NN I-Disease
, NN NN O
and NN NN O
weight NN NN B-Disease
gain NN NN I-Disease
. NN NN O
   
The NN NN O
newer NN NN O
atypical NN NN O
agents NN NN O
have NN NN O
a NN NN O
lower NN NN O
risk NN NN O
of NN NN O
EPS NN NN B-Disease
, NN NN O
but NN NN O
are NN NN O
associated NN NN O
in NN NN O
varying NN NN O
degrees NN NN O
with NN NN O
sedation NN NN O
, NN NN O
cardiovascular NN NN O
effects NN NN O
, NN NN O
anticholinergic NN NN O
effects NN NN O
, NN NN O
weight NN NN B-Disease
gain NN NN I-Disease
, NN NN O
sexual NN NN B-Disease
dysfunction NN NN I-Disease
, NN NN O
hepatic NN NN O
effects NN NN O
, NN NN O
lowered NN NN O
seizure NN NN B-Disease
threshold NN NN O
( NN NN O
primarily NN NN O
clozapine NN NN O
) NN NN O
, NN NN O
and NN NN O
agranulocytosis NN NN B-Disease
( NN NN O
clozapine NN NN O
only NN NN O
) NN NN O
. NN NN O
   
Since NN NN O
the NN NN O
incidence NN NN O
and NN NN O
severity NN NN O
of NN NN O
specific NN NN O
adverse NN NN O
effects NN NN O
differ NN NN O
among NN NN O
the NN NN O
various NN NN O
atypicals NN NN O
, NN NN O
the NN NN O
clinician NN NN O
should NN NN O
carefully NN NN O
consider NN NN O
which NN NN O
side NN NN O
effects NN NN O
are NN NN O
most NN NN O
likely NN NN O
to NN NN O
lead NN NN O
to NN NN O
the NN NN O
individual NN NN O
' NN NN O
s NN NN O
dissatisfaction NN NN O
and NN NN O
noncompliance NN NN O
before NN NN O
choosing NN NN O
an NN NN O
antipsychotic NN NN O
for NN NN O
a NN NN O
particular NN NN O
patient NN NN O
. NN NN O
   
A NN NN O
randomized NN NN O
, NN NN O
placebo NN NN O
- NN NN O
controlled NN NN O
dose NN NN O
- NN NN O
comparison NN NN O
trial NN NN O
of NN NN O
haloperidol NN NN O
for NN NN O
psychosis NN NN B-Disease
and NN NN O
disruptive NN NN B-Disease
behaviors NN NN I-Disease
in NN NN O
Alzheimer NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
The NN NN O
goal NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
compare NN NN O
the NN NN O
efficacy NN NN O
and NN NN O
side NN NN O
effects NN NN O
of NN NN O
two NN NN O
doses NN NN O
of NN NN O
haloperidol NN NN O
and NN NN O
placebo NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
psychosis NN NN B-Disease
and NN NN O
disruptive NN NN B-Disease
behaviors NN NN I-Disease
in NN NN O
patients NN NN O
with NN NN O
Alzheimer NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
METHOD NN NN O
: NN NN O
In NN NN O
a NN NN O
6 NN NN O
- NN NN O
week NN NN O
random NN NN O
- NN NN O
assignment NN NN O
, NN NN O
double NN NN O
- NN NN O
blind NN NN O
, NN NN O
placebo NN NN O
- NN NN O
controlled NN NN O
trial NN NN O
( NN NN O
phase NN NN O
A NN NN O
) NN NN O
, NN NN O
haloperidol NN NN O
, NN NN O
2 NN NN O
- NN NN O
3 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
( NN NN O
standard NN NN O
dose NN NN O
) NN NN O
, NN NN O
and NN NN O
haloperidol NN NN O
, NN NN O
0 NN NN O
. NN NN O
50 NN NN O
- NN NN O
0 NN NN O
. NN NN O
75 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
( NN NN O
low NN NN O
dose NN NN O
) NN NN O
, NN NN O
were NN NN O
compared NN NN O
in NN NN O
71 NN NN O
outpatients NN NN O
with NN NN O
Alzheimer NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
For NN NN O
the NN NN O
subsequent NN NN O
6 NN NN O
- NN NN O
week NN NN O
double NN NN O
- NN NN O
blind NN NN O
crossover NN NN O
phase NN NN O
( NN NN O
phase NN NN O
B NN NN O
) NN NN O
, NN NN O
patients NN NN O
taking NN NN O
standard NN NN O
- NN NN O
or NN NN O
low NN NN O
- NN NN O
dose NN NN O
haloperidol NN NN O
were NN NN O
switched NN NN O
to NN NN O
placebo NN NN O
, NN NN O
and NN NN O
patients NN NN O
taking NN NN O
placebo NN NN O
were NN NN O
randomly NN NN O
assigned NN NN O
to NN NN O
standard NN NN O
- NN NN O
or NN NN O
low NN NN O
- NN NN O
dose NN NN O
haloperidol NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
For NN NN O
the NN NN O
60 NN NN O
patients NN NN O
who NN NN O
completed NN NN O
phase NN NN O
A NN NN O
, NN NN O
standard NN NN O
- NN NN O
dose NN NN O
haloperidol NN NN O
was NN NN O
efficacious NN NN O
and NN NN O
superior NN NN O
to NN NN O
both NN NN O
low NN NN O
- NN NN O
dose NN NN O
haloperidol NN NN O
and NN NN O
placebo NN NN O
for NN NN O
scores NN NN O
on NN NN O
the NN NN O
Brief NN NN O
Psychiatric NN NN O
Rating NN NN O
Scale NN NN O
psychosis NN NN B-Disease
factor NN NN O
and NN NN O
on NN NN O
psychomotor NN NN B-Disease
agitation NN NN I-Disease
. NN NN O
   
Response NN NN O
rates NN NN O
according NN NN O
to NN NN O
three NN NN O
sets NN NN O
of NN NN O
criteria NN NN O
were NN NN O
greater NN NN O
with NN NN O
the NN NN O
standard NN NN O
dose NN NN O
( NN NN O
55 NN NN O
% NN NN O
- NN NN O
60 NN NN O
% NN NN O
) NN NN O
than NN NN O
the NN NN O
low NN NN O
dose NN NN O
( NN NN O
25 NN NN O
% NN NN O
- NN NN O
35 NN NN O
% NN NN O
) NN NN O
and NN NN O
placebo NN NN O
( NN NN O
25 NN NN O
% NN NN O
- NN NN O
30 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
The NN NN O
advantage NN NN O
of NN NN O
standard NN NN O
dose NN NN O
over NN NN O
low NN NN O
dose NN NN O
was NN NN O
replicated NN NN O
in NN NN O
phase NN NN O
B NN NN O
. NN NN O
   
In NN NN O
phase NN NN O
A NN NN O
, NN NN O
extrapyramidal NN NN B-Disease
signs NN NN I-Disease
tended NN NN O
to NN NN O
be NN NN O
greater NN NN O
with NN NN O
the NN NN O
standard NN NN O
dose NN NN O
than NN NN O
in NN NN O
the NN NN O
other NN NN O
two NN NN O
conditions NN NN O
, NN NN O
primarily NN NN O
because NN NN O
of NN NN O
a NN NN O
subgroup NN NN O
( NN NN O
20 NN NN O
% NN NN O
) NN NN O
who NN NN O
developed NN NN O
moderate NN NN O
to NN NN O
severe NN NN O
signs NN NN O
. NN NN O
   
Low NN NN O
- NN NN O
dose NN NN O
haloperidol NN NN O
did NN NN O
not NN NN O
differ NN NN O
from NN NN O
placebo NN NN O
on NN NN O
any NN NN O
measure NN NN O
of NN NN O
efficacy NN NN O
or NN NN O
side NN NN O
effects NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
The NN NN O
results NN NN O
indicated NN NN O
a NN NN O
favorable NN NN O
therapeutic NN NN O
profile NN NN O
for NN NN O
haloperidol NN NN O
in NN NN O
doses NN NN O
of NN NN O
2 NN NN O
- NN NN O
3 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
, NN NN O
although NN NN O
a NN NN O
subgroup NN NN O
developed NN NN O
moderate NN NN O
to NN NN O
severe NN NN O
extrapyramidal NN NN B-Disease
signs NN NN I-Disease
. NN NN O
   
A NN NN O
starting NN NN O
dose NN NN O
of NN NN O
1 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
with NN NN O
gradual NN NN O
, NN NN O
upward NN NN O
dose NN NN O
titration NN NN O
is NN NN O
recommended NN NN O
. NN NN O
   
The NN NN O
narrow NN NN O
therapeutic NN NN O
window NN NN O
observed NN NN O
with NN NN O
haloperidol NN NN O
may NN NN O
also NN NN O
apply NN NN O
to NN NN O
other NN NN O
neuroleptics NN NN O
used NN NN O
in NN NN O
Alzheimer NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
patients NN NN O
with NN NN O
psychosis NN NN B-Disease
and NN NN O
disruptive NN NN B-Disease
behaviors NN NN I-Disease
. NN NN O
   
Effects NN NN O
of NN NN O
acetylsalicylic NN NN O
acid NN NN O
, NN NN O
dipyridamole NN NN O
, NN NN O
and NN NN O
hydrocortisone NN NN O
on NN NN O
epinephrine NN NN O
- NN NN O
induced NN NN O
myocardial NN NN B-Disease
injury NN NN I-Disease
in NN NN O
dogs NN NN O
. NN NN O
   
A NN NN O
reproducible NN NN O
model NN NN O
for NN NN O
producing NN NN O
diffuse NN NN O
myocardial NN NN B-Disease
injury NN NN I-Disease
( NN NN O
epinephrine NN NN O
infusion NN NN O
) NN NN O
has NN NN O
been NN NN O
developed NN NN O
to NN NN O
study NN NN O
the NN NN O
cardioprotective NN NN O
effects NN NN O
of NN NN O
agents NN NN O
or NN NN O
maneuvers NN NN O
which NN NN O
might NN NN O
alter NN NN O
the NN NN O
evolution NN NN O
of NN NN O
acute NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
. NN NN O
   
Infusions NN NN O
of NN NN O
epinephrine NN NN O
( NN NN O
4 NN NN O
mug NN NN O
per NN NN O
kilogram NN NN O
per NN NN O
minute NN NN O
for NN NN O
6 NN NN O
hours NN NN O
) NN NN O
increased NN NN O
radiocalcium NN NN O
uptakes NN NN O
into NN NN O
intact NN NN O
myocardium NN NN O
and NN NN O
each NN NN O
of NN NN O
its NN NN O
subcellular NN NN O
components NN NN O
with NN NN O
the NN NN O
mitochondrial NN NN O
fraction NN NN O
showing NN NN O
the NN NN O
most NN NN O
consistent NN NN O
changes NN NN O
when NN NN O
compared NN NN O
to NN NN O
saline NN NN O
- NN NN O
infused NN NN O
control NN NN O
animals NN NN O
( NN NN O
4 NN NN O
, NN NN O
957 NN NN O
vs NN NN O
. NN NN O
827 NN NN O
counts NN NN O
per NN NN O
minute NN NN O
per NN NN O
gram NN NN O
of NN NN O
dried NN NN O
tissue NN NN O
or NN NN O
fraction NN NN O
) NN NN O
. NN NN O
   
Myocardial NN NN O
concentrations NN NN O
of NN NN O
calcium NN NN O
also NN NN O
increased NN NN O
significantly NN NN O
( NN NN O
12 NN NN O
. NN NN O
0 NN NN O
vs NN NN O
. NN NN O
5 NN NN O
. NN NN O
0 NN NN O
mg NN NN O
. NN NN O
per NN NN O
100 NN NN O
Gm NN NN O
. NN NN O
of NN NN O
fat NN NN O
- NN NN O
free NN NN O
dry NN NN O
weight NN NN O
) NN NN O
. NN NN O
   
Infusions NN NN O
of NN NN O
calcium NN NN O
chloride NN NN O
sufficient NN NN O
to NN NN O
raise NN NN O
serum NN NN O
calcium NN NN O
concentrations NN NN O
2 NN NN O
mEq NN NN O
. NN NN O
per NN NN O
liter NN NN O
failed NN NN O
to NN NN O
increase NN NN O
calcium NN NN O
influx NN NN O
into NN NN O
the NN NN O
myocardial NN NN O
cell NN NN O
. NN NN O
   
Mitochondrial NN NN O
radiocalcium NN NN O
uptakes NN NN O
were NN NN O
significantly NN NN O
decreased NN NN O
in NN NN O
animals NN NN O
pretreated NN NN O
with NN NN O
acetylsalicylic NN NN O
acid NN NN O
or NN NN O
dipyridamole NN NN O
or NN NN O
when NN NN O
hydrocortisone NN NN O
was NN NN O
added NN NN O
to NN NN O
the NN NN O
epinephrine NN NN O
infusion NN NN O
( NN NN O
2 NN NN O
, NN NN O
682 NN NN O
, NN NN O
2 NN NN O
, NN NN O
803 NN NN O
, NN NN O
and NN NN O
3 NN NN O
, NN NN O
424 NN NN O
counts NN NN O
per NN NN O
minute NN NN O
per NN NN O
gram NN NN O
of NN NN O
dried NN NN O
fraction NN NN O
, NN NN O
respectively NN NN O
) NN NN O
. NN NN O
   
Myocardial NN NN O
calcium NN NN O
concentrations NN NN O
also NN NN O
were NN NN O
decreased NN NN O
( NN NN O
11 NN NN O
. NN NN O
2 NN NN O
, NN NN O
8 NN NN O
. NN NN O
3 NN NN O
, NN NN O
and NN NN O
8 NN NN O
. NN NN O
9 NN NN O
mg NN NN O
. NN NN O
per NN NN O
100 NN NN O
Gm NN NN O
. NN NN O
of NN NN O
fat NN NN O
- NN NN O
free NN NN O
dry NN NN O
weight NN NN O
, NN NN O
respectively NN NN O
) NN NN O
in NN NN O
the NN NN O
three NN NN O
treatment NN NN O
groups NN NN O
, NN NN O
being NN NN O
significantly NN NN O
decreased NN NN O
only NN NN O
in NN NN O
the NN NN O
last NN NN O
two NN NN O
. NN NN O
   
Evidence NN NN O
of NN NN O
microscopic NN NN O
damage NN NN O
was NN NN O
graded NN NN O
as NN NN O
less NN NN O
severe NN NN O
in NN NN O
the NN NN O
three NN NN O
treatment NN NN O
groups NN NN O
. NN NN O
   
Acetylsalicylic NN NN O
acid NN NN O
, NN NN O
dipyridamole NN NN O
, NN NN O
and NN NN O
hydrocortisone NN NN O
all NN NN O
appear NN NN O
to NN NN O
have NN NN O
cardioprotective NN NN O
effects NN NN O
when NN NN O
tested NN NN O
in NN NN O
this NN NN O
model NN NN O
. NN NN O
   
Clinical NN NN O
and NN NN O
histopathologic NN NN O
examination NN NN O
of NN NN O
renal NN NN O
allografts NN NN O
treated NN NN O
with NN NN O
tacrolimus NN NN O
( NN NN O
FK506 NN NN O
) NN NN O
for NN NN O
at NN NN O
least NN NN O
one NN NN O
year NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
We NN NN O
clinically NN NN O
and NN NN O
pathologically NN NN O
analyzed NN NN O
renal NN NN O
allografts NN NN O
from NN NN O
1 NN NN O
9 NN NN O
renal NN NN O
transplant NN NN O
patients NN NN O
treated NN NN O
with NN NN O
tacrolimus NN NN O
( NN NN O
FK506 NN NN O
) NN NN O
for NN NN O
more NN NN O
than NN NN O
1 NN NN O
year NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Twenty NN NN O
- NN NN O
six NN NN O
renal NN NN O
allograft NN NN O
biopsy NN NN O
specimens NN NN O
from NN NN O
1 NN NN O
9 NN NN O
renal NN NN O
transplant NN NN O
patients NN NN O
who NN NN O
underwent NN NN O
transplantations NN NN O
between NN NN O
1991 NN NN O
and NN NN O
1993 NN NN O
were NN NN O
evaluated NN NN O
. NN NN O
   
Thirteen NN NN O
biopsies NN NN O
were NN NN O
performed NN NN O
from NN NN O
stable NN NN O
functioning NN NN O
renal NN NN O
allografts NN NN O
with NN NN O
informed NN NN O
consent NN NN O
( NN NN O
nonepisode NN NN O
biopsy NN NN O
) NN NN O
and NN NN O
the NN NN O
other NN NN O
13 NN NN O
were NN NN O
from NN NN O
dysfunctional NN NN O
renal NN NN O
allografts NN NN O
with NN NN O
a NN NN O
clinical NN NN O
indication NN NN O
for NN NN O
biopsy NN NN O
( NN NN O
episode NN NN O
biopsy NN NN O
) NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
The NN NN O
main NN NN O
pathologic NN NN O
diagnoses NN NN O
( NN NN O
some NN NN O
overlap NN NN O
) NN NN O
were NN NN O
acute NN NN O
rejection NN NN O
( NN NN O
AR NN NN O
; NN NN O
n NN NN O
= NN NN O
4 NN NN O
) NN NN O
, NN NN O
chronic NN NN O
rejection NN NN O
( NN NN O
CR NN NN O
; NN NN O
n NN NN O
= NN NN O
5 NN NN O
) NN NN O
, NN NN O
AR NN NN O
+ NN NN O
CR NN NN O
( NN NN O
n NN NN O
= NN NN O
4 NN NN O
) NN NN O
, NN NN O
recurrent NN NN O
IgA NN NN B-Disease
nephropathy NN NN I-Disease
( NN NN O
n NN NN O
= NN NN O
5 NN NN O
) NN NN O
, NN NN O
normal NN NN O
findings NN NN O
( NN NN O
n NN NN O
= NN NN O
2 NN NN O
) NN NN O
, NN NN O
minimal NN NN O
- NN NN O
type NN NN O
chronic NN NN O
FK506 NN NN O
nephropathy NN NN B-Disease
( NN NN O
n NN NN O
= NN NN O
9 NN NN O
) NN NN O
, NN NN O
and NN NN O
mild NN NN O
- NN NN O
type NN NN O
FK506 NN NN O
nephropathy NN NN B-Disease
( NN NN O
n NN NN O
= NN NN O
11 NN NN O
) NN NN O
. NN NN O
   
Of NN NN O
the NN NN O
nonepisode NN NN O
biopsies NN NN O
, NN NN O
7 NN NN O
and NN NN O
4 NN NN O
biopsies NN NN O
showed NN NN O
minimal NN NN O
- NN NN O
type NN NN O
and NN NN O
mild NN NN O
- NN NN O
type NN NN O
chronic NN NN O
FK506 NN NN O
nephropathy NN NN B-Disease
, NN NN O
respectively NN NN O
. NN NN O
   
Chronic NN NN O
FK506 NN NN O
nephropathy NN NN B-Disease
consisted NN NN O
of NN NN O
rough NN NN O
and NN NN O
foamy NN NN O
tubular NN NN O
vacuolization NN NN O
( NN NN O
5 NN NN O
biopsies NN NN O
) NN NN O
, NN NN O
arteriolopathy NN NN O
( NN NN O
angiodegeneration NN NN O
of NN NN O
the NN NN O
arteriolar NN NN O
wall NN NN O
; NN NN O
20 NN NN O
biopsies NN NN O
) NN NN O
, NN NN O
focal NN NN B-Disease
segmental NN NN I-Disease
glomerulosclerosis NN NN I-Disease
( NN NN O
4 NN NN O
biopsies NN NN O
) NN NN O
and NN NN O
the NN NN O
striped NN NN O
form NN NN O
of NN NN O
interstitial NN NN B-Disease
fibrosis NN NN I-Disease
( NN NN O
11 NN NN O
biopsies NN NN O
) NN NN O
. NN NN O
   
The NN NN O
serum NN NN O
creatinine NN NN O
levels NN NN O
of NN NN O
patients NN NN O
in NN NN O
the NN NN O
mild NN NN O
- NN NN O
type NN NN O
chronic NN NN O
FK506 NN NN O
nephropathy NN NN B-Disease
group NN NN O
, NN NN O
which NN NN O
included NN NN O
7 NN NN O
episode NN NN O
biopsies NN NN O
, NN NN O
were NN NN O
statistically NN NN O
higher NN NN O
than NN NN O
those NN NN O
in NN NN O
the NN NN O
minimum NN NN O
- NN NN O
type NN NN O
chronic NN NN O
FK506 NN NN O
- NN NN O
nephropathy NN NN B-Disease
group NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
This NN NN O
study NN NN O
demonstrates NN NN O
that NN NN O
chronic NN NN O
FK506 NN NN O
nephropathy NN NN B-Disease
consists NN NN O
primarily NN NN O
of NN NN O
arteriolopathy NN NN O
manifesting NN NN O
as NN NN O
insudative NN NN O
hyalinosis NN NN O
of NN NN O
the NN NN O
arteriolar NN NN O
wall NN NN O
, NN NN O
and NN NN O
suggests NN NN O
that NN NN O
mild NN NN O
- NN NN O
type NN NN O
chronic NN NN O
FK506 NN NN O
nephropathy NN NN B-Disease
is NN NN O
a NN NN O
condition NN NN O
which NN NN O
may NN NN O
lead NN NN O
to NN NN O
deterioration NN NN O
of NN NN O
renal NN NN O
allograft NN NN O
function NN NN O
. NN NN O
   
Different NN NN O
lobular NN NN O
distributions NN NN O
of NN NN O
altered NN NN O
hepatocyte NN NN O
tight NN NN O
junctions NN NN O
in NN NN O
rat NN NN O
models NN NN O
of NN NN O
intrahepatic NN NN B-Disease
and NN NN I-Disease
extrahepatic NN NN I-Disease
cholestasis NN NN I-Disease
. NN NN O
   
Hepatocyte NN NN O
tight NN NN O
junctions NN NN O
( NN NN O
TJs NN NN O
) NN NN O
, NN NN O
the NN NN O
only NN NN O
intercellular NN NN O
barrier NN NN O
between NN NN O
the NN NN O
sinusoidal NN NN O
and NN NN O
the NN NN O
canalicular NN NN O
spaces NN NN O
, NN NN O
play NN NN O
a NN NN O
key NN NN O
role NN NN O
in NN NN O
bile NN NN O
formation NN NN O
. NN NN O
   
Although NN NN O
hepatocyte NN NN O
TJs NN NN O
are NN NN O
impaired NN NN O
in NN NN O
cholestasis NN NN B-Disease
, NN NN O
attempts NN NN O
to NN NN O
localize NN NN O
the NN NN O
precise NN NN O
site NN NN O
of NN NN O
hepatocyte NN NN O
TJ NN NN O
damage NN NN O
by NN NN O
freeze NN NN O
- NN NN O
fracture NN NN O
electron NN NN O
microscopy NN NN O
have NN NN O
produced NN NN O
limited NN NN O
information NN NN O
. NN NN O
   
Recently NN NN O
, NN NN O
several NN NN O
TJ NN NN O
- NN NN O
associated NN NN O
proteins NN NN O
like NN NN O
ZO NN NN O
- NN NN O
1 NN NN O
and NN NN O
7H6 NN NN O
have NN NN O
been NN NN O
identified NN NN O
and NN NN O
characterized NN NN O
. NN NN O
   
Immunolocalization NN NN O
of NN NN O
7H6 NN NN O
appears NN NN O
to NN NN O
closely NN NN O
correlate NN NN O
with NN NN O
paracellular NN NN O
permeability NN NN O
. NN NN O
   
We NN NN O
used NN NN O
rat NN NN O
models NN NN O
of NN NN O
intrahepatic NN NN B-Disease
cholestasis NN NN I-Disease
by NN NN O
ethinyl NN NN O
estradiol NN NN O
( NN NN O
EE NN NN O
) NN NN O
treatment NN NN O
and NN NN O
extrahepatic NN NN B-Disease
cholestasis NN NN I-Disease
by NN NN O
bile NN NN O
duct NN NN O
ligation NN NN O
( NN NN O
BDL NN NN O
) NN NN O
to NN NN O
precisely NN NN O
determine NN NN O
the NN NN O
site NN NN O
of NN NN O
TJ NN NN O
damage NN NN O
. NN NN O
   
Alterations NN NN O
in NN NN O
hepatocyte NN NN O
TJs NN NN O
were NN NN O
assessed NN NN O
by NN NN O
double NN NN O
- NN NN O
immunolabeling NN NN O
for NN NN O
7H6 NN NN O
and NN NN O
ZO NN NN O
- NN NN O
1 NN NN O
using NN NN O
a NN NN O
confocal NN NN O
laser NN NN O
scanning NN NN O
microscope NN NN O
. NN NN O
   
In NN NN O
control NN NN O
rats NN NN O
, NN NN O
immunostaining NN NN O
for NN NN O
7H6 NN NN O
and NN NN O
ZO NN NN O
- NN NN O
1 NN NN O
colocalized NN NN O
to NN NN O
outline NN NN O
bile NN NN O
canaliculi NN NN O
in NN NN O
a NN NN O
continuous NN NN O
fashion NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
7H6 NN NN O
and NN NN O
ZO NN NN O
- NN NN O
1 NN NN O
immunostaining NN NN O
was NN NN O
more NN NN O
discontinuous NN NN O
, NN NN O
outlining NN NN O
the NN NN O
bile NN NN O
canaliculi NN NN O
after NN NN O
BDL NN NN O
. NN NN O
   
Immunostaining NN NN O
for NN NN O
7H6 NN NN O
, NN NN O
not NN NN O
ZO NN NN O
- NN NN O
1 NN NN O
, NN NN O
decreased NN NN O
and NN NN O
predominantly NN NN O
appeared NN NN O
as NN NN O
discrete NN NN O
signals NN NN O
in NN NN O
the NN NN O
submembranous NN NN O
cytoplasm NN NN O
of NN NN O
periportal NN NN O
hepatocytes NN NN O
after NN NN O
BDL NN NN O
. NN NN O
   
After NN NN O
EE NN NN O
treatment NN NN O
, NN NN O
changes NN NN O
in NN NN O
immunostaining NN NN O
for NN NN O
7H6 NN NN O
and NN NN O
ZO NN NN O
- NN NN O
1 NN NN O
were NN NN O
similar NN NN O
to NN NN O
those NN NN O
seen NN NN O
in NN NN O
periportal NN NN O
hepatocytes NN NN O
after NN NN O
BDL NN NN O
, NN NN O
but NN NN O
distributed NN NN O
more NN NN O
diffusely NN NN O
throughout NN NN O
the NN NN O
lobule NN NN O
. NN NN O
   
This NN NN O
study NN NN O
is NN NN O
the NN NN O
first NN NN O
to NN NN O
demonstrate NN NN O
that NN NN O
impairment NN NN O
of NN NN O
hepatocyte NN NN O
TJs NN NN O
occurs NN NN O
heterogenously NN NN O
in NN NN O
the NN NN O
liver NN NN O
lobule NN NN O
after NN NN O
BDL NN NN O
and NN NN O
suggests NN NN O
that NN NN O
BDL NN NN O
and NN NN O
EE NN NN O
treatments NN NN O
produce NN NN O
different NN NN O
lobular NN NN O
distributions NN NN O
of NN NN O
increased NN NN O
paracellular NN NN O
permeability NN NN O
. NN NN O
   
Memory NN NN O
facilitation NN NN O
and NN NN O
stimulation NN NN O
of NN NN O
endogenous NN NN O
nerve NN NN O
growth NN NN O
factor NN NN O
synthesis NN NN O
by NN NN O
the NN NN O
acetylcholine NN NN O
releaser NN NN O
PG NN NN O
- NN NN O
9 NN NN O
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
PG NN NN O
- NN NN O
9 NN NN O
( NN NN O
3alpha NN NN O
- NN NN O
tropyl NN NN O
2 NN NN O
- NN NN O
( NN NN O
p NN NN O
- NN NN O
bromophenyl NN NN O
) NN NN O
propionate NN NN O
) NN NN O
, NN NN O
the NN NN O
acetylcholine NN NN O
releaser NN NN O
, NN NN O
on NN NN O
memory NN NN O
processes NN NN O
and NN NN O
nerve NN NN O
growth NN NN O
factor NN NN O
( NN NN O
NGF NN NN O
) NN NN O
synthesis NN NN O
were NN NN O
evaluated NN NN O
. NN NN O
   
In NN NN O
the NN NN O
mouse NN NN O
passive NN NN O
- NN NN O
avoidance NN NN O
test NN NN O
, NN NN O
PG NN NN O
- NN NN O
9 NN NN O
( NN NN O
10 NN NN O
- NN NN O
30 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
, NN NN O
administered NN NN O
20 NN NN O
min NN NN O
before NN NN O
the NN NN O
training NN NN O
session NN NN O
, NN NN O
prevented NN NN O
amnesia NN NN B-Disease
induced NN NN O
by NN NN O
both NN NN O
the NN NN O
non NN NN O
selective NN NN O
antimuscarinic NN NN O
drug NN NN O
scopolamine NN NN O
and NN NN O
the NN NN O
M1 NN NN O
- NN NN O
selective NN NN O
antagonist NN NN O
S NN NN O
- NN NN O
( NN NN O
- NN NN O
) NN NN O
- NN NN O
ET NN NN O
- NN NN O
126 NN NN O
. NN NN O
   
In NN NN O
the NN NN O
same NN NN O
experimental NN NN O
conditions NN NN O
, NN NN O
PG NN NN O
- NN NN O
9 NN NN O
( NN NN O
5 NN NN O
- NN NN O
20 NN NN O
microg NN NN O
per NN NN O
mouse NN NN O
, NN NN O
i NN NN O
. NN NN O
c NN NN O
. NN NN O
v NN NN O
. NN NN O
) NN NN O
was NN NN O
also NN NN O
able NN NN O
to NN NN O
prevent NN NN O
antimuscarine NN NN O
- NN NN O
induced NN NN O
amnesia NN NN B-Disease
, NN NN O
demonstrating NN NN O
a NN NN O
central NN NN O
localization NN NN O
of NN NN O
the NN NN O
activity NN NN O
. NN NN O
   
At NN NN O
the NN NN O
highest NN NN O
effective NN NN O
doses NN NN O
, NN NN O
PG NN NN O
- NN NN O
9 NN NN O
did NN NN O
not NN NN O
produce NN NN O
any NN NN O
collateral NN NN O
symptoms NN NN O
as NN NN O
revealed NN NN O
by NN NN O
the NN NN O
Irwin NN NN O
test NN NN O
, NN NN O
and NN NN O
it NN NN O
did NN NN O
not NN NN O
modify NN NN O
spontaneous NN NN O
motility NN NN O
and NN NN O
inspection NN NN O
activity NN NN O
, NN NN O
as NN NN O
revealed NN NN O
by NN NN O
the NN NN O
hole NN NN O
- NN NN O
board NN NN O
test NN NN O
. NN NN O
   
PG NN NN O
- NN NN O
9 NN NN O
was NN NN O
also NN NN O
able NN NN O
to NN NN O
increase NN NN O
the NN NN O
amount NN NN O
of NN NN O
NGF NN NN O
secreted NN NN O
in NN NN O
vitro NN NN O
by NN NN O
astrocytes NN NN O
in NN NN O
a NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
. NN NN O
   
The NN NN O
maximal NN NN O
NGF NN NN O
contents NN NN O
obtained NN NN O
by NN NN O
PG NN NN O
- NN NN O
9 NN NN O
were NN NN O
17 NN NN O
. NN NN O
6 NN NN O
- NN NN O
fold NN NN O
of NN NN O
the NN NN O
control NN NN O
value NN NN O
. NN NN O
   
During NN NN O
culture NN NN O
, NN NN O
no NN NN O
morphological NN NN O
changes NN NN O
were NN NN O
found NN NN O
at NN NN O
effective NN NN O
concentrations NN NN O
of NN NN O
PG NN NN O
- NN NN O
9 NN NN O
. NN NN O
   
The NN NN O
current NN NN O
work NN NN O
indicates NN NN O
the NN NN O
ability NN NN O
of NN NN O
PG NN NN O
- NN NN O
9 NN NN O
to NN NN O
induce NN NN O
beneficial NN NN O
effects NN NN O
on NN NN O
cognitive NN NN O
processes NN NN O
and NN NN O
stimulate NN NN O
activity NN NN O
of NN NN O
NGF NN NN O
synthesis NN NN O
in NN NN O
astroglial NN NN O
cells NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
PG NN NN O
- NN NN O
9 NN NN O
could NN NN O
represent NN NN O
a NN NN O
potential NN NN O
useful NN NN O
drug NN NN O
able NN NN O
to NN NN O
improve NN NN O
the NN NN O
function NN NN O
of NN NN O
impaired NN NN O
cognitive NN NN O
processes NN NN O
. NN NN O
   
Mechanisms NN NN O
of NN NN O
FK NN NN O
506 NN NN O
- NN NN O
induced NN NN O
hypertension NN NN B-Disease
in NN NN O
the NN NN O
rat NN NN O
. NN NN O
   
- NN NN O
Tacrolimus NN NN O
( NN NN O
FK NN NN O
506 NN NN O
) NN NN O
is NN NN O
a NN NN O
powerful NN NN O
, NN NN O
widely NN NN O
used NN NN O
immunosuppressant NN NN O
. NN NN O
   
The NN NN O
clinical NN NN O
utility NN NN O
of NN NN O
FK NN NN O
506 NN NN O
is NN NN O
complicated NN NN O
by NN NN O
substantial NN NN O
hypertension NN NN B-Disease
and NN NN O
nephrotoxicity NN NN B-Disease
. NN NN O
   
To NN NN O
clarify NN NN O
the NN NN O
mechanisms NN NN O
of NN NN O
FK NN NN O
506 NN NN O
- NN NN O
induced NN NN O
hypertension NN NN B-Disease
, NN NN O
we NN NN O
studied NN NN O
the NN NN O
chronic NN NN O
effects NN NN O
of NN NN O
FK NN NN O
506 NN NN O
on NN NN O
the NN NN O
synthesis NN NN O
of NN NN O
endothelin NN NN O
- NN NN O
1 NN NN O
( NN NN O
ET NN NN O
- NN NN O
1 NN NN O
) NN NN O
, NN NN O
the NN NN O
expression NN NN O
of NN NN O
mRNA NN NN O
of NN NN O
ET NN NN O
- NN NN O
1 NN NN O
and NN NN O
endothelin NN NN O
- NN NN O
converting NN NN O
enzyme NN NN O
- NN NN O
1 NN NN O
( NN NN O
ECE NN NN O
- NN NN O
1 NN NN O
) NN NN O
, NN NN O
the NN NN O
endothelial NN NN O
nitric NN NN O
oxide NN NN O
synthase NN NN O
( NN NN O
eNOS NN NN O
) NN NN O
activity NN NN O
, NN NN O
and NN NN O
the NN NN O
expression NN NN O
of NN NN O
mRNA NN NN O
of NN NN O
eNOS NN NN O
and NN NN O
C NN NN O
- NN NN O
type NN NN O
natriuretic NN NN O
peptide NN NN O
( NN NN O
CNP NN NN O
) NN NN O
in NN NN O
rat NN NN O
blood NN NN O
vessels NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
the NN NN O
effect NN NN O
of NN NN O
the NN NN O
specific NN NN O
endothelin NN NN O
type NN NN O
A NN NN O
receptor NN NN O
antagonist NN NN O
FR NN NN O
139317 NN NN O
on NN NN O
FK NN NN O
506 NN NN O
- NN NN O
induced NN NN O
hypertension NN NN B-Disease
in NN NN O
rats NN NN O
was NN NN O
studied NN NN O
. NN NN O
   
FK NN NN O
506 NN NN O
, NN NN O
5 NN NN O
mg NN NN O
. NN NN O
   
kg NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
d NN NN O
- NN NN O
1 NN NN O
given NN NN O
for NN NN O
4 NN NN O
weeks NN NN O
, NN NN O
elevated NN NN O
blood NN NN O
pressure NN NN O
from NN NN O
102 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
13 NN NN O
to NN NN O
152 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
15 NN NN O
mm NN NN O
Hg NN NN O
and NN NN O
increased NN NN O
the NN NN O
synthesis NN NN O
of NN NN O
ET NN NN O
- NN NN O
1 NN NN O
and NN NN O
the NN NN O
levels NN NN O
of NN NN O
ET NN NN O
- NN NN O
1 NN NN O
mRNA NN NN O
in NN NN O
the NN NN O
mesenteric NN NN O
artery NN NN O
( NN NN O
240 NN NN O
% NN NN O
and NN NN O
230 NN NN O
% NN NN O
, NN NN O
respectively NN NN O
) NN NN O
. NN NN O
   
Little NN NN O
change NN NN O
was NN NN O
observed NN NN O
in NN NN O
the NN NN O
expression NN NN O
of NN NN O
ECE NN NN O
- NN NN O
1 NN NN O
mRNA NN NN O
and NN NN O
CNP NN NN O
mRNA NN NN O
. NN NN O
   
FK NN NN O
506 NN NN O
decreased NN NN O
eNOS NN NN O
activity NN NN O
and NN NN O
the NN NN O
levels NN NN O
of NN NN O
eNOS NN NN O
mRNA NN NN O
in NN NN O
the NN NN O
aorta NN NN O
( NN NN O
48 NN NN O
% NN NN O
and NN NN O
55 NN NN O
% NN NN O
, NN NN O
respectively NN NN O
) NN NN O
. NN NN O
   
The NN NN O
administration NN NN O
of NN NN O
FR NN NN O
139317 NN NN O
( NN NN O
10 NN NN O
mg NN NN O
. NN NN O
kg NN NN O
- NN NN O
1 NN NN O
. NN NN O
d NN NN O
- NN NN O
1 NN NN O
) NN NN O
prevented NN NN O
FK NN NN O
506 NN NN O
- NN NN O
induced NN NN O
hypertension NN NN B-Disease
in NN NN O
rats NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
FK NN NN O
506 NN NN O
may NN NN O
increase NN NN O
blood NN NN O
pressure NN NN O
not NN NN O
only NN NN O
by NN NN O
increasing NN NN O
ET NN NN O
- NN NN O
1 NN NN O
production NN NN O
but NN NN O
also NN NN O
by NN NN O
decreasing NN NN O
NO NN NN O
synthesis NN NN O
in NN NN O
the NN NN O
vasculature NN NN O
. NN NN O
   
   
